{ "meta": { "tracker_site_url": "https://psilocybin-research.com", "publication_tracker_url": "https://psilocybin-research.com/", "generated_at_utc": "2026-07-09 21:23:04", "record_count": 925 }, "papers": [ { "id": 5676, "title": "Psilocybin therapy for adult females with anorexia nervosa: pilot study.", "normalized_title": "psilocybin therapy for adult females with anorexia nervosa pilot study", "authors": "Douglass HM, Spriggs MJ, Godfrey K, Danby JL, de Magalhaes FJC, Macdonald L, Alderton KL, Archer S, Ahmad K, Martell J, Frias JT, Sawicka G, Read T, Blemings A, Lafrance A, Nicholls D, Erritzoe D, Park RJ, Nutt DJ, Carhart-Harris RL.", "abstract": "BackgroundAnorexia nervosa is a debilitating eating disorder with high mortality and chronicity rates owing to the paucity of effective existing treatments. Several clinical trials using psilocybin therapy have demonstrated therapeutic efficacy and safety in psychiatric conditions, including anorexia nervosa.AimsThis study aimed to further assess the safety, feasibility and potential efficacy of psilocybin therapy in anorexia nervosa.MethodThis single-blind, within-individual pilot study recruited 21 females with anorexia nervosa, who underwent three dosing sessions with oral psilocybin (COMP360) over 6 weeks in a fixed order (1 mg, 25 mg, 25 mg), alongside talk therapy and adjunctive to treatment as usual. Adverse events were monitored throughout the study. Primary clinical outcome measures were global Eating Disorder Examination Interview (EDE) and Readiness and Motivation Questionnaire (RMQ) precontemplation scores. Primary time points for the EDE were the 6-week final visit, 3-month follow-up and 6-month follow-up; and for the RMQ, they were the 6-week final visit and comparison between dosing days. Global EDE Questionnaire scores were a key secondary outcome. Key time points were the 6-week final visit and comparison between dosing days. There was a 12-month remote follow-up.ResultsPsilocybin was well tolerated by all participants. The most common adverse events were headache, nausea and dizziness. Two serious adverse events (suicide attempts) were reported for one participant within the 6-12-month period. Relative to baseline, participants displayed significant improvements in their eating disorder symptoms (EDE scores: p < 0.0001, d = 0.98, 6 months) and motivation to change (RMQ scores: p = 0.0017, d = 0.65, 12 months). However, there was a large variation in improvement and maintenance during the follow-up.ConclusionsThis study further provides preliminary support for the feasibility, safety and potential efficacy of this intervention to treat adult females with anorexia nervosa, and warrants further investigation in larger and more rigorously designed studies.", "journal": "The British Journal of Psychiatry", "publication_date": "2026-07-07", "publication_year": 2026, "doi": "10.1192/bjp.2026.10687", "pubmed_id": "42414058", "source_url": "https://doi.org/10.1192/bjp.2026.10687", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-08 01:20:22", "last_checked": "2026-07-09 01:20:15", "raw_json": "{\"europe_pmc_id\":\"42414058\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167587921\",\"openalex_url\":\"https://openalex.org/W7167587921\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1539080424\",\"https://openalex.org/W1554763052\",\"https://openalex.org/W1994387760\",\"https://openalex.org/W2001008250\",\"https://openalex.org/W2001060580\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2070836248\",\"https://openalex.org/W2093980670\",\"https://openalex.org/W2108143240\",\"https://openalex.org/W2564469912\",\"https://openalex.org/W2619816586\",\"https://openalex.org/W2753989225\",\"https://openalex.org/W2777124046\",\"https://openalex.org/W2883430979\",\"https://openalex.org/W2901877120\",\"https://openalex.org/W2998935314\",\"https://openalex.org/W3046100757\",\"https://openalex.org/W3080226154\",\"https://openalex.org/W3083797211\",\"https://openalex.org/W3087074748\",\"https://openalex.org/W3153606049\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3205506305\",\"https://openalex.org/W4221114092\",\"https://openalex.org/W4361279088\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4387026668\",\"https://openalex.org/W4387674199\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4395110324\"],\"authorships\":[{\"id\":\"https://openalex.org/A5031966441\",\"display_name\":\"Hannah Douglass\",\"orcid\":\"https://orcid.org/0000-0002-4033-385X\"},{\"id\":\"https://openalex.org/A5140199765\",\"display_name\":\"Meg J. Spriggs\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121806282\",\"display_name\":\"K. Godfrey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5046578118\",\"display_name\":\"Jennifer L. Danby\",\"orcid\":null},{\"id\":\"https://openalex.org/A5140220796\",\"display_name\":\"Frederico J. C. de Magalhaes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109728412\",\"display_name\":\"Lauren Macdonald\",\"orcid\":null},{\"id\":\"https://openalex.org/A5008058826\",\"display_name\":\"Kirsty L. Alderton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5140174385\",\"display_name\":\"Stephanie Archer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5100595075\",\"display_name\":\"Kirran Ahmad\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036560266\",\"display_name\":\"Jonny Martell\",\"orcid\":\"https://orcid.org/0000-0002-4194-7669\"},{\"id\":\"https://openalex.org/A5140192900\",\"display_name\":\"Jennifer T. Frias\",\"orcid\":null},{\"id\":\"https://openalex.org/A5115003013\",\"display_name\":\"Gabriela Sawicka\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104065435\",\"display_name\":\"Tim Read\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048534479\",\"display_name\":\"Allan Blemings\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035542356\",\"display_name\":\"Adèle Lafrance\",\"orcid\":\"https://orcid.org/0000-0002-4935-7786\"},{\"id\":\"https://openalex.org/A5030053635\",\"display_name\":\"Dasha Nicholls\",\"orcid\":\"https://orcid.org/0000-0001-7257-6605\"},{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5005010143\",\"display_name\":\"Rebecca J. Park\",\"orcid\":\"https://orcid.org/0000-0002-8611-4409\"},{\"id\":\"https://openalex.org/A5016082897\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-1286-1401\"},{\"id\":\"https://openalex.org/A5140218191\",\"display_name\":\"Robin L. Carhart-Harris\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S127936299\",\"source_display_name\":\"The British Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1192/bjp.2026.10687\",\"is_oa\":false}}}", "topic_tags": "Eating Disorders,Headache / Migraine,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7167587921" }, { "id": 3652, "title": "Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation", "normalized_title": "phase i study of the safety and adjunctive effects of psilocybin in adults with opioid use disorder maintained on a buprenorphine naloxone formulation", "authors": "University of Wisconsin, Madison", "abstract": "Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy. Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain. The primary objective of this clinical trial is to determine the safety of psilocybin in adult patients with opioid use disorder concurrently taking buprenorphine-naloxone. Eligible participants will be adults with active opioid use disorder (OUD) who are willing to begin and maintain a daily dose of buprenorphine-naloxone throughout study participation. Initiation, stabilization, and maintenance of buprenorphine-naloxone will be overseen by a qualified study medical provider. After psychological screening and at least 6 hours of preparatory counseling and preparation for the psilocybin dosing, set, and setting, each participant will ingest 1 oral dose of psilocybin. All dosing sessions will be attended by 2 specially trained facilitators, in a dedicated Clinical Research Facility. After eight hours of observation in the dosing room, the participant will be kept overnight in the hospital Clinical Research Unit, and complete an integration session with a psychologist before discharge to home. Approximately 4 weeks after the first dose, the participant will receive a second oral dose of psilocybin, with the same length of observation. Participants who have been administered the first dose but decline to receive the second dose will remain evaluable. At study termination, their active study participation will end, but completion of the 28 day post-dose follow up will be requested. The primary endpoint is the assessment of the safety of concurrent administration of a buprenorphine-naloxone formulation and psilocybin as determined by physiological measures (ECG, respiratory rate, blood pressure, body temperature, and blood oxygen saturation) and validated clinical and self-report measures (Clinical Opiate Withdrawal Scale (COWS), Opioid Craving Scale (OCS), Timeline Follow-Back (TLFB)). If you are interested in participating in this study, please fill out a brief 1-minute survey at the link in the \"More Information\" section at the bottom of this record.", "journal": "ClinicalTrials.gov", "publication_date": "2026-07-06", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04161066", "keywords": "Opioid Use Disorder, Psilocybin with facilitated counseling, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-09 01:22:31", "raw_json": "{\"nct_id\":\"NCT04161066\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Addiction,Chronic Pain,Clinical Trial,Observational Study,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3495, "title": "A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults", "normalized_title": "a multicenter phase 1 safety and tolerability trial of psilocybin in healthy older adults", "authors": "University of Colorado, Denver", "abstract": "This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85. The purpose of this study is to learn whether psilocybin, a psychedelic compound, can be given safely to older adults. We want to understand how psilocybin affects the body and mind, including blood pressure, heart rhythm, and mood. We also want to see how the body processes psilocybin (how quickly it is absorbed and cleared) and whether it affects thinking, memory, or wellbeing. * Primary Objective: Evaluate the safety and tolerability of psychedelic administration in two cohorts of healthy older adults. * Cohort 1a Psilocybin Moderate Dose: 2 doses of oral psilocybin (10mg and then 25mg) 30 days apart. * Cohort 1b Psilocybin High Dose: 2 doses of oral psilocybin (15mg and then 30mg) 30 days apart. * Secondary Objectives: Evaluate the pharmacokinetics of Psilocybin for each Cohort of healthy older adults. * Exploratory Objectives: Evaluate patient-reported outcomes related to Psilocybin administration (e.g., psychedelic experience and well-being) in each Cohort. Assess the relationships between the pharmacokinetic profile, safety endpoints, and patient-reported outcomes in each Cohort.", "journal": "ClinicalTrials.gov", "publication_date": "2026-07-05", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07516405", "keywords": "Healthy Volunteer, Older Adults (65-85 Years), Psilocybin (Usona Institute), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-09 01:22:31", "raw_json": "{\"nct_id\":\"NCT07516405\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Pharmacology,Aging,Wellbeing,Clinical Trial,Observational Study,Healthy Volunteers,Older Adults,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 5672, "title": "Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development", "normalized_title": "naturally derived psilocybin for therapeutic use a six criterion framework for evidence safety and benefit risk considerations in policy and clinical development", "authors": "Enriquez-Geppert Stefanie, Bevers Lisa, Rosander Arvid, Fodran Peter, Polito Vince", "abstract": "Naturally derived psilocybin is widely used, yet its therapeutic potential, pharmacological distinctiveness and regulatory feasibility remain understudied. This review evaluates the potential of naturally derived psilocybin using a six-criterion framework to evaluate: (1) therapeutic benefit, (2) safety and tolerability, (3) pharmacological uniqueness vs. synthetic psilocybin, (4) identity and composition control, (5) dose precision and stability, and (6) ecological sustainability. This paper answers three key questions about naturally derived psilocybin: Does it show therapeutic potential? Does it differ from synthetic psilocybin? Can it meet medicinal standards? Findings suggest perceived therapeutic benefits from naturally derived psilocybin across mental health domains, though evidence of causal efficacy is mixed. Safety profiles are favorable but context-dependent, with risks in vulnerable populations. Some preliminary preclinical evidence indicates possible entourage effects, but human validation is lacking. Dose precision varies, with purified psilocybin being most reliable, followed by standardized extracts, alcoholic, aqueous, and whole biomass preparations. Scalable cultivation is feasible but faces sustainability challenges. Key gaps include a lack of controlled trials, longitudinal safety evaluations, and standardization. We provide a phased research roadmap, which proposes short-term studies to establish safety, mid-term mechanistic and standardization efforts, and long-term integration into therapeutic, cultural, and ecological systems. This review highlights the promise of naturally derived psilocybin but underscores the need for rigorous evidence to support regulatory acceptance and clinical use.", "journal": "Biomolecules", "publication_date": "2026-07-02", "publication_year": 2026, "doi": "10.3390/biom16070983", "pubmed_id": null, "source_url": "https://doi.org/10.3390/biom16070983", "keywords": "", "substance_tags": "psilocybin", "source_name": "Crossref", "date_added": "2026-07-05 01:20:15", "last_checked": "2026-07-09 01:20:16", "raw_json": "{\"doi\":\"10.3390/biom16070983\",\"reference_dois\":[\"10.1016/j.psychres.2023.115531\",\"10.1016/j.neubiorev.2025.106163\",\"10.1016/bs.irn.2025.03.001\",\"10.1016/j.ajp.2024.104242\",\"10.1057/s41292-025-00369-y\",\"10.1556/2054.2025.00432\",\"10.1556/2054.2023.00297\",\"10.3389/fpsyt.2024.1169686\",\"10.1615/intjmedmushr.v10.i3.20\",\"10.1016/j.funbio.2022.01.003\",\"10.1038/s41429-020-0311-8\",\"10.4103/indianjpsychiatry.indianjpsychiatry_707_23\",\"10.1007/978-981-97-1203-8\",\"10.3389/fpsyg.2021.747999\",\"10.1038/npp.2017.84\",\"10.1016/b0-08-043076-7/00180-7\",\"10.2307/3090197\",\"10.1038/s41467-022-32310-3\",\"10.7326/0003-4819-144-5-200603070-00013\",\"10.1016/j.jep.2017.08.015\",\"10.1556/2054.2020.00159\",\"10.1016/j.drugpo.2024.104507\",\"10.3389/fpsyt.2023.1199642\",\"10.1186/s12955-020-01423-y\",\"10.1371/journal.pone.0321648\",\"10.1556/2054.2025.00375\",\"10.1089/psymed.2023.0074\",\"10.1177/0269881115598338\",\"10.1016/j.jpsychores.2018.04.004\",\"10.3389/fpsyt.2023.1169692\",\"10.1177/0269881114565653\",\"10.1177/0269881117735685\",\"10.1177/0269881114568039\",\"10.1371/journal.pone.0063972\",\"10.3389/fpsyt.2021.780696\",\"10.1177/20494637251319497\",\"10.1177/02698811231158245\",\"10.1177/02698811221131997\",\"10.1016/j.jad.2024.10.058\",\"10.3389/fphar.2018.00897\",\"10.3389/fphar.2021.623985\",\"10.1556/2054.2021.00162\",\"10.1016/j.neubiorev.2022.104706\",\"10.1177/0269881120953994\",\"10.1038/s41598-021-01811-4\",\"10.1038/s41598-022-14512-3\",\"10.3389/fpsyt.2019.00672\",\"10.1007/s00213-020-05477-0\",\"10.1192/j.eurpsy.2024.8\",\"10.1001/jamapsychiatry.2025.0044\",\"10.56522/bmchap.0130010280003\",\"10.1111/anoc.12168\",\"10.1186/s13002-025-00779-z\",\"10.1080/00275514.2024.2363137\",\"10.1111/anoc.12163\",\"10.1556/2054.2025.00436\",\"10.1080/02791072.2023.2246459\",\"10.1177/0269881119857204\",\"10.1007/s00213-018-5049-7\",\"10.1080/02791072.2019.1580804\",\"10.7554/elife.62878\",\"10.1038/s41398-022-02039-0\",\"10.1177/02698811211050556\",\"10.1016/j.neuropharm.2025.110722\",\"10.1016/j.neuropharm.2025.110732\",\"10.1098/rstb.2023.0095\",\"10.1016/j.neuropharm.2018.05.012\",\"10.1016/j.euroneuro.2013.12.006\",\"10.1093/qjmed/hcu145\",\"10.1177/0269881108093587\",\"10.1016/j.ijchp.2022.100349\",\"10.1016/j.tips.2023.12.007\",\"10.1177/02698811221084063\",\"10.1371/journal.pone.0229067\",\"10.1038/s41598-023-40856-5\",\"10.1002/hup.2234\",\"10.1177/02698811231211219\",\"10.1177/02698811231179910\",\"10.1007/s00213-024-06585-x\",\"10.1080/02791072.2024.2368617\",\"10.1016/j.toxicon.2025.108450\",\"10.1021/acscentsci.5c01146\",\"10.3897/imafungus.16.148070\",\"10.1080/02791072.2024.2401982\",\"10.9758/cpn.24.1180\",\"10.1186/s12888-024-06303-z\",\"10.1016/j.ajoc.2025.102359\",\"10.3390/ijms23126713\",\"10.1001/jamanetworkopen.2024.5960\",\"10.1016/j.nsa.2024.104060\",\"10.1038/s41386-022-01297-2\",\"10.1038/s41386-019-0324-9\",\"10.1002/anie.201705489\",\"10.1002/cbic.202200183\",\"10.1016/j.euroneuro.2016.05.001\",\"10.1038/s41386-022-01389-z\",\"10.3389/fncel.2016.00272\",\"10.1016/j.tips.2025.08.012\",\"10.1007/s43440-024-00660-y\",\"10.1523/jneurosci.1384-23.2023\",\"10.1038/s41380-025-03257-w\",\"10.1038/s41467-023-44016-1\",\"10.1038/s41380-025-03100-2\",\"10.1126/science.abl8615\",\"10.1073/pnas.2416106122\",\"10.1126/science.adf0435\",\"10.1038/s41586-024-07624-5\",\"10.1016/j.nlm.2013.04.015\",\"10.1016/j.neuron.2012.08.036\",\"10.1016/j.tibs.2024.02.001\",\"10.1038/s41593-023-01316-5\",\"10.1016/j.neuron.2025.06.012\",\"10.1038/s41583-019-0212-7\",\"10.1016/j.mehy.2019.109406\",\"10.1038/s41514-025-00244-x\",\"10.1016/s0014-2999(98)00392-6\",\"10.3389/fpls.2018.01969\",\"10.1002/chem.201904363\",\"10.1038/s41598-026-39483-7\",\"10.3390/toxins7041018\",\"10.1038/s41380-024-02477-w\",\"10.1021/acs.jnatprod.9b01061\",\"10.1111/bph.16466\",\"10.1271/bbb.90095\",\"10.1192/j.eurpsy.2022.2297\",\"10.1080/02791072.2024.2446445\",\"10.1615/intjmedmushr.v7.i12.280\",\"10.3390/ph18070989\",\"10.3390/ph18030380\",\"10.1002/jps.2600571006\",\"10.3390/jof8060598\",\"10.1055/s-2007-969526\",\"10.1520/jfs2004276\",\"10.1021/np50015a023\",\"10.1016/0378-8741(82)90013-7\",\"10.1002/jps.2600541104\",\"10.1002/jps.2600560132\",\"10.1002/jps.2600571007\",\"10.1016/s0015-3796(89)80023-x\",\"10.1002/cbic.202200249\",\"10.1016/j.jep.2023.117415\",\"10.1016/s0021-9673(01)99190-3\",\"10.1016/s0021-9673(01)81831-8\",\"10.1002/jobm.3620290608\",\"10.1016/s0379-0738(00)00211-5\",\"10.1021/acsomega.5c02751\",\"10.1016/j.talanta.2004.11.031\",\"10.1016/j.scijus.2018.08.005\",\"10.1016/j.aca.2023.342161\",\"10.1615/intjmedmushrooms.2024056373\",\"10.1016/j.forsciint.2003.08.009\",\"10.1520/jfs14725j\",\"10.1080/00032717908067906\",\"10.1016/0021-9673(92)80287-5\",\"10.1093/jat/22.1.45\",\"10.1515/znc-1988-7-806\",\"10.1016/s0021-9673(00)85700-3\",\"10.1016/s0021-9673(01)96375-7\",\"10.1016/s0015-3796(86)80079-8\",\"10.1016/s0007-1536(69)80066-5\",\"10.1016/s0378-4347(97)00127-8\",\"10.1016/j.talanta.2004.11.038\",\"10.1016/s1355-0306(06)71579-9\",\"10.1071/ch9700853\",\"10.1016/s0379-0738(98)00168-6\",\"10.1556/2054.2023.00332\",\"10.1124/jpet.122.001454\",\"10.1002/dta.2950\",\"10.1093/jaoacint/qsaf072\",\"10.1002/anie.201910175\",\"10.1016/j.biortech.2021.126157\",\"10.1007/s00253-018-9226-8\",\"10.3389/fsufs.2022.1026508\",\"10.1016/j.cub.2023.10.059\",\"10.3389/fmicb.2024.1337398\",\"10.1007/978-981-19-5041-4\",\"10.3390/f14020382\"],\"reference_count\":213,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167239267\",\"openalex_url\":\"https://openalex.org/W7167239267\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W113471454\",\"https://openalex.org/W294456830\",\"https://openalex.org/W1903260451\",\"https://openalex.org/W1948675593\",\"https://openalex.org/W1970807094\",\"https://openalex.org/W1977511640\",\"https://openalex.org/W1981430494\",\"https://openalex.org/W1983348446\",\"https://openalex.org/W1984431812\",\"https://openalex.org/W1984696579\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2002070445\",\"https://openalex.org/W2002488633\",\"https://openalex.org/W2009390034\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2012142575\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2027191929\",\"https://openalex.org/W2027679864\",\"https://openalex.org/W2031832463\",\"https://openalex.org/W2035946761\",\"https://openalex.org/W2045514302\",\"https://openalex.org/W2050577168\",\"https://openalex.org/W2057353445\",\"https://openalex.org/W2067240620\",\"https://openalex.org/W2067405887\",\"https://openalex.org/W2074146187\",\"https://openalex.org/W2080507858\",\"https://openalex.org/W2081244857\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093746690\",\"https://openalex.org/W2094530511\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2108432873\",\"https://openalex.org/W2111452082\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2126698385\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2135562277\",\"https://openalex.org/W2143976354\",\"https://openalex.org/W2164453648\",\"https://openalex.org/W2164981793\",\"https://openalex.org/W2165984877\",\"https://openalex.org/W2166997091\",\"https://openalex.org/W2332145281\",\"https://openalex.org/W2333398807\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2409505272\",\"https://openalex.org/W2549512121\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2741562499\",\"https://openalex.org/W2745417039\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2797787314\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2883434454\",\"https://openalex.org/W2888502690\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2907562503\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2917218353\",\"https://openalex.org/W2951080359\",\"https://openalex.org/W2958413903\",\"https://openalex.org/W2969627127\",\"https://openalex.org/W2971683016\",\"https://openalex.org/W2975681496\",\"https://openalex.org/W2983552824\",\"https://openalex.org/W2988070888\",\"https://openalex.org/W3004910645\",\"https://openalex.org/W3007379062\",\"https://openalex.org/W3008629222\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3036680904\",\"https://openalex.org/W3092151265\",\"https://openalex.org/W3094690508\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W3156510154\",\"https://openalex.org/W3207288198\",\"https://openalex.org/W3211089224\",\"https://openalex.org/W3211842562\",\"https://openalex.org/W4200583144\",\"https://openalex.org/W4210474529\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4221018864\",\"https://openalex.org/W4225114051\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4280616839\",\"https://openalex.org/W4281253144\",\"https://openalex.org/W4281661929\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4283719838\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4290756542\",\"https://openalex.org/W4291383525\",\"https://openalex.org/W4293802544\",\"https://openalex.org/W4294203445\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4304004488\",\"https://openalex.org/W4311448180\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4313343874\",\"https://openalex.org/W4317600184\",\"https://openalex.org/W4320729123\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4323294129\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4382931678\",\"https://openalex.org/W4385969211\",\"https://openalex.org/W4386069067\",\"https://openalex.org/W4386165916\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4388486766\",\"https://openalex.org/W4388714298\",\"https://openalex.org/W4388827052\",\"https://openalex.org/W4389306740\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4389912710\",\"https://openalex.org/W4390732376\",\"https://openalex.org/W4391177392\",\"https://openalex.org/W4391784419\",\"https://openalex.org/W4391817579\",\"https://openalex.org/W4391924240\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4392350911\",\"https://openalex.org/W4392888270\",\"https://openalex.org/W4393954510\",\"https://openalex.org/W4393993168\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396518351\",\"https://openalex.org/W4398182074\",\"https://openalex.org/W4399276098\",\"https://openalex.org/W4399897612\",\"https://openalex.org/W4399977372\",\"https://openalex.org/W4400043767\",\"https://openalex.org/W4400240547\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401981685\",\"https://openalex.org/W4402516078\",\"https://openalex.org/W4402564741\",\"https://openalex.org/W4402678596\",\"https://openalex.org/W4403450928\",\"https://openalex.org/W4403615858\",\"https://openalex.org/W4403628871\",\"https://openalex.org/W4405735206\",\"https://openalex.org/W4407157019\",\"https://openalex.org/W4407380636\",\"https://openalex.org/W4408041085\",\"https://openalex.org/W4408226956\",\"https://openalex.org/W4408591537\",\"https://openalex.org/W4409415903\",\"https://openalex.org/W4409449345\",\"https://openalex.org/W4409676357\",\"https://openalex.org/W4410005099\",\"https://openalex.org/W4410030136\",\"https://openalex.org/W4410444635\",\"https://openalex.org/W4410645269\",\"https://openalex.org/W4410946123\",\"https://openalex.org/W4411116696\",\"https://openalex.org/W4411961287\",\"https://openalex.org/W4411981579\",\"https://openalex.org/W4412073006\",\"https://openalex.org/W4412102657\",\"https://openalex.org/W4412138274\",\"https://openalex.org/W4412520959\",\"https://openalex.org/W4413116294\",\"https://openalex.org/W4413975935\",\"https://openalex.org/W4414031406\",\"https://openalex.org/W4414171615\",\"https://openalex.org/W4414267802\",\"https://openalex.org/W4415356003\",\"https://openalex.org/W4415775160\",\"https://openalex.org/W7128912015\"],\"authorships\":[{\"id\":\"https://openalex.org/A5079573410\",\"display_name\":\"Stefanie Enriquez-Geppert\",\"orcid\":\"https://orcid.org/0000-0001-7305-0111\"},{\"id\":\"https://openalex.org/A5139990795\",\"display_name\":\"Lisa Bevers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139974022\",\"display_name\":\"Arvid Rosander\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079289829\",\"display_name\":\"Peter Fodran\",\"orcid\":\"https://orcid.org/0000-0003-0348-8331\"},{\"id\":\"https://openalex.org/A5045686739\",\"display_name\":\"Vince Polito\",\"orcid\":\"https://orcid.org/0000-0003-3242-9074\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236520\",\"source_display_name\":\"Biomolecules\",\"landing_page_url\":\"https://doi.org/10.3390/biom16070983\",\"is_oa\":true}}}", "topic_tags": "Review Article,Animal Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7167239267" }, { "id": 3976, "title": "Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.", "normalized_title": "psilocybin as a transdiagnostic treatment for eating disorders and comorbid psychopathology implications for clinical nosology and research directions", "authors": "Koning E, Richard J, Keshen A.", "abstract": "ObjectiveEating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the implications for alternative nosological frameworks, trial design, and clinical care.MethodA narrative review was conducted synthesizing clinical, mechanistic, and conceptual literature on PT for EDs and common psychiatric comorbidities. Searches of academic databases were supplemented by hand-searching and clinical trial registries. Thematic synthesis focused on transdiagnostic clinical evidence, mechanistic theories, and implications for the Hierarchical Taxonomy of Psychopathology (HiTOP), Research Domain Criteria (RDoC), treatment development, and clinical trial design.ResultsPreliminary clinical evidence supports the feasibility, safety, and therapeutic effects of PT for EDs, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms (i.e., serotonergic receptor agonism, psychoplastogenic effects, neural network desynchronization) target shared vulnerabilities that map onto dimensional constructs in HiTOP (Emotional Dysfunction superspectrum, Internalizing spectrum) and RDoC (negative/positive valence, cognitive, and social process domains) nosologies. Future research should explore pragmatic trial designs and dimensional outcome measures to capture the real-world complexities of PT for EDs.DiscussionPT demonstrates transdiagnostic therapeutic potential for EDs, and the advancement of dimensional nosologies, complex intervention frameworks, and personalized treatment protocols may address existing gaps in research and clinical care.", "journal": "International Journal of Eating Disorders", "publication_date": "2026-07-01", "publication_year": 2026, "doi": "10.1002/eat.70164", "pubmed_id": "42393007", "source_url": "https://doi.org/10.1002/eat.70164", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-04 01:20:05", "last_checked": "2026-07-09 01:20:16", "raw_json": "{\"europe_pmc_id\":\"42393007\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167014213\",\"openalex_url\":\"https://openalex.org/W7167014213\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1191653087\",\"https://openalex.org/W1931781407\",\"https://openalex.org/W1944481685\",\"https://openalex.org/W1968733266\",\"https://openalex.org/W1969577526\",\"https://openalex.org/W1972883514\",\"https://openalex.org/W1976624064\",\"https://openalex.org/W1985513874\",\"https://openalex.org/W1986348004\",\"https://openalex.org/W2006378117\",\"https://openalex.org/W2007644698\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2030842831\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2052565335\",\"https://openalex.org/W2052804935\",\"https://openalex.org/W2080055550\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2095960650\",\"https://openalex.org/W2115430216\",\"https://openalex.org/W2118540296\",\"https://openalex.org/W2120654343\",\"https://openalex.org/W2140540881\",\"https://openalex.org/W2298540806\",\"https://openalex.org/W2339503814\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2599264051\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2733159797\",\"https://openalex.org/W2740567311\",\"https://openalex.org/W2795870103\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2888612576\",\"https://openalex.org/W2892307734\",\"https://openalex.org/W2896480657\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2908155319\",\"https://openalex.org/W2914496888\",\"https://openalex.org/W2914520605\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2979620240\",\"https://openalex.org/W2986368852\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3031144616\",\"https://openalex.org/W3049509808\",\"https://openalex.org/W3084249337\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3112525124\",\"https://openalex.org/W3120551831\",\"https://openalex.org/W3134803076\",\"https://openalex.org/W3135628799\",\"https://openalex.org/W3135635133\",\"https://openalex.org/W3136402846\",\"https://openalex.org/W3148497253\",\"https://openalex.org/W3153796079\",\"https://openalex.org/W3166604621\",\"https://openalex.org/W3194472989\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4200408156\",\"https://openalex.org/W4205400385\",\"https://openalex.org/W4210332402\",\"https://openalex.org/W4280584826\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4310942020\",\"https://openalex.org/W4318933953\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4362656963\",\"https://openalex.org/W4376279493\",\"https://openalex.org/W4381548553\",\"https://openalex.org/W4384154266\",\"https://openalex.org/W4385664009\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4386606492\",\"https://openalex.org/W4387019277\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389139111\",\"https://openalex.org/W4389975182\",\"https://openalex.org/W4390794276\",\"https://openalex.org/W4391893692\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4397049758\",\"https://openalex.org/W4398195443\",\"https://openalex.org/W4398782381\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4400364503\",\"https://openalex.org/W4401212791\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4403216984\",\"https://openalex.org/W4403509916\",\"https://openalex.org/W4404160271\",\"https://openalex.org/W4404286681\",\"https://openalex.org/W4404836981\",\"https://openalex.org/W4405376152\",\"https://openalex.org/W4406338182\",\"https://openalex.org/W4408186822\",\"https://openalex.org/W4408221975\",\"https://openalex.org/W4408328158\",\"https://openalex.org/W4409313347\",\"https://openalex.org/W4409449345\",\"https://openalex.org/W4409687073\",\"https://openalex.org/W4409729252\",\"https://openalex.org/W4411355052\",\"https://openalex.org/W4411969620\",\"https://openalex.org/W4412489091\",\"https://openalex.org/W4412570375\",\"https://openalex.org/W4413411862\",\"https://openalex.org/W4413839750\",\"https://openalex.org/W4414072214\",\"https://openalex.org/W4414745665\",\"https://openalex.org/W4415622018\",\"https://openalex.org/W4417031290\",\"https://openalex.org/W4417397706\",\"https://openalex.org/W7125961702\",\"https://openalex.org/W7128441230\",\"https://openalex.org/W7133234785\",\"https://openalex.org/W7134072318\",\"https://openalex.org/W7134891055\",\"https://openalex.org/W7135170485\",\"https://openalex.org/W7148242223\"],\"authorships\":[{\"id\":\"https://openalex.org/A5060209926\",\"display_name\":\"Elena Koning\",\"orcid\":\"https://orcid.org/0000-0001-5241-0288\"},{\"id\":\"https://openalex.org/A5006203775\",\"display_name\":\"Jérémie Richard\",\"orcid\":\"https://orcid.org/0000-0001-9893-1353\"},{\"id\":\"https://openalex.org/A5023552725\",\"display_name\":\"Aaron Keshen\",\"orcid\":\"https://orcid.org/0000-0003-0462-9749\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S74080386\",\"source_display_name\":\"International Journal of Eating Disorders\",\"landing_page_url\":\"https://doi.org/10.1002/eat.70164\",\"is_oa\":false}}}", "topic_tags": "Eating Disorders,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7167014213" }, { "id": 3662, "title": "Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms", "normalized_title": "efficacy in relapse prevention psilocybin in alcohol use disorder with depressive symptoms", "authors": "Centre Hospitalier Universitaire de Nīmes", "abstract": "Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \\[0.16-1.65\\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-30", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07638553", "keywords": "Alcohol Use Disorder, Depressive Sympotoms, Psilocybin, Psilocybin (high dose), Psilocybin (low dose), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-07 01:23:04", "raw_json": "{\"nct_id\":\"NCT07638553\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3547, "title": "A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)", "normalized_title": "a phase 2 open label study investigating the safety and efficacy of psilocybin assisted therapy for sexual assault related posttraumatic stress disorder ptsd", "authors": "Sunstone Medical", "abstract": "A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-30", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06902974", "keywords": "Post Traumatic Stress Disorder, PTSD, Psilocybin 25 mg, Psilocybin-assisted therapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-07 01:23:04", "raw_json": "{\"nct_id\":\"NCT06902974\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 107, "title": "Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.", "normalized_title": "implementing psilocybin assisted therapy in palliative care settings a survey of stakeholders", "authors": "Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group", "abstract": "While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges. To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and facilitators to its implementation. We conducted a cross-sectional online survey between April 15 and December 18, 2024. The survey assessed perceived knowledge, attitudes, and perceived barriers and facilitators to the effective integration of psilocybin-assisted therapy into palliative care settings. One hundred and twenty-one adults involved in palliative care (physicians, other healthcare professionals, caregivers, and managers) were recruited from Canada's four most populous provinces: Québec, Ontario, Alberta, and British Columbia. Forty-three percent of stakeholders reported having good knowledge of psilocybin's potential benefits and risks. Attitudes towards psilocybin-assisted therapy were predominantly non-favourable (61%), yet varied across occupational groups ( Translating the potential of psilocybin-assisted therapy for existential distress from clinical trials into palliative care settings requires careful consideration and collaboration with stakeholders. Given the significant divergence in perspectives between clinical and non-clinical groups, tailored interprofessional education could help build shared understanding and support effective implementation. Being conducted in Canada, transferability to different regulatory frameworks may be limited.", "journal": "Palliative medicine", "publication_date": "2026-06-30", "publication_year": 2026, "doi": "10.1177/02692163261446141", "pubmed_id": "42154482", "source_url": "https://pubmed.ncbi.nlm.nih.gov/42154482/", "keywords": "attitude of health personnel, hallucinogens, palliative care, psilocybin, surveys and questionnaires", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-08 01:20:05", "raw_json": "{\"pubmed_id\":\"42154482\"}", "topic_tags": "End-of-Life Distress,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 303, "title": "Study Protocol for \"Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults\".", "normalized_title": "study protocol for exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults", "authors": "Sjöström D, Schau Rybäck O, Claesdotter Knutsson E, Kajonius P, Jensen Sondén O, Carlbring P, Björkstrand J, Movahed Rad P.", "abstract": "BackgroundAnorexia nervosa (AN) is a severe psychiatric disorder with high morbidity, mortality, and relapse rates, most commonly emerging during adolescence. Despite specialized psychological and nutritional treatments, outcomes remain suboptimal, with high rates of relapse and chronicity. Psilocybin has been investigated with preliminary efficacy in other psychiatric conditions characterized by rigidity and treatment resistance, but clinical evidence in AN-particularly in adolescents-is limited.ObjectiveThe psiAN study aims to evaluate the safety, tolerability, and feasibility of psilocybin therapy combined with psychological support in adolescents and young adults with relapsing AN, while exploring clinical, experiential, and neurobiological correlates of change.MethodsA phase IIa, open-label, randomized controlled trial enrolling individuals aged 16-35 years with DSM-5 AN and a history of relapse. Participants are randomized to receive either two administrations of psilocybin (25 mg) with manualized psychological support plus treatment as usual (TAU), or TAU alone. Primary outcomes focus on safety and tolerability, assessed through adverse events, psychiatric monitoring, and medical parameters measured from first dosing to primary endpoint. Secondary outcomes include change in eating disorder symptom severity, relapse composite measures, mood, well-being, personality traits from baseline to primary endpoint with follow-up to 12 months. Functional magnetic resonance imaging (fMRI) and peripheral brain-derived neurotrophic factor are included as exploratory mechanistic measures. fMRI will evaluate pre- to post-intervention changes in structural and functional connectivity and task-related responses during a simplified Monetary Incentive Delay task (MIDT) and a Calorie-Cue Task (CCT). ClinicalTrials.gov Identifier: NCT07169747.Ethics and disseminationThe study follows Good Clinical Practice (GCP), the Declaration of Helsinki, and EU Clinical Trials Regulation requirements, with staged inclusion of adolescents (16-17-year-olds) after a safety board review of adult data (18-35-year-olds). This protocol was prepared with reference to the SPIRIT 2025 guidelines (Chan et al., 2025) to enhance transparency and inform future trials.", "journal": "PLoS ONE", "publication_date": "2026-06-29", "publication_year": 2026, "doi": "10.1371/journal.pone.0352246", "pubmed_id": "42378255", "source_url": "https://doi.org/10.1371/journal.pone.0352246", "keywords": "Humans, Hallucinogens, Treatment Outcome, Anorexia Nervosa, Adolescent, Adult, Female, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Young Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:03", "last_checked": "2026-07-07 01:20:41", "raw_json": "{\"europe_pmc_id\":\"42378255\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166779507\",\"openalex_url\":\"https://openalex.org/W7166779507\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W808601510\",\"https://openalex.org/W1650564827\",\"https://openalex.org/W1827685313\",\"https://openalex.org/W1932805014\",\"https://openalex.org/W1967922673\",\"https://openalex.org/W1972412818\",\"https://openalex.org/W1992829239\",\"https://openalex.org/W2001008250\",\"https://openalex.org/W2003015777\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2027828087\",\"https://openalex.org/W2029342244\",\"https://openalex.org/W2042181481\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2093980670\",\"https://openalex.org/W2103167256\",\"https://openalex.org/W2109309568\",\"https://openalex.org/W2110534460\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2129493600\",\"https://openalex.org/W2131615411\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2139888794\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2162090451\",\"https://openalex.org/W2162686834\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2397026969\",\"https://openalex.org/W2407700395\",\"https://openalex.org/W2481387317\",\"https://openalex.org/W2528004326\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2602783119\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2753989225\",\"https://openalex.org/W2766441616\",\"https://openalex.org/W2793484468\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2901877120\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2926851885\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2950670678\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3012274617\",\"https://openalex.org/W3022725218\",\"https://openalex.org/W3082850425\",\"https://openalex.org/W3124410800\",\"https://openalex.org/W3132244982\",\"https://openalex.org/W3162130219\",\"https://openalex.org/W3195156262\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4206759226\",\"https://openalex.org/W4210956615\",\"https://openalex.org/W4220722752\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4224069788\",\"https://openalex.org/W4225257168\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4292994367\",\"https://openalex.org/W4295048117\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313251651\",\"https://openalex.org/W4313593941\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4323108445\",\"https://openalex.org/W4323312401\",\"https://openalex.org/W4323846866\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4380080162\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4380684709\",\"https://openalex.org/W4381548553\",\"https://openalex.org/W4386541001\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4391540455\",\"https://openalex.org/W4392762192\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4395038625\",\"https://openalex.org/W4395110324\",\"https://openalex.org/W4395688958\",\"https://openalex.org/W4396744370\",\"https://openalex.org/W4396893361\",\"https://openalex.org/W4399525469\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4400767446\",\"https://openalex.org/W4401411513\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4402993015\",\"https://openalex.org/W4405955644\",\"https://openalex.org/W4406946828\",\"https://openalex.org/W4406959828\",\"https://openalex.org/W4407269486\",\"https://openalex.org/W4408518438\",\"https://openalex.org/W4410539818\",\"https://openalex.org/W4410748059\",\"https://openalex.org/W4411913879\",\"https://openalex.org/W4412722688\",\"https://openalex.org/W4413411862\",\"https://openalex.org/W4413938545\",\"https://openalex.org/W4414152565\",\"https://openalex.org/W7130402425\",\"https://openalex.org/W7134902434\"],\"authorships\":[{\"id\":\"https://openalex.org/A5057871065\",\"display_name\":\"David K. Sjöström\",\"orcid\":\"https://orcid.org/0000-0003-0004-1892\"},{\"id\":\"https://openalex.org/A5073798116\",\"display_name\":\"Olea Schau Rybäck\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111008178\",\"display_name\":\"Emma Claesdotter Knutsson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135752675\",\"display_name\":\"Petri Kajonius\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139709727\",\"display_name\":\"Oskar Jensen Sondén\",\"orcid\":null},{\"id\":\"https://openalex.org/A5082635131\",\"display_name\":\"Per Carlbring\",\"orcid\":\"https://orcid.org/0000-0002-2172-8813\"},{\"id\":\"https://openalex.org/A5017431485\",\"display_name\":\"Johannes Björkstrand\",\"orcid\":\"https://orcid.org/0000-0002-1786-1064\"},{\"id\":\"https://openalex.org/A5018302853\",\"display_name\":\"Pouya Movahed\",\"orcid\":\"https://orcid.org/0000-0003-2041-3550\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S202381698\",\"source_display_name\":\"PLoS ONE\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pone.0352246\",\"is_oa\":true}}}", "topic_tags": "Eating Disorders,Brain Imaging,Aging,Wellbeing,Personality Change,Clinical Trial,Randomized Controlled Trial,Review Article,Adolescents,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7166779507" }, { "id": 3979, "title": "Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development", "normalized_title": "naturally derived psilocybin for therapeutic use a six criterion framework for evidence safety and benefit risk considerations in policy and clinical development", "authors": "Stefanie Enriquez Geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito", "abstract": "", "journal": "University of Groningen research database (University of Groningen / Centre for Information Technology)", "publication_date": "2026-06-28", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://research.rug.nl/en/publications/370a82bd-d8db-4a02-b644-bf0c9131680b", "keywords": "Psilocybin, Drug development, Psychology, Medicine, Psychotherapist, MEDLINE, Psychiatry, Clinical trial, Intensive care medicine, Perspective (graphical), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 01:20:27", "last_checked": "2026-07-06 01:20:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7167168218\",\"openalex_url\":\"https://openalex.org/W7167168218\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5139873851\",\"display_name\":\"Stefanie Enriquez Geppert\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139893961\",\"display_name\":\"Lisa Bevers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139856970\",\"display_name\":\"Arvid Rosander\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079289829\",\"display_name\":\"Peter Fodran\",\"orcid\":\"https://orcid.org/0000-0003-0348-8331\"},{\"id\":\"https://openalex.org/A5045686739\",\"display_name\":\"Vince Polito\",\"orcid\":\"https://orcid.org/0000-0003-3242-9074\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400420\",\"source_display_name\":\"University of Groningen research database (University of Groningen / Centre for Information Technology)\",\"landing_page_url\":\"https://research.rug.nl/en/publications/370a82bd-d8db-4a02-b644-bf0c9131680b\",\"is_oa\":false}}", "topic_tags": "Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7167168218" }, { "id": 3561, "title": "The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease", "normalized_title": "the efficacy of psilocybin therapy for depression in parkinson s disease", "authors": "Yale University", "abstract": "The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy. This is a randomized controlled trial of oral psilocybin therapy for depression in people with Parkinson's disease (PD). The primary goal is to examine efficacy of psilocybin therapy in this patient population. Investigators will enroll participants with clinically diagnosed early to moderate stage Parkinson's disease (Hoehn and Yahr Stage 1-3 during an \"on\" period), who meet criteria for moderate or greater depression severity and meet all other inclusion and exclusion criteria at screening. Participants will complete two drug administration sessions where they will each receive a dose of oral psilocybin ranging from low (\"microdose\") to high in a medically monitored setting with psychotherapeutic support. Participants will also complete a series of psychotherapy sessions before and after each drug administration session. Clinical assessments will be used to quantify changes in depression as well as other relevant outcomes (non-motor and motor symptoms of PD, cognitive performance, quality of life). Follow-up will continue to 3 months after the second session. Endpoints will evaluate efficacy, safety, and tolerability of study procedures. After posting of these trial results, this data will be combined with the data from the trial at UCSF (NCT06455293) for publication purposes.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-28", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07610369", "keywords": "Depression, Parkinson's Disease (PD), Psilocybin (drug), 4-phosphoryloxy- N, N-dimethyltryptamine, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-05 01:22:40", "raw_json": "{\"nct_id\":\"NCT07610369\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Microdosing,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3621, "title": "Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial", "normalized_title": "psilocybin assisted massed cognitive processing therapy for chronic posttraumatic stress disorder an open label trial", "authors": "Unity Health Toronto", "abstract": "This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD). Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD. Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-25", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06386003", "keywords": "Post Traumatic Stress Disorder, PTSD, Chronic PTSD, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-02 23:06:03", "raw_json": "{\"nct_id\":\"NCT06386003\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3522, "title": "Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]", "normalized_title": "psilocybin assisted therapy for physician well being and burnout feasibility safety clinical effectiveness and biomarkers of response pat b psilocybin assisted therapy for physician well being and burnout", "authors": "University of California, San Diego", "abstract": "Through an open-label study involving a small group of UCSD physicians experiencing burnout, the investigators will evaluate the feasibility, safety, and preliminary effectiveness of PAT to reduce burnout symptoms. Physician burnout is a critical issue. Research shows that physician burnout is increasing, that physicians suffer higher rates of burnout than the general population, and that physician burnout is associated with poor mental health outcomes. Psilocybin is a naturally occurring alkaloid within certain fungi that elicits acute perceptual, cognitive, and emotional changes when ingested, due to action on neurotransmitter and neurocirculatory systems. The combination of psilocybin with psychological support, termed Psilocybin-Assisted Therapy (PAT), is a promising new mental health intervention shown to produce rapid and sustained improvements in psychological domains affected in burnout. PAT demonstrates preliminary efficacy as a treatment for depression and substance use disorders, is associated with brain changes measured with electroencephalography (EEG) and is a strong candidate treatment for physician burnout. The primary aim of this study is to investigate the safety, feasibility, and preliminary efficacy of PAT to enhance well-being in University of California, San Diego (UCSD) physicians experiencing burnout. A secondary aim is to identify neurophysiological changes associated with response to PAT. Physicians experiencing burnout will be recruited in an open-label trial involving preparatory therapy sessions, psilocybin treatment, and post-treatment integration. Burnout will be measured with the Stanford Professional Fulfillment Index (PFI).", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-25", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06814522", "keywords": "Burnout, Burnout, Healthcare Workers, Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-02 23:06:03", "raw_json": "{\"nct_id\":\"NCT06814522\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Addiction,Brain Imaging,Biomarkers,Wellbeing,Emotional Processing,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3595, "title": "Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects", "normalized_title": "acute effects of mdma co administration on the response to psilocybin in healthy subjects", "authors": "University Hospital, Basel, Switzerland", "abstract": "The acute subjective effects of serotonin (5-HT)2A receptor stimulation with psilocybin in humans are mostly positive. However, negative effects such as anxiety, paranoid thinking, or loss of trust towards other people are common effects, depending on the dose administered, the personality traits of the person consuming it (set), or the environment in which psilocybin is taken (setting). Negative psychedelic effects may cause acute distress to the subject and acute anxiety has been linked to less favorable long-term outcomes in patients experimentally treated with psilocybin or similar substances for the treatment of depression. The 5-HT and oxytocin releaser 3,4-methylenedioxymethamphetamine (MDMA) reliably induces positive mood, euphoria, comfort, empathy, and feelings of trust. If administered in combination with psilocybin, MDMA may increase positive subjective drug effects including positive mood, empathy, and trust and reduce negative emotions and anxiety associated with psilocybin and overall produce a more positive over negative experience. The present study will assess subjective and autonomic effects of psilocybin alone and in combination with MDMA. Psilocybin is a classic serotonergic psychedelic. Clinically, the acute effects of psilocybin last shorter than those of lysergic acid diethylamide (LSD) but are qualitatively very similar. Currently, psilocybin is the most investigated psychedelic substance among the classic psychedelics including LSD, psilocybin, mescaline, and dimethyltryptamine (DMT). Psilocybin is capable of inducing exceptional subjective effects such as a dream-like alteration of consciousness, affective changes, psychological insight, visual imagery, pseudo-hallucinations and ego-dissolution. The acute subjective effects elicited by psilocybin are mostly positive in humans. However, psychedelic substances like psilocybin may also cause unpleasant subjective effects like negative thoughts, rumination, anxiety, panic, paranoia, loss of trust towards other people and perceived loss of control, depending on the dose of psilocybin used, the personality traits of the person consuming it (i.e. 'set'), the environment in which it is consumed (i.e. 'setting'), and other factors. Acute negative psychological effects are considered the main risk of psychedelic substance use in humans. Inducing an overall positive acute response to the psychedelic is critical because several studies showed that a more positive experience is predictive of a greater therapeutic long-term effect of the psychedelic. The present study uses 3,4-methylenedioxymethamphetamine (MDMA) as a pharmacological tool to optimize the effects of psilocybin by inducing positive mood. MDMA is an amphetamine derivative which, unlike prototypical amphetamines, predominantly enhances serotonergic neurotransmission via release of 5-HT through the serotonin transporter (SERT). Furthermore, MDMA is known to trigger oxytocin release which may contribute to its effects to increase trust, prosociality, and enhanced empathy. The state of well-being induced by MDMA including increased activation and emotional excitation is known to be associated with a better response to psychedelics. Due to its psychological profile, MDMA could be a reliable pharmacological tool to serve as an optimizer of a psychedelic experience by inducing positive emotions.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-24", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06884514", "keywords": "Healthy, Psilocybin, 3,4-Methylenedioxymethamphetamine, Psilocybin placebo, 3,4-Methylenedioxymethamphetamine placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 23:13:10", "raw_json": "{\"nct_id\":\"NCT06884514\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,Addiction,Receptor Pharmacology,Consciousness,Wellbeing,Personality Change,Emotional Processing,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 30, "title": "The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.", "normalized_title": "the intersection between psychedelics and schizophrenia spectrum disorders reevaluating risk and therapeutic potential", "authors": "Brar PS, Price RB, Ross S, Tofighi B, Sarpal DK", "abstract": "In the past decade, interest in studying psychedelic compounds as potential therapeutic agents has resurged. These studies carefully exclude individuals at risk for developing psychotic symptoms in response to psychedelic use. Given the potential for psychedelics to be established as treatments in psychiatry, it is important to more robustly understand their link with psychosis and schizophrenia spectrum disorders (SSDs). In this narrative review, we examine the historical and theoretical relationship between psychedelic drugs and SSDs, including the origins of the psychotomimetic hypothesis. For key psychedelic compounds, we review their phenomenological manifestations in relation to the experiential alterations characteristic of SSDs, revealing both areas of overlap and important qualitative differences that challenge the uniform psychotomimetic classification. We also review putative neural mechanisms underlying altered experiential states associated with psychedelic use and SSDs, with attention to serotonergic, dopaminergic, and glutamatergic contributions. Clinical evidence demonstrates that psychedelics can exacerbate pre-existing psychotic illness and may trigger psychosis in vulnerable individuals, though the magnitude of these risks remains inadequately quantified. However, phenomenological and mechanistic distinctions suggest that potential therapeutic applications may exist for carefully selected symptoms (negative symptoms, depression) in stable patients using low-dose, controlled approaches. Based on published work, we provide recommendations regarding psychosis-related risk and potential avenues for the treatment of SSDs as psychedelics gain traction as therapeutics.", "journal": "Journal of psychopharmacology (Oxford, England)", "publication_date": "2026-06-24", "publication_year": 2026, "doi": "10.1177/02698811261456191", "pubmed_id": "42345450", "source_url": "https://pubmed.ncbi.nlm.nih.gov/42345450/", "keywords": "DMT, LSD, mescaline, phenomenology, psilocybin, psychedelics, psychosis, schizophrenia", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-02 23:03:18", "raw_json": "{\"pubmed_id\":\"42345450\"}", "topic_tags": "Depression,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3684, "title": "TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy", "normalized_title": "trip treatment to improve depression and or anxiety using psilocybin assisted psychotherapy in patients with advanced cancer on maintenance therapy", "authors": "M.D. Anderson Cancer Center", "abstract": "To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer. Primary Objective To examine the feasibility, safety, effect size estimates of psilocybin-assisted psychotherapy for participants with depression and/or anxiety who are being actively treated for advanced cancer. Feasibility will be measured as: At least 20% of eligible participants consent and at least 60% of consented participants complete the two doses of treatment. Secondary Objectives 1. Determine whether psilocybin-assisted psychotherapy improves measures of quality of life (e.g., sleep, pain, functional status) and psychosocial well-being (e.g., finding meaning and post-traumatic growth), as measured by the following: PHQ-9, GAD-7, PROMIS-10, PROMIS-A, PROMIS-D, MEQ30 (mystical experience), Flourishing scale, mDES, 5D-ASC (altered states), and Posttraumatic Growth Inventory. 2. Determine whether psilocybin-assisted psychotherapy improves functional status per clinician-rated outcome measures. 3. Assess the effects of psilocybin-assisted psychotherapy on cancer treatment adherence determined by the likelihood that participants will follow the prescribed treatment (adherence) and continue the treatment for the duration prescribed (persistence) for these maintenance therapies. 4. Measure the change in inflammatory markers (IL6, TNF, and CRP) and in frequency and activation status of peripheral immune cell populations assessed by immune monitoring through flow cytometry. 5. Examine changes in central nervous system plasticity through the use of fMRI, specifically changes in 5-HT2A-rich and higher-order functional networks, as well as a global increase in brain network integration. 6. Evaluate the Impact on MDASI measurements.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-23", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06200155", "keywords": "Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer, Psilocybin, Niacin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06200155\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Chronic Pain,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Biomarkers,Wellbeing,Mystical Experience,Healthcare Workers,Safety,Inflammation,Immune Function", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3674, "title": "TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors", "normalized_title": "trips treatment to improve depression and or anxiety using psilocybin assisted psychotherapy in cancer survivors", "authors": "M.D. Anderson Cancer Center", "abstract": "This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety. Primary Objective: To examine the feasibility, safety, effect size estimates of psilocybin-assisted psychotherapy for cancer survivor patients with depression and/or anxiety. Feasibility will be measured as: At least 20% of eligible patients consent (inclusion rate), at least 60% of consented patients completing the two doses of treatment (treatment completion rate), and at least 80% and 65% consenting patients completing assessments at the 2- and 6-month follow-ups (adherence rates), respectively. Secondary Objectives: 1. Determine whether psilocybin-assisted psychotherapy improves measures of quality of life (e.g., sleep, pain, functional status) and psychosocial well-being (e.g., finding meaning and post-traumatic growth), as measured by the following: PHQ-9, GAD-7, PROMIS-10, PROMIS-A, PROMIS-D, MEQ30 (mystical experience), Flourishing scale, mDES, PIQ (altered states), and Posttraumatic Growth Inventory. 2. Determine whether psilocybin-assisted psychotherapy improves functional status per clinician-rated outcome measures. 3. Measure the change in inflammatory markers (IL6, TNF, and CRP) and in frequency and activation status of peripheral immune cell populations assessed by immune monitoring through flow cytometry. 4. Examine changes in central nervous system plasticity through the use of fMRI, specifically changes in 5-HT2A-rich and higher-order functional networks, as well as a global increase in brain network integration. 5. Evaluate the Impact on MDASI measurements.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-23", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06801041", "keywords": "Depression, Anxiety, Cancer, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06801041\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Chronic Pain,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Biomarkers,Wellbeing,Mystical Experience,Healthcare Workers,Safety,Inflammation,Immune Function", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3705, "title": "Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study", "normalized_title": "effects of psilocybin microdosing on cognition mood and quality of life a pilot study", "authors": "Yale University", "abstract": "This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences. This study is being conducted to evaluate the effects of 30 days of intermittently microdosed psilocybin in a parallel arm double-blind manner on mood, cognition, subjective well-being and structural/functional MRI compared to placebo, using validated psychological assessments and cognitive tests. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences. Demonstrating significant results in a population of healthy psychedelic non-users will establish a strong precedent for studying the effects of microdosing psychedelics in patient populations, such as those with treatment-resistant depression. Showing that microdosing minimizes risk of adverse outcomes with psychedelic treatment while maintaining beneficial effects would provide useful information relevant to clinical research in psychedelic-assisted psychotherapy. In addition to investigating claims that microdosing psychedelics may improve cognition and mood, this study also aims to test the hypothesis that these effects including those measurable at a brain level may persist beyond the course of the 30 days of the study. There are few to no studies that assessed the longevity of psychedelic effects on the majority of the above measures, so the proposed study may further establish the longer-term benefits of microdosing. The use of structural and functional magnetic resonance imaging (fMRI) will elucidate the mechanisms by which microdosing may be exerting its effects on mood and cognition. Because this is a relatively understudied area, information gleaned from this study will provide service in informing the field in general.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-22", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07449351", "keywords": "Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI, Psliocybin, Placebo, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07449351\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Depression,Brain Imaging,Mechanism of Action,Aging,Longevity,Microdosing,Wellbeing,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3650, "title": "Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial", "normalized_title": "psilocybin assisted existential attachment and relational pearl therapy for caregivers of patients with advanced cancer a phase ii open label trial", "authors": "University Health Network, Toronto", "abstract": "The PEARL-C1 trial is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy. Caregivers of patients with advanced cancer often experience high levels of distress but there is currently little evidence-based guidance on how to help caregivers who experience depression, anxiety, anticipatory grief, spiritual suffering, caregiving burden and/or impaired quality of life. Over the past decade, research has shown that psychotherapies incorporating existential, attachment and relational approaches can address the specific needs and challenges of the advanced cancer population and thus help to reduce related distress. Simultaneously, recent research has shown that psilocybin-assisted psychotherapy, in which an individual ingests the psychoactive drug within a carefully monitored therapy, can reduce end-of-life distress and greatly benefit those with advanced disease. The multidisciplinary team has combined these two evidence-based approaches into Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory therapy sessions, a high-dose drug session, and integration sessions, with important elements from manualized individual psychotherapies designed for patients and their families facing advanced cancer. This study will assess the feasibility, acceptability, and safety of PEARL therapy among caregivers of patients with advanced cancer. This study will contribute to the growing research around the efficacy of psychedelic-assisted therapies for the psychological distress associated with advanced disease and mortality. This type of therapy has the potential to improve quality of life among caregivers of those with advanced disease, to build upon previous findings to help outline the necessary components of therapy, and to inform public policy and clinical guidelines.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-22", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07048743", "keywords": "Caregiver Distress, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07048743\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Spirituality,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 33, "title": "Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.", "normalized_title": "cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department a european drug emergencies network euro den plus study", "authors": "van den Busken WJ, Dines AM, Eyer F, Heyerdahl F, Hovda KE, Liechti ME, Miró Ò, Vallersnes OM, Wood DM, Yates C, Dargan PI, (on behalf of the Euro-DEN Plus Research Group), Gresnigt FMJ, Euro-DEN Plus Research Group", "abstract": "Recreational drugs affect the cardiovascular system through distinct mechanisms; however, data regarding their cardiovascular impact in the emergency department setting is limited. This study aimed to assess the incidence of cardiovascular effects following recreational drug use in presentations to the emergency department, identify the main drug groups involved, and compare cases with and without cardiovascular effects. Data were extracted from the European Drug Emergency Network (Euro-DEN Plus) dataset from October 2013 to December 2021. Recreational drugs were categorised into ten main drug groups: opioids, cocaine, crack cocaine, cannabis, 3,4-methylenedioxymethamfetamine, amfetamine-type stimulants, gamma-hydroxybutyrate and gamma-butyrolactone, hallucinogens, benzodiazepines, and ketamine. Among 59,571 presentations, 13,905 (23.3%) involved cardiovascular effects. Cocaine (OR3.19, 95% CI2.99-3.39) and 3,4 methylenedioxymethamphetamine (OR1.18, 95% CI1.13-1.23) showed the strongest associations with cardiovascular features, including chest pain, palpitations, hypertension, and arrhythmias. Opioids (OR0.35, 95% CI0.31-0.38) and benzodiazepines (OR0.38, 95% CI0.32-0.44) were associated with less frequent cardiovascular features. Patients with cardiovascular features exhibited higher median values for temperature, heart rate, blood pressure, and respiratory rate (p Cardiovascular effects were common in acute recreational drug toxicity. Cocaine and amfetamine-type stimulants increased the risk of chest pain and arrhythmias, with chest pain being a key indicator of acute coronary syndrome. Cardiovascular effects were more frequently observed with cocaine than with crack cocaine. Cannabis was positively associated with palpitations but not arrhythmias. Gamma-hydroxybutyrate and gamma-butyrolactone, opioids, and benzodiazepines were linked to hypotension. The presence of cardiovascular effects was associated with worse outcomes, underscoring the need for thorough cardiac assessment. Cardiovascular effects were present in almost a quarter of emergency department presentations with acute recreational drug toxicity, particularly involving cocaine and 3,4 methylenedioxymethamphetamine.", "journal": "Clinical toxicology (Philadelphia, Pa.)", "publication_date": "2026-06-22", "publication_year": 2026, "doi": "10.1080/15563650.2026.2669671", "pubmed_id": "42334445", "source_url": "https://pubmed.ncbi.nlm.nih.gov/42334445/", "keywords": "3,4 methylenedioxymeth­amphetamine, acute drug toxicity, amfetamine, amfetamine (amphetamine), amphetamine, cardio­vascular, cocaine, lysergide (lyseric acid diethylamide), midamafetamine (3,4 methylenedioxymethamphetamine, midomafetamine, psilocybine (psilocybin)", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:34", "raw_json": "{\"pubmed_id\":\"42334445\"}", "topic_tags": "Addiction,Chronic Pain,Mechanism of Action,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3574, "title": "Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids", "normalized_title": "low dose psilocybin therapy for palliative care patients with chronic cancer pain requiring opioids", "authors": "Roswell Park Cancer Institute", "abstract": "This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's \"total pain\", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain. PRIMARY OBJECTIVE: I. To evaluate the safety, tolerability, and feasibility of low dose psilocybin therapy in patients with chronic cancer pain who require opioids. SECONDARY OBJECTIVE: I. To obtain preliminary evidence for efficacy of low dose psilocybin therapy in reducing pain and opioid requirement in participants with chronic cancer pain. EXPLORATORY OBJECTIVES: I. To evaluate potential mechanisms of action for psilocybin in pain control, including its effects on resting brain network activity, inflammation, and psychological changes processes. II. To obtain preliminary evidence for efficacy of psilocybin therapy on additional outcomes related to pain control, physical function, and opioid requirement in participants with chronic cancer pain. III. To obtain preliminary evidence for efficacy of low dose psilocybin therapy in alleviating psychological symptoms associated with chronic cancer pain. IV. To evaluate potential mechanisms of action for low dose psilocybin therapy in pain control, including its effects on the following: resting brain network activity, inflammation, psychological processes and psychedelic effects. OUTLINE: Patients attend two preparatory psychotherapy sessions. Patients then receive psilocybin orally (PO) twice a week (BIW) for 4 weeks (8 doses total) in the absence of unacceptable toxicity and attend three integration psychotherapy sessions over 1.5 hours each during psilocybin dosing sessions 2, 4, and 6. Patients may optionally attend additional psychotherapy sessions as needed during follow-up. Additionally, patients undergo functional magnetic resonance imaging (fMRI) and collection of blood and urine samples throughout the study. After completion of study intervention, patients are followed up at days 28-34, 56, and 84.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06827054", "keywords": "Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Functional Magnetic Resonance Imaging, fMRI, Functional MRI, Interview, Psilocybine, CY-39, Indocybin, Psilocybin, Psychotherapy, talk therapy, Questionnaire Administration, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06827054\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,End-of-Life Distress,Chronic Pain,Brain Imaging,Mechanism of Action,Aging,Spirituality,Clinical Trial,Cancer Patients,Safety,Toxicity,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3471, "title": "Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy", "normalized_title": "psilocybin for ptsd with or without psychotherapy a pilot study of safety and efficacy", "authors": "Johns Hopkins University", "abstract": "The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin. This study uses a randomized controlled design to compare the safety and efficacy of 2 doses of psilocybin for PTSD. In addition, it will investigate the effects of trauma-focused psychotherapy (which includes standard psychological support) versus standard psychological support alone. Twenty participants will be recruited. Following the first psilocybin session, participants will be randomized to either the trauma-focused psychotherapy (which includes standard psychological support) treatment condition or the standard psychological support treatment condition (the latter being typical for the experimental administration of psilocybin therapy). Both groups will receive identical treatment prior to receiving the first dose of psilocybin, with one group receiving procedures related to trauma-focused psychotherapy (combined with standard psychological support) beginning after receipt of psilocybin. The study will include clinician and participant ratings of PTSD and mood symptoms pre- and post-drug session and monitor and participant ratings of subjective drug effects during and after each drug session. The intervention for both groups will consist of about 8 hours of preparatory meetings (over approximately 2 weeks), followed by 2 psilocybin sessions separated by approximately 2 weeks. The initial psilocybin dose will be 25 mg. The dose for the second session may be increased conditional on the strength of subjective effects, as measured by the Mystical Experiences Questionnaire (MEQ30), taken at the end of participants' first psilocybin session. This allows a dose to increase if, for example, concomitant serotonin reuptake inhibitors reduce subjective effects. Participants with a score ≥60% of the maximum on the MEQ30 will remain at a dose of 25 mg of psilocybin for the second session. Participants with an MEQ30 score below 60% will receive a dose of 40 mg for the second session. Elevation of dose will also be based on the clinical judgment of the principal investigator, study physician, and study staff that a higher dose can be safely administered. In addition, participants who prefer to not elevate the dose will remain at 25 mg for the second session. To support the participant's therapeutic integration of psilocybin experiences, following each psilocybin session, participants will meet with the session facilitator(s) at multiple scheduled time points. Additional contact hours will be scheduled if it is judged that the participant would benefit from additional meetings to discuss experiences from the session(s) or to prepare for the next session. This study is supported in part by philanthropic contributions from private individuals. These donors are not involved in the design, conduct, or analysis of the research.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06407635", "keywords": "Post Traumatic Stress Disorder, Psilocybin, Trauma-focused psychotherapy, Standard psychological support, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06407635\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "PTSD,Receptor Pharmacology,Consciousness,Wellbeing,Mystical Experience,Randomized Controlled Trial,Healthcare Workers,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3460, "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial", "normalized_title": "psilocybin assisted existential attachment and relational pearl therapy for patients with advanced cancer a phase ii open label trial", "authors": "University Health Network, Toronto", "abstract": "The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy. Individuals with advanced cancer often experience high levels of distress due to physical suffering, difficult treatment decisions, social isolation, and fear of death. While there are many treatment options for the management of physical symptoms associated with cancer, there are relatively few standard treatment approaches to help patients deal with psychological and existential suffering. Over the past decade, research has shown that psychotherapies incorporating existential, attachment and relational approaches can address the specific needs and challenges of the advanced cancer population and thus help to reduce distress. Simultaneously, recent research has shown that psilocybin-assisted psychotherapy, in which, an individual ingests the psychoactive drug within the carefully monitored therapeutic setting, can reduce end-of-life distress and greatly benefit those with advanced disease. The multidisciplinary team has combined these two evidence-based approaches into what the team calls Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory therapy sessions, a high-dose drug session, and integration sessions, with important elements from manualized individual psychotherapies designed for patients with advanced cancer. This study will assess the feasibility, acceptability, and safety of PEARL therapy among patients with advanced cancer. This study will yield important information about the feasibility of this type of therapy and contribute to the growing research around the efficacy of psychedelic-assisted therapies. This type of therapy has the potential to improve quality of life among those with advanced disease and careful research is needed to build upon previous findings to outline the necessary components of therapy and guide public policy, legislation, and clinical guidelines.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06416085", "keywords": "Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma, Stage IV Melanoma, Endocrine Cancer, Psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06416085\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "End-of-Life Distress,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1923, "title": "Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence", "normalized_title": "psilocybin assisted therapy in treatment resistant depression rapid remission uncertain durability and the next phase of clinical evidence", "authors": "Astrit Sabani, Adnan Khatak", "abstract": "Treatment-resistant depression (TRD) remains a major clinical challenge and is typically defined as the persistence of depressive symptoms despite at least two adequate antidepressant trials. Individuals with TRD experience substantial morbidity, impaired functioning, and elevated suicide risk, highlighting the need for therapeutic strategies beyond incremental refinements of conventional monoaminergic pharmacotherapy. Psilocybin-assisted therapy has recently emerged as a mechanistically distinct intervention, combining transient 5-HT2A receptor agonism with structured psychological support delivered in supervised sessions. Early randomized trials have demonstrated rapid reductions in depressive symptoms and encouraging short-term remission rates, primarily in patients with major depressive disorder, with more limited but emerging evidence in treatment-resistant populations. However, the central clinical question is not merely whether psilocybin can produce acute improvement, but whether these effects can be sustained without cumulative harm. Current evidence remains limited by modest sample sizes, relatively short follow-up periods, challenges in maintaining blinding, and limited comparisons with established TRD interventions such as esketamine, electroconvulsive therapy, and transcranial magnetic stimulation. The durability of benefit beyond several weeks remains an open clinical question, and the implications of repeated dosing are not yet well established. In addition, implementation demands substantial therapeutic infrastructure, raising questions regarding scalability, cost, and equitable access. Future research should prioritize standardized definitions of treatment resistance, recognition of clinical heterogeneity within TRD populations, longer-term outcomes, rigorous active comparators, improved trial methodology, safety monitoring, and cost-effectiveness analyses to determine the appropriate clinical role of psilocybin-assisted therapy.", "journal": "Annals of Medicine and Surgery", "publication_date": "2026-06-17", "publication_year": 2026, "doi": "10.1097/ms9.0000000000005244", "pubmed_id": null, "source_url": "https://doi.org/10.1097/ms9.0000000000005244", "keywords": "Medicine, Electroconvulsive therapy, Major depressive disorder, Dosing, Clinical trial, Psychological intervention, Intensive care medicine, Treatment-resistant depression, Antidepressant, Depression (economics), Psychiatry, Randomized controlled trial, Translational research, Clinical research, Physical medicine and rehabilitation, MEDLINE, Clinical psychology, Anxiety, Monoaminergic, Clinical endpoint, Multimodal therapy, Evidence-based medicine, Placebo, Depressive symptoms, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:49:23", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7165127045\",\"openalex_url\":\"https://openalex.org/W7165127045\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2541285986\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4320888625\",\"https://openalex.org/W4386765496\"],\"authorships\":[{\"id\":\"https://openalex.org/A5138876543\",\"display_name\":\"Astrit Sabani\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077347061\",\"display_name\":\"Adnan Khatak\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226177\",\"source_display_name\":\"Annals of Medicine and Surgery\",\"landing_page_url\":\"https://doi.org/10.1097/ms9.0000000000005244\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Receptor Pharmacology,Aging,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7165127045" }, { "id": 39, "title": "DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish", "normalized_title": "desi msi based multi organ distribution mapping of psilocin in zebrafish", "authors": "Mengxuan Dong, Yi Zhang, Manzhu Cao, Tong Shi, Liqin Li, Xingxing Zong, Chen Wang", "abstract": "Psilocybin, a psychedelic drug with reported anxiolytic and antidepressant potential, is rapidly metabolized to its active metabolite psilocin. However, a lack of adequate toxicity studies and tissue distribution studies currently restricts its development and application. This study combined behavioral assays in zebrafish with desorption electrospray ionization mass spectrometry imaging (DESI-MSI) to systematically evaluate the acute neurotoxicity of psilocybin and characterize the in vivo spatial distribution of its active metabolite, psilocin. The novel tank test was used to evaluate zebrafish following a 4 h exposure to psilocybin at three different doses (20, 40, and 80 μM; n = 6 per group). Statistical analysis of the data was performed using ANOVA. Behavioral analyses revealed that exposure to psilocybin induced pronounced neurobehavioral alterations, including hyperactivity and disrupted swimming patterns, as evidenced by significant increases in the number of zone transitions and shuttle frequency. We established a DESI-MSI-based method for quantitative mapping and visualization of psilocin in zebrafish tissues. Methodological validation indicated that a linear relationship between ion intensity, spotted amount (R2 = 0.9947), and reproducibility (RSD < 15%) is suitable for quantitative analysis of psilocin in zebrafish tissues. Spatial distribution maps showed that following continuous exposure for 4 h, psilocin was widely distributed across multiple tissues, such as the eye, brain, heart, liver, and kidney, with marked accumulation in the brain and the periportal regions of the liver. Relative psilocin signal intensity revealed a dose-dependent increase in tissue drug levels. The dose-dependent increase in both behavioral hyperactivity and brain psilocin levels points to a consistent relationship, in line with a central site of action. Collectively, these findings demonstrate that DESI-MSI provides a visual and efficient strategy for studying drug distribution in biological tissues from exposed animals. The neurobehavioral toxicity phenotypes and distinct tissue distribution patterns of psilocin uncovered in this study offer critical insights into the biological effects and potential risks of this psychoactive substance.", "journal": "Molecules", "publication_date": "2026-06-17", "publication_year": 2026, "doi": "10.3390/molecules31122143", "pubmed_id": "42357539", "source_url": "https://doi.org/10.3390/molecules31122143", "keywords": "Zebrafish, Psilocybin, Chemistry, Mass spectrometry imaging, Mass spectrometry, Metabolite, Neurotoxicity, In vivo, Biology, Electrospray ionization, Quantitative analysis (chemistry), Anxiolytic, Electrocorticography, Electrospray, Reproducibility, Biochemistry, Psychedelics and Drug Studies, Zebrafish Biomedical Research Applications, Mass Spectrometry Techniques and Applications", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7165199227\",\"openalex_url\":\"https://openalex.org/W7165199227\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1969472315\",\"https://openalex.org/W1987918216\",\"https://openalex.org/W2010004076\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2018197304\",\"https://openalex.org/W2040677997\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2080293390\",\"https://openalex.org/W2082182980\",\"https://openalex.org/W2101936201\",\"https://openalex.org/W2116504473\",\"https://openalex.org/W2165041849\",\"https://openalex.org/W2168829895\",\"https://openalex.org/W2533378657\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2771056291\",\"https://openalex.org/W2889043770\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2972662355\",\"https://openalex.org/W2981695213\",\"https://openalex.org/W3087672006\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W3214903520\",\"https://openalex.org/W4210913256\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4304695546\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4382010877\",\"https://openalex.org/W4389912710\",\"https://openalex.org/W4390951308\",\"https://openalex.org/W4394684735\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4403809829\",\"https://openalex.org/W4407980640\",\"https://openalex.org/W4408808337\",\"https://openalex.org/W4413302427\",\"https://openalex.org/W4413969371\"],\"authorships\":[{\"id\":\"https://openalex.org/A5104336641\",\"display_name\":\"Mengxuan Dong\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138840830\",\"display_name\":\"Yi Zhang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5011364880\",\"display_name\":\"Manzhu Cao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5100519813\",\"display_name\":\"Tong Shi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5006746441\",\"display_name\":\"Liqin Li\",\"orcid\":\"https://orcid.org/0000-0002-3671-9995\"},{\"id\":\"https://openalex.org/A5061698649\",\"display_name\":\"Xingxing Zong\",\"orcid\":\"https://orcid.org/0000-0002-5214-3180\"},{\"id\":\"https://openalex.org/A5138838173\",\"display_name\":\"Chen Wang\",\"orcid\":\"https://orcid.org/0000-0002-7553-0941\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S108911230\",\"source_display_name\":\"Molecules\",\"landing_page_url\":\"https://doi.org/10.3390/molecules31122143\",\"is_oa\":true}}", "topic_tags": "Brain Imaging,Aging,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7165199227" }, { "id": 3993, "title": "“I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse", "normalized_title": "i even saw four deer grazing online offline entanglements in the psilocybin pluriverse", "authors": "Michał Wanke, Paweł Matuszewski, Piotr Siuda", "abstract": "PurposeThis paper aims to examine evolving practices and discourses surrounding psilocybin mushrooms on an online drug forum. Situating use within hybrid digital and ecological contexts, it traces shifts in user engagement before and after the 2020 COVID-19 pandemic to contextualize localized realities of the contemporary psychedelic renaissance.Design/methodology/approachUsing an agential cut framework, the authors conducted a thematic analysis of approximately 3,000 qualitative posts from the largest Polish forum (mid-2000s-2023). The study tracks how forum users integrate digital tools (mapping, smartphone verification) with environmental field observations, mapping the online-offline entanglements and more-than-human relations of foraging.FindingsAnalysis reveals a post-2020 shift from immersive, metaphysical narratives toward predictive, scientifically informed and risk-managed practices. Building directly on critical drug scholarship regarding assemblage thinking and ontological multiplicity, the authors conceptualize the forum as an apparatus within a psychedelic pluriverse, where radically different versions of psilocybin simultaneously coexist, negotiate legitimacy and sustain themselves.Originality/valueBy integrating longitudinal forum analysis with a multispecies and pluriverse perspective, the study shows how digital platforms and embodied ecological practices jointly shape contemporary psychedelic practices, highlighting their relational, contingent and ethically informed character and demonstrating how shifts in discursive framings coincide with changing modes of ecological attention and risk reflexivity.", "journal": null, "publication_date": "2026-06-16", "publication_year": 2026, "doi": "10.31235/osf.io/tk4bv_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31235/osf.io/tk4bv_v1", "keywords": "Assemblage (archaeology), Psilocybin, Thematic analysis, Sociology, Narrative, Narrativity, Negotiation, Aesthetics, Embodied cognition, Field (mathematics), Ethnography, Affordance, Legitimacy, Epistemology, Qualitative research, Scholarship, Photo elicitation, Game studies, Lived experience, Discourse analysis, Psychology, Participant observation, Paranormal, Media studies, Legibility, Science studies, Metaphor, Interrogation, Sensemaking, Sketch, Social psychology, Citizen science, Subjectivity, Sociotechnical system, Object (grammar), Technoscience, Mediation, Actor-network theory, Fetishism, Agency (philosophy), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, HIV, Drug Use, Sexual Risk", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:35", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7165030356\",\"openalex_url\":\"https://openalex.org/W7165030356\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5012759919\",\"display_name\":\"Michał Wanke\",\"orcid\":\"https://orcid.org/0000-0003-0413-9838\"},{\"id\":\"https://openalex.org/A5072195170\",\"display_name\":\"Paweł Matuszewski\",\"orcid\":\"https://orcid.org/0000-0003-0069-157X\"},{\"id\":\"https://openalex.org/A5080888476\",\"display_name\":\"Piotr Siuda\",\"orcid\":\"https://orcid.org/0000-0002-1644-5915\"}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://doi.org/10.31235/osf.io/tk4bv_v1\",\"is_oa\":true}}", "topic_tags": "Aging,Safety,Toxicity", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7165030356" }, { "id": 1924, "title": "Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico", "normalized_title": "community engagement as a foundation for implementation research for group psilocybin assisted therapy in new mexico", "authors": "Lawrence Leeman, Maya Armstrong, Dara Menashi, Hanifa Nayo-Washington, Elliot Marseille, Janus Herrera, Crystal Romero, Janet Page-Reeves", "abstract": "Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models is essential to ensuring that those most impacted have access to-and trust in-the treatments being developed. Guided by the principle of “nothing about us without us,” the proposed study was designed from the outset to be community-informed and co-designed. We established a tripartite collaborative partnership among researchers from the University of New Mexico (UNM) Department of Family & Community Medicine (DFCM) and the UNM Office for Community Health (OCH), the Bernalillo County Health Equity Council, and the national Psychedelic Mental Health Access (PMHA) Alliance. The protocol for the FDA-approved study uses a group therapy model incorporating peer facilitators with shared affinity with the participant group. There will be six groups of six participants, including veterans/first responders and women survivors of sexual violence. The study is aligned with the New Mexico Therapeutic Psilocybin Program in its focus on access and equity, as well as the use of state-regulated whole psilocybin mushrooms rather than synthesized psilocybin. Each group will participate in two sessions using psilocybin mushroom-infused chocolates containing 20 mg and 30 mg of psilocybin, along with both group and individual therapy sessions. Outcomes will include safety and feasibility measures, as well as standard measures of PTSD, including the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). An extended integration model provides longer-term support to participants both within and beyond the clinical trial. A barrier to scaling psychedelic-assisted therapy is understanding what it actually costs to deliver a safe, comprehensive model of care, particularly for populations facing structural barriers to access. The University of California, Berkeley Collaborative for the Economics of Psychedelics (CEP) will conduct a prospective micro-costing study in parallel with GPAT. The analysis will capture delivery costs for community engagement, the group psilocybin therapy model, and the post-clinical protocol extended integration program. Study protocol registration https://clinicaltrials.gov/study/NCT07506395.", "journal": "Frontiers in Public Health", "publication_date": "2026-06-16", "publication_year": 2026, "doi": "10.3389/fpubh.2026.1845943", "pubmed_id": null, "source_url": "https://doi.org/10.3389/fpubh.2026.1845943", "keywords": "Psilocybin, Mental health, Focus group, General partnership, Community engagement, Psychology, Implementation research, Checklist, Group psychotherapy, Nursing, Medicine, Medical education, Health care, Protocol (science), Health equity, Mental illness, Psychiatry, Posttraumatic stress, Community-based participatory research, Collaborative Care, Program evaluation, Scale (ratio), Community health, Stigma (botany), Qualitative research, Documentation, Public health, Peer support, Family medicine, Pharmacy, Debriefing, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:49:23", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7165032301\",\"openalex_url\":\"https://openalex.org/W7165032301\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2021182031\",\"https://openalex.org/W2059262594\",\"https://openalex.org/W2081938075\",\"https://openalex.org/W2090482282\",\"https://openalex.org/W2260448316\",\"https://openalex.org/W2334201740\",\"https://openalex.org/W2558552875\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2788524689\",\"https://openalex.org/W2899851487\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W3012301731\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3089173757\",\"https://openalex.org/W3096392826\",\"https://openalex.org/W3154528253\",\"https://openalex.org/W4205393550\",\"https://openalex.org/W4224443490\",\"https://openalex.org/W4289745468\",\"https://openalex.org/W4321435530\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4388419802\",\"https://openalex.org/W4389392873\",\"https://openalex.org/W4391226316\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4397021797\",\"https://openalex.org/W4403502370\",\"https://openalex.org/W4403860154\",\"https://openalex.org/W4406630811\",\"https://openalex.org/W4406955835\",\"https://openalex.org/W4407883822\",\"https://openalex.org/W4411816768\",\"https://openalex.org/W4411961287\",\"https://openalex.org/W4413839750\",\"https://openalex.org/W4415230887\",\"https://openalex.org/W7128687864\",\"https://openalex.org/W7128912015\"],\"authorships\":[{\"id\":\"https://openalex.org/A5138788190\",\"display_name\":\"Lawrence Leeman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5081093073\",\"display_name\":\"Maya Armstrong\",\"orcid\":null},{\"id\":\"https://openalex.org/A5066280104\",\"display_name\":\"Dara Menashi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138765107\",\"display_name\":\"Hanifa Nayo-Washington\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138810814\",\"display_name\":\"Elliot Marseille\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138819624\",\"display_name\":\"Janus Herrera\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138800675\",\"display_name\":\"Crystal Romero\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138781439\",\"display_name\":\"Janet Page-Reeves\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2595931848\",\"source_display_name\":\"Frontiers in Public Health\",\"landing_page_url\":\"https://doi.org/10.3389/fpubh.2026.1845943\",\"is_oa\":true}}", "topic_tags": "PTSD,Chronic Pain,Aging,Clinical Trial,Veterans,Healthcare Workers,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7165032301" }, { "id": 3440, "title": "Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial", "normalized_title": "psilocybin assisted psychotherapy for the treatment of severe alcohol use disorder a double blind dose comparison concurrent control randomized trial", "authors": "Brigham and Women's Hospital", "abstract": "This study aims to determine the safety and preliminary efficacy of psilocybin-assisted psychotherapy in improving alcohol-related outcomes among adults with severe alcohol use disorder in a a double-blind, dose-comparison concurrent control, randomized trial. Participants will undergo structured psychotherapy and will be randomized to two psilocybin sessions to receive either a full dose (30mg or 40mg) or low dose (10mg or 15mg). This study is a double-blind, dose-comparison concurrent control randomized trial designed to evaluate the effects of psilocybin-assisted psychotherapy on alcohol-related outcomes, neurocognitive processes related to craving and stress, and neural circuits involved in reward and regulation among adults with severe alcohol use disorder (AUD). Participants are recruited up to 3 months after completing inpatient alcohol withdrawal treatment to ensure medical stabilization prior to psilocybin administration. The study examines both preliminary efficacy and safety while also exploring mechanistic pathways through behavioral assessments and functional neuroimaging. Participants (N=36) are randomized in a 1:1 ratio to receive either a full-dose psilocybin (30 mg, with option to escalate to 40 mg on the second session) or a low-dose (10 mg, with option to escalate to 15 mg on the second session). All participants complete two dosing sessions spaced four weeks apart. The psychotherapy is delivered by a dyad of trained therapists before, during, and after the dosing sessions and is based on established therapeutic frameworks used in prior psilocybin-assisted therapy trials. The aim of the therapeutic support is to prepare participants for the psilocybin experience, facilitate psychological processing during and after dosing, and support integration of insights into daily life. A peer recovery coach is integrated into the study to support relapse prevention, enhance coping skills, and encourage engagement in ongoing addiction treatment. All participants are offered follow-up services at the institution's outpatient addiction treatment program (including the BWH Bridge Clinic), regardless of study arm. This combination of medical oversight, psychotherapy, and recovery support reflects an effort to embed the intervention within real-world addiction care settings. Alcohol-related outcomes are assessed repeatedly from baseline through 48 weeks after the second dosing session. The primary clinical outcome is the percentage of heavy drinking days during the 24-week follow-up period, measured using Timeline Follow-Back. Secondary alcohol outcomes include drinking quantity and frequency, relapse timing, direct alcohol biomarkers (phosphatidylethanol and ethylglucuronide), withdrawal symptoms, treatment expectancy, blinding integrity, and quality of life measures. Additional exploratory outcomes assess peer support engagement and 12-step attendance. Safety is evaluated throughout the study using structured assessments of adverse events, vital signs, and mood and anxiety symptoms. Because participants have severe AUD and recent withdrawal treatment, careful medical screening is conducted prior to each dosing session. The study includes multiple follow-up assessments up to 48 weeks after the second psilocybin dose, allowing characterization of both acute and longer-term safety. Two mechanistic components are incorporated. First, neurocognitive tasks assess cue-induced craving, attentional bias, stress reactivity, delayed discount, decision making, and distress tolerance. These measures evaluate whether psilocybin influences cognitive and affective processes known to contribute to alcohol use and relapse. Second, participants complete two fMRI scans-first within one week prior to the first dosing session and the second within one week after the second dosing session. The fMRI tasks evaluate neural response to alcohol-related cues and the ability to down-regulate craving, focusing on the nucleus accumbens (NAcc) and dorsolateral prefrontal cortex (DLPFC). Connectivity analyses examine changes in functional coupling between these regions during alcohol cue processing. Together, these approaches allow the study to evaluate whether full-dose psilocybin, compared to low-dose, produces greater reductions in heavy drinking and craving, whether the treatment is safe and tolerable for individuals with severe AUD, and whether changes in cognitive, emotional, and neural functioning help explain clinical outcomes. By recruiting individuals immediately following inpatient detoxification, the study also examines the feasibility of incorporating psilocybin-assisted therapy into a critical window of early recovery. Results will inform whether a larger, fully powered clinical trial is justified and will contribute to the broader understanding of psilocybin's therapeutic potential in alcohol use disorder.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-14", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07296094", "keywords": "Alcohol Use Disorder, Psilocybin, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07296094\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Anxiety,Addiction,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Emotional Processing,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1927, "title": "Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA", "normalized_title": "psilocybin and mental health outcomes scoping review with saimsara", "authors": "SAIMSARA", "abstract": "This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studies with 271241797 total participants/sample observations (topic-deduplicated ΣN). This review indicates that the most consistent and replicated signal for psilocybin and health is rapid, large, and sustained reduction of depressive symptoms in clinical populations, with a randomized, waiting-list-controlled major depressive disorder (MDD) trial reporting Cohen's d=2.5 at week 5 and benefits in treatment-resistant depression persisting up to 6 months. Converging evidence suggests broader therapeutic potential for anxiety, Post-Traumatic Stress Disorder (PTSD), and existential distress, alongside preliminary signals for substance use disorders, though risks such as manic or psychotic episodes in vulnerable individuals warrant rigorous screening. A recurring caveat is that real-world benefits and access are moderated by race and ethnicity, with protective associations and program participation concentrated among White participants. These findings support a cautiously optimistic but equity-conscious role for psilocybin-assisted therapy in psychiatric and palliative care. Future work should prioritize controlled, prospective trials that test mechanisms and confirm durability while embedding culturally adapted, equitable access strategies.", "journal": "SAIMSARA Journal", "publication_date": "2026-06-14", "publication_year": 2026, "doi": "10.62487/saimsara7a54f680", "pubmed_id": null, "source_url": "https://doi.org/10.62487/saimsara7a54f680", "keywords": "Psilocybin, Mental health, Psychiatry, Psychology, Major depressive disorder, Clinical psychology, PsycINFO, Psychotherapist, Mental illness, Medicine, Depression (economics), Clinical trial, MEDLINE, Warrant, Race (biology), Epidemiology, Obsessive compulsive, Test (biology), Bipolar disorder, White paper, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:49:23", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164845889\",\"openalex_url\":\"https://openalex.org/W7164845889\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1037524820\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2889504249\",\"https://openalex.org/W2907379922\",\"https://openalex.org/W2990036135\",\"https://openalex.org/W3006069447\",\"https://openalex.org/W3054886531\",\"https://openalex.org/W3080679302\",\"https://openalex.org/W3087462486\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112172827\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3174895070\",\"https://openalex.org/W3211842562\",\"https://openalex.org/W4200445562\",\"https://openalex.org/W4205164075\",\"https://openalex.org/W4205618858\",\"https://openalex.org/W4210325795\",\"https://openalex.org/W4220885585\",\"https://openalex.org/W4223525754\",\"https://openalex.org/W4226057129\",\"https://openalex.org/W4282945619\",\"https://openalex.org/W4283204986\",\"https://openalex.org/W4283719838\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4294796248\",\"https://openalex.org/W4304118763\",\"https://openalex.org/W4307758883\",\"https://openalex.org/W4307773202\",\"https://openalex.org/W4311273096\",\"https://openalex.org/W4311439362\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4311778131\",\"https://openalex.org/W4312129485\",\"https://openalex.org/W4315488427\",\"https://openalex.org/W4362471804\",\"https://openalex.org/W4366089680\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W4372405576\",\"https://openalex.org/W4385442764\",\"https://openalex.org/W4385987387\",\"https://openalex.org/W4386165916\",\"https://openalex.org/W4386624716\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387063622\",\"https://openalex.org/W4387259638\",\"https://openalex.org/W4388141328\",\"https://openalex.org/W4388441105\",\"https://openalex.org/W4388486766\",\"https://openalex.org/W4390790998\",\"https://openalex.org/W4391115210\",\"https://openalex.org/W4391542137\",\"https://openalex.org/W4391610480\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4392242862\",\"https://openalex.org/W4392866789\",\"https://openalex.org/W4392888270\",\"https://openalex.org/W4393270574\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4396599639\",\"https://openalex.org/W4396954050\",\"https://openalex.org/W4398182074\",\"https://openalex.org/W4399276098\",\"https://openalex.org/W4399722371\",\"https://openalex.org/W4399756902\",\"https://openalex.org/W4399977372\",\"https://openalex.org/W4400167794\",\"https://openalex.org/W4400492401\",\"https://openalex.org/W4400495765\",\"https://openalex.org/W4401257064\",\"https://openalex.org/W4402476560\",\"https://openalex.org/W4403117441\",\"https://openalex.org/W4403196849\",\"https://openalex.org/W4403219178\",\"https://openalex.org/W4403263004\",\"https://openalex.org/W4404109323\",\"https://openalex.org/W4404152712\",\"https://openalex.org/W4404342030\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4405381556\",\"https://openalex.org/W4406062303\",\"https://openalex.org/W4406930915\",\"https://openalex.org/W4406959828\",\"https://openalex.org/W4406960487\",\"https://openalex.org/W4407209307\",\"https://openalex.org/W4407268240\",\"https://openalex.org/W4407380636\",\"https://openalex.org/W4407407526\",\"https://openalex.org/W4408158656\",\"https://openalex.org/W4408177956\",\"https://openalex.org/W4408225472\",\"https://openalex.org/W4408226956\",\"https://openalex.org/W4408648372\",\"https://openalex.org/W4408792078\",\"https://openalex.org/W4409500508\",\"https://openalex.org/W4409528946\",\"https://openalex.org/W4410148514\",\"https://openalex.org/W4410695397\",\"https://openalex.org/W4410737616\",\"https://openalex.org/W4410859687\",\"https://openalex.org/W4410874041\",\"https://openalex.org/W4411116696\",\"https://openalex.org/W4411571625\",\"https://openalex.org/W4412096805\",\"https://openalex.org/W4412107589\",\"https://openalex.org/W4412138274\",\"https://openalex.org/W4412433881\",\"https://openalex.org/W4412555614\",\"https://openalex.org/W4412727285\",\"https://openalex.org/W4412819218\",\"https://openalex.org/W4413002573\",\"https://openalex.org/W4413020215\",\"https://openalex.org/W4413116294\",\"https://openalex.org/W4413851486\",\"https://openalex.org/W4413958478\",\"https://openalex.org/W4413969371\",\"https://openalex.org/W4414072214\",\"https://openalex.org/W4414130775\",\"https://openalex.org/W4414167818\",\"https://openalex.org/W4414250218\",\"https://openalex.org/W4415159952\",\"https://openalex.org/W4415464487\",\"https://openalex.org/W4415713367\",\"https://openalex.org/W4415929140\",\"https://openalex.org/W4417166023\",\"https://openalex.org/W4417535188\",\"https://openalex.org/W7117295770\",\"https://openalex.org/W7117732707\",\"https://openalex.org/W7118124310\",\"https://openalex.org/W7131357000\",\"https://openalex.org/W7133986324\",\"https://openalex.org/W7134166104\",\"https://openalex.org/W7138877198\",\"https://openalex.org/W7154564588\",\"https://openalex.org/W7156314554\",\"https://openalex.org/W7160017394\",\"https://openalex.org/W7160534089\",\"https://openalex.org/W7161045271\",\"https://openalex.org/W7161640395\",\"https://openalex.org/W7161692886\",\"https://openalex.org/W7161714083\"],\"authorships\":[{\"id\":\"https://openalex.org/A5138686834\",\"display_name\":\"SAIMSARA\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S7407053708\",\"source_display_name\":\"SAIMSARA Journal\",\"landing_page_url\":\"https://doi.org/10.62487/saimsara7a54f680\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,End-of-Life Distress,Chronic Pain,Mechanism of Action,Clinical Trial,Review Article,Observational Study,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164845889" }, { "id": 1926, "title": "Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis", "normalized_title": "efficacy of psilocybin assisted therapy in major depressive disorder a systematic review and meta analysis", "authors": "Angel Labra-Lorenzana, Dania Nimbe Lima Sanchez, Christian Alejandro Delaflor-Wagner, Diana Martínez-Hernández, Christian Ramos-Jiménez, Christian Gabriel Toledo-Lozano", "abstract": "Background: This systematic review and meta-analysis evaluates the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for adults with major depressive disorder (MDD). Methods: A PROSPERO-registered search (CRD42024561979) of CENTRAL, Scopus, PsycINFO, and MEDLINE (2010-2024) identified clinical trials assessing PAP. Risk of bias was assessed using RoB 2 for randomized controlled trials (RCTs), while non-randomized studies were appraised separately. Evidence certainty was evaluated using GRADE. Results: Ten trials were included; eight provided quantitative data. PAP was associated with large short-term reductions in depressive symptom severity. The overall pooled effect was large (d = 1.15, 95% CI0.83-1.48), though within-subject designs yielded larger estimates (d = 1.63) than between-subject controlled comparisons (d = 0.96). Adverse events were transient and manageable, with no increased risk of serious adverse events on dosing days. Primary risk-of-bias concerns included functional unblinding. Conclusions: PAP may produce clinically meaningful, large short-term reductions in depressive symptoms. However, long-term efficacy remains understudied, and the overall certainty of evidence is low to moderate. Larger, rigorously blinded trials are required.", "journal": "Psychiatry International", "publication_date": "2026-06-14", "publication_year": 2026, "doi": "10.3390/psychiatryint7030137", "pubmed_id": null, "source_url": "https://doi.org/10.3390/psychiatryint7030137", "keywords": "Medicine, Adverse effect, Major depressive disorder, Dosing, Meta-analysis, Clinical trial, Randomized controlled trial, MEDLINE, Systematic review, Depressive symptoms, Depression (economics), Psychiatry, Certainty, Research design, Risk assessment, Intensive care medicine, Relative risk, Severity of illness, Evidence-based medicine, Clinical psychology, Major depressive episode, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:49:23", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164820747\",\"openalex_url\":\"https://openalex.org/W7164820747\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2098923148\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2912654919\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3044729970\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3129740058\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4302773366\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4384557644\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4401700752\",\"https://openalex.org/W4402748917\",\"https://openalex.org/W4404295609\"],\"authorships\":[{\"id\":\"https://openalex.org/A5138646510\",\"display_name\":\"Angel Labra-Lorenzana\",\"orcid\":null},{\"id\":\"https://openalex.org/A5072252637\",\"display_name\":\"Dania Nimbe Lima Sanchez\",\"orcid\":\"https://orcid.org/0000-0002-3647-6540\"},{\"id\":\"https://openalex.org/A5126057939\",\"display_name\":\"Christian Alejandro Delaflor-Wagner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135188546\",\"display_name\":\"Diana Martínez-Hernández\",\"orcid\":null},{\"id\":\"https://openalex.org/A5106551101\",\"display_name\":\"Christian Ramos-Jiménez\",\"orcid\":\"https://orcid.org/0000-0003-1637-6179\"},{\"id\":\"https://openalex.org/A5087349807\",\"display_name\":\"Christian Gabriel Toledo-Lozano\",\"orcid\":\"https://orcid.org/0000-0001-7418-1228\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210214788\",\"source_display_name\":\"Psychiatry International\",\"landing_page_url\":\"https://doi.org/10.3390/psychiatryint7030137\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164820747" }, { "id": 51, "title": "Balancing safety and access in Oregon’s psilocybin services", "normalized_title": "balancing safety and access in oregon s psilocybin services", "authors": "Katherine Cheung, Caleigh Propes, David B. Yaden", "abstract": "", "journal": "International Journal of Drug Policy", "publication_date": "2026-06-12", "publication_year": 2026, "doi": "10.1016/j.drugpo.2026.105384", "pubmed_id": "42288041", "source_url": "https://doi.org/10.1016/j.drugpo.2026.105384", "keywords": "Psilocybin, Hallucinogen, Internet privacy, Psychology, Business, MEDLINE, Public relations, Psychiatry, Nursing, Medical emergency, Poison control, Expanded access, Human factors and ergonomics, Medicine, Occupational safety and health, Substance use, Suicide prevention, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164654902\",\"openalex_url\":\"https://openalex.org/W7164654902\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W3186707907\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W4387902564\",\"https://openalex.org/W4390589662\",\"https://openalex.org/W4390975880\",\"https://openalex.org/W4396599258\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4404352311\",\"https://openalex.org/W4404863611\",\"https://openalex.org/W4406325134\",\"https://openalex.org/W4406960487\",\"https://openalex.org/W4411371495\",\"https://openalex.org/W4416008623\",\"https://openalex.org/W7125489213\",\"https://openalex.org/W7128687864\",\"https://openalex.org/W7161045271\"],\"authorships\":[{\"id\":\"https://openalex.org/A5102839143\",\"display_name\":\"Katherine Cheung\",\"orcid\":\"https://orcid.org/0009-0003-3529-4109\"},{\"id\":\"https://openalex.org/A5099023959\",\"display_name\":\"Caleigh Propes\",\"orcid\":\"https://orcid.org/0009-0002-3198-480X\"},{\"id\":\"https://openalex.org/A5138569187\",\"display_name\":\"David B. Yaden\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S60503757\",\"source_display_name\":\"International Journal of Drug Policy\",\"landing_page_url\":\"https://doi.org/10.1016/j.drugpo.2026.105384\",\"is_oa\":false}}", "topic_tags": "Addiction,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164654902" }, { "id": 49, "title": "Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders.", "normalized_title": "barriers and facilitators for psychedelic research and regulation in brazil insights from diverse stakeholders", "authors": "Guimarães AL, Beserra FR, Cruz L, Bienemmann B, Freind JMK, Guinle V, Rodrigues RS, Regalado JA, Mograbi DC", "abstract": "The interest in psychedelics for health-related purposes has grown significantly over the past decade. However, there is an insufficient representation of stakeholders (eg, Indigenous groups, activists, policymakers) in discussions about research and regulation. Many psychedelics originate from traditional practices historically developed in low- and middle-income countries, but these regions are seldom represented in stakeholder perspectives research. The present study will examine the barriers, facilitators, and perspectives identified by a wide array of key stakeholders regarding the research and regulation of psychedelics in Brazil. Twenty-six stakeholders, including Indigenous leaders, formal industry actors, clinicians, activists, policymakers, and informal sellers, were interviewed. The data were analyzed using inductive thematic analysis. Code-group co-occurrence indexing was used to capture the relevance of each theme across stakeholder groups. Thematic analysis revealed 4 barriers (\"accessibility,\" \"regulation,\" \"limited knowledge,\" and \"risks\"), 3 facilitators (1need for innovation,\" \"scientific advancements,\" and \"legal loopholes\"), and 4 perspectives (\"integration of ancestral knowledge,\" \"idealization, mysticism and scientific rigor,\" \"user autonomy,\" and \"tangible social benefits\"). Themes were similarly present among stakeholders' discourse, though with varying frequencies and weights, allowing comparisons of the particular relevance of themes for each group. We detail cultural, political, scientific, and clinical barriers, facilitators, and perspectives for psychedelic research and regulation within a region with a rich history of traditional psychedelic use, and discuss their ethical, regulatory, and clinical implications.", "journal": "Clinical therapeutics", "publication_date": "2026-06-12", "publication_year": 2026, "doi": "10.1016/j.clinthera.2026.05.012", "pubmed_id": "42288429", "source_url": "https://pubmed.ncbi.nlm.nih.gov/42288429/", "keywords": "Ayahuasca, Drug policy, Esketamine, Indigenous perspectives, Psilocybin, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:34", "raw_json": "{\"pubmed_id\":\"42288429\"}", "topic_tags": "Mystical Experience,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3238, "title": "Altered States, Enhanced Potential: Psychedelics and Physical Performance", "normalized_title": "altered states enhanced potential psychedelics and physical performance", "authors": "", "abstract": "Interest in psychedelics has expanded beyond clinical treatment contexts, yet little empirical work has examined how users describe psychedelic use in relation to sport and physical activity. This study conducted a qualitative content analysis of Reddit discussions involving psychedelics and physical performance. A Reddit search for “sports psychedelics” returned 253 threads. After screening, 39 threads and 290 comments met inclusion criteria. Analysis identified eight content categories: physical performance enhancement; flow state/automaticity; perceptual and cognitive enhancement; risks, limitations, and safety concerns; reduced fatigue/pain perception; microdosing as strategy; psychological and emotional benefits; and fairness, ethics, and governance. Psilocybin mushrooms and LSD were the most frequently mentioned substances. Across accounts, users most often described psychedelics as enhancing performance indirectly through altered attention, increased mind-body connection, flow-like absorption, and reduced pain or fatigue. Some users reported greater perceived strength, speed, endurance, coordination, or overall capability during activity, while others described effortless movement, reduced self-consciousness, sharper perception, and improved focus. Reports were predominantly positive or mixed, with concerns about overexertion, injury risk, impaired judgment, and fairness in competitive settings. These findings suggest that psychedelics may be understood less as traditional performance-enhancing drugs and more as potential-enhancing substances that alter the subjective conditions under which performance occurs. However, because all accounts were self-reported, it remains unclear whether perceived performance gains correspond to measurable physiological or behavioral improvement. Future controlled research using objective performance outcomes is needed to clarify the relationship between psychedelic use, subjective experience, and physical performance.", "journal": "PsyArXiv", "publication_date": "2026-06-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/txgq2_v2", "keywords": "exercise, flow state, harm reduction, LSD, microdosing, pain perception, performance-enhancing drugs, physical performance, psilocybin, psychedelics, qualitative content analysis, qualitative research, Reddit, sport psychology, Neuroscience, Social and Behavioral Sciences, Sport Psychology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"txgq2_v2\",\"version\":2,\"reviews_state\":\"accepted\"}", "topic_tags": "Chronic Pain,Consciousness,Microdosing,Emotional Processing,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3565, "title": "Psilocybin as a Treatment for Chronic Pain in Smokers", "normalized_title": "psilocybin as a treatment for chronic pain in smokers", "authors": "Yale University", "abstract": "The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in \"magic mushrooms.\" Psilocybin is currently being studied in clinical trials but has no current medical use in the United States. Some studies have shown that a dose of psilocybin can help people quit smoking. Other studies have shown that a dose of psilocybin may improve certain chronic pain conditions, such as migraine headaches. We believe that it may also be helpful for people who smoke and have chronic pain, but this has not been tested yet. This will be an open-label pilot study examining the feasibility and potential efficacy of psilocybin in individuals who smoke and have chronic pain. Following the screening visit, the potential participants will have 1) an adaptation/preparation session, 2) a treatment session, and 3) two post-treatment follow-up sessions: 1 and 4 weeks after the treatment session. During study participation, participants will also complete surveys 4 times per day on a mobile device for 5 weeks (1 week before the treatment session and 4 weeks post-treatment session). General Procedures: Potential participants will undergo extensive medical and psychiatric screening to minimize the risk of study participation. Psilocybin will be administered as a 25 mg oral dose under close medical and psychiatric monitoring. For the 24 hours before the treatment session, subjects will be asked to abstain from consuming alcoholic beverages and any illicit drugs, verified by urine drug screening and breathalyzer. Non-compliant subjects will be rescheduled or discharged from the study if they are repeatedly non-compliant. Subjects will be instructed to drink their typical number of caffeinated beverages and smoke cigarettes as usual to minimize caffeine and tobacco withdrawal, which could confound the study measures. Subjects will be instructed not to eat for 4 hours before the treatment sessions because a light snack will be provided before the beginning of the session, and lunch will be provided at the end.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-08", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07118332", "keywords": "Smokers With Chronic Pain, Psilocybin (drug), NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07118332\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Addiction,Chronic Pain,Headache / Migraine,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1929, "title": "Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001)", "normalized_title": "psilocybin assisted physiotherapy for refractory motor functional neurological disorder a randomized dose comparison pilot study p7 17 001", "authors": "Alexander Bryson, Chiranth Bhagavan, O. Carter, Glenn Nielsen, David Berlowitz, Sara Issak, Zachary Attard, Dina Eleftheriadis, Gina Oliver, Deanne Mayne, Greg Roebuck, James Rucker, Matthew Butler, Richard Kanaan", "abstract": "To assess the safety and feasibility of administering physiotherapy following psilocybin in patients with refractory motor Functional Neurological Disorder (FND), and to determine a treatment regimen that optimises symptom improvement.", "journal": "Neurology", "publication_date": "2026-06-08", "publication_year": 2026, "doi": "10.1212/wnl.0000000000212934", "pubmed_id": null, "source_url": "https://doi.org/10.1212/wnl.0000000000212934", "keywords": "Medicine, Physical medicine and rehabilitation, Physical therapy, Refractory (planetary science), Randomized controlled trial, Motor activity, Rehabilitation, Motor symptoms, Neurological disorder, Motor function, Activities of daily living, Central nervous system disease, Functional movement, Exercise therapy, Pilot trial, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:49:23", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164192013\",\"openalex_url\":\"https://openalex.org/W7164192013\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5133705726\",\"display_name\":\"Alexander Bryson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5059079864\",\"display_name\":\"Chiranth Bhagavan\",\"orcid\":\"https://orcid.org/0000-0002-7983-4280\"},{\"id\":\"https://openalex.org/A5049486527\",\"display_name\":\"O. Carter\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138319629\",\"display_name\":\"Glenn Nielsen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130669066\",\"display_name\":\"David Berlowitz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014383854\",\"display_name\":\"Sara Issak\",\"orcid\":\"https://orcid.org/0000-0003-0042-3452\"},{\"id\":\"https://openalex.org/A5000011887\",\"display_name\":\"Zachary Attard\",\"orcid\":\"https://orcid.org/0000-0003-0790-817X\"},{\"id\":\"https://openalex.org/A5042488247\",\"display_name\":\"Dina Eleftheriadis\",\"orcid\":\"https://orcid.org/0000-0002-0671-8422\"},{\"id\":\"https://openalex.org/A5121174897\",\"display_name\":\"Gina Oliver\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104987882\",\"display_name\":\"Deanne Mayne\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112602098\",\"display_name\":\"Greg Roebuck\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130354031\",\"display_name\":\"James Rucker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133665971\",\"display_name\":\"Matthew Butler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125536499\",\"display_name\":\"Richard Kanaan\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S79704628\",\"source_display_name\":\"Neurology\",\"landing_page_url\":\"https://doi.org/10.1212/wnl.0000000000212934\",\"is_oa\":false}}", "topic_tags": "Chronic Pain,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164192013" }, { "id": 3452, "title": "A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease", "normalized_title": "a double blind randomized trial investigating the safety feasibility and mechanisms of psychedelics in healthy older adults with low well being as moderated by biomarkers for preclinical alzheimer s disease", "authors": "Jennifer Mitchell", "abstract": "This study is being conducted to understand changes in brain activity following administration of two different drugs (Psilocybin and Dextromethorphan) in older adults with low well-being. The main questions it aims to answer are, does psilocybin: 1. Acutely increase complexity of EEG activity in older adults with low well-being, as modulated by the presence of biomarkers of Alzheimer's disease (AD) pathology. 2. Longitudinally decrease plasma markers of neuroinflammation, as modulated by the presence of biomarkers of AD pathology. 3. Explore longitudinal changes in autonomic physiology via wearable recording devices as well as longitudinal structural and functional brain changes measured in the MRI Participants will be in the study for up to 3 months, which will include 3 to 4 in person visits and 3 to 4 remote visits. Most visits will be between 1 to 3 hours, but the dosing visit will last a minimum of 8 hours and could be as long as 12 hours. During the dosing visit, all participants will receive a single dose of the study drugs and dosages listed below. Researchers will compare participants who receive the following drug options: * A low-to-moderate dose of Psilocybin (5-10 mg) * A moderate-to-high dose of Psilocybin (25-30 mg) * A low-to-moderate dose of Dextromethorphan (30-60 mg) * A moderate-to-high dose of Dextromethorphan (80-90 mg)", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-07", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07386730", "keywords": "Anhedonia in Healthy Volunteers, Older Adults (50-90 Years), Psilocybin (drug), Dextromethorphan (DXM), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07386730\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Brain Imaging,Mechanism of Action,Biomarkers,Aging,Wellbeing,Animal Study,Healthy Volunteers,Older Adults,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3472, "title": "A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans", "normalized_title": "a multi site randomized controlled trial of psilocybin for treatment resistant depression trd in veterans", "authors": "VA Office of Research and Development", "abstract": "The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder. Treatment-resistant depression (TRD) is a serious mental health problem in Veterans, frequently comorbid with post-traumatic stress disorder (PTSD), and in need of novel and effective treatments. Clinical studies have revealed antidepressant effects of psilocybin for depression in civilians, but less is known about its efficacy and safety in Veterans. Very limited data is available on the effects of psilocybin in the treatment of PTSD. Thus, it is important to evaluate the safety and efficacy of psilocybin in the treatment of TRD with and without PTSD among Veterans. The purpose of this multi-site, double-blind, randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of TRD in U.S. military Veterans with and without (±) concurrent PTSD. Eligible and consenting Veterans will two psilocybin dosing sessions along with preparation, administration, and integration psychological support provided by a facilitator. For the 1st psilocybin administration, participants will be randomized to one of two doses under blinded conditions. One month later, all participants will receive a 25mg dose at their 2nd psilocybin visit. Outcomes will be measured by an independent evaluator masked from all treatments at 2 and 4 weeks after each dosing session. Longer-term follow-up will be conducted over 6 months. Both expected and unanticipated adverse events will be collected by type, severity and relatedness to the study drug.", "journal": "ClinicalTrials.gov", "publication_date": "2026-06-04", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07226232", "keywords": "Major Depression, Psilocybin, COMP360, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07226232\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,PTSD,Randomized Controlled Trial,Treatment-Resistant Depression,Veterans,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 60, "title": "Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity", "normalized_title": "prenatal stress excitatory inhibitory imbalance and adhd risk a hypothesis driven perspective on psilocybin induced neuroplasticity", "authors": "Samaneh Ahmadian-Moghadam, Shiva Roshan-Milani, Ehsan Saboory", "abstract": "Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition in which prenatal stress and long-lasting disruptions of excitatory-inhibitory (E/I) balance have been implicated as key vulnerability factors. Although established pharmacological and behavioral treatments are effective for many individuals, they are not universally successful and do not directly target upstream neurodevelopmental mechanisms. In this hypothesis-driven perspective, we examine whether psilocybin-induced neuroplasticity could theoretically modulate stress-related neurodevelopmental risk pathways relevant to ADHD. Rather than presenting psilocybin as an evidence-based intervention, we synthesize findings from related preclinical and clinical literatures to explore conceptual plausibility. Preclinical studies in non-ADHD models indicate that psilocybin can induce rapid and sustained synaptic plasticity, alter cortical E/I dynamics, and reverse stress-associated structural and functional alterations. Human clinical trials in adults-primarily in mood, trauma-related, and substance use disorders-demonstrate durable changes in emotional regulation, cognitive flexibility, and large-scale brain network organization, processes that overlap with neural systems implicated in ADHD. Research into the use of psilocybin for ADHD is in its early stages, with emerging, largely self-reported, and preliminary studies suggesting potential benefits for managing symptoms like inattention, impulsivity, and emotional dysregulation. We therefore frame psilocybin as a speculative (secondary/tertiary) approach that could, in principle, be explored to probe mechanisms of E/I rebalancing and neuroplasticity. Key mechanistic uncertainties-including the state-dependent effects of psilocybin on excitation and inhibition and the possibility of exacerbating existing imbalances-are explicitly discussed. Ethical and developmental considerations, particularly regarding vulnerable populations, are emphasized as critical constraints on translation. Finally, we propose a translational research roadmap encompassing preclinical prenatal-stress models, biomarker-driven pilot studies in ADHD, and multimodal outcome measures integrating neuroimaging, electrophysiology, and molecular indices. By clearly distinguishing established evidence from hypothesis, this perspective aims to stimulate rigorous and ethically grounded research rather than to advocate premature clinical application.", "journal": "Translational Psychiatry", "publication_date": "2026-06-04", "publication_year": 2026, "doi": "10.1038/s41398-026-04151-x", "pubmed_id": "42248832", "source_url": "https://doi.org/10.1038/s41398-026-04151-x", "keywords": "Perspective (graphical), Neuroplasticity, Psychology, Schizophrenia (object-oriented programming), Psychotherapist, Clinical psychology, Developmental psychology, MEDLINE, Psychiatry, Medicine, Neuroscience, Psychosis, Psychopathology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Substance Abuse Treatment and Outcomes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7163694045\",\"openalex_url\":\"https://openalex.org/W7163694045\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5041308716\",\"display_name\":\"Samaneh Ahmadian-Moghadam\",\"orcid\":\"https://orcid.org/0000-0003-1970-561X\"},{\"id\":\"https://openalex.org/A5137987953\",\"display_name\":\"Shiva Roshan-Milani\",\"orcid\":\"https://orcid.org/0000-0003-1078-9386\"},{\"id\":\"https://openalex.org/A5060625948\",\"display_name\":\"Ehsan Saboory\",\"orcid\":\"https://orcid.org/0000-0003-4777-4751\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S163345920\",\"source_display_name\":\"Translational Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1038/s41398-026-04151-x\",\"is_oa\":true}}", "topic_tags": "Addiction,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Emotional Processing,Clinical Trial,Animal Study,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7163694045" }, { "id": 3367, "title": "Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults", "normalized_title": "prolonged grief symptom outcomes during at home ketamine assisted therapy a real world retrospective analysis of 503 adults", "authors": "Carter D, Reardon I, Swain J, Vando L.", "abstract": "Abstract Background Prolonged grief disorder (PGD) is a clinically distinguishable bereavement-related condition characterized by persistent yearning, identity disruption, and impaired functioning, formalized in DSM-5-TR and ICD-11 (6L72) and empirically distinguishable from but frequently co-occurring with major depressive disorder. Approximately 7 to 10 percent of bereaved adults meet criteria for PGD, with elevated suicide risk and functional impairment. Complicated grief therapy is the targeted psychotherapy most often referenced for prolonged grief, and existing PGD treatments have been studied primarily in specialty academic and clinical settings without examining at-home telehealth delivery. A small psychedelic-grief literature has emerged in psilocybin and ayahuasca observational and pilot studies. Prior real-world ketamine cohorts have characterized depression outcomes without focusing on prolonged grief. Objective This exploratory, hypothesis-generating analysis describes prolonged grief symptom outcomes among adults with clinically elevated baseline grief who received at-home ketamine-assisted therapy through Mindbloom, a telehealth ketamine therapy platform. Methods We conducted a retrospective cohort analysis of 503 bereaved adults with clinically elevated prolonged grief symptoms (PGD-13 Total grief score ≥ 30 at baseline, a pragmatic severity threshold consistent with the score-based caseness cut used in the Shear randomized trials of complicated grief therapy on the predecessor Inventory of Complicated Grief) who confirmed the loss of a significant person on the PGD-13 gating question and received guided at-home sublingual or subcutaneous ketamine-assisted therapy through Mindbloom. Prolonged grief symptoms were assessed using the PGD-13 (mean baseline = 37.18) at post-session 2 (n = 282), post-session 4 (n = 196), and post-session 6 (n = 121). The primary study-defined response was a ≥ 5-point improvement in PGD-13 Total grief score from baseline. We additionally applied an adapted version of a formal Prolonged Grief Disorder caseness algorithm at baseline and post-session 6 to characterize diagnostic remission. Results Mean PGD-13 Total grief score declined from 37.18 at baseline (95% bootstrap CI36.72-37.63) to 31.07 at post-session 2 (mean change − 6.11), 27.61 at post-session 4 (− 9.57), and 25.81 at post-session 6 (− 11.37). Among the 121 post-session 6 completers (24% of the eligible cohort), study-defined response (≥ 5-point improvement) was achieved by 51.8% at post-session 2 (95% Wilson CI46.0-57.5%), 68.4% at post-session 4 (61.6-74.5%), and 76.0% at post-session 6 (67.7-82.8%); any improvement (≥ 1-point) was achieved by 90.1% of post-session 6 completers (83.5-94.2%). The proportion of post-session 6 completers below the score-based threshold of 30 was 63.6% (95% CI54.8-71.7%); 0.8% reported no change and 9.1% reported any worsening. Applying the adapted PGD caseness algorithm, 42.7% of baseline participants met full diagnostic criteria for Prolonged Grief Disorder under the ICD-11 duration threshold (95% CI38.5-47.1%); 35.6% met DSM-5-TR criteria (95% CI31.5-39.9%). Among completers who met caseness at baseline, 73.2% no longer met ICD-11 criteria at post-session 6 (n = 41/56; 95% CI60.4-83.0%); 71.1% no longer met DSM-5-TR criteria (n = 32/45; 95% CI56.6-82.3%). In a worst-case sensitivity analysis in which all non-completers were assumed to retain full caseness, the confirmed diagnostic remission rates were 19.1% (ICD-11; 95% CI14.4-24.8%) and 17.9% (DSM-5-TR; 95% CI13.0-24.1%). Item-level analysis revealed that the single largest mean change across the 10 PGD-13 symptom items occurred on the identity/role confusion item (mean 4.12 to 2.64; change − 1.48, 95% bootstrap CI − 1.70 to − 1.24, corresponding to a 35.9% reduction from baseline to post-session 6). In contrast, the emotional pain item most closely overlapping major depressive disorder phenomenology improved 26.4% over the same interval, ranking sixth of ten. Side effects of any type were uncommon (7.4% at post-session 2, 5.6% at post-session 4, 4.1% at post-session 6). Subgroup patterns of larger mean change in more recently bereaved patients were observed (largest at post-session 6 in the 6-to-11-months-since-loss band, mean change − 13.83 points; smallest in the 12-months-or-longer band, − 10.40 points). Conclusions In this retrospective cohort of 503 adults with PGD-13 Total grief score ≥ 30 at baseline receiving at-home ketamine-assisted therapy through Mindbloom, prolonged grief symptoms declined monotonically across post-session timepoints; among the 121 post-session 6 completers, 76% achieved the primary study-defined response (≥ 5-point improvement) and 64% dropped below the score-based threshold of 30. Among completers meeting formal PGD caseness at baseline, the majority (73% under ICD-11, 71% under DSM-5-TR) no longer met diagnostic criteria at post-session 6, and item-level patterns showed the largest improvement on a non-depression-overlapping grief-specific symptom. Observed PGD-13 changes cannot be cleanly disentangled from concurrent depression-symptom changes in this uncontrolled design, because the cohort was treated for depression and the PGD-13 shares symptom content with depression instruments. The observed subgroup gradient runs opposite to what a strict mood-mediation account would predict, though concurrent depression improvement remains a compatible explanation. Randomized controlled trials with PGD-13 (or comparable independent grief instrument) as primary outcome, depression-independent comparator arms, and longer follow-up are needed to confirm these findings and to characterize the mechanism and durability of any observed effects.", "journal": "Research Square", "publication_date": "2026-06-01", "publication_year": 2026, "doi": "10.21203/rs.3.rs-9839240/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-9839240/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR1243670\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Chronic Pain,Emotional Processing,Randomized Controlled Trial,Observational Study,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3615, "title": "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)", "normalized_title": "a phase 3 randomized double blind multicenter study to evaluate the efficacy safety and tolerability of psilocybin in adults with major depressive disorder mdd", "authors": "Usona Institute", "abstract": "Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between groups in change in depressive symptoms from Baseline to Day 43 post-dose, and to characterize the durability of initial treatment effect and subsequent response to optional Psilocybin 25 mg re-administration(s) during the 1-year Follow-up Period. Double-blind Period: Participants who show stable depression symptoms between Screening and Trial Baseline will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. Investigational Product (IP) will be administered in the context of a \"Set and Setting\" (SaS) Protocol for psychosocial support, comprised of 1) a period of preparation with Facilitators prior to dosing; 2) administration of IP in an aesthetically pleasing room under the supervision of two Facilitators; and 3) post-dose integration sessions during which participants will discuss their dosing experience with the Facilitators. Trial outcome measures will assess depressive symptoms, functional disability, health-related quality of life, and clinical global impression of disease severity. Long-term Follow-up Period: After the initial 6-week Double-blind Period and completion of the post-dosing Trial Day 43 assessments, all participants will proceed into a 1-year Follow-up Period. During the 1-year Follow-up Period, participants will be followed regularly by clinic staff to assess MDD symptom severity, functional disability, and health-related quality of life; long-term safety data will also be collected. In addition to scheduled clinic visits, clinic staff will contact participants by telephone every two weeks to assess for changes in MDD symptom severity, concomitant medications, adverse events (AEs), and suicidal ideation and behavior. Participants who meet the pre-defined MDD severity criteria and meet all re-administration eligibility criteria may be offered re-administration(s) of open-label Psilocybin 25 mg administered under a \"Set and Setting\" (SaS) Protocol. Psychosocial support, including psychoeducation, is also incorporated in the long-term Follow-up Period.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-31", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06308653", "keywords": "Depressive Disorder, Major, Psilocybin 25 mg, Psilocybine, Psilocibin, Indocybin, Inactive Placebo, Microcrystalline Cellulose (MCC), Placebo, Psilocybin 5 mg, Psilocybine, Psilocibin, Indocybin, Active Comparator, Psychosocial Support, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06308653\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3095, "title": "Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey", "normalized_title": "patient perceptions towards psychedelics for musculoskeletal pain a cross sectional survey", "authors": "Li EJ, Mosharraf B, Ali H, Noyes M, Doshi P, Wallace C, Petranker R, Adili A, Khan M, Busse JW, MacKillop J, Madden K.", "abstract": "Background: Psychedelics are emerging as potential management options for chronic musculoskeletal pain due to preliminary evidence of effectiveness and low addictive potential, but patients’ perceptions remain unknown. This study assessed patient perceptions regarding psilocybin for musculoskeletal pain. Methods: We conducted a cross-sectional survey of adults (≥19) with musculoskeletal pain attending a hospital-based orthopaedic clinic. Participants reported demographics, perceptions of psychedelics for pain management, and willingness to participate in psychedelic research. Multivariable regression explored factors associated with perceived analgesic potential, and willingness to try a full therapeutic dose of psilocybin or a microdose. Results: Among 295 participants, 73% reported moderate-to-severe pain; 75% used analgesics; of these, 41% used opioids (86/209). While 24% reported prior psychedelic use, only 3% had discussed psychedelics with a healthcare provider. Most perceived that psilocybin had moderate-to-high effectiveness for pain (76%). Most respondents endorsed a moderate-to-high willingness to try microdoses (58%) and macrodoses (53%) of psilocybin for pain. Prior non-therapeutic psychedelic use predicted a 1.05-unit increase in perceived analgesic potential on the 10-point scale (p=.013). Willingness to try a macrodose of psilocybin was most strongly associated with prior non-therapeutic (B=3.16) and therapeutic (B=2.42) psychedelic use; in contrast, pain severity had a significant but modest association, with a 0.21-point increase in willingness for every 1-unit increase in pain severity (p=.017). Similarly, willingness to try a microdose of psilocybin was predicted by non-therapeutic (B=2.82) and therapeutic (B=2.48) use, whereas the effects of pain severity (B=0.20) and younger age (B=−0.30) were significant but small. Most respondents (52%) reported moderate-to-high willingness to participate in a trial of psilocybin for pain relief, and health risks were the primary concern (33%). Conclusions: Study findings suggest a majority hold neutral-to-positive perceptions of psilocybin for pain. Addressing perceived barriers, including health effects and gaps in patient knowledge, should be considered when designing future trials.", "journal": "medRxiv", "publication_date": "2026-05-31", "publication_year": 2026, "doi": "10.64898/2026.05.29.26354422", "pubmed_id": null, "source_url": "https://doi.org/10.64898/2026.05.29.26354422", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1243498\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Chronic Pain,Microdosing,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 53, "title": "Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats", "normalized_title": "psilocybin restores behavior and 5 ht2a signaling while reducing microglial density after chronic traumatic brain injury in rats", "authors": "Josh Allen, Bianca Jupp, Tamara L. Baker, Mohammad B. Haskali, Robert Brkljača, Zoe Plummer, Mujun Sun, Justin Brand, Brian R. Christie, Chantel T. Debert, Stuart J. McDonald, Terence J. O’Brien, Pablo M. Casillas-Espinosa, Sandy R. Shultz", "abstract": "Traumatic brain injury (TBI) causes persistent neurobehavioral deficits and increases the risk of psychiatric disorders, including depression, anxiety, and cognitive dysfunction linked to disrupted neuroplasticity, neuroinflammation, and serotonergic (5-HT) signaling. No effective pharmacotherapies exist for chronic TBI. Psilocybin, a psychedelic 5-HT2A receptor agonist, shows promise due to its neuroplasticity-enhancing, anti-inflammatory, and antidepressant effects. Here, male rats received fluid-percussion or sham injury, followed one year later by a single psilocybin (1 mg/kg) or saline injection. Behavioral testing began 24 h later, and positron emission tomography assessed 5-HT2A binding after two weeks. TBI produced persistent sensorimotor, learning and memory, and affective deficits; reduced 5-HT2A binding; and microglial alterations in the medial prefrontal cortex characterized by decreased process branching and enlarged soma size. Psilocybin treatment could improve sensorimotor function, restore 5-HT2A binding, and reduce microglial cell counts. These findings highlight psilocybin's therapeutic potential in chronic TBI and support further investigation of psychedelic treatments.", "journal": "Cell Reports Medicine", "publication_date": "2026-05-31", "publication_year": 2026, "doi": "10.1016/j.xcrm.2026.102867", "pubmed_id": "42285092", "source_url": "https://doi.org/10.1016/j.xcrm.2026.102867", "keywords": "Serotonergic, Traumatic brain injury, Prefrontal cortex, Medicine, Neuroscience, Psilocybin, Antidepressant, Psychology, Depression (economics), Neuroplasticity, Anesthesia, Cognition, Fluoxetine, Central nervous system, Hippocampus, Pharmacology, Hippocampal formation, Hallucinogen, Cognitive flexibility, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Alkaloids: synthesis and pharmacology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164582898\",\"openalex_url\":\"https://openalex.org/W7164582898\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W282097497\",\"https://openalex.org/W1582179550\",\"https://openalex.org/W1599691548\",\"https://openalex.org/W1882482010\",\"https://openalex.org/W1964223116\",\"https://openalex.org/W1967189169\",\"https://openalex.org/W1968345651\",\"https://openalex.org/W1996965924\",\"https://openalex.org/W1999934730\",\"https://openalex.org/W2005114459\",\"https://openalex.org/W2016647678\",\"https://openalex.org/W2025845189\",\"https://openalex.org/W2035408187\",\"https://openalex.org/W2048443834\",\"https://openalex.org/W2066333062\",\"https://openalex.org/W2067451082\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2080017034\",\"https://openalex.org/W2080185746\",\"https://openalex.org/W2087412997\",\"https://openalex.org/W2150025648\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2178224036\",\"https://openalex.org/W2290718261\",\"https://openalex.org/W2345917271\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2586825713\",\"https://openalex.org/W2767813783\",\"https://openalex.org/W2796819223\",\"https://openalex.org/W2799831564\",\"https://openalex.org/W2801625478\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2907553313\",\"https://openalex.org/W2909897542\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2919241137\",\"https://openalex.org/W2941251312\",\"https://openalex.org/W2942350530\",\"https://openalex.org/W3027590463\",\"https://openalex.org/W3039107584\",\"https://openalex.org/W3086471578\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3122084099\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3163918973\",\"https://openalex.org/W3164793453\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3184845084\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4200055187\",\"https://openalex.org/W4200506456\",\"https://openalex.org/W4206233669\",\"https://openalex.org/W4210297019\",\"https://openalex.org/W4221057587\",\"https://openalex.org/W4238168837\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4285591556\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4316036302\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4321501908\",\"https://openalex.org/W4323041020\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387259638\",\"https://openalex.org/W4387969794\",\"https://openalex.org/W4388268207\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4390064715\",\"https://openalex.org/W4390615076\",\"https://openalex.org/W4394757998\",\"https://openalex.org/W4395006819\",\"https://openalex.org/W4403450928\",\"https://openalex.org/W4403809829\",\"https://openalex.org/W4406974730\",\"https://openalex.org/W4409147414\",\"https://openalex.org/W4411302754\",\"https://openalex.org/W4411662399\",\"https://openalex.org/W4414171615\",\"https://openalex.org/W4415923681\"],\"authorships\":[{\"id\":\"https://openalex.org/A5021165179\",\"display_name\":\"Josh Allen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078740195\",\"display_name\":\"Bianca Jupp\",\"orcid\":\"https://orcid.org/0000-0002-9163-9170\"},{\"id\":\"https://openalex.org/A5026428711\",\"display_name\":\"Tamara L. Baker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035832224\",\"display_name\":\"Mohammad B. Haskali\",\"orcid\":\"https://orcid.org/0000-0003-3084-2084\"},{\"id\":\"https://openalex.org/A5065884453\",\"display_name\":\"Robert Brkljača\",\"orcid\":\"https://orcid.org/0000-0001-6190-2276\"},{\"id\":\"https://openalex.org/A5138484014\",\"display_name\":\"Zoe Plummer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5026851012\",\"display_name\":\"Mujun Sun\",\"orcid\":\"https://orcid.org/0000-0002-9923-9913\"},{\"id\":\"https://openalex.org/A5004717925\",\"display_name\":\"Justin Brand\",\"orcid\":\"https://orcid.org/0009-0005-4927-8438\"},{\"id\":\"https://openalex.org/A5007027911\",\"display_name\":\"Brian R. Christie\",\"orcid\":\"https://orcid.org/0000-0002-6830-0160\"},{\"id\":\"https://openalex.org/A5138530957\",\"display_name\":\"Chantel T. Debert\",\"orcid\":null},{\"id\":\"https://openalex.org/A5075491539\",\"display_name\":\"Stuart J. McDonald\",\"orcid\":\"https://orcid.org/0000-0001-5190-3179\"},{\"id\":\"https://openalex.org/A5138536180\",\"display_name\":\"Terence J. O’Brien\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138494799\",\"display_name\":\"Pablo M. Casillas-Espinosa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078165559\",\"display_name\":\"Sandy R. Shultz\",\"orcid\":\"https://orcid.org/0000-0002-2525-8775\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210207453\",\"source_display_name\":\"Cell Reports Medicine\",\"landing_page_url\":\"https://doi.org/10.1016/j.xcrm.2026.102867\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Safety,Toxicity,Inflammation", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164582898" }, { "id": 3576, "title": "A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression", "normalized_title": "a phase 2a study of group retreat psilocybin therapy for cancer related anxiety and depression", "authors": "University of Washington", "abstract": "This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies. OUTLINE: Patients attend group preparation therapy sessions on days -14 (virtual), -7 (virtual) and -1 (in person), and also attend an individual preparation therapy session on day -1 (in person). Patients receive psilocybin orally (PO) on day 0. Patients may receive an additional \"booster\" dose 60-90 minutes after the initial dose based on their subjective report combined with the physician's clinical judgement. Patients attend group integration therapy sessions on days 1 (in person), 8 (virtual), 15 (virtual), and 22 (virtual), and attend individual integration therapy sessions on days 1 (in person) and 8 (virtual). After completion of study treatment, patients are followed up at 2 weeks and at 1, 2, 3, and 6 months.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-28", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07336238", "keywords": "Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Psychotherapy, therapy, talk therapy, Psilocybin, psilocybine, Survey Administration, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07336238\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Clinical Trial,Observational Study,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 90, "title": "Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.", "normalized_title": "psychedelic induced hypomania and mania a systematic review and meta analysis", "authors": "Eskinazi M, Nasserdine R, Cusin RM, Baniotoupoulos P, Saccaro LF, De Pieri M, Corino T, Seragnoli F, Briefer JF, Aboulafia Brakha T, Richard-Lepouriel H, Penzenstadler L, Böge K, Kirchner M, Zullino D, Højlund M, Sapienza J, Bosia M, Catalan A, Vieta E, Solmi M, Sabé M.", "abstract": "Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transition remains unclear. We conducted a systematic review of human studies examining manic or hypomanic symptoms following exposure to serotonergic psychedelics (psilocybin, LSD, mescaline, DMT/ayahuasca) or MDMA (CRD420251160656). Databases and trial registries were searched through January 26, 2026. Eligible designs included randomized and non-randomized clinical studies, registry-based cohorts, cross-sectional surveys, and longitudinal observational studies. Outcomes included dysphoria/euphoria, manic or hypomanic symptoms and transition to bipolar disorder. Risk of bias was assessed using ROBINS-I, ROB2 or NIH tools. Twenty-three studies met inclusion criteria, four contributing to meta-analysis. Rates of psychedelic-associated dysphoria/euphoria, hypomania or mania ranged from 5.8% in controlled trials of psilocybin-assisted psychotherapy for major depressive disorders to 30% in naturalistic studies of individuals with bipolar disorder. When present, manic symptoms were typically acute and self-limited. Observational studies identified higher risks among individuals with bipolar I disorder, familial vulnerability, polysubstance use, and unsupervised or illegal use. Registry-based cohorts examining diagnostic transitions showed a prevalence of subsequent transition to bipolar disorder of 4% (95% CI2-8%; N = 7478; I² = 32.1%), with little evidence for a hallucinogen-specific signal. Overall, serotonergic psychedelics appear to pose a low but clinically meaningful relative risk of transient mood-related symptoms in susceptible individuals while remaining relatively safe in controlled clinical settings. Long-term outcomes and repeated exposure remain insufficiently studied, underscoring the need for rigorous longitudinal research.", "journal": null, "publication_date": "2026-05-28", "publication_year": 2026, "doi": "10.1038/s41380-026-03657-6", "pubmed_id": "42215638", "source_url": "https://doi.org/10.1038/s41380-026-03657-6", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"42215638\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Meta-Analysis,Systematic Review,Review Article,Observational Study,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 97, "title": "Psilocybin-induced neurocardiogenic syncope: a case report", "normalized_title": "psilocybin induced neurocardiogenic syncope a case report", "authors": "Mazen A. Atiq, Eli Weisman, Rodrigo B. Guerra, Luis Luna Martinez, David B. Yaden, Frederick S. Barrett, Sandeep Nayak, Ceyda Sayalı", "abstract": "BACKGROUND: Psilocybin is among the serotonergic psychedelics closest to potential FDA approval, with growing evidence of therapeutic benefit across psychiatric conditions. As clinical trials expand, systematic characterization of adverse events (AEs) remains essential. While transient hypertensive responses are well documented, hypotensive events such as neurocardiogenic syncope (NCS) are rarely reported. CASE PRESENTATION: We describe a healthy 35-year-old male enrolled in an open-label study investigating psilocybin-evoked changes in brain function during transcranial magnetic stimulation and electroencephalography (TMS-EEG). Approximately 60 minutes after receiving 25 mg oral psilocybin, and shortly after initiation of an eye-open resting-state EEG, he experienced prodromal lightheadedness followed by a brief loss of consciousness and postural tone. Immediate blood pressure was 93/51 mmHg with tachycardia and diaphoresis. Supportive measures, including leg elevation and oral hydration, led to rapid stabilization, and no further cardiovascular abnormalities occurred. The participant reported an emotionally intense experience, and contextual factors - including upright seated posture, restrictive EEG equipment, and anticipatory anxiety surrounding TMS - may have contributed to heightened autonomic arousal and susceptibility to NCS. CONCLUSIONS: This case highlights a rare hypotensive AE during psilocybin administration and underscores the importance of vigilant cardiovascular monitoring, particularly during procedures that may amplify emotional arousal. Given that fewer than one-quarter of contemporary psychedelic trials report systematic AE assessment, transparent documentation of both hypertensive and hypotensive events is critical for defining psilocybin's safety profile as clinical applications expand. PARENT TRIAL REGISTRATION: Open Label Psilocybin Brain Stimulation and Imaging Pilot Study; ClinicalTrials.gov: NCT06835699. Date registered: 02/13/2025. The parent-study consent form explicitly permits publication of de-identified participant data, and separate institutional approval for this case report was obtained (IRB00543773).", "journal": "Psychopharmacology", "publication_date": "2026-05-27", "publication_year": 2026, "doi": "10.1007/s00213-026-07079-8", "pubmed_id": "42207275", "source_url": "https://doi.org/10.1007/s00213-026-07079-8", "keywords": "Psilocybin, Medicine, Adverse effect, Anxiety, Anesthesia, Transcranial magnetic stimulation, Clinical trial, Arousal, Electroencephalography, Psychology, Blood pressure, Tachycardia, Lightheadedness, Psychiatry, Bradycardia, Orthostatic vital signs, Depression (economics), Serotonergic, Neuroscience, Lamotrigine, Hallucinogen, Vasovagal syncope, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162662445\",\"openalex_url\":\"https://openalex.org/W7162662445\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2104188272\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2159580288\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4392242862\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4416839507\"],\"authorships\":[{\"id\":\"https://openalex.org/A5060369515\",\"display_name\":\"Mazen A. Atiq\",\"orcid\":\"https://orcid.org/0000-0001-5598-480X\"},{\"id\":\"https://openalex.org/A5137214587\",\"display_name\":\"Eli Weisman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040974568\",\"display_name\":\"Rodrigo B. Guerra\",\"orcid\":\"https://orcid.org/0009-0006-9044-0457\"},{\"id\":\"https://openalex.org/A5135659235\",\"display_name\":\"Luis Luna Martinez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5137208332\",\"display_name\":\"David B. Yaden\",\"orcid\":null},{\"id\":\"https://openalex.org/A5137283236\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":null},{\"id\":\"https://openalex.org/A5137299515\",\"display_name\":\"Sandeep Nayak\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079100962\",\"display_name\":\"Ceyda Sayalı\",\"orcid\":\"https://orcid.org/0000-0002-3420-5499\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S80334769\",\"source_display_name\":\"Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1007/s00213-026-07079-8\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Brain Imaging,Consciousness,Aging,Emotional Processing,Clinical Trial,Case Report,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162662445" }, { "id": 3660, "title": "The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD", "normalized_title": "the safety and acceptability of psilocybin with support and with massed prolonged exposure therapy for ptsd", "authors": "Emory University", "abstract": "This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy. The Primary objective is to pilot and investigate tolerability, safety, and acceptability of psilocybin-assisted supportive therapy and psilocybin-assisted massed prolonged exposure (PE) therapy and conduct exploratory analyses related to comparative effectiveness of these treatments, including preliminary outcomes from pre-treatment to 1-month follow-up on post-traumatic stress disorder (PTSD) symptoms. Safety and tolerability of the treatment will be assessed and evaluated using the Swiss Psychedelic Side Effects Inventory (SPSI), Psychedelic-assisted Therapy After Effects (PATAE), and the Accessibility Questionnaire (AQ). The study will also evaluate the effect of psilocybin and massed exposure therapy using Subjective Units of Distress (SUDS) during imaginal exposure sessions; to assess self-reported PTSD and depression symptoms across treatment and investigate effect on fear extinction learning and fear extinction recall as assessed via fear potentiated startle. Given that this is a pilot study with small sample, analyses will be preliminary.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-25", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07332143", "keywords": "PTSD, psilocybin, 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate, Supportive Therapy, Prolonged Exposure Therapy, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07332143\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,PTSD,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 2, "title": "Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.", "normalized_title": "mystery shopper assessments of cannabis retailer practices and regulatory compliance in five u s states 2025", "authors": "Berg CJ, LoParco CR, Rossheim ME, McCready DM, Langan L, Platt E, Romm KF, Johnson M, Speer MB, Burris S, Cavazos-Rehg PA.", "abstract": "ObjectiveThis study used mystery shoppers to assess cannabis retail practices in 5 US states regulating legal nonmedical cannabis retail.MethodsThis mystery shopper study assessed 130 cannabis retailers in 5 cities (Los Angeles [LA], California; Las Vegas [LV], Nevada; Denver, Colorado; Portland, Oregon; Seattle, Washington) in summer 2025. Researchers recorded: 1) age verification; and 2) retail staff responses to inquiries about: a) use for anxiety, sleep, pregnancy-related nausea, etc.; b) use-related risks/cautions; c) interstate cannabis transport; and d) availability of derived intoxicating cannabis products (DICPs) and 'mushrooms' (psilocybin).ResultsMystery shoppers were asked for ID at 87.7% of retailers. When asked, most (>88%) retail staff responded that cannabis helps with anxiety and insomnia. While 40.8% warned against use for pregnancy-related nausea, 36.2% suggested it helps and 24.6% said it depends on the person/situation. Over half (58.5%) warned against driving post-use, but 50.0% said it depends (on person/situation). When asked about interstate transport, several indicated not to (42.3%) and/or it was illegal (39.2%); however, 44.6% indicated ways to pack cannabis to be undetectable, and 27.7% said not to worry about getting caught. Retail staff generally indicated DICPs are not as safe as delta-9 THC (27.7%) or are illegal (20.0%). The majority said mushrooms were illegal (67.7%), but 53.8% indicated they were easy to obtain, and 29.2% suggested their mental health benefits.ConclusionsCannabis retailer frequently made prohibited health claims and minimized risks, reinforcing public health concerns and the need for ongoing cannabis retail surveillance and stronger regulatory oversight and enforcement.", "journal": null, "publication_date": "2026-05-25", "publication_year": 2026, "doi": "10.1016/j.drugalcdep.2026.113218", "pubmed_id": "42224931", "source_url": "https://doi.org/10.1016/j.drugalcdep.2026.113218", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"42224931\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 52, "title": "Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.", "normalized_title": "overcoming pharmacokinetic and peripheral safety challenges in psychedelic therapies the promise of advanced drug delivery systems", "authors": "Zhang T, Lin C, Wang X.", "abstract": "Classic serotonergic psychedelics-such as lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT)-hold remarkable promise for treating neuropsychiatric disorders, yet their clinical translation is severely constrained by first-pass metabolism, erratic pharmacokinetics, unsuitable action profiles, and off-target peripheral serotonin effects. To overcome these barriers, advanced delivery systemssuch as transdermal and microneedle patches, intranasal sprays, sublingual films, and injectable formulationshave been developed, alongside molecular strategies including prodrugs, \"off-switch\" 5-HT receptor antagonists for session control, selective receptor bias, and adjunctive pharmacological approaches. These innovations help bypass hepatic metabolism, enable precise control over onset and duration of action, and minimize peripheral receptor activation. Preclinical and early clinical evidence shows gains in bioavailability, half-life extension, and conversion of fleeting psychedelic effects into manageable windows. These platforms offer a path to safer, patient-centered therapies. Despite regulatory and trial-design challenges, delivery innovations provide the essential pharmacokinetic toolkit to advance the field and clinical adoption.", "journal": null, "publication_date": "2026-05-24", "publication_year": 2026, "doi": "10.1021/acsptsci.6c00146", "pubmed_id": "42312173", "source_url": "https://doi.org/10.1021/acsptsci.6c00146", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"42312173\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4012, "title": "Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential", "normalized_title": "psilocybin for treatment resistant depression a comprehensive review of mechanisms and therapeutic potential", "authors": "Dallas T Mason", "abstract": "ABSTRACT Treatment-resistant depression (TRD) is characterized by chronic symptoms, impaired functioning, and limited response to conventional antidepressant therapy. Contemporary reviews have highlighted increasing interest in psilocybin-assisted therapy as a mechanistically novel approach for depressive disorders, grounded in early feasibility work demonstrating clinically meaningful symptom reductions in TRD populations and strengthened by subsequent randomized trials in major depressive disorder (MDD).¹,²,³ Open-label findings in TRD showed rapid and sustained reductions in depressive symptoms, while controlled trials in MDD demonstrated significant improvements from baseline after one or two psilocybin-assisted therapy sessions.¹,²,³ Systematic reviews of mechanistic work indicate that psilocybin modulates multiple neurobiological and psychological domains relevant to depression, including 5-HT₂A-mediated signaling functional network reorganization and emotional or cognitive shifts associated with therapeutic processes such as openness and acceptance.²,⁴‾⁷ Neuroimaging studies show acute alterations in default mode network dynamics and broader changes in connectivity during the psychedelic experience, findings interpreted as consistent with increased cognitive and emotional flexibility.²,⁵,⁷ Meta-analytic reviews report substantial antidepressant effects across different psilocybin dosing strategies and indicate that improvements often persist for several weeks.⁸,⁹ Safety reviews describe psilocybin’s acute adverse effects as generally mild, transient, and self-limiting, whereas recent systematic analyses highlight substantial variability and methodological limitations in harms reporting across trials.¹⁰,¹¹ Ethical, legal, and implementation challenges remain, including the constraints imposed by psilocybin’s Schedule I classification and the intensive training, therapeutic support, and clinical infrastructure required for safe delivery of psilocybin-assisted therapy.¹²,¹³ This narrative review synthesizes mechanistic, clinical, safety, and regulatory evidence to evaluate the potential role of psilocybin-assisted therapy for individuals with TRD.", "journal": "Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)", "publication_date": "2026-05-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6", "keywords": "Psilocybin, Major depressive disorder, Antidepressant, Treatment-resistant depression, Cognition, Psychology, Default mode network, Adverse effect, Systematic review, Clinical trial, Medicine, Neuroimaging, Clinical psychology, Psychotherapist, Depression (economics), Electroconvulsive therapy, Randomized controlled trial, Psychiatry, Narrative review, Hallucinogen, MEDLINE, Neuroscience, Dosing, Functional neuroimaging, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:35", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162235135\",\"openalex_url\":\"https://openalex.org/W7162235135\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5136833991\",\"display_name\":\"Dallas T Mason\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196904\",\"source_display_name\":\"Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)\",\"landing_page_url\":\"https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Aging,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162235135" }, { "id": 4011, "title": "The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach", "normalized_title": "the use of psilocybin for managing refractory behavioral health conditions a new and promising approach", "authors": "Rachel N Clark", "abstract": "The purpose of this review is to evaluate the possible benefits of using psilocybin(C12H17N2O4P), a naturally occurring psychoactive compound found in certain species of mushrooms, in the treatment of multiple forms of mental illness and substance abuse in either monotherapy or in conjunction with traditional psychiatric medications. The compound acts as a high-affinity agonist for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, which are densely located throughout the cerebral cortex and thalamus. Following a comprehensive search of electronic databases, this review evaluates the pharmacokinetics, therapeutic efficacy, and safety profile of psilocybin in treating depression, anxiety, and addiction disorders. The findings are promising and support its efficacy with decreased symptoms in multiple psychiatric disorders with a rapid onset. Significant research barriers remain, including methodological limitations, regulatory constraints, and limited population diversity in clinical trials conducted to date. United States (US) federal funding for the study of psilocybin as a potential therapeutic option has not yet been approved. Biosynthetic production of the compound and enhanced integration into psychotherapy are necessary to ensure scalability, safety, and accessibility. Future research is essential to evaluate and to refine its therapeutic applications on a larger scale.", "journal": "Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)", "publication_date": "2026-05-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694&context=dmscjournal", "keywords": "Psilocybin, Psychiatry, Addiction, Medicine, Hallucinogen, Population, Clinical trial, Substance abuse, Psychology, Mental illness, Psychotherapist, Mental health, Pharmacology, Addiction medicine, Drug, Substance use, MEDLINE, Adjunctive treatment, Global population, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:35", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162225828\",\"openalex_url\":\"https://openalex.org/W7162225828\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5136836285\",\"display_name\":\"Rachel N Clark\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196904\",\"source_display_name\":\"Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)\",\"landing_page_url\":\"https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694&context=dmscjournal\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Addiction,Pharmacology,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162225828" }, { "id": 4010, "title": "Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients", "normalized_title": "psilocybin assisted therapy in the management of anxiety and depression among cancer patients", "authors": "Caleb Lemus", "abstract": "Psychological distress, such as anxiety and depression, is common among people with cancer and is often worsened by existential worries about mortality, loss of meaning, and decreased quality of life. Standard treatments, including medication and psychotherapy, often offer limited or short-term relief, highlighting the need for new, integrative psychosocial oncology approaches. Psilocybin-assisted therapy (PAT) has shown promise in addressing both mood symptoms and existential distress. This review aims to summarize current evidence on the role of psilocybin therapy in managing anxiety and depression in cancer patients. It includes findings from randomized controlled trials, long-term follow-up studies, and feasibility research on psilocybin within structured psychotherapeutic frameworks, sourced from electronic databases. Overall, psilocybin therapy is linked to quick and meaningful reductions in anxiety and depression, often after just one or two supervised doses. These clinical improvements are supported by the Relaxed Beliefs Under Psychedelics (REBUS) model, which suggests that psilocybin facilitates a relaxation of rigid, maladaptive cognitive patterns while promoting neuroplasticity. This allows for a significant shift in perspective regarding mortality and existential distress. These benefits are long-lasting, with improvements remaining months after treatment. Patients also report improved psychological well-being, emotional acceptance, and a stronger sense of meaning, indicating benefits beyond mood stabilization. This review identifies the importance of preparatory counseling, therapeutic support during dosing, and post-session integration to maximize results, emphasizing psilocybin’s role as a catalyst in psychotherapy rather than as a stand-alone drug. When administered in controlled clinical environments with proper screening and monitoring, psilocybin exhibits a favorable safety profile, although psychological risks necessitate careful oversight. Situating these findings within psychosocial oncology and palliative care, this review emphasizes psilocybin therapy’s potential to meet unmet mental health needs in cancer patients. Limitations such as small sample sizes, homogenous populations, and regulatory hurdles are acknowledged. Overall, the evidence supports PAT as an emerging intervention with significant clinical potential, meriting further research into long-term effects, scalability, and integration into comprehensive cancer care.", "journal": "Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)", "publication_date": "2026-05-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3713&context=dmscjournal", "keywords": "Psilocybin, Anxiety, Psychotherapist, Mood, Clinical psychology, Cancer, Psychosocial, Psychology, Cognition, Depression (economics), Existentialism, Psychiatry, Perspective (graphical), Cognitive therapy, Guided imagery, Psycho-oncology, Cognitive behavioral therapy, Medicine, Relaxation (psychology), Psychological therapy, Schizophrenia (object-oriented programming), Randomized controlled trial, Exposure therapy, MEDLINE, Mental health, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:35", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162222410\",\"openalex_url\":\"https://openalex.org/W7162222410\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5136847142\",\"display_name\":\"Caleb Lemus\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196904\",\"source_display_name\":\"Digital Showcase Research, Scholarship, & Creative Works (University of Lynchburg)\",\"landing_page_url\":\"https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3713&context=dmscjournal\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Chronic Pain,Neuroplasticity,Aging,Wellbeing,Emotional Processing,Randomized Controlled Trial,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162222410" }, { "id": 3614, "title": "Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder", "normalized_title": "group psilocybin assisted therapy for post traumatic stress disorder", "authors": "University of New Mexico", "abstract": "This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity. This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity. These will be assessed by the following outcome measures: * Proportion of participants completing the study protocol * Incidence of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 * Mean change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and PTSD checklist for DSM-5 (PCL-5). The CAPS-5 and PCL-5 are based on the DSM-5 not the DSM-5-TR.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07506395", "keywords": "PTSD, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07506395\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "PTSD,Clinical Trial,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3529, "title": "Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial", "normalized_title": "evaluating the feasibility clinical effects and safety of psilocybin assisted psychotherapy for treatment resistant obsessive compulsive disorder an open label clinical trial", "authors": "Centre for Addiction and Mental Health", "abstract": "Psilocybin, the chemical component of \"magic mushrooms\", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms. Literature suggests that up to 40 percent of individuals with OCD do not respond to conventional treatment and experience treatment resistant OCD (TROCD) (1, 2). Psilocybin, the chemical component of \"magic mushrooms\", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects (3). Results of these trials have led to growing calls for transition to clinical use, as well as increased research for other mental health disorders. It is presumed that psilocybin's therapeutic effects are induced by the psychedelic \"trip\", which is dependent on serotonin 2A receptor (5-HT2AR) activation (4, 5). All studies have used psilocybin in conjunction with psychotherapy involving two therapists present during full-day dosing sessions. There is a need for more data in the TROCD population as there is only one clinical trial published for this specific population, followed by various case reports. Using a proof-of-concept, open-label, clinical trial approach, 10 participants with TROCD will receive 2 doses of 25mg of psilocybin, with two weeks between each dosing day. The objectives of this study are as follows: 1. To assess the safety, and feasibility, of psilocybin, administered with psychological support to adult participants with TROCD. Hypothesis 1: The investigators will be able to recruit and retain ten participants with TROCD for the duration of the trial and that psychedelic-assisted psychotherapy for obsessive compulsive disorder (PAP-OCD) will be safe in those with TROCD, as measured by monitoring adverse events and using the Columbia Suicide Severity Rating Scale (C-SSRS). 2. To assess the clinical effects of PAP in those with TROCD. Hypothesis 2: Two sessions of psilocybin (25mg) administered under supportive conditions to participants with TROCD will lead to significant reductions in OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS) when comparing baseline to Week 3. 3. Provide pilot data on the effect of psilocybin and supportive therapy on TROCD in preparation of a future larger RCT. Overview of Study Design: All 10 participants will follow the same study design. Each participant will undergo a screening assessment where they will complete lab tests, and clinical and psychiatric assessments to determine eligibility. Following the screening visit, participants will undergo a washout period where they will be tapered off concomitant medications over a medication the participant is being tapered off (based on the half-life of the medication) and the participant's preference for the length of the tapering period. All medications will require a minimum of a 2-week tapering period with the exception of fluoxetine which will require a minimum of 4-weeks. Additional time may be added at the discretion of the study investigator. During this period, there will be weekly check-ins with the study physician. At study Visit 2 (Baseline, V2), participants will complete a series of questionnaires and assessments, preparatory therapy with trained study therapists, and undergo a brain functional magnetic resonance imaging (fMRI). The preparatory therapy sessions will build a therapeutic alliance, and provide psychoeducation about, and set intentions for, the psilocybin session. To reduce participant burden, baseline can be broken up into multiple days, however all assessments must be completed within 7-days of the first dose. At study Visit 3 (V3), neurophysiological measurements will be performed. Upon completion of V2 and V3, participants will undergo the first psilocybin dosing session at Visit 4 (V4) where they will receive an active dose (25mg) of psilocybin in conjunction with supportive therapy. The psilocybin session will last 5 to 6 hours and will be conducted in the existing psychedelic treatment suite developed at the Centre for Addiction and Mental Health (CAMH). Two trained study therapists will be supporting each participant during the dosing session. After 5 hours of dose administration, participants will be evaluated for safety by the study psychiatrist and discharged home in the company of a caregiver or a family member. On the day after the dosing session (Visit 5, V5) and one-week after the dosing session (Visit 6, V6), participants will be asked to complete the same questionnaires that were done at Baseline (V2) and will undergo an integrative therapy session with the trained study therapist. Between Visit 5 (V5) and Visit 7 (V7), during study Visit 6 (V6), the same neurophysiological measurements will be performed as during Visit 3 (V3). Follow-up assessments will also occur at 3, 6, 9 and 12 weeks (Visit 7, 8, 9 and 10) after the second psilocybin dosing session. The same questionnaires administered at Baseline (V2) will be repeated at each of these study visits.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-17", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06299319", "keywords": "Obsessive-Compulsive Disorder, Psilocybin, PEX010, ENROLLING_BY_INVITATION", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06299319\",\"overall_status\":\"ENROLLING_BY_INVITATION\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Addiction,OCD,Brain Imaging,Receptor Pharmacology,Aging,Clinical Trial,Randomized Controlled Trial,Case Report,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 109, "title": "Corrigendum to: “Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape”", "normalized_title": "corrigendum to psilocybin in the real world regulatory ethical and operational challenges in australia s clinical landscape", "authors": "", "abstract": "", "journal": "Australian & New Zealand Journal of Psychiatry", "publication_date": "2026-05-17", "publication_year": 2026, "doi": "10.1177/00048674261450797", "pubmed_id": "42145135", "source_url": "https://doi.org/10.1177/00048674261450797", "keywords": "Computer science, Risk analysis (engineering), Key (lock), Systems engineering, MEDLINE, Work (physics), Medicine, Engineering, Component (thermodynamics), Data science, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pharmaceutical Quality and Counterfeiting", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7161606725\",\"openalex_url\":\"https://openalex.org/W7161606725\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S179943861\",\"source_display_name\":\"Australian & New Zealand Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1177/00048674261450797\",\"is_oa\":false}}", "topic_tags": "Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7161606725" }, { "id": 3606, "title": "Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)", "normalized_title": "exploring the safety acceptability and efficacy of psilocybin among non small cell lung cancer patients with major depressive disorder a proof of concept trial dream lung study", "authors": "Alan Davis", "abstract": "This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer. A cancer diagnosis is life-changing, resulting in significant levels of psychological symptoms, including a combination of depression, anxiety, stress, including feelings of existential distress (i.e., loss of meaning, demoralization, despair). Among all cancer patients, those diagnosed with lung cancer have the highest prevalence of mood disorders, such as depression (up to 40%) leading to profound deterioration in quality of life, prolonged hospital stays, poorer treatment adherence, decreased survival rates, and high rates of suicide (5- and 3-times higher than the general population and other cancer patients, respectively). Psilocybin is substance being studied in the treatment of anxiety or depression in patients with advanced cancer. It is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). Psilocybin in combination with therapy may be safe and effective in treating major depressive disorder in patients with non-small cell lung cancer. PRIMARY OBJECTIVE: I. To determine the safety and acceptability of psilocybin-assisted psychotherapy with non-small cell lung cancer (NSCLC) patients. SECONDARY OBJECTIVE: I. To determine the efficacy of psilocybin-assisted therapy in the reduction of depression and the impact of treatment on quality of life, cancer-related stress, and existential distress. OUTLINE: Patients participate in two preparation therapy sessions over 4 hours each on days 7 and 14, then patients receive psilocybin orally (PO) on day 21 and participate in a single dosing therapy session for over 8-10 hours on study. Patients also complete two post-dosing therapy sessions over 2 hours each on days 22 and 28 on study. Patients additionally undergo blood and urine sample collection throughout the study. After completion of study treatment, patients are followed up at 4 and 12 weeks.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-13", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07216404", "keywords": "Lung Non-Small Cell Carcinoma, Unipolar Depression, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Counseling, Counseling Intervention, Interview, Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Survey Administration, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07216404\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Clinical Trial,Observational Study,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3035, "title": "Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.", "normalized_title": "low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder a study protocol for a double blind randomized controlled trial", "authors": "", "abstract": "Background: Social anxiety disorder is a chronic and disabling condition with limited response to standard therapies. Low-dose psilocybin may enhance the effectiveness of exposure-based treatments by modulating neural circuits associated with fear and avoidance. Virtual reality exposure therapy offers a controlled and individualized platform for intervention. Objective: This phase 2b, double-blind clinical trial (n = 32) investigates feasibility and tolerability of low-dose psilocybin as an adjunct to virtual reality exposure therapy in individuals with social anxiety disorder. Design and Methods: Participants will be randomized to receive either low-dose psilocybin or placebo alongside virtual reality exposure therapy. The primary outcome is the change in social anxiety symptoms, measured by the Liebowitz Social Anxiety Scale (LSAS). The primary endpoint is a Cohen’s d ≥ 0.5 for LSAS reduction in the psilocybin group versus placebo. Secondary outcomes include identification of multimodal biomarkers predictive of treatment response. Neuroimaging (e.g., amygdala reactivity, thalamo-cortical connectivity), psychophysiological (e.g., heart rate variability, galvanic skin response, sleep quality), and behavioral task measures (e.g., Affective Shift Task, Emotional Go/No-Go Task) will be analyzed to stratify participants and predict therapeutic response. Successful biomarker stratification is defined as a significant correlation with LSAS change and classification accuracy >70%. Conclusion: This study will provide proof-of-concept evidence for low-dose psilocybin as an adjunct to virtual reality exposure therapy in social anxiety disorder and evaluate multimodal biomarkers for patient stratification. Positive results will support progression to a larger phase 3 trial and inform precision-based approaches for treatment of social anxiety disorder.", "journal": "PsyArXiv", "publication_date": "2026-05-13", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/3b9fx_v1", "keywords": "microdosing, psilocybin, social anxiety, Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"3b9fx_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Anxiety,Brain Imaging,Biomarkers,Aging,Microdosing,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 110, "title": "Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care", "normalized_title": "psilocybin assisted therapy for adolescent anorexia nervosa clinical considerations and emerging models of care", "authors": "Jamarie Geller, Rachel Pacilio, Amanda E. Downey, Anya Ragnhildstveit, Marissa Raymond-Flesch, Stephanie Knatz-Peck, Natalie Gukasyan", "abstract": "PURPOSE OF REVIEW: There is growing evidence that psychedelics and associated treatment modalities may offer therapeutic benefits across a range of psychiatric conditions. Anorexia nervosa (AN), a serious and often treatment-resistant illness associated with significant morbidity and mortality, is one such condition for which psilocybin-assisted therapy (PAT) may hold promise. RECENT FINDINGS: To date, research on PAT for AN has focused primarily on adults, despite the fact that AN frequently begins in adolescence, and early age of onset portends poorer prognosis, including more severe AN, more lifetime psychiatric comorbidity, and greater life difficulties. Given these risks, an exploration of the theoretical potential of PAT for adolescent populations is warranted. Important considerations include biological implications, developmental stage, and consent. Adaptations to the current models of psilocybin-assisted therapy in studies of adults are proposed, and emerging models that address the unique challenges of these patients are discussed.", "journal": "Current Psychiatry Reports", "publication_date": "2026-05-13", "publication_year": 2026, "doi": "10.1007/s11920-026-01679-z", "pubmed_id": "42128951", "source_url": "https://doi.org/10.1007/s11920-026-01679-z", "keywords": "Anorexia nervosa, Psychiatry, Modalities, Medicine, Anorexia, Treatment modality, Psychotherapist, Therapeutic modalities, MEDLINE, Psychology, Clinical psychology, Therapeutic approach, Intensive care medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7161007383\",\"openalex_url\":\"https://openalex.org/W7161007383\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W191267285\",\"https://openalex.org/W1929332534\",\"https://openalex.org/W1964116811\",\"https://openalex.org/W1966419092\",\"https://openalex.org/W1972188670\",\"https://openalex.org/W1974781892\",\"https://openalex.org/W1983594043\",\"https://openalex.org/W1993329984\",\"https://openalex.org/W2006740326\",\"https://openalex.org/W2007872653\",\"https://openalex.org/W2010390718\",\"https://openalex.org/W2050445803\",\"https://openalex.org/W2061250136\",\"https://openalex.org/W2067637201\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2078436067\",\"https://openalex.org/W2093980670\",\"https://openalex.org/W2104374596\",\"https://openalex.org/W2106410954\",\"https://openalex.org/W2110000194\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2113750392\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2134521319\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2156759015\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163215199\",\"https://openalex.org/W2163659555\",\"https://openalex.org/W2165474463\",\"https://openalex.org/W2168303875\",\"https://openalex.org/W2172235018\",\"https://openalex.org/W2234976985\",\"https://openalex.org/W2317322687\",\"https://openalex.org/W2417732505\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2554715860\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2589293646\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2610531139\",\"https://openalex.org/W2611597342\",\"https://openalex.org/W2753989225\",\"https://openalex.org/W2767814720\",\"https://openalex.org/W2777124046\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2885121314\",\"https://openalex.org/W2885939515\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2901877120\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2931582381\",\"https://openalex.org/W2941211759\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2979620240\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3043981803\",\"https://openalex.org/W3083797211\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3122951191\",\"https://openalex.org/W3157290450\",\"https://openalex.org/W3162226086\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3175441262\",\"https://openalex.org/W3181418921\",\"https://openalex.org/W3205826958\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4220935625\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4294132366\",\"https://openalex.org/W4301370297\",\"https://openalex.org/W4310497335\",\"https://openalex.org/W4312093969\",\"https://openalex.org/W4321002369\",\"https://openalex.org/W4321377299\",\"https://openalex.org/W4322765453\",\"https://openalex.org/W4362506603\",\"https://openalex.org/W4362678102\",\"https://openalex.org/W4367664319\",\"https://openalex.org/W4381548553\",\"https://openalex.org/W4383371376\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4386385744\",\"https://openalex.org/W4386828200\",\"https://openalex.org/W4387442719\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4387902564\",\"https://openalex.org/W4387907603\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4390223843\",\"https://openalex.org/W4391352455\",\"https://openalex.org/W4392214448\",\"https://openalex.org/W4392816111\",\"https://openalex.org/W4394693273\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4395110324\",\"https://openalex.org/W4395675481\",\"https://openalex.org/W4395688958\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4396938024\",\"https://openalex.org/W4399525469\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4399592592\",\"https://openalex.org/W4400279567\",\"https://openalex.org/W4400577678\",\"https://openalex.org/W4401554225\",\"https://openalex.org/W4403620011\",\"https://openalex.org/W4404460166\",\"https://openalex.org/W4404961618\",\"https://openalex.org/W4405376152\",\"https://openalex.org/W4405712086\",\"https://openalex.org/W4405890967\",\"https://openalex.org/W4406246123\",\"https://openalex.org/W4406633420\",\"https://openalex.org/W4406893346\",\"https://openalex.org/W4408537793\",\"https://openalex.org/W4411021677\",\"https://openalex.org/W4411177710\",\"https://openalex.org/W4411969620\"],\"authorships\":[{\"id\":\"https://openalex.org/A5000765190\",\"display_name\":\"Jamarie Geller\",\"orcid\":\"https://orcid.org/0000-0001-9049-4400\"},{\"id\":\"https://openalex.org/A5136036664\",\"display_name\":\"Rachel Pacilio\",\"orcid\":\"https://orcid.org/0000-0001-6568-267X\"},{\"id\":\"https://openalex.org/A5037114160\",\"display_name\":\"Amanda E. Downey\",\"orcid\":\"https://orcid.org/0000-0002-5206-7798\"},{\"id\":\"https://openalex.org/A5006257142\",\"display_name\":\"Anya Ragnhildstveit\",\"orcid\":\"https://orcid.org/0000-0002-5796-3428\"},{\"id\":\"https://openalex.org/A5136081842\",\"display_name\":\"Marissa Raymond-Flesch\",\"orcid\":\"https://orcid.org/0000-0003-0037-8970\"},{\"id\":\"https://openalex.org/A5034387137\",\"display_name\":\"Stephanie Knatz-Peck\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S124600697\",\"source_display_name\":\"Current Psychiatry Reports\",\"landing_page_url\":\"https://doi.org/10.1007/s11920-026-01679-z\",\"is_oa\":true}}", "topic_tags": "Eating Disorders,Review Article,Adolescents,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7161007383" }, { "id": 1944, "title": "Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study", "normalized_title": "ethical complexities and best practices in informed consent processes for psilocybin services a qualitative study", "authors": "Christina Chwyl, Alissa Bazinet, Adrianne R. Wilson-Poe, Kim Hoffman, Kellie Pertl, R. Cameron Wolf, P. Todd Korthuis, Jason B. Luoma", "abstract": "Informed consent in psychedelic-assisted services is ethically complex, difficult to implement, and remains largely unstudied and unstandardized. The current study sought expert recommendations on informed consent challenges, best practices and recommendations for supervised psilocybin experiences across various settings. Participants with psilocybin content expertise and psilocybin providers were recruited with purposive sampling. Qualitative interviews on informed consent best practices and recommendations were analyzed using Thematic Analysis. Participants (N = 36; 71% white; 53% female) reported providing psilocybin services (64%) for a mean of 15.2 (SD = 13.1) years in clinical trial, underground, or ceremonial settings. Participants viewed informed consent as a process (Theme 1), necessitating a strong therapeutic relationship, centering client empowerment, and occurring as an ongoing process. Potential risks and benefits should be comprehensively conveyed (Theme 2), including potential long-term psychological and social changes from psychedelic use, and the potential for disappointing experiences. Participants specifically recommended detailed consent processes around touch and boundaries (Theme 3), including explicitly establishing boundaries prior to psychedelic administration, maintaining those boundaries throughout, and recognizing subtle non-verbal cues that may indicate lack of true consent. For provider training (Theme 4), participants emphasized cultivating a deep respect for client agency, and experientially learning relational and boundary setting skills. Findings may inform provider training programs, consent practices in varied psychedelic service settings, and improved safety practices.", "journal": "Neuroethics", "publication_date": "2026-05-12", "publication_year": 2026, "doi": "10.1007/s12152-026-09645-5", "pubmed_id": null, "source_url": "https://doi.org/10.1007/s12152-026-09645-5", "keywords": "Best practice, Psilocybin, Qualitative research, Psychology, Informed consent, Neuropsychology, Psychotherapist, Medical education, Engineering ethics, Ethical issues, MEDLINE, Best evidence, Best interests, CLARITY, Work (physics), Qualitative analysis, Research ethics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Death Anxiety and Social Exclusion", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160917606\",\"openalex_url\":\"https://openalex.org/W7160917606\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1543380695\",\"https://openalex.org/W1691424746\",\"https://openalex.org/W1949616959\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2088693609\",\"https://openalex.org/W2170572063\",\"https://openalex.org/W2199473922\",\"https://openalex.org/W3029961383\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W3124618094\",\"https://openalex.org/W3173955184\",\"https://openalex.org/W3197011626\",\"https://openalex.org/W4283075222\",\"https://openalex.org/W4285890909\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4383334773\",\"https://openalex.org/W4388822593\",\"https://openalex.org/W4390404690\",\"https://openalex.org/W4390988530\",\"https://openalex.org/W4391841842\",\"https://openalex.org/W4394676778\",\"https://openalex.org/W4394693273\",\"https://openalex.org/W4399780176\",\"https://openalex.org/W4402645543\",\"https://openalex.org/W4406325093\",\"https://openalex.org/W4406325134\",\"https://openalex.org/W4406325139\",\"https://openalex.org/W4406325367\",\"https://openalex.org/W4406326126\",\"https://openalex.org/W4406633420\",\"https://openalex.org/W4406960487\",\"https://openalex.org/W4412072125\",\"https://openalex.org/W4412488390\",\"https://openalex.org/W4412984573\",\"https://openalex.org/W7155048769\"],\"authorships\":[{\"id\":\"https://openalex.org/A5075422198\",\"display_name\":\"Christina Chwyl\",\"orcid\":\"https://orcid.org/0000-0002-9257-6650\"},{\"id\":\"https://openalex.org/A5135928668\",\"display_name\":\"Alissa Bazinet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135963136\",\"display_name\":\"Adrianne R. Wilson-Poe\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135986566\",\"display_name\":\"Kim Hoffman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073745691\",\"display_name\":\"Kellie Pertl\",\"orcid\":\"https://orcid.org/0009-0008-0861-3609\"},{\"id\":\"https://openalex.org/A5135947024\",\"display_name\":\"R. Cameron Wolf\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135925843\",\"display_name\":\"P. Todd Korthuis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135991594\",\"display_name\":\"Jason B. Luoma\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S112842941\",\"source_display_name\":\"Neuroethics\",\"landing_page_url\":\"https://doi.org/10.1007/s12152-026-09645-5\",\"is_oa\":true}}", "topic_tags": "Anxiety,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160917606" }, { "id": 112, "title": "Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization", "normalized_title": "inaugural year of regulated psilocybin services in oregon safety motivations and utilization", "authors": "Feliciano Yu, Joe Tafur, Francisco Moreno, Stephen Dahmer", "abstract": "Importance: The Oregon Psilocybin Services (OPS) program is the first statewide, regulated framework for legal psilocybin in the U.S. Analyzing inaugural-year utilization and safety is essential for informing policy and equity monitoring. Methods: We conducted a descriptive analysis of statewide aggregate data from the OPS Public Dashboard (January 1-December 31, 2025). Outcomes included service volume, client demographics, motivations, and acute adverse events. Results: In 2025, 5,935 clients participated in 5,375 sessions. Volume peaked in Q2 (n=1,758) before stabilizing in Q4 (n=1,358). Service tourism was significant, with 32.6% of participants residing outside Oregon. The largest segment was aged 35-49 (~40%); women (57.4%) and LGBTQ+ individuals (27.2%) represented substantial portions of the annual cohort. Racial diversity was limited, with White participants representing 84.1%-91.5% quarterly, while Hispanic/Latino (7.1%) and African American (2.1%) participation lagged. Adverse events were rare, with annual behavioral and medical rates of 2.42 and 2.79 per 1,000 sessions, respectively. Discussion: Full-year data indicate stabilized utilization by a predominantly midlife adult population. While the program successfully reaches sexual and gender minorities, racial disparities persist. High service tourism suggests significant socioeconomic barriers. These findings underscore the program's dual role as a wellness modality and a functional alternative for addressing mental health distress.", "journal": "Frontiers in Psychiatry", "publication_date": "2026-05-12", "publication_year": 2026, "doi": "10.3389/fpsyt.2026.1777387", "pubmed_id": "42233004", "source_url": "https://doi.org/10.3389/fpsyt.2026.1777387", "keywords": "Psilocybin, Socioeconomic status, Mental health, Medicine, Anxiety, Equity (law), Gerontology, Public health, Psychiatry, Health equity, Psychology, Adverse effect, Diversity (politics), Service (business), Family medicine, Service delivery framework, Human services, Service provider, Ethnic group, Marital status, Tourism, Public sector, Partial hospitalization, Descriptive statistics, Cultural diversity, Health care, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7161045271\",\"openalex_url\":\"https://openalex.org/W7161045271\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W191977393\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W4200117112\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4302773366\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4313551556\",\"https://openalex.org/W4378782231\",\"https://openalex.org/W4380715240\",\"https://openalex.org/W4383888973\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386305913\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4402500386\",\"https://openalex.org/W4404145612\",\"https://openalex.org/W4405261412\",\"https://openalex.org/W4405686929\",\"https://openalex.org/W4407768133\",\"https://openalex.org/W4409313347\",\"https://openalex.org/W4409704666\",\"https://openalex.org/W4412197020\",\"https://openalex.org/W4414751415\"],\"authorships\":[{\"id\":\"https://openalex.org/A5136005161\",\"display_name\":\"Feliciano Yu\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005257368\",\"display_name\":\"Joe Tafur\",\"orcid\":null},{\"id\":\"https://openalex.org/A5136049237\",\"display_name\":\"Francisco Moreno\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135114180\",\"display_name\":\"Stephen Dahmer\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2026.1777387\",\"is_oa\":true}}", "topic_tags": "Anxiety,Wellbeing,Observational Study,Safety,Adverse Events,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7161045271" }, { "id": 3710, "title": "A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.", "normalized_title": "a randomized double masked dose controlled trial to assess the tolerability safety subjective experience and efficacy of repeated administration of three different doses of psilocybin whole mushroom for the treatment of obsessive compulsive disorder", "authors": "Francisco A Moreno", "abstract": "The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute. Participants will come to the University of Arizona CATS Research Unit in Tucson for assessment, if they are found to be fit for study participation, they will be scheduled for a preparation session with a study therapist and then will participate in a dosing session when they will ingest three pieces of chocolate containing psilocybin mushroom. They will answer questions of how they are feeling, and will be monitored for safety by two study staff members, and their vital signs will be checked every hour on the day they receive the study drug. The will be sent home with a responsible adult selected by the patient after they are felt to be safe once the effects of the drug have resolved. Participants will receive four different doses separated by about three weeks. After they complete the treatment phase, they will be contacted monthly for follow up assessment of efficacy, and safety.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07347405", "keywords": "Obsessive-Compulsive Disorder, Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07347405\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "OCD,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3527, "title": "Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample", "normalized_title": "safety and feasibility of psilocybin in methamphetamine use disorder in a community based sample", "authors": "University of Wisconsin, Madison", "abstract": "The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks. The objective of this study is to determine the safety of psilocybin in adult participants with MUD. Eligible participants will be adults with methamphetamine use disorder recruited from the community. After physical and psychological screening, and at least 6 hours of psychological support for the psilocybin dosing, each participant will ingest 1 oral dose of psilocybin. All dosing sessions will be attended by 2 specially trained facilitators, in a dedicated Session Room at the University of Wisconsin School of Pharmacy. After eight hours of observation in the dosing room, the participant will stay overnight in the hospital Clinical Research Unit, and complete an integration session with at least one of the session facilitators before discharge to home. Approximately 4 weeks after the first dose, the participant will receive a second oral dose of psilocybin, with the same length of observation. Participants who decide not to proceed to the second dose will complete two additional integration sessions and study measures through the two-month follow-up. If you are interested in participating in this study, please fill out a brief 1-minute survey at the link in the \"More Information\" section at the bottom of this record.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05322954", "keywords": "Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder, Psilocybin, TERMINATED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05322954\",\"overall_status\":\"TERMINATED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Addiction,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3490, "title": "A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder", "normalized_title": "a phase 2b 3 multicentre randomised double blind controlled trial with an open label extension to investigate the efficacy safety and tolerability of comp360 in participants with post traumatic stress disorder", "authors": "COMPASS Pathways", "abstract": "The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07570654", "keywords": "PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder, COMP360 psilocybin, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07570654\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\",\"PHASE3\"]}", "topic_tags": "PTSD,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1945, "title": "Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin", "normalized_title": "rapid acting interventions in treatment resistant depression a comparative review of esketamine and psilocybin", "authors": "Bartłomiej Kosiarski, Anna Skrzypek, Patrycja Markowicz, Mikołaj Zbrożek, Krzysztof Biłyk, Maciej Hutkowski, Zuzanna Chwostek, Hanna Maruchniak, Wiktoria Marzec, Paulina Biedroń", "abstract": "Introduction and Objective.Treatment-resistant depression (TRD) remains a major clinical challenge affecting patients who fail to respond to at least two adequate antidepressant trials.The development of rapid-acting interventions targeting non-monoaminergic pathways has introduced new therapeutic possibilities.The aim of the review is to critically examine intranasal esketamine and psilocybin-assisted psychotherapy in TRD, comparing their mechanisms of action, clinical efficacy, durability of response, and safety profiles.Materials and Method.A narrative review method consisting of a literature review was conducted using PubMed and Google Scholar databases.Randomized controlled trials, phase II-IV clinical trials, systematic reviews, and meta-analyses published primarily within the last eight years were analyzed.Case reports and preclinical studies were excluded.Brief description of the state of knowledge.Esketamine, an NMDA receptor antagonist, has demonstrated rapid antidepressant effects within hours and has received regulatory approval for TRD.While effect sizes are generally modest, relapse prevention has been shown in maintenance trials.Psilocybin, a 5-HT2A receptor agonist administered within a structured psychotherapeutic framework, has shown promising antidepressant effects in early-phase trials, including a large phase IIb study, with sustained improvement following limited dosing.However, its evidence base remains constrained by methodological challenges and limited long-term data.Summary.Both agents converge on neuroplasticity-related mechanisms yet differ substantially in clinical implementation.Esketamine is an approved rapid-acting option for TRD, whereas psilocybin remains investigational.Further adequately powered trials and long-term safety data are required to define their roles within evolving treatment paradigms.", "journal": "Journal of Pre-Clinical and Clinical Research", "publication_date": "2026-05-11", "publication_year": 2026, "doi": "10.26444/jpccr/221219", "pubmed_id": null, "source_url": "https://doi.org/10.26444/jpccr/221219", "keywords": "Medicine, Depression (economics), Psilocybin, Psychological intervention, Psychiatry, Treatment-resistant depression, Major depressive disorder, Anxiety, MEDLINE, Depressive symptoms, Clinical psychology, Psychology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Treatment of Major Depression", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160910785\",\"openalex_url\":\"https://openalex.org/W7160910785\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5124992076\",\"display_name\":\"Bartłomiej Kosiarski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5136000378\",\"display_name\":\"Anna Skrzypek\",\"orcid\":\"https://orcid.org/0009-0007-6771-3186\"},{\"id\":\"https://openalex.org/A5124981381\",\"display_name\":\"Patrycja Markowicz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5006502767\",\"display_name\":\"Mikołaj Zbrożek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125011428\",\"display_name\":\"Krzysztof Biłyk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125059894\",\"display_name\":\"Maciej Hutkowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125072333\",\"display_name\":\"Zuzanna Chwostek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124993719\",\"display_name\":\"Hanna Maruchniak\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135973834\",\"display_name\":\"Wiktoria Marzec\",\"orcid\":\"https://orcid.org/0009-0006-6395-6263\"},{\"id\":\"https://openalex.org/A5125013949\",\"display_name\":\"Paulina Biedroń\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764897176\",\"source_display_name\":\"Journal of Pre-Clinical and Clinical Research\",\"landing_page_url\":\"https://doi.org/10.26444/jpccr/221219\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Case Report,Animal Study,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160910785" }, { "id": 113, "title": "Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation", "normalized_title": "efficacy and safety of a single dose of psilocybin for chronic suicidal ideation", "authors": "Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm, Scott T. Aaronson", "abstract": "To evaluate the efficacy, safety, and durability of a single 25-mg dose of a proprietary, synthetic formulation of psilocybin with psychological support for reducing chronic suicidal ideation in a treatment-resistant population. ), and ≥2 prior antidepressant treatment failures received a single 25-mg dose of psilocybin administered within a structured preparatory and integration psychotherapy protocol. The primary outcome was change from baseline in the Modified Scale for Suicidal Ideation (MSSI) at week 3. Secondary outcomes included change in MSSI at weeks 1 and 12 and change in Montgomery-Asberg Depression Rating Scale (MADRS) scores at weeks 1, 3, and 12. Outcomes were analyzed using 1-way repeated-measures analysis of variance with Bonferroni-adjusted pairwise comparisons. = 1.63-1.97). No serious adverse events occurred. In this open-label single-arm study of adults with chronic suicidal ideation and prior treatment failures, a single administration of psilocybin with psychological support was associated with rapid, large-magnitude, and durable reductions in suicidal ideation and depressive symptoms through 12 weeks. These preliminary findings support further evaluation in larger randomized controlled trials. ClinicalTrials.gov Identifier: NCT05220410.", "journal": "The Journal of Clinical Psychiatry", "publication_date": "2026-05-11", "publication_year": 2026, "doi": "10.4088/jcp.26m16338", "pubmed_id": "42138588", "source_url": "https://doi.org/10.4088/jcp.26m16338", "keywords": "Psilocybin, Suicidal ideation, Medicine, Psychiatry, Poison control, Hallucinogen, Clinical psychology, Suicide prevention, Human factors and ergonomics, Depression (economics), MEDLINE, Psychology, Injury prevention, Paroxetine, Clinical trial, Psychotherapist, Occupational safety and health, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160906477\",\"openalex_url\":\"https://openalex.org/W7160906477\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5026620795\",\"display_name\":\"Andrew van der Vaart\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093433058\",\"display_name\":\"Jeffrey LaPratt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112139669\",\"display_name\":\"Kimberly Swartz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054892136\",\"display_name\":\"Audrey Shoultz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135921394\",\"display_name\":\"Margo Lauterbach\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135924331\",\"display_name\":\"Trisha Suppes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021365968\",\"display_name\":\"Harold A. Sackeïm\",\"orcid\":\"https://orcid.org/0000-0002-1107-4553\"},{\"id\":\"https://openalex.org/A5135997839\",\"display_name\":\"Scott T. Aaronson\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S17992710\",\"source_display_name\":\"The Journal of Clinical Psychiatry\",\"landing_page_url\":\"https://doi.org/10.4088/jcp.26m16338\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160906477" }, { "id": 3022, "title": "Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review", "normalized_title": "safety and efficacy of psilocybin in the management of treatment resistant depression a systematic review", "authors": "Walters CK, Chetty S, Rants’o TA, Gossayn S, Lerotholi LJ.", "abstract": "Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin-assisted therapy has emerged as a promising modality due to its rapid-acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin-assisted therapy the evidence for its use remains fragmented. Aim: To systematically review the evidence on the safety and efficacy of psilocybin in adults with TRD. Methods: This review follows the Preferred Reporting Items for Systematic Reviews (PRISMA) and JBI Manual for Systematic Reviews of Effectiveness. PubMed ®, MEDLINE ®, the Cochrane Collaboration's CENTRAL ® trials registry, PsycINFO ® and EMBASE ® were searched between 2014 and 2025 for clinical trials and observational studies that met the inclusion criteria for psilocybin versus other antidepressants for TRD. The JBI Critical Appraisal Checklists were used to assess the quality of the clinical trials. The review protocol was registered on PROSPERO (CRD420251063913) Results: Six trials met the inclusion criteria. Psilocybin showed promising results in lowering depressive scores in participants with TRD. Common adverse events included anxiety, nausea, headache, fatigue and suicidal ideation. No serious safety concerns or cases of physiological toxicity were identified. Study limitations included small sample sizes, open-label designs, and heterogeneous psychotherapy protocols. Conclusions: Psilocybin as a novel therapy for TRD demonstrates promising efficacy and tolerability safety profile. Nonetheless, current evidence remains preliminary, and larger, methodologically robust randomized trials are needed to confirm efficacy, optimize dosing, and standardize psychological support frameworks.", "journal": "Research Square", "publication_date": "2026-05-10", "publication_year": 2026, "doi": "10.21203/rs.3.rs-9283280/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-9283280/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:45", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1188752\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Observational Study,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3570, "title": "The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.", "normalized_title": "the safety and efficacy of psilocybin therapy compared to low dose control in reducing depressive symptoms in patients with copd als ms or apd", "authors": "University Medical Center Groningen", "abstract": "The goal of this clinical trial is to evaluate whether psilocybin therapy can effectively treat depression and psychological distress in adult patients with COPD, ALS, MS, or APD who have at least 6 months life expectancy. The main questions it aims to answer are: * Can psilocybin therapy safely reduce depressive symptoms compared to low-dose control? * Will the therapeutic effects be rapid and sustained over a 6-month period? Researchers will compare patients receiving two escalating doses of psilocybin (15mg followed by 25mg) against those receiving two low doses (1mg) to see if the higher doses lead to greater improvements in depression, anxiety, demoralization, and quality of life. Participants will: * Attend three preparation sessions with psychotherapists (1-2 hours each) * Undergo two supervised psilocybin dosing sessions (6-8 hours each) * Complete five integration therapy sessions following the dosing sessions * Participate in follow-up assessments at 6 weeks, 3 months, and 6 months * Have access to a digital care platform and peer support groups during the 6-month follow-up period * Optional: Control group participants may receive one high-dose psilocybin session (25mg) after the initial study period Rationale Patients with chronic obstructive pulmonary disorder (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), or atypical and advanced Parkinsonian disorder (APD) often suffer from severe psychological distress with demoralization and death anxiety, which may culminate in to depressive disorder. Treatments of depression in palliative care currently involves psychotherapy and/or the use of antidepressants. However, these treatments have shown limited efficacy which urgently calls for new and innovative approaches. In recent years, a number of studies have shown very promising results of psilocybin therapy in alleviating psychological distress in patients with advanced cancer. The current study (PsyPal) aims to evaluate whether psilocybin therapy can also lead to rapid and sustained decreases in depressive symptoms, demoralization and other facets of psychological distress in patients who suffer from COPD, ALS, MS and APD. Objective The primary objective of the PsyPal study is to assess the safety and efficacy of psilocybin therapy compared to low-dose control in reducing depressive symptoms in patients with COPD, ALS, MS, or APD. Secondary objectives of PsyPal are to assess change in clinical functioning, end-of-life anxiety, psychological/existential distress, health-related quality of life, and how it impacts caregiver 's health- and economic burden. The safety objective of PsyPal is to evaluate the difference in adverse events between high and low dose groups before, during and after the dosing session. Exploratory objectives include the investigation of psychological mechanism, subjective effects, biomarkers (EEG and blood-based), cost-effectiveness, and the usefulness of a digital care platform, with a mixed methods approach. Main trial endpoints The main trial endpoint for PsyPal is the change in depression severity from baseline to 6 weeks after the second dose of psilocybin (high dose session). Adverse events and change in depression symptoms will also be assessed at 3- and 6-month follow-up to determine the safety and sustained effects of psilocybin therapy. Secondary trial endpoints Secondary trial endpoints will be assessed at baseline and 6 weeks after the second dose of psilocybin. These include response rate, anxiety, demoralization, health-related quality of life, experiential avoidance, coping with illness, death anxiety, the wish to hasten death, self-compassion, spirituality, attachment, pain, healthcare resource use, blood-based biomarkers, and functional brain changes. Some secondary endpoints will also be assessed at the 3- and 6-month follow-up, including anxiety, demoralization, health-related quality of life, experiential avoidance, and coping with illness. These endpoints aim to improve our understanding of the effects of psilocybin therapy, how psilocybin therapy works, and to see which patients show the best response. Finally, changes in (religious/spiritual) beliefs/understandings and the experience(s) with psilocybin therapy will be assessed through in-depth qualitative interviews with patients that are conducted 6 weeks after the second dose of psilocybin. Trial design PsyPal trial consists of a double-blind randomized low-dose controlled clinical trial with long term follow-up. Patients who are enrolled in the trial will be actively participating for ten weeks. After the primary endpoint, patients who received a low dose of psilocybin (1 mg) will be offered an optional single open label high-dose of psilocybin (25mg) together with three integration sessions. During long-term follow-up, patients will have access to a digital care platform and peer support groups. Trial population The trial population in PsyPal consists of patients with COPD, ALS, MS, or APD and co-morbid depression. The main further inclusion criteria for participation are an age of 18 or higher, having an identified caregiver or support person, and a life expectancy of at least 6 months. The main exclusion criteria are current use of antipsychotic drugs, suicidal ideations, schizophrenia or other psychotic disorders, bipolar I/II disorder, other major neurological conditions, cardiovascular conditions, diabetes, and/or moderate to severe hepatic impairment (i.e., liver failure). Other exclusion criteria are a first-degree relative on the schizophrenia spectrum, other psychotic disorders, or bipolar I disorder. Interventions Patients will receive psilocybin therapy consisting of three phases; 1) preparation, 2) dosing, and 3) integration: Preparation - The preparation phase consists of three psychotherapy sessions of 1-2 hours each. The purpose of these sessions is threefold: to build a therapeutic alliance between the patient and the therapist, to make a psychotherapeutic treatment plan for the patient using a process-based approach, and to educate patients about psilocybin's acute effects and how patients and therapists together can handle difficult experiences during the dosing sessions. Dosing - The dosing phase of PsyPal starts 1-3 days after the last preparation session. It consists of two escalating dosing sessions of 6-8 hours each. The patient first receives a moderate dose of psilocybin (15mg). Two weeks later, the patient receives a high dose of psilocybin (25mg). Patients in the control group will receive two doses of psilocybin (1mg). All dosing sessions take place under supervision of two trained therapists within a treatment room specifically designed for psilocybin therapy and with a medical doctor on call. Integration - The integration phase consists of five psychotherapeutic sessions of 1-2 hours each. There are two integration sessions following the first dosing session and three integration sessions following the second dosing session. The integration sessions are intended for further psychotherapeutic work, including working with the experience(s) that may have emerged during dosing sessions, and clinical assessment of the patient. Central topics may include the relationship with their life-limiting illness, death, meaning, sense of purpose, personal (religious/spiritual) beliefs, (social) relationships, and conflict resolution. The patient can also share thoughts and feelings about the PsyPal trial. Long-term follow-up After the intervention, patients will be returned to regular care and followed for a period of 6 months, tracking usage of healthcare resources, the digital care platform, and peer support groups. Qualitative aspects of the intervention will be evaluated for patients, caregivers and therapists. Long-term safety data of psilocybin therapy will be collected for the four patient populations.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-07", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06782724", "keywords": "COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major Depressive Disorder (MDD), Atypical Parkinson Disease, Psilocybin therapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06782724\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Chronic Pain,Brain Imaging,Biomarkers,Spirituality,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3496, "title": "Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial", "normalized_title": "does psilocybin require psychedelic effects to treat depression a4 week double blind proof of concept randomized controlled trial", "authors": "Centre for Addiction and Mental Health", "abstract": "Psilocybin, the chemical component of \"magic mushrooms\", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of serotonin (5HT)2A receptor antagonists such as risperidone. The purpose of this \"double dummy\" proof-of-concept trial is to evaluate whether psilocybin's antidepressant effects are dependent on its psychedelic effects. Sixty participants with treatment-resistant depression will be randomly assigned to one of three groups: 1) Psilocybin 25 mg plus risperidone 1 mg; 2) Psilocybin 25 mg plus placebo; and 3) Placebo plus risperidone 1 mg. The investigator's hypothesize that the combination of psilocybin and risperidone will be well tolerated, safe, and will block the psychedelic effects of psilocybin in patients diagnosed with treatment-resistant depression. This study is a three-arm, 4-week, double blind, proof-of concept RCT for investigating psilocybin-assisted psychotherapy (PAP) administered with risperidone in treating TRD. This three-arm \"double dummy\" design allows for an assessment of risperidone's anti-psychedelic effects, while allowing for an assessment of psilocybin's antidepressant effects alone and combined with risperidone, compared to an \"active placebo\" (i.e. placebo plus risperidone 1 mg). Overview of Study Design: A study team member will obtain informed consent from interested participants prior to study activities being initiated. Following this, participants will undergo a screening assessment where they will complete lab tests, and clinical and psychiatric assessments to determine eligibility. Following the screening visit, eligible participants will undergo a washout period where they will be tapered off concomitant medication over a period of 4 to 6 weeks. The length of the tapering period will depend on the type of medication the participant is being tapered off (based on the half-life of the medication) and the participant's preference for the length of the tapering period. Most medications will require a minimum of a 2-week tapering period before the baseline, with the exception of fluoxetine, which will require a minimum of 4-weeks. Additional time may be added at the discretion of the study investigator. During the tapering period, the study psychiatrist will see participants weekly (V1a, V1b, etc.) for at least 4 weeks to monitor for withdrawal and worsening of depressive symptoms and suicidality. Suicidality will be closely monitored using the Columbia Suicide Severity Rating Scale (C-SSRS). Participants and their family members/carers will be educated on the signs and symptoms of worsening depression and suicidality and will be given contact details of the study team in case of major decline in mental state. At the Baseline visit (V2), which occurs the day before the dosing session, participants will complete clinical measures, and undergo a preparatory session (up to 4 hours) with the study therapists. These sessions will build a therapeutic alliance, provide psychoeducation about, and set intentions for, the psilocybin session. To reduce participant burden, baseline can be broken up into multiple days, however all assessments must be completed within 7-days of the intervention. Ideally, baseline occurs the day before the intervention is administered. The psilocybin session (Day 0 \\[V3\\]) will last 5 to 6 hours and will be conducted in the existing psychedelic treatment suite developed at the Centre for Addiction and Mental Health (CAMH) Mood Disorder Service by Dr. Husain (PI). Two trained study therapists will be supporting each participant during the dosing session. Participants will receive psilocybin 25 mg plus risperidone 1 mg, or psilocybin 25 mg plus placebo, or placebo plus risperidone 1 mg. All participants will receive 10 hours of manualized supportive psychotherapy (which includes the 5-6 hour dosing session). After 5 hours of dose administration, participants will be evaluated for safety by the study psychiatrist and discharged home in the company of a caregiver or a family member. After the dosing session, participants will be seen for two 1-hour integration sessions (Day 1 \\[V4\\], Week 1 \\[V5\\]). Thereafter, participants will be followed-up after 2 \\[V6\\], 3 \\[V7\\] and 4 weeks \\[V8\\] post-dosing (see Figure 1). A study psychiatrist will be available throughout the duration of the RCT to respond to any concerns or changes in mental/physical state. Participants will not start other interventions for MDD during the study.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-06", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05710237", "keywords": "Treatment-resistant Depression, Psilocybin 25 mg, Risperidone 1 MG, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05710237\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Addiction,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1947, "title": "Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review", "normalized_title": "psilocybin assisted therapy in depressive disorders efficacy safety and persistence of clinical effects a narrative review", "authors": "Kinga Zachar, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Zuzanna Marczak, Monika Jarowicz, Jędrzej Czmyr", "abstract": "Introduction and purpose: Depressive disorders, particularly major depressive disorder (MDD) and treatment-resistant depression (TRD), remain major causes of disability worldwide. Conventional treatments are limited by delayed onset, incomplete response, relapse, and adverse effects. This review summarizes current evidence on the efficacy, safety, and durability of psilocybin-assisted therapy in depressive disorders. Brief description of the state of knowledge: Evidence from randomized trials, open-label studies, follow-up analyses, and meta-analyses indicates that psilocybin-assisted therapy can produce rapid reductions in depressive symptoms, often within days, in carefully selected patients treated in controlled settings. Short-term benefits have been reported in both MDD and TRD, although findings in TRD are less consistent. In a head-to-head trial, psilocybin was not superior to escitalopram on the primary endpoint, while several secondary outcomes favored psilocybin. Follow-up studies suggest that benefits may persist for weeks to months, but longer-term evidence remains limited and heterogeneous. Under supervision, psilocybin was generally well tolerated, with mostly transient adverse effects, including anxiety, nausea, headache, dizziness, and brief cardiovascular activation. Summary: Psilocybin-assisted therapy appears to be a promising investigational approach for depressive disorders, with rapid onset and possible medium-term benefit in some patients. However, the evidence base remains limited by small samples, heterogeneous designs, restricted comparative data, and delivery in specialized settings. Larger and longer-term studies are needed to clarify comparative efficacy, durability, long-term safety, and feasibility in routine clinical practice.", "journal": "Journal of Education Health and Sport", "publication_date": "2026-05-06", "publication_year": 2026, "doi": "10.12775/jehs.2026.91.70672", "pubmed_id": null, "source_url": "https://doi.org/10.12775/jehs.2026.91.70672", "keywords": "Major depressive disorder, Escitalopram, Narrative review, Persistence (discontinuity), Depression (economics), Adverse effect, Medicine, Psychiatry, Depressive symptoms, Randomized controlled trial, Psilocybin, Clinical trial, Clinical psychology, Psychology, Systematic review, MEDLINE, Meta-analysis, Placebo, Treatment-resistant depression, Psychotherapist, Evidence-based medicine, Intensive care medicine, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160694792\",\"openalex_url\":\"https://openalex.org/W7160694792\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5130856364\",\"display_name\":\"Kinga Zachar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5029490084\",\"display_name\":\"Maksymilian Sito\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130867938\",\"display_name\":\"Filip Jurkowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135762224\",\"display_name\":\"Łukasz Wójcik\",\"orcid\":\"https://orcid.org/0009-0003-1516-3478\"},{\"id\":\"https://openalex.org/A5037631537\",\"display_name\":\"Natalia Gawron\",\"orcid\":\"https://orcid.org/0000-0002-6052-1946\"},{\"id\":\"https://openalex.org/A5133327046\",\"display_name\":\"Hubert Tomasz Bojanowski\",\"orcid\":\"https://orcid.org/0009-0000-6899-6914\"},{\"id\":\"https://openalex.org/A5130834411\",\"display_name\":\"Aleksandra Dobracka\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030096899\",\"display_name\":\"Zuzanna Marczak\",\"orcid\":\"https://orcid.org/0009-0002-9539-9255\"},{\"id\":\"https://openalex.org/A5118987347\",\"display_name\":\"Monika Jarowicz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092030361\",\"display_name\":\"Jędrzej Czmyr\",\"orcid\":\"https://orcid.org/0000-0002-3898-5322\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737571363\",\"source_display_name\":\"Journal of Education Health and Sport\",\"landing_page_url\":\"https://doi.org/10.12775/jehs.2026.91.70672\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160694792" }, { "id": 127, "title": "Psilocybin in the Treatment of Cocaine Use Disorder", "normalized_title": "psilocybin in the treatment of cocaine use disorder", "authors": "Peter S. Hendricks, Sara Lappan, Richard C. Shelton, Adrienne C. Lahti, Karen L. Cropsey, Matthew W. Johnson, Melissa Bradley, Otto Simonsson, Lori L. Davis, Daniel H. Grossman, Cynthia E. Ortiz", "abstract": "Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete abstinence from cocaine, and a greater latency to first cocaine lapse through 180 days after end of treatment. Design, Setting, and Participants: Randomized, quadruple-blind, placebo-controlled clinical trial at a major medical research center in the Deep South of the US. Participants were individuals with cocaine use disorder who were motivated to quit and without significant comorbidities, recruited between May 2015 and August 2023 with data collection completed in May 2024. Interventions: Participants were randomized (1:1) to receive a single oral dose of psilocybin (25 mg per 70 kg of body weight) or active placebo (100 mg diphenhydramine). All participants received manualized psychotherapy that incorporated cognitive-behavioral treatment approximately 1 month before and 1 month after an all-day investigational drug treatment session. Main Outcomes and Measures: Percentage of cocaine abstinent days, rates of complete cocaine abstinence, and time to first cocaine lapse through 180 days after end of treatment, assessed by timeline followback interview and confirmed with urinalysis. Hypotheses were formulated before data collection and analyses followed intention-to-treat principles. Results: Of the 40 participants, 33 (82.5%) were men, the median (IQR) age was 50.0 (43.8-56.0) years, 33 (82.5%) were Black, and 7 (17.5%) were White. Most participants had lower socioeconomic status, with 26 participants (65%) having an annual income of $20 000 or less. Four participants were lost to follow-up, resulting in 36 participants who completed assessments through 180 days after end of treatment. Psilocybin recipients had a higher percentage of cocaine abstinent days (β = 28.95; 95% CI, 18.22-39.67; P", "journal": "JAMA Network Open", "publication_date": "2026-05-06", "publication_year": 2026, "doi": "10.1001/jamanetworkopen.2026.11029", "pubmed_id": "42096204", "source_url": "https://doi.org/10.1001/jamanetworkopen.2026.11029", "keywords": "Psilocybin, Abstinence, Cocaine dependence, Cocaine use, Placebo, Medicine, Psychiatry, Hallucinogen, Stimulant, Clinical trial, Randomized controlled trial, Psychology, Substance abuse, Adverse effect, Young adult, Alcohol use disorder, Addiction, Analysis of variance, Anesthesia, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160534089\",\"openalex_url\":\"https://openalex.org/W7160534089\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1584365622\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1984486655\",\"https://openalex.org/W1987027845\",\"https://openalex.org/W1989789611\",\"https://openalex.org/W2013416277\",\"https://openalex.org/W2017152382\",\"https://openalex.org/W2018820143\",\"https://openalex.org/W2027462039\",\"https://openalex.org/W2035126508\",\"https://openalex.org/W2050266605\",\"https://openalex.org/W2079140185\",\"https://openalex.org/W2088785539\",\"https://openalex.org/W2107899339\",\"https://openalex.org/W2280637367\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2609037098\",\"https://openalex.org/W2800619177\",\"https://openalex.org/W2952695707\",\"https://openalex.org/W3001993019\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3157239742\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W4210930773\",\"https://openalex.org/W4220895732\",\"https://openalex.org/W4245872552\",\"https://openalex.org/W4280579129\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4362507376\",\"https://openalex.org/W4375852011\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4391109410\",\"https://openalex.org/W4399497774\",\"https://openalex.org/W4401774886\",\"https://openalex.org/W4403320347\",\"https://openalex.org/W4408345055\",\"https://openalex.org/W4408424120\",\"https://openalex.org/W4409483458\",\"https://openalex.org/W4410309291\",\"https://openalex.org/W4412642858\",\"https://openalex.org/W4412738512\",\"https://openalex.org/W4413257359\",\"https://openalex.org/W4414083606\",\"https://openalex.org/W7134891055\"],\"authorships\":[{\"id\":\"https://openalex.org/A5004506349\",\"display_name\":\"Peter S. Hendricks\",\"orcid\":null},{\"id\":\"https://openalex.org/A5090928571\",\"display_name\":\"Sara Lappan\",\"orcid\":\"https://orcid.org/0000-0002-0956-3702\"},{\"id\":\"https://openalex.org/A5101995217\",\"display_name\":\"Richard C. Shelton\",\"orcid\":\"https://orcid.org/0000-0003-4054-9906\"},{\"id\":\"https://openalex.org/A5135567726\",\"display_name\":\"Adrienne C. Lahti\",\"orcid\":\"https://orcid.org/0000-0002-5565-7662\"},{\"id\":\"https://openalex.org/A5040663799\",\"display_name\":\"Karen L. Cropsey\",\"orcid\":\"https://orcid.org/0000-0001-6921-3440\"},{\"id\":\"https://openalex.org/A5135541930\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088441598\",\"display_name\":\"Melissa Bradley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070434156\",\"display_name\":\"Otto Simonsson\",\"orcid\":\"https://orcid.org/0000-0003-4197-7566\"},{\"id\":\"https://openalex.org/A5031284323\",\"display_name\":\"Lori L. Davis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5026664487\",\"display_name\":\"Daniel H. Grossman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063009369\",\"display_name\":\"Cynthia E. Ortiz\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210217848\",\"source_display_name\":\"JAMA Network Open\",\"landing_page_url\":\"https://doi.org/10.1001/jamanetworkopen.2026.11029\",\"is_oa\":true}}", "topic_tags": "Addiction,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160534089" }, { "id": 117, "title": "The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus", "normalized_title": "the magic of mushrooms psilocybin influences behavior in the mangrove rivulus fish kryptolebias marmoratus", "authors": "Dayna Forsyth, Nicoletta Faraone, Simon G. Lamarre, Suzanne Currie", "abstract": "Non-human models, including fish, are increasingly important for investigating how pharmacological agents such as hallucinogens influence behavior, physiology, and cellular processes. These models help to reveal underlying mechanisms and to support assessments of toxicological impact, efficacy, and safety. In this study, we used isogenic lineages of the amphibious mangrove rivulus ( Kryptolebias marmoratus ), an emerging model fish known for high activity and socially dynamic interactions. This species often display aggression towards conspecifics making it well-suited to study behavioral effects of low doses of the psychoactive compound, psilocybin. We determined whether psilocybin could induce calming effects and reduce social aggression and activity. We socially stimulated fish using pairs of size-matched fish from different isogenic lineages and compared baseline social behavior following a waterborne dose of psilocybin. Waterborne psilocybin treatment resulted in a significant decrease in activity levels and in the frequency of swimming bursts (an aggressive behavior) towards a conspecific fish from a different lineage, with modest alterations on other behaviors. Our results also revealed considerable intraspecific variation in the behavioral response of these homozygous fish, suggesting the effects of psilocybin were largely independent of genotype. This study demonstrates that psilocybin reduces aggression and activity in an emerging fish model, adding to the evidence supporting its potential as a therapeutic agent for future clinical translation.", "journal": "Frontiers in Behavioral Neuroscience", "publication_date": "2026-05-06", "publication_year": 2026, "doi": "10.3389/fnbeh.2026.1767175", "pubmed_id": "42182826", "source_url": "https://doi.org/10.3389/fnbeh.2026.1767175", "keywords": "Psilocybin, Hallucinogen, Intraspecific competition, Aggression, Biology, Zoology, Fish, Ecology, Psychology, Mangrove, Animal behavior, Social behavior, Predation, Psychedelics and Drug Studies, Marine Invertebrate Physiology and Ecology, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7160487085\",\"openalex_url\":\"https://openalex.org/W7160487085\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1775663747\",\"https://openalex.org/W1806947502\",\"https://openalex.org/W1951724000\",\"https://openalex.org/W1966711563\",\"https://openalex.org/W1975499949\",\"https://openalex.org/W1982402721\",\"https://openalex.org/W1984431812\",\"https://openalex.org/W2009849979\",\"https://openalex.org/W2013666549\",\"https://openalex.org/W2016681203\",\"https://openalex.org/W2019531106\",\"https://openalex.org/W2024868516\",\"https://openalex.org/W2028800792\",\"https://openalex.org/W2034905373\",\"https://openalex.org/W2036881907\",\"https://openalex.org/W2038786381\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2046502793\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2071926809\",\"https://openalex.org/W2082640247\",\"https://openalex.org/W2095796830\",\"https://openalex.org/W2122753637\",\"https://openalex.org/W2129427539\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2138545270\",\"https://openalex.org/W2151228900\",\"https://openalex.org/W2162700737\",\"https://openalex.org/W2168821442\",\"https://openalex.org/W2170274565\",\"https://openalex.org/W2170867618\",\"https://openalex.org/W2171928686\",\"https://openalex.org/W2182762473\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2263689053\",\"https://openalex.org/W2460061147\",\"https://openalex.org/W2499216663\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2899395995\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2954885324\",\"https://openalex.org/W3004861067\",\"https://openalex.org/W3004880168\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3045246175\",\"https://openalex.org/W3084004974\",\"https://openalex.org/W3112700248\",\"https://openalex.org/W3135022192\",\"https://openalex.org/W3153999239\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4319298186\",\"https://openalex.org/W4319461950\",\"https://openalex.org/W4384818943\",\"https://openalex.org/W4386519754\",\"https://openalex.org/W4390951308\",\"https://openalex.org/W4391842082\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4399608030\",\"https://openalex.org/W4401212791\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4407760356\",\"https://openalex.org/W4413969371\",\"https://openalex.org/W7125978309\"],\"authorships\":[{\"id\":\"https://openalex.org/A5132543467\",\"display_name\":\"Dayna Forsyth\",\"orcid\":null},{\"id\":\"https://openalex.org/A5025284474\",\"display_name\":\"Nicoletta Faraone\",\"orcid\":\"https://orcid.org/0000-0002-9246-3672\"},{\"id\":\"https://openalex.org/A5134934519\",\"display_name\":\"Simon G. Lamarre\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091764470\",\"display_name\":\"Suzanne Currie\",\"orcid\":\"https://orcid.org/0000-0002-7734-7200\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S76576941\",\"source_display_name\":\"Frontiers in Behavioral Neuroscience\",\"landing_page_url\":\"https://doi.org/10.3389/fnbeh.2026.1767175\",\"is_oa\":true}}", "topic_tags": "Mechanism of Action,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7160487085" }, { "id": 3620, "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer", "normalized_title": "a phase 2 randomized double blind placebo controlled study to evaluate the efficacy and safety of up to two doses of psilocybin for the treatment of major depressive disorder in adults with cancer", "authors": "Sunstone Medical", "abstract": "This is a Phase 2, single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks in patients with MDD and cancer. This two-part study will administer a fixed dose (25 mg) of psilocybin in a double-blind, randomized, placebo-controlled portion (Dosing Session 1) and subsequently allow rollover into an open-label portion (Dosing Session 2; fixed dose of psilocybin, 25 mg) for patients who do not achieve remission of MDD symptoms after the first dose. In Dosing Session 1, groups of two to four patients will be randomized, as a cohort, to receive either psilocybin 25 mg or niacin 100 mg (active placebo) in a group session, with each patient supported by their dedicated study therapist and monitored by a second therapist via video feed. In Dosing Session 2, all eligible participants (i.e., patients who have not achieved remission defined as MADRS \\< 10 at V7) will receive psilocybin 25 mg in an open-label fashion using the group session model. The study population will include adult men and women who are 18 years of age or older and have diagnoses of both MDD and a malignant neoplasm. MDD is defined as the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnostic criteria for a single or recurrent episode of MDD without psychotic features. A diagnosis of a malignant neoplasm is defined as having a diagnostic code from C00 to C97 according to the International Classification of Diseases, 10th edition (ICD-10). Participants will be recruited through referrals from specialized psychiatric and oncology services as well as through patient self-referrals. The majority of participants will have no prior exposure to psilocybin or so-called \"magic mushrooms\"; however, participants with prior recreational experience with psilocybin or \"magic mushrooms\" are eligible.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-05", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05947383", "keywords": "Cancer, Major Depressive Disorder, Psilocybin, Placebo, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05947383\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Observational Study,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3536, "title": "A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder", "normalized_title": "a phase 2 randomized study examining the safety feasibility and effectiveness of masking psilocybin therapy with general anesthesia in major depressive disorder", "authors": "Stanford University", "abstract": "Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is that participants can usually tell whether they received the active drug - making it hard to conduct fully blinded studies. This study (Studying Psilocybin with Anesthesia Controlled by EEG \\[SPACE\\]) tests a new approach: administering psilocybin while participants are under general anesthesia, so that the noticeable psychological effects of psilocybin are masked. This allows both participants and outcome assessors to remain unaware of whether psilocybin or placebo was given, improving the scientific rigor of the research. Participants with MDD will be randomly assigned to receive either psilocybin or placebo across four dosing sessions conducted under general anesthesia. The study will assess whether this approach is safe and feasible, and will collect early data on whether it may reduce depression symptoms. Participants will receive four dosing sessions spaced one week apart. Each session involves taking an oral capsule containing either psilocybin (10 mg or 25 mg) or placebo, followed by general anesthesia with propofol. All sessions take place at Stanford Hospital under the supervision of a board-certified anesthesiologist. Between and after sessions, participants complete questionnaires about mood, sleep, wellbeing, and anxiety. Participants may also wear a consumer-grade EEG headband at home to track sleep patterns. The total study duration per participant is approximately 7 weeks, across around 25 visits, most of which are conducted remotely. Psilocybin is not FDA-approved and is administered under an FDA Investigational New Drug (IND) authorization for research purposes only.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-05", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07479550", "keywords": "Major Depression, Psilocybin (Usona Institute), Propofol, Placebo, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07479550\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Brain Imaging,Wellbeing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3559, "title": "A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression", "normalized_title": "a phase 2 sequential dose finding study of preparation for group retreat psilocybin therapy for healthcare clinicians with loss of meaning in their work and symptoms of depression", "authors": "University of Washington", "abstract": "In this single-arm Phase 2 study, the researchers are assessing the feasibility of the group retreat format for clinicians and explores different 'doses' of preparation. A sequential dose-escalation design is used. The study will recruit healthcare clinicians (physicians, nurses, nurse practitioners, physician assistants) aged 25-70 years currently in clinical practice with moderate or greater symptoms of depression and loss of meaning during the past 5 years. Each participant will be in a group cohort of 8, and 3 cohorts will be tested at each dose level. The objectives are safety, feasibility, mechanism testing, and outcomes. This is a single-arm study that examines the feasibility of the group retreat format for clinicians and explores different 'doses' of preparation. Population: Healthcare clinicians (physicians, nurses, nurse practitioners, physician assistants) aged 25-70 years currently in clinical practice with moderate or greater symptoms of depression (PHQ-9 ≥10) and loss of meaning during the past 5 years. Study Design: Phase 2, non-randomized, sequential cohort dose-escalation study examining the optimal number of preparation sessions for group retreat psilocybin therapy. Three cohorts will receive different \"doses\" of preparation: Cohort 1 receives 7 total preparation sessions (6 virtual + 1 in-person), Cohort 2 receives 4 total preparation sessions (3 virtual + 1 in-person), and Cohort 3 receives 2 total preparation sessions (1 virtual + 1 in-person). Each cohort includes 3 retreats with 8 participants per retreat. Sample Size: 72 participants total (24 per cohort, distributed across 3 retreats of 8 participants each) Study Duration: 18-24 months from enrollment of first participant to completion of final data analysis. Individual participant involvement spans approximately 8-10 months including 6-month post-retreat follow-up. Primary Objectives: (1) Safety: Assess incidence and severity of challenging experiences and adverse events across preparation dose levels using the Challenging Experience Questionnaire (CEQ), adverse event monitoring, and psychiatric symptom scales (PHQ-9, GAD-7, C-SSRS). (2) Feasibility: Determine completion rates for preparation sessions at each dose level. Secondary Objectives: (1) Mechanism Testing: Examine relationship between preparation dose, group cohesion, and challenging experiences. (2) Clinical Outcomes: Explore effects on depression and burnout for future power calculations. (3) Participant Preference: Assess participant-reported optimal preparation length. Summary: Psilocybin therapy has demonstrated promising efficacy for symptoms of depression related to frontline work during the COVID pandemic for clinicians. The group retreat format offers potential advantages over individual treatment, including enhanced accessibility, reduced cost per participant, and potential therapeutic benefits from group cohesion and shared experience. However, a critical unanswered question concerns the optimal number of preparation sessions. A sequential dose-finding design is appropriate because: (1) the dose-response curve for preparation sessions in group format is unknown; (2) attrition/completion rate is a critical feasibility outcome, particularly for time-constrained healthcare clinicians; (3) the design allows protocol refinement between cohorts based on emerging data; (4) this approach is more scientifically honest about genuine uncertainty regarding optimal preparation dose than premature randomization; and (5) it seeks to establish a minimum effective dose of preparation for practical feasibility and future scalability.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-03", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07565909", "keywords": "Depression, Anxiety, Psilocybin, Group Retreat Psilocybin Therapy, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07565909\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Clinical Trial,Observational Study,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3531, "title": "Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury", "normalized_title": "safety tolerability outcomes of psilocybin for depression stop depression in veterans with spinal cord injury", "authors": "James J. Peters Veterans Affairs Medical Center", "abstract": "The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg). The main question the study aims to answer is: does psilocybin increase the number and severity of adverse (bad) events reported by people with SCI? These may include pain, muscle spasms, symptoms of depression, and symptoms of low or high blood pressure. The investigators will also measure how well people with SCI tolerate the psychedelic experience, and compare responses between the low (5mg), medium (10mg), and high (25mg) doses. Participants will: * Agree to be enrolled in the study for up to 13 months. * Agree to complete the seven (7) visits that are included in the psilocybin-assisted therapy. * Agree to complete follow-up study visits, including in-person visits to the James J Peters VA Medical Center, located in the Bronx, New York and remote visits. * Agree to keep a log of how they are feeling and any change in the frequency or severity of adverse events. Background: Depression may be explained partly by decreased signaling of serotonin in the nervous system. Psilocybin, the active component of 'magic mushrooms', is a drug that activates serotonin pathways in the nervous system. Some scientists think psilocybin could help people with major depression, but it is not currently approved as a medicine in the United States. People with spinal cord injuries (SCI) often feel depressed, even more commonly than people without injuries. People with SCI have not been included in psilocybin studies. The goals of this study are first to see if psilocybin can be safely administered, and to determine if psilocybin can help improve symptoms of depression in people with SCI. Study Goals: The investigators will look at how safe psilocybin is for people with SCI, how people with SCI respond to different doses, and whether it helps reduce the severity of depression and other problems, like pain or muscle spasms. The study team will also check to see if psilocybin improves quality of life and wellbeing. The study will track these effects for a year after participants receive psilocybin. Study Plan: Thirty people with chronic SCI with a depressive disorder will be asked to join-15 with paraplegia and 15 with tetraplegia. They will be split into three groups to try different psilocybin doses: low (5mg), medium (10mg), and high (25mg). The study will take a stepwise approach to safety, but participants will not know the dose of psilocybin they receive. There will be at least 16 study visits, including medical and mental health check-ups, psilocybin assisted therapy, primary study endpoint and follow-up visits. What Will Be Measured: The study focus is to see if psilocybin is safe and tolerable in people with SCI. The study will track side effects, how people feel, and any changes in mood, pain, medication use, or body reactions. Doctors will check for problems like chest pain, high blood pressure, and changes in suicidal thoughts. The study team will also measure satisfaction with the therapy, experiences during the psilocybin sessions, and changes in depression. Why It Matters: Some people wrongly believe depression is just a normal part of living with SCI, so their depression may not be adequately treated. Also, people with SCI often can't join trials of new treatments because they have other health problems. Psilocybin could help treat depression and may improve many body functions affected by SCI if it is shown to be safe and effective.", "journal": "ClinicalTrials.gov", "publication_date": "2026-05-03", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07251491", "keywords": "Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran, Psilocybin (Usona Institute), Magic Mushrooms, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07251491\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Chronic Pain,Mechanism of Action,Receptor Pharmacology,Wellbeing,Veterans,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3600, "title": "Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial", "normalized_title": "psilocybin assisted therapy for treatment resistant depression in bipolar ii disorder a randomized controlled trial", "authors": "Lakshmi N Yatham", "abstract": "This study is a 12-week (in addition to up to 30 days of screening) randomized, double-blind, placebo-controlled, parallel-group trial. The primary objective of this study is to assess the effectiveness, safety, and tolerability of single-dose psilocybin (25 mg)-assisted therapy in comparison to active placebo (1 mg micro-dose) psilocybin-assisted therapy in patients with bipolar II depression who have not responded to adequate trials with at least two first or second-line treatments for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy). The active placebo is a substance that looks identical to the study medication but contains less therapeutic ingredients, and thus is less capable of producing the transformative and meaningful aspects of psychedelic experience compared to the 25 mg dose. Participants will have a total of 11 study visits over a period of up to 16 weeks, which includes 5 therapy sessions from trained study therapists. Bipolar disorders (BD) are lifelong conditions characterized by recurrent episodes of depression and (hypo)mania. Statistics Canada data indicate over a million Canadians are affected by this illness. Bipolar II disorder is characterised by recurrent episodes of hypomania and depression and individuals with BD-II are symptomatic about 50% of the time despite treatment. The majority of this time is spent being depressed thus there is an urgent need to develop new treatments that are safe and effective. Psilocybin, a naturally occurring psychedelic compound found in mushrooms, has been noted to result in an increase in psychological well-being in healthy volunteers as well as have antidepressant effects when administered in conjunction with psychological support. Two recent open-label pilot trials of Psilocybin-Assisted Therapy (PAT) in treatment-resistant depression, including BD-II participants, demonstrated high response rates and excellent tolerability, thereby providing strong justification for the current study.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-30", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06943573", "keywords": "Bipolar II Depression, psilocybin (25 mg), psilocybin 1mg micro-dose, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06943573\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Wellbeing,Randomized Controlled Trial,Healthy Volunteers,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1958, "title": "Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA", "normalized_title": "prevalence and correlates of past year psilocybin use in the u s 2024 usa", "authors": "R Andrew Yockey, Amber Amis, Elise Devier, Aminul Apu, Rachel Hoopsick", "abstract": "AbstractIntroduction Psilocybin, a naturally occurring psychedelic compound found in certain mushroom species, has gained substantial clinical, scientific, and cultural attention in recent years. Despite this growing interest and evolving policy landscape, nationally representative estimates of recent psilocybin use in the United States remain limited. Understanding the current prevalence and demographic and behavioral correlates of use is critical for informing prevention, harm reduction, and public health responses. The present study examined the prevalence and correlates of past-year psilocybin use among U.S. adolescents and adults. Methods Data were drawn from the 2024 National Survey on Drug Use and Health (NSDUH), a nationally representative survey of the U.S. civilian, noninstitutionalized population aged 12 years and older. The analytic sample included 58,633 respondents. Weighted descriptive and multivariable analyses estimated the prevalence of past-year psilocybin use and its association with demographic and substance use correlates. Analyses were conducted in 2026. Results An estimated 2.78% (95% CI: 2.56-3.02) of individuals in the U.S. reported past-year psilocybin use. Increased odds of use were higher among males, young adults, non-Hispanic White individuals, and those with higher household incomes. Past-year use of tobacco, alcohol, cannabis, cocaine, and LSD was each significantly associated with psilocybin use. Conclusions Psilocybin use in the United States is most observed among young adults, males, and individuals with higher incomes, and it often occurs alongside the use of other substances. These patterns underscore the need for continued surveillance to track emerging trends and to inform public health strategies as policy landscapes and societal attitudes toward psychedelics continue to evolve.", "journal": "AJPM Focus", "publication_date": "2026-04-30", "publication_year": 2026, "doi": "10.1016/j.focus.2026.100518", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.focus.2026.100518", "keywords": "Psilocybin, Public health, Harm, Population, Odds, Medicine, Environmental health, Psychology, Substance use, Demography, Psychiatry, Gerontology, Epidemiology, Harm reduction, Descriptive statistics, Hallucinogen, Ethnic group, Population health, Mental health, National Health Interview Survey, National Health and Nutrition Examination Survey, Survey sampling, Telephone survey, Health care, Young adult, Behavioral Risk Factor Surveillance System, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162075570\",\"openalex_url\":\"https://openalex.org/W7162075570\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1948675593\",\"https://openalex.org/W2096688894\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2169138007\",\"https://openalex.org/W2283026346\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2885556179\",\"https://openalex.org/W3024299552\",\"https://openalex.org/W3139397908\",\"https://openalex.org/W3185700361\",\"https://openalex.org/W4389086750\",\"https://openalex.org/W4396977515\",\"https://openalex.org/W4404109323\",\"https://openalex.org/W4405955628\",\"https://openalex.org/W4408033191\",\"https://openalex.org/W4415929140\",\"https://openalex.org/W7116829252\"],\"authorships\":[{\"id\":\"https://openalex.org/A5121848013\",\"display_name\":\"R Andrew Yockey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119591179\",\"display_name\":\"Amber Amis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119591178\",\"display_name\":\"Elise Devier\",\"orcid\":null},{\"id\":\"https://openalex.org/A5136108200\",\"display_name\":\"Aminul Apu\",\"orcid\":null},{\"id\":\"https://openalex.org/A5136162712\",\"display_name\":\"Rachel Hoopsick\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4220651960\",\"source_display_name\":\"AJPM Focus\",\"landing_page_url\":\"https://doi.org/10.1016/j.focus.2026.100518\",\"is_oa\":true}}", "topic_tags": "Addiction,Observational Study,Adolescents,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162075570" }, { "id": 130, "title": "Trip killers: Addressing a critical knowledge gap in psychedelic research.", "normalized_title": "trip killers addressing a critical knowledge gap in psychedelic research", "authors": "O'Mahony B, Harrington C, Harkin A, Lally N", "abstract": "Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a \"bad trip.\" Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require presentation to accident and emergency departments and psychiatric hospital admission. Managing such cases requires careful consideration, with priority given to non-pharmacological strategies. When these measures prove insufficient, an alternative approach may be necessary, one that can effectively attenuate or terminate the psychedelic state and restore psychological stability. Despite clinical relevance, there is no systematic evaluation of pharmacological interventions to terminate such experiences. This review identifies and critically appraises candidate medications with potential utility as abortive agents, including serotonin antagonists, drugs for psychosis, and select drugs for anxiety and depression. We review these agents, their mechanisms of action, pharmacokinetics, safety profiles, and applicability in acute care settings. Binding strength at the molecular level, potency to functionally block receptor-mediated effects, and lack of side effects are key considerations. We conclude by proposing a provisional framework for the pharmacologic management of adverse psychedelic experiences and highlight key priorities for future research.", "journal": "Journal of psychopharmacology (Oxford, England)", "publication_date": "2026-04-30", "publication_year": 2026, "doi": "10.1177/02698811261431056", "pubmed_id": "41869862", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41869862/", "keywords": "5-HT2A, LSD, antipsychotics, bad trips, psilocybin, psychedelic", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:34", "raw_json": "{\"pubmed_id\":\"41869862\"}", "topic_tags": "Depression,Anxiety,Pharmacology,Mechanism of Action,Receptor Pharmacology,Aging,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3041, "title": "The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder", "normalized_title": "the ecstasy of gold in neurodiversity focus on the use of psychedelics in autism spectrum disorder", "authors": "Marini S, De Berardis D.", "abstract": "Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal regeneration. These properties could be used in the pharmacological treatment of selected mental disorders. Autism spectrum disorders include a group of developmental disorders characterized by social communication issues, the presence of restricted interests as well as repetitive behaviors that impact the quality of life of patients and their caregivers. Currently, there are no authorized drugs for the treatment of the symptomatic features of ASD, but drugs are used for comorbid psychopathological aspects, but the efficacy and tolerability of such treatments are often questionable. Here, studies demonstrating the therapeutic utility of using psychedelic substances in autism are reported. These findings suggest a therapeutic potential of psychedelics for some aspects of symptoms associated with autism spectrum disorder.", "journal": "Preprints.org", "publication_date": "2026-04-28", "publication_year": 2026, "doi": "10.20944/preprints202604.1998.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202604.1998.v1", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1183908\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1952, "title": "6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy", "normalized_title": "6 open label extension of psilocybin assisted therapy in patients with alcohol use disorder continued safety and short term efficacy signal for drinking craving and self efficacy", "authors": "Broc Pagni, Stephen Ross, Yuna Kim, Michael Bogenschutz", "abstract": "", "journal": "Biological Psychiatry", "publication_date": "2026-04-24", "publication_year": 2026, "doi": "10.1016/j.biopsych.2026.03.240", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.biopsych.2026.03.240", "keywords": "Medicine, Extension (predicate logic), Alcohol, SIGNAL (programming language), Physical medicine and rehabilitation, Intensive care medicine, Alcohol use disorder, Anesthesia, Emergency medicine, MEDLINE, Physical therapy, Psychedelics and Drug Studies, Substance Abuse Treatment and Outcomes, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7155643158\",\"openalex_url\":\"https://openalex.org/W7155643158\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5134610041\",\"display_name\":\"Broc Pagni\",\"orcid\":null},{\"id\":\"https://openalex.org/A5134589094\",\"display_name\":\"Stephen Ross\",\"orcid\":null},{\"id\":\"https://openalex.org/A5134612062\",\"display_name\":\"Yuna Kim\",\"orcid\":null},{\"id\":\"https://openalex.org/A5134570196\",\"display_name\":\"Michael Bogenschutz\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S205482884\",\"source_display_name\":\"Biological Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/j.biopsych.2026.03.240\",\"is_oa\":false}}", "topic_tags": "Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7155643158" }, { "id": 159, "title": "Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations", "normalized_title": "methamphetamine fentanyl polysubstance administration produces social deficits and corticolimbic stress reward circuit adaptations", "authors": "Salinsky LM, Fox JL, Diaz KC, Timmons BC, Ferguson SM.", "abstract": "Abstract Rationale and Objectives: Polysubstance use involving psychostimulants and opioids is increasingly prevalent and associated with elevated overdose risk, relapse vulnerability, and poor treatment outcomes. However, the neurobehavioral consequences of opioid-stimulant use remain poorly understood. We evaluated whether repeated methamphetamine-fentanyl polysubstance treatment disrupts social preference during withdrawal, whether psilocybin treatment restores sociability, and whether these manipulations alter corticolimbic expression of stress- and opioid-related genes. Methods Male and female rats received injections of methamphetamine and fentanyl or saline and were assessed for social preference at baseline and following 10 days of withdrawal. On withdrawal day 10, rats received psilocybin or saline and were reassessed for sociability 24 h later. CRHR1 and OPRM1 expression in the medial prefrontal cortex (mPFC) and nucleus accumbens (NAc) were quantified by RT-qPCR. Results Withdrawal from 14-days of polysubstance treatment reduced social preference, replicating prior findings of withdrawal-associated social dysfunction. Psilocybin pretreatment did not restore social preference at the time point examined. In the mPFC, psilocybin bidirectionally altered CRHR1 expression depending on drug history, decreasing expression in saline-treated controls, while increasing expression following polysubstance treatment. In the NAc, polysubstance administration reduced CRHR1 expression. OPRM1 expression showed sex-dependent regulation with a marked reduction in the NAc of females following polysubstance treatment and evidence of sex-dependent effects in the mPFC. Conclusions Methamphetamine-fentanyl treatment produces persistent social deficits during withdrawal and region- and sex-dependent corticolimbic transcriptional adaptations in vivo. Although psilocybin did not restore sociability, it produced drug history-dependent regulation of cortical CRHR1.", "journal": "Research Square", "publication_date": "2026-04-22", "publication_year": 2026, "doi": "10.21203/rs.3.rs-9306429/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-9306429/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR1181545\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 35, "title": "Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.", "normalized_title": "serotonergic psychedelics for autism spectrum disorder neurobiological mechanisms and translational prospects", "authors": "Low ZXB.", "abstract": "Autism Spectrum Disorder (ASD) is characterized by persistent social-communication deficits, cognitive rigidity, and atypical sensory processing. Current pharmacological treatments, including risperidone and aripiprazole, provide only limited symptomatic relief and do not address the underlying neurobiological mechanisms. Converging evidence implicates dysregulated serotonergic signaling, impaired neuroplasticity, and chronic neuroimmune activation as central features of ASD pathophysiology. Serotonergic psychedelics, such as psilocybin and LSD, act as high-affinity 5-HT2A receptor agonists and have re-emerged as candidates for modulating these core pathways. In this Review, we synthesize molecular, cellular, and systems-level findings suggesting that psychedelics may transiently relax overly rigid cortical priors, reopen critical periods for social learning, and recalibrate dysfunctional neural circuits in ASD. These compounds enhance synaptic plasticity via BDNF and mTOR signaling, modulate cortical oscillations, and suppress neuroinflammation by shifting microglial phenotypes and suppressing pro-inflammatory cytokines. Systems-level frameworks, including the REBUS and anarchic brain hypotheses, contextualize how psychedelics induce globally integrated, less constrained brain states that may counteract the hyper-segregated connectivity commonly observed in ASD. While preclinical and early human studies report improvements in sociability, sensory responsiveness, and behavioural flexibility, rigorous clinical trials are urgently needed to establish safety, efficacy, and optimal developmental windows for intervention. We conclude by outlining a translational roadmap to guide future research, emphasizing the need for structured integration with behavioural therapies, attention to ASD heterogeneity, ethical considerations, and the potential to shift ASD treatment beyond symptomatic management toward disease-modifying intervention.", "journal": null, "publication_date": "2026-04-22", "publication_year": 2026, "doi": "10.1016/j.pnpbp.2026.111717", "pubmed_id": "42034276", "source_url": "https://doi.org/10.1016/j.pnpbp.2026.111717", "keywords": "Brain, Animals, Humans, Serotonin, Hallucinogens, Neuronal Plasticity, Autism Spectrum Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"42034276\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Animal Study,Safety,Inflammation,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3658, "title": "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder", "normalized_title": "psilocybin enhanced psychotherapy for methamphetamine use disorder", "authors": "Portland VA Research Foundation, Inc", "abstract": "This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder. The trial will take place with individuals admitted to a residential rehabilitation treatment program. The treatment protocol will consist of 4 preparatory therapy visits, 2 psilocybin sessions (25-30mg), and 8 total integration therapy visits. Primary aims assess acceptability, feasibility, and safety with a primary endpoint at the conclusion of the study intervention. An additional aim assesses preliminary efficacy for methamphetamine use disorder and overall functioning at follow-up assessments 60 and 180 days after discharge from the residential treatment program.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04982796", "keywords": "Amphetamine-Related Disorders, Psilocybin, Treatment-as-usual, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04982796\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3596, "title": "A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)", "normalized_title": "a randomized double blind study of single dose psilocybin for major depressive disorder mdd", "authors": "Usona Institute", "abstract": "One hundred participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose. Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the United States will experience an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depression is associated with greater disability than are most other chronic illnesses and is a risk factor for mortality. Additionally, depression predicts the later development of a number of medical conditions, including cardiac and cerebrovascular disease, hypertension, diabetes, obesity, metabolic syndrome, dementia, and cancer. Unfortunately, most patients with depression do not experience a complete resolution of symptoms with antidepressant treatment. Partial-but incomplete-response to antidepressants is associated with an increased risk of full symptomatic relapse (even when on therapy) and a worse long-term disease course. Combined with the high prevalence and significant disability associated with MDD, the fact that currently available treatments are not fully adequate highlights the tremendous need to identify novel treatment strategies. Data suggest that psilocybin may have behavioral effects relevant to the treatment of depression and recent studies also suggest that psilocybin may possess antidepressant properties. To further assess the effects of psilocybin on MDD signs and symptoms, this trial will enroll 100 participants, ages 21 to 65, who meet criteria for MDD. Participants will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo. To enhance participant safety, a Set and Setting (SaS) protocol will be utilized similar to the protocol that has been used in all modern studies of psilocybin. The SaS protocol for this study includes: 1) a period of preparation with session Facilitators prior to dosing; 2) administration of study medications in an aesthetically pleasing room under the supervision of two Facilitators who are present throughout the session; and 3) three post-dose integration sessions during which participants are encouraged to discuss their intervention experience with the Facilitators. The SaS protocol will be identical for those randomized to psilocybin or active placebo. The primary objective of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo (niacin), assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 43 post-dose.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT03866174", "keywords": "Depressive Disorder, Major, Psilocybin, Psilocybine, Psilocibin, Indocybin, Niacin, Vitamin B3, Set and Setting (SaS) Protocol, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT03866174\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3567, "title": "Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy", "normalized_title": "toward patient tailored care for treatment resistant depression a pilot patient preference clinical trial of music and mindfulness in psilocybin assisted psychotherapy", "authors": "Kyle Greenway", "abstract": "The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences. The study also aims to explore whether two different psychotherapy styles, music-centered and mindfulness-centered, influence how people respond to psilocybin treatment. The main questions it aims to answer are: * Is it feasible to conduct a patient-preference randomized trial of psilocybin-assisted psychotherapy? * Does receiving a preferred psychotherapy style improve treatment experiences or outcomes? * How do music-centered and mindfulness-centered PAP approaches compare in their effects on improving mood and well-being? Researchers will compare music-centered PAP to mindfulness-centered PAP to see if aligning psychotherapy with individual preferences is a practical and potentially beneficial approach for improving treatment efficacy and tolerability. Participants will: * Be adults with treatment-resistant depression * Receive two 25 mg psilocybin (PEX010, Filament Health) sessions, spaced four weeks apart * Experience one session with music-centered psychotherapy and one with mindfulness-centered psychotherapy * Before treatment, rate their preference for the two psychotherapy approaches * Be randomly assigned to receive their preferred or non-preferred approach first, followed by the other * Complete preparation and integration sessions before and after each psilocybin session This feasibility trial will also collect information on participants' cultural and personal factors influencing psychotherapy preferences using a modified Cultural Formulation Interview, and explore physiological measures of therapeutic alliance, an important factor in psychotherapy outcomes. Depression is one of the top causes of disability worldwide. Psilocybin-assisted psychotherapy (PAP) is an emerging treatment for Treatment-Resistant Depression (TRD) that pairs one or two doses of psilocybin, a serotonergic psychedelic, with a brief course of psychotherapy. While multiple studies of PAP have found safe, rapid, and lasting antidepressant effects, much remains unknown about how to optimize this promising intervention's psychotherapy component. This pilot study aims to explore a novel strategy for improving the efficacy and tolerability of PAP: individually-tailoring its psychotherapy based on patient preferences for two important nonpharmacological treatment elements: music and mindfulness. These core treatment components were selected based on their ubiquitousness in psilocybin studies and their potential for significant patient preference effects. The investigators will conduct a patient-preference randomized clinical trial where 16 patients with TRD will receive two doses of psilocybin (PEX010, Filament Health, 25mg). For each patient, one psilocybin dose will be administered with music-centered psychological support and the other with mindfulness-centered psychological support. In the first 4-week phase, patients will be asked to rate their preferences for these different psychotherapeutic approaches. Patients will then be 50:50 randomized to first receive either their preferred or their non-preferred treatment approach. In a second 4-week crossover phase, patients will receive the other treatment approach. All patients will thus undergo both music-centered and mindfulness-centered PAP interventions, but in an order dictated by their preferences and randomization. Each treatment phase entails pre-treatment and post-treatment psychotherapy following standard protocols. Similar patient-preference clinical trial designs have shown that preferences can significantly influence the efficacy and tolerability of existing psychiatric treatments. The primary aim of this pilot trial is to examine this design's feasibility for exploring such preference effects in PAP, which the investigators hypothesize will be substantial. As secondary aims, the trial will generate preliminary estimates about the magnitude of preference effects, compare the music- and mindfulness-centered approaches, and yield qualitative data about the diverse sociocultural factors that influence patient preferences, including with a modified Cultural Formulation Interview administered at baseline. An additional exploratory aim is to examine novel physiological measures of therapeutic alliance, a crucial factor in psychiatric care. Depression affects millions of Canadians and new treatments are sorely needed. This line of research seeks to produce systematic approaches to tailoring the psychotherapy of PAP for TRD. Its ultimate goal is to improve this promising intervention's efficacy, safety, and applicability to diverse populations.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07373535", "keywords": "Treatment-Resistant Major Depressive Disorder, Psilocybin 25mg, PEX010(25), Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07373535\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Wellbeing,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1968, "title": "Psilocybin as an alternative to conventional treatments: A systematic review", "normalized_title": "psilocybin as an alternative to conventional treatments a systematic review", "authors": "Deivid Antonio Cahuasqui-Mendoza", "abstract": "Introduction. Limitations of conventional treatments for depression and anxiety, particularly in treatment-resistant cases, have driven interest in alternative therapeutic approaches. Psilocybin, a serotonergic agonist with demonstrated effects on neuroplasticity and large-scale brain networks, has emerged as a promising therapeutic option. Materials and methods: A systematic review of controlled clinical trials published between 2020 and 2025 was conducted in accordance with PRISMA guidelines. Searches were performed in PubMed/MEDLINE, Scopus, PsycINFO, Web of Science, and the Cochrane Library. Eligible studies included adults aged 18-65 years with DSM-5 diagnoses of depression and/or anxiety who received psilocybin-assisted therapy with psychotherapeutic support. Risk of bias was assessed using RoB 2, the Jadad scale, and the Newcastle-Ottawa Scale. Due to methodological heterogeneity, a qualitative narrative synthesis was performed.", "journal": "Gaceta Médica de Caracas", "publication_date": "2026-04-21", "publication_year": 2026, "doi": "10.47307/gmc.2026.134.s2.32", "pubmed_id": null, "source_url": "https://doi.org/10.47307/gmc.2026.134.s2.32", "keywords": "Psilocybin, Medicine, Systematic review, Anxiety, Psychotherapist, Psychiatry, Depression (economics), Psychology, Jadad scale, MEDLINE, Clinical psychology, Randomized controlled trial, Serotonergic, Narrative review, Clinical trial, Fluoxetine, Systematic desensitization, Complicated grief, Duloxetine, Placebo, Anhedonia, Meta-analysis, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7155199454\",\"openalex_url\":\"https://openalex.org/W7155199454\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5134220190\",\"display_name\":\"Deivid Antonio Cahuasqui-Mendoza\",\"orcid\":\"https://orcid.org/0009-0009-7492-4445\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210231111\",\"source_display_name\":\"Gaceta Médica de Caracas\",\"landing_page_url\":\"https://doi.org/10.47307/gmc.2026.134.s2.32\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Neuroplasticity,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7155199454" }, { "id": 2978, "title": "The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes", "normalized_title": "the efficacy and safety of psilocybin assisted therapy for major depressive disorder a meta analytic review of clinical outcomes", "authors": "Mohsen Khosravi, Domenico De Berardis, Massimo Tusconi", "abstract": "This systematic review and meta-analysis synthesized data from 13 clinical trials (n=606) evaluating psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. Despite early enthusiasm, the pooled standardized mean difference (-0.79, 95% confidence interval: -3.98 to 2.40, p=0.63) revealed no statistically significant overall antidepressant effect, with extreme heterogeneity (I2=96.9%) across studies. Notably, the type of control group (active comparator vs. placebo/waitlist) accounted for 98.7% of between-study variance, with waitlist and low-dose comparators producing exaggerated effect sizes. Session frequency was a significant moderator: 2 to 5 psilocybin sessions yielded larger effects, while more intensive protocols attenuated benefit. Neither participant age nor follow-up duration significantly influenced outcomes. Evidence of reporting bias and small-study effects was detected (Egger’s test p=0.012). Sensitivity analyses demonstrated that no single study accounted for the non-significant pooled result. Overall, psilocybin’s antidepressant efficacy appears highly context-dependent-shaped by trial design, comparator, and session structure-rather than universally robust. These findings underscore the need for larger, rigorously controlled trials to clarify psilocybin’s therapeutic role in depression.", "journal": "Mental Wellness", "publication_date": "2026-04-20", "publication_year": 2026, "doi": "10.4081/mw.2026.40", "pubmed_id": null, "source_url": "https://doi.org/10.4081/mw.2026.40", "keywords": "Major depressive disorder, Medicine, Meta-analysis, Antidepressant, Clinical trial, Depression (economics), Confidence interval, Clinical psychology, Strictly standardized mean difference, Treatment-resistant depression, Psychiatry, Randomized controlled trial, MEDLINE, Mean difference, Depressive symptoms, Session (web analytics), Internal medicine, Significant difference, Psilocybin, Major depressive episode, Placebo response, Intervention (counseling), Research design, Observational study, Treatment effect, Placebo, Imipramine, Test (biology), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:55:42", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7155066504\",\"openalex_url\":\"https://openalex.org/W7155066504\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2003424951\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4393253405\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4408765639\"],\"authorships\":[{\"id\":\"https://openalex.org/A5134179887\",\"display_name\":\"Mohsen Khosravi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062268890\",\"display_name\":\"Domenico De Berardis\",\"orcid\":\"https://orcid.org/0000-0003-4415-5058\"},{\"id\":\"https://openalex.org/A5035141310\",\"display_name\":\"Massimo Tusconi\",\"orcid\":\"https://orcid.org/0000-0002-9155-4740\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S5407046027\",\"source_display_name\":\"Mental Wellness\",\"landing_page_url\":\"https://doi.org/10.4081/mw.2026.40\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Observational Study,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7155066504" }, { "id": 2977, "title": "Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials", "normalized_title": "efficacy and safety of psilocybin assisted therapy for depression a meta analysis of randomised controlled trials", "authors": "Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira, Mustika Suci Mahardikaningrum, Teresa Lalita Wiryarini, Devira Ayu Wulandari", "abstract": "Psilocybin-assisted therapy shows promise for depression, though current evidence relies on Phase 2 trials with notable methodological limitations. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating psilocybin-assisted therapy for major or treatment-resistant depression up to February 2024. We evaluated depressive symptom severity using random-effects meta-analysis, moderator analyses, Cochrane Risk of Bias 2, and GRADE methodology. Nine RCTs (N=514) were included. Psilocybin therapy demonstrated a large pooled effect size for symptom reduction (SMD = 1.270, 95% CI: 0.865-1.676, p", "journal": "Open Access Indonesian Journal of Medical Reviews", "publication_date": "2026-04-20", "publication_year": 2026, "doi": "10.37275/oaijmr.v6i2.883", "pubmed_id": null, "source_url": "https://doi.org/10.37275/oaijmr.v6i2.883", "keywords": "Medicine, Blinding, Randomized controlled trial, Meta-analysis, Confounding, Clinical trial, Depression (economics), Placebo, Systematic review, Physical therapy, MEDLINE, Treatment effect, Research design, Intensive care medicine, Relative risk, Sample size determination, Publication bias, Moderation, Cochrane Library, Exposure therapy, Clinical psychology, Anxiety, Pharmacotherapy, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:55:42", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7155091271\",\"openalex_url\":\"https://openalex.org/W7155091271\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5134107220\",\"display_name\":\"Siti Nashria Rusdhy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079536508\",\"display_name\":\"Andrian Fajar Kusumadewi\",\"orcid\":\"https://orcid.org/0000-0001-6610-2470\"},{\"id\":\"https://openalex.org/A5034760407\",\"display_name\":\"Carla Raymondalexas Marchira\",\"orcid\":\"https://orcid.org/0000-0003-3848-1092\"},{\"id\":\"https://openalex.org/A5134157899\",\"display_name\":\"Mustika Suci Mahardikaningrum\",\"orcid\":null},{\"id\":\"https://openalex.org/A5134166752\",\"display_name\":\"Teresa Lalita Wiryarini\",\"orcid\":null},{\"id\":\"https://openalex.org/A5134141631\",\"display_name\":\"Devira Ayu Wulandari\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210182354\",\"source_display_name\":\"Open Access Indonesian Journal of Medical Reviews\",\"landing_page_url\":\"https://doi.org/10.37275/oaijmr.v6i2.883\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7155091271" }, { "id": 4036, "title": "Oregon’s Psilocybin Services: A summary and public health commentary", "normalized_title": "oregon s psilocybin services a summary and public health commentary", "authors": "Cassidy R. LoParco, Carlton Bone, Annalynn M. Galvin, Matthew E. Rossheim, Carla Berg", "abstract": "Psilocybin is a federally illegal psychedelic substance that carries positive (e.g., treatment for mood disorders) and negative (e.g., emotional distress) consequences. In 2020, Oregon legalized psilocybin for adult use (21+) at the state level, restricted to designated service centers. In Fall 2024 and Spring 2026 we summarized and compared Oregon’s legal/regulatory psilocybin context and highlighted public health considerations. We found there are no limits on the number of licenses that can be issued, and there are mandated trainings to obtain facilitator licensure (e.g., 120/128 hours of instruction in 2024/2026, requiring a test score of 75% [unlimited number of testing attempts]). Regulations specify manufacturing rules, including allowable ingredients and testing for contaminants and concentration. One serving includes 25mg of psilocybin analyte; 2 servings per person are allowed. Labeling guidelines are provided (e.g., safety warnings, no youth-oriented wording). We identified the presence of psilocybin-related websites that were not age gated. We found pricing information related to administration ($15-$3,500/person) and facilitator training ($3,000-$14,175). Given the inability to limit the number of psilocybin licensees, numbers of service centers are likely to increase. Since Oregon psilocybin services does not license training programs, and the unlimited number of testing attempts allowed, there may be issues ensuring individuals have adequately acquired the necessary knowledge. Longitudinal research is needed to assess the health impact of these programs and the long-term impacts of psilocybin use.", "journal": "New Prairie Press (Kansas State University)", "publication_date": "2026-04-16", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://newprairiepress.org/hbr/vol9/iss1/20", "keywords": "Psilocybin, Context (archaeology), Facilitator, Hallucinogen, Licensure, Psychology, Psychiatry, Public health, Test (biology), Medicine, Mood, License, Service (business), Health care, Mental health, Nursing, Service provider, Business, Medical education, Addiction, Mescaline, Public relations, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Religious Studies and Spiritual Practices", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:35", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7154872659\",\"openalex_url\":\"https://openalex.org/W7154872659\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5035917827\",\"display_name\":\"Cassidy R. LoParco\",\"orcid\":\"https://orcid.org/0000-0003-4206-4179\"},{\"id\":\"https://openalex.org/A5075967165\",\"display_name\":\"Carlton Bone\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073247877\",\"display_name\":\"Annalynn M. Galvin\",\"orcid\":\"https://orcid.org/0000-0003-0868-8316\"},{\"id\":\"https://openalex.org/A5049624115\",\"display_name\":\"Matthew E. Rossheim\",\"orcid\":\"https://orcid.org/0000-0003-4388-5251\"},{\"id\":\"https://openalex.org/A5027428229\",\"display_name\":\"Carla Berg\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196407\",\"source_display_name\":\"New Prairie Press (Kansas State University)\",\"landing_page_url\":\"https://newprairiepress.org/hbr/vol9/iss1/20\",\"is_oa\":true}}", "topic_tags": "Addiction,Emotional Processing,Spirituality,Adolescents,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7154872659" }, { "id": 3117, "title": "Psilocybin’s Kinematic Effect on Manual Dexterity", "normalized_title": "psilocybin s kinematic effect on manual dexterity", "authors": "Klintefors P, Bhagavan C, Kanaan R, Bryson A, Berlowitz D, Attard Z, Carter O.", "abstract": "Abstract Rationale Clinical interest in psilocybin-assisted rehabilitation for motor disorders is growing. However, psilocybin’s motor effects are under-researched, and quantifying them is essential for assessing treatment risks and outcomes. Objectives This study aims to clarify whether acute effects of psilocybin disrupts established patterns of manual dexterity and coordination. Specifically, we evaluate the impact of psilocybin on velocity, smoothness and kinematic synergies. Methods In a randomised, blinded trial, healthy participants received three doses of psilo-cybin (5-20 mg) administered one week apart. Manual dexterity was assessed using the Box and Block Test (BBT) at baseline and 1.5, 3, and 4.5 hours post-drug administration. Task performance was analysed using a Bayesian mixed-effects model. For kinematic analysis, 21 hand landmarks were tracked from video recordings obtained at baseline and 1.5 hours post-administration. Principal component analysis (PCA) was the basis for evaluating the stability and dimensionality of kinematic synergies. Results BBT performance showed a modest biphasic dose-response pattern at higher doses (10-20 mg), with slight impairment during peak effects and slight improvement 4.5 hours post-administration relative to baseline. Effect sizes were small compared to inter-individual baseline variability. Kinematic analyses revealed no substantial changes in movement smoothness or velocity. Dimensionality metrics indicated a stable coordination structure, although finger movements showed a subtle increase in complexity. Conclusions Low to moderate doses of psilocybin did not meaningfully disrupt manual dexterity or the latent structure of hand coordination. These findings support the feasibility of combining psilocybin administration with active motor rehabilitation. Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12621000560897 Date registered: 12 May 2021 URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id= 381526&isReview=true", "journal": "Research Square", "publication_date": "2026-04-14", "publication_year": 2026, "doi": "10.21203/rs.3.rs-9291780/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-9291780/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR1177862\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Review Article,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3019, "title": "Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration", "normalized_title": "psilocybin in older adults therapeutic opportunities in inflammation driven disorders of aging from depression to neurodegeneration", "authors": "Jóźwiak-Bębenista M, Stasiak A, Sienkiewicz M, Kwiatkowski P, Kowalczyk E.", "abstract": "Aging is associated with chronic, low-grade inflammation (“inflammaging”), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer’s disease, and Parkinson’s disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug-drug interactions. Psilocybin, a serotonergic psychedelic acting primarily as a 5-HT2A receptor agonist and currently undergoing accelerated clinical development, has emerged as a potential multimodal therapeutic agent addressing these challenges. Acting via its active metabolite psilocin, 5-HT2A-mediated signaling biases cortical glutamatergic transmission, enhances TrkB/BDNF pathways, and modulates neuro-immune cascades (including NF-κB), with convergent systems-level effects such as re-organization of the default mode network. Human studies report acute reductions in TNF-α with variable effects on IL-6 and CRP, consistent with an immunomodulatory profile. Pharmacokinetically, psilocybin shows properties advantageous in geriatric care: rapid onset, short half-life, and predominant phase-II glucuronidation, reducing interaction risk. Controlled studies demonstrate rapid antidepressant and anxiolytic effects in major depressive disorder, treatment-resistant depression, and existential distress, with emerging feasibility signals in neurodegeneration. Together, these find-ings support the hypothesis that a time-limited, mechanism-based intervention may improve mood and cognition while attenuating inflammation. This review integrates current evidence on psilocybin’s neuroimmune and pharmacokinetic mechanisms rel-evant to aging, outlining its potential role in inflammation-related disorders and high-lighting the need for targeted studies in older adults, who remain underrepresented in psychedelic research.", "journal": "Preprints.org", "publication_date": "2026-04-14", "publication_year": 2026, "doi": "10.20944/preprints202604.1125.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202604.1125.v1", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:45", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1179388\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Aging,Inflammaging,Review Article,Older Adults,Treatment-Resistant Depression,Safety,Drug Interactions,Inflammation,Immune Function", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 172, "title": "A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience", "normalized_title": "a phase 1 study of a second experience with group retreat psilocybin therapy for partial responders after a first experience", "authors": "Anthony L. Back, Bonnie A. McGregor, Leslie L. Thorn, Kalin Harvey, Dianna Blom, George Callan, John Guy, Sameet Kumar, Rob Hershberg, Melissa Layer, Jackie Levin, Susanna Myers, Juliana Perez, Kathy Salmonson, Peter Thompson, Joseph Whinney", "abstract": "Introduction: Psilocybin therapy has demonstrated efficacy for cancer-related anxiety and depression, but resource-intensive individual treatment models raise important questions for psychedelic public health about equitable access and scalability. In our prior Phase 1/2 study of group retreat psilocybin therapy for patients with metastatic cancer, we observed partial responders who did not achieve full therapeutic benefit. No published research has examined whether partial responders might benefit from a second psilocybin therapy experience. Methods: We conducted a single-arm Phase 1 study to assess the safety of a second experience of Group Retreat Psilocybin Therapy for partial responders from our prior study. Protocol modifications addressed dose as a potential contributor to partial response: the initial dose was increased to 35 mg, and an optional 10 mg booster could be requested by participants who reported low subjective effect at 60-90 min and passed a safety check. Pre-retreat antidepressant tapering was not required. The intervention was delivered in a group retreat format with four primary facilitators and included three preparation sessions, a single psilocybin dosing day, and four integration sessions. Results: = 1). Seven participants (54%) received the booster dose. Mean Hospital Anxiety and Depression Scale (HADS) Total scores decreased from 15.08 (SD4.35) at baseline to 9.00 (SD4.62) at Day +8, with improvements maintained through 24-week follow-up (mean 10.42, SD6.93); 69% achieved HADS scores below the clinical threshold. The proportion of participants with a \"complete\" mystical experience (Mystical Experience Questionnaire ≥ 60%) increased from 38% in the first experience to 77% in the second, without an increase in challenging experiences (Challenging Experiences Questionnaire). Social support, social identification, and group cohesion scores showed progressive improvements that persisted at 24 weeks. Discussion: A second experience of group retreat psilocybin therapy was safe and feasible for partial responders with metastatic cancer. The protocol modifications-higher dose, optional booster, and no antidepressant tapering requirement-did not introduce new safety concerns and were associated with substantially enhanced mystical experiences and preliminary efficacy signals. These findings support further investigation of retreatment protocols for partial responders and contribute to developing scalable group-based models relevant to psychedelic public health, where the resource intensity of individual treatment remains a fundamental barrier to population-level access.", "journal": "Frontiers in Public Health", "publication_date": "2026-04-13", "publication_year": 2026, "doi": "10.3389/fpubh.2026.1810904", "pubmed_id": "42058096", "source_url": "https://doi.org/10.3389/fpubh.2026.1810904", "keywords": "Psilocybin, Adverse effect, Nausea, Medicine, Anxiety, Dosing, Depression (economics), Psychiatry, Antidepressant, Hallucinogen, Placebo, Clinical trial, Partial hospitalization, Pharmacotherapy, Exposure therapy, Psychology, Internal medicine, Clinical psychology, Psychological intervention, Relapse prevention, Anesthesia, Physical therapy, Major depressive disorder, Partial agonist, Mental health, Tolerability, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7154396122\",\"openalex_url\":\"https://openalex.org/W7154396122\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1972968676\",\"https://openalex.org/W2005457676\",\"https://openalex.org/W2058150514\",\"https://openalex.org/W2082535915\",\"https://openalex.org/W2086214501\",\"https://openalex.org/W2105258029\",\"https://openalex.org/W2165986495\",\"https://openalex.org/W2166281097\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2350952069\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2889931714\",\"https://openalex.org/W2902935653\",\"https://openalex.org/W2904473517\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2981695213\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W4234193547\",\"https://openalex.org/W4251745849\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4389392873\",\"https://openalex.org/W4407866135\",\"https://openalex.org/W4410974136\",\"https://openalex.org/W4412982879\"],\"authorships\":[{\"id\":\"https://openalex.org/A5071781938\",\"display_name\":\"Anthony L. Back\",\"orcid\":\"https://orcid.org/0000-0002-7903-0477\"},{\"id\":\"https://openalex.org/A5030340063\",\"display_name\":\"Bonnie A. McGregor\",\"orcid\":\"https://orcid.org/0000-0003-0531-9347\"},{\"id\":\"https://openalex.org/A5133603732\",\"display_name\":\"Leslie L. Thorn\",\"orcid\":null},{\"id\":\"https://openalex.org/A5075648744\",\"display_name\":\"Kalin Harvey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121109585\",\"display_name\":\"Dianna Blom\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121094019\",\"display_name\":\"George Callan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133625498\",\"display_name\":\"John Guy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5110006341\",\"display_name\":\"Sameet Kumar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133609804\",\"display_name\":\"Rob Hershberg\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121098160\",\"display_name\":\"Melissa Layer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121107381\",\"display_name\":\"Jackie Levin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113200747\",\"display_name\":\"Susanna Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133612814\",\"display_name\":\"Juliana Perez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133593291\",\"display_name\":\"Kathy Salmonson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133601737\",\"display_name\":\"Peter Thompson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121054901\",\"display_name\":\"Joseph Whinney\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2595931848\",\"source_display_name\":\"Frontiers in Public Health\",\"landing_page_url\":\"https://doi.org/10.3389/fpubh.2026.1810904\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Mystical Experience,Clinical Trial,Cancer Patients,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7154396122" }, { "id": 1970, "title": "Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol", "normalized_title": "psilocybin for treatment of prolonged grief disorder an open label feasibility study protocol", "authors": "J. Morgan Penberthy, Fatma Wise, Nicholas P. Cherup, Evaline Mitchell, Madeline Burns, Oluwafunmilayo Akinlade, David Chung, Harshit Parmar, Jonathan Singer", "abstract": "Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a psychedelic compound, in treating PGD in adults, with a focus on young adults. The study will involve 20 participants diagnosed with PGD. Each participant will undergo a structured therapeutic process that includes a preparatory session, a single 25 mg dose of psilocybin, and post-session integration. Throughout the study, participants will be monitored via symptom assessments, including qualitative and quantitative data, with the main aims related to safety, feasibility and acceptability. Functional MRIs will be obtained pre- and post-dosing and collected during a standardized grief-elicitation methodology. Key outcome measures include changes in the severity of PGD and trauma symptoms, cognitive flexibility, openness to experience, meaning in life and subjective experiences during the psilocybin session. Neural activity will also be evaluated through fMRI to better understand the neurobiological effects of the treatment. This research represents one of the first clinical protocols specifically focused on the potential of psilocybin for treating PGD. The goal is to assess feasibility and safety while laying the groundwork for future randomized controlled trials.", "journal": "Psychoactives", "publication_date": "2026-04-12", "publication_year": 2026, "doi": "10.3390/psychoactives5020012", "pubmed_id": null, "source_url": "https://doi.org/10.3390/psychoactives5020012", "keywords": "Psilocybin, Grief, Psychotherapist, Protocol (science), Psychology, Clinical psychology, Medicine, Psychiatry, Complicated grief, Randomized controlled trial, Clinical trial, Cognition, Openness to experience, Exposure therapy, Research design, Single-subject design, Depression (economics), Qualitative research, MEDLINE, Major depressive disorder, Psychedelics and Drug Studies, Paranormal Experiences and Beliefs, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7153973756\",\"openalex_url\":\"https://openalex.org/W7153973756\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1966524739\",\"https://openalex.org/W1977106921\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2014833927\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2027845679\",\"https://openalex.org/W2055769378\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2082494913\",\"https://openalex.org/W2095888968\",\"https://openalex.org/W2102083811\",\"https://openalex.org/W2123778879\",\"https://openalex.org/W2127461282\",\"https://openalex.org/W2130746449\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2138769072\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2169463832\",\"https://openalex.org/W2277633149\",\"https://openalex.org/W2412386965\",\"https://openalex.org/W2481432072\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2580400906\",\"https://openalex.org/W2582745336\",\"https://openalex.org/W2883252198\",\"https://openalex.org/W2921631604\",\"https://openalex.org/W3001118513\",\"https://openalex.org/W3015902292\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161861567\",\"https://openalex.org/W4321070975\",\"https://openalex.org/W4398248553\",\"https://openalex.org/W4401689244\",\"https://openalex.org/W4402490731\",\"https://openalex.org/W4403053992\",\"https://openalex.org/W4406512218\",\"https://openalex.org/W4409142060\",\"https://openalex.org/W4414745551\",\"https://openalex.org/W4415616586\",\"https://openalex.org/W4416976899\"],\"authorships\":[{\"id\":\"https://openalex.org/A5133504338\",\"display_name\":\"J. Morgan Penberthy\",\"orcid\":\"https://orcid.org/0000-0002-0572-9904\"},{\"id\":\"https://openalex.org/A5133504338\",\"display_name\":\"J. Morgan Penberthy\",\"orcid\":\"https://orcid.org/0000-0002-0572-9904\"},{\"id\":\"https://openalex.org/A5018583128\",\"display_name\":\"Fatma Wise\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056701766\",\"display_name\":\"Nicholas P. Cherup\",\"orcid\":\"https://orcid.org/0000-0001-6181-3863\"},{\"id\":\"https://openalex.org/A5133504338\",\"display_name\":\"J. Morgan Penberthy\",\"orcid\":\"https://orcid.org/0000-0002-0572-9904\"},{\"id\":\"https://openalex.org/A5133504338\",\"display_name\":\"J. Morgan Penberthy\",\"orcid\":\"https://orcid.org/0000-0002-0572-9904\"},{\"id\":null,\"display_name\":\"Evaline Mitchell\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079839413\",\"display_name\":\"Madeline Burns\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001877959\",\"display_name\":\"Oluwafunmilayo Akinlade\",\"orcid\":\"https://orcid.org/0000-0002-3548-870X\"},{\"id\":\"https://openalex.org/A5100826419\",\"display_name\":\"David Chung\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070832958\",\"display_name\":\"Harshit Parmar\",\"orcid\":\"https://orcid.org/0000-0003-1506-6873\"},{\"id\":\"https://openalex.org/A5084354488\",\"display_name\":\"Jonathan Singer\",\"orcid\":\"https://orcid.org/0000-0002-7789-5047\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387280156\",\"source_display_name\":\"Psychoactives\",\"landing_page_url\":\"https://doi.org/10.3390/psychoactives5020012\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Brain Imaging,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7153973756" }, { "id": 177, "title": "Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.", "normalized_title": "severe illness associated with eating mushroom containing chocolate products united states january october 2024", "authors": "Rumph JT, Winquist A, Troeschel AN, Pulver S, Schnall AH, Ebersole J, Yeh M, Burt B, Federman SL, Klontz K, Dasenbrock C, Leahy HL, Brady S, Stuteville H, Patel K, Daniel J, Chang A", "abstract": "In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In response to this alert, CDC and the Food and Drug Administration coordinated a nationwide outbreak investigation to characterize the potential poisonings associated with eating Diamond Shruumz microdosing chocolate bars. A case of poisoning was defined as an illness with moderate or major clinical effects (i.e., symptoms) as defined by America's Poison Centers in a person who ate any Diamond Shruumz product or another mushroom-containing chocolate product during January-October 2024. In total, 180 cases were reported in 34 states. Among these, 73 persons were hospitalized, including 38 persons who required intensive care unit (ICU) admission, 29 who required endotracheal intubation, and two deaths. Eating Diamond Shruumz chocolate bars was associated with higher odds of hospitalization (odds ratio [OR] = 3.29; 95% CI = 1.51-7.40), ICU admission (OR = 6.30; 95% CI = 2.17-22.6), seizures (OR = 8.45; 95% CI = 3.00-27.9), and endotracheal intubation (OR = 8.04; 95% CI = 2.24-44.2), compared with eating other mushroom-containing chocolate products. Eating larger amounts of Diamond Shruumz chocolate bars was associated with an increased likelihood of hospitalization, ICU admission, and endotracheal intubation (p-value for trend tests [p-trend] = 0.023, 0.004, and", "journal": "MMWR. Morbidity and mortality weekly report", "publication_date": "2026-04-08", "publication_year": 2026, "doi": "10.15585/mmwr.mm7513a2", "pubmed_id": "41955162", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41955162/", "keywords": "", "substance_tags": "psilocin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 06:54:12", "raw_json": "{\"pubmed_id\":\"41955162\"}", "topic_tags": "Microdosing,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3656, "title": "Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder", "normalized_title": "safety profile of 25 mg psilocybin in individuals with cocaine use disorder", "authors": "University of California, Los Angeles", "abstract": "The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder and express an interest in ceasing cocaine use. 25 mg oral psilocybin will be administered to 10 individuals (separately) during a single laboratory visit. The laboratory visit will take place from 9 am until 3 pm within a comfortable, living room like environment. Within this study session room, participants will be accompanied by two clinicians. Participants will then consume the psilocybin capsule, and thereafter will be encouraged to lie down on a couch and introspect on the experience. At one-hour intervals following ingestion, participants will be tested briefly for changes in heart rate, blood pressure, and subjective effects. No blood draws, behavioral assessments, or neuroimaging is included in the study. Following the laboratory visit, investigators will check-in on participants remotely, after 48 hours, and 10, 50, and 90 days from the psilocybin session.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-06", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06102434", "keywords": "Cocaine Use Disorder, Psilocybin, SUSPENDED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06102434\",\"overall_status\":\"SUSPENDED\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Addiction,Brain Imaging,Aging,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3542, "title": "Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin", "normalized_title": "activating neuroplasticity to enhance the perception box expanding effects of psilocybin", "authors": "University of Wisconsin, Madison", "abstract": "This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS. One hundred and eight medically healthy adult volunteers with a modest decrement in wellbeing will receive a single open-label 25 mg dose of psilocybin administered within a \"set and setting\" (SaS) framework of psychological support provided by trained facilitators, such as has been successfully employed in prior psychedelic studies at UW-Madison. The SaS protocol will include 2-4 hours of preparation, a 6- to 8-hour psilocybin dosing session and an hour-long integration session 1 day and 9 days post dosing. All subjects will receive various combinations of active taVNS or sham taVNS prior to, or following, psilocybin dosing. Active and sham taVNS sessions will last 20 minutes and will occur twice daily (morning and afternoon/evening) for 7 consecutive days, using an \"at home\" protocol that has been used safely and effectively by study collaborators. taVNS is a non-invasive low-risk procedure. Subjects will be randomized with equal allocation to one of four conditions: 1) seven days of sham taVNS prior to psilocybin dosing and 7 days of active taVNS post- psilocybin dosing (Group 1: n=27); 2) seven days of sham taVNS prior to psilocybin dosing and 7 days of sham taVNS post- psilocybin dosing (Group 2: n=27); 3) seven days of sham taVNS prior to psilocybin dosing and psilocybin with psychosocial support post-dosing (Group 3: n=27); and 4) seven days of active taVNS prior to psilocybin dosing and 7 days of sham taVNS post- psilocybin dosing (Group 4: n=27). Importantly, participants in all groups will receive psychosocial support in addition to their randomization status (i.e., taVNS or sham taVNS prior to, or following psilocybin, or psychosocial support alone), as the provision of psychosocial support is the current standard of care for the use of psychedelics in FDA-regulated clinical trials (FDA2023). It is anticipated that a total sample of 108 subjects will be enrolled to provide 100 subjects who complete study activities/assessments sufficient to provide evaluable data for testing study primary and exploratory outcomes.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-02", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05866471", "keywords": "Healthy, Psychedelic Experiences, Vagus Nerve Stimulation, Psilocybin, Psilocybine, Psilocibin, Filament Health Psilocybin, PEX010, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05866471\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Neuroplasticity,Wellbeing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3651, "title": "Effects of Psilocybin in Obsessive Compulsive Disorder", "normalized_title": "effects of psilocybin in obsessive compulsive disorder", "authors": "Johns Hopkins University", "abstract": "This study will test the feasibility, safety, and evidence for efficacy of psilocybin administration in participants with obsessive compulsive disorder (OCD). This will serve as a preliminary proof of concept study for future larger studies aimed to investigate the utility, cognitive mechanisms, and neural correlates of this intervention. Participants in this study will receive two doses of psilocybin approximately two weeks apart. Assessments will be conducted during screening visits, psilocybin sessions, and at follow up visits up to 6 months after the final psilocybin session. Thirty participants will complete all study visits including follow-up visits. Primary objectives: 1. Investigate the feasibility, safety, and acceptability of psilocybin for OCD. 2. Investigate the effect of psilocybin on OCD symptoms and concomitant depression and anxiety symptoms. 3. Investigate the effect of psilocybin on quality of life. Secondary objectives: 1. Investigate the effect of psilocybin on metacognition of episodic memory and decision-making. 2. Investigate the effect of psilocybin on model-based learning. 3. Investigate the effect of psilocybin on the ERN. 4. Investigate the effect of psilocybin on affect and social connection. 5. Investigate the effect of psilocybin on movement and communications.", "journal": "ClinicalTrials.gov", "publication_date": "2026-04-01", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05546658", "keywords": "Obsessive-Compulsive Disorder, Psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05546658\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Depression,Anxiety,OCD,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1972, "title": "Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications", "normalized_title": "therapeutic potential of psilocybin in psychiatric disorders mechanisms efficacy and clinical implications", "authors": "Shakila Meshkat, Manish K. Jha, Venkat Bhat", "abstract": "Psilocybin, a serotonergic psychedelic, has gained attention as a potential treatment for various psychiatric conditions. In this review, the authors summarize current clinical evidence related to psilocybin’s efficacy, safety, and mechanisms of action across psychiatric disorders. Findings from early-phase and small-scale clinical trials suggest rapid but variable reductions in depressive symptoms, with some studies reporting sustained effects. Psilocybin has also shown preliminary benefits in alleviating anxiety related to life-threatening illness and in reducing substance use, including alcohol and tobacco dependence. Emerging but limited evidence supports possible therapeutic effects in the treatment of obsessive-compulsive disorder, body dysmorphic disorder, anorexia nervosa, and posttraumatic stress disorder. Reported adverse events, such as headache, nausea, and short-lived anxiety, are typically transient and mild; however, notable adverse reactions have occurred in larger randomized trials. Mechanistically, psilocybin may act by modulating limbic-prefrontal circuits, promoting synaptic plasticity, and enhancing emotional and cognitive flexibility, in particular when administered alongside structured psychotherapeutic support. Although the existing data are encouraging, the evidence base remains limited by small sample sizes, highly selective populations, and short follow-up durations. Larger, rigorously designed trials are required to confirm efficacy, establish long-term safety, and refine therapeutic protocols. Overall, psilocybin represents a promising but still experimental intervention that warrants further systematic investigation under controlled conditions.", "journal": "FOCUS The Journal of Lifelong Learning in Psychiatry", "publication_date": "2026-03-31", "publication_year": 2026, "doi": "10.1176/appi.focus.20250043", "pubmed_id": null, "source_url": "https://doi.org/10.1176/appi.focus.20250043", "keywords": "Psilocybin, Medicine, Psychiatry, Depression (economics), Schizophrenia (object-oriented programming), MEDLINE, Hallucinogen, Psychology, Disease, Psychotherapist, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pharmaceutical Quality and Counterfeiting", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7154344405\",\"openalex_url\":\"https://openalex.org/W7154344405\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2043197532\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2133351239\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2612228298\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2926011243\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2945335566\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3000549374\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4210511938\",\"https://openalex.org/W4210625095\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4318455092\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4361279088\",\"https://openalex.org/W4362457938\",\"https://openalex.org/W4362604463\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4386849390\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4390629750\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4400364503\",\"https://openalex.org/W4402462242\",\"https://openalex.org/W4402554692\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4402912774\",\"https://openalex.org/W4403083745\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4405955624\",\"https://openalex.org/W4405955644\",\"https://openalex.org/W4408033191\",\"https://openalex.org/W4408424120\",\"https://openalex.org/W4408808337\",\"https://openalex.org/W4411969620\",\"https://openalex.org/W4412642858\",\"https://openalex.org/W4413190735\",\"https://openalex.org/W4413839750\",\"https://openalex.org/W4414366251\",\"https://openalex.org/W4414374510\",\"https://openalex.org/W7117359786\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037985605\",\"display_name\":\"Shakila Meshkat\",\"orcid\":\"https://orcid.org/0000-0002-7010-1785\"},{\"id\":\"https://openalex.org/A5133594333\",\"display_name\":\"Manish K. Jha\",\"orcid\":null},{\"id\":\"https://openalex.org/A5133579308\",\"display_name\":\"Venkat Bhat\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210193920\",\"source_display_name\":\"FOCUS The Journal of Lifelong Learning in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1176/appi.focus.20250043\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Eating Disorders,End-of-Life Distress,Headache / Migraine,Neuroplasticity,Mechanism of Action,Aging,Emotional Processing,Clinical Trial,Review Article,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7154344405" }, { "id": 207, "title": "In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin", "normalized_title": "in silico toxicity study of tryptamine psilocin psilocybin n n dimethyltryptamine 5 methoxy n n dimethyltryptamine and o acetylpsilocin", "authors": "Kamil Jurowski, Damian Kobylarz, Maciej Noga", "abstract": "", "journal": "Archives of Toxicology", "publication_date": "2026-03-30", "publication_year": 2026, "doi": "10.1007/s00204-026-04365-4", "pubmed_id": "41915186", "source_url": "https://doi.org/10.1007/s00204-026-04365-4", "keywords": "Toxicity, Pharmacology, Medicine, Chemistry, Toxicology, Acute toxicity, MEDLINE, Drug, Thiocarbamates, Risk assessment, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Medical and Pharmaceutic Studies", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7144218147\",\"openalex_url\":\"https://openalex.org/W7144218147\",\"openalex_relevance_score\":8,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"title:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1965925823\",\"https://openalex.org/W1975456763\",\"https://openalex.org/W1993086151\",\"https://openalex.org/W1998958839\",\"https://openalex.org/W2018957682\",\"https://openalex.org/W2019500309\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2055718658\",\"https://openalex.org/W2067669075\",\"https://openalex.org/W2078127729\",\"https://openalex.org/W2084087750\",\"https://openalex.org/W2091016019\",\"https://openalex.org/W2093606873\",\"https://openalex.org/W2099060738\",\"https://openalex.org/W2107375130\",\"https://openalex.org/W2159917347\",\"https://openalex.org/W2225235469\",\"https://openalex.org/W2263340761\",\"https://openalex.org/W2287286529\",\"https://openalex.org/W2538276222\",\"https://openalex.org/W2608547303\",\"https://openalex.org/W2809153532\",\"https://openalex.org/W2946443174\",\"https://openalex.org/W2970196665\",\"https://openalex.org/W3023042104\",\"https://openalex.org/W3106917591\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3110928451\",\"https://openalex.org/W3112564761\",\"https://openalex.org/W3116610475\",\"https://openalex.org/W3129872227\",\"https://openalex.org/W3153901006\",\"https://openalex.org/W3186959004\",\"https://openalex.org/W3204569170\",\"https://openalex.org/W4200506456\",\"https://openalex.org/W4220970406\",\"https://openalex.org/W4226086528\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4283657643\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4307373402\",\"https://openalex.org/W4308486832\",\"https://openalex.org/W4313907362\",\"https://openalex.org/W4382874060\",\"https://openalex.org/W4385834760\",\"https://openalex.org/W4386314831\",\"https://openalex.org/W4387893679\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4390176357\",\"https://openalex.org/W4390271004\",\"https://openalex.org/W4390792000\",\"https://openalex.org/W4391480853\",\"https://openalex.org/W4394582518\",\"https://openalex.org/W4399276098\",\"https://openalex.org/W4399282081\",\"https://openalex.org/W4401233456\",\"https://openalex.org/W4402748917\",\"https://openalex.org/W4403626087\",\"https://openalex.org/W4405070512\",\"https://openalex.org/W4406894271\",\"https://openalex.org/W4407937116\",\"https://openalex.org/W4408304698\",\"https://openalex.org/W4408452335\",\"https://openalex.org/W4411111467\",\"https://openalex.org/W4411661857\",\"https://openalex.org/W4414083571\"],\"authorships\":[{\"id\":\"https://openalex.org/A5062024099\",\"display_name\":\"Kamil Jurowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092680358\",\"display_name\":\"Damian Kobylarz\",\"orcid\":\"https://orcid.org/0009-0001-2731-4152\"},{\"id\":\"https://openalex.org/A5053602589\",\"display_name\":\"Maciej Noga\",\"orcid\":\"https://orcid.org/0000-0002-4621-3429\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S87018847\",\"source_display_name\":\"Archives of Toxicology\",\"landing_page_url\":\"https://doi.org/10.1007/s00204-026-04365-4\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7144218147" }, { "id": 3478, "title": "Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder", "normalized_title": "psilocybin assisted psychotherapy for treatment resistant depression and co occurring substance use disorder", "authors": "Indiana University", "abstract": "The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder (SUD) in veterans and first responders. We seek to answer: * Whether 5mgs, 10mgs and 25mgs of psilocybin are safe in individuals with co-occurring TRD and SUD * Whether psilocybin assisted psychotherapy will reduce substance use severity and depression symptoms * What neurobiological processes are associated with the effects of psilocybin assisted psychotherapy. The researchers will compare the effects of a single dose of psilocybin (either 5mgs or 10mgs or 25mg) alongside psychotherapy on substance use severity and depression symptoms over six weeks in veterans and first responders with TRD and co-occurring SUD. In this 14-week study, participants will: * Visit the clinic for two intake sessions * Complete seven psychotherapy sessions. This will include three sessions before psilocybin administration, an 8 to 10 hour dosing session, and three sessions following psilocybin administration * Complete short, repeated daily assessments for six weeks, in total, before and after psilocybin administration * Complete two brain scans before and after psilocybin administration This is a double-blind randomized clinical trial to examine the safety and efficacy of a single dose of psilocybin (5mg or 10mg or 25mg) in reducing substance use severity and depression symptoms in N=50 veterans and first responders with treatment resistant depression (TRD) and co-occurring substance use disorder (SUD). The study will be conducted at Goodman Hall outpatient clinic located at Indiana University, Department of Psychiatry. All participants will take part in two intake visits (one to conduct safety tests and establish eligibility, and one to collect baseline and covariate data). They will then participate in three preparatory psychotherapy sessions with a certified psilocybin counselor before receiving one of three, randomly assigned, psilocybin doses during an 8 to 10 hour administration session. Following psilocybin administration, participants will participate in three weekly integrative psychotherapy sessions. We will also conduct three, two-week bursts of Ecological Momentary Assessment (EMA) during weeks 1 and 2, weeks 5 and 6 and weeks 10 and 11 of study participation, to measure daily substance use patterns and depression symptoms both during stressful and non-stressful situations. A pre- and post- fMRI paradigm will additionally be conducted to determine psilocybin-related changes within and between the default mode network, the salience mode network and the central executive network, during both resting state and stress. We will also explore the extent to which elevations in subjective mystical and existential experience contributes to psilocybin's therapeutic and mechanistic effects. It is anticipated that all three doses of psilocybin will be safe and well-tolerated in this sample of veterans and first responders. We additionally expect that 25mgs of psilocybin compared with 5mgs will attenuate substance use severity and depressive symptoms six weeks following administration, and during both stressful and non-stressful situations. In addition, we expect that 25mg Vs 5mg psilocybin will decrease resting state functional connectivity within the default mode network (DMN) and modulate connectivity between the DMN, salience network, central executive network, and the amygdala during stress exposure.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-29", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07499583", "keywords": "Treatment Resistant Depression, Substance Use Disorders, Psilocybin, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07499583\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Addiction,Brain Imaging,Default Mode Network,Mystical Experience,Clinical Trial,Treatment-Resistant Depression,Veterans,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3696, "title": "Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression", "normalized_title": "psilocybe cubensis mushrooms with or without fluoxetine for refractory depression", "authors": "Federal University of Latin American Integration", "abstract": "This Phase 2a pilot, exploratory, randomized, double-blind, placebo-controlled, parallel-group trial will estimate whether concurrent fluoxetine alters the antidepressant effect, acute psychedelic experience, or safety of a psychedelic-assisted psychotherapy session in adults with treatment-resistant major depressive disorder (TRD). Eligible participants (ages 25-64) have DSM-5-TR MDD, moderate-severe, MADRS ≥20, and partial response in the current episode (≥1 adequate antidepressant trial of 6-12 weeks with \\", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-26", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06898606", "keywords": "Depressive Disorder, Psilocybin and Psilocyn, Placebo, Psychotherapy-assisted session, Fluoxetine, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06898606\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3037, "title": "Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial", "normalized_title": "safety and efficacy of psilocybin assisted therapy for alcohol use disorder open label extension of a phase ii randomized controlled trial", "authors": "", "abstract": "Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods: Adults with AUD (N = 59) received a single administration of psilocybin (25-40mg/70kg) along with four total hours of therapy. Of this cohort, 30 participants had originally received psilocybin during the blinded phase of the RCT and 29 received active placebo (diphenhydramine). Mixed-Effects Models for Repeated Measures examined the effects of PAT on (a) alcohol consumption (percent heavy drinking [PHDD], drinks per day [DpD], and percent drinking days [PDD]), (b) alcohol craving, (c) abstinence self-efficacy, (d) and treatment readiness across a four-month follow-up. Results: Psilocybin was well tolerated, with no serious adverse events. Across participants, PDD decreased at 1-month but returned to baseline by Months 2-4. Among those with higher baseline drinking, PHDD, DpD, and PDD showed similar transient reductions. Participants from both double-blind groups demonstrated improvements in craving, self-efficacy, and treatment readiness one week after psilocybin with variable trajectories over follow-up. Discussion: Results suggest that a single administration of psilocybin in an open-label context may produce short-term improvements in alcohol use and core predictors of clinical change. Given long-lasting efficacy in the double-blind phase, it remains unclear if the short-term durability in the open-label extension is due to baseline floor effects, treatment resistance, lower treatment readiness and motivation, or fewer medication/therapy sessions.", "journal": "PsyArXiv", "publication_date": "2026-03-25", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/7xfek_v1", "keywords": "alcohol use disorder, clinical trial, craving, psilocybin, psychedelic, short inventory of problems, treatment readiness, Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"7xfek_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Addiction,Clinical Trial,Randomized Controlled Trial,Observational Study,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 129, "title": "Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.", "normalized_title": "pharmacotherapy in disorders of consciousness a mechanism based review", "authors": "Gillet A, Geron C, Vitello MM, Lejeune N.", "abstract": "Disorders of consciousness pose major therapeutic challenges owing to the complexity of underlying brain dysfunctions. Current pharmacological interventions explored in disorders of consciousness target distinct molecular systems, including dopaminergic modulators (amantadine, levodopa, apomorphine, bromocriptine, selegiline, methylphenidate, and modafinil), GABAergic agents (zolpidem and baclofen), and other neuromodulatory compounds acting on glutamatergic, opioid, or serotonergic receptors (ketamine, remifentanil, and psilocin). These treatments aim to modulate disrupted neural circuits, including the mesocircuit, a thalamocortical-striatal network critically involved in consciousness and motor control. This review explores the pathophysiological mechanisms underlying disorders of consciousness and the pharmacological profile of these agents. It summarizes reported clinical improvements and discusses determinants of therapeutic response, highlighting the role of biomarkers derived from neurophysiological and neuroimaging assessments. Safety profiles associated with these treatments are also critically evaluated to guide clinical decision making. By integrating current knowledge on pharmacological modulation of key neural systems, including dopaminergic and GABAergic pathways, this article provides a comprehensive framework for understanding treatment strategies in disorders of consciousness.", "journal": null, "publication_date": "2026-03-23", "publication_year": 2026, "doi": "10.1007/s40263-026-01274-z", "pubmed_id": "41876835", "source_url": "https://doi.org/10.1007/s40263-026-01274-z", "keywords": "Animals, Humans, Consciousness Disorders, Dopamine Agents, GABA Agents", "substance_tags": "psilocin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"41876835\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Consciousness,Biomarkers,Aging,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3657, "title": "Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies", "normalized_title": "precision phenotyping of behavioral risk and response to electromagnetic and psychedelic therapies", "authors": "University of New Mexico", "abstract": "PRE-EMPT will assemble a study group of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm). The investigators will obtain clinical assessments, MRI, and blood levels for circular RNA (circRNA). The teams will then administer three interventions (neurofeedback, transcranial magnetic stimulation, and psilocybin assisted therapy), and repeat the tests above. A team with expertise in artificial intelligence will then use our data to try to find patterns that identify who is at high risk versus low risk with a high degree of accuracy. For U.S. Service Members, deployment and combat exposure can result in significant mental strain, with high rates of disability and suicide. Unfortunately our ability to predict and treat those at high risk of intentional self-harm is limited. PRE-EMPT (Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies) seeks to transform the assessment and treatment of the spectrum of depression, posttraumatic stress, and self-harm. PRE-EMPT will utilize multimodal neuroimaging, blood-based biomarkers, and predictive analytics to devise highly accurate models of behavioral risk, and to characterize response to three neuroplasticity-enhancing interventions. Background: Rates of suicide have increased 37% since the year 2000 despite concerted governmental and institutional programs to address root causes such as stigma and lack of access. Suicide was the number one cause of active-duty fatality from 2014 to 2019, highlighting the vulnerability of Service Members and Veterans. Suicide is a highly multifactorial event and may be conceptualized as a state in which individuals cannot come up with any other option to endure difficult circumstances or intense feelings, representing failures of cognitive control (CC) and emotion regulation (ER). Similarly, the heritability of suicide risk is well known, and transcriptomics, or the study of transcript molecules such as RNA that regulate gene expression, has potential to reveal mechanisms of risk not fully explained by DNA analysis. Better methods of classifying suicide risk according to objective and measurable factors are needed to proactively identify persons at risk and provide interventions tailored to risk. Research Plan: PRE-EMPT will assemble a cohort of 150 civilian and Veteran participants from three populations (low risk, intermediate risk, and high risk for self-harm). The investigators will obtain baseline clinical assessments, structural and functional MRI utilizing tasks pioneered by our team to assess cognitive control (CC) and emotion regulation (ER), and peripheral circular RNA (circRNA) levels to characterize the molecular brain states associated with behavioral risk. In parallel, investigators will mine publicly available databases to identify network nodes and use deep learning techniques on multivariate patterns of brain activation, structural topography, and functional connectivity. The clinical, imaging, and transcriptomic data will be fused and jointly analyzed to increase the accuracy of risk prediction models. PRE-EMPT in three separate arms will then prospectively assess three promising and innovative interventions for their potential to reduce suicidal ideation and alter activity in key neural networks: 1) neurofeedback (NF) using real-time fMRI with simultaneous electroencephalography (EEG), 2) accelerated intermittent theta burst stimulation (aiTBS) with dose optimization through electric field modeling; and 3) psilocybin assisted therapy (PSI), with flexible dosing plan to maximize the depth of psychedelic experience. Assessments will be repeated at post-treatment and at 1, 3, and 6 months after intervention. These therapies were chosen based on our team's prior work in all three interventions demonstrating rapid action and large effects. Each clinical arm will contribute independent insights into mediators of efficacy for the specific interventions and risk groups, while pooling data to identify predictors across the risk spectrum. Specific Aim 1: To construct a neurobehavioral model from structural and functional MRI, clinical, and transcriptomic data that accurately predicts behavioral risk. Specific Aim 2: To test three potential rapid-acting therapies for suicidal ideation and identify mechanistic mediators of response.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-19", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07484906", "keywords": "Suicidal Ideation, fMRI Neurofeedback, Accelerated theta burst stimulation, Psilocybin assisted therapy, WITHDRAWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07484906\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,PTSD,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Emotional Processing,Observational Study,Veterans,Safety,Transcriptomics", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3582, "title": "Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism", "normalized_title": "psilocybin for treatment resistant depression in autism a pilot trial with pre post brain and cognitive measurement to understand mechanism", "authors": "Centre for Addiction and Mental Health", "abstract": "We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020). They will also receive psilocybin at 2 different time points, firstly a safety dose of 10mg, followed by a treatment dose of 25mg. This study design is in accordance with previous studies investigating the use of psilocybin with psilocybin-assisted therapy (PAT) to treat TRD (Carhart-Harris et al., 2016, 2018) Each participant will begin with a screening visit (V1), during which eligibility will be determined through clinical and psychiatric assessments of the participant's physical and mental health. Following confirmation of eligibility, the study procedures will begin. The participant will begin with a 2-4 week tapering period during which they will taper and discontinue any conventional antidepressants. Most conventional antidepressants will require a minimum 2-week tapering period, with the exception of fluoxetine, which will require a 4-week tapering period. Additional time may be added at the discretion of the study investigator. During the tapering period, there will be weekly check-ins with a study psychiatrist by in-person assessment or brief telephone calls to monitor for worsening depression and suicidality. Following the tapering period, participant eligibility will be re-assessed for the eligibility. At Study Visit 2 (Baseline, V2), participants will complete a series of questionnaires and assessments (Table 2) and preparatory therapy with trained study therapists. The participant will also receive a brain MRI scan lasting for about 45 minutes. At Study Visits 3 \\& 4 (V3/V4), participants will receive oral doses of psilocybin (safety dose of 10 mg at V3, treatment dose of 25 mg at V4), to assess the tolerability and efficacy of psilocybin. These sessions will be held one week apart and will last 6 to 8 hours each. These sessions will take place in a pre-decorated treatment room at CAMH. Throughout the entire duration of the dosing sessions, participants will be monitored by a minimum of two trained therapists. At the end of each session, participants will be evaluated for safety by a study psychiatrist before being discharged. Participants will also rate the 11-Dimension Altered States of Consciousness (11D-ASC) at the end of each dosing day when the subjective effects of psilocybin have subsided to a negligible level. In addition, the participant will also receive a second brain MRI scan lasting for about 30 minutes (V3a) following V3 Safety dosing. To reduce participant burden, MRI scan can be completed on the following day or within 1-3 days following safety dosing (V3). The participants will also be required to complete the self-rated questionnaires at this additional MRI assessment. Visit 5 (V5) will be held one day after administration of the treatment dose (V4). During V5 the participants will complete post-treatment clinical and cognitive assessments, alongside the third and final MRI scan (of the main clinical trial design). Participants will also undergo a 1-hour integration therapy session to debrief their experiences the day before. Visit 6 (V6) will be held one week following the treatment dose (V4). During V6 a second 1-hour integration therapy session takes place and all post-treatment clinical assessments will be repeated. Subsequent clinical progress will be evaluated virtually at V7, V8, V9, which will respectively be held 2, 4, and 12 weeks following the treatment session (V4). 10 participants out of 20 participants in the main clinical trial could opt to receive 7 additional brain MRI scans besides the MRI scans at V2, V3a and V5 required in the main clinical trial. These 7 additional scans will be assessed at V1, in the middle of medication washout/tapering period V6, V7, V8, 8 weeks following the treatment dose (V4), and V9, respectively. At each optional MRI visit, self-rated assessments will also be collected.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-19", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06731621", "keywords": "Treatment Resistant Depression, Autism Spectrum Disorder, Psilocybin, Psilocybin-Assisted Therapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06731621\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Consciousness,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1975, "title": "Raman Activity Investigation and Utilization of Psilocybin", "normalized_title": "raman activity investigation and utilization of psilocybin", "authors": "Mingyu Sun, Xiaoyu Zhao, Fandi Kong, Jinsong Wang, Yunchang Lu, Liang Tong", "abstract": "ABSTRACT Accidental ingestion of psilocybin-containing mushrooms can cause poisoning and hallucinations, making their rapid detection a public health priority. Conventional methods such as HPLC, GC-MS, LC-MS, TLC, CE, and ELISA provide sensitivity but are often destructive, time-consuming, or impractical for real-time applications. This study introduces a Raman spectroscopy-based approach for rapid, nondestructive identification of psilocybin. The molecular geometry of psilocybin was optimized using density functional theory (B3LYP/6-31G(d,p)), and theoretical Raman spectra were generated to assign characteristic vibrational peaks, confirming its Raman activity. Experimental spectra of fresh and heat-treated Psilocybe cubensis mushroom samples were collected, with peak alignment demonstrating good agreement with theoretical predictions, thus establishing psilocybin fingerprint features. For classification, raw and preprocessed spectra (MSC, SNV, 1st-D, detrending) were evaluated. Among feature extraction methods (PCA, SPA, UVE, CARS), CARS yielded the most discriminative variables. An XGBoost model was developed and optimized via Bayesian tuning, while SMOTE addressed class imbalance. Furthermore, psilocybin fingerprint features were fused with CARS features to enhance interpretability and model robustness. Finally, a Bagging framework integrating XGBoost, KNN, SVM, and Decision Tree was implemented to improve generalization and noise resistance. The final Bagging-based model achieved high performance (accuracy 0.984, F1-score 0.984, ROC AUC0.976), with strong stability under storage conditions. Overall, this study elucidates psilocybin's Raman spectral characteristics and establishes a machine learning-assisted detection model. The approach enables rapid, accurate, cost-effective, and contamination-free identification of psilocybin, with potential applications in food safety monitoring and on-site toxic mushroom screening.", "journal": "Journal of Raman Spectroscopy", "publication_date": "2026-03-18", "publication_year": 2026, "doi": "10.1002/jrs.70133", "pubmed_id": null, "source_url": "https://doi.org/10.1002/jrs.70133", "keywords": "Psilocybin, Raman spectroscopy, Artificial intelligence, Pattern recognition (psychology), Interpretability, Biological system, Sensitivity (control systems), Chemistry, Discriminative model, Identification (biology), Fingerprint (computing), Computer science, Support vector machine, Mushroom, Noise (video), False alarm, Feature (linguistics), Analytical Chemistry (journal), Feature extraction, Generalization, Machine learning, Wavelet, Materials science, Naive Bayes classifier, Overlayer, Psychedelics and Drug Studies, Silymarin and Mushroom Poisoning, Spectroscopy and Chemometric Analyses", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7139132619\",\"openalex_url\":\"https://openalex.org/W7139132619\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1962467645\",\"https://openalex.org/W1972295548\",\"https://openalex.org/W1976088117\",\"https://openalex.org/W1992132841\",\"https://openalex.org/W1996216090\",\"https://openalex.org/W1997270149\",\"https://openalex.org/W2001354744\",\"https://openalex.org/W2004133695\",\"https://openalex.org/W2011640160\",\"https://openalex.org/W2019916133\",\"https://openalex.org/W2031679043\",\"https://openalex.org/W2050390172\",\"https://openalex.org/W2069337288\",\"https://openalex.org/W2071586426\",\"https://openalex.org/W2123754499\",\"https://openalex.org/W2136132422\",\"https://openalex.org/W2155024142\",\"https://openalex.org/W2160907505\",\"https://openalex.org/W2187618673\",\"https://openalex.org/W2229396693\",\"https://openalex.org/W2294067692\",\"https://openalex.org/W2317373418\",\"https://openalex.org/W2562841969\",\"https://openalex.org/W2575712535\",\"https://openalex.org/W2619230229\",\"https://openalex.org/W2725171488\",\"https://openalex.org/W2736435690\",\"https://openalex.org/W2752495893\",\"https://openalex.org/W2801068453\",\"https://openalex.org/W2895269073\",\"https://openalex.org/W2940981726\",\"https://openalex.org/W2997150204\",\"https://openalex.org/W3014008355\",\"https://openalex.org/W3044469818\",\"https://openalex.org/W3091912750\",\"https://openalex.org/W3094690508\",\"https://openalex.org/W3106302714\",\"https://openalex.org/W3148181069\",\"https://openalex.org/W3157976194\",\"https://openalex.org/W4200350840\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4224903330\",\"https://openalex.org/W4303959125\",\"https://openalex.org/W4386393168\",\"https://openalex.org/W4391994576\",\"https://openalex.org/W4392713894\",\"https://openalex.org/W4399851148\",\"https://openalex.org/W4403474683\",\"https://openalex.org/W4405694559\"],\"authorships\":[{\"id\":null,\"display_name\":\"Mingyu Sun\",\"orcid\":\"https://orcid.org/0009-0003-4085-0122\"},{\"id\":null,\"display_name\":\"Xiaoyu Zhao\",\"orcid\":\"https://orcid.org/0000-0002-2642-486X\"},{\"id\":\"https://openalex.org/A5130189481\",\"display_name\":\"Fandi Kong\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130181488\",\"display_name\":\"Jinsong Wang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130029237\",\"display_name\":\"Yunchang Lu\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130206820\",\"display_name\":\"Liang Tong\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4206644\",\"source_display_name\":\"Journal of Raman Spectroscopy\",\"landing_page_url\":\"https://doi.org/10.1002/jrs.70133\",\"is_oa\":false}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7139132619" }, { "id": 1974, "title": "PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS", "normalized_title": "psilocybin as an adjunctive treatment for depression and psychological distress in oncology current evidence and clinical implications", "authors": "Anna Komarczewska, Michał Kociński, Patryk Iglewski, Michał Pietrasz, Jakub Idziński, Anna Lubomska", "abstract": "Depression and psychological distress are highly prevalent among patients with cancer and are associated with impaired quality of life, reduced treatment adherence, and poorer clinical outcomes. Standard pharmacological and psychosocial interventions often demonstrate limited efficacy or delayed onset of action in oncological and palliative settings. Psilocybin-assisted therapy has recently emerged as a potential adjunctive approach for the treatment of depression, anxiety, and existential distress in patients with life-threatening cancer. This narrative review synthesizes current clinical and neurobiological evidence regarding the use of psilocybin as an adjunctive treatment in oncology. Randomized controlled trials, systematic reviews, and case reports indicate that psilocybin administered within a structured psychotherapeutic framework may produce rapid and sustained reductions in depressive symptoms and anxiety, including improvements in existential well-being. Mechanistic findings suggest involvement of serotonergic 5-HT2A receptor activation, large-scale brain network modulation, and enhanced neuroplasticity. When applied in controlled clinical settings with appropriate screening and psychological support, psilocybin demonstrates a favorable safety profile. Although current evidence is promising, limitations related to sample size and methodological heterogeneity require cautious interpretation. Further well-designed trials are necessary to determine long-term efficacy and optimal integration into comprehensive cancer and palliative care.", "journal": "International Journal of Innovative Technologies in Social Science", "publication_date": "2026-03-18", "publication_year": 2026, "doi": "10.31435/ijitss.1(49).2026.5034", "pubmed_id": null, "source_url": "https://doi.org/10.31435/ijitss.1(49).2026.5034", "keywords": "Psilocybin, Distress, Psychosocial, Psychological intervention, Psychiatry, Psychotherapist, Medicine, Clinical psychology, Depression (economics), Adjunctive treatment, Clinical trial, Randomized controlled trial, Psychopathology, Palliative care, Psychology, Serotonergic, Anxiety, Quality of life (healthcare), Cancer, Intervention (counseling), Clinical study design, Hallucinogen, Symptom relief, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7164003040\",\"openalex_url\":\"https://openalex.org/W7164003040\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2559739670\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W4309360340\",\"https://openalex.org/W4362471767\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4411787106\",\"https://openalex.org/W4412939048\",\"https://openalex.org/W7118088637\"],\"authorships\":[{\"id\":\"https://openalex.org/A5138214715\",\"display_name\":\"Anna Komarczewska\",\"orcid\":\"https://orcid.org/0009-0006-7378-2607\"},{\"id\":\"https://openalex.org/A5117509697\",\"display_name\":\"Michał Kociński\",\"orcid\":null},{\"id\":\"https://openalex.org/A5117509696\",\"display_name\":\"Patryk Iglewski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124479078\",\"display_name\":\"Michał Pietrasz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5138262915\",\"display_name\":\"Jakub Idziński\",\"orcid\":\"https://orcid.org/0009-0006-1058-9615\"},{\"id\":\"https://openalex.org/A5121444146\",\"display_name\":\"Anna Lubomska\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210206754\",\"source_display_name\":\"International Journal of Innovative Technologies in Social Science\",\"landing_page_url\":\"https://doi.org/10.31435/ijitss.1(49).2026.5034\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Chronic Pain,Neuroplasticity,Receptor Pharmacology,Wellbeing,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Case Report,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7164003040" }, { "id": 3641, "title": "Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study", "normalized_title": "safety and efficacy of psilocybin assisted psychotherapy for demoralization syndrome in patients diagnosed with advanced stage cancer a pilot study", "authors": "Gustavo Vazquez", "abstract": "Demoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness. The relevance of demoralization syndrome in oncology is tied to this syndrome's association with other mental health ailments such as depression, anxiety, suicidal ideation, and quality of life. Unfortunately, so far no pharmacological strategy has been devised for demoralization, and only a few psychotherapeutic approaches have been trialed in this population, though no psychotherapeutic treatments have been tested for demoralization specifically. The new wave of psychedelic research has been showing encouraging results in a broad spectrum of psychiatric diagnosis, including depression and anxiety in patients diagnosed with cancer and other life-threatening diseases. To date, no clinical trials have been published in which the potential therapeutic effects of psychedelics are explored for the treatment of demoralization syndrome. The aim of this open label pilot study is to assess the safety and efficacy of psilocybin-assisted psychotherapy as a treatment for demoralization syndrome in patients diagnosed with cancer. Fifteen participants between the ages of 18 to 70 years with advanced stage cancer and demoralization syndrome will be enrolled in a treatment program which will include 6 psychotherapeutic sessions and one psilocybin (25 mg) dosing session. Our outcome of interest will be a decrease in demoralization, as measured by the Demoralization Scale at baseline and at the end of the study, and adverse events registration. Other measures of interest include Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, and the Columbia Suicide Severity Rating Scale. Those patients with partial response a month after the psilocybin intervention will be offered the possibility of a second psilocybin 25 mg dosing session.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-17", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06818994", "keywords": "Demoralization, Safety, Psilocybin-assisted Psychotherapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06818994\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Aging,Clinical Trial,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 133, "title": "Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression", "normalized_title": "efficacy and safety of psilocybin in treatment resistant major depression", "authors": "Lea J. Mertens, Michael Koslowski, Felix Betzler, Manuela Brand, Ricarda Evens, Laura Kärtner, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Christian N. Schmitz, Andreas Ströhle, Dennis Scharf, Moritz Spangemacher, Max Wolff, Zahra Assadi, Scharif Bahri, Lilith Becher, Luca V. Färber, Niklas Kirchen, Eugenia Kulakova, Linda C. Kunz, Andy Meijer, Barbara Rohrmoser, Stefan Wellek, Moritz Berger, Gerhard Gründer", "abstract": "Importance: Psilocybin shows promise in treating depression, although limitations of previous research warrant further research. Objective: To investigate the efficacy and safety of oral psilocybin, 25 mg, with adjunct psychotherapy in treatment-resistant depression (TRD). Design, Setting, and Participants: This was a 2-center, triple-blinded (investigator, participant, rater), phase 2b, active placebo-controlled randomized clinical trial. Participants were randomized to 4 groups in ratios 2:2:1:1, receiving 2 doses 6 weeks apart (week 0, week 6) as follows: (1) placebo (nicotinamide, 100 mg) then psilocybin, 25 mg; (2) psilocybin, 5 mg, then 25 mg; and (3) psilocybin, 25 mg, then 5 mg or psilocybin, 25 mg, twice embedded in psychotherapeutic sessions. Participants aged 25 to 65 years with TRD and withdrawn from antidepressant medication were recruited predominantly from 2 outpatient settings in Germany. Study data were analyzed from April 2024 to November 2025. Interventions: Oral synthetic psilocybin, 25 mg; psilocybin, 5 mg; or nicotinamide, 100 mg administered with psychotherapeutic sessions. Main Outcomes and Measures: The primary end point was treatment response (≥50% reduction on the Hamilton Rating Scale for Depression [HAMD17]) at week 6 before the second dose. Key secondary end points were response on the Beck Depression Inventory II (BDI-II) and mean change from baseline on the HAMD17 and BDI-II at week 6. Results: A total of 144 participants (mean [SD] age, 42.6 [10.8] years; 85 male [59.0%]) were randomized, and 142 were included in the primary efficacy analysis: psilocybin, 25 mg (n = 47), psilocybin, 5 mg (n = 48), and nicotinamide (n = 47). Response rates on the primary end point were 17.0% in the group receiving psilocybin, 25 mg; 12.5% in the group receiving psilocybin, 5 mg; and 10.6% in the group receiving nicotinamide. The first hierarchical comparison was nonsignificant (psilocybin, 25 mg vs nicotinamide, adjusted odds ratio [OR], 1.73; 95% CI, 0.53-6.23; P =.19; 1-sided α P =.03); consequently, further formal testing was not performed. Analyses of key secondary end points (mean changes from baseline on HAMD17 and BDI-II) provided exploratory evidence of a clinically meaningful effect of psilocybin, 25 mg. Psilocybin, 25 mg, was linked to adverse events, predominantly acutely, and was associated with higher reports of suicidal ideation on dosing days (4% vs 1%-2% in comparator conditions). Two serious adverse reactions were reported after psilocybin, 25 mg, including 1 case of hallucinogen persisting perception disorder. Conclusion and Relevance: In this randomized clinical trial, psilocybin, 25 mg, with adjunct psychotherapy, was associated with a clinically meaningful reduction in depressive symptoms in individuals with TRD, although findings did not show a significant effect on the primary outcome. The treatment was well tolerated by most participants, although safety signals were observed. While overall this constituted an inconclusive trial, these results add to the existing evidence on the potential of psilocybin treatment for depression. Trial Registration: ClinicalTrials.gov Identifier: NCT04670081.", "journal": "JAMA Psychiatry", "publication_date": "2026-03-17", "publication_year": 2026, "doi": "10.1001/jamapsychiatry.2026.0132", "pubmed_id": "41848690", "source_url": "https://doi.org/10.1001/jamapsychiatry.2026.0132", "keywords": "Psilocybin, Medicine, Depression (economics), Psychiatry, MEDLINE, Hallucinogen, Treatment-resistant depression, Major depressive disorder, Major depressive episode, Severity of illness, Adverse effect, Young adult, Clinical trial, Psychedelics and Drug Studies, Pharmaceutical Quality and Counterfeiting, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7138853109\",\"openalex_url\":\"https://openalex.org/W7138853109\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W1655045766\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2069520581\",\"https://openalex.org/W2072833030\",\"https://openalex.org/W2089799315\",\"https://openalex.org/W2098644261\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2964840460\",\"https://openalex.org/W3058958332\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3129586996\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3193440797\",\"https://openalex.org/W4220708535\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311432965\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4379598244\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4394894573\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4405029114\",\"https://openalex.org/W4412738512\"],\"authorships\":[{\"id\":\"https://openalex.org/A5070309082\",\"display_name\":\"Lea J. Mertens\",\"orcid\":\"https://orcid.org/0000-0003-4415-3941\"},{\"id\":\"https://openalex.org/A5045306689\",\"display_name\":\"Michael Koslowski\",\"orcid\":\"https://orcid.org/0000-0001-8798-9875\"},{\"id\":\"https://openalex.org/A5130062020\",\"display_name\":\"Felix Betzler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051417409\",\"display_name\":\"Manuela Brand\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054444045\",\"display_name\":\"Ricarda Evens\",\"orcid\":\"https://orcid.org/0000-0002-2834-2171\"},{\"id\":\"https://openalex.org/A5044522468\",\"display_name\":\"Laura Kärtner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016321877\",\"display_name\":\"Andrea Jungaberle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001710309\",\"display_name\":\"Henrik Jungaberle\",\"orcid\":\"https://orcid.org/0000-0001-7634-4211\"},{\"id\":\"https://openalex.org/A5065637165\",\"display_name\":\"Tomislav Majić\",\"orcid\":\"https://orcid.org/0000-0003-2950-6673\"},{\"id\":\"https://openalex.org/A5077142042\",\"display_name\":\"Christian N. Schmitz\",\"orcid\":\"https://orcid.org/0009-0005-1908-4026\"},{\"id\":\"https://openalex.org/A5129883243\",\"display_name\":\"Andreas Ströhle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5000942578\",\"display_name\":\"Dennis Scharf\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129983509\",\"display_name\":\"Moritz Spangemacher\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129781273\",\"display_name\":\"Max Wolff\",\"orcid\":null},{\"id\":\"https://openalex.org/A5130191345\",\"display_name\":\"Zahra Assadi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067811740\",\"display_name\":\"Scharif Bahri\",\"orcid\":null},{\"id\":\"https://openalex.org/A5090562448\",\"display_name\":\"Lilith Becher\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093390890\",\"display_name\":\"Luca V. Färber\",\"orcid\":null},{\"id\":\"https://openalex.org/A5080849074\",\"display_name\":\"Niklas Kirchen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5031576236\",\"display_name\":\"Eugenia Kulakova\",\"orcid\":\"https://orcid.org/0000-0001-7206-4802\"},{\"id\":\"https://openalex.org/A5102613407\",\"display_name\":\"Linda C. Kunz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129846065\",\"display_name\":\"Andy Meijer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093861751\",\"display_name\":\"Barbara Rohrmoser\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063934463\",\"display_name\":\"Stefan Wellek\",\"orcid\":\"https://orcid.org/0000-0001-8369-8122\"},{\"id\":\"https://openalex.org/A5080177315\",\"display_name\":\"Moritz Berger\",\"orcid\":\"https://orcid.org/0000-0002-0656-5286\"},{\"id\":\"https://openalex.org/A5081339058\",\"display_name\":\"Gerhard Gründer\",\"orcid\":\"https://orcid.org/0000-0001-7868-3903\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2495708506\",\"source_display_name\":\"JAMA Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1001/jamapsychiatry.2026.0132\",\"is_oa\":true}}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7138853109" }, { "id": 1976, "title": "Explainable AI framework for psilocybin depression treatment optimization", "normalized_title": "explainable ai framework for psilocybin depression treatment optimization", "authors": "Akey Sungheetha, R. Rajesh Sharma, Oluwasegun Julius Aroba, Sheila Mahapatra, P. D. Mahendhiran", "abstract": "Introduction This computational modeling study introduces a novel Explainable Artificial Intelligence (XAI) framework for optimizing single-dose psilocybin treatment protocols through personalized intervention modeling using publicly available mental health datasets. All results presented are derived from novel simulated data and predictive modeling only, not from real-time clinical implementations or actual patient treatments. Methods The mathematical optimization model integrates digital twin technologies, multimodal depression detection systems, and Bayesian optimization algorithms to create comprehensive computational patient profiles with temporal resolution processing capabilities at 250 Hz sampling frequency. Validation employed three publicly available datasets: (1) the Psilocybin Precision Functional Mapping dataset from OpenNeuro containing neuroimaging data from 7 participants, (2) the MODMA multimodal mental disorder dataset with 53 participants including electroencephalography and audio signals, and (3) a meta-analytic psilocybin therapy outcomes dataset containing aggregated results from 10 clinical trials. The framework incorporates pharmacokinetic modeling with an absorption rate constant of 0.45 per hour and an elimination rate constant of 0.23 per hour, receptor occupancy dynamics based on a dissociation constant of 6.3 nanomolar, and simulated real-time monitoring protocols processing physiological parameters including heart rate variability, blood pressure measurements, and cortisol levels at a 1 Hz frequency. Results The simulated computational model demonstrates significant improvements in prediction accuracy, reaching 94.7%, and therapeutic transparency, achieving 89.3% explainability scores. Simulated validation demonstrates computational precision of 92.8% in predicting treatment response patterns across diverse patient populations in silico. The proposed computational methodology addresses key challenges in psychedelic-assisted therapy modeling through interpretable artificial intelligence models, achieving 96.2% computational safety index scores and 91.5% algorithmic compliance metrics in simulation environments. Energy-efficient computational architecture achieves 73.4% carbon footprint reduction through optimized algorithm design and sparse matrix representations. Discussion This study presents a theoretical computational framework for modeling therapeutic outcomes through simulation and prediction, establishing a foundation for future clinical validation through prospective randomized controlled trials. The framework supports sustainable digital mental healthcare delivery systems compatible with renewable energy infrastructure. All findings represent computational predictions and simulated scenarios requiring extensive clinical validation before any practical application.", "journal": "Frontiers in Computer Science", "publication_date": "2026-03-15", "publication_year": 2026, "doi": "10.3389/fcomp.2025.1652190", "pubmed_id": null, "source_url": "https://doi.org/10.3389/fcomp.2025.1652190", "keywords": "Computer science, Psilocybin, Artificial intelligence, Computational model, Machine learning, Major depressive disorder, Neuroimaging, Key (lock), Data mining, Data modeling, Computational complexity theory, Modular design, Pattern recognition (psychology), Global optimization, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7136253679\",\"openalex_url\":\"https://openalex.org/W7136253679\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W166169566\",\"https://openalex.org/W1566641586\",\"https://openalex.org/W1631913055\",\"https://openalex.org/W1977733462\",\"https://openalex.org/W1981552604\",\"https://openalex.org/W1984398689\",\"https://openalex.org/W1991473840\",\"https://openalex.org/W1994682257\",\"https://openalex.org/W2000359198\",\"https://openalex.org/W2007213925\",\"https://openalex.org/W2013270989\",\"https://openalex.org/W2017766892\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2052341330\",\"https://openalex.org/W2061144551\",\"https://openalex.org/W2067978628\",\"https://openalex.org/W2073241381\",\"https://openalex.org/W2075286650\",\"https://openalex.org/W2078483536\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2087381130\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2100697007\",\"https://openalex.org/W2105934661\",\"https://openalex.org/W2109935313\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2112081648\",\"https://openalex.org/W2115098571\",\"https://openalex.org/W2118502261\",\"https://openalex.org/W2119910794\",\"https://openalex.org/W2122646361\",\"https://openalex.org/W2128495200\",\"https://openalex.org/W2131241448\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2146048262\",\"https://openalex.org/W2151554678\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2154286581\",\"https://openalex.org/W2157825442\",\"https://openalex.org/W2165010366\",\"https://openalex.org/W2170892587\",\"https://openalex.org/W2239141610\",\"https://openalex.org/W2282821441\",\"https://openalex.org/W2302501749\",\"https://openalex.org/W2318802957\",\"https://openalex.org/W2328176404\",\"https://openalex.org/W2487898712\",\"https://openalex.org/W2498119267\",\"https://openalex.org/W2525984666\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2770877241\",\"https://openalex.org/W2787427645\",\"https://openalex.org/W2787894218\",\"https://openalex.org/W2788029111\",\"https://openalex.org/W2789894922\",\"https://openalex.org/W2789970635\",\"https://openalex.org/W2801752756\",\"https://openalex.org/W2807593075\",\"https://openalex.org/W2895763047\",\"https://openalex.org/W2899768131\",\"https://openalex.org/W2899876413\",\"https://openalex.org/W2902802452\",\"https://openalex.org/W2903777941\",\"https://openalex.org/W2905810301\",\"https://openalex.org/W2908201961\",\"https://openalex.org/W2910707576\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2927351257\",\"https://openalex.org/W2934399013\",\"https://openalex.org/W2945976633\",\"https://openalex.org/W2951103577\",\"https://openalex.org/W2951617899\",\"https://openalex.org/W2951665052\",\"https://openalex.org/W2953073956\",\"https://openalex.org/W2953532875\",\"https://openalex.org/W2962862931\",\"https://openalex.org/W2963809228\",\"https://openalex.org/W2977883299\",\"https://openalex.org/W2981869278\",\"https://openalex.org/W2985355520\",\"https://openalex.org/W3000603264\",\"https://openalex.org/W3000716014\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3012875567\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3023658191\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3106889297\",\"https://openalex.org/W3116201721\",\"https://openalex.org/W3138819813\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3209901185\",\"https://openalex.org/W3211271338\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W3214897310\",\"https://openalex.org/W4205210034\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4233026002\",\"https://openalex.org/W4236876623\",\"https://openalex.org/W4241727697\",\"https://openalex.org/W4287204036\",\"https://openalex.org/W4287643567\",\"https://openalex.org/W4288090629\",\"https://openalex.org/W4289761856\",\"https://openalex.org/W4308245305\",\"https://openalex.org/W4385245566\",\"https://openalex.org/W4403918657\"],\"authorships\":[{\"id\":\"https://openalex.org/A5129572525\",\"display_name\":\"Akey Sungheetha\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129471237\",\"display_name\":\"R. Rajesh Sharma\",\"orcid\":null},{\"id\":\"https://openalex.org/A5061417005\",\"display_name\":\"Oluwasegun Julius Aroba\",\"orcid\":\"https://orcid.org/0000-0002-3693-7255\"},{\"id\":\"https://openalex.org/A5045493683\",\"display_name\":\"Sheila Mahapatra\",\"orcid\":\"https://orcid.org/0000-0001-6502-0772\"},{\"id\":\"https://openalex.org/A5129426571\",\"display_name\":\"P. D. Mahendhiran\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210211086\",\"source_display_name\":\"Frontiers in Computer Science\",\"landing_page_url\":\"https://doi.org/10.3389/fcomp.2025.1652190\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Brain Imaging,Pharmacology,Receptor Pharmacology,Aging,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7136253679" }, { "id": 134, "title": "A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder", "normalized_title": "a randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive compulsive disorder", "authors": "Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand, Rajan Dunne, James I. Prickett, Brian Bayze, John J. B. Allen", "abstract": "BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses in OCD patients. METHODS: = 5 per condition), followed by four additional high-dose sessions (single-blind Phase 2). OCD severity was assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS) following each session, and prospectively for 6 months. Safety was evaluated via adverse event systematic assessment, suicide severity rating, and psychosis screening. RESULTS: Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (⩾35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment. CONCLUSIONS: Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials are needed to further support efficacy and refine treatment protocols. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03300947.", "journal": "Journal of Psychopharmacology", "publication_date": "2026-03-12", "publication_year": 2026, "doi": "10.1177/02698811261424214", "pubmed_id": "41825921", "source_url": "https://doi.org/10.1177/02698811261424214", "keywords": "Psilocybin, Randomized controlled trial, Adverse effect, Placebo, Medicine, Psychosis, Clinical trial, Reuptake inhibitor, Fluoxetine, Dosing, Hallucinogen, Psychology, Anesthesia, Psychiatry, Severity of illness, Internal medicine, Rating scale, Anxiety disorder, Obsessive compulsive, Agonist, Post-hoc analysis, Serotonin reuptake inhibitor, Crossover study, Schizophrenia (object-oriented programming), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7135170485\",\"openalex_url\":\"https://openalex.org/W7135170485\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W122113993\",\"https://openalex.org/W2006001020\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2087854982\",\"https://openalex.org/W2108696783\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2138204170\",\"https://openalex.org/W2141403362\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2306891185\",\"https://openalex.org/W2792086414\",\"https://openalex.org/W2902990194\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3027721867\",\"https://openalex.org/W3109908198\",\"https://openalex.org/W3172784626\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W3214305299\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4310735641\",\"https://openalex.org/W4385954214\",\"https://openalex.org/W4391286658\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4394566107\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4411969620\",\"https://openalex.org/W7113899315\"],\"authorships\":[{\"id\":null,\"display_name\":\"Francisco A. Moreno\",\"orcid\":\"https://orcid.org/0009-0008-0700-6508\"},{\"id\":\"https://openalex.org/A5104303567\",\"display_name\":\"Katja Ehrmann Allen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005073454\",\"display_name\":\"Christopher B. Wiegand\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109080350\",\"display_name\":\"Rajan Dunne\",\"orcid\":null},{\"id\":\"https://openalex.org/A5023032729\",\"display_name\":\"James I. Prickett\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129046947\",\"display_name\":\"Brian Bayze\",\"orcid\":null},{\"id\":null,\"display_name\":\"John J. B. Allen\",\"orcid\":\"https://orcid.org/0000-0002-3417-6720\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261424214\",\"is_oa\":false}}", "topic_tags": "Anxiety,OCD,Chronic Pain,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7135170485" }, { "id": 3517, "title": "Psilocybin-facilitated Treatment for Chronic Pain", "normalized_title": "psilocybin facilitated treatment for chronic pain", "authors": "University of Alabama at Birmingham", "abstract": "The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients. Participants will be randomized to two groups: Psilocybin or Active Placebo. Those in the Psilocybin condition will receive.36 mg/kg of psilocybin. Based on previous research,.36 mg/kg of psilocybin is expected to balance the intention to increase the probability of having a full mystical-type experience against the odds of having a subjectively challenging psychological experience. Those in the Active Placebo condition will receive 2.6 mg/kg of dextromethorphan (DXM). DXM was selected as the placebo drug in the current study because its subjective and behavioral effects at higher doses can resemble those of classical hallucinogens. Participants will be blinded to what drug they are administered. Participants will be unblinded at the end of the study. Participants will attend between 7 to 9 study sessions to complete the protocol. Interested individuals who call research staff will undergo an initial telephone prescreen by a trained member of the research staff: the study aims, protocol, and any possible risks will be described and a series of questions will be asked to determine interest and eligibility for screening for the study. Initial eligibility may also be assessed via an online questionnaire through Qualtrics. Qualified participants will be scheduled for an in-person screening. In-person screening sessions will be conducted by the PI or trained research staff. Individuals will first undergo informed consent; the consent form will describe the necessary eligibility confirmation that takes place before proceeding with the full study. A physical examination, a detailed psychiatric interview, several self-report questionnaires, and a detailed medical history will be completed at the screening session, which takes place at the UAB Clinical Research Unit. Participants will also have their blood drawn for screening tests. Study staff will provide participants with a hand-held tablet device and instructions on how to complete the daily symptom questionnaire via the tablet. They will be asked to begin reporting daily symptoms on their tablet from home that evening. Eligible participants will be contacted by study staff by phone to inform them of their eligibility. All participants will undergo at least 2 weekly preparation sessions of approximately 2 hours each, with the possibility of 1-2 additional weekly preparatory sessions per the discretion of the investigator. These sessions are to educate participants on the study protocol, psilocybin administration, and study treatment rationale. Participants will be randomly assigned in a double-blind manner to the Psilocybin or Active Placebo group following their final preparation session. One week after the final preparation session, participants will be instructed to eat a low-fat breakfast prior to presenting for their drug administration session at 8:00 am, approximately 1 hour before drug administration. A urine sample will be collected to verify drug-free and non-pregnant status and participants will be encouraged to relax and reflect before drug administration. The drug administration session will take place over the course of 8 hours. The guide and secondary monitor will be present with and monitor participants throughout this session (at least one individual will always be present with the participant, even during brief intervals when the guide or monitor may be using the restroom). Participants will be monitored for physical symptoms of distress and encouraged to report any symptoms experienced. Blood pressure will be assessed pre-administration via automatic blood pressure monitor, and will also be assessed at 30, 60, 90, 120, 180, 240, 300, and 360 minutes post-administration. Eight hours after drug administration, when the major drug effects have subsided, participants will complete questionnaires assessing their experience. Participants will then be released into the care of a friend or family member oriented to be emotionally supportive of the participant (as arranged during preparation sessions) and instructed not to drive an automobile or engage in any other potentially dangerous activity for the remainder of the day. Participants will be provided with the guide's contact information by phone should they feel the need for support that evening. An immediate post-session meeting will be held the day following the drug administration session. Participants will meet with the guide for approximately 2 hours to discuss and reflect on their experience. A final study visit will take place approximately 6 weeks later; some questionnaires that were administered at Visit 1 will be administered again at the final visit. At the conclusion of the final study visit, participants will be debriefed.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-10", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05068791", "keywords": "Fibromyalgia, Primary, Psilocybin, Dextromethorphan, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05068791\",\"overall_status\":\"RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Chronic Pain,Personality Change,Emotional Processing,Mystical Experience,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3473, "title": "Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study", "normalized_title": "safety feasibility and tolerability of psilocybin treatment for individuals with functional impairment related to mood anxiety trauma and or addiction symptoms an open label proof of concept study", "authors": "Yale University", "abstract": "The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing. The investigators will recruit individuals with mood, anxiety, trauma, addictive, or related symptomatology, and who have functional impairment associated with these symptoms. A DSM-5 diagnosis is not required (nor is it an exclusion). The investigators will allow for comorbidity and only exclude based on psychological and physiological safety considerations. Critically, this approach will allow us to assess the tolerability of our interventions in individuals who would typically be excluded from efficacy studies due to various comorbid DSM-5 conditions. The investigators will employ an open-label study where participants will be given one dose of oral psilocybin 25mg. The investigators will also have follow-up visits at 1, 4, and 6 weeks and an optional long-term follow-up at 3, 6, and 12 months. In this Phase 1b proof-of-concept clinical trial, the investigators aim to investigate the safety, feasibility, and tolerability of treatment of oral psilocybin in participants with functional impairment due to depressive, anxiety, trauma addictive, or other psychiatric symptomatology, allowing for comorbidity and diagnostic complexity to mirror potential real-world clinical scenarios. Secondarily, The investigators will assess improvement in functional status and symptomatology. The investigators will employ an open-label study design, with participants receiving one dose of oral psilocybin. This is an open-label clinical trial with a single treatment arm and no blinding. All participants will receive 25 mg of oral psilocybin. All dosing will be accompanied by non-directive support before, during, and after treatment sessions.The rationale for conducting this study lies in recognizing that the narrow inclusion and exclusion criteria commonly employed in clinical trials may raise issues of external validity. While previous research has predominantly focused on specific diagnostic categories, our study aims to address these limitations by exploring the safety, feasibility, and tolerability of psilocybin in a heterogeneous population. This study also recognizes the importance of symptom-related functional impairment as a cross-cutting construct relevant to all diagnostic categories.This is a Phase 1b open-label clinical trial to determine the feasibility, tolerability and safety of psilocybin to reduce psychiatric symptoms in participants experiencing functional impairment. Participants will receive one dose of oral psilocybin (25mg). Follow-up visits for assessments and measures at 1-week, 4-week, and 6-week post psilocybin dosing. Long-term follow-up visits assessments and measures for participants who consent to long-term follow-up (reassessments of study measures) for 3-month, 6-month, and 12-month post dosing. Psilocybin (4-hydroxy-N,N-dimethyltryptamine) occurs in nature in many species of mushrooms, including the genera Psilocybe, Conocybe, Gymnopilus, Panaeolus, and Strophparia. Its chemical formula is C12H17N2O4P. Psilocybin is a potent agonist at 5-HT2A/C receptors; potency of binding by related compounds to these receptors correlates with human potency as hallucinogens. Psilocybin is currently a Schedule I substance. Psilocybin will be orally administered in this study. Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg. Descriptives for all safety measures (e.g., C-SSRS total and subscale scores, vitals, documented adverse events) will be compiled at all assessment intervals. Classification of adverse events will follow institute and regulatory body guidelines. Subsequent summary descriptives may focus on safety indices surrounding the dosing session and 1-week, 4 weeks, and 6-weeks after dosing. In addition, The investigators will perform descriptives and non-parametric analysis screen failure rates (including analysis of ineligibility), drop out rates pre and post dosing to determine feasibility and tolerability.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-10", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06442423", "keywords": "Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06442423\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Receptor Pharmacology,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3228, "title": "Age moderates the relationship between psychedelics use and mental health in naturalistic settings", "normalized_title": "age moderates the relationship between psychedelics use and mental health in naturalistic settings", "authors": "Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M.", "abstract": "Abstract Depression and anxiety affect one in five adults, with age affecting prevalence. While clinical trials suggest classic psychedelics (e.g., psilocybin, LSD) and non-classic psychedelics (e.g., MDMA, ketamine) may alleviate these symptoms, it remains unclear how these relationships function in naturalistic settings or how they vary across the lifespan. We conducted a cross-sectional survey of 1,088 adults (18-55 + years) to assess how lifetime psychedelic use - categorized as classic, non-classic, or mixed - relates to mental health. Using structural equation modeling, we found that age significantly moderates the relationship between psychedelic use and mental health outcomes. Specifically, classic psychedelic use was linked to lower depression and anxiety among younger adults, but these effects diminished with age - even reversing for anxiety in older participants. These age-related effects persisted independently of drug-use parameters - including dosage, frequency, and recency of use - and were moderated by mystical experiences for depression, but not for anxiety. Our findings suggest that age may be a meaningful moderator of mental health outcomes from psychedelic use. This underscores the potential value of age-stratified research to optimize the efficacy and safety of psychedelic-assisted interventions, including in aging populations.", "journal": "Research Square", "publication_date": "2026-03-09", "publication_year": 2026, "doi": "10.21203/rs.3.rs-9022170/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-9022170/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR1164283\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Aging,Longevity,Mystical Experience,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3028, "title": "Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response", "normalized_title": "enhancing cgmp signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response", "authors": "Floris G, Jefferson SJ, Rondeau J, Yu AL, Menniti FS, Kwan AC, De Aquino JP, Krystal JH, Pittenger C, Kaye AP.", "abstract": "Psilocybin has antidepressant effects, but its 5-HT2 AR-mediated perceptual effects limit tolerability. We combined psilocybin with a phosphodiesterase-9 inhibitor (PDE9i) and observed suppression of head-twitch response, but maintenance of antidepressant-like behavior. Proteomics showed that PDE9i-psilocybin reduced 5-HT2 AR-mediated pathways while enhancing synaptogenesis. These results suggest that PDE9i-psilocybin represents a promising therapeutic strategy.", "journal": "bioRxiv", "publication_date": "2026-03-09", "publication_year": 2026, "doi": "10.64898/2026.03.06.710108", "pubmed_id": null, "source_url": "https://doi.org/10.64898/2026.03.06.710108", "keywords": "", "substance_tags": "psilocybin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1214698\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Safety,Proteomics", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3654, "title": "An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD", "normalized_title": "an open label phase 1 study of the safety pharmacokinetic profile and preliminary efficacy of organic whole psilocybin containing mushrooms in patients suffering from ptsd", "authors": "Suzanne \"Sue\" Sisley MD", "abstract": "This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-08", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07275970", "keywords": "PTSD, Psychedelic, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07275970\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "PTSD,Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1978, "title": "Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review", "normalized_title": "behavioural investigations of psilocybin in non human animals 1962 2021 a scoping review", "authors": "Shore Ronald, Dobson Kat, Thomson Nina, Barnim Nigel, Bergman Hailey, Rideout Katie, McKeown Sandra, Olmstead Mary C., Goldie Craig, Dumont Eric", "abstract": "Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review of pre-clinical behavioural investigations of psilocybin in non-human animals to identify behavioural effects, studies completed, behavioural tests employed, and what dosing modalities had been studied. Methods A librarian-conducted literature search was performed using predefined key terms and search criteria and additional searching was conducted by reviewers using electronic databases, grey literature sources, and reference lists of relevant articles or reviews. The final search updated occurred in October, 2021. Studies were reviewed, screened and selected against an a priori protocol using Covidence software by multiple reviewers with results plotted across the Research Domains Criteria construct. Results From 4,124 records identified by database searching, 260 publications were subjected to full-text review with 77 studies included in this scoping review, published between 1962 and 2021. The preponderance of studies ( n = 64) investigated behavioural outcomes in rodents. Only 43 studies (55.8%) reported on housing conditions, and seventeen studies (22.1%) failed to report sample size. All studies reported behavioural outcomes following drug administration, with fifty-one studies (66.2%) using psilocybin, thirty studies (42.9%) psilocin, four studies (5.2%) administering whole mushroom extracts (WME), and a further eight studies investigating both psilocybin and psilocin and one study reporting the effects of both psilocin and WME. One hundred and thirty distinct behavioural investigations using fifty different behavioral paradigms were identified. Few adverse events were reported, and even exceedingly high doses were apparently well tolerated. Conclusion With seventy-seven publications spanning close to sixty years, there is significant variation in study design and quality. Overall, psilocybin presents a unique and strong safety profile with no found evidence of biological toxicity. Psilocybin treatment was characterized by unique time and dose-dependent effects; pattern of drug action appears significantly context and training-sensitive. Data suggest effects of psilocybin to include acute arousal, dose-dependent sedation, reductions in fear conditioning at low doses, reduced aggression, improved valence, acute disruption of working memory, the rescuing of deficits from chronic stress, and improved learning when combined with repeated environmental exposure after resolution of drug effect.", "journal": "Journal of Psychedelic Studies", "publication_date": "2026-03-08", "publication_year": 2026, "doi": "10.1556/2054.2025.00364", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2025.00364", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Crossref", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-01 11:21:33", "raw_json": "{\"doi\":\"10.1556/2054.2025.00364\",\"reference_dois\":[\"10.1016/0091-3057(81)90211-2\",\"10.1016/j.ynstr.2017.03.003\",\"10.3791/50978\",\"10.1007/s00204-015-1513-x\",\"10.1080/1364557032000119616\",\"10.1038/npp.2016.215\",\"10.4155/fso.15.63\",\"10.1016/j.neuroimage.2020.116980\",\"10.1016/j.neubiorev.2010.07.002\",\"10.1186/2045-5380-1-9\",\"10.1371/journal.pone.0229067\",\"10.1016/0024-3205(79)90590-3\",\"10.1093/schbul/sbl049\",\"10.1016/bs.pbr.2018.09.013\",\"10.1016/0091-3057(76)90020-4\",\"10.1007/s00213-017-4701-y\",\"10.1073/pnas.1119598109\",\"10.1124/pr.118.017160\",\"10.1038/npp.2017.84\",\"10.3389/fnhum.2014.00020\",\"10.1038/s41598-017-13282-7\",\"10.1162/089892905774597191\",\"10.1007/s00213-007-0930-9\",\"10.1007/s00221-013-3579-0\",\"10.1021/acschemneuro.7b00042\",\"10.1186/1741-7015-11-126\",\"10.1523/jneurosci.1659-20.2020\",\"10.1016/bs.pbr.2018.07.008\",\"10.3389/fpsyt.2021.724606\",\"10.1016/j.euroneuro.2020.11.013\",\"10.1093/brain/awab406\",\"10.1371/journal.pbio.3000411\",\"10.1038/s41380-021-01314-8\",\"10.1111/acps.12904\",\"10.1080/09540261.2018.1481827\",\"10.1016/0091-3057(86)90368-0\",\"10.1177/0269881121991822\",\"10.1016/0024-3205(84)90436-3\",\"10.1177/0269881116675513\",\"10.1007/s00213-011-2358-5\",\"10.1016/j.bbr.2014.07.016\",\"10.1177/0269881110388326\",\"10.1007/7854_2009_7\",\"10.1021/cn300138m\",\"10.1111/j.2042-7158.1981.tb13790.x\",\"10.1007/s00213-020-05756-w\",\"10.3389/fpsyt.2018.00512\",\"10.1073/pnas.2022489118\",\"10.1021/acschemneuro.9b00493\",\"10.1096/fasebj.2019.33.1_supplement.666.1\",\"10.3389/fphar.2021.640241\",\"10.1186/1471-2288-14-43\",\"10.1016/0041-008x(62)90102-3\",\"10.1186/s13073-018-0526-5\",\"10.1038/nrn.2015.28\",\"10.1016/j.cell.2014.03.001\",\"10.3389/fpsyt.2021.800072\",\"10.1590/s0102-695x2010000300017\",\"10.1159/000136297\",\"10.1016/j.nicl.2015.08.009\",\"10.1016/j.mehy.2019.02.029\",\"10.1007/7854_2017_478\",\"10.1177/00221678211048049\",\"10.1186/s12967-019-1976-2\",\"10.1002/hup.348\",\"10.1177/0269881117748902\",\"10.1111/pcn.12830\",\"10.22127/rjp.2018.58486\",\"10.1038/npp.2008.173\",\"10.1111/bph.12783\",\"10.1038/s41386-020-0694-z\",\"10.1126/sciadv.abh2399\",\"10.1523/jneurosci.2063-13.2013\",\"10.1007/bf02805983\",\"10.4103/0976-0105.177703\",\"10.1007/7854\",\"10.1002/cpt.557\",\"10.1002/jrsm.1123\",\"10.1113/jphysiol.2010.192278\",\"10.1016/j.jocrd.2019.03.001\",\"10.3389/fpsyt.2019.00881\",\"10.1016/j.euroneuro.2020.09.589\",\"10.1096/fj.07-9574lsf\",\"10.1016/0031-9384(67)90057-1\",\"10.1016/j.neuropharm.2017.12.041\",\"10.1002/hbm.23224\",\"10.1093/ijnp/pyy083\",\"10.3389/fphar.2018.00177\",\"10.1016/j.neuron.2021.06.008\",\"10.1101/2019.12.04.19013896\",\"10.1038/nprot.2012.044\",\"10.1016/j.neuroimage.2019.04.009\",\"10.1186/s42826-020-00054-0\",\"10.1590/1516-4446-2013-1182\",\"10.1016/j.imlet.2020.10.001\",\"10.2307/1602247\",\"10.1016/j.euroneuro.2013.12.006\",\"10.1097/fbp.0000000000000198\",\"10.3389/fpsyg.2017.01454\",\"10.1038/s41583-021-00428-w\",\"10.1016/j.jacbts.2019.10.008\",\"10.1016/0024-3205(79)90451-x\",\"10.31887/dcns.2001.3.4/fxvollenweider\",\"10.1111/j.1749-6632.1962.tb50119.x\",\"10.1016/j.jcbs.2019.12.004\",\"10.1016/b978-0-444-63462-7.00005-1\",\"10.1007/bf00427414\",\"10.1007/s00213-015-4034-7\",\"10.3389/fnins.2017.00539\",\"10.7554/elife.56344\",\"10.1007/bf00412109\",\"10.1016/j.copsyc.2015.01.004\",\"10.3390/toxins7041018\",\"10.1111/psyp.12588\"],\"reference_count\":344}", "topic_tags": "Mechanism of Action,Review Article,Safety,Adverse Events,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3296, "title": "Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report", "normalized_title": "substance induced manic psychosis in which delusions were corroborated by a chatbot case report", "authors": "Shah S, Morrin H.", "abstract": "Abstract Background: This case describes a substance-induced manic episode with psychotic features in which interaction with an AI (artificial intelligence) chatbot appeared to corroborate and reinforce the patient’s delusional thought content and to contradict medical advice. Excerpts from the patient’s interactions with the AI chatbot provide novel clinical insight into this phenomenon, which to date has primarily been reported in news media. Case Presentation: A man in his 30s presented to the emergency department with a one-week history of escalating behavioural disturbance, severe insomnia, pressured and overinclusive speech, and grandiose beliefs. Symptom onset followed heavy polysubstance use at a recreational event, including psilocybin (dried mushrooms and liquid preparation), ketamine, cocaine, and alcohol. During this period, the patient reported extensive interaction with an AI chatbot (ChatGPT). The AI chatbot reportedly affirmed his perceived “spiritual awakening,” minimised the possibility that his presentation represented a manic episode, and provided medical advice, including discouragement of prescribed antipsychotic medication. Mental state examination was consistent with a manic episode with psychotic features, without evidence of perceptual disturbance. He was detained under mental health legislation for further assessment and commenced on olanzapine, with adjunctive sleep restoration and psychological interventions. Behavioural management included implementation of a care plan restricting AI chatbot use. Over several weeks, psychotic symptoms and behavioural disinhibition diminished, with subsequent improvement in insight. Conclusions: Concerns regarding potentially harmful interactions between AI chatbots and individuals with mental illness have largely been raised in news media. This case demonstrates that, in patients with psychotic symptoms, AI chatbots may reinforce delusional beliefs and impair the development of insight, and may also interfere with engagement with treatment by providing advice that conflicts with clinical recommendations. These observations raise clinical, ethical, and risk-management considerations regarding AI chatbot use during acute psychiatric illness. As AI chatbot use becomes increasingly widespread, clinicians should consider assessing their use and impact within clinical assessments and, where clinically indicated, implementing interventions to mitigate associated risks, ranging from psychoeducation to use-restriction strategies. Future population-level studies are required to establish the epidemiology of AI-associated mental health harms, and AI companies must bolster efforts to implement harm minimisation strategies and safeguards.", "journal": "Research Square", "publication_date": "2026-03-07", "publication_year": 2026, "doi": "10.21203/rs.3.rs-8919841/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-8919841/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:50", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"PPR1163168\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Spirituality,Case Report,Healthcare Workers,Safety,Drug Interactions", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 237, "title": "The combination of exercise and psychedelics for the treatment of major depressive disorder.", "normalized_title": "the combination of exercise and psychedelics for the treatment of major depressive disorder", "authors": "Fabiano N, Stubbs B, Lawrence DW, Rosenblat JD, Teixeira PJ, Wong S, Zhou C, Carhart-Harris R", "abstract": "Upwards of 50% of people do not respond to the primary treatment modalities for major depressive disorder (MDD), which has led to increased attention and use of alternative methods, including exercise and psychedelics. While interventions using either exercise or psychedelics have demonstrated largely positive results in isolation, their synergistic potential has yet to be explored. As such, this commentary provides an overview of exercise/psychedelics as a treatment for depression and their potential synergy and/or complementarity. From a biological perspective, psychedelics acutely enhance brain-derived neurotrophic factor (BDNF) signalling, while exercise provides sustained BDNF elevation; psychedelics enhance neuroplasticity largely in the cortex (with only modest effects in the hippocampus), while exercise boosts hippocampal neurogenesis; psychedelics increase glutamate release via stimulation of 5-HT receptors on pyramidal neurons, while exercise enhances glutamatergic transmission via the endocannabinoid system and reduction of systemic inflammation; both boost serotonin release; and psychedelics temporarily disrupt functional connectivity between the hippocampus and default mode network (DMN), while exercise normalizes this connectivity, which may sustain post-psychedelic gains. Through the lens of psychological and behaviour change, psychedelics appear to facilitate the adoption or maintenance of physical activity habits, increase psychological flexibility, and since exercise is associated with emotional resilience to acute stress, this may allow users to experience deeper immersion and exploration during their psychedelic experience, improving antidepressant outcomes. In summary, exercise and psychedelics have numerous potential complementary mechanisms, therefore, future research is warranted to explore the efficacy, tolerability, safety, and neurobiology of this combination.", "journal": "Discover mental health", "publication_date": "2026-03-06", "publication_year": 2026, "doi": "10.1007/s44192-026-00408-5", "pubmed_id": "41793582", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41793582/", "keywords": "Exercise, Depression, Major depressive disorder, Physical activity, Psilocybin, Psychedelic", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:34", "raw_json": "{\"pubmed_id\":\"41793582\"}", "topic_tags": "Depression,Neuroplasticity,Neurogenesis,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Resilience,Emotional Processing,Psychological Flexibility,Safety,Inflammation", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3626, "title": "The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults", "normalized_title": "the therapeutic potential of psilocybin in anorexia nervosa in young adults", "authors": "Region Skane", "abstract": "The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that may help the brain form new connections, which could make it easier for people with anorexia nervosa to develop healthier ways of thinking. The main questions this study aims to answer are: * Is psilocybin with psychological support safe and well-tolerated? * Does psilocybin with psychological support help lower symptoms of anorexia nervosa? * How might psilocybin work in the brain to support recovery from anorexia? This study will compare psilocybin with psychological support to Treatment as Usual (TAU). Participants in the study will be randomly placed into one of the two groups. There will be 40 patients with anorexia nervosa included, 20 per group. TAU includes the standard care people receive for anorexia nervosa in a specialized eating disorder clinic in Region Skåne, Sweden. Participants will: * Be between 16 and 35 years old and have anorexia nervosa * Take psilocybin (25 mg) by mouth two times, four weeks apart * Receive psychological support before, during, and after each dosing session (including preparation and integration sessions) * Complete questionnaires, have brain scans (magnetic resonance imaging) and blood tests to learn more about how psilocybin may work * Share their personal experiences as part of a qualitative interview This study hopes to learn if psilocybin, when given with the right support, can be a helpful and safe option for people living with anorexia nervosa. Background and Rationale Anorexia Nervosa (AN) is one of the most lethal psychiatric disorders, with mortality rates approximately five times higher than that of the general population. AN affects multiple organ systems due to severe weight loss and malnutrition and hence leads to a substantial decline in health-related quality of life. While psychotherapies have shown partial efficacy, data suggest that only 46% of patients recover within four years, and 20% remain chronically ill. Relapse rates exceed 50% among those who recover, underscoring the need for more effective treatments. Research suggests that several psychological factors, such as challenges in regulating emotions, black-and-white thinking, mental rigidity, and a limited capacity for mentalization may contribute to the persistence of severe, chronic anorexia nervosa. The age of onset for AN typically shows a bimodal distribution, peaking at 14 and 18 years of age, motivating the design of including patients as young as 16 years old in this study. Psilocybin, a serotonergic psychedelic compound, primarily acts as an agonist of the 5-HT2A receptor, inducing profound effects on cognition, emotion, perception, and self-awareness. Although research on psilocybin remains limited, clinical trials across psychiatric disorders suggest its potential therapeutic benefit. For example personality changes such as increased openness, have been observed to persist up to a year following a single high dose. The inclusion of 16-17-year-olds in this study is particularly novel, as research on psychedelic therapy in adolescents and young adults remains scarce. Emerging evidence highlights how psychedelics may benefit AN patients, such as enhanced serotonin signaling and cognitive flexibility. The ability of psychedelics to foster cognitive flexibility, a well-documented phenomenon, is considered a key factor in therapeutic processes. This is especially relevant for AN, where rigid thinking and behavior contribute to treatment resistance. One pilot study demonstrated that a 25 mg psilocybin dose, combined with psychological support, was well-tolerated by female AN patients with a body mass index (BMI) \\>16. The study reported significant reductions in eating disorder symptoms at one month post-treatment, with only mild and transient adverse events. Recent studies indicate that psilocybin induces significant changes in brain function and network organization across key regions. Notably, psilocybin disrupts connectivity in the default mode network by causing desynchronization across spatial scales. These findings suggest a neurobiological basis for psilocybin´s therapeutic effect. However, further research is needed to elucidate long-term effects, particularly in clinical context. Functional magnetic resonance imaging (fMRI) has demonstrated utility in detecting neuronal abnormalities in AN. This study's use of fMRI before and after psilocybin treatment will provide critical insights into the neurobiological impacts of psilocybin on AN. Brain-Derived Neurotrophic Factor (BDNF) is a protein that plays a crucial role in neuroplasticity. Preclinical studies show that psilocybin promotes neuritogenesis and synaptic plasticity, potentially via increased cortical BDNF expression. Given that individuals with AN exhibit reduced serum BDNF levels, this study will assess changes in BDNF pre- and post-treatment to elucidate psilocybin's impact on neurobiological mechanisms. These insights may advance treatment optimization and efficacy predictions for AN patients. Study Objectives Primary Objective is to assess the safety and tolerability of psilocybin 25 mg in young adults (16-35 years old) with anorexia nervosa. Secondary objectives include evaluating the efficacy of psilocybin with psychological support in reducing AN symptom compared to treatment as usual (TAU), investigate potential mechanisms of action through self-report questionnaires, neuroimaging and BDNF analysis, and conduct qualitative analysis of subjective experiences. Neuroimaging will investigate changes in brain resting state connectivity (measured by fMRI), and commonly used task-based fMRI paradigms. The task-based paradigms will involve food-related conditions, commonly used in the population (Celeghin et al., 2023; Bronleigh et al., 2022) as well as established paradigms involved in processing reward anticipation (Knutson et al., 2000; Ventorp et al 2022) Trial Design and Procedures This is a phase II, open-label, randomized controlled trial with two arms: 1. Active treatment arm; Two dosing sessions with psilocybin 25mg with psychological support alongside TAU. 2. Active comparator control arm; TAU only. The study will include 40 participants, 20 in each group. If the active treatment arm is determined to be safe, tolerable, and preliminarily effective during the follow-up assessment, participants in the control group will have the option to switch to the active treatment while maintaining their usual specialized care. The switch to psilocybin treatment will follow the same preparation, dosing, and integration protocols as outlined for the intervention group. This design minimizes ethical concerns regarding withholding a potentially effective treatment. Participants will be randomly assigned (1:1) to either the intervention or control group. Block randomization stratified by age group (16-18 and 19-35 years) will ensure balanced representation. Given the small sample size of 40 participants (20 per group), the statistical power to detect between-group differences is inherently limited, irrespective of blinding. As such, the trial is appropriately designed as a pilot study, with a primary focus on assessing safety, feasibility, and tolerability. To enhance interpretation, qualitative and neurobiological measures are also included. A formal power calculation was not conducted, in line with the exploratory nature of the study. The sample size was determined based on practical feasibility and aligns with current recommendations for early-phase trials of novel interventions. A post-hoc power analysis will be conducted to evaluate whether the sample size was sufficient to detect clinically meaningful changes in the primary outcomes. Details on location and Data Collection Methods All procedures will be conducted at the University Hospital for Psychiatry, Baravägen 1, Lund, except the fMRI assessments which are performed at the The National 7 Tesla (7T) Facility in Lund. All assessments will be carried out by qualified personnel appointed by the principal investigator, including medical doctors, nurses, and psychologists. The National 7T Facility will appoint qualified personnel for fMRI assessment. The duration of the entire trial is from the first screening of the first patient to the last follow up of the last patient. For each patient participant, the duration of the trial is from the screening to the last follow up at week 52 (12 month). Patient rehospitalization and additional interventions data are collected in patient journal registers. Pre-Study Activity Following ethical approval, a focus group will be conducted with patients with anorexia nervosa in two different groups, one aged 16-18 and one 19-35 years. The purpose is to provide study information, gather feedback on the clarity and ethical aspects of the protocol, and identify ways to improve potential benefit. Input from this focus group will inform study quality, recruitment materials, communication strategies and ethical aspects of psilocybin research experienced by the population. Any amendments based on this will be processed according to CTIS protocol. Screening Phase Screening includes psychiatric and medical history, inclusion/exclusion criteria assessment, safety blood tests (glucose, liver, kidney), electrocardiogram (ECG), informed consent (with a 2-week consideration period), pregnancy test and urine toxicology (U-tox). The time from screening to the first psilocybin dose must not exceed 8 weeks, regardless of washout status. Potential participants will be screened by a psychiatric clinician appointed by the principal investigator to ensure eligibility and understanding of the study requirements. Preparation Phase Preparation Session 1 \\& Baseline Assessment (Week -1): Psychoeducation about psilocybin, breathing and relaxation techniques, rapport-building with therapists, and discussion of expectations and concerns. Includes full baseline assessments (list provided as attachment to protocol: * Expectation of Treatment Scale (ETS-BF) * Readiness and Motivation Questionnaire (RMQ) * General Change Mechanisms Questionnaire (GCMQ) * Patient Health Questionnaire (PHQ-9) * Generalized Anxiety Disorder scale (GAD-7) * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * Life Satisfaction Scale (LS) * Positive and Negative Affect Schedule (PANAS) * Harmony in Life Scale (HILS) * Ten Item Personality Inventory (TIPI) * Honesty-Humility Scale (HH) Vital signs, ECG, fasting glucose, urine drug screening, fMRI, BMI, metric assessment of body size perception and blood sampling for BDNF and safety labs are also conducted. Preparation Session 2 (Week 0): 7-10 days after Preparation 1, and 2-3 days before psilocybin dosing. Dosing and Integration Phase Dosing Session 1 (Week 0): Psilocybin 25 mg under therapeutic support with ECG and blood pressure/pulse monitoring. Integration Session 1 (Day after Dosing 1): Reflection, fMRI, blood sampling (including glucose, liver, kidney, BDNF), and reassessments with RMQ, GCMQ, PHQ-9, GAD-7, C-SSRS, BPRS+, LS, PANAS, HILS, TIPI, ECG and blood pressure/pulse. Psychedelic Experience related scales; Altered States of Consciousness Rating Scale (5D-ASC), Mystical Experience Questionnaire (MEQ-4), Meaningful Life Experience Rating (MLE). Integration Session 2 (Week 1): Continued psychological integration support. Integration Session 3 (Week 2-3): Summary of first dosing experience and preparation for second dosing. Dosing Session 2 (Week 4): Second psilocybin 25 mg administration under identical conditions as first dosing session. Integration Session 4 (Day after Dosing 2): Reflection, blood sampling (including glucose, liver, kidney, BDNF), and reassessments with RMQ, GCMQ, PHQ-9, GAD-7, C-SSRS, BPRS+, LS, PANAS, HILS, TIPI, ECG and blood pressure/pulse. Psychedelic Experience related scales; Altered States of Consciousness Rating Scale (5D-ASC), Mystical Experience Questionnaire (MEQ-4), Meaningful Life Experience Rating (MLE). Integration Session 5 (Week 5-6): Final integration session and preparation for long-term follow-up. Primary Endpoint (Week 8) Includes full safety and outcome evaluations: * fMRI * blood sampling (including glucose, liver, kidney, glucose, BDNF) * Vital signs, ECG, U-tox * BMI * Metric assessment of body size perception * Adverse Event/Serious Adverse Event (AE/SAE) monitoring * Readiness and Motivation Questionnaire (RMQ) * General Change Mechanisms Questionnaire (GCMQ) * Patient Health Questionnaire (PHQ-9) * Generalized Anxiety Disorder scale (GAD-7) * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * Life Satisfaction Scale (LS) * Positive and Negative Affect Schedule (PANAS) * Harmony in Life Scale (HILS) * Ten Item Personality Inventory (TIPI) * Honesty-Humility Scale (HH) Intensive Follow-Up Phase (Week 8-24) Follow-up visits at Week 12, 16, and 20 include: * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * AE/SAE monitoring * BMI, blood pressure, ECG * Fasting glucose, U-tox 6-Month Follow-Up (Week 24) Same as primary endpoint assessments, including: * blood sampling (including glucose, liver, kidney, BDNF) * Vital signs, ECG, U-tox * BMI * Metric assessment of body size perception * AE/SAE monitoring * Readiness and Motivation Questionnaire (RMQ) * General Change Mechanisms Questionnaire (GCMQ) * Patient Health Questionnaire (PHQ-9) * Generalized Anxiety Disorder scale (GAD-7) * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * Life Satisfaction Scale (LS) * Positive and Negative Affect Schedule (PANAS) * Harmony in Life Scale (HILS) * Ten Item Personality Inventory (TIPI) * Honesty-Humility Scale (HH) Extended Follow-Up Phase (Week 24-52) 9-Month Follow-Up (Week 36) * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * AE/SAE monitoring * BMI, blood pressure, ECG * Fasting glucose, U-tox 12-Month Final Follow-Up (Week 52) * Eating Disorder Examination Questionnaire (EDE-Q ) * Columbia-Suicide Severity Rating Scale (C-SSRS) * Brief Psychiatric Rating Scale - Extended (BPRS+) * Patient Health Questionnaire (PHQ-9) * Generalized Anxiety Disorder scale (GAD-7) * Ten Item Personality Inventory (TIPI) * Meaningful Life Experience Rating (MLE). * AE/SAE monitoring * BMI, blood pressure, ECG * Fasting glucose, U-tox Participants who show signs of psychological or physical deterioration at any point during the study between follow-ups are instructed to contact the research team at any time and will be offered additional assessment and support. Description of Psilocybin Administration and Psychological support Psychological support includes a non-directive preparation and integration pre- and post-dosing sessions according to protocol manual, alongside support for the patient on the dosing session day. The study follows the guidelines for safe research with psychedelics. Preparation session will include psychoeducation of the effects of psilocybin, breathing techniques, getting to know the two therapists (one male and one female). A standardized preparation script will ensure consistency across participants. The two integration sessions following each dosing session last 1-2 h and focus on exploring the session's effects and offer support in integrating the experience. Integration sessions will include structured discussions about insights gained, with therapists facilitating connections between the experience and the participant's therapeutic goals. The therapists couple will contain at least one licensed healthcare personnel (psychologist, nurse, physiotherapist or physician). The assistant therapist can be non-licensed healthcare personnel experienced with the anorexia nervosa population, such as a healthcare assistant. All psychological support therapists must have done all specific 5-day training in the psiAN manual. Dosing session day The dosing session, lasting 6-8 hours, is supported by the therapists introduced during preparation sessions. The psilocybin's acute effects persist for 4-6 hours, recorded via video and audio. Participants, lie down with an optional eye mask, experience the session in a comfortable room with a pre-selected music playlist, respecting individual preferences. Therapists provide support and guidance if requested but with minimal psychotherapeutic focus. Therapists will follow pre-established protocols for de-escalation and grounding in case of distressing experiences. Parents are introduced at the session's end with participant approval. During the dosing session, a medically trained study doctor will be available, equipped for emergencies in the unlikely event of serious adverse events related to psilocybin risks. Biological Sampling Procedures Blood samples will be collected for the analysis of Brain-Derived Neurotrophic Factor (BDNF) as the primary biomarker and for tolerance and safety measurements. Additionally, we aim to collect one tube of additional whole blood per occasion for future analysis. BDNF samples will be taken at five key time points: (1) before treatment (baseline), (2) and (3) at first integration session after Psilocybin 25mg dosing, (4) at 8 weeks, and (5) during the 6-month follow-up. This ensures comprehensive longitudinal data collection. Blood samples of glucose, kidney and liver status will be measured at the same time points as above for safety and tolerance reasons. None of these blood samples are collected or stored. All blood samples are done by a standard peripheral venous sampling method performed by a nurse at the research facility at the university hospital clinic for psychiatry at Baravägen 1, Lund. Procedures will be implemented to minimize discomfort during blood collection, such as using pediatric needles for younger participants when necessary. Blood collection and processing will follow standardized protocols to ensure sample integrity. Discontinuation from the Clinical Trial A participant will be discontinued entirely from the clinical trial (i.e., all further participation and follow-up will end) only under the following condition: Withdrawal of informed consent at any time, for any reason, without the need to justify. Discontinuation from the Intervention (Dosing) Participants may be discontinued from the intervention (i.e., psilocybin administration - first or second dose), without being excluded from the trial. Participants will be encouraged to continue with follow-up assessments unless they explicitly withdraw consent. This approach allows for continued safety and data collection in accordance with the intention-to-treat principle. Reasons for discontinuing intervention may include: * Development or discovery of exclusion criteria after inclusion (e.g. new psychiatric diagnosis, pregnancy). * Emergence of a serious adverse event (SAE) or medical condition that, in the investigator's judgment, makes continued treatment unsafe. * Initiation of treatment with prohibited medication according to protocol. * Failure to adhere to critical aspects of the study protocol (e.g. repeated missed visits, non-compliance with preparation or safety procedures). * Investigator decision in consultation with the medical monitor. The reason for discontinuation will be documented. Participants will be offered a final follow-up visit when appropriate. Non-compliance to fMRI will not lead to study exclusion nor discontinuation of the intervention. Methods for Measurement of Endpoints for Clinical Safety Continuous clinical safety monitoring will be performed by licensed healthcare professionals at Lund University Hospital throughout the trial, from baseline to the final 12-month follow-up. The safety evaluations cover physical, biochemical, and psychological parameters relevant to psilocybin administration. Measurements for assessing clinical safety will include blood samples of hepatic and renal function, glucose, urine toxicology, cardiovascular parameters, assessment of suicidality, assessment of mental health symptoms and and assessment of Adverse Events/Serious Adverse Events/Suspected Unexpected Serious Adverse Reactions (AE/SAE/SUSARs). Assessment of Adverse Events Participants are instructed to contact the research team during daytime hours for urgent concerns. Outside of study hours, they are directed to seek emergency services. Events will be assessed by the clinical team for causality, intensity, and seriousness and potential relationship to treatment (psilocybin 25mg). The investigator is responsible for determining whether there is a causal relationship between the AE/SAE and use of the investigational medicinal product. Consideration should be given to whether there is a reasonable possibility of establishing a causal relationship between the adverse event and the investigational medicinal product based on the analysis of the available evidence. All AE can be categorized as either likely related, possibly related, unlikely related or not related. Those AEs which are suspected of having a causal relationship to the investigational medicinal product will be followed up until the subject has recovered or is well taken care of and on the way to good recovery. Each adverse event shall be classified by an investigator as mild, moderate or severe. Follow-up of Adverse Events Follow-up visits will be scheduled for all participants experiencing AEs to ensure resolution and ongoing safety. Participants with unresolved AEs at the end of the trial will be monitored until resolution or stabilization. For SAEs, additional follow-ups will be scheduled at least every two weeks until resolution. The frequency can be changed by the Safety Review Committee or Principal Investigator. Procedures in Case of Emergencies and Overdose Emergency protocols are in place, including immediate medical care and monitoring. In case of an overdose, the participant will be transferred to an emergency facility. Emergency kits, including benzodiazepines for anxiety or seizures, will be available during all dosing sessions. Pregnancy Management Participants who can become pregnant must use a highly effective form of contraception during the study and for two months after the last psilocybin dose. Approved methods include hormonal contraception, IUDs, sterilization, vasectomized partner, or abstinence. Urine pregnancy tests will be done at screening, before each psilocybin session, and as needed during follow-up. Psilocybin's effects on pregnancy are unknown. To reduce possible risks, strict contraception and testing protocols are required. Interim Analysis Following two administration sessions of 25mg psilocybin, a panel of three senior psychiatrists, who are not part of the research team, will conduct an evaluation of the safety data and adherence to the protocol. This analysis will be repeated after a total of 20 psilocybin administrations have been completed. After 25 patients over 18 have been through dosing sessions, patients 16-17 will be recruited. Methods for Measurement of Endpoints for Clinical Efficacy Composite Relapse Endpoint: BMI Decrease: Measured at baseline, 8 weeks, and 6 months using calibrated equipment and standardized protocols. Hospitalization Data: Collected through patient reports and confirmed by medical records. Symptom Deterioration: Assessed using validated tools such as the EDE-Q6.0 and clinical interviews conducted by trained staff. Clinical Intervention Use: Recorded in patient files, including initiation of new treatments during follow-up. Statistics Analysis Population Both the Intention-to-treat (ITT) and per-protocol populations will be analyzed. ITT analysis will include all participants who are randomized, regardless of protocol adherence, to ensure generalizability. Per-protocol analysis will focus on participants who completed the study as planned, ensuring the assessment of efficacy under ideal conditions. Statistical Analyses Primary Baseline Analyses: The primary analyses will involve descriptive statistics for demographic and baseline characteristics, ensuring comparability across groups, and control for follow-up measurements. Primary Endpoints analysis We will analyze differences in the number of participants and severity experiencing adverse event/serious adverse event (AE/SAE) between the groups standardized forms for AE/SAE capturing: Event description, Start and end dates, Severity (e.g., mild, moderate, severe), Relatedness to intervention (assessed by safety review committee), Action taken. The primary statistical methods will be: Descriptive Frequencies and Percentages. Comparing Proportions (Most Common for \"Incidence\") (Chi-squared test (or Fisher's Exact Test): Fisher's exact test is preferred for small cell counts (\\ 1 would indicate a higher risk in the intervention group. Comparing Severity and Relatedness is assessed with Mann-Whitney U test or Student t-test to compare severity distributions between groups. Secondary Endpoints: For secondary endpoints (e.g., changes in fMRI connectivity, BDNF, rating scales), group comparisons, including t-test, Analysis of Variance (ANOVA), and Repeated Measures ANOVA will be utilized. When controlling for variables such as individual differences, ANCOVA or Multivariate Analysis of Covariance (MANCOVA) will be utilized. Principal component analysis (PCA) or independent component analysis (ICA) may be applied to identify patterns in fMRI data. Endpoints include longitudinal between- and within-person analyses. When dichotomous (binary) outcome variables: Binary outcomes (e.g., remission, response rates) will be analyzed using logistic regression models, adjusting for baseline characteristics such as age, baseline BMI, and symptom severity. The odds ratios and 95% confidence intervals will be reported. When continuous (dimensional) variables (e.g., BMI, BDNF levels, cognitive flexibility) will be analyzed using linear mixed-effects models, and regression models of various types. Other: Exploratory Subgroup Analyses: Exploratory subgroup analyses will assess treatment effects across different strata (e.g., age groups, baseline severity) using interaction terms in regression models or stratified analyses to explore heterogeneity in treatment responses. Other: Sensitivity Analyses: Sensitivity analyses will address missing data using methods such as multiple imputation or maximum likelihood estimation. These methods ensure robustness of the findings by accounting for the potential impact of missing data on primary and secondary outcomes. Adjustment of Significance and Confidence Interval A Bonferroni correction or false discovery rate (FDR) adjustment will be applied for multiple comparisons to control Type I error. Results will be presented with 95% confidence intervals, and significance will be set at a two-tailed p-value of \\", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-05", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07169747", "keywords": "Anorexia Nervosa, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07169747\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Anxiety,Eating Disorders,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Consciousness,Biomarkers,Aging,Personality Change,Emotional Processing,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Adolescents,Healthcare Workers,Safety,Adverse Events,Toxicity,Drug Interactions", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3497, "title": "Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial", "normalized_title": "examining the safety and clinical efficacy of psilocybin therapy for veterans with ptsd an open label proof of concept trial", "authors": "Ohio State University", "abstract": "The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans. The objective of this study is to determine the safety and efficacy of psilocybin assisted psychotherapy in the treatment of Veterans with PTSD. This study will recruit 15 United States Military Veterans, age 21 to 64, primarily from the Columbus and Central Ohio Region who meet the criteria for PTSD. After enrollment and informed consent, participants will receive two separate doses of psilocybin in conjunction with preparatory and post-psilocybin therapy sessions. Each psilocybin session will last approximately 8 hours and will be facilitated by two trained session facilitators. Before the first psilocybin session, participants will meet with one or both of the session facilitators for a total of 6-8 hours of contact time (or up to 4 meetings) before the first psilocybin session day. Two post psilocybin therapy session visits will follow Psilocybin Sessions 1 and 2. Psilocybin Sessions 1 and 2 will occur about two weeks apart. Follow-up visits will occur 1 and 2 weeks and 1, 3, and 6 months after the final psilocybin session, with additional contact hours scheduled as needed. Thus, the intervention and follow-up requires at least 13 visits over a period of about 8-10 months.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-03", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05554094", "keywords": "PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder, Psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05554094\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Veterans,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3616, "title": "A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.", "normalized_title": "a phase 2b double blind randomized low dose comparator controlled clinical trial to assess the efficacy and safety of npx 5 in psilocybin assisted psychotherapy for the treatment of adjustment disorder associated with cancer", "authors": "Psyence Australia Pty Ltd", "abstract": "This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg NPX-5 dose group, a 10 mg NPX-5 dose group or a 1mg NPX-5 dose group. Participants will be allocated a dose that will be administered during their psilocybin-assisted psychotherapy (PAP) dosing session. The PAP dosing session will run approximately 8 hours, with NPX-5 administered at Day 14 (dosing day). At Week 10, non-responders that continue to meet the study eligibility criteria may commence an additional PAP cycle (at 25 mg NPX-5). A maximum of 2 PAP cycles may be administered. Long term follow up will comprise of a study visit at 3 months post Week 10 (of the final cycle) to assess safety and tolerability of NPX-5. It is hoped that this research will develop important scientific knowledge that could contribute to the development of a potential new treatment for anxiety and depression after adjusting to an acutely stressful event such as a cancer diagnosis. This is a randomized, double-blind, low-dose comparator-controlled Phase IIb study to investigate the efficacy and safety of PAP with 25 mg, 10 mg and 1 mg \\[low-dose comparator) NPX-5, for the treatment of adjustment disorder symptoms in participants diagnosed with cancer. The referring oncologist will indicate that the participant is physically capable of undergoing psychedelic encounter and is likely to have a minimum life expectancy of 6 months. At least 87 adult participants (age 18 to 80 at screening) with a diagnosis of AjD due to cancer diagnosis will be enrolled in this study. Participants will be randomly assigned with a ratio of 1:1:1 to receive Psilocybin-Assisted Psychotherapy (PAP) with either 25 mg, 10 mg or 1 mg NPX-5. Both the site staff treating participants and the participants themselves will be blinded to the treatments being administered. The study consists of a combination of clinic visits and telehealth phone calls to support this vulnerable participant population. The clinic will have experience with conducting PAP. All study visits be carried out by suitably qualified individuals and wherever possible, the same therapist will meet with study participants for in-person and telehealth appointments. Participants will undertake a screening visit between Day -45 and Day -2 to determine eligibility to participate in the study. Those participants that meet the eligibility criteria will attend the study site on Day 1 when continued eligibility will be assessed and baseline assessments performed. Participants must complete three preparation sessions with the therapist prior to dosing session. Two of these sessions can be completed remotely via telehealth and have flexible timing, provided there is at least one day between each session. One preparation session must be done in person in the dosing room, ideally during a site visit on Day 13. Additionally, at least one preparation session must include the sitter or secondary therapist. The primary therapist has the discretion to include the sitter or secondary therapist in more preparation or integration sessions based on their assessment. The clinic site visits will comprise Day 1, Day 13 (day prior dosing session), Day 14 (dosing session), Day 15 (integration session) and Day 70/Week 10 (follow-up) post-randomization. There will be ± 3 days for a dosing session allowed. Subsequently, all relevant visits will be adjusted accordingly. In addition, participants will be required to attend following telehealth appointments: * Two telehealth appointments for preparatory sessions within 2 weeks prior to dosing session. * One telehealth appointment for integration therapy session in the two weeks following the dosing session. * Follow up telehealth appointments on Day 28 (Week 4), Day 42 (Week 6). * Final study follow-up telehealth appointment at 3 months post the Day 70 (Week 10) visit of the final PAP cycle for final safety assessments. Non responders (for criteria see Section 5.5.2) at Day 70 (Week 10) that continue to meet the study eligibility criteria, may commence an additional PAP cycle (at 25 mg NPX-5). These participants will repeat the schedule described above, including the visit the day prior to dosing session, the actual dosing session, and the integration sessions. A maximum of 2 PAP cycles may be administered.", "journal": "ClinicalTrials.gov", "publication_date": "2026-03-02", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07072728", "keywords": "Adjustment Disorder, Adjustment Disorder With Anxious Mood, Cancer, Cancer Cachexia, Cancer of Endometrium, Cancer of Kidney, Cancer of Prostate, Cancer of the Breast, Cancer of Stomach, Cancer Melanoma Skin, Cancer Pancreas, Psilocybin therapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07072728\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 258, "title": "Meaning and Psychedelics in Palliative Care: A Narrative Review.", "normalized_title": "meaning and psychedelics in palliative care a narrative review", "authors": "Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA", "abstract": "Meaning is a primary existential concern in those with advanced illnesses and functions as an important coping mechanism. Loss of meaning contributes to existential distress, and, in particular, may manifest as demoralization, a syndrome of poor coping that is associated with negative outcomes. Psychedelics are unique psychoactive compounds that, among other properties, are proposed to enhance meaning. In the palliative setting, psychedelic therapies are under investigation for existential distress, including demoralization. To synthesize the literature on meaning in palliative care, including the clinical impact of loss of meaning, particularly demoralization, and evidence for proposed interventions including existential psychological interventions and psychedelic therapies. We conducted a narrative review based on a structured search within Pubmed. Articles were screened for those addressing prespecified questions derived from our objectives, and results were synthesized in narrative format. Loss of meaning is a hallmark feature of demoralization syndrome, a prevalent and distinct condition linked with diminished quality of life, increased symptom burden, and increased suicide risk. Existential psychological interventions improve numerous psychosocial outcomes, although evidence for their efficacy in demoralization is limited. In psychedelic therapy, meaning-making is a typical feature, and existential interventions are commonly integrated. Finally, early clinical trial data indicate that psychedelic therapies show promise for existential distress, including demoralization. Novel approaches are needed to address existential distress, especially when manifested as demoralization. Psychedelic therapy is a promising combined pharmacologic and psychological intervention that promotes meaning-making and shows potential for improving demoralization, warranting further investigation.", "journal": "Journal of pain and symptom management", "publication_date": "2026-02-28", "publication_year": 2026, "doi": "10.1016/j.jpainsymman.2025.10.015", "pubmed_id": "41173063", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41173063/", "keywords": "Demoralization, LSD, existential distress, meaning, palliative, psilocybin, psychedelic", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"41173063\"}", "topic_tags": "End-of-Life Distress,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4076, "title": "Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making", "normalized_title": "psilocybin assisted therapy for major depressive disorder implications for clinical effectiveness health economics and regulatory decision making", "authors": "C Faria, Diana Dias da Silva, João José Sousa", "abstract": "Background: Major depressive disorder (MDD) is a highly prevalent and disabling psychiatric condition associated with substantial clinical, social, and economic burden [1,2]. Despite the availability of conventional antidepressants, their limited effectiveness, delayed onset of action, and high relapse rates have renewed interest in innovative therapeutic approaches [3,4,5]. Psilocybin-assisted therapy (PAT) has emerged as a promising intervention, but its potential integration into national health systems remains uncertain due to regulatory, ethical, and economic constraints [6]. Objective: This scoping review aimed to map and critically appraise the available evidence on efficacy and safety of psilocybin for treatment of MDD in otherwise healthy adults, with a particular focus on its relevance for health economic evaluation and regulatory decision-making. Methods: A scoping literature review was conducted using PubMed, ClinicalTrials.gov, Cochrane Library, SciELO databases. Clinical trials, systematic reviews, and meta-analyses assessing psilocybin’s effects on depressive symptoms in adults diagnosed with MDD were included to comprehensively map existing evidence. Studies addressing secondary depression were excluded from primary analysis. Data extraction focused on study design, population characteristics, intervention protocols, clinical outcomes, safety profiles, and parameters relevant to future pharmacoeconomic modelling. Results: Available evidence suggests psilocybin administration is associated with rapid and clinically meaningful reductions in depressive symptoms, with effects observed shortly after treatment and, in some cases, sustained over time. Compared with rapid-acting antidepressants, such as ketamine, psilocybin appears to present lower risk of dependence and fewer toxic adverse effects [7,8]. However, evidence base is limited by small sample sizes, heterogeneous study designs, and scarcity of trials conducted exclusively in patients with primary MDD, restricting robust comparative and economic analyses. Conclusions: Psilocybin-assisted therapy represents a potentially transformative intervention for MDD. Nevertheless, current evidence remains insufficient to support definitive conclusions regarding its cost-effectiveness, scalability, and regulatory integration within public health systems. These findings highlight need for multidisciplinary research combining clinical evidence, health economics, regulatory science, and ethical analysis to inform evidence-based policy decisions regarding adoption of psychedelic-assisted therapies.", "journal": "Instituto Politécnico do Porto", "publication_date": "2026-02-26", "publication_year": 2026, "doi": "10.26537/prpaeh.v4i3.7173", "pubmed_id": null, "source_url": "https://doi.org/10.26537/prpaeh.v4i3.7173", "keywords": "Major depressive disorder, Medicine, Psychiatry, Psilocybin, Depression (economics), Adverse effect, Population, Clinical trial, MEDLINE, Mental health, Depressive symptoms, Intervention (counseling), Cochrane Library, Systematic review, Treatment-resistant depression, Intensive care medicine, Randomized controlled trial, Economic evaluation, Data extraction, Meta-analysis, Population health, Health care, Public health, Scarcity, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:36", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7166641777\",\"openalex_url\":\"https://openalex.org/W7166641777\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5063634882\",\"display_name\":\"C Faria\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139632863\",\"display_name\":\"Diana Dias da Silva\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139706169\",\"display_name\":\"João José Sousa\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S7407051319\",\"source_display_name\":\"Instituto Politécnico do Porto\",\"landing_page_url\":\"https://doi.org/10.26537/prpaeh.v4i3.7173\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7166641777" }, { "id": 247, "title": "Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.", "normalized_title": "pharmacological regulation of adult brain neuroplasticity synergistic roles of neuropeptide signaling psychedelics and synaptic modulators", "authors": "Shokr MM, Fawzy MN, Abdelaziz AM.", "abstract": "Neuroplasticity refers to the ability of the brain to modify synaptic connections and reorganize neural circuits, underpinning cognitive function, emotional regulation, and recovery from injury. Recent advances have redefined adult neuroplasticity as more dynamic and therapeutically accessible than previously thought, spurring investigation into pharmacological interventions that can augment these adaptive processes. This review dissects current evidence for drug strategies targeting synaptic modulators (NMDA, AMPA, and GABA receptors), neuropeptide systems (including BDNF, oxytocin, vasopressin), and psychedelic compounds (psilocybin, LSD, ketamine), integrating insights from cellular, preclinical, and clinical studies. We detail how these agents modulate molecular pathways governing synaptic transmission, dendritic remodeling, and gene expression linked to neuronal growth and resilience. Highlighted findings include the rapid-acting antidepressant effects of NMDA antagonists, the structural and functional reorganization induced by classic psychedelics via 5-HT2A receptor activation, and the neurorestorative roles of neuropeptides in synaptic and network adaptation. Alongside these advances, we critically address safety, ethical considerations, and the risk of maladaptive plasticity, underscoring the importance of dosing, patient selection, and controlled therapeutic environments. Non-hallucinogenic neuroplastogens and combinatorial approaches that are still emerging offer new avenues to fine-tune plasticity with an improved safety profile. The collective evidence positions neuroplasticity-targeting pharmacology as a promising and complex frontier for the treatment of neuropsychiatric and neurodegenerative disorders in adulthood.", "journal": null, "publication_date": "2026-02-25", "publication_year": 2026, "doi": "10.1016/j.mcn.2026.104076", "pubmed_id": "41763341", "source_url": "https://doi.org/10.1016/j.mcn.2026.104076", "keywords": "Brain, Synapses, Animals, Humans, Neuropeptides, Hallucinogens, Signal Transduction, Synaptic Transmission, Neuronal Plasticity", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41763341\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Resilience,Emotional Processing,Review Article,Animal Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 83, "title": "Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations", "normalized_title": "psilocybin for psychiatric disorders history clinical trials neuroimaging and regulations", "authors": "Kengo Yonezawa, M. Hirata, Hiroaki Takano, Keisuke Kusudo, Sota Tomiyama, Lisa Harada, Kota Suzuki, DJ Nutt, H. Uchida, Hideaki Tani", "abstract": "Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin was in the early 1970s subjected to strict legal restrictions that stalled research for decades. However, renewed scientific interest began in the 1990s, with studies demonstrating psilocybin's therapeutic potential for psychiatric disorders. Clinical trials have reported therapeutic effects of psilocybin in major depressive disorder (MDD), depressive symptoms associated with life-threatening illnesses, and in some substance use disorders. Moreover, several phase III clinical trials of psilocybin for depression are currently underway, though trial data for obsessive-compulsive disorder and bipolar depression are limited. Short-term side effects are reportedly generally mild and transient, but long-term effects still need further investigation. Neuroimaging research using magnetic resonance imaging and electroencephalography is still limited and focuses mainly on MDD. However, ongoing clinical trials include neuroimaging studies for psychiatric disorders beyond MDD, as well as positron emission tomography studies for MDD. Regulatory frameworks vary internationally. While many countries continue to classify psilocybin as a prohibited substance, use of psilocybin under controlled conditions is now permitted in Switzerland, parts of the United States, Canada, and Australia. Despite encouraging data, challenges remain, including the need for larger, blinded trials, standardized protocols, and clarification of long-term efficacy and safety. Psilocybin represents a novel therapeutic approach in psychiatric treatment, warranting further rigorous scientific and regulatory research.", "journal": "Psychiatry and Clinical Neurosciences", "publication_date": "2026-02-25", "publication_year": 2026, "doi": "10.1111/pcn.70042", "pubmed_id": "41749057", "source_url": "https://doi.org/10.1111/pcn.70042", "keywords": "Psilocybin, Neuroimaging, Psychiatry, Clinical trial, Medicine, Hallucinogen, Major depressive disorder, Depression (economics), Psychology, Functional neuroimaging, Psychotherapist, Bipolar disorder, MEDLINE, Functional magnetic resonance imaging, Clinical psychology, Systematic review, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7131868995\",\"openalex_url\":\"https://openalex.org/W7131868995\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5127386279\",\"display_name\":\"Kengo Yonezawa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109735297\",\"display_name\":\"M. Hirata\",\"orcid\":null},{\"id\":\"https://openalex.org/A5049484871\",\"display_name\":\"Hiroaki Takano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5050308935\",\"display_name\":\"Keisuke Kusudo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111309172\",\"display_name\":\"Sota Tomiyama\",\"orcid\":null},{\"id\":\"https://openalex.org/A5127280306\",\"display_name\":\"Lisa Harada\",\"orcid\":null},{\"id\":\"https://openalex.org/A5046895954\",\"display_name\":\"Kota Suzuki\",\"orcid\":\"https://orcid.org/0000-0002-2473-0724\"},{\"id\":\"https://openalex.org/A5113762702\",\"display_name\":\"DJ Nutt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121811233\",\"display_name\":\"H. Uchida\",\"orcid\":null},{\"id\":\"https://openalex.org/A5127390839\",\"display_name\":\"Hideaki Tani\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S111042112\",\"source_display_name\":\"Psychiatry and Clinical Neurosciences\",\"landing_page_url\":\"https://doi.org/10.1111/pcn.70042\",\"is_oa\":false}}", "topic_tags": "Depression,Addiction,OCD,End-of-Life Distress,Chronic Pain,Brain Imaging,Aging,Spirituality,Clinical Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7131868995" }, { "id": 4078, "title": "Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico Evidence", "normalized_title": "psilocin as a broad inhibitor of cyp450 enzymes integrated in vitro and in silico evidence", "authors": "Diana Silva, Andreia Machado Brito-da-Costa, Mariana Carvalho, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Sérgio F. Sousa", "abstract": "Background: Psilocybin is a psychoactive compound found in hallucinogenic mushrooms and is rapidly dephosphorylated in vivo to psilocin, its pharmacologically active metabolite. Despite the growing clinical and scientific interest in these substances, information regarding their interaction with cytochrome P450 (CYP450) enzymes remains scarce, raising concerns about potential drug-drug interactions. Objective: To evaluate, using combined in vitro and in silico approaches, the inhibitory potential of psilocybin and psilocin toward the human CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4 isoenzymes. Methods: Enzyme inhibition was assessed in vitro using fluorometric assays based on Vivid® substrates and recombinant human CYP enzymes expressed in baculosomes. Half-maximal inhibitory concentration (IC₅₀) values were calculated. In silico analyses comprised molecular dynamics simulations performed with the PMEMD.cuda module of AMBER16, followed by MM/GBSA binding free energy calculations, per-residue energy decomposition, and hydrogen bond analysis over the final 100 ns of stabilized trajectories. Results: Psilocin exhibited inhibitory activity against all evaluated isoenzymes, with IC₅₀ values (µM) of 2.06 for CYP2A6, 6.17 for CYP2B6, 11.89 for CYP2D6, 6.37 for CYP2E1, and 2.36 for CYP3A4. MM/GBSA results supported a strong binding affinity of psilocin, driven by specific interactions with key amino acid residues within the active sites, including stabilizing hydrogen bonds. Conclusions: These findings indicate that psilocin acts as a relevant inhibitor of multiple CYP450 isoenzymes, particularly CYP2A6 and CYP3A4, highlighting a potential risk for metabolic drug-drug interactions that should be considered in both clinical and toxicological contexts.", "journal": "Instituto Politécnico do Porto", "publication_date": "2026-02-24", "publication_year": 2026, "doi": "10.26537/prpaeh.v4i3.7159", "pubmed_id": null, "source_url": "https://doi.org/10.26537/prpaeh.v4i3.7159", "keywords": "In silico, Chemistry, Psilocybin, Biochemistry, In vitro, Enzyme, Active site, Cytochrome P450, CYP1A2, In vivo, Inhibitory postsynaptic potential, Stereochemistry, Binding site, CYP2A6, CYP3A4, Molecular model, Pharmacology, Förster resonance energy transfer, Structure-activity relationship, Enzyme inhibitor, Systematic evolution of ligands by exponential enrichment, Drug discovery, In vitro toxicology, Psychedelics and Drug Studies, Pharmacogenetics and Drug Metabolism, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:36", "last_checked": "2026-07-04 07:00:31", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7166650553\",\"openalex_url\":\"https://openalex.org/W7166650553\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5139701034\",\"display_name\":\"Diana Silva\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048312717\",\"display_name\":\"Andreia Machado Brito-da-Costa\",\"orcid\":\"https://orcid.org/0000-0001-7327-1598\"},{\"id\":\"https://openalex.org/A5101564174\",\"display_name\":\"Mariana Carvalho\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139701164\",\"display_name\":\"Ricardo Jorge Dinis-Oliveira\",\"orcid\":null},{\"id\":\"https://openalex.org/A5135288359\",\"display_name\":\"Áurea Madureira-Carvalho\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139691350\",\"display_name\":\"Sérgio F. Sousa\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S7407051319\",\"source_display_name\":\"Instituto Politécnico do Porto\",\"landing_page_url\":\"https://doi.org/10.26537/prpaeh.v4i3.7159\",\"is_oa\":true}}", "topic_tags": "Neuroplasticity,Pharmacology,In Vitro Study,Safety,Toxicity,Drug Interactions", "study_type": "In Vitro Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7166650553" }, { "id": 244, "title": "Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.", "normalized_title": "efficacy and safety of psychoactive tryptamines in addiction a systematic review", "authors": "van der Meer PB, Schukking N, Dik M, van Reemst A, Fuentes JJ, Kaptein AA, Schoones JW, Verboeket S, de Waal MM, Goudriaan AE, Kramers C, Schellekens A, Bossong MG, Somers M, Batalla A.", "abstract": "BackgroundPsychedelics such as lysergic acid diethylamide (LSD) and psilocybin have shown a beneficial effect on substance use disorder (SUD) symptoms. In this systematic review, we aimed to assess the efficacy and safety of psychoactive tryptamines in patients with an SUD or non-substance-related disorder (i.e., gambling disorder) in order to provide a comprehensive overview of the available evidence and identify potential research gaps.MethodsA systematic literature search was performed in eight different databases up to February 2024. Clinical trials were included that assessed the efficacy and safety of psychoactive tryptamines other than psilocybin and ibogaine. A quality assessment of the included trials was done based on the revised Cochrane risk-of-bias tools.ResultsA total of four clinical trials (three randomized controlled trials and one single-arm clinical trial; n = 176 patients) were included, all in patients with alcohol use disorder. Dipropyltryptamine and diethyltryptamine were the two investigated psychoactive tryptamines. Abstinence ranged from 10% (duration of follow-up unknown) to 38% at 26 weeks of follow-up, and severity of alcohol use did not differ between the psychoactive tryptamine group and the control groups. Adverse effects were not well reported in the trials.ConclusionStudies assessing the efficacy of psychoactive tryptamines other than psilocybin and ibogaine in addiction are scarce and show limited evidence for effectiveness in the treatment of addictive disorders.", "journal": null, "publication_date": "2026-02-23", "publication_year": 2026, "doi": "10.1177/28314425251364182", "pubmed_id": "42130778", "source_url": "https://doi.org/10.1177/28314425251364182", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"42130778\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3602, "title": "Safety for Home Administration of Microdose Psilocybin Use", "normalized_title": "safety for home administration of microdose psilocybin use", "authors": "Johns Hopkins University", "abstract": "The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments. This study aims to enroll 20 healthy participants who will complete all study procedures. Participants will undergo a standard screening procedure. Baseline measures will be completed before the first dose. Participants will then be given ascending doses of psilocybin trihydrate (1.2 mg, 2.0 mg, 3.0 mg, and 4.2 mg) and a single, interspersed, randomized placebo on separate days in double-blind fashion at the research site. A1 mg dose of psilocybin anhydrate is equivalent to a 1.19 mg dose of psilocybin trihydrate (used in this study). For each session, participants will be assessed with criteria for the safety of home dosing. If any dose meets criteria for at-home dosing, and a lower dose did not fail these criteria, that dose will be identified as the safe dose for the given participant. After administration of all doses of psilocybin to all participants, if a safe at-home dose was identified for all participants, that will be considered the highest safe dose for at-home administration to be used for future studies. Visit summary: Initial screening: Medical and psychological screening (Approx. 4 hours though portions of this may be completed remotely). Dosing sessions: There will be 5 double-blind laboratory dosing sessions involving administration of ascending doses of psilocybin and a single, interspersed, randomized placebo dose. Baseline questionnaires will be completed on the day of the first dosing visit, and safety assessments will be administered during and at the end of each session.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-22", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06450210", "keywords": "Psychedelic Experiences, psilocybin trihydrate, Placebo, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06450210\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Microdosing,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3032, "title": "Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial", "normalized_title": "safety and efficacy of microdosing psilocybin over 8 weeks for major depressive disorder a randomized clinical trial", "authors": "Petranker R, Farb N, Syed O, Li E, Shore D, Anderson T, Blackman A.", "abstract": "Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two centers: a pediatric clinic and a dedicated psychedelic therapy clinic. PARTICIPANTS were 39 adults aged 27 to 65 years with a diagnosis of MDD and mild to moderate symptom severity. INTERVENTIONS Participants received four weekly doses of placebo or 2 mg psilocybin, followed by four weekly open-label psilocybin doses. MAIN OUTCOMES AND MEASURES Primary outcome: Patient Health Questionnaire with Self-Directed Assessment Scales (PHQ-9) score from baseline week four. Secondary outcome measures were symptom counts measured by the Structured Clinical Interview for DSM-5 (SCID-5) symptom count, Quick Inventory of Depressive Symptomatology (QIDS), and the Dysfunctional Attitudes Scale (DAS-A-17) from baseline to week four. RESULTS 39 participants (mean age 44.4; 56.4% female) reported similar reductions in PHQ-scores regardless of group assignment after four weeks (psilocybin: mean difference -5.4; placebo: -6.0). Similar trends were observed in the QIDS and SCID-5, but participants in the microdose-first group showed more symptoms reduction than those in the placebo-first group (psilocybin: mean difference -1.2; placebo: -0.1) for the DAS-A-17. Symptom reductions persisted through open-label phase, with no serious treatment-emergent adverse events. CONCLUSIONS AND RELEVANCE Repeated low doses of psilocybin were safe and well tolerated but did not demonstrate statistically greater efficacy than placebo. Trial participation itself contributed to clinically significant symptom improvement. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT05259943", "journal": "Research Square", "publication_date": "2026-02-22", "publication_year": 2026, "doi": "10.21203/rs.3.rs-8319478/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-8319478/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1157780\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Microdosing,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3182, "title": "Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives", "normalized_title": "ethical complexities and best practices in informed consent for psychedelic services a qualitative study on expert perspectives", "authors": "", "abstract": "Background: Informed consent in psychedelic-assisted services is ethically complex, difficult to implement, and remains largely unstudied and unstandardized. Objective: The current study sought expert recommendations from experienced psychedelic facilitators on what constitutes informed consent best practices for supervised psychedelic experiences across various settings. Methods: Participants with expertise in facilitating psilocybin-assisted experiences or other expertise in the psychedelic field were recruited with purposive sampling. Qualitative interviews on informed consent best practices and recommendations were analyzed using Thematic Analysis. Results: Participants (N = 36; 71% white; 56% heterosexual; 53% female) reported facilitating psilocybin services (64%) for a mean of 15.2 (SD = 13.1) years in clinical trial, licensed service center, underground, or ceremonial settings. Participants viewed informed consent as a process (Theme 1), necessitating a strong therapeutic relationship, centering client empowerment, and occurring as an ongoing process. Potential risks and benefits should be comprehensively conveyed (Theme 2), including potential long-term psychological and social changes, and the potential for disappointing experiences. Participants recommended detailed consent processes around touch and boundaries (Theme 3), including explicitly establishing boundaries prior to psychedelic administration, maintaining those boundaries throughout, and recognizing subtle non-verbal cues that may indicate lack of true consent. Within facilitator trainings (Theme 4), participants emphasized cultivating a deep respect for client agency, and experientially learning relational and boundary setting skills. Conclusions: Findings may inform practitioner training, consent practices in varied settings, and policy development for state-regulated psychedelic services.", "journal": "PsyArXiv", "publication_date": "2026-02-18", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/mdz73_v2", "keywords": "Neuroscience, Clinical Neuroscience, Social and Behavioral Sciences, Clinical Psychology, Psychotherapy, Clinical Ethics, Health Psychology, Mental Health", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"mdz73_v2\",\"version\":2,\"reviews_state\":\"accepted\"}", "topic_tags": "Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3520, "title": "Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study", "normalized_title": "pilot study of psilocybin assisted therapy for demoralization in patients receiving hospice care path study", "authors": "Yvan Beaussant, MD, MSci", "abstract": "The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care. -The name of the study drug involved in this study is Psilocybin The purpose of this research is to understand how psilocybin-assisted therapy may be adapted in the context of hospice care, in order to test its safety in people with terminal illness who experience demoralization, and to study how well it works to lessen symptoms of psychological and existential distress. * This research study involves a combined drug and psychotherapeutic (talk therapy) intervention. The research study procedures include screening for eligibility, and study intervention including preparation, evaluations, one psilocybin session and follow up visits. * The treatment regimen consists of a single administration of psilocybin with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions * The name of the study drug involved in this study is Psilocybin. Psilocybin is a naturally occurring psychedelic drug produced by more than 200 species of mushrooms, which is manufactured for medical use to control potency and purity. * Participants will be followed for up to 24 weeks (approximately 6 months) after the study treatment. It is expected that about 15 people will take part in this research study. * This research study is a Feasibility Study, which mean it is the first time investigators are examining psilocybin-assisted therapy in the context of hospice care. Psilocybin is an \"Investigational\" drug, meaning that the study drug has not been approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease. However, the FDA has granted psilocybin the status of \"breakthrough therapy\" in the treatment of depression and the investigators have permission from the FDA to use this drug in this research study.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-16", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04950608", "keywords": "Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04950608\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,End-of-Life Distress,Cancer Patients,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 269, "title": "Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial", "normalized_title": "microdosing psilocybin for major depressive disorder study protocol for a phase ii double blind placebo controlled randomised partial crossover trial", "authors": "Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily C. Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Magdalena Jaglinska, Tatiana Son, Norman Farb, Rotem Petranker", "abstract": "BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled trials have failed to produce compelling evidence for this. AIMS: To conduct a phase II, double-blind, placebo-controlled, randomised partial crossover trial to compare microdosing psilocybin to placebo for MDD, evaluating its safety, tolerability and preliminary antidepressant effects. METHOD: Forty adults with MDD will be randomised to four doses of psilocybin (2 mg) or placebo (maltodextrin) once weekly over 4 weeks, then four doses of psilocybin (2 mg) once weekly for an additional 4 weeks. The primary efficacy end-point will be change in depression symptoms, as measured at baseline (0 weeks), after the experimental phase (4 weeks), and after the open-label phase (8 weeks). A battery of mood, well-being, attention, creativity, mindfulness and pro-sociality measures will be administered at each time point. Follow-ups will occur every 6 months for up to 2 years after the trial start date, as part of a long-term extension study. RESULTS: The results of the primary outcome of this trial will be published as a manuscript in a peer-reviewed science or medical journal regardless of the magnitude or direction of effect. CONCLUSIONS: Findings will inform future research on microdosing psilocybin for MDD, regarding dose regimens, effect sizes and expectancy bias. Findings will also facilitate discussions on the comparable benefits of sub- versus threshold doses of psilocybin and the therapeutic value of radically altered perception. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05259943.", "journal": "BJPsych Open", "publication_date": "2026-02-15", "publication_year": 2026, "doi": "10.1192/bjo.2025.10968", "pubmed_id": "41693474", "source_url": "https://doi.org/10.1192/bjo.2025.10968", "keywords": "Medicine, Psilocybin, Protocol (science), Crossover study, Phase (matter), Pharmacology, Clinical trial, Depression (economics), Internal medicine, Depressive symptoms, Phases of clinical research, Anesthesia, Randomized controlled trial, Placebo, Component (thermodynamics), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7129015437\",\"openalex_url\":\"https://openalex.org/W7129015437\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1970133878\",\"https://openalex.org/W2021482385\",\"https://openalex.org/W2043713516\",\"https://openalex.org/W2057468507\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2269974365\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2624535799\",\"https://openalex.org/W2789213216\",\"https://openalex.org/W2895986834\",\"https://openalex.org/W2907379922\",\"https://openalex.org/W2926011243\",\"https://openalex.org/W2944038128\",\"https://openalex.org/W2946918750\",\"https://openalex.org/W2951080359\",\"https://openalex.org/W2957955970\",\"https://openalex.org/W2958413903\",\"https://openalex.org/W2971897729\",\"https://openalex.org/W2981686921\",\"https://openalex.org/W3002125030\",\"https://openalex.org/W3004910645\",\"https://openalex.org/W3007315114\",\"https://openalex.org/W3093109301\",\"https://openalex.org/W3112904824\",\"https://openalex.org/W3122801192\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3135650175\",\"https://openalex.org/W3136880453\",\"https://openalex.org/W3159653784\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3166553838\",\"https://openalex.org/W3211842562\",\"https://openalex.org/W4200408156\",\"https://openalex.org/W4206388601\",\"https://openalex.org/W4210925784\",\"https://openalex.org/W4229753260\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4385257581\",\"https://openalex.org/W4391537440\",\"https://openalex.org/W4402554692\"],\"authorships\":[{\"id\":\"https://openalex.org/A5114541934\",\"display_name\":\"Zeina Beidas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5006257142\",\"display_name\":\"Anya Ragnhildstveit\",\"orcid\":\"https://orcid.org/0000-0002-5796-3428\"},{\"id\":\"https://openalex.org/A5008844555\",\"display_name\":\"Adam Blackman\",\"orcid\":\"https://orcid.org/0000-0003-0467-040X\"},{\"id\":\"https://openalex.org/A5082063863\",\"display_name\":\"Thomas Anderson\",\"orcid\":\"https://orcid.org/0000-0002-2387-5219\"},{\"id\":\"https://openalex.org/A5093863231\",\"display_name\":\"Emily C. Fewster\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062369777\",\"display_name\":\"Omer A. Syed\",\"orcid\":\"https://orcid.org/0000-0002-4027-5223\"},{\"id\":\"https://openalex.org/A5120500161\",\"display_name\":\"Valentyne Sobolenko\",\"orcid\":\"https://orcid.org/0009-0001-9574-4648\"},{\"id\":\"https://openalex.org/A5120355300\",\"display_name\":\"Ismail Kaan Kanca\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120403954\",\"display_name\":\"Magdalena Jaglinska\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070812247\",\"display_name\":\"Tatiana Son\",\"orcid\":\"https://orcid.org/0000-0003-0351-8596\"},{\"id\":\"https://openalex.org/A5126008050\",\"display_name\":\"Norman Farb\",\"orcid\":null},{\"id\":\"https://openalex.org/A5012017884\",\"display_name\":\"Rotem Petranker\",\"orcid\":\"https://orcid.org/0000-0001-6354-0109\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764831659\",\"source_display_name\":\"BJPsych Open\",\"landing_page_url\":\"https://doi.org/10.1192/bjo.2025.10968\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Pharmacology,Microdosing,Wellbeing,Creativity,Clinical Trial,Randomized Controlled Trial,Review Article,Observational Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7129015437" }, { "id": 3541, "title": "A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers", "normalized_title": "a phase 1 translational study to assess brain activity using functional magnetic resonance imaging fmri and to evaluate the safety tolerability and pharmacokinetics of multiple doses of mls101 psilocybin in healthy volunteers", "authors": "MycoMedica Life Sciences PBC", "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants. In recent years, high-dose psilocybin has gained attention for it potential therapeutic benefit in many psychiatric conditions, however existing clinical data for low psilocybin doses are limited. The multiple-dose regimen proposed in this study is designed to optimize the pharmacology of MLS101 and elucidate whether it provides a longer period of positive effects, which could be used in future studies in chronic indications such as PMDD, obsessive compulsive disorder and opioid use disorder. Translational functional magnetic resonance imaging (fMRI) imaging will confirm the central nervous system (CNS) activity of priming and repeat low-dose psilocybin, which will serve as a computational evaluation of efficacy and complement the cognitive and perceptual scales and questionnaires.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-12", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07050368", "keywords": "Healthy Volunteer, Psilocybin, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07050368\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Addiction,Brain Imaging,Pharmacology,Aging,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3425, "title": "Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability", "normalized_title": "psychedelic healing adjunct therapy harnessing opened malleability", "authors": "Johns Hopkins University", "abstract": "The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke. Stroke is the leading cause of death and adult disability worldwide, and every year more than 795,000 people in the United States have a stroke. According to the National Stroke Association, only 10 percent of people who have a stroke recover completely, while 50 percent experience moderate to severe long-term disability, including significant impairment in language, cognition, motor, and sensory skills, which require special care or long-term care in a nursing home or other facility. Therefore, in the United States alone, nearly 400,000 people per year will suffer the lasting debilitating consequences of stroke. Previous studies have indicated that rehabilitation following stroke is constrained by a so-called 'critical' or 'sensitive' period. While this learning window can be extended or enhanced, once the post-stroke rehabilitation critical period has closed, clinically applicable manipulations that can reopen it are lacking. Recently the investigators have shown that the psychedelic compounds like psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxmethamphetamine (MDMA) can reopen a novel critical period for social reward learning. The adage \"you can't teach an old dog new tricks\" captures a certain truth about the brain. Specifically, a young person's brain is much more malleable (e.g., able to make new motor-memories and store new motor-memories) compared to an adult's brain. Neuroscientists call these periods of heightened sensitivity to input \"critical periods.\" Based on these observations the investigators posit that psychedelic compounds serve as the long sought-after \"master key\" for unlocking critical periods across the brain. Ongoing preclinical studies are examining this possibility, with the goal of determining the therapeutic potential of psychedelics (including psilocybin) as adjunct therapies for any intervention whose clinical efficacy may be constrained by critical period closure, including post-stroke rehabilitation. The main purpose of the proposed studies is to evaluate the safety and tolerability of psilocybin in stroke patients (Phase 1). as a secondary aim the investigators will collect data on the efficacy of psilocybin in effecting motor recovery in post-stroke patients.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-12", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07053917", "keywords": "Stroke, Chronic Stroke, Intracerebral Haemorrhage, Intracerebral Haemorrhage (ICH), Intracerebral Hemorrhage Basal Ganglia, Ischemic Stroke, Ischemic Stroke and Hemorrhagic Stroke, Hemiparesis After Stroke, Hemiplegia Following Ischemic Stroke, Hemiplegia and Hemiparesis, Hemiplegia and/or Hemiparesis Following Stroke, Middle Cerebral Artery Stroke, Psilocybin (Usona Institute), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07053917\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Clinical Trial,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3704, "title": "Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder", "normalized_title": "single dose psilocybin for a post surgical trauma inpatient population for pain mood and opioid use disorder", "authors": "Trent Emerick", "abstract": "The goal of this clinical trial is to evaluate whether a single dose of psilocybin is feasible and safe for adults with opioid use disorder (OUD) who are recovering from trauma surgery. The main questions it aims to answer are: 1. Is a single psilocybin dose feasible to administer during postoperative hospitalization? 2. Is psilocybin safe in this patient population? 3. How does psilocybin affect postoperative pain, opioid use, anxiety, and depression after hospital discharge? Participants will: Receive one oral dose of psilocybin during their postoperative inpatient stay Complete assessments of pain, mood, and opioid use during recovery This is an open-label pilot feasibility trial conducted at a single academic medical center. Fourteen participants receive a single oral dose of psilocybin during inpatient hospitalization following trauma surgery. Outcomes in the psilocybin group are compared with a retrospectively identified standard-of-care cohort of 56 trauma surgery patients with opioid use disorder, identified through electronic medical record review. The standard-of-care cohort is selected using propensity score methods based on baseline characteristics, including age, sex, trauma diagnosis, psychiatric comorbidities, baseline medications, comorbid conditions, type of surgery, and baseline opioid consumption measured in morphine milligram equivalents. No interim efficacy analyses are planned. After the first three participants have received psilocybin and completed the one-week follow-up assessments, the Data and Safety Monitoring Board reviews safety data to assess ongoing risk and determine whether study procedures should continue unchanged.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07406828", "keywords": "Pain Management, Postoperative Pain, Psilocybin (Usona Institute), Postoperative analgesia, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07406828\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Clinical Trial,Review Article,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3624, "title": "Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial", "normalized_title": "psilocybin assisted therapy for comorbid major depressive disorder and alcohol use disorder a pilot randomized clinical trial", "authors": "Centre for Addiction and Mental Health", "abstract": "The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \\- What is the feasibility and safety of administering PAT in adults with MDD-AUD by evaluating recruitment, retention, tolerability, and safety? Researchers will compare the psilocybin (25 mg) and placebo groups to see if there are any significant differences in frequency of dropouts or serious adverse events. Participants will: * be randomized to receive either psilocybin (25 mg) or placebo * visit the site (in-person and remotely) for a total of 14 times to complete study tasks * receive psilocybin-assisted therapy (PAT) at five various timepoints", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07405606", "keywords": "Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Psilocybin 25 mg, Placebo, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07405606\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Addiction,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 86, "title": "Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects", "normalized_title": "therapeutic effects of psilocybin in major depressive disorder a systematic review and meta analysis exploring dose effects", "authors": "Ziping He, Yijie Wang, Jie Chen, Junzhe Cheng, Yuxin Feng, Shuliang Niu, J. Yan", "abstract": "", "journal": "European Archives of Psychiatry and Clinical Neuroscience", "publication_date": "2026-02-11", "publication_year": 2026, "doi": "10.1007/s00406-025-02165-y", "pubmed_id": "41677823", "source_url": "https://doi.org/10.1007/s00406-025-02165-y", "keywords": "Psilocybin, Tolerability, Dosing, Adverse effect, Medicine, Cochrane Library, Clinical trial, Meta-analysis, Major depressive disorder, Placebo, Randomized controlled trial, Regimen, Psychiatry, Depression (economics), Therapeutic effect, MEDLINE, Pharmacology, Systematic review, Treatment-resistant depression, Hallucinogen, Therapeutic index, Internal medicine, Psychology, Clinical psychology, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7128718542\",\"openalex_url\":\"https://openalex.org/W7128718542\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2094667953\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2463496270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2801092899\",\"https://openalex.org/W2905782592\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3011986535\",\"https://openalex.org/W3019350884\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3216258226\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310494020\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4315436620\",\"https://openalex.org/W4319081635\",\"https://openalex.org/W4322719045\",\"https://openalex.org/W4324045013\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386305913\",\"https://openalex.org/W4391842082\",\"https://openalex.org/W4392731282\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4400415795\",\"https://openalex.org/W4401774886\"],\"authorships\":[{\"id\":\"https://openalex.org/A5125689977\",\"display_name\":\"Ziping He\",\"orcid\":null},{\"id\":\"https://openalex.org/A5100429817\",\"display_name\":\"Yijie Wang\",\"orcid\":\"https://orcid.org/0000-0001-6959-8619\"},{\"id\":\"https://openalex.org/A5100333011\",\"display_name\":\"Jie Chen\",\"orcid\":\"https://orcid.org/0000-0003-3435-0351\"},{\"id\":\"https://openalex.org/A5125770360\",\"display_name\":\"Junzhe Cheng\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125702445\",\"display_name\":\"Yuxin Feng\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125772117\",\"display_name\":\"Shuliang Niu\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124195334\",\"display_name\":\"J. Yan\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S105662685\",\"source_display_name\":\"European Archives of Psychiatry and Clinical Neuroscience\",\"landing_page_url\":\"https://doi.org/10.1007/s00406-025-02165-y\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Pharmacology,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7128718542" }, { "id": 3690, "title": "Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers", "normalized_title": "safety and psychological effects of psilocybin and d serine formulation in healthy volunteers", "authors": "Hadassah Medical Organization", "abstract": "The goal of this open-label, dose-escalation, prospective study is to evaluate the safety and psychological effects of a Psilocybin and D-Serine formulation in healthy volunteers. The main objectives are: 1. To assess the psychological and physiological effects of psilocybin administered with D-Serine in healthy adults. 2. To determine whether D-Serine modulates or attenuates the psychedelic effects of psilocybin. 3. To evaluate the safety and tolerability of psilocybin and D-Serine co-administration. Study population includes: 10 healthy male or female volunteers aged 25-60 years with no history of psychiatric or major medical disorders and no current evidence of such disorders. The study includes two cohorts. The first cohort of 5 participants will receive 15 mg of Psilocybin and 5 g of D-Serine. Safety data will be collected and submitted in an interim report to the Ethics Committee. If no safety concerns arise, the second cohort will receive an increased dose of 25 mg of Psilocybin and 7 g of D-Serine to help determine the optimal dose for a future Phase IIa clinical trial. This is a first-in-human, Phase I, exploratory clinical trial designed to evaluate the safety, tolerability, and initial psychological and physiological responses to a single administration of psilocybin in combination with D-Serine in healthy adult volunteers. The rationale for this combination stems from preclinical evidence indicating that D-Serine, a naturally occurring co-agonist at the NMDA receptor, may attenuate the acute psychedelic effects of psilocybin while preserving its neuroplastic and therapeutic properties. Preclinical studies demonstrated that D-Serine reduced the psilocybin-induced head-twitch response (HTR) in rodent models and enhanced the expression of synaptic plasticity markers (e.g., GAP43, PSD95, SV2A, synaptophysin) across multiple brain regions, with effects sustained up to 12 days post-treatment. These findings suggest that the combination may improve the safety and tolerability of psilocybin, particularly for populations sensitive to its psychoactive effects. The trial will consist of four sequential components: Screening Phase - to assess eligibility. Preparation Phase - to establish therapeutic rapport and baseline assessments. Administration Phase - involving a single oral administration of the investigational combination (psilocybin + D-Serine). Follow-up Phase - including in-person follow-up visits on Day 2, Day 7, Day 28, and Day 84 post-treatment to monitor safety outcomes, subjective responses, and potential delayed effects.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-04", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07079930", "keywords": "Healthy Volunteers, Psilocybin and D-Serine, Physical Examination, Vital signs, ECG test, Comprehensive Blood Panel, SMAC-20, Complete Blood Count, CBC, Urinalysis, Urine Toxicology Screen, A pregnancy Urine test, Electroencephalogram, EEG, Plasma Amino Acid Levels, Plasma Inflammation Markers, Plasma Brain-Derived Neurotrophic Facto, Plasma BDNF, Mini International Neuropsychiatric Interview, MINI, Family Psychiatric History Assessment, FPHA, Beck Depression Inventory, BDI, State-Trait Anxiety Inventory, STAI, Profile of Mood States, POMS, Subjective Units of Distress Scale, SUDS, Five-Dimensional Altered States of Consciousness questionnaire, 5D-ASC, Integration, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07079930\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Consciousness,Biomarkers,Clinical Trial,Observational Study,Animal Study,Healthy Volunteers,Safety,Toxicity,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3550, "title": "A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design", "normalized_title": "a phase 2a open label pilot study to assess the safety and efficacy of oral psilocybin trp 8802 administration in concert with psychotherapy among adult patients with irritable bowel syndrome a randomized delayed treatment control design", "authors": "TRYP Therapeutics", "abstract": "Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study. This study will involve a randomized waitlist control design to investigate the rapid and sustained effects of TRP-8802 following two experimental sessions in which an oral dose of TRP-8802 is administered to participants with IBS. The study will include clinician and participant ratings of depression and anxiety pre- and post-drug-session, monitor and participant ratings of subjective drug effects during and after each drug session. This study comprises approximately a 28-day screening period (Days 28 to 1). After screening and enrollment, participants will be randomized to an immediate treatment group or a delayed treatment group (\"waitlist control\" condition). Participants in the immediate treatment group will proceed directly into three weeks of baseline and preparation (Days 1 to 18), a 2-dose administration period (Days 22 and 37), integration (Days 23, 30, 38, and 45), the End of Therapy (EOT) visit (Day 52). Participants in the delayed treatment group will wait 8 weeks after enrollment before beginning the study interventions and neuroimaging assessments. As a safety precaution, participants in the delayed treatment group will be assessed weekly via telephone calls or in-person visits during the wait period (i.e., telephone assessments during post-randomization weeks 1, 2, 3, 4, 5, 6, and 7; in-person assessment during post-randomization week 8) to assess suicide risk to determine if intervention is warranted. During week 8, IBS symptoms will also be assessed. At the end of the delay period, all participants in the delayed treatment group will complete the same intervention as the participants in the immediate treatment group. Validated and commonly used assessment tools will be used to evaluate symptoms at baseline and repeatedly after each session. The weekly average of worst daily pain score and weekly stool frequency and consistency for the 7 days immediately prior to EOT visit will be assessed for change from baseline and at the 3-, 6, and 12- month follow-up visits (Days 120, 240, 365).", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-04", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06206265", "keywords": "Irritable Bowel Syndrome, TRYP-0082, Psychotherapy, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06206265\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Chronic Pain,Brain Imaging,Aging,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3486, "title": "Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study", "normalized_title": "psilocybin assisted psychotherapy for the treatment of gambling disorder a pilot study", "authors": "Nantes University Hospital", "abstract": "The PASSENGER project aims to conduct a pilot feasibility study of the implementation of a randomized clinical trial on psilocybin-assisted psychotherapy for the treatment of gambling disorder. Feasibility will be assessed by estimating the ability to retain participants until the end of the protocol. Other objectives of the study will be to generate preliminary efficacy data, identify clinical factors potentially associated with the intensity of the psychedelic experience (which determines the expected therapeutic effect), and conduct a preliminary assessment of the safety of the treatment under study.", "journal": "ClinicalTrials.gov", "publication_date": "2026-02-04", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07391332", "keywords": "Gambling Disorder, Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate), Psychotherapy assisted by low-dose psilocybin (1 mg), NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07391332\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3272, "title": "Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models", "normalized_title": "can llms get high a dual metric framework for evaluating psychedelic simulation and safety in large language models", "authors": "Ben-Zion Z, Simon G, Lazebnik T.", "abstract": "Abstract Large language models (LLMs) are increasingly consulted by individuals for support during psychedelic experiences (\"trip sitting\"), yet no framework exists to evaluate whether these models can accurately simulate or safely respond to altered states of consciousness. We aimed to determine if LLMs can be induced to generate narratives resembling human psychedelic experiences and to quantify this behavior using psychometric and linguistic metrics. We developed a dual-metric evaluation framework comparing 3,000 LLM-generated narratives (from Gemini 2.5, Claude Sonnet 3.5, ChatGPT-5, Llama-2 70B, and Falcon 40B) against 1,085 human trip reports sourced from Erowid.org. Models were prompted under neutral and psychedelic-induction conditions across five substances (psilocybin, LSD, DMT, ayahuasca, and mescaline). We assessed outcomes using semantic similarity (Sentence-BERT embeddings) to human reports and the Mystical Experience Questionnaire-30 (MEQ-30). Psychedelic induction prompts produced a significant shift in model outputs compared to neutral conditions. Semantic similarity to human reports increased from a mean of 0.156 (neutral) to 0.548 (psychedelic), and mystical-experience scores rose from 0.046 to 0.748. While models demonstrated substance-specific linguistic styles (e.g., generating distinct semantic profiles for substances like LSD versus ayahuasca), they exhibited uniformly high mystical intensity across all substances. Contemporary LLMs can be \"dosed\" via text prompts to generate convincingly realistic psychedelic narratives. However, the dissociation between their high linguistic mimicry and lack of genuine phenomenology suggests they simulate the form of altered states without the experiential content. This capability raises significant safety concerns regarding anthropomorphism and the potential for AI to inadvertently amplify distress or delusional ideation in vulnerable users.", "journal": "Research Square", "publication_date": "2026-02-01", "publication_year": 2026, "doi": "10.21203/rs.3.rs-8682370/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-8682370/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR1149771\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Consciousness,Mystical Experience,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 295, "title": "Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.", "normalized_title": "difficulties following naturalistic psychedelic use and associations with adverse childhood experiences", "authors": "Olofsson M, Osika W, Goldberg SB, Hendricks PS, Petrovic P, White T, Stenfors CUD, Chaturvedi S, Simonsson O", "abstract": "Naturalistic psychedelic use can result in a range of difficulties that impair social, occupational, and other important areas of functioning. Yet, the prevalence, phenomenology, and etiology of these outcomes remain poorly understood. Recent qualitative research has shown that individuals with long-term difficulties after psychedelic use sometimes attribute their challenges to childhood trauma. Further studies are needed to investigate these relationships. In this cross-sectional mixed-methods study of U.S. adults with lifetime psychedelic use (n = 3168), we examined the prevalence, duration, and nature of psychedelic-related difficulties, as well as associations with adverse childhood experiences (ACEs). Of all participants (n = 3168), most (n = 2785, 87.9 %) reported no difficulties; 6.4 % (n = 203) reported post-acute difficulties that lasted for more than one day, and 1.3 % (n = 40) for more than one year. Among those who reported difficulties (n = 383), 47 % (n = 180) reported that their difficulties resolved in one day or less. The most frequently reported post-acute difficulties were general anxiety (33.9 %), negative changes in self-concept (25.9 %), and social disconnection (23.0 %). In covariate-adjusted regression models, 2 ACEs (aOR: 2.24, p = 0.007), 3 ACEs (aOR: 2.27, p = 0.006), and ≥4 ACEs (aOR: 2.84, p < 0.001) were associated with higher odds of psychedelic-related difficulties compared to 0 ACEs. ≥4 ACEs were also associated with higher odds of difficulties that lasted more than one day (aOR: 2.37, p = 0.015) and more than one week (aOR: 2.89, p = 0.042). There are a range of difficulties that can follow psychedelic use and childhood adversity may represent a risk factor for persistent adverse effects.", "journal": "The International journal on drug policy", "publication_date": "2026-01-31", "publication_year": 2026, "doi": "10.1016/j.drugpo.2025.105105", "pubmed_id": "41389560", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41389560/", "keywords": "Adverse, Challenging experiences, Childhood, Psilocybin, Psychedelics, Trauma", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"41389560\"}", "topic_tags": "Anxiety,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 288, "title": "Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy", "normalized_title": "participant experiences of therapeutic touch in psilocybin assisted therapy", "authors": "Rachel Ham, John Gardner, Adrian Carter, Paul Liknaitzky", "abstract": "INTRODUCTION: Although commonly used in psychedelic-assisted therapy, the role of therapeutic touch remains loosely defined and ethically sensitive. Gaining insight into how participants experience and interpret touch during psychedelic sessions is essential for informing safe and effective clinical practice. METHODS: Participants were sampled from a large randomized clinical trial of psilocybin-assisted therapy that permitted protocol-defined supportive touch. Longitudinal qualitative data (39 semi-structured interviews) were analyzed from n = 18 participants. Interviews covered expectations, experiences, and reflections on the use of touch during acute psychedelic states, before and after dosing. Thematic analysis was used to identify major themes. RESULTS: Participants expressed varied preferences and responses to therapeutic touch. Most valued its availability, particularly after firsthand experience, describing its capacity to foster emotional connection, provide grounding during intense affective states, and modulate the depth of psychedelic experience. Several reported perceiving therapeutic benefit directly attributable to touch. Acceptability was consistently linked to the quality of the therapeutic relationship and robust consent processes. Some participants also identified potential for discomfort or distraction, underscoring the need for sensitivity to individual history and context. CONCLUSIONS: Therapeutic touch may support emotional safety and affect regulation during acute psychedelic states. Findings highlight the importance of explicit preparation, consent, and attunement when incorporating touch into psychedelic therapy. Further research should inform therapist training, individualized consent frameworks, and safety protocols to guide ethical and effective use in clinical practice.", "journal": "Brain and Behavior", "publication_date": "2026-01-31", "publication_year": 2026, "doi": "10.1002/brb3.71262", "pubmed_id": "41699875", "source_url": "https://doi.org/10.1002/brb3.71262", "keywords": "Attunement, Therapeutic touch, Psychology, Psychotherapist, Affect (linguistics), Informed consent, Therapeutic relationship, Qualitative research, MEDLINE, Clinical psychology, Medicine, Ethical issues, Protocol (science), Intervention (counseling), Attachment theory, Patient safety, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7129297531\",\"openalex_url\":\"https://openalex.org/W7129297531\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W572836215\",\"https://openalex.org/W1628654790\",\"https://openalex.org/W1973933342\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2000909913\",\"https://openalex.org/W2028348095\",\"https://openalex.org/W2037317432\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2086825438\",\"https://openalex.org/W2091063737\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121291806\",\"https://openalex.org/W2129660502\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2582692487\",\"https://openalex.org/W2588779606\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2790381919\",\"https://openalex.org/W2793930179\",\"https://openalex.org/W2797335301\",\"https://openalex.org/W2944434778\",\"https://openalex.org/W2950844909\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2969964941\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3035524447\",\"https://openalex.org/W3111336391\",\"https://openalex.org/W3122951191\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3159976828\",\"https://openalex.org/W3164217764\",\"https://openalex.org/W3166553838\",\"https://openalex.org/W3181638694\",\"https://openalex.org/W3200610329\",\"https://openalex.org/W4220875482\",\"https://openalex.org/W4230864812\",\"https://openalex.org/W4317469231\",\"https://openalex.org/W4381282948\",\"https://openalex.org/W4388822593\",\"https://openalex.org/W4396893361\",\"https://openalex.org/W4406240577\",\"https://openalex.org/W4406325139\"],\"authorships\":[{\"id\":\"https://openalex.org/A5126262758\",\"display_name\":\"Rachel Ham\",\"orcid\":null},{\"id\":\"https://openalex.org/A5126246054\",\"display_name\":\"John Gardner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5126197792\",\"display_name\":\"Adrian Carter\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030212190\",\"display_name\":\"Paul Liknaitzky\",\"orcid\":\"https://orcid.org/0000-0001-5690-2263\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764450051\",\"source_display_name\":\"Brain and Behavior\",\"landing_page_url\":\"https://doi.org/10.1002/brb3.71262\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Emotional Processing,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7129297531" }, { "id": 1989, "title": "PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION", "normalized_title": "psilocybin in psychiatric practice and psychedelic assisted therapy for treatment resistant depression", "authors": "Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska", "abstract": "This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing from systematic reviews, meta-analyses, and clinical trials identified through targeted database searches. Key findings indicate that psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects, with high response and remission rates, often after one or two sessions. Its safety profile is generally favorable, with transient and mild adverse events. Mechanistically, psilocybin primarily acts on serotonin 5-HT2A receptors, modulating brain networks and enhancing neuroplasticity. However, significant challenges exist in terms of high costs, limited accessibility due to the intensive therapeutic model, and regulatory hurdles. In conclusion, psilocybin-assisted therapy offers a promising alternative for depression, particularly where standard treatments fail, by providing rapid and durable symptom reduction through unique neurobiological pathways. Future research should focus on optimizing treatment protocols, exploring long-term outcomes, identifying predictors of response, and addressing systemic barriers to accessibility and cost-effectiveness to facilitate its integration into broader mental healthcare.", "journal": "International Journal of Innovative Technologies in Social Science", "publication_date": "2026-01-27", "publication_year": 2026, "doi": "10.31435/ijitss.1(49).2026.4711", "pubmed_id": null, "source_url": "https://doi.org/10.31435/ijitss.1(49).2026.4711", "keywords": "Psilocybin, Antidepressant, Psychiatry, Major depressive disorder, Depression (economics), Medicine, Adverse effect, Psychotherapist, Narrative review, Clinical trial, Psychology, Treatment-resistant depression, Clinical Practice, Ketamine, MEDLINE, Systematic review, Clinical psychology, Electroconvulsive therapy, Mental health, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7125929049\",\"openalex_url\":\"https://openalex.org/W7125929049\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2030224179\",\"https://openalex.org/W2062101624\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2996555671\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3192281797\",\"https://openalex.org/W3203928800\",\"https://openalex.org/W3209277823\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4281666404\",\"https://openalex.org/W4291227674\",\"https://openalex.org/W4297478109\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4379095570\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4386420994\",\"https://openalex.org/W4386894189\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4388447053\",\"https://openalex.org/W4388732506\",\"https://openalex.org/W4389392873\",\"https://openalex.org/W4389868195\",\"https://openalex.org/W4390753253\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4391842082\",\"https://openalex.org/W4393253405\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396814296\",\"https://openalex.org/W4396900907\",\"https://openalex.org/W4398780811\",\"https://openalex.org/W4399323719\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4400099913\",\"https://openalex.org/W4400335852\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4402748917\",\"https://openalex.org/W4403113128\",\"https://openalex.org/W4403775020\",\"https://openalex.org/W4404764894\",\"https://openalex.org/W4404930798\",\"https://openalex.org/W4409528946\",\"https://openalex.org/W4413817374\"],\"authorships\":[{\"id\":\"https://openalex.org/A5122407127\",\"display_name\":\"Łukasz Deska\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122670377\",\"display_name\":\"Cezary Kosmecki\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121581785\",\"display_name\":\"Dawid Głaz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124103319\",\"display_name\":\"Natalia Kamińska\",\"orcid\":null},{\"id\":\"https://openalex.org/A5057447553\",\"display_name\":\"Wojciech Sołtys\",\"orcid\":\"https://orcid.org/0009-0008-7052-7058\"},{\"id\":\"https://openalex.org/A5124074784\",\"display_name\":\"Magdalena Stolarczyk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121597028\",\"display_name\":\"Maksymilian Głaz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121545950\",\"display_name\":\"Mateusz Stronczyński\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121599306\",\"display_name\":\"Aleksandra Jagura-Sukiennik\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093377457\",\"display_name\":\"Julia Wawerska\",\"orcid\":\"https://orcid.org/0009-0006-0145-6204\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210206754\",\"source_display_name\":\"International Journal of Innovative Technologies in Social Science\",\"landing_page_url\":\"https://doi.org/10.31435/ijitss.1(49).2026.4711\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7125929049" }, { "id": 3502, "title": "PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial", "normalized_title": "psilocybin microdose for psychological and existential distress in palliative care psyched pal a multi site phase 3 double blind placebo controlled parallel arm clinical trial", "authors": "Bruyère Health Research Institute.", "abstract": "About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. We need treatments that work well, quickly, and can be available to all patients with advanced illness who have psychological distress. Psilocybin, a psychedelic medication (commonly called 'magic mushrooms') works well for improving psychological distress in people with cancer or chronic illness when given in high doses with specific forms of therapy. However, psilocybin has not been well-studied among people with advanced illness, and there are concerns about safety and side effects in people approaching the end of life. However, reports on psilocybin microdosing, which involves taking small doses that do not cause hallucinations and do not require therapy, suggest that this may be effective, safer, and more acceptable for people with advanced illness. We recently completed a small study of psilocybin microdosing. Our results showed psilocybin microdose improved psychological distress in most participants with advanced illness, without serious side effects. Our next step is to do a randomized clinical trial where some patients receive psilocybin microdose and some receive placebo (a drug that contains no medicinal ingredients). By comparing these two groups, we can remove the possibility that improvements in symptoms are only because patients thought they were getting treatment. We will enroll 120 patients from inpatient, outpatient, and community care settings across seven sites. Participants in the microdose psilocybin group will receive 2 or 3 mg of psilocybin daily, 4 days per week, for two consecutive weeks. The placebo group will receive placebo with the same treatment schedule. All participants will be offered microdose psilocybin after 2-week follow-up. If this study is successful, we have the potential to change how psychological distress is managed in patients with advanced illness. Patients with advanced illness report feeling a sense of hopelessness, loss of autonomy and relationships, and a lack of purpose in life. These feelings of psychological suffering have been described as \"existential distress\" and are associated with poor outcomes, including decreased medication adherence and quality of life, increased desire for hastened death and rates of suicide, and has been identified as a primary reason why individuals pursue medical assistance in dying (MAiD). Current treatments for psychological and existential suffering have low efficacy and are challenging to use in a palliative context. Pharmacological approaches for treating psychological suffering may reduce symptoms of depression and anxiety, but evidence to support their efficacy in palliative care (PC) is underwhelming. Antidepressant and anxiolytic medications also take time to work and can cause serious side effects such as falls and confusion, which can be substantial deterrents for patients. Similarly, results from randomized controlled trials (RCTs) and meta-analyses have demonstrated psychotherapeutic interventions show limited benefit in a PC population. Further, psychotherapy can be time consuming and slow to work, which is not ideal for patients with limited life expectancy. Given the burden of psychological and existential distress among patients followed by PC providers, there is a need to develop scalable, brief, and rapidly effective therapeutic approaches to reduce this distress. Psychedelic medications offer an innovative, safe, complementary approach to address psychological and existential suffering in patients receiving PC. Studies from the 1950's showed serotonergic hallucinogens (\"psychedelics\") improved depression and anxiety symptoms in cancer patients. However, legislative changes restricted the use of these medications in clinical care and research. Interest in psychedelic medications has been rekindled by two recently published RCTs that studied the use of psilocybin (a mushroom-derived 5HT2A agonist) during a single psychotherapeutic session in cancer patients with anxiety and/or depression. These trials demonstrated rapid, clinically meaningful, and long-lasting reductions in depressed mood and/or anxiety symptoms and improvements in quality of life and death acceptance. Although the exact mechanism by which psilocybin affects mood symptoms is unclear, functional MRI studies of the brain show psilocybin disrupts the functional connectivity between anterior hippocampus (involved in memory and anticipation of future events) and the default mode network (associated with anhedonia and rumination on negative themes). There is also evidence suggesting psilocybin microdosing - taking sub-hallucinogenic doses continuously over longer time periods, rather than a one-time hallucinogenic dose - can improve mood and anxiety. The effects of microdosing, however, have not been rigorously evaluated, particularly in patients with life limiting illness. Results from recent trials are encouraging but knowledge gaps remain. First, studies to date primarily enrolled patients with localized disease who experience different distress than that of patients with advanced disease who are near the end of life. Second, it is unclear if Canadians would find psilocybin an attractive option in the context of MAiD legalization, which provides an alternative option for patients with severe psychological suffering. Third, there is no empirical research on the therapeutic effects of psilocybin microdosing, as most studies have followed macrodosing protocols. While preliminary efficacy of macrodosing has been demonstrated, there are important barriers to administering this therapy in a PC context. Previous trials had slow recruitment rates, suggesting there may be barriers related to the acceptability of psilocybin macrodosing from the perspectives of patients and families. Macrodosing requires the patient to dedicate an entire day to participating in a guided hallucinogenic experience and remain in an acute care setting where they can be closely monitored. It also requires patients to engage in preparatory sessions with monitors and a post-therapy session. In a PC context, this time commitment may not be acceptable or feasible for patients who are nearing the end of life. Macrodosing requires at least two trained moderators to guide the patient through their psychedelic experience and facilitate the pre- and post-dosing sessions. In most PC settings, it is not feasible to have clinicians dedicate two days to a single patient, thus limiting the scalability of this intervention. Anecdotally, concerns about the safety of high-dose psilocybin in the terminally ill, as well as access to psychotherapy, may also be substantial barriers in this population. Moreover, randomized trials of psychedelic medications are methodologically challenging because patients cannot be blinded to having a psychedelic experience. This \"functional unblinding\" was one major reason why the US FDA chose not to approve psychedelic medication for the treatment of post-traumatic stress disorder in August 2024, despite strongly positive trial results. Psilocybin microdosing may be safer and more feasible than psilocybin macrodosing in palliative setting. Psychedelic microdosing involves taking 5-10% of a psychedelic dose of a substance such as psilocybin on a regular basis (daily or several times per week). It does not produce a psychedelic experience, nor does it involve psychotherapy, but large surveys and anecdotal reports suggest that microdosing produces substantial and sustained improvements in mood and anxiety symptoms without any important side effects. By removing the requirement for trained moderators, minimizing the time commitment required of patients, eliminating the hallucinogenic effects of the therapy, and allowing patients to receive treatment either as an inpatient or in the community, microdosing may be a more acceptable option to patients and families and allow psychedelic therapy to be scalable across various PC settings. We have completed a phase 2 dose-finding and proof of concept study for microdosing psilocybin in people with advanced illness receiving PC. Using progressively increasing microdoses of psilocybin over a 3-week period (from 1 mg to 3 mg daily), we found that a large proportion of participants experienced dramatic improvements in their psychological distress, with minimal side effects. This effect was durable after stopping the medication but diminished after 4 weeks. Given the encouraging findings from our phase 2 study, and the potential feasibility, scalability, and safety of psilocybin microdosing for a population with few effective options, proceeding to a phase 3 placebo-controlled trial is warranted. Objectives Primary Objectives: To determine the efficacy of microdose psilocybin for improving psychological distress among patients with advanced illness followed by a palliative care provider. Secondary Objectives: 1. Assess whether microdose psilocybin improves quality of life and desire to die among patients with advanced illness followed by a palliative care provider. 2. Determine the safety of long-term (up to 1 year) use of psilocybin microdose to treat psychological distress among patients with advanced illness followed by a palliative care provider. Open-Label Access and Extension Phase Following the primary study 2-week follow-up completion, all participants will have the option to participate in an open-label access phase. In this phase, participants will be offered open-label psilocybin for two consecutive weeks (same dosing and schedule as the primary study). Two weeks after the access phase has been completed, all participants will have the option to participate in the open-label extension period for up to 1 year. The open-label extension will follow a three-week dosing cycle, where all participants will take psilocybin microdoses for two consecutive weeks, and then no doses on the third week, before starting the cycle again. The open-label and open-label extension phase include safety and primary and secondary outcomes (see Outcome Measures), in line with the primary study protocol. Sample Size We require a sample size of 60 patients per arm (120 patients in total). This assumes a 20% loss to attrition/deterioration and 10% withdrawal (based on our phase 2 study). This sample would have 80% power to detect a change of 0.30 from 30% PGIC response (control) to 60% PGIC response (intervention) at last treatment day, corresponding to an effect size (Cohen's d) of 0.61. Statistical Analysis We will follow an intent-to-treat approach. We will use chi-square tests to compare the proportion of participants in the microdose psilocybin vs. placebo arm with a PGIC score of ≥5 at the last day of treatment and at 2-week follow-up, and to compare the proportion of participants who demonstrate a minimal clinically important difference (MCID) in secondary efficacy outcomes. To minimize type I error, a correction will be performed on the multiple secondary endpoint analyses. Safety and feasibility outcomes will be analyzed using descriptive statistics with 95% confidence intervals.", "journal": "ClinicalTrials.gov", "publication_date": "2026-01-26", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07063862", "keywords": "Psychological Distress, Psilocybin, Placebo, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07063862\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Anxiety,PTSD,End-of-Life Distress,Receptor Pharmacology,Default Mode Network,Aging,Microdosing,Clinical Trial,Randomized Controlled Trial,Observational Study,Cancer Patients,Healthcare Workers,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4100, "title": "The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence", "normalized_title": "the therapeutic efficacy of psilocybin in major depressive disorder a review of recent clinical and mechanistic evidence", "authors": "Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker, Olger Herrera Barboza, David Diaz Polo, Daniela Consumi Cordero", "abstract": "This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analyses, and mechanistic research. A comprehensive literature search across major scientific databases identified empirical studies evaluating psilocybin’s effects on depressive symptomatology, safety, and underlying neurobiological mechanisms. Psilocybin’s primary pharmacological action as a 5-HT2A receptor agonist leads to alterations in brain connectivity, particularly within networks associated with self-referential processing and emotional regulation. These receptor-level effects are accompanied by neuroplastic changes, including enhanced synaptogenesis and functional reorganization, which contribute to the rapid and sustained antidepressant outcomes observed in clinical settings. Neuroimaging studies further support these mechanisms by demonstrating reductions in amygdala activity and modifications within default mode and executive networks following administration. Clinical evidence consistently indicates that psilocybin produces substantial reductions in depressive symptoms, with meta-analyses reporting large effect sizes and durable benefits lasting from several weeks to as long as one year. Randomized controlled trials highlight its rapid onset of action, with remission rates notably higher than those achieved with conventional treatments, including in populations with treatment-resistant depression. Open-label studies reinforce the durability of these effects and emphasize the essential role of psychotherapeutic support in optimizing therapeutic outcomes. Across studies, psilocybin demonstrates a favorable safety profile, with adverse events being mild, transient, and predictable. Despite these promising findings, methodological limitations such as small sample sizes, high heterogeneity, and variability in treatment protocols underscore the need for larger, standardized Phase III trials. Future research should also include direct comparisons with established antidepressants and efforts to identify biomarkers that may guide personalized treatment approaches.", "journal": "Zenodo (CERN European Organization for Nuclear Research)", "publication_date": "2026-01-25", "publication_year": 2026, "doi": "10.5281/zenodo.18375715", "pubmed_id": null, "source_url": "https://doi.org/10.5281/zenodo.18375715", "keywords": "Psilocybin, Antidepressant, Neuroimaging, Psychology, Default mode network, Major depressive disorder, Clinical trial, Adverse effect, Amygdala, Clinical psychology, Functional neuroimaging, Neuroscience, Medicine, Hallucinogen, Neuroplasticity, Psychiatry, Randomized controlled trial, Depressive symptoms, Depression (economics), Psychotherapist, MEDLINE, Disengagement theory, Clinical Practice, Animal studies, Mechanism (biology), Synaptogenesis, Cognition, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:36", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7125699554\",\"openalex_url\":\"https://openalex.org/W7125699554\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5044911442\",\"display_name\":\"Fernando Mora López\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123855282\",\"display_name\":\"Johynny Solís Solís\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123879550\",\"display_name\":\"Ekaterina Daniela Hernández Baker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123829836\",\"display_name\":\"Olger Herrera Barboza\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123850173\",\"display_name\":\"David Diaz Polo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123876686\",\"display_name\":\"Daniela Consumi Cordero\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.18375715\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Biomarkers,Aging,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7125699554" }, { "id": 1991, "title": "The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression", "normalized_title": "the evaluation of the efficacy and safety of the use of psilocybin in the treatment of adults with treatment resistant depression", "authors": "Rishika Scott, James Smith", "abstract": "Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. The review will also compare selective serotonin reuptake inhibitors (SSRIs) with psychotherapy to draw conclusions and recommendations of psilocybin therapy to improve day-to-day living for affected patients. PubMed and the University of Portsmouth Discovery online database (EBSCOhost) were individually utilised from December 2024 to March 2025. Five open-label studies and 2 randomised controlled trials (RCTs) were selected to assess psilocybin efficacy and safety. Appraisal checklists along with search criteria were used to determine eligibility and reliability of these data. The random-effects meta-analyses demonstrated that psilocybin at 25 mg within specific integrated sessions was effective at treating TRD compared to 10 mg and 1 mg by comparing clinical trials between two doses and single doses. Psilocybin at 25 mg was found to significantly reduce patients’ depressive severity compared to the baseline, which was prevalent in the two-dose studies (n = 5) compared to the single-dose studies (n = 2), due to the number of studies produced. The overall evidence suggests that psilocybin is an effective therapeutic for treatment-resistant depression, with a dosage unit of 25 mg administered as a single capsule per dosing session, with one dose per clinical session. Limitations to the evidence and this review have affected the overall results; therefore, more relevant studies are needed.", "journal": "Emerging Minds Journal for Student Research", "publication_date": "2026-01-24", "publication_year": 2026, "doi": "10.59973/emjsr.317", "pubmed_id": null, "source_url": "https://doi.org/10.59973/emjsr.317", "keywords": "Psilocybin, Dosing, Medicine, Depression (economics), Psychiatry, Clinical trial, Hallucinogen, Pharmacology, Randomized controlled trial, MEDLINE, Treatment-resistant depression, Psychology, Evidence-based medicine, Major depressive disorder, Therapeutic effect, Systematic review, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7125652025\",\"openalex_url\":\"https://openalex.org/W7125652025\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5123818412\",\"display_name\":\"Rishika Scott\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123804606\",\"display_name\":\"James Smith\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387290763\",\"source_display_name\":\"Emerging Minds Journal for Student Research\",\"landing_page_url\":\"https://doi.org/10.59973/emjsr.317\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Pharmacology,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7125652025" }, { "id": 3673, "title": "A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment", "normalized_title": "a phase 2 trial of psilocybin as an adjunctive treatment for oud patients who continue to use illicit opioids despite adherence to methadone treatment", "authors": "NYU Langone Health", "abstract": "This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-care treatment with methadone. Up to 480 participations will be consented to yield 240 randomized participants. This study is part of the NIH HEAL Initiative (https://heal.nih.gov/). In Stage 1, subjects will be randomly assigned to one of three groups: psilocybin 30 mg (high dose), psilocybin 20 mg (medium dose), and psilocybin 1 mg (control condition). By the end of Stage 1, an interim statistical analysis will be performed. The study will proceed to Stage 2 if at least one of the active dosages of psilocybin demonstrates 1) acceptable safety, based on analysis of safety data from Stage 1; and 2) conditional power of at least 25%, based on effect size estimates for the primary opioid use outcome (weeks of biologically-verified abstinence during 24 weeks of follow-up). Using a priori decision rules, the interim analysis will determine which of the active treatment groups (30 mg, 20 mg, or both) will be retained in Stage 2 of the trial. Stage 2 will continue the study, using the same treatment and assessment protocols, but retaining only the active dosage or dosages with a high probability of demonstrating efficacy relative to the psilocybin 1 mg control condition. The primary aims are to 1) Evaluate safety and efficacy outcomes in Stage 1 subjects in order to optimize design of the Stage 2, 2) Determine whether treatment with a single high (30 mg) or medium (20 mg) dose of psilocybin improves OUD treatment outcomes, relative to psilocybin 1 mg (control condition), in patients who continue to use illicit opioids despite adherence to methadone treatment, 3) Evaluate the effects of high-dose psilocybin and medium dose psilocybin on self-reported OUD-related neuropsychopathology, and 4) Identify likely responders to psilocybin treatment by using machine learning to model post-treatment OUD outcomes, based on pretreatment characteristics including all relevant clinical data, evaluations, and questionnaires.", "journal": "ClinicalTrials.gov", "publication_date": "2026-01-22", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06796062", "keywords": "Opioid Use Disorder, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06796062\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1992, "title": "THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS", "normalized_title": "the psychedelic renaissance a systematic review of psilocybin and lsd in the treatment of psychiatric disorders", "authors": "Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska", "abstract": "The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called \"Psychedelic Renaissance,\" focusing on the clinical resurgence of classical serotonergic hallucinogens: psilocybin and Lysergic Acid Diethylamide (LSD). The review adopts an interdisciplinary structure to evaluate the efficacy, safety, and societal implications of these compounds. Firstly, the paper traces the historical evolution of psychedelics from indigenous sacramental use, through the research proliferation of the 1950s, to the prohibitive legislation of the late 20th century. Secondly, it delineates the neurobiological mechanisms of action, specifically 5-HT2A receptor agonism and the disintegration of the Default Mode Network (DMN), which correlates with the alleviation of rigid cognitive patterns in depression and anxiety. Thirdly, the review synthesizes data from contemporary clinical trials demonstrating significant therapeutic potential in Treatment-Resistant Depression (TRD), end-of-life existential distress, and substance use disorders. Unlike standard pharmacological reviews, this paper also analyzes the distinct psychotherapeutic framework (\"set and setting\"), integration processes, and socio-economic factors, including cost-effectiveness and access equity. The findings suggest that psychedelic-assisted therapy represents a transformative shift from chronic symptom management to rapid, episodic curative interventions, provided that regulatory and ethical challenges are adequately addressed.", "journal": "International Journal of Innovative Technologies in Social Science", "publication_date": "2026-01-22", "publication_year": 2026, "doi": "10.31435/ijitss.1(49).2026.4582", "pubmed_id": null, "source_url": "https://doi.org/10.31435/ijitss.1(49).2026.4582", "keywords": "Psilocybin, Hallucinogen, Psychotherapist, Psychology, Psychiatry, Monoaminergic, Serotonergic, Transformative learning, Medicine, Mental health, Modalities, Clinical trial, Depression (economics), Lysergic acid diethylamide, Cognition, Addiction, Default mode network, Clinical psychology, Transpersonal, Mental illness, Legislation, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7127606273\",\"openalex_url\":\"https://openalex.org/W7127606273\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1144621943\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2098923148\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2552761136\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2581696375\",\"https://openalex.org/W2607844825\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2759174152\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2911514809\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3093269897\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4214940428\",\"https://openalex.org/W4283075222\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4308146113\"],\"authorships\":[{\"id\":\"https://openalex.org/A5124045804\",\"display_name\":\"Jakub Klepacz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123925115\",\"display_name\":\"Radosław Swędrak\",\"orcid\":null},{\"id\":\"https://openalex.org/A5125010452\",\"display_name\":\"Marzena Swojnóg\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124022275\",\"display_name\":\"Zuzanna Dobrakowska\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210206754\",\"source_display_name\":\"International Journal of Innovative Technologies in Social Science\",\"landing_page_url\":\"https://doi.org/10.31435/ijitss.1(49).2026.4582\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Chronic Pain,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Clinical Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7127606273" }, { "id": 196, "title": "Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin", "normalized_title": "consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving mdma and psilocybin", "authors": "Marija Franka Žuljević, Antonija Mijatović, Renata Orhanović, Glenn Goasdoué, Diana Gujinović", "abstract": "", "journal": "Journal of Clinical Epidemiology", "publication_date": "2026-01-22", "publication_year": 2026, "doi": "10.1016/j.jclinepi.2026.112170", "pubmed_id": "41581835", "source_url": "https://doi.org/10.1016/j.jclinepi.2026.112170", "keywords": "Psilocybin, MDMA, Credibility, Medicine, Protocol (science), Psychological intervention, Clinical trial, Transparency (behavior), Consistency (knowledge bases), Checklist, Reporting bias, Documentation, Psychiatry, MEDLINE, Protocol design, Mephedrone, Consolidated Standards of Reporting Trials, Alternative medicine, Hallucinogen, Clinical pharmacology, Comparability, Stakeholder, Medical emergency, Stakeholder engagement, Research design, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7125471543\",\"openalex_url\":\"https://openalex.org/W7125471543\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1993595811\",\"https://openalex.org/W2022936635\",\"https://openalex.org/W2035759032\",\"https://openalex.org/W2043658255\",\"https://openalex.org/W2067330083\",\"https://openalex.org/W2125346676\",\"https://openalex.org/W2321045434\",\"https://openalex.org/W2424135425\",\"https://openalex.org/W2519918803\",\"https://openalex.org/W2749043159\",\"https://openalex.org/W2792588201\",\"https://openalex.org/W2972150870\",\"https://openalex.org/W2982152979\",\"https://openalex.org/W3003581149\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3041972496\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W3195478505\",\"https://openalex.org/W4220795497\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4289597870\",\"https://openalex.org/W4292229870\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4307987398\",\"https://openalex.org/W4387793665\",\"https://openalex.org/W4388686851\",\"https://openalex.org/W4394684735\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4395034174\",\"https://openalex.org/W4396223530\",\"https://openalex.org/W4398780811\",\"https://openalex.org/W4401244642\",\"https://openalex.org/W4401512431\",\"https://openalex.org/W4403463774\",\"https://openalex.org/W4408107853\"],\"authorships\":[{\"id\":\"https://openalex.org/A5027013788\",\"display_name\":\"Marija Franka Žuljević\",\"orcid\":\"https://orcid.org/0000-0001-9805-7491\"},{\"id\":\"https://openalex.org/A5045974436\",\"display_name\":\"Antonija Mijatović\",\"orcid\":\"https://orcid.org/0000-0003-1733-582X\"},{\"id\":\"https://openalex.org/A5119819715\",\"display_name\":\"Renata Orhanović\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119819716\",\"display_name\":\"Glenn Goasdoué\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119819717\",\"display_name\":\"Diana Gujinović\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S64418186\",\"source_display_name\":\"Journal of Clinical Epidemiology\",\"landing_page_url\":\"https://doi.org/10.1016/j.jclinepi.2026.112170\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7125471543" }, { "id": 4106, "title": "Does psilocybin help with mental health conditions?", "normalized_title": "does psilocybin help with mental health conditions", "authors": "Tripdatabase", "abstract": "Psilocybin therapy shows potential benefits for mental health conditions such as depression and substance use disorders, though further research is needed to confirm long-term safety and efficacy.", "journal": "Zenodo (CERN European Organization for Nuclear Research)", "publication_date": "2026-01-21", "publication_year": 2026, "doi": "10.5281/zenodo.18339283", "pubmed_id": null, "source_url": "https://doi.org/10.5281/zenodo.18339283", "keywords": "Psilocybin, Mental health, Psychiatry, Depression (economics), Psychology, Substance use, Medicine, Mental health care, Hallucinogen, Psychotherapist, Major depressive disorder, MEDLINE, Clinical psychology, Mental illness, Health care, Mental health service, Anxiety, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:36", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7125428177\",\"openalex_url\":\"https://openalex.org/W7125428177\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5123613984\",\"display_name\":\"Tripdatabase\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.18339283\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7125428177" }, { "id": 3703, "title": "The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma", "normalized_title": "the starlight protocol state funded trial assessing recovery and long term impact of guided psilocybin for healing trauma", "authors": "Baylor College of Medicine", "abstract": "The principal investigator for this study plans to build upon the psilocybin-assisted therapy intervention used in prior completed trials to conduct an open-label trial of two psilocybin administration sessions combined with psychotherapy to investigate the safety, tolerability, and clinical efficacy of psilocybin-assisted therapy for the treatment of PTSD in US Veterans.", "journal": "ClinicalTrials.gov", "publication_date": "2026-01-21", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06888128", "keywords": "PTSD, Psilocybin 15mg, Psilocybin 25mg, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06888128\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Veterans,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 141, "title": "Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts", "normalized_title": "insights into psilocybin use among people with bipolar disorder a thematic analysis of reddit posts", "authors": "Laura Mills, Susan L. Rossell, Sean Carruthers", "abstract": "Psilocybin has been reported to decrease depression symptoms among individuals with bipolar disorder (BD), but has also been associated with reports of mania, psychosis and increased depression. With increasing recreational use of psilocybin, and the potential for psilocybin to be used as a treatment for depression, a better understanding of the risks and benefits of this psychedelic among individuals with BD is warranted. Individuals have used social media sites like Reddit to share their experiences with psilocybin, providing an opportunity to understand a range of perspectives and experiences. The current study aimed to further explore psilocybin experiences as shared on Reddit, with a focus on posts related to BD. A thematic analysis of Reddit posts and comments was undertaken, with a focus on those identified with search terms, \"bipolar\" AND \"psilocybin\" OR \"mushrooms\". A total of 354 comments with a first-hand psilocybin experience were identified and included in the thematic analysis which revealed four core themes: (1) mania, (2) depression, (3) mixed experiences, and (4) broader perspectives. Psilocybin was reported to have benefits in some comments, including reduced depression symptoms and shifts in perspective about oneself and/or the world. However, reports of increased or new mania and psychosis symptoms were also reported, as well as increased depression. While psilocybin may benefit some individuals with BD, there may be potential for increased mania, psychosis and depression symptoms. Understanding the factors that contribute positive and negative outcomes among individuals with BD will be important in future research.", "journal": "Journal of Affective Disorders", "publication_date": "2026-01-19", "publication_year": 2026, "doi": "10.1016/j.jad.2026.121220", "pubmed_id": "41571194", "source_url": "https://doi.org/10.1016/j.jad.2026.121220", "keywords": "Psilocybin, Thematic analysis, Psychology, Mania, Psychosis, Bipolar disorder, Psychiatry, Perspective (graphical), Clinical psychology, Hallucinogen, Depression (economics), Paranoia, Focus group, Psychotic depression, Psychotherapist, Schizophrenia (object-oriented programming), Mental health, Disconnection, Mental illness, Mood, Psychedelics and Drug Studies, Bipolar Disorder and Treatment, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7124978464\",\"openalex_url\":\"https://openalex.org/W7124978464\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1966185144\",\"https://openalex.org/W1995256288\",\"https://openalex.org/W2028825681\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W3158216155\",\"https://openalex.org/W3160183306\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W4220776312\",\"https://openalex.org/W4237330839\",\"https://openalex.org/W4249972766\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310598708\",\"https://openalex.org/W4311439362\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4324101362\",\"https://openalex.org/W4388014245\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4391264477\",\"https://openalex.org/W4392762192\",\"https://openalex.org/W4404345667\",\"https://openalex.org/W4416987269\"],\"authorships\":[{\"id\":\"https://openalex.org/A5123418380\",\"display_name\":\"Laura Mills\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073606057\",\"display_name\":\"Susan L. Rossell\",\"orcid\":\"https://orcid.org/0000-0002-7415-8252\"},{\"id\":\"https://openalex.org/A5046325936\",\"display_name\":\"Sean Carruthers\",\"orcid\":\"https://orcid.org/0000-0001-9140-3494\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S113871862\",\"source_display_name\":\"Journal of Affective Disorders\",\"landing_page_url\":\"https://doi.org/10.1016/j.jad.2026.121220\",\"is_oa\":true}}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7124978464" }, { "id": 1993, "title": "Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study", "normalized_title": "group retreat psilocybin therapy for people with metastatic cancer with symptoms of anxiety and depression safety and efficacy outcomes of a phase 1 2 study", "authors": "Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker, T. Gooley, Mendel Kaelen, Kalin Harvey, John M. Guy, Susanna Myers, Juliana Pérez, Peter Thompson, Lindsay Billingsley, Cheryl Sesnon", "abstract": "Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility criteria included metastatic cancer, moderate-to-severe symptoms of anxiety or depression without a pre-cancer mental health diagnosis, performance status adequate to attend a 3-day retreat that required self-care, and tapering of antidepressants. Exclusion criteria included enrollment in hospice. The design of the intervention included: two virtual preparatory sessions; a 3-day in-person retreat in a rustic setting that included the third prep session, the psilocybin session, and the first integration session; and two additional virtual integration sessions. Psilocybin was administered in oral capsules at 25 mg. A retreat team of four core facilitators and two backup facilitators conducted a series of eight retreats. The first retreat had five participants. For subsequent retreats, we used the primary safety outcome from each cohort, other safety outcomes, and qualitative feedback to make decisions to increase, decrease, or hold steady the participant number. The primary safety outcome was “unattended episodes of participant distress” during the psilocybin session requiring a backup facilitator. The primary exploratory efficacy outcome was reduction in anxiety and depression symptoms measured using the Hospital Anxiety and Depression Scale (HADS). Results: We enrolled 55 participants, of whom 3 withdrew prior to the retreat, leaving a total of 52. Their mean age was 53, and mean duration of living with cancer was 36 months, mean (range 5, 176); anticancer therapy was ongoing for 46 (88%); antidepressants were tapered for 18 (35%). The first retreat cohort had five participants, and the final retreat cohort had eight. For the primary safety outcome, there was not a single episode of unattended participant distress requiring a backup facilitator. The mean baseline at Day −14 (D −14) HADS total score was 17.5 (range 6-28); at D +28, the mean HADS total score was 10.2 (1-30), so the mean decrease in HADS from D −14 to D +28 was 7.3. ( p < 0.0001). Conclusion: The Group Retreat Psilocybin Therapy was safe and well tolerated, and exploratory measures show efficacy that is promising. A group configuration of eight participants with four core facilitators can be safe for future studies with participants with serious medical illness.", "journal": "Psychedelic Medicine", "publication_date": "2026-01-17", "publication_year": 2026, "doi": "10.1177/28314425251413856", "pubmed_id": null, "source_url": "https://doi.org/10.1177/28314425251413856", "keywords": "Psilocybin, Anxiety, Medicine, Depression (economics), Psychiatry, Cancer, Mental health, Discontinuation, Hospital Anxiety and Depression Scale, Clinical psychology, Intervention (counseling), Adverse effect, Physical therapy, Distress, Randomized controlled trial, Psychological intervention, Exploratory research, Psychology, Clinical trial, Anxiety disorder, Qualitative research, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7124682544\",\"openalex_url\":\"https://openalex.org/W7124682544\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1537416593\",\"https://openalex.org/W1564241828\",\"https://openalex.org/W1977733462\",\"https://openalex.org/W1992514016\",\"https://openalex.org/W2058150514\",\"https://openalex.org/W2078836440\",\"https://openalex.org/W2105258029\",\"https://openalex.org/W2128868698\",\"https://openalex.org/W2153303099\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166281097\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2350952069\",\"https://openalex.org/W2408203670\",\"https://openalex.org/W2430893194\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2803238382\",\"https://openalex.org/W2904473517\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W4251745849\",\"https://openalex.org/W4312196530\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4366448658\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4396720923\",\"https://openalex.org/W4402354248\",\"https://openalex.org/W4409687565\",\"https://openalex.org/W4409797469\"],\"authorships\":[{\"id\":\"https://openalex.org/A5071781938\",\"display_name\":\"Anthony L. Back\",\"orcid\":\"https://orcid.org/0000-0002-7903-0477\"},{\"id\":\"https://openalex.org/A5030340063\",\"display_name\":\"Bonnie A. McGregor\",\"orcid\":\"https://orcid.org/0000-0003-0531-9347\"},{\"id\":\"https://openalex.org/A5096909520\",\"display_name\":\"Leslie Lazar Thorn\",\"orcid\":null},{\"id\":\"https://openalex.org/A5041041464\",\"display_name\":\"Kelsey K. Baker\",\"orcid\":\"https://orcid.org/0000-0002-8062-8839\"},{\"id\":\"https://openalex.org/A5018824299\",\"display_name\":\"T. Gooley\",\"orcid\":null},{\"id\":null,\"display_name\":\"Mendel Kaelen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5075648744\",\"display_name\":\"Kalin Harvey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123327116\",\"display_name\":\"John M. Guy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113200747\",\"display_name\":\"Susanna Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104052443\",\"display_name\":\"Juliana Pérez\",\"orcid\":null},{\"id\":null,\"display_name\":\"Peter Thompson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121110928\",\"display_name\":\"Lindsay Billingsley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123319675\",\"display_name\":\"Cheryl Sesnon\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/28314425251413856\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Observational Study,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7124682544" }, { "id": 3029, "title": "Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial", "normalized_title": "psilocybin for treatment resistant ocd a randomized controlled trial", "authors": "", "abstract": "Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD. Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with treatment-resistant OCD to receive a single dose of psilocybin (0.25 mg/kg; n=14) or niacin (250 mg; n=14), in a supportive controlled setting. Primary outcomes were Acute Yale-Brown Obsessive-Compulsive Scale (A-YBOCS) from baseline to 48 hours post-treatment and weekly Y-BOCS assessments through 12 weeks. Secondary outcomes included depression symptoms (MADRS) and functional disability (SDS). All participants initially assigned to niacin crossed over to open-label psilocybin after 1 week. Results: At 48 hours, A-YBOCS scores decreased from 24.07±6.02 to 14.31±8.83 in the psilocybin group versus no change (24.29±4.81 to 24.36±3.95) in the niacin group (between-group difference, 9.83 points; 95% CI, 5.19-14.91; P", "journal": "PsyArXiv", "publication_date": "2026-01-14", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/atfum_v1", "keywords": "Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"atfum_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,OCD,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 184, "title": "The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?", "normalized_title": "the psychological support model in psilocybin research psychotherapy in disguise", "authors": "Celia Faye Jacobsen, Dea Siggaard Stenbæk, Stig Poulsen, Sophia Armand", "abstract": "A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing session is combined with bona fide psychotherapy or with what is referred to as “psychological support” (1-3). The most developed model of psychological support is the Compass Psychological Support Model (CPSM; 1). Kirlić and colleagues specifically describe the CPSM as “not an evidence-based treatment for depression” (1, p. 127). In our work as psychologists, we apply distinct understandings of psychotherapy. The European Federation of Psychologists' Association (EFPA) employ the following definition: “Psychotherapy is the informed and intentional application of clinical methods and interpersonal stances derived from established psychological principles for the purpose of assisting people to modify their behaviors, cognitions, and emotions, (…) in directions that the participants deem desirable” (4, p. 218). When observing the CPSM through the lens of this definition, the psychological support model appears, to us, to be a distinctly psychotherapeutic treatment model. The CPSM consists of two components, psychoeducation and psychological support, and is delivered in three phases: the preparation phase, the administration phase, and the integration phase (1). The psychoeducation component consists of psychoeducation on the psychedelic experience, whereas the psychological support component aims to facilitate the optimal emotional valence in the client during especially the administration and integration phase, their engagement with the psychedelic experience, and their subsequent exploration of salient themes with the goal of generating insight and self-discovery. Three principles further guide the psychological support component, namely trust and psychological safety, a present-moment focus, and the client's self-direction and autonomy. Delving into the specifics of the CPSM, the therapist's role in the psychoeducation component is, for example, to “explore and manage expectations,” “generate trust,” and “set the stage for a collaborative preparation process” (p. 127). These therapist tasks closely correspond to the management of client expectations and alliance development, which are considered key therapeutic factors in psychotherapy (5, 6). Particularly invoking positive outcome expectations and establishing a trusting and collaborative client-therapist alliance have demonstrated robust associations with improved clinical outcomes in psychotherapy (7-10), and all bona fide psychotherapy models encompass these factors in varying degrees and format (11). Accordingly, these tasks correspond to the EFPA's definition of psychotherapy in that they involve “the application of clinical methods and interpersonal stances derived from established psychological principles.” Moreover, the three principles in the CPSM, trust and psychological safety, present-moment focus, and self-direction and autonomy, closely align with the therapeutic skills, tasks, and style emphasized in humanistic-experiential psychotherapy (12), for example, in client-centered (13) or emotion-focused psychotherapy (EFT; 14, 15). Specifically, trust and psychological safety are established in the CPSM by the therapist showing “genuine interest, empathy, and unconditional positive regard (…)” (1, p. 128). The wording of these skills appears directly transferred from the humanistic-experiential models of psychotherapy, where “empathy, unconditional positive regard, and genuineness” constitute the foundation of a curative client-therapist alliance (13). Moreover, one of the goals pertaining to the principle of trust and psychological safety in the CPSM is to “eventually address unhelpful cognitive, emotional, or behavioral patterns” (1, p. 128). This goal directly speaks to the purpose of psychotherapy as defined by the EFPA, that is, assisting people to modify their behaviors, cognitions, and emotions in more desirable directions (4). The present-moment focus in the CPSM is meant to counteract experiential avoidance and prompt emotional breakthroughs in the client, and the therapists are trained to ask open-ended questions to facilitate the client's exploration and encourage their acceptance and curiosity about especially challenging emotions (1). This CPSM principle appears closely aligned with the tasks and goals of especially EFT (14). Specifically, EFT utilizes methods meant to stimulate and deepen (i.e., focus) emotional experiencing and promotes the client's internal exploration in order to facilitate the processing and expression of emotional material (14). Emotional expression in psychotherapy has been robustly linked to improved clinical outcomes (d = 0.85; 16), and conversely, experiential avoidance to worse treatment and mental health outcomes (17, 18). EFT, and more recent Cognitive-Behavioral Therapy approaches such as Acceptance and Commitment Therapy (16), specifically target experiential avoidance and promote emotional expression. Finally, the self-direction and autonomy principle centers on a non-directive therapeutic style, a style which is a point of contention within the humanistic-experiential psychotherapies (12). Whereas client-centered psychotherapy makes use of a primarily non-directive style, EFT prescribes a “process guiding” approach and employs more directive techniques (14). In this regard, the CPSM aligns best with person-centered psychotherapy. However, the therapist's use of breathing exercises and verbal cues to prompt emotional grounding and deepening during the administration session in the CPSM (e.g., “be open,” “go in and through”; 1) could be considered a subtle act of therapist direction and a therapeutic technique in its own right. Considering EFPA's definition of psychotherapy, alongside the tasks, goals, and therapeutic style described above, the CPSM constitutes, in our view, bona fide psychotherapy and more specifically a humanistic-experiential model of psychotherapy. Describing an arguably bona fide psychotherapeutic treatment as “psychological support” comes with a set of potentially problematic implications. For instance, arguing that the psychological framework serves only as “support” undermines methodological transparency and integrity in psilocybin research. Presenting the framework as merely supportive, and not therapeutic, may ease regulatory approval (e.g., by the FDA) by positioning psilocybin as the sole active ingredient. However, this assessment rests on an incomplete and potentially misleading foundation, as the contribution of the psychological framework to efficacy has yet to be fully examined. Moreover, characterizing the CPSM as “not evidence-based” reflects a lack of scientific rigor and nuance, given that the model's constituent methods and principles have demonstrated efficacy across broader clinical contexts and diagnostic categories, including within psilocybin treatments. For instance, research finds that a strong therapeutic alliance between the patient and the psychotherapist significantly improves clinical outcomes in psilocybin treatments (19-21). Moreover, experiential avoidance and prolonged hyperarousal, which the CPSM aims to mitigate, have been linked to worse outcomes (22). Finally, the CPSM's present-moment focus is intended to facilitate emotional breakthroughs, a strong predictor of better outcomes in psilocybin therapy (23). Thus, what are arguably psychotherapeutic components of the CPSM may significantly influence the effect of psilocybin treatment, and Kirlić et al. (1) themselves reference such findings. Accordingly, while direct research on the specific effects of the CPSM is still lacking, the efficacy of its constituent methods is largely supported. Framing the psychological components of psilocybin treatment as supportive and only serving a safety function, rather than contributors to efficacy, is inconsistent with research and risks oversimplifying the complexities of administering a potent pharmacological agent within a psychological framework. Finally, suggesting that trained psychologists deliberately follow an intervention designed to not exert a therapeutic effect goes against the integrity and training of our profession and will not translate into clinical reality. Not only does it leave the psychologist without guidelines on how to apply (or not apply) their expertise, it negates the “raison d'être” of our profession. Few trained psychologists will accept, or be capable of, complying with a specifically non-therapeutic intervention. Overall, negating the contribution of the psychological framework surrounding psilocybin dosing sessions, or treating it as error variance meant to be minimized, runs the risk of overlooking potentially vital variability in treatment outcomes. Moreover, it poses a threat to the integrity of psilocybin research and the psychological profession. Conversely, considering the psychological framework as a potential contributor to efficacy in psilocybin treatments might pave the way for its optimization. For instance, important client factors (e.g., outcome expectations or emotional expression; 7, 22, 24), therapist skills (e.g., facilitative interpersonal skills; 25) or interpersonal components (e.g., the alliance; 20) might be detected, facilitated, and trained. Such efforts would transparently support the integration of evidence-based psychotherapy practices with the pharmacological effects of psilocybin, ultimately enhancing clinical outcomes for patients. This scenario, however, may only be realized if the methodology and practical implementation of “psychological support” versus bona-fide psychotherapy is transparently defined, and the contribution of each framework to the efficacy of psilocybin is being researched and ultimately differentiated. Until then, the debate surrounding the role of the psychological framework will not be resolved.", "journal": "Psychiatric Research and Clinical Practice", "publication_date": "2026-01-13", "publication_year": 2026, "doi": "10.1176/appi.prcp.20250113", "pubmed_id": "42022021", "source_url": "https://doi.org/10.1176/appi.prcp.20250113", "keywords": "Psychoeducation, Psychology, Psychotherapist, Psilocybin, Psychological intervention, Interpersonal communication, Mindfulness, Dyad, Session (web analytics), Clinical psychology, Psychological distress, Cognitive therapy, DSM-5, Psychological Theory, Component (thermodynamics), Cognition, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7123730053\",\"openalex_url\":\"https://openalex.org/W7123730053\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1998435247\",\"https://openalex.org/W2041889512\",\"https://openalex.org/W2074503869\",\"https://openalex.org/W2097564751\",\"https://openalex.org/W2803499312\",\"https://openalex.org/W2888858694\",\"https://openalex.org/W2896003347\",\"https://openalex.org/W2896053783\",\"https://openalex.org/W2897586961\",\"https://openalex.org/W3135707442\",\"https://openalex.org/W3183684219\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4392797453\",\"https://openalex.org/W4405978069\",\"https://openalex.org/W4405978092\",\"https://openalex.org/W4410217856\"],\"authorships\":[{\"id\":\"https://openalex.org/A5067442902\",\"display_name\":\"Celia Faye Jacobsen\",\"orcid\":\"https://orcid.org/0000-0001-7221-0427\"},{\"id\":\"https://openalex.org/A5121257127\",\"display_name\":\"Dea Siggaard Stenbæk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5066485542\",\"display_name\":\"Stig Poulsen\",\"orcid\":\"https://orcid.org/0000-0002-0536-1820\"},{\"id\":\"https://openalex.org/A5086179765\",\"display_name\":\"Sophia Armand\",\"orcid\":\"https://orcid.org/0000-0001-6368-3329\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210213065\",\"source_display_name\":\"Psychiatric Research and Clinical Practice\",\"landing_page_url\":\"https://doi.org/10.1176/appi.prcp.20250113\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Emotional Processing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7123730053" }, { "id": 3532, "title": "A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression", "normalized_title": "a phase iii multicentre randomised double blind controlled study to investigate the efficacy safety and tolerability of two administrations of comp360 in participants with treatment resistant depression", "authors": "COMPASS Pathways", "abstract": "Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD) This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged ≥18 years with TRD. Overall, 568 participants are to be randomised in a 2:1:1 ratio to receive COMP360 25 mg, 10 mg or 1 mg. The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week screening period. Part A will include a nine-week follow-up from initial investigational product (IP) administration. Part B will include a further 17 weeks follow-up out to 26 weeks from initial IP administration. Part C will include a further 26 weeks follow-up out to 52 weeks from initial IP administration. In this study, the aim is to assess the efficacy of COMP360, administered with psychological support in adult participants with TRD, in improving symptoms of depression.", "journal": "ClinicalTrials.gov", "publication_date": "2026-01-11", "publication_year": 2026, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05711940", "keywords": "Treatment Resistant Depression, Psilocybin, COMP360, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05711940\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 333, "title": "An open-label pilot study of psilocybin-assisted therapy for binge eating disorder", "normalized_title": "an open label pilot study of psilocybin assisted therapy for binge eating disorder", "authors": "Jesse Dallery, Jennifer L. Miller, Jeff Boissoneault, Lauren Harvey, Lindsey Ives, Alexandra Knerr, Shelby Blaes, Morgan N. Ransom, Melissa S. Munson, James P. Gilligan, Michael H. Silverman, Peter R. Guzzo, Beverlee Loeser", "abstract": "Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, and decreased quality of life. Emerging evidence suggests that psilocybin-assisted therapy may promote cognitive and emotional flexibility and disrupt maladaptive behavioral patterns, making it a promising candidate for BED treatment. This open-label pilot study evaluated the feasibility, safety, and preliminary therapeutic effects of a single 25 mg dose of psilocybin administered in the context of Acceptance and Commitment Therapy (ACT)-based psychotherapy in adults with BED (N = 5). Primary outcomes included safety measures, and exploratory outcomes included self-reported binge eating frequency, depression, anxiety, psychological flexibility, anthropometric indices, and neuroimaging biomarkers assessed over a 14-week follow-up. Psilocybin was well tolerated, with no serious adverse events. Reductions in self-reported binge eating frequency were observed across all participants and sustained through week 14. Improvements were also noted in depression, anxiety, and psychological inflexibility. Three participants showed reductions in body mass index and waist circumference. Given the open label design and small sample size, causality cannot be inferred. fMRI analyses generated preliminary signals of change-such as increased functional activation from pre- to post-intervention in the middle frontal gyrus, angular gyrus, and supramarginal gyrus in response to processed versus unprocessed food cues. Psilocybin-assisted therapy was feasible and well-tolerated in individuals with BED. The clinical and neurobiological observations provide directions for future adequately powered trials.", "journal": "Journal of Eating Disorders", "publication_date": "2026-01-02", "publication_year": 2026, "doi": "10.1186/s40337-025-01508-3", "pubmed_id": "41485073", "source_url": "https://doi.org/10.1186/s40337-025-01508-3", "keywords": "Binge-eating disorder, Context (archaeology), Cognitive behavioral therapy, Clinical psychology, Binge eating, Psychiatry, Psychology, Eating disorders, Cognitive therapy, Medicine, Bulimia nervosa, Cognition, Anxiety, Quality of life (healthcare), Exposure therapy, Psychoeducation, Adverse effect, Cognitive flexibility, Relapse prevention, Flexibility (engineering), Cognitive reappraisal, Neuroimaging, Exploratory research, Rumination, Psychotherapist, Body mass index, Intervention (counseling), Supramarginal gyrus, Disordered eating, Biopsychosocial model, Psychedelics and Drug Studies, Bipolar Disorder and Treatment, Animal Law and Welfare", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7118124310\",\"openalex_url\":\"https://openalex.org/W7118124310\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W164629299\",\"https://openalex.org/W1903077781\",\"https://openalex.org/W1966524739\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2028641024\",\"https://openalex.org/W2056853212\",\"https://openalex.org/W2063207922\",\"https://openalex.org/W2072370722\",\"https://openalex.org/W2086564524\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2147488774\",\"https://openalex.org/W2166281097\",\"https://openalex.org/W2170420830\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2499216663\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2576619110\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2784069100\",\"https://openalex.org/W2792120884\",\"https://openalex.org/W2905971773\",\"https://openalex.org/W2951199936\",\"https://openalex.org/W2951757964\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W2985188679\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112525124\",\"https://openalex.org/W3130765246\",\"https://openalex.org/W3134897339\",\"https://openalex.org/W3214305299\",\"https://openalex.org/W4221007471\",\"https://openalex.org/W4291170424\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4300960088\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4307697584\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4381548553\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4396951853\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4402993015\",\"https://openalex.org/W4403151209\",\"https://openalex.org/W4403620011\",\"https://openalex.org/W4409215134\",\"https://openalex.org/W4409286565\",\"https://openalex.org/W4412645629\"],\"authorships\":[{\"id\":\"https://openalex.org/A5004332083\",\"display_name\":\"Jesse Dallery\",\"orcid\":\"https://orcid.org/0000-0002-2882-1105\"},{\"id\":null,\"display_name\":\"Jennifer L. Miller\",\"orcid\":\"https://orcid.org/0000-0003-4370-3438\"},{\"id\":\"https://openalex.org/A5015297036\",\"display_name\":\"Jeff Boissoneault\",\"orcid\":\"https://orcid.org/0000-0002-2268-6491\"},{\"id\":\"https://openalex.org/A5121906938\",\"display_name\":\"Lauren Harvey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121886094\",\"display_name\":\"Lindsey Ives\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047376810\",\"display_name\":\"Alexandra Knerr\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121891541\",\"display_name\":\"Shelby Blaes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121886191\",\"display_name\":\"Morgan N. Ransom\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016742627\",\"display_name\":\"Melissa S. Munson\",\"orcid\":\"https://orcid.org/0009-0009-1666-5350\"},{\"id\":\"https://openalex.org/A5121890582\",\"display_name\":\"James P. Gilligan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121900265\",\"display_name\":\"Michael H. Silverman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047963260\",\"display_name\":\"Peter R. Guzzo\",\"orcid\":\"https://orcid.org/0009-0007-4773-8052\"},{\"id\":\"https://openalex.org/A5121890272\",\"display_name\":\"Beverlee Loeser\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210234357\",\"source_display_name\":\"Journal of Eating Disorders\",\"landing_page_url\":\"https://doi.org/10.1186/s40337-025-01508-3\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Eating Disorders,Brain Imaging,Biomarkers,Aging,Emotional Processing,Psychological Flexibility,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7118124310" }, { "id": 337, "title": "Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress", "normalized_title": "daily administration of psilocin mucate l 130 produces a favorable safety profile and anxiolytic effects in rodents exposed to chronic unpredictable mild stress", "authors": "Frederick D. Sancilio, Maghsoud Dariani, Purvi Chavda, Harsha Mysore Rajagopal, Lyl Tomlinson", "abstract": "Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, provides an anxiolytic effect; however, when orally administered as psilocybin, it only offers a moderate level of bioavailability and less predictable pharmacokinetics, potentially making effects after absorption variable and increasing the risk of adverse hallucinations, depending on the dose. As such, we investigated a recently developed stable salt of psilocin, psilocin mucate (L-130), which delivers increased bioavailability and, thus, more precise control of therapeutic levels. We examined factors related to L-130's safety, as well as its effectiveness in addressing anxiety at a commonly used macro dose level, along with dosing schedules similar to those noted in the literature. Clinical assessments and blood analyses suggest psilocin mucate is safe and has no toxicological effects. Compared to vehicle controls, daily dosing of L-130 led to significant reductions in cortisol levels and improved performances on several anxiety-related behavioral tasks: the Elevated Plus Maze, the Open Field Test, and the Novel Object Recognition Task. However, weekly dosing did not generally produce significant results. Overall, daily dosing of L-130 was able to produce anxiolytic behaviors, but larger studies are needed to determine optimal doses and dosing schedules.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2026-01-01", "publication_year": 2026, "doi": "10.1080/02791072.2025.2607726", "pubmed_id": "41482437", "source_url": "https://doi.org/10.1080/02791072.2025.2607726", "keywords": "Dosing, Anxiolytic, Bioavailability, Pharmacology, Medicine, Open field, Anxiety, Adverse effect, Anesthesia, Pharmacokinetics, Oral administration, Anti-Anxiety Agents, Elevated plus maze, Drug, Self-administration, Absorption (acoustics), Safety profile, Pharmacodynamics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7118088356\",\"openalex_url\":\"https://openalex.org/W7118088356\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1790118405\",\"https://openalex.org/W1897149844\",\"https://openalex.org/W1897852281\",\"https://openalex.org/W2013374926\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2139103520\",\"https://openalex.org/W2145839824\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2883224466\",\"https://openalex.org/W2892343289\",\"https://openalex.org/W2893284231\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3010604170\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W4210474529\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4281253144\",\"https://openalex.org/W4306947630\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4323041020\",\"https://openalex.org/W4381308495\",\"https://openalex.org/W4385479997\",\"https://openalex.org/W4388714298\",\"https://openalex.org/W4394602238\",\"https://openalex.org/W4400335852\",\"https://openalex.org/W4402624021\",\"https://openalex.org/W4412489091\"],\"authorships\":[{\"id\":\"https://openalex.org/A5113872007\",\"display_name\":\"Frederick D. Sancilio\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078710159\",\"display_name\":\"Maghsoud Dariani\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092423614\",\"display_name\":\"Purvi Chavda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070868248\",\"display_name\":\"Harsha Mysore Rajagopal\",\"orcid\":null},{\"id\":\"https://openalex.org/A5017865855\",\"display_name\":\"Lyl Tomlinson\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2025.2607726\",\"is_oa\":true}}", "topic_tags": "Anxiety,Pharmacology,Receptor Pharmacology,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7118088356" }, { "id": 336, "title": "The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis", "normalized_title": "the effects of psilocybin on psychological distress in cancer patients a systematic review and meta analysis", "authors": "Reza Moshfeghinia, Sara Mostafavi, Kimia Jazi, Amir Reza Ghasemi, Yasamin Khosravaninezhad, Santhosshi Narayanan, Jamshid Ahmadi, Mehdi Pasalar", "abstract": "INTRODUCTION: Psilocybin may effectively treat psychological distress in cancer patients. A meta-analysis assessed its safety and effectiveness in this context. METHODS: A comprehensive search across six databases (Scopus, PsycINFO, PubMed, Cochrane, CINAHL Complete, and Web of Science) was conducted to identify studies on psilocybin's effects on mental health in cancer patients up to November 2024. Both randomized and non-randomized trials were included, assessing anxiety, depression, and other mental outcomes at short-term (2-5 weeks) and long-term (6 months) follow-ups. Study quality was assessed using Cochrane tools, and statistical analyses were performed with Stata version 17. RESULTS: In randomized controlled trials (RCTs), psilocybin significantly reduced depressive symptoms, with the Beck Depression Inventory (BDI) (standardized mean difference [SMD] = - 2.87, 95% confidence interval [CI]: - 3.99 to - 1.76, p < 0.001) and the Hospital Anxiety and Depression Scale-Depression subscale (HADS-D) (SMD = - 2.97, 95% CI: - 3.60 to - 2.33, p < 0.001) showing strong effects. Anxiety outcomes were mixed: the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) was not significant (SMD = - 3.63, p = 0.11), while the State-Trait Anxiety Inventory (STAI) also showed inconsistent results. Short-term analyses (2-5 weeks) revealed significant improvements in the BDI (SMD = - 1.17), HADS-D (SMD = - 1.58), and HADS-A (SMD = - 1.99), all p < 0.001. Long-term analyses (6 months) demonstrated sustained benefits on the BDI (SMD = - 2.60, p = 0.04) and HADS-D (SMD = - 3.56, p = 0.01). Measures of quality of life (QOL) and spiritual well-being using the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT-Sp) scale also improved significantly after psilocybin treatment. CONCLUSION: Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being and (in single-arm data) quality of life. Given the small number of studies, high heterogeneity, challenges with blinding/expectancy, and frequent co-intervention with psychotherapy, these findings are preliminary. Larger, rigorously blinded trials are needed to determine clinical effectiveness and safety.", "journal": "BMC Psychology", "publication_date": "2026-01-01", "publication_year": 2026, "doi": "10.1186/s40359-025-03935-y", "pubmed_id": "41484687", "source_url": "https://doi.org/10.1186/s40359-025-03935-y", "keywords": "Psilocybin, Psychological distress, Anxiety, Clinical psychology, Cancer, Psychology, Distress, Psychiatry, Depression (economics), Clinical trial, Psychological therapy, Psychotherapist, Psychological research, Depressive symptoms, Quality of life (healthcare), MEDLINE, Emotional distress, Quality (philosophy), Medicine, Research design, Randomized controlled trial, Anxiety disorder, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Religion, Spirituality, and Psychology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7118088637\",\"openalex_url\":\"https://openalex.org/W7118088637\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1529403805\",\"https://openalex.org/W1598602811\",\"https://openalex.org/W1791587479\",\"https://openalex.org/W1979206718\",\"https://openalex.org/W2013263319\",\"https://openalex.org/W2050864561\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2169248741\",\"https://openalex.org/W2318307729\",\"https://openalex.org/W2464886977\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2531269403\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2605759386\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2754418103\",\"https://openalex.org/W2789541163\",\"https://openalex.org/W2796179442\",\"https://openalex.org/W2803238382\",\"https://openalex.org/W2886232664\",\"https://openalex.org/W2964775179\",\"https://openalex.org/W2965983154\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W2990323914\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3029961383\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112576667\",\"https://openalex.org/W3120632631\",\"https://openalex.org/W3127181543\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W3158985447\",\"https://openalex.org/W3159976828\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3191550608\",\"https://openalex.org/W3196833323\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W3214774976\",\"https://openalex.org/W3216164364\",\"https://openalex.org/W3217313813\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4220685738\",\"https://openalex.org/W4283011480\",\"https://openalex.org/W4284665615\",\"https://openalex.org/W4289861025\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4291111113\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4295345823\",\"https://openalex.org/W4304690665\",\"https://openalex.org/W4306177192\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309508591\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4312196530\",\"https://openalex.org/W4315928547\",\"https://openalex.org/W4319984222\",\"https://openalex.org/W4320491739\",\"https://openalex.org/W4323924592\",\"https://openalex.org/W4362471804\",\"https://openalex.org/W4377096690\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4383187032\",\"https://openalex.org/W4385173317\",\"https://openalex.org/W4388731626\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4400697733\"],\"authorships\":[{\"id\":\"https://openalex.org/A5121872062\",\"display_name\":\"Reza Moshfeghinia\",\"orcid\":null},{\"id\":\"https://openalex.org/A5038317446\",\"display_name\":\"Sara Mostafavi\",\"orcid\":\"https://orcid.org/0000-0002-5635-8912\"},{\"id\":\"https://openalex.org/A5121838596\",\"display_name\":\"Kimia Jazi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109512426\",\"display_name\":\"Amir Reza Ghasemi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5106707424\",\"display_name\":\"Yasamin Khosravaninezhad\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053986931\",\"display_name\":\"Santhosshi Narayanan\",\"orcid\":\"https://orcid.org/0000-0003-0591-1500\"},{\"id\":\"https://openalex.org/A5027778328\",\"display_name\":\"Jamshid Ahmadi\",\"orcid\":\"https://orcid.org/0000-0002-7060-469X\"},{\"id\":\"https://openalex.org/A5110607826\",\"display_name\":\"Mehdi Pasalar\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764871139\",\"source_display_name\":\"BMC Psychology\",\"landing_page_url\":\"https://doi.org/10.1186/s40359-025-03935-y\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Wellbeing,Emotional Processing,Spirituality,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7118088637" }, { "id": 4179, "title": "Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review", "normalized_title": "psychedelics and mental health psilocybin and depression a sistematic review", "authors": "Marta Gómez Álvarez, Javier Calleja-Conde, Víctor Echeverry-Alzate", "abstract": "This systematic review evaluates the efficacy and safety of psilocybin in the treatment of depressive disorders in adult populations, including major depressive disorder and treatment-resistant depression. PRISMA guidelines were followed to identify and analyze clinical trials comparing psilocybin with different control conditions. Variables related to the reduction of depressive symptoms, speed of therapeutic response, and safety profile were examined. The findings suggest that psilocybin may represent a promising intervention in controlled clinical settings; however, methodological heterogeneity and limited sample sizes highlight the need for further studies to confirm its long-term efficacy and safety.", "journal": "Open Science Framework", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.17605/osf.io/yu3n9", "pubmed_id": null, "source_url": "https://doi.org/10.17605/osf.io/yu3n9", "keywords": "Psilocybin, Psychology, Hallucinogen, Major depressive disorder, Clinical psychology, Psychiatry, Psychotherapist, Clinical trial, Intervention (counseling), Depression (economics), Depressive symptoms, Randomized controlled trial, Medicine, Substance use, Systematic review, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7162447643\",\"openalex_url\":\"https://openalex.org/W7162447643\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5136996917\",\"display_name\":\"Marta Gómez Álvarez\",\"orcid\":\"https://orcid.org/0009-0009-9299-5095\"},{\"id\":\"https://openalex.org/A5073461895\",\"display_name\":\"Javier Calleja-Conde\",\"orcid\":\"https://orcid.org/0000-0003-0573-3863\"},{\"id\":\"https://openalex.org/A5056731763\",\"display_name\":\"Víctor Echeverry-Alzate\",\"orcid\":\"https://orcid.org/0000-0001-9059-3513\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S7407050956\",\"source_display_name\":\"Open Science Framework\",\"landing_page_url\":\"https://doi.org/10.17605/osf.io/yu3n9\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7162447643" }, { "id": 4163, "title": "Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken", "normalized_title": "psilocybin therapie vorteilhaft für stimmungsstörungen von parkinsonkranken", "authors": "", "abstract": "Stimmungsstörungen bei Menschen mit Parkinson-Krankheit sind häufig und ein Hauptprädiktor für den Funktionsabfall. Die Behandlung dieser Störung ist aktuell jedoch nicht einfach und der Bedarf nach neuartigen Interventionen hoch. Psilocybin ist bisher vielversprechend zur Behandlung von Depressionen und Angstzuständen eingesetzt worden. Das Potenzial bei Parkinsonpatient*innen ist unbekannt, da Menschen mit neurodegenerativen Erkrankungen aufgrund von Sicherheitsbedenken bisher aus Studien ausgeschlossen wurden.", "journal": "Fortschritte der Neurologie · Psychiatrie", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1055/a-2700-8978", "pubmed_id": null, "source_url": "https://doi.org/10.1055/a-2700-8978", "keywords": "Medicine, Gynecology, Context (archaeology), Disease, Population, Clinical trial, Randomized controlled trial, Quality of life (healthcare), Coronary heart disease, Risk factor, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7124268562\",\"openalex_url\":\"https://openalex.org/W7124268562\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W4409286565\"],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S5647071\",\"source_display_name\":\"Fortschritte der Neurologie · Psychiatrie\",\"landing_page_url\":\"https://doi.org/10.1055/a-2700-8978\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7124268562" }, { "id": 4161, "title": "‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injury", "normalized_title": "shroom for concern a case of psychedelic mushroom induced acute kidney injury", "authors": "Maurice Lam, C. Khor, S. Hultin, J. J. Cheung, N. A. Shah", "abstract": "Psilocybe cubensis mushrooms are typically not consumed for their nutritional value. The main reason people ingest these mushrooms is for their psychoactive effects. Recently, there has been growing interest in the potential therapeutic applications of psilocybin-containing mushrooms in a range of psychiatric conditions, including depression, anxiety disorders, obsessive-compulsive disorder, alcohol dependence and tobacco dependence. Here, we present a case in which ingestion of psilocybin-containing mushrooms was the presumed cause of acute kidney injury (AKI). A man in his early thirties presented with acute bilateral flank pain 48 h following recreational ingestion of 0.5 g of psilocybin-containing mushrooms in dry whole form. He experienced the desired and expected hallucinogenic effects upon initial consumption. He developed a non-oliguric AKI with a peak serum creatinine of 189 μmol/L, elevated from a known baseline of 83 μmol/L. Urinalysis demonstrated an elevated albumin-creatinine ratio (40.4 mg/mmol) and bland urinary sediment. Non-contrast computed tomography of the kidneys, ureter and bladder was unremarkable. A comprehensive work-up for glomerulonephritis was negative. Serum electrolytes remained within normal limits, and there was no peripheral eosinophilia. Liver function tests were unremarkable apart from a borderline elevation in aspartate aminotransferase at 39 U/L, and serum lipase was mildly elevated at 82 U/L. A creatine kinase was normal at 155 U/L. No alternative nephrotoxic exposures or contributing factors were identified on detailed clinical history. More specifically, he had no symptoms of vomiting or diarrhoea that may have contributed to a state of dehydration. Physical examination was unremarkable, with no costovertebral angle tenderness and evidence of clinical euvolaemia. The patient received supportive management with intravenous fluids, resulting in resolution of flank pain within 48 h. Serum creatinine improved to 136 μmol/L by day 4, so a kidney biopsy was not pursued. At 1 month follow-up, renal function had fully recovered, with his serum creatinine returning to 85 μmol/L. Psilocybin-containing mushrooms are primarily associated with transient neuropsychiatric effects - altered mood, perception and cognition - emerging within 20-40 min of ingestion and resolving within 6 h. While not traditionally associated with nephrotoxicity, it is hypothesised that their serotonergic activity, particularly via 5-HT2A receptor agonism, may lead to vasoconstriction and tubular injury.1 Several cases of nephrotoxicity linked to psilocybin ingestion have been reported.1-3 These exposures rely on correct preparation and sufficiently skilful identification of the product to ensure there are no contaminants which could contribute to the development of AKI. Nephrotoxicity secondary to mushroom ingestion is usually associated with the orellanine-containing Cortinarius species and the amatoxin-producing Amanita species. Orellanine nephrotoxicity is characterised by a delayed-onset AKI, typically manifesting 3-20 days after ingestion. Histopathology demonstrates tubular necrosis, interstitial oedema and fibrosis. These cases often progress to chronic kidney disease requiring dialysis and transplant.4 Amatoxins - most notably from Amanita phalloides, A. verna, and A. virosa - are classically hepatotoxic, but nephrotoxicity has been reported due to severe dehydration from profuse diarrhoea, direct tubular toxicity or secondary to hepatorenal syndrome.5 Histopathology typically reveals tubular necrosis and interstitial nephritis. Other Amanita species may cause an early-onset AKI, typically within 24-72 h, with more favourable prognosis and renal recovery.6 Mechanistically, orellanine is thought to inhibit protein synthesis and induce oxidative damage via free radical generation,7 while amatoxins inhibit RNA polymerase II, promoting apoptotic pathways with a predilection for metabolically active tissues that are dependent on high rates of protein synthesis such as the gastrointestinal tract, hepatocytes and proximal convoluted tubules.8, 9 This case describes a reversible AKI potentially related to psychedelic mushroom ingestion. As psilocybin prescribing becomes more widespread in Australia, clinical awareness of its potential renal effects is essential to ensuring patient safety. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.", "journal": "Internal Medicine Journal", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1111/imj.70313", "pubmed_id": "41518153", "source_url": "https://doi.org/10.1111/imj.70313", "keywords": "Medicine, Ingestion, Acute kidney injury, Urinalysis, Vomiting, Creatinine, Renal function, Creatine kinase, Internal medicine, Urinary system, Gastroenterology, Liver function tests, Physical examination, Anesthesia, Urine, Nausea, Nephrotoxicity, Blurred vision, Physiology, Rhabdomyolysis, Adverse effect, Urology, Acute tubular necrosis, Liver function, Poison control, Abdominal pain, Hallucinogen, Flank pain, Kidney, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Silymarin and Mushroom Poisoning", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7119893738\",\"openalex_url\":\"https://openalex.org/W7119893738\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2046048354\",\"https://openalex.org/W2103373693\",\"https://openalex.org/W2197595197\",\"https://openalex.org/W2906587679\",\"https://openalex.org/W4324018694\",\"https://openalex.org/W4387409508\",\"https://openalex.org/W4393131815\",\"https://openalex.org/W4397047853\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034787774\",\"display_name\":\"Maurice Lam\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122507695\",\"display_name\":\"C. Khor\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122471184\",\"display_name\":\"S. Hultin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122633185\",\"display_name\":\"J. J. Cheung\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122443640\",\"display_name\":\"N. A. Shah\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S60716783\",\"source_display_name\":\"Internal Medicine Journal\",\"landing_page_url\":\"https://doi.org/10.1111/imj.70313\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,OCD,Chronic Pain,Mechanism of Action,Receptor Pharmacology,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7119893738" }, { "id": 4158, "title": "Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial", "normalized_title": "efficacy and safety of psilocybin in treatment resistant major depression episode results of a randomized active placebo controlled trial", "authors": "L.J. Mertens, M. Koslowski, F. Betzler, M. Brand, R. Evens, L. Krätner, A. Jungaberle, H. Jungaberle, T. Majić, C.N. Schmitz, A. Ströhle, D. Scharf, M. Spangemacher, M. Wolff, Z. Assadi, B. Scharif, L. Becher, L.V. Färber, N. Kirchen, E. Kulakova, L. Kunz, A. Meijer, B. Rohrmoser, S. Wellek, M. Berger, G. Gründer", "abstract": "", "journal": "Neuroscience Applied", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1016/j.nsa.2025.105779", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.nsa.2025.105779", "keywords": "Medicine, Depression (economics), Psilocybin, Randomized controlled trial, Internal medicine, Psychiatry, Major depressive disorder, Clinical trial, Treatment-resistant depression, Adverse effect, Anxiety, Placebo, Placebo response, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7118005769\",\"openalex_url\":\"https://openalex.org/W7118005769\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5121822190\",\"display_name\":\"L.J. Mertens\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121824543\",\"display_name\":\"M. Koslowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121783775\",\"display_name\":\"F. Betzler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121792507\",\"display_name\":\"M. Brand\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121791537\",\"display_name\":\"R. Evens\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121810759\",\"display_name\":\"L. Krätner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121833521\",\"display_name\":\"A. Jungaberle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121791366\",\"display_name\":\"H. Jungaberle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121773388\",\"display_name\":\"T. Majić\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121822296\",\"display_name\":\"C.N. Schmitz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121811371\",\"display_name\":\"A. Ströhle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121789885\",\"display_name\":\"D. Scharf\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121826605\",\"display_name\":\"M. Spangemacher\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121785997\",\"display_name\":\"M. Wolff\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121758999\",\"display_name\":\"Z. Assadi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121789441\",\"display_name\":\"B. Scharif\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121823024\",\"display_name\":\"L. Becher\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121824758\",\"display_name\":\"L.V. Färber\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121806858\",\"display_name\":\"N. Kirchen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121800185\",\"display_name\":\"E. Kulakova\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121759413\",\"display_name\":\"L. Kunz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121774631\",\"display_name\":\"A. Meijer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121756009\",\"display_name\":\"B. Rohrmoser\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121827624\",\"display_name\":\"S. Wellek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121760402\",\"display_name\":\"M. Berger\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121772024\",\"display_name\":\"G. Gründer\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"https://doi.org/10.1016/j.nsa.2025.105779\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7118005769" }, { "id": 4155, "title": "An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes", "normalized_title": "an open label study of single dose comp360 psilocybin for post traumatic stress disorder safety tolerability and secondary efficacy outcomes", "authors": "N. Mcgowan, J. Rucker, R. Yehuda, M. Agrawal, H. Simmons, S. Das, G. Goodwin", "abstract": "", "journal": "Neuroscience Applied", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1016/j.nsa.2025.106821", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.nsa.2025.106821", "keywords": "Medicine, Stress (linguistics), Psilocybin, Internal medicine, Depression (economics), Fight-or-flight response, Clinical trial, Disease, Pharmacology, Placebo, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7117964120\",\"openalex_url\":\"https://openalex.org/W7117964120\",\"openalex_relevance_score\":8,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5121770090\",\"display_name\":\"N. Mcgowan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121788394\",\"display_name\":\"J. Rucker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121776293\",\"display_name\":\"R. Yehuda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121806605\",\"display_name\":\"M. Agrawal\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121802584\",\"display_name\":\"H. Simmons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121797777\",\"display_name\":\"S. Das\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121813176\",\"display_name\":\"G. Goodwin\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"https://doi.org/10.1016/j.nsa.2025.106821\",\"is_oa\":true}}", "topic_tags": "Depression,PTSD,Chronic Pain,Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7117964120" }, { "id": 4152, "title": "Psilocybin Treatment for Refractory Depression: A Clinical Review", "normalized_title": "psilocybin treatment for refractory depression a clinical review", "authors": "Jensen, Hailey A", "abstract": "Introduction: Depression is a widespread mental illness that affects a large portion of the world population and many of those who suffer from depression are resistant to treatment currently available. The purpose of this review is to compare the efficacy of psilocybin to the current available methods for the treatment of refractory depression. Methods: PubMed was searched with the key search terms: resistant depression, psilocybin therapy, and adults. Operators and filters narrowed down the search to 43 results. Four articles were then chosen based on quality and specificity with this review. Results: The articles included in this review compare the effectiveness of psilocybin to the currently available treatment methods for depression. Each of these articles found psilocybin to be a fast acting, effective treatment for treatment resistant depression. Discussion: Early results regarding psilocybin as a treatment for treatment resistant depression suggest psilocybin is efficacious. Due to the hallucinogenic nature of psilocybin and the current stigma surrounding the drug, more research is needed to determine safety profile and effective doses.", "journal": "Digital Commons - Gardner-Webb University (Gardner-Webb University)", "publication_date": "2025-12-31", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63", "keywords": "Psilocybin, Hallucinogen, Medicine, Refractory (planetary science), Treatment-resistant depression, Population, Psychiatry, Depression (economics), Clinical trial, Pharmacology, Intensive care medicine, Clinical efficacy, Psychology, Quality of life (healthcare), MEDLINE, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7110564344\",\"openalex_url\":\"https://openalex.org/W7110564344\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Jensen, Hailey A\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196844\",\"source_display_name\":\"Digital Commons - Gardner-Webb University (Gardner–Webb University)\",\"landing_page_url\":\"https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7110564344" }, { "id": 374, "title": "Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.", "normalized_title": "pharmacological properties of psychedelics with a special focus on potential harms", "authors": "Holze F, Liechti ME, Müller F.", "abstract": "Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psychedelics exert profound alterations in various mental domains, including sensation, cognition, emotions, and self-perception. Psychedelics comprise phenethylamines (e.g., mescaline), tryptamines (e.g., psilocybin), and ergolines (e.g., LSD). These drugs have been used recreationally for decades but have also regained attention as potential treatments for various psychiatric as well as neurological illnesses. While psychedelics are generally considered to be relatively safe from a physiological standpoint, especially when compared to other recreational drugs, they are not without risks. The main safety concerns are lasting psychological adverse reactions such as persisting anxiety, dissociation, or flashbacks.This chapter provides a comprehensive overview of the pharmacology of classic psychedelics, including their origins, psychological and autonomic effects, interactions, and potential risks and side effects. Furthermore, the origin, dosing, and consumption methods are discussed. It differentiates psychedelics from other psychoactive drugs, such as MDMA and ketamine, and elaborates on their distinct receptor profiles. Overall, this chapter provides an overview of the pharmacological underpinnings necessary for understanding the harms caused by psychedelic drugs.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/7854_2024_510", "pubmed_id": "39080236", "source_url": "https://doi.org/10.1007/7854_2024_510", "keywords": "Animals, Humans, Tryptamines, Hallucinogens", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39080236\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Pharmacology,Receptor Pharmacology,Emotional Processing,Safety,Adverse Events,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 372, "title": "Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.", "normalized_title": "anxiety and affective symptoms related to the use of classic psychedelics a systematic review", "authors": "Viljoen G, Betzler F", "abstract": "There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to qualitatively synthesize the current literature on anxiety and affective disorders related to the use of classic psychedelics. Persisting disorders were less frequent but generally occurred in individuals who presented with several risk factors (overdose, polydrug use, unstructured recreational setting, psychosocial stress, personal/familial psychiatric histories). When psychedelics were administered in clinical studies under the framework of psychedelic-assisted therapy, the incidence of enduring anxiety and affective symptoms was low. In most cases, acute transient anxiety emerged and resolved during the dosing session without the need for additional treatment interventions. The nuance of such cases is discussed, shedding light on the role of emotional catharsis in the therapeutic process. Several suggestions are proposed to enhance patient safety including strengthening the therapeutic alliance, ensuring adequate mental preparation, acclimating to high doses and providing on-going therapeutic support.", "journal": "Current topics in behavioral neurosciences", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/7854_2024_534", "pubmed_id": "39436632", "source_url": "https://pubmed.ncbi.nlm.nih.gov/39436632/", "keywords": "Affective disorders, Anxiety, Depression, LSD, Psilocybin, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"39436632\"}", "topic_tags": "Depression,Anxiety,Emotional Processing,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 367, "title": "Informed Consent in Psychedelic-Assisted Therapy.", "normalized_title": "informed consent in psychedelic assisted therapy", "authors": "Bradberry MM, Appelbaum PS, Gukasyan N.", "abstract": "Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed \"psychedelics,\" for therapeutic purposes in Western clinical settings. Care in these settings is governed by standards for the communication and assumption of risk in the process of informed consent. Rigorous informed consent standards in psychedelic medicine are not only essential for quality care but also critical to the mitigation of risk, particularly in research settings and for vulnerable individuals. This chapter describes practical elements of informed consent in psychedelic therapy, with a focus on effective communication of the risks and potential benefits of classical psychedelic and entactogen treatments as they are currently understood.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/7854_2024_559", "pubmed_id": "39739178", "source_url": "https://doi.org/10.1007/7854_2024_559", "keywords": "Humans, Hallucinogens, Informed Consent", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"39739178\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 363, "title": "Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability.", "normalized_title": "building standards of psychedelic care qualitative examination of expert perspectives on safety inclusion and accountability", "authors": "Chwyl C, Wilson-Poe AR, Hoffman KA, Bazinet A, Pertl K, Luoma JB, des Jarlais D, Bielavitz S, Korthuis PT", "abstract": "There remain significant gaps in knowledge about best practices for facilitated psychedelic care and psychedelic-assisted therapy. To inform the development of service models that support safe and beneficial experiences, this qualitative study explored expert perspectives on current and ideal standards of care, including key practices (e.g., screening, adapting care to diverse contexts) and regulatory and research challenges that influence service delivery. Online focus groups (n = 8) were conducted with a purposive U.S. sample of people with psychedelic content knowledge expertise, including providers (psychiatrists, clinical psychologists, addiction medicine experts, and licensed/unlicensed practitioners) and harm reduction specialists. Transcripts were analyzed through Thematic Analysis team-based coding using a combined inductive-deductive approach within a semantic framework. Participants (N = 38, mean age 47 (SD = 10) years, 53 % women, 84 % white) had an average of 10 years of psychedelic service experience (SD = 11) across diverse settings, including festivals/events, service centers, and clinical, research, ceremonial, community and 'underground' contexts. Five key themes emerged: (1) 'Strengthening Safety through Credibility and Accountability'; (2) 'Advancing Culturally Responsive and Inclusive Psychedelic Care'; (3) 'Healing in Community: The Crucial Role of Ongoing Support and Integration'; (4) 'Ensuring Safe Psychedelic Use: Preparation, Screening, Vulnerability, and Medication Management'; and (5) 'Providing Informed Guidance and Navigating Legal and Informational Gray Areas.' Overall, results underscore the need for stronger provider accountability structures, culturally inclusive practices, accessible and integrated community support, robust safety and screening protocols, and clearer guidelines to help providers navigate legal complexities, ensure safety, and optimize outcomes across diverse populations.", "journal": "The International journal on drug policy", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1016/j.drugpo.2025.104938", "pubmed_id": "40803962", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40803962/", "keywords": "Harm reduction, Psilocybin, Psychedelics, Qualitative research, Standards of care", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40803962\"}", "topic_tags": "Addiction,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 360, "title": "Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.", "normalized_title": "psychedelic drug checking analytical and strategic challenges in harm reduction for classic psychedelics", "authors": "Hirschfeld T, Blei F, Stegemann L, van der Gouwe D, Smit-Rigter L.", "abstract": "Classic psychedelics such as LSD, psilocybin, and DMT from unregulated markets pose considerable risks through unknown adulterants and potencies. In this chapter, we explore the importance of drug checking in minimizing harm among users of classic psychedelics and examine the opportunities and challenges associated with intervention settings, analytical techniques, and risk communication strategies. Gas chromatography (GC) and liquid chromatography (LC) coupled with mass spectrometry (MS) provide the most reliable and comprehensive analysis results for classic psychedelics. However, they are relatively costly, stationary, and require legal permission to obtain reference standards. Combined presumptive tests, such as thin-layer chromatography (TLC) and reagent testing, offer a time-efficient and cost-effective approach to initial substance screening. For certain compounds, Fourier-transform infrared spectroscopy (FTIR) serves as a valuable complementary technique, although potent psychedelics, such as LSD and NBOMe on blotter paper or in diluted solution, and complex botanical matrices challenge its detection limit, requiring the use of multiple analytical methods to confirm results. Such combination can effectively prevent acute risks, while confirmatory instrumental analysis remains essential for ongoing monitoring and public health efforts. Alongside robust testing procedures, drug checking's consultative component is crucial for clarifying analytical constraints, promoting safer use practices, and offering referrals to health services. By identifying mislabeled samples and ensuring tailored risk communication, drug checking not only protects individual users but also informs the public and health professionals regarding dangerous or novel substances. This chapter situates drug checking as a key public health measure that reduces acute harm from misrepresented psychedelic substances while supporting monitoring efforts.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/7854_2025_606", "pubmed_id": "41087826", "source_url": "https://doi.org/10.1007/7854_2025_606", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Substance Abuse Detection, Harm Reduction, Drug Contamination, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41087826\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 347, "title": "Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin", "normalized_title": "pharmacological management of anxiety in end of life care a systematic review of benzodiazepines opioids and psilocybin", "authors": "Brunno Freitas da Costa, Paula Hartmann, Daniel Pagnin", "abstract": "OBJECTIVE: Anxiety is common in patients receiving end-of-life care and significantly impacts their quality of life. However, pharmacological management remains challenging due to complex clinical presentations and potential side effects, emphasizing the need for systematically reviewing existing treatments. Here we aim to systematically evaluate the efficacy and safety of pharmacological treatments for anxiety in end-of-life care. DESIGN: Systematic review following PRISMA guidelines, prospectively registered in PROSPERO (CRD42024556913). Comprehensive searches were performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Eligible studies included adults receiving end-of-life care and evaluated pharmacological interventions targeting anxiety. RESULTS: Five studies met inclusion criteria: two assessing benzodiazepines combined with opioids and three evaluating psilocybin. Both benzodiazepine-opioid combinations and psilocybin reduced anxiety symptoms. Psilocybin studies reported rapid and sustained anxiety relief, with approximately 60%-80% of participants experiencing clinically significant improvements. Both treatment categories showed good tolerability without serious adverse events. However, the evidence base was limited by small sample sizes and narrow study contexts. CONCLUSIONS: Benzodiazepine-opioid combinations and psilocybin show promise for anxiety relief in end-of-life patients. Nevertheless, limited high-quality evidence highlights an important research gap. Further robust clinical trials are needed to confirm these findings and guide clinical practice in palliative care.", "journal": "Human Psychopharmacology Clinical and Experimental", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1002/hup.70032", "pubmed_id": "41502021", "source_url": "https://doi.org/10.1002/hup.70032", "keywords": "Psilocybin, Anxiety, Clinical trial, Psychotherapist, Psychology, Psychiatry, Clinical Practice, Medicine, Hallucinogen, Clinical psychology, MEDLINE, Anti-Anxiety Agents, Palliative care, Symptom relief, Systematic review, Depression (economics), Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Death Anxiety and Social Exclusion", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7118595574\",\"openalex_url\":\"https://openalex.org/W7118595574\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1964060279\",\"https://openalex.org/W1978479511\",\"https://openalex.org/W2012160863\",\"https://openalex.org/W2088351477\",\"https://openalex.org/W2088378149\",\"https://openalex.org/W2148893203\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2531269403\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W3010262839\",\"https://openalex.org/W3017244297\",\"https://openalex.org/W3019350884\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4387019277\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4402564741\"],\"authorships\":[{\"id\":\"https://openalex.org/A5060359012\",\"display_name\":\"Brunno Freitas da Costa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122215912\",\"display_name\":\"Paula Hartmann\",\"orcid\":null},{\"id\":\"https://openalex.org/A5038617698\",\"display_name\":\"Daniel Pagnin\",\"orcid\":\"https://orcid.org/0000-0002-5213-3935\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S154207414\",\"source_display_name\":\"Human Psychopharmacology Clinical and Experimental\",\"landing_page_url\":\"https://doi.org/10.1002/hup.70032\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Clinical Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7118595574" }, { "id": 342, "title": "Classifying Psychedelic-Related Complications.", "normalized_title": "classifying psychedelic related complications", "authors": "Majić T, Gouzoulis-Mayfrank E, Evens R.", "abstract": "Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effects in the treatment of certain mental health conditions. Enthusiastic claims about their therapeutic potential have led to overly optimistic reactions in the media and the public, subsequently resulting in increased use outside of clinical contexts and a heightened rate of psychedelic-related complications. As psychedelics exhibit low toxicity and hardly any habit-forming potential, the typical risks and harms of these substances are often overlooked by mental health professionals and under-assessed in psychedelic research. Similar to the medical history of other psychoactive substances introduced as medicines such as opioids, cocaine, and benzodiazepines, awareness for psychedelic-related complications has emerged with delay. Psychedelics are characterized by a wide range of acute effects on the human psyche and by a particular temporal dynamic in which these effects unfold, including acute, subacute, and long-term effects. Knowledge of how psychedelic effects unfold is not only essential for their use in therapy but also for the understanding and management of risks and complications.Here we provide an overview of complications that may be associated with the use of classic psychedelics, drawing on historical and current classification approaches and using the typical temporal dynamics of drug effects as a guiding thread. We will also discuss to what extent psychedelic-related disorders can be causally and specifically attributed to psychedelic use. Finally, considerations regarding the placement of psychedelic-related disorders within nosological-diagnostic classification systems will be discussed. The increasing interest in using psychedelics within the framework of psychotherapy and the rise of non-medical use underscore the need for a more nuanced classification of psychedelic-related risks and harms. The suggested classification can be used as a comprehensive starting point for the assessment of psychedelic-related complications, contributing to maximizing benefits and minimizing risks of these substances in research, therapy, and beyond.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/7854_2026_614", "pubmed_id": "41749025", "source_url": "https://doi.org/10.1007/7854_2026_614", "keywords": "Humans, Hallucinogens", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41749025\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 340, "title": "New Antidepressant Development in the Treatment of Depression.", "normalized_title": "new antidepressant development in the treatment of depression", "authors": "Spiti A, Caldirola D, Perna G.", "abstract": "Major depressive disorder (MDD) continues to pose a major therapeutic challenge due to its clinical heterogeneity. This chapter looks at the development of antidepressant treatments, starting with early interventions such as electroconvulsive therapy (ECT), monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Although these treatments targeted the monoaminergic system, they had significant limitations in terms of safety and efficacy. The introduction of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) improved tolerability but left unmet needs, particularly in terms of treatment resistance and side effects. In response, research has expanded beyond monoamines and focused on new mechanisms. A breakthrough came with N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine and esketamine, which achieved fast-acting effects and shifted the focus to glutamatergic modulation. Other developments in this area include modulators such as partial agonists, positive allosteric modulators (PAMs), and negative allosteric modulators (NAMs). In addition, gamma-aminobutyric acid (GABA) modulation has gained attention, with neurosteroids such as zurolone (approved for postpartum depression [PPD]) representing a new therapeutic approach. Other new strategies target the opioid system, particularly kappa-opioid receptor (KOR) antagonism, whose role in the treatment of anhedonia and depression is being investigated. Psychedelics, including psilocybin, have come back into focus as potential treatments due to their ability to elicit rapid and sustained antidepressant effects via agonism of the serotonin 2A receptor (5-HT2A), although their efficacy and safety require further research. In addition, innovative treatments targeting orexin, trace amine-associated receptor 1 (TAAR1) and members of the Q subfamily of voltage-gated potassium channels (KCNQ) are also in development. Despite these advances, some challenges remain. These include diagnostic heterogeneity, incomplete understanding of neurobiological mechanisms, limitations of preclinical models, lack of reliable biomarkers, and economic obstacles. Future advances could be driven by artificial intelligence (AI), which has the potential to revolutionize drug discovery, optimize clinical trials, and personalize treatments for patients.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1007/978-981-95-6872-7_23", "pubmed_id": "42036580", "source_url": "https://doi.org/10.1007/978-981-95-6872-7_23", "keywords": "Animals, Humans, Antidepressive Agents, Electroconvulsive Therapy, Drug Development, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"42036580\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Mechanism of Action,Receptor Pharmacology,Biomarkers,Clinical Trial,Animal Study,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 323, "title": "[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].", "normalized_title": "clinical application and mechanistic studies of psychedelics for treatment of depression progress and future challenges", "authors": "Xia K, Gao T.", "abstract": "Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed onset and insufficient efficacy. Classic psychedelics, most notably psilocybin, have recently emerged as promising candidates for treatment of depression and demonstrated rapid, robust, and sustained antidepressant effects in controlled clinical settings. Their unique mechanisms of action and clinical prospects have become a key research focus in psychiatry and neuroscience. This review synthesizes the latest advances in the field over the past 5 years. Results from multiple randomized controlled trials indicate that a single or limited number of sessions of psychedelic-assisted psychotherapy can induce rapid and durable antidepressant effects in patients with treatment-resistant depression. At the mechanistic level, psychedelics rapidly promote the release of neurotrophic factors, enhance neuroplasticity, and facilitate brain network reorganization, thereby creating a critical \"neuroplastic window\" for psychotherapeutic intervention. However, the specific molecular and circuit-level mechanisms have not been fully understood with ongoing debate primarily over the 5-HT2A receptor-dependent hypothesis versus the TrkB neurotrophic pathway-dependent hypothesis. Despite the promising outlook, translational applications of these substances faces several key challenges, including psychedelic-related risks, incomplete mechanistic understanding, lack of standardized treatment protocols, and insufficient long-term safety data. Future research should focus on elucidating the underlying neurobiological mechanisms, developing non-hallucinogenic derivatives, establishing standardized treatment frameworks, and identifying precise biomarkers to advance this therapeutic approach toward safer, more standardized, and personalized clinical implementation.", "journal": null, "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.12122/j.issn.1673-4254.2026.01.01", "pubmed_id": "41540686", "source_url": "https://doi.org/10.12122/j.issn.1673-4254.2026.01.01", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Depression, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41540686\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Biomarkers,Randomized Controlled Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 235, "title": "Psychedelic therapy and postpartum depression: priorities and prospects.", "normalized_title": "psychedelic therapy and postpartum depression priorities and prospects", "authors": "Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, Harkin A, Kelly JR", "abstract": "Approximately 15% of pregnant women experience postpartum depression (PPD). Even with currently available antidepressant treatments, many women will continue to be impaired by symptoms. Psychedelic therapy offers a promising transdiagnostic therapeutic strategy for several mental health disorders, and early results from current trials suggest that serotonergic psychedelics may represent a viable therapeutic approach for PPD. However, there is marked variability in the therapeutic response to psychedelic therapy, and the benefit-risk ratio in this population is not yet clear. To inform the rationale for the use of serotonergic psychedelics in the treatment of PPD, this review summarises the existing knowledge of immune, endocrine and neural pathways underpinning PPD and explores how serotonergic psychedelics interact with these pathways in the context of maternal motivation, bonding and caregiving behaviours. Finally, special considerations for psychedelic therapy in the postpartum period are outlined and future perspectives explored. Despite the rationale and encouraging early findings, further research is required to determine efficacy and safety profiles. Future studies, particularly longitudinal trials, should include adaptations and safeguards tailored to the unique physiological, psychological and caregiving contexts of the postpartum period.", "journal": "Therapeutic advances in psychopharmacology", "publication_date": "2025-12-31", "publication_year": 2025, "doi": "10.1177/20451253251408280", "pubmed_id": "41816502", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41816502/", "keywords": "5-MeO-DMT, major depression, postpartum depression, psilocybin, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:20:34", "raw_json": "{\"pubmed_id\":\"41816502\"}", "topic_tags": "Depression,Mechanism of Action,Aging,Review Article,Safety,Immune Function", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3479, "title": "A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial", "normalized_title": "a randomized double blinded controlled trial for the treatment of persisting symptoms after concussion with psilocybin assisted therapy a safety and feasibility trial", "authors": "University of Calgary", "abstract": "The goal of this randomized controlled trial is to evaluate the safety, feasibility, and efficacy of psilocybin assisted therapy as an intervention to reduce symptom burden in adult patients (aged 18-65) with persisting symptoms after concussion (PSaC). This trail will test the following 2 aims: AIM1: To test the safety and feasibility of an active psilocybin-assisted psychotherapy to an active control for patients with PSaC. AIM2: To evaluate the efficacy of an active psilocybin-assisted psychotherapy compared to an active control as a treatment for PSaC. Participants will be asked to: * Complete a 2-part screening process * Attend a baseline assessment * Complete a psychoeducation preparation session(s) * Attend psilocybin administration session (receive high dose \\[25mg\\] or low dose psilocybin \\[1mg\\]) * Complete 5 weekly sessions of Acceptance and commitment therapy (ACT) * Repeat outcome measures at 1-week, 4 weeks, 3 months, and 6 months post-psilocybin administration (online only at 6 months). The overall objective of this study is to evaluate the safety, feasibility, and efficacy of psilocybin assisted therapy administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce symptom burden in patients with persisting symptoms after concussion (PSaC). This trail will test the following 2 aims: AIM1: To test the safety and feasibility of an active/high dose (25mg) psilocybin-assisted psychotherapy to an active control (1mg) for adults with PSaC. Safety will be determined through the reporting of adverse events and response following psilocybin for each participant up to 6-months. Feasibility will be determined through recruitment, enrollment, and adherence rates. AIM2: To evaluate the efficacy of an active/high dose (25mg) psilocybin-assisted psychotherapy compared to an active control (1mg) as a treatment for PPCS at 1-week, 4 weeks, 3 months, and 6 months post-psilocybin administration. The primary efficacy outcome will be the change in PSaC burden (RPQ). The secondary efficacy outcomes will include measures of headache, dizziness, mood, anxiety, post-traumatic stress, cognitive flexibility, emotional regulation, and quality of life. A total of 40 male and female patients between the ages of 18-65 with a diagnosis of mild traumatic brain injury (American College of Rehabilitation Medicine 2023 criteria) who meet criteria for persisting symptoms after concussion (ICD-10) within 3 months to 5 years will be recruited from Calgary brain injury clinics and the community. All patients will undergo a thorough, 2-part screening procedure. Eligible participants will be randomly allocated 1:1 to either the high dose (20 participants) or low dose (20 participants) psilocybin groups. All participants will be asked to attend a baseline session consisting of clinical and behavioural outcome measures, followed by a pre-dosing psychoeducation session. Following the single dosing session, participants will complete 5 weekly ACT sessions. Outcome measure assessments will be repeated at 1-week, 4 weeks, 3 months, and 6 months post-dosing.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-29", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06615908", "keywords": "Persisting Symptoms After Concussion, Psilocybin, magic mushrooms, PEX010, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06615908\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Anxiety,PTSD,Headache / Migraine,Emotional Processing,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3464, "title": "Microdosing Psychedelics to Improve Mood", "normalized_title": "microdosing psychedelics to improve mood", "authors": "Rotem Petranker", "abstract": "This trial aims to examine the safety and efficacy of small (2mg) sub-hallucinogenic doses of psilocybin in people with Major Depressive Disorder. This protocol is for a University of Toronto - sponsored, randomized, placebo-controlled crossover phase 2 study of the safety and efficacy of low doses of psilocybin in subjects with depressive symptoms who meet Diagnostic and Statistical Manual 5 (DSM-5) criteria for diagnosis of a major depressive disorder (MDD) and who are either unwilling to pursue standard treatment (psychotherapy and/or pharmacotherapy) or have previously been non-responsive to standard treatment. This feasibility study will assess whether microdosing has a short-term impact on participant ratings of depressive symptoms. Participants will be administered one dose of either placebo or psilocybin once weekly for four weeks, and then all participants will be administered a dose of psilocybin once weekly for four additional weeks. Short surveys will be collected once weekly three days after the administration of psilocybin/placebo, and follow-ups will occur for up to two years following the beginning of the trial. Using this design will maximize the experimental power to detect an effect if one exists and would inform future research on microdosing in terms of duration, effect size, and expectancy bias.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-29", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05259943", "keywords": "Major Depressive Disorder, Psilocybin first, Placebo first, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05259943\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Microdosing,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3017, "title": "Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks", "normalized_title": "psilocybin as a serotonergic therapy in epilepsy narrative review of therapeutic potentials and seizure risks", "authors": "Miguel Benjamín Cervera-Sánchez, Daniel San-Juan, Roberto Díaz-Peregrino, Evelin Zulema Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd", "abstract": "Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods: A narrative review was conducted up to November 23, 2025. We conducted structured literature searches across PubMed/MEDLINE, Scopus, Web of Science. and Google Scholar using MeSH terms and keywords to identify studies on psilocybin, magic mushrooms, or psilocin related to seizures or epilepsy. We also covered our research on serotonergic modulation and epilepsy. We selected a set of core studies directly addressing the research question and additional publications providing mechanistic and contextual evidence for the narrative synthesis. The Risk of Bias of the studies was assessed according to their type. Results: Experimental models demonstrate that psilocybin’s action on 5-HT2A receptors may confer anticonvulsant effects, reducing seizure severity in certain contexts. Preclinical findings support serotonergic modulation as a therapeutic strategy, notably in Dravet syndrome models. However, observational studies report seizures associated with recreational psilocybin use, raising concerns about its pro-convulsant potential, particularly outside controlled environments. Our risk of bias assessment of this evidence revealed significant methodological limitations, urging a cautious interpretation. Nevertheless, clinical trials in neuropsychiatric populations have not shown increased seizure risks under medical supervision. Conclusions: Psilocybin holds potential as a novel adjunctive therapy for epilepsy through selective serotonergic modulation, although conflicting data emphasize the caution with which psilocybin should be implemented clinically, especially in high doses. Animal studies and clinical trials in the future should verify the efficacy and safety of psilocybin in the treatment of epilepsy.", "journal": null, "publication_date": "2025-12-28", "publication_year": 2025, "doi": "10.22541/au.176701186.65064859/v1", "pubmed_id": null, "source_url": "https://doi.org/10.22541/au.176701186.65064859/v1", "keywords": "Psilocybin, Narrative review, Serotonergic, Medicine, Narrative, Psychotherapist, Psychiatry, Psychology, Neuroscience, Epilepsy, Hallucinogen, Review article, MEDLINE, Obsessive compulsive, Depression (economics), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 11:03:45", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7117461912\",\"openalex_url\":\"https://openalex.org/W7117461912\",\"openalex_relevance_score\":14,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5114582204\",\"display_name\":\"Miguel Benjamín Cervera-Sánchez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121441793\",\"display_name\":\"Daniel San-Juan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077433028\",\"display_name\":\"Roberto Díaz-Peregrino\",\"orcid\":\"https://orcid.org/0000-0003-2991-2874\"},{\"id\":\"https://openalex.org/A5117633819\",\"display_name\":\"Evelin Zulema Camacho-Castillo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5117464135\",\"display_name\":\"Sthefany Anahi Bringas-Ortiz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121481342\",\"display_name\":\"Christian Padilla-Cabezutd\",\"orcid\":null}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://doi.org/10.22541/au.176701186.65064859/v1\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Receptor Pharmacology,Clinical Trial,Review Article,Observational Study,Animal Study,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7117461912" }, { "id": 200, "title": "Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial", "normalized_title": "comparing single and repeat dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial", "authors": "Emmanuelle A. D. Schindler, Christopher Gottschalk, Brian Pittman, Deepak D'Souza", "abstract": "OBJECTIVE: The goals of this study were to examine the therapeutic effects and safety of psilocybin given as a pulsed regimen for the prevention of migraine and to consider the blinding integrity of an active control agent. BACKGROUND: The administration of a single low dose of psilocybin was observed to have lasting therapeutic effects in one small pilot trial in migraine, although the ability of a pulse dose regimen, as practiced by patients with cluster headache, to potentially improve magnitude and/or duration of transitional preventive effects has not been studied. Furthermore, comparison to an active placebo agent that adequately mimics the acute subjective effects of psilocybin is required to improve blinding integrity and measure placebo effects. METHODS: In an exploratory randomized, double-blind, placebo-controlled, parallel group study, adults with migraine having at least two weekly migraine days at baseline (n = 18) participated in two drug administration sessions separated by 7 days during which they received zero, one, or two doses of psilocybin (10 mg; psi). Whenever participants did not receive psilocybin, they received diphenhydramine (25 mg; diph). Participant recruitment took place between September 2021 and August 2023. The primary outcome measure was a change in migraine frequency using headache diary data collected starting 2 weeks before and continuing through 8 weeks after the second drug session. RESULTS: = 4.56, p = 0.102], despite large effect sizes against the placebo group in the those receiving one (diph-psi; d = 1.66) or two (psi-psi; d = 0.69) doses of psilocybin. Similar reductions in migraine frequency approximating 50% were seen in all groups over the 8 weeks measured. The difference in 50% response rate among groups over 2 weeks, however, approached significance (diph-diph: 17%; diph-psi: 80%; psi-psi: 80%; p = 0.087). Drug confidence ratings (i.e., blinding integrity) suggested that diphenhydramine partially substituted for the acute effects of psilocybin. No correlations were observed between changes in migraine frequency after psilocybin and drug confidence, acute general drug effects, or acute psychedelic effects. No serious or unexpected adverse events occurred. CONCLUSION: This exploratory study found similar reductions in migraine frequency with single-dose psilocybin, a two-dose pulse of psilocybin, or diphenhydramine placebo. Whereas blinding was incomplete in this study, this important topic is highlighted in the study design and findings. The potential for psilocybin to serve as a transitional treatment in migraine remains but will require careful planning in future studies to separate drug and non-drug effects. Furthermore, the inclusion of headache specialists in the design and execution of these future studies is necessary to preserve the viability of psilocybin treatment in headache medicine.", "journal": "Headache The Journal of Head and Face Pain", "publication_date": "2025-12-28", "publication_year": 2025, "doi": "10.1111/head.70024", "pubmed_id": "41459830", "source_url": "https://doi.org/10.1111/head.70024", "keywords": "Psilocybin, Migraine, Medicine, Blinding, Placebo, Clinical trial, Randomized controlled trial, Anesthesia, Sumatriptan, Flunarizine, Cephalalgia, Psychiatry, Nausea, Placebo response, Exploratory research, Psychotomimetic, Modalities, Alternative medicine, Adverse effect, Physical therapy, Crossover study, Clinical study design, Vomiting, Diphenhydramine, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7117472148\",\"openalex_url\":\"https://openalex.org/W7117472148\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2007980951\",\"https://openalex.org/W2020646491\",\"https://openalex.org/W2052698649\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2141092268\",\"https://openalex.org/W2148935649\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2151828427\",\"https://openalex.org/W2154524838\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2483415541\",\"https://openalex.org/W2726799618\",\"https://openalex.org/W2769724041\",\"https://openalex.org/W2901995644\",\"https://openalex.org/W3010491167\",\"https://openalex.org/W3045626136\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3125023528\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4281703399\",\"https://openalex.org/W4292202439\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4312994437\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4376613152\",\"https://openalex.org/W4389264439\",\"https://openalex.org/W4391036082\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4393107532\",\"https://openalex.org/W4393489617\",\"https://openalex.org/W4409155786\"],\"authorships\":[{\"id\":\"https://openalex.org/A5121489154\",\"display_name\":\"Emmanuelle A. D. Schindler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056904977\",\"display_name\":\"Christopher Gottschalk\",\"orcid\":\"https://orcid.org/0000-0002-1105-6910\"},{\"id\":\"https://openalex.org/A5056238262\",\"display_name\":\"Brian Pittman\",\"orcid\":\"https://orcid.org/0000-0002-0353-5604\"},{\"id\":\"https://openalex.org/A5105000063\",\"display_name\":\"Deepak D'Souza\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S96331937\",\"source_display_name\":\"Headache The Journal of Head and Face Pain\",\"landing_page_url\":\"https://doi.org/10.1111/head.70024\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7117472148" }, { "id": 3701, "title": "The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation", "normalized_title": "the safety and efficacy of psilocybin in patients with treatment resistant depression and chronic suicidal ideation", "authors": "Sheppard Pratt Health System", "abstract": "This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-23", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05220410", "keywords": "Treatment Resistant Depression, Suicidal Ideation, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05220410\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3506, "title": "An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder", "normalized_title": "an open label study of single dose psilocybin for major depressive disorder with co occurring borderline personality disorder", "authors": "University of Chicago", "abstract": "The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). The primary objective of the proposed study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD). Ten subjects with MDD and BPD will receive a single 25 mg oral dose of psilocybin. The hypothesis to be tested is that psilocybin will result significant reduction in symptoms of both MDD and BPD after 1 week and sustained for 4 weeks compared to baseline (improvement in symptoms will be indicated by lower scores on established outcome measures of MDD and BPD symptoms that have been used in prior studies).", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-22", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05399498", "keywords": "Borderline Personality Disorder, Major Depressive Disorder, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05399498\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Personality Change,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3055, "title": "A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants", "normalized_title": "a randomised triple blind dose finding study of the impact of psilocybin on motor function in healthy participants", "authors": "Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA.", "abstract": "Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study’s primary objectives examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers. Methods Healthy participants were randomly assigned three psilocybin doses consisting of either (1) 5mg, 10mg, and 15mg, or (2) 10mg, 15mg, and 20mg, with at least one week between doses. Movement tasks were administered during the acute drug effects. Participants, physiotherapists, and statisticians were blinded to the dosing order. Feasibility was assessed by evaluating completion of the de Morton Mobility Index and Functional Movement Exploration (measures of gross motor function). Safety outcomes included vital signs and adverse events. Additional exploratory motor outcomes included the Action Research Arm Test (assessing dexterity), Box and Block Test (Original and Modified versions) (combining dexterity with motor speed), Digit Symbol Substitution Test (combining motor speed with intellectual functions), and Reaction Time Ruler Drop Test (assessing reaction time). The 5-Dimensional Altered States of Consciousness and Ego-Dissolution Inventory assessed changes in states of consciousness. Blinding efficacy was assessed by asking participants and physiotherapists to guess the doses administered. Results Thirteen participants were randomised: seven to 5mg, 10mg, and 15mg; six to 10mg, 15mg, and 20mg. One participant was unable to complete several movement tasks at 20mg. Nausea (n=8, 62%) and headache (n=7, 54%) were the most common adverse events. No serious adverse events or adverse events related to movement task administration occurred. Median values [interquartile ranges] remained near-perfect across doses for the de Morton Mobility Index (92.5-100.0 [85.0-100.0]), Functional Movement Exploration (100.0 [96.0-100.0]), and Action Research Arm Test (56.0-57.0 [52.0-57.0]). Baseline Box and Block Test (Original) median scores (65.0 [60.0-67.0]) improved to 79.0 [70.0-83.0] at 5mg and 4.5 hours post-dose (5mg-4.5H), and worsened to 57.5 [51.0-64.0] at 20mg-1.5H. Baseline Box and Block Test (Modified) median scores (48.0 [47.0-53.0]) worsened to 43.0 [35.0-45.0] at 20mg-1.5H. Baseline Digit Symbol Substitution Test median scores (73.0 [66.0-77.0]) improved to 87.0 [81.0-90.0] at 10mg-4.5H, and worsened to 62.0 [54.0-86.0] at 20mg-1.5H. Reaction Time Ruler Drop Test scores lacked consistent dose-related changes across participants. Changes in states of consciousness were greatest at 20mg. Participants and physiotherapists correctly guessed the administered dose 53% and 50% of the time, respectively. Conclusions Movement tasks were feasible during psilocybin dosing up to 15mg. Impairments emerged at 20mg in tasks that combined motor and additional cognitive functions. These findings support the feasibility of performing complex movement tasks during psilocybin dosing and will inform the conduct of trials utilising psilocybin-assisted physical rehabilitation in neuropsychiatric disorders. Trial Registration Australian New Zealand Clinical Trials Registry: ACTRN12621000560897 Date registered: 12 May 2021 URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381526&isReview=true Key Findings There is growing interest for psychedelic-assisted physical therapy in neuropsychiatric disorders of motor dysfunction, however, the impact of psychedelics on motor function remains unclear. This study investigated the feasibility, safety, and impact on motor function of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers. These findings support the feasibility of performing complex movement tasks during psilocybin dosing up to 15mg and will inform the conduct of trials utilising psilocybin-assisted physical therapy in neuropsychiatric disorders.", "journal": "medRxiv", "publication_date": "2025-12-22", "publication_year": 2025, "doi": "10.64898/2025.12.22.25342874", "pubmed_id": null, "source_url": "https://doi.org/10.64898/2025.12.22.25342874", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1254240\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Headache / Migraine,Consciousness,Clinical Trial,Review Article,Healthy Volunteers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1990, "title": "Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study", "normalized_title": "group retreat psilocybin therapy for people with metastatic cancer with anxiety and depression a rite of passage facilitation model for a phase 1 2 study", "authors": "Anthony L. Back, Bonnie A. McGregor, Lindsay Billingsley, Dianna Blom, George Callan, Susanna Myers, John Guy, Sameet Kumar, Melissa Layer, Jackie Levin, Juliana Pérez, Peter Thompson, Kathy Salmonson, Joseph Whinney, Leslie Lazar Thorn", "abstract": "Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community. Purpose: This technical report describes a group facilitation model developed for an food and drug administration (FDA)-approved Phase 1 to 2 clinical trial that recruited people with metastatic cancer who had moderate or severe symptoms of anxiety or depression in which psilocybin was administered at a 3-day, in-person retreat. Results: The facilitation model we developed for this intervention is based on anthropological studies of ritual, specifically rites of passage, to develop a secular ritual with therapeutic aims. Using rites of passage terminology, “separation” corresponds to preparation, “liminal” corresponds to the psilocybin dosing session, and “reincorporation” corresponds to integration. In our usage, the term “ritual” refers to intentionally structured, symbolic acts that embody and reinforce shared meaning, guiding participants through experiences that may otherwise feel unbounded or overwhelming. In the group psilocybin retreat model, ritual functions both psychologically-by supporting emotional regulation, orientation, and meaning-making-and communally-by embedding the individual’s process within a shared field of intention and care. Conclusion: To our knowledge this is the first FDA-approved clinical trial of a secular ritual-based group facilitation model for psychedelic therapy that is associated with empirically demonstrated safety and efficacy outcomes.", "journal": "Psychedelic Medicine", "publication_date": "2025-12-22", "publication_year": 2025, "doi": "10.1177/28314425251404460", "pubmed_id": null, "source_url": "https://doi.org/10.1177/28314425251404460", "keywords": "Psilocybin, Psychotherapist, Facilitation, Anxiety, Psychology, Psychiatry, Clinical trial, Clinical psychology, Mediation, Explanatory model, Intervention (counseling), Group psychotherapy, Medicine, Cancer, Depression (economics), Mental health, Existentialism, Phase (matter), Randomized controlled trial, Hallucinogen, Trance, Rite of passage, Marital Therapy, Attachment theory, Rite, Psychosocial, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7116873484\",\"openalex_url\":\"https://openalex.org/W7116873484\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1537416593\",\"https://openalex.org/W2153303099\",\"https://openalex.org/W2430893194\",\"https://openalex.org/W2803238382\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3114414169\",\"https://openalex.org/W3210625928\",\"https://openalex.org/W4313201591\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4389895437\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4391924240\",\"https://openalex.org/W4396720923\",\"https://openalex.org/W4402500386\"],\"authorships\":[{\"id\":\"https://openalex.org/A5071781938\",\"display_name\":\"Anthony L. Back\",\"orcid\":\"https://orcid.org/0000-0002-7903-0477\"},{\"id\":\"https://openalex.org/A5030340063\",\"display_name\":\"Bonnie A. McGregor\",\"orcid\":\"https://orcid.org/0000-0003-0531-9347\"},{\"id\":\"https://openalex.org/A5121110928\",\"display_name\":\"Lindsay Billingsley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121109585\",\"display_name\":\"Dianna Blom\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121094019\",\"display_name\":\"George Callan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113200747\",\"display_name\":\"Susanna Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104069668\",\"display_name\":\"John Guy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5110006341\",\"display_name\":\"Sameet Kumar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121098160\",\"display_name\":\"Melissa Layer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121107381\",\"display_name\":\"Jackie Levin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104052443\",\"display_name\":\"Juliana Pérez\",\"orcid\":null},{\"id\":null,\"display_name\":\"Peter Thompson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086140656\",\"display_name\":\"Kathy Salmonson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121054901\",\"display_name\":\"Joseph Whinney\",\"orcid\":null},{\"id\":\"https://openalex.org/A5096909520\",\"display_name\":\"Leslie Lazar Thorn\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/28314425251404460\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Cancer Patients,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7116873484" }, { "id": 3585, "title": "Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter", "normalized_title": "effects of psilocybin on speech fluency struggle and brain activity in people who stutter", "authors": "NYU Langone Health", "abstract": "This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted therapy for improving clinical outcomes in individuals who stutter, is warranted. The aims of this study include: * Aim 1: Assess the safety and feasibility of psilocybin as a therapeutic agent for stuttering. * Aim 2: Evaluate the effects of psilocybin on objective and subjective measures of stuttering severity, struggle, and well-being. * Aim 3: Explore the therapeutic neural mechanisms of psilocybin in stuttering.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-21", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07296328", "keywords": "Stuttering, Psilocybin, Speech therapy, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07296328\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Mechanism of Action,Wellbeing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4197, "title": "Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research", "normalized_title": "assessing the readiness of psychiatrists in louisiana to incorporate psilocybin into clinical practice lessons learned from a state underrepresented in clinical psychedelic research", "authors": "Amanda Husein, Madalynn Traylor, M. Frances Vest, Bo Jarrett Wood, Madison Brogan, Alfred Thomas, Shawn E. McNeil, M Alfrad Nobel Bhuiyan, Peter S. Hendricks, John R. Kelly, Andrew Gribben, Sultan Alqahtani, Kelsea Keys, Amber N. Edinoff, J C Patterson, Kevin S. Murnane", "abstract": "Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing psychiatrists in Louisiana. Louisiana serves as a representative state, modeling other areas with limited exposure to psychedelic research. Methods: A30-question survey was distributed via mail and digital newsletter to all registered Louisiana psychiatrists. The survey consisted of demographic questions and questions pertaining to how strongly respondents agreed or disagreed with statements about psilocybin and psychedelics on a five-point Likert scale. The statements aimed to assess knowledge and exposure to psilocybin including opinions on research and legalization, safety and addiction potential, medical use, and potential benefits and usages. Results: Forty-nine responses were recorded. Eighty-two percent of participants reported having “some knowledge” of psilocybin. Eighty-six percent believed psilocybin should be researched for medicinal value, and 71% would prescribe psilocybin if it were proven beneficial for their patient’s illness. Fifty-seven percent believed it should be considered a first-line treatment for certain conditions, while 73% believed it should be used only after exhausting all other treatment modalities. The study had an overall 10.5% response rate, potentially limiting the generalizability of the findings. Conclusion: Louisiana psychiatrists in our sample appear open to integrating psilocybin into their practice if there is strong regulatory support. Psilocybin research is rapidly expanding and will soon reach Louisiana and other states with a limited history of psychedelic clinical research. These findings warrant the development of an educational program on psychedelics to arm psychiatrists and patients with the knowledge to make the most informed decisions.", "journal": "Psychedelic Medicine", "publication_date": "2025-12-18", "publication_year": 2025, "doi": "10.1177/28314425251381806", "pubmed_id": null, "source_url": "https://doi.org/10.1177/28314425251381806", "keywords": "Psilocybin, Generalizability theory, Psychology, Hallucinogen, Psychiatry, Medicine, Lysergic acid diethylamide, Limiting, Clinical psychology, Likert scale, Addiction, Medical education, Clinical Practice, Addiction medicine, Computer-assisted web interviewing, Clearance, MEDLINE, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:37", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7117566828\",\"openalex_url\":\"https://openalex.org/W7117566828\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1842727300\",\"https://openalex.org/W2001972521\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093274439\",\"https://openalex.org/W2108914738\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2129576675\",\"https://openalex.org/W2131364204\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2551733333\",\"https://openalex.org/W2749043159\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2773072410\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2790698047\",\"https://openalex.org/W2804532410\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2889504249\",\"https://openalex.org/W2895529315\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2927237494\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3137933781\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3215496863\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4386021334\",\"https://openalex.org/W4389203746\",\"https://openalex.org/W4404152712\"],\"authorships\":[{\"id\":\"https://openalex.org/A5114560873\",\"display_name\":\"Amanda Husein\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121546186\",\"display_name\":\"Madalynn Traylor\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054807419\",\"display_name\":\"M. Frances Vest\",\"orcid\":\"https://orcid.org/0000-0002-3411-2874\"},{\"id\":\"https://openalex.org/A5015353144\",\"display_name\":\"Bo Jarrett Wood\",\"orcid\":\"https://orcid.org/0000-0002-3893-260X\"},{\"id\":\"https://openalex.org/A5121585739\",\"display_name\":\"Madison Brogan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121572079\",\"display_name\":\"Alfred Thomas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037900321\",\"display_name\":\"Shawn E. McNeil\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063595984\",\"display_name\":\"M Alfrad Nobel Bhuiyan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5004506349\",\"display_name\":\"Peter S. Hendricks\",\"orcid\":null},{\"id\":\"https://openalex.org/A5046590180\",\"display_name\":\"John R. Kelly\",\"orcid\":\"https://orcid.org/0000-0002-9545-0615\"},{\"id\":\"https://openalex.org/A5027012302\",\"display_name\":\"Andrew Gribben\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067743810\",\"display_name\":\"Sultan Alqahtani\",\"orcid\":\"https://orcid.org/0000-0002-8761-9513\"},{\"id\":\"https://openalex.org/A5087571172\",\"display_name\":\"Kelsea Keys\",\"orcid\":null},{\"id\":\"https://openalex.org/A5003576927\",\"display_name\":\"Amber N. Edinoff\",\"orcid\":\"https://orcid.org/0000-0001-7436-6206\"},{\"id\":\"https://openalex.org/A5044139472\",\"display_name\":\"J C Patterson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5087345721\",\"display_name\":\"Kevin S. Murnane\",\"orcid\":\"https://orcid.org/0000-0002-8143-0541\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/28314425251381806\",\"is_oa\":false}}", "topic_tags": "Addiction,Observational Study,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7117566828" }, { "id": 3093, "title": "Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development", "normalized_title": "psilocybin treatment as an adjunct to cognitive behavioral therapy for eating disorders therapeutic rationale considerations for protocol development", "authors": "Koning E, Gamberg S, Keshen A.", "abstract": "Eating disorders (ED) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psilocybin treatment (PT) demonstrates therapeutic potential to enhance CBT-ED by exerting several neurobiological, psychological, and experiential effects (e.g., antidepressant, neuroplasticity, emotional openness) that are hypothesized to increase psychotherapeutic engagement, reduce dropout, and improve clinical outcomes. This article provides the first consolidation of existing theoretical evidence for PT/CBT-ED, proposes considerations for a con-current intervention protocol, and presents clinical and research considerations to empirically test its feasibility, safety, and efficacy. This line of inquiry is expected to advance the development of approaches that improve ED treatment outcomes and, more broadly, advance the study of psychedelics as tools to enhance evidence-based psychotherapy models.", "journal": "Preprints.org", "publication_date": "2025-12-18", "publication_year": 2025, "doi": "10.20944/preprints202512.1705.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202512.1705.v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1136419\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Neuroplasticity,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3521, "title": "A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression", "normalized_title": "a phase iii multicentre randomised double blind placebo controlled study to investigate the efficacy safety and tolerability of comp360 in participants with treatment resistant depression", "authors": "COMPASS Pathways", "abstract": "Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD) This is a phase III, international, multi-centre, randomised, parallel group, fixed single-dose, double-blind, placebo-controlled study. The study population will include participants aged ≥18 years with TRD. Overall, 255 participants will be randomised in a 2:1 ratio to receive COMP360 25 mg or placebo. The study comprises three parts (A, B, and C) and will last approximately 62 weeks including a three- to ten-week Screening Period. Part A will include a six-week follow-up from initial investigational product (IP) administration. In this study, the primary aim is to assess the efficacy and safety of a single dose of COMP360 25 mg versus placebo for reducing symptom severity in TRD, when administered with psychological support. This will be assessed in a 6-week, single-dose, double-blind, placebo-controlled part of the study (Part A). Durability of efficacy and long-term safety, and the efficacy and safety of re-treatment will be assessed in a 20-week single-dose, double-blind re-treatment part (Part B), and a 26-week open-label treatment part (Part C).", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-17", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05624268", "keywords": "Treatment Resistant Depression, Psilocybin, COMP360, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05624268\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE3\"]}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 392, "title": "Psilocybin reporting in media (PRiMe) for the treatment of depression", "normalized_title": "psilocybin reporting in media prime for the treatment of depression", "authors": "Gurjot Brar, T. R. JUN. BURKE, Andrew Gribben, Colm Harrington, Guillaume Thuery, John R. Kelly", "abstract": "OBJECTIVES: Interest in psilocybin as a treatment for depression has risen over the past decade, fuelled by promising clinical trials and a rapidly evolving regulatory landscape. Media coverage plays a critical role in shaping public perceptions, yet little is known about how psilocybin is portrayed in global anglophone online news for the treatment of depression. METHODS: = 125) discussing psilocybin as a treatment for depression from January 2000 to May 2024. Articles were sourced from the top 30 global anglophone news outlets, assessed using a 13-item instrument for comprehensiveness, and analysed for sentiment across five thematic categories. A separate sub-analysis was completed for Irish media. RESULTS: Findings indicate a significant increase in coverage over time, with 43.2% of articles published between 2022 and 2024, predominantly from the USA (68%). While 90.4% of articles cited researchers, fewer addressed risks (47.2%), long-term evidence (46.4%), or patient perspectives (25%). Sentiment analysis revealed a very positive sentiment across articles which was 2.27 on a scale from -5 (most negative) to + 5 (most positive) (SD1.33), with no significant changes over the time period. Reporting on psilocybin's onset and duration of effects increased significantly, reflecting growing clinical evidence. However, coverage remains concentrated in prominent outlets, with limited attention to patient experiences and long-term safety. CONCLUSIONS: These findings highlight the media's role in shaping discourse on emerging treatments and suggest a need for more balanced reporting to align public understanding with scientific evidence. This study provides a foundation for future research on media portrayals of psilocybin and implications for public perception and policy.", "journal": "Irish Journal of Psychological Medicine", "publication_date": "2025-12-17", "publication_year": 2025, "doi": "10.1017/ipm.2025.10142", "pubmed_id": "41410115", "source_url": "https://doi.org/10.1017/ipm.2025.10142", "keywords": "Psilocybin, Foundation (evidence), Perception, Depression (economics), Psychiatry, Psychology, Psychotherapist, Medicine, Clinical psychology, Public health, MEDLINE, Public discourse, Public opinion, Media coverage, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417453981\",\"openalex_url\":\"https://openalex.org/W4417453981\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2082662662\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2170196196\",\"https://openalex.org/W2181352742\",\"https://openalex.org/W2592269420\",\"https://openalex.org/W2896529565\",\"https://openalex.org/W2981686921\",\"https://openalex.org/W2982483551\",\"https://openalex.org/W3091400816\",\"https://openalex.org/W3120059502\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3215496863\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4220953030\",\"https://openalex.org/W4292410066\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4297272067\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4318455092\",\"https://openalex.org/W4318567094\",\"https://openalex.org/W4319457565\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4320507195\",\"https://openalex.org/W4376107756\",\"https://openalex.org/W4378602926\",\"https://openalex.org/W4385173317\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4391540455\",\"https://openalex.org/W4396518351\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4398137313\",\"https://openalex.org/W4401584843\",\"https://openalex.org/W4404152712\",\"https://openalex.org/W4405376152\",\"https://openalex.org/W4405528804\",\"https://openalex.org/W4405660466\",\"https://openalex.org/W4406472189\",\"https://openalex.org/W4408424120\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090579400\",\"display_name\":\"Gurjot Brar\",\"orcid\":\"https://orcid.org/0000-0002-4273-063X\"},{\"id\":\"https://openalex.org/A5102330353\",\"display_name\":\"T. R. JUN. BURKE\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027012302\",\"display_name\":\"Andrew Gribben\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044959285\",\"display_name\":\"Colm Harrington\",\"orcid\":\"https://orcid.org/0000-0002-9540-3640\"},{\"id\":\"https://openalex.org/A5055356301\",\"display_name\":\"Guillaume Thuery\",\"orcid\":\"https://orcid.org/0000-0003-3391-5293\"},{\"id\":\"https://openalex.org/A5046590180\",\"display_name\":\"John R. Kelly\",\"orcid\":\"https://orcid.org/0000-0002-9545-0615\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S27105705\",\"source_display_name\":\"Irish Journal of Psychological Medicine\",\"landing_page_url\":\"https://doi.org/10.1017/ipm.2025.10142\",\"is_oa\":true}}", "topic_tags": "Depression,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417453981" }, { "id": 353, "title": "Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.", "normalized_title": "psilocybin assisted therapy for individuals with palliative care needs a systematic review of safety and efficacy", "authors": "Matos ARS, Silva AC, Rego L, Fernandes R, Gonçalves S.", "abstract": "BackgroundPalliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, questions arise about how to provide patients with good end-of-life care. There has been increasing interest in the beneficial effects of using psilocybin-assisted therapy in patients with severe chronic illnesses near the end of their lives and who present symptoms of depression and/or anxiety.AimExplore the role of psilocybin-assisted therapy in palliative care, synthesizing evidence from clinical trials and longitudinal studies.DesignSystematic review.Data sourcesA bibliographic search was performed in April 2024 in B-on, PubMed, Web of Science, and Scopus. Eligible studies included peer-reviewed quantitative research (RCTs, longitudinal, and observational designs) with adult participants in palliative care settings, examining the efficacy and safety of psilocybin-assisted therapy. Reviews, gray literature, and studies outside the scope of palliative care were excluded.ResultsOf the 215 articles found, six studies (n = 74 participants; age range 22-75 years) met the inclusion criteria. Across randomized and open-label trials, psilocybin-assisted therapy produced clinically significant reductions in depression and anxiety, with 57-79% of participants achieving ⩾ 50% symptom reduction on standardized scales (e.g. HAM-D, HAM-A, BDI, STAI). Improvements were sustained for up to 6-8 months in most trials, and in one follow-up study, for up to 4.5 years. Reported adverse effects were generally mild and transient, including nausea, vomiting, and temporary increases in blood pressure and heart rate; no serious adverse events were observed.ConclusionsPsilocybin-assisted therapy consistently demonstrated efficacy and safety in the reduction of depressive and anxiety symptoms. However, more studies exploring integrating psilocybin-assisted therapy into existing palliative care healthcare systems are needed. This includes investigating the feasibility, acceptability, and cost-effectiveness of integrating psilocybin-assisted therapy into routine clinical practice.", "journal": null, "publication_date": "2025-12-17", "publication_year": 2025, "doi": "10.1177/02692163251383335", "pubmed_id": "41410211", "source_url": "https://doi.org/10.1177/02692163251383335", "keywords": "Humans, Hallucinogens, Palliative Care, Depression, Anxiety, Quality of Life, Adult, Aged, Middle Aged, Female, Male, Young Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"41410211\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Observational Study,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 156, "title": "Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders", "normalized_title": "exploring psilocybin assisted schema therapy a conceptual framework for potential therapeutic synergies in personality disorders", "authors": "", "abstract": "Personality disorders (PDs) are characterized by rigid and maladaptive patterns of self- and interpersonal functioning, leading to high clinical burden and limited treatment outcomes. Schema Therapy (ST), an integrative psychotherapy rooted in cognitive-behavioral principles, conceptualizes PDs in terms of Early Maladaptive Schemas (EMS)-pervasive cognitive-affective structures formed through unmet emotional needs-and schema modes, dynamic states organizing emotion, belief, and behavior. Evidence indicates moderate efficacy of ST, mainly for borderline personality disorder, with limited research on other Cluster B and C PDs. Emerging evidence suggests that psilocybin, a serotonergic psychedelic, can induce enduring personality change, supporting its potential use in treating PDs. Within a predictive coding framework, the REBUS (“Relaxed Beliefs Under Psychedelics”) and REBAS (“Revised Beliefs After Psychedelics”) models propose that psilocybin relaxes high-level priors, facilitating cognitive flexibility and revision of maladaptive self-beliefs. Conceptual parallels between EMS and high-level priors suggest that psychedelic-induced relaxation of entrenched beliefs may enhance responsiveness to ST’s experiential and cognitive interventions. Psilocybin-Assisted Schema Therapy (PAST) is proposed as a model in which psilocybin sessions are followed by integration combining psychedelic-induced cognitive flexibility with ST techniques, aimed at strengthening adaptive modes and reducing dysfunctional EMS and dysfunctional modes. PAST could be relevant in the future for enhancing outcomes and potentially reducing treatment duration in Cluster B and C PDs, pending empirical validation. Although current literature is insufficient to recommend psilocybin-assisted interventions for PDs, this theoretical article bridges computational neuroscience and clinical psychotherapy, outlining a framework for future studies on PAST feasibility, safety, and efficacy.", "journal": "PsyArXiv", "publication_date": "2025-12-17", "publication_year": 2025, "doi": "10.47626/2237-6089-2025-1273", "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/v7pxn_v1", "keywords": "Early Maladaptive Schemas, Personality Disorder, Predictive Coding, Psilocybin, Psychedelic-Assisted Therapy, Schema Therapy, Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"v7pxn_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Personality Change,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 294, "title": "Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape", "normalized_title": "psilocybin in the real world regulatory ethical and operational challenges in australia s clinical landscape", "authors": "Megan Dutton, Paul Schwenn, Jules Mitchell, Per Hoffmann, Neil W. Bailey, Paul B. Fitzgerald, Jim Lagopoulos, Adem Can", "abstract": "Australia's reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatric policy. While this regulatory change positions Australia as a global leader in psychedelic medicine, its implementation has revealed substantial challenges. This article critically examines the regulatory, ethical and operational complexities surrounding the provision of psilocybin-assisted therapy in clinical practice. Key issues include limited prescriber access, absence of Australian Register of Therapeutic Goods-listed products, lack of standardised training pathways and significant cost barriers. Ethical considerations such as informed consent, cultural safety and therapeutic fidelity are also discussed, particularly in the context of trauma-informed care. This article proposes a series of structural recommendations to support safe and equitable deployment, including national training accreditation and fidelity monitoring tools. In addition, to maximise the efficacy of psilocybin-assisted therapy, we recommend that research explores the potential of neurobiologically informed stratification models to assist with treatment recommendations. These recommendations aim to enhance clinical integrity through evidence-based patient selection, improved safety, and to ensure that emerging psychedelic treatments are integrated responsibly within Australia's mental health system. By addressing these foundational gaps, Australia can move beyond regulatory novelty ensuring the therapeutic potential of these products is realised in a manner which is scientifically sound and upholds the integrity of psychiatric practice.", "journal": "Australian & New Zealand Journal of Psychiatry", "publication_date": "2025-12-16", "publication_year": 2025, "doi": "10.1177/00048674251398677", "pubmed_id": "41405025", "source_url": "https://doi.org/10.1177/00048674251398677", "keywords": "Mental health, Context (archaeology), Novelty, Accreditation, Fidelity, Psychology, Engineering ethics, Medicine, Multidisciplinary approach, Ethical issues, Psilocybin, Psychiatry, Psychotherapist, Health care, Patient safety, Public relations, Project commissioning, Competence (human resources), Schedule, Clinical trial, Informed consent, Key (lock), Mental illness, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417431364\",\"openalex_url\":\"https://openalex.org/W4417431364\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2012101788\",\"https://openalex.org/W2749595928\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2794329512\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W2986842001\",\"https://openalex.org/W3029961383\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3112909063\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3210625928\",\"https://openalex.org/W3214226891\",\"https://openalex.org/W4220928043\",\"https://openalex.org/W4281666404\",\"https://openalex.org/W4300960088\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4316511384\",\"https://openalex.org/W4366352039\",\"https://openalex.org/W4376107756\",\"https://openalex.org/W4378745947\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385805479\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4389035919\",\"https://openalex.org/W4393238047\",\"https://openalex.org/W4394874345\",\"https://openalex.org/W4400361932\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4405528804\",\"https://openalex.org/W4405565174\",\"https://openalex.org/W4405978092\",\"https://openalex.org/W4410851090\",\"https://openalex.org/W4412555614\",\"https://openalex.org/W4413037134\",\"https://openalex.org/W4413521552\"],\"authorships\":[{\"id\":\"https://openalex.org/A5041395883\",\"display_name\":\"Megan Dutton\",\"orcid\":\"https://orcid.org/0009-0009-5209-2801\"},{\"id\":\"https://openalex.org/A5001791405\",\"display_name\":\"Paul Schwenn\",\"orcid\":\"https://orcid.org/0000-0003-0331-8113\"},{\"id\":\"https://openalex.org/A5014308852\",\"display_name\":\"Jules Mitchell\",\"orcid\":\"https://orcid.org/0000-0002-3086-7129\"},{\"id\":\"https://openalex.org/A5026517521\",\"display_name\":\"Per Hoffmann\",\"orcid\":\"https://orcid.org/0000-0002-6573-983X\"},{\"id\":\"https://openalex.org/A5038772618\",\"display_name\":\"Neil W. Bailey\",\"orcid\":\"https://orcid.org/0000-0002-8483-1068\"},{\"id\":\"https://openalex.org/A5083159520\",\"display_name\":\"Paul B. Fitzgerald\",\"orcid\":\"https://orcid.org/0000-0003-4217-8096\"},{\"id\":\"https://openalex.org/A5041201452\",\"display_name\":\"Jim Lagopoulos\",\"orcid\":\"https://orcid.org/0000-0002-5684-8583\"},{\"id\":\"https://openalex.org/A5051802152\",\"display_name\":\"Adem Can\",\"orcid\":\"https://orcid.org/0000-0001-7686-8840\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S179943861\",\"source_display_name\":\"Australian & New Zealand Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1177/00048674251398677\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Mechanism of Action,Clinical Trial,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417431364" }, { "id": 3437, "title": "Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer", "normalized_title": "feasibility phase 2 study of psilocybin assisted therapy for opioid refractory pain in patients with advanced cancer", "authors": "Yvan Beaussant, MD, MSci", "abstract": "The overall objective of this study is to assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy to alleviate opioid-refractory pain in patients with advanced-cancer. The name of the study intervention used in this research study is: Psilocybin (a tryptamine derivative) This study is a phase 2 open label, single center, concurrent mixed-methods trial to assess the feasibility of a novel palliative-care informed psilocybin-assisted psychotherapy regimen to alleviate opioid-refractory pain in patients with advanced-cancer. Psilocybin works on the serotonin system in the brain which is linked to the regulation of mood, motivation and impulse control. Psilocybin is an \"Investigational\" drug, meaning that the study drug has not been approved by the U.S. Food and Drug Administration (FDA) as a treatment for any disease. However, investigators have permission from the FDA to use this drug in this research study. The research study procedures include screening for eligibility, an electrocardiogram, blood tests, and the study intervention includes preparation, evaluations, one psilocybin session and follow up visits. Participants will be followed for up to 12 weeks (approximately 3 months) after receiving the study treatment. It is expected that about 15 people will take part in this research study. Filament Health is supporting this research study by providing the study investigational medication, psilocybin. Cy Biopharma and Pancreatic Cancer North America are supporting this research study by providing funding.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-15", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06001749", "keywords": "Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06001749\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,End-of-Life Distress,Chronic Pain,Receptor Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 394, "title": "Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study", "normalized_title": "psilocybin assisted psychotherapy for treatment resistant obsessive compulsive disorder protocol for an open label pilot study", "authors": "Nicole Ledwos, Jenna Baer, Muhammad Ishrat Husain, Daniel M. Blumberger, Rachel Patterson, Elizabeth Hollingdrake, Ezmond S.L. Cheung, Colin Hawco, Christoph Zrenner, Brigitte Zrenner, Jamie D. Feusner, Susan L. Rossell, David Castle, Gwyneth Zai", "abstract": "BACKGROUND: Obsessive-compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, atypical antipsychotic augmentation and cognitive-behavioural therapy. However, up to 60% of people with OCD do not respond to these treatments. Therefore, a novel intervention, psilocybin-assisted psychotherapy (PAP), is an option of interest. Moreover, there is a need to better understand the mechanisms underpinning PAP's effect on OCD symptoms. AIMS: We aimed to (a) establish the feasibility, tolerability and safety of administering PAP to adults with treatment-resistant OCD; (b) provide preliminary data on the clinical effects of PAP for treatment-resistant OCD, to inform the design of larger clinical trials; and (c) compare neuroimaging and neurophysiological markers pre- and post-PAP in treatment-resistant OCD. METHOD: In this 12-week open-label trial, ten adults with treatment-resistant OCD will receive one 25 mg dose of psilocybin combined with psychological support. Feasibility, tolerability and safety will be assessed throughout. Clinical outcomes will be measured with the Yale-Brown Obsessive-Compulsive Scale. Exploratory measures will include brain imaging examining changes in dynamic connectivity from pre to post treatment, electroencephalogram to investigate changes in brain dynamics associated with psilocybin under acute conditions, and transcranial magnetic stimulation-electroencephalogram measures between baseline, provocation of OCD symptoms and up to 1-week post-dose. RESULTS: The study will provide important preliminary data on the feasibility and efficacy of PAP in adults with treatment-resistant OCD, as well as inform our understanding of neurobiological mechanisms. CONCLUSIONS: The findings of the study will inform the design of larger randomised controlled trials and advance the field of psychedelic-assisted therapies.", "journal": "BJPsych Open", "publication_date": "2025-12-14", "publication_year": 2025, "doi": "10.1192/bjo.2025.10895", "pubmed_id": "41392767", "source_url": "https://doi.org/10.1192/bjo.2025.10895", "keywords": "Protocol (science), Psychotherapist, Psychology, Pilot trial, Field (mathematics), Research design, Medicine, Intervention (counseling), Randomized controlled trial, Clinical trial, Data collection, Applied psychology, Psychiatry, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417362478\",\"openalex_url\":\"https://openalex.org/W4417362478\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W122113993\",\"https://openalex.org/W200847362\",\"https://openalex.org/W1991771535\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2008066608\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2086030840\",\"https://openalex.org/W2087854982\",\"https://openalex.org/W2092586569\",\"https://openalex.org/W2100202859\",\"https://openalex.org/W2113226993\",\"https://openalex.org/W2122126648\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2123722617\",\"https://openalex.org/W2129340715\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2149025975\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2306891185\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2596797494\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2788732613\",\"https://openalex.org/W2890759366\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2938471378\",\"https://openalex.org/W2984198212\",\"https://openalex.org/W3110345791\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3134642859\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4308485018\",\"https://openalex.org/W4310735641\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4361279088\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4390586775\",\"https://openalex.org/W4404286681\",\"https://openalex.org/W4407181198\"],\"authorships\":[{\"id\":\"https://openalex.org/A5051154946\",\"display_name\":\"Nicole Ledwos\",\"orcid\":\"https://orcid.org/0000-0002-8604-3313\"},{\"id\":\"https://openalex.org/A5066478925\",\"display_name\":\"Jenna Baer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078217449\",\"display_name\":\"Muhammad Ishrat Husain\",\"orcid\":\"https://orcid.org/0000-0001-5771-5750\"},{\"id\":\"https://openalex.org/A5003880874\",\"display_name\":\"Daniel M. Blumberger\",\"orcid\":\"https://orcid.org/0000-0002-8422-5818\"},{\"id\":\"https://openalex.org/A5080940430\",\"display_name\":\"Rachel Patterson\",\"orcid\":\"https://orcid.org/0000-0003-0131-4178\"},{\"id\":\"https://openalex.org/A5054311601\",\"display_name\":\"Elizabeth Hollingdrake\",\"orcid\":null},{\"id\":\"https://openalex.org/A5033889902\",\"display_name\":\"Ezmond S.L. Cheung\",\"orcid\":\"https://orcid.org/0009-0008-7546-0817\"},{\"id\":\"https://openalex.org/A5087321752\",\"display_name\":\"Colin Hawco\",\"orcid\":\"https://orcid.org/0000-0003-3156-4119\"},{\"id\":\"https://openalex.org/A5070264725\",\"display_name\":\"Christoph Zrenner\",\"orcid\":\"https://orcid.org/0000-0002-9595-6923\"},{\"id\":\"https://openalex.org/A5017656175\",\"display_name\":\"Brigitte Zrenner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040702751\",\"display_name\":\"Jamie D. Feusner\",\"orcid\":\"https://orcid.org/0000-0002-0391-345X\"},{\"id\":\"https://openalex.org/A5073606057\",\"display_name\":\"Susan L. Rossell\",\"orcid\":\"https://orcid.org/0000-0002-7415-8252\"},{\"id\":\"https://openalex.org/A5052884442\",\"display_name\":\"David Castle\",\"orcid\":\"https://orcid.org/0000-0002-3075-1580\"},{\"id\":\"https://openalex.org/A5104046382\",\"display_name\":\"Gwyneth Zai\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764831659\",\"source_display_name\":\"BJPsych Open\",\"landing_page_url\":\"https://doi.org/10.1192/bjo.2025.10895\",\"is_oa\":true}}", "topic_tags": "OCD,Chronic Pain,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Biomarkers,Aging,Clinical Trial,Randomized Controlled Trial,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417362478" }, { "id": 3048, "title": "Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study", "normalized_title": "real world psilocybin therapy for treatment resistant depression a retrospective observational study", "authors": "Jungwirth J, Westenhöfer S, Aicher H, Provaznikova B, Kronenberg G, Seifritz E, Prinz S, Olbrich S.", "abstract": "Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown. Although psilocybin is not yet approved as an antidepressant treatment, Switzerland’s unique legal framework allows its limited medical use for TRD. We conducted a retrospective analysis of medical records from 19 TRD patients treated with psilocybin (20-35mg) across one to four dosing sessions at the Psychiatric University Hospital Zurich. Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI). Changes from baseline to interim and post-treatment were analyzed, including response, remission, and the reliable change index. MADRS scores significantly decreased from baseline ( M = 30.78) to post-treatment ( M = 19.89), with a large effect size (Hedges’ g = 1.37, p", "journal": "Research Square", "publication_date": "2025-12-09", "publication_year": 2025, "doi": "10.21203/rs.3.rs-8079137/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-8079137/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1132641\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 354, "title": "Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety", "normalized_title": "psilocybin in late life mental health addressing depression loneliness and existential anxiety", "authors": "Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales, Muhammad Ishrat Husain, Daniel M. Blumberger", "abstract": "The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental health conditions, notably depression, loneliness, and existential distress. Traditional pharmacological treatments often exhibit limited efficacy and poor tolerability in older patients, primarily due to age-related physiological changes and the challenges associated with polypharmacy. Recently, psychedelic-assisted therapy, particularly psilocybin, has gained attention for its potential antidepressant and psychological benefits. This comprehensive review critically evaluates the current evidence supporting psilocybin's effectiveness in older populations and elucidates its neurobiological mechanisms, including serotonergic modulation, enhanced neuroplasticity, and the disruption of maladaptive default mode network activity. Clinical trials in general adult samples demonstrate sustained improvements in depressive symptoms, existential anxiety, and social connectedness following psilocybin administration, suggesting its distinct therapeutic potential beyond conventional treatments. However, geriatric populations are underrepresented in psychedelic research, creating significant knowledge gaps regarding dosing, safety profiles, and long-term outcomes. Pharmacokinetic complexities, cardiovascular risks, and drug interactions necessitate age-specific therapeutic protocols. Ethical considerations, including the complexities of informed consent in cases of cognitive impairment, further underscore the importance of tailored approaches. Future directions must prioritize dedicated geriatric studies that incorporate rigorous safety assessments and integrate findings into existing geriatric care frameworks to fully assess the potential of psilocybin for enhancing late-life mental health and quality of life.", "journal": "General Hospital Psychiatry", "publication_date": "2025-12-08", "publication_year": 2025, "doi": "10.1016/j.genhosppsych.2025.12.005", "pubmed_id": "41401486", "source_url": "https://doi.org/10.1016/j.genhosppsych.2025.12.005", "keywords": "Psilocybin, Psychological intervention, Psychology, Anxiety, Mental health, Tolerability, Cognition, Clinical psychology, Psychiatry, Psychotherapist, Antidepressant, Informed consent, Medicine, Clinical trial, MEDLINE, Mental illness, Polypharmacy, Depression (economics), Social connectedness, Quality of life (healthcare), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417166023\",\"openalex_url\":\"https://openalex.org/W4417166023\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1531988994\",\"https://openalex.org/W1975380080\",\"https://openalex.org/W2007816489\",\"https://openalex.org/W2047342826\",\"https://openalex.org/W2053580809\",\"https://openalex.org/W2054169331\",\"https://openalex.org/W2055862036\",\"https://openalex.org/W2088140721\",\"https://openalex.org/W2107441654\",\"https://openalex.org/W2108129761\",\"https://openalex.org/W2111553780\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2122879540\",\"https://openalex.org/W2127005038\",\"https://openalex.org/W2131764590\",\"https://openalex.org/W2312396951\",\"https://openalex.org/W2335478514\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2518041136\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2586877732\",\"https://openalex.org/W2609801503\",\"https://openalex.org/W2736123236\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2901739937\",\"https://openalex.org/W2952447426\",\"https://openalex.org/W2998525361\",\"https://openalex.org/W2999279320\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3021136383\",\"https://openalex.org/W3080361799\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3159481221\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W3207449839\",\"https://openalex.org/W3217718387\",\"https://openalex.org/W4200455094\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4282931386\",\"https://openalex.org/W4283524493\",\"https://openalex.org/W4294723946\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4306663560\",\"https://openalex.org/W4306913343\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4308768859\",\"https://openalex.org/W4309494777\",\"https://openalex.org/W4312196530\",\"https://openalex.org/W4323656393\",\"https://openalex.org/W4365141030\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4384664606\",\"https://openalex.org/W4385542937\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387893679\",\"https://openalex.org/W4390988530\",\"https://openalex.org/W4391115210\",\"https://openalex.org/W4391540455\",\"https://openalex.org/W4391824403\",\"https://openalex.org/W4391841842\",\"https://openalex.org/W4391959916\",\"https://openalex.org/W4391967348\",\"https://openalex.org/W4392004581\",\"https://openalex.org/W4392049752\",\"https://openalex.org/W4397049758\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401920066\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4405510726\",\"https://openalex.org/W4406599518\",\"https://openalex.org/W4407642838\",\"https://openalex.org/W4408049629\",\"https://openalex.org/W4408808337\",\"https://openalex.org/W4410119026\",\"https://openalex.org/W4410795265\"],\"authorships\":[{\"id\":\"https://openalex.org/A5051147741\",\"display_name\":\"Gerasimos Konstantinou\",\"orcid\":\"https://orcid.org/0000-0002-0303-1633\"},{\"id\":\"https://openalex.org/A5050740394\",\"display_name\":\"Joshua D. Rosenblat\",\"orcid\":\"https://orcid.org/0000-0002-4773-2191\"},{\"id\":\"https://openalex.org/A5060578045\",\"display_name\":\"Sarah Hales\",\"orcid\":\"https://orcid.org/0000-0001-6404-8124\"},{\"id\":\"https://openalex.org/A5078217449\",\"display_name\":\"Muhammad Ishrat Husain\",\"orcid\":\"https://orcid.org/0000-0001-5771-5750\"},{\"id\":\"https://openalex.org/A5108125787\",\"display_name\":\"Daniel M. Blumberger\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S45708651\",\"source_display_name\":\"General Hospital Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/j.genhosppsych.2025.12.005\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Neuroplasticity,Pharmacology,Mechanism of Action,Default Mode Network,Aging,Clinical Trial,Review Article,Safety,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417166023" }, { "id": 3625, "title": "Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study", "normalized_title": "investigating the effects of a psychedelic augmented mental imagery based intervention for young people with self harm behaviour an experimental medicine study", "authors": "Imperial College London", "abstract": "Approximately 20% of young people experience self-harm behaviour in their lives. Self-harm can occur across different mental health disorders, and lead to negative outcomes and risk of suicide. Current treatments are long, costly and do not suit all young people, making it essential to research alternative treatments. Therapy combined with psychedelic drugs has recently been shown to be helpful in a variety of mental health disorders, including depression. This research project will explore the mechanisms by which combining a low dose of psychedelic psilocybin with a cognitive technique may target self-harm behaviour in young people (aged 16-25). Previous research has shown that mental images of self-harm are common among individuals who self-harm and can increase the urge to self-harm. Imagery Re-Scripting (ImRS) is a cognitive technique that guides an individual to replace mental imagery driving self-harm with an alternative image that will instead discourage self-harm and promote alternative coping strategies. However, during ImRS individuals may fear bringing negative mental images and emotions to mind, hindering the process. Psychedelic substances can increase the ability to tolerate difficult emotions, make thinking styles more flexible and individuals more open to change. Based on this, the aim is to test if enhancing a cognitive technique with a low dose psychedelic can modify the cognitive mechanisms maintaining self- harm behaviour. The aim is to examine the effect of a sub-hallucinogenic dose of psilocybin in combination with ImRS on cognitive processes, such as experiencing vivid mental images, and whether it can reduce these mental images and associated negative emotions in young people with recent self-harm behaviour above the effects of ImRS alone. The hypothesis is that psilocybin could facilitate confronting the emotions that arise during ImRS and make it easier to generate new helpful mental imagery. These experimental data could lay the foundation for future treatment development targeting self-harm in young people.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-04", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06798636", "keywords": "Self Harm, Psilocybin 5 mg with cognitive behavioural therapy intervention, Psilocybin, Placebo with cognitive behavioural therapy intervention, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06798636\",\"overall_status\":\"RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Depression,Mechanism of Action,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3692, "title": "Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study", "normalized_title": "standardized natural psilocybin assisted psychotherapy for tapering of opioid medication in patients with chronic pain an open label feasibility study", "authors": "University of British Columbia", "abstract": "This is an open-label pilot trial to assess the safety and feasibility of a novel 8-week psilocybin-assisted psychotherapy intervention to facilitate successful tapering/discontinuation of opioid pain medication in adult patients receiving long-term opioid therapy for chronic pain. Participation will last approximately 8 months and includes one or two psilocybin-assisted therapy sessions. The study will evaluate the incidence and severity of adverse events during and after treatment, the number of participants who drop out of the study for intervention-related reasons, and the self-reported benefits and harms of the intervention. The purpose of this pilot study is to establish the safety and tolerability of a therapeutic intervention using psilocybin-assisted psychotherapy as a novel treatment for opioid tapering in a sample of patients with chronic pain. Participants will be patients who have failed previous attempts to reduce their use of opioid medication and who have no medical or psychological contraindications for psilocybin administration. This pilot study involves an 8-week open-label, non-randomized therapeutic intervention and a 6-month follow-up period. To provide a supportive context for the drug experience, participants will receive preparatory and integrative sessions following an acceptance and commitment therapy model for psychedelic therapy. The physician-supervised opioid taper will begin following the first psilocybin dosing session (25mg) after an integration session with therapists, and a second optional psilocybin dosing session (37.5mg) will be facilitated one month later. Assessments will be completed at baseline, and at follow-up points at 1-month, 3-months and 6-months post-intervention to evaluate both acute and long-term effects of the intervention. Primary outcomes of interest are rates of adverse events, retention rates, and patient perceptions of intervention tolerability. Preliminary efficacy of the treatment will be evaluated by tracking opioid reduction rates and long-term maintenance of these reductions. Other measures of interest include qualities of the psychedelic experience, opioid cravings and withdrawal, chronic pain symptoms, and psychological mechanisms.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-03", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05585229", "keywords": "Opioid Dependence, Chronic Pain, Psilocybin-assisted Psychotherapy, PEX010, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05585229\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Chronic Pain,Mechanism of Action,Safety,Adverse Events,Contraindications", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3513, "title": "A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer", "normalized_title": "a phase 2b randomized double blind placebo controlled multi center study of the effects of psilocybin assisted psychotherapy on psychiatric and existential distress in advanced cancer", "authors": "NYU Langone Health", "abstract": "The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer. This trial is designed to evaluate efficacy and psychological mechanisms of single-dose psilocybin-assisted psychotherapy (PAP) to treat psychiatric (anxiety, depression) and existential distress (demoralization, death anxiety), and quality-of-life (QOL), in 200 outpatients with late-stage or advanced cancer. The study will assess the strength and durability of therapeutic effects in a double-blind, parallel-design, placebo-controlled, two-center RCT comparing a single 25mg oral 'high' dose of psilocybin to a single 100mg dose of niacin (active placebo), both delivered in conjunction with a psychotherapy platform.", "journal": "ClinicalTrials.gov", "publication_date": "2025-12-03", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05398484", "keywords": "Advanced Cancer, Psilocybin 25 mgs, Niacin 100mg, Psychotherapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05398484\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\",\"PHASE3\"]}", "topic_tags": "Depression,Anxiety,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4212, "title": "Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears", "normalized_title": "magic mushrooms as medicine what the united states can learn from jamaica s unregulated psilocybin industry as fda approval nears", "authors": "Spohn, Kyle", "abstract": "In 1970, Congress passed the Controlled Substances Act and swiftly placed psilocybin (the active chemical in “magic mushrooms”) under Schedule I-the strictest level of regulation withheld for substances with “no currently accepted medical use.” While the United States has maintained this rigid framework, Jamaica has taken the opposite approach. Psilocybin was never listed under Jamaica’s Dangerous Drugs Act, and remains unregulated. In recent decades, research has shown that psilocybin, when administered in controlled settings, can effectively treat depression, anxiety, and other psychiatric conditions. In response, the Jamaican government has not only preserved psilocybin’s legality but has encouraged research and industry development. Today, as the United States faces a mental health crisis, pharmaceutical companies are in the final stages of FDA clinical trials for psilocybin-based treatments targeting major depressive disorder and treatment-resistant depression. If approved, this medical recognition would compel federal rescheduling and the creation of a novel American regulatory framework for psilocybin therapy. In light of potential deregulation, this Note examines the Jamaican model as a case study, where psilocybin’s legal status has fostered both innovation and inequity. The country’s “shroom boom” has advanced psychiatric research and generated economic growth, but the absence of regulation has also led to safety risks and limited access for locals. Drawing lessons from Jamaica, this Note proposes a dual-policy framework under the Controlled Substances Act. FDA-approved psilocybin formulations should be placed in Schedule III to maximize accessibility in supervised clinical settings, while natural, non-pharmaceutical psilocybin should be rescheduled to Schedule II to promote continued research under controlled conditions. This balanced framework emphasizes safety, accessibility, and scientific research, allowing psilocybin to develop into a transformative tool in American mental health treatment.", "journal": "eYLS (Yale Law School)", "publication_date": "2025-12-01", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://repository.law.miami.edu/umialr/vol57/iss1/7", "keywords": "Psilocybin, Government (linguistics), Principle of legality, Political science, Schedule, Pharmaceutical industry, Business, Public administration, Public relations, Psychiatry, Law, Clinical trial, Medicine, Mental health, Criminology, Food and drug administration, Engineering, Health care, Government regulation, Altered state, Drug approval, Federal law, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Substance Abuse Treatment and Outcomes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:38", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7112471464\",\"openalex_url\":\"https://openalex.org/W7112471464\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Spohn, Kyle\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306401049\",\"source_display_name\":\"eYLS (Yale Law School)\",\"landing_page_url\":\"https://repository.law.miami.edu/umialr/vol57/iss1/7\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7112471464" }, { "id": 4230, "title": "Efficacy of psilocybin on death anxiety in terminal patients: a narrative review", "normalized_title": "efficacy of psilocybin on death anxiety in terminal patients a narrative review", "authors": "Morris Lintong Barimbing, Dian Pritasari Jeger, Made Edwin Sridana", "abstract": "This narrative review synthesized the use of psilocybin-assisted therapy as a promising treatment for alleviating death anxiety in terminally ill patients. The insights presented are derived from findings reported in previous studies. Therefore, this review aimed to assess the efficacy, pharmacology, and mechanisms by which psilocybin alters brain function by affecting 5-HT2A receptors and disrupting the default mode network (DMN), helping to reduce existential fear. Recent randomized controlled trials (RCTs) demonstrated substantial progress in therapy, with results showing standardized mean differences in anxiety reduction ranging from −0.70 to −1.08, with effects lasting up to six months after a single dose. This review examines the implications for clinical practice, highlighting psilocybin’s favorable safety profile and its potential to fill therapeutic gaps left by conventional treatments, and also addresses the ethical issues surrounding the use of psilocybin in terminally ill patients. The findings support the integration of psychedelic-assisted methods with standard palliative care to enhance end-of-life care and also highlight potential directions for further studies.", "journal": "Progress in Palliative Care", "publication_date": "2025-11-30", "publication_year": 2025, "doi": "10.1080/09699260.2026.2657096", "pubmed_id": null, "source_url": "https://doi.org/10.1080/09699260.2026.2657096", "keywords": "Psilocybin, Medicine, Narrative review, Anxiety, Psychiatry, Terminal (telecommunication), Death anxiety, Psychotherapist, Life review, Narrative, Clinical psychology, Terminal care, Depression (economics), Palliative care, MEDLINE, Review article, Hallucinogen, Terminal cancer, Terminally ill, Psychedelics and Drug Studies, Death Anxiety and Social Exclusion, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:38", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7152631097\",\"openalex_url\":\"https://openalex.org/W7152631097\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1987559404\",\"https://openalex.org/W2058150514\",\"https://openalex.org/W2413083000\",\"https://openalex.org/W2518148997\",\"https://openalex.org/W2894694698\",\"https://openalex.org/W2902481475\",\"https://openalex.org/W2949756216\",\"https://openalex.org/W2966728360\",\"https://openalex.org/W2991985135\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3014996408\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3087328717\",\"https://openalex.org/W3113693816\",\"https://openalex.org/W3134789907\",\"https://openalex.org/W3175230374\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3194946707\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W3208196863\",\"https://openalex.org/W3213518678\",\"https://openalex.org/W4200198590\",\"https://openalex.org/W4200517619\",\"https://openalex.org/W4225106358\",\"https://openalex.org/W4281653128\",\"https://openalex.org/W4292308198\",\"https://openalex.org/W4293216995\",\"https://openalex.org/W4295828365\",\"https://openalex.org/W4306398972\",\"https://openalex.org/W4316686787\",\"https://openalex.org/W4323263931\",\"https://openalex.org/W4366280986\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4380484863\",\"https://openalex.org/W4383187233\",\"https://openalex.org/W4383912690\",\"https://openalex.org/W4384819730\",\"https://openalex.org/W4385173532\",\"https://openalex.org/W4386901577\",\"https://openalex.org/W4390509229\",\"https://openalex.org/W4391328164\",\"https://openalex.org/W4391755875\",\"https://openalex.org/W4392767026\",\"https://openalex.org/W4396869026\",\"https://openalex.org/W4401895725\",\"https://openalex.org/W4406126624\",\"https://openalex.org/W4406472518\",\"https://openalex.org/W4408459373\",\"https://openalex.org/W4409521679\",\"https://openalex.org/W4409797469\",\"https://openalex.org/W4410735628\",\"https://openalex.org/W4410910940\",\"https://openalex.org/W4411086084\",\"https://openalex.org/W4411955700\",\"https://openalex.org/W4413030984\",\"https://openalex.org/W4413190735\",\"https://openalex.org/W4414123659\",\"https://openalex.org/W4414267802\",\"https://openalex.org/W4414465307\",\"https://openalex.org/W4414541727\",\"https://openalex.org/W4414616693\",\"https://openalex.org/W4414845973\",\"https://openalex.org/W4417166023\",\"https://openalex.org/W4417184349\",\"https://openalex.org/W4417190046\",\"https://openalex.org/W7117564265\"],\"authorships\":[{\"id\":\"https://openalex.org/A5121753259\",\"display_name\":\"Morris Lintong Barimbing\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124943449\",\"display_name\":\"Dian Pritasari Jeger\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007993692\",\"display_name\":\"Made Edwin Sridana\",\"orcid\":\"https://orcid.org/0000-0001-8670-0099\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S19816070\",\"source_display_name\":\"Progress in Palliative Care\",\"landing_page_url\":\"https://doi.org/10.1080/09699260.2026.2657096\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Pharmacology,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7152631097" }, { "id": 3252, "title": "Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study", "normalized_title": "safety feasibility and tolerability of psilocybin in older adults with amnestic mci preliminary data from a sv2a pet imaging study", "authors": "Bukovsky D, Amaev A, Song J, Torres-Carmona E, Kyte S, Ueno F, Deluca V, Bowie C, Flint A, Husain I, Graff-Guerrero A, Gerretsen P.", "abstract": "", "journal": null, "publication_date": "2025-11-30", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC12740486", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PMC12740486\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Brain Imaging,Aging,Older Adults,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3154, "title": "Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland", "normalized_title": "real world effectiveness and safety of psychedelic assisted psychotherapy outcomes from a large scale compassionate use cohort in switzerland", "authors": "Aboulafia-Brakha T, Buchard A, Mabilais C, Alaux S, Amberger C, Furtado L, Seragnoli F, Briefer J, Thorens G, Sabé M, Szczesniak L, Iuga R, Zullino D, Penzenstadler L.", "abstract": "Background Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. Methods This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100 µg LSD or 25 mg psilocybin at a Swiss university hospital (May 2024-October 2025). Self-reported depression (BDI) and trait anxiety (STAI-T) were assessed at screening, one month before treatment, and 1-3 months post-treatment. In a subset of participants, cognitive emotion regulation (CERQ) was assessed pre- and post-treatment. Subjective drug effects and adverse events were recorded on the treatment day. Results The sample consisted of 115 patients (56.5% female; Mean age = 47.5 years). Depressive and anxiety symptoms significantly decreased over time (BDI: F(2,178) = 63.50, p < 0.001, partial η 2 = 0.42; STAI-T: F(1.74,145.9) = 16.97, p < 0.001, partial η 2 = 0.17), with no main effect of substance. CERQ analyses indicated reduced self-blame, rumination and catastrophizing, and increased positive refocusing and reappraisal. Perceived intensity followed distinct temporal profiles for LSD and psilocybin, but comparable subjective drug effects and clinical outcomes. Adverse events were mostly mild and transient, with no serious complications or treatment discontinuations. Conclusions In this compassionate-use real-world cohort, a first fully-active dose PAP session with LSD or psilocybin was well tolerated and associated with significant improvements in depressive and anxiety symptoms. These findings support the feasibility and effectiveness of PAP in specialised routine care.", "journal": "medRxiv", "publication_date": "2025-11-30", "publication_year": 2025, "doi": "10.1101/2025.12.01.25341335", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.12.01.25341335", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR1128175\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Emotional Processing,Observational Study,Safety,Adverse Events", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 401, "title": "Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment", "normalized_title": "investigational psilocybin treatment for post traumatic stress disorder a qualitative study of participant experience trauma engagement and differences from standard treatment", "authors": "Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin, Ekaterina Malievskaia, Merve Atli, Zsofia Elek, Alice Gaillard, Don Koelpin, Anthony J. Cleare, Manish Agrawal, Rachel Yehuda, Namik Kirlić, James Rucker", "abstract": "Background: Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequently demonstrate limited efficacy, leading to persistent symptoms and high dropout rates. Psilocybin has shown promise in treating depression, a condition that is often comorbid with PTSD. We aimed to explore participant experiences of psilocybin treatment for PTSD, emphasising the role of monitoring and support for safety, direct and indirect engagement with trauma-related material during psilocybin treatment, and differences between psilocybin and standard treatments. Methods: This qualitative study was nested within a quantitative, open-label phase 2 trial assessing the safety and tolerability of COMP360 psilocybin in adults with PTSD. Eligible participants were adults (18 years or older) who met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for PTSD secondary to a traumatic event experienced in adulthood. Recruitment was conducted at three sites across two countries: two in the United States and one in the United Kingdom. Enrolled participants underwent standardised preparation, a single psilocybin administration session, and follow-up integration sessions. Semi-structured interviews were conducted before, the day after, and 12 weeks post-treatment. Data were analysed using reflexive thematic analysis, which is a distinct and theoretically grounded approach to co-construction of recurring themes pertaining to participants' preparedness for treatment, how participants' index trauma presented during treatment, and how psilocybin compared to standard treatments. The quantitative phase 2 trial, which the present qualitative study is nested within, is registered with ClinicalTrials.gov, NCT05312151. Findings: Between June 10, 2022, and Feb 12, 2024, 21 participants were enrolled and participated in this qualitative sub-study and completed the in-person qualitative interviews. The analysis revealed four core themes: (1) non-pharmacological factors for psychological safety and trust, (2) the experiential nature of psilocybin treatment, (3) engagement with trauma-related material during psilocybin treatment, and (4) comparative reflections on prior therapies and psilocybin treatment. Emphasising safety, treatment education, and informed consent, the treatment facilitated an experience of both direct and indirect engagement with trauma-related material during psilocybin treatment. Unlike standard treatments requiring direct confrontation with trauma memories, psilocybin appears to enable a broader, indirect engagement with traumatic material via a range of affective, somatic and self-transcendent experiences (e.g., moments of perceived unity, dissolution of self, or felt connection with a larger whole). Interpretation:. Funding: Compass Pathways, plc.", "journal": "EClinicalMedicine", "publication_date": "2025-11-30", "publication_year": 2025, "doi": "10.1016/j.eclinm.2025.103692", "pubmed_id": "41497513", "source_url": "https://doi.org/10.1016/j.eclinm.2025.103692", "keywords": "Medicine, Psilocybin, Qualitative research, Psychiatry, Traumatic stress, Clinical psychology, Stress (linguistics), MEDLINE, Compass, Physical therapy, Psychotherapist, Investigational Drugs, Clinical trial, Posttraumatic stress, Acute Stress Disorder, Qualitative analysis, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417031290\",\"openalex_url\":\"https://openalex.org/W4417031290\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1534577973\",\"https://openalex.org/W2022085232\",\"https://openalex.org/W2124556602\",\"https://openalex.org/W2127046953\",\"https://openalex.org/W2152676810\",\"https://openalex.org/W2170803554\",\"https://openalex.org/W2305278139\",\"https://openalex.org/W2509310219\",\"https://openalex.org/W2598895258\",\"https://openalex.org/W2892153793\",\"https://openalex.org/W2899448494\",\"https://openalex.org/W2904943889\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3034423620\",\"https://openalex.org/W3048560297\",\"https://openalex.org/W3095098358\",\"https://openalex.org/W3125332567\",\"https://openalex.org/W3195596087\",\"https://openalex.org/W3200528712\",\"https://openalex.org/W4224257950\",\"https://openalex.org/W4229058059\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4317478735\",\"https://openalex.org/W4367835241\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W4383187376\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4386740988\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4390730351\",\"https://openalex.org/W4391053730\",\"https://openalex.org/W4394693273\",\"https://openalex.org/W4405978092\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037169539\",\"display_name\":\"Nadav Liam Modlin\",\"orcid\":\"https://orcid.org/0000-0002-3900-4354\"},{\"id\":\"https://openalex.org/A5048557173\",\"display_name\":\"Victoria Williamson\",\"orcid\":\"https://orcid.org/0000-0002-3110-9856\"},{\"id\":\"https://openalex.org/A5037628078\",\"display_name\":\"Guy M. Goodwin\",\"orcid\":\"https://orcid.org/0000-0002-1426-2816\"},{\"id\":\"https://openalex.org/A5021278348\",\"display_name\":\"Ekaterina Malievskaia\",\"orcid\":null},{\"id\":\"https://openalex.org/A5085127841\",\"display_name\":\"Merve Atli\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120688796\",\"display_name\":\"Zsofia Elek\",\"orcid\":null},{\"id\":null,\"display_name\":\"Alice Gaillard\",\"orcid\":null},{\"id\":\"https://openalex.org/A5115738022\",\"display_name\":\"Don Koelpin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088467690\",\"display_name\":\"Anthony J. Cleare\",\"orcid\":\"https://orcid.org/0000-0002-6990-939X\"},{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5088026153\",\"display_name\":\"Rachel Yehuda\",\"orcid\":\"https://orcid.org/0000-0001-8307-677X\"},{\"id\":\"https://openalex.org/A5078220787\",\"display_name\":\"Namik Kirlić\",\"orcid\":\"https://orcid.org/0000-0003-4153-8774\"},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898347799\",\"source_display_name\":\"EClinicalMedicine\",\"landing_page_url\":\"https://doi.org/10.1016/j.eclinm.2025.103692\",\"is_oa\":true}}", "topic_tags": "Depression,PTSD,Chronic Pain,Mechanism of Action,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417031290" }, { "id": 384, "title": "Griffiths et al.’s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective", "normalized_title": "griffiths et al s study of psilocybin with religious professionals a theological response from a christian perspective", "authors": "Joseph G. Lorenz, Scott A. Hawkins, Bryan C. McCarthy", "abstract": "Griffiths et al.'s recent \"Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions\" is an important study in the literature on psychedelic medicine and religious experience. In this commentary on the study, we argue: (1) The study design's implicit presupposition of perennialism in its conception of mysticism burdens it with metaphysical and theological freight it doesn't need to support its hypothesis; and (2) Psychedelic usage in pursuit of mysticism, however construed, risks two pathologies-hyper-individualism and idolatry-that religious traditions and communities are well-positioned to counter.", "journal": "Psychedelic Medicine", "publication_date": "2025-11-30", "publication_year": 2025, "doi": "10.1177/28314425251406251", "pubmed_id": "41869005", "source_url": "https://doi.org/10.1177/28314425251406251", "keywords": "Psilocybin, Mysticism, Perspective (graphical), Presupposition, Religious experience, Trance, Philosophy, Shamanism, Epistemology, Sociology, Psychology, Theology, Religious studies, Meaning (existential), Metaphysics, Psychoanalysis, Fundamentalism, Spiritual practice, Spirituality, Psychology of religion, Consciousness, Transcendence (philosophy), Religious identity, Social psychology, Religious life, Object (grammar), Religious education, Psychedelics and Drug Studies, Religious Studies and Spiritual Practices, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417034603\",\"openalex_url\":\"https://openalex.org/W4417034603\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W580133133\",\"https://openalex.org/W1900226119\",\"https://openalex.org/W2325207359\",\"https://openalex.org/W2345969582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2804070515\",\"https://openalex.org/W3005896034\",\"https://openalex.org/W3158455932\",\"https://openalex.org/W4281688759\",\"https://openalex.org/W4362623650\",\"https://openalex.org/W4390495773\",\"https://openalex.org/W4410448036\"],\"authorships\":[{\"id\":\"https://openalex.org/A5111880087\",\"display_name\":\"Joseph G. Lorenz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109547576\",\"display_name\":\"Scott A. Hawkins\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037662088\",\"display_name\":\"Bryan C. McCarthy\",\"orcid\":\"https://orcid.org/0009-0004-4459-4936\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/28314425251406251\",\"is_oa\":false}}", "topic_tags": "Consciousness,Spirituality,Mystical Experience,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417034603" }, { "id": 3681, "title": "Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder", "normalized_title": "assessing the safety tolerability and efficacy of psilocybin therapy followed by accelerated intermittent theta burst aitbs repetitive transcranial magnetic stimulation rtms for treatment resistant major depressive disorder", "authors": "University of Texas at Austin", "abstract": "The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder. This will be a phase II 2x2 design (device and dose) clinical trial. 100 participants, ages 22-76, with treatment-resistant MDD will be randomized to treatment with either: a) 25mg of COMP360 (N=50); or b) 1mg of COMP360 (low-dose comparator; N=50) with appropriate psychological preparation, support, and integration sessions with trained therapists. This will then be directly followed by one of two subsequent treatment conditions: i) the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold50,51; or ii) sham iTBS delivered in the same fashion. Individuals will undergo screening, a baseline clinical assessment and neurobiological assessment of functional magnetic resonance imaging (fMRI) and electroencephalographic (EEG) recordings. Individuals will then return on a subsequent day to begin the course of psilocybin therapy. Preparation sessions will occur on the first two out of five days (\\~1.5-2 hrs each day), psilocybin dosing will occur on the third day (\\~6-8 hours), integration session (\\~1 hour) and post-dosing assessments will occur on the fourth day, and a final integration session (\\~1 hour) and post-psilocybin clinical and neurobiological assessments will occur on the last of the five days. The following week, the individual will return to the lab to begin the course of active or sham SNT, for 10 hrs. a day (10 min once per 60 min, 50-minute inter-session interval, repeated 10 times daily) for 5 days. This is the protocol now FDA-cleared for treatment of treatment-resistant MDD, known as Stanford Neuromodulation Therapy and commercialized by Magnus Medical (see support letter from Magus Medical). In the third week, the individual will return to complete post-SNT clinical assessments and to complete a post-SNT neurobiological (fMRI and EEG) assessment. Individuals will complete long-term follow-up clinical assessments at 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, and 12 months post-initiation of first treatment (psilocybin administration) to assess durability of clinical response and identify potential points of depression relapse over a sustained period of time. Aims: To determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder. To determine if the combination of psilocybin therapy followed by SAINT demonstrates superior efficacy relative to either treatment alone acutely (primary acute endpoint will be \\~14 days after the initiation of the treatment sequence) and over time (additional endpoints at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, and 12 months following cessation of the treatment protocol). To determine the neurobiological changes following the combination treatment (assessment points at baseline, 2 days post-psilocybin, and \\~14 days post-psilocybin/2-4 days post cessation of accelerated theta burst), and if the magnitude or nature of such changes are different from those demonstrated in either treatment alone. Investigate how psychedelic treatment may impact blood biomarkers of inflammation (e.g., inflammatory cytokines) and how select functional genetic polymorphisms may moderate the effect of the psychedelic treatment on subsequent functional brain changes.", "journal": "ClinicalTrials.gov", "publication_date": "2025-11-25", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06132178", "keywords": "Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression, Psilocybin, COMP360, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Stanford Neuromodulation Therapy (SNT), Low-dose psilocybin, low-dose COMP360, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment, Sham Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Sham Stanford Neuromodulation Therapy (SNT), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06132178\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Brain Imaging,Biomarkers,Aging,Clinical Trial,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3700, "title": "Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life", "normalized_title": "pragmatic trial of psilocybin therapy in palliative care pt2pc a multicenter triple blind phase 2 randomized controlled trial of psilocybin therapy for demoralized adults near the end of life", "authors": "Charles S. Grob, M.D.", "abstract": "This multicenter, triple-blind, phase 2, randomized controlled trial will evaluate the efficacy and safety of psilocybin therapy compared to an active control in treating demoralization in adults near the end of life (≤2 years life expectancy). After providing written informed consent, participants deemed eligible for this trial will be randomized to a brief course of talk therapy plus 1 dose of oral psilocybin vs the same brief course of talk therapy plus 1 dose of oral ketamine (the active control). Participants' degree of demoralization and other clinical outcomes (e.g., depression, anxiety) will be assessed at 1, 2, and 5 weeks after the study drug administration. After completing the study, participants will have the option of being told which study drug they took (aka, \"unblinded\"); those who were randomized to the active control will be offered another brief course of talk therapy plus 1 dose of oral psilocybin, and the same sequence of outcome assessments.", "journal": "ClinicalTrials.gov", "publication_date": "2025-11-24", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05403086", "keywords": "Demoralization, Psilocybin, Hallucinogen, Ketamine, Ketalar, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05403086\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 348, "title": "Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder", "normalized_title": "advancing treatment paradigms the role of psilocybin in managing major depressive disorder", "authors": "Sana Rasheed, Rida Arif, Ahmed Asad Raza, Abedin Samadi", "abstract": "Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory challenges that hinder its broader application. Key objectives include understanding how psilocybin alleviates depressive symptoms, investigating its neurobiological effects, and identifying gaps in current research. The methodology involved analyzing clinical studies conducted between 2014 and 2024, focusing on psilocybin as an intervention, either independently or in conjunction with psychotherapy. Evidence from these studies demonstrates that psilocybin acts on serotonin 5-HT2A receptors, enhancing neuroplasticity and brain connectivity to yield rapid and sustained symptom relief. Despite these promising findings, the use and study of psilocybin remains restricted due to its classification as a Schedule I substance in many countries. Legal prohibitions and societal stigma have significantly delayed progress in exploring psilocybin's therapeutic applications. The findings highlight psilocybin's potential to transform MDD treatment paradigms but emphasize the need to overcome regulatory barriers, conduct larger and more diverse studies, and establish long-term safety and efficacy data. Addressing these challenges is critical for integrating psilocybin into mainstream mental health care and unlocking its full therapeutic potential.", "journal": "Annals of Medicine and Surgery", "publication_date": "2025-11-23", "publication_year": 2025, "doi": "10.1097/ms9.0000000000004349", "pubmed_id": "41497122", "source_url": "https://doi.org/10.1097/ms9.0000000000004349", "keywords": "Psilocybin, Major depressive disorder, Medicine, Psychiatry, Mainstream, Mental health, Psychotherapist, Hallucinogen, Psychology, Therapeutic approach, Schizophrenia (object-oriented programming), Cognition, Clinical psychology, Bipolar disorder, Vortioxetine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4416592848\",\"openalex_url\":\"https://openalex.org/W4416592848\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2113099805\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2752781070\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3027835371\",\"https://openalex.org/W3033447508\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3211143280\",\"https://openalex.org/W4280525486\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4361292040\",\"https://openalex.org/W4379051631\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4404123591\",\"https://openalex.org/W4407728103\"],\"authorships\":[{\"id\":\"https://openalex.org/A5009917648\",\"display_name\":\"Sana Rasheed\",\"orcid\":null},{\"id\":null,\"display_name\":\"Rida Arif\",\"orcid\":\"https://orcid.org/0009-0005-9884-386X\"},{\"id\":\"https://openalex.org/A5101718797\",\"display_name\":\"Ahmed Asad Raza\",\"orcid\":\"https://orcid.org/0009-0004-2930-8188\"},{\"id\":null,\"display_name\":\"Abedin Samadi\",\"orcid\":\"https://orcid.org/0009-0004-2676-9093\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226177\",\"source_display_name\":\"Annals of Medicine and Surgery\",\"landing_page_url\":\"https://doi.org/10.1097/ms9.0000000000004349\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Aging,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4416592848" }, { "id": 425, "title": "Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?", "normalized_title": "psilocybin and chronic pain a new perspective for future pain therapists", "authors": "Silvia Natoli, Arturo Cuomo, Maurizio Marchesini, Livio Luongo, Giuliano Lo Bianco, Vittorio Guardamagna, Shigeki Yamaguchi", "abstract": "BACKGROUND: Chronic pain affects nearly one in five adults worldwide and remains a major healthcare burden due to its persistence, multidimensional impact, and resistance to conventional therapies. The opioid crisis has further highlighted the urgent need for safer and more effective alternatives. Psilocybin, a serotonergic psychedelic compound, has re-emerged as a potential therapeutic option for chronic pain given its effects on neuroplasticity, neuroinflammation, and emotional regulation. METHODS: This narrative review synthesized evidence from published preclinical and clinical studies. The focus was on the mechanisms of action of psilocybin, animal models of neuropathic and inflammatory pain, and early human trials exploring its effects on pain, mood, and quality of life. RESULTS: Preclinical studies demonstrated that psilocybin promotes synaptogenesis via BDNF-TrkB signalling, modulates 5-HT2A receptor activity, and reduces neuroinflammatory processes, leading to persistent analgesic and anxiolytic effects. Animal models of chemotherapy-induced neuropathy and inflammatory pain showed long-lasting antinociceptive responses. Clinical studies, though limited, reported improvements in depression, anxiety, resilience, and quality of life in patients with advanced cancer and chronic conditions, with preliminary evidence of analgesic benefit. CONCLUSIONS: Psilocybin shows promise as a multidimensional therapy for chronic pain, addressing both sensory and affective components. However, ethical issues, safety concerns, and regulatory barriers necessitate careful management, and robust randomized controlled trials are essential to confirm efficacy and guide clinical translation.", "journal": "Medical Sciences", "publication_date": "2025-11-19", "publication_year": 2025, "doi": "10.3390/medsci13040277", "pubmed_id": "41283278", "source_url": "https://doi.org/10.3390/medsci13040277", "keywords": "Psilocybin, Medicine, Perspective (graphical), Chronic pain, Psychotherapist, Clinical trial, Psychiatry, Randomized controlled trial, Ethical issues, Hallucinogen, MEDLINE, Clinical psychology, Intensive care medicine, Pain relief, Depression (economics), Alternative medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pharmaceutical Quality and Counterfeiting", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:32", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4416407616\",\"openalex_url\":\"https://openalex.org/W4416407616\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1979233603\",\"https://openalex.org/W1988006913\",\"https://openalex.org/W2005937053\",\"https://openalex.org/W2024108603\",\"https://openalex.org/W2038839611\",\"https://openalex.org/W2046019936\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2099030247\",\"https://openalex.org/W2109309568\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2407074051\",\"https://openalex.org/W2426802935\",\"https://openalex.org/W2473063847\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2567578199\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2895986834\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2942136138\",\"https://openalex.org/W2944592785\",\"https://openalex.org/W2948376596\",\"https://openalex.org/W3004772127\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3160481424\",\"https://openalex.org/W3175441262\",\"https://openalex.org/W3195427620\",\"https://openalex.org/W3196007322\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4294804950\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4310465099\",\"https://openalex.org/W4361292040\",\"https://openalex.org/W4365442769\",\"https://openalex.org/W4378549583\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4382010877\",\"https://openalex.org/W4386305913\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389891609\",\"https://openalex.org/W4390988530\",\"https://openalex.org/W4392119029\",\"https://openalex.org/W4392660340\",\"https://openalex.org/W4393489617\",\"https://openalex.org/W4394693273\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4399323719\",\"https://openalex.org/W4400513312\",\"https://openalex.org/W4400697733\",\"https://openalex.org/W4402529371\",\"https://openalex.org/W4402697828\",\"https://openalex.org/W4402825425\",\"https://openalex.org/W4403895310\",\"https://openalex.org/W4404843727\",\"https://openalex.org/W4405021593\",\"https://openalex.org/W4406845122\",\"https://openalex.org/W4408540649\",\"https://openalex.org/W4408581056\",\"https://openalex.org/W4408780815\",\"https://openalex.org/W4410735628\",\"https://openalex.org/W4412764217\",\"https://openalex.org/W4414747399\"],\"authorships\":[{\"id\":\"https://openalex.org/A5004648701\",\"display_name\":\"Silvia Natoli\",\"orcid\":\"https://orcid.org/0000-0003-3758-5375\"},{\"id\":\"https://openalex.org/A5028425468\",\"display_name\":\"Arturo Cuomo\",\"orcid\":\"https://orcid.org/0000-0002-1165-6713\"},{\"id\":\"https://openalex.org/A5018238229\",\"display_name\":\"Maurizio Marchesini\",\"orcid\":\"https://orcid.org/0000-0002-3286-9531\"},{\"id\":\"https://openalex.org/A5052789598\",\"display_name\":\"Livio Luongo\",\"orcid\":\"https://orcid.org/0000-0002-1949-2039\"},{\"id\":\"https://openalex.org/A5060128343\",\"display_name\":\"Giuliano Lo Bianco\",\"orcid\":\"https://orcid.org/0000-0003-2705-1548\"},{\"id\":\"https://openalex.org/A5027033047\",\"display_name\":\"Vittorio Guardamagna\",\"orcid\":\"https://orcid.org/0000-0002-3554-8151\"},{\"id\":\"https://openalex.org/A5108070065\",\"display_name\":\"Shigeki Yamaguchi\",\"orcid\":\"https://orcid.org/0000-0003-3850-2818\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2739445098\",\"source_display_name\":\"Medical Sciences\",\"landing_page_url\":\"https://doi.org/10.3390/medsci13040277\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Resilience,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Safety,Toxicity,Inflammation", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4416407616" }, { "id": 3548, "title": "A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression", "normalized_title": "a double blind phase ii feasibility study to assess the safety and efficacy of psilocybin microdosing combined with psychotherapy in treatment resistant depression", "authors": "Beersheva Mental Health Center", "abstract": "Objective: To assess the safety and efficacy of a six-week microdosing regimen of psilocybin combined with short-term, experience-based psychotherapy in patients with treatment-resistant depression who have not responded to previous pharmacological or long-term psychological interventions. Hypothesis: Compared to baseline, the group that begins with psilocybin will exhibit a more rapid reduction in depressive symptoms after six weeks, compared to the group that begins with placebo and receives only psychotherapy. Following the crossover between conditions, the placebo-first group will also show an accelerated reduction in these measures after the subsequent six weeks. Alternative hypothesis: No difference will be observed between groups in the rate of symptom reduction. Objective: To examine biological markers that may mediate potential improvements in depressive symptoms among participants receiving psilocybin microdosing compared to placebo. Hypothesis: Compared to baseline, six weeks of active psilocybin dosing will result in decreased levels of cortisol and inflammatory markers, and increased levels of oxytocin and BDNF in saliva. Objective: To assess psychological factors that may mediate potential improvements in depressive symptoms among participants receiving psilocybin microdosing compared to placebo. Hypothesis: Compared to baseline, six weeks of active psilocybin dosing will lead to increased cognitive flexibility, greater self-compassion, and enhanced present-moment awareness. Objective: To explore a subpopulation of women experiencing premenstrual symptom exacerbation (PMS) and the potential for improvement in depressive symptoms in the days preceding menstruation, if any. Hypothesis: Among women with worsened premenstrual symptoms, psilocybin will reduce premenstrual symptoms, specifically depressive symptoms, compared to baseline.", "journal": "ClinicalTrials.gov", "publication_date": "2025-11-18", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07183748", "keywords": "Treatment Resistant Depression, Psilocybin (drug), Placebo, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07183748\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Biomarkers,Microdosing,Clinical Trial,Treatment-Resistant Depression,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3454, "title": "Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.", "normalized_title": "open label phase 2 study for evaluating the feasibility safety and efficacy of psychotherapy assisted psilocybin for treatment of severe obsessive compulsive disorder ocd in drug and or psychotherapy resistant patients", "authors": "Beersheva Mental Health Center", "abstract": "Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviors or mental rituals. Individuals with OCD often have diminished quality of life, and functional impairment. The disorder cause high personal, societal and economic costs. Current available treatments for OCD show moderate response rate and high rate of symptom relapse. The purpose of the current study is to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients. Specifically, The aim of this study is to investigate the feasibility, safety and efficacy of psychotherapy assisted psilocybin for treatment of severe OCD. Previous research has shown safety of treatment and high efficacy in reduction of anxiety and depression symptoms. However, only one study has evaluated the use of psilocybin for OCD patients. The protocol includes 15 therapeutic sessions, of which 12 are one-hour sessions for psychological preparation and integration, and three are eight hours' experiential sessions under the influence of psilocybin. The research will include 15 participants diagnosed with severe OCD, with at least one treatment failure. Assessments will be based on comparing ratings of the main outcome measure (Y-BOCS), at baseline, at the middle and at end of treatment. Other assessments will include data on side effects- to evaluate safety, and possible spiritual variables underlying change in symptoms via standardized questionnaires. Background and research rationale: Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by recurrent distressing thoughts and substantial anxiety, accompanied by repetitive behaviours or mental rituals performed to control or alleviate this anxiety. Individuals with OCD often have diminished quality of life, functional impairment, and cause substantial caregiver burden and personal and societal economic costs. Lifetime prevalence of OCD ranges between 1.9%-2.5%, with patients often not responding to the offered pharmacological or psychological treatment, and in extreme cases may even undergo neurosurgical interventions. There are several possible physiological mechanisms leading to the development of OCD, which may indicate several possible effective treatment options. Nowadays there is a consensus that the dopaminergic and serotonergic pathways are central to the development of the disorder with the basal ganglia as the main area of its origin. Other brain areas involved in OCD are the orbitofrontal cortex and anterior cingulate cortex which are connected to the basal ganglia and are involved in regulating attention and awareness. Abnormal activity between these areas and other subcortical areas might explain why normally unconscious information processing, becomes consciousness, and requires additional resources for its regulation. It has also been suggested that the aversive emotional activity (anxiety, fear, disgust) experienced in OCD, relates to hyperactivity in the amygdala. The momentary relief brought on by the compulsive behaviour forms a positive feedback which perpetuate the disorder. The gold standard of care for OCD today is a combination of selective serotonin reuptake inhibitors (SSRIs) and cognitive behavioural therapy (CBT). Most patients will experience at least some symptomatic relief with these interventions; however, relapse of symptoms occur in 40%-60% of patients and around 25% of patients are unresponsive to treatment. Other existing treatments (either pharmacological or neurosurgical) possess a higher risk for serious side effects. It is important to note that even for those patients who are responsive to treatment there are still significant residual, impairing symptoms. It thus seems that there is a real and immediate need to explore new alternative options for the treatment of OCD that can widely and continuously benefit patients, with lower risk and fewer side effects. A new and promising prospect of treatment in mental health is the use of psychedelic substances, which interact with the serotonergic pathways and induce a powerful subjective experience with the potential for psychological transformation. Specifically, psilocybin has received attention in research as a promising alternative in the treatment of severe mental illness. Psilocybin is a prodrug which is quickly converted by the body to psilocin (4-OH-dimethyltryptamine), a 5-HT2A receptor partial agonist. Both psilocybin and psilocin, which have psychoactive properties, are naturally occurring in Psilocybe mushrooms and are structurally similar to the endogenous neurotransmitter serotonin. As a direct 5-HT2A agonist, psilocybin has a unique therapeutic potential compared with other pharmacological treatment for OCD such as SSRIs. Animal studies have shown increased cognitive flexibility, associative learning, cortical plasticity, and anti-depressive effects in response to 5-HT2A activation. The first current clinical research with psilocybin examined the safety and efficacy of psilocybin in the treatment of psychological distress in patients with terminal advanced-stage cancer. The double-blind, placebo-controlled research was conducted in the Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center (Torrance, California). Researchers concluded that psilocybin is safe and well tolerated at 0.2 mg/kg dose. Following this research two different research groups, in Johns Hopkins University, and in New York University, have received FDA approval to administrate a higher dose of psilocybin in a similar clinical population. These trails have shown promising results for safety, psychological distress reduction, and significant improvement in anxiety and depression. In their research, Griffiths and colleagues, examined the efficacy of psilocybin in reducing anxiety and depression in 51 patients suffering from a terminal end-stage cancer and experiencing symptoms of anxiety and depression. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin. No serious adverse events attributed to psilocybin administration occurred. There were transient moderate increases in systolic and/or diastolic blood pressure after psilocybin (in 34% of participants in the high-dose session and 17% of participants in the low-dose session), none of these episodes met criteria for medical intervention. Nausea or vomiting occurred in 15% of participants in the high-dose session. An episode of physical discomfort (any type) occurred in 21% of participants in the high-dose session and 8% in the low-dose session. Psychological discomfort (any type) occurred in 32% of participants in the high-dose session and 12% in the low-dose session. An episode of anxiety occurred in 26% of participants in the high-dose session and 15% in the low-dose session. One participant had a transient episode of paranoid ideation (2% of high-dose sessions). There were no cases of hallucinogen persisting perception disorder (HPPD) or prolonged psychosis. Across the two dose sequence groups, the overall rate of clinical response at 6 months was 78% and 83% for depression and anxiety, respectively, and the overall rate of symptom remission at 6 months for all participants was 65% and 57%, respectively. Ross and colleagues conducted a double-blind, placebo-controlled, crossover trial, with 29 patients with cancer-related anxiety and depression that were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin (active placebo), both in conjunction with psychotherapy (before and after drug administration). The most common adverse effects were non-clinically significant elevations in blood pressure and heart rate (76%), headaches/migraines (28%), nausea (14%), transient anxiety (17%), and transient psychotic-like symptoms (7%). The medical and psychiatric adverse effects attributable to psilocybin are all known, were transient, and tolerable. There were no cases of prolonged psychosis or HPPD, and no participants required psychiatric hospitalization. Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression, this effect was sustained at 6.5 months follow-up. These trails and others have shown safety of treatment and high efficacy in reduction of anxiety and depression symptoms with sustained effect at 6 months follow up. These findings taken together with the theoretical understanding of psilocybin mechanism of action and with the understanding of the neuro-psychological pathology of OCD, encourage investigating the potential of psilocybin as a novel significant treatment for this disorder. Research of beneficial effects of psilocybin for patients with OCD is in its infancy, but preliminary findings show potential efficacy in treatment of the disorder. Matsushima and colleagues, used a mice model for OCD and found that psilocybin (both syntactic and in mushroom form), significantly inhibited compulsive behaviour (marble burying) without affecting locomotor activity. In addition, several case reports showed beneficial effects of psilocybin for people with OCD. For example, Leonard and Rapoport (1987) and Moreno and Delgado (1997) reported that among drug-users with OCD, there was a worsening of symptoms under the influence of cocaine, but a remission of symptoms for hours/ days following psilocybin use. Wilcox (2014) described a case in which a patient with OCD self-medicated with psilocybin, once every three weeks, experienced a preserved effect of reduced anxiety, obsessive thoughts, and compulsive behaviour. In another case report, a patient suffering from a body dysmorphic disorder (spending about 4 hours a day examining himself in the mirror), has experienced a significant reduction in distress and a notable change in body perception following multiple dosing of psilocybin. Moreno et al. 2006 conducted a semi open-label trial examining the effect of psilocybin on nine participants with mild to severe OCD, which had at least one \"treatment failure\" defined as a lack of significant improvement after an adequate treatment. Doses were 25 (very low dose \\[VLD\\]), 100 (low dose \\[LD\\]), 200 (medium dose \\[MD\\]), and 300 (high dose \\[HD\\]) µg/kg. LD, MD, and HD were assigned in that order, and VLD was inserted randomly and in a double-blind fashion at any time after the first dose (LD). In measurements during the 24 hours after each dose all participants have experienced a significant relief in symptoms (23%-100% as measured by the Yale-Brown Obsessive-Compulsive Scale \\[YBOCS\\]) in at least one of the sessions. Two of the subjects reported that their symptomatic improvement lasted most of the following week after testing. One subject achieved long-term remission at the end of the 4 test sessions, as measured at 6-month follow-up. There was, however, no clear dose-response relationship to the change in YBOCS score and no correlation between YBOCS score reduction and the perceived intensity of the psychedelic experience. These preliminary findings stress the need for further research to examine the efficacy of psilocybin in the treatment of OCD. In addition, the only clinical trial to date did not include psychotherapy for patients while under the influence of psilocybin. Earlier studies have shown that a preliminary therapeutic relationship before psilocybin administration increases the probability for a \"peak experience\" during sessions. Furthermore, two more recent studies have emphasized the importance of psychotherapy during and before psilocybin sessions, touching on 'intent' and formulating an early and strong therapeutic relationship. There is also a reference to the, \"psychedelic afterglow\", an effect lasting for days and even weeks after a psychedelic session during which there is a unique window for a meaningful transformative psychotherapeutic intervention, most likely owing to the increased psychological plasticity following a psychedelic experience. The current study has two main goals: 1. Determine the safety and efficacy of psilocybin for patients suffering from OCD. 2. Elucidate the psychological mechanisms contributing to the beneficial effect of psilocybin on OCD symptoms. Research Plan: The current research aims to examine the feasibility, safety and efficacy of psychotherapy assisted psilocybin for treatment of severe OCD. The protocol includes 15 therapeutic sessions, of which 12 are one-hour sessions, and three are eight hours' experiential sessions (session 4,8,12) under the influence of psilocybin. In the first experiential session participants will receive a safety dose of 10mg/70kg. In the second and third sessions, participants will receive a therapeutic dose of 30mg/70kg. Three preparatory sessions will take place before the first experiential session, and three integration sessions will take place after each experiential session. The research will include 15 participants, and will include the following phases: Selection phase: Research team will screen participants via phone interviews. Participants answering the inclusion criteria will be invited to receive and sign consent forms. Research member will collect demographics and health status data and register the participants according to study protocol. Preparatory and final registration phase: It is known that SSRIs have a counter effect on psilocybin; therefore, to allow a full effect of psilocybin it is necessary to avoid drug interaction and discontinue previous treatment. In a period of 4 weeks participants will undergo medication withdrawal under psychiatric supervision. During the 4 weeks period each participant will have 2-4 sessions (as needed) with the research psychiatrist, to supervise their clinical state. At the end of 4 weeks, a psychiatric evaluation will take place to determine readiness to begin psilocybin treatment. Baseline assessment, and preparatory therapeutic sessions phase: During the 5-6 weeks from registration, participants will have three preparatory psychotherapy sessions with a couple of therapists assigned to their treatment. Prior to their first psychotherapy session, participants will complete the first-baseline assessment of research questionnaires. Treatment phase: The treatment phase includes three experiential sessions with psilocybin (sessions 4, 8, 12), and three integration sessions after each experiential session. During this phase participants will complete three assessments using research questionnaires (sessions 2, 10, 15). End of treatment and follow-up phase: Primary outcome assessment will take place at the end of the last therapeutic session (no.15). Additional assessments will take place at three months, and six months/one-year follow-up. Research procedure Participants will sign consent forms, before participating in the research treatment. The treatment is based on 15 therapy sessions: * Three preliminary sessions for establishing therapeutic alliance with the therapists and preparing the participant for the first experiential session. * An 8-hour experiential session with a safety dose of psilocybin (10mg/70 kg). (V4) * Participant will spend the night at the medical facility, under the supervision of a research member. * A1-hour session with the therapists, on the following morning (V5) * Two integration sessions, and preparation for the next experiential session. (V6, V7) * An 8-hour experiential session with a therapeutic dose of psilocybin (30mg/70 kg). (V8) * Participant will spend the night at the medical facility, under the supervision of a research member. * A1-hour session with the therapists, on the following morning (V9) * Two integration sessions, and preparation for the next experiential session. (V10, V11) * An 8-hour experiential session with a therapeutic dose of psilocybin (30mg/70 kg). (V12) * Participant will spend the night at the medical facility, under the supervision of a research member. * A1-hour session with the therapists, on the following morning (V13) * Two integration and summary sessions. (V14, V15) Possible discomfort: It is possible that psilocybin and the experience it induces will cause some emotional or physical discomfort. Investigators will address all possible discomforts and appropriate measures to contain them, in the research safety instructions. Research purpose: The main objective of this research is to use standardized measuring tools to explore the safety and efficacy of psilocybin assisted psychotherapy in treating severe OCD symptoms. A secondary aim is to explore possible variables underlying change in symptoms. Research objectives: The main objective is to assess efficacy of psilocybin assisted psychotherapy in treating severe OCD symptoms. This assessment will be based on comparing ratings of the main outcome measure (Y-BOCS), at baseline (session 2) at the middle and at end of treatment (session 10, 15 respectively). A score under 14 or a reduction of 35% in the overall score will be considered as remission (Lewin, Nadai, Park, Goodman, Murphy \\& Stroch, 2011). Secondary objectives: assessing safety by collecting data on side effects, and assessing possible spiritual variables underlying change in symptoms via standardized questionnaires and semi constructed interviews. Safety: The general safety goal is to assess occurrence and frequency of adverse events during treatment. This includes suicide ideation and/or behaviour, and adverse physiological or psychological responses. The safety of psilocybin use was previously proven in several clinical research. Potential adverse effects: In general, psychedelic drugs have low levels of physiological toxicity, and previous research indicate no evidence of toxicity, organ damage or neurophysiological disfunctions. Possible physiological effects experienced under the influence of psychedelic substances may include: dizziness, weakness, tremor, paresthesia, nausea, thirst, blurred vision, dilated pupils, and hyperreflexia. These somatic effects are dynamic and relatively minor, even when the psychological effect (sensory, perceptual, and cognitive) is strong/intense. The significant risk associated with psilocybin intake, is a subjective experience of fear and anxiety, panic, dysphoria and/or paranoia. Recent clinical studies report a high safety level with no adverse effects. The high safety levels can be attributed to several control parameters described below, and to complying with safety guidelines in clinical psychotherapy with psychedelics. The use of psilocybin requires a significant psychotherapeutic holding of the subjective experience, that will provide a safe and supportive environment during the psychedelic experience. The safety guidelines in clinical psychotherapy with psychedelics describe the therapeutic presence and processes, as well as the set and settings needed to provide a supportive emotional and external environment. Safety measures: 1. Controlling the quality of psilocybin and ensuring it is manufactured under GMP conditions. 2. Controlling for appropriate and adjusted dosage. 3. Controlling a strict protocol for screening eligible participants to the study (for details see inclusion-exclusion criteria section) 4. Recruiting professional and experienced psychotherapists with the appropriate training for clinical psychotherapy with psychedelics. Professionals will undergo a unique training to work with the psychotherapy protocol written for the current research. 5. Psychotherapists will work in pairs (a man and a woman), to provide an optimal holding space for each participant. 6. A proximity of a medical team for case of emergency. 7. Providing preparatory and integration sessions before and after the psilocybin sessions. 8. Preparing and using a comfortable and friendly room for the therapeutic session. The physical environment in which the treatment takes place should be suitable to the physical as well as the emotional safety of the participant. This means creating a lenient environment, which provides a pleasant and welcoming atmosphere, and may elicit a sense of intimacy and connection. As opposed to the environment of a hospital, a space like this supports and strengthens the participant's sense of safety and connectedness, thus helping him/her contain the intense psychedelic experience. 9. Guidelines for psychotherapy process: these guidelines are based on the humanistic perspective, and concern the characteristic of the therapeutic process: * A supportive, accepting, and non-judgmental presence of the therapist. * The importance of the therapeutic alliance and trust between participant and therapists. * A non-directive approach, supportive and gentle presence that stays with the participant's unfolding experience. * Viewing the mind as multi-dimensional, making space for the diverse dimensions of the internal experience: physical, emotional, and spiritual. 10. Maintaining a well-documented monitoring of the study and the participants status during the study period. 11. Monitoring physiological measure (blood pressure, heart rate and body temperature) during the psychedelic sessions with psilocybin: before taking the drug, an hour and a half after taking the drug, and 8 hours after. In case of anomalies physiological measures will be monitor more frequently. 12. Consulting and collaborating with other research teams with similar research interests, in NYU and Imperial College in London, UK.", "journal": "ClinicalTrials.gov", "publication_date": "2025-11-18", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04882839", "keywords": "Obsessive-compulsive Disorder, psychotherapy assisted psilocybin, RECRUITING", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04882839\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,OCD,End-of-Life Distress,Headache / Migraine,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Consciousness,Emotional Processing,Spirituality,Clinical Trial,Case Report,Animal Study,Cancer Patients,Safety,Adverse Events,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3061, "title": "Psilocybin Experiential Therapist Training: Insights from a World-First Study", "normalized_title": "psilocybin experiential therapist training insights from a world first study", "authors": "Ioakimidis-MacDougall G, Gardner J, Liknaitzky P.", "abstract": "First-hand experience with psychedelics may help clinicians develop skills and knowledge needed to work with the profound changes to conscious awareness occasioned by psychedelics. However, the topic remains contentious and underexplored. In this world-first study, we investigated the utility of psilocybin experiential therapist training in a sample of 14 mental healthcare professionals training to provide psilocybin-assisted therapy. Participants received one 25 mg dose of psilocybin in a clinical research context alongside psychological support before, during, and after dosing. Quantitative measures and semi-structured interviews were then undertaken by participants to explore their experiences and reflections. Through the intervention, participants reported developing a greater and embodied understanding of key therapeutic principles and processes. Moreover, they reported increases in therapeutic qualities (e.g., empathy, attunement, emotion regulation) that underpin therapeutic alliance and promote trust and safety. While participants did not report experiencing harms from participation, they speculated about two potential risks of psychedelic experiential therapist training: first, that it could elicit challenging material that feels destabilising for a period; and second, that therapists could project their experience onto clients in a manner that narrows interpretative range and reduces attunement. Recommendations were made for psychedelic experiential therapist training design and implementation, including strategies to mitigate such risks. Participants indicated that psychedelic experiential therapist training is necessary but not sufficient for providing the highest quality of care in psychedelic-assisted therapy. Findings support the inclusion of an optional psychedelic experiential component within psychedelic therapist training programs for clinicians with prior psychotherapeutic training and well-developed reflective capacity.", "journal": "medRxiv", "publication_date": "2025-11-16", "publication_year": 2025, "doi": "10.1101/2025.11.15.25340324", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.11.15.25340324", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1121194\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Emotional Processing,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3058, "title": "Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial", "normalized_title": "microdosing psilocybin for major depressive disorder study protocol for a phase ii double blind placebo controlled randomized partial crossover trial", "authors": "", "abstract": "Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled trials have failed to produce compelling evidence for this. Aims: To conduct a phase II, double-blind, placebo-controlled, randomized partial crossover trial to compare microdosing psilocybin to placebo for MDD, evaluating its safety, tolerability, and preliminary antidepressant effects. Method: 40 adults with MDD will be randomized to four doses of psilocybin (2 mg) or placebo (maltodextrin) once weekly over four weeks, then four doses of psilocybin (2 mg) once weekly for an additional four weeks. The primary efficacy endpoint will be change in depression symptoms, as measured at baseline (0 weeks), after the experimental phase (4 weeks), and after the open-label phase (8 weeks). A battery of mood, well-being, attention, creativity, mindfulness, and pro-sociality measures will be administered at each time point. Follow ups will occur every six months for up to two years after the trial start date, as part of a long-term extension study. Conclusions: Findings will inform future research on microdosing psilocybin for MDD, regarding dose regimens, effect sizes, and expectancy bias. Findings will also facilitate discussions on the comparable benefits of sub- versus threshold doses of psilocybin, and the therapeutic value of radically altered perception.", "journal": "PsyArXiv", "publication_date": "2025-11-15", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/hmnsw_v1", "keywords": "Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"hmnsw_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Microdosing,Wellbeing,Creativity,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 443, "title": "The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample.", "normalized_title": "the relationship between psychedelic use and alcohol use disorder in a nationally representative sample", "authors": "Zech JM, Richard J, Jones GM", "abstract": "Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations between psychedelic use and AUD in a nationally representative sample ( = 139,524). Logistic regression was used to examine the association between AUD and past-year use of LSD, MDMA, and ketamine, controlling for demographics and comorbid substance use. Past-year LSD use was significantly associated with lower odds of AUD (adjusted odds ratio [aOR] = 0.70, =.006). However, use of MDMA (aOR = 1.17, =.229) and ketamine (aOR = 1.28, =.235) was not associated with AUD. In a quasi-Poisson regression analysis, past-year LSD use was found to be associated with 15.7% fewer AUD symptoms (IRR = 0.84, 95% CI: 0.72 - 0.98, =.033), but neither past-year MDMA nor past-year ketamine use were significantly associated with AUD symptoms (MDMA: IRR = 0.97, 95% CI: 0.83 - 1.13, =.731; ketamine: IRR = 1.21, 95% CI: 0.93 - 1.57, =.139). Taken together, these findings indicate differential associations between specific psychedelics and AUD, with LSD use linked to a reduced risk of AUD. The results underscore the need for further research into the mechanisms by which LSD may influence alcohol use and AUD risk.", "journal": "Journal of psychoactive drugs", "publication_date": "2025-11-08", "publication_year": 2025, "doi": "10.1080/02791072.2025.2583967", "pubmed_id": "41208129", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41208129/", "keywords": "AUD, Alcohol, LSD, MDMA, ketamine, psilocybin", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"41208129\"}", "topic_tags": "Addiction,Mechanism of Action,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 408, "title": "Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.", "normalized_title": "efficacy all cause discontinuation and safety of serotonergic psychedelics and mdma to treat mental disorders a living systematic review with meta analysis", "authors": "Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M.", "abstract": "Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in disease-specific symptoms and all-cause discontinuation. Standardized mean differences (SMD) and relative risk (RR) were estimated using random-effects meta-analysis. Risk of bias (RoB) was assessed with Cochrane's RoB-tool version 2 and certainty of evidence with GRADE. The review is maintained as living systematic review (https://ebipsyche-database.org/). We included 30 RCTs (1480 participants; female=45.8 %; with psychological support=83.3 %; high RoB=83.3 %). In post-traumatic stress disorder (PTSD), MDMA reduced PTSD symptoms compared to any control (k = 11; SMD=-0.85 [-1.09; -0.60]; I2=0 %; GRADE=low). In major depressive disorder (MDD), psilocybin/ayahuasca/LSD reduced depressive symptoms (k = 8; SMD=-0.62 [-0.97; -0.28]; I2=55 %; GRADE=very low). In anxiety disorders, both MDMA and serotonergic psychedelics reduced anxiety symptoms (SMDMDMA=-1.18 [-2.04; -0.32]; I2=0 %; k = 2; GRADE=low and SMDserotonergic=-0.88 [-1.70; -0.06]; I2=54 %;k = 5; GRADE=very low). In alcohol use disorder, neither psilocybin nor LSD reduced abstinence rates (k = 6; RR=1.42 [0.89; 2.26]; I2=7 %; GRADE=very low). In attention-deficit hyperactivity disorder (ADHD), LSD did not reduce ADHD symptoms (k = 1; SMD=0.22 [-0.32; 0.76]; GRADE=very low). Moderate certainty in evidence was only found for MDMA on PTSD symptoms when compared to placebo. MDMA/serotonergic psychedelics were not associated with higher risk of all-cause discontinuation (RRMDMA=0.74 [0.32; 1.72]; RRserotonergic=0.81 [0.56; 1.15]). Overall, MDMA/serotonergic psychedelics are promising for the treatment of PTSD, MDD, and anxiety disorders with moderate to large effect sizes. Pragmatic trials, long-term, head-to-head trials exploring the role of psychological support, aiming to identify predictors of response, and accounting for expectancy and functional unblinding are needed. Studies addressing these limitations will likely be required for regulatory approval of psychedelic drugs.", "journal": null, "publication_date": "2025-11-06", "publication_year": 2025, "doi": "10.1016/j.euroneuro.2025.09.011", "pubmed_id": "41205366", "source_url": "https://doi.org/10.1016/j.euroneuro.2025.09.011", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Serotonin Agents, Hallucinogens, Treatment Outcome, Mental Disorders, Randomized Controlled Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41205366\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3489, "title": "A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer", "normalized_title": "a phase 1 2 study of a group model of psilocybin assisted therapy for cancer related anxiety in patients with metastatic cancer", "authors": "University of Washington", "abstract": "This phase I/II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of patients with metastatic cancer and symptoms of anxiety and/or depression. Psilocybin is a substance being studied in conjunction with therapy for the treatment of anxiety and depression in patients with cancer. In this study, the psilocybin being used is derived from the mushroom psilocybe cubensis using a patented process that results in a pharmaceutical grade version of psilocybin. Psilocybin acts by activating serotonin receptors on brain cells which can change perceptions and patterns of thinking in ways that may decrease anxiety. OUTLINE: Patients receive psilocybin orally (PO) and participate in group and individual therapy sessions on trial.", "journal": "ClinicalTrials.gov", "publication_date": "2025-11-04", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05847686", "keywords": "Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Counseling, Counseling Intervention, Psilocybin, CY-39, Indocybin, psilocybine, Questionnaire Administration, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05847686\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Receptor Pharmacology,Clinical Trial,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 446, "title": "Psilocybin and chronic neuropathic pain: a systematic review.", "normalized_title": "psilocybin and chronic neuropathic pain a systematic review", "authors": "Jevotovsky DS, Chopra H, Pak DJ, Durbhakula S, Shustorovich A, Juneja T, Broachwala MY, AlFarra T, Silver C, Kreitzer G, Oreoluwa P, Weissman BB, AlFarra A, Mayrsohn BG, Orhurhu V, Emerick T, Furnish T, Castellanos JP.", "abstract": "Background/importanceChronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain management despite being classified as Schedule I.ObjectiveThis systematic review critically evaluates the evidence for psilocybin, a Schedule I substance, in the treatment of chronic pain. The exact purpose of the review is to assess the impact of psilocybin on chronic pain relief, focusing on dosing protocols, treated conditions, and patient outcomes.Evidence reviewA comprehensive review of PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE was conducted up to January 2024. Eligibility criteria included studies evaluating psilocybin for chronic pain management. The risk of bias was assessed using the MASTER (MethodologicAl STandards for Epidemiological Research) scale, and the strength of evidence was graded using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation).FindingsThe review identified 28 relevant studies focusing on dosing, treated conditions, and outcomes. The majority of the included studies (76.2%) were of low or very low quality. Several studies with moderate-to-low-quality evidence utilized a 0.14 mg/kg dosing protocol. The findings suggest promise for the use of psilocybin in chronic pain relief, though the quality of evidence is generally low.ConclusionsThe current research shows potential for psilocybin as a treatment option for chronic pain relief. However, methodological issues and a lack of high-quality evidence underscore the need for further investigations with standardized protocols. Despite these limitations, the potential for psilocybin in chronic pain management is encouraging.Prospero registration numberCRD42023493823.", "journal": null, "publication_date": "2025-11-04", "publication_year": 2025, "doi": "10.1136/rapm-2024-105532", "pubmed_id": "39106989", "source_url": "https://doi.org/10.1136/rapm-2024-105532", "keywords": "Humans, Neuralgia, Hallucinogens, Treatment Outcome, Pain Management, Chronic Pain, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39106989\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Aging,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 357, "title": "Psilocybin Outside the Clinic", "normalized_title": "psilocybin outside the clinic", "authors": "Kent E. Hutchison, Jake F. Hooper, Hollis C. Karoly", "abstract": "Importance: Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis legalization, public access and enthusiasm are outpacing regulatory oversight and scientific understanding, posing potential risks to public health. Objective: To review emerging evidence on the public health implications of unregulated psilocybin mushroom use, including trends in use, product variability, co-use with other substances, and age-related differences in outcomes. Evidence Review: Sources included peer-reviewed articles, national surveillance data (eg, poison control center reports), and publicly available chemical testing data from decriminalized jurisdictions. The review emphasizes epidemiological and pharmacological findings published between January 1, 2014, and December 31, 2024, with attention to parallels from cannabis legalization research. Studies were selected based on relevance to nonclinical psilocybin use, product composition, adverse outcomes, and co-use patterns. Findings: Psilocybin mushroom use has sharply increased in the US, particularly among adults aged 19 to 50 years, with more than 7 million individuals reporting use in the past year. This trend has coincided with a substantial increase in poison control center calls related to psychedelics. Testing data from decriminalized regions indicate more than 20-fold variability in psilocybin potency and inconsistent levels of minor tryptamines across mushroom strains. Clinical trial data on synthetic psilocybin do not generalize to public use due to strict participant selection and controlled environments. Co-use with cannabis is common and may increase the risk of adverse events. Evidence also suggests that age may moderate both risks and benefits. Conclusions and Relevance: The expanding use of unregulated psilocybin mushrooms, combined with high variability in composition and common co-use with other substances, raises urgent public health concerns. Existing clinical data are insufficient to guide harm reduction or policy. There is a pressing need to pivot from controlled efficacy trials to real-world research on psilocybin use, including public education, potency testing, and age-specific risk assessment.", "journal": "JAMA Psychiatry", "publication_date": "2025-11-04", "publication_year": 2025, "doi": "10.1001/jamapsychiatry.2025.3038", "pubmed_id": "41191341", "source_url": "https://doi.org/10.1001/jamapsychiatry.2025.3038", "keywords": "Psilocybin, Medicine, Hallucinogen, Psychiatry, Clinical trial, Public health, Harm, Pimozide, Harm reduction, MEDLINE, Potency, Health care, Psychology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415929140\",\"openalex_url\":\"https://openalex.org/W4415929140\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W1984431812\",\"https://openalex.org/W2103111367\",\"https://openalex.org/W2111070819\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2146134654\",\"https://openalex.org/W2153594880\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2253496291\",\"https://openalex.org/W2328103612\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2612688067\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2889566085\",\"https://openalex.org/W2951522488\",\"https://openalex.org/W3033060622\",\"https://openalex.org/W3043905699\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W3194325186\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W3208662682\",\"https://openalex.org/W3209302070\",\"https://openalex.org/W3210843480\",\"https://openalex.org/W3217718387\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4247582466\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293080285\",\"https://openalex.org/W4294804950\",\"https://openalex.org/W4309210963\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4378174725\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387902564\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4391842082\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4392165205\",\"https://openalex.org/W4394009974\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396977515\",\"https://openalex.org/W4398206151\",\"https://openalex.org/W4399276098\",\"https://openalex.org/W4400569719\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4403080353\",\"https://openalex.org/W4403848501\",\"https://openalex.org/W4405495073\",\"https://openalex.org/W4409632414\",\"https://openalex.org/W4410591657\",\"https://openalex.org/W4412102657\",\"https://openalex.org/W4412161399\"],\"authorships\":[{\"id\":\"https://openalex.org/A5007663400\",\"display_name\":\"Kent E. Hutchison\",\"orcid\":\"https://orcid.org/0000-0002-4805-9277\"},{\"id\":null,\"display_name\":\"Jake F. Hooper\",\"orcid\":null},{\"id\":\"https://openalex.org/A5114081754\",\"display_name\":\"Hollis C. Karoly\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2495708506\",\"source_display_name\":\"JAMA Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1001/jamapsychiatry.2025.3038\",\"is_oa\":false}}", "topic_tags": "Clinical Trial,Review Article,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415929140" }, { "id": 448, "title": "Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study", "normalized_title": "psilocybin assisted physiotherapy for refractory motor functional neurological disorder protocol for a randomised dose comparison pilot study", "authors": "Chiranth Bhagavan, Alexander Bryson, Olivia Carter, Glenn Nielsen, David J. Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Dina Eleftheriadis, Georgina Oliver, Deanne Mayne, Greg Roebuck, James Rucker, Matthew Butler, Richard Kanaan", "abstract": "BACKGROUND: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are no effective pharmacotherapies, and despite the early promise of physiotherapy studies, many suffer disabling symptoms in the long term. There is a theoretical rationale for combining psychedelics with physiotherapy; however, the potential benefit of this approach and optimal treatment model remains unexplored. Here, we present the protocol for the first study investigating the tolerability, feasibility, and potential efficacy of two distinct treatment regimens of psilocybin-assisted physiotherapy for refractory motor FND: a moderate dose that incorporates movement tasks during the acute drug effects versus a standard dose alone. METHODS: Twenty-four participants with refractory motor FND will be randomised in a 1:1 ratio to either (1) psilocybin 15 mg, with movement tasks conducted during the acute drug effects, or (2) psilocybin 25 mg alone. All participants will receive two sessions of FND-specific physiotherapy pre-dosing, six sessions of physiotherapy post-dosing, and undergo follow-up visits one week and four weeks following their final physiotherapy session. A battery of outcome measures will be completed as scheduled, assessing tolerability, feasibility, motor FND symptom severity, psychiatric and physical symptoms, quality of life, treatment expectations, intensity of the acute drug effects, personality, motor function, force-matching performance, resting-state and task-based brain imaging, and subjective experiences of the study treatment. DISCUSSION: These findings will assist the design of an adequately powered randomised controlled trial in this cohort. The findings may also inform the feasibility of psychedelic treatment in related functional and neuropsychiatric disorders.", "journal": "Acta Neuropsychiatrica", "publication_date": "2025-11-03", "publication_year": 2025, "doi": "10.1017/neu.2025.10042", "pubmed_id": "41186141", "source_url": "https://doi.org/10.1017/neu.2025.10042", "keywords": "Medicine, Protocol (science), Physical therapy, Physical medicine and rehabilitation, Refractory (planetary science), Pilot trial, Randomized controlled trial, Motor activity, Clinical trial, Treatment protocol, Functional training, Functional movement, Motor symptoms, Rehabilitation, Activities of daily living, MEDLINE, Functional electrical stimulation, Protocol design, Functional impairment, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415851344\",\"openalex_url\":\"https://openalex.org/W4415851344\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5059079864\",\"display_name\":\"Chiranth Bhagavan\",\"orcid\":\"https://orcid.org/0000-0002-7983-4280\"},{\"id\":\"https://openalex.org/A5065472002\",\"display_name\":\"Alexander Bryson\",\"orcid\":\"https://orcid.org/0000-0002-0033-8197\"},{\"id\":\"https://openalex.org/A5060157509\",\"display_name\":\"Olivia Carter\",\"orcid\":\"https://orcid.org/0000-0001-7708-6154\"},{\"id\":\"https://openalex.org/A5079230130\",\"display_name\":\"Glenn Nielsen\",\"orcid\":\"https://orcid.org/0000-0001-6053-5670\"},{\"id\":\"https://openalex.org/A5062700391\",\"display_name\":\"David J. Berlowitz\",\"orcid\":\"https://orcid.org/0000-0003-2543-8722\"},{\"id\":\"https://openalex.org/A5014383854\",\"display_name\":\"Sara Issak\",\"orcid\":\"https://orcid.org/0000-0003-0042-3452\"},{\"id\":\"https://openalex.org/A5050220299\",\"display_name\":\"Sabine Braat\",\"orcid\":\"https://orcid.org/0000-0003-1997-3999\"},{\"id\":\"https://openalex.org/A5084468237\",\"display_name\":\"Sophie Zaloumis\",\"orcid\":\"https://orcid.org/0000-0002-8253-8896\"},{\"id\":\"https://openalex.org/A5000011887\",\"display_name\":\"Zachary Attard\",\"orcid\":\"https://orcid.org/0000-0003-0790-817X\"},{\"id\":\"https://openalex.org/A5042488247\",\"display_name\":\"Dina Eleftheriadis\",\"orcid\":\"https://orcid.org/0000-0002-0671-8422\"},{\"id\":\"https://openalex.org/A5102711011\",\"display_name\":\"Georgina Oliver\",\"orcid\":\"https://orcid.org/0000-0002-9215-2225\"},{\"id\":\"https://openalex.org/A5104987882\",\"display_name\":\"Deanne Mayne\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112602098\",\"display_name\":\"Greg Roebuck\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5037837514\",\"display_name\":\"Matthew Butler\",\"orcid\":\"https://orcid.org/0000-0002-9734-6539\"},{\"id\":\"https://openalex.org/A5075094017\",\"display_name\":\"Richard Kanaan\",\"orcid\":\"https://orcid.org/0000-0003-0992-1917\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S173281865\",\"source_display_name\":\"Acta Neuropsychiatrica\",\"landing_page_url\":\"https://doi.org/10.1017/neu.2025.10042\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Brain Imaging,Aging,Personality Change,Clinical Trial,Randomized Controlled Trial,Observational Study,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415851344" }, { "id": 261, "title": "Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy", "normalized_title": "psilocybin assisted therapy for demoralisation in hospice patients feasibility safety and preliminary efficacy", "authors": "Yvan Beaussant, Zachary Sager, Caitlin W. Brennan, Isabel Kristan, Michael Ljuslin, Emanuele Mazzola, David R. Macdonald, M. Murphy, Kabir Nigam, Alden Doerner Rinaldi, Justin J. Sanders, Kristen G. Schaefer, Roxanne Sholevar, Lisa Summer, Alifia Waliji-Banglawala, Sandra Yudilevich-Espinoza, James A. Tulsky", "abstract": "OBJECTIVES: To assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy (PAT) for demoralisation in terminally ill patients receiving home hospice care. METHODS: In this open-label pilot trial, 4607 home hospice patients at a large community hospice were screened over 22 months; 66 were approached, 15 enrolled and 10 received psilocybin. Participants completed two home-based preparation sessions, a single 25 mg oral psilocybin session at an inpatient hospice facility, and two home-based integration sessions. Feasibility was assessed through recruitment, retention and acceptability. Safety was evaluated via adverse event monitoring, and preliminary efficacy was assessed using changes in demoralisation scores and other psychosocial measures. RESULTS: The intervention was well tolerated, with no serious adverse events attributed to psilocybin. At week 3, demoralisation scores significantly decreased (mean reduction: 8.8 points, p=0.0196), despite ongoing clinical decline. Grief- and peace-related themes were prominent during psilocybin sessions. While six participants rated the treatment favourably on the Reaction to Research Participation Questionnaire global evaluation factor, three rated neutral on one or more items, suggesting that the emotional intensity and demands of the intervention may influence acceptability. CONCLUSION: This study provides initial evidence that PAT can be feasibly and safely integrated into hospice care for terminally ill patients. Further research is needed to optimise delivery and further assess therapeutic potential.", "journal": "BMJ Supportive & Palliative Care", "publication_date": "2025-11-02", "publication_year": 2025, "doi": "10.1136/spcare-2025-005773", "pubmed_id": "41184102", "source_url": "https://doi.org/10.1136/spcare-2025-005773", "keywords": "Medicine, Intensive care medicine, Terminally ill, Medical emergency, MEDLINE, Nursing, Hospice care, Patient safety, Critically ill, Disease, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415820910\",\"openalex_url\":\"https://openalex.org/W4415820910\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W74705120\",\"https://openalex.org/W1507162502\",\"https://openalex.org/W2066061643\",\"https://openalex.org/W2081033553\",\"https://openalex.org/W2084343441\",\"https://openalex.org/W2115111325\",\"https://openalex.org/W2145853206\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2162420979\",\"https://openalex.org/W2165214121\",\"https://openalex.org/W2166281097\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2350952069\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2610614969\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2791432716\",\"https://openalex.org/W2904333875\",\"https://openalex.org/W2939604657\",\"https://openalex.org/W2951794277\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4389895437\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4401184397\"],\"authorships\":[{\"id\":\"https://openalex.org/A5063328366\",\"display_name\":\"Yvan Beaussant\",\"orcid\":\"https://orcid.org/0000-0003-3716-6736\"},{\"id\":\"https://openalex.org/A5064982845\",\"display_name\":\"Zachary Sager\",\"orcid\":\"https://orcid.org/0000-0001-8209-9582\"},{\"id\":\"https://openalex.org/A5018275518\",\"display_name\":\"Caitlin W. Brennan\",\"orcid\":\"https://orcid.org/0009-0004-8502-4948\"},{\"id\":\"https://openalex.org/A5120235556\",\"display_name\":\"Isabel Kristan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071091088\",\"display_name\":\"Michael Ljuslin\",\"orcid\":\"https://orcid.org/0000-0002-2386-1749\"},{\"id\":\"https://openalex.org/A5010782903\",\"display_name\":\"Emanuele Mazzola\",\"orcid\":\"https://orcid.org/0000-0003-0561-7336\"},{\"id\":\"https://openalex.org/A5111959128\",\"display_name\":\"David R. Macdonald\",\"orcid\":null},{\"id\":\"https://openalex.org/A5050187042\",\"display_name\":\"M. Murphy\",\"orcid\":\"https://orcid.org/0009-0009-5595-100X\"},{\"id\":\"https://openalex.org/A5053570913\",\"display_name\":\"Kabir Nigam\",\"orcid\":\"https://orcid.org/0000-0002-1880-0079\"},{\"id\":\"https://openalex.org/A5080450999\",\"display_name\":\"Alden Doerner Rinaldi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063712330\",\"display_name\":\"Justin J. Sanders\",\"orcid\":\"https://orcid.org/0000-0001-8928-4051\"},{\"id\":\"https://openalex.org/A5102727040\",\"display_name\":\"Kristen G. Schaefer\",\"orcid\":\"https://orcid.org/0000-0003-4937-0013\"},{\"id\":\"https://openalex.org/A5020110017\",\"display_name\":\"Roxanne Sholevar\",\"orcid\":\"https://orcid.org/0009-0008-1775-3101\"},{\"id\":\"https://openalex.org/A5079418445\",\"display_name\":\"Lisa Summer\",\"orcid\":\"https://orcid.org/0009-0005-5911-2204\"},{\"id\":\"https://openalex.org/A5038001111\",\"display_name\":\"Alifia Waliji-Banglawala\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120235555\",\"display_name\":\"Sandra Yudilevich-Espinoza\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014360467\",\"display_name\":\"James A. Tulsky\",\"orcid\":\"https://orcid.org/0000-0002-7458-0453\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210204300\",\"source_display_name\":\"BMJ Supportive & Palliative Care\",\"landing_page_url\":\"https://doi.org/10.1136/spcare-2025-005773\",\"is_oa\":false}}", "topic_tags": "End-of-Life Distress,Emotional Processing,Safety,Adverse Events,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415820910" }, { "id": 84, "title": "Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health-Dependent Associations in a National Survey", "normalized_title": "lifetime psychedelic use and opioid use disorder severity substance use pattern specific and mental health dependent associations in a national survey", "authors": "", "abstract": "Background and Aims The ongoing opioid epidemic remains a major public health crisis in the United States, with over 100,000 opioid-related deaths annually. Mental health disorders are strongly associated with opioid use disorder (OUD), compounding risks of misuse and overdose. Emerging evidence indicates that psychedelics may be associated with reduced risk of OUD. This study aimed to estimate the associations between lifetime psychedelic use and OUD severity, accounting for mental health impairment, and to test whether these associations vary by mental health status. Design Cross-sectional analysis of the 2023 National Survey on Drug Use and Health using structural equation modeling with multiple-group moderation. Reporting follows STROBE guidelines for observational studies. Setting United States, nationally representative community survey. Participants 45,133 adults aged ≥18 years (55% female; mean age = 35.6 years, SD = 13.7). Measurements The primary dependent variable was OUD severity (no disorder, mild, moderate, severe). Independent variables were two psychedelic factors: mescaline/peyote (Psychedelic_F1) and LSD, psilocybin, MDMA, DMT (Psychedelic_F2). Mental health impairment was modeled as a latent construct (psychological distress, functional impairment, major depression) and also used to define high vs. low impairment groups. Covariates were age, sex, and household income. Findings Psychedelic_F1 was associated with lower OUD severity (β = -0.34, p =.001, 95%CI [-0.550, -0.153]), while the Psychedelic_F2 was associated with higher severity (β = 0.60, p", "journal": "PsyArXiv", "publication_date": "2025-11-01", "publication_year": 2025, "doi": "10.1016/j.addbeh.2026.108652", "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/jd2rk_v1", "keywords": "Mental Health Impairment, Mescaline, National Survey on Drug Use and Health, Opioid Use Disorder, Peyote, Psychedelics, Social and Behavioral Sciences, Clinical Psychology, Substance Abuse and Addiction, Quantitative Methods, Quantitative Psychology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-06-30 22:38:07", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"jd2rk_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Addiction,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1987, "title": "Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?", "normalized_title": "ketamine and psilocybin for athletes a therapeutic breakthrough or a slippery slope", "authors": "Thomas Zandonai, Sofia Venturini, Ornella Corazza", "abstract": "• Ketamine and psilocybin show promise in athlete recovery and pain management. • Psychedelics may enhance resilience, mood, and cognitive flexibility in sports. • Growing athlete use raises concerns for safety and anti-doping regulation. • Evidence on long-term effects with exercise remains scarce, urging research.", "journal": "Performance Enhancement & Health", "publication_date": "2025-10-31", "publication_year": 2025, "doi": "10.1016/j.peh.2025.100386", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.peh.2025.100386", "keywords": "Psilocybin, Ketamine, Hallucinogen, Medicine, Cognition, Flexibility (engineering), Anesthesia, Cognitive flexibility, Pain relief, Psychology, Psychiatry, Psychotherapist, Dissociative, Addiction, Depression (economics), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415757045\",\"openalex_url\":\"https://openalex.org/W4415757045\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2599106975\",\"https://openalex.org/W4207016700\",\"https://openalex.org/W4226270886\",\"https://openalex.org/W4400803438\",\"https://openalex.org/W4401375939\",\"https://openalex.org/W4401432739\",\"https://openalex.org/W4402642931\",\"https://openalex.org/W4414003501\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066844049\",\"display_name\":\"Thomas Zandonai\",\"orcid\":\"https://orcid.org/0000-0002-7606-9675\"},{\"id\":\"https://openalex.org/A5117323956\",\"display_name\":\"Sofia Venturini\",\"orcid\":\"https://orcid.org/0009-0009-1668-8333\"},{\"id\":\"https://openalex.org/A5012791303\",\"display_name\":\"Ornella Corazza\",\"orcid\":\"https://orcid.org/0000-0001-7371-319X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764777161\",\"source_display_name\":\"Performance Enhancement & Health\",\"landing_page_url\":\"https://doi.org/10.1016/j.peh.2025.100386\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Chronic Pain,Receptor Pharmacology,Resilience,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415757045" }, { "id": 458, "title": "The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives.", "normalized_title": "the therapeutic use of psychedelic drugs legal policy and neuroscientific perspectives", "authors": "Rahmani S, Crupi R, Riley AL, Davidson T", "abstract": "After many years of stigma and neglect, there is a resurgence of interest in the therapeutic use of psychedelic drugs. Anecdotal and evidence-based reports indicate psychedelics as a possible treatment for depression, anxiety, PTSD, substance abuse, and other disorders resistant to conventional medical interventions. The available data, however, are limited and the use of psychedelic substances in therapy remains controversial. This paper presents a collection of reports based on the talks of eighteen renowned experts in science, policy, and law who spoke at a recent symposium organized by American University's Center for Neuroscience and Behavior titled \"The Therapeutic Uses of Psychedelic Drugs: Legal, Policy, and Neuroscientific Perspectives.\" These speakers presented their ideas and perspectives concerning (a) the safety and effectiveness of psychedelic-assisted therapies; (b) the brain systems on which psychedelic drugs act; (c) ethical issues for both research and clinical settings; (d) pathways to increasing access to psychedelics for medical and nonmedical purposes; (e) federal and state regulation of psychedelic drugs for research, therapy, and nonmedical uses; and (f) procedures and requirements for psychedelic drug patents and commercialization. In considering these topics, each speaker strove to make their views accessible to diverse audiences of professionals outside of their own disciplines. This paper aims to faithfully convey the substance of each talk, while also providing additional context and updates relevant to the presentations. The symposium revealed the potential of psychedelics for treating psychiatric and behavioral disorders and the scientific, legal, and policy challenges that must be met to realize this potential.", "journal": "Pharmacology, biochemistry, and behavior", "publication_date": "2025-10-31", "publication_year": 2025, "doi": "10.1016/j.pbb.2025.174087", "pubmed_id": "40849009", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40849009/", "keywords": "Drug law, Drug policy, Medical ethics, Psilocybin, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40849009\"}", "topic_tags": "Depression,Anxiety,PTSD,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 449, "title": "Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review", "normalized_title": "reporting of side effects in clinical trials of psilocybin assisted psychotherapy for psychiatric conditions systematic review", "authors": "Jonathon Marinis, Sarah Clarke, Alexandre A. Guerin, Adam J. Guastella, Gillinder Bedi", "abstract": "BACKGROUND: Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety and post-traumatic stress disorder, but understanding of its side-effects is limited. This review evaluates the quality of side-effects reporting in PAP trials, to guide treatment, policy and research. AIMS: To assess side-effects reporting quality in PAP trials for psychiatric conditions, comparing published articles and ClinicalTrials.gov records. METHOD: A PROSPERO-registered review (no. CRD42023458960) included English-language PAP trials (2005-2024) identified via Embase, CENTRAL, PubMed and reference searches. Reporting quality was assessed using the CONSORT Harms extension, categorised as either high (17-21), moderate (12-16), low (7-11) or very low (0-6). Randomised controlled trials underwent risk of bias analysis, and descriptive statistics compared side-effects across sources. RESULTS: = 9) showed high risk of bias for side-effects outcomes. Variability in reporting hindered comparisons between articles and ClinicalTrials.gov, underscoring the need for standardisation. Overall, there was no evidence of systematic underreporting of side-effects in published articles compared with trial registers. CONCLUSIONS: Side-effects reporting in PAP trials is inconsistent but is improving over time. Existing evidence has a high risk of bias. Future trials should align with best-practice guidelines for side-effects reporting. Discussions with patients should prioritise findings from high-quality studies and emphasise the current uncertainty regarding PAP side-effects.", "journal": "BJPsych Open", "publication_date": "2025-10-31", "publication_year": 2025, "doi": "10.1192/bjo.2025.10847", "pubmed_id": "41178084", "source_url": "https://doi.org/10.1192/bjo.2025.10847", "keywords": "Clinical trial, Medicine, Psychiatry, MEDLINE, Psychotherapist, Systematic review, Psychology, Alternative medicine, Drug trial, Clinical Practice, Research design, Clinical psychology, Mental health, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415782096\",\"openalex_url\":\"https://openalex.org/W4415782096\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1747918244\",\"https://openalex.org/W1986360186\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2263572070\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3090435879\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W4210376981\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213300280\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4297252613\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4361279088\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W4366974898\",\"https://openalex.org/W4367054142\",\"https://openalex.org/W4384665053\",\"https://openalex.org/W4385173317\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387115576\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4387674199\",\"https://openalex.org/W4387902564\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4395034174\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4402912774\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4405955624\",\"https://openalex.org/W4405955644\"],\"authorships\":[{\"id\":\"https://openalex.org/A5093590789\",\"display_name\":\"Jonathon Marinis\",\"orcid\":\"https://orcid.org/0009-0006-8487-4152\"},{\"id\":\"https://openalex.org/A5101504134\",\"display_name\":\"Sarah Clarke\",\"orcid\":\"https://orcid.org/0000-0003-1908-1405\"},{\"id\":\"https://openalex.org/A5041548475\",\"display_name\":\"Alexandre A. Guerin\",\"orcid\":\"https://orcid.org/0000-0003-3833-3620\"},{\"id\":\"https://openalex.org/A5014867110\",\"display_name\":\"Adam J. Guastella\",\"orcid\":\"https://orcid.org/0000-0001-8178-4625\"},{\"id\":\"https://openalex.org/A5036812133\",\"display_name\":\"Gillinder Bedi\",\"orcid\":\"https://orcid.org/0000-0002-6718-0099\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764831659\",\"source_display_name\":\"BJPsych Open\",\"landing_page_url\":\"https://doi.org/10.1192/bjo.2025.10847\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415782096" }, { "id": 4256, "title": "Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications", "normalized_title": "use of psilocybin for chronic pain a scoping review with current evidence and prospection of literature and technology for future applications", "authors": "André Leão Dantas, Lara Moreira Jalles Milani, Saulo Gabriel Moreira Falci, João Américo da Silveira, Cristina Pereira Isolan, Lia Dietrich", "abstract": "Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psilocybin, a psychedelic found in mushrooms of the Psilocybe genus, has sparked interest due to its potential to modulate serotonergic receptors and promote neuroplasticity, suggesting analgesic and psychotherapeutic effects. The objective of this scoping review was to map and synthesize the available evidence on the use of psilocybin in the management of chronic pain. The protocol was registered on the OSF platform (DOI: 10.17605/OSF.IO/MQ36X) and gathered evidence from seven databases and gray literature, including clinical and preclinical studies, and patents. Twenty studies were included: nine published, eleven ongoing clinical trials, and five filed patents. Doses ranged from 5 to 25 mg, administered in single or multiple sessions, with or without associated psychotherapy, and showed reduced pain intensity and improved mood and quality of life. In animal models, the results were heterogeneous, ranging from significant analgesia to no effect. The analyzed patents indicate industrial interest in microdosing protocols and controlled-release formulations aimed at fibromyalgia, neuropathic pain, and phantom pain. Taken together, the evidence pointed to psilocybin as a promising alternative for chronic pain management, although robust and standardized clinical trials are needed to confirm its efficacy and safety.", "journal": "Caderno Pedagógico", "publication_date": "2025-10-30", "publication_year": 2025, "doi": "10.54033/cadpedv22n12-345", "pubmed_id": null, "source_url": "https://doi.org/10.54033/cadpedv22n12-345", "keywords": "Psilocybin, Medicine, Mood, Chronic pain, Clinical trial, Hallucinogen, Analgesic, Pain assessment, Quality of life (healthcare), Dosing, Pharmacology, Neuropathic pain, Protocol (science), Psychiatry, Pain management, Serotonergic, Clinical pharmacology, Randomized controlled trial, Psychology, MEDLINE, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:38", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415830103\",\"openalex_url\":\"https://openalex.org/W4415830103\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2017462460\",\"https://openalex.org/W2082947525\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2794118706\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3165837403\",\"https://openalex.org/W4294804950\",\"https://openalex.org/W4308486832\",\"https://openalex.org/W4362508370\",\"https://openalex.org/W4386019370\",\"https://openalex.org/W4389891609\",\"https://openalex.org/W4393489617\",\"https://openalex.org/W4402529371\",\"https://openalex.org/W4402697828\",\"https://openalex.org/W4402748917\",\"https://openalex.org/W4406306242\",\"https://openalex.org/W4408540649\",\"https://openalex.org/W4408581056\",\"https://openalex.org/W4409704666\",\"https://openalex.org/W4411103150\",\"https://openalex.org/W4412080495\"],\"authorships\":[{\"id\":\"https://openalex.org/A5120237973\",\"display_name\":\"André Leão Dantas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5060273750\",\"display_name\":\"Lara Moreira Jalles Milani\",\"orcid\":\"https://orcid.org/0009-0003-7126-6877\"},{\"id\":\"https://openalex.org/A5008286933\",\"display_name\":\"Saulo Gabriel Moreira Falci\",\"orcid\":\"https://orcid.org/0000-0001-9438-5199\"},{\"id\":\"https://openalex.org/A5003622337\",\"display_name\":\"João Américo da Silveira\",\"orcid\":\"https://orcid.org/0000-0001-6529-5362\"},{\"id\":\"https://openalex.org/A5047106535\",\"display_name\":\"Cristina Pereira Isolan\",\"orcid\":\"https://orcid.org/0000-0002-1502-7383\"},{\"id\":\"https://openalex.org/A5001812672\",\"display_name\":\"Lia Dietrich\",\"orcid\":\"https://orcid.org/0000-0001-7887-8591\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210173331\",\"source_display_name\":\"Caderno Pedagógico\",\"landing_page_url\":\"https://doi.org/10.54033/cadpedv22n12-345\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Neuroplasticity,Pharmacology,Receptor Pharmacology,Microdosing,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415830103" }, { "id": 306, "title": "Psilocybin use in bipolar disorder: A comprehensive review.", "normalized_title": "psilocybin use in bipolar disorder a comprehensive review", "authors": "Do A, Cloutier L, Hébert-Tremblay L, Thauvin C.", "abstract": "IntroductionBipolar disorder (BD) is a severe and persistent mental disorder characterized by recurrent mood episodes, with BD depression accounting for most of the illness burden. Although the mainstay treatment of BD consists of pharmacotherapy with mood stabilizers and atypical antipsychotics, a large proportion of patients with BD depression do not respond to adequate trials of medications. In addition, these medications can be associated with multiple, often significant adverse effects, highlighting the need for novel therapeutic agents that are acceptable, effective and safe for patients.MethodsWe performed a comprehensive narrative review on the use of psilocybin in BD, with a focus on clinical outcomes.ResultsTwo small clinical trials show that psilocybin combined with psychotherapy was safe and effective for the treatment of BDII depression with large treatment effects. No serious adverse events, including treatment-emergent mania/hypomania or increased suicidality, were reported in both trials. However, other studies have raised concerns about the safety of psilocybin in BD patients, including the development or worsening of manic symptoms, sleep disruptions and anxiety. Overall, the majority of BD patients believe that psilocybin could benefit their mental health problems, but their experiences varied depending on several contextual factors, such as polysubstance use, psilocybin dose, solo versus social experiences and pre-psilocybin sleep deprivation.ConclusionDespite its promising potential, the efficacy and safety of psilocybin in the treatment of BD depression remain unclear, and future research is essential to clarify its therapeutic value in BD.", "journal": null, "publication_date": "2025-10-30", "publication_year": 2025, "doi": "10.1016/j.jad.2025.120485", "pubmed_id": "41177271", "source_url": "https://doi.org/10.1016/j.jad.2025.120485", "keywords": "Humans, Hallucinogens, Treatment Outcome, Combined Modality Therapy, Bipolar Disorder, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"41177271\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Clinical Trial,Review Article,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3597, "title": "A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?", "normalized_title": "a wellcome leap for the opioid crisis can the 5ht2a agonist psilocybin improve brain behavioral and clinical outcomes in opioid use disorder oud", "authors": "Anna Rose Childress, Ph.D.", "abstract": "Investigators will recruit 36 individuals on MAT for OUD for a double-blind, placebo-controlled design to determine whether PEX010 (25-mg/d) shows preliminary efficacy on neural correlates of neurocognition and on clinical outcomes. Participants will be randomized to either (single dose) 25-mg (PEX010-25 group) or 1-mg (PPEX010-1 group) PEX010 in a 2:1 ratio. Brain and behavioral testing sessions will precede Psilocybin (PSI) dosing day by 24-48 hours and will follow PSI dosing by 1 week. After an initial 6 phases, participants will come into the lab to submit a urine screen 2x/week and to complete a short survey in order to collect data on drug use, MAT adherence, and mental health symptoms. The investigators hypothesize the PEX010-25 (vs. PEX010-1) group will have better clinical outcomes (e.g., lower average percent positive urine drug screens, more late relapses, higher MAT adherence). There are research follow ups every three months out to one year post dose. The Opioid Crisis: Currently in its third wave, the opioid epidemic involves the prevalence of lethal levels of fentanyl in drugs, leading to a surge in opioid-related deaths. Reports indicate a record-breaking number of over 107,000 drug-related overdose deaths in 2021-2022, with opioids contributing to more than 75% of these fatalities. Beyond fatal overdoses, nearly 1 million non-fatal overdoses occurred in 2017, carrying significant, long-lasting consequences. Those who experience non-fatal overdoses are more prone to subsequent overdoses and have a higher likelihood of death within a year, primarily due to drug-related issues. The escalating cases of opioid use disorder (OUD) emphasize the critical need for innovative treatments to address the associated challenges, including neurocognitive difficulties and poor clinical outcomes. While medication-assisted treatment (MAT) like methadone or buprenorphine effectively alleviates withdrawal symptoms and reduces overdose risk, illicit drug use persists, and non-adherence to MAT remains a challenge. The opioid overdose crisis demands urgent attention and necessitates the development of treatments capable of making a significant impact. Psilocybin: In response to the need for improved treatments, there's a growing interest in psychedelic-assisted treatment (PAT), particularly involving psilocybin (PSI). Clinical trials support the use of PAT in controlled medical contexts, with 105 trials registered in the past 20 years covering various mental health and other conditions. PSI (at single doses in the proposed range) has shown preliminary promise for depression, alcohol use disorder, and tobacco-use disorder. However, its potential benefits for OUD remain unknown. This proposal aims to determine whether PSI enhances critical OUD clinical outcomes, such as relapse, overdose, and MAT adherence. Importantly, the investigators will test how PSI produces its benefits through its impact on brain and bio-behavioral targets, thus linking potential biomarkers to clinical outcomes. Cognitive Flexibility: The ability to change thoughts, emotions, and behaviors in response to changes in circumstance (to \"flex\") has strong survival value. When the brain cannot \"flex\", one can experience a range of mishaps, from small (turning left rather than right 'out of habit') to much larger ones. Being 'stuck' is a problem that appears in many disorders. For example, individuals with depression may get 'stuck' in dark ruminating thoughts; individuals with OCD may get 'stuck' in repetitive thoughts and behaviors; people with substance use disorders get 'stuck' over-responding to drug reward signals and pursue the drug despite negative consequences. Recent research shows that PSI facilitates intermediate and long-term improvements in cognitive flexibility, raising the hope that it can 're-set' the brain and enable new thoughts, emotions, and behaviors. Cognitive flexibility is often measured by tasks that quantify how successfully one can shift between changing mental rules to complete a task. Using such tasks, there is evidence of cognitive flexibility deficits in people with OUD, but research has not specifically examined the impact of improved cognitive flexibility on OUD clinical outcomes. To date, one study showed that neurocognitive training in executive function (EF), including cognitive flexibility, is associated with reduced opioid use, while a non-OUD study found that higher baseline cognitive flexibility was related to better substance use treatment retention. This proposal will be the first to test whether putative PSI-related improvements in cognitive flexibility will lead to more favorable OUD clinical outcomes. Other Executive Functions: Importantly, cognitive flexibility is a complex capability that depends on the integrated action of several other basic executive functions (EFs): attention, working memory, and inhibition of thoughts, feelings, or actions. Further, each of these basic EFs, together with cognitive flexibility, are needed for effective and efficient planning and decision-making. Individuals who use drugs demonstrate impairment in a variety of these fundamental EFs. In OUD populations, deficits are evident across most EF domains, including working memory, attention, inhibition, and decision-making, which may relate to or underly their cognitive inflexibility. Studies have found that performance on EF tasks (and the neural underpinnings of EF in the prefrontal cortex \\[PFC\\]) indeed correlate with clinical outcomes such as treatment non-adherence (e.g., working memory) and drug use/relapse (e.g., poor inhibition) in substance-use disorders generally, and with reduced abstinence in OUD. Whether these multiple EF deficits predate, or even predispose, drug use - they are likely compounded by drug exposure, including non-fatal opioid overdoses that produce hypoxic-related brain injuries, leading to further neurocognitive deficits. In sum, there is good preliminary evidence for deficits in the several component EFs underlying cognitive flexibility in OUD. By measuring these separately, the current proposal will be able to determine which of these targets are most impacted by PSI, and their relative importance for outcome prediction. What's \"special\" about psilocybin? PSI has likely been in use by humans for millennia, originally as a religious or spiritual agent due to its dramatic subjective effects, including hallucinations and mystical experiences. However, scientists have more recently understood that some of the effects - such as increased sense of connectedness, openness, and change in perspective - can produce long-lasting change and improved mental health. Indeed, psychometric instruments capturing non-ordinary states of consciousness and psychological constructs have reliably predicted clinical treatment outcomes, including substance use disorder outcomes. Some theorists have proposed that these dramatic drug effects may reflect a profound initial 'loosening' of top-down control over limbic and sensory regions, resulting in improved flexibility and adaptive behavior. Though the current proposal will not be able to test all features of this hypothesis, the investigators will capture the special acute phenomenology of the drug state and test for the fundamental feature of flexibility. Further, the investigators will determine the relative role of the basic EF components of flexibility and test the importance of all these factors (alone and in combination) for obtaining clinical benefit from the drug. This study will provide a critical foundation for understanding the potential of 5HT2A agonists in OUD, with treatment implications for several other disorders where cognitive inflexibility, 'getting stuck', is a core feature.", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-28", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06786325", "keywords": "Opioid Use Disorder, Psilocybin, PEX010, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06786325\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Addiction,OCD,Receptor Pharmacology,Consciousness,Biomarkers,Emotional Processing,Spirituality,Mystical Experience,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 467, "title": "Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial", "normalized_title": "psilocybin assisted existential attachment and relational pearl therapy for patients with advanced cancer protocol for a multi method feasibility trial", "authors": "Candice Richardson, Cindy Chan, Emily Macgregor, Crystal Hare, Breffni Hannon, SarahRose Black, Evan E. Schneider, Daniel Z. Buchman, Stella Wang, Valeria E. Rac, Lusine Abrahamyan, Ella Huszti, Rinat Nissim, Madeline Li, Camilla Zimmermann, Emma Hapke, Daniel M. Rosenbaum, Sarah Hales", "abstract": "BACKGROUND: Individuals with advanced cancer often experience high levels of distress for which there are few standardized treatment approaches. Our multidisciplinary team has combined existing evidence-based approaches into Psilocybin-assisted Existential, Attachment, and RelationaL (PEARL) therapy. PEARL therapy combines elements from psilocybin-assisted psychotherapy, including preparatory therapy sessions, a high-dose psilocybin session, and integration sessions, with important elements from evidence-based psychotherapies designed for patients with advanced cancer. METHOD: This open-label, single-arm clinical trial will assess the acceptability, feasibility, and safety of PEARL therapy among 15 patients with advanced cancer, using qualitative and quantitative methodologies. Participants will complete self-report questionnaires at four time points pre- and post-intervention, as well as a qualitative interview one month after PEARL completion. Feasibility will be evaluated in terms of recruitment, retention, and adherence rates, while safety will be assessed based on the number of participants experiencing no serious adverse events. DISCUSSION: This study will yield important information about the acceptability and feasibility of PEARL therapy and contribute to growing research around the efficacy of psychedelic-assisted therapies. PEARL therapy has the potential to improve quality of life among those with advanced disease, and careful research is needed to guide public policy, legislation, therapist training, and clinical guidelines. TRIAL REGISTRATION: NCT06416085; 2024-07-16.", "journal": "Pilot and Feasibility Studies", "publication_date": "2025-10-27", "publication_year": 2025, "doi": "10.1186/s40814-025-01706-5", "pubmed_id": "41152967", "source_url": "https://doi.org/10.1186/s40814-025-01706-5", "keywords": "Protocol (science), Medicine, Psychology, Clinical trial, Physical therapy, MEDLINE, Randomized controlled trial, Medical emergency, Computer science, Psychotherapist, Treatment protocol, Intervention (counseling), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4415616586\",\"openalex_url\":\"https://openalex.org/W4415616586\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1608689417\",\"https://openalex.org/W1862997372\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1988792451\",\"https://openalex.org/W2000806079\",\"https://openalex.org/W2020646491\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2058150514\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2082733011\",\"https://openalex.org/W2103903454\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2125025233\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2137904825\",\"https://openalex.org/W2145839824\",\"https://openalex.org/W2152696551\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2170182466\",\"https://openalex.org/W2313442361\",\"https://openalex.org/W2314515280\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2480994613\",\"https://openalex.org/W2552595635\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2588182016\",\"https://openalex.org/W2592273082\",\"https://openalex.org/W2625982844\",\"https://openalex.org/W2744073746\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2772834920\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2800374108\",\"https://openalex.org/W2886232664\",\"https://openalex.org/W2896015079\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3015163151\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3097681315\",\"https://openalex.org/W3107917596\",\"https://openalex.org/W3215891836\",\"https://openalex.org/W4211011432\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4231257997\",\"https://openalex.org/W4243323812\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4383187032\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4389895437\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4398774731\"],\"authorships\":[{\"id\":\"https://openalex.org/A5103148291\",\"display_name\":\"Candice Richardson\",\"orcid\":\"https://orcid.org/0000-0002-2518-0912\"},{\"id\":\"https://openalex.org/A5081797920\",\"display_name\":\"Cindy Chan\",\"orcid\":\"https://orcid.org/0000-0002-0383-855X\"},{\"id\":\"https://openalex.org/A5120160227\",\"display_name\":\"Emily Macgregor\",\"orcid\":null},{\"id\":\"https://openalex.org/A5114205104\",\"display_name\":\"Crystal Hare\",\"orcid\":null},{\"id\":\"https://openalex.org/A5041923648\",\"display_name\":\"Breffni Hannon\",\"orcid\":\"https://orcid.org/0000-0002-0881-555X\"},{\"id\":\"https://openalex.org/A5111996437\",\"display_name\":\"SarahRose Black\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030092509\",\"display_name\":\"Evan E. Schneider\",\"orcid\":\"https://orcid.org/0000-0001-9735-7484\"},{\"id\":\"https://openalex.org/A5066952814\",\"display_name\":\"Daniel Z. Buchman\",\"orcid\":\"https://orcid.org/0000-0001-8944-6647\"},{\"id\":\"https://openalex.org/A5052157511\",\"display_name\":\"Stella Wang\",\"orcid\":\"https://orcid.org/0000-0003-1338-6953\"},{\"id\":\"https://openalex.org/A5009391575\",\"display_name\":\"Valeria E. Rac\",\"orcid\":\"https://orcid.org/0000-0002-0426-4594\"},{\"id\":\"https://openalex.org/A5090644631\",\"display_name\":\"Lusine Abrahamyan\",\"orcid\":\"https://orcid.org/0000-0003-2788-4179\"},{\"id\":\"https://openalex.org/A5015263586\",\"display_name\":\"Ella Huszti\",\"orcid\":\"https://orcid.org/0000-0003-0169-4895\"},{\"id\":\"https://openalex.org/A5017464940\",\"display_name\":\"Rinat Nissim\",\"orcid\":\"https://orcid.org/0000-0002-3624-5806\"},{\"id\":\"https://openalex.org/A5064599428\",\"display_name\":\"Madeline Li\",\"orcid\":\"https://orcid.org/0000-0002-3977-7437\"},{\"id\":\"https://openalex.org/A5055774990\",\"display_name\":\"Camilla Zimmermann\",\"orcid\":\"https://orcid.org/0000-0003-4889-0244\"},{\"id\":\"https://openalex.org/A5001698290\",\"display_name\":\"Emma Hapke\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048501797\",\"display_name\":\"Daniel M. Rosenbaum\",\"orcid\":\"https://orcid.org/0000-0002-7174-4993\"},{\"id\":\"https://openalex.org/A5060578045\",\"display_name\":\"Sarah Hales\",\"orcid\":\"https://orcid.org/0000-0001-6404-8124\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764511738\",\"source_display_name\":\"Pilot and Feasibility Studies\",\"landing_page_url\":\"https://doi.org/10.1186/s40814-025-01706-5\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4415616586" }, { "id": 391, "title": "Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.", "normalized_title": "adverse event reporting and management in psilocybin therapy clinical trials a systematic review to guide clinical and research protocol development", "authors": "Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P.", "abstract": "Psilocybin, a psychedelic prodrug, has gained renewed interest for its potential to treat various psychiatric disorders, including depression, anxiety, and substance use disorders. While promising, concerns remain regarding its safety profile and the management of potential adverse events (AEs). This systematic review aimed to evaluate the incidence, nature, and severity of adverse events and serious adverse events (SAEs) associated with psilocybin use across diverse clinical populations. A comprehensive search was conducted across MEDLINE, Embase, and APA PsycInfo via the OVID platform, from database inception to June 5, 2024. A total of 42 clinical studies (N = 1068 participants) met inclusion criteria, all of which reported on AEs and/or SAEs following psilocybin administration. All studies were deemed to have a high risk of bias due to concerns regarding blinding. We synthesized information on common, uncommon, and SAEs, instances of suicidal ideation, methods of measuring AEs, and AEs requiring medical intervention. Reported AEs included headache, transient increases in blood pressure, and nausea, which typically resolved on their own. In rare instances, medical intervention was required. SAEs were reported infrequently in 2 of 42 studies and were limited to participants with underlying depressive disorders (e.g., suicidal behaviour, hospitalization). Overall, psilocybin appears to have a favourable safety profile when administered in controlled settings. Based on our findings, we provide an outline of commonly reported AEs, uncommon AEs, SAEs, and considerations for future clinical and research protocols.", "journal": null, "publication_date": "2025-10-22", "publication_year": 2025, "doi": "10.1016/j.pnpbp.2025.111541", "pubmed_id": "41138900", "source_url": "https://doi.org/10.1016/j.pnpbp.2025.111541", "keywords": "Humans, Hallucinogens, Research Design, Clinical Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"41138900\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3640, "title": "A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer", "normalized_title": "a phase 1 study of a second psilocybin group retreat for partial responders with anxiety associated with metastatic cancer", "authors": "University of Washington", "abstract": "This phase I trial tests the safety and side effects of a second episode of psilocybin-assisted group therapy and how well it works in treating anxiety and distress in patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and had a partial response to their first retreat. Up to 50% of patients with metastatic cancer have clinically significant anxiety and unaddressed anxiety and distress may add to the suffering caused by cancer itself. Psilocybin, a psychedelic drug, is made using an extract from the psilocybe mushroom, also known as \"magic mushrooms\". Psilocybin binds to serotonin receptors (natural body chemicals that control moods) on brain cells producing intense changes in mood, including anxiety. This may change perceptions and patterns of thinking in ways that may decrease anxiety. Group therapy may reduce stress and improve the well-being and quality of life of patients with metastatic cancer. A second episode of psilocybin-assisted group therapy may be safe, tolerable and or effective in treating anxiety and distress in partial responders with metastatic cancer. OUTLINE: Patients receive psilocybin orally (PO) with optional booster dose on day 0. Patients attend an individual prep visit on day -1 and an individual integration visit on day 1. Patients also attend group preparation visits on days -14, -7 and -1 and group integration visits on days 1, 8, 22 and 36. After completion of study treatment, patients are followed up at 2, 3, and 6 months.", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-13", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06644170", "keywords": "Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Behavioral Intervention, Psychedelic therapy, Group Therapy, Psilocybin, Questionnaire Administration, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06644170\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Anxiety,Receptor Pharmacology,Wellbeing,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3590, "title": "Psilocybin and Affective Function in Chronic Lower Back Pain Depression", "normalized_title": "psilocybin and affective function in chronic lower back pain depression", "authors": "Johns Hopkins University", "abstract": "This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depressive symptoms, and more general questionnaires regarding the participants experiences during the experimental sessions and the associated enduring effects. This study will investigate the effects of a single experimental psilocybin (25 mg fixed dose) administration compared to a dose of methylphenidate (40 mg fixed dose). Assessments will be conducted during screening visits, before and after the drug session, at follow up visits up to 1-month after the drug session, as well as periodically throughout study participation via a multi-time-per-day survey application. Forty participants will complete all study visits including follow-up visits. Primary objectives: 1. Investigate the feasibility, safety, and acceptability of psilocybin for CLBP+D2. Investigate the effect of psilocybin on self-report of positive affect, negative affect, and pain catastrophizing 3. Investigate the effect of psilocybin on a behavioral task called positive affective pain inhibition Secondary objectives: 1. Investigate the durability (1-month follow-up) effects of psilocybin on self-report of positive affect, negative affect, and pain catastrophizing 2. Investigate the effect of psilocybin on dynamic associations between affective measures, pain, and function on a moment-to-moment basis.", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-13", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06355414", "keywords": "Chronic Low-back Pain, Depression, Psilocybin, Methylphenidate, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06355414\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Chronic Pain,Mechanism of Action,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3455, "title": "Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study", "normalized_title": "psilocybin for chronic pelvic pain cpp in women a pilot feasibility study", "authors": "Oregon Health and Science University", "abstract": "The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions). Chronic pelvic pain (CPP) presents a significant challenge in healthcare, affecting approximately 15% of women in the United States and incurring annual healthcare costs upwards of $5.8 billion. This condition extends beyond persistent physical discomfort, profoundly impacting mental health and overall quality of life. Central to many chronic pain syndromes, CPP can lead to a heightened state of pain sensitivity known as central sensitization. This condition arises from neuroplastic changes within the central nervous system, leading to structural, functional, and chemical alterations in the brain that enhance neural reactivity, even in the absence of actual physical injuries. Central sensitization is characterized by widespread, multisite hyperalgesia and allodynia. These changes often co-occur with fatigue, mood and cognitive disturbances, sleep disruptions, and multisensory hypersensitivity, complicating the clinical picture and exacerbating the condition's impact on daily functioning. The use of psilocybin in chronic pain is a paradigm shift from conventional pain therapy where the goal is pain alleviation, to changing a person's relationship with pain, offering a re-alignment or 'reset' of one's view of their pain, this is an innovative approach. To date, there are no psilocybin studies evaluating CPP. This is a pilot feasibility and safety study to evaluate a single administration of psilocybin (25 mg) in women with CPP who have failed at least one conventional CPP therapy. The study will enroll 15 women, the primary aim is to assess feasibility that will be met when at least 80% of participants complete the study and attend 80% of 11 study visits (9/11 visits). Safety will be assessed by adverse event reports, safety labs, and vitals assessments.", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-09", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06988319", "keywords": "Chronic Pelvic Pain, Psilocybin (Usona Institute), NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06988319\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Chronic Pain,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 438, "title": "Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy.", "normalized_title": "stabilizing psilocybin pharmacology and tuning safety with atypical antipsychotic cotherapy", "authors": "Renner AC, Kargbo RB.", "abstract": "A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable psychedelic therapy with improved cardiac safety and durable neuroplastic responses across organoid and animal models.", "journal": null, "publication_date": "2025-10-09", "publication_year": 2025, "doi": "10.1021/acsmedchemlett.5c00595", "pubmed_id": "41256989", "source_url": "https://doi.org/10.1021/acsmedchemlett.5c00595", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"41256989\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Biomarkers,Animal Study,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3668, "title": "A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine", "normalized_title": "a pilot study in north louisiana to assess the tolerability of psilocybin as well as its capacity to promote abstinence from methamphetamine", "authors": "Kevin Murnane", "abstract": "The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors. This is an open-label pilot study evaluating the feasibility and tolerability of a single 25 mg psilocybin dose in promoting abstinence from methamphetamine. Participants will attend 10 to 12 study visits over a period of up to six months. Participants will be recruited from a population receiving treatment for methamphetamine dependence at a local residential treatment facility. Recruitment will involve informative presentations to current clients and counselor-facilitated referrals based on provided inclusion criteria. Prescreening will utilize information collected by the treatment center during the client's admission process. Individuals who meet prescreening criteria will be invited to an in-person screening visit, conducted after obtaining informed consent. The screening visit will include a clinical review, a detailed psychiatric interview, self-report questionnaires, a comprehensive medical history, and safety laboratory testing, including blood draws. Once eligibility is confirmed, participants will proceed with study enrollment and complete baseline assessments, which will measure substance use, quality of life, and executive function. Three preparatory sessions will follow over a two-week period to establish trust and rapport between participants and session monitors, educate participants on the study protocol, and prepare them for the psilocybin session. Two preparatory sessions may be conducted via telehealth to enhance feasibility, while the third will be conducted in person with both the primary and secondary monitors present. A medical examination will be performed within the week preceding psilocybin administration. Within a week of the third preparatory session, participants will attend a psilocybin administration session. Participants will arrive at the study location by 9:30 AM and undergo safety screenings, including breathalyzer testing, before psilocybin administration at approximately 10:00 AM. Participants will have been instructed to consume a low-fat breakfast prior to arrival. During the session, cardiovascular measures (e.g., heart rate, blood pressure) will be monitored upon arrival, hourly throughout the session, and as clinically indicated. The psilocybin session, lasting approximately 6-8 hours, will be monitored by both the primary and secondary session monitors, ensuring that at least one individual is present with the participant at all times. At the conclusion of the session, participants will complete questionnaires assessing their subjective experiences. Participants will then be released into the care of treatment center staff, who will provide emotional support. Participants will also receive contact information for the primary monitor to access support if needed. Post-session integration will include two telehealth sessions: the first within one day of the psilocybin session and the second approximately 7 days later (±3 days). These sessions will provide opportunities to discuss insights or challenges arising from the psilocybin experience, with an emphasis on promoting adaptive cognitive and behavioral changes. Follow-up assessments will occur via telehealth at 30 and 60 days post-psilocybin, with an in-person assessment conducted at 120 days. The final visit will include a urine drug screen.", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-06", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06899594", "keywords": "Methamphetamine Use Disorder, Psilocybin 25 mg, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06899594\",\"overall_status\":\"RECRUITING\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Addiction,Emotional Processing,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3575, "title": "Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)", "normalized_title": "efficacy of psilocybin and trazodone combination in treatment resistant depression a randomized controlled proof of concept study psilotraz", "authors": "Centre Hospitalier St Anne", "abstract": "Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects. The benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed. Moreover, the role of 5-HT2A receptors, involved in the psychedelic experience, on the therapeutic efficacy of psilocybin is still poorly understood. For example, pre-administration of trazodone, a 5-HT2A antagonist antidepressant, could annihilate the acute subjective effects of psilocybin without altering its beneficial effects (Rosenblat et al., 2023). We intend to test this hypothesis by comparing, in a randomized, double-blind, placebo-controlled study, the effect of two possible doses of trazodone (total or partial occupancy of 5-HT2A receptors) on the benefit/risk ratio of psilocybin. We hypothesize that the therapeutic effects of psilocybin are partially independent of 5-HT2A receptor activation and thus persist even after total or partial neutralization of its acute subjective effects. Treatment-resistant depression (TRD) is a frequent and potentially severe psychiatric disorder characterized by specific neurocognitive impairments. It has previously been demonstrated that psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improved depressive symptoms while inducing profound acute subjective effects. The benefit-risk ratio of psilocybin in TRD seems favorable, but needs to be confirmed. Moreover, the role of 5-HT2A receptors, involved in the psychedelic experience, on the therapeutic efficacy of psilocybin is still poorly understood. For example, pre-administration of trazodone, a 5-HT2A antagonist antidepressant, could annihilate the acute subjective effects of psilocybin without altering its beneficial effects (Rosenblat et al., 2023). We intend to test this hypothesis in a randomized, double-blind, placebo-controlled phase II, monocentric, 4 parallel-group proof-of-concept study involving 112 adult subjects with a depressive episode who had failed to respond to at least two lines of antidepressant treatment. Patients will be randomized in a 1:1:1:1 ratio to one of the following treatment groups: * Group 1: Psilocybin PEX010 (25 mg) + trazodone placebo (pharmaceutical master preparation prepared according to GPP) * Group 2: Psilocybin PEX010 (25 mg) + trazodone 5 mg * Group 3: Psilocybin PEX010 (25 mg) + trazodone 30 mg * Group 4: PCB2 (Placebo of PEX010 (25)) + trazodone 30 mg Stratification factors: gender (M/F).", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-06", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07210112", "keywords": "Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg, Placebo of psilocybin, Placebo of trazodone, NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07210112\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4275, "title": "Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders", "normalized_title": "neurobiological and therapeutic potential of psilocybin in psychiatric disorders", "authors": "M Loganathan, A Saravanakumar, P. Parthiban, G Anandharaj, S Gobika, D Dharshana, Mohamed Safir Ali", "abstract": "Psilocybin, an indoleamine alkaloid derived from various fungal species, is the subject of renewed, rigorous investigation for its therapeutic potential in psychiatry. This compound, a prodrug for the active metabolite psilocin, functions primarily as a partial agonist at the serotonin 2A (5-HT2A) receptor. Its administration within a structured psychotherapeutic context is associated with rapid and sustained antidepressant and anxiolytic effects, particularly in populations with treatment-resistant depression and existential distress related to life-threatening illnesses. The neurobiological mechanisms are multifaceted, initiated by acute 5-HT2A-mediated disruption of key brain networks, most importantly the Default Mode Network (DMN). This network destabilization correlates with subjective experiences of ego dissolution and is hypothesized to create a state of elevated brain entropy. This acute phase is followed by a period of enhanced neuroplasticity, driven by downstream signaling pathways involving BDNF and mTOR, which promotes synaptogenesis and dendritic spine growth in cortical neurons. This \"window of plasticity\" may facilitate the unlearning of maladaptive cognitive patterns and the formation of new, adaptive associations. Clinical trials demonstrate significant efficacy, though psychological risks necessitate careful screening, preparation, and a supportive therapeutic environment. The translation of psilocybin-assisted therapy from research to clinical practice presents challenges related to protocol optimization, clinician training, and scalability", "journal": "Journal of Pharma Insights and Research.", "publication_date": "2025-10-04", "publication_year": 2025, "doi": "10.69613/thv1dn30", "pubmed_id": null, "source_url": "https://doi.org/10.69613/thv1dn30", "keywords": "Context (archaeology), Antidepressant, Neurocognitive, Psychology, Default mode network, Cognition, Psilocybin, Anxiolytic, Medicine, Depression (economics), Neuroscience, Neuroplasticity, Psychiatry, Clinical trial, Partial agonist, Psychotherapist, Disengagement theory, Mediator, Pharmacology, Clinical psychology, Hallucinogen, Agonist, Distress, Sedative, Monoaminergic, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:38", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4416779935\",\"openalex_url\":\"https://openalex.org/W4416779935\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5112984043\",\"display_name\":\"M Loganathan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120707612\",\"display_name\":\"A Saravanakumar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101528304\",\"display_name\":\"P. Parthiban\",\"orcid\":null},{\"id\":\"https://openalex.org/A5115659770\",\"display_name\":\"G Anandharaj\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120707613\",\"display_name\":\"S Gobika\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120569896\",\"display_name\":\"D Dharshana\",\"orcid\":null},{\"id\":null,\"display_name\":\"Mohamed Safir Ali\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4404664124\",\"source_display_name\":\"Journal of Pharma Insights and Research.\",\"landing_page_url\":\"https://doi.org/10.69613/thv1dn30\",\"is_oa\":true}}", "topic_tags": "Depression,End-of-Life Distress,Chronic Pain,Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Clinical Trial,Treatment-Resistant Depression,Healthcare Workers,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4416779935" }, { "id": 480, "title": "Harm reduction practises for users of psychedelic drugs: a scoping review.", "normalized_title": "harm reduction practises for users of psychedelic drugs a scoping review", "authors": "Dutton C, North E, Chun Tie Y, Oliva J, Skeffington P", "abstract": "Psychedelic use in naturalistic settings in Australia is increasing. Although the risks and harms of psychedelics from a physical perspective are low, psychedelic drugs carry a unique psychological risk profile which is increased in uncontrolled settings. Harm reduction support services align with the Australian Government's Federal Drug strategy, which includes harm reduction as the third pillar in the overall harm minimisation approach to drug use for the period of 2017-2026. This study examined the harm reduction behaviours which users of psychedelics in naturalistic settings currently use, and any harm reduction interventions which have been developed for this population. A scoping review was undertaken using online databases, Psychinfo, Medline, CINAHL and Scopus. Articles were included if they explored or informed harm reduction practices for users of psychedelic drugs in naturalistic settings, which included articles that investigated motivations for psychedelic use. Twenty-seven papers were included, which contained only four intervention-based studies. Harm reduction or benefit enhancing strategies were categorised into three themes: before psychedelic use, during psychedelic experience and after the experience (integration). The review found that users of psychedelic drugs in naturalistic settings employ several different harm minimisation strategies, predominantly before and during use. Motivation for use, social setting and dosage amount were all found to influence the strategies used. There were a limited number of evaluated interventions for users of psychedelics in naturalistic settings, identifying the need for further research in this area. Challenges for harm reduction campaigns such as low uptake of drug checking services and low trust in government institutions were identified. Further research needs to consider the differing motivations of psychedelic users and recognise strategies that promote benefit enhancement and reduce risk.", "journal": "Harm reduction journal", "publication_date": "2025-10-02", "publication_year": 2025, "doi": "10.1186/s12954-025-01264-2", "pubmed_id": "41044617", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41044617/", "keywords": "Benefit enhancement, Hallucinogens, Harm reduction strategies, Naturalistic use, Psilocybin, Risks", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"41044617\"}", "topic_tags": "Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3677, "title": "Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment", "normalized_title": "retrospective observational study of intensity effects in psychedelic assisted treatment", "authors": "University Hospital, Geneva", "abstract": "This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive disorders. Data will be analyzed from patients treated at the University Hospitals of Geneva between June 2020 and April 2025 who obtained individual authorizations from the Swiss Federal Office of Public Health for use of LSD or psilocybin under compassionate use criteria. The main objective is to assess the effects of psychedelic-assisted psychotherapy with LSD or psilocybin on changes in depressive symptoms, anxiety symptoms. Secondary objectives include evaluating the association between psychedelic session intensity and the administered dose of LSD or psilocybin, changes in depressive symptoms, anxiety symptoms, and problematic substance use, as well as their association with intensity effects. Additionally physiological effects during session will be assessed. All data are retrospectively collected from clinical records with prior patient consent. This study aims to generate evidence on the feasibility, safety, and therapeutic potential of PAP in real-world clinical practice. The overall project is a retrospective observational study evaluating the effects of psychedelic-assisted psychotherapy (PAP) with LSD or psilocybin in treatment-resistant depressive, anxiety, and addictive disorders. Data from 200 patients treated at Geneva University Hospitals will be included, with the primary aim of assessing relationships between psychedelic dose, subjective intensity of experience, and clinical outcomes. Subset Analysis: Cardiovascular Outcomes In addition to the main objectives, a subset analysis will be conducted to evaluate cardiovascular effects of LSD and psilocybin. Routinely collected data from 30 patients with treatment-resistant depression or anxiety disorders will be included. Population: 30 patients who underwent their first psychedelic session (LSD100-200 µg or psilocybin 15-25 mg). Measurements: Heart rate and self-rated anxiety (visual analogue scale) recorded at seven time points between 30 and 300 minutes post-administration on the treatment day. A further subset analysis investigated the role of early maladaptive schemas (EMS) in psychedelic-assisted psychotherapy. Populations: 192 patients who routinely completed the Young Schema Questionnaire - Rasch version (YSQ-R) before treatment were included; of these, 97 initiated PAP with LSD or psilocybin and 74 contributed longitudinal outcomes. Measurements: Baseline EMS profiles (YSQ-R) measured at Baseline (screening or preparation visit, before first psychedelic session), immediately after each psychedelic session (sessions 1-3, up to 9 months) and 1 month after each psychedelic session (sessions 1-3, up to 12 months after baseline).", "journal": "ClinicalTrials.gov", "publication_date": "2025-10-01", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07164287", "keywords": "Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD), PTSD - Post Traumatic Stress Disorder, Lysergic Acid Diethylamide (LSD) or psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07164287\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[]}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3552, "title": "Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)", "normalized_title": "psilocybin and mdma for post traumatic stress disorder ptsd", "authors": "Johns Hopkins University", "abstract": "The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet The proposed randomized, double-blind, active control study will compare a single experimental dose of co-administered MDMA + psilocybin (exact dosages not disclosed) with a single comparator dose of co-administered MDMA + psilocybin (exact dosages not disclosed). For the co-administered dosing session, MDMA will be given initially, followed by psilocybin 30 minutes later. Approximately 1.5 months after the first dosing session, a second single-blind (participant masked) dosing session will occur. The study will recruit adult Veterans with PTSD for ≥ 6 months.", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-30", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06989957", "keywords": "Posttraumatic Stress Disorder, Psilocybin, MDMA, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06989957\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "PTSD,Veterans,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 491, "title": "Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations.", "normalized_title": "clinical psychedelic research in adolescents a scoping review and overview of ethical considerations", "authors": "Rajwani K, Jacobs E, Bruce L, Hokanson J, Almonte MT, Feroz F, Waldman E, Cheung K, Levy N, Savulescu J, Singh I, Yaden DB, Earp BD.", "abstract": "The potential use of psychedelic-assisted therapy for adolescents with mental illness has sparked both interest and concern. Modern psychedelic research has focused on adults, and adolescents younger than 18 years are typically excluded due to ethical and legal challenges. To explore whether adolescents have been included in 21st century psychedelic research, we conducted a scoping review of the medical literature from January, 2000, to April, 2025. Three trial registrations and one trial plan showed involvement of participants younger than 18 years, but none of these trials were completed and no trial findings have been published. The proposed studies would investigate 3,4-methylenedioxymethamphetamine (MDMA)-assisted or psilocybin-assisted psychotherapy as an intervention for adolescents with post-traumatic stress disorder, autism with social anxiety, or self-harm. Ethical approval and recruitment details were inconsistently reported. This scarcity of data highlights a major evidence gap that could hinder informed care. Given that many medications are used off-label in adolescents, we argue for cautious, ethically grounded research-starting with older adolescents with the highest foreseeable benefit-risk ratio due to special circumstances-to better understand the potential risks and benefits of psychedelic therapies for this vulnerable population.", "journal": null, "publication_date": "2025-09-30", "publication_year": 2025, "doi": "10.1016/s2352-4642(25)00208-1", "pubmed_id": "40908054", "source_url": "https://doi.org/10.1016/s2352-4642(25)00208-1", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Mental Disorders, Psychotherapy, Biomedical Research, Adolescent, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40908054\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,PTSD,Review Article,Adolescents,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 505, "title": "Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring", "normalized_title": "psilocybin during the postpartum period induces long lasting adverse effects in both mothers and offspring", "authors": "Cassandra J. Hatzipantelis, Min Liu, A. H. G. Love, Sadie J. Leventhal, Hero Maera, Srinidhi Viswanathan, Emily Avetisyan, Liana Belinsky, McKenna M. Rangel, Nina J. Jain, Max Kelly, C. Copeland, Yara A. Khatib, Oliver Fiehn, David E. Olson, Danielle S. Stolzenberg", "abstract": "Psilocybin increases social connectedness and has strong clinical transdiagnostic efficacy for mental illness, making it a candidate treatment to reduce maternal disconnect, anxiety, and blunted affect seen in peripartum mood disorders. However, the efficacy and safety of psilocybin in peripartum mood disorders has not been investigated. We used a social stress model to examine the effects of psilocybin in parous mice and their offspring. Social stress induced maternal withdrawal and increased stress-related behaviors - none of which were ameliorated by psilocybin. Weeks later, psilocybin-treated dams were more anxious, regardless of stress exposure. In contrast, psilocybin-treated virgin females were unaffected. Though reproductive status did not affect psilocybin pharmacokinetics, serotonin receptor transcription and 5-HT2A receptor-dependent responses were reduced in dams. Offspring exposed to maternal psilocybin during breastfeeding exhibited anhedonia in adulthood. Here, we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period.", "journal": "Nature Communications", "publication_date": "2025-09-29", "publication_year": 2025, "doi": "10.1038/s41467-025-64371-5", "pubmed_id": "41027992", "source_url": "https://doi.org/10.1038/s41467-025-64371-5", "keywords": "Psilocybin, Anhedonia, Mood, Offspring, Medicine, Affect (linguistics), Adverse effect, Postpartum period, Breastfeeding, Psychiatry, Pregnancy, Hallucinogen, Psychology, Lactation, Physiology, Postpartum depression, Internal medicine, Mood disorders, Clinical psychology, Endocrinology, Antidepressant, Psychedelics and Drug Studies, Neuroendocrine regulation and behavior, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414669838\",\"openalex_url\":\"https://openalex.org/W4414669838\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W625443388\",\"https://openalex.org/W1851689772\",\"https://openalex.org/W1955961313\",\"https://openalex.org/W1966187484\",\"https://openalex.org/W1988125482\",\"https://openalex.org/W2011521422\",\"https://openalex.org/W2044219781\",\"https://openalex.org/W2055566656\",\"https://openalex.org/W2077786958\",\"https://openalex.org/W2094125301\",\"https://openalex.org/W2102941960\",\"https://openalex.org/W2168788155\",\"https://openalex.org/W2178837340\",\"https://openalex.org/W2318447563\",\"https://openalex.org/W2515583174\",\"https://openalex.org/W2560473817\",\"https://openalex.org/W2593441557\",\"https://openalex.org/W2759876743\",\"https://openalex.org/W2787927462\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2885511794\",\"https://openalex.org/W2913988157\",\"https://openalex.org/W2921903746\",\"https://openalex.org/W2922295186\",\"https://openalex.org/W2939067679\",\"https://openalex.org/W2966981220\",\"https://openalex.org/W3024792236\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3181822178\",\"https://openalex.org/W3199380438\",\"https://openalex.org/W3204328699\",\"https://openalex.org/W3207262064\",\"https://openalex.org/W3215964700\",\"https://openalex.org/W4200373380\",\"https://openalex.org/W4206063518\",\"https://openalex.org/W4206129911\",\"https://openalex.org/W4220665505\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4292998175\",\"https://openalex.org/W4310014477\",\"https://openalex.org/W4311849771\",\"https://openalex.org/W4315620578\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4315880873\",\"https://openalex.org/W4318830229\",\"https://openalex.org/W4319461950\",\"https://openalex.org/W4323041020\",\"https://openalex.org/W4362471804\",\"https://openalex.org/W4378647709\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4385479997\",\"https://openalex.org/W4388176857\",\"https://openalex.org/W4388407376\",\"https://openalex.org/W4389365746\",\"https://openalex.org/W4391062842\",\"https://openalex.org/W4391288716\",\"https://openalex.org/W4391687248\",\"https://openalex.org/W4392203338\",\"https://openalex.org/W4395688958\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4399960079\"],\"authorships\":[{\"id\":\"https://openalex.org/A5035253557\",\"display_name\":\"Cassandra J. Hatzipantelis\",\"orcid\":\"https://orcid.org/0000-0001-5376-7887\"},{\"id\":\"https://openalex.org/A5100343900\",\"display_name\":\"Min Liu\",\"orcid\":\"https://orcid.org/0000-0002-4698-6667\"},{\"id\":\"https://openalex.org/A5113593863\",\"display_name\":\"A. H. G. Love\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119783441\",\"display_name\":\"Sadie J. Leventhal\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119783442\",\"display_name\":\"Hero Maera\",\"orcid\":null},{\"id\":null,\"display_name\":\"Srinidhi Viswanathan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119783443\",\"display_name\":\"Emily Avetisyan\",\"orcid\":\"https://orcid.org/0009-0002-5713-8281\"},{\"id\":\"https://openalex.org/A5119783444\",\"display_name\":\"Liana Belinsky\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119783445\",\"display_name\":\"McKenna M. Rangel\",\"orcid\":null},{\"id\":null,\"display_name\":\"Nina J. Jain\",\"orcid\":\"https://orcid.org/0009-0005-5347-8539\"},{\"id\":\"https://openalex.org/A5025038781\",\"display_name\":\"Max Kelly\",\"orcid\":\"https://orcid.org/0000-0002-0036-5259\"},{\"id\":\"https://openalex.org/A5108786607\",\"display_name\":\"C. Copeland\",\"orcid\":null},{\"id\":\"https://openalex.org/A5117136332\",\"display_name\":\"Yara A. Khatib\",\"orcid\":\"https://orcid.org/0000-0002-8342-7100\"},{\"id\":\"https://openalex.org/A5087349635\",\"display_name\":\"Oliver Fiehn\",\"orcid\":\"https://orcid.org/0000-0002-6261-8928\"},{\"id\":\"https://openalex.org/A5051474045\",\"display_name\":\"David E. Olson\",\"orcid\":\"https://orcid.org/0000-0002-4517-0543\"},{\"id\":\"https://openalex.org/A5033773664\",\"display_name\":\"Danielle S. Stolzenberg\",\"orcid\":\"https://orcid.org/0000-0002-1498-5299\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S64187185\",\"source_display_name\":\"Nature Communications\",\"landing_page_url\":\"https://doi.org/10.1038/s41467-025-64371-5\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Pharmacology,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414669838" }, { "id": 508, "title": "Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.", "normalized_title": "ethical issues with psychedelic assisted treatments in psychiatry a systematic scoping review", "authors": "Caporuscio C, Poppe C, Gieselmann A, Repantis D.", "abstract": "Based on promising preliminary results from clinical trials, it seems likely that psychedelic substances (classic serotonergic psychedelics, such as psilocybin, and entactogens, such as MDMA) will be introduced into psychiatry as psychedelic-assisted therapy. This also raises a range of ethical questions that urgently need to be addressed before widespread roll-out in society. This scoping review fills a gap in the literature by providing an overview of these ethical issues using a systematic search, presentation, and descriptive analysis of ethical issues in psychedelic-assisted treatments. It includes peer-reviewed studies pertaining to human study participants and psychiatric patients (population), which discuss ethical issues (concept) of psychedelic treatments (context) in clinical trials and other clinical applications. The systematic search included several databases: MEDLINE, PsycInfo, CINAHL, HeinOnline, and PsycArticles. The search strategy, including all identified keywords and index terms, was adapted for each included database. The search was completed in June 2025 and studies published until then in any language were included. After an iterative process of inductive and deductive coding of ethical issues, the scoping review comprises seven themes related to the ethics of psychedelic-assisted treatments: (1) safety and patient well-being, (2) therapeutic relationships, (3) informed consent, (4) equity and access, (5) research ethics, (6) special contexts, and (7) societal and cultural implications. The results can be used to inform and stimulate further discussion and in-depth research on the ethics of psychedelic-assisted treatments, possibly leading to more nuanced debate surrounding a safer and more ethical implementation of psychedelic-assisted treatments in the future.", "journal": null, "publication_date": "2025-09-28", "publication_year": 2025, "doi": "10.1017/s0033291725101761", "pubmed_id": "41017267", "source_url": "https://doi.org/10.1017/s0033291725101761", "keywords": "Humans, Hallucinogens, Mental Disorders, Psychiatry", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"41017267\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Wellbeing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3507, "title": "An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy", "normalized_title": "an exploratory study of feasibility efficacy and mechanisms of mindfulness assisted psychedelic therapy", "authors": "University of Southern California", "abstract": "The goal of this clinical trial is to test psilocybin in combination with mindfulness training in healthy adults. The main question it aims to answer is \"Does mindfulness training enhance the effects of psychedelic therapy (psilocybin) on mental health?\" Interested individuals will complete an initial eligibility session and eligible participants will then be randomized into one of two groups: one dose of psilocybin (administered under the supervision of study therapists) combined with 8 weeks of weekly mindfulness training classes (Arm 1) or psilocybin alone (Arm 2). Both groups will complete baseline and post-treatment assessment sessions where they will complete questionnaires, computerized cognitive tests, and have an EEG (a measure of electrical activity in the brain). Both groups will also complete 2 follow-up surveys (at 8 weeks and 1 year after the post-treatment assessment) either online through REDCap or by phone or video call with a research assistant. Psilocybin is a psychoactive compound found in a variety of mushrooms that has been used for centuries to facilitate spiritual experiences. Recent evidence suggests that the combination of psilocybin with mindfulness training may enhance the therapeutic effects of these interventions for mental health; however, to date, only few studies have investigated a combination approach, and no studies have yet investigated the effects of psilocybin in combination with a formal mindfulness training program in participants with little or no prior meditation experience. We propose here to conduct a pilot study to evaluate the efficacy of psilocybin administration in combination with 8 weeks of mindfulness training. Participants (N = 40) will complete an initial eligibility session and eligible participants will then be randomized into one of two groups: psilocybin integrated with mindfulness training (MT) (Arm 1) and psilocybin alone (Arm 2). Both groups will complete baseline and post-treatment assessment sessions where they will complete questionnaires and cognitive assessments. Both groups will also complete 2 brief follow-up surveys (at 8 weeks and 1 year after the post-treatment assessment) either online through REDCap or by phone or video call with a research assistant. The primary feasibility outcome will be retention rate at the 8-week follow-up time point (percent of eligible enrolled participants who complete the 8-week follow-up). Secondary efficacy outcomes include change in psychological and mood measures, blood inflammatory \\& neurotrophic markers and neurocognitive measures (EEG outcomes) from baseline to post-treatment. Safety outcomes will include the number of participants reporting adverse events and the mean severity of events. Logistic regression models will be used to examine the relationships between intervention group and the primary and secondary outcome variables. The results of this pilot study will be used to support a larger NIH and other external grant application as well as the extension of this intervention to clinical populations.", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-25", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06233344", "keywords": "Mental Health, Psilocybin plus mindfulness training, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06233344\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Brain Imaging,Mechanism of Action,Biomarkers,Spirituality,Clinical Trial,Observational Study,Safety,Adverse Events,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3262, "title": "“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy", "normalized_title": "so many relationships in the room participant perspectives on the affordances and challenges of co therapy in psychedelic assisted therapy", "authors": "", "abstract": "Psychedelic-assisted therapy (PAT) frequently utilises a “cotherapy” model, in which two therapists jointly support participants or patients through preparation, dosing, and integration sessions. While common in clinical trials, the experience of cotherapy from the participant perspective remains underexplored. This qualitative study examined experiences of cotherapy within a trial of psilocybin-assisted therapy for generalised anxiety disorder. Semi-structured interviews with 18 participants (29 interviews in total) were analysed thematically, guided by Affordance Theory to consider how cotherapy dynamics shaped therapeutic possibilities. Three major themes were developed: (1) Dose day cotherapy: safety, trust and the realities of access; (2) Cotherapy influences therapeutic processes; (3) Cotherapy shapes the impact and credibility of therapeutic insights. Together, these findings position cotherapy in PAT as both a safety and supportive measure, and a potentiator of therapeutic processes. In the context of a single site with high levels of clinician qualification and training, participants generally valued cotherapy. Insights from this study can guide clinical practice and future research, so that feasibility and accessibility are enhanced while preserving the safety and therapeutic benefits afforded by cotherapy.", "journal": "PsyArXiv", "publication_date": "2025-09-25", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/4cn5r_v1", "keywords": "clinical practice, cotherapy, Generalised Anxiety Disorder, psilocybin, psychedelic-assisted therapy, therapist dyad, Psychiatry, Social and Behavioral Sciences, Clinical Psychology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"4cn5r_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Anxiety,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3588, "title": "Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism", "normalized_title": "observational pilot study to explore the social and health impacts of a new model of care in oregon psilocybin services on alcoholism", "authors": "Healing Advocacy Fund", "abstract": "The purpose for this study is to observe the real world experience of participants who are receiving psilocybin in the context of (alcoholism) Alcohol Use Disorder without intervening in the model of care. The study team will engage directly with the participants to examine the outcomes in participants who have been deemed eligible and appropriate to receive psilocybin services at Oregon's Innertrek Patient Service Center (PSC) and who are willing to participate in the People Science pilot study to share their experience concurrently. Since the participant will be making the informed decision to voluntarily take part in this concurrent observational study, there will be no \"doctor-patient\" relationship between the participant and the People Science Study Investigator. Study participants will receive the standard of care and medical management from Oregon's Innertrek Patient Service Center facilitators as deemed appropriate per their existing guidelines and practices. People Science will solely be operating as an observer, using an agnostic research data capture system to collect outcomes and follow participant experiences throughout the course of their treatment journey. The study will incorporate participant-reported outcome measures, questionnaires and surveys. The primary endpoint in collecting study data will be to observe the impact of the Psilocybin-Assisted care model on the frequency of heavy drinking days through quantitative and qualitative data analysis for people who struggle with alcohol use. Non-quantitative narratives will also be captured. Throughout the People Science study observations, participants will be in the direct care of the Oregon Patient Service Center facilitators. Findings from this study will contribute knowledge toward the understanding of the use of psilocybin in individuals with self-described alcoholism (AUD). Alcoholism or Alcohol Use Disorder (AUD) is a chronic and relapsing condition characterized by an inability to control alcohol consumption, leading to significant health, social, and economic consequences. Despite the availability of various treatment modalities, including pharmacotherapies and behavioral interventions, relapse rates remain high, with many individuals failing to achieve long-term abstinence or control. This has spurred interest in exploring novel therapeutic approaches and care models, including the potential use of psychedelic compounds such as psilocybin used in a supportive care environment. Psilocybin, a naturally occurring psychoactive substance found in certain species of mushrooms, has garnered attention for its potential therapeutic effects in treating mental health disorders such as depression, anxiety, and post-traumatic stress disorder. More recently, research has suggested that psilocybin may be beneficial in addressing substance use disorders, including Alcohol Use Disorder. The mechanism by which psilocybin exerts its effects appears to involve the modulation of neural circuits related to mood regulation, behavior, and self-reflection, which can facilitate profound psychological experiences that may promote lasting changes in behavior and cognition. Early clinical trials have shown promising results, indicating that psilocybin, when administered in a therapeutic setting, can reduce alcohol consumption and cravings in individuals with Alcohol Use Disorder. In a study published in Journal of American Medical Association of Psychiatry, researchers from New York University Grossman School of Medicine found that heavy alcohol consumption among people with alcohol use disorders was 83 percent lower among participants who had received psilocybin over an 8-month period following the psilocybin administration and almost half of participants who received psilocybin stopped drinking alcohol altogether. These studies highlight the potential for psilocybin to act as a catalyst for psychological insights and behavioral change when combined with psychotherapy or a calming and supportive environment, offering a new avenue for treatment-resistant cases of Alcohol Use Disorder. In Oregon, excessive alcohol consumption causes 2,000 deaths each year, making it the third leading cause of preventable death in the state. There is a glaring need for support for Oregonians facing alcohol and substance use disorders. Alongside more traditional treatment and harm reduction models, Psilocybin shows promise for treating alcohol and substance disorders. Oregon's state-regulated psilocybin program offers an opportunity to advance real world research on Psilocybin for treating alcohol and substance use disorders. In 2020, Oregon voters approved a ballot measure (Measure 109) to create the world's first state-regulated psilocybin program to improve the physical, mental, and social well-being of all people. The measure required that the Oregon Health Authority (OHA) create a licensing and regulatory framework for a safe, accessible and equitable program. After a two-year rule making period, licensed service centers are now open and providing psilocybin services to clients in Oregon. Psilocybin services are only delivered in licensed service centers, under the supervision of a trained facilitator, and psilocybin can only be consumed in the service center during that supervised session. There are no retail sales, no off-site consumption, possession, or production of psilocybin (outside of licensed manufacturers). The sponsor of this pilot research project is the Healing Advocacy Fund (HAF). HAF is a 501c3 non-profit organization that advocates for safe, affordable state-regulated access to psychedelic services. The Healing Advocacy Fund promotes regulations that create a state psilocybin program that is of high quality, accessible, and maximizes safety; educates stakeholders, policymakers, regulators, and the general public on the Oregon psilocybin program; and serves as a convener for the Oregon psilocybin ecosystem to collaboratively address goals and challenges, organize around shared needs, and deliver services to high standards and best practices. InnerTrek will provide the psilocybin services to individuals who struggle with alcohol use for the pilot. InnerTrek is a psilocybin patient service center located in Portland, Oregon and licensed by the Oregon Health Authority to offer both individual and group psilocybin services, including preparation, administration, and integration sessions. The position of the People Science research team in this setting is to observe the practices and experiences already occurring in the context of the State of Oregon's Psilocybin Services program at the InnerTrek Patient Service Center. People Science will create the questionnaires to be offered to the participants, as well as analyze data on the observation of participants' perspectives.", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-23", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07189988", "keywords": "Alcohol Use Disorder, psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT07189988\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[]}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Wellbeing,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 453, "title": "Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.", "normalized_title": "considerations and cautions for the integration of psilocybin into routine clinical care a consensus statement from the us national network of depression centers task group on psychedelics and related compounds", "authors": "Hosein MM, Reid MJ, Walser S, Charney S, Fonzo GA, Lewis BR, Yaden DB, Suppes T, Cordner ZA, Barrett FS.", "abstract": "The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments has garnered significant attention. Consequently, there has been a great deal of interest and investment in accelerating its development and potential implementation in routine clinical practice. However, the expanding scope of scientific discovery, heightened media coverage, and commercial interests in the field risk outpacing the rate of developments in the necessary guidelines and infrastructure required for integration of psilocybin into clinical practice. The US National Network of Depression Centers (NNDC) Task Group on Psychedelics and Related Compounds-comprising psychiatrists, psychologists, neuroscientists, psychedelic researchers, and leaders in healthcare consulting affiliated with the NNDC-developed this consensus statement as a summary of clinical expertise and opinion on the matter, to recognise psilocybin's therapeutic potential while also emphasising the need for further research and careful consideration before the integration of psilocybin into routine clinical care. We outline the current state of the science on psilocybin, incorporating articles published through April 2025. We identify key areas for further research and frame them within the context of therapeutic and ethical implications surrounding psilocybin's use in future clinical practice. We highlight the need for further research to address gaps in understanding of therapeutic dosage, efficacy across diverse populations, and long-term safety. Finally, we propose an agenda which calls for diversification of funding, collaborative research efforts, standardised training for healthcare providers, and careful consideration of ethical dilemmas inherent in the theorised clinical use of psilocybin. Crucially, we advocate for a balanced approach that prioritises rigorous scientific standards while considering the urgency of the need for better treatment options, ensuring equitable access and safety as the field progresses. We acknowledge that the single-country focus of the NNDC may limit the generalisability of recommendations to international contexts with differing healthcare systems and regulatory landscapes.", "journal": null, "publication_date": "2025-09-22", "publication_year": 2025, "doi": "10.1016/j.eclinm.2025.103517", "pubmed_id": "41048658", "source_url": "https://doi.org/10.1016/j.eclinm.2025.103517", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"41048658\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 509, "title": "Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study", "normalized_title": "psilocybin assisted psychotherapy for methamphetamine use disorder a pilot open label safety and feasibility study", "authors": "Elizabeth Knock, Krista J. Siefried, Gillinder Bedi, Steven M. Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett", "abstract": "BACKGROUND & AIMS: There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin-assisted psychotherapy for methamphetamine use disorder. DESIGN: Single arm, open label pilot study. SETTING: Outpatient public stimulant treatment program at St. Vincent's Hospital, Sydney, Australia. PARTICIPANTS: We recruited 15 participants that were ≥25 years old, seeking treatment for methamphetamine use, using methamphetamine ≥4 days/month at screening, and without serious mental illness or contraindicated medical conditions or medications. INTERVENTION: Participants received three preparatory psychotherapy sessions over two weeks before a single psilocybin dosing session (25 mg oral), followed by two integration psychotherapy sessions over one week. Psychotherapy included elements of motivational enhancement and acceptance and commitment therapy. Participants were followed for 90 days post psilocybin-assisted psychotherapy session. MEASUREMENTS: Primary endpoints were safety (as measured by adverse events over the trial and vital signs during psilocybin dosing) and feasibility (as measured by enrolment and dropout rates), and secondary endpoints included measuring self-reported methamphetamine and other illicit drug use, drug craving, depression, anxiety, stress and quality of life measures. FINDINGS: Of 56 participants pre-screened, 15 were eligible and enrolled, 14 completed the intervention and 13 completed 90-day post-dose follow-up.\". No serious adverse events (AEs) occurred, and the seven treatment related AEs were self-limiting and mild to moderate in severity. AEs included hypertension during the dosing session and headache (n = 4), nausea (n = 1) and noise sensitivity (n = 1) within the week following the dose. Methamphetamine use (over the prior 28 days) was observed to be lower at screening (median 12 days, IQR7-16, n = 15) relative to day 28 (median 0 days, IQR0-2, n = 13) and 90 (median 2 days, IQR1-4, n = 14) post psilocybin. Methamphetamine craving was also observed to be lower while quality of life, depression, anxiety, and stress were observed to be higher at days 28 and 90 follow-up relative to baseline. CONCLUSIONS: Psilocybin assisted psychotherapy for methamphetamine use disorder was feasible to implement in an outpatient setting and did not appear to generate safety concerns. A larger randomised controlled trial is required to confirm efficacy and safety.", "journal": "Addiction", "publication_date": "2025-09-19", "publication_year": 2025, "doi": "10.1111/add.70187", "pubmed_id": "40974259", "source_url": "https://doi.org/10.1111/add.70187", "keywords": "Psychotherapist, Psilocybin, Psychiatry, Methamphetamine, Medicine, Psychology, Randomized controlled trial, MEDLINE, Clinical trial, Addiction, Relapse prevention, Hallucinogen, Brief psychotherapy, Depression (economics), Substance use, Pilot trial, Clinical psychology, Ambulatory care, Poison control, Addiction treatment, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414374510\",\"openalex_url\":\"https://openalex.org/W4414374510\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1924347018\",\"https://openalex.org/W1974432571\",\"https://openalex.org/W1992167600\",\"https://openalex.org/W2015666695\",\"https://openalex.org/W2020646491\",\"https://openalex.org/W2037668503\",\"https://openalex.org/W2047503435\",\"https://openalex.org/W2072839634\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2083164476\",\"https://openalex.org/W2089165963\",\"https://openalex.org/W2093274439\",\"https://openalex.org/W2095674834\",\"https://openalex.org/W2106369261\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2130544434\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2170182466\",\"https://openalex.org/W2171048870\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2754028604\",\"https://openalex.org/W2770006511\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2945519735\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2962839503\",\"https://openalex.org/W2981405421\",\"https://openalex.org/W2996321268\",\"https://openalex.org/W3010839704\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112557491\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3159976828\",\"https://openalex.org/W3185477803\",\"https://openalex.org/W4210434317\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4281687410\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4294667223\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4324145541\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W4372336620\",\"https://openalex.org/W4388731626\",\"https://openalex.org/W4390704561\",\"https://openalex.org/W4391109410\",\"https://openalex.org/W4391840511\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4405122998\",\"https://openalex.org/W4411392672\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042111294\",\"display_name\":\"Elizabeth Knock\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040818661\",\"display_name\":\"Krista J. Siefried\",\"orcid\":\"https://orcid.org/0000-0002-6534-3325\"},{\"id\":\"https://openalex.org/A5036812133\",\"display_name\":\"Gillinder Bedi\",\"orcid\":\"https://orcid.org/0000-0002-6718-0099\"},{\"id\":\"https://openalex.org/A5049197924\",\"display_name\":\"Steven M. Albert\",\"orcid\":\"https://orcid.org/0000-0001-6786-9956\"},{\"id\":\"https://openalex.org/A5067007569\",\"display_name\":\"Richard O. Day\",\"orcid\":\"https://orcid.org/0000-0002-6045-6937\"},{\"id\":\"https://openalex.org/A5028911674\",\"display_name\":\"Nadine Ezard\",\"orcid\":\"https://orcid.org/0000-0002-7495-8305\"},{\"id\":\"https://openalex.org/A5101561809\",\"display_name\":\"Margaret Ross\",\"orcid\":\"https://orcid.org/0000-0002-3368-6614\"},{\"id\":\"https://openalex.org/A5030212190\",\"display_name\":\"Paul Liknaitzky\",\"orcid\":\"https://orcid.org/0000-0001-5690-2263\"},{\"id\":\"https://openalex.org/A5090300123\",\"display_name\":\"Jonathan Brett\",\"orcid\":\"https://orcid.org/0000-0003-3065-7495\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S70513841\",\"source_display_name\":\"Addiction\",\"landing_page_url\":\"https://doi.org/10.1111/add.70187\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414374510" }, { "id": 513, "title": "Reappraisal of the hype and hope offered by psilocybin treatment of depression.", "normalized_title": "reappraisal of the hype and hope offered by psilocybin treatment of depression", "authors": "Beaglehole B, Manuel J.", "abstract": "AimTo provide a balanced account of psilocybin treatment of depression for expectations to be appropriately set.MethodReview and discussion of key psilocybin efficacy studies. Reporting of side effects and risk of harm with psychedelic treatments. Comparisons and contrasts with ketamine studies of treatment-resistant depression (TRD).ResultEarly psilocybin studies offer promise but expectation bias and functional unblinding are factors in the treatment response. Psilocybin is generally well tolerated but side effects are often not systematically reported, and some recipients may experience harm. The ketamine research has similar methodological considerations, but the weight of positive evidence is stronger for a treatment-resistant group.ConclusionThe evidence for psilocybin treatment of depression is insufficient to press for wider availability and use.", "journal": null, "publication_date": "2025-09-18", "publication_year": 2025, "doi": "10.26635/6965.7138", "pubmed_id": "40966702", "source_url": "https://doi.org/10.26635/6965.7138", "keywords": "Humans, Ketamine, Hallucinogens, Treatment Outcome, Depression, Depressive Disorder, Treatment-Resistant, Hope, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40966702\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 512, "title": "Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial", "normalized_title": "psilocybin assisted group psychotherapy and mindfulness based stress reduction for frontline healthcare provider covid 19 related depression and burnout a randomized controlled trial", "authors": "Benjamin R. Lewis, John Hendrick, Kevin Byrne, Madeleine Odette, Chaorong Wu, Eric L. Garland", "abstract": "BACKGROUND: Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR versus MBSR alone for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. We hypothesized that psilocybin would augment the antidepressant effects of MBSR in this population. METHODS AND FINDINGS: We conducted a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and burnout. (ClinicalTrials.gov Identifier: NCT05557643) Participants were enrolled between January 2nd, 2023 and January 16th, 2024, and randomized in a 1:1 ratio to either an 8-week MBSR curriculum alone or an 8-week MBSR curriculum plus group psilocybin-assisted psychotherapy (PAP) with 25 mg psilocybin. Evaluation of safety and feasibility of enrollment and retention was a primary objective of the study. The primary efficacy endpoint was change in depressive symptoms, as measured by the Quick Inventory of Depressive Symptoms (QIDS-SR-16) at 2 weeks post-intervention. Symptoms of depression and burnout were assessed at baseline, and 2 weeks and 6 months post-intervention utilizing the Quick Inventory of Depressive Symptoms (QIDS-SR-16) and Maslach Burnout Inventory Human Services Survey for Medical Professionals (MBI-HSS-MP), respectively. Secondary outcome measures included the Demoralization Scale (DS-II) and the Watt's Connectedness Scale (WCS). Adverse events (AEs) and suicidality were assessed through a 6-month follow-up. Twenty-five participants were enrolled and randomized. Safety was a study outcome and assessed by rate and severity of AEs and any incident suicidality or significant mental health symptoms. Baseline and outcome data were summarized using descriptive statistics, with continuous variables reported as means and standard deviations. We recorded 12 study-related, Grade 1-2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; p = 0.008). This effect waned at the 6-month follow-up. Secondary outcome measures for burnout (subscales of the MBI-HSS-MP), demoralization (DS II), and connectedness (WCS) favored the MBSR + PAP arm; however, these effects did not survive correction for multiple comparisons. A mixed RM-ANCOVA was conducted to control for baseline differences in outcome measures. Sensitivity analyses were conducted, adjusting for baseline differences in gender and clustering within group cohorts. Study limitations that affect the generalizability of results include a small sample size, homogenous study population, and significant differences in intervention intensity. CONCLUSIONS: This trial met its primary endpoint: group psilocybin-assisted therapy plus MBSR was associated with clinically significant improvement in depressive symptoms without serious AEs and with greater reduction in symptoms than MBSR alone. Our findings suggest that integrating psilocybin with mindfulness training may represent a promising treatment for depression and burnout among physicians and nurses. Larger trials are needed to establish efficacy, generalizability, and durability of these effects.", "journal": "PLoS Medicine", "publication_date": "2025-09-18", "publication_year": 2025, "doi": "10.1371/journal.pmed.1004519", "pubmed_id": "40972137", "source_url": "https://doi.org/10.1371/journal.pmed.1004519", "keywords": "Mindfulness-based stress reduction, Randomized controlled trial, Medicine, Mindfulness, Depression (economics), Stress reduction, Health care, Physical therapy, Depressive symptoms, Psychiatry, Clinical trial, Quality of life (healthcare), Burnout, Group psychotherapy, MEDLINE, Alternative medicine, Clinical psychology, Primary care, Mental health, Major depressive disorder, Pharmacotherapy, Stress management, Psychotherapist, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414366251\",\"openalex_url\":\"https://openalex.org/W4414366251\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":5,\"referenced_works\":[\"https://openalex.org/W1970133878\",\"https://openalex.org/W1978969044\",\"https://openalex.org/W1983742160\",\"https://openalex.org/W2017152382\",\"https://openalex.org/W2124126925\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2350952069\",\"https://openalex.org/W2488757378\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2886043371\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W2990800371\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3014277121\",\"https://openalex.org/W3021065879\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3088381375\",\"https://openalex.org/W3095596619\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3136469907\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3163282265\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3198977306\",\"https://openalex.org/W3207929442\",\"https://openalex.org/W4281899337\",\"https://openalex.org/W4285392796\",\"https://openalex.org/W4286790062\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4317355030\",\"https://openalex.org/W4380082779\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4380740293\",\"https://openalex.org/W4384563223\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4388418934\",\"https://openalex.org/W4389392873\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4391109410\",\"https://openalex.org/W4393183693\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4396813127\",\"https://openalex.org/W4405176234\",\"https://openalex.org/W4407394179\"],\"authorships\":[{\"id\":\"https://openalex.org/A5062983107\",\"display_name\":\"Benjamin R. Lewis\",\"orcid\":\"https://orcid.org/0000-0003-0118-1053\"},{\"id\":\"https://openalex.org/A5084238679\",\"display_name\":\"John Hendrick\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047333818\",\"display_name\":\"Kevin Byrne\",\"orcid\":\"https://orcid.org/0000-0003-0409-5273\"},{\"id\":\"https://openalex.org/A5047851156\",\"display_name\":\"Madeleine Odette\",\"orcid\":\"https://orcid.org/0000-0003-2214-8324\"},{\"id\":\"https://openalex.org/A5042522991\",\"display_name\":\"Chaorong Wu\",\"orcid\":\"https://orcid.org/0000-0002-1569-0978\"},{\"id\":\"https://openalex.org/A5033325414\",\"display_name\":\"Eric L. Garland\",\"orcid\":\"https://orcid.org/0000-0003-2891-857X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S197939330\",\"source_display_name\":\"PLoS Medicine\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pmed.1004519\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Observational Study,Healthcare Workers,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414366251" }, { "id": 511, "title": "Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US", "normalized_title": "evolution and comparative analysis of clinical trials on psilocybin in the treatment of psychopathologies trends in the eu and the us", "authors": "Anastasia Calin, Ana Flavia Burlec, Cornelia Mircea, Irina Macovei, Monica Hăncianu, Andreia Corciovă", "abstract": "Background/Objectives: This study examines the development of clinical trials investigating psilocybin for the treatment of psychopathologies, with a comparative focus on the United States (US) and the European Union (EU). The objective is to identify regional differences in trial progression, research infrastructure, and regulatory frameworks. Methods: A mixed-methods approach was applied, combining case studies, qualitative and quantitative research. Key variables included trial phase, geographical distribution, demographic factors, funding, governmental support, and public health policies. Results: The US demonstrated a substantially higher number of psilocybin trials across both early and advanced phases. This reflects a strong research infrastructure, growing financial investment, and increasing interest in psychedelic-assisted therapies. In contrast, the EU showed fewer trials and slower advancement, reflecting a more cautious stance that emphasizes patient safety and therapeutic efficacy. These divergences are shaped by differences in regulation, funding mechanisms, and sociocultural attitudes toward psychedelics in psychiatry. Conclusion: This comparative analysis highlights the uneven pace of psilocybin research across different regions. It also emphasizes the importance of international collaboration, harmonization of public health policies, and the development of standardized procedures prioritizing safety and effectiveness. Integrating psilocybin-assisted interventions into psychiatric practice has the potential to expand treatment options and strengthen mental health care, but coordinated global efforts are essential to ensure both scientific rigor and patient protection.", "journal": "Journal of Clinical Medicine", "publication_date": "2025-09-18", "publication_year": 2025, "doi": "10.3390/jcm14186613", "pubmed_id": "41010814", "source_url": "https://doi.org/10.3390/jcm14186613", "keywords": "Psilocybin, Medicine, Clinical trial, Harmonization, European union, Public health, Pace, Mental health, Psychological intervention, Psychiatry, Sociocultural evolution, Standardization, Alternative medicine, MEDLINE, Drug development, Health care, Clinical study design, Public relations, Psychedelics and Drug Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414341779\",\"openalex_url\":\"https://openalex.org/W4414341779\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2033580394\",\"https://openalex.org/W2042181481\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2100182643\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2110747672\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2161339188\",\"https://openalex.org/W2291443053\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2337964085\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2491859250\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2831064708\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W2940033607\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W4200405004\",\"https://openalex.org/W4211189621\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4282931386\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4382010877\",\"https://openalex.org/W4386314831\",\"https://openalex.org/W4391879161\",\"https://openalex.org/W4394684735\",\"https://openalex.org/W4400311237\",\"https://openalex.org/W4401512431\",\"https://openalex.org/W4406246123\",\"https://openalex.org/W4406850204\",\"https://openalex.org/W4407595168\",\"https://openalex.org/W4408151066\",\"https://openalex.org/W4414123257\"],\"authorships\":[{\"id\":null,\"display_name\":\"Anastasia Calin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035008326\",\"display_name\":\"Ana Flavia Burlec\",\"orcid\":\"https://orcid.org/0000-0002-6675-2796\"},{\"id\":\"https://openalex.org/A5034639074\",\"display_name\":\"Cornelia Mircea\",\"orcid\":\"https://orcid.org/0000-0002-1981-8246\"},{\"id\":\"https://openalex.org/A5052835824\",\"display_name\":\"Irina Macovei\",\"orcid\":\"https://orcid.org/0000-0002-2827-3217\"},{\"id\":\"https://openalex.org/A5055827335\",\"display_name\":\"Monica Hăncianu\",\"orcid\":\"https://orcid.org/0000-0002-2571-681X\"},{\"id\":\"https://openalex.org/A5017793460\",\"display_name\":\"Andreia Corciovă\",\"orcid\":\"https://orcid.org/0000-0003-4061-2143\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737969411\",\"source_display_name\":\"Journal of Clinical Medicine\",\"landing_page_url\":\"https://doi.org/10.3390/jcm14186613\",\"is_oa\":true}}", "topic_tags": "Mechanism of Action,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414341779" }, { "id": 3435, "title": "The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.", "normalized_title": "the impact of psilocybin on pain in fibromyalgia patients a multicentre trial", "authors": "Maastricht University", "abstract": "Rationale: Recent evidence shows that Lysergic Acid Diethylamide (LSD), even when administered in low, non-hallucinogenic doses, can produce analgesic effects and improve pain tolerance in a sample of healthy volunteers. Such results complement what was already observed with other serotonergic psychedelics such as psilocybin: survey studies and case series indicate that its use may lead to improvements in chronic pain conditions such as migraines, cluster headaches and phantom limb pain even at low, non-psychedelic doses. These effects have however not yet been investigated and confirmed in clinical populations under controlled experimental conditions. Fibromyalgia (FM) is a chronic condition characterised by widespread pain, hyperalgesia, anxiety, disturbed sleep patterns, impaired cognitive functioning and comorbid mood disorders. Most suggested therapies are only associated with small improvements in pain ratings and quality of life. Currently, there is no data concerning the effectiveness of serotonergic psychedelics in improving pain ratings in fibromyalgia patients. Objective: The present study will explore the effects that the administration of a placebo and 2 low psilocybin doses (5 mg or 10 mg) will have on pain perception in a group of fibromyalgia patients. Study design: The present study uses a double-blind, randomized, placebo-controlled design. All participants will receive a placebo and 2 doses of psilocybin (5 mg or 10 mg) and will undergo the Cold Pressor Test (CPT) and the Pain Pressure Threshold Task (PPT) o test its analgesic effects. Rationale: Recent evidence shows that Lysergic Acid Diethylamide (LSD), even when administered in low, non-hallucinogenic doses, can produce analgesic effects and improve pain tolerance in a sample of healthy volunteers. Such results complement what was already observed with other serotonergic psychedelics such as psilocybin: survey studies and case series indicate that its use may lead to improvements in chronic pain conditions such as migraines, cluster headaches and phantom limb pain even at low, non-psychedelic doses. These effects have however not yet been investigated and confirmed in clinical populations under controlled experimental conditions. Fibromyalgia (FM) is a chronic condition characterised by widespread pain, hyperalgesia, anxiety, disturbed sleep patterns, impaired cognitive functioning and comorbid mood disorders. It has high direct and indirect costs and it is considered challenging to treat. Most suggested therapies, in fact, are only associated with small improvements in pain ratings and quality of life. Currently, there is no data concerning the effectiveness of serotonergic psychedelics in improving pain ratings in fibromyalgia patients. Objective: The present study will explore the effects that the administration of a placebo and 2 low psilocybin doses (5 mg or 10 mg) will have on pain perception in a group of fibromyalgia patients. Study design: The present study uses a double-blind, randomized, placebo-controlled design. All participants will receive a placebo and 2 doses of psilocybin (5 mg or 10 mg) and will undergo the Cold Pressor Test (CPT) and the Pain Pressure Threshold Task (PPT) o test its analgesic effects. Study population: 35 fibromyalgia patients aged 18 to 65 years. Intervention: Placebo, 5 mg or 10 mg of psilocybin in randomized order. Main study parameters/endpoints: Primary outcomes will be subjective and objective measures of pain perception. Secondary measures will assess the effects that placebo and psilocybin will have on mood, cognition and psychedelic experience. Finally, participants will take part to an additional CPT after receiving hypnotic suggestions of analgesia to test whether such intervention may moderate pain ratings of individuals who took small doses of psilocybin. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will visit the research lab 5 times during 5 weeks. Before the first study day, subjects will come for a screening visit during which they will also be familiarized with tests and study procedures. This includes a medical screening by a licensed physician (medical history review, laboratory screening, electrocardiogram recording). The study visits will consist of taking the study treatment (5 mg or 10 mg of psilocybin or placebo), taking part to the experimental tasks, taking blood samples, completing computer tasks and filling out questionnaires. Finally, participants will take part to a final online visit to administer post-study questionnaires.", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-14", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06368492", "keywords": "Fibromyalgia, Psilocybin, Hypnosis script, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06368492\",\"overall_status\":\"RECRUITING\",\"phase\":[\"NA\"]}", "topic_tags": "Anxiety,Chronic Pain,Headache / Migraine,Review Article,Case Report,Observational Study,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 504, "title": "Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds", "normalized_title": "multianalytical investigation of psilocybe cubensis mushrooms physicochemical characterization and biological evaluation of psilocybin and psilocin compounds", "authors": "Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo da Silva Pedro, Lucas Cordeiro de Oliveira, Mateus Araújo da Luz, Antônio Gilson Barbosa de Lima, Suédina Maria de Lima Silva, Marcus Vinícius Lia Fook", "abstract": "High Resolution Image Download MS PowerPoint Slide Mental disorders of the global population have been evaluated statistically by decades. Psilocybin has medicinal properties with potential pharmaceutical applications for treatment of psychological disorders. This component is present naturally in mushrooms of the Psilocybe genus and is primarily responsible for their psychoactive properties. It exhibits a low risk of acute toxicity and has shown no evidence of neurotoxicity, carcinogenicity, or mutagenicity in current toxicological assessments. This study aimed to develop an active pharmaceutical ingredient (API) derived from Psilocybe mushrooms for application in the management of mental health disorders. The primary objectives include extraction of bioactive compounds, quantitative analysis, and evaluation of their physicochemical and biological properties. Following the extraction procedures, the experiments achieved yields of approximately 20%, demonstrating effective isolation of the target compounds. The presence of alkaloids was confirmed through phytochemical screening and validated by high-performance liquid chromatography (HPLC) analysis. The obtained API exhibited thermal and spectroscopic characteristics consistent with those of edible mushroom extracts, enabling a comprehensive understanding of its physicochemical behavior. Additionally, analytical assays demonstrated high solubility, low toxicity, and compliance with acceptable limits for heavy metal content and microbial load, including aerobic microorganisms, fungi, and yeasts. Quantitative HPLC analysis revealed psilocybin and psilocin contents of 3.26 and 0.34%, respectively, supporting the formulation of drug delivery systems with standardized concentrations of psilocybin. The results indicated that the extracted API is stable, highly pure, and compatible with polymeric matrices for controlled release applications. Furthermore, the assays confirmed high solubility in polar solvents and minimal risk of adverse effects. In conclusion, the study showed that the development of a psilocybin- and psilocin-based API is feasible and represents a significant advancement in the treatment of mental disorders, standing out as a promising solution in the pursuit of innovative therapeutic alternatives.", "journal": "ACS Omega", "publication_date": "2025-09-14", "publication_year": 2025, "doi": "10.1021/acsomega.5c05606", "pubmed_id": "41048717", "source_url": "https://doi.org/10.1021/acsomega.5c05606", "keywords": "Psilocybin, Chemistry, Active ingredient, Phytochemical, Mushroom, Chromatography, Ingredient, Extraction (chemistry), High-performance liquid chromatography, Traditional medicine, Solid phase extraction, Quantitative analysis (chemistry), Population, Drug, Hallucinogen, Psychoactive substance, Toxicology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414250218\",\"openalex_url\":\"https://openalex.org/W4414250218\",\"openalex_relevance_score\":18,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1960614917\",\"https://openalex.org/W1980106895\",\"https://openalex.org/W1995741425\",\"https://openalex.org/W1996913637\",\"https://openalex.org/W1997320856\",\"https://openalex.org/W2004307973\",\"https://openalex.org/W2009390034\",\"https://openalex.org/W2010781778\",\"https://openalex.org/W2018097408\",\"https://openalex.org/W2049780841\",\"https://openalex.org/W2050577168\",\"https://openalex.org/W2067074477\",\"https://openalex.org/W2094309241\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114646867\",\"https://openalex.org/W2147686129\",\"https://openalex.org/W2325854181\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2480674088\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2807894922\",\"https://openalex.org/W2811381825\",\"https://openalex.org/W2911680005\",\"https://openalex.org/W2930929083\",\"https://openalex.org/W2934110515\",\"https://openalex.org/W3012256305\",\"https://openalex.org/W3020787224\",\"https://openalex.org/W3044469818\",\"https://openalex.org/W3115524456\",\"https://openalex.org/W3137772046\",\"https://openalex.org/W3144925063\",\"https://openalex.org/W3160765419\",\"https://openalex.org/W4224903330\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4319439526\",\"https://openalex.org/W4389433837\",\"https://openalex.org/W4397002865\",\"https://openalex.org/W4404080173\",\"https://openalex.org/W4404302417\",\"https://openalex.org/W4407091607\",\"https://openalex.org/W4408226956\",\"https://openalex.org/W4410735628\",\"https://openalex.org/W4412138274\"],\"authorships\":[{\"id\":\"https://openalex.org/A5080197981\",\"display_name\":\"Taynah Pereira Galdino\",\"orcid\":\"https://orcid.org/0000-0003-4177-6430\"},{\"id\":\"https://openalex.org/A5119637292\",\"display_name\":\"Antônio Braz de Medeiros Bisneto\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002842556\",\"display_name\":\"Marcelo da Silva Pedro\",\"orcid\":\"https://orcid.org/0000-0002-9427-7478\"},{\"id\":\"https://openalex.org/A5087489433\",\"display_name\":\"Lucas Cordeiro de Oliveira\",\"orcid\":\"https://orcid.org/0000-0002-0853-3472\"},{\"id\":\"https://openalex.org/A5015725104\",\"display_name\":\"Mateus Araújo da Luz\",\"orcid\":\"https://orcid.org/0000-0003-1713-4825\"},{\"id\":\"https://openalex.org/A5017271286\",\"display_name\":\"Antônio Gilson Barbosa de Lima\",\"orcid\":\"https://orcid.org/0000-0003-1691-1872\"},{\"id\":\"https://openalex.org/A5051005007\",\"display_name\":\"Suédina Maria de Lima Silva\",\"orcid\":\"https://orcid.org/0000-0002-2073-0989\"},{\"id\":\"https://openalex.org/A5045392401\",\"display_name\":\"Marcus Vinícius Lia Fook\",\"orcid\":\"https://orcid.org/0000-0002-8566-920X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210239500\",\"source_display_name\":\"ACS Omega\",\"landing_page_url\":\"https://doi.org/10.1021/acsomega.5c05606\",\"is_oa\":true}}", "topic_tags": "Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414250218" }, { "id": 487, "title": "Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China", "normalized_title": "dynamic myocardial injury and variable hallucination latency in psilocybe keralensis poisoning a molecularly confirmed case series from china", "authors": "Zhifan He, Rui Tang, Min Feng, Xiaohui Li, Changhong Zhang, Jing Li", "abstract": "Introduction Psychoactive Psilocybe spp. mushrooms pose significant public health risks. We report a cluster of Psilocybe keralensis poisonings in Chengdu, China, highlighting its unique clinical features and cardiovascular complications.Case Series Four patients ingested 16-90 g of wild mushrooms (misidentified as an edible species, but later molecularly confirmed as Psilocybe keralensis). Prodromal symptoms (e.g., dizziness) emerged within 5-20 min, but the onset of hallucinations varied widely (10-180 min). All patients developed hypertension (systolic blood pressure >150 mmHg), with one patient exhibiting rapid blood pressure elevation to 182/110 mmHg at 4 h post-ingestion, which was accompanied by evidence of myocardial injury (peak cardiac troponin T concentration 188.70 pg/mL [reference range", "journal": "Clinical Toxicology", "publication_date": "2025-09-14", "publication_year": 2025, "doi": "10.1080/15563650.2025.2552438", "pubmed_id": "40948398", "source_url": "https://doi.org/10.1080/15563650.2025.2552438", "keywords": "Medicine, Identification (biology), Comorbidity, Psilocybin, Latency (audio), Public health, Variable (mathematics), Psychiatry, Medical emergency, Audiology, China, Psychology, Psychosis, Warning signs, Electroencephalography, MEDLINE, Physical medicine and rehabilitation, Poison control, Intensive care medicine, Computer science, Anhedonia, Clinical trial, Neuroscience, Case series, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Hallucinations in medical conditions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414167818\",\"openalex_url\":\"https://openalex.org/W4414167818\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2010427019\",\"https://openalex.org/W2169910517\",\"https://openalex.org/W2551258974\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4321596086\",\"https://openalex.org/W4390725475\",\"https://openalex.org/W4391511952\"],\"authorships\":[{\"id\":\"https://openalex.org/A5046541811\",\"display_name\":\"Zhifan He\",\"orcid\":\"https://orcid.org/0009-0009-4163-1339\"},{\"id\":\"https://openalex.org/A5045106460\",\"display_name\":\"Rui Tang\",\"orcid\":\"https://orcid.org/0000-0002-6445-7283\"},{\"id\":\"https://openalex.org/A5113601629\",\"display_name\":\"Min Feng\",\"orcid\":null},{\"id\":\"https://openalex.org/A5100338521\",\"display_name\":\"Xiaohui Li\",\"orcid\":\"https://orcid.org/0000-0001-7667-9644\"},{\"id\":\"https://openalex.org/A5101752887\",\"display_name\":\"Changhong Zhang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5100337049\",\"display_name\":\"Jing Li\",\"orcid\":\"https://orcid.org/0000-0003-0961-0932\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S101107869\",\"source_display_name\":\"Clinical Toxicology\",\"landing_page_url\":\"https://doi.org/10.1080/15563650.2025.2552438\",\"is_oa\":false}}", "topic_tags": "Clinical Trial,Case Report,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414167818" }, { "id": 456, "title": "Emerging mechanisms of psilocybin-induced neuroplasticity.", "normalized_title": "emerging mechanisms of psilocybin induced neuroplasticity", "authors": "Sonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A.", "abstract": "Psilocybin, a serotonergic psychedelic, is gaining attention for its rapid and sustained therapeutic effects in depression and other hard-to-treat neuropsychiatric conditions, potentially through its capacity to enhance neuronal plasticity. While its neuroplastic and therapeutic effects are commonly attributed to serotonin 2A (5-HT2A) receptor activation, emerging evidence reveals a more nuanced pharmacological profile involving multiple serotonin receptor subtypes and nonserotonergic targets such as TrkB. This review integrates current findings on the molecular interactome of psilocin (psilocybin active metabolite), emphasizing receptor selectivity, biased agonism, and intracellular receptor localization. Together, these insights offer a refined framework for understanding psilocybin's enduring effects and guiding the development of next-generation neuroplastogens with improved specificity and safety.", "journal": null, "publication_date": "2025-09-14", "publication_year": 2025, "doi": "10.1016/j.tips.2025.08.012", "pubmed_id": "40957728", "source_url": "https://doi.org/10.1016/j.tips.2025.08.012", "keywords": "Animals, Humans, Hallucinogens, Neuronal Plasticity, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40957728\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 326, "title": "Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.", "normalized_title": "temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder a systematic review and critical appraisal", "authors": "Sabbah SG, Li S, Wong S, Le GH, Badulescu S, Hawco C, Rosenblat JD, McIntyre RS.", "abstract": "BackgroundPsychedelics are emerging as promising treatments for major depressive disorder (MDD) and treatment-resistant depression (TRD). Functional magnetic resonance imaging (fMRI) offers a powerful tool to study neural mechanisms underlying therapeutic response.MethodsThis systematic review (PROSPERO #CRD42024557973) examined neuroimaging studies of psilocybin in MDD and TRD, with a focus on the temporal evolution of neuroimaging changes post-treatment. A secondary aim was to correlate imaging findings with validated clinical outcomes to assess their relevance in predicting treatment response.ResultsEleven eligible studies were included, using diverse fMRI modalities such as resting-state functional connectivity, task-based BOLD imaging, amplitude of low-frequency fluctuations (ALFF), dynamic functional connectivity, and magnetic resonance spectroscopy. Early (0-4 weeks) post-treatment changes included reduced network modularity and increased global brain integration, alongside modulation of affective circuits involving the amygdala, default mode network, and prefrontal regions. These changes were significantly associated with reductions in BDI, QIDS, and SHAPS scores, reflecting improvements in mood and anhedonia. Longer-term changes (5+ weeks) involved sustained reorganization of large-scale networks, particularly increased connectivity between the prefrontal and parietal cortices and salience network.ConclusionsAlthough these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, several limitations must be acknowledged. Many studies reused overlapping datasets with high exploratory flexibility and risk of bias. The generalizability of results is therefore constrained. Future research should emphasize independent datasets, pre-registered imaging endpoints, and longitudinal designs to clarify the mechanisms underlying psychedelic therapy for depression.", "journal": null, "publication_date": "2025-09-14", "publication_year": 2025, "doi": "10.1016/j.jad.2025.120335", "pubmed_id": "40962065", "source_url": "https://doi.org/10.1016/j.jad.2025.120335", "keywords": "Brain, Humans, Hallucinogens, Magnetic Resonance Imaging, Treatment Outcome, Neuroimaging, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"40962065\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 488, "title": "Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.", "normalized_title": "serotonin 5 ht2c receptor signaling analysis reveals psychedelic biased agonism", "authors": "Bonniwell EM, Alabdali R, Hennessey JJ, McKee JL, Cavalco NG, Lammers JC, Moore EJ, Franchini L, Orlandi C, McCorvy JD.", "abstract": "The serotonin 2C receptor (5-HT2C) is a G protein-coupled receptor implicated in multiple physiological and psychological processes and has been investigated as a therapeutic target for neuropsychiatric conditions such as obesity, drug abuse, and depression. With renewed interest in serotonergic psychedelics for treating depression, 5-HT2C may contribute to psychedelic-induced therapeutic effects. Despite earlier evidence of 5-HT2C G protein coupling promiscuity, the full signaling landscape remains incompletely characterized, which may help explain the limited efficacy and potential cancer risks associated with lorcaserin. Here, we provide a comprehensive analysis of 5-HT2C signaling, confirming and building upon previous findings that the receptor engages Gi/o/z and G12/13 proteins in addition to its primary Gq/11 pathway, and that it preferentially recruits β-arrestin2 over β-arrestin1. We also show that increased RNA editing of the receptor attenuates signaling across all G protein pathways, particularly for G12/13, while preserving β-arrestin recruitment. Profiling of both 5-HT2C-selective and psychedelic ligands reveals diverse signaling profiles, with serotonergic psychedelics such as LSD and psilocin exhibiting a striking Gq/11 bias due to minimal secondary G protein activation. Altogether, this work provides a foundation for incorporating a broader view of 5-HT2C signaling modalities into future investigations of 5-HT2C drug development efforts.", "journal": null, "publication_date": "2025-09-12", "publication_year": 2025, "doi": "10.1021/acschemneuro.5c00647", "pubmed_id": "40944639", "source_url": "https://doi.org/10.1021/acschemneuro.5c00647", "keywords": "Animals, Humans, Receptor, Serotonin, 5-HT2C, Hallucinogens, Signal Transduction, HEK293 Cells, Serotonin 5-HT2 Receptor Agonists, beta-Arrestin 2", "substance_tags": "psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40944639\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414162276" }, { "id": 517, "title": "Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy", "normalized_title": "supporting meaningful choices a decision aid for individuals facing existential distress and considering psilocybin assisted therapy", "authors": "Ariane Bélanger, Sue-Ling Chang, Jean-François Stephan, Florence Moureaux, Diane Tapp, Robert Foxman, Pierre Gagnon, Johanne Hébert, Houman Farzin, Michel Dorval", "abstract": "Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assisted therapy (PAT) has emerged as a promising treatment option. However, weighing up the potential risks and benefits of this approach can be challenging for both healthcare professionals and patients. Decision aids can play a key role in supporting shared decision making by clarifying options, improving knowledge, and enhancing decision quality. To date, there is no decision aid specific to PAT. This descriptive study aimed to develop a decision aid for individuals considering this therapy. Methods: A paper-based/electronic decision aid was developed with a multidisciplinary steering committee following the International Patient Decision Aids Standards Collaboration (IPDAS). Development included conducting a literature review and prototype design, evaluating acceptability and usability by potential users (i.e., patients and healthcare professionals), and producing a final version. Questionnaires, direct feedback, and semi-structured interviews with potential users allowed for evaluation and refinement of design and content. Results: The final version of the decision aid is presented as a booklet, covering areas such as PAT education, comparison of treatment options, and personal reflection. Feedback from patients (n = 5) and healthcare professionals (n = 5) guided improvements, helping clarify content, ensuring balanced information, optimizing its length for usability, and providing decision-making support. Conclusions: The decision aid developed in this study demonstrated satisfactory acceptability and usability, meeting IPDAS criteria. By providing balanced and accessible information, it may facilitate shared decision-making for individuals considering PAT, representing a significant step forward in this emerging area of palliative care.", "journal": "Healthcare", "publication_date": "2025-09-11", "publication_year": 2025, "doi": "10.3390/healthcare13182290", "pubmed_id": "41008422", "source_url": "https://doi.org/10.3390/healthcare13182290", "keywords": "Decision aids, Usability, Multidisciplinary approach, Distress, Health professionals, Health care, Psychology, Decision support system, Existentialism, Palliative care, R-CAST, Decision analysis, Medicine, Nursing, MEDLINE, Key (lock), Multiple-criteria decision analysis, Applied psychology, Qualitative research, Needs assessment, Computer science, Management science, Knowledge management, Clinical decision making, Medical education, Multidisciplinary team, Patient participation, Mental Health and Psychiatry, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414258408\",\"openalex_url\":\"https://openalex.org/W4414258408\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1507711477\",\"https://openalex.org/W1978408850\",\"https://openalex.org/W2037394322\",\"https://openalex.org/W2049440528\",\"https://openalex.org/W2060831503\",\"https://openalex.org/W2076347685\",\"https://openalex.org/W2081358848\",\"https://openalex.org/W2086090702\",\"https://openalex.org/W2106032353\",\"https://openalex.org/W2142779078\",\"https://openalex.org/W2145853206\",\"https://openalex.org/W2158796716\",\"https://openalex.org/W2165844264\",\"https://openalex.org/W2171620790\",\"https://openalex.org/W2305278139\",\"https://openalex.org/W2395936517\",\"https://openalex.org/W2490574984\",\"https://openalex.org/W2518308679\",\"https://openalex.org/W2546467165\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2763882359\",\"https://openalex.org/W2784340661\",\"https://openalex.org/W2889467857\",\"https://openalex.org/W2902500724\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3004612364\",\"https://openalex.org/W3015163151\",\"https://openalex.org/W3023639742\",\"https://openalex.org/W3089309273\",\"https://openalex.org/W3175314351\",\"https://openalex.org/W3194460113\",\"https://openalex.org/W3215511316\",\"https://openalex.org/W4229645494\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4318212889\",\"https://openalex.org/W4386021261\",\"https://openalex.org/W4396230194\",\"https://openalex.org/W4403219178\",\"https://openalex.org/W4405244747\",\"https://openalex.org/W4409687565\",\"https://openalex.org/W4411787106\"],\"authorships\":[{\"id\":\"https://openalex.org/A5109797253\",\"display_name\":\"Ariane Bélanger\",\"orcid\":null},{\"id\":\"https://openalex.org/A5045951431\",\"display_name\":\"Sue-Ling Chang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027250223\",\"display_name\":\"Jean-François Stephan\",\"orcid\":\"https://orcid.org/0009-0000-7376-208X\"},{\"id\":\"https://openalex.org/A5117187654\",\"display_name\":\"Florence Moureaux\",\"orcid\":null},{\"id\":\"https://openalex.org/A5084030574\",\"display_name\":\"Diane Tapp\",\"orcid\":\"https://orcid.org/0000-0002-2818-0141\"},{\"id\":\"https://openalex.org/A5093764770\",\"display_name\":\"Robert Foxman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002305085\",\"display_name\":\"Pierre Gagnon\",\"orcid\":\"https://orcid.org/0000-0001-5625-4745\"},{\"id\":\"https://openalex.org/A5052738130\",\"display_name\":\"Johanne Hébert\",\"orcid\":\"https://orcid.org/0000-0003-4023-9246\"},{\"id\":\"https://openalex.org/A5040374734\",\"display_name\":\"Houman Farzin\",\"orcid\":\"https://orcid.org/0009-0006-4095-3596\"},{\"id\":\"https://openalex.org/A5068576397\",\"display_name\":\"Michel Dorval\",\"orcid\":\"https://orcid.org/0000-0002-3207-8211\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210214101\",\"source_display_name\":\"Healthcare\",\"landing_page_url\":\"https://doi.org/10.3390/healthcare13182290\",\"is_oa\":true}}", "topic_tags": "End-of-Life Distress,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414258408" }, { "id": 489, "title": "Concomitant use of antidepressants and classic psychedelics: A scoping review.", "normalized_title": "concomitant use of antidepressants and classic psychedelics a scoping review", "authors": "Tap SC, Thomas K, Páleníček T, Stenbæk DS, Oliveira-Maia AJ, van Dalfsen JH, Schoevers RA.", "abstract": "Classic psychedelics are increasingly studied as potential treatments for different psychiatric disorders. Current research protocols often require patients to discontinue antidepressants (ADs) for at least 2 weeks before psychedelic administration to decrease the risk of serotonin syndrome and limit their effect on efficacy and the acute subjective effects of psychedelics. Moreover, the discontinuation of ADs represents a significant burden to patients that could also worsen their depression status and increase suicidal ideation. Together, this suggests that the general recommendation for AD discontinuation might be unnecessary and even detrimental to the therapeutic efficacy of psychedelics. In this scoping review, we summarise the existing literature on the concomitant use of conventional ADs with classic psychedelics in humans with the aims to assess safety, tolerability, efficacy, and subjective effects. Following PRISMA-ScR guidelines, we searched MEDLINE, Embase, and Scopus databases to retrieve relevant literature from inception to March 3, 2025. Data were systematically charted from included studies. We included 18 studies and found that the concomitant use of ADs and classic psychedelics is generally safe and tolerable, with no increased risk of serotonin syndrome, particularly for psilocybin. Some studies reported significant improvements in depression and other mental health symptoms. While some evidence indicates a potential attenuation of acute subjective psychedelic effects, this was not observed in all studies. Accordingly, we conclude that the use of ADs can be maintained to enhance patient access to psychedelic treatments and avoid the risk of AD discontinuation syndrome. Finally, this review highlights limitations and several knowledge gaps in the current literature that need to be addressed in future randomized double-blind, placebo-controlled trials.", "journal": null, "publication_date": "2025-09-11", "publication_year": 2025, "doi": "10.1177/02698811251368360", "pubmed_id": "40937732", "source_url": "https://doi.org/10.1177/02698811251368360", "keywords": "Humans, Serotonin Syndrome, Hallucinogens, Antidepressive Agents, Mental Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40937732\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Receptor Pharmacology,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4296, "title": "The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting", "normalized_title": "the legal perspective on psilocybin for medical use in czechia a key milestone and the case for broader consideration beyond the clinical setting", "authors": "Tereza Dleštíková", "abstract": "Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves the way for regulated therapeutic applications of psilocybin within clinical settings, while simultaneously prompting a timely discussion on the potential uses of psychedelics beyond strictly medical contexts. This commentary first outlines the legal status of psilocybin for therapeutic use in Czechia and situates this reform within broader international policy trends. Drawing on the publication How to Regulate Psychedelics and qualitative findings from a ketamine-assisted therapy program conducted as part of the Czech Destigmatizing the Therapeutic Use of Psychedelics in Psychiatry project, it then examines the regulation of non-clinical psychedelic use, while also highlighting the persistent legal ambiguity surrounding the Czech offence of “spreading toxicomania.” The commentary advocates for a rational, evidence-based regulatory approach, arguing that while the medicalization of psilocybin constitutes a significant legal milestone, the framework will remain incomplete without clear pathways for non-clinical use to ensure safety and legal clarity.", "journal": "Psychoactives", "publication_date": "2025-09-10", "publication_year": 2025, "doi": "10.3390/psychoactives4030034", "pubmed_id": null, "source_url": "https://doi.org/10.3390/psychoactives4030034", "keywords": "Psilocybin, Perspective (graphical), Milestone, Ambiguity, Medicalization, Engineering ethics, Psychology, Public relations, Political science, Key (lock), Interpretation (philosophy), Psychiatry, Psychotherapist, Law, Sociology, Medicine, Lysergic acid diethylamide, Czech, Hallucinogen, Complaint, Corporate governance, Criminology, Thematic analysis, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414123257\",\"openalex_url\":\"https://openalex.org/W4414123257\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W2161555895\",\"https://openalex.org/W2234681180\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4308266180\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4403257190\",\"https://openalex.org/W4405565174\"],\"authorships\":[{\"id\":\"https://openalex.org/A5073300363\",\"display_name\":\"Tereza Dleštíková\",\"orcid\":\"https://orcid.org/0000-0002-0994-0678\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387280156\",\"source_display_name\":\"Psychoactives\",\"landing_page_url\":\"https://doi.org/10.3390/psychoactives4030034\",\"is_oa\":true}}", "topic_tags": "Mechanism of Action,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414123257" }, { "id": 3699, "title": "Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.", "normalized_title": "measurement of serum cytokine levels in samples collected as part of a clinical trial of psilocybin for treatment resistant depression", "authors": "King's College London", "abstract": "About one in three people with major depression respond poorly to standard antidepressant treatments. This kind of depression is called treatment-resistant depression, and it can lead to long-term disability, financial challenges, and a higher risk of suicide. Psilocybin-a compound found in certain mushrooms-has shown early promise as a new treatment for this difficult-to-treat depression. Scientists believe it works by affecting a specific brain receptor (called 5-HT2A), which helps the brain become more flexible and adaptable. But there's another possible mechanism of psilocybin that hasn't been studied much: its ability to influence the immune system. Recent research suggests that inflammation in the body might play a role in depression, especially when treatments don't work. High levels of certain inflammatory markers (called cytokines) are linked to poor response to antidepressants, while lower levels are tied to feeling better. Psilocybin may help reduce this inflammation, which could be part of why it helps some people feel better. Still, we don't fully understand how a person's inflammation levels before treatment, and how those levels change afterward, relate to how well psilocybin works. Figuring this out could help doctors better match patients to psychedelic therapy and discover new ways to treat depression. In this study, blood samples from a recent study (called the PsiDeR trial) that tested psilocybin in people with treatment-resistant depression will be analyzed. Cytokine levels in these blood samples, as well as levels of another type of molecule linked to inflammation, called mRNA, will be measured. Chronic and elevated inflammation is associated with depression. Depressed patients tend to have raised inflammatory markers compared to healthy controls, and studies have reported that the greatest elevation is seen in patients with treatment-resistant depression (TRD). Previous studies highlight the bidirectional relationship between inflammation and depression. Elevated pro-inflammatory cytokines are linked to poor antidepressant response, while reductions in these markers are associated with symptom improvement. While neuroinflammation may play a role in the pathophysiology of depression, inflammation is also a causal risk factor for physical illnesses that are often co-morbid with depression, such as cardiovascular disease. As such, targeting inflammation in patients with depression may have significant implications for both their mental and physical health. Psychedelics are emerging as a potential new class of therapeutic agents for psychiatric illness, including depression. It has been suggested that their therapeutic effect may partly be due to reducing inflammation. Psychedelics have been shown reduce markers of inflammation in models of human inflammatory disease, both in vitro and in vivo. While, as might be expected, psilocybin was not found to reduce markers of inflammation in healthy human volunteers, in a clinical sample of people with treatment-resistant depression, use of ayahuasca (containing the psychedelic N,N DMT) resulted in a significant reduction in CRP levels compared to participants given placebo, with the reduction in CRP levels significantly correlated with a reduction in depressive symptoms. Ayahuasca consists of an admixture of multiple different compounds. As such, the relative contribution of the psychedelic to the anti-inflammatory effect that was observed is unknown. The effect of isolated psychedelic compounds such as psilocybin on the systemic inflammatory state of patients, specifically patients with depression, therefore, remains to be investigated. Psilocybin's capacity to reduce inflammation, as evidenced in preclinical models, may be a crucial mechanism underlying its therapeutic effects. Moreover, while it is recognised that baseline inflammation levels can influence the effectiveness of conventional antidepressants, it is unclear whether this is also the case for psilocybin. This study aims to evaluate serum cytokine and inflammatory-related mRNA levels in samples collected from participants with TRD who took part in the (Psi)locybin in (De)pression (R)esistant to Standard Treatments (PsiDeR) Trial, and the relationships between these and psilocybin treatment response. PsiDeR was a randomised, placebo-controlled trial of psilocybin as a treatment for TRD that has now completed.", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-09", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT07164755", "keywords": "Depression - Major Depressive Disorder, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT07164755\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[]}", "topic_tags": "Depression,Receptor Pharmacology,Biomarkers,Clinical Trial,Animal Study,In Vitro Study,Treatment-Resistant Depression,Safety,Inflammation,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3562, "title": "Processing Intergenerational Trauma With Psilocybin-Assisted Therapy", "normalized_title": "processing intergenerational trauma with psilocybin assisted therapy", "authors": "Rachel Yehuda", "abstract": "This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience. This study is investigating whether Psilocybin-assisted therapy improves depression, anxiety and stress symptoms in the offspring (biological children) of genocide survivors. Intergenerational trauma is the concept that the effects of experiencing extreme stress can be perpetuated to future generations. A genocide here is defined by the extinction or threat of extinction of a racial, religious or ethnic group, by an oppressive regime. A genocide survivor here is defined by an individual who survived or escaped a genocide in their country of origin. Currently, there are no evidence-based treatments developed specifically for the syndrome associated with Intergenerational trauma. This study aims to assess the safety and tolerability of psilocybin-assisted therapy, and assess the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience. Participants will be asked to attend one or more screening visits to assess eligibility. If eligible, participants will be treated with two separate doses of the study medication, Psilocybin, 3-4 weeks apart. This is an open-label research study, meaning all participants will receive Psilocybin (25mg). Two trained clinical practitioners will work with participants across preparation, dosing, and integration processes. Participants will complete assessments throughout the study until their participation has ended. Safety measures are in place to check the overall health and well-being of participants Participation will consist of: * Screening Period (up to 4 weeks): Phone screen, informed consent, eligibility assessment. * Tapering \\& Enrollment Period (variable): Enrollment, supervised medical tapering where necessary as discussed with the study doctor, biomarker collection and psychometric baseline assessments. * Preparatory \\& Treatment Period (up to 14 weeks): Three preparatory sessions with study clinicians, assessments; two dosing days at least three weeks apart, three weekly integration sessions with study clinicians following each dose, a 72-hour check-in call after each dosing day, assessments. * Follow-Up Period (up to 5 weeks): Follow-up one month after final integration session, assessments, clinical evaluation, biomarker collection", "journal": "ClinicalTrials.gov", "publication_date": "2025-09-07", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06899165", "keywords": "Psychological Stress, Depression, Anxiety, Psilocybin, Psilocybin-Assisted Therapy, Integration sessions, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06899165\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Biomarkers,Wellbeing,Resilience,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 521, "title": "Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.", "normalized_title": "effect of psilocybin therapy on suicidal ideation attempts and deaths in people with psychiatric diagnoses a systematic review and meta analysis", "authors": "Wong S, Meckling G, Fabiano N, Lee S, Jones BDM, Shorr R, Dargel A, Davis AK, Fiedorowicz JG, Solmi M, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI.", "abstract": "BackgroundSuicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have shown promise in treating treatment-resistant depression and have found a reduction in suicidal ideation. Given the growth of PT research, there is a need to further understand its effect on suicidal ideation, attempts, and deaths.ObjectiveTo assess and synthesize evidence on the effects of PT on suicidal ideation, attempts, and deaths in psychiatric patients.DesignPRISMA-compliant systematic review and meta-analysis.Data sourceMEDLINE, EMBASE, Cochrane, and PsychINFO.MethodDatabases were searched for randomized controlled trials of PT in adults with psychiatric diagnoses that reported suicide outcomes (ideation, attempts, and deaths). Abstract and full-text screening were conducted, and suicide outcomes were extracted. Meta-analysis was performed with a random effects model to assess changes in suicide outcomes compared to control through the standardized mean difference (SMD). Assessment of heterogeneity, risk of bias, and subgroup analysis was completed.ResultsNine studies were included (N = 593; 335 psilocybin & 258 control). Two studies were excluded from meta-analysis because suicide-related outcomes data were not available. Participants with PT experienced a small and significant decrease in suicidal ideation compared to control (k = 7, SMD = -0.24, 95% CI -0.42 to -0.06, p = 0.008, I2 = 0%). There was no publication bias found. Subgroup analysis found no significant differences between groups. No study reported suicide attempts or suicide deaths. Two studies had a high risk of bias.ConclusionPsilocybin therapy may reduce suicidal ideation in adults with psychiatric diagnoses. Current studies are limited by small sample size, lack of follow-up data, and assessment of blinding.Trial registrationCRD42023445706.", "journal": null, "publication_date": "2025-09-06", "publication_year": 2025, "doi": "10.1177/20451253251372449", "pubmed_id": "40933784", "source_url": "https://doi.org/10.1177/20451253251372449", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40933784\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4297, "title": "Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder", "normalized_title": "five year outcomes of psilocybin assisted therapy for major depressive disorder", "authors": "Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda, Adam W. Levin, Mary P Cosimano, Hillary Shaub, Washington Taylor, Peter M. Gooch, Shoval Gilead, Skylar J. Gaughan, Stacey B. Armstrong, Frederick S. Barrett", "abstract": "Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period. Methods Individuals who previously participated in an RCT studying the effects of PAT for patients with MDD were contacted for a long-term follow-up (LTFU) study. This study uses a parallel convergent mixed methods design. Of the original 24 RCT participants, 21 enrolled in the LTFU study, with 18 (75%) completing it. For the six non-completers, baseline scores were used in quantitative analyses as conservative estimates. The primary outcome was clinician-rated change in depression severity from baseline to LTFU. Secondary outcomes included anxiety, functional impairment, and qualitative assessments of participants' experiences and mental health. Results Significant and sustained reductions in depression were observed, with 67% in remission for at least five years post-treatment. Anxiety and functional impairment also improved. Qualitative interviews revealed lasting positive changes in mindset, emotional health, and relationships. Participants reported enhanced empathy, self-acceptance, and improved interpersonal relationships. No severe adverse events were reported. Conclusion This study supports the long-term efficacy and safety of PAT in reducing depressive symptoms and improving mental health in patients with MDD. Further research is needed to determine if these findings can be replicated, and to explore the mechanisms behind the sustained benefits of PAT, potentially validating an approach that could transform the treatment of MDD.", "journal": "Journal of Psychedelic Studies", "publication_date": "2025-09-03", "publication_year": 2025, "doi": "10.1556/2054.2025.00461", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2025.00461", "keywords": "Psilocybin, Major depressive disorder, Psychology, Psychotherapist, Psychiatry, Clinical psychology, Medicine, Hallucinogen, Cognition, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413975912\",\"openalex_url\":\"https://openalex.org/W4413975912\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1914972138\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1981198734\",\"https://openalex.org/W2014087423\",\"https://openalex.org/W2015666695\",\"https://openalex.org/W2030962294\",\"https://openalex.org/W2073441573\",\"https://openalex.org/W2084779737\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2141217193\",\"https://openalex.org/W2141305471\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2201421223\",\"https://openalex.org/W2418769740\",\"https://openalex.org/W2463496270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2738334969\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2804876758\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W3031742716\",\"https://openalex.org/W3048560297\",\"https://openalex.org/W3093223973\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3157759986\",\"https://openalex.org/W3210887564\",\"https://openalex.org/W4205567434\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4224044203\",\"https://openalex.org/W4229447912\",\"https://openalex.org/W4232488826\",\"https://openalex.org/W4235220276\",\"https://openalex.org/W4236038590\",\"https://openalex.org/W4291162385\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386894189\",\"https://openalex.org/W4388574768\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4392797453\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4406870441\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038141719\",\"display_name\":\"Alan K. Davis\",\"orcid\":\"https://orcid.org/0000-0003-4770-8893\"},{\"id\":\"https://openalex.org/A5063981201\",\"display_name\":\"Meghan DellaCrosse\",\"orcid\":\"https://orcid.org/0000-0001-5554-277X\"},{\"id\":\"https://openalex.org/A5061776312\",\"display_name\":\"Nathan D. Sepeda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048202842\",\"display_name\":\"Adam W. Levin\",\"orcid\":\"https://orcid.org/0000-0002-9167-462X\"},{\"id\":\"https://openalex.org/A5025469924\",\"display_name\":\"Mary P Cosimano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119535269\",\"display_name\":\"Hillary Shaub\",\"orcid\":null},{\"id\":\"https://openalex.org/A5028633108\",\"display_name\":\"Washington Taylor\",\"orcid\":\"https://orcid.org/0000-0001-8566-6706\"},{\"id\":\"https://openalex.org/A5081593427\",\"display_name\":\"Peter M. Gooch\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119535270\",\"display_name\":\"Shoval Gilead\",\"orcid\":null},{\"id\":\"https://openalex.org/A5115863901\",\"display_name\":\"Skylar J. Gaughan\",\"orcid\":\"https://orcid.org/0000-0002-3851-7430\"},{\"id\":\"https://openalex.org/A5015911875\",\"display_name\":\"Stacey B. Armstrong\",\"orcid\":\"https://orcid.org/0000-0003-0869-7511\"},{\"id\":\"https://openalex.org/A5005540871\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":\"https://orcid.org/0000-0001-7443-3237\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2025.00461\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Mechanism of Action,Emotional Processing,Randomized Controlled Trial,Healthcare Workers,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413975912" }, { "id": 3775, "title": "Blunted psychedelic drug effects in older adults", "normalized_title": "blunted psychedelic drug effects in older adults", "authors": "Aday JS, Carhart-Harris R, Boehnke KF.", "abstract": "Classic psychedelic drugs, including psilocybin, lysergic acid diethylamide, and ayahuasca/N,N-dimethyltryptamine, are increasingly being studied as therapeutics for myriad health conditions; however, predicting individual responses is notoriously difficult. An arguably underappreciated variable potentially moderating responses to psychedelics is age. Older adults exhibit unique pathogenesis of various neuropsychiatric disorders and, accordingly, have unique treatment considerations. In the case of psychedelics, differences in life circumstances, peripheral physiology, polypharmacy, weight, and neurobiology may present unique theoretical risks and opportunities for older adults. Here, we overview increased interest in studying psychedelics in older adults and spotlight an overlooked but consistent trend that has emerged in the literature-blunted psychedelic drug effects across the lifespan.", "journal": "PsyArXiv", "publication_date": "2025-09-03", "publication_year": 2025, "doi": "10.31234/osf.io/yz4cd_v2", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/yz4cd_v2", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:20", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR1079275\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Aging,Longevity,Older Adults,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3239, "title": "Blunted psychedelic drug effects in older adults", "normalized_title": "blunted psychedelic drug effects in older adults", "authors": "", "abstract": "Classic psychedelic drugs, including psilocybin, lysergic acid diethylamide, and ayahuasca/N,N-dimethyltryptamine, are increasingly being studied as therapeutics for myriad health conditions; however, predicting individual responses is notoriously difficult. An arguably underappreciated variable potentially moderating responses to psychedelics is age. Older adults exhibit unique pathogenesis of various neuropsychiatric disorders and, accordingly, have unique treatment considerations. In the case of psychedelics, differences in life circumstances, peripheral physiology, polypharmacy, weight, and neurobiology may present unique theoretical risks and opportunities for older adults. Here, we overview increased interest in studying psychedelics in older adults and spotlight an overlooked but consistent trend that has emerged in the literature-blunted psychedelic drug effects across the lifespan.", "journal": "PsyArXiv", "publication_date": "2025-09-03", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/yz4cd_v2", "keywords": "Psychiatry, Neuroscience, Social and Behavioral Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"yz4cd_v2\",\"version\":2,\"reviews_state\":\"accepted\"}", "topic_tags": "Aging,Longevity,Older Adults,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 524, "title": "Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.", "normalized_title": "therapeutic use of psilocybin in depression a systematic review of clinical evidence", "authors": "Andrade FRT, Buchborn T, Thalheimer G, Meinhardt MW, Joca S, de Almeida RMM.", "abstract": "BackgroundMajor depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression. It primarily acts through the serotonin 5-HT2A receptor but interacts with 5-HT1A and 5-HT2C receptors. Its precise mechanisms remain under investigation.Objectives(1) To consolidate evidence on psilocybin’s efficacy and safety for depression and the role of 5HT2a, (2) to identify limitations in the literature, and (3) to highlight areas needing further research.MethodsThis systematic review follows PRISMA guidelines and analyses 22 studies, including randomised controlled trials (RCTs) and open-label studies. The studies cover various populations, including individuals with treatment-resistant depression, different dosing regimens, and adjunctive therapies.ResultsPsilocybin therapy shows substantial and rapid antidepressant effects, often after one or two sessions with psychological support. Improvements are sustained for weeks or months in many cases. Psilocybin is generally well-tolerated, with mild adverse effects such as anxiety during administration and transient headaches, which are manageable in controlled settings.ConclusionsPsilocybin demonstrates promise as a novel treatment for depression, especially for individuals unresponsive to conventional antidepressants. Further research is needed to refine dosing, explore long-term effects, and understand its mechanisms of action.", "journal": null, "publication_date": "2025-09-02", "publication_year": 2025, "doi": "10.1017/neu.2025.10039", "pubmed_id": "40899152", "source_url": "https://doi.org/10.1017/neu.2025.10039", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Treatment Outcome, Randomized Controlled Trials as Topic, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40899152\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Mechanism of Action,Receptor Pharmacology,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4305, "title": "Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report", "normalized_title": "psilocybin assisted psychotherapy for chronic somatoform pain disorder a case report", "authors": "M Mercier, Cédric Mabilais, Vasileios Chytas, Leonice Furtado, Federico Seragnoli, Albert Buchard, Tatiana Aboulafia Brakha, Gabriel Thorens, Daniele Zullino, Louise Penzenstadler", "abstract": "Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatment of psychiatric disorders such as depression and anxiety. While evidence regarding their role in chronic pain management remains limited, emerging studies suggest potential therapeutic benefits. This case report describes a patient with persistent somatoform pain disorder and recurrent depressive disorder who underwent four sessions of psilocybin-assisted psychotherapy. The intervention was associated with a reduction in the negative impact of pain on daily life, increased pain acceptance, improved quality of life, and reduction in depressive symptoms. These findings contribute to the growing body of literature suggesting that psychedelics, when combined with psychotherapy, may offer a novel and holistic approach to the treatment of chronic pain. Further controlled studies are needed to explore the safety, efficacy, and underlying mechanisms.", "journal": "Psychoactives", "publication_date": "2025-08-31", "publication_year": 2025, "doi": "10.3390/psychoactives4030030", "pubmed_id": null, "source_url": "https://doi.org/10.3390/psychoactives4030030", "keywords": "Psilocybin, Chronic pain, Psychotherapist, Medicine, Psychology, Psychiatry, Hallucinogen, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413893315\",\"openalex_url\":\"https://openalex.org/W4413893315\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2023687307\",\"https://openalex.org/W2041124713\",\"https://openalex.org/W2125228745\",\"https://openalex.org/W2217880633\",\"https://openalex.org/W2329316201\",\"https://openalex.org/W2462596148\",\"https://openalex.org/W2464715703\",\"https://openalex.org/W2512716401\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2743855088\",\"https://openalex.org/W2804789712\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3081126678\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3165837403\",\"https://openalex.org/W3213721934\",\"https://openalex.org/W4211119836\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294804950\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4386019370\",\"https://openalex.org/W4386466628\",\"https://openalex.org/W4386624716\",\"https://openalex.org/W4402529371\",\"https://openalex.org/W4402697828\",\"https://openalex.org/W4404843727\",\"https://openalex.org/W4406120474\",\"https://openalex.org/W4406510641\",\"https://openalex.org/W4411103150\"],\"authorships\":[{\"id\":\"https://openalex.org/A5018529574\",\"display_name\":\"M Mercier\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091929997\",\"display_name\":\"Cédric Mabilais\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065669141\",\"display_name\":\"Vasileios Chytas\",\"orcid\":\"https://orcid.org/0000-0002-1897-3578\"},{\"id\":\"https://openalex.org/A5091929996\",\"display_name\":\"Leonice Furtado\",\"orcid\":null},{\"id\":\"https://openalex.org/A5076109553\",\"display_name\":\"Federico Seragnoli\",\"orcid\":\"https://orcid.org/0000-0001-9261-770X\"},{\"id\":\"https://openalex.org/A5098758615\",\"display_name\":\"Albert Buchard\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116852081\",\"display_name\":\"Tatiana Aboulafia Brakha\",\"orcid\":\"https://orcid.org/0000-0001-6878-4276\"},{\"id\":\"https://openalex.org/A5011794985\",\"display_name\":\"Gabriel Thorens\",\"orcid\":\"https://orcid.org/0000-0002-3622-9179\"},{\"id\":\"https://openalex.org/A5024403583\",\"display_name\":\"Daniele Zullino\",\"orcid\":\"https://orcid.org/0000-0003-2468-8965\"},{\"id\":\"https://openalex.org/A5054543118\",\"display_name\":\"Louise Penzenstadler\",\"orcid\":\"https://orcid.org/0000-0003-1379-0243\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387280156\",\"source_display_name\":\"Psychoactives\",\"landing_page_url\":\"https://doi.org/10.3390/psychoactives4030030\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Mechanism of Action,Case Report,Safety", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413893315" }, { "id": 483, "title": "Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial", "normalized_title": "psilocybin with psychotherapeutic support for treatment resistant depression a pilot clinical trial", "authors": "Sally Meikle, Olivia Carter, Paul Liknaitzky, Lauren Johansen, Ravi Iyer, Nigel Strauss, M.L. Williams, David Castle, Susan L. Rossell", "abstract": "Background: Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research. Objectives: This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of treatment outcomes and deepen understanding of individual variability in response. Design: Open-label, single-arm pilot trial with mixed-methods assessment. Methods: Treatment consisted of two 25 mg psilocybin sessions, alongside three preparatory and six integration sessions. Depression severity was assessed using the self-rated Quick Inventory of Depressive Symptomatology at 3 weeks (primary endpoint) and at 20 weeks post-dose 2 (long-term follow-up). Potential predictors of clinical outcomes were evaluated using questionnaires, and qualitative interviews were used to capture individual experiences. Results: = 0.02; Hedges' g = -1.27; 95% CI [-2.40, -0.37]) and maintained long-term. Individual participant data revealed diverse response patterns. Two participants displayed a sustained treatment response, three relapsed, and two exhibited no substantial improvement. Exploratory analyses identified mindset prior to dosing, spiritual experiences and perceptual shifts during dosing as predictors of treatment trajectory, while treatment expectations were not a reliable predictor. Adverse events were largely consistent with previous studies, with no serious adverse events. Conclusion: Findings add to the growing evidence base for psilocybin therapy and provide direction for further research on individual variability in response to better tailor treatments and enhance efficacy. Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12621001097831).", "journal": "Therapeutic Advances in Psychopharmacology", "publication_date": "2025-08-31", "publication_year": 2025, "doi": "10.1177/20451253251377187", "pubmed_id": "41050149", "source_url": "https://doi.org/10.1177/20451253251377187", "keywords": "Psilocybin, Clinical trial, Medicine, Psychiatry, Psychotherapist, MEDLINE, Pilot trial, Depression (economics), Clinical psychology, Psychology, Hallucinogen, Alternative medicine, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414745551\",\"openalex_url\":\"https://openalex.org/W4414745551\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1480828298\",\"https://openalex.org/W1560134422\",\"https://openalex.org/W1730751745\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2039518223\",\"https://openalex.org/W2047503435\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2085758661\",\"https://openalex.org/W2093627832\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2149402043\",\"https://openalex.org/W2166423316\",\"https://openalex.org/W2253311584\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2397862430\",\"https://openalex.org/W2429180991\",\"https://openalex.org/W2537963806\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2766521428\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2777253753\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2795594181\",\"https://openalex.org/W2810880335\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2896003347\",\"https://openalex.org/W2919124707\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2964840460\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3167074068\",\"https://openalex.org/W3210887564\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4236206848\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4289841582\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W4367053025\",\"https://openalex.org/W4368356691\",\"https://openalex.org/W4381598621\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387019277\",\"https://openalex.org/W4387115576\",\"https://openalex.org/W4390674606\",\"https://openalex.org/W4391109410\",\"https://openalex.org/W4391734876\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4394894573\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4399215777\",\"https://openalex.org/W4401184397\",\"https://openalex.org/W4402912774\",\"https://openalex.org/W4410132242\"],\"authorships\":[{\"id\":\"https://openalex.org/A5033945101\",\"display_name\":\"Sally Meikle\",\"orcid\":\"https://orcid.org/0000-0001-7500-141X\"},{\"id\":\"https://openalex.org/A5060157509\",\"display_name\":\"Olivia Carter\",\"orcid\":\"https://orcid.org/0000-0001-7708-6154\"},{\"id\":\"https://openalex.org/A5030212190\",\"display_name\":\"Paul Liknaitzky\",\"orcid\":\"https://orcid.org/0000-0001-5690-2263\"},{\"id\":\"https://openalex.org/A5029788824\",\"display_name\":\"Lauren Johansen\",\"orcid\":\"https://orcid.org/0000-0003-1180-0428\"},{\"id\":\"https://openalex.org/A5066637196\",\"display_name\":\"Ravi Iyer\",\"orcid\":\"https://orcid.org/0000-0001-7699-0846\"},{\"id\":\"https://openalex.org/A5044554133\",\"display_name\":\"Nigel Strauss\",\"orcid\":null},{\"id\":\"https://openalex.org/A5010417984\",\"display_name\":\"M.L. Williams\",\"orcid\":\"https://orcid.org/0000-0002-9483-3008\"},{\"id\":\"https://openalex.org/A5052884442\",\"display_name\":\"David Castle\",\"orcid\":\"https://orcid.org/0000-0002-3075-1580\"},{\"id\":\"https://openalex.org/A5073606057\",\"display_name\":\"Susan L. Rossell\",\"orcid\":\"https://orcid.org/0000-0002-7415-8252\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2765027927\",\"source_display_name\":\"Therapeutic Advances in Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/20451253251377187\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Spirituality,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414745551" }, { "id": 490, "title": "US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022", "normalized_title": "us poison center encounters for psilocybin related exposures 2013 2022", "authors": "Juan Carlos C. Montoy, Ralph C. Wang, Allison R. Coker, Craig G. Smollin, B. Anderson", "abstract": "Objectives: Given the increasing use of psilocybin-containing substances across a variety of use settings, understanding the potential risks is imperative for informing public health policy, health care providers, and consumers. Poison centers (PCs) receive calls following exposures to potential toxins to support the detection, prevention, and treatment of toxin-related health emergencies. This report assesses trends in PC encounters of psilocybin and a subset of other comparator substances. Methods: A retrospective study of PC encounters documenting exposure to psilocybin, other psychedelic substances (lysergic acid diethylamide, mescaline/peyote, and hallucinogenic plants), or toxic plants and mushrooms from 2013 to 2022 was performed. The primary outcome was the occurrence of psilocybin-related encounters, with and without other coingestants. Psilocybin-related encounters were presented overall and stratified by age groups, and the clinical outcomes were described. Results: There were 6933 PC encounters for psilocybin-containing substances between 2013 and 2022. PC encounters for psilocybin-containing substances (alone or with coingestants) increased over time-from 477 in 2013 to 1441 in 2022. Psilocybin-related encounters increased over the study period among all age groups (years) and were most common in the 18 to 24 and 25 to 44 year-old age groups. Across all years, the number of psilocybin-related encounters was similar to those for lysergic acid diethylamide and mescaline/peyote, and far lower than those for other mushrooms and toxic plants. Conclusion: From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was not observed with other substances. Although the number of encounters remains low, this trend could continue as psilocybin use increases.", "journal": "Journal of the American College of Emergency Physicians Open", "publication_date": "2025-08-29", "publication_year": 2025, "doi": "10.1016/j.acepjo.2025.100231", "pubmed_id": "40927687", "source_url": "https://doi.org/10.1016/j.acepjo.2025.100231", "keywords": "Psilocybin, Center (category theory), Poison control center, Hallucinogen, Psychology, Environmental health, Medicine, Poison control, Human factors and ergonomics, Psychiatry, Chemistry, Crystallography, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413851486\",\"openalex_url\":\"https://openalex.org/W4413851486\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W2154105276\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2889566085\",\"https://openalex.org/W2919499504\",\"https://openalex.org/W3040125782\",\"https://openalex.org/W3158872618\",\"https://openalex.org/W4210376981\",\"https://openalex.org/W4221018864\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4392165205\"],\"authorships\":[{\"id\":\"https://openalex.org/A5063679161\",\"display_name\":\"Juan Carlos C. Montoy\",\"orcid\":\"https://orcid.org/0000-0001-7438-0243\"},{\"id\":\"https://openalex.org/A5074553395\",\"display_name\":\"Ralph C. Wang\",\"orcid\":\"https://orcid.org/0000-0001-5382-9486\"},{\"id\":\"https://openalex.org/A5033235412\",\"display_name\":\"Allison R. Coker\",\"orcid\":\"https://orcid.org/0000-0001-5353-4653\"},{\"id\":\"https://openalex.org/A5089933209\",\"display_name\":\"Craig G. Smollin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5009662036\",\"display_name\":\"B. Anderson\",\"orcid\":\"https://orcid.org/0000-0001-5023-660X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210207081\",\"source_display_name\":\"Journal of the American College of Emergency Physicians Open\",\"landing_page_url\":\"https://doi.org/10.1016/j.acepjo.2025.100231\",\"is_oa\":true}}", "topic_tags": "Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413851486" }, { "id": 557, "title": "Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis", "normalized_title": "psilocybin assisted therapy for treatment resistant depression in the us a model based cost effectiveness analysis", "authors": "Anton L.V. Avanceña, Linh N. Vuong, James G. Kahn, Elliot Marseille", "abstract": "Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individual-level, probabilistic simulation model that portrays representative US adults with TRD who receive SOC (pharmacotherapy, psychotherapy, electroconvulsive therapy, and esketamine nasal spray) and PAT over 12 months. We assumed the total cost of PAT was $5000, which we varied in sensitivity analyses ($3000-20,000). We calculated total costs, health effects (in terms of quality-adjusted life years [QALYs] gained), and incremental cost-effectiveness ratio (ICER) from limited healthcare and societal perspectives. PAT leads to an additional 0.031 QALYs and $3639 costs compared to SOC over 12 months, giving an ICER of $117,517 per QALY gained from a limited healthcare perspective. Using a $150,000 cost-effectiveness threshold, PAT had a 75% probability of being the cost-effective choice, and it was associated with a lower expected loss than SOC ($301 vs. $1307). Results were sensitive to uncertainty in model parameters, particularly the cost of PAT. PAT had a 1% probability of being cost-effective when its overall costs were $10,000 and 95% when its costs were $3000. This cost-effectiveness analysis found that when its costs are $5000 or less, PAT may offer economic value compared to available TRD treatments. Future studies can explore ways to reduce the cost of PAT and to understand its long-term effectiveness in maintaining remission and reducing the risk of relapse.", "journal": "Translational Psychiatry", "publication_date": "2025-08-28", "publication_year": 2025, "doi": "10.1038/s41398-025-03556-4", "pubmed_id": "40883271", "source_url": "https://doi.org/10.1038/s41398-025-03556-4", "keywords": "Medicine, Treatment-resistant depression, Quality-adjusted life year, Cost effectiveness, Depression (economics), Quality of life (healthcare), Cost-utility analysis, Cost-effectiveness analysis, Cost-benefit analysis, Psychiatry, Major depressive disorder, Nursing, Biology, Macroeconomics, Cognition, Economics, Ecology, Risk analysis (engineering), Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413817374\",\"openalex_url\":\"https://openalex.org/W4413817374\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1970708247\",\"https://openalex.org/W1986111824\",\"https://openalex.org/W1996198481\",\"https://openalex.org/W2005180789\",\"https://openalex.org/W2014841928\",\"https://openalex.org/W2039156670\",\"https://openalex.org/W2047150120\",\"https://openalex.org/W2063636797\",\"https://openalex.org/W2081775967\",\"https://openalex.org/W2118707799\",\"https://openalex.org/W2129106427\",\"https://openalex.org/W2130587165\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2166394031\",\"https://openalex.org/W2256478365\",\"https://openalex.org/W2302122362\",\"https://openalex.org/W2541285986\",\"https://openalex.org/W2551536312\",\"https://openalex.org/W2787885435\",\"https://openalex.org/W2792270412\",\"https://openalex.org/W2792698409\",\"https://openalex.org/W2802320676\",\"https://openalex.org/W2804598038\",\"https://openalex.org/W2810894650\",\"https://openalex.org/W2914902447\",\"https://openalex.org/W2946080221\",\"https://openalex.org/W2946661342\",\"https://openalex.org/W2948816951\",\"https://openalex.org/W2952578240\",\"https://openalex.org/W2961020354\",\"https://openalex.org/W2973759191\",\"https://openalex.org/W2978338010\",\"https://openalex.org/W2979128349\",\"https://openalex.org/W2984280663\",\"https://openalex.org/W2998434856\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3008073826\",\"https://openalex.org/W3011083165\",\"https://openalex.org/W3015092527\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3093269897\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3110634754\",\"https://openalex.org/W3114414169\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3149986569\",\"https://openalex.org/W3152628277\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160306775\",\"https://openalex.org/W3164632875\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3171546624\",\"https://openalex.org/W3175374335\",\"https://openalex.org/W3206510151\",\"https://openalex.org/W4205208574\",\"https://openalex.org/W4205900283\",\"https://openalex.org/W4206006624\",\"https://openalex.org/W4210376981\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4214531716\",\"https://openalex.org/W4214556654\",\"https://openalex.org/W4225403218\",\"https://openalex.org/W4226062002\",\"https://openalex.org/W4283809381\",\"https://openalex.org/W4291721232\",\"https://openalex.org/W4296888858\",\"https://openalex.org/W4298087471\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4379095570\",\"https://openalex.org/W4384925625\",\"https://openalex.org/W4385396235\",\"https://openalex.org/W4386021334\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387473380\",\"https://openalex.org/W4388603987\",\"https://openalex.org/W4389392873\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4405638624\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066710208\",\"display_name\":\"Anton L.V. Avanceña\",\"orcid\":\"https://orcid.org/0000-0002-4903-870X\"},{\"id\":\"https://openalex.org/A5016155904\",\"display_name\":\"Linh N. Vuong\",\"orcid\":null},{\"id\":\"https://openalex.org/A5052308665\",\"display_name\":\"James G. Kahn\",\"orcid\":\"https://orcid.org/0000-0002-1259-7233\"},{\"id\":\"https://openalex.org/A5010247183\",\"display_name\":\"Elliot Marseille\",\"orcid\":\"https://orcid.org/0000-0001-8518-1143\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S163345920\",\"source_display_name\":\"Translational Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1038/s41398-025-03556-4\",\"is_oa\":true}}", "topic_tags": "Depression,Receptor Pharmacology,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413817374" }, { "id": 361, "title": "Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial", "normalized_title": "investigating the safety and tolerability of single dose psilocybin for post traumatic stress disorder a nonrandomized open label clinical trial", "authors": "Niall M. McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Nadav Liam Modlin, Hollie Simmons, Agata Tofil-Kaluza, Shriya Das, Guy M. Goodwin", "abstract": "Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being studied for use in treatment-resistant depression but has not yet been investigated in PTSD. Aims: The trial’s primary outcome was to investigate the safety and tolerability of single-dose psilocybin in participants with PTSD. Methods: This was a Phase 2, nonrandomized, open-label, multicenter trial. Secondary outcomes were changes in PTSD symptoms (Clinician-Administered PTSD Scale for DSM-5 (CAPS-5); PTSD Checklist for DSM-5 (PCL-5)), functional impairment (Sheehan Disability Scale; SDS) and quality of life (EQ-5D-5L index score). Results: Amongst the 22 participants enrolled (63.6% female; mean (SD) age, 39.0 (7.91) years), there was a total of 117 treatment-emergent adverse events (TEAEs); 70 (59.8%) were reported on administration day, of which 64/70 (91.4%) resolved by the end of the next day. TEAEs commonly included headache ( n = 11; 50.0%), nausea ( n = 8; 36.4%), crying ( n = 6; 27.3%) and fatigue ( n = 6; 27.3%). There were no serious TEAEs or TEAEs leading to study withdrawal. Pre-post comparisons indicated a clinically meaningful change from Baseline in mean CAPS-5 total score at Week 4 (−29.9 (14.06)) and Week 12 (−29.5 (15.43)), which was associated with the intensity of psychedelic experience on Day 1. PCL-5 scores showed symptom reduction was rapid and sustained until Week 12. SDS total score and EQ-5D-5L index score showed similar improvements. Conclusions: Psilocybin at a dose of 25 mg, administered with psychological support, may be safe, well-tolerated and associated with symptomatic improvement in adults with PTSD. Further investigation is warranted. Clinical trial registration: ClinicalTrials.gov Identifier: NCT05312151 (https://clinicaltrials.gov/study/NCT05312151)", "journal": "Journal of Psychopharmacology", "publication_date": "2025-08-28", "publication_year": 2025, "doi": "10.1177/02698811251362390", "pubmed_id": "40883964", "source_url": "https://doi.org/10.1177/02698811251362390", "keywords": "Tolerability, Psilocybin, Open label, Traumatic stress, Psychology, Medicine, Clinical trial, Hallucinogen, Anesthesia, Psychiatry, Pharmacology, Adverse effect, Internal medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413839750\",\"openalex_url\":\"https://openalex.org/W4413839750\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W78677904\",\"https://openalex.org/W1976447964\",\"https://openalex.org/W1979826898\",\"https://openalex.org/W1990166011\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2057489037\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2132981258\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2473786944\",\"https://openalex.org/W2550807593\",\"https://openalex.org/W2588077070\",\"https://openalex.org/W2592166393\",\"https://openalex.org/W2598895258\",\"https://openalex.org/W2604674575\",\"https://openalex.org/W2612417324\",\"https://openalex.org/W2766807714\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2899448494\",\"https://openalex.org/W2912922214\",\"https://openalex.org/W2912959213\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2948678705\",\"https://openalex.org/W2950709739\",\"https://openalex.org/W2961809588\",\"https://openalex.org/W2970546318\",\"https://openalex.org/W2991873828\",\"https://openalex.org/W2993548698\",\"https://openalex.org/W2994854287\",\"https://openalex.org/W3008102555\",\"https://openalex.org/W3041627357\",\"https://openalex.org/W3082872736\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3125332567\",\"https://openalex.org/W3127909847\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3171418018\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3197569079\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211189621\",\"https://openalex.org/W4224257950\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4282919933\",\"https://openalex.org/W4292737458\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4383186500\",\"https://openalex.org/W4386740988\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4390628394\",\"https://openalex.org/W4405528804\",\"https://openalex.org/W4405978092\"],\"authorships\":[{\"id\":\"https://openalex.org/A5062136892\",\"display_name\":\"Niall M. McGowan\",\"orcid\":\"https://orcid.org/0000-0001-8183-8558\"},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5088026153\",\"display_name\":\"Rachel Yehuda\",\"orcid\":\"https://orcid.org/0000-0001-8307-677X\"},{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5037169539\",\"display_name\":\"Nadav Liam Modlin\",\"orcid\":\"https://orcid.org/0000-0002-3900-4354\"},{\"id\":\"https://openalex.org/A5030406378\",\"display_name\":\"Hollie Simmons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119481589\",\"display_name\":\"Agata Tofil-Kaluza\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048446187\",\"display_name\":\"Shriya Das\",\"orcid\":\"https://orcid.org/0000-0002-3988-6326\"},{\"id\":\"https://openalex.org/A5037628078\",\"display_name\":\"Guy M. Goodwin\",\"orcid\":\"https://orcid.org/0000-0002-1426-2816\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251362390\",\"is_oa\":true}}", "topic_tags": "Depression,PTSD,Chronic Pain,Headache / Migraine,Pharmacology,Clinical Trial,Treatment-Resistant Depression,Healthcare Workers,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413839750" }, { "id": 3485, "title": "A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)", "normalized_title": "a phase 2 single site double blind placebo controlled randomized clinical trial with an open label extension phase to examine the safety subjective experiences acute effects and suitability of psilocybin combined with psychological support psi ps for military veterans and first responders with co occurring alcohol use disorder aud and posttraumatic stress disorder ptsd", "authors": "Nathan Brashares Sackett", "abstract": "This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD). Psychological support is defined as providing safety, reassurance, active listening, and empathetic presence during the drug administration session in a nondirective manner. We hypothesize that Psi-PS may provide a safe treatment for participants. The primary objective of study is to characterize the safety of psilocybin combined with psychological support (Psi-PS) for individuals with co-occurring alcohol use disorder (AUD) and PTSD. There is growing evidence suggesting that psychedelic drugs, when paired with therapy, may constitute a safe and effective form of treating a diverse range of psychopathological issues such as alcohol use disorder (AUD) and PTSD (Bogenschutz et al., 2015, 2022; Dakwar et al., 2020; Grabski et al., 2022; Mitchell et al., 2021, 2023). However, to date, no studies have explored any form of psychedelic-assisted therapy in the treatment of patients with co-occurring AUD and PTSD, despite high rates of comorbidity. This study will be the first of its kind to evaluate the safety of psilocybin paired with therapy to target symptoms of comorbid AUD and PTSD. Data derived from this clinical trial will help shed light on whether Psi-PS may be safe for those suffering from both PTSD and AUD. Taken together, we propose the following primary, secondary, and exploratory objectives: 1. Primary Objective: Characterize the safety of psilocybin combined with psychological support (Psi-PS) for participants during the drug administration session (DAS) while the drug's acute effects are ongoing, approximately 24 hours after the DAS when the drug's acute effects have subsided, and approximately one-week post-DAS. 2. Exploratory Objective: (1) Explore the subjective experiences of Psi-PS within approximately 24 hours following the DAS, i.e., when the drug's acute effects have subsided, approximately one-week following the DAS, and at follow-up at approximately three-months. (2) Assess acute effects of Psi-PS on a range of variables at baseline and weeks 1, 2, 4, 12, and 24 post-DAS; (3) Further, assess suitability at baseline and approximately 4-weeks post-DAS. This study is a single-site, double-blinded, placebo-controlled, randomized clinical trial with an open-label extension phase assessing safety in two conditions: 1. Psi-PS (psilocybin combined with psychological support); and 2. placebo and nondirective psychological support. The study will last approximately 26-32 weeks and is composed of two preparation sessions; one Drug Administration Session (DAS), where 25 mg of oral psilocybin (PEX010) or inert placebo (PCB2) is administered in a clinical setting with two facilitators present; and three integration sessions. Placebo conditions will receive the same psychological support but will receive an inert placebo. 4-weeks after DAS, the study will be unblinded and those who received placebo will be offered Psi-PS for the open-label extension phase, following the same procedures. The intended sample size for the study is approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD). Study drug shipments will arrive on-site pre randomized by the manufacturer, and double-blinding will be maintained throughout the study by using a placebo that is designed to have similar physical characteristics as the study drug. All participants will then be followed for a total of 6 months (24 weeks) following the DAS to assess durability of potential effects.", "journal": "ClinicalTrials.gov", "publication_date": "2025-08-27", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06853912", "keywords": "Alcohol Use Disorder (AUD), PTSD, Psilocybin 25 mg, PEX010, PYEX, Maltodextrin (Placebo), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06853912\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Addiction,Clinical Trial,Veterans,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4314, "title": "“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy", "normalized_title": "to have the encounter with our own finiteness in that existential way descriptions of existential experience in patients with cancer and major depression participating in psilocybin assisted group therapy", "authors": "Elise C. Tarbi, Skye A. Miner, Kabir Nigam, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Kimberly Roddy, James A. Tulsky, Manish Agrawal, Yvan Beaussant", "abstract": "Background: Cancer poses an existential threat for patients and caregivers. Psilocybin-assisted therapy (PAT) has emerged as a potential tool to meet these existential needs, yet little is known about how patients describe this element of their cancer journey, and how it might be affected by PAT, especially in the group therapy context. Purpose: To explore how patients with cancer and depression describe their existential journey through the experience of cancer and group PAT. Methods: Grounded in the Conceptual Model of Existential Experience in Adults with Advanced Cancer, this study is a qualitative analysis of existing data from semi-structured exit interviews with participants ( n = 28) of the psilocybin trial, “The Safety and Efficacy of Psilocybin in Cancer Patients with Major Depressive Disorder” (NCT04593563). This study uses a qualitative descriptive approach paired with template analysis to analyze interview transcripts. Results: Our analysis revealed three overarching themes: (1) Participants described cancer prompting a deepened lived understanding of their mortality, as well as a re-prioritization of their attention, relationships, and efforts; (2) Therapeutic intentions for participating in the PAT trial went beyond relief of depression and extended to gaining a new perspective toward existential worries and building spiritual resources; (3) Participants described the lasting effects of PAT as a healing, unfolding transformation, noting an enhanced sense of meaning, agency, aliveness, and connectedness. Discussion: Our findings provide important insights into the existential experiences of people with cancer and depression, as well as the potential role of PAT, in a novel group therapy context, in addressing existential suffering and fostering personal growth.", "journal": "Psychedelic Medicine", "publication_date": "2025-08-24", "publication_year": 2025, "doi": "10.1177/28314425251370303", "pubmed_id": null, "source_url": "https://doi.org/10.1177/28314425251370303", "keywords": "Existentialism, Psychotherapist, Cancer, Psychology, Perspective (graphical), Grounded theory, Qualitative research, Depression (economics), Psilocybin, Clinical psychology, Group psychotherapy, Meaning (existential), Psychiatry, Disease, Depressive symptoms, Qualitative analysis, Lived experience, Hermeneutics, Medicine, Intervention (counseling), Qualitative property, Clinical trial, Descriptive statistics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4414955208\",\"openalex_url\":\"https://openalex.org/W4414955208\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W79229537\",\"https://openalex.org/W140271714\",\"https://openalex.org/W1513859721\",\"https://openalex.org/W1891188267\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W2043673361\",\"https://openalex.org/W2060831503\",\"https://openalex.org/W2066061643\",\"https://openalex.org/W2068374682\",\"https://openalex.org/W2072384652\",\"https://openalex.org/W2121824844\",\"https://openalex.org/W2122328334\",\"https://openalex.org/W2125531802\",\"https://openalex.org/W2133094746\",\"https://openalex.org/W2138664283\",\"https://openalex.org/W2145853206\",\"https://openalex.org/W2158106196\",\"https://openalex.org/W2159165123\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166928505\",\"https://openalex.org/W2166934228\",\"https://openalex.org/W2524597629\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2571392308\",\"https://openalex.org/W2582406074\",\"https://openalex.org/W2585294071\",\"https://openalex.org/W2605759386\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2735924837\",\"https://openalex.org/W2889204985\",\"https://openalex.org/W2896551863\",\"https://openalex.org/W2904473517\",\"https://openalex.org/W2924682096\",\"https://openalex.org/W2942349161\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W2978054736\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3020531320\",\"https://openalex.org/W3084639663\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W3163199090\",\"https://openalex.org/W3196833323\",\"https://openalex.org/W3197981896\",\"https://openalex.org/W3210030168\",\"https://openalex.org/W3216164364\",\"https://openalex.org/W4200517619\",\"https://openalex.org/W4205553396\",\"https://openalex.org/W4207017214\",\"https://openalex.org/W4207020267\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4254202988\",\"https://openalex.org/W4282972140\",\"https://openalex.org/W4294884042\",\"https://openalex.org/W4312196530\",\"https://openalex.org/W4313201591\",\"https://openalex.org/W4320491739\",\"https://openalex.org/W4362471767\",\"https://openalex.org/W4386494423\",\"https://openalex.org/W4389895437\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4393278287\",\"https://openalex.org/W4401554225\",\"https://openalex.org/W4405599715\",\"https://openalex.org/W4405955623\",\"https://openalex.org/W4407174917\",\"https://openalex.org/W4408185841\"],\"authorships\":[{\"id\":\"https://openalex.org/A5017118759\",\"display_name\":\"Elise C. Tarbi\",\"orcid\":\"https://orcid.org/0000-0003-2452-6632\"},{\"id\":\"https://openalex.org/A5076256339\",\"display_name\":\"Skye A. Miner\",\"orcid\":\"https://orcid.org/0000-0002-8848-2440\"},{\"id\":\"https://openalex.org/A5053570913\",\"display_name\":\"Kabir Nigam\",\"orcid\":\"https://orcid.org/0000-0002-1880-0079\"},{\"id\":\"https://openalex.org/A5064982845\",\"display_name\":\"Zachary Sager\",\"orcid\":\"https://orcid.org/0000-0001-8209-9582\"},{\"id\":\"https://openalex.org/A5063712330\",\"display_name\":\"Justin J. Sanders\",\"orcid\":\"https://orcid.org/0000-0001-8928-4051\"},{\"id\":\"https://openalex.org/A5071091088\",\"display_name\":\"Michael Ljuslin\",\"orcid\":\"https://orcid.org/0000-0002-2386-1749\"},{\"id\":\"https://openalex.org/A5052182950\",\"display_name\":\"Benjamin Guérin\",\"orcid\":\"https://orcid.org/0000-0002-0141-7874\"},{\"id\":\"https://openalex.org/A5093431923\",\"display_name\":\"Kimberly Roddy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014360467\",\"display_name\":\"James A. Tulsky\",\"orcid\":\"https://orcid.org/0000-0002-7458-0453\"},{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5063328366\",\"display_name\":\"Yvan Beaussant\",\"orcid\":\"https://orcid.org/0000-0003-3716-6736\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/28314425251370303\",\"is_oa\":false}}", "topic_tags": "Depression,Spirituality,Clinical Trial,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4414955208" }, { "id": 561, "title": "Psychedelics and the Serotonin Hypothesis of Eating Disorders.", "normalized_title": "psychedelics and the serotonin hypothesis of eating disorders", "authors": "Bilenker D, Avena NM.", "abstract": "Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive and behavioral rigidity. This review examines the rationale for using serotonergic psychedelics-particularly 5-HT2A receptor agonists such as psilocybin-in the treatment of eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). The paper contextualizes these interventions within the broader serotonin hypothesis of EDs, emphasizing serotonergic dysregulation and impaired cognitive flexibility as central features of these conditions. Drawing from animal models, human neuroimaging studies, and emerging clinical trials, the authors outline how psychedelics may promote neuroplasticity and psychological insight through modulation of 5-HT2A signaling. Preliminary evidence from open-label studies suggests psilocybin may improve ED symptoms and quality of life, though findings are early and methodologically limited. The paper also reviews data on ayahuasca, MDMA, and non-psychedelic serotonergic agents, highlighting both the promise and complexity of psychedelic-assisted therapy in EDs. The authors conclude that while further controlled trials are needed to clarify efficacy, safety, and optimal treatment parameters, psychedelics offer a novel, mechanistically distinct avenue for addressing entrenched ED psychopathology.", "journal": null, "publication_date": "2025-08-20", "publication_year": 2025, "doi": "10.3390/brainsci15080893", "pubmed_id": "40867224", "source_url": "https://doi.org/10.3390/brainsci15080893", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"40867224\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Neuroplasticity,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3557, "title": "Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study", "normalized_title": "effect of psilocybin on the positive valence system in treatment resistant depression a pilot clinical neuroimaging study", "authors": "Centre Hospitalier Universitaire de Nīmes", "abstract": "The study hypothesis is that the antidepressant effect of psilocybin is mediated by a normalization of the functioning of the positive valence system. Depressive states, especially moderate to severe depressions that associate a certain level of anhedonia, produce an overvaluation of the cost of efforts and an infra-evaluation of the possible rewards derived from an action. Psilocybin would reduce anhedonia and the cost of efforts, facilitating the anticipation of reward. Thus, the antidepressant effect of psilocybin would be mediated by a greater anticipation of rewards (reduction of anhedonia) and a more optimistic estimation of the results of efforts (increase in motivation). Psilocybin-induced changes in the positive valence system will be observable on brain MRI images, particularly in the effort evaluation circuits: basolateral amygdala, dorsal anterior cingulate cortex, ventral pallidum, ventral striatum (VS), ventral tegmental area (VTA). The mesolimbic circuit (VS, VTA) is the anatomical substrate of anticipation of rewarding stimuli (food, sex, drugs). The amygdala also fulfills an associative function between environmental cues and rewarding stimuli. Structural and functional alterations in this circuit are associated with depressive symptoms such as anhedonia or distortions in the perception and memories of rewards. This hypothesis will be tested on a population of patients with moderate or severe depressive symptoms who meet the criteria for TRD. Depressive disorders are strongly associated with suicide risk and are the leading cause of disability in the world. Psilocybin is a natural alkaloid with psychedelic and hallucinogenic effects, produced by its active metabolite: psilocin. In recent years, there has been a resurgence of research aimed at using psilocybin in the treatment of psychiatric disorders, and in particular depression, combined or not with various psychotherapeutic programs. Psilocybin-assisted therapy is effective in treating cancer-associated depression and resistant depression. The Federal Drug Administration (FDA) has designated it as a \"Breakthrough Therapy\" in the treatment of treatment-resistant depression (TRD). Most researchers consider that the antidepressant effects of psilocybin are associated with the activation of the serotonin 5-HT2a receptor, with acute neuromodulation effects that modify the connectivity of cortico-striatal loops, but the mechanisms supporting this effect are unknown. The purpose of this study is to verify whether the antidepressant action of psilocybin is associated with an activation of the brain areas involved in the positive valence system, by comparing the activity of the neural circuits responsible for the evaluation of effort before and after taking psilocybin. The correlations between the activation of brain areas and the depression severity, behavioral activation and anhedonia scores will help establish a link with the response to treatment. Finally, the study authors wish to test the feasibility of a study with psilocybin in a French clinical population.", "journal": "ClinicalTrials.gov", "publication_date": "2025-08-19", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06650800", "keywords": "Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens, Reinforcement, Psychology, Psilocybin, MRI, COMPLETED", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06650800\",\"overall_status\":\"COMPLETED\",\"phase\":[\"NA\"]}", "topic_tags": "Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 459, "title": "Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians.", "normalized_title": "psilocybin assisted psychotherapy combined antipsychotic and antidepressant treatment for bipolar depression duration of birth control pill use and risk of depression handgrip strength and cognitive function mood disorders in epilepsy and mental health issues among physicians", "authors": "Koenig HG.", "abstract": "", "journal": null, "publication_date": "2025-08-19", "publication_year": 2025, "doi": "10.1177/00912174251369880", "pubmed_id": "40833259", "source_url": "https://doi.org/10.1177/00912174251369880", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40833259\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3466, "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder", "normalized_title": "a phase ii multicentre randomised double blind controlled study to investigate the safety tolerability pharmacokinetics and efficacy of comp360 in participants with recurrent major depressive disorder", "authors": "COMPASS Pathways", "abstract": "Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder. This is a phase II, multi-centre, randomised, double-blind, controlled study. The study population will include participants aged ≥18 years with recurrent Major Depressive Disorder (MDD) with up to four prior treatment failures of an antidepressant in their current depressive episode. Overall, 102 participants will be randomised in a 1:1:1 ratio to receive COMP360 25 mg, COMP360 10mg or COMP360 1 mg. In this study the aim is to investigate the safety and tolerability of COMP360, administered with psychological support, in adult participants with MDD with one prior treatment failure. In addition, pharmacokinetics and efficacy of COMP360 will be investigated. The study will last up to 16 weeks including a three- to ten-week Screening Period and a six-week follow-up from investigational product (IP) administration.", "journal": "ClinicalTrials.gov", "publication_date": "2025-08-18", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05733546", "keywords": "Major Depressive Disorder, Psilocybin, COMP360, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05733546\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3307, "title": "Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis", "normalized_title": "attitudes toward psychedelic assisted therapies for cancer related psychosocial symptoms a multi stakeholder analysis", "authors": "Schuman HD, Deleemans JM, Nguyen T, Savard C, Mina R, Carlson LE.", "abstract": "Abstract Background Psychedelic-assisted therapy (PAT) is gaining attention as a potential treatment for cancer-related psychosocial symptoms. While growing evidence highlights its promise, little is known about how different stakeholder groups perceive its use in oncology and palliative care. Objectives This study aimed to assess stakeholder-specific perspectives on PAT, including attitudes, perceived knowledge, agent-specific beliefs, safety and effectiveness, implementation barriers, and interest in training and access. Predictors of positive attitudes were also examined. Methods A national cross-sectional survey was conducted across Canada. Measures included the Attitudes to Psychedelics Questionnaire (APQ), self-rated knowledge, perceived effectiveness and safety of psychedelic agents, implementation barriers, and views on appropriate patient populations. Group comparisons were conducted using Kruskal-Wallis tests, ANOVA, and post hoc analyses; multivariate linear regression identified predictors of attitudes. Results A total of 742 participants were included: cancer patients (PLWC; n = 519), healthcare providers (HCP; n = 187), and policymakers (PM; n = 36). PLWC reported the most favourable attitudes toward PAT, significantly higher than both HCP and PM. Despite their positive views, PLWC self-reported the lowest knowledge. PM reported the highest perceived knowledge but also the greatest safety concerns. Across all groups, psilocybin was viewed as the most effective agent. PLWC and HCP supported PAT use across the cancer continuum, while most PM favoured restricting use to advanced-stage cases. Conclusion Stakeholder perspectives on PAT reveal high interest tempered by role-specific concerns about safety, legitimacy, and readiness. Effective and ethical integration of PAT into oncology will require stakeholder-informed education, regulatory guidance, and attention to contextual implementation needs.", "journal": "Research Square", "publication_date": "2025-08-18", "publication_year": 2025, "doi": "10.21203/rs.3.rs-6941009/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-6941009/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:50", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"PPR1070146\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "End-of-Life Distress,Observational Study,Cancer Patients,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 418, "title": "Exploring the therapeutic potential of psychedelics in treating substance use disorders.", "normalized_title": "exploring the therapeutic potential of psychedelics in treating substance use disorders", "authors": "Li Y, Li H, Wang H, Wang X.", "abstract": "Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of psychedelics in SUDs therapy, highlighting their ability to disrupt maladaptive neural circuits, promote neuroplasticity, and facilitate profound psychological insights that address the root causes of SUDs. Clinical trials demonstrate promising results across various forms of SUDs, with psilocybin-assisted therapy showing significant reductions in substance use and improved mental health outcomes. Despite the potential, challenges such as legal barriers, safety concerns, and the need for more rigorous research remain. The future of psychedelics in SUDs treatment is cautiously optimistic, with the possibility of transforming the field of SUDs therapy and offering hope to millions of individuals struggling with SUDs.", "journal": null, "publication_date": "2025-08-18", "publication_year": 2025, "doi": "10.1038/s41380-025-03168-w", "pubmed_id": "40830580", "source_url": "https://doi.org/10.1038/s41380-025-03168-w", "keywords": "Animals, Humans, Substance-Related Disorders, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"40830580\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Neuroplasticity,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3070, "title": "Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource", "normalized_title": "psilocybin treatment for symptoms of depression a living systematic review meta analysis and data resource", "authors": "Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD.", "abstract": "Importance Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment. Objective To conduct a systematic review and meta-analysis of psilocybin’s impact on depressive symptoms and provide a living open data resource. Data Sources PubMed, Embase, Scopus, Web of Science, and PsycINFO retrieved by a systematic search up to July 1, 2025. Study Selection We included randomized controlled trials of psilocybin or psilocybin-assisted therapy compared against a placebo or waitlist condition. Data Extraction and Synthesis Data extraction was completed independently by two extractors. A random-effects meta-analysis was used to synthesize data. Risk of bias was assessed with Cochrane’s RoB 2.0 tool. Main Outcomes and Measures The main outcome was the standardized mean difference (Hedges’ g ) in depression scores at the primary study endpoint. Results Twelve studies comprising 711 participants were included in the database, with nine of those studies (n = 529) included in our primary model. Of the nine studies included in the primary model, two had a high risk of bias, four had some concerns, while three had a low risk of bias. Compared to control conditions, psilocybin showed a greater reduction in depression scores, with a pooled Hedges’ g = -0.91 (95% CI, [-1.35; -0.48]; k = 9; p = 0.0013, I2 = 58.1%, tau 2 = 0.13, n = 501). Sensitivity analyses revealed robust effects consistent with the primary model across a variety of design parameters and analysis choices, while also suggesting that waitlist control and crossover design studies contribute a large amount of heterogeneity to the primary model. Meta-regression revealed that psilocybin’s effects were rapid and consistent over several weeks (intercept = -0.92 [-1.26; -0.58], p < 0.0001; slope = 0.0009 [-0.0023; 0.0041], p = 0.57). Conclusions and Relevance This systematic review and meta-analysis suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date. However, many studies have small sample sizes or risk of bias. This living systematic review, meta-analysis, database, and online dashboard will continue to be updated as evidence emerges, providing a valuable resource for researchers in a rapidly evolving field. Key Points Question What is the efficacy of psilocybin or psilocybin-assisted therapy for depressive symptoms? Findings In this living systematic review and meta-analysis, the initial evidence suggests that psilocybin is more effective in reducing depression symptoms compared to control conditions. Our publicly released database and interactive dashboard contains over 200 effect sizes from 12 randomized clinical trials testing psilocybin’s impacts on depression and will be updated regularly to keep pace with this rapidly moving field. Meaning The current evidence suggests promise for psilocybin therapy for depression, though more studies are needed.", "journal": "medRxiv", "publication_date": "2025-08-15", "publication_year": 2025, "doi": "10.1101/2025.08.13.25333530", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.08.13.25333530", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1068501\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 519, "title": "Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome.", "normalized_title": "therapeutic divergence in 5 ht2a agonism psilocybin and phenalkylamines for demoralization syndrome", "authors": "Kargbo RB.", "abstract": "Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as rational therapeutics for demoralization syndrome and depression-related conditions.", "journal": null, "publication_date": "2025-08-14", "publication_year": 2025, "doi": "10.1021/acsmedchemlett.5c00475", "pubmed_id": "40959252", "source_url": "https://doi.org/10.1021/acsmedchemlett.5c00475", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40959252\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 530, "title": "Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial", "normalized_title": "psilocybin assisted psychotherapy for depression and anxiety associated with life threatening illness a phase 2b randomized controlled trial", "authors": "Margaret Ross, Ravi Iyer, M.L. Williams, Mark Boughey, Clare O’Callaghan, Richard Hiscock, Justin Dwyer", "abstract": "IMPORTANCE: Psilocybin-assisted psychotherapy may offer a novel approach to treating depression, anxiety, and existential distress in individuals with life threatening illnesses, where current treatments show limited efficacy. OBJECTIVE: To evaluate the efficacy and safety of psilocybin-assisted psychotherapy versus active placebo and psychotherapy in adults with life-threatening illnesses. DESIGN: Double-blind, randomized controlled phase 2b trial (RCT) with an open-label extension and 6-month follow-up (January 2020 - October 2023). SETTING: Single-site study at a tertiary hospital's palliative care department (St. Vincent's Hospital Melbourne affiliated with the University of Melbourne). PARTICIPANTS: Adults aged 18-80 with a life-threatening illness and clinically significant depression and/or anxiety. INTERVENTIONS: Participants were randomized to receive 25 mg psilocybin or 100 mg niacin (active placebo), alongside three preparatory psychotherapy and six post-dose integration psychotherapy sessions. After 6-7 weeks post double blind dose, all participants received 25 mg psilocybin in an open-label extension, enabling a two dose versus one dose group comparator. Participants were followed up to 26 weeks post open label dose. MAIN OUTCOMES AND MEASURES: Primary outcome was change in depression and anxiety symptoms, assessed using the Hospital Anxiety and Depression Scale (HADS), from baseline to 6-7 weeks post-dose. Key secondary outcomes included the Beck Depression Inventory-II (BDI-II) and the State-Trait Anxiety Inventory - State version (STAI-S), which provided complementary, dimensional measures of depression and anxiety over the same time period. Additional secondary outcomes included Death Attitudes Profile, WHOQOL-BREF, State-Trait Anxiety Inventory (STAI-Trait scale), Mystical Experiences Questionnaire, and Persisting Effects Questionnaire. Exploratory outcomes included spiritual well-being, hopelessness, demoralization, and HADS-Trait scores. RESULTS: Thirty-five participants (mean age 56.0; 54.3 % female) were randomized (psilocybin: n = 17; placebo: n = 18). At 6-7 weeks, psilocybin produced significantly greater reductions in HADS depression (B = -2.49; P =.02; d = 1.12), BDI-II (B = -7.56; P =.004; d = 2.97), and STAI-State anxiety (B = -12.59; P =.005; d = 4.51) compared to placebo. Benefits were sustained at 26 weeks. Exploratory outcomes demonstrated enhanced spiritual well-being, quality of life, and significant reductions in demoralization, death anxiety and hopelessness. No serious treatment-emergent adverse events occurred. Psilocybin was associated with more mild-to-moderate adverse events. One participant withdrew due to anxiety during dosing. CONCLUSIONS AND RELEVANCE: Psilocybin-assisted psychotherapy appears safe and may offer durable relief from depression and anxiety in individuals with a life-threatening illness.", "journal": "General Hospital Psychiatry", "publication_date": "2025-08-11", "publication_year": 2025, "doi": "10.1016/j.genhosppsych.2025.08.001", "pubmed_id": "40858059", "source_url": "https://doi.org/10.1016/j.genhosppsych.2025.08.001", "keywords": "Psilocybin, Randomized controlled trial, Psychotherapist, Anxiety, Depression (economics), Psychology, Psychiatry, Clinical psychology, Hallucinogen, Medicine, Internal medicine, Economics, Macroeconomics, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413190735\",\"openalex_url\":\"https://openalex.org/W4413190735\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W362134011\",\"https://openalex.org/W1201749067\",\"https://openalex.org/W1966158258\",\"https://openalex.org/W1973763578\",\"https://openalex.org/W1976139656\",\"https://openalex.org/W1981066923\",\"https://openalex.org/W2020401373\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2027521838\",\"https://openalex.org/W2050729893\",\"https://openalex.org/W2082535915\",\"https://openalex.org/W2091131778\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2137699706\",\"https://openalex.org/W2144458512\",\"https://openalex.org/W2149564130\",\"https://openalex.org/W2155116701\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166281097\",\"https://openalex.org/W2169423683\",\"https://openalex.org/W2186868318\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2744073746\",\"https://openalex.org/W2896126560\",\"https://openalex.org/W2914765137\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3080413193\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W4251745849\",\"https://openalex.org/W4298863066\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4409987891\",\"https://openalex.org/W6634064335\",\"https://openalex.org/W6768352301\",\"https://openalex.org/W6880021014\"],\"authorships\":[{\"id\":\"https://openalex.org/A5101561809\",\"display_name\":\"Margaret Ross\",\"orcid\":null},{\"id\":\"https://openalex.org/A5031895165\",\"display_name\":\"Ravi Iyer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5010417984\",\"display_name\":\"M.L. Williams\",\"orcid\":\"https://orcid.org/0000-0002-9483-3008\"},{\"id\":\"https://openalex.org/A5026860370\",\"display_name\":\"Mark Boughey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5068658663\",\"display_name\":\"Clare O’Callaghan\",\"orcid\":\"https://orcid.org/0000-0002-3180-2781\"},{\"id\":\"https://openalex.org/A5065396072\",\"display_name\":\"Richard Hiscock\",\"orcid\":\"https://orcid.org/0000-0001-5375-041X\"},{\"id\":\"https://openalex.org/A5008902505\",\"display_name\":\"Justin Dwyer\",\"orcid\":\"https://orcid.org/0000-0001-6922-6508\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S45708651\",\"source_display_name\":\"General Hospital Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/j.genhosppsych.2025.08.001\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Chronic Pain,Wellbeing,Spirituality,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413190735" }, { "id": 567, "title": "Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.", "normalized_title": "psychedelic assisted therapy potential benefits and challenges in mental health treatment", "authors": "Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A.", "abstract": "Psychedelics, derived from the Greek words \"psyche\" (soul) and \"deloun\" (revealing), are substances historically and currently considered \"soul-revealing\". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as 3,4-methylenedioxymethamphetamine (MDMA); and dissociatives, such as phencyclidine (PCP) and ketamine. The concept of using these substances to enhance psychotherapy emerged in the 1940s, leading to the first wave of psychedelic research, which yielded promising initial results. Following a period of restricted research, modern investigations began anew around 20 years ago. In this review, we analyze the last 10 years of research, exploring the potential of psychedelics in psychotherapy. Current evidence reveals that psychedelic-assisted psychotherapy remains an experimental approach. While preliminary studies suggest potential therapeutic benefits in treating various conditions, including depression, post-traumatic stress disorder, obsessive-compulsive disorder, and substance use disorders, a definitive assessment of efficacy and safety is hampered by the scarcity of large-scale, rigorous clinical trials. Psychedilics should rather be viewed as integral components of broader therapeutic frameworks than as standalone treatment. The unique mechanisms of psychedelics, notably their effect on neuroplasticity, hint at the potential to address treatment gaps in patients unresponsive to conventional methods. However, this potential requires validation through larger, more rigorously designed studies. Future research must prioritize high-quality, randomized, double-blind, placebo-controlled trials encompassing diverse populations to produce reliable, generalizable findings and ensure responsible clinical implementation. The aim of this article is to review the current status of psychedelic-assisted psychotherapy.", "journal": null, "publication_date": "2025-08-08", "publication_year": 2025, "doi": "10.12659/msm.948302", "pubmed_id": "40781763", "source_url": "https://doi.org/10.12659/msm.948302", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Mental Health, Mental Disorders, Psychotherapy", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40781763\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,OCD,Neuroplasticity,Mechanism of Action,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 566, "title": "Psychedelics and Headache Disorders: an Update.", "normalized_title": "psychedelics and headache disorders an update", "authors": "Im JJH, Sandoe CH", "abstract": "Psychedelics are often queried as a potential therapeutic option in a multitude of conditions, including pain and mental health disorders, with a growing body of patient reports and scientific publications describing potential benefit. This article reviews recent research on psychedelic compounds for treatment of headache disorders. Observational data, case reports, and a few recent small, controlled trials suggest symptom benefit at sub-hallucinogenic doses for both migraine and cluster headache. There have not been new completed studies of psychedelics in other headache disorders. Safety signals also tend to be favorable, although there are continuing concerns for systemic and psychiatric effects in varying doses, preparations and clinical contexts. While available studies on psychedelics suggest potential benefit in cluster headache and migraine, access remains complex due to legal considerations, and additional studies are needed to confirm their effectiveness and to ensure safety before they can be recommended for use.", "journal": "Current neurology and neuroscience reports", "publication_date": "2025-08-08", "publication_year": 2025, "doi": "10.1007/s11910-025-01446-2", "pubmed_id": "40782223", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40782223/", "keywords": "Cluster headache, DMT, Headache, LSD, Migraine, Psilocybin, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40782223\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Review Article,Case Report,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 417, "title": "Between enhancement and risk: A critical review of psychedelic microdosing.", "normalized_title": "between enhancement and risk a critical review of psychedelic microdosing", "authors": "Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC.", "abstract": "Microdosing psychedelics, the regular use of low doses of LSD or psilocybin, have attracted growing public and scientific interest. This review synthesizes findings from 57 human studies on psychological and physiological outcomes in clinical and non-clinical populations. Reported benefits include improved mood, enhanced cognition, social functioning, and mental health, although findings are inconsistent and largely self-reported. Adverse effects such as anxiety, physical discomfort, and cognitive disruption are also frequently reported. Outcomes appear to be highly individual and shaped by user expectations, context, and baseline state. Notably, many experimental studies focus on the acute effects of single low doses, whereas observational studies reflect repeated use and generally report more benefits, while experimental trials tend to yield more null findings. Differences between observational and experimental findings highlight the need for rigorous, placebo-controlled research. While microdosing shows potential in some studies, current evidence remains inconclusive and warrants caution.", "journal": null, "publication_date": "2025-08-05", "publication_year": 2025, "doi": "10.1016/j.copsyc.2025.102129", "pubmed_id": "40834796", "source_url": "https://doi.org/10.1016/j.copsyc.2025.102129", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Affect, Cognition, Dose-Response Relationship, Drug, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40834796\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Microdosing,Review Article,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 574, "title": "Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models", "normalized_title": "neurobiology of psilocybin a comprehensive overview and comparative analysis of experimental models", "authors": "Dotun Adeleye Adeyinka, Dayna Forsyth, Suzanne Currie, Nicoletta Faraone", "abstract": "Psilocybin, a compound found in Psilocybe mushrooms, is emerging as a promising treatment for neurodegenerative and psychiatric disorders, including major depressive disorder. Its potential therapeutic effects stem from promoting neuroprotection, neurogenesis, and neuroplasticity, key factors in brain health. Psilocybin could help combat mild neurodegeneration by increasing synaptic density and supporting neuronal growth. With low risk for addiction and adverse effects, it presents a safe option for long-term use, setting it apart from traditional treatments. Despite their relatively simpler neuronal networks, studies using animal models, such as Drosophila and fish, have provided essential insights on the efficacy and mechanism of action of psilocybin. These models provide foundational information that guides more focused investigations, facilitating high-throughput screening, enabling researchers to quickly explore the compound’s effects on neural development, behavior, and underlying genetic pathways. While mammalian models are indispensable for comprehensive studies on psilocybin’s pharmacokinetics and its nuanced interactions within the complex nervous systems, small non-mammalian models remain valuable for identifying promising targets and mechanisms at early research stages. Together, these animal systems offer a complementary approach to drive rapid hypothesis generation to refine our understanding of psilocybin as a candidate for not only halting but potentially reversing neurodegenerative processes. This integrative strategy highlights the transformative potential of psilocybin in addressing neurodegenerative disorders, leveraging both small and mammalian models to achieve translational research success.", "journal": "Frontiers in Systems Neuroscience", "publication_date": "2025-08-04", "publication_year": 2025, "doi": "10.3389/fnsys.2025.1585367", "pubmed_id": "40894380", "source_url": "https://doi.org/10.3389/fnsys.2025.1585367", "keywords": "Psilocybin, Neuroscience, Cognitive science, Computer science, Psychology, Hallucinogen, Psychiatry, Psychedelics and Drug Studies, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4413969371\",\"openalex_url\":\"https://openalex.org/W4413969371\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W1518589663\",\"https://openalex.org/W1615535881\",\"https://openalex.org/W1695265315\",\"https://openalex.org/W1912701812\",\"https://openalex.org/W1961057301\",\"https://openalex.org/W1963722081\",\"https://openalex.org/W1967913887\",\"https://openalex.org/W1974109667\",\"https://openalex.org/W1974195654\",\"https://openalex.org/W1982006269\",\"https://openalex.org/W1983617759\",\"https://openalex.org/W1990568540\",\"https://openalex.org/W1997901204\",\"https://openalex.org/W1998613952\",\"https://openalex.org/W1999981396\",\"https://openalex.org/W2003847756\",\"https://openalex.org/W2004739431\",\"https://openalex.org/W2007326167\",\"https://openalex.org/W2007816528\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2014639769\",\"https://openalex.org/W2018733374\",\"https://openalex.org/W2019751519\",\"https://openalex.org/W2024868516\",\"https://openalex.org/W2024880767\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2041024018\",\"https://openalex.org/W2045435533\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2048184801\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2048557710\",\"https://openalex.org/W2051423370\",\"https://openalex.org/W2054193501\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2060870711\",\"https://openalex.org/W2064815984\",\"https://openalex.org/W2066231855\",\"https://openalex.org/W2071010015\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2084567915\",\"https://openalex.org/W2089049622\",\"https://openalex.org/W2089427933\",\"https://openalex.org/W2091245663\",\"https://openalex.org/W2091365260\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2097146701\",\"https://openalex.org/W2102589238\",\"https://openalex.org/W2102963347\",\"https://openalex.org/W2105356326\",\"https://openalex.org/W2105581244\",\"https://openalex.org/W2106013076\",\"https://openalex.org/W2107103572\",\"https://openalex.org/W2110643873\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114398700\",\"https://openalex.org/W2117090355\",\"https://openalex.org/W2119307393\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2133518193\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2153664306\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2161201097\",\"https://openalex.org/W2162700737\",\"https://openalex.org/W2166041737\",\"https://openalex.org/W2168821442\",\"https://openalex.org/W2170596036\",\"https://openalex.org/W2176277585\",\"https://openalex.org/W2178951179\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2262324247\",\"https://openalex.org/W2291443053\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2460061147\",\"https://openalex.org/W2499216663\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2508085936\",\"https://openalex.org/W2531905773\",\"https://openalex.org/W2542493272\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2553251493\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2566791353\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2587774385\",\"https://openalex.org/W2607000919\",\"https://openalex.org/W2621520215\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2794118706\",\"https://openalex.org/W2801092899\",\"https://openalex.org/W2802085513\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2911274412\",\"https://openalex.org/W2913614159\",\"https://openalex.org/W2919287201\",\"https://openalex.org/W2974412836\",\"https://openalex.org/W2999364864\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3027590463\",\"https://openalex.org/W3027721867\",\"https://openalex.org/W3091103931\",\"https://openalex.org/W3093454394\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3120731146\",\"https://openalex.org/W3128189719\",\"https://openalex.org/W3135237636\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3164067847\",\"https://openalex.org/W3164491540\",\"https://openalex.org/W3166891936\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3208900810\",\"https://openalex.org/W4205579585\",\"https://openalex.org/W4210332402\",\"https://openalex.org/W4210445058\",\"https://openalex.org/W4210708011\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4211248987\",\"https://openalex.org/W4220928043\",\"https://openalex.org/W4239024596\",\"https://openalex.org/W4251541038\",\"https://openalex.org/W4282963889\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4304889343\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4311448180\",\"https://openalex.org/W4311853812\",\"https://openalex.org/W4313813443\",\"https://openalex.org/W4319298186\",\"https://openalex.org/W4362457938\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4390538163\",\"https://openalex.org/W4390951308\",\"https://openalex.org/W4392048822\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4400135509\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401344585\",\"https://openalex.org/W4402462242\",\"https://openalex.org/W4403450928\",\"https://openalex.org/W4405978077\",\"https://openalex.org/W4406845122\"],\"authorships\":[{\"id\":\"https://openalex.org/A5012825340\",\"display_name\":\"Dotun Adeleye Adeyinka\",\"orcid\":\"https://orcid.org/0000-0002-7065-4830\"},{\"id\":null,\"display_name\":\"Dayna Forsyth\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091764470\",\"display_name\":\"Suzanne Currie\",\"orcid\":\"https://orcid.org/0000-0002-7734-7200\"},{\"id\":\"https://openalex.org/A5025284474\",\"display_name\":\"Nicoletta Faraone\",\"orcid\":\"https://orcid.org/0000-0002-9246-3672\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S97434221\",\"source_display_name\":\"Frontiers in Systems Neuroscience\",\"landing_page_url\":\"https://doi.org/10.3389/fnsys.2025.1585367\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Neuroplasticity,Neurogenesis,Pharmacology,Mechanism of Action,Aging,Animal Study,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4413969371" }, { "id": 3265, "title": "631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS", "normalized_title": "631 psilocybin and ketanserin vs rtms in treatment resistant depression enhancing tolerability by mitigating psychedelic effects", "authors": "", "abstract": "", "journal": null, "publication_date": "2025-07-31", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC12359594", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PMC12359594\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 582, "title": "Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.", "normalized_title": "treatment approaches and efficacy in psychedelic induced psychosis a systematic review", "authors": "Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K, Böge K, Sentissi O, Kaiser S, Solmi M, Kirschner M, Sabé M", "abstract": "Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that can experience psychedelic-induced psychosis (", "journal": "Asian journal of psychiatry", "publication_date": "2025-07-31", "publication_year": 2025, "doi": "10.1016/j.ajp.2025.104604", "pubmed_id": "40614615", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40614615/", "keywords": "Antipsychotics, Hallucinogens, Haloperidol, LSD, Psilocybin, Psychosis, Risperidone", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40614615\"}", "topic_tags": "Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 599, "title": "Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.", "normalized_title": "psilocybin in the treatment of eating disorders a systematic review of the literature and registered clinical trials", "authors": "Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A.", "abstract": "BackgroundFluoxetine remains the only pharmacological treatment approved for Bulimia Nervosa, and no other drugs have been approved for eating disorders (EDs). The rationale for exploring psilocybin as a treatment for EDs is compelling, both from biological and psychological perspectives. Moreover, its safety profile in healthy individuals appears favorable. This systematic review aims to examine original research articles and registered clinical trials to assess the current psilocybin's therapeutic potential in EDs.MethodsSystematic review following the indications of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Excerpta Medica Database (EMBASE), and the Cochrane Library from inception until 29 July 2024, with key terms: \"psilocybin\" and \"eating disorders\". Quality was assessed through the Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group released by the National Heart, Lung, and Blood Institute (NHLBI). We performed an additional search on the registry of clinical trials available at the website https://clinicaltrials.gov.ResultsTwo studies met the inclusion criteria for our analysis. The first was an open-label feasibility study involving 10 individuals with Anorexia Nervosa (AN), without a control group. The second was a single case report describing the use of psilocybin in a person with AN. In addition, six registered clinical trials of psilocybin in individuals with EDs were identified.ConclusionsThe initial evidence shows that psilocybin might be safe and well-tolerated in AN. The promising results and the need for tests in enlarged samples encourage further research on psilocybin in EDs.Level of evidence viiiEvidence from nonrandomized controlled clinical trials, nonrandomized clinical trials, cohort studies, case series, case reports, and individual qualitative studies.", "journal": null, "publication_date": "2025-07-28", "publication_year": 2025, "doi": "10.1007/s40519-025-01771-y", "pubmed_id": "40730892", "source_url": "https://doi.org/10.1007/s40519-025-01771-y", "keywords": "Humans, Hallucinogens, Clinical Trials as Topic, Feeding and Eating Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40730892\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Case Report,Observational Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 602, "title": "Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial", "normalized_title": "psilocybin in alcohol use disorder and comorbid depressive symptoms results from a feasibility randomized clinical trial", "authors": "Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul A. Rochefort, Thibault Mura, Felix Sergent", "abstract": "BACKGROUND AND AIMS: Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin-assisted psychotherapy for patients with comorbid AUD and depression. DESIGN: A prospective, single-center, double-blind, parallel (2:1), randomized controlled pilot study. SETTING: The study was conducted in a French inpatient addiction treatment program offering intensive relapse prevention interventions. PARTICIPANTS: Of 350 screened patients, 30 adults (mean age 49 ± 10 years; 43% female) with severe AUD (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5] criteria) and a Beck Depression Inventory-II (BDI-II) score ≥14 were included. Participants had completed detoxification between 14 and 60 days prior to inclusion. INTERVENTIONS: Participants received either two oral sessions of 25 mg (n = 20) or 1 mg (n = 10) psilocybin-assisted psychotherapy spaced three weeks apart, as an add-on to standard care. Patients, investigators and outcome assessors were all blinded to patient group. MEASUREMENTS: The primary outcome was feasibility, according to participation in both dosing sessions and recruitment/inclusion rates. Secondary outcomes included alcohol use (Alcohol Timeline Followback), time to relapse, craving (Craving Experience Questionnaire), depression (BDI-II), safety and blinding integrity. FINDINGS: One participant in the 25 mg group could not receive the second dose due to myocardial infarction occurring three days earlier, unrelated to the treatment. Four participants in the control group refused the second session after guessing their group assignment (p-value = 0.019), with one participant self-administering 3,4-Methylenedioxymethamphetamine (MDMA). At 12 weeks, the 25 mg group showed significantly greater abstinent rate (11/20 (55%) vs 1/9 (11%) (one lost of follow up) (difference = -44%, [95% confidence interval [CI]: -82% to -5.9%]), p = 0.043), reductions in % drinking days -100 (-100 to -49) vs - 93 (-96 to 0), p = 0.038 and craving frequency -8 (-23 to -1) vs + 7 (-2 to 11), p = 0.045, respectively in the 25 vs 1 mg groups (median [25;75]). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 [0.16 to1.65]). No efficacy differences were observed based on antidepressant use in terms of drinking and depression. Blinding was imperfect (correct guess by patients: 93.3%; investigators: 86.7%). Twenty-five adverse events were reported in 10 patients (50%) in the 25 mg group versus 6 patients (60%) in the control group. CONCLUSIONS: Psilocybin-assisted psychotherapy appears feasible, acceptable, and safe in recently detoxified patients with comorbid alcohol use disorder and depression.", "journal": "Addiction", "publication_date": "2025-07-23", "publication_year": 2025, "doi": "10.1111/add.70152", "pubmed_id": "40702912", "source_url": "https://doi.org/10.1111/add.70152", "keywords": "Craving, Alcohol use disorder, Medicine, Psychiatry, Randomized controlled trial, Psilocybin, Relapse prevention, Depression (economics), Alcohol dependence, Beck Depression Inventory, Psychology, Addiction, Anxiety, Internal medicine, Alcohol, Hallucinogen, Macroeconomics, Economics, Biochemistry, Chemistry, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412642858\",\"openalex_url\":\"https://openalex.org/W4412642858\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":17,\"referenced_works\":[\"https://openalex.org/W1562803040\",\"https://openalex.org/W1931543427\",\"https://openalex.org/W1966468755\",\"https://openalex.org/W1992167600\",\"https://openalex.org/W1992292172\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2017039362\",\"https://openalex.org/W2019331539\",\"https://openalex.org/W2039804055\",\"https://openalex.org/W2043696067\",\"https://openalex.org/W2062907782\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2098462422\",\"https://openalex.org/W2116839388\",\"https://openalex.org/W2125478133\",\"https://openalex.org/W2139474630\",\"https://openalex.org/W2152696551\",\"https://openalex.org/W2161537987\",\"https://openalex.org/W2162097818\",\"https://openalex.org/W2165758561\",\"https://openalex.org/W2174561539\",\"https://openalex.org/W2285114321\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2763784955\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2890893449\",\"https://openalex.org/W2921670614\",\"https://openalex.org/W2944914295\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3046396743\",\"https://openalex.org/W3112790012\",\"https://openalex.org/W3120343004\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160017608\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3182434925\",\"https://openalex.org/W4205341191\",\"https://openalex.org/W4206063331\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294308393\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4394015461\",\"https://openalex.org/W4396518351\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4399323719\",\"https://openalex.org/W4400847605\",\"https://openalex.org/W4402992153\",\"https://openalex.org/W4404206552\",\"https://openalex.org/W4405426689\",\"https://openalex.org/W4408033191\",\"https://openalex.org/W4408089698\",\"https://openalex.org/W4408096046\",\"https://openalex.org/W4408345055\",\"https://openalex.org/W4408424120\"],\"authorships\":[{\"id\":\"https://openalex.org/A5083120627\",\"display_name\":\"Amandine Luquiens\",\"orcid\":\"https://orcid.org/0000-0002-9402-442X\"},{\"id\":\"https://openalex.org/A5119068869\",\"display_name\":\"Dahbia Belahda\",\"orcid\":null},{\"id\":null,\"display_name\":\"Carine Graux\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119068870\",\"display_name\":\"Noe Igounenc\",\"orcid\":null},{\"id\":\"https://openalex.org/A5080840107\",\"display_name\":\"Chris Serrand\",\"orcid\":\"https://orcid.org/0000-0002-6074-8577\"},{\"id\":\"https://openalex.org/A5068681572\",\"display_name\":\"Paul A. Rochefort\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007724266\",\"display_name\":\"Thibault Mura\",\"orcid\":\"https://orcid.org/0000-0001-6420-1336\"},{\"id\":null,\"display_name\":\"Felix Sergent\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S70513841\",\"source_display_name\":\"Addiction\",\"landing_page_url\":\"https://doi.org/10.1111/add.70152\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412642858" }, { "id": 3633, "title": "The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)", "normalized_title": "the safety feasibility and acceptability of psilocybin combined with multidisciplinary palliative care in demoralized cancer survivors with chronic pain p pc", "authors": "Emory University", "abstract": "This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life. PRIMARY OBJECTIVE: I. To determine the safety, feasibility, and acceptability of a single administration of 25 mg psilocybin (psilocybin) provided under supportive conditions with multidisciplinary palliative care support (P-PC) in adult cancer survivors living with concurrent demoralization and chronic pain. EXPLORATORY OBJECTIVE: I. To evaluate for changes in demoralization, anxiety, depression, quality of life, pain, other symptoms, mysticism, awe, post-traumatic growth, social isolation, and psychosocial functioning from baseline to end-of-treatment to 3.5-month follow up. OUTLINE: Patients receive psilocybin orally (PO) and undergo observation for up to 8 hours on day 14. After completion of study intervention, patients are followed up on days 15, 21, 42, 56, and 98.", "journal": "ClinicalTrials.gov", "publication_date": "2025-07-22", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05506982", "keywords": "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Psilocybin, CY-39, Indocybin, Psychotherapy, talk therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05506982\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Chronic Pain,Mystical Experience,Clinical Trial,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 604, "title": "“I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke", "normalized_title": "i ve learned that i m open minded to this possibility a qualitative study to evaluate the acceptability of a psilocybin aided smoking cessation treatment for people with hiv who smoke", "authors": "Patricia A. Cioe, Garrett S Stang, Danish Azam, Sarah Dugal", "abstract": "BACKGROUND: People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in quitting, many PWH who smoke experience lower cessation rates with traditional treatments, in part due to their comorbid anxiety and depressive symptoms. Psilocybin, a classic psychedelic referred to as \"breakthrough therapy\" by the U.S. Food & Drug Administration (FDA), has been shown to have potential as a therapeutic treatment for psychiatric symptoms, (e.g., anxiety and depression) and substance use disorders, including tobacco dependence. Preliminary evidence has shown that administering psilocybin to people who smoke and have been previously unable to quit with traditional treatments resulted in impressive smoking abstinence rates (80%) at 6-months in a smoking cessation pilot study. OBJECTIVE: Explore, using qualitative methods, the perceptions and acceptability of a psilocybin-assisted treatment for smoking cessation among PWH who smoke. METHODS: Semi-structured, in-depth qualitative interviews were conducted with PWH who smoke. Interviews were audio-recorded, transcribed verbatim, and analyzed using rapid thematic analysis. RESULTS: Twenty-five participants were enrolled: 15 cis male, 9 cis female, and 1 transgender female. Five main themes emerged: varying previous experiences with psilocybin; uncertainty about psilocybin's effects and concern over potential side effects; need for trusted sources of information and testimonials; ultimately willing to try psilocybin-aided therapy for tobacco treatment; and, set and setting of psilocybin use matters. CONCLUSIONS: Psilocybin-assisted smoking cessation treatment appears to be acceptable among PWH who smoke. Participants highlighted the importance of addressing key concerns related to an emerging therapy to increase acceptability and willingness to try it. Further research is needed to evaluate the safety and effectiveness of psilocybin prior to incorporating this emerging therapy for smoking cessation into tobacco treatment clinical services for PWH.", "journal": "Addiction Science & Clinical Practice", "publication_date": "2025-07-20", "publication_year": 2025, "doi": "10.1186/s13722-025-00563-0", "pubmed_id": "40691651", "source_url": "https://doi.org/10.1186/s13722-025-00563-0", "keywords": "Psilocybin, Smoking cessation, Health psychology, Psychiatry, Psychology, Human immunodeficiency virus (HIV), Psychotherapist, Public health, Clinical psychology, Medicine, Hallucinogen, Family medicine, Nursing, Pathology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412510542\",\"openalex_url\":\"https://openalex.org/W4412510542\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1603977514\",\"https://openalex.org/W1747059440\",\"https://openalex.org/W1971969140\",\"https://openalex.org/W1978560738\",\"https://openalex.org/W1985454368\",\"https://openalex.org/W1993551104\",\"https://openalex.org/W2008651049\",\"https://openalex.org/W2048511933\",\"https://openalex.org/W2080436266\",\"https://openalex.org/W2088913376\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2282858459\",\"https://openalex.org/W2515306146\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2573408014\",\"https://openalex.org/W2594751923\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2614691543\",\"https://openalex.org/W2773376977\",\"https://openalex.org/W2808747181\",\"https://openalex.org/W2945855838\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3090986803\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3117921577\",\"https://openalex.org/W3125697614\",\"https://openalex.org/W3160306775\",\"https://openalex.org/W3208645186\",\"https://openalex.org/W4200514127\",\"https://openalex.org/W4211011432\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4220656556\",\"https://openalex.org/W4282982392\",\"https://openalex.org/W4283275230\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4320491739\",\"https://openalex.org/W4380371967\",\"https://openalex.org/W4381614996\",\"https://openalex.org/W4386219256\",\"https://openalex.org/W4405031949\",\"https://openalex.org/W4405412696\",\"https://openalex.org/W4406996996\"],\"authorships\":[{\"id\":\"https://openalex.org/A5000146961\",\"display_name\":\"Patricia A. Cioe\",\"orcid\":\"https://orcid.org/0000-0003-3599-7819\"},{\"id\":\"https://openalex.org/A5089469079\",\"display_name\":\"Garrett S Stang\",\"orcid\":\"https://orcid.org/0000-0001-7000-1277\"},{\"id\":\"https://openalex.org/A5117848838\",\"display_name\":\"Danish Azam\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119020915\",\"display_name\":\"Sarah Dugal\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S152134104\",\"source_display_name\":\"Addiction Science & Clinical Practice\",\"landing_page_url\":\"https://doi.org/10.1186/s13722-025-00563-0\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Safety,Adverse Events,Toxicity", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412510542" }, { "id": 3581, "title": "Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality", "normalized_title": "acceptability safety of two sequential doses of psilocybin in bipolar disorder ii depression and suicidality", "authors": "The University of Texas Health Science Center, Houston", "abstract": "The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression. This study aims to determine whether psilocybin paired with psychotherapy is a safe, feasible, and acceptable treatment for Bipolar II (BD II) depression, specifically, individuals experiencing suicidal ideation (without having an active plan or intention to act). The design is a non-randomized clinical trial, where patients will receive up to 2 doses of 25mg psilocybin in the context of psychological support informed by mindfulness-based CBT and typical elements of psychedelic treatments (e.g., preparation, intention setting, integration). The investigators will measure suicidality, depression, and acute experiences using validated questionnaires at multiple time points in the study. If this study shows psilocybin to be a feasible, acceptable, and safe treatment option, this would have huge implications for improving outcomes because highly effective treatment for suicidality in patients with Bipolar Disorder is still lacking.", "journal": "ClinicalTrials.gov", "publication_date": "2025-07-17", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06706232", "keywords": "Bipolar II Disorder, Depression, Bipolar, Suicidality, Psilocybin, Therapeutic Support, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06706232\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4344, "title": "Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns", "normalized_title": "rise of the mushrooms effects of psilocybin reforms on psychedelic usage patterns", "authors": "Ashutosh Bhave", "abstract": "This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminalization efforts in several cities and legalization in Oregon, the author analyzes drug use panel data from University of Michigan's Monitoring the Future project to assess changes in self-reported use of psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA, commonly referred to as Molly or Ecstasy). The findings reveal a substitution pattern from LSD and MDMA to psilocybin associated with psilocybin reforms. Given the potential therapeutic benefits of psilocybin and its lower associated risks than LSD and MDMA, the findings suggest a possible public health benefit associated with psilocybin reforms. Moreover, with the increased interest from venture capitalists in the psilocybin-related drug market, this study discusses important topics such as consumer safety and advises caution.", "journal": "Journal of Public Policy & Marketing", "publication_date": "2025-07-15", "publication_year": 2025, "doi": "10.1177/07439156251360774", "pubmed_id": null, "source_url": "https://doi.org/10.1177/07439156251360774", "keywords": "Psilocybin, Hallucinogen, Psychology, Marketing, Business, Advertising, Psychiatry, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412479365\",\"openalex_url\":\"https://openalex.org/W4412479365\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2015666695\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2107232050\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2810710828\",\"https://openalex.org/W2889566085\",\"https://openalex.org/W2945519735\",\"https://openalex.org/W2966696030\",\"https://openalex.org/W3022718734\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4210625095\",\"https://openalex.org/W4284991345\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4380421146\",\"https://openalex.org/W4381839757\",\"https://openalex.org/W4383186683\",\"https://openalex.org/W4400495765\",\"https://openalex.org/W4412161399\"],\"authorships\":[{\"id\":\"https://openalex.org/A5077439888\",\"display_name\":\"Ashutosh Bhave\",\"orcid\":\"https://orcid.org/0000-0001-6704-5172\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S37376905\",\"source_display_name\":\"Journal of Public Policy & Marketing\",\"landing_page_url\":\"https://doi.org/10.1177/07439156251360774\",\"is_oa\":false}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412479365" }, { "id": 556, "title": "Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.", "normalized_title": "examining the potential of psilocybin and 5 meo dmt as therapeutics for traumatic brain injury", "authors": "Plummer Z, Allen J, Brand J, Mayo LM, Shultz SR, Christie BR.", "abstract": "Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TBI is characterized by neuroinflammation, oxidative stress, impaired neuroplasticity, imbalances in neurotransmission, and cell death - factors that contribute to the development of neurological and psychiatric disorders. Emerging evidence suggests that serotonergic psychedelics psilocybin and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) may hold promise as treatments for TBI. These compounds promote neuroplasticity, exert anti-inflammatory and neuroprotective effects, and have shown efficacy in treating psychiatric conditions that share pathophysiological features with TBI. 5-HT1A and 5-HT2A receptors are implicated in their effects, but psilocybin also targets neurotrophic TrkB receptors, whereas 5-MeO-DMT targets sigma-1 receptors, known to have neuroprotective properties. This review integrates current preclinical and clinical research, highlighting both the shared and distinct mechanistic pathways through which psilocybin and 5-MeO-DMT may alleviate TBI-related impairments, such as cognitive and affective dysfunction and neuroinflammation. Additionally, the safety profiles, dosing paradigms, and clinical challenges of these psychedelics are critically examined. By bridging insights from psychedelic science and neurotrauma research, this review underscores the innovative potential of psilocybin and 5-MeO-DMT as adjunctive treatments for TBI, paving the way for novel interventions in neurorehabilitation.", "journal": null, "publication_date": "2025-07-13", "publication_year": 2025, "doi": "10.1016/j.pnpbp.2025.111448", "pubmed_id": "40669813", "source_url": "https://doi.org/10.1016/j.pnpbp.2025.111448", "keywords": "Animals, Humans, N,N-Dimethyltryptamine, Hallucinogens, Neuroprotective Agents, Psilocybin, Brain Injuries, Traumatic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40669813\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Oxidative Stress,Review Article,Animal Study,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 536, "title": "A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction.", "normalized_title": "a systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction", "authors": "Glenn DL, Choi SH, Zimmerman RS.", "abstract": "BackgroundClassic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated anti-addictive properties; however, their impact on smoking behaviors remains under-researched. This review provides a synthesis of the therapeutic potential of these compounds in promoting smoking cessation and reduction.MethodsA systematic review of peer-reviewed studies on psychedelics and smoking outcomes, published in English, was conducted. Database searches of PubMed, CINAHL, PsycINFO, and EMBASE resulted in 3547 records. ASReview, an open-source machine-learning tool, was used to improve the screening process. Abstract and initial review screening excluded 2336 articles, leaving 29 full-text articles for review. After further exclusion based on the inclusion of psychedelics and reported outcomes, eight studies were included in the analysis. All studies were assessed for risk of bias using the risk of bias in non-randomized studies of interventions (ROBINS-I) tool.ResultsHeterogeneity in the data was observed. All studies showed a serious risk of bias. Psilocybin was the most frequently reported compound (n = 7), followed by lysergic acid diethylamide (LSD; n = 5), mescaline (n = 4), ayahuasca (n = 4), peyote (n = 2), and N,N-dimethyltryptamine (n = 1). Psilocybin, LSD, and ayahuasca revealed preliminary therapeutic potential for facilitating smoking cessation.ConclusionsCurrent literature on psychedelics' anti-addictive effects on smoking behaviors is promising but limited by weak study designs and low generalizability. Future research should allow for stronger sampling methods to improve statistical power and include comparative groups within experimental or quasi-experimental designs to strengthen inference for causal mechanisms between drug and nondrug influences on smoking outcomes.", "journal": null, "publication_date": "2025-07-10", "publication_year": 2025, "doi": "10.1177/02698811251353251", "pubmed_id": "40643107", "source_url": "https://doi.org/10.1177/02698811251353251", "keywords": "Humans, Hallucinogens, Smoking, Smoking Cessation, Serotonin 5-HT2 Receptor Agonists", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40643107\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Receptor Pharmacology,Consciousness,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4347, "title": "The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin", "normalized_title": "the medial prefrontalcortex modulates psychedelic likeeffects of psilocin", "authors": "Miyuan Zhang (21677016), Haojiang Zhai (21677019), Longwei Yang (21677022), Haohong Li (5164970), Xiaohui Wang (19899)", "abstract": "Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potential therapeutic applications, particularly in the rapid and sustained treatment of depression. However, the potent acute psychedelic effects of psilocybin necessitate a deeper understanding of the neural mechanisms underlying its action. In this study, we investigated the psilocin-induced neural activity in male mice using c-Fos immunofluorescent labeling and identified brain regions associated with psychedelic-like activity. Among the medial prefrontal cortex (mPFC), orbitofrontal cortex (OFC), interstitial nucleus of the posterior limb of the anterior commissure (IPAC), and dorsomedial striatum (DMS), only the mPFC was specifically associated with the head twitch response (HTR), a hallmark of psychedelic-like behavior. A picomolar dose of psilocin in the mPFC was sufficient to induce significant HTR, suggesting that c-Fos-positive neurons in this region modulate psychedelic-like activity. To validate this hypothesis, optogenetic activation of these neurons significantly increased spontaneous HTR in TRAP2 mice, whereas acute inhibition suppressed drug-induced HTR. These findings establish the mPFC as a critical regulator of psilocin-induced psychedelic-like activity and provide valuable insights for enhancing the clinical safety and therapeutic application of psychedelics.", "journal": "Figshare", "publication_date": "2025-07-07", "publication_year": 2025, "doi": "10.1021/acsptsci.5c00324.s001", "pubmed_id": null, "source_url": "https://figshare.com/articles/journal_contribution/The_Medial_Prefrontal_Cortex_Modulates_Psychedelic-like_Effects_of_Psilocin/29500347", "keywords": "Optogenetics, Prefrontal cortex, Neuroscience, Nucleus accumbens, Neural activity, Psilocybin, Hippocampus, Orbitofrontal cortex, Striatum, Cortex (anatomy), Infralimbic cortex, Hippocampal formation, Regulator, Premovement neuronal activity, Chemistry, Caudate nucleus, Electrophysiology, Central nervous system, Biology, Long-term potentiation, Dopamine, Psychology, Cerebral cortex, Slice preparation, Nucleus, Frontal cortex, Brain mapping, Local field potential, Neuroplasticity, Thalamus, Hallucinogen, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7111003529\",\"openalex_url\":\"https://openalex.org/W7111003529\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Miyuan Zhang (21677016)\",\"orcid\":null},{\"id\":null,\"display_name\":\"Haojiang Zhai (21677019)\",\"orcid\":null},{\"id\":null,\"display_name\":\"Longwei Yang (21677022)\",\"orcid\":null},{\"id\":null,\"display_name\":\"Haohong Li (5164970)\",\"orcid\":null},{\"id\":null,\"display_name\":\"Xiaohui Wang (19899)\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196282\",\"source_display_name\":\"Figshare\",\"landing_page_url\":\"https://figshare.com/articles/journal_contribution/The_Medial_Prefrontal_Cortex_Modulates_Psychedelic-like_Effects_of_Psilocin/29500347\",\"is_oa\":true}}", "topic_tags": "Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Animal Study,Safety,Toxicity", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7111003529" }, { "id": 569, "title": "The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin", "normalized_title": "the medial prefrontal cortex modulates psychedelic like effects of psilocin", "authors": "Miyuan Zhang, Haiyan Zhai, Longwei Yang, Haohong Li, Xiaohui Wang", "abstract": "Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potential therapeutic applications, particularly in the rapid and sustained treatment of depression. However, the potent acute psychedelic effects of psilocybin necessitate a deeper understanding of the neural mechanisms underlying its action. In this study, we investigated the psilocin-induced neural activity in male mice using c-Fos immunofluorescent labeling and identified brain regions associated with psychedelic-like activity. Among the medial prefrontal cortex (mPFC), orbitofrontal cortex (OFC), interstitial nucleus of the posterior limb of the anterior commissure (IPAC), and dorsomedial striatum (DMS), only the mPFC was specifically associated with the head twitch response (HTR), a hallmark of psychedelic-like behavior. A picomolar dose of psilocin in the mPFC was sufficient to induce significant HTR, suggesting that c-Fos-positive neurons in this region modulate psychedelic-like activity. To validate this hypothesis, optogenetic activation of these neurons significantly increased spontaneous HTR in TRAP2 mice, whereas acute inhibition suppressed drug-induced HTR. These findings establish the mPFC as a critical regulator of psilocin-induced psychedelic-like activity and provide valuable insights for enhancing the clinical safety and therapeutic application of psychedelics.", "journal": "ACS Pharmacology & Translational Science", "publication_date": "2025-07-07", "publication_year": 2025, "doi": "10.1021/acsptsci.5c00324", "pubmed_id": "40810162", "source_url": "https://doi.org/10.1021/acsptsci.5c00324", "keywords": "Prefrontal cortex, Neuroscience, Psychology, Consumer neuroscience, Cognition, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412100010\",\"openalex_url\":\"https://openalex.org/W4412100010\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1974195654\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2057174717\",\"https://openalex.org/W2058601367\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2089436854\",\"https://openalex.org/W2095268995\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2336389811\",\"https://openalex.org/W2341558148\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2549067465\",\"https://openalex.org/W2905212694\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2953204260\",\"https://openalex.org/W2999364864\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3183649366\",\"https://openalex.org/W4223932635\",\"https://openalex.org/W4306888870\",\"https://openalex.org/W4307167512\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4315620578\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4378647709\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4395688958\",\"https://openalex.org/W4402747955\",\"https://openalex.org/W4402758733\",\"https://openalex.org/W4403350173\",\"https://openalex.org/W4403605401\",\"https://openalex.org/W4404297527\",\"https://openalex.org/W4404349949\",\"https://openalex.org/W4404723884\",\"https://openalex.org/W4405703294\",\"https://openalex.org/W4406627764\",\"https://openalex.org/W4407686798\",\"https://openalex.org/W4408221975\",\"https://openalex.org/W4408244928\",\"https://openalex.org/W4409147414\",\"https://openalex.org/W4409620999\"],\"authorships\":[{\"id\":\"https://openalex.org/A5051743657\",\"display_name\":\"Miyuan Zhang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112467693\",\"display_name\":\"Haiyan Zhai\",\"orcid\":null},{\"id\":null,\"display_name\":\"Longwei Yang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101832733\",\"display_name\":\"Haohong Li\",\"orcid\":\"https://orcid.org/0000-0002-3775-9075\"},{\"id\":\"https://openalex.org/A5100618787\",\"display_name\":\"Xiaohui Wang\",\"orcid\":\"https://orcid.org/0000-0002-3415-5612\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210207642\",\"source_display_name\":\"ACS Pharmacology & Translational Science\",\"landing_page_url\":\"https://doi.org/10.1021/acsptsci.5c00324\",\"is_oa\":false}}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412100010" }, { "id": 3745, "title": "An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression", "normalized_title": "an open label dose escalation trial of psilocybin assisted therapy for bipolar 2 depression", "authors": "Szigeti B.", "abstract": "Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to theoretical concerns of precipitating mania or psychosis. Although psilocybin has demonstrated antidepressant effects when combined with psychotherapy, adverse event reporting is inconsistent, and restrictive eligibility criteria limit generalizability. Aims: To evaluate the safety, tolerability, and preliminary efficacy of psilocybin therapy in individuals with BD-II experiencing moderate-to-severe depression. Method: In this open-label, single-arm pilot trial, 14 participants received 10 mg of psilocybin, followed by 25 mg if depressive symptoms persisted. Participants underwent psychotherapy before, during, and after psilocybin administration sessions and were proactively monitored for adverse events. Depression and quality of life were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and Quality of Life in Bipolar Disorder Questionnaire (QoLBD), along with exploratory measures. Results: Psilocybin was well tolerated, with transient increases in heart rate and blood pressure and no serious adverse events. Common adverse events included mild-to-moderate anxiety, nausea, and headache. Three participants experienced notable psychiatric adverse events (suicidal ideation and hypomania) which resolved with support. The frequency and nature of both serious and non-serious adverse events were broadly comparable to those reported in psilocybin studies for other conditions. MADRS scores improved at all timepoints: 21 days after 10 mg (-12.7 [2.7], p", "journal": "PsyArXiv", "publication_date": "2025-07-06", "publication_year": 2025, "doi": "10.31234/osf.io/97cqx_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/97cqx_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:18", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1049908\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3072, "title": "An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression", "normalized_title": "an open label dose escalation trial of psilocybin assisted therapy for bipolar 2 depression", "authors": "", "abstract": "Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin therapy trials due to theoretical concerns of precipitating mania or psychosis. Although psilocybin has demonstrated antidepressant effects when combined with psychotherapy, adverse event reporting is inconsistent, and restrictive eligibility criteria limit generalizability. Aims: To evaluate the safety, tolerability, and preliminary efficacy of psilocybin therapy in individuals with BD-II experiencing moderate-to-severe depression. Method: In this open-label, single-arm pilot trial, 14 participants received 10 mg of psilocybin, followed by 25 mg if depressive symptoms persisted. Participants underwent psychotherapy before, during, and after psilocybin administration sessions and were proactively monitored for adverse events. Depression and quality of life were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and Quality of Life in Bipolar Disorder Questionnaire (QoL BD), along with exploratory measures. Results: Psilocybin was well tolerated, with transient increases in heart rate and blood pressure and no serious adverse events. Common adverse events included mild-to-moderate anxiety, nausea, and headache. Three participants experienced notable psychiatric adverse events (suicidal ideation and hypomania) which resolved with support. The frequency and nature of both serious and non-serious adverse events were broadly comparable to those reported in psilocybin studies for other conditions. MADRS scores improved at all timepoints: 21 days after 10 mg (-12.7 [2.7], p", "journal": "PsyArXiv", "publication_date": "2025-07-06", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/97cqx_v1", "keywords": "bipolar, depression, psilocybin, psychedelics, Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"97cqx_v1\",\"version\":1,\"reviews_state\":\"pending\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4348, "title": "Explore the effect of psilocybin on depression and anxiety", "normalized_title": "explore the effect of psilocybin on depression and anxiety", "authors": "Yutong Song", "abstract": "Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to more discoveries, including its use in the treatment of major depression disorder, anxiety disorder, addiction, and end-of-life distress. Research on the effects and safety of psilocybin is ongoing, but preliminary studies have shown promising results. Psilocybin has the potential to revolutionize the way we treat mental health disorders and support overall well-being. Sewell and colleagues suggest that for patients with cluster headaches, psilocybin could make an effective use in the cure or prevention of the regular appearance of cluster headaches. Other than this exciting exploration, treatment of depression and anxiety disorder is also worth discussion. This essay suggests that psilocybin is useful in depression treatment, and is more suitable as a preventive rather than a therapeutic drug in the course of treatment.", "journal": "Arts Culture and Language", "publication_date": "2025-07-05", "publication_year": 2025, "doi": "10.61173/rcg8me57", "pubmed_id": null, "source_url": "https://doi.org/10.61173/rcg8me57", "keywords": "Psilocybin, Anxiety, Psychology, Depression (economics), Clinical psychology, Hallucinogen, Psychotherapist, Cognitive psychology, Psychiatry, Keynesian economics, Economics, Psychedelics and Drug Studies, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412054280\",\"openalex_url\":\"https://openalex.org/W4412054280\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1981740630\",\"https://openalex.org/W2004477428\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2144455058\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2794118706\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W2999279320\",\"https://openalex.org/W3007694136\",\"https://openalex.org/W3087672006\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3166459008\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4281899337\",\"https://openalex.org/W4307826332\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4391115210\",\"https://openalex.org/W6704851532\",\"https://openalex.org/W6959454025\"],\"authorships\":[{\"id\":\"https://openalex.org/A5016362033\",\"display_name\":\"Yutong Song\",\"orcid\":\"https://orcid.org/0000-0002-1312-9407\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387291895\",\"source_display_name\":\"Arts Culture and Language\",\"landing_page_url\":\"https://doi.org/10.61173/rcg8me57\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Headache / Migraine,Wellbeing,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412054280" }, { "id": 4352, "title": "Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report", "normalized_title": "psilocybin use in an intercollegiate athlete with persisting symptoms after concussion a case report", "authors": "David W. Lawrence, Alex P. Di Battista, Michael G. Hutchison", "abstract": "Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research highlights the potential of classic psychedelics, such as psilocybin, in managing neuropsychiatric conditions and promoting neuroprotection. Case Report: A case is presented of a 22-year-old male intercollegiate athlete who sustained a concussion and developed persisting symptoms despite multidisciplinary standard care. The symptom burden remained relatively stable for the first month post-concussion. He independently administered three 250 milligram (mg) doses of the dried fruiting body of Psilocybe cubensis (2.5 mg of psilocybin) on days 42, 45, and 46 post-injury. He reported immediate symptom relief, including improvements in headache, noise sensitivity, and cognitive function. His symptom severity score decreased from 25 to 11 and his affective symptom burden resolved completely. Functional improvements allowed him to return to full activity. No adverse effects were reported. Conclusions: This case highlights the potential role of classic psychedelics as adjuvant agents in treating persisting symptoms after concussion. Clinicians should be aware that athletes may explore psychedelics as alternative treatments. Further research is needed to evaluate the efficacy and safety of psilocybin in concussion recovery.", "journal": "Psychoactives", "publication_date": "2025-06-30", "publication_year": 2025, "doi": "10.3390/psychoactives4030022", "pubmed_id": null, "source_url": "https://doi.org/10.3390/psychoactives4030022", "keywords": "Concussion, Psilocybin, Medicine, Physical therapy, Physical medicine and rehabilitation, Hallucinogen, Injury prevention, Poison control, Psychiatry, Medical emergency, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4411885403\",\"openalex_url\":\"https://openalex.org/W4411885403\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1970807094\",\"https://openalex.org/W1991006978\",\"https://openalex.org/W2019079031\",\"https://openalex.org/W2022287986\",\"https://openalex.org/W2079092936\",\"https://openalex.org/W2085670677\",\"https://openalex.org/W2088800239\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2125368083\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2296634983\",\"https://openalex.org/W2470836345\",\"https://openalex.org/W2516626242\",\"https://openalex.org/W2518801653\",\"https://openalex.org/W2534385685\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2766202580\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2783570214\",\"https://openalex.org/W2789449947\",\"https://openalex.org/W2801772025\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3006005031\",\"https://openalex.org/W3118236223\",\"https://openalex.org/W3129508146\",\"https://openalex.org/W3150741773\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164491540\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3180121263\",\"https://openalex.org/W3184845084\",\"https://openalex.org/W3210765834\",\"https://openalex.org/W3215603581\",\"https://openalex.org/W4210535254\",\"https://openalex.org/W4220834371\",\"https://openalex.org/W4221007363\",\"https://openalex.org/W4223425053\",\"https://openalex.org/W4281386811\",\"https://openalex.org/W4295782944\",\"https://openalex.org/W4297174489\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4312090041\",\"https://openalex.org/W4313257186\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4372331827\",\"https://openalex.org/W4380574892\",\"https://openalex.org/W4385996401\",\"https://openalex.org/W4388520321\",\"https://openalex.org/W4390589662\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4403209589\",\"https://openalex.org/W6861373969\"],\"authorships\":[{\"id\":\"https://openalex.org/A5080548305\",\"display_name\":\"David W. Lawrence\",\"orcid\":\"https://orcid.org/0000-0002-1386-7127\"},{\"id\":\"https://openalex.org/A5035669801\",\"display_name\":\"Alex P. Di Battista\",\"orcid\":\"https://orcid.org/0000-0002-3325-6833\"},{\"id\":\"https://openalex.org/A5049572012\",\"display_name\":\"Michael G. Hutchison\",\"orcid\":\"https://orcid.org/0000-0003-1961-5921\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387280156\",\"source_display_name\":\"Psychoactives\",\"landing_page_url\":\"https://doi.org/10.3390/psychoactives4030022\",\"is_oa\":true}}", "topic_tags": "Headache / Migraine,Receptor Pharmacology,Aging,Case Report,Healthcare Workers,Safety", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4411885403" }, { "id": 640, "title": "Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.", "normalized_title": "disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties", "authors": "Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS", "abstract": "Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the acute subjective effects (ASE) under the influence of psychedelics and their enduring therapeutic properties. However, with potential barriers to widespread clinical implementation, including the healthcare resource-intensive nature of psychedelic sessions and the exclusion of certain at-risk patient groups, there is an active search to determine whether ASE elimination can be accompanied by the retention of persisting therapeutic benefits of these class of compounds. Recognizing the aberrant underlying neural circuitry that characterizes a range of neuropsychiatric disorders, and that classic psychedelics promote neuroplastic changes that may correct abnormal circuitry, investigators are rushing to design and discover compounds with psychoplastogenic, but not hallucinogenic (i.e., ASE), therapeutic potential. These efforts have paved the discovery of 'non-psychedelic/subjective psychedelics', or compounds that lack hallucinogenic activity but with therapeutic efficacy in preclinical models. This review aims to distill the current evidence - both clinical and preclinical - surrounding the question: can the ASE of classic psychedelics be dissociated from their sustained therapeutic properties? Several plausible clinical scenarios are then proposed to offer clarity on and potentially answer this question.", "journal": "Psychopharmacology", "publication_date": "2025-06-30", "publication_year": 2025, "doi": "10.1007/s00213-024-06599-5", "pubmed_id": "38743110", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38743110/", "keywords": "5-HT2A, Acute subjective effects, Addiction, Classic psychedelics, Major depressive disorder, Neuropsychiatry, Psilocybin, Psychedelics, Substance use disorder", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"38743110\"}", "topic_tags": "Depression,Addiction,Receptor Pharmacology,Mystical Experience,Clinical Trial,Review Article,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 635, "title": "Exploring serotonergic psychedelics as a treatment for personality disorders.", "normalized_title": "exploring serotonergic psychedelics as a treatment for personality disorders", "authors": "Carrithers BM, Roberts DE, Weiss BM, King JD, Carhart-Harris RL, Gordon AR, Pagni BA, Moreau M, Ross S, Zeifman RJ", "abstract": "Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy could hold potential for addressing core features of PDs through shared mechanisms of personality modulation. Although historical literature and observational studies suggest the potential clinical utility of psychedelics in treating PDs, rigorous research is lacking, and individuals with PDs are often excluded from modern psychedelic therapy trials. In the present review, we first discuss research on the effects of psychedelics in individuals with a PD through the conventional lens of the Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.; DSM-5-TR) categorical model. Next, using the dimensional DSM Alternative Model of Personality Disorders (DSM-AMPD) as a framework, we examine how psychedelics may affect self-functioning, interpersonal functioning, and pathological personality traits. We conclude by discussing the clinical relevance of psychedelic therapy as a treatment for personality pathology, including safety considerations, gaps and limitations, and recommendations for approaching psychedelic therapy within these more complex clinical populations.", "journal": "Neuropharmacology", "publication_date": "2025-06-30", "publication_year": 2025, "doi": "10.1016/j.neuropharm.2025.110413", "pubmed_id": "40081794", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40081794/", "keywords": "Personality disorders, Personality traits, Psilocybin-assisted therapy, Psychedelics, Psychopharmacology, Psychotherapy", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40081794\"}", "topic_tags": "Pharmacology,Mechanism of Action,Personality Change,Review Article,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 616, "title": "Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances", "normalized_title": "caffeine nicotine cannabis and psilocybin pharmacology toxicology and potential therapeutic uses of four naturally occurring psychoactive substances", "authors": "Samuel E Christen, Elias Bekka, Yasmin Schmid, Neal L. Benowitz, Evangelia Liakoni", "abstract": "Psychoactive substances are compounds that can influence perception, consciousness, cognition, and emotions. The psychoactive substances caffeine, nicotine, cannabis, and psilocybin all originate from natural sources and can be used without complex processing or synthesis. Their natural availability has contributed to a long-standing history of human use and cultural significance. Caffeine and nicotine are freely available and commonly used as everyday stimulants, whereas psilocybin is more strictly regulated and cannabis has been legalised in some countries and regions. Some of these substances have been intensively studied, and their pharmacological and toxicological properties are well known, but ongoing research continues to investigate their therapeutic use for specific diseases and disorders. This narrative review aims to provide an overview of the pharmacology and toxicology of these four naturally occurring psychoactive substances, including a summary of the currently available evidence on their therapeutic potential, health benefits, and associated risks.", "journal": "Swiss Medical Weekly", "publication_date": "2025-06-30", "publication_year": 2025, "doi": "10.57187/s.4346", "pubmed_id": "40811135", "source_url": "https://doi.org/10.57187/s.4346", "keywords": "Psilocybin, Cannabis, Nicotine, Hallucinogen, Medicine, Psychoactive drug, Pharmacology, Caffeine, Psychoactive substance, Drug, Psychiatry, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412107589\",\"openalex_url\":\"https://openalex.org/W4412107589\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W135677869\",\"https://openalex.org/W1524864547\",\"https://openalex.org/W1571957666\",\"https://openalex.org/W1603955368\",\"https://openalex.org/W1603997350\",\"https://openalex.org/W1878560743\",\"https://openalex.org/W1938303280\",\"https://openalex.org/W1963667663\",\"https://openalex.org/W1967381780\",\"https://openalex.org/W1970807094\",\"https://openalex.org/W1972199176\",\"https://openalex.org/W1975391500\",\"https://openalex.org/W1976087389\",\"https://openalex.org/W1980260349\",\"https://openalex.org/W1984409435\",\"https://openalex.org/W1990921164\",\"https://openalex.org/W1992709483\",\"https://openalex.org/W1993768203\",\"https://openalex.org/W1995013188\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2002554882\",\"https://openalex.org/W2003787466\",\"https://openalex.org/W2006764302\",\"https://openalex.org/W2007346169\",\"https://openalex.org/W2008220734\",\"https://openalex.org/W2008382699\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2012647648\",\"https://openalex.org/W2014327575\",\"https://openalex.org/W2019252988\",\"https://openalex.org/W2019483208\",\"https://openalex.org/W2020803142\",\"https://openalex.org/W2020907704\",\"https://openalex.org/W2021089766\",\"https://openalex.org/W2022599378\",\"https://openalex.org/W2023901842\",\"https://openalex.org/W2024995562\",\"https://openalex.org/W2029051866\",\"https://openalex.org/W2029170128\",\"https://openalex.org/W2032745312\",\"https://openalex.org/W2033365411\",\"https://openalex.org/W2033845529\",\"https://openalex.org/W2033970420\",\"https://openalex.org/W2034835379\",\"https://openalex.org/W2035555993\",\"https://openalex.org/W2035829435\",\"https://openalex.org/W2036628697\",\"https://openalex.org/W2037898003\",\"https://openalex.org/W2042593075\",\"https://openalex.org/W2042821764\",\"https://openalex.org/W2046422668\",\"https://openalex.org/W2050352060\",\"https://openalex.org/W2050674567\",\"https://openalex.org/W2051803340\",\"https://openalex.org/W2053969387\",\"https://openalex.org/W2054388960\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2064831811\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2070282106\",\"https://openalex.org/W2070644314\",\"https://openalex.org/W2074371541\",\"https://openalex.org/W2076166404\",\"https://openalex.org/W2078651468\",\"https://openalex.org/W2078740198\",\"https://openalex.org/W2079510041\",\"https://openalex.org/W2083372765\",\"https://openalex.org/W2083540742\",\"https://openalex.org/W2086032851\",\"https://openalex.org/W2092674780\",\"https://openalex.org/W2093250184\",\"https://openalex.org/W2095085019\",\"https://openalex.org/W2095149502\",\"https://openalex.org/W2095198965\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2097427623\",\"https://openalex.org/W2098995865\",\"https://openalex.org/W2099103834\",\"https://openalex.org/W2103392442\",\"https://openalex.org/W2104493382\",\"https://openalex.org/W2105158322\",\"https://openalex.org/W2110116881\",\"https://openalex.org/W2110202583\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2113279750\",\"https://openalex.org/W2113689031\",\"https://openalex.org/W2114729019\",\"https://openalex.org/W2116438644\",\"https://openalex.org/W2120227293\",\"https://openalex.org/W2120595117\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2122510557\",\"https://openalex.org/W2128845098\",\"https://openalex.org/W2130528241\",\"https://openalex.org/W2130834261\",\"https://openalex.org/W2132067960\",\"https://openalex.org/W2132624405\",\"https://openalex.org/W2134552151\",\"https://openalex.org/W2134878705\",\"https://openalex.org/W2134992364\",\"https://openalex.org/W2135708183\",\"https://openalex.org/W2139701553\",\"https://openalex.org/W2143207873\",\"https://openalex.org/W2148523405\",\"https://openalex.org/W2149123448\",\"https://openalex.org/W2152392393\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2154901456\",\"https://openalex.org/W2156678769\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164126649\",\"https://openalex.org/W2168963572\",\"https://openalex.org/W2169269177\",\"https://openalex.org/W2169463741\",\"https://openalex.org/W2175944226\",\"https://openalex.org/W2216806740\",\"https://openalex.org/W2260109569\",\"https://openalex.org/W2284048615\",\"https://openalex.org/W2309907686\",\"https://openalex.org/W2335126655\",\"https://openalex.org/W2341838858\",\"https://openalex.org/W2395256718\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2404390137\",\"https://openalex.org/W2404396929\",\"https://openalex.org/W2407654663\",\"https://openalex.org/W2417938246\",\"https://openalex.org/W2424748885\",\"https://openalex.org/W2461733912\",\"https://openalex.org/W2520865586\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2560843015\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2756847756\",\"https://openalex.org/W2775001793\",\"https://openalex.org/W2791121924\",\"https://openalex.org/W2793476501\",\"https://openalex.org/W2795531389\",\"https://openalex.org/W2803216659\",\"https://openalex.org/W2803345313\",\"https://openalex.org/W2804130130\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2807290966\",\"https://openalex.org/W2852302757\",\"https://openalex.org/W2896111339\",\"https://openalex.org/W2899447541\",\"https://openalex.org/W2908213986\",\"https://openalex.org/W2911592879\",\"https://openalex.org/W2912112705\",\"https://openalex.org/W2913337886\",\"https://openalex.org/W2914867142\",\"https://openalex.org/W2919038148\",\"https://openalex.org/W2945807399\",\"https://openalex.org/W2947057767\",\"https://openalex.org/W2955138165\",\"https://openalex.org/W2961460936\",\"https://openalex.org/W2963430042\",\"https://openalex.org/W2981148845\",\"https://openalex.org/W2981821899\",\"https://openalex.org/W2998394031\",\"https://openalex.org/W3000720250\",\"https://openalex.org/W3003606793\",\"https://openalex.org/W3003694623\",\"https://openalex.org/W3006451015\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3044914189\",\"https://openalex.org/W3045132465\",\"https://openalex.org/W3045750830\",\"https://openalex.org/W3080890393\",\"https://openalex.org/W3093409888\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3113337956\",\"https://openalex.org/W3121363966\",\"https://openalex.org/W3144628360\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160183306\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3170809138\",\"https://openalex.org/W3198503804\",\"https://openalex.org/W3198532185\",\"https://openalex.org/W3210796807\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4206666881\",\"https://openalex.org/W4210607766\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4214643502\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4220686515\",\"https://openalex.org/W4220766496\",\"https://openalex.org/W4221018864\",\"https://openalex.org/W4223900198\",\"https://openalex.org/W4225157449\",\"https://openalex.org/W4226486561\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4281486035\",\"https://openalex.org/W4281875153\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4297830666\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4310598708\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4319343365\",\"https://openalex.org/W4366279920\",\"https://openalex.org/W4378174725\",\"https://openalex.org/W4378549583\",\"https://openalex.org/W4379769663\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4383682615\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385145775\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4385234503\",\"https://openalex.org/W4385730068\",\"https://openalex.org/W4385783116\",\"https://openalex.org/W4387002384\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4388827052\",\"https://openalex.org/W4390790998\",\"https://openalex.org/W4391286658\",\"https://openalex.org/W4392888270\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4409677155\"],\"authorships\":[{\"id\":\"https://openalex.org/A5054309712\",\"display_name\":\"Samuel E Christen\",\"orcid\":\"https://orcid.org/0009-0006-3103-781X\"},{\"id\":\"https://openalex.org/A5020870613\",\"display_name\":\"Elias Bekka\",\"orcid\":\"https://orcid.org/0000-0001-9958-7769\"},{\"id\":\"https://openalex.org/A5045516878\",\"display_name\":\"Yasmin Schmid\",\"orcid\":\"https://orcid.org/0000-0002-3618-584X\"},{\"id\":\"https://openalex.org/A5083971769\",\"display_name\":\"Neal L. Benowitz\",\"orcid\":\"https://orcid.org/0000-0003-2041-8124\"},{\"id\":\"https://openalex.org/A5083956843\",\"display_name\":\"Evangelia Liakoni\",\"orcid\":\"https://orcid.org/0000-0002-2239-1378\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4394736658\",\"source_display_name\":\"Swiss Medical Weekly\",\"landing_page_url\":\"https://doi.org/10.57187/s.4346\",\"is_oa\":true}}", "topic_tags": "Pharmacology,Consciousness,Emotional Processing,Review Article,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412107589" }, { "id": 595, "title": "Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review.", "normalized_title": "natural hallucinogens of fungal and animal origin action and potentialapplications a narrative review", "authors": "Ciszowski K, Ziaja A, Niedzielska-Andres E, Pomierny-Chamioło L.", "abstract": "IntroductionNatural hallucinogens derived from fungi and animals have been used for centuries in shamanic, ritualistic, and medicinal practices across diverse cultures. These compounds exhibit a widerange of structures and mechanisms of action, affecting various neurotransmitter systems pathways. Fungal hallucinogens, primarily indole alkaloids like psilocybin and ergot alkaloids, as well as animal-derived toxins, such as bufotenine, ciguatoxins, or semiochemicals from insects, can induce profound alterations in perception, cognition, and mood. Despite their traditional use and psychoactive effects, many of these substances remain underexplored in terms of pharmacology and therapeutic potential. Recent studies suggest their possible roles in treating neuropsychiatric disorders, inflammatory conditions, and chronic pain, highlighting the need for a systematic review of their biological activity and medical applications.Aim of the studyThis review aims to provide an overview of hallucinogenic compounds of fungal and animal origin, focusing on their chemical nature, pharmacodynamic properties, and current evidence for potential therapeutic use.MethodologyThe review was based on publications retrieved from databases such as PubMed, Google Scholar, and ScienceDirect, covering the period from 1983 to 2025. Search terms included: fungal hallucinogens, animal-derived psychedelics, natural psychoactive compounds, toxicity, therapeutic application of hallucinogens, and psychedelic drug research.ResultsThe analyzed hallucinogens differ markedly in terms of chemical structure, receptor activity, intensity of hallucinogenic effects, and potential for clinical use. Preclinical and limited clinical data suggest beneficial effects in mood and anxiety disorders, treatment-resistant depression, pain syndromes, and potentially neurodegenerative diseases. Some compounds show promise as leads for the synthesis of novel bioactive molecules.ConclusionsHallucinogens of fungal and animal origin represent a biologically diverse and pharmacologically rich group of natural substances. Further interdisciplinary research is required to explore their mechanisms of action, safety profiles, and therapeutic potential. Their continued investigation may lead to the development of innovative treatments in neuropsychiatry and beyond.", "journal": null, "publication_date": "2025-06-30", "publication_year": 2025, "doi": "10.24425/fmc.2025.156119", "pubmed_id": "41329968", "source_url": "https://doi.org/10.24425/fmc.2025.156119", "keywords": "Animals, Humans, Fungi, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"41329968\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Chronic Pain,Pharmacology,Mechanism of Action,Receptor Pharmacology,Systematic Review,Review Article,Animal Study,Treatment-Resistant Depression,Safety,Toxicity,Inflammation", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 644, "title": "Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis.", "normalized_title": "psychedelic assisted therapies for psychosocial symptoms in cancer a systematic review and meta analysis", "authors": "Schuman HDM, Savard C, Mina R, Barkova S, Conradi HSW, Deleemans JM, Carlson LE.", "abstract": "This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library, PsycINFO, and EMBASE (2000-2024) for randomized controlled trials (RCTs) and non-randomized studies investigating psychedelic agents in cancer populations. Meta-analyses pooled RCTs of psilocybin or ketamine using random-effects models. Non-randomized studies were synthesized narratively. Risk of bias and evidence certainty were assessed via Cochrane ROB2.0, NIH Before-After tool, and GRADE. Eleven placebo-controlled RCTs and four single open-label studies were included. Meta-analysis of four ketamine RCTs (n = 354) showed large, rapid effects on depression/anxiety (Hedges' g = -1.37, 95% CI: -2.66 to -0.08; I2 = 92%). Three psilocybin RCTs (n = 101) showed a large effect of psilocybin on alleviating depression (Hedges' g = -3.13, 95% CI: -10.04 to 3.77; I2 = 95%). MDMA and LSD trials suggested promise but lacked rigor. PAT may offer meaningful relief for cancer-related distress, though effects vary by therapeutic model and context. Oncology-specific trials are needed to standardize and scale for implementation.", "journal": null, "publication_date": "2025-06-29", "publication_year": 2025, "doi": "10.3390/curroncol32070380", "pubmed_id": "40710191", "source_url": "https://doi.org/10.3390/curroncol32070380", "keywords": "Humans, Neoplasms, Ketamine, Hallucinogens, Depression, Anxiety, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"40710191\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4358, "title": "Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease", "normalized_title": "evaluating psilocybin as a treatment for neuropsychiatric symptoms in parkinson s disease", "authors": "Nayiri Barton", "abstract": "Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor symptoms such as depression, anxiety, and cognitive impairment, which significantly affect patients' quality of life. Traditional dopaminergic therapies address motor symptoms but offer limited efficacy for neuropsychiatric manifestations. Psilocybin, a serotonergic compound with strong affinity for the 5-HT2A receptor, has emerged as a promising candidate for addressing the complex symptomatology of PD, including its neuropsychiatric components. This review examines the pharmacological effects of psilocybin, particularly its ability to modulate serotonergic and dopaminergic systems, enhance neuroplasticity, and reduce neuroinflammation, offering a potential therapeutic approach for PD. While clinical research in PD remains limited, evidence from related conditions such as Major Depressive Disorder (MDD) and Substance Use Disorder (SUD) supports the notion that psilocybin could modulate both motor and non-motor symptoms in PD. Furthermore, psilocybin’s ability to induce brain network hyperconnectivity and regulate dopamine release offers mechanistic insight into its potential benefits. Despite the promising neurobiological underpinnings, ethical concerns and regulatory constraints remain barriers to widespread clinical use. Future research should prioritize disease-specific trials to explore psilocybin’s therapeutic efficacy, optimal dosing, and safety profile in PD, potentially redefining the treatment landscape for this underserved population.", "journal": "Global Journal of Medical Research", "publication_date": "2025-06-27", "publication_year": 2025, "doi": "10.34257/gjmravol25is1pg1", "pubmed_id": null, "source_url": "https://doi.org/10.34257/gjmravol25is1pg1", "keywords": "Psilocybin, Parkinson's disease, Medicine, Disease, Psychiatry, Hallucinogen, Psychology, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:39", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412955867\",\"openalex_url\":\"https://openalex.org/W4412955867\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1964157254\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2809808727\",\"https://openalex.org/W4288400169\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W6902956737\"],\"authorships\":[{\"id\":null,\"display_name\":\"Nayiri Barton\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210169248\",\"source_display_name\":\"Global Journal of Medical Research\",\"landing_page_url\":\"https://doi.org/10.34257/gjmravol25is1pg1\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Neuroplasticity,Receptor Pharmacology,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412955867" }, { "id": 585, "title": "Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.", "normalized_title": "use of psychedelic agents in older adults with treatment resistant major depressive disorder what the evidence shows", "authors": "Vinarcsik L, Smoller C, Grossberg G.", "abstract": "The use of drugs with psychedelic and dissociative effects for the treatment of psychiatric illnesses has become increasingly popular in recent years. However, few trials have been conducted to determine the efficacy of these agents in the specific setting of treatment-resistant major depressive disorder (MDD) in older adults. In this paper, we review notable aspects of treatment-resistant MDD in older adults, review classical and nonclassical psychedelic agents and dissociative agents presently being trialed mostly in younger populations for the treatment of depression, and review what is known about trialing these agents in older adults with treatment-resistant MDD. Given the limitations to extant standard treatment and the potential risks associated with first-line pharmacological agents such as selective serotonin reuptake inhibitors (SSRIs) in this population, psychedelic-assisted psychotherapy may offer an important alternative for managing treatment-resistant MDD in older adults. This subset of patients is understudied and stands to benefit significantly from improved treatment regimens. The limited research available that details psychedelic-assisted treatment in this specific group is promising. Here we focus on reviewing those agents with the most controlled data available, beginning with the dissociative anesthetic ketamine/esketamine, and the hallucinogenic agent psilocybin, and concluding with a brief review of related substances including lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), ayahuasca, ibogaine, 3,4-methylenedioxymethamphetamine (MDMA), and mescaline. Treatment-resistant MDD is highly prevalent among older adults, and while preliminary findings seem promising regarding the safety and tolerability of psychedelics, concerns remain owing to insufficient data, and therefore further research is crucial to establish the safety, efficacy, and applications of psychedelic therapy in this population.", "journal": null, "publication_date": "2025-06-23", "publication_year": 2025, "doi": "10.1007/s40266-025-01221-5", "pubmed_id": "40553322", "source_url": "https://doi.org/10.1007/s40266-025-01221-5", "keywords": "Humans, Hallucinogens, Aged, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40553322\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Receptor Pharmacology,Aging,Review Article,Older Adults,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3096, "title": "The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping Review", "normalized_title": "the emerging use of psilocybin in adult populations with alcohol use disorder a scoping review", "authors": "Daroui D, Mastrostefano A, Davini F, Giuseppe G, Terracina S.", "abstract": "Background: Alcohol Use Disorder (AUD) is a chronic pathological condition with significant burdens throughout the world. Despite the effectiveness of the current pharmacological treatments, the ongoing issues with AUD and the high relapse rates necessitate the exploration of innovative therapies, including the use of psychedelic drugs, which have shown promising initial results. The purpose of the current study is to map the evidence on potential uses of psilocybin and its neurobiological pathways, highlighting gaps in knowledge and suggesting research opportunities. Methods: A scoping review of the literature was performed according to the population, concept, and context (PCC) framework. Data were synthesized in tabular form to summarize key study characteristics. Results and discussion: After screening 757 records, we included 12 studies published between 1968 and 2025: 7 RCTs, 4 open-label studies, and 1 case report. Early Polish studies suggested long-term remission of alcohol cravings, while recent U.S.-based RCTs showed that psilocybin, when paired with psychotherapy, reduced heavy drinking days and alcohol-related and mental problems. Limitations have been identified in small sample sizes and short follow-up periods in patient safety data, particularly in those with comorbidities. Most of the studies have been carried out in a hospital and university psychiatry department setting involving physicians and psychologists. Conclusion: Psilocybin has emerged as a promising and innovative compound for the treatment of AUD in an experimental phase. Future research should be conducted to assess pharmacological effects, efficacy, and patient safety through rigorous RCTs across diverse populations. To achieve better outcomes, it is essential to address drug development and pharmaceutical legislation regarding safe therapeutic algorithms.", "journal": "Preprints.org", "publication_date": "2025-06-18", "publication_year": 2025, "doi": "10.20944/preprints202506.1536.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202506.1536.v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1039854\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Randomized Controlled Trial,Review Article,Case Report,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 654, "title": "Long-term benefits of single-dose psilocybin in depressed patients with cancer", "normalized_title": "long term benefits of single dose psilocybin in depressed patients with cancer", "authors": "Manish Agrawal, Kim Roddy, Betsy Jenkins, Celia Leeks, Ezekiel Emanuel", "abstract": "BACKGROUND: Patients with cancer often struggle with depression, which can negatively impact quality of life as well as be challenging to manage. METHODS: A phase 2 trial was conducted that demonstrated safety, feasibility, and efficacy of a single dose of psilocybin combined with psychological support in a community cancer setting in 30 patients with cancer and a major depressive disorder. Here, efficacy outcomes at 2 years' follow-up are reported. RESULTS: Of 28 patients, 15 (53.6%) demonstrated significant reduction in depression as measured by the Montgomery Asberg Depression Rating Scale (average, -15.0 points from baseline; p", "journal": "Cancer", "publication_date": "2025-06-14", "publication_year": 2025, "doi": "10.1002/cncr.35889", "pubmed_id": "40518804", "source_url": "https://doi.org/10.1002/cncr.35889", "keywords": "Psilocybin, Medicine, Rating scale, Depression (economics), Anxiety, Quality of life (healthcare), Cancer, Internal medicine, Major depressive disorder, Psychiatry, Oncology, Psychology, Hallucinogen, Cognition, Nursing, Macroeconomics, Developmental psychology, Economics, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4411327114\",\"openalex_url\":\"https://openalex.org/W4411327114\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W2120051206\",\"https://openalex.org/W2153153465\",\"https://openalex.org/W2940589604\",\"https://openalex.org/W4362471767\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W6959427619\"],\"authorships\":[{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5036339125\",\"display_name\":\"Kim Roddy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108886818\",\"display_name\":\"Betsy Jenkins\",\"orcid\":null},{\"id\":\"https://openalex.org/A5118154767\",\"display_name\":\"Celia Leeks\",\"orcid\":null},{\"id\":\"https://openalex.org/A5012567636\",\"display_name\":\"Ezekiel Emanuel\",\"orcid\":\"https://orcid.org/0000-0002-9796-5735\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S126033908\",\"source_display_name\":\"Cancer\",\"landing_page_url\":\"https://doi.org/10.1002/cncr.35889\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Clinical Trial,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4411327114" }, { "id": 656, "title": "Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress", "normalized_title": "evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress", "authors": "Ines Erkizia-Santamaría, Igor Horrillo, Nerea Martínez-Álvarez, Daniel Pérez-Martínez, Guadalupe Rivero, Amaia M. Erdozain, J. Javier Meana, Jorge E. Ortega", "abstract": "Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population. In the search for novel rapid-acting antidepressants, the psychedelic psilocybin has emerged as a promising therapy in several clinical trials. However, its antidepressant mechanism of action is still not well understood. The aim of the present study was to evaluate the therapeutic potential of psilocybin in ameliorating the adverse behavioural and neurochemical consequences of chronic stress. To this end, a chronic unpredictable mild stress (CUMS) animal model was used, and psilocybin treatment was administered (two doses of 1 mg/kg, i.p., administered 7 days apart). Psilocybin reversed impairments in anhedonia and behavioural despair dimensions of depressive phenotype but not in apathy-related behaviour. Psilocybin administration was also able to exert an anxiolytic-like effect on treated animals. Physiological alterations caused by stress, indicative of a hyperactive hypothalamic-pituitary-adrenal axis (HPA), were not reversed by psilocybin. When neuroplasticity-related proteins were assessed in cerebral cortex, brain-derived neurotrophic factor (BDNF) was found to be decreased in stressed animals, and treatment did not reverse such impairment. Psilocybin administration increased the expression and function of serotonin-2A-receptor (5HT2AR) in brain cortex of control and CUMS groups. Furthermore, psilocybin treatment caused a selective increase in the expression of glucocorticoid-receptor (GR) in brain cortex of CUMS mice. In conclusion, psilocybin was able to rescue impairments in the depressive phenotype, and to induce anxiolytic-like effects. Furthermore, an enhancement in sensitivity to psilocybin-induced HTR was observed following a booster dose. Altogether, this work provides new knowledge on the putative benefit/risk actions of psilocybin and contributes to the understanding of the therapeutic mechanism of action of psychedelics.", "journal": "Translational Psychiatry", "publication_date": "2025-06-13", "publication_year": 2025, "doi": "10.1038/s41398-025-03421-4", "pubmed_id": "40517150", "source_url": "https://doi.org/10.1038/s41398-025-03421-4", "keywords": "Neurochemical, Psilocybin, Schizophrenia (object-oriented programming), Psychology, Neuroscience, Chronic stress, Medicine, Psychiatry, Psychotherapist, Hallucinogen, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Tryptophan and brain disorders", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4411302754\",\"openalex_url\":\"https://openalex.org/W4411302754\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":15,\"referenced_works\":[\"https://openalex.org/W1581732973\",\"https://openalex.org/W1813695827\",\"https://openalex.org/W1977430165\",\"https://openalex.org/W1978235424\",\"https://openalex.org/W1980374662\",\"https://openalex.org/W1986977063\",\"https://openalex.org/W1990483753\",\"https://openalex.org/W1995694737\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2003973769\",\"https://openalex.org/W2005594217\",\"https://openalex.org/W2025500109\",\"https://openalex.org/W2026107282\",\"https://openalex.org/W2034528843\",\"https://openalex.org/W2037383099\",\"https://openalex.org/W2045595011\",\"https://openalex.org/W2074901757\",\"https://openalex.org/W2077222459\",\"https://openalex.org/W2096500024\",\"https://openalex.org/W2107355862\",\"https://openalex.org/W2115614479\",\"https://openalex.org/W2119154436\",\"https://openalex.org/W2122062108\",\"https://openalex.org/W2127722821\",\"https://openalex.org/W2131167630\",\"https://openalex.org/W2136440837\",\"https://openalex.org/W2149522089\",\"https://openalex.org/W2155081002\",\"https://openalex.org/W2157504436\",\"https://openalex.org/W2167565363\",\"https://openalex.org/W2218388581\",\"https://openalex.org/W2300741967\",\"https://openalex.org/W2318207590\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2417096145\",\"https://openalex.org/W2495510751\",\"https://openalex.org/W2500078920\",\"https://openalex.org/W2510666910\",\"https://openalex.org/W2511946169\",\"https://openalex.org/W2556564584\",\"https://openalex.org/W2602913999\",\"https://openalex.org/W2604652480\",\"https://openalex.org/W2737967373\",\"https://openalex.org/W2767817739\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2789232296\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2865698779\",\"https://openalex.org/W2904597631\",\"https://openalex.org/W2916864608\",\"https://openalex.org/W2945318261\",\"https://openalex.org/W2950435009\",\"https://openalex.org/W2977895995\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3031744338\",\"https://openalex.org/W3046870582\",\"https://openalex.org/W3047879827\",\"https://openalex.org/W3092849554\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3112700248\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3194466410\",\"https://openalex.org/W3201026109\",\"https://openalex.org/W3210887564\",\"https://openalex.org/W4200241854\",\"https://openalex.org/W4211158719\",\"https://openalex.org/W4211263234\",\"https://openalex.org/W4224254727\",\"https://openalex.org/W4236357753\",\"https://openalex.org/W4282003194\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4283733386\",\"https://openalex.org/W4288447327\",\"https://openalex.org/W4291170424\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4295679043\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4298137791\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309658621\",\"https://openalex.org/W4310014477\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4315880873\",\"https://openalex.org/W4318455092\",\"https://openalex.org/W4319081438\",\"https://openalex.org/W4323041020\",\"https://openalex.org/W4323652168\",\"https://openalex.org/W4377142748\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4381615333\",\"https://openalex.org/W4387105816\",\"https://openalex.org/W4387259638\",\"https://openalex.org/W4387893450\",\"https://openalex.org/W4388486526\",\"https://openalex.org/W4388871233\",\"https://openalex.org/W4390589986\",\"https://openalex.org/W4390755783\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4393253405\",\"https://openalex.org/W4402624021\",\"https://openalex.org/W4405244747\",\"https://openalex.org/W4406097304\"],\"authorships\":[{\"id\":\"https://openalex.org/A5064629089\",\"display_name\":\"Ines Erkizia-Santamaría\",\"orcid\":\"https://orcid.org/0000-0002-6163-4571\"},{\"id\":\"https://openalex.org/A5028869928\",\"display_name\":\"Igor Horrillo\",\"orcid\":\"https://orcid.org/0000-0003-0125-5884\"},{\"id\":\"https://openalex.org/A5115558540\",\"display_name\":\"Nerea Martínez-Álvarez\",\"orcid\":null},{\"id\":null,\"display_name\":\"Daniel Pérez-Martínez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5066437036\",\"display_name\":\"Guadalupe Rivero\",\"orcid\":\"https://orcid.org/0000-0002-2537-4047\"},{\"id\":\"https://openalex.org/A5000178647\",\"display_name\":\"Amaia M. Erdozain\",\"orcid\":\"https://orcid.org/0000-0003-0207-9122\"},{\"id\":\"https://openalex.org/A5024198476\",\"display_name\":\"J. Javier Meana\",\"orcid\":\"https://orcid.org/0000-0002-7913-6714\"},{\"id\":\"https://openalex.org/A5033481973\",\"display_name\":\"Jorge E. Ortega\",\"orcid\":\"https://orcid.org/0000-0001-8188-874X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S163345920\",\"source_display_name\":\"Translational Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1038/s41398-025-03421-4\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4411302754" }, { "id": 3482, "title": "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder", "normalized_title": "the safety and tolerability of comp360 in participants with post traumatic stress disorder", "authors": "COMPASS Pathways", "abstract": "The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder", "journal": "ClinicalTrials.gov", "publication_date": "2025-06-12", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05312151", "keywords": "Post Traumatic Stress Disorder, Psilocybin, COMP360, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05312151\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "PTSD,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3611, "title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants", "normalized_title": "a phase 1 study to evaluate the safety tolerability and pharmacokinetics of multiple doses of mls101 psilocybin in healthy participants", "authors": "MycoMedica Life Sciences PBC", "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy, adult participants. In recent years, high-dose psilocybin has gained attention for it potential therapeutic benefit in many psychiatric conditions, however existing clinical data for low psilocybin doses are limited. Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner. As a foundational study of the therapeutic use of psilocybin microdoses, this study will assess the safety, tolerability, pharmacokinetics and sensorial effects using a prospective, controlled, multiple dose regimen in healthy volunteers.", "journal": "ClinicalTrials.gov", "publication_date": "2025-06-11", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06643637", "keywords": "Healthy Volunteers, Psilocybin, MLS101, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06643637\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Pharmacology,Microdosing,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3746, "title": "Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder", "normalized_title": "psilocybin assisted therapy increases self compassion in patients with alcohol use disorder", "authors": "Agin-Liebes G, Petridis P, Zeifman R, Link M, Cordova MJ, Bogenschutz M.", "abstract": "A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking outcomes. Of the 95 participants enrolled, 86 had self-compassion and drinking outcome data. Forty-four participants were randomized to 2 medication sessions with psilocybin and forty-two to active-placebo control (diphenhydramine); all participants received 12 sessions of manualized psychotherapy. Psilocybin-assisted therapy robustly increased compassionate self-responding (CS) and decreased uncompassionate self-responding (UCS), with the largest effect sizes observed in reducing UCS components (Self-Judgment, Isolation, Over-Identification). Across the full sample, small but significant correlations emerged between improvements in self-compassion and reductions in drinking. However, group-specific analyses revealed that participants in the control group exhibited moderate associations between gains in self-compassion and decreased drinking, whereas no significant association was observed in the psilocybin group. In both groups, these associations were stronger among participants who maintained moderate-to-high-risk drinking during the first four weeks of therapy prior to medication administration. Although the control group consistently exhibited significant correlations and the psilocybin group did not, the between-group differences in correlation strength were not statistically significant. These findings underscore the clinical relevance of self-compassion in AUD treatment but suggest that self-compassion may not mediate outcomes when psilocybin is administered as part of therapy. Larger studies with additional mechanistic analyses are needed to further clarify how self-compassion interacts with psychological processes and pharmacological interventions in shaping treatment response, ultimately informing improvements to psilocybin-assisted therapy for AUD.", "journal": "PsyArXiv", "publication_date": "2025-06-09", "publication_year": 2025, "doi": "10.31234/osf.io/f27jm_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/f27jm_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:18", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR1034586\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3617, "title": "Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults", "normalized_title": "comparison of the effects of pex20 oral psilocin pex30 sublingual psilocin and pex10 oral psilocybin in healthy adults", "authors": "University of California, San Francisco", "abstract": "To compare the physiological and psychological effects of psilocin taken orally by pill or sublingually by dissolving a tablet under the tongue to those of psilocybin taken by pill in healthy adults. The primary goal of this study is to compare the physiological and psychological effects of psilocin taken orally by pill or sublingually dissolved under the tongue to those of psilocybin taken by pill. Twenty participants, ages 25 to 50, with one previous experience with psychedelics, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by drug administration, supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will then complete assessment and integration sessions with the facilitators in order to help process the experience. The same preparation, procedures, integration, and supervision will be repeated up to three more times with each participant.", "journal": "ClinicalTrials.gov", "publication_date": "2025-06-09", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05317689", "keywords": "Healthy, Psilocin, Psilocybin, Sublingual Psilocin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05317689\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3074, "title": "Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder", "normalized_title": "psilocybin assisted therapy increases self compassion in patients with alcohol use disorder", "authors": "", "abstract": "A recent randomized, double-blind, placebo-controlled, parallel-group trial (NCT02061293) found that psilocybin-assisted therapy significantly improved drinking outcomes compared to an active placebo in adults with alcohol use disorder (AUD). In this secondary analysis, we assessed whether psilocybin-assisted therapy improved self-compassion and whether these changes predicted drinking outcomes. Of the 95 participants enrolled, 86 had self-compassion and drinking outcome data. Forty-four participants were randomized to 2 medication sessions with psilocybin and forty-two to active-placebo control (diphenhydramine); all participants received 12 sessions of manualized psychotherapy. Psilocybin-assisted therapy robustly increased compassionate self-responding (CS) and decreased uncompassionate self-responding (UCS), with the largest effect sizes observed in reducing UCS components (Self-Judgment, Isolation, Over-Identification). Across the full sample, small but significant correlations emerged between improvements in self-compassion and reductions in drinking. However, group-specific analyses revealed that participants in the control group exhibited moderate associations between gains in self-compassion and decreased drinking, whereas no significant association was observed in the psilocybin group. In both groups, these associations were stronger among participants who maintained moderate-to-high-risk drinking during the first four weeks of therapy prior to medication administration. Although the control group consistently exhibited significant correlations and the psilocybin group did not, the between-group differences in correlation strength were not statistically significant. These findings underscore the clinical relevance of self-compassion in AUD treatment but suggest that self-compassion may not mediate outcomes when psilocybin is administered as part of therapy. Larger studies with additional mechanistic analyses are needed to further clarify how self-compassion interacts with psychological processes and pharmacological interventions in shaping treatment response, ultimately informing improvements to psilocybin-assisted therapy for AUD.", "journal": "PsyArXiv", "publication_date": "2025-06-09", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/f27jm_v1", "keywords": "Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"f27jm_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Addiction,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 663, "title": "Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.", "normalized_title": "clinical conceptualisation of ptsd in psilocybin treatment disrupting a pre determined and over determined maladaptive interpretive framework", "authors": "Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J.", "abstract": "Post-traumatic stress disorder (PTSD) and associated trauma and stressor-related disorders are common and debilitating, presenting significant treatment challenges due to their complex interplay of biological, cognitive, affective, somatic and social factors. Current treatments, while advancing and effective, yield limited efficacy for many individuals, underscoring the need for novel therapeutic approaches. This review explores the multifaceted nature of PTSD, emphasising its intricate predisposing and maintaining factors and explores the potential of psilocybin, a classical psychedelic, as a therapeutic agent. This review synthesises recent literature on the safety, efficacy and proposed mechanisms of action and change of psychedelic therapies for psychiatric conditions associated with traumatic stress, including treatment-resistant depression, end-of-life anxiety and anorexia nervosa. Correspondingly, it proposes a conceptual framework for psilocybin treatment in PTSD, framing the condition as a complex, maladaptive interpretive framework that is both predetermined and over-determined. A clinical narrative illustrates how psilocybin's unique psychopharmacological properties and catalysed subjective effects may facilitate therapeutic progress by disrupting this rigid and restricting framework. Finally, we offer recommendations for the safe administration of psilocybin for traumatised patients in medical research settings, emphasising the importance of rigorous and trauma-informed protocols and comprehensive patient care.", "journal": null, "publication_date": "2025-06-07", "publication_year": 2025, "doi": "10.1177/20451253251342319", "pubmed_id": "40492108", "source_url": "https://doi.org/10.1177/20451253251342319", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40492108\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Eating Disorders,End-of-Life Distress,Mechanism of Action,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 652, "title": "Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.", "normalized_title": "classic psychedelics in pain modulation mechanisms clinical evidence and future perspectives", "authors": "Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A.", "abstract": "Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for innovative treatments. Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT), primarily act on serotonin 5-HT2A receptors and have emerged as potential modulators of pain perception and mood regulation. These substances may offer an alternative to conventional analgesics, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), by influencing neuroplasticity, descending pain modulation pathways, and inflammatory processes. Evidence from case studies, preclinical research, and early phase clinical trials suggests that psychedelics may alleviate pain in conditions such as cluster headaches, migraines, fibromyalgia, and chronic pain syndromes. However, the exact mechanisms underlying their analgesic properties are yet to be fully understood. While psychedelics show promise in reshaping pain management strategies, rigorous randomized controlled trials are needed to establish their safety, efficacy, and optimal dosing. This review highlights the therapeutic potential of psychedelics for chronic pain and emphasizes the necessity of further research to validate their role in modern pain medicine.", "journal": null, "publication_date": "2025-06-05", "publication_year": 2025, "doi": "10.1021/acschemneuro.5c00152", "pubmed_id": "40474592", "source_url": "https://doi.org/10.1021/acschemneuro.5c00152", "keywords": "Animals, Humans, Pain, Lysergic Acid Diethylamide, Analgesics, Hallucinogens, Pain Management, Chronic Pain", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40474592\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Headache / Migraine,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Safety,Inflammation", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3672, "title": "Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study", "normalized_title": "low income group psilocybin assisted therapy for depression a feasibility study", "authors": "Matthew Hicks", "abstract": "Due to psilocybin-assisted therapy's success in previous research, growing cultural awareness and use of psilocybin and other psychedelics, the Oregon Psilocybin Services Act passed by ballot measure in 2020 and began offering services in 2023. While the program has had many successes, a significant problem it faces is affordability and no research to date has investigated the therapy in a low-income population. Psychedelic research in recent decades has used the model of two therapists to one client to demonstrate an abundance of caution and safety to regulators, but no evidence has demonstrated this model to be safer or more effective than one with less practitioner oversight. This feasibility study would be the first investigation of Oregon Psilocybin Services as a model of care and among the first few to use a group therapy model. This study aims to test the feasibility of the model by assessing recruitment, retention, acceptability and safety of the treatment. In addition to an appropriate medical screening and intake the following questionnaire data will be collected: the Adverse Childhood Events (ACE) questionnaire, Credibility/Expectancy Questionnaire (CEQ), Hamilton Depression Inventory, PROMIS-29, Altered States of Consciousness (11-ASC) rating scale, and a survey and structured interview. Participants will consist of adults in Oregon with an income at or below 200% of the federal poverty level. Inclusion criteria will include DSM-5 diagnosis of major depression. Participants will be individually screened by a study investigator and placed into groups of five to six participants. Treatment will consist of two group preparation sessions, two psilocybin sessions, and two group integration sessions. An additional follow-up visit to collect further data will take place three months after conclusion of the treatment. The proposed study will provide valuable information for designing future clinical trials investigating the efficacy, mechanisms, and cost-effectiveness of psilocybin-assisted group therapy for depression in low-income populations.", "journal": "ClinicalTrials.gov", "publication_date": "2025-06-04", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06372197", "keywords": "Depression, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06372197\",\"overall_status\":\"COMPLETED\",\"phase\":[\"NA\"]}", "topic_tags": "Depression,Mechanism of Action,Consciousness,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3480, "title": "Optimizing Microdosing and Meditation", "normalized_title": "optimizing microdosing and meditation", "authors": "National University of Natural Medicine", "abstract": "The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2. Acceptability, Safety and Tolerability 3. Exploratory Measures: 3.1: Explore potential changes in sleep quality and duration, heart rate variability, and other biometric outcomes captured by the Oura Ring (3rd generation). 3.2: Explore potential changes in quality of life scores 3.3: Explore potential differences in altered states of consciousness across groups 3.4: Explore qualitative data collected during sessions and at follow-up to assess satisfaction and receive feedback about the intervention. Every participant will receive the psilocybin microdosing intervention, however, half of the participants will be randomly selected to receive the meditation intervention. Research has shown that both meditation and high doses of psilocybin can produce enhanced feelings of well-being that persist. When combined, the synergistic effects might be more than the sum of the parts when treating mental health challenges like depression. The results for microdosing, on the other hand, are mixed, and there have yet to be studies on the synergy between microdosing and meditation. If the synergy between microdoses of psilocybin and meditation is significant, this suggests the possibility of a safe, effective, and low-cost intervention involving group-based meditation training and practice combined with a psilocybin microdosing protocol. The Oregon Psilocybin Services program provides a unique opportunity to test this possibility in the context of services now legally available to clients, allowing researchers to assess the safety and efficacy in a real-life context. Project aims and methods This study aims to test the feasibility of the model by assessing recruitment, retention, acceptability, safety, and preliminary efficacy of the intervention. In addition to an appropriate medical screening and intake we will collect questionnaire data using the Credibility/Expectancy Questionnaire (CEQ), PROMIS-29, Five Facet of Mindfulness Questionnaire (FFMQ), Pittsburgh Sleep Quality Index (PSQI), Altered States of Consciousness (11-ASC) rating scale, and a survey and structured interview. During a one week wash-in period, the intervention period, and for one month after the intervention, Oura rings will be used to collect over 20 biometric data points including sleep quality, respiration rate, heart rate variability, and more. Participants will consist of adults in Oregon that will be individually screened by a study investigator and then randomized into two arms. One arm will receive microdosing only consisting of one group preparation session and two microdosing sessions per week for two weeks. The other arm will receive the same microdosing protocol with the addition of morning online meditation practice Monday through Friday for both weeks, and will utilize meditation practices during their microdose sessions. The meditation sessions will include opportunities for the group to discuss their meditation experiences and a psychoeducational component to further improve outcomes. This content will provide participants with a better understanding of the ruminations that interrupt their focus while meditating and encourage greater distance from, and less distress concerning, those thoughts. Expected outcomes The authors hypothesize that the model will be feasible if we are able to recruit at least 20 out of 24 expected participants, have an 80% retention rate of participants during the two week intervention period, participants on average rate their satisfaction of the intervention as 3.0 or higher on a 5-point scale, there are no more than ten adverse events or more than one serious adverse event, and data from exploratory measures indicate that further investigation is warranted. Despite the U.S. Food and Drug Administration (FDA) granting Breakthrough Therapy status to psilocybin for the treatment of depression,56 it remains on the Drug Enforcement Agency's (DEA) Schedule I list of controlled substances alongside heroin and cocaine. While the DEA and the FDA have become increasingly more willing to grant waivers for research into psychedelic drugs, the proposed study does not require such a waiver to comply with the law. This is due to the unique construction of Oregon's Psilocybin Services Act (Chapter 475A of Oregon Statutes). The state law creates a program wherein licensed growers, inspected by licensed laboratories, can distribute psilocybin mushrooms to licensed service centers. It is only within the approved boundaries of these service centers and while supervised by a licensed facilitator that the mushrooms can be consumed by clients who must stay on site for a designated amount of time that depends on the dose. According to Oregon Health Authority Administrative rule 333-333-5130, facilitators of psilocybin service are prohibited from (1) practicing any other scope of practice they may have (e.g. naturopathic medicine) while facilitating, and (2) handling, selling, or transferring psilocybin at any time. Thus, while it is technically true that growers, services centers, and clients are liable for trafficking and possession of a Schedule I substance, the federal government has adopted a policy of allowing state programs such as this in a manner similar to their policy on cannabis. Complying with Oregon law means that study investigators are not administering or providing psilocybin, but instead are studying the facilitation of the services. At the request of the Institutional Review Board (IRB) of the National University of Natural Medicine (NUNM) for a similar study, this rationale was confirmed via direct communication with the regional DEA office who agreed with this interpretation of both federal and state law. Participants are given clear information on their liability in order to provide consent.", "journal": "ClinicalTrials.gov", "publication_date": "2025-06-04", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06560658", "keywords": "Meditation, Microdosing, Psilocybin, psilocybin microdosing, WITHDRAWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06560658\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"NA\"]}", "topic_tags": "Depression,Addiction,Consciousness,Microdosing,Wellbeing,Clinical Trial,Review Article,Observational Study,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 541, "title": "Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms", "normalized_title": "self inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms", "authors": "Abigail M. Blanton, Pooja Parikh, Scott Zhou, Mohamed Mohamed, Rafael Ufret-Vincenty, Ronald Mancini", "abstract": "Purpose: Self-inflicted penetrating orbital trauma is a rare ophthalmologic emergency requiring timely intervention and neurological monitoring to identify and treat any possible intracranial complications and to prevent irreversible vision loss. This case report aims to describe a fatal case of self-inflicted ocular trauma following the consumption of psilocybin mushrooms, necessitating urgent multidisciplinary care by the ophthalmology and neurosurgery services. Observations: A21-year-old Hispanic male presented urgently to the emergency department (ED) after self-inflicted ocular trauma with a wood-cased pencil, which was embedded in the upper eyelid and transversed the left orbit, extending to the pons, as depicted on computed tomography (CT). Physical examination of the left eye was difficult due to the risk of displacement of the pencil within the brainstem and concern for further damage. The pencil was successfully removed via fluoroscopy-guided neuro-interventional catheterization and stenting. Following the removal of the foreign body, there was no apparent damage to the globe, and a canthotomy/cantholysis was performed due to increased retro-orbital pressure. The neurovascular damage sustained by the trauma led to a progressive neurological decline in the following days and, ultimately, a fatal outcome. Conclusions and importance: With growing support in the literature for psilocybin and its therapeutic medicinal benefits for conditions such as depression and anxiety, this report details a case of self-inflicted trans-orbital trauma with brainstem injury following ingestion of this psychoactive hallucinogen along with the proper medical and surgical management.", "journal": "American Journal of Ophthalmology Case Reports", "publication_date": "2025-06-01", "publication_year": 2025, "doi": "10.1016/j.ajoc.2025.102359", "pubmed_id": "40535325", "source_url": "https://doi.org/10.1016/j.ajoc.2025.102359", "keywords": "Medicine, Psilocybin, Foreign body, Surgery, Anesthesia, Hallucinogen, Psychiatry, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Hallucinations in medical conditions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4410946123\",\"openalex_url\":\"https://openalex.org/W4410946123\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W25265873\",\"https://openalex.org/W1485232062\",\"https://openalex.org/W1488419107\",\"https://openalex.org/W1964253779\",\"https://openalex.org/W1967832780\",\"https://openalex.org/W1973153922\",\"https://openalex.org/W1982625002\",\"https://openalex.org/W1990802823\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2000163942\",\"https://openalex.org/W2000419239\",\"https://openalex.org/W2019517327\",\"https://openalex.org/W2024964629\",\"https://openalex.org/W2026792720\",\"https://openalex.org/W2031931099\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2074592380\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2079258526\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115683886\",\"https://openalex.org/W2119169680\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2140629404\",\"https://openalex.org/W2143830348\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2156414904\",\"https://openalex.org/W2186722690\",\"https://openalex.org/W2266435781\",\"https://openalex.org/W2302330318\",\"https://openalex.org/W2328027868\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2413619871\",\"https://openalex.org/W2417652823\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2531794899\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2593564506\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2757390367\",\"https://openalex.org/W2758542882\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2790481213\",\"https://openalex.org/W2793042385\",\"https://openalex.org/W2794118706\",\"https://openalex.org/W2797762872\",\"https://openalex.org/W2804789712\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2891256775\",\"https://openalex.org/W2894431596\",\"https://openalex.org/W2903619067\",\"https://openalex.org/W2905791849\",\"https://openalex.org/W2994886340\",\"https://openalex.org/W3006069447\",\"https://openalex.org/W3011879014\",\"https://openalex.org/W3014694911\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3037934079\",\"https://openalex.org/W3046147488\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3109742642\",\"https://openalex.org/W3112874964\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3135650175\",\"https://openalex.org/W3150029331\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3209897336\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4303928079\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4367043450\",\"https://openalex.org/W4378952365\",\"https://openalex.org/W4393152707\",\"https://openalex.org/W4394684735\",\"https://openalex.org/W4399265928\",\"https://openalex.org/W4406149995\",\"https://openalex.org/W4407263257\",\"https://openalex.org/W6686723187\",\"https://openalex.org/W6716841330\",\"https://openalex.org/W6728496540\",\"https://openalex.org/W6744325583\",\"https://openalex.org/W6771370531\",\"https://openalex.org/W6780142453\",\"https://openalex.org/W6793570898\",\"https://openalex.org/W6851585595\",\"https://openalex.org/W6853330759\"],\"authorships\":[{\"id\":null,\"display_name\":\"Abigail M. Blanton\",\"orcid\":\"https://orcid.org/0009-0007-6259-9265\"},{\"id\":\"https://openalex.org/A5076185892\",\"display_name\":\"Pooja Parikh\",\"orcid\":\"https://orcid.org/0000-0001-5996-6959\"},{\"id\":null,\"display_name\":\"Scott Zhou\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104560224\",\"display_name\":\"Mohamed Mohamed\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065398495\",\"display_name\":\"Rafael Ufret-Vincenty\",\"orcid\":\"https://orcid.org/0000-0001-8022-5119\"},{\"id\":\"https://openalex.org/A5043578488\",\"display_name\":\"Ronald Mancini\",\"orcid\":\"https://orcid.org/0000-0002-6454-7238\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2765008417\",\"source_display_name\":\"American Journal of Ophthalmology Case Reports\",\"landing_page_url\":\"https://doi.org/10.1016/j.ajoc.2025.102359\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Case Report,Safety,Toxicity", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4410946123" }, { "id": 680, "title": "The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.", "normalized_title": "the therapeutic effects of psychedelics for opioid use disorder a systematic review of clinical studies", "authors": "Weleff J, Pulido-Saavedra A, Aghaei AM, Ing K, Arakelian M, Fontenele R, Nero N, Barnett BS, Anand A, Bassir Nia A, Angarita GA", "abstract": "Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor system deserve attention. Preclinical, clinical, and naturalistic studies of psychedelics have shown some evidence that they may reduce opioid and other substance use. Here, we present the results of a systematic review of clinical studies investigating the therapeutic applications of psychedelics for OUD to describe the current state of the literature and guide future clinical study design in this area. Findings indicate few studies completed using serotonergic psychedelics, with most investigating ibogaine or ketamine. In addition, findings are limited by many studies of weak design focused on opioid withdrawal, and few double-blind or placebo-controlled trials with considerable methodological heterogeneity making comparisons difficult across compounds. Most studies were found to have a high risk of bias mostly related to lack of randomization, blinding, and blinding of assessment outcomes. We outline these limitations and steps towards improving the quality of future studies of psychedelics for OUD.", "journal": "Psychiatry research", "publication_date": "2025-05-31", "publication_year": 2025, "doi": "10.1016/j.psychres.2025.116446", "pubmed_id": "40147088", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40147088/", "keywords": "Ayahuasca, Ibogaine, Ketamine, LSD, Noribogaine, Opioid use disorder, Psilocybin, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40147088\"}", "topic_tags": "Addiction,Receptor Pharmacology,Systematic Review,Review Article,Animal Study,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 676, "title": "Innovation and inequity in psychedelic research at the Mayo Clinic.", "normalized_title": "innovation and inequity in psychedelic research at the mayo clinic", "authors": "Klim C, VanDreese B, Meyerhoefer T, Breitinger S", "abstract": "This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and ethical practices. We highlight instances where researchers prioritized scientific progress over the autonomy, safety, and equitable treatment of research subjects, and discuss this history in the context of ongoing challenges with informed consent and equity in contemporary psychedelic research.", "journal": "History of psychiatry", "publication_date": "2025-05-31", "publication_year": 2025, "doi": "10.1177/0957154x251318489", "pubmed_id": "40293719", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40293719/", "keywords": "Bioethics, LSD, psilocybin, psychedelics, schizophrenia", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:35", "raw_json": "{\"pubmed_id\":\"40293719\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 690, "title": "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa", "normalized_title": "therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa", "authors": "Stéphanie Knatz Peck, Timothy D. Brewerton, Hannah M. Fisher, Julie Trim, Samantha Shao, Nadav Liam Modlin, Jessie Kim, Daphna M. Finn, Walter H. Kaye", "abstract": "BACKGROUND: Psychedelic treatment is a rapidly emerging therapeutic approach for a host of chronic, difficult to treat psychiatric disorders, including anorexia nervosa (AN). Trauma and its sequelae, such as dissociation, often contribute to comorbidity and treatment refractoriness. AIMS: In this report, we describe the therapeutic emergence of previously dissociated traumatic memories of sexual assault in 2 of 10 research participants with AN while receiving psilocybin treatment. METHODS: Ten female adults who met DSM-5 criteria for AN or pAN (partial remission) participated in an open pilot study evaluating the safety, tolerability and preliminary efficacy of psilocybin-assisted psychotherapy. Participants received a 25-mg dose of investigational drug COMP360, a proprietary pharmaceutical-grade synthetic psilocybin formulation developed by COMPASS Pathfinder Ltd. administered in conjunction with psychological support. Participants also received two integration therapy sessions on days 1 and 7 after dosing, and they were reassessed at 1 and 3 months. Participants were interviewed using a semi-structured interview to understand qualitative perspectives of treatment and its effect on AN. RESULTS/OUTCOMES: Both patients described in this report significantly benefited from the emergence and processing of previously dissociated information (dissociative amnesia), and both patients subsequently attained remission of their AN psychopathology at 3-month follow-up as determined by global scores on the Eating Disorder Examination Questionnaire (EDE-Q) and clinically meaningful weight gain. CONCLUSIONS/INTERPRETATION: PT may hold promise not only in the treatment of eating disorders but also trauma-related disorders, including PTSD and dissociative amnesia. Potential mechanisms of psilocybin's facilitation of remembering and processing traumatic material is reviewed.", "journal": "Journal of Eating Disorders", "publication_date": "2025-05-25", "publication_year": 2025, "doi": "10.1186/s40337-025-01274-2", "pubmed_id": "40420197", "source_url": "https://doi.org/10.1186/s40337-025-01274-2", "keywords": "Psilocybin, Anorexia nervosa, Psychotherapist, Anorexia, Psychology, Hallucinogen, Psychiatry, Medicine, Eating disorders, Internal medicine, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4410748059\",\"openalex_url\":\"https://openalex.org/W4410748059\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":14,\"referenced_works\":[\"https://openalex.org/W200611915\",\"https://openalex.org/W1037524820\",\"https://openalex.org/W1550747465\",\"https://openalex.org/W1670638839\",\"https://openalex.org/W1700831417\",\"https://openalex.org/W1745013798\",\"https://openalex.org/W1981459575\",\"https://openalex.org/W1985388019\",\"https://openalex.org/W2016528883\",\"https://openalex.org/W2018758190\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2047326118\",\"https://openalex.org/W2058396187\",\"https://openalex.org/W2074099337\",\"https://openalex.org/W2080226432\",\"https://openalex.org/W2080942111\",\"https://openalex.org/W2087755851\",\"https://openalex.org/W2090755443\",\"https://openalex.org/W2091537705\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2103550195\",\"https://openalex.org/W2108198599\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2121654107\",\"https://openalex.org/W2124556602\",\"https://openalex.org/W2128395670\",\"https://openalex.org/W2146205180\",\"https://openalex.org/W2152313829\",\"https://openalex.org/W2245231029\",\"https://openalex.org/W2274028393\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2413044490\",\"https://openalex.org/W2478045598\",\"https://openalex.org/W2495524933\",\"https://openalex.org/W2546678366\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2574342053\",\"https://openalex.org/W2578935374\",\"https://openalex.org/W2594295003\",\"https://openalex.org/W2614942140\",\"https://openalex.org/W2624901555\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2760803310\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2790387088\",\"https://openalex.org/W2801553051\",\"https://openalex.org/W2890244914\",\"https://openalex.org/W2890413513\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2986535718\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3083797211\",\"https://openalex.org/W3086711439\",\"https://openalex.org/W3095504969\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3100349700\",\"https://openalex.org/W3118672806\",\"https://openalex.org/W3132599860\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3189409675\",\"https://openalex.org/W3203772461\",\"https://openalex.org/W3205506305\",\"https://openalex.org/W3215956939\",\"https://openalex.org/W4211102005\",\"https://openalex.org/W4214560099\",\"https://openalex.org/W4220695431\",\"https://openalex.org/W4220877964\",\"https://openalex.org/W4220956513\",\"https://openalex.org/W4224926134\",\"https://openalex.org/W4229073012\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293242421\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4308899803\",\"https://openalex.org/W4308953446\",\"https://openalex.org/W4309561826\",\"https://openalex.org/W4311498973\",\"https://openalex.org/W4312064886\",\"https://openalex.org/W4318052287\",\"https://openalex.org/W4320896428\",\"https://openalex.org/W4362457938\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4382813188\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4385664009\",\"https://openalex.org/W4385812248\",\"https://openalex.org/W4385812348\",\"https://openalex.org/W4389274137\",\"https://openalex.org/W4396789594\",\"https://openalex.org/W4401228042\",\"https://openalex.org/W7074234824\"],\"authorships\":[{\"id\":\"https://openalex.org/A5011897192\",\"display_name\":\"Stéphanie Knatz Peck\",\"orcid\":\"https://orcid.org/0000-0001-9421-9158\"},{\"id\":\"https://openalex.org/A5015213864\",\"display_name\":\"Timothy D. Brewerton\",\"orcid\":\"https://orcid.org/0000-0001-9655-3600\"},{\"id\":\"https://openalex.org/A5041834457\",\"display_name\":\"Hannah M. Fisher\",\"orcid\":\"https://orcid.org/0000-0001-8769-6060\"},{\"id\":\"https://openalex.org/A5002166417\",\"display_name\":\"Julie Trim\",\"orcid\":null},{\"id\":\"https://openalex.org/A5057873669\",\"display_name\":\"Samantha Shao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037169539\",\"display_name\":\"Nadav Liam Modlin\",\"orcid\":\"https://orcid.org/0000-0002-3900-4354\"},{\"id\":\"https://openalex.org/A5104262515\",\"display_name\":\"Jessie Kim\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051999008\",\"display_name\":\"Daphna M. Finn\",\"orcid\":\"https://orcid.org/0000-0003-2572-7778\"},{\"id\":\"https://openalex.org/A5086371093\",\"display_name\":\"Walter H. Kaye\",\"orcid\":\"https://orcid.org/0000-0002-4478-4906\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210234357\",\"source_display_name\":\"Journal of Eating Disorders\",\"landing_page_url\":\"https://doi.org/10.1186/s40337-025-01274-2\",\"is_oa\":true}}", "topic_tags": "PTSD,Eating Disorders,Chronic Pain,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4410748059" }, { "id": 881, "title": "Clinical pharmacology.", "normalized_title": "clinical pharmacology", "authors": "Vogt SB, Liechti ME.", "abstract": "To design therapeutic trials and select the most appropriate substance and dose for an indication, a detailed understanding of clinical pharmacology is crucial. In recent years, several studies have explored the human pharmacology of different psychedelics and 3,4-methylendioxymethylamphetamin (MDMA). This chapter summarizes pharmacological characteristics of the serotonergic psychedelics psilocybin, lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT (5-MeO-DMT), and MDMA. We summarize their mechanisms of action, pharmacokinetics, pharmacodynamics, metabolism, and safety, with a focus on human data from modern clinical trials. Additionally, we provide recommendations for dosing, dose adjustment, and interactions with other medications. We show that the different serotonergic psychedelics produce overall comparable acute subjective and somatic effects primarily through interactions with 5-HT2A receptors. However, the exact mechanisms of their potential therapeutic benefits in patients remain to be elucidated. Moreover, classic psychedelics differ substantially in their pharmacokinetics and metabolism, resulting mainly in different durations of action, which may influence their suitability for specific therapeutic uses and indications. In contrast, MDMA has a psychopharmacological profile that is distinct from serotonergic psychedelics, characterized by acute stimulant-like and empathogenic effects. In terms of pharmacokinetic-pharmacodynamic relationships, acute effects of the psychedelics mirror their plasma-concentration-time curves, whereas acute effects of MDMA are shorter-lasting than its presence in the body. Thus, MDMA, but not the psychedelics, exhibits marked acute pharmacological tolerance. A good understanding of the pharmacology of classic psychedelics and MDMA forms the basis for their clinical use and the design of clinical therapeutic trials.", "journal": null, "publication_date": "2025-05-22", "publication_year": 2025, "doi": "10.1016/bs.irn.2025.02.003", "pubmed_id": "40541320", "source_url": "https://doi.org/10.1016/bs.irn.2025.02.003", "keywords": "Animals, Humans, Hallucinogens, Pharmacology, Clinical, Clinical Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40541320\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 588, "title": "Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.", "normalized_title": "lessons learned from the regulatory alignment in ketamine esketamine and arketamine clinical trials a cross sectional analysis of protocols from clinicaltrials gov", "authors": "Swieczkowski D, Kwaśny A, Sadko K, Pruc M, Gaca Z, Szarpak L, Cubała WJ.", "abstract": "Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-sectional study evaluates the regulatory alignment of 40 clinical trials listed on ClinicalTrials.gov, focusing on the methodological challenges. The study highlights methodological inconsistencies, particularly around the challenges of functional unblinding caused by ketamine's dissociative effects, addressing expectancy bias, and the inadequate safety monitoring practices in many trials. A notable concern is the variability in blinding techniques, with many trials failing to adequately mask the perceptual effects of ketamine, potentially compromising outcome assessments. Furthermore, the placebo response, which accounts for a significant portion of treatment effects, was not consistently managed across trials, and safety strategies, particularly for monitoring adverse events such as dissociation and abuse potential, were not uniformly robust. Another critical issue is the lack of long-term follow-up in most trials, limiting the understanding of ketamine's safety profile over extended periods. The findings emphasize the need for harmonized and rigorous methodological frameworks to support the effective use of ketamine and its enantiomers in clinical practice. The potential lessons learned from these trials could be instrumental in guiding future research on other psychedelics currently under investigation for mental health disorders, such as psilocybin and DMT, ensuring both efficacy and safety in future therapeutic approaches. Such harmonization will be crucial to improve regulatory approval and achieve therapeutic success in real-world applications, making these treatments more accessible and reliable for patients with TRD.", "journal": null, "publication_date": "2025-05-21", "publication_year": 2025, "doi": "10.1016/j.psychres.2025.116559", "pubmed_id": "40440859", "source_url": "https://doi.org/10.1016/j.psychres.2025.116559", "keywords": "Humans, Ketamine, Antidepressive Agents, Cross-Sectional Studies, Clinical Trials as Topic, Depressive Disorder, Treatment-Resistant, Outcome Assessment, Health Care", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40440859\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3762, "title": "Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments", "normalized_title": "under pressure stronger depressive symptoms are associated with more positive expectations towards experimental treatments", "authors": "Basedow LA, Lottes L, Falkenberg I, Vogelbacher C, Yildiz C.", "abstract": "Background: Despite significant advancements in the treatment of depression, challenges such as inadequate response rates and high placebo effects highlight the need for improved therapies and a deeper understanding of treatment expectations. Patient expectations play a crucial role in treatment outcomes but have not been systematically investigated in the context of novel interventions like ketamine and psilocybin. Objectives: This study aimed to assess patient acceptance, experiences, and expectations regarding established depression treatments (psychotherapy, psychotherapy plus antidepressants) and novel interventions (ketamine-assisted therapy, psilocybin-assisted therapy, psychotherapy plus placebo). Methods: A web-based survey (N = 404) was conducted using a case vignette depicting a patient diagnosed with severe depression. Participants rated treatment acceptance, ranked treatment preferences, and reported expectations regarding improvement, worsening, and side effects for each intervention. Depression severity was assessed using the Patient Health Questionnaire-9 (PHQ-9). Repeated-measures analyses of variance (RM-ANOVA) and multilevel modeling were used to examine the relationship between treatment expectations and depression severity. Results: Established treatments were more accepted and preferred over novel interventions, with psychotherapy receiving the highest acceptance (98.3%) and psilocybin the lowest (47.5%). Participants expected greater symptom improvement from traditional treatments compared to ketamine and psilocybin, which were associated with higher expectations of worsening and side effects. However, higher depression severity was linked to more favorable expectations of ketamine- and psilocybin-assisted therapy. This effect was specific to novel treatments and was not observed for psychotherapy or antidepressants. Conclusions: Traditional depression treatments are viewed as more acceptable and effective, while novel interventions evoke skepticism, likely due to unfamiliarity and concerns about risks. However, individuals with more severe depressive symptoms exhibit greater openness to innovative treatments. These findings underline the importance of managing patient expectations in psychedelic-assisted therapy and suggest that clinician education and well-balanced informed consent procedures could improve treatment acceptance.", "journal": "PsyArXiv", "publication_date": "2025-05-15", "publication_year": 2025, "doi": "10.31234/osf.io/6hjkm_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/6hjkm_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:19", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR1022290\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Aging,Observational Study,Healthcare Workers,Safety,Adverse Events", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3183, "title": "Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments", "normalized_title": "under pressure stronger depressive symptoms are associated with more positive expectations towards experimental treatments", "authors": "", "abstract": "Background: Despite significant advancements in the treatment of depression, challenges such as inadequate response rates and high placebo effects highlight the need for improved therapies and a deeper understanding of treatment expectations. Patient expectations play a crucial role in treatment outcomes but have not been systematically investigated in the context of novel interventions like ketamine and psilocybin. Objectives: This study aimed to assess patient acceptance, experiences, and expectations regarding established depression treatments (psychotherapy, psychotherapy plus antidepressants) and novel interventions (ketamine-assisted therapy, psilocybin-assisted therapy, psychotherapy plus placebo). Methods: A web-based survey (N = 404) was conducted using a case vignette depicting a patient diagnosed with severe depression. Participants rated treatment acceptance, ranked treatment preferences, and reported expectations regarding improvement, worsening, and side effects for each intervention. Depression severity was assessed using the Patient Health Questionnaire-9 (PHQ-9). Repeated-measures analyses of variance (RM-ANOVA) and multilevel modeling were used to examine the relationship between treatment expectations and depression severity. Results: Established treatments were more accepted and preferred over novel interventions, with psychotherapy receiving the highest acceptance (98.3%) and psilocybin the lowest (47.5%). Participants expected greater symptom improvement from traditional treatments compared to ketamine and psilocybin, which were associated with higher expectations of worsening and side effects. However, higher depression severity was linked to more favorable expectations of ketamine- and psilocybin-assisted therapy. This effect was specific to novel treatments and was not observed for psychotherapy or antidepressants. Conclusions: Traditional depression treatments are viewed as more acceptable and effective, while novel interventions evoke skepticism, likely due to unfamiliarity and concerns about risks. However, individuals with more severe depressive symptoms exhibit greater openness to innovative treatments. These findings underline the importance of managing patient expectations in psychedelic-assisted therapy and suggest that clinician education and well-balanced informed consent procedures could improve treatment acceptance.", "journal": "PsyArXiv", "publication_date": "2025-05-15", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/6hjkm_v1", "keywords": "Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"6hjkm_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Aging,Observational Study,Healthcare Workers,Safety,Adverse Events", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 383, "title": "Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions", "normalized_title": "effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions", "authors": "Roland R. Griffiths, Robert L. Jesse, William A. Richards, Matthew W. Johnson, Nathan D. Sepeda, Anthony P. Bossis, Stephen Ross", "abstract": "Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy. Methods: = 16) at 6 months after screening using self-report measures. The effects of psilocybin were also assessed on session days and 4 and 16 months after the second psilocybin session in the 24 participants who completed both sessions. Results: The primary outcome assessment at 6 months after screening showed that, compared with the delayed control group, participants who had received psilocybin reported significantly greater positive changes in their religious practices, attitudes about their religion, and effectiveness as a religious leader, as well as in their non-religious attitudes, moods, and behavior. Follow-up assessments showed that positive changes in religious and non-religious attitudes and behavior were sustained through 16 months after the second psilocybin session. At that time, participants rated at least one of their psilocybin experiences to be among the top five most spiritually significant (96%), profoundly sacred (92%), psychologically insightful (83%), and psychologically meaningful (79%) of their lives. Furthermore, 42% rated one of their experiences to be the single most profound of their lifetime. At 16-months follow-up, most (79%) strongly endorsed that the experiences had positive effects on their religious practices (e.g., prayer or meditation) and their daily sense of the sacred, and most (71%) reported positive changes in their appreciation of religious traditions other than their own. Although no serious adverse events were reported, 46% rated a psilocybin experience as among the top five most psychologically challenging of their lives. Conclusions: In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.", "journal": "Psychedelic Medicine", "publication_date": "2025-05-15", "publication_year": 2025, "doi": "10.1089/psymed.2023.0044", "pubmed_id": "41869007", "source_url": "https://doi.org/10.1089/psymed.2023.0044", "keywords": "Psilocybin, Psychology, Hallucinogen, Social psychology, Psychotherapist, Sociology, Psychiatry, Psychedelics and Drug Studies, Religion, Spirituality, and Psychology, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4410448036\",\"openalex_url\":\"https://openalex.org/W4410448036\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":14,\"referenced_works\":[\"https://openalex.org/W566412202\",\"https://openalex.org/W1622279043\",\"https://openalex.org/W1965146355\",\"https://openalex.org/W1976379854\",\"https://openalex.org/W1992059353\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2025224127\",\"https://openalex.org/W2040034137\",\"https://openalex.org/W2051861629\",\"https://openalex.org/W2066387909\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2077348308\",\"https://openalex.org/W2079106221\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114302411\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2139192721\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2164158534\",\"https://openalex.org/W2325207359\",\"https://openalex.org/W2332087446\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2537027964\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2604452528\",\"https://openalex.org/W2738683289\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2940999002\",\"https://openalex.org/W2943533317\",\"https://openalex.org/W2981695213\",\"https://openalex.org/W3005896034\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107835125\",\"https://openalex.org/W3156830775\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4213359974\",\"https://openalex.org/W4229920826\",\"https://openalex.org/W4240789427\",\"https://openalex.org/W4283584241\",\"https://openalex.org/W4291417178\",\"https://openalex.org/W4293101934\",\"https://openalex.org/W4293756089\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4302573313\",\"https://openalex.org/W4307838483\",\"https://openalex.org/W4309139242\",\"https://openalex.org/W4322495849\",\"https://openalex.org/W4378782231\",\"https://openalex.org/W4390495773\",\"https://openalex.org/W4399646075\"],\"authorships\":[{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"},{\"id\":\"https://openalex.org/A5109843219\",\"display_name\":\"Robert L. Jesse\",\"orcid\":null},{\"id\":\"https://openalex.org/A5039889194\",\"display_name\":\"William A. Richards\",\"orcid\":\"https://orcid.org/0000-0003-0730-9249\"},{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5061776312\",\"display_name\":\"Nathan D. Sepeda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5015516801\",\"display_name\":\"Anthony P. Bossis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2023.0044\",\"is_oa\":false}}", "topic_tags": "Wellbeing,Spirituality,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4410448036" }, { "id": 885, "title": "Serotonergic psychedelics for depression: A comprehensive overview.", "normalized_title": "serotonergic psychedelics for depression a comprehensive overview", "authors": "Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D.", "abstract": "Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatment-resistant cases. Over the past decade, advances in research have elucidated the antidepressant potential of psilocybin and other 5-HT₂A receptor agonists in patients with major depressive disorder (MDD) and treatment-resistant depression (TRD). Phase I and II clinical trials have consistently demonstrated that even a single administration can yield rapid and sustained symptom reduction. These effects compare favourably with conventional pharmacotherapies such as SSRIs and ketamine. The distinctive pharmacological profile and robust safety data associated with serotonergic psychedelics make them particularly promising candidates, especially for patients who do not respond to standard treatments. Nonetheless, several challenges impede their integration into routine clinical practice, including the resource-intensive nature of psychedelic-assisted therapy, which demands specialized training and controlled settings. Despite those limitations, some countries including Australia, Switzerland or Canada are paving the way by allowing the use of psilocybin in TRD cases. This chapter reviews the antidepressant potential of psilocybin, DMT, ayahuasca and 5-MeO-DMT based on modern clinical trial data, comparing effect sizes of psychedelics to conventional treatments like SSRIs and ketamine, and provides a brief overview of their potential neurobiological mechanisms.", "journal": null, "publication_date": "2025-05-13", "publication_year": 2025, "doi": "10.1016/bs.irn.2025.04.009", "pubmed_id": "40541312", "source_url": "https://doi.org/10.1016/bs.irn.2025.04.009", "keywords": "Animals, Humans, Hallucinogens, Antidepressive Agents, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"40541312\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 674, "title": "The pharmacological treatment of anxiety in people with eating disorders: A systematic review.", "normalized_title": "the pharmacological treatment of anxiety in people with eating disorders a systematic review", "authors": "Morris R, Keeler J, Treasure J, Himmerich H.", "abstract": "People with eating disorders experience high rates of psychiatric comorbidities, including anxiety disorders such as generalised anxiety disorder, social anxiety disorder and specific phobias. Anxiety can influence the prognosis of an eating disorder, by worsening symptoms, and acting as a barrier to treatment. Therefore, targeting treatment efforts towards anxiety may improve eating disorder outcomes. The primary aim of this systematic review was to summarise the evidence base for the pharmacological treatment of anxiety symptoms in people with eating disorders. An electronic search of three databases (PubMed, Medline, and PsycInfo) was conducted. Papers were included if they investigated pharmacotherapy (antidepressants, antipsychotics, antianxiety, psychedelics, etc.) in eating disorder samples, with primary or secondary outcomes of anxiety. A total of 51 studies were included, and results were mixed across drug classes documenting both favourable and non-significant anxiety outcomes. There was evidence for the use of fluoxetine for anxiety in anorexia and bulimia nervosa, but not for binge eating disorder. Evidence for the use of olanzapine was documented for anxiety in AN, and preliminary case reports suggested its use in ARFID for anxiety symptoms. Preliminary evidence for developing pharmacological agents, such as psilocybin and ketamine, reported favourable outcomes in AN patients. More RCTs are required to explore efficacy and safety of pharmacological agents in treating anxiety in people with eating disorders.", "journal": null, "publication_date": "2025-05-13", "publication_year": 2025, "doi": "10.1016/j.phrs.2025.107782", "pubmed_id": "40378942", "source_url": "https://doi.org/10.1016/j.phrs.2025.107782", "keywords": "Animals, Humans, Anti-Anxiety Agents, Antipsychotic Agents, Antidepressive Agents, Anxiety, Anxiety Disorders, Feeding and Eating Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40378942\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Eating Disorders,Randomized Controlled Trial,Systematic Review,Review Article,Case Report,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3426, "title": "A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder", "normalized_title": "a phase 2a placebo controlled randomized double blind trial to evaluate the safety tolerability and preliminary efficacy of psilocybin oral solution in adults with generalized anxiety disorder", "authors": "Queen's University", "abstract": "This Phase 2a clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of a 3 mg dose of psilocybin oral solution for the treatment of Generalized Anxiety Disorder (GAD). The study consists of three sequential phases: Screening Phase (up to 4 weeks), Open-label Run-in Phase (4 weeks), Double-blind Treatment Phase (4 weeks) Screening Phase During the Screening Visit, participants will provide informed consent and undergo a comprehensive medical evaluation, including an abbreviated psychiatric assessment, to determine eligibility. To qualify, patients must have a clinician-rated Hamilton Anxiety Rating Scale (HAM-A) score ≥14. Additionally, participants must not be on regular anxiolytic treatment or must have discontinued such treatment at least 4 weeks prior to the start of the Open-label Run-in Phase. Open-label Run-in Phase Eligible patients will proceed to the 4-week Open-label Run-in Phase. During this phase, patients will attend four weekly clinic visits, supplemented by weekly remote contacts (via phone or email). At different timepoints during the OL Run-in Phase, participants will complete safety assessments, undergo cognitive testing and EEG and other patient reported outcomes (PROs). Double-blind Treatment Phase Participants who demonstrate a treatment response during the Open-label Phase-defined as a ≥50% reduction in GAD-7 score from baseline-will be randomized 1:1 to receive either psilocybin oral solution or placebo at the Double-blind Baseline Visit. Patients not meeting the response criteria will undergo End-of-Treatment (ET) procedures at this visit. At different timepoints during the DB Treatment Phase, participants will complete safety assessments, undergo cognitive testing and EEG and other patient reported outcomes (PROs). Completion of the End of Treatment (ET) phase will be 2 weeks to further assess safety and PROs.", "journal": "ClinicalTrials.gov", "publication_date": "2025-05-12", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06969170", "keywords": "Generalized Anxiety Disorder (GAD), Psilocybin (drug), Placebo, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06969170\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Anxiety,Brain Imaging,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 630, "title": "The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.", "normalized_title": "the effect of psychedelic microdosing on animal behavior a review with recommendations for the field", "authors": "Syed OA, Petranker R, Tsang B.", "abstract": "Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is associated with many benefits to mood, well-being and health, research in this area is in its early stages and predominantly centered on human applications. In this narrative review, we synthesize the findings from studies investigating the effects of microdosing on the behaviors of three animal species: rats, mice, and zebrafish. A total of 12 studies were identified that implemented a microdosing regimen of LSD, psilocybin, or DMT in these animal models. Overall, microdosing caused little changes in behaviors associated with anxiety- and depressive-like states. Moreover, while microdosing was well-tolerated across species, further research is needed to capture specific safety concerns. Finally, we critically appraise the studies included in this review based on their methodologies and discuss further avenues of research to advance the preclinical literature on psychedelic microdosing. Specifically, we recommend that future research prioritize the replication of existing findings to inform the development of robust study designs and dosing protocols, as well as establish standardized methodologies to enable effective comparisons across different animal models. Furthermore, future investigations should explore the therapeutic potential of mescaline microdosing, examine sex-dependent effects, and extend research to additional models of psychiatric conditions, including those related to obsessive-compulsive disorder and post-traumatic stress disorder.", "journal": null, "publication_date": "2025-05-08", "publication_year": 2025, "doi": "10.1016/j.neubiorev.2025.106204", "pubmed_id": "40348309", "source_url": "https://doi.org/10.1016/j.neubiorev.2025.106204", "keywords": "Animals, Mice, Rats, N,N-Dimethyltryptamine, Lysergic Acid Diethylamide, Hallucinogens, Behavior, Animal, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40348309\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,OCD,Microdosing,Wellbeing,Review Article,Animal Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 703, "title": "A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.", "normalized_title": "a protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end of life", "authors": "Kratina S, Strike C, Schwartz R, Nayfeh A, Jopling S, Lo C, Rush B.", "abstract": "Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their outcomes related to anxiety and depression, long-term effects and safety. Despite this progress, a wide range of both substances (such as ayahuasca, psilocybin, ketamine) and therapeutic approaches (such as psychedelics alone, or psychotherapy assisted with a psychedelic) in the use of psychedelic interventions specifically for end-of-life populations, has not been adequately covered by reviews to date. The aim of this scoping review is to identify and learn from the variety of psychedelic substances and therapeutic approaches that exists within the research on therapeutic psychedelic interventions reported in populations coping with psychological suffering associated with life-threatening illness and the end of life itself. We will follow Arksey and O'Malley's (2005) framework for scoping reviews while incorporating updated methodological guidance. The Preferred Reporting Items for Systematic Review and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guideline will be used to organize the search and identification of research focusing on psychedelic interventions, psychological suffering, and end-of-life issues. Health science databases such as Medline, Embase, APA PsychINFO, and CINAHL will be searched. The search will be limited to empirical published data on 'end-of-life', 'psychedelics', and 'psychological suffering'. Data extracted from selected studies will cover intervention details, participant characteristics, measured outcomes, and theorised mechanisms. The insights gained from this review will be used to inform future research and discussions on how psychedelics can be integrated into care strategies for populations coping with end-of-life concerns. This scoping review does not require ethics approval.", "journal": null, "publication_date": "2025-05-05", "publication_year": 2025, "doi": "10.1371/journal.pone.0318343", "pubmed_id": "40327705", "source_url": "https://doi.org/10.1371/journal.pone.0318343", "keywords": "Humans, Hallucinogens, Terminal Care, Stress, Psychological, Psilocybin, Scoping Reviews As Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40327705\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Mechanism of Action,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4381, "title": "Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi Study", "normalized_title": "improving best practice indicators for psilocybin assisted therapy using a mul tiphase mixed methods delphi study", "authors": "Kim Hoffman, Todd P. Korthuis, Kellie Pertl, David Morgan", "abstract": "Most Delphi studies primarily rely on questionnaires and subsequent quantitative ratings across multiple rounds to learn about a complex issue. This article demonstrates the integration of qualitative inquiry into a Delphi study to enhance and complement quantitative findings. We conducted a mixed methods Delphi study to establish a comprehensive list of quality and safety indicators for best practices in psilocybin therapy. Our qualitative methods entailed interviewing 37 providers and content experts with significant knowledge of Psilocybin Assisted Therapy to address one or more of the following goals: (a) provide a rationale for maintaining or removing quality and safety indicators, (b) improve indicator wording, (c) consolidate them or alter the timing of their consideration during therapy, and (d) provide contextual explanations for our decisions. Qualitative inquiry yielded important findings, as participants identified new dimensions of safety that extended beyond our initial scope. By using a mixed methods design, we demonstrate that both exploratory and explanatory qualitative methods can make a vital contribution to Delphi methods, extending beyond the use of quantitative ratings.", "journal": "International Journal of Multiple Research Approaches", "publication_date": "2025-04-29", "publication_year": 2025, "doi": "10.29034/ijmra.v17n1a1", "pubmed_id": null, "source_url": "https://doi.org/10.29034/ijmra.v17n1a1", "keywords": "Delphi method, Psilocybin, Best practice, Delphi, Qualitative research, Psychology, Interview, Quality (philosophy), Qualitative property, Project commissioning, Exploratory research, Medical education, Applied psychology, Multimethodology, Qualitative analysis, Medicine, Management science, Nursing, Likert scale, Knowledge management, Publishing, Psychedelics and Drug Studies, Digital Mental Health Interventions, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7155048769\",\"openalex_url\":\"https://openalex.org/W7155048769\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W404881792\",\"https://openalex.org/W1966931250\",\"https://openalex.org/W2057327092\",\"https://openalex.org/W2169150420\",\"https://openalex.org/W2494023991\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2889856658\",\"https://openalex.org/W2893125316\",\"https://openalex.org/W2955805233\",\"https://openalex.org/W3006405313\",\"https://openalex.org/W3026401238\",\"https://openalex.org/W3088209892\",\"https://openalex.org/W3095323780\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4205194127\",\"https://openalex.org/W4256578005\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4323924535\",\"https://openalex.org/W4385265010\",\"https://openalex.org/W4399780176\",\"https://openalex.org/W4402516078\",\"https://openalex.org/W7130518933\"],\"authorships\":[{\"id\":\"https://openalex.org/A5082885757\",\"display_name\":\"Kim Hoffman\",\"orcid\":\"https://orcid.org/0000-0003-3063-7881\"},{\"id\":\"https://openalex.org/A5134138286\",\"display_name\":\"Todd P. Korthuis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073745691\",\"display_name\":\"Kellie Pertl\",\"orcid\":\"https://orcid.org/0009-0008-0861-3609\"},{\"id\":\"https://openalex.org/A5041896752\",\"display_name\":\"David Morgan\",\"orcid\":\"https://orcid.org/0000-0002-6571-5731\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S78581589\",\"source_display_name\":\"International Journal of Multiple Research Approaches\",\"landing_page_url\":\"https://doi.org/10.29034/ijmra.v17n1a1\",\"is_oa\":false}}", "topic_tags": "Chronic Pain,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7155048769" }, { "id": 4386, "title": "Psilocybin-assisted therapy shows range of benefits in cancer patients", "normalized_title": "psilocybin assisted therapy shows range of benefits in cancer patients", "authors": "", "abstract": "Psychotherapy in combination with pharmacological treatments is often used to treat affective symptoms in patients with cancer. However, the effectiveness of the most commonly used medications is limited by the risk of adverse effects. Two ­placebo-controlled trials have found that patients with cancer-related psychiatric distress experienced rapid and sustained reductions in depressive and anxiety symptoms following one session of psilocybin-assisted psychotherapy. A new analysis of data from the two studies examined the effects of psilocybin-assisted therapy on a broader range of psychiatric symptoms. The trials employed a crossover design in which patients with cancer received high-dose psilocybin in one session and a control of niacin or low-dose psilocybin in the other. Investigators used the Brief Symptom Inventory to evaluate the effect of psilocybin-assisted therapy on nine psychiatric symptom dimensions: anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, somatization, paranoia, phobia, and psychosis. Among the studies' 79 participants, psilocybin-assisted psychotherapy significantly improved anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, and somatization. Psilocybin-assisted therapy also did not induce lasting paranoia, phobia, or psychosis, with the study's authors writing that these findings add “further evidence that psilocybin can be safely administered following rigorous screening under close medical supervision.” The researchers attributed the multidimensional effects of psilocybin in part to its action on the serotonin 2A receptor. “While larger clinical trials will ultimately be needed to validate these findings, our study suggests that [psilocybin-assisted psychotherapy] has the potential to be a comprehensive mental health treatment for patients with cancer,” the authors wrote. [P. Petridis et al. Nature Mental Health (2024), https://doi.org/10.1038/s44220-024-00331-0]", "journal": "The Brown University Psychopharmacology Update", "publication_date": "2025-04-28", "publication_year": 2025, "doi": "10.1002/pu.31316", "pubmed_id": null, "source_url": "https://doi.org/10.1002/pu.31316", "keywords": "Psilocybin, Medicine, Cancer, Cancer therapy, Pharmacology, Hallucinogen, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409945764\",\"openalex_url\":\"https://openalex.org/W4409945764\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S1022177896\",\"source_display_name\":\"The Brown University Psychopharmacology Update\",\"landing_page_url\":\"https://doi.org/10.1002/pu.31316\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Pharmacology,Receptor Pharmacology,Clinical Trial,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409945764" }, { "id": 3591, "title": "Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial", "normalized_title": "treatment with psilocybin for chronic neuropathic pain and depression transcend an open label clinical trial", "authors": "Centre for Addiction and Mental Health", "abstract": "Psilocybin, the chemical component of \"magic mushrooms\", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.", "journal": "ClinicalTrials.gov", "publication_date": "2025-04-24", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06518720", "keywords": "Treatment Resistant Depression, Chronic Pain, Psilocybin 25 mg, PEX010, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06518720\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 463, "title": "Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis", "normalized_title": "psilocybin assisted psychotherapy as a rapid acting treatment for cancer related depression and anxiety evidence from a network meta analysis", "authors": "Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, Zuzanna Gaca, Łukasz Szarpak, Wiesław Jerzy Cubała", "abstract": "Objective To evaluate psilocybin's efficacy in reducing depressive and anxiety symptoms in cancer patients based on randomized controlled trials (RCTs). Methods This systematic review and network meta-analysis (NMA) followed PRISMA and Cochrane Handbook guidelines. PubMed, Embase and Cochrane Library data up to July 2024 were analyzed. Two RCTs met the inclusion criteria. Changes in Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory (STAI) scores were assessed on day 1 and on 2-week follow-up. The risk of bias was evaluated with the Cochrane Risk of Bias Tool 2.0. Results Psilocybin significantly reduced BDI scores at day 1 post-administration (MD = 2.26; P = 0.01), though effects were not sustained at 2 weeks. STAI state scores showed substantial reductions at both day 1 (MD = 11.52; P < 0.001) and 2 weeks (MD = 12.66; P < 0.001). STAI trait scores also improved on both day 1 and day 14. The highest psilocybin dose (0.3 mg/kg) was the most effective, with SUCRA values of 87.81% (BDI), 91.58% (STAI state), and 94.2% (STAI trait). Conclusions Findings suggest psilocybin may rapidly reduce depressive and anxiety symptoms in cancer patients, but methodological limitations, including the small number of trials, necessitate cautious interpretation. Larger, high-quality RCTs are needed to verify its clinical potential.", "journal": "The International Journal of Psychiatry in Medicine", "publication_date": "2025-04-24", "publication_year": 2025, "doi": "10.1177/00912174251337572", "pubmed_id": "40279353", "source_url": "https://doi.org/10.1177/00912174251337572", "keywords": "Anxiety, Randomized controlled trial, Meta-analysis, Psilocybin, Cochrane Library, Medicine, Beck Depression Inventory, Depression (economics), Systematic review, Psychiatry, Internal medicine, Clinical psychology, MEDLINE, Hallucinogen, Political science, Macroeconomics, Law, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409797469\",\"openalex_url\":\"https://openalex.org/W4409797469\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1529403805\",\"https://openalex.org/W1537972189\",\"https://openalex.org/W1617328014\",\"https://openalex.org/W2042474539\",\"https://openalex.org/W2065621119\",\"https://openalex.org/W2082535915\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2764275027\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W3019350884\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3118615836\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W4233408923\",\"https://openalex.org/W4361292040\",\"https://openalex.org/W4362471767\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4390271950\",\"https://openalex.org/W4391953134\",\"https://openalex.org/W4396223530\",\"https://openalex.org/W4396230194\",\"https://openalex.org/W4401779935\",\"https://openalex.org/W4402500386\",\"https://openalex.org/W4405244747\",\"https://openalex.org/W4405695737\",\"https://openalex.org/W4406306242\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037446509\",\"display_name\":\"Damian Świeczkowski\",\"orcid\":\"https://orcid.org/0000-0002-5648-4652\"},{\"id\":\"https://openalex.org/A5113262565\",\"display_name\":\"Aleksander Kwaśny\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065893595\",\"display_name\":\"Michał Pruc\",\"orcid\":\"https://orcid.org/0000-0002-2140-9732\"},{\"id\":\"https://openalex.org/A5050968304\",\"display_name\":\"Zuzanna Gaca\",\"orcid\":\"https://orcid.org/0009-0004-7200-0402\"},{\"id\":\"https://openalex.org/A5022117993\",\"display_name\":\"Łukasz Szarpak\",\"orcid\":\"https://orcid.org/0000-0002-0973-5455\"},{\"id\":\"https://openalex.org/A5070339940\",\"display_name\":\"Wiesław Jerzy Cubała\",\"orcid\":\"https://orcid.org/0000-0001-6343-8454\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S48834210\",\"source_display_name\":\"The International Journal of Psychiatry in Medicine\",\"landing_page_url\":\"https://doi.org/10.1177/00912174251337572\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409797469" }, { "id": 500, "title": "Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.", "normalized_title": "incremental efficacy systematic review and meta analysis of psilocybin for depression rcts", "authors": "Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA, Aita SL, Hill BD.", "abstract": "RationalePsilocybin is a potentially paradigm-shifting depression intervention. We conducted a systematic review and meta-analysis of psilocybin-for-depression randomized controlled trials (RCTs).ObjectivesSystematically assess harm reporting, risk of bias, action mechanism specification, and incremental therapeutic effect sizes in the psilocybin-for-depression RCT literature.MethodsAssessed databases included PsycINFO, CINAHL, Embase, Medline, Web of Science, and Scopus. Search terms \"Psilocybin\" or \"Psychedelic\" were paired with \"Depression\", and \"Randomized Controlled Trial\" or \"RCT\".ResultsWe identified k = 9 RCTs (k = 10 subgroups) involving n = 602 participants (56% psilocybin). Five studies had low/very low harm quality reporting, opposed to two with high. Most studies demonstrated a high risk of bias. Therapeutic mechanisms of action (MoAs) were discussed in varying detail but rarely assessed in original publications. Psilocybin was moderately superior to controls at reducing depression (g = 0.62; 95% CI = 0.27, 0.98). Effects were heterogenous (τ =.47). Smaller studies evidenced stronger effects that favored psilocybin (Egger's b0 = 3.63, p =.014). Almost all studies documented financial conflicts of interests.ConclusionPsilocybin demonstrates significant depression reduction relative to controls. However, researchers, clinicians, and stakeholders should consider several contextual factors. Effects were moderate and attenuated in larger and better-controlled studies. Harms reporting and risk of bias was high, though partly driven by unique challenges of psilocybin research. MoAs were variably specified but rarely assessed; suggesting it is unclear how depression is reduced. We advise researchers conduct RCTs with active control conditions, larger samples, and include MoA assessments. Independent RCTs from researchers without financial conflicts of interest are needed.", "journal": null, "publication_date": "2025-04-22", "publication_year": 2025, "doi": "10.1007/s00213-025-06788-w", "pubmed_id": "40266291", "source_url": "https://doi.org/10.1007/s00213-025-06788-w", "keywords": "Humans, Hallucinogens, Depression, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40266291\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Healthcare Workers,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 734, "title": "Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.", "normalized_title": "evaluating the effectiveness of psilocybin in alleviating distress among cancer patients a systematic review", "authors": "Lapid MI, Pagali SR, Randall AL, Donovan KA, Bronars CA, Gauthier TA, Bock J, Lim SD, Carey EC, Sokolowski E, Ulrich AM, Hassett LC, Kung S, Whitford KJ, Olivier KR, D'Andre SD.", "abstract": "ObjectivesPsychological and existential distress is prevalent among patients with life-threatening cancer, significantly impacting their quality of life. Psilocybin-assisted therapy has shown promise in alleviating these symptoms. This systematic review aims to synthesize the evidence on the efficacy and safety of psilocybin in reducing cancer-related distress.MethodsWe searched MEDLINE, APA PsycINFO, Cochrane database, Embase, and Scopus from inception to February 8, 2024, for randomized controlled trials (RCTs), open-label trials, qualitative studies, and single case reports that evaluated psilocybin for cancer-related distress. Data were extracted on study characteristics, participant demographics, psilocybin and psychotherapy intervention, outcome measures, and results. Two authors independently screened, selected, and extracted data from the studies. Cochrane Risk of Bias for RCTs and Methodological Index for Non-Randomized Studies criteria were used to evaluate study quality. This study was registered with PROSPERO (CRD42024511692).ResultsFourteen studies met the inclusion criteria, comprising three RCTs, five open-label trials, five qualitative studies, and one single case report. Psilocybin therapy consistently showed significant reductions in depression, anxiety, and existential distress, with improvements sustained over several months. Adverse effects were generally mild and transient.Significance of resultsThis systematic review highlights the potential of psilocybin-assisted therapy as an effective treatment for reducing psychological and existential distress in cancer patients. Despite promising findings, further large-scale, well-designed RCTs are needed to confirm these results and address existing research gaps.", "journal": null, "publication_date": "2025-04-21", "publication_year": 2025, "doi": "10.1017/s147895152500032x", "pubmed_id": "40259688", "source_url": "https://doi.org/10.1017/s147895152500032x", "keywords": "Humans, Neoplasms, Hallucinogens, Stress, Psychological, Psilocybin, Psychological Distress", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40259688\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Randomized Controlled Trial,Systematic Review,Review Article,Case Report,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 708, "title": "Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.", "normalized_title": "rapid and sustained antidepressant effects of vaporized n n dimethyltryptamine a phase 2a clinical trial in treatment resistant depression", "authors": "Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D.", "abstract": "Depression affects over 185 million people worldwide, with approximately one-third classified as treatment-resistant depression (TRD). Current treatments, such as oral antidepressants, often take around 3 weeks to become effective, with no immediate anti-suicidal benefits. The field urgently needs innovative therapies that provide rapid relief. Psychedelics like psilocybin and ayahuasca have shown promising antidepressant effects; however, their long duration (several hours) makes them costly and impractical for public health systems. N,N-Dimethyltryptamine (DMT), an endogenous psychedelic also found in ayahuasca, offers a viable alternative with a short duration of action (10-20 min) and non-invasive inhalation administration. Unlike ayahuasca, which contains monoamine oxidase inhibitors, vaporized DMT acts quickly and poses fewer pharmacological interaction risks. This open-label trial evaluated inhaled DMT for TRD for the first time, within the framework of interventional psychiatry. Fourteen patients (Nfemale = 6) participated in a fixed-order, dose-escalation study (15 mg and 60 mg). The treatment was safe, well-tolerated, and produced manageable psychedelic effects with no serious adverse events. A subpopulation using antidepressants showed similar safety outcomes. Results showed rapid and sustained antidepressant effects, with an average reduction of 21.14 points on the Montgomery-Asberg Depression Rating Scale by day 7 (p", "journal": null, "publication_date": "2025-04-21", "publication_year": 2025, "doi": "10.1038/s41386-025-02091-6", "pubmed_id": "40258990", "source_url": "https://doi.org/10.1038/s41386-025-02091-6", "keywords": "Humans, N,N-Dimethyltryptamine, Antidepressive Agents, Treatment Outcome, Administration, Inhalation, Adult, Aged, Middle Aged, Female, Male, Depressive Disorder, Treatment-Resistant", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40258990\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 884, "title": "Psychedelics and substance use disorder treatment.", "normalized_title": "psychedelics and substance use disorder treatment", "authors": "DuPont CM, Johnson MW.", "abstract": "The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced drinking and abstinence. Small clinical trials have also shown promising initial results for both tobacco and opioid use disorders. In contrast, no trials have yet been conducted for stimulant and cannabis use disorders. Furthermore, the majority of studies described are naturalistic observational studies or correlational survey data. However, if such observational studies reflect causal therapeutic potential, these studies, combined with clinical trials, suggest potential broad transdiagnostic efficacy of psychedelics across multiple addictive drugs. The transdiagnostic effects of psychedelics are likely due to a combination of biological and psychological factors. Biologically, psychedelics appear to ameliorate deficits in brain areas involved in reward and emotional processing, which may reduce the risk of relapse. Psychologically, the insights gained during a psychedelic experience may reinforce personal motivations for sobriety and support subsequent behavior change. Overall, more work is needed to better characterize the potential benefits and limitations of psychedelic treatment for substance use disorders.", "journal": null, "publication_date": "2025-04-20", "publication_year": 2025, "doi": "10.1016/bs.irn.2025.03.005", "pubmed_id": "40541314", "source_url": "https://doi.org/10.1016/bs.irn.2025.03.005", "keywords": "Humans, Substance-Related Disorders, Hallucinogens", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40541314\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Emotional Processing,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 737, "title": "Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.", "normalized_title": "comparative efficacy and functional outcomes of psychedelic assisted therapies in treatment resistant depression a systematic review of recent clinical trials", "authors": "Mimms C, Sotelo K, Khaliq AS.", "abstract": "This systematic review explores the comparative efficacy and functional outcomes of psychedelic-assisted therapies in the management of treatment-resistant depression (TRD). Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted across PubMed, Scopus, and Web of Science for randomized controlled trials (RCTs) published in the last 12 months. Ten RCTs were included, evaluating agents such as ketamine, esketamine, and psilocybin. Most studies demonstrated significant reductions in depressive symptom severity, with oral and intranasal esketamine and high-dose psilocybin showing sustained antidepressant effects. Functional improvements, such as workplace productivity and cognitive stability, were reported in select trials, notably those involving esketamine. Risk of bias was low in four studies and moderate in six due to open-label or observational extensions. Overall, psychedelic therapies were well tolerated, with favorable safety profiles and minimal cognitive adverse effects. These findings support the integration of psychedelic-assisted therapies as viable alternatives or adjuncts in the treatment of TRD and highlight the importance of assessing both clinical and functional endpoints for a more holistic understanding of therapeutic benefit.", "journal": null, "publication_date": "2025-04-17", "publication_year": 2025, "doi": "10.7759/cureus.82532", "pubmed_id": "40385821", "source_url": "https://doi.org/10.7759/cureus.82532", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"40385821\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 738, "title": "Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care", "normalized_title": "roadmap for equitable access and responsible use of psilocybin assisted psychotherapy in palliative care", "authors": "Michel Dorval, Sue-Ling Chang, Houman Farzin, Olivia Nguyen, Jean-François Stephan, Diane Tapp, P. Deschamps, Yann Joly, Florence Moureaux, Robert Foxman, Marianne Masse-Grenier, Jean-Sébastien Fallu", "abstract": "Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addressing existential distress. Despite its safety and effectiveness, this therapy remains limited in Canada, underscoring the need for improved access to ease suffering from life-threatening illnesses. However, important questions remain regarding how to integrate psilocybin-assisted psychotherapy into existing health care frameworks, navigate regulatory challenges, and ensure equitable access for all patients. These unanswered questions highlight the complexity of expanding access and the need for thoughtful, informed approaches to its implementation. To address this, the P3A team (Psilocybin at End of Life: Audacity, Acceptability, Access) held a forum on March 22, 2024, in Quebec, Canada, to explore actionable steps for the responsible use and equitable access to psilocybin-assisted psychotherapy. A total of 57 participants with knowledge in palliative care, including professional and patient associations, patients, health care professionals, researchers, and policymakers, attended the event, which featured presentations, a panel discussion, and small-group workshops. This report provides 16 recommendations across six previously identified key topics: (1) patient eligibility and equity, (2) regulatory framework and respect for autonomy, (3) logistical and organizational aspects, (4) professional education and training, (5) public awareness and information, and (6) research. The elements and recommendations discussed in this article could offer valuable insights for expanding access to psilocybin-assisted psychotherapy in other jurisdictions, particularly in global contexts where similar barriers to care exist.", "journal": "Palliative Medicine Reports", "publication_date": "2025-04-16", "publication_year": 2025, "doi": "10.1089/pmr.2024.0108", "pubmed_id": "40385526", "source_url": "https://doi.org/10.1089/pmr.2024.0108", "keywords": "Psilocybin, Palliative care, Psychotherapist, Psychology, Hallucinogen, Psychiatry, Nursing, Medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409528946\",\"openalex_url\":\"https://openalex.org/W4409528946\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1892347931\",\"https://openalex.org/W2051155462\",\"https://openalex.org/W2060831503\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2145853206\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2168286172\",\"https://openalex.org/W2557987083\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2787305141\",\"https://openalex.org/W2809775049\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2940589604\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3023463185\",\"https://openalex.org/W3157608139\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W3190247282\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4280525486\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4313648119\",\"https://openalex.org/W4364353531\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4382515410\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4400697733\",\"https://openalex.org/W4401779935\",\"https://openalex.org/W4402018491\",\"https://openalex.org/W4402554692\",\"https://openalex.org/W4402960550\"],\"authorships\":[{\"id\":\"https://openalex.org/A5068576397\",\"display_name\":\"Michel Dorval\",\"orcid\":\"https://orcid.org/0000-0002-3207-8211\"},{\"id\":\"https://openalex.org/A5045951431\",\"display_name\":\"Sue-Ling Chang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040374734\",\"display_name\":\"Houman Farzin\",\"orcid\":\"https://orcid.org/0009-0006-4095-3596\"},{\"id\":\"https://openalex.org/A5112421240\",\"display_name\":\"Olivia Nguyen\",\"orcid\":\"https://orcid.org/0000-0001-8335-3773\"},{\"id\":\"https://openalex.org/A5027250223\",\"display_name\":\"Jean-François Stephan\",\"orcid\":\"https://orcid.org/0009-0000-7376-208X\"},{\"id\":\"https://openalex.org/A5084030574\",\"display_name\":\"Diane Tapp\",\"orcid\":\"https://orcid.org/0000-0002-2818-0141\"},{\"id\":\"https://openalex.org/A5087948982\",\"display_name\":\"P. Deschamps\",\"orcid\":\"https://orcid.org/0000-0001-8862-9046\"},{\"id\":\"https://openalex.org/A5018546125\",\"display_name\":\"Yann Joly\",\"orcid\":\"https://orcid.org/0000-0002-8775-2322\"},{\"id\":\"https://openalex.org/A5117187654\",\"display_name\":\"Florence Moureaux\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093764770\",\"display_name\":\"Robert Foxman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093764771\",\"display_name\":\"Marianne Masse-Grenier\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053736941\",\"display_name\":\"Jean-Sébastien Fallu\",\"orcid\":\"https://orcid.org/0000-0002-2300-1335\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210231122\",\"source_display_name\":\"Palliative Medicine Reports\",\"landing_page_url\":\"https://doi.org/10.1089/pmr.2024.0108\",\"is_oa\":true}}", "topic_tags": "End-of-Life Distress,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409528946" }, { "id": 633, "title": "Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis", "normalized_title": "regulatory alignment of psilocybin clinical trials in major depressive disorder on clinicaltrials gov a cross sectional analysis", "authors": "Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, Zuzanna Gaca, Łukasz Szarpak, Wiesław Jerzy Cubała", "abstract": "Regulatory compliance is crucial in the clinical development of psychedelic substances, including psilocybin. This study aimed to examine the alignment of clinical trial protocols for psilocybin in the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD) with established regulatory requirements.A cross-sectional investigation was conducted on ClinicalTrials.gov using the keywords: \"Psilocybin\" and \"Psilocin\" to identify interventional studies with posted trial protocols. Only protocols for MDD and TRD were included. Data extraction focused on key regulatory aspects, including safety, functional unblinding, expectancy bias, and the distribution of investigational medical products.Eleven psilocybin trial protocols were identified, with four meeting the inclusion criteria. The most commonly studied psilocybin dose was 25 mg. Two trials were double-blind. Although the analyzed protocols superficially adhered to regulatory requirements, there were gaps in addressing potential drug interactions, the acute and chronic concurrent use of antidepressants, and prohibited medications. Certain aspects, such as functional unblinding or expectancy bias, did not share all pathways. Risk mitigation strategies were primarily based on external criteria. Patients with bipolar spectrum disorders or schizoaffective disorders were excluded.This study underscores the importance of conducting clinical trials on psychedelics in strict adherence to regulatory standards. Future research should focus on improving regulatory compliance and exploring the efficacy of psychedelics in broader patient populations.", "journal": "Pharmacopsychiatry", "publication_date": "2025-04-16", "publication_year": 2025, "doi": "10.1055/a-2529-7029", "pubmed_id": "40245934", "source_url": "https://doi.org/10.1055/a-2529-7029", "keywords": "Psilocybin, Clinical trial, Expectancy theory, Major depressive disorder, Schizoaffective disorder, Medicine, Treatment-resistant depression, Psychiatry, Psychology, Hallucinogen, Psychosis, Cognition, Internal medicine, Social psychology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409534321\",\"openalex_url\":\"https://openalex.org/W4409534321\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1992059353\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2499216663\",\"https://openalex.org/W2588071311\",\"https://openalex.org/W2789034326\",\"https://openalex.org/W2794420673\",\"https://openalex.org/W3031683123\",\"https://openalex.org/W3157866107\",\"https://openalex.org/W4210932781\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4220708535\",\"https://openalex.org/W4225982601\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4291227674\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4301605941\",\"https://openalex.org/W4378549583\",\"https://openalex.org/W4378640469\",\"https://openalex.org/W4378783566\",\"https://openalex.org/W4382133350\",\"https://openalex.org/W4383187032\",\"https://openalex.org/W4383197511\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4386138110\",\"https://openalex.org/W4386765496\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4390484734\",\"https://openalex.org/W4390484761\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4395034174\",\"https://openalex.org/W4399864483\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4402625697\",\"https://openalex.org/W4403502370\",\"https://openalex.org/W4403667484\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037446509\",\"display_name\":\"Damian Świeczkowski\",\"orcid\":\"https://orcid.org/0000-0002-5648-4652\"},{\"id\":\"https://openalex.org/A5113262565\",\"display_name\":\"Aleksander Kwaśny\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065893595\",\"display_name\":\"Michał Pruc\",\"orcid\":\"https://orcid.org/0000-0002-2140-9732\"},{\"id\":\"https://openalex.org/A5050968304\",\"display_name\":\"Zuzanna Gaca\",\"orcid\":\"https://orcid.org/0009-0004-7200-0402\"},{\"id\":\"https://openalex.org/A5022117993\",\"display_name\":\"Łukasz Szarpak\",\"orcid\":\"https://orcid.org/0000-0002-0973-5455\"},{\"id\":\"https://openalex.org/A5070339940\",\"display_name\":\"Wiesław Jerzy Cubała\",\"orcid\":\"https://orcid.org/0000-0001-6343-8454\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4122505\",\"source_display_name\":\"Pharmacopsychiatry\",\"landing_page_url\":\"https://doi.org/10.1055/a-2529-7029\",\"is_oa\":false}}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Treatment-Resistant Depression,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409534321" }, { "id": 3465, "title": "A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia", "normalized_title": "a phase 2a open label pilot study to assess the safety and efficacy of psilocybin administration in concert with psychotherapy among adult patients with fibromyalgia", "authors": "Kevin Boehnke", "abstract": "The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral psilocybin in concert with psychotherapy to treat chronic pain symptoms in patients with FM. Fibromyalgia is a chronic syndrome of widespread musculoskeletal pain that often manifests with a cluster of co-occurring symptoms, including sleep disturbances, fatigue, cognitive dysfunction, and mood problems including anxiety and depression. Recent studies have provided evidence of altered central pain pathways. Current management of FM typically takes a multidimensional approach including behavioral therapy, exercise, and medication. However, current medications provide only modest benefit and carry significant side effect burden, leading many people with FM to seek other alternatives. Psilocybin therapy (psilocybin delivered in concert with psychotherapy) may be a potentially safe and effective treatment for symptoms associated with FM. Indeed, psilocybin therapy has shown positive effects in treating cancer-related psychiatric distress, depression and anxiety, treatment-resistant depression, and nicotine or alcohol addiction. The United States Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for psilocybin in treatment-resistant depression and major depressive disorder. Psilocybin therapy is generally safe and well-tolerated when conducted under controlled conditions. While no clinical studies have explored psychedelic effects among people with FM, a recent review outlined potential mechanisms through which psychedelics could alleviate chronic pain symptoms.", "journal": "ClinicalTrials.gov", "publication_date": "2025-04-15", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05128162", "keywords": "Fibromyalgia, Psilocybin, Psychotherapy, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05128162\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Mechanism of Action,Clinical Trial,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 677, "title": "Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.", "normalized_title": "efficacy and safety of psilocybin for the treatment of substance use disorders a systematic review", "authors": "Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC, Zhang Y, Burback L, Winkler O, Greenshaw A, Vermetten E, Mayo LM, Tanguay R, Jetly R, Bhat V.", "abstract": "Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remain uncertain. This systematic review assessed the safety and efficacy of psilocybin for SUDs through a systematic database search conducted via OVID on May 22, 2024, and summarized 26 ongoing clinical trials registered on clinicaltrials.gov. Among 16 published included studies, 7 (43.75 %) focused on Alcohol Use Disorder (AUD), 5 (31.25 %) on Tobacco Use Disorder (TUD), and the remainder on Cocaine Use Disorder (CUD) (1, 6.25 %), Opioid Use Disorder (1, 6.25 %), Nicotine Use Disorder (1, 6.25 %), and multiple SUDs (1, 6.25 %). Study designs included open-label trials (5, 31.25 %), cross-sectional observational studies (6, 37.5 %), qualitative analyses (2, 12.5 %), one double-blind RCT (6.25 %), one pilot fMRI study (6.25 %), and one long-term follow-up (6.25 %). Psilocybin-assisted psychotherapy (PAP) was used in 10 studies (62.5 %), with doses ranging from microdosing to 20-40 mg/70 kg. PAP was associated with significant reductions in alcohol consumption, smoking cessation, and related psychological improvements. AUD studies reported fewer heavy drinking days, increased abstinence rates, and neuroimaging data indicating normalization of brain activity. TUD studies demonstrated high smoking abstinence rates, with mystical experiences predicting long-term outcomes. Findings for other SUDs were mixed, though psilocybin showed potential in reducing opioid dependence and nicotine use. Preliminary evidence supports psilocybin's efficacy and safety for AUD and TUD, particularly with psychotherapy, but larger clinical trials are needed to confirm these findings.", "journal": null, "publication_date": "2025-04-14", "publication_year": 2025, "doi": "10.1016/j.neubiorev.2025.106163", "pubmed_id": "40245969", "source_url": "https://doi.org/10.1016/j.neubiorev.2025.106163", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Psilocybin, Outcome Assessment, Health Care", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40245969\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Brain Imaging,Aging,Microdosing,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Observational Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3612, "title": "The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training", "normalized_title": "the role of personal experience for the therapeutic attitude in the context of substance assisted therapy training", "authors": "Felix Mueller", "abstract": "The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced altered states of consciousness for physicians or psychotherapists in the context of a training course for substance-assisted therapy. Specifically, the study aims to assess changes in therapeutic attitude and other factors important in interactions between patients and therapists (such as empathy and cognitive flexibility).", "journal": "ClinicalTrials.gov", "publication_date": "2025-04-13", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05570708", "keywords": "Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD, MDMA, LSD, psilocybin, ENROLLING_BY_INVITATION", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05570708\",\"overall_status\":\"ENROLLING_BY_INVITATION\",\"phase\":[\"NA\"]}", "topic_tags": "Consciousness,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3288, "title": "Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice", "normalized_title": "assessing the potential cardiovascular risk of microdosing the psychedelic lsd in mice", "authors": "Effinger DP, Schalk SS, King JL, Strong JR, O’Connell CK, Calderon JR, McCorvy JD, Thompson SM.", "abstract": "Summary Microdosing, the prolonged ingestion of psychedelics at sub-hallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT2B receptors, which cause heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on cardiovascular health in mice using electrocardiography after chronically administering either serotonin as a positive control or lysergic acid diethylamide (LSD) at two sub-hallucinogenic doses. Serotonin produced significant ventricular thickening at 4- and 8-weeks. No significant changes were observed in vehicle or LSD groups. We determined the affinity and potency of LSD, psilocybin, and norfenfluramine at mouse and human 5-HT2B Rs and observed no significant differences. We calculated that levels of 5-HT2B activation by low-dose LSD were substantial, but short-lived, compared to the cardiotoxin d -fenfluramine. Together, these data provide no evidence of cardiovascular risk associated with prolonged administration of low-dose LSD in mice.", "journal": "bioRxiv", "publication_date": "2025-04-13", "publication_year": 2025, "doi": "10.1101/2025.04.08.647757", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.04.08.647757", "keywords": "", "substance_tags": "psilocybin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR1003831\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Microdosing,Emotional Processing,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4396, "title": "13. Safety, Feasibility, and Tolerability of Psilocybin in Older Adults With Amnestic MCI: Preliminary Data From a SV2a PET Imaging Study", "normalized_title": "13 safety feasibility and tolerability of psilocybin in older adults with amnestic mci preliminary data from a sv2a pet imaging study", "authors": "Danielle Bukovsky, Aron Amaev, Jianmeng Song, Edgardo Torres Carmona, S. Lauren Kyte, Fumihiko Ueno, Vincenzo De Luca, Christopher R. Bowie, Alastair J. Flint, Muhammad Ishrat Husain, Ariel Graff-Guerrero, Philip Gerretsen", "abstract": "", "journal": "Biological Psychiatry", "publication_date": "2025-04-08", "publication_year": 2025, "doi": "10.1016/j.biopsych.2025.02.250", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.biopsych.2025.02.250", "keywords": "Psilocybin, Tolerability, Medicine, Neuroscience, Psychology, Psychiatry, Internal medicine, Adverse effect, Hallucinogen, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409280654\",\"openalex_url\":\"https://openalex.org/W4409280654\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5117083140\",\"display_name\":\"Danielle Bukovsky\",\"orcid\":null},{\"id\":\"https://openalex.org/A5081312231\",\"display_name\":\"Aron Amaev\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030191843\",\"display_name\":\"Jianmeng Song\",\"orcid\":\"https://orcid.org/0000-0001-8223-8845\"},{\"id\":\"https://openalex.org/A5110764509\",\"display_name\":\"Edgardo Torres Carmona\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079547878\",\"display_name\":\"S. Lauren Kyte\",\"orcid\":null},{\"id\":\"https://openalex.org/A5026307364\",\"display_name\":\"Fumihiko Ueno\",\"orcid\":\"https://orcid.org/0000-0003-3463-5672\"},{\"id\":\"https://openalex.org/A5028939354\",\"display_name\":\"Vincenzo De Luca\",\"orcid\":\"https://orcid.org/0000-0002-5421-3584\"},{\"id\":\"https://openalex.org/A5007991853\",\"display_name\":\"Christopher R. Bowie\",\"orcid\":\"https://orcid.org/0000-0002-1983-8861\"},{\"id\":\"https://openalex.org/A5010961636\",\"display_name\":\"Alastair J. Flint\",\"orcid\":\"https://orcid.org/0000-0001-6806-0235\"},{\"id\":\"https://openalex.org/A5078217449\",\"display_name\":\"Muhammad Ishrat Husain\",\"orcid\":\"https://orcid.org/0000-0001-5771-5750\"},{\"id\":\"https://openalex.org/A5044840695\",\"display_name\":\"Ariel Graff-Guerrero\",\"orcid\":\"https://orcid.org/0000-0001-9301-2171\"},{\"id\":\"https://openalex.org/A5017059941\",\"display_name\":\"Philip Gerretsen\",\"orcid\":\"https://orcid.org/0000-0003-4053-6814\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S205482884\",\"source_display_name\":\"Biological Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/j.biopsych.2025.02.250\",\"is_oa\":false}}", "topic_tags": "Brain Imaging,Receptor Pharmacology,Aging,Older Adults,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409280654" }, { "id": 745, "title": "The Emergence of Psilocybin in Psychiatry and Neuroscience.", "normalized_title": "the emergence of psilocybin in psychiatry and neuroscience", "authors": "Omidian H, Omidian A.", "abstract": "Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin's pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.", "journal": null, "publication_date": "2025-04-08", "publication_year": 2025, "doi": "10.3390/ph18040555", "pubmed_id": "40283990", "source_url": "https://doi.org/10.3390/ph18040555", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"40283990\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Pharmacology,Mechanism of Action,Clinical Trial,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 634, "title": "Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial", "normalized_title": "psilocybin therapy for mood dysfunction in parkinson s disease an open label pilot trial", "authors": "Ellen Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold, Balázs Szigeti, Connie Ludwig, Jill L. Ostrem, Caroline M. Tanner, Meredith Bock, Katiah Llerena, Patrick R. Finley, Aoife O’Donovan, José Rafael P. Zuzuárregui, Zachary Busby, Amber McKernan, Andrew Penn, Aliss C.C. Wang, Raymond C. Rosen, Joshua Woolley", "abstract": "Mood dysfunction is highly prevalent in Parkinson's disease (PD), a main predictor of functional decline, and difficult to treat-novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot (NCT04932434), we examined the feasibility of psilocybin therapy among people with mild to moderate stage PD plus depression and/or anxiety. 12 participants (mean age 63.2 ± 8.2 years, 5 women) received psilocybin (one 10 mg followed by one 25 mg dose) with psychotherapy. There were no serious adverse events, no medical interventions required to manage effects of psilocybin, and no exacerbation of psychosis. Ten participants experienced treatment-emergent adverse events; the most frequent were anxiety, nausea, and increased blood pressure. We observed no worsening of PD symptomology measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). On the contrary, non-motor (MDS-UPDRS Part I: -13.8 ± 1.3, p < 0.001, Hedges' g = 3.0) and motor symptoms (Part II: -7.5 ± 0.9, p < 0.001, g = 1.2; Part III: -4.6 ± 1.3, p = 0.001; g = 0.3) as well as performance in select cognitive domains (Paired Associates Learning [-0.44 ± 0.14, p =.003, g = 0.4], Spatial Working Memory [-0.52 ± 0.17, p = 0.003, g = 0.7], and Probabilistic Reversal Learning [2.9 ± 0.9, p = 0.003, g = 1.3]) improved post-treatment, and improvements were sustained until the final safety assessment one month following drug exposure. Baseline Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A) scores were 21.0 ± 8.7 and 17.0 ± 3.7, respectively. Both improved to a clinically meaningful degree post-treatment; these improvements persisted to the final assessment three months following drug exposure (MADRS: -9.3 ± 2.7, p =.001, g = 1.0; HAM-A: -3.8 ± 1.7; p = 0.031, g = 0.7). This study provides the first data on psilocybin's effects in any neurodegenerative disease. Results suggest that psilocybin therapy in PD warrants further investigation.", "journal": "Neuropsychopharmacology", "publication_date": "2025-04-08", "publication_year": 2025, "doi": "10.1038/s41386-025-02097-0", "pubmed_id": "40205013", "source_url": "https://doi.org/10.1038/s41386-025-02097-0", "keywords": "Psilocybin, Adverse effect, Psychology, Anxiety, Mood, Parkinson's disease, Nausea, Psychiatry, Psychosis, Exacerbation, Depression (economics), Medicine, Internal medicine, Disease, Hallucinogen, Economics, Macroeconomics, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409286565\",\"openalex_url\":\"https://openalex.org/W4409286565\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":21,\"referenced_works\":[\"https://openalex.org/W1485498001\",\"https://openalex.org/W1522923028\",\"https://openalex.org/W1556623372\",\"https://openalex.org/W1917647149\",\"https://openalex.org/W1967630951\",\"https://openalex.org/W1968896798\",\"https://openalex.org/W1981706712\",\"https://openalex.org/W1986425243\",\"https://openalex.org/W1990326740\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2021803359\",\"https://openalex.org/W2022533807\",\"https://openalex.org/W2026136738\",\"https://openalex.org/W2039203737\",\"https://openalex.org/W2046969478\",\"https://openalex.org/W2059034217\",\"https://openalex.org/W2076143792\",\"https://openalex.org/W2077299896\",\"https://openalex.org/W2081299043\",\"https://openalex.org/W2084311288\",\"https://openalex.org/W2091506038\",\"https://openalex.org/W2095362051\",\"https://openalex.org/W2105121811\",\"https://openalex.org/W2105706680\",\"https://openalex.org/W2106350754\",\"https://openalex.org/W2106776924\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2117062466\",\"https://openalex.org/W2131168315\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2140978740\",\"https://openalex.org/W2144389919\",\"https://openalex.org/W2146400446\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2153641048\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2155757287\",\"https://openalex.org/W2178282635\",\"https://openalex.org/W2191787161\",\"https://openalex.org/W2318411418\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2460740376\",\"https://openalex.org/W2513927570\",\"https://openalex.org/W2549336896\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2590370461\",\"https://openalex.org/W2595101472\",\"https://openalex.org/W2614847871\",\"https://openalex.org/W2619097621\",\"https://openalex.org/W2621775373\",\"https://openalex.org/W2727991808\",\"https://openalex.org/W2749408017\",\"https://openalex.org/W2756938911\",\"https://openalex.org/W2796744291\",\"https://openalex.org/W2806019824\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2892307734\",\"https://openalex.org/W2895936070\",\"https://openalex.org/W2901519529\",\"https://openalex.org/W2908548900\",\"https://openalex.org/W2937934820\",\"https://openalex.org/W2992322507\",\"https://openalex.org/W3001341272\",\"https://openalex.org/W3013365113\",\"https://openalex.org/W3027590463\",\"https://openalex.org/W3046860178\",\"https://openalex.org/W3093435520\",\"https://openalex.org/W3093454394\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3129586996\",\"https://openalex.org/W3135111051\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3201526264\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W3217718387\",\"https://openalex.org/W4200145162\",\"https://openalex.org/W4200177688\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4214833982\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4280629250\",\"https://openalex.org/W4292560074\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4296799823\",\"https://openalex.org/W4308113930\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310598708\",\"https://openalex.org/W4321377299\",\"https://openalex.org/W4324020741\",\"https://openalex.org/W4376132007\",\"https://openalex.org/W4386278874\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4387893542\",\"https://openalex.org/W4392762192\",\"https://openalex.org/W4405978092\"],\"authorships\":[{\"id\":\"https://openalex.org/A5023606467\",\"display_name\":\"Ellen Bradley\",\"orcid\":\"https://orcid.org/0000-0001-6787-1490\"},{\"id\":\"https://openalex.org/A5088265750\",\"display_name\":\"Kimberly Sakai\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054841824\",\"display_name\":\"Gisele Fernandes-Osterhold\",\"orcid\":\"https://orcid.org/0000-0003-2449-5776\"},{\"id\":\"https://openalex.org/A5085028754\",\"display_name\":\"Balázs Szigeti\",\"orcid\":\"https://orcid.org/0000-0003-3809-6442\"},{\"id\":\"https://openalex.org/A5101383503\",\"display_name\":\"Connie Ludwig\",\"orcid\":null},{\"id\":\"https://openalex.org/A5019667316\",\"display_name\":\"Jill L. Ostrem\",\"orcid\":\"https://orcid.org/0000-0001-7018-9521\"},{\"id\":\"https://openalex.org/A5080273687\",\"display_name\":\"Caroline M. Tanner\",\"orcid\":\"https://orcid.org/0000-0002-3775-5082\"},{\"id\":\"https://openalex.org/A5074840299\",\"display_name\":\"Meredith Bock\",\"orcid\":\"https://orcid.org/0000-0002-8704-916X\"},{\"id\":\"https://openalex.org/A5063520767\",\"display_name\":\"Katiah Llerena\",\"orcid\":\"https://orcid.org/0000-0002-9769-172X\"},{\"id\":\"https://openalex.org/A5026709893\",\"display_name\":\"Patrick R. Finley\",\"orcid\":\"https://orcid.org/0000-0002-8581-6441\"},{\"id\":\"https://openalex.org/A5101509105\",\"display_name\":\"Aoife O’Donovan\",\"orcid\":\"https://orcid.org/0000-0003-2353-7217\"},{\"id\":\"https://openalex.org/A5040469818\",\"display_name\":\"José Rafael P. Zuzuárregui\",\"orcid\":\"https://orcid.org/0000-0002-8556-5275\"},{\"id\":\"https://openalex.org/A5036026069\",\"display_name\":\"Zachary Busby\",\"orcid\":null},{\"id\":\"https://openalex.org/A5099336938\",\"display_name\":\"Amber McKernan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053850619\",\"display_name\":\"Andrew Penn\",\"orcid\":\"https://orcid.org/0000-0001-5552-7078\"},{\"id\":\"https://openalex.org/A5104332490\",\"display_name\":\"Aliss C.C. Wang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111522839\",\"display_name\":\"Raymond C. Rosen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101826991\",\"display_name\":\"Joshua Woolley\",\"orcid\":\"https://orcid.org/0000-0001-6753-2093\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S175030738\",\"source_display_name\":\"Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1038/s41386-025-02097-0\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Receptor Pharmacology,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409286565" }, { "id": 886, "title": "Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?", "normalized_title": "potential therapeutic effects of psychedelics in small doses is there a role for microdosing in psychiatry", "authors": "Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC.", "abstract": "Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of physical and psychological conditions. Anecdotal reports indicate that even very small amounts of these substances may provide therapeutic benefits, though robust clinical studies are still needed. This chapter reviews the current experimental studies in humans using psychedelics in small doses to better understand their therapeutic potential. Research in both neurotypical individuals (n = 18 studies) and patients (n = 3) suggests that small doses of LSD and psilocybin produce subtle, acute, effects on neural connectivity, brain electrophysiology, blood pressure, sleep duration, pain perception, temporal processing, and mood; and show reductions in symptoms of depression and obsessive-compulsive behavior in patient samples. The chapter also discusses the influence of extra-pharmacological factors, such as the baseline subjective state, expectations, and individual differences in drug metabolism, on treatment outcomes. Overall, controlled microdosing studies suggest the potential therapeutic applications of small psychedelic doses, warranting further exploration through large-scale trials in clinical populations.", "journal": null, "publication_date": "2025-04-01", "publication_year": 2025, "doi": "10.1016/bs.irn.2025.03.002", "pubmed_id": "40541311", "source_url": "https://doi.org/10.1016/bs.irn.2025.03.002", "keywords": "Brain, Animals, Humans, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40541311\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,OCD,Chronic Pain,Pharmacology,Microdosing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2999, "title": "A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.", "normalized_title": "a rapid review of psychedelic assisted therapy in the context of palliative care", "authors": "Miller M, Meyers M, Martin A, Napolitano S, Dorsen C, Penn A, Rosa WE", "abstract": "Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of PAT in the context of palliative care. Through a systematic process, we identified 34 articles published between January 2021 and July 2024. Protocols varied yet included common components of participant screening, preparation, dosing, and integration. Psilocybin was the most commonly studied compound. Results support safety and initial efficacy of PAT for psycho-spiritual-existential outcomes among carefully screened and highly homogonous samples of patients with serious illness (predominantly cancer). Current efforts and challenges around integrating PAT into systems of palliative care were highlighted. Additional work is needed to (1) explore PAT's safety and efficacy within more diverse samples and contexts, (2) train palliative care providers on PAT, (3) determine systems of care delivery best suited for translation of PAT into practice, and (4) begin developing policy solutions to support safe and equitable access to PAT. Because many patients lack access to basic psychosocial-spiritual-existential care, careful consideration is needed around integration of PAT.", "journal": "Journal of hospice and palliative nursing: JHPN: the official journal of the Hospice and Palliative Nurses Association", "publication_date": "2025-03-31", "publication_year": 2025, "doi": "10.1097/njh.0000000000001113", "pubmed_id": "40042324", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40042324/", "keywords": "", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 07:01:03", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"40042324\"}", "topic_tags": "End-of-Life Distress,Spirituality,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 739, "title": "Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement", "normalized_title": "psilocybin assisted supportive psychotherapy in the treatment of prolonged grief parting trial protocol for an open label pilot trial for cancer related bereavement", "authors": "Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum, Margaret Ross, Renee Harvey, Susan L. Rossell, Jerome Sarris, Daniel Perkins, Rachel Ε. Neale, James Bennett-Levy, Shevaugn Johnson, Hanna Beebe, Natalie Roset, Jörg Strobel, Stephen Parker", "abstract": "INTRODUCTION: Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial is the first study to consider psilocybin-assisted psychotherapy as a potential treatment for prolonged grief. METHODS AND ANALYSIS: PARTING is an open-label pilot trial of psilocybin-assisted psychotherapy for approximately 15 people with cancer-related PGD. It aims to investigate feasibility, safety, acceptability, participant experience and participant-reported therapeutic effects. Over a 5-week intervention period, participants will undergo three preparation sessions before receiving a psychoactive (25 mg) dose of psilocybin alongside non-directive supportive guidance, followed by four integration sessions. All sessions will be delivered by a psychologist and either a nurse or Indigenous Therapist. An artificial intelligence-assisted tool will be used to create an artwork of participants' psychedelic experience.Outcomes will be investigated over a 12-month follow-up period. Feasibility will be assessed through recruitment/retention rates and completion of follow-up assessments. Safety will be evaluated via adverse events over 12 months and the comparison of physiological measures (vital signs, biochemistry, haematology, ECG) recorded during screening and 1 day after the psilocybin dose. Qualitative thematic analysis of semistructured interviews with participants and trial therapists will assess acceptability and the therapeutic potential of the treatment. Diagnostic clinical interviews for PGD and quantitative participant-reported measures of therapeutic effects are also being collected. Participant-reported measures include grief severity, depression, anxiety, grief avoidance, psychological flexibility, connectedness, and quality of life. ETHICS AND DISSEMINATION: Ethics approval has been obtained from QIMR Berghofer Medical Research Institute Human Research Ethics Committee (P3801). Dissemination of results will occur via conference presentations, peer-reviewed publications and media. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ACTRN12623000827639).", "journal": "BMJ Open", "publication_date": "2025-03-31", "publication_year": 2025, "doi": "10.1136/bmjopen-2024-095992", "pubmed_id": "40233965", "source_url": "https://doi.org/10.1136/bmjopen-2024-095992", "keywords": "Psilocybin, Medicine, Grief, Thematic analysis, Psychotherapist, Clinical trial, Psychiatry, Qualitative research, Hallucinogen, Psychology, Internal medicine, Social science, Sociology, Psychedelics and Drug Studies, Paranormal Experiences and Beliefs, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:33", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4409449177\",\"openalex_url\":\"https://openalex.org/W4409449177\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W176265305\",\"https://openalex.org/W197605164\",\"https://openalex.org/W1520239921\",\"https://openalex.org/W1622644686\",\"https://openalex.org/W1968620173\",\"https://openalex.org/W1977106921\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1991533751\",\"https://openalex.org/W1997669167\",\"https://openalex.org/W1999029302\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2007710432\",\"https://openalex.org/W2009709978\",\"https://openalex.org/W2015114767\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2043590980\",\"https://openalex.org/W2043696469\",\"https://openalex.org/W2054754029\",\"https://openalex.org/W2055769378\",\"https://openalex.org/W2056793574\",\"https://openalex.org/W2069122038\",\"https://openalex.org/W2079559446\",\"https://openalex.org/W2082494913\",\"https://openalex.org/W2085039988\",\"https://openalex.org/W2089272794\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2099281541\",\"https://openalex.org/W2100248176\",\"https://openalex.org/W2105512904\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114330737\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2128675712\",\"https://openalex.org/W2130746449\",\"https://openalex.org/W2133963272\",\"https://openalex.org/W2138664283\",\"https://openalex.org/W2139639147\",\"https://openalex.org/W2141463901\",\"https://openalex.org/W2141674457\",\"https://openalex.org/W2143888211\",\"https://openalex.org/W2150104558\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166934228\",\"https://openalex.org/W2170182466\",\"https://openalex.org/W2273012122\",\"https://openalex.org/W2330686105\",\"https://openalex.org/W2395013989\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2401478574\",\"https://openalex.org/W2412386965\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2557428091\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2605607381\",\"https://openalex.org/W2608583841\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2743578903\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2784069100\",\"https://openalex.org/W2784860341\",\"https://openalex.org/W2809961707\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2912962873\",\"https://openalex.org/W2914265865\",\"https://openalex.org/W2921778412\",\"https://openalex.org/W2936122789\",\"https://openalex.org/W2966006993\",\"https://openalex.org/W2981070831\",\"https://openalex.org/W2996233343\",\"https://openalex.org/W2996321268\",\"https://openalex.org/W2999812626\",\"https://openalex.org/W3004462725\",\"https://openalex.org/W3013947271\",\"https://openalex.org/W3016353993\",\"https://openalex.org/W3025292620\",\"https://openalex.org/W3040238034\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112064661\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3120487758\",\"https://openalex.org/W3121104075\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3143826889\",\"https://openalex.org/W3148517140\",\"https://openalex.org/W3156750443\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3159976828\",\"https://openalex.org/W3176091535\",\"https://openalex.org/W3181480707\",\"https://openalex.org/W3182390788\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4225420820\",\"https://openalex.org/W4225525501\",\"https://openalex.org/W4232488826\",\"https://openalex.org/W4244453275\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4285066034\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4294349218\",\"https://openalex.org/W4303982116\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311770283\",\"https://openalex.org/W4313544662\",\"https://openalex.org/W4315880802\",\"https://openalex.org/W4321749435\",\"https://openalex.org/W4323049021\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W4380151127\",\"https://openalex.org/W4387264560\",\"https://openalex.org/W4389900078\",\"https://openalex.org/W4390603975\",\"https://openalex.org/W4391522039\",\"https://openalex.org/W4391924240\",\"https://openalex.org/W4392249465\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4393965864\",\"https://openalex.org/W4393993372\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4395071724\",\"https://openalex.org/W4398248553\",\"https://openalex.org/W4401700752\",\"https://openalex.org/W4402310254\",\"https://openalex.org/W4404158896\",\"https://openalex.org/W6797933299\",\"https://openalex.org/W6862121830\"],\"authorships\":[{\"id\":\"https://openalex.org/A5018444630\",\"display_name\":\"Vanessa L. Beesley\",\"orcid\":\"https://orcid.org/0000-0002-5081-1800\"},{\"id\":\"https://openalex.org/A5021835786\",\"display_name\":\"Tom Kennedy\",\"orcid\":\"https://orcid.org/0000-0003-4621-5974\"},{\"id\":\"https://openalex.org/A5057700963\",\"display_name\":\"Fiona Maccallum\",\"orcid\":\"https://orcid.org/0000-0002-3006-0712\"},{\"id\":\"https://openalex.org/A5101561809\",\"display_name\":\"Margaret Ross\",\"orcid\":\"https://orcid.org/0000-0002-3368-6614\"},{\"id\":\"https://openalex.org/A5076649329\",\"display_name\":\"Renee Harvey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073606057\",\"display_name\":\"Susan L. Rossell\",\"orcid\":\"https://orcid.org/0000-0002-7415-8252\"},{\"id\":\"https://openalex.org/A5114087434\",\"display_name\":\"Jerome Sarris\",\"orcid\":null},{\"id\":\"https://openalex.org/A5049230775\",\"display_name\":\"Daniel Perkins\",\"orcid\":\"https://orcid.org/0000-0002-2055-1649\"},{\"id\":\"https://openalex.org/A5077862296\",\"display_name\":\"Rachel Ε. Neale\",\"orcid\":\"https://orcid.org/0000-0001-7162-0854\"},{\"id\":\"https://openalex.org/A5034483864\",\"display_name\":\"James Bennett-Levy\",\"orcid\":\"https://orcid.org/0000-0003-0998-116X\"},{\"id\":\"https://openalex.org/A5074779884\",\"display_name\":\"Shevaugn Johnson\",\"orcid\":\"https://orcid.org/0000-0002-5294-3874\"},{\"id\":\"https://openalex.org/A5004497324\",\"display_name\":\"Hanna Beebe\",\"orcid\":null},{\"id\":\"https://openalex.org/A5117151723\",\"display_name\":\"Natalie Roset\",\"orcid\":null},{\"id\":\"https://openalex.org/A5041258476\",\"display_name\":\"Jörg Strobel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062304624\",\"display_name\":\"Stephen Parker\",\"orcid\":\"https://orcid.org/0000-0002-6022-3981\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S79054089\",\"source_display_name\":\"BMJ Open\",\"landing_page_url\":\"https://doi.org/10.1136/bmjopen-2024-095992\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Aging,Psychological Flexibility,Clinical Trial,Review Article,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4409449177" }, { "id": 3635, "title": "Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN", "normalized_title": "psilocybin for enhanced analgesia in chronic neuropathic pain", "authors": "Unity Health Toronto", "abstract": "This is a feasibility study to examine the use of use of Psilocybin (magic mushrooms) to alleviate pain in chronic neuropathic pain. While theoretical mechanisms demonstrate promise, there is no clinical evidence. This vacuum of clinical evidence has been occupied by a \"psychedelic hype bubble\" with media communications touting psychedelics as a 'miracle cures'. The mismatch between evidence and perception creates an urgent need for RCT to fill this significant gap. This trial aims to address this gap by conducting a pilot trial assessing the feasibility, tolerability, and preliminary efficacy of psilocybin for chronic neuropathic pain to inform a future larger, multi-centre study. The purpose is to conduct a randomized control double-blinded trial of psilocybin and active placebo (dextromethorphan). At this time, the aim of the trial is to recruit 30 participants from St. Michael's Hospital, to learn whether it will be feasible to plan a larger study in the future. Brief title PEACE-PAIN Trial Indication Adult patients suffering from chronic neuropathic pain Condition(s) of focus of study Moderate-to-severe chronic neuropathic pain Number of participants 30 Primary outcome Feasibility (recruitment success, consent rate, adherence, patient withdrawal, missing data, adverse outcomes) Secondary outcome Change in pain intensity and pain interference Study design Study type: An intervention trial Allocation: Randomized Intervention model: 2-Arm Parallel Group Primary purpose: Feasibility Phase: Phase II Masking Participants, all study team including outcome assessors Test Products, Dose, and Mode of Administration Treatment arm: Psilocybin 25mg + placebo PO single dose plus psychological support Placebo arm: Dextromethorphan 400mg PO single dose plus psychological support Follow-Up Days: 1, 7, 14, 30, and 90", "journal": "ClinicalTrials.gov", "publication_date": "2025-03-29", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06731335", "keywords": "Chronic Neuropathic Pain, Pain Management, Psilocybin, Psychotherapy, Active Placebo, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06731335\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Chronic Pain,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4423, "title": "Psilocybin-assisted therapy leads to personality shifts in patients with alcohol use disorder", "normalized_title": "psilocybin assisted therapy leads to personality shifts in patients with alcohol use disorder", "authors": "", "abstract": "Adults with alcohol use disorder who received two sessions of psilocybin-assisted therapy demonstrated personality shifts toward normalization of abnormal trait expression, a secondary analysis of a randomized trial has found. A decrease in impulsiveness was found to be associated with reduced drinking post-treatment, with the strongest effect for psilocybin-treated individuals who had engaged in moderate- or high-risk drinking before treatment.", "journal": "The Brown University Psychopharmacology Update", "publication_date": "2025-03-26", "publication_year": 2025, "doi": "10.1002/pu.31300", "pubmed_id": null, "source_url": "https://doi.org/10.1002/pu.31300", "keywords": "Psilocybin, Alcohol use disorder, Medicine, Psychotherapist, Psychiatry, Alcohol, Psychology, Hallucinogen, Chemistry, Biochemistry, Psychedelics and Drug Studies, Digital Mental Health Interventions, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4408975325\",\"openalex_url\":\"https://openalex.org/W4408975325\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S1022177896\",\"source_display_name\":\"The Brown University Psychopharmacology Update\",\"landing_page_url\":\"https://doi.org/10.1002/pu.31300\",\"is_oa\":true}}", "topic_tags": "Addiction,Personality Change,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4408975325" }, { "id": 3544, "title": "An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study", "normalized_title": "an 8 week phase 2 clinical trial to evaluate the safety tolerability and efficacy of psilocybin assisted psychotherapy in adults with cannabis use disorder a proof of concept study", "authors": "McMaster University", "abstract": "Cannabis is the most commonly used psychoactive substance in Canada (Lowry \\& Corsi, 2020). A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013). A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD. Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD. The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses \\[25 mg\\] of psilocybin administered as part of an 8-week Motivational Enhancement Therapy (MET) and supportive therapy. This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.", "journal": "ClinicalTrials.gov", "publication_date": "2025-03-18", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06225232", "keywords": "Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe, Psilocybin combined with Psychotherapy, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06225232\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3457, "title": "Psilocybin in Alcohol Use Disorder With Comorbid Depression", "normalized_title": "psilocybin in alcohol use disorder with comorbid depression", "authors": "Centre Hospitalier Universitaire de Nīmes", "abstract": "Up to 40% of people with alcohol use disorder (AUD) experience depression. Depression is a risk factor for early relapse of AUD after withdrawal in a controlled environment. Promising data suggest the effectiveness of psilocybin, a psychedelic-type treatment, in depression and AUD. Following the acute effects of the psychedelic experience, which lasts approximately 6 hours, psilocybin action appears to be beneficial for preventing alcohol relapse in recently weaned people suffering from comorbid depression. Whilst the public perception of psilocybin therapy is poorly documented in France, the rapid changes in the legal status of psilocybin elsewhere, the positive media coverage of recent trials in depression, and the recent designation as an \"innovative therapy\" by the FDA could lead to the refusal of randomization of eligible participants. It is therefore essential to evaluate the feasibility and acceptability of psilocybin treatment and blinded randomized design in our clinical population of hospitalized patients with AUD and depressive symptoms. Recent data suggest that the effect size of psilocybin is much higher than other currently available treatments. However, this paradigm shift must be confirmed in our cohort of people with AUD and depressive symptoms, and in the context of treatment in addition to usual care, by an estimation of the expected effect size based on real data. This will allow the sample size to be accurately calculated for a large-scale randomized clinical trial. Finally, the potential mechanisms of action of psilocybin to prevent relapse in AUD with comorbid depression after withdrawal need to be documented. The objective of this pilot study is to evaluate the feasibility, acceptability, neural mechanisms and preliminary results of the effectiveness of psilocybin in the treatment of AUD and depressive symptoms after withdrawal, in addition to usual treatment. The study authors hypothesize that two oral administrations of 25 mg psilocybin at three-week intervals versus a control condition (1 mg psilocybin), in addition to the usual treatment, will be acceptable and feasible in recently withdrawn individuals suffering from AUD and depressive symptoms, between 14 and 60 days after their last alcohol consumption", "journal": "ClinicalTrials.gov", "publication_date": "2025-03-18", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06235411", "keywords": "Alcohol-Related Disorders, Depressive Disorder, Addiction, Psilocybin therapy, Inactive Psilocybin therapy, Electroencephalogram, Blood samples for the analysis of immune and inflammatory profiles, stool samples, MRI functional and cerebral, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06235411\",\"overall_status\":\"COMPLETED\",\"phase\":[\"NA\"]}", "topic_tags": "Depression,Addiction,Mechanism of Action,Clinical Trial,Observational Study,Safety,Inflammation,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 778, "title": "A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.", "normalized_title": "a modern overview of the potential therapeutic effects of psilocybin in the treatment of depressive disorders treatment resistant depression and end of life distress", "authors": "Dino F.", "abstract": "The purpose of this review is to provide a comprehensive overview of the current findings and data on the therapeutic effects of psilocybin, a naturally occurring psychedelic alkaloid primarily found in Psilocybe mushrooms. This review covers psilocybin's efficacy and safety profile, therapeutic effects, proposed indications and contraindications, drug-drug interactions, adverse reactions, pharmacokinetics, pharmacodynamics, and dosing regimens as treatment guidelines. The goal is to offer a consolidated resource containing the essential pharmaceutical information on psilocybin currently available.", "journal": null, "publication_date": "2025-03-16", "publication_year": 2025, "doi": "10.7759/cureus.80707", "pubmed_id": "40242672", "source_url": "https://doi.org/10.7759/cureus.80707", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"40242672\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,End-of-Life Distress,Pharmacology,Review Article,Treatment-Resistant Depression,Safety,Drug Interactions,Contraindications", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 715, "title": "IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain", "normalized_title": "iuphar article psilocybin induces long lasting effects via 5 ht2a receptors in mouse models of chronic pain", "authors": "Eda Köşeli, Belle Buzzi, Torin Honaker, Yogesh Rakholia, Melissa J. Lewis, Maya Gaines-Smith, Alaina M. Jaster, Javier González-Maeso, M. Imad Damaj", "abstract": "Chronic pain is a debilitating disease with current treatments lacking efficacy and safety, therefore discovery of new treatments is crucial. Initial studies suggest that psychedelics may be feasible for targeting pain, however clinical and preclinical controlled studies are necessary to further investigate that possibility. In this study we assessed the effects of two classical psychedelics psilocybin and 2,5-Dimethoxy-4-iodoamphetamine (DOI) in two models of chronic pain after systemic administration in male and female mice. Psilocybin and DOI dose-dependently reversed mechanical and cold hypersensitivity in the chemotherapy-induced peripheral neuropathy (CIPN) mouse model with different time-course of action. Similarly, psilocybin and DOI dose-dependently reversed thermal hypersensitivity in the chronic inflammatory mouse model of Complete Freud’s Adjuvant (CFA). The effects of Psilocybin and DOI in both models were mediated by activation of 5-HT2A receptors (5-HT2A R). Overall, the present study suggests that classical psychedelics psilocybin and DOI are effective in reducing pain-like behaviors via 5-HT2A R activation in two mouse models of chronic pain. • Classical psychedelics psilocybin and DOI dose-dependently reversed pain-like behaviors in two chronic pain mouse models. • In contrast to DOI, the effects of psilocybin in the two models of pain lasted for several days. • Both psilocybin and DOI are effective in reducing pain-like behaviors via 5-HT2AR mechanism.", "journal": "Pharmacological Research", "publication_date": "2025-03-16", "publication_year": 2025, "doi": "10.1016/j.phrs.2025.107699", "pubmed_id": "40107634", "source_url": "https://doi.org/10.1016/j.phrs.2025.107699", "keywords": "Psilocybin, Receptor, Pharmacology, Chronic pain, Medicine, Neuroscience, Psychology, Hallucinogen, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4408540649\",\"openalex_url\":\"https://openalex.org/W4408540649\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":11,\"referenced_works\":[\"https://openalex.org/W1985993123\",\"https://openalex.org/W1986222973\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2038839611\",\"https://openalex.org/W2045076787\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2923081322\",\"https://openalex.org/W2979144408\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3081126678\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212990475\",\"https://openalex.org/W4214819177\",\"https://openalex.org/W4224861883\",\"https://openalex.org/W4282962482\",\"https://openalex.org/W4291398459\",\"https://openalex.org/W4293282462\",\"https://openalex.org/W4365442769\",\"https://openalex.org/W4387105778\",\"https://openalex.org/W4389891609\",\"https://openalex.org/W4399729525\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042887851\",\"display_name\":\"Eda Köşeli\",\"orcid\":\"https://orcid.org/0000-0002-4812-4024\"},{\"id\":\"https://openalex.org/A5071605633\",\"display_name\":\"Belle Buzzi\",\"orcid\":\"https://orcid.org/0000-0003-0031-7377\"},{\"id\":\"https://openalex.org/A5077348626\",\"display_name\":\"Torin Honaker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5095378260\",\"display_name\":\"Yogesh Rakholia\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021823042\",\"display_name\":\"Melissa J. Lewis\",\"orcid\":\"https://orcid.org/0000-0001-6643-191X\"},{\"id\":\"https://openalex.org/A5116667308\",\"display_name\":\"Maya Gaines-Smith\",\"orcid\":null},{\"id\":\"https://openalex.org/A5039127091\",\"display_name\":\"Alaina M. Jaster\",\"orcid\":\"https://orcid.org/0000-0002-3237-394X\"},{\"id\":\"https://openalex.org/A5047587284\",\"display_name\":\"Javier González-Maeso\",\"orcid\":\"https://orcid.org/0000-0003-3105-3204\"},{\"id\":\"https://openalex.org/A5112311729\",\"display_name\":\"M. Imad Damaj\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S54485712\",\"source_display_name\":\"Pharmacological Research\",\"landing_page_url\":\"https://doi.org/10.1016/j.phrs.2025.107699\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Pharmacology,Receptor Pharmacology,Animal Study,Safety,Inflammation", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4408540649" }, { "id": 565, "title": "Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.", "normalized_title": "current evidence for the role of rapid acting antidepressants in bipolar depression a perspective and plan for action", "authors": "Repple J, Bayas M, Möser C, Kobayashi NF, Reif A.", "abstract": "After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression due to the reduced risk of mania induction, research on RAADs, such as (es)ketamine, remains scarce despite their demonstrated safety and effectiveness. In this review, we give an overview of current developments in RAADs in the context of bipolar disorder. Both published studies as well as phase II, III, and IV studies on bipolar depression (based on ClinicalTrials.gov) are reviewed in this work. The following RAAD substance classes have been or are currently being investigated as possible treatments for bipolar depression: NMDA antagonists and indirect AMPA agonists (ketamine, esketamine, riluzole, felbamate), GABAA (gamma-aminobutyric acid A) activators or positive allosteric modulators (zuranolone, pregnenolone, PEA), psychedelics (psilocybin, 5-MeO-DMT), muscarine receptor antagonists (scopolamine), and kappa opioid receptor antagonists (navacaprant). Other than the well-established efficacy and safety of (es)ketamine in treating bipolar depression, there has been little research effort in the treatment of bipolar depression. Recent research into RAADs demonstrates the growing field of novel mechanisms of action in the pharmacological treatment of bipolar depression. However, there is an urgent need for well-controlled clinical studies on RAADs in bipolar depression to expand treatment options and improve outcomes for millions of affected individuals worldwide.", "journal": null, "publication_date": "2025-03-07", "publication_year": 2025, "doi": "10.1016/j.biopsych.2025.02.903", "pubmed_id": "40064389", "source_url": "https://doi.org/10.1016/j.biopsych.2025.02.903", "keywords": "Humans, Antidepressive Agents, Bipolar Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40064389\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 740, "title": "Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond.", "normalized_title": "psychedelics and eating disorders exploring the therapeutic potential for anorexia nervosa and beyond", "authors": "Hu S, Lin C, Wang H, Wang X.", "abstract": "Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted body image, leading to significant morbidity and mortality. Conventional treatments such as cognitive-behavioral therapy (CBT) and pharmacotherapy often prove inadequate, especially in severe cases, highlighting the need for novel therapeutic approaches. Recent research into psychedelics, such as psilocybin and 3,4-methylenedioxymethamphetamine (MDMA), offers promising avenues for treating anorexia nervosa by targeting its neurobiological and psychological underpinnings. These psychedelics disrupt maladaptive neural circuits, enhance cognitive flexibility, and facilitate emotional processing, offering potential relief for patients unresponsive to traditional therapies. Early studies have shown positive outcomes with psychedelics, including reductions in anorexia nervosa symptoms and improvements in psychological well-being. However, further research is needed to establish their long-term safety, efficacy, and integration into clinical practice. Addressing the legal, ethical, and safety challenges will be crucial in determining whether psychedelics can transform the treatment landscape for anorexia nervosa and other eating disorders.", "journal": null, "publication_date": "2025-03-06", "publication_year": 2025, "doi": "10.1021/acsptsci.5c00094", "pubmed_id": "40242584", "source_url": "https://doi.org/10.1021/acsptsci.5c00094", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40242584\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Wellbeing,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4431, "title": "Risks of using psilocybin in treatment of treatment-resistant depression", "normalized_title": "risks of using psilocybin in treatment of treatment resistant depression", "authors": "Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek, Jan Karczmarz, Aleksandra Paprocka, Marika Gutowska, Agnieszka Kosińska, Urszula Świrk, Wiktoria Belcarz, Katarzyna Kalinowska", "abstract": "IntroductionAs depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper focuses on addressing the risks associated with psilocybin therapy. We believe this paper can help understand risks as a platform for safety based treatment. Material and Methods A comprehensive literature search was conducted using the PubMed and Google Scholar databases, supplemented by references cited in the initially identified articles. The search focused on studies and reviews addressing the challenges and risks associated with psilocybin use in the treatment of treatment-resistant depression (TRD).", "journal": "Journal of Education Health and Sport", "publication_date": "2025-03-05", "publication_year": 2025, "doi": "10.12775/jehs.2025.79.58319", "pubmed_id": null, "source_url": "https://doi.org/10.12775/jehs.2025.79.58319", "keywords": "Psilocybin, Depression (economics), Medicine, Treatment-resistant depression, Psychiatry, Hallucinogen, Antidepressant, Anxiety, Macroeconomics, Economics, Psychedelics and Drug Studies, Digital Mental Health Interventions, Psychotherapy Techniques and Applications", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4408197223\",\"openalex_url\":\"https://openalex.org/W4408197223\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5116219617\",\"display_name\":\"Michał Orzechowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036777199\",\"display_name\":\"Joanna Orzechowska\",\"orcid\":\"https://orcid.org/0000-0001-9458-5991\"},{\"id\":\"https://openalex.org/A5116219611\",\"display_name\":\"Paulina Fijałek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116222341\",\"display_name\":\"Jan Karczmarz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116219614\",\"display_name\":\"Aleksandra Paprocka\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067279655\",\"display_name\":\"Marika Gutowska\",\"orcid\":null},{\"id\":\"https://openalex.org/A5060513934\",\"display_name\":\"Agnieszka Kosińska\",\"orcid\":\"https://orcid.org/0009-0008-3041-274X\"},{\"id\":\"https://openalex.org/A5116222337\",\"display_name\":\"Urszula Świrk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116186409\",\"display_name\":\"Wiktoria Belcarz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070497769\",\"display_name\":\"Katarzyna Kalinowska\",\"orcid\":\"https://orcid.org/0009-0007-2657-7165\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737571363\",\"source_display_name\":\"Journal of Education Health and Sport\",\"landing_page_url\":\"https://doi.org/10.12775/jehs.2025.79.58319\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4408197223" }, { "id": 3666, "title": "Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects", "normalized_title": "acute effects of 2c b compared with mdma and psilocybin in healthy subjects", "authors": "University Hospital, Basel, Switzerland", "abstract": "4-bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive substance with reportedly similar acute effects to both the prototypical empathogen 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and the classic psychedelic substance psilocybin (contained in \"magic, hallucinogenic mushrooms\"). Pharmacologically, MDMA mainly releases serotonin (5-HT) via the serotonin transporter (SERT) and psilocybin mainly acts as direct agonist at 5-HT2A receptors. 2C-B interacts with both the 5-HT2A receptor and SERT which is in line with its reported mixed effects profile. However, scientific studies are lacking. There is an increased interest in psychiatric research on the therapeutic properties of MDMA and psilocybin and also on mixed empathogenic-psychedelic substances. 2C-B is a phenethylamine and belongs to the so-called 2C drugs, a group of novel psychoactive substances (NPS) with some structural similarity to the classic psychedelic mescaline. 2C-B is relatively widely used as recreational substance often replacing or mimicking classic substances such as LSD or MDMA. 2C-B also ranks high among the substances found as substitutes or adulterants of tablets sold as MDMA or Ecstasy. Users report that 2C-B has similar acute effects to MDMA when used at low (5-10 mg) and medium doses (10-25 mg) and more psychedelic effects when used at a high doses (25-40 mg). Additionally, in two open labeled studies the effects have been defined by the researchers as entactogenic (MDMA-like) with psychedelic/hallucinogenic properties when administering 20 mg and on the other hand as psychedelic-psychostimulant like when administering a mean dose of 16 mg (4 used 10 mg, 5 used 15 mg and 7 used 20 mg). Subjective effects peaked at 1-2h and lasted 5h. The 2C drugs act mainly as agonists on the 5-HT2A receptor very similar to classic psychedelics like LSD or psilocybin. Furthermore, 2C-B may interact with monoaminergic systems more similar to MDMA and may share some empathogenic or even stimulant-type actions. 2C-B also inhibits the SERT similar to MDMA, however, only at low potency in vitro. Thus, taken together, the pharmacology of 2C-B in vitro is somewhat inconclusive but would be consistent with both MDMA- and psychedelic-type actions in vivo in humans. Increases in blood pressure and heart rate are moderate and regarded as lower than those of MDMA. No severe cases were observed. The safety profile of 2C-B is considered to be similar to MDMA. Psilocybin is a classic serotonergic psychedelic. Psilocybin is a prodrug which is activated to psilocin within the body. The psychoactive action of psilocin primarily involves an interaction with the serotonin 5-HT2A receptor. Currently, psilocybin is the most investigated psychedelic substance among the classic psychedelics. In particular, there are high hopes of using psilocybin in patients with treatment resistant major depression and pharmaceutical companies are currently conducting phase III studies. MDMA is an amphetamine derivative which, unlike prototypical amphetamines, predominantly enhances serotonergic neurotransmission via release of 5-HT through the SERT and it less potently also releases dopamine and norepinephrine through the dopamine transporter (DAT) and norepinephrine transporter (NET), respectively. Furthermore, MDMA is known to trigger oxytocin release which may contribute to its effects to increase trust, prosociality, and enhanced empathy and is therefore referred to as an \"entactogen\" or \"empathogen\". Being granted as a \"breakthrough therapy\" by the FDA, MDMA is currently investigated in substance-assisted psychotherapy for treatment of PTSD. By using a placebo-controlled double-blind cross-over design the study will provide insight into the effects profiles of recreationally used psychoactive substances relevant for psychiatric research. Therefore the study will compare the acute subjective, physiological and endocrine effects of low (10 mg), medium (20 mg) and high (30 mg) doses of 2C-B with standard doses of MDMA (125 mg) and psilocybin (25 mg) in healthy subjects. Finally, the study will also allow to newly directly compare MDMA and psilocybin effects at representative doses and within the same subjects which will provide for a better characterization of these substances increasingly used in psychiatric research.", "journal": "ClinicalTrials.gov", "publication_date": "2025-03-04", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05523401", "keywords": "Healthy, 4-bromo-2,5-dimethoxyphenethylamine (10 mg), 2C-B, 4-bromo-2,5-dimethoxyphenethylamine (20 mg), 4-bromo-2,5-dimethoxyphenethylamine (30 mg), 3,4-methylenedioxymethamphetamine, MDMA, Psilocybin, Placebo, COMPLETED", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05523401\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,PTSD,Pharmacology,Receptor Pharmacology,Clinical Trial,In Vitro Study,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4433, "title": "Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?", "normalized_title": "could psilocin rescue chronic stress accelerated transcriptional aging in brain", "authors": "Craig, Danny R, Blalock, Eric M.", "abstract": "Brain aging (BA) processes are complex, often affect multiple systems, and frequently lead to cognitive decline and increased susceptibility to insults. BA appears to be a primary risk for the development of many prominent neurodegenerative pathologies. The US Census Bureau predicts that the aging population (65+) will represent a greater proportion of the US population than children (under 18) by 2034, dramatically increasing the burden on health-care infrastructure.17 Several mechanisms of stress driven, aging-related neurologic dysfunction have been advanced in the past 50 years and include: Stress hormone exposure and glucocorticoid cascade;7, 16 calcium ion dyshomeostasis;8 allostatic load;10 and neuroinflammation.14 Taken together, these data suggest that many aspects of BA are accelerated, or even recapitulated, by stress. Here, the hippocampus (HIP) is an appropriate model structure based on its well-established role in cognition and memory, its manifestation of aging and stress-driven changes in gray (GM) and white matter (WM) transcriptional profiles, and its vulnerability to neurodegeneration; further, the HIP is a major target for stress hormones. It is well-recognized that stress’ influence on the limbic system is long-lasting. This may be due to its subcortical localization, evolutionarily conserved pathways, and potentially novel entrainment mechanism compared to the highly plastic neocortical memory processes ordinarily associated with cognition. Despite years of research clearly establishing a link between stress exposure and BA, no interventions targeting this interaction have been approved. We hypothesize that healthy BA and successful resilience to chronic stress would be indicated by improved hippocampal dependent, cognition, reduced stress-behavior, and reduced inflammatory transcriptional signatures; and not merely the persistence of youthful brain dynamics. Taken together, we refer to this constellation of beneficial responses in the aged and/or stressed subject as adaptive remodeling. Psilocin (PSI), the active metabolite of psilocybin, has agonist or partial agonist activity at serotonin [5-Hydroxtryptamine (5-HT)] receptors, including the G-protein coupled receptor subtypes: 5-HT1A, 5-HT1D, 5-HT2A, and 5-HT2C; functional interactions with central dopaminergic systems have also been demonstrated.12 Despite PSI’s known role in 5-HT and dopaminergic signaling, other agents engaging with these systems do not appear to exert similar effects; moreover, it is not clear to what extent PSI engages other glial and neuronal monoaminergic (e.g., serotonin, dopamine, epinephrine, and norepinephrine) systems. PSI has shown strong benefits in human studies and has twice been designated by the FDA as breakthrough therapy; first in 2018 for treatment resistant depression, and again in 2019 for major depressive disorder. Despite substantial interest in the therapeutic potential of PSI, little is known about the mechanisms through which it exerts its effects. An exhaustive search on the Gene Expression Omnibus revealed a single study using transcriptional profiling in ‘brain’ in conjunction with ‘PSI’ treatment (Donovan et al., 2021; GSE172074). Our lab analyzed raw RNAseq data from this study and identified genes associated with myelin sheath, synapse, and neuron, among others, to be significantly down regulated (p < 0.001) one week after treatment in pig prefrontal cortex. We propose a multi-level study in balanced groups of young and aged, male and female, Fischer 344 rats to investigate PSI’s effects on stress-accelerated BA. In Aim 1, using an ex-vivo hippocampal slice preparation, we will study the acute effects of PSI treatment on HIP. This model will be used to establish PSI concentration-effect relationships, identify responding HIP cell-types using immunohistochemistry or in situ hybridization, as well as to investigate, using RNA-seq, transcriptional profiles from laser capture microdissected hippocampal GM vs WM. Using this nonbiased approach to look at sub-region-specific profiles, will help establish a more complete account of PSI’s mechanism of action. In this prep, we will also measure PSI’s influence on basic electrophysiology properties like synaptic strength, conduction velocity and after-hyperpolarizing potential. PSI’s chronic effect on HIP-dependent cognitive behavior has also not been fully elucidated in prior studies. We will address this gap in Aim 2 of our study by using the Morris water maze test after 12-week chronic restraint [3hrs/day, 4days/week, using disposable DecapiCone restraint (or 3D printed ‘Restraint Device’ if approved)]. In human trials,1, 3, 5, 15 PSI has been used as an adjunct to guided psychotherapy (PT). To date, there are no recognized animal models of PT; though, enriched environments such as, social interaction, have been shown to be beneficial in animal models of neurodegenerative disease.9 We will attempt to mimic PT in our animal model with enriched group housing vs single housing. Regardless of whether results support our hypothesis, the significance of this project derives from its potential both for elucidating basic mechanisms of interactions between stress and BA, and for suggesting new therapeutic approaches to major health-related problems that widely affect the elderly. References Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619-627. Dalva MB, McClelland AC, Kayser MS. Cell adhesion molecules: signaling functions at the synapse (2007). Nat Rev Neurosci 8:206-220. https://doi.org/10.1038/nrn20 75. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021 May 1;78(5):481-489. Donovan LL, Johansen JV, Ros NF, Jaberi E, Linnet K, Johansen SS, Ozenne B, Issazadeh-Navikas S, Hansen HD, & Knudsen GM. Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. (2021). European neuropsychopharmacology: The journal of the European College of Neuropsychopharmacology, 42, 1-11. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197. Hargis K, Buechel HM, Popovic J, Blalock EM: Acute psychosocial stress in mid-aged male rats causes hyperthermia, cognitive decline, and increased deep sleep power, but does not alter deep sleep duration. Neurobiol Aging 2018, 70:78-85. Landfield PW. An endocrine hypothesis of brain aging and studies on brain-endocrine correlations and monosynaptic neurophysiology during aging. Adv.Exp.Med.Biol. (1978). 113, 179-199.doi:10.1007/978-1-4684-8893-7_11. Landfield PW, Pitler TA. Prolonged Ca2+-dependent afterhyperpolarizations in hippocampal neurons of aged rats. Science (New York, N.Y.) 226, 4678 (1984): 1089-92. Laviola G, Hannan AJ, Macrì S, Solinas M, & Jaber M. (2008). Effects of enriched environment on animal models of neurodegenerative diseases and psychiatric disorders. Neurobiology of Disease, 31, 159-168. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to disease. Arch Intern Med. 1993 Sep 27;153(18):2093-101. PMID: 8379800. Nichols CD, Martin DA (2015). Serotonergic hallucinogens preferentially activate subsets of cortical neurons, interneurons, and glial cells in the mPFC, somato- sensory cortex, and claustrum, and induce rapid redistribution of 5-HT2A receptor protein in neurons ACNP 54th Annual meeting, Abstract T182. Passie T, Seifert J, Schneider U, Emrich H M. The pharmacology of psilocybin. Addict. Biol. 7, 357-364 (2002). Pourhamzeh M, Moravej FG, Arabi M, Shahriari E, Mehrabi S, Ward R, Ahadi R, Joghataei MT. The Roles of Serotonin in Neuropsychiatric Disorders. Cell Mol Neurobiol. 2021 Mar 2. doi: 10.1007/s10571-021-01064-9. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P. Inflammation and Alzheimer’s disease pathogenesis. (1996) Neurobiol Aging 17:681-686. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180. Sapolsky RM, Krey LC, McEwen BS. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. 1986. Endocr.Rev. 7, 284-301. doi: 10.1210/edrv-7-3-284. United States Census Bureau. (2018). An Aging Nation. https://www.census.gov/content/dam/Census/library/visualizations/2018/comm/pop-projections-1.jpg.", "journal": "UKnowledge (University of Kentucky)", "publication_date": "2025-03-03", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://uknowledge.uky.edu/jpns/vol2/iss1/1", "keywords": "Hippocampal formation, Neuroscience, Cognition, Population, Cognitive decline, Biology, Chronic stress, Hippocampus, Affect (linguistics), Disease, Glucocorticoid, Psychology, Mechanism (biology), Vulnerability (computing), Medicine, Allostatic load, Bioinformatics, Psychological resilience, Transcriptome, Zebrafish, Aging brain, Hormone, Torpor, Amygdala, Stressor, Allostasis, Senescence, Fight-or-flight response, Cognitive aging, Psychological intervention, Psychedelics and Drug Studies, Sleep and Wakefulness Research, Memory and Neural Mechanisms", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:40", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7110662772\",\"openalex_url\":\"https://openalex.org/W7110662772\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Craig, Danny R\",\"orcid\":null},{\"id\":null,\"display_name\":\"Blalock, Eric M.\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306402623\",\"source_display_name\":\"UKnowledge (University of Kentucky)\",\"landing_page_url\":\"https://uknowledge.uky.edu/jpns/vol2/iss1/1\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Aging,Cellular Senescence,Resilience,Clinical Trial,Randomized Controlled Trial,Animal Study,Older Adults,Adolescents,Treatment-Resistant Depression,Safety,Drug Interactions,Transcriptomics,Inflammation", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7110662772" }, { "id": 797, "title": "Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.", "normalized_title": "psychedelics for cancer pain and associated psychological distress a narrative review of a potential strategy", "authors": "Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB.", "abstract": "PurposeTo evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychological distress.ContentPain is a common symptom of cancer and treatment. However, there are high rates of undertreatment of cancer pain due to the complex underlying biology of the condition, and potentially due to a decrease in opioid prescribing in response to the opioid epidemic. A diagnosis of cancer and cancer-related pain can trigger high levels of psychological distress throughout cancer treatment. Cancer pain can also be exacerbated by anxiety, depression, quality of life challenges, and fear of death and dying, as well as by fear of recurrence or progression. Several pharmacologic and non-pharmacologic approaches have been utilized to mitigate pain and symptom burden with some success. However, there remains an unmet need for better management of cancer pain and associated symptoms. Psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, mescaline, and N,N-dimethyltryptamine (DMT), are under consideration as new pharmacologic strategies for mitigating pain and the distress associated with cancer pain and associated symptom burden. Although published studies are limited, regulatory hurdles have decreased. Many clinical trials are underway to assess further the use of psychedelics and behavioral counseling for patients with cancer and comorbidities such as anxiety or depression. These studies examine both the feasibility and efficacy of psychedelics for pain and psychological distress. Early results are promising, and additional research is needed to understand efficacy and tolerability in broader cancer populations.ImplicationsThere is an unmet need to improve pain management in patients with cancer and to mitigate psychological distress. Further research is required to understand the efficacy of psychedelics for the treatment of cancer pain and distress. Recent regulatory changes have paved the way for increased research on the clinical efficacy of psychedelics in cancer.", "journal": null, "publication_date": "2025-02-28", "publication_year": 2025, "doi": "10.1002/cam4.70586", "pubmed_id": "40052631", "source_url": "https://doi.org/10.1002/cam4.70586", "keywords": "Humans, Neoplasms, Hallucinogens, Quality of Life, Pain Management, Cancer Pain, Psychological Distress", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40052631\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Clinical Trial,Review Article,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3748, "title": "Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms", "normalized_title": "tū wairua development of an indigenous rongoā māori approach to healing with psilocybin containing mushrooms", "authors": "Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P.", "abstract": "Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and spiritual purposes. While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy being developed lack Indigenous wisdom and input, raising concerns about safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with psilocybin-assisted therapy (PAT) for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by kaupapa Māori methodology and rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti, a community with a high Māori population and a significant burden of PMU, the project aims to develop a culturally-appropriate PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelics. In creating sustainable pathways for healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.", "journal": "PsyArXiv", "publication_date": "2025-02-27", "publication_year": 2025, "doi": "10.31234/osf.io/93x5h_v3", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/93x5h_v3", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:18", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR984247\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3110, "title": "Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms", "normalized_title": "tū wairua development of an indigenous rongoā māori approach to healing with psilocybin containing mushrooms", "authors": "Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P.", "abstract": "Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and spiritual purposes. While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy being developed lack Indigenous wisdom and input, raising concerns about safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with psilocybin-assisted therapy (PAT) for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by kaupapa Māori methodology and rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti, a community with a high Māori population and a significant burden of PMU, the project aims to develop a culturally-appropriate PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelics. In creating sustainable pathways for healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.", "journal": "PsyArXiv", "publication_date": "2025-02-27", "publication_year": 2025, "doi": "10.31234/osf.io/93x5h_v2", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/93x5h_v2", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR984267\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3109, "title": "Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms", "normalized_title": "tū wairua development of an indigenous rongoā māori approach to healing with psilocybin containing mushrooms", "authors": "", "abstract": "Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and spiritual purposes. While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy being developed lack Indigenous wisdom and input, raising concerns about safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with psilocybin-assisted therapy (PAT) for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by kaupapa Māori methodology and rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti, a community with a high Māori population and a significant burden of PMU, the project aims to develop a culturally-appropriate PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelics. In creating sustainable pathways for healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.", "journal": "PsyArXiv", "publication_date": "2025-02-27", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/93x5h_v3", "keywords": "Psychiatry, Neuroscience, Social and Behavioral Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"93x5h_v3\",\"version\":3,\"reviews_state\":\"accepted\"}", "topic_tags": "Addiction,Mechanism of Action,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 793, "title": "A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.", "normalized_title": "a field wide review and analysis of study materials used in psilocybin trials assessment of two decades of research", "authors": "Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME.", "abstract": "IntroductionSerotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information-but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes.MethodsTo better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents.ResultsWhile these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research.ConclusionsIdeally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.", "journal": null, "publication_date": "2025-02-26", "publication_year": 2025, "doi": "10.1089/psymed.2024.0019", "pubmed_id": "40351554", "source_url": "https://doi.org/10.1089/psymed.2024.0019", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"40351554\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Consciousness,Wellbeing,Review Article,Safety,Adverse Events,Contraindications", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 815, "title": "A review of psychedelics trials completed in depression, informed by European regulatory perspectives.", "normalized_title": "a review of psychedelics trials completed in depression informed by european regulatory perspectives", "authors": "Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P.", "abstract": "There is a growing body of clinical research on the therapeutic potential of psychedelics for the treatment of mental health disorders, notably depression. Accordingly, the new revision of the European Medicines Agency guideline on the clinical investigation of products for depression will incorporate a section covering specific regulatory recommendations for the design of studies with psychedelics. The present review investigated the methodological approaches adopted in completed controlled trials of psychedelics for depression in light of initial considerations included in the draft guideline revision. A systematic search conducted on scientific databases (Embase and Medline) and clinical trial registries (clinicaltrials.gov and WHO ICTPR) identified 8 completed trials as of February 2024. The trials tested psilocybin, LSD, Ayahuasca, and DMT, for major depressive disorder or treatment-resistant depression, and were all pahse 2 or 1/2. Patterns in pre-defined methodological variables pertaining to trial design, population, interventions, outcome measures and safety assessments were analysed and collated against considerations on unblinding and expectancy, choice of comparator, the definition of treatment frameworks, the characterisation of the subjective psychedelic experience and the specification of adverse events in relation to subjective psychedelic effects. Areas for future research, including long-term efficacy and safety and the influence of inter-individual differences, can be investigated in larger studies, necessary for marketing authorisation applications. Ultimately, balancing the intricacies of conducting trials with psychedelics with ensuring adherence to regulatory requirements can be facilitated by early dialogue with medicines regulators, and will be essential for the medical development of psychedelics to address unmet patient needs.", "journal": null, "publication_date": "2025-02-25", "publication_year": 2025, "doi": "10.1016/j.nsa.2025.105516", "pubmed_id": "40654583", "source_url": "https://doi.org/10.1016/j.nsa.2025.105516", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40654583\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3077, "title": "The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.", "normalized_title": "the impact of communicating the benefits and safety of psilocybin on policy support a survey based experiment", "authors": "Hitchins K, Reynolds J.", "abstract": "Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies. Objectives: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies. Methods: In an online survey experiment, 804 participants were randomised to receive one of four interventions in a 2 (no information vs evidence for psilocybin benefits) x 2 (no information vs evidence for psilocybin safety) design. Public support for four psilocybin policies and beliefs about the benefits and safety of psilocybin were measured before and after participants were randomised to a group. Results: In a two-way ANCOVA, the Benefits Intervention significantly increased policy support overall and for two of four psilocybin policies when analysed separately. Furthermore, the Benefits Intervention significantly strengthened beliefs that psilocybin is beneficial and safe. The Safety Intervention increased psilocybin policy support overall (d =.10, p =.003); and for three of four psilocybin policies when analysed separately. The Safety Intervention also strengthened beliefs that psilocybin is safe but not that it is beneficial. Conclusions: Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further research is needed to explore the longevity of these results.", "journal": "PsyArXiv", "publication_date": "2025-02-24", "publication_year": 2025, "doi": "10.31234/osf.io/48yg7_v2", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/48yg7_v2", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR982614\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Longevity,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 532, "title": "The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.", "normalized_title": "the impact of communicating the benefits and safety of psilocybin on policy support a survey based experiment", "authors": "", "abstract": "Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies. Objectives: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies. Methods: In an online survey experiment, 804 participants were randomised to receive one of four interventions in a 2 (no information vs evidence for psilocybin benefits) x 2 (no information vs evidence for psilocybin safety) design. Public support for four psilocybin policies and beliefs about the benefits and safety of psilocybin were measured before and after participants were randomised to a group. Results: In a two-way ANCOVA, the Benefits Intervention significantly increased policy support overall and for two of four psilocybin policies when analysed separately. Furthermore, the Benefits Intervention significantly strengthened beliefs that psilocybin is beneficial and safe. The Safety Intervention increased psilocybin policy support overall (d =.10, p =.003); and for three of four psilocybin policies when analysed separately. The Safety Intervention also strengthened beliefs that psilocybin is safe but not that it is beneficial. Conclusions: Communicating the benefits and safety of psilocybin can increase psilocybin policy support and strengthen beliefs about psilocybin, however further research is needed to explore the longevity of these results.", "journal": "PsyArXiv", "publication_date": "2025-02-24", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/48yg7_v2", "keywords": "Acceptability, Acceptance, Attitudes, Policy Support, Psilocybin, Psychedelics, Social and Behavioral Sciences, Social and Personality Psychology, Attitudes and Persuasion, Health Psychology, Mental Health", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"48yg7_v2\",\"version\":2,\"reviews_state\":\"accepted\"}", "topic_tags": "Longevity,Personality Change,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3080, "title": "The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.", "normalized_title": "the impact of communicating the benefits and safety of psilocybin on policy support a survey based experiment", "authors": "Hitchins K, Reynolds J.", "abstract": "Background: Preliminary evidence suggests psilocybin may have therapeutic value for various mental health conditions; despite this, it is currently illegal in the UK. Less is known about how people form their attitudes towards psilocybin policies. Objectives: To explore whether beliefs about the benefits and safety of psilocybin influence support for psilocybin policies. Methods: In an online survey experiment, 804 participants were randomised to receive one of four interventions in a 2 (no information vs evidence for psilocybin benefits) x 2 (no information vs evidence for psilocybin safety) design. Public support for four psilocybin policies and beliefs about the benefits and safety of psilocybin were measured before and after participants were randomised to a group. Results: In a two-way ANCOVA, the Benefits Intervention significantly increased policy support overall (d =.11, p", "journal": "PsyArXiv", "publication_date": "2025-02-23", "publication_year": 2025, "doi": "10.31234/osf.io/48yg7_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/48yg7_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR982270\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Longevity,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 816, "title": "Psychedelics and Suicide-Related Outcomes: A Systematic Review.", "normalized_title": "psychedelics and suicide related outcomes a systematic review", "authors": "Meshkat S, Malik T, Zeifman R, Swainson J, Zhang Y, Burback L, Winkler O, Greenshaw AJ, Claire Reichelt A, Vermetten E, Erritzoe D, Jha MK, Dunn W, Jetly R, Husain MI, Bhat V.", "abstract": "Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and ClinicalTrials.gov was conducted up to November 2024. Results: Four randomized controlled trials (RCTs) evaluated suicidality as a secondary outcome or safety measure, showing significant reductions in suicidal ideation with psilocybin (three studies) and MDMA-assisted therapy (MDMA-AT; one study). Effect sizes, measured by Cohen's d, ranged from =0.52 to 1.25 (p = 0.01 to 0.005), with no safety issues reported. Five additional RCTs assessed suicidality as a safety measure, showing reductions in suicidal ideation with psilocybin (two studies) and MDMA-AT (three studies; p = 0.02 to 0.04). Among 24 non-randomized and cross-sectional studies, results were mixed. Psilocybin (three studies) reduced suicidal ideation, with odds ratios (OR) of 0.40-0.75. MDMA-AT (five studies in PTSD patients) had a pooled effect size of d = 0.61 (95% CI: 0.32-0.89). LSD (six studies) showed increased odds of suicidality, with odds ratios ranging from 1.15 to 2.08. Studies involving DMT (two studies) and multiple psychedelics (three studies) showed mixed results, with DMT studies not showing significant effects on suicidality and studies involving multiple psychedelics showing varying outcomes, some reporting reductions in suicidal ideation and others showing no significant change. Conclusions: The effect of psychedelic therapies on suicide-related outcomes remains inconclusive, highlighting the need for further trials to clarify safety and therapeutic mechanisms.", "journal": null, "publication_date": "2025-02-19", "publication_year": 2025, "doi": "10.3390/jcm14051416", "pubmed_id": "40094838", "source_url": "https://doi.org/10.3390/jcm14051416", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"40094838\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Mechanism of Action,Randomized Controlled Trial,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 720, "title": "Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.", "normalized_title": "anaesthetic implications of psilocybin and lysergic acid diethylamide what is old is now new a narrative review on psychedelics and anaesthesia", "authors": "Dave M, Shore R, Cupido T, Haley C, Clinkard D.", "abstract": "Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As exploratory studies demonstrate clinical efficacy with few adverse events, it is expected that more patients will ingest psychedelic drugs. For therapeutic reasons, as with any drug, anaesthesiologists must be aware of its physiological effects and contraindications to ensure the safe provision of anaesthesia. Psilocybin is a 5HT 1A and 5HT 2A serotonin receptor agonist thought to act on excitatory and inhibitory neurons in the brain. Acute ingestion causes sympathetic nervous system activation, which can precipitate haemodynamic instability. Activation of the 5HT serotonin receptors can also place the patient at risk of serotonin syndrome. Chronic use increases plasma concentrations of cortisol, which has implications on prophylactic stress-dosing of glucocorticoids preoperatively. Lysergic acid diethylamide (LSD), a synthetic psychoactive substance, is also a 5HT2 A agonist. LSD has been shown to potentiate opioid analgesics, and monoamine oxidase (MAO) inhibition. Historical reports suggest that LSD has anticholinesterase activity and can prolong neuromuscular block with depolarising muscle relaxants. Mescaline is a poorly understood psychedelic with similar autonomic effects. Historical studies have shown decreased neuromuscular transmission and an association with malignant hyperthermia. When managing patients who have consumed psychedelics drugs, it is important to consider delaying surgery whenever possible, to allow acute intoxication to wane. A high degree of suspicion and an understanding of management principles is vital to the safe conduct of anaesthesia. Future research should explore therapeutic doses of psychedelic drugs to understand physiologic effects at various concentrations.", "journal": null, "publication_date": "2025-02-17", "publication_year": 2025, "doi": "10.1097/eja.0000000000002138", "pubmed_id": "39967455", "source_url": "https://doi.org/10.1097/eja.0000000000002138", "keywords": "Humans, Lysergic Acid Diethylamide, Anesthetics, Hallucinogens, Anesthesia, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39967455\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Chronic Pain,Receptor Pharmacology,Aging,Review Article,Safety,Adverse Events,Contraindications", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 820, "title": "Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology", "normalized_title": "psilocybin as a treatment for repetitive mild head injury evidence from neuroradiology and molecular biology", "authors": "Brengel EK, Axe B, Maheswari A, Abeer MI, Ortiz RJ, Woodward TJ, Walhof R, Utama R, Sawada C, Balaji S, Kulkarni PP, Bradshaw HB, Gitcho MA, Ferris CF.", "abstract": "Repetitive mild head injuries incurred while playing organized sports, during car accidents and falls, or in active military service are a major health problem. These head injuries induce cognitive, motor, and behavioral deficits that can last for months and even years with an increased risk of dementia, Parkinson’s disease, and chronic traumatic encephalopathy. There is no approved medical treatment for these types of head injuries. To this end, we tested the healing effects of the psychedelic psilocybin, as it is known to reduce neuroinflammation and enhance neuroplasticity. Using a model of mild repetitive head injury in adult female rats, we provide unprecedented data that psilocybin can reduce vasogenic edema, restore normal vascular reactivity and functional connectivity, reduce phosphorylated tau buildup, enhance levels of brain-derived neurotrophic factor and its receptor TrkB, and modulate lipid signaling molecules.", "journal": "bioRxiv", "publication_date": "2025-02-05", "publication_year": 2025, "doi": "10.1101/2025.02.03.636248", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.02.03.636248", "keywords": "", "substance_tags": "psilocybin", "source_name": "bioRxiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR975392\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Safety,Inflammation", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4443, "title": "Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners", "normalized_title": "psilocybin mushroom stewardship a qualitative inquiry into practices and priorities of underground psilocybin mushroom practitioners", "authors": "Shannon Hughes, Lucia Terpak, Reilly Capps, Pam Peters, Nicole Lilly, Dylan Rivard", "abstract": "Abstract Background and Aims Networks of so-called underground, or illegal, psilocybin mushroom practitioners are popularly known to exist, though few systematic investigations of their practices have been conducted. We sought to uncover the experiences of a hidden community of psilocybin practitioners in order to inform scientific and policy dialogues about safe and effective practices in this area. Methods An academic-community partnered research team used snowball sampling to recruit 17 underground psilocybin practitioners in a western U.S. state for in-depth individual interviews focused on training, protocols, practices, and policy priorities. Combined deductive and inductive analysis with three independent coders was completed using NVivo v12. Results Practitioners were white (76.5%), female-identified (64.7%), aged 31 to 50 (64.7%), non-therapists by training (58.8%), and moderately to highly experienced facilitators. All described multiple years of often difficult personal inner-directed work with psilocybin before guiding others. Benefits ranged from reduction in symptoms of depression, obsessive-compulsive disorder, and addictions to greater self-knowledge, reduced death anxiety, and a greater ability to experience joy. Client screening protocols revealed precautions for persons with severe trauma backgrounds, personality disorders, or lacking social support. Moving too quickly into a high dose mushroom session without adequate preparation or internal resourcing was perceived as a significant risk for harm. Practitioners' direct personal relationship with mushrooms was highlighted as critical to safe practice. Policy priorities centered on respectful reciprocity, defined as an ethos of giving back rather than extraction, and equitable access. Conclusions While some psychedelic research actively examines the role of the mystical-type experience in clients' positive outcomes, findings from underground practitioners suggest an even greater role of mysticism, relationality, and expanded concepts of holistic healing that can inform the development of best practice paradigms of an emerging profession.", "journal": "Journal of Psychedelic Studies", "publication_date": "2025-02-04", "publication_year": 2025, "doi": "10.1556/2054.2025.00375", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2025.00375", "keywords": "Psilocybin, Stewardship (theology), Mushroom, Mushroom poisoning, Psychology, Hallucinogen, Political science, Chemistry, Psychiatry, Food science, Politics, Law, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4407157019\",\"openalex_url\":\"https://openalex.org/W4407157019\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W63354357\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2143350277\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2541735118\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2739506888\",\"https://openalex.org/W3023499422\",\"https://openalex.org/W3198659533\",\"https://openalex.org/W3199302798\",\"https://openalex.org/W3204171992\",\"https://openalex.org/W3215626177\",\"https://openalex.org/W4210764005\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4236038590\",\"https://openalex.org/W4241052343\",\"https://openalex.org/W4244982232\",\"https://openalex.org/W4245006944\",\"https://openalex.org/W4248607037\",\"https://openalex.org/W4251929576\",\"https://openalex.org/W4255816404\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4283584241\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4289522809\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4322757924\",\"https://openalex.org/W4361248485\",\"https://openalex.org/W4383998917\",\"https://openalex.org/W4386827794\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4387580925\",\"https://openalex.org/W4387763972\",\"https://openalex.org/W4399215777\",\"https://openalex.org/W6804346829\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066575824\",\"display_name\":\"Shannon Hughes\",\"orcid\":\"https://orcid.org/0000-0002-4152-3831\"},{\"id\":\"https://openalex.org/A5116155320\",\"display_name\":\"Lucia Terpak\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116155321\",\"display_name\":\"Reilly Capps\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116155322\",\"display_name\":\"Pam Peters\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112334947\",\"display_name\":\"Nicole Lilly\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116155324\",\"display_name\":\"Dylan Rivard\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2025.00375\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,OCD,Receptor Pharmacology,Personality Change,Mystical Experience,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4407157019" }, { "id": 836, "title": "Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.", "normalized_title": "evaluating the value and risks of psychedelics for psychiatric medicine a clinical perspective", "authors": "Marazziti D, Weiss F, Gurrieri R, Russomanno G, Gambini M, Magnesa A, Coccoglioniti A, Perugi G", "abstract": "After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during the last two decades. However, the resounding enthusiasm linked to such 'psychedelic renaissance' runs the risk to unduly minimize the possible hazards associated with these compounds, while expanding their alleged benefits to improbable panacea-like proportions. In order to avoid mystifying or demonizing the properties of 5-HT2a agonists on emotional grounds, this subject requires a strictly unprejudiced and cautious approach to the evidence. In this article, the authors attempted to comprehensively analyze the available literature to provide a balanced overview of the possible benefits of psychedelics in healthcare, taking into account their potential risks. To date, psychedelics have shown a therapeutic potential in a wide range of conditions, with a seemingly limited risk of inducing adverse reactions, including abuse and dependence, when administered in a controlled environment by specialized personnel. In any case, although several questions remain unanswered before drawing firm conclusions, further studies are needed to establish which conditions and subjects could benefit from psychedelics and which patients bear the greater risk of adversities.", "journal": "Expert review of neurotherapeutics", "publication_date": "2025-01-31", "publication_year": 2025, "doi": "10.1080/14737175.2024.2445016", "pubmed_id": "39699299", "source_url": "https://pubmed.ncbi.nlm.nih.gov/39699299/", "keywords": "5-HT2a agonist, DMT, LSD, Psychedelic, mescaline, psilocin, psilocybin, use in clinical psychiatry", "substance_tags": "psilocybin,psilocin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"39699299\"}", "topic_tags": "Receptor Pharmacology,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 846, "title": "Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.", "normalized_title": "psychedelic assisted treatment for substance use disorder a narrative systematic review", "authors": "Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J.", "abstract": "Background and aimsThis is the first systematic review of the extant literature on all major psychedelic-assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic-assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for research.MethodsThis was a prospectively registered narrative systematic review of open-label, randomised controlled trials (RCT), and observational studies of d-lysergic acid diethylamide (LSD), mescaline, psilocybin, ayahuasca, ketamine, ibogaine and 3,4-methylenedioxymethamphetamine (MDMA). Eligible studies had SUD outcome measures including craving, substance use, relapse, and remission. Study quality was evaluated using the Cochrane Collaboration Risk of Bias (RoB), and Cochrane Collaboration RoB in Non-randomised Studies of Interventions tool. Certainty of evidence for RCTs was judged using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) tool.Findings37 studies (2035 participants) were reviewed: LSD (14; n = 1047); mescaline (1; n = 7); psilocybin (4; n = 135); ayahuasca (3; n = 101); ketamine (10; n = 579); ibogaine (5; n = 166); and MDMA (1; n = 14). There were no serious adverse events reported in any study. A two-centre, placebo-controlled, phase 2 superiority RCT of psilocybin for AUD, and a two-centre, double-blind, four-arm, placebo-controlled phase 2 RCT of ketamine for AUD yielded the best evidence of efficacy. Progression support to a phase 3 trials was secured from an open-label phase 2 study of psilocybin for TUD and nine phase 2 RCTs of ketamine for AUD, cannabis use disorder, cocaine use disorder, and opioid use disorder (all nine with high-RoB and low-GRADE evidence certainty).ConclusionsPsilocybin-assisted treatment for alcohol use disorder appears to have the best evidence of efficacy among all major psychedelic-assisted treatments for alcohol, tobacco, and other substance use disorders. Future research of psychedelic-assisted treatment should report all safety events; screen for person-level characteristics indicating that psychedelic-assisted substance use disorders treatment is contraindicated; strive to mitigate blinding of participants to interventions; use factorial designs for drug and psychotherapy randomised controlled trials; and build consensus for a field-specific Core Outcome Set.", "journal": null, "publication_date": "2025-01-29", "publication_year": 2025, "doi": "10.1111/add.16762", "pubmed_id": "39887551", "source_url": "https://doi.org/10.1111/add.16762", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"39887551\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Observational Study,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4461, "title": "Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?", "normalized_title": "experiential dimension of psilocybin assisted therapy training necessity or hindrance to wider accessibility", "authors": "Louis Plourde, Sue-Ling Chang, Houman Farzin, Jean-François Stephan, Jean-Sébastien Fallu, Michel Dorval", "abstract": "Abstract The discussion surrounding the necessity of acquiring personal experience of non-ordinary states of consciousness in the course of psilocybin-assisted therapy training is crucial, as it can affect treatment safety, effectiveness and accessibility. As such, the ethical and practical issues associated with such a training standard require timely consideration in jurisdictions where this intervention is endorsed and integrated into healthcare. We believe the most balanced and ethical approach is to make psilocybin legally available for professional training without making it a requirement.", "journal": "Journal of Psychedelic Studies", "publication_date": "2025-01-20", "publication_year": 2025, "doi": "10.1556/2054.2024.00431", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2024.00431", "keywords": "Psilocybin, Experiential learning, Dimension (graph theory), Psychotherapist, Psychology, Training (meteorology), Hallucinogen, Psychiatry, Pedagogy, Mathematics, Meteorology, Pure mathematics, Physics, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4406667242\",\"openalex_url\":\"https://openalex.org/W4406667242\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W140271714\",\"https://openalex.org/W356352827\",\"https://openalex.org/W562964222\",\"https://openalex.org/W564195063\",\"https://openalex.org/W1754961979\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2014087423\",\"https://openalex.org/W2015114767\",\"https://openalex.org/W2111459052\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2143976056\",\"https://openalex.org/W2181847988\",\"https://openalex.org/W2316003297\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2484178742\",\"https://openalex.org/W2502147470\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2767026933\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2895740693\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2965468106\",\"https://openalex.org/W3024609058\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3114028558\",\"https://openalex.org/W3139397908\",\"https://openalex.org/W3144810457\",\"https://openalex.org/W3157058636\",\"https://openalex.org/W3162204693\",\"https://openalex.org/W3163974662\",\"https://openalex.org/W3177153100\",\"https://openalex.org/W3183684219\",\"https://openalex.org/W3210625928\",\"https://openalex.org/W4220813054\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4244164154\",\"https://openalex.org/W4280525486\",\"https://openalex.org/W4293080285\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4321016287\",\"https://openalex.org/W4322757924\",\"https://openalex.org/W4366590080\",\"https://openalex.org/W4378976526\",\"https://openalex.org/W4385495585\",\"https://openalex.org/W4386206113\",\"https://openalex.org/W4399650907\",\"https://openalex.org/W4401417544\",\"https://openalex.org/W4401920850\",\"https://openalex.org/W4404043063\",\"https://openalex.org/W6630948633\"],\"authorships\":[{\"id\":\"https://openalex.org/A5093764769\",\"display_name\":\"Louis Plourde\",\"orcid\":null},{\"id\":\"https://openalex.org/A5045951431\",\"display_name\":\"Sue-Ling Chang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040374734\",\"display_name\":\"Houman Farzin\",\"orcid\":\"https://orcid.org/0009-0006-4095-3596\"},{\"id\":\"https://openalex.org/A5027250223\",\"display_name\":\"Jean-François Stephan\",\"orcid\":\"https://orcid.org/0009-0000-7376-208X\"},{\"id\":\"https://openalex.org/A5053736941\",\"display_name\":\"Jean-Sébastien Fallu\",\"orcid\":\"https://orcid.org/0000-0002-2300-1335\"},{\"id\":\"https://openalex.org/A5068576397\",\"display_name\":\"Michel Dorval\",\"orcid\":\"https://orcid.org/0000-0002-3207-8211\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2024.00431\",\"is_oa\":true}}", "topic_tags": "Consciousness,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4406667242" }, { "id": 3679, "title": "A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression", "normalized_title": "a phase ii randomized double blind active placebo controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment resistant major depression", "authors": "Central Institute of Mental Health, Mannheim", "abstract": "The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD). The study is a bi-centric, prospective, randomized, active placebo-controlled study investigating the effects of 25 mg and 5 mg (p.o.) psilocybin versus placebo (100 mg nicotinamide) in a psychotherapeutic context in 144 patients with TRD from moderate to severe degree (ICD-10 F32/F33). After giving written informed consent and down-titration of their monoaminergic medication under supervision of the treating psychiatrist and the study team, patients will be randomly assigned to one of four trial arms using an online randomization tool: 1) receiving placebo (100 mg nicotinamide) at the first session and the full dose (25 mg) at the second; 2) receiving the presumably sub-effective dose (5 mg) at the first session and the full dose (25 mg) at the second; 3a) receiving the full dose (25 mg) at the first session and 5 mg at the second; 3b) receiving the full dose at both sessions. The two dosing sessions are accompanied by three preparatory and four integration sessions. Drug administration must occur under psychotherapeutic conditions. Two trained therapists (one male, one female) will be assigned to each patient and be present during each dosing, preparatory and integration sessions. We will follow the safety guidelines provided by Johnson et al. (2), including a thorough preparation, establishment of trust/rapport, a safe and pleasing physical environment and sufficient interpersonal support. For safety reasons and close monitoring, patients will stay hospitalized for one night after each dosing session (i.e. in-patient setting).", "journal": "ClinicalTrials.gov", "publication_date": "2025-01-19", "publication_year": 2025, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04670081", "keywords": "Treatment-resistant Depression, Psilocybin, Nicotinamide, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04670081\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 854, "title": "Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.", "normalized_title": "uncovering psychedelics from neural circuits to therapeutic applications", "authors": "Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M.", "abstract": "Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due to their profound effects on consciousness, emotional processing, mood, and neural plasticity. This review explores the mechanisms underlying psychedelics' effects, focusing on their ability to modulate brain connectivity and neural circuit activity, including the default mode network (DMN), cortico-striatal thalamo-cortical (CSTC) loops, and the relaxed beliefs under psychedelics (REBUS) model. Advanced neuroimaging techniques reveal psychedelics' capacity to enhance functional connectivity between sensory cerebral areas while reducing the connections between associative brain areas, decreasing the rigidity and rendering the brain more plastic and susceptible to external changings, offering insights into their therapeutic outcome. The most relevant clinical trials of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD) demonstrate significant efficacy in treating treatment-resistant psychiatric conditions such as post-traumatic stress disorder (PTSD), depression, and anxiety, with favorable safety profiles. Despite these advancements, critical gaps remain in linking psychedelics' molecular actions to their clinical efficacy. This review highlights the need for further research to integrate mechanistic insights and optimize psychedelics as tools for both therapy and understanding human cognition.", "journal": null, "publication_date": "2025-01-18", "publication_year": 2025, "doi": "10.3390/ph18010130", "pubmed_id": "39861191", "source_url": "https://doi.org/10.3390/ph18010130", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39861191\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Neuroplasticity,Brain Imaging,Mechanism of Action,Default Mode Network,Consciousness,Aging,Emotional Processing,Spirituality,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 855, "title": "Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial", "normalized_title": "psilocybin assisted massed cognitive processing therapy for chronic posttraumatic stress disorder protocol for an open label pilot feasibility trial", "authors": "Shakila Meshkat, Richard J. Zeifman, Kathleen E. Stewart, Reinhard Janssen-Aguilar, Wendy Lou, Rakesh Jetly, Candice M. Monson, Venkat Bhat", "abstract": "BACKGROUND: Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches. Preliminary evidence supports the potential therapeutic action of psilocybin to alleviate PTSD symptoms. This open-label pilot study aims to evaluate the feasibility, tolerability, and preliminary efficacy of a single dose 25 mg psilocybin in combination with one week of massed CPT in patients with chronic PTSD. METHOD: Fifteen participants with chronic PTSD will undergo 12 CPT sessions, two psilocybin-related psychotherapy sessions, and one psilocybin dosing session over a 7-days period. The primary outcomes are feasibility and tolerability, which will be measured by recruitment rates, withdrawal, data completion, adherence, number and nature of adverse events. Secondary objectives include assessing the preliminary efficacy of psilocybin-assisted CPT in reducing PTSD severity, self-reported treatment outcomes and exploring putative mechanisms of change. Participants will be monitored weekly for 12 weeks post-treatment and passive data relevant to mental health and well-being will be collected using a wearable device. DISCUSSION: This trial will generate important preliminary data on the use of psilocybin-assisted CPT for treating PTSD. The findings will guide the design of a multi-site, large-scale randomized control trial to more rigorously assess the efficacy of this intervention. De-identified data from this study will be available upon request after publication of the results. This study represents a promising and innovative approach to PTSD treatment, potentially offering an alternative therapeutic option for individuals unresponsive to conventional therapies. TRIAL REGISTRATION: ClinicalTrials.gov NCT06386003.", "journal": "PLoS ONE", "publication_date": "2025-01-16", "publication_year": 2025, "doi": "10.1371/journal.pone.0313741", "pubmed_id": "39823496", "source_url": "https://doi.org/10.1371/journal.pone.0313741", "keywords": "Psilocybin, Posttraumatic stress, Medicine, Cognition, Cognitive processing therapy, Cognitive behavioral therapy, Hallucinogen, Psychiatry, Psychology, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4406512218\",\"openalex_url\":\"https://openalex.org/W4406512218\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W98962507\",\"https://openalex.org/W1704280769\",\"https://openalex.org/W2007100403\",\"https://openalex.org/W2014553268\",\"https://openalex.org/W2037445719\",\"https://openalex.org/W2042593075\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2047503435\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2130232395\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2138959943\",\"https://openalex.org/W2147791664\",\"https://openalex.org/W2154051205\",\"https://openalex.org/W2242133324\",\"https://openalex.org/W2269592175\",\"https://openalex.org/W2330001440\",\"https://openalex.org/W2412976663\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2612417324\",\"https://openalex.org/W2798096119\",\"https://openalex.org/W2801115059\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2973210190\",\"https://openalex.org/W3011233335\",\"https://openalex.org/W3047886920\",\"https://openalex.org/W3080571288\",\"https://openalex.org/W3082540939\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W3185477803\",\"https://openalex.org/W4211189621\",\"https://openalex.org/W4211262802\",\"https://openalex.org/W4213100499\",\"https://openalex.org/W4220989975\",\"https://openalex.org/W4221108429\",\"https://openalex.org/W4230198769\",\"https://openalex.org/W4236983761\",\"https://openalex.org/W4292528167\",\"https://openalex.org/W4293003987\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W6941129350\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037985605\",\"display_name\":\"Shakila Meshkat\",\"orcid\":\"https://orcid.org/0000-0002-7010-1785\"},{\"id\":\"https://openalex.org/A5000949886\",\"display_name\":\"Richard J. Zeifman\",\"orcid\":\"https://orcid.org/0000-0003-3478-4483\"},{\"id\":\"https://openalex.org/A5070956539\",\"display_name\":\"Kathleen E. Stewart\",\"orcid\":\"https://orcid.org/0000-0002-9674-8720\"},{\"id\":\"https://openalex.org/A5007543039\",\"display_name\":\"Reinhard Janssen-Aguilar\",\"orcid\":\"https://orcid.org/0000-0001-5340-9078\"},{\"id\":\"https://openalex.org/A5014930895\",\"display_name\":\"Wendy Lou\",\"orcid\":\"https://orcid.org/0000-0001-5590-8719\"},{\"id\":\"https://openalex.org/A5054146035\",\"display_name\":\"Rakesh Jetly\",\"orcid\":\"https://orcid.org/0000-0001-6610-9365\"},{\"id\":\"https://openalex.org/A5048101320\",\"display_name\":\"Candice M. Monson\",\"orcid\":\"https://orcid.org/0000-0001-6179-0788\"},{\"id\":\"https://openalex.org/A5054349344\",\"display_name\":\"Venkat Bhat\",\"orcid\":\"https://orcid.org/0000-0002-8768-1173\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S202381698\",\"source_display_name\":\"PLoS ONE\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pone.0313741\",\"is_oa\":true}}", "topic_tags": "PTSD,Chronic Pain,Mechanism of Action,Wellbeing,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4406512218" }, { "id": 857, "title": "Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.", "normalized_title": "exploring the potential of psychedelics in the treatment of headache disorders clinical considerations and exploratory insights", "authors": "Henderson I, Elsaadany R, Chan G, Bajaj V, Duarte D, Goodman S, Grunstein M, Vadhan NP, Duarte RA.", "abstract": "Purpose of reviewExploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.Recent findingsPsychedelics demonstrate promising outcomes as treatments for headache disorders. Recent findings indicated that some patients who underwent brief periods of treatment with psychedelics experienced a reduction in headache attack frequency, severity, or duration. When prescription medications are ineffective at treating headache disorders, or are habit-forming, patients often turn to alternative options. There is anecdotal evidence that psychedelic drugs like LSD and psilocybin can effectively treat and prevent pain in patients with headache disorders, such as migraine or cluster headache. It is vital that physicians treating patients who self-treat with psychedelics be well-informed about the mechanisms and their effects to best advise their patients and coordinate their care well. This is a review assessing the literature on the mechanisms, safety, and efficacy of psychedelic drugs as a headache management intervention. We believe there is evidence that may support further investigation into the clinical use of psychedelic medications to treat cluster headache and migraine, including the consideration of use in conjunction with other interventions like cognitive behavioral therapy or acceptance and commitment training.", "journal": null, "publication_date": "2025-01-15", "publication_year": 2025, "doi": "10.1007/s11916-024-01321-8", "pubmed_id": "39820774", "source_url": "https://doi.org/10.1007/s11916-024-01321-8", "keywords": "Humans, Headache Disorders, Lysergic Acid Diethylamide, Hallucinogens, Treatment Outcome, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39820774\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 856, "title": "Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.", "normalized_title": "self reported experiences and perspectives on using psychedelics to manage opioid use among participants of two reddit communities", "authors": "Krawczyk N, Miller M, Gu EY, Irvine N, Ramirez E, Santaella-Tenorio J, Lippincott T, Bogenschutz M, Bunting AM, Meacham MC", "abstract": "The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these experiences are perceived to impact opioid use and what these lessons imply for future research and practice. We conducted a qualitative study using the Reddit online community platform. We extracted posts that contained key psychedelic terms from the two most subscribed-to subreddits dedicated to discussions of OUD treatment (r/OpiatesRecovery and r/Methadone) from 2018 to 2021. We thematically analyzed content from 151 relevant posts and their respective comments. Two prominent themes identified in discussions were perspectives on the effectiveness of psychedelics in treating OUD, and mechanisms through which psychedelics were thought to impact use and desire to use opioids. For many, psychedelics were deemed to have a strong impact on opioid use via multiple mechanisms, including alleviating physical symptoms of dependence, shifting motivations around desire to use opioids and addressing underlying mental health problems and reasons for use. Others saw the potential promise around psychedelics as exaggerated, acknowledging many people eventually return to use, or even considered psychedelics dangerous. There appear to be diverse perspectives on the effects of using psychedelics to treat opioid use disorder and an urgent need for controlled studies to better understand the impact of different psychedelics on opioid use, how they may be used in the context of existing treatments and what strategies they must be combined with to ensure safety and effectiveness. Integrating the experiences of people who use drugs will help guide psychedelics research toward effective person-centered interventions to enhance health and wellness.", "journal": "Addiction (Abingdon, England)", "publication_date": "2025-01-15", "publication_year": 2025, "doi": "10.1111/add.16767", "pubmed_id": "39821493", "source_url": "https://pubmed.ncbi.nlm.nih.gov/39821493/", "keywords": "ibogaine, on-line communities, opioid use disorder, opioids, peer support, psilocybin, psychedelics, psychedelics-assisted recovery, reddit, treatment", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"39821493\"}", "topic_tags": "Addiction,Mechanism of Action,Wellbeing,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3086, "title": "Age- and estrous-dependent effects of psilocybin in rats", "normalized_title": "age and estrous dependent effects of psilocybin in rats", "authors": "Zylko A, Rakoczy R, Roberts B, Wilson M, Powell A, Page A, Heitkamp M, Fiest D, Jones J, McMurray M.", "abstract": "Psilocybin, a psychedelic compound in “magic” mushrooms, has promise as a novel treatment for psychiatric disorders, many of which are more prevalent in females and have onsets during adolescence. However, there is a lack of research about how factors such as sex and age affect responses to psilocybin, as well as potential safety concerns with developmental exposure. The primary objectives of this preclinical study were to determine if psilocybin-induced head twitch responses differ between adolescent and adult rats, and if estrous phase contributes to variation in female head twitch responses. Secondarily, this study sought to determine if treatment with psilocybin during adolescence has long-term effects on anxiety-associated behaviors and behavioral flexibility. Results showed that 1 mg/kg intraoral psilocybin failed to elicit head twitch responses in adolescents (P35 and P45) but elicited robust responses in adult rats. Further, adolescent psilocybin exposure did not cause long-term differences in performance on the elevated zero maze or probabilistic reversal learning tasks. Lastly, adult females in diestrus showed increased head twitch responses after 1 mg/kg psilocybin compared to females in proestrus. Head twitch responses are thought to be mediated by 5-HT2A receptors, but no age-or estrous-related differences in 5-HT2A receptor expression were observed in the medial prefrontal cortex. Collectively, these results highlight the existence of age-and sex-dependent differences in the effects of psychedelics, while finding no long-term effects on selected behaviors after adolescent exposure. These findings have implications on psychedelic study design, emphasizing the need for inclusive research considering age, sex, and hormonal status.", "journal": "bioRxiv", "publication_date": "2025-01-13", "publication_year": 2025, "doi": "10.1101/2025.01.10.632408", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2025.01.10.632408", "keywords": "", "substance_tags": "psilocybin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR966388\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Receptor Pharmacology,Animal Study,Adolescents,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4463, "title": "Study finds encouraging results in psilocybin treatment for TRD patients", "normalized_title": "study finds encouraging results in psilocybin treatment for trd patients", "authors": "Valerie A. Canady", "abstract": "Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depressive symptoms. Researchers of the open-label study also found significant safety and efficacy of synthetic psilocybin in TRD patients.", "journal": "Mental Health Weekly", "publication_date": "2025-01-09", "publication_year": 2025, "doi": "10.1002/mhw.34292", "pubmed_id": null, "source_url": "https://doi.org/10.1002/mhw.34292", "keywords": "Psilocybin, Psychology, Medicine, Hallucinogen, Pharmacology, Psychedelics and Drug Studies, Mental Health and Psychiatry, Sexuality, Behavior, and Technology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4406243180\",\"openalex_url\":\"https://openalex.org/W4406243180\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5008734541\",\"display_name\":\"Valerie A. Canady\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S1030938293\",\"source_display_name\":\"Mental Health Weekly\",\"landing_page_url\":\"https://doi.org/10.1002/mhw.34292\",\"is_oa\":true}}", "topic_tags": "Depression,Pharmacology,Aging,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4406243180" }, { "id": 869, "title": "Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.", "normalized_title": "pain and perception exploring psychedelics as novel therapeutic agents in chronic pain management", "authors": "Strand NH, Whitney M, Johnson B, Dunn T, Attanti S, Maloney J, Misra L, Gomez D, Viswanath O, Emami E, Leathem J.", "abstract": "Purpose of reviewChronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.Recent findingsThese substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.", "journal": null, "publication_date": "2025-01-06", "publication_year": 2025, "doi": "10.1007/s11916-024-01353-0", "pubmed_id": "39775134", "source_url": "https://doi.org/10.1007/s11916-024-01353-0", "keywords": "Humans, Analgesics, Hallucinogens, Pain Perception, Pain Management, Chronic Pain", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39775134\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Chronic Pain,Headache / Migraine,Neuroplasticity,Mechanism of Action,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 863, "title": "Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.", "normalized_title": "clinical and preclinical evidence of psilocybin as antidepressant a narrative review", "authors": "Erkizia-Santamaría I, Horrillo I, Meana JJ, Ortega JE.", "abstract": "In the rapidly growing field of psychedelic research, psilocybin (and active metabolite psilocin) has been proposed as a promising candidate in the search for novel treatments for neuropsychiatric disorders. Clinical trials have revealed that psilocybin has a large, rapid, and persistent effect in the improvement of symptoms of depression and anxiety. The safety profile is considered favourable, with low toxicity and good tolerance. Several preclinical studies have also been carried out to determine the long-term mechanism of action of this drug. In this sense, preclinical studies in naïve animals as well as in animal models of disease have shown somewhat discrepant results in conventional tests for assessment of depression- and anxiety-like phenotype in response to psilocybin, but overall suggest positive outcomes. Additionally, several valuable assays in rodent models have been developed over the years to elucidate the neurochemical correlates of serotonin 2A receptor (5HT2AR) activation in the brain, primary molecular target of psilocin. This review aims to provide a general overview of the current and most recent literature in the therapeutic potential of psilocybin through a description of clinical trials of psilocybin-assisted psychotherapy, and to showcase the scene in the up-to-date preclinical research. A detailed description of preclinical rodent models and experimental approaches that have been used to study the neurobiological and behavioural actions of psilocybin is provided, and potential therapeutic mechanisms of action are discussed.", "journal": null, "publication_date": "2025-01-05", "publication_year": 2025, "doi": "10.1016/j.pnpbp.2025.111249", "pubmed_id": "39778644", "source_url": "https://doi.org/10.1016/j.pnpbp.2025.111249", "keywords": "Animals, Humans, Disease Models, Animal, Hallucinogens, Antidepressive Agents, Drug Evaluation, Preclinical, Depression, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39778644\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Animal Study,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 761, "title": "Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.", "normalized_title": "psychedelic treatments in adolescent psychopharmacology considering safety ethics and scientific rigor", "authors": "Sutherland I, Ho MF, Croarkin PE.", "abstract": "Interest in psychedelic therapies for adults is rapidly growing, with substances like 3,4-methylenedioxymethamphetamine for posttraumatic stress disorder, psilocybin for treatment-resistant depression, and lysergic acid diethylamide for generalized anxiety disorder showing promise. However, research on these therapies in children and adolescents is limited, with no recent trials. Despite this lack of scientific exploration, adolescents may still experiment with these substances for both recreational and therapeutic purposes as accessibility continues to increase. This raises significant concerns, as adolescents are a vulnerable population requiring heightened caution and safety measures. Therefore, we advocate for structured, safe, and well-controlled exploration of psychedelic therapies in adolescents.", "journal": null, "publication_date": "2025-01-05", "publication_year": 2025, "doi": "10.1089/cap.2024.0082", "pubmed_id": "39761065", "source_url": "https://doi.org/10.1089/cap.2024.0082", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Anxiety Disorders, Stress Disorders, Post-Traumatic, Psychopharmacology, Adolescent, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39761065\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Pharmacology,Adolescents,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4498, "title": "Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke", "normalized_title": "additional file 1 of i ve learned that i m open minded to this possibility a qualitative study to evaluate the acceptability of a psilocybin aided smoking cessation treatment for people with hiv who smoke", "authors": "Patricia A. Cioe, Garrett S Stang, Danish Azam, Sarah Dugal", "abstract": "Supplementary Material 1", "journal": "Figshare", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.6084/m9.figshare.29615217", "pubmed_id": null, "source_url": "https://doi.org/10.6084/m9.figshare.29615217", "keywords": "Medicine, Qualitative research, Smoking cessation, Human immunodeficiency virus (HIV), Smoke, Qualitative analysis, Family medicine, Environmental health, Public health, Epidemiology, Disease, Psychedelics and Drug Studies, HIV, Drug Use, Sexual Risk, Substance Abuse Treatment and Outcomes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7130712582\",\"openalex_url\":\"https://openalex.org/W7130712582\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5000146961\",\"display_name\":\"Patricia A. Cioe\",\"orcid\":\"https://orcid.org/0000-0003-3599-7819\"},{\"id\":\"https://openalex.org/A5089469079\",\"display_name\":\"Garrett S Stang\",\"orcid\":\"https://orcid.org/0000-0001-7000-1277\"},{\"id\":\"https://openalex.org/A5117848838\",\"display_name\":\"Danish Azam\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119020915\",\"display_name\":\"Sarah Dugal\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196282\",\"source_display_name\":\"Figshare\",\"landing_page_url\":\"https://doi.org/10.6084/m9.figshare.29615217\",\"is_oa\":true}}", "topic_tags": "Addiction,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7130712582" }, { "id": 4488, "title": "Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD", "normalized_title": "psilocybin assisted therapy for trauma related disorders a scoping review of a depression dominated evidence base with implications for intimate partner violence related ptsd", "authors": "Hancock, Mackenzie, Shambhu Prasad Adhikari, Getz, Nicole", "abstract": "This scoping review examines the emerging evidence for psilocybin-assisted therapy (PAP) in treating trauma-related disorders such as posttraumatic stress disorder (PTSD), depression, and persistent post-concussion symptoms (PPCS), with specific implications for intimate partner violence (IPV)-related brain injury and PTSD. Guided by PRISMA-ScR methodology, we systematically searched Medline, Embase, CINAHL, PsycINFO, and grey literature from 2015-2025 to map existing research, identify gaps, and inform the design of future clinical trials of PaT for IPV survivors.", "journal": "Open Science Framework", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.17605/osf.io/ar2s4", "pubmed_id": null, "source_url": "https://doi.org/10.17605/osf.io/ar2s4", "keywords": "Domestic violence, Posttraumatic stress, Psychology, Psychiatry, Psychotherapist, Clinical psychology, Poison control, Human factors and ergonomics, Medicine, Grey literature, Systematic review, Intimate partner, Suicide prevention, Clinical trial, Injury prevention, MEDLINE, Mental health, Occupational safety and health, DSM-5, Cognitive behavioral therapy, Psychological intervention, Evidence-based practice, Family therapy, Psychedelics and Drug Studies, Paranormal Experiences and Beliefs, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7106330185\",\"openalex_url\":\"https://openalex.org/W7106330185\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Hancock, Mackenzie\",\"orcid\":null},{\"id\":null,\"display_name\":\"Shambhu Prasad Adhikari\",\"orcid\":null},{\"id\":null,\"display_name\":\"Getz, Nicole\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S7407050956\",\"source_display_name\":\"Open Science Framework\",\"landing_page_url\":\"https://doi.org/10.17605/osf.io/ar2s4\",\"is_oa\":true}}", "topic_tags": "Depression,PTSD,Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7106330185" }, { "id": 4484, "title": "Alternative therapy for neurological and psychiatric disorders using psilocybin", "normalized_title": "alternative therapy for neurological and psychiatric disorders using psilocybin", "authors": "Henrique Tofoli Vieira Machado, GEOVANA MENDES DE SEIXAS, L. Silva, Mariana Duarte Garcia Brito, Gabriella Assink de Castro", "abstract": "Introduction: In recent years, psilocybin has been explored as an alternative therapy for neurological and psychiatric disorders, such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance dependence. Studies suggest that when administered under professional supervision, psilocybin can offer relief for patients with treatment-resistant disorders. Objective: The aim of this study was to analyze the therapeutic potential of psilocybin in treating difficult-to-treat conditions, including treatment-resistant depression, PTSD, anxiety, and substance dependence. Methods: A systematic review of clinical and experimental studies published in the past 5 years was conducted. The research was based on databases such as PubMed, Scopus, and SciELO, prioritizing studies on psilocybin in psychiatric disorder treatment. Randomized clinical trials, meta-analyses, and case studies were reviewed. Results: Studies showed that psilocybin positively affected patients with treatment-resistant depression, improving symptoms significantly with just a few doses. In patients with anxiety and PTSD, psilocybin reduced symptom intensity and improved emotional well-being. It also showed efficacy in reducing addictions such as alcohol and nicotine, offering new perspectives on addiction. The mechanisms of action suggest that psilocybin enhances brain connectivity, aiding in trauma reprocessing and restructuring negative thought patterns. Conclusion: Psilocybin is a promising alternative therapy for hard-to-treat disorders, including treatment-resistant depression, PTSD, and substance dependence. Administered under professional supervision, it offers benefits and a favorable safety profile. However, more research is required to understand its mechanisms, effects, and risks.", "journal": null, "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.5327/1516-3180.cpn.1123", "pubmed_id": null, "source_url": "https://doi.org/10.5327/1516-3180.cpn.1123", "keywords": "Psilocybin, Hallucinogen, Psychiatry, Medicine, Anxiety, Addiction, Clinical trial, Randomized controlled trial, Psychology, Psychotherapist, Substance use, Clinical psychology, Relapse prevention, Exposure therapy, Psychedelics and Drug Studies, Diverse academic research themes, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:41", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4417514861\",\"openalex_url\":\"https://openalex.org/W4417514861\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5068591211\",\"display_name\":\"Henrique Tofoli Vieira Machado\",\"orcid\":\"https://orcid.org/0009-0003-0332-9071\"},{\"id\":\"https://openalex.org/A5008778192\",\"display_name\":\"GEOVANA MENDES DE SEIXAS\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062744880\",\"display_name\":\"L. Silva\",\"orcid\":\"https://orcid.org/0000-0003-3411-2484\"},{\"id\":\"https://openalex.org/A5039308215\",\"display_name\":\"Mariana Duarte Garcia Brito\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113236876\",\"display_name\":\"Gabriella Assink de Castro\",\"orcid\":null}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://doi.org/10.5327/1516-3180.cpn.1123\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Chronic Pain,Mechanism of Action,Wellbeing,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4417514861" }, { "id": 3687, "title": "Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study", "normalized_title": "psilocybin therapy for depression and anxiety in parkinson s disease a pilot study", "authors": "Joshua Woolley, MD, PhD", "abstract": "The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease. This is an open-label single-arm pilot study of oral psilocybin therapy for depression and anxiety in people with Parkinson's Disease (PD). The primary goal is to examine safety, tolerability, and feasibility of the intervention in this patient population. We will enroll people ages 40 to 75 with clinically diagnosed early stage Parkinson's Disease (Hoehn and Yahr Stage 1-3 during an \"off\" period), who meet DSM-5 criteria for a depressive or anxious disorder and meet all other inclusion and exclusion criteria at screening. After baseline assessments, participants will complete preparation sessions designed to provide information about the psilocybin experience and to build rapport/trust with the study team. Next, participants will complete a first psilocybin administration session, receiving a low-moderate dose of 10 mg oral psilocybin in a supervised setting with safety monitoring by a physician. Participants who do not experience significant adverse events during or following the session will complete a second psilocybin administration session approximately two weeks later. During the second psilocybin administration session, participants will receive a moderate-high dose of 25 mg oral. The second session will involve the same procedures and level of monitoring as the first. Participants will subsequently complete multiple follow-up sessions designed to assess PD and psychiatric symptoms as well as to provide support as they process their psilocybin experiences. Follow-up will continue to 3 months after the second psilocybin administration session. Primary endpoints will assess safety, tolerability, and feasibility of study procedures. Exploratory efficacy endpoints will assess changes in depressive symptoms, anxious symptoms, and related measures of function.", "journal": "ClinicalTrials.gov", "publication_date": "2024-12-31", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04932434", "keywords": "Parkinson Disease, Depression, Anxiety, Psilocybin therapy, 4-phosphoryloxy-N,N-dimethyltryptamine, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04932434\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 902, "title": "Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial", "normalized_title": "single dose psilocybin for depression with severe treatment resistance an open label trial", "authors": "Scott T. Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm", "abstract": "OBJECTIVE: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of this study was to document the safety and efficacy of psilocybin in patients with severe TRD. METHODS: This was a 12-week, open-label trial conducted at Sheppard Pratt Hospital. Participants were 18-65 years of age, in a major depressive episode with documented insufficient benefit from at least five treatments during the current episode. A single dose of synthetic psilocybin (25 mg) was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing through at least 3 weeks post-dosing. Therapists met with patients for three sessions during pretreatment, during the 8-hour dosing day, and for three integration sessions posttreatment. The primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures including MADRS scores up to 12 weeks posttreatment, and subject-rated scales capturing depression and level of function were completed at baseline and all subsequent visits. RESULTS: Twelve participants (six male, six female; mean age=40.6 years [SD=9.6]) with severe TRD were followed over the study period. Depressive symptoms were significantly decreased at week 3 (MADRS least-squares mean change=-15.8, 95% CI=-25.4 to -6.3) and Week 12 (MADRS least-squares mean change=-17.2, 95% CI=-25.2 to -9.1). In exploratory analyses, the Oceanic Boundlessness (OB) dimension of the psychedelic experience correlated with post-dosing antidepressant responses. Patients with comorbid PTSD (N=5) showed significantly less antidepressant effect of psilocybin. CONCLUSIONS: This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.", "journal": "American Journal of Psychiatry", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1176/appi.ajp.20231063", "pubmed_id": "39741440", "source_url": "https://doi.org/10.1176/appi.ajp.20231063", "keywords": "Psilocybin, Treatment-resistant depression, Depression (economics), Open label, Medicine, Hallucinogen, Psychiatry, Clinical trial, Psychology, Major depressive disorder, Internal medicine, Cognition, Economics, Macroeconomics, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4405955624\",\"openalex_url\":\"https://openalex.org/W4405955624\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":30,\"referenced_works\":[\"https://openalex.org/W57359236\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1978161441\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2111663098\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2149402043\",\"https://openalex.org/W2169211107\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2599051175\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2796957480\",\"https://openalex.org/W2935372078\",\"https://openalex.org/W3033291488\",\"https://openalex.org/W4231622706\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4386305655\"],\"authorships\":[{\"id\":\"https://openalex.org/A5064457148\",\"display_name\":\"Scott T. Aaronson\",\"orcid\":\"https://orcid.org/0000-0001-7616-8801\"},{\"id\":\"https://openalex.org/A5026620795\",\"display_name\":\"Andrew van der Vaart\",\"orcid\":null},{\"id\":\"https://openalex.org/A5110607035\",\"display_name\":\"Tammy Miller\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093433058\",\"display_name\":\"Jeffrey LaPratt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083104068\",\"display_name\":\"Kimberly Swartz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054892136\",\"display_name\":\"Audrey Shoultz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5032946050\",\"display_name\":\"Margo Lauterbach\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036510139\",\"display_name\":\"Trisha Suppes\",\"orcid\":\"https://orcid.org/0000-0003-4560-6180\"},{\"id\":\"https://openalex.org/A5021365968\",\"display_name\":\"Harold A. Sackeïm\",\"orcid\":\"https://orcid.org/0000-0002-1107-4553\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S116025658\",\"source_display_name\":\"American Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1176/appi.ajp.20231063\",\"is_oa\":false}}", "topic_tags": "Depression,PTSD,Chronic Pain,Clinical Trial,Treatment-Resistant Depression,Safety,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4405955624" }, { "id": 900, "title": "Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial", "normalized_title": "multidimensional personality changes following psilocybin assisted therapy in patients with alcohol use disorder results from a double blind placebo controlled clinical trial", "authors": "Broc A. Pagni, Richard J. Zeifman, Sarah E. Mennenga, Brennan M. Carrithers, Noam Goldway, Snehal Bhatt, Kelley C. O’Donnell, Stephen Ross, Michael P. Bogenschutz", "abstract": "OBJECTIVE: Evidence suggests that psilocybin-assisted therapy (PAT) leads to durable shifts in personality structure. However, such changes have yet to be characterized in disorders of addiction. In this secondary analysis from a randomized controlled trial, the authors examined the effect of PAT on personality dimensions in patients with alcohol use disorder (AUD), hypothesizing that PAT would attenuate personality abnormalities in AUD and that reductions in trait impulsiveness would be associated with lower drinking. METHODS: Eighty-four adults with AUD were randomized to two medication sessions of either psilocybin (N=44) or active placebo (diphenhydramine; N=40), received 12 weekly psychotherapy sessions, and completed follow-up for an additional 24 weeks. Changes in personality traits (week 36 vs. baseline) were assessed with the revised NEO Personality Inventory; daily alcohol consumption was quantified using the timeline followback. RESULTS: Relative to the placebo group, the psilocybin group showed significant reductions in neuroticism and increases in extraversion and openness. Secondary analyses showed that reductions in neuroticism were driven by decreases in the facets depression, impulsiveness, and vulnerability; increases in openness were driven by increases in the facets openness toward feelings and fantasy. Across all participants, decreases in impulsiveness were associated with lower posttreatment alcohol consumption, and an exploratory analysis revealed that these associations were strongest among psilocybin-treated participants who continued moderate- or high-risk drinking prior to the first medication session. CONCLUSIONS: PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.", "journal": "American Journal of Psychiatry", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1176/appi.ajp.20230887", "pubmed_id": "39741446", "source_url": "https://doi.org/10.1176/appi.ajp.20230887", "keywords": "Psilocybin, Placebo, Alcohol use disorder, Personality, Psychology, Psychiatry, Clinical psychology, Personality disorders, Alcohol dependence, Randomized controlled trial, Addiction, Trait, Alcohol, Psychotherapist, Medicine, Hallucinogen, Internal medicine, Alternative medicine, Chemistry, Pathology, Biochemistry, Programming language, Social psychology, Computer science, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4405955644\",\"openalex_url\":\"https://openalex.org/W4405955644\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":21,\"referenced_works\":[\"https://openalex.org/W655349596\",\"https://openalex.org/W1494270537\",\"https://openalex.org/W1967802941\",\"https://openalex.org/W2023741295\",\"https://openalex.org/W2029087690\",\"https://openalex.org/W2043185143\",\"https://openalex.org/W2045883408\",\"https://openalex.org/W2050111921\",\"https://openalex.org/W2052457671\",\"https://openalex.org/W2056861749\",\"https://openalex.org/W2058301890\",\"https://openalex.org/W2061577872\",\"https://openalex.org/W2066266046\",\"https://openalex.org/W2073524171\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2136236048\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2143060888\",\"https://openalex.org/W2159375941\",\"https://openalex.org/W2170041614\",\"https://openalex.org/W2266766602\",\"https://openalex.org/W2473482891\",\"https://openalex.org/W2480710602\",\"https://openalex.org/W2513173335\",\"https://openalex.org/W2537388000\",\"https://openalex.org/W2550963195\",\"https://openalex.org/W2568037688\",\"https://openalex.org/W2592284024\",\"https://openalex.org/W2606286005\",\"https://openalex.org/W2788524689\",\"https://openalex.org/W2789944707\",\"https://openalex.org/W2790959730\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2921551456\",\"https://openalex.org/W2925851520\",\"https://openalex.org/W2964151936\",\"https://openalex.org/W2986870760\",\"https://openalex.org/W2986989334\",\"https://openalex.org/W2996270584\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3024994975\",\"https://openalex.org/W3044516305\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3107630502\",\"https://openalex.org/W3109765150\",\"https://openalex.org/W3117338048\",\"https://openalex.org/W3155431951\",\"https://openalex.org/W3212419057\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W3216348943\",\"https://openalex.org/W4243504487\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4297998585\",\"https://openalex.org/W4307167512\",\"https://openalex.org/W4307554429\",\"https://openalex.org/W4308040950\",\"https://openalex.org/W4308449502\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4318920879\",\"https://openalex.org/W4379093876\",\"https://openalex.org/W4380684709\",\"https://openalex.org/W4385978292\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066934485\",\"display_name\":\"Broc A. Pagni\",\"orcid\":\"https://orcid.org/0000-0002-9496-7604\"},{\"id\":\"https://openalex.org/A5000949886\",\"display_name\":\"Richard J. Zeifman\",\"orcid\":\"https://orcid.org/0000-0003-3478-4483\"},{\"id\":\"https://openalex.org/A5087382833\",\"display_name\":\"Sarah E. Mennenga\",\"orcid\":null},{\"id\":\"https://openalex.org/A5095894414\",\"display_name\":\"Brennan M. Carrithers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091191033\",\"display_name\":\"Noam Goldway\",\"orcid\":\"https://orcid.org/0000-0001-8816-5667\"},{\"id\":\"https://openalex.org/A5069591665\",\"display_name\":\"Snehal Bhatt\",\"orcid\":\"https://orcid.org/0000-0003-0004-7987\"},{\"id\":\"https://openalex.org/A5042151214\",\"display_name\":\"Kelley C. O’Donnell\",\"orcid\":\"https://orcid.org/0000-0001-9983-2699\"},{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"},{\"id\":\"https://openalex.org/A5086692011\",\"display_name\":\"Michael P. Bogenschutz\",\"orcid\":\"https://orcid.org/0000-0003-4530-3470\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S116025658\",\"source_display_name\":\"American Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1176/appi.ajp.20230887\",\"is_oa\":false}}", "topic_tags": "Depression,Addiction,Chronic Pain,Personality Change,Clinical Trial,Randomized Controlled Trial,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4405955644" }, { "id": 899, "title": "Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.", "normalized_title": "exploring psychedelics pharmacology a scoping review charting the course of psilocybin pharmacokinetics", "authors": "Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM.", "abstract": "ObjectivesThis scoping review aimed to synthesize the existing data about psilocybin pharmacokinetics to learn what has been described regarding body disposition and safety when psilocybin was used in controlled research settings.MethodsWe performed a scoping literature review following the framework proposed by the JBI manual for evidence synthesis. Controlled clinical trials reporting pharmacokinetic data of psilocybin were considered appropriate for inclusion. We extracted the data on psilocybin pharmacokinetics and summarized it from the available literature on this topic. We also performed an exploratory-descriptive analysis using study level data to examine the relationship between dose of psilocybin and maximum serum concentrations (Cmax).ResultsWe initially identified 850 articles, of which 5 were included. These trials included 112 healthy volunteers who received psilocybin in a controlled clinical setting. The peak concentration of psilocin in plasma (Cmax) ranged from 8.2 ng/mL to 37.2 ng/mL (median = 17, IQR = 11.9 to 23.5). The maximal concentrations (Cmax) of psilocin were reached (Tmax) around 2 hours, ranging from 1.7 hours to 2.2 hours (median = 2, IQR = 1.9 to 2.1) after psilocybin oral administration. Elimination half-life was between 1.2 hours and 3.3 hours (median = 2.0, IQR = 1.6 to 2.8). A strong positive relationship between dose and Cmax ( R2 = 0.95) was found. No serious adverse events were observed. We did not find studies reporting pharmacokinetic data from patients with depression or cancer patients transitioning to palliative care.ConclusionsIn summary, this review unveils oral psilocybin pharmacokinetics in healthy adults, revealing gaps in its application to target populations like those with depression or in palliative care.", "journal": null, "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1097/wnf.0000000000000617", "pubmed_id": "39787428", "source_url": "https://doi.org/10.1097/wnf.0000000000000617", "keywords": "Humans, Hallucinogens, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39787428\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,End-of-Life Distress,Pharmacology,Clinical Trial,Review Article,Healthy Volunteers,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 898, "title": "Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial", "normalized_title": "psilocybin assisted group psychotherapy mindfulness based stress reduction mbsr for frontline healthcare provider covid 19 related depression and burnout a randomized clinical trial", "authors": "Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL.", "abstract": "Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and burnout. Participants were randomized in a 1:1 ratio to either an 8-week MBSR curriculum alone or an 8-week MBSR curriculum plus group psilocybin-assisted psychotherapy (PAP) with 25mg psilocybin. Symptoms of depression and burnout were assessed at baseline, and 2-weeks and 6-months post intervention utilizing the Quick Inventory of Depressive Symptoms (QIDS-SR-16) and Maslach Burnout Inventory Human Services Survey for Medical Professionals (MBI-HSS-MP), respectively. Secondary outcome measures included the Demoralization Scale (DS-II) and the Watt’s Connectedness Scale (WCS). Adverse events and suicidality were assessed through 6-month follow-up. Results 25 participants were enrolled and randomized. There were 12 study-related AEs recorded that were Grade 1-2 and no serious AEs. There was larger decrease in QIDS score for the MBSR+PAP arm compared to MBSR-only from baseline to 2-weeks post-intervention and significant between-group differences favoring MBSR+PAP on subscales of the MBI-HSS-MP as well as the DS-II and WCS. Conclusions Group psilocybin-assisted therapy plus MBSR was associated with clinically significant improvement in depressive symptoms without serious adverse events and with greater reduction in symptoms than MBSR alone. Study findings suggest that integrating psilocybin with mindfulness training may represent a promising treatment for depression and burnout among physicians and nurses.", "journal": "medRxiv", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1101/2024.12.31.24319806", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.12.31.24319806", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR961100\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Observational Study,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 875, "title": "\"\" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.", "normalized_title": "a qualitative analysis of patient perspectives on psychedelic assisted therapy for cancer related psychosocial symptoms", "authors": "D M Schuman H, Barkova S, Mina R, Deleemans JM, Nguyen T, Carlson LE", "abstract": "People living with cancer (PLWC) often face profound existential distress that is insufficiently addressed by conventional psychosocial supports. This qualitative study explored PLWC's attitudes, beliefs, and experiences regarding psychedelic-assisted therapy (PAT) as a novel approach to addressing psychosocial suffering, particularly existential distress. Fifteen participants with varying cancer types and stages were recruited from a national survey. Semi-structured interviews were analyzed using reflexive thematic analysis informed by the Theory of Planned Behavior. Four key themes were identified: (1) Cautious Optimism and Substance-Specific Attitudes Toward Psychedelics reflected varied knowledge, openness, and perceptions of specific agents; (2) Relational and Societal Influences: Stigma, Support, and Cultural Framing; (3) Structural and Systemic Barriers: Cost, Legality, Provider Attitudes, and Unequal Access; and (4) Cancer Context and Psychosocial Needs: Seeking Relief from Existential and Emotional Distress captured the emotional, spiritual, and existential dimensions of living with and beyond cancer. Participants expressed cautious optimism about PAT, driven by unmet needs in conventional care, particularly after active treatment and at advanced stages of cancer, where existential and spiritual concerns often go unaddressed. PAT was seen as a potential adjunct that could meaningfully engage with suffering beyond symptom management. However, concerns about safety, access, and stigma underscore the need for culturally responsive, patient-informed, and equity-focused implementation strategies. Integrating PAT into oncology will require dismantling structural barriers and shifting toward a model of care that embraces the full human experience of serious illness.", "journal": "Integrative cancer therapies", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1177/15347354251370982", "pubmed_id": "41013977", "source_url": "https://pubmed.ncbi.nlm.nih.gov/41013977/", "keywords": "cancer, existential distress, psilocybin, psychedelic-assisted therapy, psychosocial symptoms", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"41013977\"}", "topic_tags": "Emotional Processing,Spirituality,Observational Study,Cancer Patients,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 597, "title": "Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns", "normalized_title": "psychedelic treatment with psilocybin addressing medical malpractice risk and physicians concerns", "authors": "Katherine Cheung, Maxwell Brodie, Sue-Ling Chang, P. Deschamps, Jean-Sébastien Fallu, Houman Farzin, Johanne Hébert, Jean-François Stephan, Michel Dorval, Yann Joly, for the P3A Study Group", "abstract": "Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medical malpractice liability. This paper explores whether psilocybin treatment gives rise to a risk of medical malpractice liability for physicians. Following an overview of psilocybin treatment and its regulatory regime in Canada, exploratory vignettes are used to highlight the relevance and limits of malpractice claims. This paper argues that the lack of established medical standards, standardized training, and credentialing contribute to liability risks surrounding psilocybin treatment. More clinical trials, meta-studies of research analyses, and knowledge sharing will help to develop training programs and medical standards of practice to better realize psilocybin's potential.", "journal": "The Journal of Law Medicine & Ethics", "publication_date": "2024-12-31", "publication_year": 2024, "doi": "10.1017/jme.2025.10109", "pubmed_id": "40739983", "source_url": "https://doi.org/10.1017/jme.2025.10109", "keywords": "Psilocybin, Medical malpractice, Liability, Psychiatry, Psychology, Malpractice, Medicine, Hallucinogen, Political science, Law, Psychedelics and Drug Studies, Complementary and Alternative Medicine Studies, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4412810429\",\"openalex_url\":\"https://openalex.org/W4412810429\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W114929610\",\"https://openalex.org/W2106188235\",\"https://openalex.org/W2114277899\",\"https://openalex.org/W2145673018\",\"https://openalex.org/W2152959326\",\"https://openalex.org/W2412515498\",\"https://openalex.org/W2512668841\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2989680519\",\"https://openalex.org/W2998157771\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3039625792\",\"https://openalex.org/W3099585958\",\"https://openalex.org/W3149986569\",\"https://openalex.org/W3157058636\",\"https://openalex.org/W3204230901\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4223893856\",\"https://openalex.org/W4226172056\",\"https://openalex.org/W4230000135\",\"https://openalex.org/W4232838523\",\"https://openalex.org/W4289745468\",\"https://openalex.org/W4291227674\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4312084004\",\"https://openalex.org/W4313201591\",\"https://openalex.org/W4313441617\",\"https://openalex.org/W4322757924\",\"https://openalex.org/W4361248485\",\"https://openalex.org/W4399323719\",\"https://openalex.org/W6715183095\",\"https://openalex.org/W6802639978\",\"https://openalex.org/W6810682564\",\"https://openalex.org/W6841045541\",\"https://openalex.org/W6847791157\",\"https://openalex.org/W6850240496\"],\"authorships\":[{\"id\":\"https://openalex.org/A5102839143\",\"display_name\":\"Katherine Cheung\",\"orcid\":\"https://orcid.org/0009-0003-3529-4109\"},{\"id\":null,\"display_name\":\"Maxwell Brodie\",\"orcid\":null},{\"id\":\"https://openalex.org/A5045951431\",\"display_name\":\"Sue-Ling Chang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5087948982\",\"display_name\":\"P. Deschamps\",\"orcid\":\"https://orcid.org/0000-0001-8862-9046\"},{\"id\":\"https://openalex.org/A5053736941\",\"display_name\":\"Jean-Sébastien Fallu\",\"orcid\":\"https://orcid.org/0000-0002-2300-1335\"},{\"id\":\"https://openalex.org/A5040374734\",\"display_name\":\"Houman Farzin\",\"orcid\":\"https://orcid.org/0009-0006-4095-3596\"},{\"id\":\"https://openalex.org/A5052738130\",\"display_name\":\"Johanne Hébert\",\"orcid\":\"https://orcid.org/0000-0003-4023-9246\"},{\"id\":\"https://openalex.org/A5027250223\",\"display_name\":\"Jean-François Stephan\",\"orcid\":\"https://orcid.org/0009-0000-7376-208X\"},{\"id\":\"https://openalex.org/A5068576397\",\"display_name\":\"Michel Dorval\",\"orcid\":\"https://orcid.org/0000-0002-3207-8211\"},{\"id\":\"https://openalex.org/A5018546125\",\"display_name\":\"Yann Joly\",\"orcid\":\"https://orcid.org/0000-0002-8775-2322\"},{\"id\":null,\"display_name\":\"for the P3A Study Group\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S171945920\",\"source_display_name\":\"The Journal of Law Medicine & Ethics\",\"landing_page_url\":\"https://doi.org/10.1017/jme.2025.10109\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4412810429" }, { "id": 921, "title": "Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.", "normalized_title": "exploring the neurobiological correlates of psilocybin assisted psychotherapy in eating disorders a review of potential methodologies and implications for the psychedelic study design", "authors": "Koning E, Chaves C, Kirkpatrick RH, Brietzke E.", "abstract": "Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dysfunction, directly affecting 1-3% of the population. Standard treatments are not effective in approximately one third of ED cases, representing the need for scientific advancement. There is emerging evidence for the safety and efficacy of psilocybin-assisted psychotherapy (PAP) to improve treatment outcomes in individuals with EDs. However, the limited knowledge of the neurobiological mechanisms underlying the therapeutic effects of PAP restricts the ability to confirm its clinical utility. This narrative review presents an overview of methodologies used to elucidate the pathophysiological mechanisms of EDs or the effects of psilocybin that could be employed to probe the neurobiological correlates of PAP in EDs, including magnetic resonance imaging and molecular neuroimaging techniques, electrophysiological approaches, and neuroplasticity markers. Finally, the implications of these methodologies are described in relation to the unique features of the psychedelic study design, challenges, limitations, and future directions to advance the field. This paper represents a valuable resource for scientists during study conceptualization and design phases and stimulates advancement in the identification of effective therapeutic interventions for EDs.", "journal": null, "publication_date": "2024-12-26", "publication_year": 2024, "doi": "10.1186/s40337-024-01185-8", "pubmed_id": "39731144", "source_url": "https://doi.org/10.1186/s40337-024-01185-8", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39731144\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Neuroplasticity,Brain Imaging,Mechanism of Action,Biomarkers,Aging,Emotional Processing,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 833, "title": "Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.", "normalized_title": "efficacy and safety of psilocybin in the treatment of major depressive disorder mdd a dose response network meta analysis of randomized placebo controlled clinical trials", "authors": "Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ.", "abstract": "Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of Randomized Placebo-Controlled Clinical Trials (RCTs) registered with PROSPERO was conducted. Databases searched included Embase, PubMed, Cochrane Library, Scopus, Web of Science, and Google Scholar, up to July 2024. The PICOS framework defined eligibility criteria: P: adult patients with MDD; I: psilocybin; C: placebo; O: changes in MADRS scores at Days 2, 8 and 15, and adverse events; S: RCT. Independent researchers performed data extraction and bias assessment. From 5419 search results, three RCTs involving 389 patients were included. Psilocybin significantly reduced symptoms compared to placebo at Day 8 (MD = -7.42; 95 % CI:10.07 to -4.78; p < 0.001) and Day 15 (MD = -9.55; 95 % CI:12.44 to -6.65; p < 0.001), without significant effects on Day 2. The NMA indicated that a 25 mg dose was the most effective, with a SUCRA value of 92.25 %, compared to doses of 0.215 mg/kg and 10 mg. However, psilocybin was associated with a higher risk of adverse events, particularly nausea (RR = 8.35; p < 0.001). This meta-analysis supports psilocybin's efficacy in treating MDD, particularly at a 25 mg dose, showing a time-dependent therapeutic effect. The recommended timing of efficacy evaluation by regulatory authorities is validated by this evidence, underscoring its importance in clinical trial design for psychedelic substances.", "journal": null, "publication_date": "2024-12-22", "publication_year": 2024, "doi": "10.1016/j.psychres.2024.116337", "pubmed_id": "39754904", "source_url": "https://doi.org/10.1016/j.psychres.2024.116337", "keywords": "Humans, Hallucinogens, Dose-Response Relationship, Drug, Adult, Randomized Controlled Trials as Topic, Depressive Disorder, Treatment-Resistant, Psilocybin, Outcome Assessment, Health Care, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39754904\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 723, "title": "ALSUntangled #77: Psilocybin.", "normalized_title": "alsuntangled 77 psilocybin", "authors": "Bakshi B, Yerraguntla S, Armon C, Barkhaus P, Bertorini T, Bowser R, Breevoort S, Bromberg M, Brown A, Carter GT, Chang V, Crayle J, Fullam T, Greene M, Heiman-Patterson T, Jackson C, Jhooty S, Mallon E, Cadavid JM, Mcdermott CJ, Pattee G, Pierce K, Ratner D, Sun Y, Wang O, Wicks P, Wiedau M, Bedlack R.", "abstract": "ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.", "journal": null, "publication_date": "2024-12-21", "publication_year": 2024, "doi": "10.1080/21678421.2024.2441274", "pubmed_id": "39709547", "source_url": "https://doi.org/10.1080/21678421.2024.2441274", "keywords": "Animals, Humans, Amyotrophic Lateral Sclerosis, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39709547\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neurogenesis,Mechanism of Action,Review Article,Case Report,Safety,Adverse Events,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 835, "title": "Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.", "normalized_title": "therapeutic potential of mdma and psychedelic assisted psychotherapy for adolescent depression and trauma", "authors": "Geller J, Whitney E.", "abstract": "Purpose of reviewThere is a mental health crisis affecting youth, and the utility of existing treatments is often limited by lack of effectiveness and tolerability. The aim of this review is to report on outcomes of clinical trials for psilocybin-assisted psychotherapy for adults with depression and MDMA-assisted psychotherapy for adults with post-traumatic stress disorder (PTSD) and discuss recommendations for exploring these treatments in adolescent populations.Recent findingsThere have been encouraging data supporting the use of psilocybin-assisted psychotherapy for depression, including previously treatment-resistant symptoms. MDMA-assisted psychotherapy is showing similar promise in treating PTSD, with excellent response and remission rates that appear durable. However, no studies have looked at the use of these treatments in younger patients. The safety and efficacy of psychedelic- and MDMA-assisted psychotherapies should be investigated in adolescents, especially considering the burden of untreated and undertreated psychiatric illness in youth, and the benefits of a potentially earlier, more effective, and more tolerable recovery process. Research and implementation should be tailored to the needs of this population, and equity and access should be considered at every stage. In this novel and rapidly evolving landscape, the psychiatric community is encouraged to advocate for safe, appropriate, and inclusive inquiry into, and application and scaling of these treatment models in adolescent patients.", "journal": null, "publication_date": "2024-12-18", "publication_year": 2024, "doi": "10.1007/s11920-024-01577-2", "pubmed_id": "39699759", "source_url": "https://doi.org/10.1007/s11920-024-01577-2", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Stress Disorders, Post-Traumatic, Psychotherapy, Adolescent, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39699759\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Aging,Clinical Trial,Review Article,Adolescents,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 757, "title": "A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.", "normalized_title": "a rapid review of psychedelic assisted therapy in the context of palliative care", "authors": "Miller M, Meyers M, Martin A, Napolitano S, Dorsen C, Penn A, Rosa WE.", "abstract": "Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence suggests possible utility of PAT for addressing psychosocial-spiritual-existential concerns, yet gaps remain in understanding findings related to PAT's role in palliative care. This rapid review aims to synthesize current literature on applications of PAT in the context of palliative care. Through a systematic process, we identified 34 articles published between January 2021 and July 2024. Protocols varied yet included common components of participant screening, preparation, dosing, and integration. Psilocybin was the most commonly studied compound. Results support safety and initial efficacy of PAT for psycho-spiritual-existential outcomes among carefully screened and highly homogonous samples of patients with serious illness (predominantly cancer). Current efforts and challenges around integrating PAT into systems of palliative care were highlighted. Additional work is needed to (1) explore PAT's safety and efficacy within more diverse samples and contexts, (2) train palliative care providers on PAT, (3) determine systems of care delivery best suited for translation of PAT into practice, and (4) begin developing policy solutions to support safe and equitable access to PAT. Because many patients lack access to basic psychosocial-spiritual-existential care, careful consideration is needed around integration of PAT. The psychedelic substances which are the topic of this article are not currently FDA approved for use in the United States.", "journal": null, "publication_date": "2024-12-18", "publication_year": 2024, "doi": "10.1097/njh.0000000000001096", "pubmed_id": "39699865", "source_url": "https://doi.org/10.1097/njh.0000000000001096", "keywords": "Humans, Hallucinogens, Palliative Care", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39699865\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "End-of-Life Distress,Spirituality,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 637, "title": "Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.", "normalized_title": "psychedelic therapeutics for adolescents ethics safety opportunities and equipoise", "authors": "Croarkin PE, Sutherland I, Ho MF.", "abstract": "We read with great interest the commentary by Jeffrey et al. entitled \"Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.\"1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine. We agree that there is a compelling rationale for timely, rigorous studies with adolescents as it is likely that these compounds have been and will be used in adolescents with therapeutic intent. We are writing to catalyze further collegial dialogue and advocacy in our field. We do have some considerations for the authors.", "journal": null, "publication_date": "2024-12-18", "publication_year": 2024, "doi": "10.1016/j.jaac.2024.12.003", "pubmed_id": "39709009", "source_url": "https://doi.org/10.1016/j.jaac.2024.12.003", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Adolescent, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39709009\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Adolescents,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 834, "title": "Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.", "normalized_title": "exploring the role of psychedelic assisted therapy in enhancing spirituality and mystical experiences in patients with life threatening illnesses a systematic review", "authors": "Ferreira AE, Reis-Pina P.", "abstract": "IntroductionPsychedelic-Assisted Therapy (PAT) is gaining traction as a novel approach to addressing the psychological and existential distress experienced by patients.ObjectivesThis systematic review aimed to investigate the impact of PAT on spirituality, mystical experiences, and spiritual well-being (SpWB) in patients with life-threatening, incurable, or terminal illnesses.MethodsA comprehensive search was conducted across PubMed, Web of Science, and Cochrane databases to identify relevant studies published between 2013 and 2023. The study population comprised patients diagnosed with life-threatening illnesses. Various forms of PAT, encompassing both typical and atypical psychedelic substances, were considered as interventions, with no specific comparators outlined. The primary outcomes of interest included spirituality, mystical experience, and SpWB. Risk of bias assessment was performed using Cochrane's tools.ResultsSix studies with a high risk of bias were included in the review, all conducted in the United States of America, involving 140 patients, the majority of whom had cancer (99 %). PAT, especially with psilocybin, demonstrated significant enhancements in spirituality, mystical experiences, and SpWB. Notably, SpWB showed improvements in all studies which assessed this spiritual outcome following PAT. Mystical experiences were correlated with improvements in spirituality in one study.ConclusionsThis systematic review underscores the potential of PAT to address unmet spiritual needs and enhance SpWB in patients with life-threatening illnesses. However, further research is needed to elucidate the mechanisms underlying these therapeutic effects. Rigorous evaluation of healthcare practitioners' role in guiding patients through PAT protocols is essential to ensure safe and effective implementation in palliative care settings.", "journal": null, "publication_date": "2024-12-16", "publication_year": 2024, "doi": "10.1016/j.jpsychores.2024.112020", "pubmed_id": "39705901", "source_url": "https://doi.org/10.1016/j.jpsychores.2024.112020", "keywords": "Humans, Hallucinogens, Spirituality, Mysticism", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39705901\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "End-of-Life Distress,Mechanism of Action,Wellbeing,Spirituality,Mystical Experience,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 837, "title": "The safety of psilocybin-assisted psychotherapy: A systematic review.", "normalized_title": "the safety of psilocybin assisted psychotherapy a systematic review", "authors": "Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB.", "abstract": "IntroductionPsilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data from psilocybin-assisted psychotherapy clinical trials and evaluate its definition, way of measurement and reporting.MethodsA systematic method was employed to identify clinical trials related to the use of psilocybin-assisted psychotherapy in clinical populations that reported on adverse events. The quality assessment focused on relevant criteria related to adverse event definition, monitoring and reporting methods.ResultsA total of 24 articles were included. The studies reported heterogeneous psilocybin doses, study designs and indications. Physical and psychological adverse events during and after psilocybin sessions were examined, revealing variations in measuring, reporting methods and occurrences. The most common adverse events during and after sessions included elevated blood pressure, headaches, nausea, vomiting, fatigue and anxiety. In addition, both suicidal ideation and behaviour were observed infrequently and mainly in participants with a history of suicidal ideation or suicide attempt(s).ConclusionThe review highlights the need to standardise the defintion of an adverse event, including how they are measured and reported, in psychedelic clinical trials to ensure consistent reporting across studies. In addition, screening participants for suicidality history and ongoing monitoring remains important, given the potential risk identified in the literature. However, based on the available data, the safety of psilocybin-assisted psychotherapy is generally supported, and no deaths were attributed to psilocybin. Nevertheless, cautious optimism is needed due to the preliminary nature and heterogeneity of the safety data.", "journal": null, "publication_date": "2024-12-12", "publication_year": 2024, "doi": "10.1177/00048674241289024", "pubmed_id": "39670342", "source_url": "https://doi.org/10.1177/00048674241289024", "keywords": "Humans, Hallucinogens, Psychotherapy, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39670342\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 942, "title": "The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.", "normalized_title": "the revival of psilocybin between scientific excitement evidence of efficacy and real world challenges", "authors": "Scala M, Fabbri C, Fusar-Poli P, Di Lorenzo G, Ferrara M, Amerio A, Fusar-Poli L, Pichiecchio A, Asteggiano C, Menchetti M, De Ronchi D, MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli G, Serretti A.", "abstract": "The revival of psilocybin in psychopharmacological research heralds a potential paradigm shift for treating mood and anxiety disorders, and other psychiatric conditions beyond the psychotic spectrum. This critical review evaluates current evidence on psilocybin's efficacy, juxtaposing potential benefits with the practical aspects of psychedelic-assisted psychotherapy (PAP) and the methodological constraints of existing research.An electronic literature search was conducted using PubMed/MEDLINE, selecting studies published up to December 2023 that explored the clinical use of psilocybin in mood and anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, and substance use disorder. Despite promising preliminary results suggesting psilocybin's efficacy in alleviating depression and anxiety, as well as obsessions, compulsions, and addictive behaviors, significant evidence gaps persist. These include evaluating the efficacy of psilocybin compared to standard antidepressants or anxiolytic molecules and identifying patient subpopulations that might benefit most from PAP. Concerns about psilocybin's safety, long-term efficacy, and optimal dosage remain unclear due to previous trials' limitations. Real-world implementation faces challenges, including infrastructural requirements, personnel training, and unresolved legal and ethical issues. This paper argues for further research to substantiate the evidence base, emphasizing the need for larger studies that overcome current methodological limitations and explore psilocybin's full therapeutic potential. While psilocybin holds promise for psychiatry, its successful translation from research to clinical practice demands more robust evidence on efficacy, safety, and methodological rigor. In addition, other factors, such as cultural stigma and legal/ethical issues, need to be successfully addressed to facilitate psilocybin's implementation in healthcare systems.", "journal": null, "publication_date": "2024-12-09", "publication_year": 2024, "doi": "10.1017/s1092852924002268", "pubmed_id": "39655426", "source_url": "https://doi.org/10.1017/s1092852924002268", "keywords": "Humans, Hallucinogens, Anxiety Disorders, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39655426\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 368, "title": "Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis.", "normalized_title": "psychedelics as an intervention for psychological existential distress in terminally ill patients a systematic review and network meta analysis", "authors": "Marchi M, Farina R, Rachedi K, Laonigro F, Žuljević MF, Pingani L, Ferrari S, Somers M, Boks MPM, Galeazzi GM.", "abstract": "BackgroundThe interest in psychedelics as a therapeutic intervention for existential distress of people with terminal illness grounds on their mechanism of action and effect on the spiritual/existential aspects accompanying end-of-life experiences.AimsThis systematic review and network meta-analysis aimed at examining the efficacy and safety of psychedelic compounds for existential distress in terminally ill people.MethodsPubMed, CINAHL, PsycINFO, EMBASE, and clinicaltrials.gov were searched for randomized controlled trials (RCTs) administering psychedelics for existential distress in people with terminal illnesses. Meta-analysis estimated the standardized mean difference (SMD) and odds ratio (OR), with corresponding 95% confidence intervals (95% CI), between treated and control groups in pairwise and network comparisons, using random-effects models. Post-treatment measures of depression and anxiety, as proxies of existential distress, and tolerability were the primary outcomes.ResultsNine studies, involving 606 participants (362 treated with psychedelics: psilocybin, ketamine, 3,4-methylenedioxymethamphetamine, and lysergic acid diethylamide (LSD)) were included. The meta-analysis supported the efficacy of psychedelics on depression (SMD: -0.80 (95% CI: -0.98, -0.63)) and anxiety (SMD: -0.84 (95% CI: -1.20, -0.48)). Network meta-analysis identified psilocybin as the most effective compound for depression, and LSD for anxiety. However, head-to-head comparison between psychedelics did not reach statistical significance. The rates of treatment discontinuation and adverse events between psychedelics and controls were comparable.ConclusionsPsychedelics, especially psilocybins and LSD, showed promising effects on depression and anxiety in people with terminal illnesses. Limitations include the small number of RCTs, methodological issues related to blinding, and the lack of direct comparisons between psychedelic compounds. Larger studies and comparative research are needed to consolidate these findings.", "journal": null, "publication_date": "2024-12-09", "publication_year": 2024, "doi": "10.1177/02698811241303594", "pubmed_id": "39655749", "source_url": "https://doi.org/10.1177/02698811241303594", "keywords": "Humans, Hallucinogens, Depression, Stress, Psychological, Anxiety, Terminally Ill, Randomized Controlled Trials as Topic, Psychological Distress, Network Meta-Analysis as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39655749\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Mechanism of Action,Spirituality,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 908, "title": "Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.", "normalized_title": "quality of reporting on psychological interventions in psychedelic treatments a systematic review", "authors": "Seybert C, Schimmers N, Silva L, Breeksema JJ, Veraart J, Bessa BS, d'Orsi D, Schoevers RA, Oliveira-Maia AJ.", "abstract": "Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic component. In this systematic review, we summarised the quality of reporting on psychological interventions in research about psychedelic treatments. The design followed PRISMA guidelines and was preregistered in PROSPERO (CRD42022319221). We searched MEDLINE, PsycINFO, and Embase for original studies on psychedelic-assisted psychotherapy and included 45 studies assessing psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (known as LSD), or ayahuasca, for the treatment of mental disorders. Psychological interventions were done heterogeneously across studies, and completeness of information reported about these interventions was mostly low, according to an adaptation of the Template for Intervention Description and Replication checklist. In studies including MDMA, psychotherapy was more homogeneous and more procedural details were provided. Improved reporting on psychological interventions of psychedelic treatments will support replicability, generalisability, and accurate interpretation of research, while enhancing feasibility and safety of future clinical research and real-world implementation of treatments.", "journal": null, "publication_date": "2024-12-08", "publication_year": 2024, "doi": "10.1016/s2215-0366(24)00333-x", "pubmed_id": "39667373", "source_url": "https://doi.org/10.1016/s2215-0366(24)00333-x", "keywords": "Humans, Banisteriopsis, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39667373\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 928, "title": "Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use", "normalized_title": "psilocybin assisted psychotherapy for methamphetamine dependence a case report involving daily methamphetamine use", "authors": "Jonathan Brett, Elizabeth Knock, Kathy Watson, Steven M. Albert, Krista J. Siefried, Jeffrey Guss", "abstract": "Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin, the active component in numerous mushrooms of the Psilocybe genus, has shown potential for enhancing psychotherapy for various addiction and mental health issues due to its effects on perception, cognition, and affect. Psilocybin-assisted psychotherapy (PAT) has demonstrated initial safety and efficacy in treating alcohol, cocaine, and nicotine dependence. The case presented here describes a 36-year-old transwoman and daily MA user, who participated in a single-arm open-label clinical trial assessing feasibility and safety of PAT for MA dependence at St. Vincent’s Hospital, Sydney. Following inpatient withdrawal management and one session of psilocybin-assisted therapy, she experienced significant cognitive and emotional shifts and sustained MA abstinence. She reported improved mental health over 3 months following treatment completion. She also noted increased self-esteem, mindfulness, and distress tolerance. This study suggests that PAT (following inpatient MA withdrawal management) may offer a scalable, safe, and effective approach for treating MA dependence. However, further research is required to confirm the generalisability and efficacy of PAT for broader populations of people using MA. It is encouraging that this participant, a daily MA user, showed improvements in mood and cognition, in addition to abstinence from MA.", "journal": "Frontiers in Psychiatry", "publication_date": "2024-12-05", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1490907", "pubmed_id": "39713770", "source_url": "https://doi.org/10.3389/fpsyt.2024.1490907", "keywords": "Psilocybin, Methamphetamine, Hallucinogen, Psychology, Psychotherapist, Medicine, Psychiatry, Pharmacology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4405122998\",\"openalex_url\":\"https://openalex.org/W4405122998\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1924347018\",\"https://openalex.org/W1989346195\",\"https://openalex.org/W2000961004\",\"https://openalex.org/W2106369261\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2130544434\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2754028604\",\"https://openalex.org/W2763897668\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2981405421\",\"https://openalex.org/W3010839704\",\"https://openalex.org/W3174234800\",\"https://openalex.org/W3195045424\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4246595021\",\"https://openalex.org/W4249317412\",\"https://openalex.org/W4286494502\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4324145541\",\"https://openalex.org/W4385661344\",\"https://openalex.org/W4391840511\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090300123\",\"display_name\":\"Jonathan Brett\",\"orcid\":\"https://orcid.org/0000-0003-3065-7495\"},{\"id\":\"https://openalex.org/A5042111294\",\"display_name\":\"Elizabeth Knock\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109187755\",\"display_name\":\"Kathy Watson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5049197924\",\"display_name\":\"Steven M. Albert\",\"orcid\":\"https://orcid.org/0000-0001-6786-9956\"},{\"id\":\"https://openalex.org/A5040818661\",\"display_name\":\"Krista J. Siefried\",\"orcid\":\"https://orcid.org/0000-0002-6534-3325\"},{\"id\":\"https://openalex.org/A5026405762\",\"display_name\":\"Jeffrey Guss\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2024.1490907\",\"is_oa\":true}}", "topic_tags": "Addiction,Pharmacology,Receptor Pharmacology,Aging,Emotional Processing,Clinical Trial,Case Report,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4405122998" }, { "id": 3689, "title": "Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study", "normalized_title": "efficacy and safety of comp360 psilocybin therapy in anorexia nervosa a proof of concept study", "authors": "COMPASS Pathways", "abstract": "Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa", "journal": "ClinicalTrials.gov", "publication_date": "2024-12-03", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05481736", "keywords": "Anorexia Nervosa, Psilocybin, COMP360, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05481736\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Eating Disorders,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 932, "title": "Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.", "normalized_title": "synergistic multi level understanding of psychedelics three systematic reviews and meta analyses of their pharmacology neuroimaging and phenomenology", "authors": "Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML.", "abstract": "Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, including depression and addiction. Yet their modes of action are not fully understood. Here, we provide a novel, synergistic understanding of psychedelics arising from systematic reviews and meta-analyses of three hierarchical levels of analysis: (1) subjective experience (phenomenology), (2) neuroimaging and (3) molecular pharmacology. Phenomenologically, medium and high doses of LSD yield significantly higher ratings of visionary restructuralisation than psilocybin on the 5-dimensional Altered States of Consciousness Scale. Our neuroimaging results reveal that, in general, psychedelics significantly strengthen between-network functional connectivity (FC) while significantly diminishing within-network FC. Pharmacologically, LSD induces significantly more inositol phosphate formation at the 5-HT2A receptor than DMT and psilocin, yet there are no significant between-drug differences in the selectivity of psychedelics for the 5-HT2A, 5-HT2C, or D2 receptors, relative to the 5-HT1A receptor. Our meta-analyses link DMT, LSD, and psilocybin to specific neural fingerprints at each level of analysis. The results show a highly non-linear relationship between these fingerprints. Overall, our analysis highlighted the high heterogeneity and risk of bias in the literature. This suggests an urgent need for standardising experimental procedures and analysis techniques, as well as for more research on the emergence between different levels of psychedelic effects.", "journal": null, "publication_date": "2024-12-03", "publication_year": 2024, "doi": "10.1038/s41398-024-03187-1", "pubmed_id": "39632810", "source_url": "https://doi.org/10.1038/s41398-024-03187-1", "keywords": "Brain, Humans, Dimethoxyphenylethylamine, Lysergic Acid Diethylamide, Hallucinogens, Neuroimaging, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39632810\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness,Aging,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 931, "title": "Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.", "normalized_title": "comparative antidepressant effects and safety of intravenous racemic ketamine psilocybin and theta burst stimulation for major depressive disorder a systematic review and network meta analyses of randomized controlled trials", "authors": "Terao I, Kodama W.", "abstract": "The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta-analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined. We systematically searched the CENTRAL, Medline, CINHAL, and ClinicalTrials.gov databases for randomized controlled trials up to July 4, 2024. Random-effects network meta-analyses were conducted to compare the Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorderantidepressant efficacy, tolerability, and acceptability of IV ketamine, psilocybin, and TBS. Twenty-eight RCTs were included. All treatments were superior to placebo, with IV ketamine and psilocybin showing significantly greater antidepressant efficacy than TBS. No significant differences were detected between all treatments and placebo in tolerability and acceptability. In a subgroup analysis focusing on short periods of 1 week or less, only IV ketamine was significantly more effective than placebo. In another subgroup analysis focusing on periods of 4 weeks or longer, IV ketamine and psilocybin showed significantly better antidepressant effects than placebo. The confidence in the evidence ranged from very low to moderate. Specifically, there is a scarcity of studies on psilocybin and a lack of direct comparison trials. The findings suggest that IV ketamine and psilocybin may be more effective treatments compared to TBS. Additionally, IV ketamine may have an advantage in terms of rapid onset of action. The number of included studies is limited, especially for psilocybin, and therefore the current findings are preliminary, necessitating further accumulation of direct-comparison RCTs.", "journal": null, "publication_date": "2024-12-03", "publication_year": 2024, "doi": "10.1002/pcn5.70042", "pubmed_id": "39641126", "source_url": "https://doi.org/10.1002/pcn5.70042", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39641126\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Randomized Controlled Trial,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 915, "title": "Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.", "normalized_title": "therapeutic potential of psychedelic drugs navigating high hopes strong claims weak evidence and big money", "authors": "Humphreys K, Todd Korthuis P, Stjepanović D, Hall W.", "abstract": "Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening, however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.", "journal": null, "publication_date": "2024-12-02", "publication_year": 2024, "doi": "10.1146/annurev-psych-020124-023532", "pubmed_id": "39094057", "source_url": "https://doi.org/10.1146/annurev-psych-020124-023532", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Ketamine, Hallucinogens, Stress Disorders, Post-Traumatic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39094057\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,Mechanism of Action,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 724, "title": "Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.", "normalized_title": "randomized controlled trials of psilocybin assisted therapy in the treatment of major depressive disorder systematic review and meta analysis", "authors": "Menon V, Ramamurthy P, Venu S, Andrade C.", "abstract": "IntroductionThere is growing interest in the use of psychedelic-assisted therapy (PAT) for major depressive disorder (MDD), including treatment-resistant depression. We used randomized controlled trial (RCT) data to compare summary estimates of change in depression ratings with PAT versus comparator treatments in MDD. We also compared response and remission rates, and adverse effects.MethodsWe searched MEDLINE, EMBASE, Cochrane Central Register for Controlled Trials (CENTRAL), and SCOPUS from inception till April 2024. Our primary efficacy outcome was 1-week (or nearest) between-group change in depression ratings. Secondary efficacy outcomes were changes in depression ratings at days 2, 14, and 42 (or nearest) and study-defined response and remission rates at week 1 (or nearest). Safety outcomes were reported adverse effects. We pooled outcomes in random-effects meta-analyses using standardized mean difference (SMD; Hedges g) for continuous outcomes and risk ratio (RR) for categorical outcomes.ResultsWe found 6 eligible RCTs (pooled N = 427), all on psilocybin. The pooled SMD for 1-week between-group change in depression ratings was -0.72 [95% CI, -0.95 to -0.49; I2 = 17%; 5 RCTs; n = 403], favouring PAT; results were similar at days 2, 14, and 42. The response [RR = 3.42; 95% CI, 2.35-4.97; I2 = 0%; 4 RCTs; n = 373] and remission [RR = 3.66; 95% CI, 2.26-5.92; I2 = 0%; 4 RCTs; n = 373] rates also favored PAT. The PAT group had a small but significantly increased risk of developing any adverse event [RR = 1.20; 95% CI, 1.01-1.42; I2 = 43%; 4 RCTs; n = 373] and a significantly higher risk of experiencing headache [RR = 1.78; 95% CI, 1.10-2.86; I2 = 52%; 4 RCTs; n = 373] and dizziness [RR = 6.52; 95% CI, 1.19-35.87; I2 = 0%; 3 RCTs; n = 269]. Low heterogeneity characterized most analyses and findings were similar in sensitivity analyses.ConclusionAntidepressant effects of psilocybin-assisted therapy are superior (with at least medium effect sizes) to comparator interventions for at least up to 6 weeks postintervention.", "journal": null, "publication_date": "2024-12-02", "publication_year": 2024, "doi": "10.1111/acps.13778", "pubmed_id": "39627679", "source_url": "https://doi.org/10.1111/acps.13778", "keywords": "Humans, Hallucinogens, Treatment Outcome, Randomized Controlled Trials as Topic, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39627679\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Headache / Migraine,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 933, "title": "Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.", "normalized_title": "protective behavioral strategies for psychedelic use a mini review of the evidence", "authors": "Piercey CJ, Gray B, Sung A, Henry D, Karoly HC.", "abstract": "BackgroundApproximately 8.5 million Americans over the age of 12 endorsed past year psychedelic use in 2022, with 1.4 million individuals initiating use during this time. Although emerging evidence indicates there may be beneficial aspects of psychedelic use, there is a need to understand how individuals might mitigate potential risks within nonclinical contexts, such as through the use of protective behavioral strategies (PBS).MethodPubMed and Google Scholar databases were searched to identify articles reporting on PBS (i.e., harm reduction strategies implemented at the individual level) for psychedelic use within nonclinical contexts. We include articles pertaining to both classical serotonergic psychedelics (e.g., lysergic acid diethylamide [LSD], psilocybin) and nonclassical psychedelics (e.g., 3,4-methylenedioxymethamphetamine [MDMA], ketamine).ResultsAlthough research on psychedelic PBS use is limited, evidence suggests a culture of harm reduction present within psychedelic communities. Psychedelic PBS identified in the literature include strategies related to drug acquisition, dosing, set and setting, bodily nourishment, planning for and working through challenging experiences, and integration of psychedelic experiences. Few studies have examined the relationship between psychedelic PBS use and outcomes, but emerging evidence suggests that psychedelic PBS use may be associated with decreased consequences.ConclusionThere is a need to continue developing and validating measures of psychedelic PBS and outcomes for use within research and intervention settings. Additional research examining associations between psychedelic PBS use and outcomes is also critical to best serving the needs of individuals who use psychedelics within nonclinical contexts.", "journal": null, "publication_date": "2024-12-01", "publication_year": 2024, "doi": "10.1089/psymed.2023.0052", "pubmed_id": "40051484", "source_url": "https://doi.org/10.1089/psymed.2023.0052", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"40051484\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 951, "title": "Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.", "normalized_title": "adverse events in studies of classic psychedelics a systematic review and meta analysis", "authors": "Hinkle JT, Graziosi M, Nayak SM, Yaden DB.", "abstract": "ImportanceA clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its application to new populations and indications.ObjectiveTo assess adverse events (AEs) associated with classic psychedelics, particularly serious AEs (SAEs) and nonserious AEs (NSAEs) requiring medical or psychiatric evaluation.Data sourcesThe search for potentially eligible studies was conducted in the Scopus, MEDLINE, PsycINFO, and Web of Science databases from inception through February 8, 2024.Study selectionTwo independent reviewers screened articles of classic psychedelics (lysergic acid diethylamide [LSD], psilocybin, dimethyltryptamine [DMT], and 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT]) involving administration in clinical or research contexts.Data extraction and synthesisAE data were extracted and synthesized by 2 reviewers and were used for random-effects meta-analysis of AE frequency and heterogeneity. Risk of bias assessment focused on AE ascertainment (eg, systematic assessment and quality of follow-up).Main outcomes and measuresA hybrid approach was used for capture of all reported AEs following high-dose classic psychedelic exposure and confirmatory capture of AEs of special interest, including suicidality, psychotic disorder, manic symptoms, cardiovascular events, and hallucinogen persisting perception disorder. AEs were stratified by timescale and study population type. Forest plots of common AEs were generated, and the proportions of participants affected by SAEs or NSAEs requiring medical intervention were summarized descriptively.ResultsA total of 214 unique studies were included, of which 114 (53.3%) reported analyzable AE data for 3504 total participants. SAEs were reported for no healthy participants and for approximately 4% of participants with preexisting neuropsychiatric disorders; among these SAEs were worsening depression, suicidal behavior, psychosis, and convulsive episodes. NSAEs requiring medical intervention (eg, paranoia, headache) were similarly rare. In contemporary research settings, there were no reports of deaths by suicide, persistent psychotic disorders, or hallucinogen persisting perception disorders following administration of high-dose classic psychedelics. However, there was significant heterogeneity in the quality of AE monitoring and reporting. Of 68 analyzed studies published since 2005, only 16 (23.5%) described systematic approaches to AE assessment, and 20 studies (29.4%) reported all AEs, as opposed to only adverse drug reactions. Meta-analyses of prevalence for common AEs (eg, headache, anxiety, nausea, fatigue, and dizziness) yielded comparable results for psilocybin and LSD.Conclusions and relevanceIn this systematic review and meta-analysis, classic psychedelics were generally well tolerated in clinical or research settings according to the existing literature, although SAEs did occur. These results provide estimates of common AE frequencies and indicate that certain catastrophic events reported in recreational or nonclinical contexts have yet to be reported in contemporary trial participants. Careful, ongoing, and improved pharmacovigilance is required to understand the risk and benefit profiles of these substances and to communicate such risks to prospective study participants and the public.", "journal": null, "publication_date": "2024-11-30", "publication_year": 2024, "doi": "10.1001/jamapsychiatry.2024.2546", "pubmed_id": "39230883", "source_url": "https://doi.org/10.1001/jamapsychiatry.2024.2546", "keywords": "Humans, N,N-Dimethyltryptamine, Lysergic Acid Diethylamide, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39230883\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Meta-Analysis,Systematic Review,Review Article,Healthy Volunteers,Safety,Adverse Events", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 941, "title": "Psilocybin and hallucinogenic mushrooms.", "normalized_title": "psilocybin and hallucinogenic mushrooms", "authors": "Fradet M, Kelly CM, Donnelly AJ, Suppes T.", "abstract": "Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summarizes the most recent data on its safety and efficacy. The delivery of psilocybin therapy and its subjective effects are also presented. Furthermore, this chapter outlines our current understanding of psilocybin's pharmacology and neurobiological effects. Other similar psychedelic substances with encouraging therapeutic potential are briefly presented.", "journal": null, "publication_date": "2024-11-30", "publication_year": 2024, "doi": "10.1017/s1092852924002487", "pubmed_id": "39789676", "source_url": "https://doi.org/10.1017/s1092852924002487", "keywords": "Humans, Agaricales, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39789676\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 838, "title": "Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.", "normalized_title": "effects of psychoplastogens on blood levels of brain derived neurotrophic factor bdnf in humans a systematic review and meta analysis", "authors": "Calder AE, Hase A, Hasler G.", "abstract": "BackgroundPeripheral levels of brain-derived neurotrophic factor (BDNF) are often used as a biomarker for the rapid plasticity-promoting effects of ketamine, psychedelics, and other psychoplastogens in humans. However, studies analyzing peripheral BDNF after psychoplastogen exposure show mixed results. In this meta-analysis, we aimed to test whether the rapid upregulation of neuroplasticity seen in preclinical studies is detectable using peripheral BDNF in humans.MethodsThis analysis was pre-registered (PROSPERO ID: CRD42022333096) and funded by the University of Fribourg. We systematically searched PubMed, Web of Science, and PsycINFO to meta-analyze the effects of all available psychoplastogens on peripheral BDNF levels in humans, including ketamine, esketamine, LSD, psilocybin, ayahuasca, DMT, MDMA, scopolamine, and rapastinel. Risk of bias was assessed using Cochrane Risk of Bias Tools. Using meta-regressions and mixed effects models, we additionally analyzed the impact of several potential moderators.ResultsWe included 29 studies and found no evidence that psychoplastogens elevate peripheral BDNF levels in humans (SMD = 0.024, p = 0.64). This result was not affected by drug, dose, blood fraction, participant age, or psychiatric diagnoses. In general, studies with better-controlled designs and fewer missing values reported smaller effect sizes. Later measurement timepoints showed minimally larger effects on BDNF.ConclusionThese data suggest that peripheral BDNF levels do not change after psychoplastogen administration in humans. It is possible that peripheral BDNF is not an informative marker of rapid changes in neuroplasticity, or that preclinical findings on psychoplastogens and neuroplasticity may not translate to human subjects. Limitations of this analysis include the reliability and validity of BDNF measurement and low variation in some potential moderators. More precise methods of measuring rapid changes in neuroplasticity, including neuroimaging and stimulation-based methods, are recommended for future studies attempting to translate preclinical findings to humans.", "journal": null, "publication_date": "2024-11-28", "publication_year": 2024, "doi": "10.1038/s41380-024-02830-z", "pubmed_id": "39613915", "source_url": "https://doi.org/10.1038/s41380-024-02830-z", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Ketamine, Lysergic Acid Diethylamide, Brain-Derived Neurotrophic Factor, Hallucinogens, Psychotropic Drugs, Neuronal Plasticity, Biomarkers, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"39613915\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Brain Imaging,Biomarkers,Aging,Meta-Analysis,Systematic Review,Review Article,Animal Study,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3157, "title": "Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration", "normalized_title": "synergistic behavioral and neuroplastic effects of psilocybin nmdar modulator administration", "authors": "Ben-Tal T, Pogodin I, Botvinnik A, Lifschytz T, Heresco-Levy U, Lerer B.", "abstract": "The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the synergistic benefits of combining psilocybin (PSIL) with N-methyl-D-aspartate receptor (NMDAR) modulators D-serine (DSER) and D-cycloserine (DCS) to enhance both efficacy and safety. Using ICR male mice, we examined head twitch response (HTR), MK-801-induced hyperlocomotion, and neuroplasticity related synaptic protein levels in the frontal cortex, hippocampus, amygdala, and striatum. Our results indicate that PSIL significantly increased HTR-a surrogate measure for hallucinogenic effects-which was reduced by the co-administration of DSER or DCS in a dose-dependent manner. Similarly, combining PSIL with DSER or DCS significantly decreased MK-801-induced hyperactivity, modeling antipsychotic effects. Neuroplasticity-related synaptic protein assays demonstrated that the PSIL-DSER combination enhanced GAP43 expression over all 4 brain examined and overall expression of the 4 assayed synaptic proteins in the hippocampus, while PSIL-DCS elevated PSD95 levels across all 4 brain regions, suggesting a synaptogenic synergy. These findings support the hypothesis that combinations of SP with NMDAR modulators could optimize the therapeutic potential of SP by mitigating adverse effects and enhancing neuroplasticity. Future studies should focus on refining administration protocols and evaluating translational applicability for broader clinical use.", "journal": "bioRxiv", "publication_date": "2024-11-27", "publication_year": 2024, "doi": "10.1101/2024.11.28.625811", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.11.28.625811", "keywords": "", "substance_tags": "psilocybin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR947201\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Neuroplasticity,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 811, "title": "Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.", "normalized_title": "reconsidering evidence for psychedelic induced psychosis an overview of reviews a systematic review and meta analysis of human studies", "authors": "Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M.", "abstract": "BackgroundPersons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders.MethodsWe conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality.ResultsFrom 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results.ConclusionIn summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.", "journal": null, "publication_date": "2024-11-26", "publication_year": 2024, "doi": "10.1038/s41380-024-02800-5", "pubmed_id": "39592825", "source_url": "https://doi.org/10.1038/s41380-024-02800-5", "keywords": "Humans, Psychoses, Substance-Induced, Lysergic Acid Diethylamide, Hallucinogens, Psychotic Disorders, Schizophrenia, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39592825\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3512, "title": "A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder", "normalized_title": "a phase 2a safety and feasibility study evaluating psilocybin trp 8802 administration in concert with psychotherapy in the treatment of binge eating disorder", "authors": "TRYP Therapeutics", "abstract": "To better understand the potential benefits of psychedelics in overeating disorders, Tryp Therapeutics will conduct a safety and feasibility clinical trial using TRP8802 among individuals with Binge Eating Disorder. This is a single-center phase 2a open-label study to assess the safety and feasibility of a single dose of TRP8802 in subjects with BED. Subjects will undergo screening, preparation therapy sessions, dosing, integration therapy sessions, and follow-up for 12 weeks following the dose of TRP8802. The total participation in the study will be up to approximately 5 months. Binge eating disorder is the most common eating disorder and is associated with obesity and psychiatric comorbidities, including depression, and impulsive and compulsive disorders. Binge eating disorder is marked by severe disturbance to a person's control over their eating behaviors and high anxiety around food. Various programs using psilocybin paired with psychotherapy have shown positive effects in treating a variety of psychiatric and behavioral conditions, including cancer-related psychiatric distress, anxiety, treatment-resistant depression, and nicotine and alcohol addiction. Based on clinical precedents, relevant neuropharmacology, and mechanistic similarities, psilocybin is theorized to have the potential to be part of the treatment of overeating disorders. TRP-8802 could accomplish this by moderating overall anxiety, anxiety around food, perseveration, and repetitive and intrusive thoughts about food in people with BED. The primary objective of this study is to: 1\\. Assess the safety of a single dose of TRP8802 in participants with binge eating disorder (BED) during the TRP8802 dosing session, and through 12 weeks following dosing (i.e., Week 14).", "journal": "ClinicalTrials.gov", "publication_date": "2024-11-18", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05035927", "keywords": "Binge Eating Disorder, TRYP-0082, Psilocybin, Psychotherapy, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05035927\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Eating Disorders,Pharmacology,Clinical Trial,Cancer Patients,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 794, "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder", "normalized_title": "psilocybin assisted psychotherapy for treatment resistant depression in bipolar ii disorder", "authors": "Shakila Meshkat, Erica Kaczmarek, Zoe Doyle, Ryan M. Brudner, Fabiano A. Gomes, Marc G. Blainey, Geneva Weiglein, Roger S McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat", "abstract": "Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown promise for its rapid-acting antidepressant effects, though its impact on bipolar depression remains unexplored. In the present subgroup analysis of an already published trial on treatment-resistant depression (TRD), we aimed to preliminarily evaluate the safety and efficacy of psilocybin in patients with BD-II. Methods: Adults with TRD associated with BD-II, excluding those with psychosis were included. Participants underwent one or two psilocybin sessions, each with a dose of 25 mg, along with preparatory and integrative psychotherapy sessions. Results: A total of four participants with a mean age of 37.5 ± 4.15 years were included. At baseline, the mean Montgomery-Åsberg Depression Rating Scale (MADRS) score was 32.5 (95% CI: 26.3-38.7, SD = 3.87). By week 2 post-dose, mean MADRS decreased to 20.3, and 2 weeks after dose 2, it further dropped to 19. At the end of the 6-month study, the mean MADRS score was 21.3. Young Mania Rating Scale scores remained stable at a mean of one throughout the study with no evidence of treatment emergent mania, hypomania or psychosis observed in any participants. Conclusions: These findings suggest potential improvement in depressive symptoms with psilocybin administration in BD-II. Future studies with larger sample size are required to replicate our results and further evaluate antidepressant effects of psilocybin in bipolar depression.", "journal": "Psychedelic Medicine", "publication_date": "2024-11-17", "publication_year": 2024, "doi": "10.1089/psymed.2024.0032", "pubmed_id": "40337756", "source_url": "https://doi.org/10.1089/psymed.2024.0032", "keywords": "Psilocybin, Bipolar disorder, Depression (economics), Psychotherapist, Treatment-resistant depression, Psychology, Psychiatry, Hallucinogen, Major depressive disorder, Lithium (medication), Cognition, Economics, Macroeconomics, Psychedelics and Drug Studies, Bipolar Disorder and Treatment, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4404460385\",\"openalex_url\":\"https://openalex.org/W4404460385\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":8,\"referenced_works\":[\"https://openalex.org/W2567379065\",\"https://openalex.org/W2612228298\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W4210998119\",\"https://openalex.org/W4294953492\",\"https://openalex.org/W4311439362\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4311688634\",\"https://openalex.org/W4316340089\",\"https://openalex.org/W4386961159\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4391069738\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4393364883\",\"https://openalex.org/W4399215777\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037985605\",\"display_name\":\"Shakila Meshkat\",\"orcid\":\"https://orcid.org/0000-0002-7010-1785\"},{\"id\":\"https://openalex.org/A5104243612\",\"display_name\":\"Erica Kaczmarek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048402159\",\"display_name\":\"Zoe Doyle\",\"orcid\":\"https://orcid.org/0000-0002-0140-8994\"},{\"id\":\"https://openalex.org/A5093927192\",\"display_name\":\"Ryan M. Brudner\",\"orcid\":\"https://orcid.org/0009-0004-8381-7434\"},{\"id\":\"https://openalex.org/A5000765029\",\"display_name\":\"Fabiano A. Gomes\",\"orcid\":\"https://orcid.org/0000-0002-7690-1580\"},{\"id\":\"https://openalex.org/A5089394793\",\"display_name\":\"Marc G. Blainey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5114681119\",\"display_name\":\"Geneva Weiglein\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111237412\",\"display_name\":\"Roger S McIntyre\",\"orcid\":null},{\"id\":\"https://openalex.org/A5032613018\",\"display_name\":\"Rodrigo B. Mansur\",\"orcid\":\"https://orcid.org/0000-0002-3968-3297\"},{\"id\":\"https://openalex.org/A5050740394\",\"display_name\":\"Joshua D. Rosenblat\",\"orcid\":\"https://orcid.org/0000-0002-4773-2191\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2024.0032\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4404460385" }, { "id": 958, "title": "Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals", "normalized_title": "knowledge attitudes and concerns about psilocybin and mdma as novel therapies among u s healthcare professionals", "authors": "Erin Y. Wang, David S. Mathai, Natalie Gukasyan, Sandeep M. Nayak, Albert Garcia-Romeu", "abstract": "Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression was used to identify predictors of openness to clinical use. Most participants (71.2%) were female and White (85.8%), with a mean (SD) age of 45.5 (12.7) years. Registered nurses (25.4%) and physicians (17.7%) comprised the largest professional groups. Respondents endorsed strong belief in therapeutic promise, and moderate openness to clinical use and support for legal access to both substances, with higher overall ratings for psilocybin compared to MDMA. Objective knowledge items revealed low knowledge of therapeutic uses, risks, and pharmacology. Primary concerns were lack of trained providers, financial cost, and potential contraindications. Prior psychedelic use, self-rated knowledge, younger age, and professional role predicted openness to clinical use of psilocybin and MDMA, with physicians reporting lower openness. As psychedelics continue to garner popular and scientific interest, results indicate a pressing need for additional formal training to provide balanced, evidence-based information from trusted sources.", "journal": "Scientific Reports", "publication_date": "2024-11-13", "publication_year": 2024, "doi": "10.1038/s41598-024-78736-1", "pubmed_id": "39543323", "source_url": "https://doi.org/10.1038/s41598-024-78736-1", "keywords": "Psilocybin, MDMA, Openness to experience, Hallucinogen, Health care, Medicine, Psychology, Psychiatry, Clinical psychology, Social psychology, Economic growth, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4404374254\",\"openalex_url\":\"https://openalex.org/W4404374254\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":18,\"referenced_works\":[\"https://openalex.org/W1810864195\",\"https://openalex.org/W2018057120\",\"https://openalex.org/W2026781905\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2090826913\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2490107109\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2624901555\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2804532410\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2912723046\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3027946860\",\"https://openalex.org/W3116749687\",\"https://openalex.org/W3132728164\",\"https://openalex.org/W3133542189\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3171671394\",\"https://openalex.org/W3191608162\",\"https://openalex.org/W3193605940\",\"https://openalex.org/W3195045424\",\"https://openalex.org/W3197311089\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4221070625\",\"https://openalex.org/W4281556927\",\"https://openalex.org/W4283329324\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4313855425\",\"https://openalex.org/W4321377299\",\"https://openalex.org/W4378220014\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4391527378\",\"https://openalex.org/W4399040580\",\"https://openalex.org/W4400279567\"],\"authorships\":[{\"id\":\"https://openalex.org/A5055827580\",\"display_name\":\"Erin Y. Wang\",\"orcid\":\"https://orcid.org/0000-0003-1042-2541\"},{\"id\":\"https://openalex.org/A5020492413\",\"display_name\":\"David S. Mathai\",\"orcid\":\"https://orcid.org/0000-0001-9972-601X\"},{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"},{\"id\":\"https://openalex.org/A5040929530\",\"display_name\":\"Sandeep M. Nayak\",\"orcid\":\"https://orcid.org/0000-0002-6832-0639\"},{\"id\":\"https://openalex.org/A5091708678\",\"display_name\":\"Albert Garcia-Romeu\",\"orcid\":\"https://orcid.org/0000-0003-2182-1644\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S196734849\",\"source_display_name\":\"Scientific Reports\",\"landing_page_url\":\"https://doi.org/10.1038/s41598-024-78736-1\",\"is_oa\":true}}", "topic_tags": "Depression,PTSD,Pharmacology,Observational Study,Safety,Contraindications", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4404374254" }, { "id": 910, "title": "Associations between psychedelic use and cannabis use disorder in a nationally representative sample.", "normalized_title": "associations between psychedelic use and cannabis use disorder in a nationally representative sample", "authors": "Zech JM, Yaden DB, Jones GM.", "abstract": "BackgroundCannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently been investigated for their therapeutic potential in treating substance use disorders, yet no prior work has examined the relationship between naturalistic use of specific psychedelic compounds and rates of disordered cannabis use.MethodsUsing a nationally representative sample of U.S adults from the National Survey on Drug Use and Health (2015 - 2019, 2021 - 2022), we used a series of survey-weighted multivariable logistic regressions to examine the association between past year disordered cannabis use and use of several classic psychedelics (i.e., LSD, psilocybin, mescaline, peyote, DMT) and non-classic psychedelics (i.e., ketamine, MDMA).Resultslifetime psilocybin use as well as past year LSD use were both associated with higher rates of past year DSM-5 CUD (adjusted risk ratio [aRR] range: 1.89 - 2.04), controlling for a variety of sociodemographic factors. These associations remained significant in the case of moderate-to-severe past year CUD (aRR range: 1.65 - 2.07). Past year LSD use also predicted three of eleven CUD symptoms among individuals with past year cannabis use (aRR range: 1.45 - 1.73).DiscussionDespite preliminary findings regarding the potential for psychedelic substances to help treat substance use disorders, our findings suggest a relationship between psychedelic use and disordered cannabis use, suggesting that certain psychedelic substances used in certain naturalistic settings are an indicator of greater risk of maladaptive cannabis use. Future directions to further disentangle these relationships are discussed.", "journal": null, "publication_date": "2024-11-13", "publication_year": 2024, "doi": "10.1016/j.drugalcdep.2024.112502", "pubmed_id": "39586127", "source_url": "https://doi.org/10.1016/j.drugalcdep.2024.112502", "keywords": "Humans, Marijuana Abuse, Lysergic Acid Diethylamide, Hallucinogens, Health Surveys, Adolescent, Adult, Middle Aged, United States, Female, Male, Young Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39586127\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 961, "title": "Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial", "normalized_title": "prospective preference assessment for the psilocybin for enhanced analgesia in chronic neuropathic pain peace pain trial", "authors": "Jiwon Lee, Kaylyssa Philip, Duminda N. Wijeysundera, Hance Clarke, Cheryl Pritlove, Joel Katz, Paul Ritvo, Akash Goel, Muhammad Ishrat Husain, Karim S. Ladha", "abstract": "Background: Negative perceptions of psilocybin and challenges of participant enrollment may represent barriers to conducting a randomized controlled trial examining psilocybin for chronic neuropathic pain. Aim: Prior to trial initiation, we aimed to examine patient attitudes toward the trial via a prospective preference assessment. Methods: Twenty-six patients with chronic neuropathic pain participated in a prospective preference assessment comprising quantitative (survey) and qualitative (interview) components. Content analysis was used to inductively and deductively identify factors that would motivate or discourage participation in the proposed trial. Demographics, clinical characteristics, and perceptions of psilocybin were collected to explore differences in characteristics between patients who were willing and unwilling to participate. Results: Survey results showed that most participants (76.9%) were willing to participate in the PEACE-PAIN trial. \"Willing\" participants reported higher prior psychedelic use (75%) as compared to the \"maybe willing\" (0%) and \"not willing\" participants (0%). Interviews indicated that the top two factors that motivated participation included the need for new treatment options (31.7%) and benefits to personal pain management (31.7%). The top two discouraging factors included practical difficulties of research participation (16.7%), and adverse events associated with psilocybin (16.7%). Conclusions: The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discussions of the current evidence for efficacy, safety, tolerability, and approaches to address adverse effects of psilocybin. Additionally, the interest in participation by individuals with prior psychedelic use holds important methodological implications for the inclusion/exclusion criteria of the trial.", "journal": "Canadian Journal of Pain", "publication_date": "2024-11-07", "publication_year": 2024, "doi": "10.1080/24740527.2024.2406285", "pubmed_id": "39529994", "source_url": "https://doi.org/10.1080/24740527.2024.2406285", "keywords": "Neuropathic pain, Psilocybin, Chronic pain, Medicine, Anesthesia, Psychology, Physical therapy, Psychiatry, Hallucinogen, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4404189888\",\"openalex_url\":\"https://openalex.org/W4404189888\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W75450688\",\"https://openalex.org/W116730420\",\"https://openalex.org/W1943094646\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2014243214\",\"https://openalex.org/W2043678991\",\"https://openalex.org/W2125416355\",\"https://openalex.org/W2142225512\",\"https://openalex.org/W2153646932\",\"https://openalex.org/W2206489433\",\"https://openalex.org/W2302893657\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2784098876\",\"https://openalex.org/W2913855113\",\"https://openalex.org/W2944592785\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3213721934\",\"https://openalex.org/W4205164075\",\"https://openalex.org/W4220864059\",\"https://openalex.org/W4234814399\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4294804950\",\"https://openalex.org/W4318918369\",\"https://openalex.org/W4362508370\",\"https://openalex.org/W4386019370\",\"https://openalex.org/W4392660340\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034966707\",\"display_name\":\"Jiwon Lee\",\"orcid\":\"https://orcid.org/0000-0002-7903-1883\"},{\"id\":\"https://openalex.org/A5009458131\",\"display_name\":\"Kaylyssa Philip\",\"orcid\":\"https://orcid.org/0000-0002-9207-9427\"},{\"id\":\"https://openalex.org/A5026073227\",\"display_name\":\"Duminda N. Wijeysundera\",\"orcid\":\"https://orcid.org/0000-0002-5897-8605\"},{\"id\":\"https://openalex.org/A5036161954\",\"display_name\":\"Hance Clarke\",\"orcid\":\"https://orcid.org/0000-0003-4975-3823\"},{\"id\":\"https://openalex.org/A5011298374\",\"display_name\":\"Cheryl Pritlove\",\"orcid\":\"https://orcid.org/0000-0001-9627-7562\"},{\"id\":\"https://openalex.org/A5011326651\",\"display_name\":\"Joel Katz\",\"orcid\":\"https://orcid.org/0000-0002-8686-447X\"},{\"id\":\"https://openalex.org/A5067357561\",\"display_name\":\"Paul Ritvo\",\"orcid\":\"https://orcid.org/0000-0003-1141-0083\"},{\"id\":\"https://openalex.org/A5101426205\",\"display_name\":\"Akash Goel\",\"orcid\":\"https://orcid.org/0000-0001-8545-9782\"},{\"id\":\"https://openalex.org/A5078217449\",\"display_name\":\"Muhammad Ishrat Husain\",\"orcid\":\"https://orcid.org/0000-0001-5771-5750\"},{\"id\":\"https://openalex.org/A5056143246\",\"display_name\":\"Karim S. Ladha\",\"orcid\":\"https://orcid.org/0000-0001-7303-2458\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210205933\",\"source_display_name\":\"Canadian Journal of Pain\",\"landing_page_url\":\"https://doi.org/10.1080/24740527.2024.2406285\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Aging,Randomized Controlled Trial,Observational Study,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4404189888" }, { "id": 3128, "title": "Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms", "normalized_title": "tū wairua development of an indigenous rongoā māori approach to healing with psilocybin containing mushrooms", "authors": "Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P.", "abstract": "Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and spiritual purposes. While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy being developed lack Indigenous wisdom and input, raising concerns about safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with psilocybin-assisted therapy (PAT) for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by kaupapa Māori methodology and rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti, a community with a high Māori population and a significant burden of PMU, the project aims to develop a culturally-appropriate PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelics. In creating sustainable pathways for healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.", "journal": "PsyArXiv", "publication_date": "2024-11-06", "publication_year": 2024, "doi": "10.31234/osf.io/93x5h", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/93x5h", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR937024\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3127, "title": "Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms", "normalized_title": "tū wairua development of an indigenous rongoā māori approach to healing with psilocybin containing mushrooms", "authors": "Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P.", "abstract": "Psilocybin, a naturally occurring psychedelic compound found in certain fungi, has long been used by Indigenous cultures worldwide for healing and spiritual purposes. While emerging evidence points to psychedelic agents being novel avenues for the treatment of substance use disorders, the predominantly Western medical models of psychedelic-assisted therapy being developed lack Indigenous wisdom and input, raising concerns about safety, efficacy, ownership, and continuing colonial dynamics. In Aotearoa (New Zealand), the enduring impacts of colonisation on Māori include the suppression of Indigenous wisdom, even as research affirming the knowledge and practice of traditional Māori healing is on the rise. The Tū Wairua project will explore the integration of rongoā Māori (traditional Māori healing practices) with psilocybin-assisted therapy (PAT) for addressing problematic methamphetamine use (PMU) in Māori communities. This Māori-led project is driven by kaupapa Māori methodology and rongoā Māori conceptualisations of health and informed by biomedical psychedelic science. Based at Rangiwaho Marae in Te Tairāwhiti, a community with a high Māori population and a significant burden of PMU, the project aims to develop a culturally-appropriate PAT to explore the efficacy of psilocybin in treating PMU. This research represents a shift toward health interventions that respect and extend Indigenous wisdom, addressing the unique needs of Māori communities. It also seeks to develop a skilled Māori workforce to continue these healing practices, and challenge current legislation that restricts the use of Indigenous psychedelics. In creating sustainable pathways for healing through a community-driven, culturally-resonant PAT, Tū Wairua charts new directions in Indigenous-led psychedelic science.", "journal": "PsyArXiv", "publication_date": "2024-11-06", "publication_year": 2024, "doi": "10.31234/osf.io/93x5h_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/93x5h_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR984269\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3669, "title": "PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)", "normalized_title": "psilocd evaluating the effects of the 5 ht2a agonist psilocybin on the neurocognitive and clinical correlates of compulsivity a pharmacological challenge feasibility study", "authors": "Imperial College London", "abstract": "The purpose of this study is to assess the impact of psilocybin on cognitive inflexibility and neural plasticity in a cohort of people with obsessive-compulsive disorder (OCD). This mechanistic study will utilise a within-subjects design, administering up to 10mg of psilocybin to participants with OCD (DSM-5 criteria) on two separate instances spaced four weeks apart. To ensure consistency and participant safety, dosing will occur under medical supervision with psychological support from two experienced therapists. Before and after each session, participants will engage in virtual preparation and integration sessions led by their therapists. Cognitive tasks will be administered in the days following each dosing session. Additionally, acute post-dosing EEG recordings will be conducted, and blood samples will be taken after each dosing session. OCD symptoms will also be assessed seven times throughout the trial by an external blinded psychiatrist, serving as a secondary outcome. Collectively, these measures aim to evaluate changes in cognitive inflexibility, decision-making abilities, neuroplasticity (peripheral blood markers and EEG measures), inflammation (peripheral blood markers), and symptomatology following each dosing session.", "journal": "ClinicalTrials.gov", "publication_date": "2024-11-05", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06258031", "keywords": "Obsessive-Compulsive Disorder, Psilocybin (COMP360), O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06258031\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "OCD,Neuroplasticity,Brain Imaging,Receptor Pharmacology,Biomarkers,Observational Study,Safety,Inflammation", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 893, "title": "Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions", "normalized_title": "psilocybin mushrooms and public health in brazil insights from a retrospective analysis of adverse events and their implications for regulatory discussions", "authors": "Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto, Leonardo Zanella Marques", "abstract": "Current drug policy classifies psilocybin, a compound found in psychoactive mushrooms, as having high abuse potential while overlooking its therapeutic properties. We evaluated the risk of psilocybin mushrooms to Brazilian public health compared to other toxic agents and assessed the need for regulatory discussions. This retrospective cross-sectional study followed STROBE guidelines, using data from the Notifiable Diseases Information System (SINAN) on adverse events reported from 2007 to 2022. Participants were categorized into a general drug abuse group, which was further divided into psilocybin and unknown mushroom subgroups. Clinical outcomes included non-hospitalization, hospitalization, and death, with associations analyzed via the Chi-square test. Out of 112,451 individuals seeking medical attention for drug abuse-related events, men predominated (n = 79,514; 70.7%), with alcohol being the primary agent (n = 71,824; 49.2%). The psilocybin mushroom group included 13 participants, and the unknown mushroom group included 51. Hospitalization rates were 19.5% (n = 21,923) for drug abuse, 46.2% (n = 6) for psilocybin mushrooms (0.02% of all hospitalizations) (99% CI: 10.6%-81.6%), and 23.5% (n = 12) for unknown mushrooms (99% CI: 8.3%-38.7%). Mortality was 1.8% (n = 2035) for drug abuse group, with no fatal events in the psilocybin or unknown mushroom groups. Deaths were mainly linked to cocaine (33.3%). These findings suggest a low risk for psilocybin mushrooms, though underreporting may be a factor. This study underscores the need for evidence-based regulatory discussions to ensure safe access to psilocybin for clinical and ceremonial use.", "journal": "International journal of medicinal mushrooms", "publication_date": "2024-11-04", "publication_year": 2024, "doi": "10.1615/intjmedmushrooms.2024057053", "pubmed_id": "40096533", "source_url": "https://doi.org/10.1615/intjmedmushrooms.2024057053", "keywords": "Psilocybin, Adverse effect, Public health, Mushroom poisoning, Medicine, Hallucinogen, Environmental health, Traditional medicine, Pharmacology, Nursing, Poison control, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4404063451\",\"openalex_url\":\"https://openalex.org/W4404063451\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1857921554\",\"https://openalex.org/W1983350514\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2051579023\",\"https://openalex.org/W2095349468\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W3134897339\",\"https://openalex.org/W3137814255\",\"https://openalex.org/W3154999065\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4281762597\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4290990311\",\"https://openalex.org/W4292229870\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309648711\",\"https://openalex.org/W4313201591\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4319298186\",\"https://openalex.org/W4323294129\",\"https://openalex.org/W4366464082\",\"https://openalex.org/W4382515410\",\"https://openalex.org/W4383186044\",\"https://openalex.org/W4385777618\",\"https://openalex.org/W4385969211\",\"https://openalex.org/W4386735204\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387389328\",\"https://openalex.org/W4388014221\",\"https://openalex.org/W4388203254\",\"https://openalex.org/W4388714298\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4392165205\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4396728212\",\"https://openalex.org/W4398137313\",\"https://openalex.org/W4398156492\",\"https://openalex.org/W6945971758\"],\"authorships\":[{\"id\":\"https://openalex.org/A5103228690\",\"display_name\":\"Marcel Nogueira\",\"orcid\":\"https://orcid.org/0000-0001-8357-674X\"},{\"id\":\"https://openalex.org/A5104421765\",\"display_name\":\"Solimary García-Hernández\",\"orcid\":\"https://orcid.org/0000-0002-9348-0511\"},{\"id\":\"https://openalex.org/A5104421766\",\"display_name\":\"Gleicy Sotéro Roberto\",\"orcid\":\"https://orcid.org/0000-0001-8808-8614\"},{\"id\":\"https://openalex.org/A5107146462\",\"display_name\":\"Leonardo Zanella Marques\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S79925788\",\"source_display_name\":\"International journal of medicinal mushrooms\",\"landing_page_url\":\"https://doi.org/10.1615/intjmedmushrooms.2024057053\",\"is_oa\":false}}", "topic_tags": "Addiction,Pharmacology,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4404063451" }, { "id": 3134, "title": "Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial", "normalized_title": "preliminary safety and effectiveness of psilocybin assisted therapy in adults with fibromyalgia an open label pilot clinical trial", "authors": "Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF.", "abstract": "Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM. Here, we report findings from an open-label, proof-of-concept trial of PAT for FM (N=5; NCT05128162). In conjunction with psychotherapy (two preparatory, four integration sessions), participants received two doses of oral psilocybin (15mg and 25mg) delivered two weeks apart. Regarding safety (primary outcome), there were transient elevations of blood pressure or heart rate during dosing which normalized by the end of treatment, with no serious adverse events. Four of five participants reported transient headaches following dosing. Compared to baseline, participants reported clinically meaningful improvements in the following secondary outcomes one month following their second psilocybin dose (reported as Cohen’s d): pain severity (d=-2.1, 95% CI[-3.7 to -0.49]), pain interference (d=-1.8, 95% CI [-3.27 to -0.24]), and sleep disturbance (d=-2.5, 95% CI [-4.21 to -0.75]). Using the Patient Global Impression of Change, one participant reported their symptoms “very much improved,” two reported “much improved,” and two reported “minimally improved.” Compared to baseline, there were improvements in the following exploratory outcomes after the intervention: FM symptoms, anxiety, and fatigue. This small open-label trial preliminarily supports that PAT is well-tolerated by people with FM, establishing a basis for larger randomized controlled trials.", "journal": "PsyArXiv", "publication_date": "2024-11-03", "publication_year": 2024, "doi": "10.31234/osf.io/j8zb5", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/j8zb5", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR935081\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 776, "title": "Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial", "normalized_title": "preliminary safety and effectiveness of psilocybin assisted therapy in adults with fibromyalgia an open label pilot clinical trial", "authors": "", "abstract": "Fibromyalgia (FM) is the prototypical nociplastic pain condition, characterized by widespread pain and issues with cognition, mood, and sleep. Currently, there are limited treatment options available that effectively treat FM symptoms. Psilocybin-assisted therapy (PAT) is an emerging combined drug-therapy intervention, but no studies to-date have investigated PAT for FM. Here, we report findings from an open-label, proof-of-concept trial of PAT for FM (N=5; NCT05128162). In conjunction with psychotherapy (two preparatory, four integration sessions), participants received two doses of oral psilocybin (15mg and 25mg) delivered two weeks apart. Regarding safety (primary outcome), there were transient elevations of blood pressure or heart rate during dosing which normalized by the end of treatment, with no serious adverse events. Four of five participants reported transient headaches following dosing. Compared to baseline, participants reported clinically meaningful improvements in the following secondary outcomes one month following their second psilocybin dose (reported as Cohen’s d): pain severity (d=-2.1, 95% CI[-3.7 to -0.49]), pain interference (d=-1.8, 95% CI [-3.27 to -0.24]), and sleep disturbance (d=-2.5, 95% CI [-4.21 to -0.75]). Using the Patient Global Impression of Change, one participant reported their symptoms “very much improved,” two reported “much improved,” and two reported “minimally improved.” Compared to baseline, there were improvements in the following exploratory outcomes after the intervention: FM symptoms, anxiety, and fatigue. This small open-label trial preliminarily supports that PAT is well-tolerated by people with FM, establishing a basis for larger randomized controlled trials.", "journal": "PsyArXiv", "publication_date": "2024-11-03", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/j8zb5_v1", "keywords": "Psychiatry, Social and Behavioral Sciences, Life Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"j8zb5_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Anxiety,Chronic Pain,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3136, "title": "Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts", "normalized_title": "personal psychedelic experience as a training qualification for facilitators a thematic analysis of qualitative interviews with psilocybin experts", "authors": "Luoma JB, Wilson-Poe A, Pertl K, Hoffman K, Bazinet A, Stauffer C, McCarty D, Korthuis P.", "abstract": "Emerging legal frameworks in Oregon and Colorado license facilitators to support adults receiving psychedelic services. The current legal frameworks are silent regarding facilitators’ personal experience with psychedelics. An eDelphi process recruited 36 experts with at least 5 years’ experience facilitating psilocybin experiences in ceremonial settings, indigenous practices, or clinical trials. Respondents completed in-depth, semi-structured qualitative interviews via secure web links. Interviews were recorded, transcribed, and analyzed using Thematic Analysis. Experts with a mean of 15.2 (SD13.1) years’ experience providing psilocybin services expressed the importance of first-hand experience with psychedelics as a qualification for the emerging workforce. One participant questioned the necessity of personal psychedelic experience. Experts suggested that personal experience may indirectly support high-quality care because it enhances facilitators’ personal wellbeing, and may help facilitators understand the complexity and nature of their clients’ psychedelic experiences. Novel statelegal psychedelic paradigms create a real-world opportunity to assess associations between facilitators’ personal psychedelic experience and the safety and outcomes of psychedelic services.", "journal": "PsyArXiv", "publication_date": "2024-10-30", "publication_year": 2024, "doi": "10.31234/osf.io/dwhcu_v1", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/dwhcu_v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR1055707\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Wellbeing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 551, "title": "Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts", "normalized_title": "personal psychedelic experience as a training qualification for facilitators a thematic analysis of qualitative interviews with psilocybin experts", "authors": "", "abstract": "Emerging legal frameworks in Oregon and Colorado license facilitators to support adults receiving psychedelic services. The current legal frameworks are silent regarding facilitators’ personal experience with psychedelics. An e Delphi process recruited 36 experts with at least 5 years’ experience facilitating psilocybin experiences in ceremonial settings, indigenous practices, or clinical trials. Respondents completed in-depth, semi-structured qualitative interviews via secure web links. Interviews were recorded, transcribed, and analyzed using Thematic Analysis. Experts with a mean of 15.2 (SD13.1) years’ experience providing psilocybin services expressed the importance of first-hand experience with psychedelics as a qualification for the emerging workforce. One participant questioned the necessity of personal psychedelic experience. Experts suggested that personal experience may indirectly support high-quality care because it enhances facilitators’ personal wellbeing, and may help facilitators understand the complexity and nature of their clients’ psychedelic experiences. Novel state legal psychedelic paradigms create a real-world opportunity to assess associations between facilitators’ personal psychedelic experience and the safety and outcomes of psychedelic services.", "journal": "PsyArXiv", "publication_date": "2024-10-30", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/dwhcu_v1", "keywords": "experts, personal experience, psychedelics, qualitative, Psychiatry, Social and Behavioral Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"dwhcu_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Wellbeing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3584, "title": "A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study", "normalized_title": "a registered clinical trial of pex010 assisted therapy for stimulant use disorder a safety feasibility and efficacy study", "authors": "Filament Health Corp.", "abstract": "The goal of this clinical trial is to learn if PEX010 is effective for the treatment of Stimulant Use Disorder in adults. The study will also assess the safety and feasibility of administering PEX010 to this population. The main questions it aims to answer are: Does PEX010 reduce stimulant use? What medical problems do participants experience when taking PEX010? Researchers will compare an active PEX010 dose containing 25 mg psilocybin to an active placebo arm, to see if PEX010 works to reduce stimulant use. Participants will: Take PEX010 or the active placebo once during the study, engage in cognitive behavioural therapy, and visit the clinic twice weekly for study intervention and follow-up assessments. In this randomized, controlled trial study participants will receive one capsule of PEX010 containing 25 mg or 1 mg of psilocybin, in conjunction with therapy. Following screening and baseline visits, participants will receive 2 preparation sessions, 1 PEX010 dosing session, 1 integration session, and 7 follow-up visits.", "journal": "ClinicalTrials.gov", "publication_date": "2024-10-29", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06666010", "keywords": "Stimulant Use Disorder, PEX010-Assisted Therapy, PEX010(01), NOT_YET_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06666010\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 986, "title": "A narrative exploration of psilocybin's potential in mental health.", "normalized_title": "a narrative exploration of psilocybin s potential in mental health", "authors": "Min H, Park SY, Park J, Na S, Lee HS, Kim T, Ham J, Park YT.", "abstract": "Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investigated the multifaceted aspects of psilocybin, highlighting its chemical properties, mechanisms of action, and burgeoning role in psychiatric treatment. Furthermore, we examined the clinical applications and potential therapeutic benefits of psilocybin in the treatment of various mental health disorders, supported by accumulating clinical evidence. This review aims to deepen our understanding of the clinical impact of psilocybin, elucidate its therapeutic value, and propose directions for future research, thereby paving the way for its integration into mainstream psychiatric treatments. Psilocybin has been shown to be safe in clinical trials with manageable side effects. However, additional safety measures are required after this discussion, including dosing protocols, patient monitoring, and distress management strategies.", "journal": null, "publication_date": "2024-10-29", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1429373", "pubmed_id": "39540010", "source_url": "https://doi.org/10.3389/fpsyt.2024.1429373", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"39540010\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Clinical Trial,Review Article,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4537, "title": "The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment", "normalized_title": "the therapeutic potential and mechanisms of action of psilocybin assisted therapy in anorexia nervosa treatment", "authors": "Hannah Douglass", "abstract": "Anorexia nervosa (AN) is a serious eating disorder (ED) with high rates of mortality and chronicity. Given the ambivalence towards engaging in treatment and recovery that is characteristic of this condition, the identification of novel treatment avenues that can target motivation and demonstrate superior efficacy to existing treatment options is desperately needed. Psilocybin-therapy has demonstrated efficacy in safely alleviating symptoms of multiple psychiatric conditions, primarily depressive disorders. Although indicated by psychological and neurobiological mechanisms of action, the efficacy of psilocybin-therapy in AN had not been investigated at the commencement of this PhD project. The study detailed in this thesis was a single-blind and within-subject feasibility study in which 21 adult female participants diagnosed with AN were administered with 1mg, 25mg, and 25mg psilocybin in a fixed-order design over a 6-week period, with a subsequent remote 12-month follow-up period. The first aim of this thesis was to investigate the feasibility, safety, and efficacy of this psilocybin-therapy protocol. The feasibility and safety of this treatment protocol was demonstrated. Efficacy in improving ED psychopathology and readiness and motivation to change up to the 12-month follow-up was also reported. The second aim of this thesis was to elucidate causal mechanisms of action of psilocybin-therapy in AN, specifically neuroplasticity and interoception. An electroencephalography (EEG) paradigm reported ED severity-dependent deficits in neuroplasticity at baseline and demonstrated trend-level enhancements in neuroplasticity after high-dose psilocybin. Increases in interoceptive sensibility (IS) were demonstrated via a self-report questionnaire, with trend-level improvements in interoceptive accuracy (iACC) reported via a cardioceptive behavioural task. Enhanced interoception was found to correlate with positive clinical outcomes. This thesis demonstrates the feasibility, safety, and efficacy of this psilocybin-therapy protocol to treat this cohort of adult females with AN. Using multimodal methodologies, potential causal mechanisms of enhanced neuroplasticity and interoception were indicated, warranting their further investigation.", "journal": "Open MIND", "publication_date": "2024-10-09", "publication_year": 2024, "doi": "10.25560/118978", "pubmed_id": null, "source_url": "https://hdl.handle.net/10044/1/118978", "keywords": "Anorexia nervosa, Psychopathology, Neuroplasticity, Psychology, Interoception, Psychotherapist, Anxiety, Disengagement theory, Medicine, Psychiatry, Clinical psychology, Behaviour therapy, Action (physics), Major depressive disorder, Eating disorders, Ambivalence, Exposure therapy, Affect (linguistics), Electroencephalography, Convalescence, Mindfulness, Prodrome, Anorexia, Bulimia nervosa, Neural correlates of consciousness, Neuropsychiatry, Endophenotype, Allostasis, Anxiety disorder, Psychological resilience, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Bipolar Disorder and Treatment", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:42", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7166080670\",\"openalex_url\":\"https://openalex.org/W7166080670\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5063975352\",\"display_name\":\"Hannah Douglass\",\"orcid\":\"https://orcid.org/0000-0002-2768-8875\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4406922384\",\"source_display_name\":\"Open MIND\",\"landing_page_url\":\"https://hdl.handle.net/10044/1/118978\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Eating Disorders,Chronic Pain,Neuroplasticity,Brain Imaging,Mechanism of Action,Consciousness,Aging,Resilience,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7166080670" }, { "id": 3469, "title": "A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants", "normalized_title": "a phase 1 dose escalation study to evaluate the safety tolerability and pharmacokinetics of mls101 psilocybin in healthy participants", "authors": "MycoMedica Life Sciences PBC", "abstract": "MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions. The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants. In recent years, high-dose psilocybin has gained attention for its potential therapeutic benefits in many psychiatric indications, however existing clinical data for low psilocybin doses are limited. Microdoses are generally considered to be those absent of profound sensory and cognitive effects that would interfere with normal everyday functioning, but only a small number of prospective studies have evaluated microdoses and/or low doses in a controlled manner. As a foundational study of the therapeutic use of low doses of psilocybin, this study will evaluate the safety, tolerability, pharmacokinetics, and sensorial effects using a prospective, controlled, single ascending dose/multiple ascending doses in healthy volunteers.", "journal": "ClinicalTrials.gov", "publication_date": "2024-10-08", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06326606", "keywords": "Healthy Volunteers, Psilocybin, MLS101, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06326606\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Pharmacology,Microdosing,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 947, "title": "Impact of psilocybin on cognitive function: A systematic review.", "normalized_title": "impact of psilocybin on cognitive function a systematic review", "authors": "Meshkat S, Tello-Gerez TJ, Gholaminezhad F, Dunkley BT, Reichelt AC, Erritzoe D, Vermetten E, Zhang Y, Greenshaw A, Burback L, Winkler O, Jetly R, Mayo LM, Bhat V.", "abstract": "Psilocybin is a classic psychedelic with demonstrated preliminary clinical efficacy in a range of psychiatric disorders. Evaluating the impact of psilocybin on cognitive function is essential to unravel its potential benefits and risks. In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to January 2024, identifying 20 articles involving 2,959 participants. While 85% of studies were conducted in healthy volunteers, most of these studies (85%) used macrodoses, ranging from 45 μg/kg to 30 mg/70 kg. Various cognitive aspects were evaluated and yielded mixed results. Global cognitive function, and processing speed remained mostly unchanged in healthy individuals; However, a limited number of studies reported improvements in certain areas such as sustained attention, working memory, and executive function especially in patients with treatment-resistant depression (TRD). Emotional processing was positively modified, particularly in TRD patients. Psilocybin was observed to enhance emotional empathy without significantly altering cognitive empathy and social cognition. Cognitive flexibility and creative cognition were noted to initially decline but could potentially improve over time. Additionally, with respect to learning and memory skills, psilocybin showed promise in improving specific memory types such as semantic associations and associative learning, while its effects on episodic and verbal memory have been less pronounced compared to other cognitive enhancers. The observed mixed findings underscore the complexity of psilocybin's cognitive influence. Further research is essential to provide a clearer understanding of psilocybin's impact on cognitive domains and to guide the development of safe and effective interventions.", "journal": null, "publication_date": "2024-09-30", "publication_year": 2024, "doi": "10.1111/pcn.13741", "pubmed_id": "39354706", "source_url": "https://doi.org/10.1111/pcn.13741", "keywords": "Humans, Hallucinogens, Cognition, Executive Function, Depressive Disorder, Treatment-Resistant, Psilocybin, Cognitive Dysfunction", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"39354706\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Emotional Processing,Creativity,Systematic Review,Review Article,Healthy Volunteers,Treatment-Resistant Depression,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1015, "title": "Beyond the numbers: reimagining healing with psychedelics for eating disorders.", "normalized_title": "beyond the numbers reimagining healing with psychedelics for eating disorders", "authors": "Lafrance A, Spriggs MJ, Gukasyan N, Peck SK", "abstract": "Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these models of care to eating disorders (EDs) given the limited efficacy of available treatment models, especially for those living with anorexia nervosa. Preliminary findings across a number of studies suggest promise. In this commentary, researchers with experience in psychedelics and EDs present a rationale and considerations for the application of psychedelic medicine, including psychedelic-assisted therapy (PAT) for EDs. These contributions are informed by those with lived experience as well as the authors' experiences in the field. By addressing underlying psychological and transpersonal factors and improving treatment engagement, psychedelic medicine, though not without risks, may offer a valuable adjunct to existing treatments, enhancing overall outcomes for some living with an ED. This commentary also aims to provide a multi-dimensional perspective to inform the field, including with respect to the etiology of these illnesses, as psychedelic medicine becomes more accessible in naturalistic, research and clinical settings.", "journal": "Journal of eating disorders", "publication_date": "2024-09-29", "publication_year": 2024, "doi": "10.1186/s40337-024-01111-y", "pubmed_id": "39350242", "source_url": "https://pubmed.ncbi.nlm.nih.gov/39350242/", "keywords": "Anorexia nervosa, Eating disorders, Psilocybin treatment, Psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"39350242\"}", "topic_tags": "Eating Disorders,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 914, "title": "Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.", "normalized_title": "harnessing pharmacogenomics in clinical research on psychedelic assisted therapy", "authors": "Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D.", "abstract": "Psychedelics have recently re-emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these topics to explore the utility of pharmacogenomics (a key component of personalized medicine) in psychedelic-assisted therapies. We summarized the literature and explored the potential implications of genetic variability on the pharmacodynamics and pharmacokinetics of psychedelic drugs including lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine and 3,4-methylenedioxymethamphetamine (MDMA). Although existing evidence is limited, particularly concerning pharmacodynamics, studies investigating pharmacokinetics indicate that genetic variants in drug-metabolizing enzymes, such as cytochrome P450, impact the intensity of acute psychedelic effects for LSD and ibogaine, and that a dose reduction for CYP2D6 poor metabolizers may be appropriate. Furthermore, based on the preclinical evidence, it can be hypothesized that CYP2D6 metabolizer status might contribute to altered acute psychedelic experiences with 5-MeO-DMT and psilocybin when combined with monoamine oxidase inhibitors. In conclusion, considering early evidence that genetic factors can influence the effects of certain psychedelics, we suggest that pharmacogenomic testing should be further investigated in clinical research. This is necessary to evaluate its utility in improving the safety and therapeutic profile of psychedelic therapies and a potential future role in personalizing psychedelic-assisted therapies, should these treatments become available.", "journal": null, "publication_date": "2024-09-29", "publication_year": 2024, "doi": "10.1002/cpt.3459", "pubmed_id": "39345195", "source_url": "https://doi.org/10.1002/cpt.3459", "keywords": "Humans, Hallucinogens, Mental Disorders, Pharmacogenetics, Precision Medicine", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39345195\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Review Article,Animal Study,Safety,Genomics", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3592, "title": "An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder", "normalized_title": "an open label pilot study examining the feasibility safety and effectiveness of psilocybin therapy for depression in bipolar ii disorder", "authors": "University of California, San Francisco", "abstract": "The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder. The primary goal of this study is to examine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder (BD II). Fourteen participants, ages 18 to 70 with clinically diagnosed BD II with active depression, in active outpatient mental health treatment, and who meet all other inclusion and exclusion criteria at screening will be enrolled. After baseline assessments, participants will engage in preparatory visits with trained facilitators, followed by an initial drug administration of oral psilocybin,supervised by the facilitators and a clinician who will conduct safety monitoring throughout. Participants will complete assessment and integration sessions with the facilitators subsequently in order to help process the experience. Participants who tolerated the first dosage may be asked to complete a second psilocybin dosing session, involving the same preparation, procedures, integration, and supervision as the first. Primary outcome measures will assess safety, tolerability, and feasibility of study procedures. Efficacy will be measured by change in depression as measured by the MADRS three weeks after the final psilocybin administration. Exploratory outcome measures will assess changes in sleep, quality of life, and therapeutic engagement.", "journal": "ClinicalTrials.gov", "publication_date": "2024-09-24", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05065294", "keywords": "Bipolar II Disorder, Psilocybin therapy, 4-phosphoryloxy-N,N-dimethyltryptamine, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05065294\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1017, "title": "Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.", "normalized_title": "psilocybin for major depressive disorder a systematic review of randomized controlled studies", "authors": "Li LJ, Mo Y, Shi ZM, Huang XB, Ning YP, Wu HW, Yang XH, Zheng W.", "abstract": "ObjectivesThe purpose of this systematic review of randomized controlled trials (RCTs) was to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major depressive disorder (MDD).MethodsA systematic search (up to September 14, 2023) was conducted for RCTs that examined the efficacy, safety, and tolerability of psilocybin in physically healthy adult patients with MDD. Three independent researchers extracted data from publications where the primary outcome was a change in depressive symptoms, and key secondary outcomes were changes in anxiety symptoms and suicidal ideation, discontinuation rates for any reason, and adverse drug reactions (ADRs).ResultsFive RCTs with 472 adult patients with MDD on psilocybin (n = 274) and controls (n = 198) were included. Two of the five RCTs (40%) reported mixed results, while the other three (60%) found that psilocybin had a beneficial effect on MDD treatment. Four RCTs (80%) assessing the anxiolytic effects of psilocybin for treating MDD found that psilocybin was significantly more effective than the control group in improving anxiety symptoms. Psilocybin was more effective than the control group in improving suicidal ideation in one out of five RCTs. Discontinuation rates were similar for any reason between the psilocybin group (2-13%) and the control group (4-21%) (P > 0.05). Four RCTs (80%) reported ADRs in detail. The most common ADR in both groups was headache.ConclusionPsilocybin was effective in improving depressive symptoms in over half of the included studies and reduced anxiety symptoms in patients with MDD. The long-term efficacy and safety of psilocybin for MDD treatment needs to be further investigated in large RCTs.", "journal": null, "publication_date": "2024-09-22", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1416420", "pubmed_id": "39376971", "source_url": "https://doi.org/10.3389/fpsyt.2024.1416420", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39376971\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Randomized Controlled Trial,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 997, "title": "Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial", "normalized_title": "effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate to severe major depressive disorder observational 6 month follow up of a phase 2 double blind randomised controlled trial", "authors": "David Erritzøe, Tommaso Barba, Kyle T. Greenway, Roberta Murphy, Jonny Martell, Bruna Giribaldi, Christopher Timmermann, Ashleigh Murphy-Beiner, Michelle Baker Jones, David Nutt, Brandon Weiss, Robin Carhart-Harris", "abstract": "Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination. Methods: This is a 6-month follow-up study of a phase 2, double-blind, randomised, controlled trial involving patients with moderate-to-severe MDD. Participants were recruited from a hospital in the UK. Male or female patients with major depressive disorder (DSM-IV), moderate to severe depression (HAM-D ≥17), no MRI or SSRI contraindications, confirmed diagnosis by a GP or mental healthcare professional, aged 18-80, and competent in English were eligible. Patients were randomly assigned (1:1) to receive either two 25 mg doses of the psychedelic drug psilocybin administered orally combined with psychological support ('psilocybin therapy' or PT) and book-ended by further support or a 6-week course of the selective serotonin reuptake inhibitor (SSRI) escitalopram (administered daily at 10 mg for three weeks and 20 mg for the subsequent three weeks) plus matched psychological support ('escitalopram treatment' or ET). The primary outcome measure was change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) at week 6, which has been reported previously. Herein, we present results at the 6-month follow-up time point. Measures of social functioning, connectedness, and meaning in life constituted the study's secondary outcomes during follow-up. Safety in the follow-up period was not assessed. This trial is registered at ClinicalTrials.gov, NCT03429075. Findings: Between January 15th, 2019 and March 20th, 2020, 59 patients were enrolled and 30 (11 females [37%] and 19 males [63%]) were assigned to the psilocybin group and 29 (9 females [31%] and 20 males [69%]) to the escitalopram group. 25 participants in the PT group and 21 in the ET group completed the 6-month follow-up. At the 6-month follow-up, both PT and ET conditions yielded sustained improvements in depressive symptom severity. The mean between-condition difference in QIDS-SR-16 scores at 6-months was 1.51 (95% CI: -1.35, 4.38; p = 0.311). Secondary outcomes demonstrated that PT had greater mean between-condition differences in functioning (WSAS: -7.46; 95% CI: -12.4, -2.47; p < 0.001), psychological connectedness (WCS: 11.02; 95% CI: 1.25, 20.83; p = 0.033), and meaning in life (MLQ: 4.86; 95% CI: 0.67, 9.05; p = 0.021) compared to ET. Interpretation: Six-week intensive treatments with either psilocybin or escitalopram (with psychological support) for MDD were associated with long-term improvements in depressive symptom severity. The greater degree of improvement in the PT arm at follow-up on psychosocial functioning, meaning in life, and psychological connectedness suggests warrant future research. However, these results are descriptive and should be interpreted with caution. Key limitations of the study include its suboptimal power to detect small but meaningful differences between treatments, missing data, the potential use of additional interventions during the follow-up period, and reliance on self-reported treatment assessments. These factors may affect the interpretation of the study findings and should be considered when evaluating the results. Funding: The Alexander Mosley Charitable Trust and by the founding partners of Imperial College London's Centre for Psychedelic Research.", "journal": "EClinicalMedicine", "publication_date": "2024-09-22", "publication_year": 2024, "doi": "10.1016/j.eclinm.2024.102799", "pubmed_id": "39764567", "source_url": "https://doi.org/10.1016/j.eclinm.2024.102799", "keywords": "Medicine, Escitalopram, Observational study, Randomized controlled trial, Depression (economics), Double blind, Psilocybin, Psychiatry, Major depressive disorder, Internal medicine, Placebo, Alternative medicine, Hallucinogen, Antidepressant, Anxiety, Mood, Pathology, Economics, Macroeconomics, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4402747955\",\"openalex_url\":\"https://openalex.org/W4402747955\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":45,\"referenced_works\":[\"https://openalex.org/W243214355\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1974739407\",\"https://openalex.org/W1977897138\",\"https://openalex.org/W1981738711\",\"https://openalex.org/W1983358521\",\"https://openalex.org/W2013523345\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2063225659\",\"https://openalex.org/W2082645015\",\"https://openalex.org/W2096230543\",\"https://openalex.org/W2101540672\",\"https://openalex.org/W2102133850\",\"https://openalex.org/W2105435220\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2115086661\",\"https://openalex.org/W2115905656\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2129310294\",\"https://openalex.org/W2140505555\",\"https://openalex.org/W2201421223\",\"https://openalex.org/W2277633149\",\"https://openalex.org/W2293194104\",\"https://openalex.org/W2346275821\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2519531315\",\"https://openalex.org/W2605671917\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2787695989\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2804876758\",\"https://openalex.org/W2908544178\",\"https://openalex.org/W2912654919\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2926011243\",\"https://openalex.org/W2940262672\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2971304551\",\"https://openalex.org/W3031742716\",\"https://openalex.org/W3046057820\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3182390788\",\"https://openalex.org/W3203310594\",\"https://openalex.org/W4200330438\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4220790925\",\"https://openalex.org/W4223962004\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4313251651\",\"https://openalex.org/W4323567563\",\"https://openalex.org/W4323652410\",\"https://openalex.org/W4367053025\",\"https://openalex.org/W4379284995\",\"https://openalex.org/W4382182909\",\"https://openalex.org/W4385173317\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4391630740\",\"https://openalex.org/W6736394996\",\"https://openalex.org/W6748127778\",\"https://openalex.org/W6850232825\",\"https://openalex.org/W6853949751\"],\"authorships\":[{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5005427567\",\"display_name\":\"Tommaso Barba\",\"orcid\":\"https://orcid.org/0000-0003-2565-4628\"},{\"id\":\"https://openalex.org/A5086630833\",\"display_name\":\"Kyle T. Greenway\",\"orcid\":\"https://orcid.org/0000-0002-7829-493X\"},{\"id\":\"https://openalex.org/A5111666675\",\"display_name\":\"Roberta Murphy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036560266\",\"display_name\":\"Jonny Martell\",\"orcid\":\"https://orcid.org/0000-0002-4194-7669\"},{\"id\":\"https://openalex.org/A5061472267\",\"display_name\":\"Bruna Giribaldi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5055329548\",\"display_name\":\"Christopher Timmermann\",\"orcid\":\"https://orcid.org/0000-0002-2281-377X\"},{\"id\":\"https://openalex.org/A5020659258\",\"display_name\":\"Ashleigh Murphy-Beiner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113396956\",\"display_name\":\"Michelle Baker Jones\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113982589\",\"display_name\":\"David Nutt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5015600817\",\"display_name\":\"Brandon Weiss\",\"orcid\":\"https://orcid.org/0000-0003-2989-2981\"},{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898347799\",\"source_display_name\":\"EClinicalMedicine\",\"landing_page_url\":\"https://doi.org/10.1016/j.eclinm.2024.102799\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Observational Study,Safety,Contraindications", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4402747955" }, { "id": 974, "title": "Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study", "normalized_title": "low dose psilocybin in short lasting unilateral neuralgiform headache attacks results from an open label phase ib ascending dose study", "authors": "James Rucker, Matthew Butler, Sadie Hambleton, Catherine Bird, Mathieu Seynaeve, Sanjay Cheema, Kete Campbell-Coker, Carolina Maggio, Fiona Dunbar, Giorgio Lambru, Manjit Matharu", "abstract": "BACKGROUND: Short-lasting unilateral neuralgiform headache attacks (SUNHA) are trigeminal autonomic cephalalgias that feature intense and recurrent paroxysms of pain and autonomic symptoms. Many patients are left with debilitating symptoms despite best-available treatment. Psychedelics, such as the serotonin 2A partial agonist psilocybin, have shown promise in related disorders such as migraine and cluster headache. In this open-label phase Ib ascending dose study, we aimed to assess the effects of low-dose oral psilocybin with psychological support in six to 12 patients with chronic SUNHA. Study objectives were to determine effects on cognition, as well as safety, tolerability, and effects on headache severity and frequency. METHODS: Oral psilocybin in ascending doses of 5, 7.5, and 10 mg (one dose per session; three dosing sessions in total) were administered. Cognition was assessed via the Cambridge Neuropsychological Tests Automated Battery. Headache attacks were assessed via headache diaries and the six-item Headache Impact Test (HIT-6). Subjective dose intensity was assessed via the five-Dimensional Altered States of Consciousness Questionnaire (5D-ASC). The study was terminated early due to recruitment difficulties; four patients were enrolled, three of whom were study completers. Post hoc, we undertook a thematic analysis of the applicable free-text clinical trial notes from the dosing and subsequent visits (n = 22). An inductive method was employed to establish emergent themes. RESULTS: No significant adverse events were recorded. We were unable to collect data as planned on cognitive function during the acute experience due to high ratings of subjective dose intensity (mean 5D-ASC scores 37.8-45.7). The impact of the headaches remained severe throughout the duration of the trial (HIT-6 mean scores 64.3-65.7). There were limited effects on headache duration and severity based on the diaries; however, mean daily attack frequency decreased by >50% in two participants at final follow-up (22.9 to 11.0 and 56.4 to 28.0, respectively). Completing participants and their clinicians recorded \"much\" (two participants) or \"minimal\" improvements (one participant) at final follow-up via the Clinical Global Impression rating scale. Thematic analysis indicated that psychological insights were key features of participants' experience; these insights included re-configured relationships to their headache pain. CONCLUSION: The study met with recruitment difficulties and cognition could not be assessed during the acute experience due to subjective dose intensity, likely mediated in part by expectancy effects. The clinical results provide no conclusive evidence for the use of psilocybin in SUNHA. We suggest that accounting for psychological factors in chronic SUNHA may be an important facet of treatment.", "journal": "Headache The Journal of Head and Face Pain", "publication_date": "2024-09-19", "publication_year": 2024, "doi": "10.1111/head.14837", "pubmed_id": "39301810", "source_url": "https://doi.org/10.1111/head.14837", "keywords": "Psilocybin, Tolerability, Medicine, Migraine, Anesthesia, Adverse effect, Internal medicine, Pharmacology, Hallucinogen, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Migraine and Headache Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4402697828\",\"openalex_url\":\"https://openalex.org/W4402697828\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W1532044842\",\"https://openalex.org/W1742833546\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1984379622\",\"https://openalex.org/W1999460576\",\"https://openalex.org/W2002681598\",\"https://openalex.org/W2022233689\",\"https://openalex.org/W2049199131\",\"https://openalex.org/W2068058964\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2134578184\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2151828427\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2361632205\",\"https://openalex.org/W2797337501\",\"https://openalex.org/W2801085490\",\"https://openalex.org/W2804789712\",\"https://openalex.org/W2895315021\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2982708806\",\"https://openalex.org/W3010491167\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3025954068\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3116233806\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W3207135103\",\"https://openalex.org/W4220758381\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4292117563\",\"https://openalex.org/W4294667223\",\"https://openalex.org/W4297497355\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4318913756\",\"https://openalex.org/W4391036082\",\"https://openalex.org/W4391109410\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5037837514\",\"display_name\":\"Matthew Butler\",\"orcid\":\"https://orcid.org/0000-0002-9734-6539\"},{\"id\":\"https://openalex.org/A5107421289\",\"display_name\":\"Sadie Hambleton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5033191459\",\"display_name\":\"Catherine Bird\",\"orcid\":\"https://orcid.org/0000-0002-8656-6931\"},{\"id\":\"https://openalex.org/A5063914720\",\"display_name\":\"Mathieu Seynaeve\",\"orcid\":null},{\"id\":\"https://openalex.org/A5069926672\",\"display_name\":\"Sanjay Cheema\",\"orcid\":\"https://orcid.org/0000-0002-5438-6549\"},{\"id\":\"https://openalex.org/A5071185535\",\"display_name\":\"Kete Campbell-Coker\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047075726\",\"display_name\":\"Carolina Maggio\",\"orcid\":\"https://orcid.org/0000-0001-5550-5557\"},{\"id\":\"https://openalex.org/A5015903430\",\"display_name\":\"Fiona Dunbar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5023034194\",\"display_name\":\"Giorgio Lambru\",\"orcid\":\"https://orcid.org/0000-0002-2780-4776\"},{\"id\":\"https://openalex.org/A5016058429\",\"display_name\":\"Manjit Matharu\",\"orcid\":\"https://orcid.org/0000-0002-4960-2294\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S96331937\",\"source_display_name\":\"Headache The Journal of Head and Face Pain\",\"landing_page_url\":\"https://doi.org/10.1111/head.14837\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Headache / Migraine,Pharmacology,Receptor Pharmacology,Consciousness,Clinical Trial,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4402697828" }, { "id": 3528, "title": "Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus", "normalized_title": "psilocybin assisted psychotherapy in the treatment of patients hospitalized for treatment resistant depression an open label feasibility study with an experiential and systemic focus", "authors": "University Hospital, Ghent", "abstract": "The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression. The proposed study will assess the safety, feasibility, preliminary results and neurological aspects of psilocybin-assisted psychotherapy in the treatment of hospitalized patients with treatment-resistant depression. Screening, after signing the ICF, is done in patients newly admitted to the psychiatric service of Ghent University Hospital or patients referred for hospitalization through the outpatient clinic of the psychiatric service of Ghent University Hospital. Involved patients are hospitalized at the Anxiety, Compulsion and Mood Unit for 8 weeks. They will receive add-on treatment with psilocybin-supported psychotherapy in addition to standard treatment (daily group therapies, mainly non-verbal and activating). This consists of a preparatory phase (4 sessions of 1.5 hours before the first psilocybin session and 1 session of 1.5 hours before the second psilocybin session), the psilocybin sessions themselves (2 sessions, week 3 and week 6) and an integration phase (3 sessions of 1.5 hours after each psilocybin session). All sessions occur with the same 2 therapists throughout the entire course. Therapists are trained to provide experiential and systemic psychotherapeutic interventions. After hospitalization, weekly outpatient follow-up consultations continue until 12 weeks after the last psilocybin session. Subsequently, patients may still agree to a prospective, observational and naturalistic follow-up until 1 year after the last psilocybin session, during which they will be called monthly by a psychiatrist from the research team to inquire about current mental status and any therapies undertaken in the interim. During the study, patients are required to fill out questionnaires at regular intervals. Video-recordings will be made of certain parts of the preparation and integration sessions, for analysis with the client experience scale (EXP). The morning of each psilocybin session, female patients must provide a blood sample for a pregnancy test. The morning of each psilocybin session, all patients must provide a urine sample for toxicology screening. EEGs are also taken from patients the day before each psilocybin session, the morning of the first integration session after each psilocybin session and 12 weeks after the last psilocybin session (at the last outpatient consultation). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the patient to gauge expectations on the one hand and experiences on the other. Throughout the study, the patient's partner will be involved. The partner must complete a number of questionnaires at baseline and throughout the study and will have to be present at 3 EEGs. In addition, the partner will also participate in 1 preparatory session and 2 integration sessions. The partner will also be given the opportunity to spend the night of a psilocybin session with the patient in the hospital (rooming-in). At the start and at the end of the hospitalization phase, a semi-structured interview will be conducted with the partner to gauge expectations on the one hand and experiences on the other.", "journal": "ClinicalTrials.gov", "publication_date": "2024-09-18", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06378229", "keywords": "Treatment Resistant Depression, Psilocybin, PEX010, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06378229\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Brain Imaging,Observational Study,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1018, "title": "Psychedelic research at a crossroads.", "normalized_title": "psychedelic research at a crossroads", "authors": "Armstrong SB, Davis AK.", "abstract": "There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have been combined with psychotherapy and studied in clinical trials in the United States and Europe. Psychedelics are hallucinogenic drugs that alter brain activity and facilitate altered states of consciousness. The proposed benefits of psychedelic-assisted therapy (PAT) include relatively short treatment times and stronger effects compared to other treatments. Although results of trials using MDMA for trauma or psilocybin for depression are promising, PAT is controversial because many questions about its safety and effectiveness are unanswered. This is evident in the recent ruling by the US Food and Drug Administration against the approval of MDMA therapy for post-traumatic stress disorder and the retraction of several papers about MDMA trials owing to unethical conduct by study therapists and data integrity, among other concerns. This field is at a crossroads, and the research community must address several obstacles to transition from exploratory trials to established, evidence-based treatments while avoiding pitfalls that can hinder advancement.", "journal": null, "publication_date": "2024-09-18", "publication_year": 2024, "doi": "10.1126/science.adt1024", "pubmed_id": "39298596", "source_url": "https://doi.org/10.1126/science.adt1024", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Drug Approval, Mental Disorders, Psychotherapy, United States Food and Drug Administration, United States, Clinical Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39298596\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Consciousness,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3122, "title": "Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress", "normalized_title": "exploring u k cancer doctors attitudes toward psilocybin assisted psychotherapy for cancer related distress", "authors": "Mageean S, Daniel A, Tai S.", "abstract": "Abstract Background A diagnosis of cancer is often associated with significant psychological distress. Current approaches to cancer-related distress predominantly fall short of meeting the needs of patients. Recent investigations have shown that administering psilocybin in combination with psychotherapy might be effective at reducing distress in cancer patients. Oncologists are often ‘gatekeepers’, who oversee cancer patient care; if this intervention were to become more routinely available, it is important to understand doctors’ attitudes toward psilocybin-assisted psychotherapy. Method Nine oncologists who worked across two National Health Service Trusts in England were interviewed using a semi-structured interview approach. Thematic analysis was used to analyse the interviews and guide the development of overarching themes and subthemes. Results The analysis revealed five overarching themes relating to oncologists’ experiences of cancer-related distress and attitudes towards psilocybin-assisted psychotherapy: current approaches to distress; attitudes towards psychedelics and psilocybin; quality research; service design and delivery; distress and patients from different backgrounds. Limitations: Future research should aim to explore the experiences and attitudes of other professionals, such as specialist cancer nurses, who are more likely to broach the subject of distress with cancer patients. Conclusions Oncologists are open to novel interventions for supporting patients experiencing cancer-related psychological distress. Future research should aim to address their concerns regarding the safety and potential interactions of psilocybin with anticancer treatments and should stratify trials with different patient groups, owing to the idiosyncratic nature of specific types of cancer.", "journal": "Research Square", "publication_date": "2024-09-17", "publication_year": 2024, "doi": "10.21203/rs.3.rs-4862438/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-4862438/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR911306\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Cancer Patients,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4551, "title": "Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials", "normalized_title": "use of psilocybin in the treatment of mental disorders systematic review of clinal trials", "authors": "Danielle B Rodrigues", "abstract": "Title: Use of psilocybin in the treatment of mental disorders: systematic review of clinical trials. Objective: To evaluate the high-impact evidence on the neurobiology, efficacy, safety, and feasibility of using psilocybin in the treatment of mental disorders such as depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), smoking, and alcoholism", "journal": "Journal of Complementary Medicine & Alternative Healthcare", "publication_date": "2024-09-16", "publication_year": 2024, "doi": "10.19080/jcmah.2024.13.555852", "pubmed_id": null, "source_url": "https://doi.org/10.19080/jcmah.2024.13.555852", "keywords": "Psilocybin, Medicine, Clinical trial, Psychiatry, Psychology, Hallucinogen, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:42", "last_checked": "2026-07-04 07:00:34", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4408545862\",\"openalex_url\":\"https://openalex.org/W4408545862\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Danielle B Rodrigues\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210238017\",\"source_display_name\":\"Journal of Complementary Medicine & Alternative Healthcare\",\"landing_page_url\":\"https://doi.org/10.19080/jcmah.2024.13.555852\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4408545862" }, { "id": 1020, "title": "Psychedelics as a potential treatment for tobacco use disorder: a systematic review.", "normalized_title": "psychedelics as a potential treatment for tobacco use disorder a systematic review", "authors": "Spoelstra SK, Schoevers RA, Venema SD, Knegtering H.", "abstract": "IntroductionDespite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation therapies is limited, leading to a growing interest in alternative treatment approaches such as psychedelics.AimThe aim of this review is to evaluate the scientific evidence regarding the role of psychedelics in smoking cessation.MethodsTo identify relevant literature on psychedelics and smoking cessation, a search was conducted in four academic literature databases PubMed, MEDLINE, PsycINFO, and Embase. Databases were searched from their inception up to March 24, 2024.ResultsOut of the 1073 articles identified in databases, 8 publications (both clinical and non-clinical studies) met the inclusion criteria, of which a total of 4 publications originated from a single study. The majority of the studies focused on psilocybin (n = 7), for which supportive evidence was suggested for the treatment of tobacco use disorder. Additionally, research was conducted with other psychedelics for smoking cessation, such as ayahuasca, mescaline, peyote, lysergic acid diethylamide (LSD), lysergic acid amide (LSA) and (dimethyltryptamine (DMT), but the evidence base for these psychedelics is too small to draw definitive conclusions.ConclusionsThere is, although limited, evidence that psychedelics, in particular psilocybin, may offer a potential avenue for combating tobacco use disorder, though more research is needed to understand their effectiveness and safety fully.", "journal": null, "publication_date": "2024-09-16", "publication_year": 2024, "doi": "10.1007/s44192-024-00095-0", "pubmed_id": "39289250", "source_url": "https://doi.org/10.1007/s44192-024-00095-0", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39289250\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 949, "title": "Exploring the regulatory framework of psychedelics in the US & Europe.", "normalized_title": "exploring the regulatory framework of psychedelics in the us europe", "authors": "Behera HK, Joga R, Yerram S, Karnati P, Mergu T, Gandhi K, M S, Nathiya D, Singh RP, Srivastava S, Kumar S.", "abstract": "Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory approvals of key psychedelic substances like psilocybin, 3,4-Methyl enedioxy methamphetamine (MDMA), mescaline, ketamine, and Lysergic acid diethylamide (LSD). It also provides an overview of legal aspects, and regulations surrounding psychedelics in the US & Europe, emphasizing their Schedule I classification due to potential misuse. The United States Food & Drug Administration (USFDA) closely monitors psychedelics, employing expedited pathways for evaluation. Further, recent guidance from the FDA on considerations for clinical Investigations supports the safe development of psychedelics for human welfare. European Medicines Agency (EMA) regulators focus on atypical psychedelics, addressing challenges in safety and efficacy. Marketed products, such as Spravato nasal spray, face limited distribution due to safety concerns. The call for careful regulation and legislation is essential for harnessing psychedelics' potential for therapeutic benefits and human welfare.", "journal": null, "publication_date": "2024-09-16", "publication_year": 2024, "doi": "10.1016/j.ajp.2024.104242", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.ajp.2024.104242", "keywords": "Humans, Hallucinogens, Drug Approval, United States Food and Drug Administration, United States, Europe", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39305768\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W39305768" }, { "id": 1025, "title": "Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.", "normalized_title": "psychedelic assisted therapy for treating anxiety depression and existential distress in people with life threatening diseases", "authors": "Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C.", "abstract": "BackgroundPsychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians, psychologists, and others. It has been hypothesised that psychedelic-assisted therapy may reduce symptoms of anxiety, depression, and existential distress in patients facing life-threatening diseases (e.g. cancer). However, these substances are illegal in most countries and have been associated with potential risks.ObjectivesTo assess the benefits and harms of psychedelic-assisted therapy compared to placebo or active comparators (e.g. antidepressants) for treatment of anxiety, depression, and existential distress in people with life-threatening diseases.Search methodsWe searched CENTRAL, MEDLINE, Embase, and two trial registers on 30 March 2024. In addition, we undertook reference checking, citation searching, and contact with study authors to identify additional studies. We used no language or date restrictions.Selection criteriaWe included randomised controlled trials (RCTs), with no restrictions regarding comorbidity, sex, or ethnicity. Interventions comprised a substance-induced psychedelic experience preceded by preparatory therapeutic sessions and followed by integrative therapeutic sessions.Data collection and analysisWe used the standard methodological procedures expected by Cochrane.Main resultsWe included six studies in the review, which evaluated two different interventions: psychedelic-assisted therapy with classical psychedelics (psilocybin ('magic mushrooms') and lysergic acid diethylamide (LSD)), and psychedelic-assisted therapy with 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). The studies randomised 149 participants with life-threatening diseases and analysed data for 140 of them. The age range of participants was 36 to 64 years. The studies lasted between 6 and 12 months, and were conducted in outpatient settings in the USA and in Switzerland. Drug companies were not involved in study funding, but funding was provided by organisations that promote psychedelic-assisted therapy. Primary outcomes (at 1 to 12 weeks) Anxiety Psychedelic-assisted therapy using classical psychedelics (psilocybin, LSD) may result in a reduction in anxiety when compared to active placebo (or low-dose psychedelic): State Trait Anxiety Inventory (STAI-Trait, scale 20 to 80) mean difference (MD) -8.41, 95% CI -12.92 to -3.89; STAI-State (scale 20 to 80) MD -9.04, 95% CI -13.87 to -4.21; 5 studies, 122 participants; low-certainty evidence. The effect of psychedelic-assisted therapy using MDMA on anxiety, compared to placebo, is very uncertain: STAI-T MD -14.70, 95% CI -29.45 to 0.05; STAI-S MD -16.10, 95% CI -33.03 to 0.83; 1 study, 18 participants; very low certainty evidence. Depression Psychedelic-assisted therapy using classical psychedelics (psilocybin, LSD) may result in a reduction in depression when compared to active placebo (or low-dose psychedelic): Beck Depression Inventory (BDI, scale 0 to 63) MD -4.92, 95% CI -8.97 to -0.87; 4 studies, 112 participants; standardised mean difference (SMD) -0.43, 95% CI -0.79 to -0.06; 5 studies, 122 participants; low-certainty evidence. The effect of psychedelic-assisted therapy using MDMA on depression, compared to placebo, is very uncertain: BDI-II (scale: 0 to 63) MD -6.30, 95% CI -16.93 to 4.33; 1 study, 18 participants; very low certainty evidence. Existential distress Psychedelic-assisted therapy using classical psychedelics (psilocybin, LSD) compared to active placebo (or low-dose psychedelic) may result in a reduction in demoralisation, one of the most common measures of existential distress, but the evidence is very uncertain (Demoralisation Scale, 1 study, 28 participants): post treatment scores, placebo group 39.6 (SEM3.4), psilocybin group 18.8 (3.6), P ≤ 0.01). Evidence from other measures of existential distress was mixed. Existential distress was not measured in people receiving psychedelic-assisted therapy with MDMA. Secondary outcomes (at 1 to 12 weeks) Quality of life When classical psychedelics were used, one study had inconclusive results and two reported improved quality of life, but the evidence is very uncertain. MDMA did not improve quality of life measures, but the evidence is also very uncertain. Spirituality Participants receiving psychedelic-assisted therapy with classical psychedelics rated their experience as being spiritually significant (2 studies), but the evidence is very uncertain. Spirituality was not assessed in participants receiving MDMA. Adverse events No treatment-related serious adverse events or adverse events grade 3/4 were reported. Common minor to moderate adverse events for classical psychedelics were elevated blood pressure, nausea, anxiety, emotional distress, and psychotic-like symptoms (e.g. pseudo-hallucination where the participant is aware they are hallucinating); for MDMA, common minor to moderate adverse events were anxiety, dry mouth, jaw clenching, and headaches. Symptoms subsided when drug effects wore off or up to one week later. Certainty of the evidence Although all six studies had intended to blind participants, personnel, and assessors, blinding could not be achieved as this is very difficult in studies investigating psychedelics. Using GRADE criteria, we judged the certainty of evidence to be low to very low, mainly due to high risk of bias and imprecision (small sample size).Authors' conclusionsImplications for practice Psychedelic-assisted therapy with classical psychedelics (psilocybin, LSD) may be effective for treating anxiety, depression, and possibly existential distress, in people facing a life-threatening disease. Psychedelic-assisted therapy seemed to be well tolerated, with no treatment-emergent serious adverse events reported in the studies included in this review. However, the certainty of evidence is low to very low, which means that we cannot be sure about these results, and they might be changed by future research. At the time of this review (2024), psychedelic drugs are illegal in many countries. Implications for research The risk of bias due to 'unblinding' (participants being aware of which intervention they are receiving) could be reduced by measuring expectation bias, checking blinding has been maintained before cross-over, and using active placebos. More studies with larger sample sizes are needed to reduce imprecision. As the US Drug Enforcement Administration (DEA) currently classifies psychedelics as Schedule I substances (i.e. having no accepted medical use and a high potential for abuse), research involving these drugs is restricted, but is steadily increasing.", "journal": null, "publication_date": "2024-09-11", "publication_year": 2024, "doi": "10.1002/14651858.cd015383.pub2", "pubmed_id": "39260823", "source_url": "https://doi.org/10.1002/14651858.cd015383.pub2", "keywords": "Humans, Neoplasms, Lysergic Acid Diethylamide, Hallucinogens, Antidepressive Agents, Placebos, Combined Modality Therapy, Depression, Anxiety, Existentialism, Psychotherapy, Randomized Controlled Trials as Topic, Psilocybin, Bias, Psychological Distress", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39260823\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Headache / Migraine,Emotional Processing,Spirituality,Randomized Controlled Trial,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 867, "title": "The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.", "normalized_title": "the immunomodulatory effects of classical psychedelics a systematic review of preclinical studies", "authors": "Low ZXB, Ng WS, Lim ESY, Goh BH, Kumari Y.", "abstract": "Emerging evidence suggests that classical psychedelics possess immunomodulatory and anti-inflammatory properties; however, these effects are yet to be well-established. This systematic review aims to provide a timely and comprehensive overview of the immunomodulatory effects of classical psychedelics in preclinical studies. A systematic search was conducted on six databases, including CINAHL, EMBASE, MEDLINE, PsychINFO, Scopus, and Web of Science. Eligible studies targeting classical psychedelics for evaluation of their effects on inflammatory markers and immunomodulation have been included for analysis. Data was extracted from 40 out of 2822 eligible articles, and their risk of bias was assessed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) tool and Quality Assessment Tool for In Vitro Studies (QUIN). Studies examined 2,5-dimethoxy-4-iodoamphetamine (DOI; n = 18); psilocybin (4-PO-DMT; n = 9); N,N-dimethyltryptamine (DMT; n = 8); lysergic acid diethylamide (LSD; n = 6); 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; n = 3); psilocin (4-HO-DMT; n = 3); and mescaline (n = 2). In 36 studies where inflammatory cytokine levels were measured following psychedelic administration, a decrease in at least one inflammatory cytokine was observed in 29 studies. Immune cell activity was assessed in 10 studies and findings were mixed, with an equal number of studies (n = 5 out of 10) reporting either an increase or decrease in immune cell activity. Classical psychedelics were found to alleviate pre-existing inflammation but promote inflammation when administered under normal physiological conditions. This information is anticipated to inform future clinical trials, exploring classical psychedelics' potential to alleviate inflammation in various pathologies.", "journal": null, "publication_date": "2024-09-06", "publication_year": 2024, "doi": "10.1016/j.pnpbp.2024.111139", "pubmed_id": "39251080", "source_url": "https://doi.org/10.1016/j.pnpbp.2024.111139", "keywords": "Animals, Humans, Hallucinogens, Immunologic Factors, Drug Evaluation, Preclinical, Immunomodulation, Immunomodulating Agents", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39251080\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Biomarkers,Clinical Trial,Systematic Review,Review Article,Animal Study,In Vitro Study,Safety,Inflammation,Immune Function", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 977, "title": "Psychoactive substances for the treatment of neuropsychiatric disorders.", "normalized_title": "psychoactive substances for the treatment of neuropsychiatric disorders", "authors": "Zhen Z, Sun X, Yuan S, Zhang J.", "abstract": "In the contemporary landscape of psychiatric medicine, critical advancements have been noted in the utilization of psychoactive substances such as hallucinogens, 3,4-methylenedioxymethamphetamine (MDMA), and ketamine for the treatment of severe mental health disorders. This review provides a detailed evaluation of these substances, focusing on their mechanisms of action and the profound clinical outcomes observed in controlled environments. Hallucinogens like lysergic acid diethylamide and psilocybin primarily target the 5-HT2A receptor agonist-2 (5-HT2AR), inducing substantial perceptual and cognitive shifts that facilitate deep psychological introspection and significant therapeutic advances, particularly in patients suffering from depression and anxiety disorders. MDMA, influencing multiple neurotransmitter systems including 5-Hydroxytryptamine (5-HT), dopamine, and norepinephrine, has been demonstrated to effectively alleviate symptoms of post-traumatic stress disorder, enhancing patients' emotional engagement and resilience during psychotherapy. Meanwhile, ketamine, a glutamate receptor antagonist, rapidly alleviates depressive symptoms, offering a lifeline for individuals with treatment-resistant depression through its fast-acting antidepressant properties. The integration of these substances into psychiatric practice has shown promising results, fundamentally changing the therapeutic landscape for patients unresponsive to traditional treatment modalities. However, the potent effects of these agents also necessitate a cautious approach in clinical application, ensuring careful dosage control, monitoring, and risk management to prevent potential abuse and mitigate adverse effects.", "journal": null, "publication_date": "2024-09-02", "publication_year": 2024, "doi": "10.1016/j.ajp.2024.104193", "pubmed_id": "39243659", "source_url": "https://doi.org/10.1016/j.ajp.2024.104193", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Ketamine, Hallucinogens, Psychotropic Drugs, Mental Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39243659\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Mechanism of Action,Receptor Pharmacology,Resilience,Emotional Processing,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1027, "title": "Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.", "normalized_title": "traditional medicine culture and psychedelic science new pathways for recovery from substance use disorders", "authors": "Loizaga-Velder A, Loizaga Pazzi A.", "abstract": "ObjectiveThis article provides an intercultural transdisciplinary perspective on the Indigenous roots of the resurging field of psychedelic science in the management of substance use disorders (SUDs). Ritual uses of entheogens (i.e., psychedelics of natural origin) are elaborate technologies for navigating, containing, and therapeutically directing non-ordinary states of consciousness induced by these compounds.MethodA narrative review of the literature on the therapeutic potential of ayahuasca, peyote, psilocybin-containing mushrooms, Incilius alvarius-derived 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), and iboga for the treatment of SUDs was conducted. This article also describes the application of some of these entheogens within a pilot intercultural clinical program implemented by the Yaqui tribe in Sonora, Mexico, for the treatment of SUDs and other mental health challenges.ResultsObservational research and preliminary clinical studies indicate the therapeutic potential and relative safety of these compounds in appropriate contexts, including the use of careful screening practices and complementary psychotherapeutic interventions.ConclusionsPreliminary research points to the potential therapeutic value of integrating entheogenic plant and fungi medicine with culturally attuned therapeutic strategies. Respectful intercultural dialogue across worldviews and scientific paradigms allows for the further development of new perspectives at the intersection of entheogens, addiction treatment, mental health, and traditional medicine. More interdisciplinary research is necessary in this field.", "journal": null, "publication_date": "2024-08-31", "publication_year": 2024, "doi": "10.15288/jsad.23-00011", "pubmed_id": "39400118", "source_url": "https://doi.org/10.15288/jsad.23-00011", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Medicine, Traditional, Culture, Mexico, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39400118\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Consciousness,Review Article,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1026, "title": "Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.", "normalized_title": "understanding psychedelic assisted psychotherapy providers perspective and insights a qualitative analysis", "authors": "Smith CL, Sackett N, Stark BC, Dinh V, Romesburg EW, Roll J", "abstract": "There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, research has rapidly expanded in the past decade. Multiple states and cities have drafted their own policies regarding the use of psychedelics. Assuming interest in psychedelics continues to expand; every opportunity should be explored to better understand how psychedelics may be helping or harming people. This study examined underground psychedelic-assisted psychotherapy providers' protocols and perspectives, to better inform policy and public health, as psychedelics increasingly are used in the United States. Transcripts of interviews were examined through qualitative content analysis. The following four themes were identified: (1) personal experiences and self-healing motivated sharing and promotion of the positive effects of psychedelics as an expression of altruism, (2) guides articulated consistent, yet flexible processes, (3) guides believed that the client benefit was actualized through their own intrinsic ability to heal themselves, and (4) guides expressed an overwhelming sense of dissonance regarding psychedelic legalization, not only desiring increased access and decreased risk but also expressing concern about potential negative impacts on provider flexibility, and depersonalization that could come with standardizing this field of practice. In order for current research and policy to be best informed, information must be gathered from both clinical trials and observational studies of current practice. This study identified themes within the latter to provide perspectives, practices, and insights of current underground practice, so it can be used to inform research and policy moving forward.", "journal": "Psychedelic medicine (New Rochelle, N.Y.)", "publication_date": "2024-08-31", "publication_year": 2024, "doi": "10.1089/psymed.2023.0074", "pubmed_id": "40051684", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40051684/", "keywords": "LSD, MDMA, empathogen, psilocybin, psychedelic facilitators", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"40051684\"}", "topic_tags": "Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1030, "title": "[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].", "normalized_title": "psychedelic and dissociative agents in psychiatry challenges in the treatment", "authors": "Jungwirth J, Bavato F, Quednow BB.", "abstract": "With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of new psychotropic drugs, the psychiatric research into the clinical application of hallucinogens in psychiatry has literally blossomed in the last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic acid diethylamide (LSD) and psilocybin, and dissociative agents, such as ketamine and esketamine, have raised great hopes among researchers, clinicians and patients in recent years, so that there was already talk of a new era in psychiatry. As one of the first of these substances, in December 2019 intranasal esketamine was approved in the USA and the EU for the treatment of treatment-resistant depression and Switzerland followed in 2020. Recently, psilocybin was approved in Australia, Canada and Switzerland for compassionate use in exceptional cases for the treatment of depression, while large approval studies with various psychedelic agents are currently ongoing worldwide. The medical application of psychedelic agents and ketamine/esketamine is considered to be safe; however, as with all new forms of treatment it is of crucial importance that, in addition to the hopes, the specific challenges of these new treatment approaches must also be carefully considered and assessed. Excessive expectations and an insufficient risk-benefit estimation are detrimental to the patients and the reputation of the treating physician. Although a possible paradigm shift in the care of mental health is already being discussed, this review article consciously concentrates on the possible risks of treatment and the methodological weaknesses of the studies carried out so far.", "journal": null, "publication_date": "2024-08-27", "publication_year": 2024, "doi": "10.1007/s00115-024-01727-0", "pubmed_id": "39196383", "source_url": "https://doi.org/10.1007/s00115-024-01727-0", "keywords": "Humans, Ketamine, Lysergic Acid Diethylamide, Hallucinogens, Treatment Outcome, Mental Disorders, Psychiatry, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39196383\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Review Article,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1003, "title": "The role of psilocybin in depressive disorders.", "normalized_title": "the role of psilocybin in depressive disorders", "authors": "Najib J.", "abstract": "Depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a promising potential in the treatment of depressive disorders. A review of psilocybin use in patients with depressive disorders is presented.A search was conducted investigating the use of psilocybin in patients with depressive disorders and treatment resistant depression via PubMed/MEDLINE, EMBASE, and Google Scholar in October 2023; all publication types were permitted and limited for English-language. Keyword search terms included: \"psilocybin\" or \"psychedelics\" and \"depression\", or \"major depressive disorder\", or \"treatment-resistant depression\". Controlled and uncontrolled clinical trials utilizing psilocybin with psychological support for major depressive disorder and treatment-resistant depression, as well as in patients with depression and cancer related anxiety have demonstrated immediate and sustained antidepressant and anxiolytic effects. Psilocybin has a favorable safety profile and was well-tolerated in clinical trials. Psilocybin's abuse potential is low and clinical research suggests the potential of psilocybin to produce rapid and lasting antidepressant effects up to 12 months post-treatment. Psilocybin may offer a valuable contribution as an option to the currently available pharmacological and psychotherapeutic agents for patients with major depressive disorders, treatment-resistant depression as well as for patients with depression and comorbid terminal cancer. Future studies are needed to demonstrate these findings and any synergistic interaction between psilocybin and the psychological support offered to patients during sessions.", "journal": null, "publication_date": "2024-08-27", "publication_year": 2024, "doi": "10.1080/03007995.2024.2396536", "pubmed_id": "39177339", "source_url": "https://doi.org/10.1080/03007995.2024.2396536", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Depressive Disorder, Psychotherapy, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39177339\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3141, "title": "The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting", "normalized_title": "the phenomenology of psilocybin s experience mediates subsequent persistent psychological effects independently of sex previous experience or setting", "authors": "Klučková T, Nikolič M, Tylš F, Viktorin V, Vejmola Č, Viktorinová M, Bravermanová A, Androvičová R, Andrashko V, Korčák J, Zach P, Hájková K, Kuchař M, Balíková M, Brunovský M, Horáček J, Páleníček T.", "abstract": "Background Recent studies have intensively explored the potential antidepressant effects of psilocybin. However, important variables such as previous experience, repeated administration, setting and sex remain underexplored. This study describes the acute psilocybin experience and long-term effects in a small sample of healthy individuals. Methods In a double-blind, placebo-controlled, cross-over study, 40 healthy participants (20 females, mean age 38, sd 8) received two doses of psilocybin 0.26 mg/kg per os at least 56 days apart (mean 354 days) in two study arms (EEG and fMRI). Near half of participants had experience with psychedelics. The Altered State of Consciousness Scale (ASC) and a visual analogue scale (VAS) on emotional valence of the phenomenology assessed acute phenomenology. The Persisting Effects Questionnaire (PEQ) assessed long- term effects. Venous blood samples were taken to measure serum psilocin levels. Results All results were independent of previous experience, sex, EEG or fMRI arm/setting. Acute psychedelic effects were of moderate intensity on ASC. The VAS showed mostly pleasant and fluctuating, and only one unpleasant only experience. All experiences resolved in a positive or neutral state at the end of the session. Psilocybin induced sustained positive effects on all domains of the PEQ, with negligible negative effects. Oceanic Boundlessness and Visual Restructuralization were associated with positive effects on PEQ. Contrary to expectations, Dread of Ego Dissolution, typically associated with fearful experiences, was not associated with PEQ negative outcomes. The type of experience (pleasant or mixed) did not correlate with the intensity or direction of the lasting effect; however, peak experiences culminating in a positive mood were associated with positive long- term effects. Conclusion In our sample repeated administration of psilocybin to healthy volunteers, induces positive, lasting effects. This underscores the psychological safety of psilocybin in a laboratory setting and supports its repeated use in clinical trials. In particular, challenging or anxiety-provoking experiences in controlled environments did not lead to adverse long-term outcomes. Clinical trial registration: EudraCT 2012-004579-37, https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004579-37/CZ.", "journal": "medRxiv", "publication_date": "2024-08-25", "publication_year": 2024, "doi": "10.1101/2024.08.26.24311611", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.08.26.24311611", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR902135\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Brain Imaging,Consciousness,Emotional Processing,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3075, "title": "­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study", "normalized_title": "single dose psilocybin therapy for alcohol use disorder pharmacokinetics feasibility safety and efficacy in an open label study", "authors": "Jensen ME, Stenbæk DS, Messell CD, Poulsen ED, Varga TV, Fisher PM, Nielsen MKK, Johansen SS, Volkow ND, Knudsen GM, Fink-Jensen A.", "abstract": "Abstract Background Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, shows promise as a novel treatment for alcohol use disorder (AUD). While current studies involve two dosing sessions, the effects a single dose have not been investigated. Aims To investigate the pharmacokinetics, feasibility, safety, and efficacy of single-dose psilocybin therapy in AUD. Methods This open-label, single-group study investigated single-dose psilocybin therapy in ten treatment-seeking adults (eight men and two women; median age 44 years) with severe AUD. The treatment involved two preparation sessions, a high-dose psilocybin session (25 mg), and two integration sessions. Pharmacokinetics were determined by noncompartmental analysis, and changes in alcohol consumption, craving and self-efficacy, were assessed with a linear mixed model. Results Notable between-participant pharmacokinetic variations were observed, with peak plasma psilocin concentrations ranging from 14-59 µg/L. Alcohol consumption significantly decreased over the 12 weeks following psilocybin administration. Heavy drinking days were reduced by 37.5 percentage points (95% CI, -61.1, -13.9, p = 0.005), and drinks per day decreased by 3.4 units (95% CI: -6.5, -0.3), p = 0.035). This was corroborated by reports of rapid and sustained reductions in craving and increases in self-efficacy. Conclusions Despite pharmacokinetic variations, a single 25 mg psilocybin dose was safe and effective in reducing alcohol consumption in AUD patients. Larger randomised, placebo-controlled, single-dose AUD trials are warranted. Funding This work was supported by The Novo Nordisk Foundation (NNF19OC0058412), The Lundbeck Foundation (R-355-2020-945), The Health Foundation(21-B-0358) and The Ivan Nielsen Foundation. Clinical trial registration: NCT05347849", "journal": "Research Square", "publication_date": "2024-08-22", "publication_year": 2024, "doi": "10.21203/rs.3.rs-4947184/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-4947184/v1", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR899973\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Pharmacology,Receptor Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3428, "title": "A24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)", "normalized_title": "a24 week multicentre randomised double blind placebo controlled parallel group phase 2 clinical trial to evaluate efficacy and safety of psilocybin assisted psychotherapy in adults with alcohol use disorder aud", "authors": "Clairvoyant Therapeutics", "abstract": "The goal of this clinical trial is to investigate treatment with psilocybin and psychotherapy for the treatment of people with Alcohol Use Disorder (AUD). The main question\\[s\\] it aims to answer are: * Does treatment with psilocybin and therapy help reduce alcohol consumption more than placebo and therapy? * Is treatment with psilocybin and therapy safe for participants? Participants will * Attend 13 study visits * Take part in therapy sessions including 2 treatment sessions with either psilocybin or placebo * Record their daily alcohol consumption on study specific device Researchers will compare psilocybin and placebo groups to see if alcohol consumption is decreased.", "journal": "ClinicalTrials.gov", "publication_date": "2024-08-14", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05646303", "keywords": "Alcohol Use Disorder, Psilocybin, Placebo, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05646303\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3609, "title": "An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)", "normalized_title": "an open label study of the safety and efficacy of psilocybin in participants with treatment resistant depression p trd", "authors": "Sheppard Pratt Health System", "abstract": "The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.", "journal": "ClinicalTrials.gov", "publication_date": "2024-08-08", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04433858", "keywords": "Treatment Resistant Depression, Psilocybin, COMP360, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04433858\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3467, "title": "PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial", "normalized_title": "psilocybin for psychological and existential distress in palliative care psyched pal a multi site open label single arm phase i ii proof of concept dose finding and feasibility clinical trial", "authors": "Ottawa Hospital Research Institute", "abstract": "The goal of this multi-centre phase I/II open-label, single-arm study is to determine the safety, feasibility, therapeutic dose, and preliminary efficacy of psilocybin microdosing to treat psychological distress among patients with advanced illness. Forty patients will receive psilocybin drug product (1-3mg per day, Mon-Fri) for 4 weeks to be administered via oral capsules by the participant. Feasibility (recruitment rate, rate of intervention and follow-up completion), safety (rate of adverse events), dosing, and preliminary efficacy (depression, anxiety, overall well-being, and global impression of change) will be measured. Patients with advanced illness report feeling a sense of hopelessness, loss of autonomy and relationships, and a lack of purpose in life. These feelings of psychological suffering have been described as \"existential distress\" and are associated with poor outcomes, including decreased medication adherence and quality of life, increased desire for hastened death and rates of suicide, and has been identified as a primary reason why individuals pursue medical assistance in dying (MAiD). Current treatments for psychological and existential suffering have low efficacy and are challenging to use in a palliative context. Pharmacological approaches for treating psychological suffering may reduce symptoms of depression and anxiety, but evidence to support their efficacy in palliative care (PC) is underwhelming. Antidepressant and anxiolytic medications also take time to work and can cause serious side effects such as falls and confusion, which can be substantial deterrents for patients. Similarly, results from randomized controlled trials (RCTs) and meta-analyses have demonstrated psychotherapeutic interventions show limited benefit in a PC population. Further, psychotherapy can be time consuming and slow to work, which is not ideal for patients with limited life expectancy. Given the burden of psychological and existential distress among patients followed by PC providers, there is a need to develop scalable, brief, and rapidly effective therapeutic approaches to reduce this distress. Psychedelic medications offer an innovative, safe, complementary approach to address psychological and existential suffering in patients receiving PC. Studies from the 1950's showed serotonergic hallucinogens (\"psychedelics\") improved depression and anxiety symptoms in cancer patients. However, legislative changes restricted the use of these medications in clinical care and research. Interest in psychedelic medications has been rekindled by two recently published RCTs that studied the use of psilocybin (a mushroom-derived 5HT2A agonist) during a single psychotherapeutic session in cancer patients with anxiety and/or depression. These trials demonstrated rapid, clinically meaningful, and long-lasting reductions in depressed mood and/or anxiety symptoms and improvements in quality of life and death acceptance. There is also evidence suggesting psilocybin microdosing - taking sub-hallucinogenic doses continuously over longer time periods, rather than a one-time hallucinogenic dose - can improve mood and anxiety. The effects of microdosing, however, have not been rigorously evaluated, particularly in patients with life limiting illness. Results from recent trials are encouraging but knowledge gaps remain. First, studies to date primarily enrolled patients with localized disease who experience different distress than that of patients with advanced disease who are near the end of life. Second, it is unclear if Canadians would find psilocybin an attractive option in the context of MAiD legalization, which provides an alternative option for patients with severe psychological suffering. Third, there is no empirical research on the therapeutic effects of psilocybin microdosing, as most studies have followed macrodosing protocols. While preliminary efficacy of macrodosing has been demonstrated, there are important barriers to administering this therapy in a PC context. Previous trials had slow recruitment rates, suggesting there may be barriers related to the acceptability of psilocybin macrodosing from the perspectives of patients and families. Macrodosing requires the patient to dedicate an entire day to participating in a guided hallucinogenic experience and remain in an acute care setting where they can be closely monitored. It also requires patients to engage in preparatory sessions with monitors and a post-therapy session. In a PC context, this time commitment may not be acceptable or feasible for patients who are nearing the end of life. Additionally, macrodosing requires at least two trained moderators to guide the patient through their psychedelic experience and facilitate the pre- and post-dosing sessions. In most PC settings, it is not feasible to have clinicians dedicate two days to a single patient, thus limiting the scalability of this intervention. Psilocybin microdosing has the potential to overcome barriers to the feasibility and acceptability of macrodosing. By removing the requirement for trained moderators, minimizing the time commitment required of patients, eliminating the hallucinogenic effects of the therapy, and allowing patients to receive treatment either as an inpatient or in the community, microdosing may be a more acceptable option to patients and families and allow psychedelic therapy to be scalable across various PC settings. Psilocybin microdosing is a novel, complementary therapy that, while still unproven for patients near the end of life, has the potential to fundamentally change the way psychological and existential distress is responded to in PC, improving the lives of the 30% of patients who experience this suffering at the end of life. Objective To determine if psilocybin microdosing is a safe and feasible treatment for psychological distress among patients nearing the end of life followed by palliative care providers. All participants will receive a 4-week psilocybin microdosing intervention. The secondary objective is to examine the preliminary efficacy of psilocybin microdosing. Sample Size As this is a feasibility study, no formal sample size calculation was performed to determine the number of patients required to reach a level of precision on any study endpoint. Rather, the goal of this study is to provide estimates, along with their margins of error, of the recruitment rate and efficacy outcomes which will inform a subsequent two-arm randomized controlled trial. Participating sites see approximately 5,300 patients per year. It is anticipated that 30% will have psychological distress. Assuming a minimum of 1 in 6 patients are eligible and 15% of eligible patients will enroll, the goal is to enroll a sample of 20 participants in up to 1-year period. Statistical Analysis Analyses will adopt an intent-to-treat approach. Because the goal of this trial is to demonstrate feasibility and preliminary measures of efficacy, the main analyses will include calculation of feasibility outcomes using descriptive statistics and 95% confidence intervals (CIs), as well as effect sizes with 95% CIs for primary and secondary efficacy measures, comparing patients' 4-week follow-up assessments to baseline assessments. Participants will also be stratified based on demographic and clinical characteristics to assess trends in outcomes. Notably, there is some evidence that selective serotonin reuptake inhibitors (SSRIs) in particular may attenuate the effects of psilocybin. As such, sub-analyses will evaluate outcomes in participants taking an SSRI medication versus those who are not. A sub-group analysis by setting of care (inpatient vs outpatient/community) will also be conducted. Analyses of safety data will include the mean and standard deviation of the peak effect observed (i.e. highest observed blood pressure, heart rate) and proportion of participants experiencing adverse mood and behaviour events. The incidence of delirium and serotonin syndrome will also be recorded. Details of Eligibility, Intervention Protocol, and Outcome Measures are provided elsewhere.", "journal": "ClinicalTrials.gov", "publication_date": "2024-08-08", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04754061", "keywords": "Depression, Anxiety, Distress, Emotional, Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04754061\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE1\",\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Receptor Pharmacology,Aging,Microdosing,Wellbeing,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Cancer Patients,Healthcare Workers,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3438, "title": "Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms", "normalized_title": "psilocybin assisted therapy for severe alcohol use disorder feasibility clinical efficacy neuro cognitive mechanisms", "authors": "Brugmann University Hospital", "abstract": "Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial A substantial proportion of patients with alcohol use disorder does not respond to available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study aims to determine the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy as a complementary intervention during inpatient rehabilitation for severe alcohol use disorder, and to characterize associated changes in the two key neurocognitive systems identified by dual-process models of addiction. In this double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial, 62 participants aged 21-64 years will be enrolled to undergo psilocybin-assisted therapy within the context of a 4-week inpatient rehabilitation for severe alcohol use disorder. The experimental group will receive a high dose of psilocybin (30 mg), whereas the control group will receive an active placebo dose of psilocybin, both within the context of a brief standardized psychotherapeutic intervention. The primary clinical outcome is the between-group difference in terms of the change in percentage of heavy drinking days from baseline to four weeks post-hospital discharge, whilst safety and feasibility metrics will also be reported as primary outcomes. Key secondary assessments include between-group differences in terms of changes in 1) drinking behavior parameters up to six months post-hospital discharge, 2) phosphatidyl-ethanol blood concentration, an objective biomarker of alcohol consumption, 3) symptoms of depression, anxiety, trauma, and global functioning, 4) neuroplasticity and key neurocognitive mechanisms associated with addiction, 5) psychological processes and alcohol-related parameters.", "journal": "ClinicalTrials.gov", "publication_date": "2024-08-06", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06160232", "keywords": "Severe Alcohol Use Disorder, Psilocybin (high dose), Active placebo (low dose of psilocybin), RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06160232\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Neuroplasticity,Mechanism of Action,Biomarkers,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1055, "title": "Psilocybin-assisted therapy and HIV-related shame", "normalized_title": "psilocybin assisted therapy and hiv related shame", "authors": "Nicky J. Mehtani, Mallory O. Johnson, Peter S. Hendricks, Jennifer Mitchell, B. Anderson", "abstract": "As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in part due to limited success of conventional psychotherapies in addressing HIV-related shame. In a pilot clinical trial (N = 12), receipt of psilocybin-assisted group therapy was associated with a large pre-post decrease in HIV-related shame as measured by the HIV and Abuse Related Shame Inventory, with a median (IQR) change of - 5.5 (- 6.5, - 3.5) points from baseline to 3-months follow-up (Z = - 2.6, p = 0.009, r = - 0.75). A paradoxical exacerbation of sexual abuse-related shame experienced by two participants following receipt of psilocybin raises critical questions regarding the use of psilocybin therapy among patients with trauma. These preliminary findings carry potential significance for the future of HIV care.", "journal": "Scientific Reports", "publication_date": "2024-08-01", "publication_year": 2024, "doi": "10.1038/s41598-024-68908-4", "pubmed_id": "39095420", "source_url": "https://doi.org/10.1038/s41598-024-68908-4", "keywords": "Shame, Psilocybin, Psychiatry, Medicine, Clinical psychology, Psychology, Mental health, Psychotherapist, Social psychology, Hallucinogen, Psychedelics and Drug Studies, HIV, Drug Use, Sexual Risk, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4401257064\",\"openalex_url\":\"https://openalex.org/W4401257064\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W2058515103\",\"https://openalex.org/W2080874345\",\"https://openalex.org/W2090714490\",\"https://openalex.org/W2557936610\",\"https://openalex.org/W2745646537\",\"https://openalex.org/W2955777027\",\"https://openalex.org/W2996460582\",\"https://openalex.org/W3027491449\",\"https://openalex.org/W3042383105\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W4206102250\",\"https://openalex.org/W4206158010\",\"https://openalex.org/W4210935731\",\"https://openalex.org/W4226458408\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4383186683\",\"https://openalex.org/W4383823637\",\"https://openalex.org/W4385063925\",\"https://openalex.org/W4386740988\",\"https://openalex.org/W4390186718\"],\"authorships\":[{\"id\":\"https://openalex.org/A5029973096\",\"display_name\":\"Nicky J. Mehtani\",\"orcid\":\"https://orcid.org/0000-0003-4277-6889\"},{\"id\":\"https://openalex.org/A5077848733\",\"display_name\":\"Mallory O. Johnson\",\"orcid\":\"https://orcid.org/0000-0003-0480-2804\"},{\"id\":\"https://openalex.org/A5004506349\",\"display_name\":\"Peter S. Hendricks\",\"orcid\":null},{\"id\":\"https://openalex.org/A5013684475\",\"display_name\":\"Jennifer Mitchell\",\"orcid\":\"https://orcid.org/0000-0003-4956-1530\"},{\"id\":\"https://openalex.org/A5009662036\",\"display_name\":\"B. Anderson\",\"orcid\":\"https://orcid.org/0000-0001-5023-660X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S196734849\",\"source_display_name\":\"Scientific Reports\",\"landing_page_url\":\"https://doi.org/10.1038/s41598-024-68908-4\",\"is_oa\":true}}", "topic_tags": "Addiction,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4401257064" }, { "id": 1065, "title": "Psychedelic-assisted psychotherapy: where is the psychotherapy research?", "normalized_title": "psychedelic assisted psychotherapy where is the psychotherapy research", "authors": "Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD", "abstract": "Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been surprisingly little empirical investigation of the \"psychotherapy\" in PAP, leaving critical questions about the necessary and sufficient components of PAP unanswered. As clinical trials for psychedelic compounds continue the transition from safety- and feasibility-testing to evaluating efficacy, the role of the accompanying psychotherapy must be better understood to enhance scientific understanding of the mechanisms underlying therapeutic change, optimize clinical outcomes, and inform cost-effectiveness. The present paper first reviews the current status of psychotherapy in the PAP literature, starting with recent debates regarding \"psychotherapy\" versus \"psychological support\" and then overviewing published clinical trial psychotherapy models and putative models informed by theory. We then delineate lessons that PAP researchers can leverage from traditional psychotherapy research regarding standardizing treatments (e.g., publish treatment manuals, establish eligibility criteria for providers), identifying mechanisms of change (e.g., measure established mechanisms in psychotherapy), and optimizing clinical trial designs (e.g., consider dismantling studies, comparative efficacy trials, and cross-lagged panel designs). Throughout this review, the need for increased research into the psychotherapeutic components of treatment in PAP is underscored. PAP is a distinct, integrative, and transdisciplinary intervention. Future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.", "journal": "Psychopharmacology", "publication_date": "2024-07-31", "publication_year": 2024, "doi": "10.1007/s00213-024-06620-x", "pubmed_id": "38782821", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38782821/", "keywords": "Psilocybin, Psychedelic, Psychedelic-assisted psychotherapy, Psychotherapy, Psychotherapy models, Review", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:36", "raw_json": "{\"pubmed_id\":\"38782821\"}", "topic_tags": "Depression,Addiction,Mechanism of Action,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1072, "title": "Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants", "normalized_title": "psilocybin and motor function a triple blind dose finding study in healthy participants", "authors": "Chiranth Bhagavan, Richard Kanaan, Olivia Carter, Glenn Nielsen, David J. Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Georgina Oliver, Deanne Mayne, David McKernon, Greg Roebuck, James Rucker, Matthew Butler, Alexander Bryson", "abstract": "Background: There has been a resurgence of research into the potential therapeutic benefits of psychedelics for neuropsychiatric disorders. Classic psychedelics, such as psilocybin, exert complex effects on higher cognitive functions such as perception and awareness, but their impact on motor function remains unexplored. Moreover, there is a theoretical rationale for using psychedelics to promote motor retraining in certain neuropsychiatric conditions associated with motor dysfunction. This protocol paper outlines the first study to investigate the feasibility and safety of performing movement tasks during the acute effects of psilocybin in healthy participants. The findings from this study will further our understanding of the impact of psychedelics on motor function, and inform future studies that combine classic psychedelics with motor retraining in clinical populations. Methods: 12 healthy participants will each receive three doses of psilocybin (between 5 and 20 mg) in a randomized order, with each dose administered at least 1 week apart. Participants, the trial physiotherapists, and statisticians will remain blinded to the psilocybin dose. A battery of measures assessing motor function will be completed during the acute drug effects. In addition, measures of safety, pre- and post-dose resting-state brain activity via functional magnetic resonance imaging, and participants' subjective experience will be assessed.", "journal": "Psychiatric Research and Clinical Practice", "publication_date": "2024-07-22", "publication_year": 2024, "doi": "10.1176/appi.prcp.20240047", "pubmed_id": "39669539", "source_url": "https://doi.org/10.1176/appi.prcp.20240047", "keywords": "Psilocybin, Psychology, Hallucinogen, Physical medicine and rehabilitation, Cognition, Subliminal stimuli, Perception, Motor function, Medicine, Psychiatry, Audiology, Neuroscience, Cognitive psychology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4400913466\",\"openalex_url\":\"https://openalex.org/W4400913466\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1966578260\",\"https://openalex.org/W1977086599\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2028672360\",\"https://openalex.org/W2033748464\",\"https://openalex.org/W2043924162\",\"https://openalex.org/W2079124738\",\"https://openalex.org/W2093274439\",\"https://openalex.org/W2107376791\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2146308331\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2526261005\",\"https://openalex.org/W2600495561\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2888254436\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2980962023\",\"https://openalex.org/W3025954068\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3110773874\",\"https://openalex.org/W3123764886\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3184845084\",\"https://openalex.org/W4240642163\",\"https://openalex.org/W4246333130\",\"https://openalex.org/W4280520428\",\"https://openalex.org/W4281738922\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4380684709\",\"https://openalex.org/W4390589662\"],\"authorships\":[{\"id\":\"https://openalex.org/A5059079864\",\"display_name\":\"Chiranth Bhagavan\",\"orcid\":\"https://orcid.org/0000-0002-7983-4280\"},{\"id\":\"https://openalex.org/A5075094017\",\"display_name\":\"Richard Kanaan\",\"orcid\":\"https://orcid.org/0000-0003-0992-1917\"},{\"id\":\"https://openalex.org/A5060157509\",\"display_name\":\"Olivia Carter\",\"orcid\":\"https://orcid.org/0000-0001-7708-6154\"},{\"id\":\"https://openalex.org/A5079230130\",\"display_name\":\"Glenn Nielsen\",\"orcid\":\"https://orcid.org/0000-0001-6053-5670\"},{\"id\":\"https://openalex.org/A5062700391\",\"display_name\":\"David J. Berlowitz\",\"orcid\":\"https://orcid.org/0000-0003-2543-8722\"},{\"id\":\"https://openalex.org/A5014383854\",\"display_name\":\"Sara Issak\",\"orcid\":\"https://orcid.org/0000-0003-0042-3452\"},{\"id\":\"https://openalex.org/A5050220299\",\"display_name\":\"Sabine Braat\",\"orcid\":\"https://orcid.org/0000-0003-1997-3999\"},{\"id\":\"https://openalex.org/A5084468237\",\"display_name\":\"Sophie Zaloumis\",\"orcid\":\"https://orcid.org/0000-0002-8253-8896\"},{\"id\":\"https://openalex.org/A5000011887\",\"display_name\":\"Zachary Attard\",\"orcid\":\"https://orcid.org/0000-0003-0790-817X\"},{\"id\":\"https://openalex.org/A5102711011\",\"display_name\":\"Georgina Oliver\",\"orcid\":\"https://orcid.org/0000-0002-9215-2225\"},{\"id\":\"https://openalex.org/A5104987882\",\"display_name\":\"Deanne Mayne\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104972158\",\"display_name\":\"David McKernon\",\"orcid\":null},{\"id\":\"https://openalex.org/A5112602098\",\"display_name\":\"Greg Roebuck\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5037837514\",\"display_name\":\"Matthew Butler\",\"orcid\":\"https://orcid.org/0000-0002-9734-6539\"},{\"id\":\"https://openalex.org/A5065472002\",\"display_name\":\"Alexander Bryson\",\"orcid\":\"https://orcid.org/0000-0002-0033-8197\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210213065\",\"source_display_name\":\"Psychiatric Research and Clinical Practice\",\"landing_page_url\":\"https://doi.org/10.1176/appi.prcp.20240047\",\"is_oa\":true}}", "topic_tags": "Chronic Pain,Brain Imaging,Aging,Healthy Volunteers,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4400913466" }, { "id": 1008, "title": "Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.", "normalized_title": "current perspectives on the clinical research and medicalization of psychedelic drugs for addiction treatments safety efficacy limitations and challenges", "authors": "Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F, Idrees Chaudhary N, van der Meer PB, Batalla A.", "abstract": "Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, including entactogens and dissociative substances, are currently being explored for the treatment of SUDs, yet with less empirical clinical evidence than for other mental health disorders, such as depression or post-traumatic stress disorder (PTSD). In this narrative review, we discuss the current clinical research evidence, therapeutic potential and safety of psilocybin, lysergic acid diethylamide (LSD), ketamine, 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine, particularly in the context of the SUD treatment. Our aim was to provide a balanced overview of the current research and findings on potential benefits and harms of psychedelics in clinical settings for SUD treatment. We highlight the need for more clinical research in this particular treatment area and point out some limitations and challenges to be addressed in future research.", "journal": null, "publication_date": "2024-07-19", "publication_year": 2024, "doi": "10.1007/s40263-024-01101-3", "pubmed_id": "39033264", "source_url": "https://doi.org/10.1007/s40263-024-01101-3", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Biomedical Research", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"39033264\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1076, "title": "Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report", "normalized_title": "serotoninergic antidepressants combination in psilocybin assisted psychotherapy a case report", "authors": "André Do, Vanessa Michaud, Jean-François Stephan, Miltiadis Moreau, Élise Benoît, Felix-Antoine Berubé, Antoine Bibaud-De Serres, Alain Taillefer, Philippe Vincent", "abstract": "Psilocybin has reemerged as a promising treatment for difficult-to-treat depression (DTD). Although there is limited evidence regarding interactions between psilocybin and other psychotropic drugs, clinical trials require that patients discontinue their antidepressants before study entry to isolate the benefits of psilocybin and to minimize the risk of adverse events. We present the first case of an adult patient with DTD who received psilocybin-assisted psychotherapy (PAP) in combination with two serotoninergic antidepressants (duloxetine and vortioxetine). Since he displayed a partial response after the first PAP session, he agreed to discontinue duloxetine (but refused to stop vortioxetine) before the second PAP session to see if it could improve the therapeutic efficacy of psilocybin. However, his anxiety and depressive symptoms worsened. Psilocybin was well-tolerated in both PAP sessions; mild headaches were the main adverse effects experienced by the patient, and there were no cardiovascular safety concerns. This case report suggests that serotoninergic antidepressants combination with psilocybin appears to be safe and that antidepressant discontinuation prior to PAP may not be necessary. Since the continuation of antidepressants during PAP has the potential to improve treatment acceptability and accessibility, future research should assess whether psilocybin can be administered concurrently with antidepressants.", "journal": "Frontiers in Psychiatry", "publication_date": "2024-07-15", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1394962", "pubmed_id": "39086732", "source_url": "https://doi.org/10.3389/fpsyt.2024.1394962", "keywords": "Psilocybin, Adverse effect, Vortioxetine, Duloxetine, Antidepressant, Discontinuation, Medicine, Psychiatry, Serotonergic, Psychology, Major depressive disorder, Anxiety, Mirtazapine, Hallucinogen, Pharmacology, Internal medicine, Mood, Alternative medicine, Serotonin, Pathology, Receptor, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4400695899\",\"openalex_url\":\"https://openalex.org/W4400695899\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W4220686515\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4384130479\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037237207\",\"display_name\":\"André Do\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113291624\",\"display_name\":\"Vanessa Michaud\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027250223\",\"display_name\":\"Jean-François Stephan\",\"orcid\":\"https://orcid.org/0009-0000-7376-208X\"},{\"id\":\"https://openalex.org/A5071526629\",\"display_name\":\"Miltiadis Moreau\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108529244\",\"display_name\":\"Élise Benoît\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042633452\",\"display_name\":\"Felix-Antoine Berubé\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044793939\",\"display_name\":\"Antoine Bibaud-De Serres\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104605528\",\"display_name\":\"Alain Taillefer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063210785\",\"display_name\":\"Philippe Vincent\",\"orcid\":\"https://orcid.org/0000-0001-9194-6755\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2024.1394962\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Pharmacology,Receptor Pharmacology,Clinical Trial,Case Report,Safety,Adverse Events,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4400695899" }, { "id": 3638, "title": "Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study", "normalized_title": "psilocybin for treatment of alcohol use disorder a feasibility study", "authors": "Anders Fink-Jensen, MD, DMSci", "abstract": "The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD. The investigators will evaluate the feasibility and safety of administering psilocybin to 10 patients diagnosed with AUD. Following informed consent, patients will be screened for eligibility as per in- and exclusion criteria and baseline values will be recorded as per outcome measures. All patients will receive a single administration of 25 mg of psilocybin. As per safety guidelines patients will be monitored the entire dosing session by study staff familiar with the psychedelic effects of psilocybin. In addition, the patients will meet before and after the dosing session with a psychologist connected to the study for preparation and post-session debriefing, respectively. During dosing session, the investigators will collect blood plasma psilocin levels in order to establish pharmacokinetics and an estimated brain 5-HT2AR occupancy. When the effects of psilocybin subside, the investigators will ask the patients to fill out questionnaires encapsulating the psychedelic experience. One week after drug administration the patients are required to meet for an end-of-study assessment of outcome measures including adverse events.", "journal": "ClinicalTrials.gov", "publication_date": "2024-07-11", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04718792", "keywords": "Alcohol Use Disorder (AUD), Psilocybin, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04718792\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Pharmacology,Receptor Pharmacology,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3132, "title": "Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions", "normalized_title": "psilocybin mushrooms and public health in brazil a low risk adverse event profile calls for evidence based regulatory discussions", "authors": "Nogueira M, García-Hernández S, Roberto GS, Marques LZ.", "abstract": "Background Current drug policy classifies psilocybin, a substance produced by psychoactive mushrooms, as having a high potential for abuse, neglecting its therapeutic properties. We aimed to investigate if psilocybin mushrooms pose a risk to Brazilian public health compared to other toxic agents and whether evidence-based regulatory discussions are needed. Methods A retrospective cross-sectional study was conducted following STROBE guidelines. Data were obtained from the Sistema de Agravos de Notificação (SINAN) on adverse events reported from 2007 to 2022. Participants were categorized into three groups: drug abuse, psilocybin mushrooms, and unknown mushrooms. Clinical outcomes assessed included non-hospitalization, hospitalization, and death. Associations between variables were analyzed using the Chi-square test. Results A total of 112,451 individuals sought medical attention for drug abuse-related adverse events. Among them, men constituted the majority (n = 79,514; 70.7%), followed by whites (n = 37,565; 33.4%) and those aged 26-35 (n = 29,163; 25.9%) (p < 0.001). Alcohol was the primary toxic agent (n = 71,824; 49.2%) (p < 0.001). The psilocybin mushroom group reported 13 adverse events, and the unknown mushroom group recorded 51 adverse events. Hospitalization rates were 19.5% (n = 21,923) for drug abuse, 46.2% (n = 6) for psilocybin mushrooms (0.02% of all hospitalizations) (99% CI: 10.6% - 81.6%), and 23.5% (n = 12) for unknown mushrooms (0.04% of hospitalizations) (99% CI: 8.3% - 38.7%). The mortality rate was 1.8% (n = 2035) for drug abuse, with no fatalities in the psilocybin or unknown mushroom groups. Most hospitalizations involved alcohol (45.0%), and deaths were mainly associated with cocaine (33.3%). Conclusion Our findings suggest that psilocybin mushrooms have a low-risk profile for adverse events, although underreporting may be a factor. This study highlights the need for evidence-based regulatory discussions to prevent arbitrary arrests and ensure safe access to psilocybin for clinical and ceremonial use.", "journal": "medRxiv", "publication_date": "2024-07-11", "publication_year": 2024, "doi": "10.1101/2024.07.11.24310147", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.07.11.24310147", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR880121\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1077, "title": "Psilocybin for the treatment of Alzheimer's disease.", "normalized_title": "psilocybin for the treatment of alzheimer s disease", "authors": "Zheng S, Ma R, Yang Y, Li G.", "abstract": "Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency for innovative treatment modalities. Psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. Nonetheless, its potential as a therapeutic avenue for AD remains largely uncharted. This comprehensive review endeavors to encapsulate the pharmacological effects of psilocybin while elucidating the existing evidence concerning its potential mechanisms contributing to a positive impact on AD. Specifically, the active metabolite of psilocybin, psilocin, elicits its effects through the modulation of the 5-hydroxytryptamine 2A receptor (5-HT2A receptor). This modulation causes heightened neural plasticity, diminished inflammation, and improvements in cognitive functions such as creativity, cognitive flexibility, and emotional facial recognition. Noteworthy is psilocybin's promising role in mitigating anxiety and depression symptoms in AD patients. Acknowledging the attendant adverse reactions, we proffer strategies aimed at tempering or mitigating its hallucinogenic effects. Moreover, we broach the ethical and legal dimensions inherent in psilocybin's exploration for AD treatment. By traversing these avenues, We propose therapeutic potential of psilocybin in the nuanced management of Alzheimer's disease.", "journal": null, "publication_date": "2024-07-09", "publication_year": 2024, "doi": "10.3389/fnins.2024.1420601", "pubmed_id": "39050672", "source_url": "https://doi.org/10.3389/fnins.2024.1420601", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"39050672\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Creativity,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 554, "title": "Magic of the Mushrooms: Effects of Psilocybin Decriminalization", "normalized_title": "magic of the mushrooms effects of psilocybin decriminalization", "authors": "Ashutosh Bhave", "abstract": "In the past few years, psilocybin, a psychedelic compound found in \"magic mushrooms\" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the safest psychedelic option, with lower potency and a reduced risk of overdoses and emergency hospitalizations compared to other prevalent psychedelics, such as LSD (lysergic acid diethylamide) and MDMA (3,4-methylenedioxymethamphetamine). We analyzed the impact of psilocybin reforms on public interest in psilocybin, as well as their cross-commodity effects on LSD and MDMA, utilizing extensive web-based search data. We observe a significant increase in psilocybin search volume and a notable reduction in search volume associated with LSD and MDMA. Our results are consistent nationwide across states, irrespective of their stance on psilocybin reforms. The shift in public interest toward psilocybin, which is considered the safest psychedelic, away from LSD and MDMA, carries positive implications for public health.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2024-07-09", "publication_year": 2024, "doi": "10.1080/02791072.2024.2376755", "pubmed_id": "38984875", "source_url": "https://doi.org/10.1080/02791072.2024.2376755", "keywords": "Psilocybin, Decriminalization, Hallucinogen, MAGIC (telescope), Parapsychology, Psychology, Art, Medicine, Pharmacology, Criminology, Physics, Alternative medicine, Quantum mechanics, Pathology, Psychedelics and Drug Studies, Diverse academic research themes, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4400495765\",\"openalex_url\":\"https://openalex.org/W4400495765\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W1986911450\",\"https://openalex.org/W2014906262\",\"https://openalex.org/W2015666695\",\"https://openalex.org/W2107232050\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2168878119\",\"https://openalex.org/W2556046024\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2889566085\",\"https://openalex.org/W2945519735\",\"https://openalex.org/W2966611129\",\"https://openalex.org/W2990240756\",\"https://openalex.org/W3122136669\",\"https://openalex.org/W3125728782\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4379769663\",\"https://openalex.org/W4381839757\",\"https://openalex.org/W4383186683\"],\"authorships\":[{\"id\":\"https://openalex.org/A5077439888\",\"display_name\":\"Ashutosh Bhave\",\"orcid\":\"https://orcid.org/0000-0001-6704-5172\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2024.2376755\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4400495765" }, { "id": 1052, "title": "Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method", "normalized_title": "addressing a major interference in the quantification of psilocin in mouse plasma development of a validated liquid chromatography tandem mass spectrometry method", "authors": "Amir Khajavinia, Déborah Michel, Udoka C. Ezeaka, Randy W. Purves, Robert B. Laprairie, Anas El-Aneed", "abstract": "Psilocybin is a psychedelic compound found in some hallucinogenic \"magic mushrooms\". Psilocin is the active metabolite of Psilocybin, and it is the subject of several studies for the treatment of psychological disorders, such as anxiety, depression, and post-traumatic stress disorder. As such, the pharmacokinetic properties of psilocin should be evaluated to ensure its safety and efficacy as part of the drug development process. Based on the previously published studies, reversed-phase liquid chromatography (LC) was tested for psilocin quantification. The analysis, however, showed a major interference in mouse plasma that was not, to the best of our knowledge, reported previously. We, therefore, aimed to identify and separate the interference, using various chromatographic columns, mobile phase conditions, and mass spectrometers (MS) instruments. Chromatographic separation was achieved on an ultra high performance liquid chromatography (UHPLC) system, and a quadrupole-linear ion trap equipped with an electrospray ionization (ESI) source was used in positive ion mode with multiple reaction monitoring (MRM). Several chromatographic conditions and column chemistries, including C-18 and Phenyl-hexyl were initially tested, and failed to separate the interference. Exact mass measurement and MS/MS analysis were used to determine the structure of the interfering compound, which was confirmed to be tryptophan. Using the identified structure of the interfering compound, a fast and reliable hydrophilic interaction liquid chromatography (HILIC)-MS/MS method was developed and validated, that was capable of separating psilocin from the interference while achieving a 0.5 ng/ml lower limit of quantification (LLOQ). The validated method was successfully applied to a pharmacokinetic study where psilocin was orally administered to C57BL/6 mouse subjects. Psilocin concentration in all the analyzed mouse plasma samples was successfully determined.", "journal": "Journal of Chromatography A", "publication_date": "2024-07-03", "publication_year": 2024, "doi": "10.1016/j.chroma.2024.465123", "pubmed_id": "38981146", "source_url": "https://doi.org/10.1016/j.chroma.2024.465123", "keywords": "Chemistry, Chromatography, Mass spectrometry, Electrospray ionization, Selected reaction monitoring, Hydrophilic interaction chromatography, Tandem mass spectrometry, Liquid chromatography-mass spectrometry, Analyte, Ion suppression in liquid chromatography-mass spectrometry, High-performance liquid chromatography, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4400333801\",\"openalex_url\":\"https://openalex.org/W4400333801\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"title:psilocin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W2015854884\",\"https://openalex.org/W2017425875\",\"https://openalex.org/W2018904000\",\"https://openalex.org/W2026114562\",\"https://openalex.org/W2041480771\",\"https://openalex.org/W2048765051\",\"https://openalex.org/W2071926809\",\"https://openalex.org/W2082182980\",\"https://openalex.org/W2097781250\",\"https://openalex.org/W2121160760\",\"https://openalex.org/W2122510557\",\"https://openalex.org/W2141387425\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2735371049\",\"https://openalex.org/W2903619067\",\"https://openalex.org/W2911578096\",\"https://openalex.org/W2985052748\",\"https://openalex.org/W3007973331\",\"https://openalex.org/W3110345791\",\"https://openalex.org/W3112557491\",\"https://openalex.org/W3113337956\",\"https://openalex.org/W3127123233\",\"https://openalex.org/W3134320342\",\"https://openalex.org/W3171789670\",\"https://openalex.org/W3176131373\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W4205618858\",\"https://openalex.org/W4206486089\",\"https://openalex.org/W4220659540\",\"https://openalex.org/W4225113209\",\"https://openalex.org/W4282946726\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4390665254\",\"https://openalex.org/W4391036082\",\"https://openalex.org/W6791614198\"],\"authorships\":[{\"id\":\"https://openalex.org/A5079489909\",\"display_name\":\"Amir Khajavinia\",\"orcid\":\"https://orcid.org/0000-0002-1170-9213\"},{\"id\":\"https://openalex.org/A5025639143\",\"display_name\":\"Déborah Michel\",\"orcid\":\"https://orcid.org/0000-0001-5161-8677\"},{\"id\":\"https://openalex.org/A5027458374\",\"display_name\":\"Udoka C. Ezeaka\",\"orcid\":null},{\"id\":\"https://openalex.org/A5008718839\",\"display_name\":\"Randy W. Purves\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037819900\",\"display_name\":\"Robert B. Laprairie\",\"orcid\":\"https://orcid.org/0000-0002-9994-433X\"},{\"id\":\"https://openalex.org/A5042906285\",\"display_name\":\"Anas El-Aneed\",\"orcid\":\"https://orcid.org/0000-0003-1060-3609\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S176136234\",\"source_display_name\":\"Journal of Chromatography A\",\"landing_page_url\":\"https://doi.org/10.1016/j.chroma.2024.465123\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Pharmacology,Receptor Pharmacology,Animal Study,Safety,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4400333801" }, { "id": 2993, "title": "Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study", "normalized_title": "psilocybin therapy for females with anorexia nervosa a phase 1 open label feasibility study", "authors": "Stéphanie Knatz Peck, Samantha Shao, Tessa Gruen, Kevin H. Yang, Alexandra Babakanian, Julie Trim, Daphna M. Finn, Walter H. Kaye", "abstract": "Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m−2; s.d. 3.7) who met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for AN or pAN (partial remission) were recruited to a study conducted at an academic clinical research institute. Participants received a single 25-mg dose of synthetic psilocybin in conjunction with psychological support. The primary aim was to assess safety, tolerability and feasibility at post-treatment by incidences and occurrences of adverse events (AEs) and clinically significant changes in electrocardiogram (ECG), laboratory tests, vital signs and suicidality. No clinically significant changes were observed in ECG, vital signs or suicidality. Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. Participants’ qualitative perceptions suggest that the treatment was acceptable for most participants. Results suggest that psilocybin therapy is safe, tolerable and acceptable for female AN, which is a promising finding given physiological dangers and problems with treatment engagement. ClinicalTrials.gov identifier NCT04661514.", "journal": "FOCUS The Journal of Lifelong Learning in Psychiatry", "publication_date": "2024-06-30", "publication_year": 2024, "doi": "10.1176/appi.focus.24022013", "pubmed_id": "38988455", "source_url": "http://dx.doi.org/10.1176/appi.focus.24022013", "keywords": "Anorexia nervosa, Psilocybin, Medicine, Open label, Anorexia, Body mass index, Psychiatry, Food and drug administration, Hallucinogen, Internal medicine, Eating disorders, Pharmacology, Clinical trial, Psychedelics and Drug Studies, Sexuality, Behavior, and Technology, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 07:01:03", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4400572892\",\"openalex_url\":\"https://openalex.org/W4400572892\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1892606999\",\"https://openalex.org/W1903077781\",\"https://openalex.org/W2004621490\",\"https://openalex.org/W2042181481\",\"https://openalex.org/W2067637201\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2077841696\",\"https://openalex.org/W2093980670\",\"https://openalex.org/W2101248618\",\"https://openalex.org/W2113750392\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2133548434\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2753989225\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3001118513\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3044609744\",\"https://openalex.org/W3060925268\",\"https://openalex.org/W3083797211\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112557632\",\"https://openalex.org/W3132599860\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3203772461\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4220677780\",\"https://openalex.org/W4220695431\",\"https://openalex.org/W4226049185\",\"https://openalex.org/W4229050031\",\"https://openalex.org/W4244071564\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4292689891\",\"https://openalex.org/W4308953446\"],\"authorships\":[{\"id\":\"https://openalex.org/A5011897192\",\"display_name\":\"Stéphanie Knatz Peck\",\"orcid\":\"https://orcid.org/0000-0001-9421-9158\"},{\"id\":\"https://openalex.org/A5057873669\",\"display_name\":\"Samantha Shao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092530283\",\"display_name\":\"Tessa Gruen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044401296\",\"display_name\":\"Kevin H. Yang\",\"orcid\":\"https://orcid.org/0000-0002-1451-258X\"},{\"id\":\"https://openalex.org/A5092530284\",\"display_name\":\"Alexandra Babakanian\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002166417\",\"display_name\":\"Julie Trim\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051999008\",\"display_name\":\"Daphna M. Finn\",\"orcid\":\"https://orcid.org/0000-0003-2572-7778\"},{\"id\":\"https://openalex.org/A5086371093\",\"display_name\":\"Walter H. Kaye\",\"orcid\":\"https://orcid.org/0000-0002-4478-4906\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210193920\",\"source_display_name\":\"FOCUS The Journal of Lifelong Learning in Psychiatry\",\"landing_page_url\":\"http://dx.doi.org/10.1176/appi.focus.24022013\",\"is_oa\":true}}", "topic_tags": "Eating Disorders,Pharmacology,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4400572892" }, { "id": 1079, "title": "The Black Book of Psychotropic Dosing and Monitoring.", "normalized_title": "the black book of psychotropic dosing and monitoring", "authors": "DeBattista C, Schatzberg AF.", "abstract": "Introduction Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and the first disease modifying drug for the treatment of Alzheimer's disease. Three new antidepressants have come to the market in the past 18 months. The first of those, Auvelity, the combination of bupropion and dextromethorphan, takes advantage of a pharmacokinetic and pharmacodynamic synergism between the two drugs.85 Dextromethorphan has several pharmacodynamic properties including actions on the NMDA receptor and the Sigma 1 receptor, adding to the indirect norepinephrine agonist properties of bupropion. How Dextromethorphan is rapidly metabolized via the CYP2D6 isoenzyme to dextrophan that may have mu opioid agonist properties. The combination with bupropion, a CYP2D6 inhibitor, inhibits the metabolism of dextromethorphan allowing for more consistent therapeutic levels. The combination of dextromethorphan 45 mg twice per day and bupropion SR105 mg twice daily appears to be more effective than an equivalent dose of bupropion alone both in speeding up antidepressant response and achieving remission. However, it's not clear at this time how the combination would compare with a more typical dose of bupropion of 300-450 milligrams a day range. The phase III program for Auvelity, showed that the drug was well tolerated with the most common side effects being dizziness, headache, and dry mouth.86 Another novel antidepressant agent approved in 2023 is zuranolone (Zurzuvae). Zuranolone is an oral analog of IV brexanalone, and like brexanolone, was approved for the treatment of post-partum depression.83 The advantages of zuranolone over brexanalone are many. While brexanolone is a 60-hour intravenous infusion that must be administered in a health care facility, zuranolone is a once/day oral medication that is usually taken at home. Like brexanolone, and unlike most antidepressants, zuranolone has a short course of treatment, lasting just 14 days. Zuranolone's, as does brexanolone, is thought to act primarily as allosteric modulator of the GABA-a receptors. Despite only 14 days of treatment, zuranolone produced in depression in post-partum patients a clinically and significantly meaningful improvement at day 15 and continued to day 45 or 1 month past the end of treatment. Zuranolone is a schedule IV drug. The most common side effect in clinical trials was somnolence with 36% of participants reporting this side effect vs only 6% of those on placebo.84 Other common side effects included dizziness, diarrhea and fatigue. While the FDA declined to approve zuranolone as monotherapy or as an adjunctive treatment to standard antidepressants in major depression itself, there are positive studies in non-post-partum major depression albeit with smaller effect sizes and less consistent duration of activity. It is likely that zuranolone will continue to be studied in other depressive syndromes such as depression with anxious distress. The third \"new\" antidepressant approved late 2023 was gepirone (Exxua). Gepirone is not exactly a new or novel antidepressant and originally sought approval in the US about 20 years ago.88 There had been two positive studies of gepirone during the original NDA application but also a number of failed, negative, or non-informative studies as well. Thus, the FDA declined to originally approve the drug. However, failed and negative trials are common with antidepressants and after much internal debate, the FDA ultimately agreed to approve the drug based on the positive trials and a relatively favorable side effect profile. Gepirone, like buspirone, is a partial agonist of the 5HT1a receptor and a 5HT2 antagonist. As such, gepirone does not tend to be associated with sexual side effects, weight gain, or sedation. The most common side effects are dizziness, nausea, and insomnia which tend to improve in many patients over time. Second generation antipsychotics (SGAs) continue to be the only class of agents [other than esketamine (Spravato)] approved in adjunctive treatment of resistant major depression. In addition to olanzapine (combined with fluoxetine; Symbyax), aripiprazole (Abilify), quetiapine (Seroquel), brexpiprazole (Rexulti), cariprazine (Vraylar) became the latest SGA to be approved in 2022.90 Adjunctive cariprazine at 1.5 mg daily was significantly more effective than adjunctive placebo in patients with MDD who had failed to achieve an adequate response with an antidepressant alone after 6 weeks of treatment. Interestingly, a 3 mg dose of cariprazine was less consistently effective.91 The major advantage of cariprazine over some of the other approved adjunctive SGA's is easy dosing, with the starting 1.5 mg dose being the optimal therapeutic dose for most people, and a lower metabolic side effect burden with most subjects having limited or no weight gain in short term trials. The most common side effect were akathisia/restlessness, fatigue, and nausea. Lumateperone (Caplyta) is also has positive phase III data in the adjunctive treatment of major depression and is expective file for approval in late 2024. Another recent major development in psychopharmacology is the reemergence of psychedelics in the treatment of psychiatric disorders. The first of these is MDMA (phenethylamine 3,4-methylenedioxymethamphetamine) assisted psychotherapy for the treatment of PTSD. A New Drug Application (NDA) was accepted by the FDA for MDMA in the treatment of PTSD in late 2023.87 Because the drug is being fast tracked as a \"breakthrough\" treatment by the FDA, it was expected to see approval in the summer of 2024. The phase II and III data for MDMA assisted psychotherapy in the treatment of PTSD have been quite consistent and impressive. However, independent reviews have pointed to significant deficiencies in these studies including the bias introduced because of functional unblinding; virtually all patients in psychedelic studies can guess whether they got the active drug or placebo. The functional unblinding, the lack of standardization of adjunctive psychotherapy as well as the abuse potential of MDMA, may delay an FDA approval. The typical regimen in these trials included 3 preparatory psychotherapy sessions followed by once/month dosing sessions (lasting about 8 hours) and using doses of 120-160 mg in a split dose. There were typically 3 monthly dosing sessions, each followed by 3 integrative psychotherapy sessions to help subjects process and understand their experiences during the dosing sessions. In the most recent phase 3 trials, over 70% of subjects no longer met criteria for PTDS compared to 46% of those treated with psychotherapy and placebo alone.89 The only approved medications for treating PTSD are two SSRIs, paroxetine and sertraline. These drugs effect only some dimensions of PTSD with only 20-30% achieving a remission level response with these drugs. Thus, MDMA assisted psychotherapy appears to achieve much higher levels of remission and response than has been true for the SSRIs. Since MDMA is not taken continuously, side effects from MDMA tend to be short lived. Side effects have included muscle tightness, nausea, diminished appetite, excessive sweating, feeling cold and dizziness among others. Since MDMA is currently a schedule I drug, it is likely that a rigorous Risk Evaluation Mitigation (REMs) program will be put in place and a limited number of centers and clinicians will be designated to perform MDMA assisted psychotherapy for PTSD. In addition to MDMA, psilocybin-assisted psychotherapy is in phase 3 trials for treating resistant depression but unlikely to be available before late 2025 at the earliest. An argument can be made that there has not been a truly novel antipsychotic since the introduction of clozapine in the US in 1990. All first-generation antipsychotics have been dopamine 2 antagonists and second-generation drugs have involved some ratio of 5HT2 antagonism to D2 blockade. In 2023, the FDA accepted the application of xenomaline/tropsium (KarXT) which may become the first muscarinic M1M4 agonist approved for the treatment of schizophrenia.82,83 Tropsium is added as a muscarine antagonist to block the peripheral cholinergic effects of a muscarine agonist. Xenomaline/tropsium appears to be effective in treating both positive and negative symptoms of schizophrenia. In a phase 3 study of 407 patients with schizophrenia, xenomaline/tropsium at doses of xenomaline/50 mg/tropsium 20 mg twice daily up to 125 mg/30 mg twice daily was significantly more effective than placebo in treating both and negative symptoms over 5 weeks of treatment. As would be expected, the side effect profile of xenomaline/tropsium is very different that all currently available antipsychotics. There is no risk of EPS as it is not a dopamine antagonist, and xenomaline/tropsium is not associated with significant metabolic effects. The side effects are cholinergic in nature and include constipation, dry mouth, and nausea. A decision is expected in September of 2024. The year 2023 also saw the approval of the first disease modifying drug in the treatment of Alzheimer's disease, lecanemab (Lequembi). While acetylcholinesterase inhibitors and memantine have been available for decades, these drugs modestly improve cognition in Alzheimer's disease patients and do not alter the progressive course of the illness. Lecanemab is an IV monoclonal antibody that targets the removal of beta-amyloid in the brain as well proto-fibrils that are also known to be toxic to neuronal tissue. When given early in the course of the illness, patients treated with Lecanemab showed 27% less decline on some measures of cognition and function than did patients treated with a placebo over 18 months (about 1 and a half years). It is not known whether treatment for longer than 18 months would show lesser or greater decline over time. However, there are simulation studies that suggest that Lecanemab may modestly reduce the number of patients who progress to severe Alzheimer's disease and require institutional care. The standard dose is 10 mg/kg given via IV over one hour every 2 weeks for 18 months. Lecanemab is typically administered in an infusion center so that side effects can be monitored. The most serious side effects of Lecanemab are amyloid related imaging abnormalities (ARIA) that are associated with brain edema and microhemorrhages. ARIA can occur in up to 15% of patients. More common side effects are headache and nausea. While it remains to be seen how useful these new agents will be in clinical practice, they do represent an approach to treating neuropsychiatric disorders that are a notable departure from the pharmacotherapy of the past half century. It seems likely that some patients who have not been able to respond to or tolerate traditional pharmacotherapy will find hope in these new medications.", "journal": null, "publication_date": "2024-06-30", "publication_year": 2024, "doi": "10.64719/pb.4493", "pubmed_id": "38993656", "source_url": "https://doi.org/10.64719/pb.4493", "keywords": "Humans, Bupropion, Dextromethorphan, Psychotropic Drugs, Antidepressive Agents, Drug Monitoring, Dose-Response Relationship, Drug", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"38993656\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Headache / Migraine,Brain Imaging,Pharmacology,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3184, "title": "Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials", "normalized_title": "rapid and prolonged antidepressant and antianxiety effects of psilocybin lysergic acid diethylamide ayahuasca and 3 4 methylenedioxy methamphetamine a systematic review and meta analysis of randomized controlled trials", "authors": "Fluyau D, Kailasam VK, Revadigar N.", "abstract": "Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms. We performed a meta-analysis using a random effects model when data permitted it. The protocol of the review is registered in PROSPERO; CRD42022341325. Results Psilocybin produced a rapid and sustained reduction in depressive and anxiety symptoms in patients with major depressive disorder, severe, and in patients with life-threatening cancer. A decrease in depressive symptoms was observed with 3, 4-methylenedioxymethamphetamine (MDMA), primarily in patients with life-threatening cancer, autism spectrum disorder, and post-traumatic stress disorder. MDMA reduced social anxiety symptoms. However, MDMA’s effect size was either negligible or negative for anxiety symptoms overall. Ayahuasca reduced depressive symptoms in individuals with treatment-resistant major depressive and personality disorders. Lysergic acid diethylamide (LSD) reduced anxiety symptoms in individuals with life-threatening cancer. Psilocybin’s adverse effects were noticeable for elevated blood pressure, headaches, and panic attacks. For MDMA, elevated blood pressure, headaches, panic attacks, and feeling cold were noticeable. Conclusions Psilocybin, MDMA, ayahuasca, and LSD appear to have the potential to reduce depressive and anxiety symptoms. Adverse effects are noticed. Rigorous randomized controlled studies with larger sample sizes utilizing outcome measures instruments with better reliability and validity are warranted.", "journal": "medRxiv", "publication_date": "2024-06-19", "publication_year": 2024, "doi": "10.1101/2024.06.17.24308787", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.06.17.24308787", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR869769\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,End-of-Life Distress,Headache / Migraine,Aging,Personality Change,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1062, "title": "The cyclical revival of psychedelics in psychiatric treatment.", "normalized_title": "the cyclical revival of psychedelics in psychiatric treatment", "authors": "Appiani FJ, Caroff SN.", "abstract": "There is an increasing demand for effective treatments for depression, particularly for individuals grappling with treatment-resistant depression. Over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. However, preliminary findings from phase 2 studies have been inconclusive, prompting critical examination of issues such as maintaining blinding and the role of adjunctive psychotherapy. The maintenance of double-blinding and the role of adjunctive psychotherapy introduce biases that complicate the attainment of conclusive results in clinical research. Examining historical data reveals a recurrent pattern linked to the use of psychoactive substances, which starts with an excess of optimism and ends with general addictive behaviors and a heightened risk of serious public health problems. Considering these findings, a cautious and measured approach is imperative, given that the efficacy and safety of psilocybin treatment have yet to be unequivocally established. The potential for excessive optimism among researchers is a notable concern, as unwarranted enthusiasm may inadvertently facilitate the widespread adoption of this treatment without sufficient empirical support. In navigating the complexities of depression treatment, it is necessary to strike a balance between innovation and prudence to ensure evidence-based advancement of therapeutic approaches.", "journal": null, "publication_date": "2024-06-19", "publication_year": 2024, "doi": "10.1080/03007995.2024.2368725", "pubmed_id": "38880945", "source_url": "https://doi.org/10.1080/03007995.2024.2368725", "keywords": "Humans, Hallucinogens, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38880945\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1034, "title": "Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.", "normalized_title": "efficacy and safety of eight enhanced therapies for treatment resistant depression a systematic review and network meta analysis of rcts", "authors": "Guo Q, Guo L, Wang Y, Shang S.", "abstract": "BackgroundTreatment-Resistant Depression (TRD) challenges psychiatric treatment, with existing guidelines covering only a subset of augmentation strategies.MethodsA network meta-analysis following PRISMA guidelines examined the efficacy and safety of TRD treatments, analyzing 72 randomized controlled trials from eight databases, assessing response and remission rates, tolerability, and safety through the Cochrane Risk of Bias Tool and CINeMA framework.FindingsIncluding 12,105 participants, the analysis highlighted ECT, Ketamine, Esketamine, and Psilocybin as superior first-line treatments due to their optimal balance between effectiveness and tolerability. Brexpiprazole and Quetiapine showed no significant efficacy over placebo in response rates, while Esketamine and Psilocybin exhibited lower tolerability.InterpretationThe results advocate for ECT, Ketamine, Esketamine, and Psilocybin as preferred treatments for TRD, guiding clinical practice with evidence-based recommendations for enhancing treatment outcomes. This study underscores the importance of considering both efficacy and safety in selecting augmentation strategies for TRD.", "journal": null, "publication_date": "2024-06-19", "publication_year": 2024, "doi": "10.1016/j.psychres.2024.116018", "pubmed_id": "38924903", "source_url": "https://doi.org/10.1016/j.psychres.2024.116018", "keywords": "Humans, Ketamine, Antidepressive Agents, Electroconvulsive Therapy, Randomized Controlled Trials as Topic, Depressive Disorder, Treatment-Resistant, Psilocybin, Outcome Assessment, Health Care", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38924903\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1061, "title": "Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study", "normalized_title": "developing the open psychedelic evaluation nexus consensus measures for assessment of supervised psilocybin services an e delphi study", "authors": "P. Todd Korthuis, Kim Hoffman, Adrianne R. Wilson-Poe, Jason B. Luoma, Alissa Bazinet, Kellie Pertl, David L. Morgan, Ryan Cook, Sarann Bielavitz, Renae Myers, R. Cameron Wolf, Dennis McCarty, Christopher S. Stauffer", "abstract": "BACKGROUND: Voter initiatives in Oregon and Colorado authorize legal frameworks for supervised psilocybin services, but no measures monitor safety or outcomes. AIMS: To develop core measures of best practices. METHODS: A three-phase e-Delphi process recruited 36 experts with 5 or more years' experience facilitating psilocybin experiences in various contexts (e.g., ceremonial settings, indigenous practices, clinical trials), or other pertinent psilocybin expertise. Phase I, an on-line survey with qualitative, open-ended text responses, generated potential measures to assess processes, outcomes, and structure reflecting high quality psilocybin services. In Phase II, experts used seven-point Likert scales to rate the importance and feasibility of the Phase I measures. Measures were priority ranked. Qualitative interviews and analysis in Phase III refined top-rated measures. RESULTS: = 36; 53% female; 71% white; 56% heterosexual) reported currently providing psilocybin services (64%) for a mean of 15.2 [SD13.1] years, experience with indigenous psychedelic practices (67%), and/or conducting clinical trials (36%). Thematic analysis of Phase I responses yielded 55 candidate process measures (e.g., preparatory hours with client, total dose of psilocybin administered, documentation of touch/sexual boundaries), outcome measures (e.g., adverse events, well-being, anxiety/depression symptoms), and structure measures (e.g., facilitator training in trauma informed care, referral capacity for medical/psychiatric issues). In Phase II and III, experts prioritized a core set of 11 process, 11 outcome, and 17 structure measures that balanced importance and feasibility. CONCLUSION: Service providers and policy makers should consider standardizing core measures developed in this study to monitor the safety, quality, and outcomes of community-based psilocybin services.", "journal": "Journal of Psychopharmacology", "publication_date": "2024-06-17", "publication_year": 2024, "doi": "10.1177/02698811241257839", "pubmed_id": "38888164", "source_url": "https://doi.org/10.1177/02698811241257839", "keywords": "Psilocybin, Delphi method, Thematic analysis, Psychology, Applied psychology, Medicine, Qualitative research, Clinical psychology, Psychiatry, Hallucinogen, Computer science, Social science, Artificial intelligence, Sociology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4399780176\",\"openalex_url\":\"https://openalex.org/W4399780176\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":14,\"referenced_works\":[\"https://openalex.org/W1551186209\",\"https://openalex.org/W1967766053\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2045507107\",\"https://openalex.org/W2100069180\",\"https://openalex.org/W2110142496\",\"https://openalex.org/W2122884679\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2905110776\",\"https://openalex.org/W2964311550\",\"https://openalex.org/W3124902931\",\"https://openalex.org/W3149986569\",\"https://openalex.org/W3170399214\",\"https://openalex.org/W4250639036\",\"https://openalex.org/W4281666404\",\"https://openalex.org/W4291227674\",\"https://openalex.org/W4296481593\",\"https://openalex.org/W4385265010\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037879583\",\"display_name\":\"P. Todd Korthuis\",\"orcid\":\"https://orcid.org/0000-0001-5556-3597\"},{\"id\":\"https://openalex.org/A5082885757\",\"display_name\":\"Kim Hoffman\",\"orcid\":\"https://orcid.org/0000-0003-3063-7881\"},{\"id\":\"https://openalex.org/A5056650801\",\"display_name\":\"Adrianne R. Wilson-Poe\",\"orcid\":\"https://orcid.org/0000-0002-6304-5295\"},{\"id\":\"https://openalex.org/A5009587541\",\"display_name\":\"Jason B. Luoma\",\"orcid\":\"https://orcid.org/0000-0002-3601-7037\"},{\"id\":\"https://openalex.org/A5042118065\",\"display_name\":\"Alissa Bazinet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073745691\",\"display_name\":\"Kellie Pertl\",\"orcid\":\"https://orcid.org/0009-0008-0861-3609\"},{\"id\":\"https://openalex.org/A5060032144\",\"display_name\":\"David L. Morgan\",\"orcid\":\"https://orcid.org/0000-0001-6014-7643\"},{\"id\":\"https://openalex.org/A5017059128\",\"display_name\":\"Ryan Cook\",\"orcid\":\"https://orcid.org/0000-0001-8754-995X\"},{\"id\":\"https://openalex.org/A5017040379\",\"display_name\":\"Sarann Bielavitz\",\"orcid\":\"https://orcid.org/0000-0003-2104-6991\"},{\"id\":\"https://openalex.org/A5038473517\",\"display_name\":\"Renae Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058096595\",\"display_name\":\"R. Cameron Wolf\",\"orcid\":\"https://orcid.org/0009-0004-8332-0321\"},{\"id\":\"https://openalex.org/A5060056667\",\"display_name\":\"Dennis McCarty\",\"orcid\":\"https://orcid.org/0000-0001-9014-2894\"},{\"id\":\"https://openalex.org/A5077197149\",\"display_name\":\"Christopher S. Stauffer\",\"orcid\":\"https://orcid.org/0000-0002-0888-095X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241257839\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Wellbeing,Clinical Trial,Observational Study,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4399780176" }, { "id": 1106, "title": "A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?", "normalized_title": "a plea for nuance should people with a family history of bipolar disorder be excluded from clinical trials of psilocybin therapy", "authors": "Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J.", "abstract": "BackgroundAs the field of psychedelic therapy grows, it is vital to consider who can safely engage with psilocybin therapy. In most modern clinical trials of psilocybin therapy, individuals with a family history of bipolar disorder (BD) have been excluded from participation because of their genetic predisposition for developing BD.ReviewCase studies and survey data shed light on the risks of psilocybin therapy among those with a family history of BD in the absence of data from modern clinical trials. We review existing evidence that could inform risk stratification for these individuals, including genetic proximity to the affected relative, BD type, age at onset in the relative, and participant age. Hypothesizing that the risk of developing BD may predict the risk of developing serious adverse events when engaging with psilocybin therapy, we propose a risk stratification tool to be utilized when determining the relative risks of psilocybin therapy to those with a family history of BD in the context of clinical trials.ConclusionBalancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family history of BD, we argue for caution in psychedelic clinical trials but not outright exclusion of these individuals. Our risk stratification tool allows for more nuanced inclusion and exclusion criteria.", "journal": null, "publication_date": "2024-06-16", "publication_year": 2024, "doi": "10.1089/psymed.2023.0051", "pubmed_id": "40051581", "source_url": "https://doi.org/10.1089/psymed.2023.0051", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"40051581\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Aging,Clinical Trial,Review Article,Observational Study,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1063, "title": "Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.", "normalized_title": "is microdosing a placebo a rapid review of low dose lsd and psilocybin research", "authors": "Polito V, Liknaitzky P.", "abstract": "Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing. We conducted a PubMed search for all studies investigating psychedelic microdosing with controlled doses and a placebo comparator. We identified 19 placebo-controlled microdosing studies and summarised all positive and null findings across this literature. Risk of bias was assessed using the Cochrane risk-of-bias tool for randomised trials. The reviewed papers indicated that microdosing with LSD and psilocybin leads to changes in neurobiology, physiology, subjective experience, affect, and cognition relative to placebo. We evaluate methodological gaps and challenges in microdosing research and suggest eight reasons why current claims that microdosing is predominately a placebo are premature and possibly wrong: (1) there have been only a small number of controlled studies; (2) studies have had small sample sizes; (3) there is evidence of dose-dependent effects; (4) studies have only investigated the effects of a small number of doses; (5) the doses investigated may have been too small; (6) studies have looked only at non-clinical populations; (7) studies so far have been susceptible to selection bias; and (8) the measured impact of expectancy is small. Considering the available evidence, we conclude that it is not yet possible to determine whether microdosing is a placebo.", "journal": null, "publication_date": "2024-06-13", "publication_year": 2024, "doi": "10.1177/02698811241254831", "pubmed_id": "38877715", "source_url": "https://doi.org/10.1177/02698811241254831", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Placebo Effect, Dose-Response Relationship, Drug, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"38877715\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Microdosing,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1110, "title": "Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder", "normalized_title": "unlocking the healing power of psilocybin an overview of the role of psilocybin therapy in major depressive disorder obsessive compulsive disorder and substance use disorder", "authors": "Sandra Szafoni, Piotr Gręblowski, Klaudia Grabowska, Gniewko Więckiewicz", "abstract": "Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conducted to find effective alternatives to traditional therapies. One of these alternatives is psilocybin, a psychedelic substance that has been tested in clinical trials as an adjunct to psychotherapy. These studies focus on patients with major depressive disorder (MDD), obsessive-compulsive disorder (OCD) and substance use disorder (SUD), particularly alcohol and nicotine dependence. This article looks at the current understanding of psilocybin, including data from clinical trials conducted, psilocybin's mechanism of action, its safety and the level of risk associated with it.", "journal": "Frontiers in Psychiatry", "publication_date": "2024-06-10", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1406888", "pubmed_id": "38919636", "source_url": "https://doi.org/10.3389/fpsyt.2024.1406888", "keywords": "Psilocybin, Obsessive compulsive, Psychiatry, Major depressive disorder, Psychology, Psychotherapist, Clinical trial, Hallucinogen, Clinical psychology, Medicine, Cognition, Pathology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4399572299\",\"openalex_url\":\"https://openalex.org/W4399572299\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W77478258\",\"https://openalex.org/W1587734848\",\"https://openalex.org/W1966424565\",\"https://openalex.org/W1970165113\",\"https://openalex.org/W1983350514\",\"https://openalex.org/W1986426704\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2036448465\",\"https://openalex.org/W2041591334\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2044704612\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2050383033\",\"https://openalex.org/W2057120528\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2093994427\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2097355938\",\"https://openalex.org/W2100861230\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2134756982\",\"https://openalex.org/W2147289447\",\"https://openalex.org/W2155757287\",\"https://openalex.org/W2155961498\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2194924010\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2654923513\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2759054628\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2805577811\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2892307734\",\"https://openalex.org/W2895197076\",\"https://openalex.org/W2896040605\",\"https://openalex.org/W2904660484\",\"https://openalex.org/W2911514809\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2927836703\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2950564037\",\"https://openalex.org/W2979100461\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2996321268\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3027590463\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3112173414\",\"https://openalex.org/W3117921577\",\"https://openalex.org/W3143773781\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3171833614\",\"https://openalex.org/W3183684219\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W3201512146\",\"https://openalex.org/W3203928800\",\"https://openalex.org/W3204944997\",\"https://openalex.org/W3215301772\",\"https://openalex.org/W4200471428\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4214779885\",\"https://openalex.org/W4214940428\",\"https://openalex.org/W4220829235\",\"https://openalex.org/W4224116256\",\"https://openalex.org/W4241294122\",\"https://openalex.org/W4281666404\",\"https://openalex.org/W4281762597\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4297478109\",\"https://openalex.org/W4298055464\",\"https://openalex.org/W4307134464\",\"https://openalex.org/W4308040950\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4353070324\",\"https://openalex.org/W4367664319\",\"https://openalex.org/W4378549583\",\"https://openalex.org/W4379383539\",\"https://openalex.org/W4382133350\",\"https://openalex.org/W4382240642\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4386069067\",\"https://openalex.org/W4387818312\",\"https://openalex.org/W4387941143\",\"https://openalex.org/W4393349118\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W6634905416\",\"https://openalex.org/W6641677328\",\"https://openalex.org/W6660805464\",\"https://openalex.org/W6661898125\",\"https://openalex.org/W6662749299\",\"https://openalex.org/W6674380826\",\"https://openalex.org/W6679984609\",\"https://openalex.org/W6683883610\",\"https://openalex.org/W6708533747\",\"https://openalex.org/W6712001975\",\"https://openalex.org/W6752234185\",\"https://openalex.org/W6755541052\",\"https://openalex.org/W6758932831\",\"https://openalex.org/W6777529714\",\"https://openalex.org/W6782802736\",\"https://openalex.org/W6786823634\",\"https://openalex.org/W6797335148\",\"https://openalex.org/W6852560692\",\"https://openalex.org/W6855225731\",\"https://openalex.org/W6855914970\"],\"authorships\":[{\"id\":\"https://openalex.org/A5010700554\",\"display_name\":\"Sandra Szafoni\",\"orcid\":\"https://orcid.org/0000-0003-4980-5734\"},{\"id\":\"https://openalex.org/A5099102094\",\"display_name\":\"Piotr Gręblowski\",\"orcid\":null},{\"id\":\"https://openalex.org/A5099102095\",\"display_name\":\"Klaudia Grabowska\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086168835\",\"display_name\":\"Gniewko Więckiewicz\",\"orcid\":\"https://orcid.org/0000-0003-2404-393X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2024.1406888\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,OCD,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4399572299" }, { "id": 3791, "title": "Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies", "normalized_title": "who believes psychedelic assisted therapies work risky cannabis use and other factors are associated with positive treatment outcome expectancies", "authors": "Petrovitch D, Mitchell SM, Van Allen J, Littlefield AK.", "abstract": "Introduction: Treatment-outcome expectancies are an individual’s beliefs about how a medical or psychological intervention will affect them and others. These response expectancies represent serious potential confounds to clinical trials of psychedelic-assisted therapies for a variety of conditions because of difficulties associated with blinding psychedelic trials. On the other hand, expectancies also represent opportunities for practitioners to promote desired clinical outcomes. Therefore, a stronger understanding of factors associated with positive treatment-outcome expectancies for psychedelics could be useful to both scientists and clinicians. Method: The present study examined treatment-outcome expectancies for psychedelic-assisted therapies with psilocybin or lysergic acid diethylamide (LSD) among undergraduates (73% female, 81% White, 30% Hispanic, and 22% psychedelic-experienced; Mage = 19.95 years, median = 19.0, SD = 3.14). A generalized linear mixed model (GLMM) was used to test the hypothesis that riskier alcohol, cannabis, and other substance use would be associated with more positive treatment-outcome expectancies. Results: Consistent with our hypothesis, riskier cannabis use was significantly associated with more positive expectancies. However, neither riskier drinking nor other drug use were significant predictors. Prior engagement with psychedelic-related media and exposure to other peoples’ psychedelic experiences also predicted treatment-outcome expectancies. Conclusion: Individuals with riskier cannabis use may hold stronger beliefs in the transdiagnostic effectiveness of psychedelic-assisted therapies. This suggests that clinical trials of psychedelic-assisted interventions for cannabis use disorder may be particularly vulnerable to expectancy-related confounds. Psychedelic-therapy practitioners treating patients with risky cannabis use may consider patients’ beliefs in the effectiveness of psychedelics when discussing treatment options and delivering psychedelic interventions.", "journal": "PsyArXiv", "publication_date": "2024-06-09", "publication_year": 2024, "doi": "10.31234/osf.io/adnpg", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/adnpg", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:22", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR865245\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3445, "title": "A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder", "normalized_title": "a multi centre double blinded placebo controlled randomised phase ii clinical trial for psilocybin assisted therapy for alcohol use disorder", "authors": "University of Sydney", "abstract": "To explore the effectiveness of psilocybin-assisted therapy on reducing alcohol consumption in a double-blind, randomised, phase II clinical trial. New strategies for treating Alcohol Use Disorder (AUD) are urgently needed. Recent evidence has shown promising results for psychedelic-assisted therapies, particularly psilocybin, which has demonstrated efficacy in reducing alcohol consumption and improving psychological well-being. This study aims to evaluate the clinical efficacy and tolerability of psilocybin-assisted therapy compared to a control (niacin) in reducing heavy drinking days (HDD) per week among individuals with AUD. Primary Objective To conduct a double-blind, randomised controlled trial with 90 participants diagnosed with Alcohol Use Disorder (AUD). The primary aim is to compare the efficacy of psilocybin-assisted therapy (two sessions of psilocybin, 25 mg per dosing session) versus control (niacin 250mg) and therapy in reducing alcohol consumption, specifically measuring the number of heavy drinking days (HDD) per week. Secondary Objectives To compare the efficacy of psilocybin-assisted therapy versus control in improving the characteristics of AUD and addressing common comorbidities associated with AUD, including depression and anxiety. Study Design The trial will employ a double-blind, randomised, controlled design. A sample of 90 individuals with AUD will undergo 14 weeks of treatment, which includes 12 therapy sessions and 2 dosing sessions with either psilocybin (25 mg) or control (niacin 250mg). Participants will be assessed for changes in alcohol consumption patterns and improvements in symptoms of depression and anxiety.", "journal": "ClinicalTrials.gov", "publication_date": "2024-06-09", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06444243", "keywords": "Alcohol Use Disorder, Alcohol Dependence, Depression, Anxiety, Psilocybin, Niacin, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06444243\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Wellbeing,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3355, "title": "Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies", "normalized_title": "who believes psychedelic assisted therapies work risky cannabis use and other factors are associated with positive treatment outcome expectancies", "authors": "", "abstract": "Introduction: Treatment-outcome expectancies are an individual’s beliefs about how a medical or psychological intervention will affect them and others. These response expectancies represent serious potential confounds to clinical trials of psychedelic-assisted therapies for a variety of conditions because of difficulties associated with blinding psychedelic trials. On the other hand, expectancies also represent opportunities for practitioners to promote desired clinical outcomes. Therefore, a stronger understanding of factors associated with positive treatment-outcome expectancies for psychedelics could be useful to both scientists and clinicians. Method: The present study examined treatment-outcome expectancies for psychedelic-assisted therapies with psilocybin or lysergic acid diethylamide (LSD) among undergraduates (73% female, 81% White, 30% Hispanic, and 22% psychedelic-experienced; Mage = 19.95 years, median = 19.0, SD = 3.14). A generalized linear mixed model (GLMM) was used to test the hypothesis that riskier alcohol, cannabis, and other substance use would be associated with more positive treatment-outcome expectancies. Results: Consistent with our hypothesis, riskier cannabis use was significantly associated with more positive expectancies. However, neither riskier drinking nor other drug use were significant predictors. Prior engagement with psychedelic-related media and exposure to other peoples’ psychedelic experiences also predicted treatment-outcome expectancies. Conclusion: Individuals with riskier cannabis use may hold stronger beliefs in the transdiagnostic effectiveness of psychedelic-assisted therapies. This suggests that clinical trials of psychedelic-assisted interventions for cannabis use disorder may be particularly vulnerable to expectancy-related confounds. Psychedelic-therapy practitioners treating patients with risky cannabis use may consider patients’ beliefs in the effectiveness of psychedelics when discussing treatment options and delivering psychedelic interventions.", "journal": "PsyArXiv", "publication_date": "2024-06-09", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/adnpg_v1", "keywords": "cannabis use disorder, internal validity, placebo effects, psychedelic-assisted therapy, treatment-outcome expectancy, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Clinical Decision Making, Substance Abuse and Addiction, Depressive Disorders, Therapy, Psychotherapy, Psychopharmacology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"adnpg_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Addiction,Pharmacology,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3341, "title": "Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA", "normalized_title": "validation of the swiss psychedelic side effects inventory standardized assessment of adverse effects in studies of psychedelics and mdma", "authors": "Calder A, Hasler G.", "abstract": "Introduction: Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effects. Measuring side effects is challenging because they are not always easily differentiated from treatment effects or disease symptoms and show high heterogeneity, variable duration and impact, and sensitivity to context. A systematic questionnaire describing important characteristics of side effects of psychedelics and MDMA would greatly improve on previous methods. We aimed to create a standardized tool for recording clinically relevant side effects of psychedelics and MDMA, including their severity, duration, impact, and treatment-relatedness. Methods: We constructed the Swiss Psychedelic Side Effects Inventory (SPSI) based on insights from previous research. It was pilot tested in 145 participants from three studies. Structured feedback from an expert panel was used to improve validity and feasibility. Results: The final SPSI contains 32 side effects and standardized follow-up questions about their severity, impact, treatment-relatedness, and duration. It is compatible with any study design and can be administered as an interview or self-report at any timepoint after treatment with psychedelics or MDMA.Limitations: The SPSI omits relatively unimportant side effects for brevity’s sake, though space for additional symptoms is given. Future studies are needed to confirm its validity in different contexts. Conclusions: The SPSI is available in English and German for collecting systematic data on side effects from psychedelics and MDMA. This information is vital for improving clinical decisions, informed consent, and patient safety.", "journal": "PsyArXiv", "publication_date": "2024-06-06", "publication_year": 2024, "doi": "10.31234/osf.io/um2cy", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/um2cy", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR864350\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 956, "title": "Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA", "normalized_title": "validation of the swiss psychedelic side effects inventory standardized assessment of adverse effects in studies of psychedelics and mdma", "authors": "", "abstract": "Introduction: Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effects. Measuring side effects is challenging because they are not always easily differentiated from treatment effects or disease symptoms and show high heterogeneity, variable duration and impact, and sensitivity to context. A systematic questionnaire describing important characteristics of side effects of psychedelics and MDMA would greatly improve on previous methods. We aimed to create a standardized tool for recording clinically relevant side effects of psychedelics and MDMA, including their severity, duration, impact, and treatment-relatedness. Methods: We constructed the Swiss Psychedelic Side Effects Inventory (SPSI) based on insights from previous research. It was pilot tested in 145 participants from three studies. Structured feedback from an expert panel was used to improve validity and feasibility. Results: The final SPSI contains 32 side effects and standardized follow-up questions about their severity, impact, treatment-relatedness, and duration. It is compatible with any study design and can be administered as an interview or self-report at any timepoint after treatment with psychedelics or MDMA. Limitations: The SPSI omits relatively unimportant side effects for brevity’s sake, though space for additional symptoms is given. Future studies are needed to confirm its validity in different contexts. Conclusions: The SPSI is available in English and German for collecting systematic data on side effects from psychedelics and MDMA. This information is vital for improving clinical decisions, informed consent, and patient safety.", "journal": "PsyArXiv", "publication_date": "2024-06-06", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/um2cy_v1", "keywords": "adverse effects, MDMA, psychedelics, safety, side effects, Swiss Psychedelic Side Effects Inventory (SPSI), Psychiatry, Social and Behavioral Sciences, Clinical Psychology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"um2cy_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1012, "title": "Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms", "normalized_title": "pharmacological and behavioural effects of tryptamines present in psilocybin containing mushrooms", "authors": "Ryan J. Rakoczy, Grace N. Runge, Abhishek K. Sen, Oscar Sandoval, Hunter G. Wells, Quynh Nguyen, B. Roberts, Jon H. Sciortino, William J. Gibbons, Lucas M. Friedberg, J. Andrew Jones, Matthew S. McMurray", "abstract": "Background and Purpose Demand for new antidepressants has resulted in a re-evaluation of the therapeutic potential of psychedelic drugs. Several tryptamines found in psilocybin-containing “magic” mushrooms share chemical similarities with psilocybin. Early work suggests they may share biological targets. However, few studies have explored their pharmacological and behavioural effects. Experimental Approach We compared baeocystin, norbaeocystin and aeruginascin with psilocybin to determine if they are metabolized by the same enzymes, similarly penetrate the blood-brain barrier, serve as ligands for similar receptors and modulate behaviour in rodents similarly. We also assessed the stability and optimal storage and handling conditions for each compound. Key Results In vitro enzyme kinetics assays found that all compounds had nearly identical rates of dephosphorylation via alkaline phosphatase and metabolism by monoamine oxidase. Further, we found that only the dephosphorylated products of baeocystin and norbaeocystin crossed a blood-brain barrier mimetic to a similar degree as the dephosphorylated form of psilocybin, psilocin. The dephosphorylated form of norbaeocystin was found to activate the 5-HT2A receptor with similar efficacy to psilocin and norpsilocin in in vitro cell imaging assays. Behaviourally, only psilocybin induced head twitch responses in rats, a marker of 5-HT2A -mediated psychedelic effects and hallucinogenic potential. However, like psilocybin, norbaeocystin improved outcomes in the forced swim test. All compounds caused minimal changes to metrics of renal and hepatic health, suggesting innocuous safety profiles. Conclusions and Implications Collectively, this work suggests that other naturally occurring tryptamines, especially norbaeocystin, may share overlapping therapeutic potential with psilocybin, but without causing hallucinations.", "journal": "British Journal of Pharmacology", "publication_date": "2024-06-01", "publication_year": 2024, "doi": "10.1111/bph.16466", "pubmed_id": "38825326", "source_url": "https://doi.org/10.1111/bph.16466", "keywords": "Psilocybin, Tryptamines, Hallucinogen, Pharmacology, Tryptamine, Psychology, Medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Silymarin and Mushroom Poisoning", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4399276098\",\"openalex_url\":\"https://openalex.org/W4399276098\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":22,\"referenced_works\":[\"https://openalex.org/W1974195654\",\"https://openalex.org/W1980361506\",\"https://openalex.org/W1991575926\",\"https://openalex.org/W1995013188\",\"https://openalex.org/W2003973769\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2009147840\",\"https://openalex.org/W2012142575\",\"https://openalex.org/W2015811644\",\"https://openalex.org/W2032865438\",\"https://openalex.org/W2036251618\",\"https://openalex.org/W2038786381\",\"https://openalex.org/W2038839611\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2057200138\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2069027411\",\"https://openalex.org/W2090703082\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2132257230\",\"https://openalex.org/W2132937104\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2196303538\",\"https://openalex.org/W2327221240\",\"https://openalex.org/W2413606534\",\"https://openalex.org/W2416183456\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2752192887\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2802656036\",\"https://openalex.org/W2886020856\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2973895336\",\"https://openalex.org/W2983552824\",\"https://openalex.org/W2984194970\",\"https://openalex.org/W2987819628\",\"https://openalex.org/W3008629222\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3039630529\",\"https://openalex.org/W3042519295\",\"https://openalex.org/W3086773311\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3127285408\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3175025894\",\"https://openalex.org/W4210474529\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4220669239\",\"https://openalex.org/W4236357753\",\"https://openalex.org/W4282941439\",\"https://openalex.org/W4294203445\",\"https://openalex.org/W4295755919\",\"https://openalex.org/W4297459205\",\"https://openalex.org/W4308486832\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4313680817\",\"https://openalex.org/W4319298186\",\"https://openalex.org/W4323305766\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4381309423\",\"https://openalex.org/W4385196900\",\"https://openalex.org/W4390032737\",\"https://openalex.org/W6687595114\"],\"authorships\":[{\"id\":\"https://openalex.org/A5053666839\",\"display_name\":\"Ryan J. Rakoczy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093110366\",\"display_name\":\"Grace N. Runge\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077644431\",\"display_name\":\"Abhishek K. Sen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111218483\",\"display_name\":\"Oscar Sandoval\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111218484\",\"display_name\":\"Hunter G. Wells\",\"orcid\":null},{\"id\":\"https://openalex.org/A5057147486\",\"display_name\":\"Quynh Nguyen\",\"orcid\":\"https://orcid.org/0000-0003-1330-9026\"},{\"id\":\"https://openalex.org/A5113237357\",\"display_name\":\"B. Roberts\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093110367\",\"display_name\":\"Jon H. Sciortino\",\"orcid\":null},{\"id\":null,\"display_name\":\"William J. Gibbons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5028069840\",\"display_name\":\"Lucas M. Friedberg\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070067902\",\"display_name\":\"J. Andrew Jones\",\"orcid\":\"https://orcid.org/0000-0002-9068-2126\"},{\"id\":\"https://openalex.org/A5072282809\",\"display_name\":\"Matthew S. McMurray\",\"orcid\":\"https://orcid.org/0000-0002-1898-2933\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S55107261\",\"source_display_name\":\"British Journal of Pharmacology\",\"landing_page_url\":\"https://doi.org/10.1111/bph.16466\",\"is_oa\":true}}", "topic_tags": "Brain Imaging,Pharmacology,Receptor Pharmacology,Biomarkers,Aging,In Vitro Study,Safety,Toxicity", "study_type": "In Vitro Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4399276098" }, { "id": 4614, "title": "Therapeutic Implications of Psilocybin in the Wake of Decriminalization", "normalized_title": "therapeutic implications of psilocybin in the wake of decriminalization", "authors": "Nikola Lash, George Tadros, Eman Tadros", "abstract": "Psilocybin fungi, also more informally known as psychedelic mushrooms, have a rich, cultural history and were criminalized in the 1970s. However, recent developments, including Food and Drug Administration breakthrough status and state-level legalization, revive interest in these substances. They may be able to treat many disorders without the addictiveness or risk of overdose of cocaine, heroin, methamphetamine, and other psychoactive chemicals. This article analyzes the therapeutic potential and economic impact of psilocybin amid its nationwide decriminalization. Oregon and Colorado are at the forefront, anticipating changes in legislation, while approximately 25 states are contemplating measures. The cost-effectiveness of psilocybin in the treatment of mental health disorders, addiction, and positive legal indications highlights its appeal. Yet, ethical considerations, careful prescription methods, and strategic legalization are highlighted. This article calls for continuous research, adherence and understanding of ethical standards, and a holistic approach to psilocybin’s accessibility for potential therapeutic advantages.", "journal": "Integrative and Complementary Therapies", "publication_date": "2024-05-31", "publication_year": 2024, "doi": "10.1089/ict.2024.27206.nl", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1089/ict.2024.27206.nl", "keywords": "Psilocybin, Decriminalization, Wake, Hallucinogen, Psychology, Criminology, Engineering, Psychiatry, Aerospace engineering, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4399645755\",\"openalex_url\":\"https://openalex.org/W4399645755\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1983350514\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2123230679\",\"https://openalex.org/W2126551814\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W3009264042\",\"https://openalex.org/W3094549229\",\"https://openalex.org/W3118857539\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3203095924\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W3216485471\",\"https://openalex.org/W4210325795\",\"https://openalex.org/W4210913256\",\"https://openalex.org/W4221070625\",\"https://openalex.org/W4281397183\",\"https://openalex.org/W4281556927\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4379095570\",\"https://openalex.org/W4386740988\",\"https://openalex.org/W4388446727\",\"https://openalex.org/W4391672475\"],\"authorships\":[{\"id\":\"https://openalex.org/A5099119739\",\"display_name\":\"Nikola Lash\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062341642\",\"display_name\":\"George Tadros\",\"orcid\":\"https://orcid.org/0000-0001-5820-7643\"},{\"id\":\"https://openalex.org/A5053776114\",\"display_name\":\"Eman Tadros\",\"orcid\":\"https://orcid.org/0000-0001-8224-5391\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4220651434\",\"source_display_name\":\"Integrative and Complementary Therapies\",\"landing_page_url\":\"http://dx.doi.org/10.1089/ict.2024.27206.nl\",\"is_oa\":false}}", "topic_tags": "Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4399645755" }, { "id": 1123, "title": "Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.", "normalized_title": "single dose synthetic psilocybin with psychotherapy for treatment resistant bipolar type ii major depressive episodes a nonrandomized open label trial", "authors": "Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T.", "abstract": "ImportanceBipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression.ObjectiveTo establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode.Design, setting, and participantsThis was a 12-week, open-label nonrandomized open-label trial conducted at Sheppard Pratt Hospital. Participants aged 18 to 65 years with BDII, a current depressive episode longer than 3 months, and documented insufficient benefit with at least 2 pharmacologic treatments during the current episode were invited to participate. Of 70 approached, 19 met inclusion criteria and were enrolled. The trial was conducted between April 14, 2021, and January 5, 2023.InterventionsA single dose of synthetic psilocybin, 25 mg, was administered. Psychotropic medications were discontinued at least 2 weeks prior to dosing. Therapists met with patients for 3 sessions during pretreatment, during the 8-hour dosing day, and for 3 integration sessions posttreatment.Main outcomes and measuresThe primary outcome measure was change in Montgomery-Åsberg Depression Rating scale (MADRS) at 3 weeks posttreatment. Secondary measures included MADRS scores 12 weeks posttreatment, the self-rated Quick Inventory of Depression Symptoms-Self Rating (QIDS-SR), and the self-rated Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), each completed at baseline and all subsequent visits. Safety measures included the Columbia Suicide Severity Rating Scale (CSSRS) and the Young Mania Rating Scale (YMRS) completed at each visit.ResultsOf the 15 participants in this study (6 male and 9 female; mean [SD] age, 37.8 [11.6] years), all had lower scores at week 3, with a mean (SD) change of -24.00 (9.23) points on the MADRS, (Cohen d = 4.08; 95% CI, -29.11 to -18.89; P", "journal": null, "publication_date": "2024-05-31", "publication_year": 2024, "doi": "10.1001/jamapsychiatry.2023.4685", "pubmed_id": "38055270", "source_url": "https://doi.org/10.1001/jamapsychiatry.2023.4685", "keywords": "Humans, Hallucinogens, Treatment Outcome, Combined Modality Therapy, Bipolar Disorder, Psychotherapy, Adult, Middle Aged, Female, Male, Young Adult, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38055270\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1119, "title": "Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.", "normalized_title": "treating bipolar depression using psilocybin validity threats regarding efficacy and safety reply", "authors": "Aaronson ST, van der Vaart A, Sackeim HA.", "abstract": "", "journal": null, "publication_date": "2024-05-31", "publication_year": 2024, "doi": "10.1001/jamapsychiatry.2024.0423", "pubmed_id": "38598225", "source_url": "https://doi.org/10.1001/jamapsychiatry.2024.0423", "keywords": "Humans, Hallucinogens, Treatment Outcome, Reproducibility of Results, Bipolar Disorder, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"38598225\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1064, "title": "Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.", "normalized_title": "protocols and practices in psilocybin assisted psychotherapy for depression a systematic review", "authors": "Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD.", "abstract": "BackgroundPsilocybin-assisted psychotherapy (PAP) is a promising treatment option for depression, with randomized controlled trials (RCTs) providing preliminary support for its safety and efficacy. However, there is a lack of consistency across existing treatment protocols and psychotherapeutic approaches. The objective of this review is to summarize and compare current psychotherapy methods of PAP in treating depression and distress in life-threatening illnesses. We sought to comprehensively summarize published psychotherapy protocols from clinical trials to provide insights for future practices.MethodsA systematic search of four databases (Embase, MEDLINE, PsycINFO, CINAHL) for data relating to psychotherapy protocols was conducted by two independent reviewers.ResultsIn total, our search identified 1869 articles; after removing duplicates, we screened 1107 articles. We included 70 articles in the full-text review and determined that 28 were eligible for the final review. All protocols include sessions before (preparatory) and after (integration) the psychedelic dosing session with supportive monitoring. However, there was substantial variability and inconsistencies in all other aspects of therapy protocols (e.g., duration and number of sessions, model of therapy). Additionally, significant limitations were identified in the frequent need for more clarity in the description of therapeutic approaches.ConclusionIn published clinical trials, PAP has consisted of preparation, supportive dosing, and integration sessions. Beyond this basic framework, significant heterogeneity and lack of clarity were identified in reported psychotherapy protocols, meaning a validated and universally agreed upon protocol for PAP currently does not exist. Future studies should more clearly define and report psychotherapeutic components to identify the safest and most efficacious approaches to PAP.", "journal": null, "publication_date": "2024-05-30", "publication_year": 2024, "doi": "10.1016/j.jpsychires.2024.05.051", "pubmed_id": "38850581", "source_url": "https://doi.org/10.1016/j.jpsychires.2024.05.051", "keywords": "Humans, Hallucinogens, Clinical Protocols, Depression, Depressive Disorder, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"38850581\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1114, "title": "Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report", "normalized_title": "long covid symptoms improved after mdma and psilocybin therapy a case report", "authors": "Harman Chopra, Timothy Furnish, Monica Verduzco-Gutierrez, David S. Jevotovsky, Joel Castellanos", "abstract": "Key Clinical Message: Long-COVID syndrome lacks effective holistic treatment options. We present a case of a 41-year-old fully vaccinated female with Long-COVID syndrome who obtained significant symptomatic relief after self-medicating with psilocybin and MDMA. Abstract: Long-COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID-19), lacks effective holistic treatment options. We present a case of a 41-year-old fully vaccinated female with Long-COVID syndrome who obtained significant symptomatic relief by self-prescribing psilocybin and MDMA. Future research is needed to assess safety and efficacy.", "journal": "Clinical Case Reports", "publication_date": "2024-05-27", "publication_year": 2024, "doi": "10.1002/ccr3.8791", "pubmed_id": "38813452", "source_url": "https://doi.org/10.1002/ccr3.8791", "keywords": "Psilocybin, Medicine, MDMA, Coronavirus disease 2019 (COVID-19), Coronavirus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 2019-20 coronavirus outbreak, Intensive care medicine, Hallucinogen, Psychiatry, Disease, Internal medicine, Outbreak, Infectious disease (medical specialty), Virology, Psychedelics and Drug Studies, Complementary and Alternative Medicine Studies, Biochemical Analysis and Sensing Techniques", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4399135187\",\"openalex_url\":\"https://openalex.org/W4399135187\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W2733751315\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3165449608\",\"https://openalex.org/W3177256923\",\"https://openalex.org/W3192668131\",\"https://openalex.org/W3196993476\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4220686515\",\"https://openalex.org/W4294723946\",\"https://openalex.org/W4295789857\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4313482383\",\"https://openalex.org/W4316014106\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090111607\",\"display_name\":\"Harman Chopra\",\"orcid\":\"https://orcid.org/0000-0003-1574-278X\"},{\"id\":\"https://openalex.org/A5000306300\",\"display_name\":\"Timothy Furnish\",\"orcid\":\"https://orcid.org/0000-0002-4615-3366\"},{\"id\":\"https://openalex.org/A5032545533\",\"display_name\":\"Monica Verduzco-Gutierrez\",\"orcid\":\"https://orcid.org/0000-0003-0964-5908\"},{\"id\":\"https://openalex.org/A5015898636\",\"display_name\":\"David S. Jevotovsky\",\"orcid\":\"https://orcid.org/0009-0004-0236-2600\"},{\"id\":\"https://openalex.org/A5017645194\",\"display_name\":\"Joel Castellanos\",\"orcid\":\"https://orcid.org/0000-0002-7365-7260\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737168579\",\"source_display_name\":\"Clinical Case Reports\",\"landing_page_url\":\"https://doi.org/10.1002/ccr3.8791\",\"is_oa\":true}}", "topic_tags": "Case Report,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4399135187" }, { "id": 939, "title": "Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.", "normalized_title": "narrative review of the potential for psychedelics to treat prolonged grief disorder", "authors": "Ehrenkranz R, Agrawal M, Penberthy JK, Yaden DB.", "abstract": "Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTSD) with a prevalence of up to 10% in bereaved populations. Hallmarks of PGD include functional impairment a year or more post-bereavement and intense yearning for the deceased. Current treatments for PGD are typically psychological rather than psychopharmacological, and more treatment options are needed. Psychedelics such as psilocybin and MDMA may be a promising treatment avenue for PGD. Randomized clinical trials demonstrated the efficacy of psilocybin in reducing symptom severity in depression and MDMA in reducing PTSD symptomatology. Furthermore, psychedelics often produce subjective effects (such as transcendence, mystical experiences, and a sense of oneness) that may be uniquely relevant to the existential distress experienced in PGD. No randomized clinical trials have thus far been conducted on the safety and efficacy of psychedelics for PGD. Initial research, including survey-based studies and an open-label trial, has begun to shed light on the possible benefits of psychedelics in the alleviation of grief. While the evidence from these studies is preliminary, it suggests a consistent trend towards the effectiveness of psychedelics in grief reduction. Conducting a randomized clinical trial would be an appropriate next step to explore the potential efficacy of using psychedelics to treat PGD.", "journal": null, "publication_date": "2024-05-22", "publication_year": 2024, "doi": "10.1080/09540261.2024.2357668", "pubmed_id": "39980217", "source_url": "https://doi.org/10.1080/09540261.2024.2357668", "keywords": "Humans, Hallucinogens, Grief, Stress Disorders, Post-Traumatic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39980217\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,Mystical Experience,Clinical Trial,Review Article,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1091, "title": "Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis.", "normalized_title": "efficacy and safety of psilocybin on treatment resistant depression a systematic review and meta analysis", "authors": "Fang Q, Chan VKY, Chan SSM, Jiao Y, Wang J, Li X.", "abstract": "", "journal": null, "publication_date": "2024-05-21", "publication_year": 2024, "doi": "10.1016/j.psychres.2024.115960", "pubmed_id": "38781672", "source_url": "https://doi.org/10.1016/j.psychres.2024.115960", "keywords": "Humans, Hallucinogens, Treatment Outcome, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"38781672\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 953, "title": "A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient", "normalized_title": "a case report of psilocybin induced psychosis in a predisposed patient", "authors": "S Morris", "abstract": "Psilocybin is gaining popularity as research shows potential benefits to those with anxiety, depression, and other mental health conditions. Individuals with risk factors for psychosis are typically excluded from such studies, limiting the empiric research of the risks and benefits in vulnerable populations. In the real-world setting, many individuals who seek treatment with psilocybin will have comorbid psychiatric conditions and other factors that predispose them to psychosis. We report a case of a patient with multiple predisposing risk factors, including a history of depression, personality disorder traits, and cannabis use, who experienced a psychotic episode with catatonic features and suicidality after several months of heavy psilocybin use. A review of similar previously published case reports demonstrates a pattern of psilocybin-induced psychosis occurring primarily in individuals with predisposing factors who have consumed either high or repeated doses of the drug. This case report furthers this pattern, which serves as both a warning that psilocybin use is not without risks and reassurance for researchers using much lower doses to treat mental illness.", "journal": "Clinical Psychopharmacology and Neuroscience", "publication_date": "2024-05-20", "publication_year": 2024, "doi": "10.9758/cpn.24.1180", "pubmed_id": "39420616", "source_url": "http://dx.doi.org/10.9758/cpn.24.1180", "keywords": "Psilocybin, Psychosis, Hallucinogen, Medicine, Psychiatry, Psychology, Neuroscience, Psychedelics and Drug Studies, Mental Health and Psychiatry, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4398182074\",\"openalex_url\":\"https://openalex.org/W4398182074\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1966197040\",\"https://openalex.org/W1995256288\",\"https://openalex.org/W2025684297\",\"https://openalex.org/W2028825681\",\"https://openalex.org/W2061372721\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2800624902\",\"https://openalex.org/W2901140666\",\"https://openalex.org/W3158216155\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4249972766\",\"https://openalex.org/W4288513893\",\"https://openalex.org/W4310598708\"],\"authorships\":[{\"id\":\"https://openalex.org/A5006127904\",\"display_name\":\"S Morris\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764824292\",\"source_display_name\":\"Clinical Psychopharmacology and Neuroscience\",\"landing_page_url\":\"http://dx.doi.org/10.9758/cpn.24.1180\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Personality Change,Review Article,Case Report,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4398182074" }, { "id": 4624, "title": "Psilocybin as a new way for depression treatment", "normalized_title": "psilocybin as a new way for depression treatment", "authors": "Mateusz Pawlicki, Aleksandra Kłos, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Gregułą, Aleksandra Mazurek, Wiktoria Wilanowska", "abstract": "Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look for help as fast as possible. Currently available treatment methods are not always efficient enough to deal with more complex cases. Therefore it is important to look for new therapy options incrementing chances of fast and successful treatment. Results: Studies showed that psilocybin is not only able to lower depression and anxiety scores in patients with major depressive disorders or with serious life-threatening conditions but also proved this effect to be long-lasting. At the same time, no or little adverse side effects were noticed. Conclusions: Psilocybin is potentially a good method for depression treatment in some groups of patients. It should be considered if other, better known therapies show little or no effects.", "journal": "Journal of Education Health and Sport", "publication_date": "2024-05-14", "publication_year": 2024, "doi": "10.12775/jehs.2024.68.50168", "pubmed_id": null, "source_url": "http://dx.doi.org/10.12775/jehs.2024.68.50168", "keywords": "Psilocybin, Depression (economics), Psychology, Hallucinogen, Psychotherapist, Psychiatry, Medicine, Keynesian economics, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4396937684\",\"openalex_url\":\"https://openalex.org/W4396937684\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5066244133\",\"display_name\":\"Mateusz Pawlicki\",\"orcid\":\"https://orcid.org/0000-0001-8318-6573\"},{\"id\":\"https://openalex.org/A5038428023\",\"display_name\":\"Aleksandra Kłos\",\"orcid\":\"https://orcid.org/0009-0008-6870-2590\"},{\"id\":\"https://openalex.org/A5093703384\",\"display_name\":\"Karol Stachyrak\",\"orcid\":\"https://orcid.org/0009-0008-3175-1866\"},{\"id\":\"https://openalex.org/A5103057913\",\"display_name\":\"Dawid Mika\",\"orcid\":\"https://orcid.org/0009-0003-5254-5344\"},{\"id\":\"https://openalex.org/A5012775469\",\"display_name\":\"Bartosz Mazur\",\"orcid\":\"https://orcid.org/0000-0003-0601-4350\"},{\"id\":\"https://openalex.org/A5093703385\",\"display_name\":\"Kamila Turek\",\"orcid\":\"https://orcid.org/0009-0000-6888-8913\"},{\"id\":\"https://openalex.org/A5010306637\",\"display_name\":\"Maciej Lambach\",\"orcid\":\"https://orcid.org/0009-0004-3348-4272\"},{\"id\":\"https://openalex.org/A5093703383\",\"display_name\":\"Anna Gregułą\",\"orcid\":\"https://orcid.org/0009-0007-3712-7960\"},{\"id\":\"https://openalex.org/A5038601968\",\"display_name\":\"Aleksandra Mazurek\",\"orcid\":\"https://orcid.org/0009-0007-5298-782X\"},{\"id\":\"https://openalex.org/A5093703382\",\"display_name\":\"Wiktoria Wilanowska\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737571363\",\"source_display_name\":\"Journal of Education Health and Sport\",\"landing_page_url\":\"http://dx.doi.org/10.12775/jehs.2024.68.50168\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4396937684" }, { "id": 3350, "title": "Psychedelics Use and the Risk of Reduced Formal Mental Health Care", "normalized_title": "psychedelics use and the risk of reduced formal mental health care", "authors": "Viña S.", "abstract": "Abstract Background: Due to increasing cultural and legal acceptance of psychedelics, there is a need to understand their potential influence on formal mental health care. This paper examines the connection between psychedelics, distress, and treatment utilization. Are psychedelic users less likely to use formal mental health care? Methods This study tests the relationship between psychedelics use (MDMA, Psilocybin, DMT, Ayahuasca, Peyote/Mescaline, and LSD) on stigma, psychological distress (K6), and formal mental health care use (medication, outpatient, and any use). This project also tests the impact of one measure of classic psychedelics (LCPU) use on distress and care. This project uses pooled data from the National Survey of Drug Use and Health (NSDUH) (2010 to 2018) (N=458,372). Results The analysis involved conducting a series of nested logistic regression models in Stata 18. The results provided evidence of an independent association between psychedelics use and a decreased likelihood of using mental health medication, outpatient treatment, and any formal mental health care. Additionally, the interaction terms revealed that as distress levels increase, psychedelics users are even less inclined to seek formal mental health care compared to non-psychedelic users. Conclusion Overall, the results suggest psychedelic users are less likely to use formal mental health care, even when they are particularly distress, indicating a heightened societal risk of self-medication as these drugs become more widely available.", "journal": "Research Square", "publication_date": "2024-05-12", "publication_year": 2024, "doi": "10.21203/rs.3.rs-4378944/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-4378944/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR852229\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Observational Study,Safety,Drug Interactions", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4628, "title": "Calls to Poison Centers Involving Psilocybin Rising in Youth", "normalized_title": "calls to poison centers involving psilocybin rising in youth", "authors": "Terri D’Arrigo", "abstract": "Back to table of contents Next article Clinical & ResearchFull AccessCalls to Poison Centers Involving Psilocybin Rising in YouthTerri D'ArrigoTerri D'ArrigoPublished Online:10 May 2024https://doi.org/10.1176/appi.pn.2024.06.6.2AbstractDecriminalization, legalization of psilocybin likely play roles in both increased exposure and poisoning.Getty Images/iStock/YarphotoSince 2019, calls to U.S. poison centers involving youth or young adults who took the psychedelic psilocybin have risen sharply, according to a study in the Journal of Adolescent Health. The timing is notable as 2019 was the start of a psilocybin decriminalization movement across numerous states and cities.\"Decriminalization most likely plays a role in the increase in psilocybin exposure calls reported to poison centers. Poison centers in the U.S. experienced similar increases related to cannabis when cannabis was decriminalized and legalized,\" lead author Rita Farah, Pharm.D, Ph.D., M.P.H. told Psychiatric News. She is an epidemiologist in the Medical Toxicology Division at the University of Virginia (UVA) School of Medicine.Farah and colleagues analyzed data from the National Poison Data System, which collects de-identified data from poison centers across the country. The researchers examined all cases of psilocybin exposure between 2013 and 2022 involving young people aged 13 to 25.Psilocybin exposure in youth is alarming because the states that have decriminalized psilocybin do not allow people younger than 21 years to use it, said Rita Farah, Pharm.D., Ph.D., M.P.H.University of VirginiaOver the 10-year period, there were 4,055 calls for psilocybin exposure, of which about 66% involved psilocybin alone. The most commonly reported clinical effects were hallucinations or delusions, agitation, elevated heart rate, or confusion. While most of the exposures required professional medical attention, there were only two reported deaths, and both involved a secondary substance (fentanyl and amphetamine).Between 2013 and 2018, the number of psilocybin calls per year remained steady among both adolescents aged 13 to 19 years and young adults aged 20 to 25 years. However, calls began to increase each year starting in 2019. Compared with calls in 2018, calls involving young adults more than doubled to approximately 300 calls in 2022. Over the same timeframe, calls involving adolescents more than tripled to approximately 450.Farah said that the increase seen among teenagers is alarming, especially because states and cities that have decriminalized psilocybin still prohibit anyone younger than 21 from using it.\"The emerging question is: To what extent psilocybin decriminalization is responsible of the increase seen in our study? For that, we need to compare trends between states and [between] cities where psilocybin was decriminalized and states and cities where psilocybin remains illegal,\" Farah said.Psychiatrists should counsel their patients that psilocybin should not be used out of controlled clinical settings, said Christopher Holstege, M.D.University of VirginiaIn the meantime, psychiatrists and other mental health professionals should counsel their patients about the risks of psilocybin, said study researcher Christopher Holstege, M.D. He is a professor of emergency medicine and pediatrics and Chief, Division of Medical Toxicology at the UVA School of Medicine as well as Director of UVA Health's Blue Ridge Poison Control Center.\"To date, studies conducted to explore potential indications of psilocybin in treating major depressive disorders or alcohol use disorder have been done in a controlled setting and use a defined dose,\" Holstege said. \"Psychiatrists and mental health professionals should explain to their patients that the use of psilocybin is not without adverse events and should not be used outside clinical controlled settings and with unregulated products that do not have defined doses based on quality control measures.\"Holstege emphasized the need for action on curtailing the burgeoning trend of psilocybin poisonings.\"[P]racticing clinicians, public educators, and policy makers must assure that such products that contain psilocybin remain out of the reach of young children, are not sold to youth, and are not taken by individuals outside of evidence-based or emerging science,\" he said. He added that vigilant quality control and a focus on labeling are critical. \"Surveillance must occur to determine if there are adverse consequences to assure the safety of the population in a similar manner as other pharmaceutical products.\"The researchers reported no outside funding for this study. ■Resource\"Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade\" ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2024-05-09", "publication_year": 2024, "doi": "10.1176/appi.pn.2024.06.6.2", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1176/appi.pn.2024.06.6.2", "keywords": "Psilocybin, Hallucinogen, Psychology, Criminology, Psychiatry, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4396797833\",\"openalex_url\":\"https://openalex.org/W4396797833\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5056763663\",\"display_name\":\"Terri D’Arrigo\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"http://dx.doi.org/10.1176/appi.pn.2024.06.6.2\",\"is_oa\":false}}", "topic_tags": "Depression,Addiction,Adolescents,Healthcare Workers,Safety,Adverse Events,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4396797833" }, { "id": 952, "title": "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.", "normalized_title": "clinical research trials of psychedelic assisted therapy in adolescents aged 16 to 17 years rationale balanced with caution", "authors": "Jeffrey JK, Weintraub MJ, Grob CS.", "abstract": "Youth today are burdened by significant mental health challenges. In 2022, 25% of adolescents aged 12 to 17 years experienced a mental illness, with 20% experiencing a depressive episode, 12.5% reporting serious thoughts of suicide, and 17% meeting criteria for a substance use disorder.1 Close to 5% of adolescents experience posttraumatic stress disorder.2 Impairing psychiatric symptoms remain present in upwards of 40% of adolescents after receiving existing mental health services,3 so it is necessary to identify additional and more effective treatment options. We propose there is an acceptable benefit-to-risk calculation that supports trialing classic serotonergic psychedelics (eg, psilocybin) and phenethylamine compounds with empathogenic and entactogenic range of effects (eg, 3,4-methylenedioxymethamphetamine [MDMA]) in combination with psychotherapy among select adolescents aged 16 to 17 years. Specifically, we propose testing these treatments among adolescents aged 16 to 17 years who are experiencing treatment-resistant manifestations of psychiatric disorders (ie, multiple failed trials of current evidence-based treatments) or psychiatric disorders that are in line with the current evidence base for adults as determined, for example, by the breakthrough designation of the US Food and Drug Administration for a particular psychedelic medicine (eg, psilocybin for major depressive disorder, MDMA for posttraumatic stress disorder).", "journal": null, "publication_date": "2024-05-08", "publication_year": 2024, "doi": "10.1016/j.jaac.2024.03.021", "pubmed_id": "38734406", "source_url": "https://doi.org/10.1016/j.jaac.2024.03.021", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Combined Modality Therapy, Psychotherapy, Adolescent, Clinical Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38734406\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,Clinical Trial,Adolescents,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 934, "title": "Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy", "normalized_title": "evolving guidelines for the use of touch during a clinical trial of group psilocybin assisted therapy", "authors": "Anthony L. Back, Susanna Myers, John Guy, Juliana Pérez, Leslie Lazar Thorn, Bonnie A. McGregor", "abstract": "For a new clinical trial testing a group retreat-based format of psilocybin-assisted therapy, our research team created an initial set of practice guidelines that aimed to describe facilitator use of touch in a way that is ethical, supportive, and minimizes harm. In our first three retreats, however, we had two unexpected experiences with touch that led us to iterate our initial guidelines into a new version of guidelines. In this Technical Report, we describe our evolving guidelines specifying acceptable practices for facilitator use of touch to ensure a safe, supportive, and therapeutic participant experience. Our primary goal with these guidelines is to create a haptic experience during the psilocybin session that reinforces the participants' sense of safety and supports their own experience during the psilocybin session. Our secondary goal is to allow the facilitator team to notice and maintain therapeutic boundaries and to respond to participant experiences with empathy and openness in the context of those boundaries (Clinical Trials No: NCT05847686).", "journal": "Psychedelic Medicine", "publication_date": "2024-05-07", "publication_year": 2024, "doi": "10.1089/psymed.2023.0069", "pubmed_id": "40051480", "source_url": "https://doi.org/10.1089/psymed.2023.0069", "keywords": "Psilocybin, Therapeutic touch, Psychotherapist, Psychology, Clinical trial, Medicine, Hallucinogen, Alternative medicine, Psychiatry, Internal medicine, Pathology, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications, Sexuality, Behavior, and Technology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4396720923\",\"openalex_url\":\"https://openalex.org/W4396720923\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1973933342\",\"https://openalex.org/W1978969109\",\"https://openalex.org/W2055578227\",\"https://openalex.org/W2134718184\",\"https://openalex.org/W2792455188\",\"https://openalex.org/W4207068356\",\"https://openalex.org/W4361301344\"],\"authorships\":[{\"id\":\"https://openalex.org/A5071781938\",\"display_name\":\"Anthony L. Back\",\"orcid\":\"https://orcid.org/0000-0002-7903-0477\"},{\"id\":\"https://openalex.org/A5113200747\",\"display_name\":\"Susanna Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104069668\",\"display_name\":\"John Guy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5104052443\",\"display_name\":\"Juliana Pérez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5096909520\",\"display_name\":\"Leslie Lazar Thorn\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030340063\",\"display_name\":\"Bonnie A. McGregor\",\"orcid\":\"https://orcid.org/0000-0003-0531-9347\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2023.0069\",\"is_oa\":false}}", "topic_tags": "Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4396720923" }, { "id": 1146, "title": "Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.", "normalized_title": "safety and risk assessment of psychedelic psychotherapy a meta analysis and systematic review", "authors": "Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Verroust V, Piolino P, Benyamina A", "abstract": "Psychotherapies assisted by psychedelic substances have shown promising results in the treatment of psychiatric disorders. The aim of this systematic review and meta-analysis was to evaluate safety data in human subjects. We carried out a search on MEDLINE, Embase and PsycINFO databases between 2000 and 2022. Standardized mean differences between different dose ranges and between acute and subacute phases were calculated for cardiovascular data after psychedelic administration. Risk differences were calculated for serious adverse events and common side effects. Thirty studies were included in this meta-analysis. There were only nine serious adverse events for over 1000 administrations of psychedelic substances (one during the acute phase and 8 during the post-acute phase). There were no suicide attempts during the acute phase and 3 participants engaged in self-harm during the post-acute phase. There was an increased risk for elevated heart rate, systolic and diastolic blood pressure for all dose range categories, as well as an increased risk of nausea during the acute phase. Other common side effects included headaches, anxiety, and decreased concentration or appetite. This meta-analysis demonstrates that psychedelics are well-tolerated, with a low risk of emerging serious adverse events in a controlled setting with appropriate inclusion criteria.", "journal": "Psychiatry research", "publication_date": "2024-04-30", "publication_year": 2024, "doi": "10.1016/j.psychres.2024.115880", "pubmed_id": "38579460", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38579460/", "keywords": "Adverse events, LSD, Meta-analysis, Psilocybin, Psychedelic, Side effects", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"38579460\"}", "topic_tags": "Anxiety,Headache / Migraine,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1142, "title": "Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.", "normalized_title": "efficacy of psilocybin for treating symptoms of depression systematic review and meta analysis", "authors": "Metaxa AM, Clarke M.", "abstract": "ObjectiveTo determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs.DesignSystematic review and meta-analysis.Data sourcesFive electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four databases of unpublished and international literature (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, ProQuest Dissertations and Theses Global, and PsycEXTRA), and handsearching of reference lists, conference proceedings, and abstracts.Data synthesis and study qualityInformation on potential treatment effect moderators was extracted, including depression type (primary or secondary), previous use of psychedelics, psilocybin dosage, type of outcome measure (clinician rated or self-reported), and personal characteristics (eg, age, sex). Data were synthesised using a random effects meta-analysis model, and observed heterogeneity and the effect of covariates were investigated with subgroup analyses and metaregression. Hedges’ g was used as a measure of treatment effect size, to account for small sample effects and substantial differences between the included studies’ sample sizes. Study quality was appraised using Cochrane’s Risk of Bias 2 tool, and the quality of the aggregated evidence was evaluated using GRADE guidelines.Eligibility criteriaRandomised trials in which psilocybin was administered as a standalone treatment for adults with clinically significant symptoms of depression and change in symptoms was measured using a validated clinician rated or self-report scale. Studies with directive psychotherapy were included if the psychotherapeutic component was present in both experimental and control conditions. Participants with depression regardless of comorbidities (eg, cancer) were eligible.ResultsMeta-analysis on 436 participants (228 female participants), average age 36-60 years, from seven of the nine included studies showed a significant benefit of psilocybin (Hedges’ g=0.66, 95% confidence interval (CI) 0.46 to 0.86, P", "journal": null, "publication_date": "2024-04-30", "publication_year": 2024, "doi": "10.1136/bmj-2023-078084", "pubmed_id": "38692686", "source_url": "https://doi.org/10.1136/bmj-2023-078084", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Treatment Outcome, Depression, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38692686\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Healthcare Workers,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3362, "title": "Do undergraduates’ views of psychedelics relate to the context for psychedelic use?", "normalized_title": "do undergraduates views of psychedelics relate to the context for psychedelic use", "authors": "Petrovitch D, Van Allen J, Mitchell SM, Littlefield AK.", "abstract": "Background. Psychedelic drug policy is beginning to change, both in the U.S. and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for therapeutic efficacy, user safety, likely future legality, and other important characteristics. We compared psychedelic-naïve undergraduates’ views (expectancies, perceptions of benefits, and perceptions of harms) of psilocybin and lysergic acid diethylamide (LSD) across each context, assessed via multiple item pools. Methods. Item-level data were analyzed using non-parametric methods, correcting for multiple comparisons. Participants were 277 psychedelic-naïve undergraduates (75.81% female; 81.95% White; 76.17% non-Hispanic), with a mean age of approximately 19.50 years (SD = 2.01). Results. Only 19 out of 79 omnibus tests assessing views of psychedelics across contexts were statistically significant; when participants’ views of psychedelics were context dependent, they generally had the most positive views of clinical contexts, then microdosing, and, lastly, naturalistic contexts. Conclusion. This indicates that psychedelic-naïve undergraduates make limited distinctions between contexts for psychedelic use, suggesting that a) researchers should define the type of use they intend to study as explicitly as possible when surveying psychedelic-naïve populations and b) in the U.S., psychedelic-naïve undergraduates may benefit from education about differences between contexts, especially considering their potential to impact public policy. Future work should extend these findings to undergraduates (i.e., potential voters) from different U.S. states and international countries to better understand emerging policy phenomena surrounding psychedelics.", "journal": "PsyArXiv", "publication_date": "2024-04-23", "publication_year": 2024, "doi": "10.31234/osf.io/xnu5c", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/xnu5c", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR843121\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Microdosing,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1162, "title": "Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.", "normalized_title": "psilocybin therapy and anorexia nervosa a narrative review of safety considerations for researchers and clinicians", "authors": "Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M.", "abstract": "BackgroundClinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities. The purpose of this review is to describe how the common physiologic adverse effects of psilocybin may impact medical complications experienced by individuals with AN in clinical trials of psilocybin therapy.Main bodyThe physiologic underpinnings of common adverse effects following psilocybin administration are described, including tachycardia, hypertension, electrocardiogram changes, nausea, headache, and lightheadedness. These anticipated physiologic changes are described in relation to the common medical correlates seen in individuals with AN. Risk mitigation strategies for each adverse effect are proposed.ConclusionEarly evidence suggests that psilocybin therapy is well-tolerated in individuals with AN. Understanding the unique medical complications of AN, and how they may be impacted by common physiologic adverse effects of psilocybin administration, leads to tailored risk mitigation strategies to enhance safety and tolerability of this novel intervention.", "journal": null, "publication_date": "2024-04-23", "publication_year": 2024, "doi": "10.1186/s40337-024-01005-z", "pubmed_id": "38659049", "source_url": "https://doi.org/10.1186/s40337-024-01005-z", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38659049\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Headache / Migraine,Clinical Trial,Review Article,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 527, "title": "Do undergraduates’ views of psychedelics relate to the context for psychedelic use?", "normalized_title": "do undergraduates views of psychedelics relate to the context for psychedelic use", "authors": "", "abstract": "Background. Psychedelic drug policy is beginning to change, both in the U.S. and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for therapeutic efficacy, user safety, likely future legality, and other important characteristics. We compared psychedelic-naïve undergraduates’ views (expectancies, perceptions of benefits, and perceptions of harms) of psilocybin and lysergic acid diethylamide (LSD) across each context, assessed via multiple item pools. Methods. Item-level data were analyzed using non-parametric methods, correcting for multiple comparisons. Participants were 277 psychedelic-naïve undergraduates (75.81% female; 81.95% White; 76.17% non-Hispanic), with a mean age of approximately 19.50 years (SD = 2.01). Results. Only 19 out of 79 omnibus tests assessing views of psychedelics across contexts were statistically significant; when participants’ views of psychedelics were context dependent, they generally had the most positive views of clinical contexts, then microdosing, and, lastly, naturalistic contexts. Conclusion. This indicates that psychedelic-naïve undergraduates make limited distinctions between contexts for psychedelic use, suggesting that a) researchers should define the type of use they intend to study as explicitly as possible when surveying psychedelic-naïve populations and b) in the U.S., psychedelic-naïve undergraduates may benefit from education about differences between contexts, especially considering their potential to impact public policy. Future work should extend these findings to undergraduates (i.e., potential voters) from different U.S. states and international countries to better understand emerging policy phenomena surrounding psychedelics.", "journal": "PsyArXiv", "publication_date": "2024-04-23", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/xnu5c_v1", "keywords": "expectancies, microdosing, naturalistic psychedelic use, perceptions of benefits, psychedelic-assisted therapy, risk perceptions, Social and Behavioral Sciences, Clinical Psychology, Substance Abuse and Addiction", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"xnu5c_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Addiction,Microdosing,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4638, "title": "MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More", "normalized_title": "medcheck psilocybin for depression lsd for anxiety donanemab lsd and more", "authors": "Terri D’Arrigo", "abstract": "Back to table of contents Previous article Next article Med CheckFull AccessMedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and MoreTerri D'ArrigoTerri D'ArrigoPublished Online:23 Apr 2024https://doi.org/10.1176/appi.pn.2024.05.5.1Vanda Gets Yes for Iloperidone for Bipolar, No for InsomniaVanda Pharmaceuticals Inc. announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009.The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder. After four weeks of treatment, patients treated with iloperidone exhibited a 14-point drop on the Young Mania Rating Scale, compared with a 10-point drop among patients taking placebo. A statistically significant difference in mania improvement between iloperidone and placebo was evident after two weeks.The success of iloperidone offsets the decision that Vanda received in March, when the FDA rejected its melatonin receptor-blocking drug Hetlioz (tasimelteon) as a treatment for insomnia. The agency stated that it \"identified deficiencies that precluded discussion of labeling and postmarketing requirements/commitments.\"Psilocybin Analog Gets Breakthrough Designation From FDAIn March, the FDA granted Breakthrough Therapy designation to the psilocybin analog CYB003 for the adjunctive treatment of major depressive disorder (MDD), Cybin announced. The FDA's Breakthrough Therapy designation expedites the development and review of drugs for serious conditions. The criteria for Breakthrough Therapy designation require preliminary clinical evidence that indicates that the drug may demonstrate substantial improvement over available therapy on at least one clinically significant endpoint.The Breakthrough Designation was based on data from a phase 2 trial that compared CYB003 and placebo in 34 patients with moderate to severe MDD. Patients in the trial who received two doses of either 12 mg or 16 mg of CYB003 experienced an average 22-point reduction from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) after four months. Sixty percent of patients who received 12 mg and 75% of those who received 16 mg were in remission (MADRS score of less than or equal to 10) after four months.There were no drug-related serious adverse events, incidents of suicidal ideation or behavior, or discontinuations due to adverse events.Form of LSD Granted Breakthrough Therapy Designation for AnxietyThe FDA also gave Breakthrough Therapy designation to another psychedelic therapy in March, Mind Medicine Inc's MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder. MM120 is a tartrate salt form of lysergide, more commonly known as LSD. The FDA granted the designation based on data from the phase 2 MMED008 study.The study included 194 patients who had severe symptoms of generalized anxiety disorder with an average baseline score of roughly 30 on the Hamilton Anxiety Rating Scale (HAM-A). Patients were then randomized to receive treatment with 25, 50, 100, or 200 μg of MM120 or placebo. Those who received 100 µg had an average 21.3-point reduction in HAM-A score at week 4, compared with an average reduction of 13.7-point reduction in those who took placebo. Results were similar at week 12, suggesting this medication provides a durable response.Pimavanserin Fails Phase 3 Schizophrenia TrialPatients with schizophrenia who took Nuplazid (pimavanserin) in the phase 3 ADVANCE-2 trial did not experience a statistically significant improvement in their negative symptoms compared with patients who took placebo, Acadia Pharmaceuticals announced in March.In the 26-week trial, 454 adults with predominant negative symptoms of schizophrenia were randomized to receive either two 17 mg tablets of pimavanserin or placebo daily. At study's end, those who took pimavanserin experienced a mean reduction of 11.8 points from baseline on the Negative Symptom Assessment-16, compared with a mean reduction of 11.1 points among those in the placebo group.\"We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,\" said Steve Davis, J.D., Acadia's chief executive officer in the announcement. \"We will continue to analyze these data with our scientific advisors, but we do not intend to conduct any further clinical trials with pimavanserin.\"FDA Meeting Will Delay Decision on Donanemab For Early Alzheimer'sIn March Eli Lilly & Co. announced that the FDA's Peripheral and Central Nervous System Drugs Advisory Committee will hold a meeting to discuss the Phase 3 TRAILBLAZER-ALZ2 trial on the efficacy and safety of donanemab in early symptomatic Alzheimer's disease. As Psychiatric News went to press, the FDA had not yet set a date for the meeting. Lilly had expected the FDA to approve donanemab in the first quarter of 2024, and this meeting will delay that decision.According to the statement by Lilly, the FDA wanted to further understand the safety results in donanemab-treated patients and how the unique trial design of the TRAILBLAZER-ALZ2 study might affect efficacy findings. The study required participants to have evidence of both amyloid and tau pathology and featured a limited-duration dosing regimen that allowed patients to complete treatment based on an assessment of amyloid plaque.The FDA had previously granted Breakthrough Therapy designation to donanemab based on the Phase 2 clinical trial TRAILBLAZER-ALZ. In that trial, patients who received donanemab experienced less cognitive and functional decline over the course of the trial, as measured by the change from baseline on the Integrated Alzheimer's Disease Rating Scale.The FDA later declined to accept donanemab into the accelerated approval pathway. ■ ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2024-04-22", "publication_year": 2024, "doi": "10.1176/appi.pn.2024.05.5.1", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1176/appi.pn.2024.05.5.1", "keywords": "Psilocybin, Hallucinogen, Anxiety, Lysergic acid diethylamide, Depression (economics), Psychology, Clinical psychology, Psychiatry, Medicine, Internal medicine, Serotonin, Economics, Macroeconomics, Receptor, Psychedelics and Drug Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4395032120\",\"openalex_url\":\"https://openalex.org/W4395032120\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"compound:cyb003\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5056763663\",\"display_name\":\"Terri D’Arrigo\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"http://dx.doi.org/10.1176/appi.pn.2024.05.5.1\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4395032120" }, { "id": 3434, "title": "The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study", "normalized_title": "the effect of psilocybin on mdd symptom severity and synaptic density a single dose randomized double blind placebo controlled phase 2 positron emission tomography study", "authors": "Section for Affective Disorders; Northern Stockholm Psychiatry", "abstract": "PROTOCOL SYNOPSIS Title The effect of psilocybin on Major depressive disorder (MDD) symptom severity and synaptic density - a single dose randomized, double blind, placebo-controlled phase 2b positron emission tomography study Study Code PSIPET Name of Sponsor SLSO Organisationsnr: 232100-0016 Sponsor representative: Andreas Carlborg Norra Stockholms Psykiatri Vårdvägen 3 112 19 Stockholm Sweden Medical Monitor Inspira Medical AB Phase of Study Phase 2b Sample Size 30 randomized Name of Investigational Product (IP) Psilocybin, 3-\\[2-(dimethylamino)ethyl\\]-1H-indol-4-yl\\] dihydrogen phosphate Name of Active Placebo Niacin EudraCT 2020-002790-94 Description of IP and Active Placebo PSIPET Protocol 5 200821 Page 14 Study Intervention Name: Psilocybin (active drug product) Niacin (active placebo product) Dosage formulation: One active capsule contains 25 mg of psilocybin One active placebo capsule contains 100 mg of niacin Capsule: Size 2 hydroxypropyl methylcellulose (HPMC), opaque Size 2 HPMC, opaque Unit dose strength: 25 mg 100 mg Route of Administration: Oral (solid dose) Oral (solid dose) Dosing instructions: One capsule administered with water One capsule administered with water Packaging and Labeling: Study Intervention will be provided in a high-density polyethylene (HDPE) bottle. Each bottle will contain one capsule (psilocybin or niacin) and will be labeled as required per Swedish requirement for blinded study. Study Description and Overview Thirty participants (males and females) ages 20 to 65 inclusive, who, at Screening, meet ICD-10 criteria for major depressive disorder (MDD), have a current depressive episode of at least 30-day duration, have a Screening Montgomery-Asberg Depression Rating Scale (MADRS) total score \\>= 22 and meet all other inclusion/exclusion criteria will be randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo control that provides an acute physiological response (flushing) that is intended to aid in blinding of intervention allocation. All randomized participants will be included in the Full Analysis Set (FAS) population used in analyzing primary and secondary study endpoints. Only participants who meet depressive symptom severity criteria at web screening (MADRS self-rating (MADRS-S) score \\> =19) and who do not show an unacceptably large degree of symptom improvement between the web screening and in-person screening (indexed by change in MADRS-S (improvement) 30% (MADRS representing web screening will be approximated to MADRS-S + 3) will be eligible for randomization. This is to minimize the risk for spontaneous remission before dosing. Participants deemed eligible following successful completion of all screening assessments including a structural Magnetic Resonance Imaging (MRI) examination will be determined as eligible. Eligible participants at Baseline will submit cerebrospinal fluid (CSF), submit blood samples, be examined with positron emission tomography (PET) and the radioligand \\[11C\\]UCB-J and receive one preparation session (see further below) to be eligible for randomization on Dosing (Day 0) to receive either psilocybin or niacin active-placebo. They will complete follow-up visits, including outcome measures assessments, on study Day 1, 8, 15, 42 and 365 (within corresponding visit windows). At day 15 the sampling of CSF, blood and \\[11C\\]UCB-J PET will be repeated. PSIPET Protocol 5 200821 Page 15 After day 42, all participants will be given follow-up visits at Norra Stockholms Psykiatri for up to one year after dosing, to study dedicated physicians or nurses at a frequency determined by the health care professional. If needed to reach/stay in remission, the participants will be provided antidepressant treatment in accordance with the regional guidelines for antidepressant treatment (https://psykiatristod.se/regionala-vardprogram/ depression). At least monthly the participants will be asked to provide on-line symptom rating data (via 1177.se). At the 365-day visit, symptoms will be evaluated using MADRS, Clinical Global Impression Improvement (CGI-I) and Severity (CGI-S) scales. After completing the study (one year or withdrawal), participants will be subject to standard care, including referral in accordance with regional guidelines. The study outcome measures will be used to assess depressive symptoms, clinical global functioning, functional disability, anxiety symptoms and health-related quality of life. Safety outcome measures will be collected at all assessment time points from the time of consent through the end of study. To enhance participant safety, the current study proposes to test psilocybin within a \"set and setting\" (SaS) protocol similar to the protocol that has been used in all modern studies of psilocybin in both diseased and normal healthy populations. The SaS protocol for this study includes: 1) a preparation with session Facilitators (licensed psychologists) prior to dosing; 2) administration of study medications in an aesthetically neutral room under the supervision of two Facilitators who are present throughout the session (with the exception of short, temporary allowances for facilitator breaks; e.g. bathroom breaks); and 3) three post-dose integration sessions during which participants are encouraged to discuss their intervention experience with the Facilitators. To evaluate the Facilitators' adherence to the study manual, and the role of Facilitators' and participants' in-session behaviors for treatment outcome, all five sessions in the trial with Facilitators present will be recorded. The SaS will be identical for those randomized to psilocybin or niacin active placebo. Study Duration The planned maximum study duration for each participant will be approximately one year, with variation primarily dependent on the length of the screening period, the number of days between baseline and dosing, and the visit windows provided for each post-dose assessment. For each participant, the study will be divided into two phases: Phase A or treatment phase (day 0 to and including day 42), and phase B or follow-up phase (day 43 -365). The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an active placebo (niacin) in otherwise medically-healthy participants between the ages of 20 and 65, assessed as the difference between groups in changes in depressive symptoms. Primary Outcome Measure Change in blinded rater MADRS total score from Baseline to Day 8.", "journal": "ClinicalTrials.gov", "publication_date": "2024-04-18", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04630964", "keywords": "Major Depressive Disorder, Depression, Psilocybin, Niacin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04630964\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Brain Imaging,Aging,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1164, "title": "Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress", "normalized_title": "palliative care patients attitudes and openness towards psilocybin assisted psychotherapy for existential distress", "authors": "Julia R. Wang, Samuel J. Mendez Araque, Gina Micciche, Andrew McMillan, Emily Coughlin, Rosalie Mattiola, Diana P. English, Kristopher Kaliebe", "abstract": "Introduction: Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approaches have limitations in addressing these burdens. Psilocybin, a promising psychedelic compound, may offer therapeutic benefits. This pilot survey study aimed to investigate the attitudes and openness toward psilocybin-assisted psychotherapy (PAT) among patients with incurable illnesses. The objective is to assess patients' attitudes toward PAT and identify potential barriers and concerns, including exploring the association between beliefs in psilocybin's therapeutic benefits and interest in receiving this treatment. Methods: The survey study was conducted at the Tampa General Hospital Palliative Care Outpatient office in the United States. Participants were 32 English-fluent patients, aged 18 or older, with incurable illnesses. The survey included demographic questions, a validated tool to measure existential distress, and questions about knowledge and concerns regarding psilocybin. Attitudes toward PAT and interest in its future use were assessed using Likert scale responses. Results: Among the 31 analyzed participants, 51.6% expressed interest in future psilocybin treatment, while 32.3% did not indicate interest. Belief in the psilocybin's therapeutic benefits for stress and anxiety significantly correlated with interest in use. Concerns included risk of psychosis, lack of trained providers, and potential for exploitation. No demographic factors were associated with interest or levels of distress. Conclusions: This pilot study provides insights into the attitudes and concerns toward PAT among patients with incurable illnesses. Over half of participants expressed interest. However, concerns regarding its use were identified, with patients' concern for the risk of exploitation associated with PAT as an especially novel concern documented in this patient population. This highlighted the need for further education of risks and benefits or PAT by trained clinicians and rigorous training of clinicians with the establishment of safeguards against exploitation. Further research is necessary to explore the potential benefits of PAT and related non-psilocybin psychedelic compounds in addressing existential distress among patients with incurable illnesses.", "journal": "Frontiers in Psychiatry", "publication_date": "2024-04-17", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1301960", "pubmed_id": "38699449", "source_url": "https://doi.org/10.3389/fpsyt.2024.1301960", "keywords": "Psilocybin, Psychotherapist, Openness to experience, Existentialism, Distress, Psychology, Palliative care, Psychiatry, Grief, Clinical psychology, Medicine, Hallucinogen, Nursing, Social psychology, Political science, Law, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4394924908\",\"openalex_url\":\"https://openalex.org/W4394924908\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W173089895\",\"https://openalex.org/W2060831503\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2145853206\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2538927475\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2619881061\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107917596\",\"https://openalex.org/W3195045424\",\"https://openalex.org/W3199302798\",\"https://openalex.org/W3216164364\",\"https://openalex.org/W4200517619\",\"https://openalex.org/W4225525501\",\"https://openalex.org/W4308057267\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W4385581517\",\"https://openalex.org/W4386069067\",\"https://openalex.org/W4391115210\"],\"authorships\":[{\"id\":\"https://openalex.org/A5114150902\",\"display_name\":\"Julia R. Wang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5114034914\",\"display_name\":\"Samuel J. Mendez Araque\",\"orcid\":null},{\"id\":\"https://openalex.org/A5095771419\",\"display_name\":\"Gina Micciche\",\"orcid\":null},{\"id\":\"https://openalex.org/A5103102159\",\"display_name\":\"Andrew McMillan\",\"orcid\":\"https://orcid.org/0009-0000-1101-3729\"},{\"id\":\"https://openalex.org/A5075377158\",\"display_name\":\"Emily Coughlin\",\"orcid\":\"https://orcid.org/0000-0002-9801-1861\"},{\"id\":\"https://openalex.org/A5049279590\",\"display_name\":\"Rosalie Mattiola\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101855593\",\"display_name\":\"Diana P. English\",\"orcid\":\"https://orcid.org/0000-0002-1251-715X\"},{\"id\":\"https://openalex.org/A5070488401\",\"display_name\":\"Kristopher Kaliebe\",\"orcid\":\"https://orcid.org/0000-0001-8395-0252\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2024.1301960\",\"is_oa\":true}}", "topic_tags": "Anxiety,End-of-Life Distress,Chronic Pain,Wellbeing,Observational Study,Healthcare Workers,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4394924908" }, { "id": 1120, "title": "Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety", "normalized_title": "treating bipolar depression using psilocybin validity threats regarding efficacy and safety", "authors": "Eiko I. Fried, Ioana A. Cristea, Florian Naudet", "abstract": "To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.", "journal": "JAMA Psychiatry", "publication_date": "2024-04-09", "publication_year": 2024, "doi": "10.1001/jamapsychiatry.2024.0420", "pubmed_id": "38598200", "source_url": "https://doi.org/10.1001/jamapsychiatry.2024.0420", "keywords": "Psilocybin, Depression (economics), Psychiatry, Bipolar disorder, Psychology, Hallucinogen, Medicine, Clinical psychology, Cognition, Economics, Macroeconomics, Psychedelics and Drug Studies, Pharmaceutical industry and healthcare, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4394676727\",\"openalex_url\":\"https://openalex.org/W4394676727\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1714980748\",\"https://openalex.org/W2115881392\",\"https://openalex.org/W2899754826\",\"https://openalex.org/W4387019277\",\"https://openalex.org/W4389397550\"],\"authorships\":[{\"id\":\"https://openalex.org/A5072520929\",\"display_name\":\"Eiko I. Fried\",\"orcid\":\"https://orcid.org/0000-0001-7469-594X\"},{\"id\":\"https://openalex.org/A5025084207\",\"display_name\":\"Ioana A. Cristea\",\"orcid\":\"https://orcid.org/0000-0002-9854-7076\"},{\"id\":\"https://openalex.org/A5081976341\",\"display_name\":\"Florian Naudet\",\"orcid\":\"https://orcid.org/0000-0003-3760-3801\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2495708506\",\"source_display_name\":\"JAMA Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1001/jamapsychiatry.2024.0420\",\"is_oa\":false}}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4394676727" }, { "id": 3724, "title": "Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.", "normalized_title": "psilocybin for dementia prevention the potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases", "authors": "Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S.", "abstract": "Major depression is an established risk factor for subsequent dementia, and depression in late life may also represent a prodromal state of dementia. Considering current challenges in the clinical development of disease modifying therapies for dementia, the focus of research is shifting towards prevention and modification of risk factors to alter the neurodegenerative disease trajectory. Understanding mechanistic commonalities underlying affective symptoms and cognitive decline may reveal biomarkers to aid early identification of those at risk of progressing to dementia during the preclinical phase of disease, thus allowing for timely intervention. Adult hippocampal neurogenesis (AHN) is a phenomenon that describes the birth of new neurons in the dentate gyrus throughout life and it is associated with spatial learning, memory and mood regulation. Microglia are innate immune system macrophages in the central nervous system that carefully regulate AHN via multiple mechanisms. Disruption in AHN is associated with both dementia and major depression and microgliosis is a hallmark of several neurodegenerative diseases. Emerging evidence suggests that psychedelics promote neuroplasticity, including neurogenesis, and may also be immunomodulatory. In this context, psilocybin, a serotonergic agonist with rapid-acting antidepressant properties has the potential to ameliorate intersecting pathophysiological processes relevant for both major depression and neurodegenerative diseases. In this narrative review, we focus on the evidence base for the effects of psilocybin on adult hippocampal neurogenesis and microglial form and function; which may suggest that psilocybin has the potential to modulate multiple mechanisms of action, and may have implications in altering the progression from major depression to dementia in those at risk.", "journal": null, "publication_date": "2024-04-05", "publication_year": 2024, "doi": "10.1016/j.pharmthera.2024.108641", "pubmed_id": "38583670", "source_url": "https://doi.org/10.1016/j.pharmthera.2024.108641", "keywords": "Hippocampus, Microglia, Animals, Humans, Dementia, Neurodegenerative Diseases, Hallucinogens, Antidepressive Agents, Neurogenesis, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:08:41", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38583670\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Neuroplasticity,Neurogenesis,Mechanism of Action,Biomarkers,Review Article,Animal Study,Safety,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4644, "title": "A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions", "normalized_title": "a double edged sword insights from practitioners on the short and long term negative effects of psilocybin assisted psychological interventions", "authors": "M. Nordin, Jón Ingi Hlynsson, Jakob Håkansson Eklund, Per Carlbring", "abstract": "Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybin, in combination with therapy, has shown promising results as a treatment for a range of psychiatric conditions. However, the negative effects and risks of psilocybin-assisted treatment are not well-established. The purpose of this study was to investigate the potential negative effects of psilocybin-assisted psychological interventions in both the short and long term. Method Semi-structured interviews were conducted with eight psychedelic treatment providers and facilitators. Their content was thematically interpreted. Results Three themes of short-term negative effects were identified. They included negative reactions to psilocybin dosing sessions, undesirable processes in the therapeutic relationship, and difficult self-experiences. Four themes of long-term negative effects were identified. They included destabilization of the client, difficulties adapting to life post-treatment, complications in the treatment relationship, and undesirable outcomes. Conclusions These results highlight the multifaceted challenges clients may face, emphasizing the need for thorough pre-intervention assessment and post-intervention support. The findings both confirm previous research and highlight new aspects that can contribute to increased safety and be relevant for clinical implementation. Further rigorous research is needed to ensure safety, establish ethical guidelines, and optimize the positive effects of these experimental medicines. Integrating various research approaches and types of measurements will be vital to further our understanding of negative effects of psychedelic-assisted therapy.", "journal": "Journal of Psychedelic Studies", "publication_date": "2024-04-01", "publication_year": 2024, "doi": "10.1556/2054.2024.00337", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2024.00337", "keywords": "Psilocybin, SWORD, Psychological intervention, Psychology, Term (time), Psychotherapist, Computer science, Psychiatry, Hallucinogen, World Wide Web, Physics, Quantum mechanics, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4393547236\",\"openalex_url\":\"https://openalex.org/W4393547236\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":17,\"referenced_works\":[\"https://openalex.org/W1552593762\",\"https://openalex.org/W1575674910\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2091383190\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2105822909\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2320474352\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2525015314\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2757674554\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2784069100\",\"https://openalex.org/W2883140809\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W4206965048\",\"https://openalex.org/W4210496680\",\"https://openalex.org/W4211080744\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4238155059\",\"https://openalex.org/W4241522357\",\"https://openalex.org/W4248739613\",\"https://openalex.org/W4255564469\",\"https://openalex.org/W4281687410\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4312059979\",\"https://openalex.org/W4315928396\",\"https://openalex.org/W4317881824\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4364348136\",\"https://openalex.org/W4385173317\",\"https://openalex.org/W4389139111\",\"https://openalex.org/W7062190157\"],\"authorships\":[{\"id\":\"https://openalex.org/A5085178989\",\"display_name\":\"M. Nordin\",\"orcid\":\"https://orcid.org/0009-0000-0841-1267\"},{\"id\":\"https://openalex.org/A5093694073\",\"display_name\":\"Jón Ingi Hlynsson\",\"orcid\":\"https://orcid.org/0009-0000-5703-1068\"},{\"id\":\"https://openalex.org/A5051827104\",\"display_name\":\"Jakob Håkansson Eklund\",\"orcid\":\"https://orcid.org/0000-0001-7839-7245\"},{\"id\":\"https://openalex.org/A5082635131\",\"display_name\":\"Per Carlbring\",\"orcid\":\"https://orcid.org/0000-0002-2172-8813\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2024.00337\",\"is_oa\":true}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4393547236" }, { "id": 3610, "title": "Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)", "normalized_title": "psilocybin assisted psychotherapy for treatment resistant depression a randomized phase ii clinical trial comparing one versus two psychedelic doses of psilocybin psi 1v2", "authors": "University Health Network, Toronto", "abstract": "The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD). Researchers also want to know if a second dose of psilocybin is safe and well-tolerated. This study will see if psilocybin is effective, safe, and well-tolerated by tracking changes in depressive symptoms, suicidality, and side effects. This study will also see if a second dose of psilocybin has an effect on quality of life, functioning, cognition (thinking, reasoning, remembering), and how long depressive symptoms improve (or worsen) after psilocybin is administered. During the past decade, there has been increased interest in the use of psilocybin as a novel treatment for mental health disorders, including treatment-resistant depression (TRD). Recent studies have suggested that psilocybin has the potential to relieve depressive symptoms when combined with psychotherapy (i.e., psilocybin-assisted psychotherapy \\[PAP\\]). Each psilocybin dosing session requires the use of extensive resources, including two specialized therapists supporting the patient for 6-8 hours per dosing session. If two doses of psilocybin prove to be more effective than a single dose of psilocybin in relieving depressive symptoms, then two doses should be the standard intervention for future trials and clinical application. However, if a second dose of psilocybin does not offer increased anti-depressant benefit from the first dose, then a second dose of psilocybin would only increase the risk of adverse side effects and cost of treatment. Therefore, the purpose of this study is to determine whether a second dose of psilocybin provides better efficacy, safety and tolerability than a single dose. The investigators hypothesize that two doses of psilocybin will be more beneficial compared to a single dose, and that there will be no significant difference between the groups (one dose versus two doses) in safety or tolerability. The primary objective of assessing antidepressant efficacy will be evaluated by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) between baseline and Week 8. Safety and tolerability will be assessed using standardized adverse effects monitoring, in addition to close participant monitoring during the dosing day (e.g., blood pressure changes, dissociative and psychotomimetic effects, treatment-emergent manic symptoms, and suicidality). Secondary objectives include evaluating the effects of one versus two psilocybin doses on suicidality, quality of life, functioning, cognition, and duration of clinical benefits during the six month observational follow-up period. Exploratory objectives include evaluating predictors of response, such as static and dynamic clinical factors and expectancy effects, and cost-effectiveness of one versus two psilocybin doses.", "journal": "ClinicalTrials.gov", "publication_date": "2024-04-01", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06341426", "keywords": "Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders, Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin, RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06341426\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Observational Study,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 4658, "title": "Current situation regarding psychedelics and magic mushroom in Korea", "normalized_title": "current situation regarding psychedelics and magic mushroom in korea", "authors": "J. S. Seo", "abstract": "Introduction Recently, the pros and cons have been debating in Korea even before the approval of use of medical marijuana with very strict limitations. And the next controversial topic is psychedelics. In 1890, when mescaline was first isolated from peyote cactus, clinical researches began, but due to its harmful effects, it was thereafter legally prohibited in 1970 in USA. However, a pernicious debate over the medical efficacy of psychedelic drugs has begun again with the release of a study that uses psychedelic mushrooms to be effective against treatment-resistant depression, alcohol dependence, and depression and anxiety in terminal cancer patient. Objectives To make a consensus on the medical use of these, we reviewed wild mushrooms containing hallucinogenic ingredients living in Korea. Methods To make a consensus on the medical use of these, we reviewed wild mushrooms containing hallucinogenic ingredients living in Korea. Results Mushrooms have long been popular as a food ingredient in Korea. Psilocybin, a classical psychedelic, can be obtained from magic mushroom (Psilocybe cubensis). The psilocybin on the CNS and causes hallucinations. Intoxication symptoms include pleasant or nervousness, sudden laughter, hallucinations, visual impairment, tachycardia and hypertension, reflexes, agitation, cognitive impairment, confusion, and aggressive behavior. These symptoms last for 2-4 hours after ingestion, and most disappear within six hours. Among 114 species of Psilocybe containing psilocybin around the world, only five wild mushrooms found in Korea that cause nervous system hallucinations are as follows: P. argentipes, P. coprophila, P. perdaria, and P. subcarulipes. In Korea, there is acute poisoning case suffering with GI symptoms caused by mushrooms, but it is difficult to find records of abuse or dependences case caused by psychedelic mushrooms. In addition, although oriental medicine treatment is relatively active, it is not used as an herbal medicine. Conclusions Currently, the Korean government classifies psychedelic mushroom-derived substances, Psilocybin and Psilocin, as psychotropic drugs by law. If researcher intends to clinical trial with eve very small amount of it for academic purpose, it is only possible after obtaining approval from Korean FDA. In order to determine the usefulness of psychedelics, many clinical studies are needed in Korea. Disclosure of Interest None Declared", "journal": "European Psychiatry", "publication_date": "2024-03-31", "publication_year": 2024, "doi": "10.1192/j.eurpsy.2024.1695", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1192/j.eurpsy.2024.1695", "keywords": "Mushroom, MAGIC (telescope), Psychology, Biology, Physics, Food science, Astronomy, Food Quality and Safety Studies, Ecology and Conservation Studies, Plant and animal studies", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4401921810\",\"openalex_url\":\"https://openalex.org/W4401921810\",\"openalex_relevance_score\":8,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5111303550\",\"display_name\":\"J. S. Seo\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S87202501\",\"source_display_name\":\"European Psychiatry\",\"landing_page_url\":\"http://dx.doi.org/10.1192/j.eurpsy.2024.1695\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4401921810" }, { "id": 1172, "title": "Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.", "normalized_title": "acute adverse effects of therapeutic doses of psilocybin a systematic review and meta analysis", "authors": "Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J.", "abstract": "ImportancePsilocybin has been studied in the treatment of depression and anxiety disorders. Clinical studies have mainly focused on efficacy, with systematic reviews showing favorable efficacy; however, none have primarily focused on psilocybin safety.ObjectiveTo evaluate the acute adverse effects of psilocybin at therapeutic doses in the treatment of depression and anxiety.Data sourcesMEDLINE via PubMed, Web of Science, and ClinicalTrials.gov were searched for publications available between 1966 and November 30, 2023.Study selectionRandomized, double-blind clinical trials that reported adverse effects of psilocybin in patients treated for depression and anxiety were screened.Data extraction and synthesisData were independently extracted by 2 authors and verified by 2 additional authors following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. The inverse variance method with the Hartung-Knapp adjustment for the random-effects model was used, with a continuity correction of 0.5 for studies with 0 cell frequencies. Sensitivity analysis was conducted by sequentially removing 1 study at a time to assess the robustness of the results.Main outcomes and measuresThe primary outcome was considered as the adverse effects of psilocybin at high and moderate (ie, therapeutic) dose regimens and compared with placebo, low-dose psilocybin, or other comparator in the treatment of depression and/or anxiety.ResultsSix studies met the inclusion criteria with a total sample of 528 participants (approximately 51% female; median age 39.8 years; IQR, 39.8-41.2). Seven adverse effects were reported in multiple studies and included in the analysis. Among these, headache (relative risk [RR], 1.99; 95% CI1.06-3.74), nausea (RR, 8.85; 95% CI, 5.68-13.79), anxiety (RR, 2.27; 95% CI, 1.11-4.64), dizziness (RR, 5.81; 95% CI, 1.02-33.03), and elevated blood pressure (RR, 2.29; 95% CI, 1.15- 4.53) were statistically significant. Psilocybin use was not associated with risk of paranoia and transient thought disorder.Conclusions and relevanceIn this meta-analysis, the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be tolerable and resolved within 48 hours. However, future studies need to more actively evaluate the appropriate management of adverse effects.", "journal": null, "publication_date": "2024-03-31", "publication_year": 2024, "doi": "10.1001/jamanetworkopen.2024.5960", "pubmed_id": "38598236", "source_url": "https://doi.org/10.1001/jamanetworkopen.2024.5960", "keywords": "Humans, Dizziness, Anxiety, Anxiety Disorders, Adult, Female, Male, Randomized Controlled Trials as Topic, Drug-Related Side Effects and Adverse Reactions, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38598236\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1147, "title": "Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.", "normalized_title": "efficacy and safety of psychedelics for the treatment of mental disorders a systematic review and meta analysis", "authors": "Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP, Lu L, Han Y.", "abstract": "We aim to systematically review and meta-analyze the effectiveness and safety of psychedelics [psilocybin, ayahuasca (active component DMT), LSD and MDMA] in treating symptoms of various mental disorders. Web of Science, Embase, EBSCO, and PubMed were searched up to February 2024 and 126 articles were finally included. Results showed that psilocybin has the largest number of articles on treating mood disorders (N = 28), followed by ayahuasca (N = 7) and LSD (N = 6). Overall, psychedelics have therapeutic effects on mental disorders such as depression and anxiety. Specifically, psilocybin (Hedges' g = -1.49, 95% CI [-1.67, -1.30]) showed the strongest therapeutic effect among four psychedelics, followed by ayahuasca (Hedges' g = -1.34, 95% CI [-1.86, -0.82]), MDMA (Hedges' g = -0.83, 95% CI [-1.33, -0.32]), and LSD (Hedges' g = -0.65, 95% CI [-1.03, -0.27]). A small amount of evidence also supports psychedelics improving tobacco addiction, eating disorders, sleep disorders, borderline personality disorder, obsessive-compulsive disorder, and body dysmorphic disorder. The most common adverse event with psychedelics was headache. Nearly a third of the articles reported that no participants reported lasting adverse effects. Our analyses suggest that psychedelics reduce negative mood, and have potential efficacy in other mental disorders, such as substance-use disorders and PTSD.", "journal": null, "publication_date": "2024-03-27", "publication_year": 2024, "doi": "10.1016/j.psychres.2024.115886", "pubmed_id": "38574699", "source_url": "https://doi.org/10.1016/j.psychres.2024.115886", "keywords": "Humans, Banisteriopsis, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38574699\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Eating Disorders,Headache / Migraine,Personality Change,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4660, "title": "MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide", "normalized_title": "medcheck psilocybin roluperidone latozinemab lacosamide", "authors": "Terri D’Arrigo", "abstract": "Back to table of contents Previous article Next article Med CheckFull AccessMedCheck; Psilocybin, Roluperidone, Latozinemab, LacosamideTerri D'ArrigoTerri D'ArrigoPublished Online:26 Mar 2024https://doi.org/10.1176/appi.pn.2024.04.4.1Psilocybin Promising for Anxiety DisorderIncannex's investigational psilocybin product PSX-001 appeared to be effective in relieving symptoms of generalized anxiety disorder in a phase 2 clinical trial, the company announced in February.In the PsiGAD1 trial, 72 patients with generalized anxiety disorder were randomized> to receive psychotherapy with either psilocybin or placebo for seven weeks. Their symptoms were measured with the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at 11 weeks.The reduction in HAM-A score from baseline in the psilocybin group was 12.8 points, compared with a reduction of 3.6 points in the placebo group. In addition, 44% of patients in the psilocybin group showed a clinically meaningful improvement (at least a 50% reduction in anxiety scores from baseline), which was more than four times higher than that of the placebo group. Further, 27% of patients in the psilocybin group achieved full disease remission, a rate more than five times higher than that of the placebo group.FDA Rejects Roluperidone for Negative Symptoms of SchizophreniaIn February the Food and Drug Administration (FDA) rejected the New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia, Minerva Neurosciences announced.In its Complete Response Letter, the FDA cited several clinical deficiencies:Although one study (MIN-101C03) demonstrated statistical improvements in negative symptoms, it is insufficient on its own to establish substantial evidence of effectiveness.The NDA submission also did not establish that the change in negative symptoms with roluperidone treatment was clinically meaningful.The NDA submission lacked data on concomitant antipsychotic administration.The safety data did not include enough patients exposed to roluperidone at the proposed 64 mg dose for at least 12 months.The FDA's letter stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms of schizophrenia. The letter added that Minerva must also provide additional data to demonstrate the safety and efficacy of roluperidone co-administered with antipsychotic medications, to support that observed effect on negative symptoms with roluperidone treatment corresponds to a clinically meaningful change, and to demonstrate the long-term safety of the proposed dose.Latozinemab Gets Breakthrough Status for Frontotemporal DementiaThe FDA granted Breakthrough Therapy designation to latozinemab for frontotemporal dementia with a progranulin gene mutation, Alector Inc. announced in February. Progranulin regulates immune activity in the brain and helps keep neurons and other brain cells healthy.A Breakthrough Therapy designation expedites the development and review of drugs for serious conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing options on at least one clinically significant endpoint.The FDA granted Breakthrough Therapy designation for latozinemab based on the results of the phase 2 clinical trial INFRONT-2. This trial evaluated 12 patients with a progranulin mutation causative of frontotemporal dementia who were treated with 60 mg/kg of latozinemab every four weeks over 12 months. The study found that treatment with latozinemab in these patients slowed disease progression by about 47% over one year compared with a control group of frontotemporal dementia patients. The study also found that latozinemab elevated progranulin in both plasma and cerebrospinal fluid in the patients for the duration of treatment.Motpoly XR Now Available For Treatment of Partial-Onset SeizuresIn February Aucta Pharmaceuticals Inc. announced its launch of Motpoly XR (lacosamide) extended-release capsules C-V in the 100 mg, 150 mg, and 200 mg doses for the treatment of partial-onset seizures in adults and in pediatric patients who weigh at least 50 kg (110.2) pounds. Motopoly XR is bioequivalent to Vimpat (lacosamide) film-coated tablets C-V and provides a once-daily option at equivalent doses. It will be available through retail pharmacies.The prescribing information for Motopoly XR notes that prescribers should monitor patients for suicidal behavior and ideation. It also notes that the drug may cause dizziness, ataxia, and fainting. In addition, it recommends that prescribers obtain an electrocardiogram before beginning the medication and after titration to steady-state maintenance and to closely monitor patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction. Finally, Motopoly XR should be gradually withdrawn to minimize the potential of increased seizure frequency. ■ ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2024-03-25", "publication_year": 2024, "doi": "10.1176/appi.pn.2024.04.4.1", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1176/appi.pn.2024.04.4.1", "keywords": "Lacosamide, Psilocybin, Computer science, Medicine, Psychology, Pharmacology, Neuroscience, Hallucinogen, Epilepsy, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:43", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4393210403\",\"openalex_url\":\"https://openalex.org/W4393210403\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5056763663\",\"display_name\":\"Terri D’Arrigo\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"http://dx.doi.org/10.1176/appi.pn.2024.04.4.1\",\"is_oa\":false}}", "topic_tags": "Anxiety,Pharmacology,Clinical Trial,Review Article,Safety,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4393210403" }, { "id": 1148, "title": "Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression", "normalized_title": "effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression", "authors": "David Erritzøe, Tommaso Barba, Meg J. Spriggs, Fernando E. Rosas, David Nutt, Robin Carhart-Harris", "abstract": "BACKGROUND: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in psychedelic trials are usually required to discontinue SNRI/SNRIs prior to enrolling. AIMS: Using data from a recent clinical trial examining the comparative efficacy the psychedelic drug psilocybin (P) combined with approximately 20 h of psychological support to a 6-week (daily) course of the SSRI escitalopram plus matched psychological support for major depressive disorder, we explored the effects of discontinuing SSRI/SNRIs prior to study enrolment on study outcomes. METHODS: Exploratory post hoc analyses using linear mixed effects model were performed to investigate the discontinuation effect on various validated depression symptom severity scales and well-being. The impact of SSRI/SNRIs discontinuation on the acute psychedelic experience was also explored. RESULTS/OUTCOMES: In the psilocybin group, there was a reduced treatment effect on all outcome measures for SSRI/SNRIs discontinuers compared with unmedicated patients at trial entry. However, no effects of discontinuation on measures of the acute psychedelic experience were found. CONCLUSION: Discontinuation of SSRI/SNRIs before psilocybin might diminish response to treatment; however, as we did not test SSRI/SNRI continuation in our trial, we cannot infer such causation. Moreover, the exploratory nature of the analyses makes them hypothesis generating, and not confirmatory. A controlled trial of SSRI/SNRI discontinuation versus continuation prior to psilocybin is urgently required.", "journal": "Journal of Psychopharmacology", "publication_date": "2024-03-21", "publication_year": 2024, "doi": "10.1177/02698811241237870", "pubmed_id": "38520045", "source_url": "https://doi.org/10.1177/02698811241237870", "keywords": "Escitalopram, Psilocybin, Discontinuation, Psychology, Paroxetine, Major depressive disorder, Psychiatry, Medicine, Hallucinogen, Antidepressant, Anxiety, Cognition, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4393118291\",\"openalex_url\":\"https://openalex.org/W4393118291\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":26,\"referenced_works\":[\"https://openalex.org/W202333777\",\"https://openalex.org/W265240844\",\"https://openalex.org/W1575252642\",\"https://openalex.org/W1951724000\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1977708183\",\"https://openalex.org/W2001284148\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2023687307\",\"https://openalex.org/W2042510791\",\"https://openalex.org/W2045488830\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2060307846\",\"https://openalex.org/W2071034105\",\"https://openalex.org/W2078389180\",\"https://openalex.org/W2092475629\",\"https://openalex.org/W2099634048\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2155959499\",\"https://openalex.org/W2162510673\",\"https://openalex.org/W2169083980\",\"https://openalex.org/W2170904543\",\"https://openalex.org/W2329873939\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2397862430\",\"https://openalex.org/W2408297962\",\"https://openalex.org/W2410085988\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2519531315\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2567636536\",\"https://openalex.org/W2605671917\",\"https://openalex.org/W2639909134\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2783948250\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2804151801\",\"https://openalex.org/W2912654919\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2919124707\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2980350741\",\"https://openalex.org/W3003710034\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3094909023\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107283988\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3122801192\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3182390788\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W3191247672\",\"https://openalex.org/W3197897999\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4243810801\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4292338862\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4313251651\",\"https://openalex.org/W4367053025\",\"https://openalex.org/W4372336620\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4390186718\",\"https://openalex.org/W6674913956\"],\"authorships\":[{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5005427567\",\"display_name\":\"Tommaso Barba\",\"orcid\":\"https://orcid.org/0000-0003-2565-4628\"},{\"id\":\"https://openalex.org/A5025030452\",\"display_name\":\"Meg J. Spriggs\",\"orcid\":\"https://orcid.org/0000-0002-7800-1586\"},{\"id\":\"https://openalex.org/A5020498855\",\"display_name\":\"Fernando E. Rosas\",\"orcid\":\"https://orcid.org/0000-0001-7790-6183\"},{\"id\":\"https://openalex.org/A5101507504\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-6423-9411\"},{\"id\":\"https://openalex.org/A5072682798\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":\"https://orcid.org/0000-0002-6062-7150\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241237870\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Receptor Pharmacology,Wellbeing,Clinical Trial,Safety,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4393118291" }, { "id": 3697, "title": "A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer", "normalized_title": "a pilot study of psilocybin enhanced group psychotherapy in patients with cancer", "authors": "University of Utah", "abstract": "This pilot project is an open-label trial that will offer psilocybin in a group format to assess the feasibility of offering psilocybin therapy in a group setting with a decreased therapist to subject ratio. Study intervention will involve a group of six patients with one therapist per subject for a 1:1 ratio, thus significantly reducing the total number of therapist hours per subject compared to standard individual therapy protocols. Two groups of six will be treated on this trial. After the enrollment and treatment of the first group of six patients, accrual will be placed on hold to ensure subject safety. If stopping rules are not met (Section 11), the next group of six patients will be enrolled and treated on study. The study intervention will include a total of seven group therapy sessions including three 2-hour preparatory sessions, one 8-hour psilocybin session, and one two-hour integration session. The group therapy sessions will occur on a weekly basis, followed one week later by the psilocybin session. The first integration group session will occur 1-2 days following the psilocybin session.", "journal": "ClinicalTrials.gov", "publication_date": "2024-03-19", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04522804", "keywords": "Cancer, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04522804\",\"overall_status\":\"COMPLETED\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1211, "title": "Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometry.", "normalized_title": "screening and confirmation of psilocin mitragynine phencyclidine ketamine and ketamine metabolites by liquid chromatography tandem mass spectrometry", "authors": "Wood ME, Brown GJ, Karschner EL, Seither JZ, Brown JT, Knittel JL, Walterscheid JP.", "abstract": "A safe and productive workplace requires a sober workforce, free from substances that impair judgment and concentration. Although drug monitoring programs already exist, the scope and loopholes of standard workplace testing panels are well known, allowing other substances to remain a source of risk. Therefore, a high-throughput urine screening method for psilocin, mitragynine, phencyclidine, ketamine, norketamine and dehydronorketamine was developed and validated in conjunction with a urine and blood confirmation method. There are analytical challenges to overcome with psilocin and mitragynine, particularly when it comes to drug stability and unambiguous identification in authentic specimens. Screening and confirmation methods were validated according to the American National Standards Institute/Academy Standards Board (ANSI/ASB) Standard 036, Standard Practices for Method Validation in Forensic Toxicology. An automated liquid handling system equipped with dispersive pipette extraction tips was utilized for preparing screening samples, whereas an offline solid-phase extraction method was used for confirmation sample preparation. Both methods utilized liquid chromatography-tandem mass spectrometry to achieve limits of detection between 1-5 ng/mL for the screening method and 1 ng/mL for the confirmation method. Automation allows for faster throughput and enhanced quality assurance, which improves turnaround time. Compared to previous in-house methods, specimen volumes were substantially decreased for both blood and urine, which is an advantage when volume is limited. This screening technique is well suited for evaluating large numbers of specimens from those employed in safety-sensitive workforce positions. This method can be utilized by workplace drug testing, human performance and postmortem laboratories seeking robust qualitative screening and confirmation methods for analytes that have traditionally been challenging to routinely analyze.", "journal": null, "publication_date": "2024-02-29", "publication_year": 2024, "doi": "10.1093/jat/bkae002", "pubmed_id": "38287693", "source_url": "https://doi.org/10.1093/jat/bkae002", "keywords": "Humans, Ketamine, Secologanin Tryptamine Alkaloids, Phencyclidine, Chromatography, Liquid, Tandem Mass Spectrometry, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38287693\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4391462932" }, { "id": 1209, "title": "Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin", "normalized_title": "psychedelic therapy a primer for primary care clinicians psilocybin", "authors": "Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir", "abstract": "BACKGROUND: The primary psychoactive drug in magic mushrooms, psilocybin, induces profound alterations in consciousness through the 5-HT2A receptor. This review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. AREAS OF UNCERTAINTY: Despite initial concerns that psilocybin could cause psychosis, contemporary research has demonstrated that psilocybin is generally safe. The most common adverse effects are nausea and headache, yet both tend to be transient. Serious adverse events can generally be avoided in controlled settings such as clinical trials. However, in the largest clinical trial to date, there were a total of 7 reported cases of suicidal ideation, up to 12 weeks after receiving a single 25 mg dose of psilocybin. That being said, all 7 cases did not respond to the treatment. Although selective serotonin reuptake inhibitors may blunt the hallucinogenic qualities of psilocybin, preliminary research suggests that they may enhance its antidepressant effects. THERAPEUTIC ADVANCES: In clinical trials, psilocybin has shown promise for treating major depressive disorder and treatment-resistant depression. Initial studies indicated that 42%-57% of patients underwent remission after psilocybin-assisted therapy, which suggests that psilocybin is more effective than existing antidepressant medications. Clinical data have also demonstrated that psilocybin can manage substance use disorders and end-of-life anxiety with clinical outcomes that are sustained for months and sometimes years after 1 or 2 doses. LIMITATIONS: However, larger Phase II trials with more than 100 depressed participants have shown a much smaller remission rate of 25%-29%, though these studies still observed that psilocybin causes a significant reduction in depressive symptoms. CONCLUSIONS: Aside from ketamine, psilocybin is the most clinically well-researched psychedelic drug, with trials that have enrolled hundreds of participants and multiple therapeutic applications. Phase III trials will determine whether psilocybin lives up to the promise that it showed in previous clinical trials.", "journal": "American Journal of Therapeutics", "publication_date": "2024-02-29", "publication_year": 2024, "doi": "10.1097/mjt.0000000000001724", "pubmed_id": "38518269", "source_url": "https://doi.org/10.1097/mjt.0000000000001724", "keywords": "Psilocybin, Hallucinogen, Medicine, Adverse effect, Psychiatry, Antidepressant, Clinical trial, Fluoxetine, Pharmacology, Anxiety, Internal medicine, Serotonin, Receptor, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4393098899\",\"openalex_url\":\"https://openalex.org/W4393098899\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":14,\"referenced_works\":[\"https://openalex.org/W1543683634\",\"https://openalex.org/W1643307304\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1982686584\",\"https://openalex.org/W1991029061\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2016516315\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2040712539\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2059274457\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2069122038\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2080820439\",\"https://openalex.org/W2085758661\",\"https://openalex.org/W2093994427\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2099586135\",\"https://openalex.org/W2102963347\",\"https://openalex.org/W2114587449\",\"https://openalex.org/W2119763231\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2124073673\",\"https://openalex.org/W2154013799\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2284048615\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2398117252\",\"https://openalex.org/W2411060220\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2612228298\",\"https://openalex.org/W2738971267\",\"https://openalex.org/W2755283369\",\"https://openalex.org/W2766194567\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2790415409\",\"https://openalex.org/W2804876758\",\"https://openalex.org/W2808873358\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2891737179\",\"https://openalex.org/W2954339234\",\"https://openalex.org/W2963936193\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3016448445\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3115524456\",\"https://openalex.org/W3127186731\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3191550608\",\"https://openalex.org/W3203928800\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W3208689015\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4206759226\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4220938183\",\"https://openalex.org/W4225857844\",\"https://openalex.org/W4281797075\",\"https://openalex.org/W4281898042\",\"https://openalex.org/W4282841864\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4301006693\",\"https://openalex.org/W4307429083\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4308486832\",\"https://openalex.org/W4310794030\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4383668248\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385257581\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4387007980\",\"https://openalex.org/W4387324672\",\"https://openalex.org/W6674060032\",\"https://openalex.org/W6675319417\",\"https://openalex.org/W6682876083\",\"https://openalex.org/W6714902611\",\"https://openalex.org/W6754218928\",\"https://openalex.org/W6776045936\",\"https://openalex.org/W6810923332\",\"https://openalex.org/W6929930661\",\"https://openalex.org/W7074195594\"],\"authorships\":[{\"id\":\"https://openalex.org/A5014505307\",\"display_name\":\"Burton J. Tabaac\",\"orcid\":\"https://orcid.org/0000-0001-7862-5471\"},{\"id\":\"https://openalex.org/A5000417271\",\"display_name\":\"Kenneth Shinozuka\",\"orcid\":\"https://orcid.org/0000-0002-2859-9161\"},{\"id\":\"https://openalex.org/A5109694269\",\"display_name\":\"Alejandro Arenas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5013379706\",\"display_name\":\"Bryce D. Beutler\",\"orcid\":\"https://orcid.org/0000-0002-5071-1826\"},{\"id\":\"https://openalex.org/A5084494931\",\"display_name\":\"Kirsten Cherian\",\"orcid\":\"https://orcid.org/0000-0002-6058-0081\"},{\"id\":\"https://openalex.org/A5109694684\",\"display_name\":\"Viviana D. Evans\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108242803\",\"display_name\":\"Chelsey Fasano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016829878\",\"display_name\":\"Owen S. Muir\",\"orcid\":\"https://orcid.org/0000-0002-4003-338X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S67118044\",\"source_display_name\":\"American Journal of Therapeutics\",\"landing_page_url\":\"https://doi.org/10.1097/mjt.0000000000001724\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Chronic Pain,Headache / Migraine,Pharmacology,Receptor Pharmacology,Consciousness,Clinical Trial,Review Article,Treatment-Resistant Depression,Healthcare Workers,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4393098899" }, { "id": 1222, "title": "Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.", "normalized_title": "corrigendum safety feasibility tolerability and clinical effects of repeated psilocybin dosing combined with non directive support in the treatment of obsessive compulsive disorder protocol for a randomized waitlist controlled trial with blinded ratings", "authors": "Ching THW, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B.", "abstract": "[This corrects the article DOI: 10.3389/fpsyt.2023.1278823.].", "journal": null, "publication_date": "2024-02-15", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1372373", "pubmed_id": "38435972", "source_url": "https://doi.org/10.3389/fpsyt.2024.1372373", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"38435972\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "OCD,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1225, "title": "Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.", "normalized_title": "efficacy and acceptability of psilocybin for primary or secondary depression a systematic review and meta analysis of randomized controlled trials", "authors": "Fang S, Yang X, Zhang W.", "abstract": "IntroductionPsilocybin is a classic psychedelics, which has been shown to have antidepressant effects by many studies in recent years. In this study, we aim to evaluate the efficacy, acceptability and tolerability of psilocybin in the treatment of primary (major depressive disorder) or secondary (experiencing distress related to life-threatening diagnoses and terminal illness) depression.MethodsWe searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov for clinical trials of psilocybin for depression (updated to 4 October, 2023). Effect size Hedges' g was used as an indicator of efficacy, and other outcomes included response rate, drop-out rate, and adverse events.ResultsA total of 10 studies were finally included in systematic review. 8 studies were included in the meta-analysis, involving a total of 524 adult patients, and produced a large effect size in favor of psilocybin (Hedge's g =-0.89, 95% CI -1.25~-0.53, I² = 70.19%, P", "journal": null, "publication_date": "2024-02-14", "publication_year": 2024, "doi": "10.3389/fpsyt.2024.1359088", "pubmed_id": "38426002", "source_url": "https://doi.org/10.3389/fpsyt.2024.1359088", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38426002\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1228, "title": "The Effects of Psychedelics on Neuronal Physiology.", "normalized_title": "the effects of psychedelics on neuronal physiology", "authors": "Hatzipantelis CJ, Olson DE", "abstract": "Psychedelics are quite unique among drugs that impact the central nervous system, as a single administration of a psychedelic can both rapidly alter subjective experience in profound ways and produce sustained effects on circuits relevant to mood, fear, reward, and cognitive flexibility. These remarkable properties are a direct result of psychedelics interacting with several key neuroreceptors distributed across the brain. Stimulation of these receptors activates a variety of signaling cascades that ultimately culminate in changes in neuronal structure and function. Here, we describe the effects of psychedelics on neuronal physiology, highlighting their acute effects on serotonergic and glutamatergic neurotransmission as well as their long-lasting effects on structural and functional neuroplasticity in the cortex. We propose that the neurobiological changes leading to the acute and sustained effects of psychedelics might be distinct, which could provide opportunities for engineering compounds with optimized safety and efficacy profiles.", "journal": "Annual review of physiology", "publication_date": "2024-02-11", "publication_year": 2024, "doi": "10.1146/annurev-physiol-042022-020923", "pubmed_id": "37931171", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37931171/", "keywords": "5-HT2A receptor, DMT, LSD, hallucinogen, neuroplasticity, psilocybin, psychedelic", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"37931171\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1235, "title": "Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study", "normalized_title": "patient perspectives and experiences with psilocybin treatment for treatment resistant depression a qualitative study", "authors": "Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, T.L. Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert A. Schoevers", "abstract": "Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a double-blind randomized clinical trial with a single session of oral (1, 10 or 25 mg) psilocybin treatment. After qualitative analysis, three major themes were identified: (1) challenges with trust-building and expectation management; (2) navigating the experience; and (3) the need for a more comprehensive treatment. Subthemes of the first theme include a general distrust in mental healthcare, trust in study therapists, limited time for preparation, and managing expectations. The second theme included the following subthemes: trusting to surrender, profound and overwhelming experiences, and music as a guide. The third theme addressed a desire for multiple psilocybin sessions, and challenges with sensemaking. Patients' perspectives provided important insights into potential optimization of psilocybin treatment of TRD, including individualized preparation, investment in trust-building, offering additional psilocybin sessions, providing access to sustained (psycho)therapy with trusted therapists, and personalizing treatment approaches, which may also enhance real-world adaption of these treatments.", "journal": "Scientific Reports", "publication_date": "2024-02-04", "publication_year": 2024, "doi": "10.1038/s41598-024-53188-9", "pubmed_id": "38316896", "source_url": "https://doi.org/10.1038/s41598-024-53188-9", "keywords": "Psilocybin, Distrust, Psychotherapist, Qualitative research, Psychology, Medicine, Psychiatry, Hallucinogen, Sociology, Social science, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:35", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4391540455\",\"openalex_url\":\"https://openalex.org/W4391540455\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":49,\"referenced_works\":[\"https://openalex.org/W1784519638\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2003976001\",\"https://openalex.org/W2029087690\",\"https://openalex.org/W2044661514\",\"https://openalex.org/W2106030064\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2116639785\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2138664283\",\"https://openalex.org/W2171340584\",\"https://openalex.org/W2331393505\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2502147470\",\"https://openalex.org/W2520334349\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2571392308\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2788181968\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2789340345\",\"https://openalex.org/W2793096639\",\"https://openalex.org/W2809850625\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2950747661\",\"https://openalex.org/W2954134279\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2981767691\",\"https://openalex.org/W2990036135\",\"https://openalex.org/W2997219409\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3052679762\",\"https://openalex.org/W3082721315\",\"https://openalex.org/W3095953401\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3122801192\",\"https://openalex.org/W3134897339\",\"https://openalex.org/W3148252514\",\"https://openalex.org/W3154641856\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3193440797\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4200016418\",\"https://openalex.org/W4205765055\",\"https://openalex.org/W4206130674\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4214898817\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4281703399\",\"https://openalex.org/W4283719838\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4294667223\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4302773366\",\"https://openalex.org/W4303509980\",\"https://openalex.org/W4307426414\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4310044456\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4318393298\",\"https://openalex.org/W4320491739\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4361248485\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4386305655\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090242296\",\"display_name\":\"Joost J. Breeksema\",\"orcid\":\"https://orcid.org/0000-0002-8787-4610\"},{\"id\":\"https://openalex.org/A5084276313\",\"display_name\":\"Alistair Niemeijer\",\"orcid\":\"https://orcid.org/0000-0002-4893-7930\"},{\"id\":\"https://openalex.org/A5083050291\",\"display_name\":\"Erwin Krediet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035856925\",\"display_name\":\"T.L. Karsten\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016694325\",\"display_name\":\"Jeanine Kamphuis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040746759\",\"display_name\":\"Eric Vermetten\",\"orcid\":\"https://orcid.org/0000-0003-0579-4404\"},{\"id\":\"https://openalex.org/A5071695786\",\"display_name\":\"Wim van den Brink\",\"orcid\":\"https://orcid.org/0000-0001-8301-0121\"},{\"id\":\"https://openalex.org/A5026480246\",\"display_name\":\"Robert A. Schoevers\",\"orcid\":\"https://orcid.org/0000-0003-0760-9866\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S196734849\",\"source_display_name\":\"Scientific Reports\",\"landing_page_url\":\"https://doi.org/10.1038/s41598-024-53188-9\",\"is_oa\":true}}", "topic_tags": "Depression,Receptor Pharmacology,Aging,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4391540455" }, { "id": 1247, "title": "The development of psilocybin therapy for treatment-resistant depression: an update.", "normalized_title": "the development of psilocybin therapy for treatment resistant depression an update", "authors": "Borissova A, Rucker JJ.", "abstract": "Psilocybin is a classic psychedelic drug that has attracted increasing research interest over the past 10 years as a possible treatment for mood, anxiety and related conditions. Initial phase 2 clinical trials of psilocybin given alongside psychological support for major depression and treatment-resistant depression (TRD) demonstrated encouraging signs of basic safety, further confirmed by a large study in groups of healthy volunteers. The first international multi-centre randomised controlled trial was published in 2022, with signs of efficacy for the 25 mg dose condition in people with TRD when compared with an active placebo. Phase 3 trials in TRD are scheduled to start in 2023. Early evidence suggests that single doses of psilocybin given with psychological support induce rapid improvement in depressive symptoms that endure for some weeks. We therefore provide a timely update to psychiatrists on what psilocybin therapy is, what it is not, and the current state of the evidence-base.", "journal": null, "publication_date": "2024-01-31", "publication_year": 2024, "doi": "10.1192/bjb.2023.25", "pubmed_id": "37357767", "source_url": "https://doi.org/10.1192/bjb.2023.25", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37357767\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Aging,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1245, "title": "The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.", "normalized_title": "the impact of psychedelics on patients with alcohol use disorder a systematic review with meta analysis", "authors": "Sicignano D, Hernandez AV, Schiff B, Elmahy N, White CM", "abstract": "Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic literature search of PubMed was completed from 1960 to 9/9/2023. We pooled randomized controlled trials comparing psychedelics to control therapy for the treatment of alcohol use disorder. At the first recorded follow-up, LSD [ = 3, Odds Ratio (OR) 1.99 (95% Confidence interval (CI): 1.10 to 3.61)] and any psychedelic [ = 4, OR2.16 (95%CI: 1.26 to 3.69)] enhanced the odds of patients achieving abstinence or a substantial reduction in drinking alcohol versus placebo in randomized, double-blind, placebo-controlled trials. When the inclusion criteria were relaxed to include controlled trials without double-blinding or placebo control, LSD [ = 5, OR1.79 (95%CI: 1.36 to 2.34)] and any psychedelic therapy [ = 6, OR1.89 (95%CI: 1.42 to 2.50)] still enhanced the odds of patients achieving abstinence or a substantial reduction in drinking alcohol. Four of 6 trials had high risk of bias and other methodological issues. One trial found an instance of suicidal ideation as well as transient increases in blood pressure that requires further exploration before the balance of benefits to harms can be determined. The use of psychedelics to treat alcohol use disorder is promising, but the weaknesses in the literature base preclude making definitive statements about its value. Future trials with greater methodological rigor are needed.", "journal": "Current medical research and opinion", "publication_date": "2024-01-31", "publication_year": 2024, "doi": "10.1080/03007995.2023.2296968", "pubmed_id": "38111216", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38111216/", "keywords": "LSD, alcohol use disorder, meta-analysis, psilocybin", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"38111216\"}", "topic_tags": "Addiction,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1154, "title": "Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.", "normalized_title": "serotonergic psychedelics a comparative review of efficacy safety pharmacokinetics and binding profile", "authors": "Holze F, Singh N, Liechti ME, D'Souza DC.", "abstract": "Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.", "journal": null, "publication_date": "2024-01-31", "publication_year": 2024, "doi": "10.1016/j.bpsc.2024.01.007", "pubmed_id": "38301886", "source_url": "https://doi.org/10.1016/j.bpsc.2024.01.007", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Serotonin 5-HT2 Receptor Agonists, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38301886\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Receptor Pharmacology,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4681, "title": "Psilocybin-assisted psychotherapy for cancer patients", "normalized_title": "psilocybin assisted psychotherapy for cancer patients", "authors": "Houman Farzin", "abstract": "Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individuals suffering from demoralization, death anxiety, and existential distress. Psilocybin-assisted psychotherapy employs psilocybin-containing mushrooms or synthetic psilocybin grounded in indigenous traditions and within the context of a therapeutic mindset and environment (\"set and setting\") to achieve altered states of consciousness that promote healing and psychospiritual growth while reducing suffering. Current research evidence suggests that this form of therapy could serve as a safe and effective therapeutic tool for such patients. This presentation will describe a case series of patients with advanced cancer who received physician-supervised home-based psilocybin-assisted psychotherapy in Montreal, Canada. Our experience postulates the safety and efficacy of this laborious treatment process. By executing this clinical practice in the public healthcare system of Quebec for the first time, we have made an attempt to provide equitable access to these clinical therapies. Having performed these treatments outside the context of clinical trials, we have been able to tailor the therapeutic frame and treatment approach to a more patient-centric and culturally-informed manner. That being said, given the existing ​societal discrimination and stigma against this form of therapy, including by healthcare professionals, there remain further barriers to overcome in the equitable provision of care, especially to certain segments of the population. ​The authors will discuss these and potential solutions to addressing them.", "journal": "International Journal of Whole Person Care", "publication_date": "2024-01-28", "publication_year": 2024, "doi": "10.26443/ijwpc.v11i1.390", "pubmed_id": null, "source_url": "http://dx.doi.org/10.26443/ijwpc.v11i1.390", "keywords": "Psilocybin, Psychotherapist, Medicine, Cancer, Psychology, Psychiatry, Hallucinogen, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4391329406\",\"openalex_url\":\"https://openalex.org/W4391329406\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5040374734\",\"display_name\":\"Houman Farzin\",\"orcid\":\"https://orcid.org/0009-0006-4095-3596\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737307235\",\"source_display_name\":\"International Journal of Whole Person Care\",\"landing_page_url\":\"http://dx.doi.org/10.26443/ijwpc.v11i1.390\",\"is_oa\":true}}", "topic_tags": "Anxiety,Consciousness,Spirituality,Clinical Trial,Case Report,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4391329406" }, { "id": 1252, "title": "Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.", "normalized_title": "trauma informed care in psychedelic therapy research a qualitative literature review of evidence based psychotherapy interventions in ptsd and psychedelic therapy across conditions", "authors": "Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V.", "abstract": "IntroductionPost-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT) has shown preliminary promise across difficult-to-treat conditions, including MDMA-assisted therapy for PTSD, however trials of classical psychedelics in PTSD are lacking. Understanding patients' experiences of EBPI could help promote safety in PT.AimTo systematically review qualitative research on patients' subjective experience of EBPI for PTSD, and of PT, and examine areas of overlap and divergence between them.MethodsSystematic literature searches for studies published between 2010 and 2023 were conducted on OVID, PubMed, Web of Science, and PsycInfo. Included were original studies in English that presented qualitative data of patient experiences of EBPI in PTSD, or PT for any indication. Extracted data from included studies were analysed using thematic synthesis. Syntheses were completed separately for EBPI and PT, before similarities and differences between the therapies were identified.Results40 research articles were included for review: 26 studies on EBPI for PTSD, and 14 studies on PT. EBPI studied were CBT, EMDR, CPT and PE. Psychedelic compounds studied were psilocybin, ibogaine, LSD, MDMA and ketamine, for treatment of substance use disorders, anxiety relating to physical illness, depression, and PTSD. Core themes from patient experiences of EBPI: 1) patient burden in PTSD treatment; 2) readiness; 3) key mechanisms of change; 4) psychological safety and trust. Themes identified in the review of PT: 1) indirect trauma processing; 2) reorganisation of self-narratives via processes of relatedness and identification; 3) key treatment characteristics.ConclusionThis study suggests overlap between patients' experience of EBPI and PT in terms of key mechanisms of change, the importance of psychological safety and readiness to engage in treatment. Trauma-informed care paradigms and practices may improve safety and acceptability of PT research.", "journal": null, "publication_date": "2024-01-19", "publication_year": 2024, "doi": "10.2147/ndt.s432537", "pubmed_id": "38268571", "source_url": "https://doi.org/10.2147/ndt.s432537", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"38268571\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1272, "title": "Older adults in psychedelic-assisted therapy trials: A systematic review.", "normalized_title": "older adults in psychedelic assisted therapy trials a systematic review", "authors": "Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y.", "abstract": "BackgroundGrowing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress, and posttraumatic stress disorder.AimsThe goal of this study was to quantify the prevalence of older adults enrolled in psychedelic clinical trials and explore safety data in this population.MethodsA systematic review was conducted following the 2020 PRISMA guidelines. Search criteria included all trials published in English using psychedelic substances to treat psychiatric conditions, including addiction as well as existential distress related to serious illness. Articles were identified from literature searches on PubMed, EBSCO, and EMBASE.Results4376 manuscripts were identified, of which 505 qualified for further review, with 36 eventually meeting eligibility criteria. Of the 1400 patients enrolled in the 36 studies, only 19 were identified as 65 or older, representing less than 1.4% of all trial participants. For 10 of these 19 older adults, detailed safety data was obtained. No serious adverse events (AEs) occurred in any older adults and only transient mild-to-moderate AEs related to anxiety, gastrointestinal upset, and hypertension were reported during the psychedelic dosing sessions.ConclusionsWhile existing data in older adults is limited, it suggests that psychedelic-assisted psychotherapy can be safe and well tolerated in older adults. Therefore, psychedelic-assisted psychotherapy should be more rigorously investigated for the treatment of psychiatric conditions in this population.", "journal": null, "publication_date": "2024-01-18", "publication_year": 2024, "doi": "10.1177/02698811231215420", "pubmed_id": "38240068", "source_url": "https://doi.org/10.1177/02698811231215420", "keywords": "Humans, Hallucinogens, Mental Disorders, Aged, Clinical Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"38240068\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Aging,Clinical Trial,Systematic Review,Review Article,Older Adults,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4687, "title": "Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma", "normalized_title": "abstract c001 a pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma", "authors": "Kelsey Klute, Lou Lukas, Soonjo Hwang, Yeongjin Gwon, Mridula Krishnan, Jean L. Grem, Sunil R. Hingorani, Jody Koenig Kellas", "abstract": "Abstract Background: Psychological distress is a common reaction to a cancer diagnosis and its treatment. Distress impacts quality of life, adherence to treatment, decision making and survival. Patients with pancreatic adenocarcinoma (PDAC) experience exceptionally high rates of psychological distress, most commonly depression, anxiety and suicidality. Psilocybin, a serotonergic psychedelic which is the active component in “magic mushrooms,” is a promising treatment for several mental health disorders. Prior studies in patients with cancer have combined a single dose of psilocybin with preparation and integration counseling and have shown significant, rapid and sustained improvement in depression, anxiety and quality of life. These studies have primarily been conducted in psychiatry or neuroscience clinics in heterogenous groups of patients, many of whom had completed cancer treatment. This study will evaluate the feasibility and safety of psilocybin-assisted therapy delivered in the outpatient palliative care clinic in patients with advanced PDAC who are receiving chemotherapy. Methods: This is a single center, open label pilot study of a psilocybin-assisted therapy integrated with palliative care in patients with advanced PDAC. The primary endpoints are the feasibility and safety of this strategy when integrated into routine palliative care. Secondary endpoints include short term changes in depression, anxiety and demoralization and changes in neuronal activity by functional MRI (fMRI). After 2-4 outpatient preparation sessions with a palliative medicine physician (PMP), the subject will take psilocybin (25mg capsule) at an individual session supported by a PMP and a trained mental health professional. Up to 3 integration sessions with a PMP will follow. Patient-reported measures of psychological distress and quality of life will be assessed at baseline, after the psilocybin dose and periodically during follow-up. Neuronal changes will be measured using fMRI before and after the psilocybin dose. Eligible patients are adults (ECOG0-3) with advanced PDAC with adequate organ function. Patients with psychiatric conditions which preclude safe cessation of psychotropic drugs or requires hospitalization, a personal or family history of schizophrenia, psychotic disorder or bipolar disorder, who have a high risk of suicide or have serious or uncontrolled hypertension or cardiovascular disease are ineligible. Given the exploratory nature of the study, a formal statistical assessment of the sample size was not conducted. Twelve evaluable subjects will provide sufficient power to detect large effect sizes (Cohen’s d1.0) in the secondary endpoints. Wilcoxon signed rank test will determine the reduction in distress scores before and after the psilocybin session. Enrollment began in June 2023; two subjects have enrolled. The study is funded by the Jim Young Pancreatic Cancer Research Memorial Fund. Psilocybin is provided by Usona. ClinicalTrials.gov Identifier: NCT05220046 Citation Format: Kelsey A. Klute, Lou Lukas, Soonjo Hwang, Yeongjin Gwon, Mridula Krishnan, Jean Grem, Sunil Hingorani, Jody Koenig Kellas. A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl):Abstract nr C001.", "journal": "Cancer Research", "publication_date": "2024-01-15", "publication_year": 2024, "doi": "10.1158/1538-7445.panca2023-c001", "pubmed_id": null, "source_url": "https://doi.org/10.1158/1538-7445.panca2023-c001", "keywords": "Psilocybin, Medicine, Anxiety, Quetiapine, Quality of life (healthcare), Palliative care, Distress, Mental health, Psychiatry, Depression (economics), Cancer, Oncology, Internal medicine, Clinical psychology, Schizophrenia (object-oriented programming), Nursing, Hallucinogen, Macroeconomics, Economics, Psychedelics and Drug Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4390915346\",\"openalex_url\":\"https://openalex.org/W4390915346\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5008464992\",\"display_name\":\"Kelsey Klute\",\"orcid\":\"https://orcid.org/0000-0002-4748-8520\"},{\"id\":\"https://openalex.org/A5082676852\",\"display_name\":\"Lou Lukas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5000189944\",\"display_name\":\"Soonjo Hwang\",\"orcid\":\"https://orcid.org/0000-0001-5117-2468\"},{\"id\":\"https://openalex.org/A5068510005\",\"display_name\":\"Yeongjin Gwon\",\"orcid\":\"https://orcid.org/0000-0001-6974-337X\"},{\"id\":\"https://openalex.org/A5041873250\",\"display_name\":\"Mridula Krishnan\",\"orcid\":\"https://orcid.org/0000-0002-6388-5219\"},{\"id\":\"https://openalex.org/A5045440420\",\"display_name\":\"Jean L. Grem\",\"orcid\":\"https://orcid.org/0000-0002-1672-9416\"},{\"id\":\"https://openalex.org/A5013925502\",\"display_name\":\"Sunil R. Hingorani\",\"orcid\":\"https://orcid.org/0000-0002-3869-8729\"},{\"id\":\"https://openalex.org/A5073702990\",\"display_name\":\"Jody Koenig Kellas\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S168522863\",\"source_display_name\":\"Cancer Research\",\"landing_page_url\":\"https://doi.org/10.1158/1538-7445.panca2023-c001\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Brain Imaging,Cancer Patients,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4390915346" }, { "id": 1212, "title": "Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.", "normalized_title": "microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy comparison to known cardiotoxins", "authors": "Rouaud A, Calder AE, Hasler G.", "abstract": "Though microdosing psychedelics has become increasingly popular, its long-term effects on cardiac health remain unknown. Microdosing most commonly involves ingesting sub-threshold doses of lysergic acid diethylamide (LSD), psilocybin, or other psychedelic drugs 2-4 times a week for at least several weeks, but potentially months or years. Concerningly, both LSD and psilocybin share structural similarities with medications which raise the risk of cardiac fibrosis and valvulopathy when taken regularly, including methysergide, pergolide, and fenfluramine. 3,4-Methylenedioxymethamphetamine, which is also reportedly used for microdosing, is likewise associated with heart valve damage when taken chronically. In this review, we evaluate the evidence that microdosing LSD, psilocybin, and other psychedelics for several months or more could raise the risk of cardiac fibrosis. We discuss the relationship between drug-induced cardiac fibrosis and the 5-HT2B receptor, and we make recommendations for evaluating the safety of microdosing psychedelics in future studies.", "journal": null, "publication_date": "2024-01-11", "publication_year": 2024, "doi": "10.1177/02698811231225609", "pubmed_id": "38214279", "source_url": "https://doi.org/10.1177/02698811231225609", "keywords": "Humans, Fibrosis, Lysergic Acid Diethylamide, Hallucinogens, Cardiotoxins, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"38214279\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Microdosing,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1261, "title": "Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings", "normalized_title": "safety feasibility tolerability and clinical effects of repeated psilocybin dosing combined with non directive support in the treatment of obsessive compulsive disorder protocol for a randomized waitlist controlled trial with blinded ratings", "authors": "Terence H. W. Ching, Lucia Amoroso, Calvin Bohner, Elizabeth J. D’Amico, Jeffrey Eilbott, Tara Entezar, Madison Fitzpatrick, Geena Fram, Rachael Grazioplene, Jamila Hokanson, Anastasia Jankovsky, Stephen A. Kichuk, Bradford Martins, Prerana Patel, Henry Schaer, Sarah Shnayder, Chelsea Witherow, Christopher Pittenger, Benjamin Kelmendi", "abstract": "Background: To date, few randomized controlled trials of psilocybin with non-directive support exist for obsessive-compulsive disorder (OCD). Results and participant feedback from an interim analysis of an ongoing single-dose trial (NCT03356483) converged on the possibility of administering a higher fixed dose and/or more doses of psilocybin in future trials for presumably greater benefits. Objectives: This trial aims to evaluate the safety, feasibility, tolerability, and clinical effects of two doses of psilocybin paired with non-directive support in the treatment of OCD. This trial also seeks to examine whether two doses of psilocybin lead to greater OCD symptom reduction than a single dose, and to elucidate psychological mechanisms underlying the effects of psilocybin on OCD. Design: A randomized (1:1), waitlist-controlled design with blinded ratings will be used to examine the effects of two doses of oral psilocybin paired with non-directive support vs. waitlist control on OCD symptoms. An adaptive dose selection strategy will be implemented (i.e., first dose: 25 mg; second dose: 25 or 30 mg). Methods and analysis: This single-site trial will enroll 30 adult participants with treatment-refractory OCD. Aside from safety, feasibility, and tolerability metrics, primary outcomes include OCD symptoms assessed on the Yale-Brown Obsessive-Compulsive Scale - Second Edition (Y-BOCS-II). A blinded independent rater will assess primary outcomes at baseline and the primary endpoint at the end of the second dosing week. Participants will be followed up to 12 months post-second dosing. Participants randomized to waitlist will be rescreened after 7 weeks post-randomization, and begin their delayed treatment phase thereafter if still eligible. Ethics: Written informed consent will be obtained from participants. The institutional review board has approved this trial (protocol v. 1.7; HIC #2000032623). Discussion:: ClinicalTrials.gov, identifier NCT05370911.", "journal": "Frontiers in Psychiatry", "publication_date": "2024-01-08", "publication_year": 2024, "doi": "10.3389/fpsyt.2023.1278823", "pubmed_id": "38264632", "source_url": "https://doi.org/10.3389/fpsyt.2023.1278823", "keywords": "Tolerability, Dosing, Obsessive compulsive, Randomized controlled trial, Psilocybin, Protocol (science), Medicine, Clinical trial, Psychology, Psychiatry, Adverse effect, Pharmacology, Hallucinogen, Internal medicine, Alternative medicine, Pathology, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4390753253\",\"openalex_url\":\"https://openalex.org/W4390753253\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W74189053\",\"https://openalex.org/W78677904\",\"https://openalex.org/W306343222\",\"https://openalex.org/W568533716\",\"https://openalex.org/W1492283962\",\"https://openalex.org/W1498057507\",\"https://openalex.org/W1599004146\",\"https://openalex.org/W1752708916\",\"https://openalex.org/W1790886046\",\"https://openalex.org/W1897149844\",\"https://openalex.org/W1934577361\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1997161535\",\"https://openalex.org/W1998339430\",\"https://openalex.org/W2006001020\",\"https://openalex.org/W2006748124\",\"https://openalex.org/W2011329819\",\"https://openalex.org/W2017857669\",\"https://openalex.org/W2019101336\",\"https://openalex.org/W2020646491\",\"https://openalex.org/W2028960724\",\"https://openalex.org/W2030767477\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2053167650\",\"https://openalex.org/W2077686642\",\"https://openalex.org/W2079984335\",\"https://openalex.org/W2082150145\",\"https://openalex.org/W2084244487\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2100861230\",\"https://openalex.org/W2114570941\",\"https://openalex.org/W2118061336\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2123822033\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2134591365\",\"https://openalex.org/W2137320167\",\"https://openalex.org/W2145083290\",\"https://openalex.org/W2147797459\",\"https://openalex.org/W2150547685\",\"https://openalex.org/W2162090451\",\"https://openalex.org/W2168266150\",\"https://openalex.org/W2183963790\",\"https://openalex.org/W2308253549\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2401253652\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2577533646\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2792256936\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2884718173\",\"https://openalex.org/W2894541203\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2984198212\",\"https://openalex.org/W2990405759\",\"https://openalex.org/W3088502206\",\"https://openalex.org/W3090239575\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3100714436\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3122951191\",\"https://openalex.org/W3129125412\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3158498065\",\"https://openalex.org/W3195587140\",\"https://openalex.org/W3204292654\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4206717622\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4224296821\",\"https://openalex.org/W4230263701\",\"https://openalex.org/W4234021523\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4296782684\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4361279088\",\"https://openalex.org/W4366989647\",\"https://openalex.org/W6610802157\",\"https://openalex.org/W6661331907\",\"https://openalex.org/W6684564604\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038288658\",\"display_name\":\"Terence H. W. Ching\",\"orcid\":\"https://orcid.org/0000-0002-8850-2237\"},{\"id\":\"https://openalex.org/A5051611172\",\"display_name\":\"Lucia Amoroso\",\"orcid\":null},{\"id\":\"https://openalex.org/A5072571463\",\"display_name\":\"Calvin Bohner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5055980478\",\"display_name\":\"Elizabeth J. D’Amico\",\"orcid\":\"https://orcid.org/0000-0002-8527-7804\"},{\"id\":\"https://openalex.org/A5112416887\",\"display_name\":\"Jeffrey Eilbott\",\"orcid\":null},{\"id\":\"https://openalex.org/A5093705063\",\"display_name\":\"Tara Entezar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5010555213\",\"display_name\":\"Madison Fitzpatrick\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056965546\",\"display_name\":\"Geena Fram\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071673808\",\"display_name\":\"Rachael Grazioplene\",\"orcid\":\"https://orcid.org/0000-0001-8708-4531\"},{\"id\":\"https://openalex.org/A5058988830\",\"display_name\":\"Jamila Hokanson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083774019\",\"display_name\":\"Anastasia Jankovsky\",\"orcid\":\"https://orcid.org/0000-0003-1559-0958\"},{\"id\":\"https://openalex.org/A5090942004\",\"display_name\":\"Stephen A. Kichuk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007278551\",\"display_name\":\"Bradford Martins\",\"orcid\":\"https://orcid.org/0000-0002-4916-2604\"},{\"id\":\"https://openalex.org/A5077000472\",\"display_name\":\"Prerana Patel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065974780\",\"display_name\":\"Henry Schaer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5038515583\",\"display_name\":\"Sarah Shnayder\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083493446\",\"display_name\":\"Chelsea Witherow\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001094886\",\"display_name\":\"Christopher Pittenger\",\"orcid\":\"https://orcid.org/0000-0003-2117-9321\"},{\"id\":\"https://openalex.org/A5110948308\",\"display_name\":\"Benjamin Kelmendi\",\"orcid\":\"https://orcid.org/0000-0002-3141-1326\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2023.1278823\",\"is_oa\":true}}", "topic_tags": "OCD,Chronic Pain,Pharmacology,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4390753253" }, { "id": 3623, "title": "Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder", "normalized_title": "safety and tolerability of psilocybin in post traumatic stress disorder", "authors": "Johns Hopkins University", "abstract": "The purpose of this study is to evaluate the safety, tolerability, and potential efficacy of psilocybin-assisted psychotherapy to reduce post-traumatic stress disorder (PTSD) severity in a sample of individuals with PTSD. The proposed Phase I study aims to evaluate the safety, tolerability, and potential efficacy of psilocybin-assisted psychotherapy to reduce PTSD severity in a sample of individuals with PTSD. A sample of up to 30 individuals with PTSD will be recruited. All participants will receive the intervention, which will consist of three psilocybin sessions with an interval of approximately 2 weeks between each session. A3+3 Phase I trial design will be used to evaluate a range of possible dose sequences with doses ranging from 15 mg up to 45 mg. Safety, tolerability, and efficacy endpoints will be evaluated 2 weeks following each psilocybin session and at 1-month, 3-month, and 6-month follow-ups.", "journal": "ClinicalTrials.gov", "publication_date": "2024-01-04", "publication_year": 2024, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05562973", "keywords": "Post-Traumatic Stress Disorder, Psilocybin, WITHDRAWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05562973\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"PHASE1\"]}", "topic_tags": "PTSD,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3066, "title": "Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review", "normalized_title": "behavioural investigations of psilocybin in animals 1962 2021 a scoping review", "authors": "Shore R, Dobson K, Thomson N, Barnim N, Bergman H, Rideout K, McKeown S, Olmstead MC, Goldie C, Dumont E.", "abstract": "Background and Aims Psilocybin is a psychedelic drug that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review on pre-clinical behavioural investigations of psilocybin in non-human animals to help determine the behavioural effects of psilocybin in non-human animals, to identify studies completed, behavioural tests employed, and what dosing modalities had been studied. Methods A librarian-conducted literature search was performed using predefined key terms and search criteria and additional searching was conducted by reviewers, using electronic databases, grey literature sources, and reference lists of relevant articles or reviews. The final search updated occurred in October, 2021. Studies were reviewed, screened and selected against an a priori protocol using Covidence software by multiple reviewers with results plotted across the Research Domains Criteria construct. Results From 4124 records identified by database searching, 260 publications were subjected to full-text review with 77 studies included in this scoping review, published between 1962-2021. The preponderance of studies (n=64) investigated behavioural outcomes in rodents. Only 43 studies (55.8%) reported on housing conditions, and seventeen studies (22.1%) failed to report sample size. All studies reported behavioural outcomes following drug administration, with fifty-one studies (66.2%) using psilocybin, thirty studies (42.9%) psilocin, four studies (5.2%) administering whole mushroom extracts (WME), and a further eight studies investigating both psilocybin and psilocin and one study reporting the effects of both psilocin and WME. One hundred and thirty distinct behavioural investigations using fifty different behavioral paradigms were identified. Few adverse events were reported, and even exceedingly high doses were apparently well tolerated. Conclusion With seventy-seven publications spanning close to sixty years, there is huge variation in study design and quality. Overall psilocybin presents a unique and strong safety profile with no evidence of biological toxicity, is characterized by unique time and dose-dependent effects, and its pattern of drug action is significantly context and training-sensitive. Data suggest putative effects of psilocybin include acute arousal, dose-dependent sedation, reductions in fear conditioning at low doses, reduced aggression, improved valence, acute disruption of working memory, the rescuing of deficits from chronic stress, and improved learning when combined with repeated environmental exposure after resolution of drug effect.", "journal": "bioRxiv", "publication_date": "2024-01-04", "publication_year": 2024, "doi": "10.1101/2024.01.04.574146", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2024.01.04.574146", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR782675\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Review Article,Safety,Adverse Events,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3174, "title": "Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial", "normalized_title": "psilocybin assisted therapy for severe alcohol use disorder protocol for a double blind randomized placebo controlled 7 month parallel group phase ii superiority trial", "authors": "Vanderijst L, Hever F, Buot A, Dauré C, Benoit J, Hanak C, Veeser J, Morgiève M, Campanella S, Kornreich C, Mallet L, Leys C, Noël X.", "abstract": "Background: A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical efficacy of psilocybin-assisted therapy when incorporated as an auxiliary intervention during inpatient rehabilitation for severe alcohol use disorder. Moreover, it intends to pinpoint the modifications in the two core neurocognitive systems underscored by dual-process models of addiction. Methods:: In this double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial, 62 participants aged 21-64 years will be enrolled to undergo psilocybin-assisted therapy as part of a 4-week inpatient rehabilitation for severe alcohol use disorder. The experimental group will receive a high dose of psilocybin (30 mg), whereas the control group will receive an active placebo dose of psilocybin (5 mg), both within the context of a brief standardized psychotherapeutic intervention drawing from key elements of acceptance and commitment therapy. The primary clinical outcome is the between-group difference regarding the change in percentage of heavy drinking days from baseline to four weeks posthospital discharge, while safety and feasibility metrics will also be reported as primary outcomes. Key secondary assessments include between-group differences in terms of changes in 1) drinking behavior parameters up to six months posthospital discharge, 2) symptoms of depression, anxiety, trauma, and global functioning, 3) neuroplasticity and key neurocognitive mechanisms associated with addiction, and 4) psychological processes and alcohol-related parameters. Discussion: The discussion outlines issues that might arise from our design. Trial registration: EudraCT 2022-002369-14 and NCT06160232", "journal": "Research Square", "publication_date": "2024-01-03", "publication_year": 2024, "doi": "10.21203/rs.3.rs-3829237/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-3829237/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR782504\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Neuroplasticity,Mechanism of Action,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4722, "title": "Psilocybin’s Role in Major Depressive Disorder: A Scoping Review", "normalized_title": "psilocybin s role in major depressive disorder a scoping review", "authors": "Barajas, Carlos", "abstract": "Psilocybe cubensis are a group of mushrooms containing psilocybin with a history of consumption dating back to ancient civilization. Researchers believe the ritual use of psilocybin dates back 3,000 years amongst the indigenous people of Mexico and Central America.1 Psilocybin is responsible for the effects associated with the consumption of “Magic Mushrooms”. These effects include hallucinations, delusions, and feelings of derealization. 2 In 1973, the United States federal government classified psilocybin as a Schedule I substance under the Controlled Substance Act, and today the DEA continues to identify the chemical as “high potential for abuse” with “no currently accepted medical use in treatment in the United States”. 3,4 Current legislation, along with a perceived stigma surrounding psilocybin, has restricted researchers’ ability to investigate the therapeutic potential of this compound. However, in recent years there has been increased funding and research related to the therapeutic potential of psilocybin and other psychedelics, highlighted by the creation of the Center for Psychedelic Consciousness Research at John Hopkins in 2019.5 Since the start of the COVID-19 pandemic, the incidence of depression has risen by 25% globally, affecting approximately 175 million individuals, the majority dealing with Major Depressive Disorder (MDD).6 The first-line therapy for patients with MDD include the selective serotonin reuptake inhibitors (SSRI) escitalopram and sertraline. In the event a patient fails treatment through two pharmacological interventions, their depression disorder is considered Treatment-Resistant Depression (TRD).6 Although difficult to know the true number of individuals with TRD, it is estimated that about 30% of the population with MDD fit the description of TRD.7 Current approved treatment for TRD include intranasal esketamine (Spravato), second generation antipsychotics, and olanzapine-fluoxetine. 7 Alternative therapeutic interventions are necessary for the treatment of patients with TRD. Psilocybin may provide potential therapeutic benefits for MDD/TRD. The purpose of this scoping review is to examine the therapeutic benefits, safety, and mechanism of psilocybin in MDD/TRD.", "journal": "Digital Commons - George Fox University (George Fox University)", "publication_date": "2023-12-31", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://digitalcommons.georgefox.edu/dmsc/31", "keywords": "Psilocybin, Psychiatry, Major depressive disorder, Population, Psychology, Depression (economics), Feeling, Hallucinogen, Medicine, Government (linguistics), Substance use, Public health, Mental health, Consumption (sociology), Psychotherapist, Clinical psychology, Schizophrenia (object-oriented programming), Escitalopram, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W7110533292\",\"openalex_url\":\"https://openalex.org/W7110533292\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":null,\"display_name\":\"Barajas, Carlos\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196430\",\"source_display_name\":\"Digital Commons - George Fox University (George Fox University)\",\"landing_page_url\":\"https://digitalcommons.georgefox.edu/dmsc/31\",\"is_oa\":false}}", "topic_tags": "Depression,Addiction,Chronic Pain,Receptor Pharmacology,Consciousness,Review Article,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W7110533292" }, { "id": 4705, "title": "Government-funded trial will test psilocybin as treatment for opioid use disorder", "normalized_title": "government funded trial will test psilocybin as treatment for opioid use disorder", "authors": "", "abstract": "A “UK first” trial will investigate whether psilocybin - the active ingredient in ‘magic mushrooms’ - can help prevent relapse in people recovering from opioid addiction. The psilocybin study, led by researchers at Imperial College London, will involve 28 participants who have recently undergone detoxification from ‘street’ opioids. Participants will receive psilocybin therapy at the […]", "journal": "Pharmaceutical journal/˜The œpharmaceutical journal", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1211/pj.2024.1.335169", "pubmed_id": null, "source_url": "https://doi.org/10.1211/pj.2024.1.335169", "keywords": "Psilocybin, Test (biology), Government (linguistics), Opioid, Psychiatry, Psychology, Hallucinogen, Medicine, Internal medicine, Biology, Paleontology, Receptor, Linguistics, Philosophy, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, HIV, Drug Use, Sexual Risk", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4403684433\",\"openalex_url\":\"https://openalex.org/W4403684433\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S80542161\",\"source_display_name\":\"Pharmaceutical journal/˜The œpharmaceutical journal\",\"landing_page_url\":\"https://doi.org/10.1211/pj.2024.1.335169\",\"is_oa\":false}}", "topic_tags": "Addiction,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4403684433" }, { "id": 4697, "title": "Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders", "normalized_title": "psychedelic mushrooms the use of psilocybin in the treatment of mental disorders", "authors": "Correa RMS", "abstract": "Psychedelics are a class of hallucinogenic drugs. They have been explored particularly for treatment-resistant psychiatric illnesses. In recent years, advances in psychopharmacology have benefited thousands of patients with some type of mental disorder. Preliminary evidence has shown that psilocybin has shown promise in the treatment of psychiatric disorders, with the support of qualified doctors. Recent clinical studies have reported marked improvements in mental health in psilocybinassisted psychotherapy. In many studies, the safety and efficacy of psilocybin have been the primary objectives to show that it is a safe and valid therapeutic alternative to other forms of psychiatric medications. Currently, some studies prove that psilocybin is safe in a controlled environment. However, the use of psilocybin needs to be further studied to determine the efficacy and safety of potential applications in medicine.", "journal": "Annals of Bioethics & Clinical Applications", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.23880/abca-16000266", "pubmed_id": null, "source_url": "https://doi.org/10.23880/abca-16000266", "keywords": "Psilocybin, Psychology, Hallucinogen, Psychiatry, Psychotherapist, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4391147144\",\"openalex_url\":\"https://openalex.org/W4391147144\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1974109667\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2071088516\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2784340661\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4297478109\",\"https://openalex.org/W4298055464\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4318455092\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4382918325\",\"https://openalex.org/W4391147144\"],\"authorships\":[{\"id\":\"https://openalex.org/A5093772190\",\"display_name\":\"Correa RMS\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236429\",\"source_display_name\":\"Annals of Bioethics & Clinical Applications\",\"landing_page_url\":\"https://doi.org/10.23880/abca-16000266\",\"is_oa\":true}}", "topic_tags": "Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4391147144" }, { "id": 4695, "title": "Psilocybin for the treatment of posttraumatic stress disorder: A magic to treat a harmony of illusions?", "normalized_title": "psilocybin for the treatment of posttraumatic stress disorder a magic to treat a harmony of illusions", "authors": "Rakesh Khanna", "abstract": "Abstract A review of the literature on posttraumatic stress disorder (PTSD) suggests it to be a complex disorder with many contributing factors. The concept of PTSD has continued to evolve over time. A diagnosis of PTSD may be hard to get right. Studies suggest a wide variation in its presentation and diagnostic stability. It is tempting to explore the possibility of using chemicals that could help shorten the process of reaching the unconscious mind that could lead to more rapid remission. This article aims to review limitations in seeing the effectiveness of psilocybin (magic mushroom)-assisted therapy for PTSD. Psilocybin is supposed to be just a catalyst for treatment, while psychotherapy is considered the mainstay of treatment. The therapy itself is to be nondirective, geared toward providing a sense of safety for the patient in a vulnerable state and allowing the person to direct the support while being in a chemically compromised state. We may repeatedly be falling into the trap of trying to find simple solutions to problems that are by their very nature quite complex. All interactions take place in a certain context, and their effect will depend on how they are taken up by the whole person/world system.", "journal": "Journal of Indira Gandhi Institute Of Medical Sciences", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.4103/jigims.jigims_60_23", "pubmed_id": null, "source_url": "https://doi.org/10.4103/jigims.jigims_60_23", "keywords": "Psilocybin, Psychotherapist, Psychology, Illusion, Posttraumatic stress, MAGIC (telescope), Psychiatry, Cognitive psychology, Hallucinogen, Quantum mechanics, Physics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4392948774\",\"openalex_url\":\"https://openalex.org/W4392948774\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1961696017\",\"https://openalex.org/W1967731461\",\"https://openalex.org/W1981416828\",\"https://openalex.org/W1985730575\",\"https://openalex.org/W1989155717\",\"https://openalex.org/W1997405299\",\"https://openalex.org/W2111393447\",\"https://openalex.org/W2418896160\",\"https://openalex.org/W2807352652\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3134642859\",\"https://openalex.org/W4310938651\",\"https://openalex.org/W4383998917\"],\"authorships\":[{\"id\":\"https://openalex.org/A5015782582\",\"display_name\":\"Rakesh Khanna\",\"orcid\":\"https://orcid.org/0000-0001-7328-3599\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210232623\",\"source_display_name\":\"Journal of Indira Gandhi Institute Of Medical Sciences\",\"landing_page_url\":\"https://doi.org/10.4103/jigims.jigims_60_23\",\"is_oa\":true}}", "topic_tags": "PTSD,Review Article,Safety,Drug Interactions", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4392948774" }, { "id": 1279, "title": "Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.", "normalized_title": "longitudinal associations between psychedelic use and unusual visual experiences in the united states and the united kingdom", "authors": "Simonsson O, Hendricks PS, Stenfors CU, Goldberg SB, Honk L, Osika W", "abstract": "Whereas findings from case reports and cross-sectional studies suggest that naturalistic psychedelic use may be associated with unusual visual experiences that occur after the acute pharmacological effects have subsided, such findings need to be replicated in longitudinal studies to better understand potential cause-and-effect relationships. To investigate longitudinal associations between naturalistic psychedelic use and unusual visual experiences. Using a longitudinal observational research design with samples representative of the US and UK adult populations with regard to sex, age, and ethnicity ( = 9732), we investigated the relationship between psychedelic use during the 2-month study period and changes in past-week unusual visual experiences. The follow-up survey was completed by 79% of respondents ( = 7667), with 100 respondents reporting psychedelic use during the 2-month study period (1.3% of those who responded at follow-up). In covariate-adjusted regression models, the results showed that, as hypothesized, psychedelic use during the 2-month study period was associated with greater increases in unusual visual experiences. Notably, there was an interaction between lifetime psychedelic use and psychedelic use during the study period on unusual visual experiences such that those who used psychedelics for the first time reported greater increases in unusual visual experiences. Psychedelic use may elicit unusual visual experiences that occur after the acute pharmacological effects have subsided, especially among those who have not used psychedelics previously. Future longitudinal studies are warranted to further elucidate these relationships.", "journal": "Journal of psychopharmacology (Oxford, England)", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1177/02698811231218931", "pubmed_id": "38140891", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38140891/", "keywords": "HPPD, LSD, Psychedelics, mescaline, psilocybin, risks, visual", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"38140891\"}", "topic_tags": "Case Report,Observational Study,Safety,Drug Interactions", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1277, "title": "Is Poorly Assisted Psilocybin Treatment an Increasing Risk?", "normalized_title": "is poorly assisted psilocybin treatment an increasing risk", "authors": "Schenberg EE, King F, da Fonseca JE, Roseman L.", "abstract": "", "journal": null, "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1176/appi.ajp.20230664", "pubmed_id": "38161296", "source_url": "https://doi.org/10.1176/appi.ajp.20230664", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"38161296\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1274, "title": "The safety of supported psilocybin use in Oregon.", "normalized_title": "the safety of supported psilocybin use in oregon", "authors": "Smith WR, Sisti DA, Appelbaum PS.", "abstract": "", "journal": null, "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1038/s41591-023-02727-4", "pubmed_id": "38238619", "source_url": "https://doi.org/10.1038/s41591-023-02727-4", "keywords": "Hallucinogens, Oregon, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"38238619\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1271, "title": "The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.", "normalized_title": "the psychedelic future of post traumatic stress disorder treatment", "authors": "Zaretsky TG, Jagodnik KM, Barsic R, Antonio JH, Bonanno PA, MacLeod C, Pierce C, Carney H, Morrison MT, Saylor C, Danias G, Lepow L, Yehuda R.", "abstract": "Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant proportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and new approaches for this and other trauma-related mental health conditions are greatly needed. Psychedelic compounds that alter cognition, perception, and mood are currently being examined for their efficacy in treating PTSD despite their current status as Drug Enforcement Administration (DEA)- scheduled substances. Initial clinical trials have demonstrated the potential value of psychedelicassisted therapy to treat PTSD and other psychiatric disorders. In this comprehensive review, we summarize the state of the science of PTSD clinical care, including current treatments and their shortcomings. We review clinical studies of psychedelic interventions to treat PTSD, trauma-related disorders, and common comorbidities. The classic psychedelics psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) and DMT-containing ayahuasca, as well as the entactogen 3,4-methylenedioxymethamphetamine (MDMA) and the dissociative anesthetic ketamine, are reviewed. For each drug, we present the history of use, psychological and somatic effects, pharmacology, and safety profile. The rationale and proposed mechanisms for use in treating PTSD and traumarelated disorders are discussed. This review concludes with an in-depth consideration of future directions for the psychiatric applications of psychedelics to maximize therapeutic benefit and minimize risk in individuals and communities impacted by trauma-related conditions.", "journal": null, "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.2174/1570159x22666231027111147", "pubmed_id": "38284341", "source_url": "https://doi.org/10.2174/1570159x22666231027111147", "keywords": "Humans, N,N-Dimethyltryptamine, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Stress Disorders, Post-Traumatic, Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"38284341\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Pharmacology,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1268, "title": "Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).", "normalized_title": "efficacy safety and tolerability of psychedelics in treatment resistant depression trd", "authors": "Olivier B, Olivier JDA.", "abstract": "Major depressive disorder (MDD) is a highly prevalent psychiatric disorder, associated with substantial burden and large economical costs. Notwithstanding various conventional antidepressant treatment options, a large portion of depressed people (ca. 30%) fails to respond to first-line treatment, resulting in treatment-resistant depression (TRD). Although non-response to multiple antidepressant interventions is a common outcome, a consensus definition of TRD is not yet available. In practice, TRD is applied when two or more successive treatments with different antidepressants are not working. The last decade's intense research into new medicines for TRD has led to two developments, using typical or serotonergic (psilocybin, ayahuasca) and atypical (glutamatergic) psychedelics (ketamine, esketamine). Both approaches, although via different entrance mechanism, exhibit a fast onset but also long-lasting antidepressant effect far beyond the biological presence of the drug in the body, strongly indicating that downstream mechanisms activated by signaling cascades in the brain are involved. The present chapter describes the clinical development of psilocybin and esketamine for TRD and discusses the problems involved in the use of a proper placebo because of the psychotomimetic (psilocybin) or dissociative (ketamine) effects that interfere with performing \"blind\" studies. Nevertheless, intranasal esketamine was developed and approved for TRD, whereas psilocybin has shown positive results. Adverse effects and tolerability of both drugs in the dose ranges used are generally acceptable. The emergence of anti-TRD medicines for treatment of a very severe disease is a breakthrough in psychiatry.", "journal": null, "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1007/978-981-97-4402-2_3", "pubmed_id": "39261423", "source_url": "https://doi.org/10.1007/978-981-97-4402-2_3", "keywords": "Humans, Ketamine, Hallucinogens, Antidepressive Agents, Treatment Outcome, Depressive Disorder, Treatment-Resistant, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"39261423\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1234, "title": "Keeping the promise: a critique of the current state of microdosing research.", "normalized_title": "keeping the promise a critique of the current state of microdosing research", "authors": "Petranker R, Anderson T, Fewster EC, Aberman Y, Hazan M, Gaffrey M, Seli P", "abstract": "The practice of taking small, sub-hallucinogenic doses of psychedelics, known as microdosing, has exploded in popularity over the last decade. Users claim benefits ranging from improved mood and enhanced creativity to an increased sense of meaning and connectedness in life. While research on microdosing is still lagging behind the shift in public opinion, several papers have been published in the last five years which attempted to assess the effects of microdosing. This review paper aimed to critically analyze the research practices used in the recent wave of microdosing research: We reviewed 15 papers published before the closing date of this review in March 2022. Our review concludes that it is premature to draw any conclusions about the efficacy or safety of microdosing since the research quality cannot be considered confirmatory. We propose some potential causes for the current state of the literature and some suggestions for how these causes may be ameliorated.", "journal": "Frontiers in psychiatry", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.3389/fpsyt.2024.1217102", "pubmed_id": "38374976", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38374976/", "keywords": "LSD, microdosing, psilocybin, psychedelics, review", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"38374976\"}", "topic_tags": "Microdosing,Creativity,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1196, "title": "Safety pharmacology of acute psilocybin administration in healthy participants", "normalized_title": "safety pharmacology of acute psilocybin administration in healthy participants", "authors": "Isabelle Straumann, Friederike Holze, A. Becker, Laura Ley, Nepomuk Halter, Matthias E. Liechti", "abstract": "Psilocybin is being studied for its therapeutic potential in various mental health disorders, such as depression, anxiety, and addiction. Initial studies suggested that psilocybin is generally safe when used under controlled conditions, but more research is needed to better understand its safety profile. We report safety pharmacology data from a pooled analysis of three randomized crossover studies that included 85 healthy participants and 113 single-dose administrations of psilocybin. Single oral doses included 15 mg, 20 mg, 25 mg, and 30 mg psilocybin dihydrate. We investigated subjective effects, blood pressure, heart rate, body temperature, acute and subacute adverse effects, reports of flashbacks, and liver and kidney function before and after the studies. The 20, 25, and 30 mg doses of psilocybin produced stronger effects than the 15 mg dose. Psilocybin at all doses induced higher \"good drug effects\" than \"bad drug effects.\" Only the 25 and 30 mg doses increased anxiety. Psilocybin elevated autonomic effects only moderately. Tachycardia (>100 beats/min) was observed with 7% of all psilocybin administrations. Body temperature >38° was reached in 7%, 9%, 17%, and 32% of the participants with the 15, 20, 25, and 30 mg doses, respectively. Kidney and liver function parameters were unaltered at the end of the study. Five participants (6%) reported transient flashback phenomena. No serious adverse reactions occurred. These findings suggest that a single administration of psilocybin is safe with regard to acute psychological and physical harm in healthy participants in a controlled research setting.", "journal": "Neuroscience Applied", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1016/j.nsa.2024.104060", "pubmed_id": "40656108", "source_url": "https://doi.org/10.1016/j.nsa.2024.104060", "keywords": "Psilocybin, Adverse effect, Hallucinogen, Anxiety, Medicine, Heart rate, Crossover study, Pharmacology, Anesthesia, Safety pharmacology, Psychology, Drug, Psychiatry, Placebo, Internal medicine, Blood pressure, Alternative medicine, Pathology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4392888270\",\"openalex_url\":\"https://openalex.org/W4392888270\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":23,\"referenced_works\":[\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2089306255\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2161950360\",\"https://openalex.org/W2165032621\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2415329247\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2552761136\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2590375860\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2790481213\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W3092027192\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3200846882\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4206965048\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4220686675\",\"https://openalex.org/W4223893856\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4378174725\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W6716751055\",\"https://openalex.org/W6839106885\"],\"authorships\":[{\"id\":\"https://openalex.org/A5069070940\",\"display_name\":\"Isabelle Straumann\",\"orcid\":\"https://orcid.org/0009-0008-2952-586X\"},{\"id\":\"https://openalex.org/A5028081191\",\"display_name\":\"Friederike Holze\",\"orcid\":\"https://orcid.org/0000-0003-3143-1519\"},{\"id\":\"https://openalex.org/A5012996786\",\"display_name\":\"A. Becker\",\"orcid\":\"https://orcid.org/0000-0001-5308-7945\"},{\"id\":\"https://openalex.org/A5102828957\",\"display_name\":\"Laura Ley\",\"orcid\":\"https://orcid.org/0009-0003-9881-4693\"},{\"id\":\"https://openalex.org/A5094174389\",\"display_name\":\"Nepomuk Halter\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071962736\",\"display_name\":\"Matthias E. Liechti\",\"orcid\":\"https://orcid.org/0000-0002-1765-9659\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"https://doi.org/10.1016/j.nsa.2024.104060\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Pharmacology,Receptor Pharmacology,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4392888270" }, { "id": 1054, "title": "Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery", "normalized_title": "exploring psychedelic use in athletes and their attitudes toward psilocybin assisted therapy in concussion recovery", "authors": "Baeleigh VanderZwaag, Albert Garcia-Romeu, Mauricio A. García-Barrera", "abstract": "Background: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. Athletes frequently sustain concussions and often experience myriad symptoms, including cognitive and mood issues, which can persist for weeks or months in 10%-30% of athletes. Psilocybin may be a potential symptom management option for athletes with persisting concussion symptoms. Objectives: This study sought to summarize athlete psychedelic use, among other substances, and to examine the willingness of the sports community to engage in or support psilocybin-assisted therapy (PAT) for concussion recovery and management of persisting concussion symptoms. Methods: = 90 staff) respondents completed an online survey distributed in Canada and the United States which queried sport involvement and demographics, substance use, concussion history, and knowledge and willingness about psilocybin. The reporting of this study conforms to the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) statement. Design: Substance use rates were summarized across athletes and team staff members and a path analysis was used for each sample to identify predictors of willingness to use PAT (athletes) or support PAT (staff) for concussion recovery. Participants were also asked to identify perceived barriers to the implementation of PAT for sports-related concussions, and to indicate their overall willingness. Results: Psychedelics were the third most used substance in the past year among athletes (35.8%) while regular psychedelic use was quite low in athletes (7.5%). A path analysis conducted in RStudio found that attitudes toward psilocybin and knowledge of psilocybin were significant predictors for both athletes and staff members of their willingness to use or support PAT for concussion recovery. Athletes reported likely engaging in PAT (61.2%) and staff (71.1%) reported that they would support their athletes using PAT. Conclusion: The results of this study suggest that the sports community may be receptive to PAT and athletes would be willing to engage in it for concussion recovery and/or the management of persisting post-concussion symptoms (PPCS). Future research should examine the effects of psilocybin for PPCS to inform whether there is any impact while addressing concerns regarding long-term effects of psilocybin use.", "journal": "Therapeutic Advances in Psychopharmacology", "publication_date": "2023-12-31", "publication_year": 2023, "doi": "10.1177/20451253241264812", "pubmed_id": "39132012", "source_url": "https://doi.org/10.1177/20451253241264812", "keywords": "Psilocybin, Athletes, Mood, Hallucinogen, Concussion, Cognition, Psychology, Psychiatry, Clinical psychology, Depression (economics), Psychotherapist, Medicine, Poison control, Physical therapy, Injury prevention, Economics, Environmental health, Macroeconomics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4401432739\",\"openalex_url\":\"https://openalex.org/W4401432739\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W2013578576\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2051521144\",\"https://openalex.org/W2051921558\",\"https://openalex.org/W2059367366\",\"https://openalex.org/W2078927525\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2146578632\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2155656611\",\"https://openalex.org/W2162090451\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2612243571\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2802295301\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2908591571\",\"https://openalex.org/W2922440307\",\"https://openalex.org/W3015119188\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3046708691\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3100320203\",\"https://openalex.org/W3109305452\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3181528408\",\"https://openalex.org/W3184845084\",\"https://openalex.org/W3211842562\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4302767823\",\"https://openalex.org/W4312084004\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4379599151\",\"https://openalex.org/W4380574892\",\"https://openalex.org/W4381598541\",\"https://openalex.org/W4382918325\"],\"authorships\":[{\"id\":\"https://openalex.org/A5019070873\",\"display_name\":\"Baeleigh VanderZwaag\",\"orcid\":\"https://orcid.org/0000-0003-3217-0031\"},{\"id\":\"https://openalex.org/A5091708678\",\"display_name\":\"Albert Garcia-Romeu\",\"orcid\":\"https://orcid.org/0000-0003-2182-1644\"},{\"id\":\"https://openalex.org/A5033732343\",\"display_name\":\"Mauricio A. García-Barrera\",\"orcid\":\"https://orcid.org/0000-0002-4302-4964\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2765027927\",\"source_display_name\":\"Therapeutic Advances in Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/20451253241264812\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Chronic Pain,Aging,Observational Study,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4401432739" }, { "id": 4723, "title": "Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge", "normalized_title": "psilocybin new remedy for patients with psychiatric disorders critical analysis of the current state of knowledge", "authors": "Karolina Wąsik, Sebastian Tomaszuk, Magda Wojtuś", "abstract": "Introduction and purpose: Nowadays, when mental disorders are considered by the World Health Organisation as a global burden, the potential usage of psychedelic drugs as supportive therapy is gaining more attention worldwide. The aim of this paper is to summarize the usefulness of psilocybin - representative of psychedelics - in psychiatric venues. In this review we describe its properties, efficacy and adverse events in treating depression, trauma and obsessive-compulsive disorders. Brief description of the state of knowledge: Psilocybin demonstrates a safety profile which does not differ from standard drugs used in therapies of psychiatric disorders. Positive results of its administration were noticed on different psychiatric scales and are considered as clinically meaningful. With depression being the most common mental disease and growing demand for new remedies, most of the conducted research is concentrated on this subject, but there is also some evidence of its purpose in the treatment of trauma and obsessive-compulsive disorders. Conclusions: Psilocybin merits further research as foregoing results of conducted studies are pointing to its efficacy. Psychedelic-assisted therapies may create noteworthy opportunities to current matter in the standard treatment of psychiatric disorders and there is a possibility that in the future in some cases they will be considered as the first line treatment. Nevertheless, still more data is needed to determine its placement in the treatments.", "journal": "Journal of Education Health and Sport", "publication_date": "2023-12-29", "publication_year": 2023, "doi": "10.12775/jehs.2023.50.01.005", "pubmed_id": null, "source_url": "http://dx.doi.org/10.12775/jehs.2023.50.01.005", "keywords": "Psilocybin, Psychiatry, Depression (economics), Psychology, Medicine, Adverse effect, Hallucinogen, Psychotherapist, Pharmacology, Macroeconomics, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:44", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4390439845\",\"openalex_url\":\"https://openalex.org/W4390439845\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W122113993\",\"https://openalex.org/W1978560738\",\"https://openalex.org/W2004762037\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2046403378\",\"https://openalex.org/W2129340715\",\"https://openalex.org/W2151375494\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2317076828\",\"https://openalex.org/W2352975345\",\"https://openalex.org/W2484333338\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2799976014\",\"https://openalex.org/W2913229070\",\"https://openalex.org/W2945658587\",\"https://openalex.org/W2981767691\",\"https://openalex.org/W2991179833\",\"https://openalex.org/W3000549374\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3110345791\",\"https://openalex.org/W3146268156\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3177513265\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4280514631\",\"https://openalex.org/W4281492138\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4288718745\",\"https://openalex.org/W4304690665\",\"https://openalex.org/W4307481727\",\"https://openalex.org/W4322774433\",\"https://openalex.org/W4366989647\",\"https://openalex.org/W4382517556\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W6940909433\"],\"authorships\":[{\"id\":\"https://openalex.org/A5043270242\",\"display_name\":\"Karolina Wąsik\",\"orcid\":\"https://orcid.org/0000-0003-2817-0848\"},{\"id\":\"https://openalex.org/A5051698645\",\"display_name\":\"Sebastian Tomaszuk\",\"orcid\":\"https://orcid.org/0000-0002-1572-5181\"},{\"id\":\"https://openalex.org/A5037981317\",\"display_name\":\"Magda Wojtuś\",\"orcid\":\"https://orcid.org/0000-0003-4299-2143\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737571363\",\"source_display_name\":\"Journal of Education Health and Sport\",\"landing_page_url\":\"http://dx.doi.org/10.12775/jehs.2023.50.01.005\",\"is_oa\":true}}", "topic_tags": "Depression,OCD,Pharmacology,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4390439845" }, { "id": 3751, "title": "Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin", "normalized_title": "psychedelic therapy a primer for primary care clinicians part iv psilocybin", "authors": "Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS.", "abstract": "Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause long-lasting mental health problems such as psychosis, contemporary research has demonstrated that psilocybin is psychologically and physiologically safe. Adverse psychiatric outcomes can generally be avoided in controlled settings such as clinical trials. However, considerations regarding optimal dosing, therapeutic protocols, and integration strategies for psychedelic experiences remain imperative for the responsible clinical implementation of psilocybin-assisted therapy. Therapeutic Advances: In clinical trials, psilocybin has shown promise for treating major depressive disorder and treatment-resistant depression. Initial studies indicated that 42-57% of patients underwent remission after psilocybin-assisted therapy, which suggests that psilocybin is more effective than existing antidepressant medications. However, larger Phase II trials with more than 100 participants have shown a much smaller remission rate of 25-29%, though these studies still observed that psilocybin causes a significant reduction in depressive symptoms. Clinical data has also demonstrated that psilocybin can manage substance use disorders and end-of-life anxiety. Conclusion: Psilocybin is the most clinically well-researched psychedelic drug, with trials that have enrolled hundreds of participants and therapeutic applications that span multiple psychiatric conditions. Phase III trials, which have already commenced, will determine whether psilocybin lives up to the promise that it showed in previous clinical trials.", "journal": "PsyArXiv", "publication_date": "2023-12-25", "publication_year": 2023, "doi": "10.31234/osf.io/a8xwk", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/a8xwk", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:18", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR779326\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Pharmacology,Receptor Pharmacology,Consciousness,Clinical Trial,Review Article,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3572, "title": "Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.", "normalized_title": "psilocybin assisted psychotherapy in the management of anxiety associated with stage iv melanoma", "authors": "Multidisciplinary Association for Psychedelic Studies", "abstract": "This study is to find out about whether two sessions of psilocybin-assisted psychotherapy are safe and will help people who are anxious as a result of having stage IV melanoma and will involve two sessions of psychotherapy combined with either 4 or 25 mg psilocybin. The study will measure anxiety, depression, quality of life and spirituality before and after psilocybin-assisted psychotherapy, natural killer cells (a type of immune cell) will be counted from blood samples taken the day after psilocybin-assisted psychotherapy, and people will keep daily diaries reporting on how anxious they feel for each day in the study. Melanoma is a cancer arising from pigment-producing cells, or melanocytes. These cells are chiefly located in the skin, but they can also be found in other parts of the body, including eyes, ears and GI tract. A diagnosis of stage IV melanoma can create great stress and anxiety for an individual and his or her caregivers. Psilocybin (4-phosphoryloxy- N,N-dimethyl-tryptamine) is a psychedelic (hallucinogenic) compound found in certain species of mushrooms that can produce spiritual or mystical experiences and that has been used in psychotherapy prior to being made illegal. This study will be a randomized, active-placebo controlled pilot study of the safety and efficacy of psilocybin-assisted psychotherapy as a means of managing anxiety in association with stage IV melanoma. This study will examine whether two sessions of psilocybin-assisted psychotherapy scheduled seen to 14 days apart will reduce anxiety, improve quality of life and be safe in people with stage IV melanoma. Subjects in this study will have a 66% chance of receiving the full dose of 25 mg psilocybin and a 33% of receiving 4 mg psilocybin. The first dose is expected to change how people feel, think and see the world, while the lower dose is expected to have only slight effects. Each subject will receive these conditions at random, as if by coin-toss. The researchers, including the therapists, and the subject will not know whether they are assigned to get 25 or 4 mg psilocybin. The entire study can last up to three and a half months (14 weeks) but the main part of the study lasts six weeks. After the researchers determine that a person with stage IV melanoma and anxiety can be in the study, there will be two introductory psychotherapy sessions with the therapist-investigators. They will prepare the participant for psilocybin-assisted psychotherapy. The subject will have a day-long psilocybin-assisted psychotherapy session after introductory sessions, and he or she will remain overnight at the clinic. There will be a psychotherapy follow-up scheduled the day after each psilocybin-assisted session to help people work with the psilocybin-assisted psychotherapy, and there will be a psychotherapy session in between the first and second psilocybin-assisted psychotherapy sessions. Two weeks after the second psilocybin-assisted psychotherapy session, subjects will return for another follow-up visit. The subjects will answer questions or fill out questionnaires about anxiety, depression, quality of life, spirituality and sense of self at the start of the study, two weeks after the second psilocybin-assisted session and at least once during the study. Subjects will have blood draws to assess liver function before each psilocybin-assisted session and they will have a blood draw to assess natural killer (NK) cells the day after each psilocybin-assisted session. On the day after each psilocybin-assisted session, subjects will also complete a questionnaire about their experiences during the psilocybin-assisted session. Two weeks after the second experimental psilocybin-assisted session, subjects will learn if they got the full or active placebo dose of psilocybin. Any of the three subjects who receive the active placebo dose can take part in an \"open-label\" study phase that will last another six weeks. The open-label phase will be nearly identical to those used in the first study phase except that there will be one, and not two, introductory psychotherapy sessions, and the subject and therapists will know that the subject will be receiving 25 mg psilocybin. People who got the full dose of 25 mg psilocybin will not take part in the open-label study phase. If they are well enough to do so, subjects who received the full dose of psilocybin will have anxiety, depression, quality of life and spirituality measured again two months after the second experimental session. Subjects who received active placebo psilocybin will have anxiety, depression, quality of life and spirituality measured two months after the second open-label psilocybin-assisted session.", "journal": "ClinicalTrials.gov", "publication_date": "2023-12-25", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT00979693", "keywords": "Anxiety, Stage IV Melanoma, psilocybin, WITHDRAWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT00979693\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Aging,Spirituality,Mystical Experience,Safety,Immune Function", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3133, "title": "Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin", "normalized_title": "psychedelic therapy a primer for primary care clinicians part iv psilocybin", "authors": "", "abstract": "Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin. Areas of Uncertainty: Despite initial concerns that psilocybin could cause long-lasting mental health problems such as psychosis, contemporary research has demonstrated that psilocybin is psychologically and physiologically safe. Adverse psychiatric outcomes can generally be avoided in controlled settings such as clinical trials. However, considerations regarding optimal dosing, therapeutic protocols, and integration strategies for psychedelic experiences remain imperative for the responsible clinical implementation of psilocybin-assisted therapy. Therapeutic Advances: In clinical trials, psilocybin has shown promise for treating major depressive disorder and treatment-resistant depression. Initial studies indicated that 42-57% of patients underwent remission after psilocybin-assisted therapy, which suggests that psilocybin is more effective than existing antidepressant medications. However, larger Phase II trials with more than 100 participants have shown a much smaller remission rate of 25-29%, though these studies still observed that psilocybin causes a significant reduction in depressive symptoms. Clinical data has also demonstrated that psilocybin can manage substance use disorders and end-of-life anxiety. Conclusion: Psilocybin is the most clinically well-researched psychedelic drug, with trials that have enrolled hundreds of participants and therapeutic applications that span multiple psychiatric conditions. Phase III trials, which have already commenced, will determine whether psilocybin lives up to the promise that it showed in previous clinical trials.", "journal": "PsyArXiv", "publication_date": "2023-12-25", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/a8xwk_v1", "keywords": "Psychiatry", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"a8xwk_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Pharmacology,Receptor Pharmacology,Consciousness,Clinical Trial,Review Article,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1324, "title": "Potential use of psilocybin drugs in the treatment of depression.", "normalized_title": "potential use of psilocybin drugs in the treatment of depression", "authors": "Śladowska K, Kawalec P, Brzostek T, Pilc A.", "abstract": "IntroductionDepression is a common disabling psychiatric disorder, which - in extreme cases - may lead to suicide if untreated or inadequately treated. Despite the availability of various treatments for depression, including pharmacotherapy, there is still a need to search for new agents with higher effectiveness and faster onset of action, especially for patients with treatment-resistant depression.Areas coveredA substance that has attracted considerable attention for nearly a decade is psilocybin, a natural psychedelic found in psilocybin mushrooms. In this study, we evaluated the efficacy and safety of psilocybin in the treatment of depression, based on pivotal randomized clinical trials. Moreover, we used findings from observational studies regarding recreational use. We also looked at ongoing clinical trials and discussed the registration status and clinical potential of the drug.Expert opinionClinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for use and administered to patients with depression, the results of large ongoing phase III clinical trials are needed to confirm its efficacy and safety and to change the way it is perceived by physicians and patients.", "journal": null, "publication_date": "2023-12-25", "publication_year": 2023, "doi": "10.1080/14728214.2023.2264180", "pubmed_id": "37817501", "source_url": "https://doi.org/10.1080/14728214.2023.2264180", "keywords": "Humans, Hallucinogens, Pharmaceutical Preparations, Depression, Randomized Controlled Trials as Topic, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37817501\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1183, "title": "Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis", "normalized_title": "acceptability of psilocybin assisted group therapy in patients with cancer and major depressive disorder qualitative analysis", "authors": "Yvan Beaussant, Elise C. Tarbi, Kabir Nigam, Skye A. Miner, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A. Tulsky, Manish Agrawal", "abstract": "BACKGROUND: The present study explored the acceptability of psilocybin-assisted group therapy from the perspective of patients with cancer and depression who participated in a clinical trial assessing the safety and efficacy of this novel intervention. METHODS: Guided by the conceptual framework of acceptability, the authors conducted semi-structured interviews with participants of the psilocybin trial. Data were analyzed using template and thematic analyses. RESULTS: Participants' (n = 28) perspectives on the acceptability of the group and simultaneous sessions was generally positive, both in terms of safety and efficacy: first, the groups contributed to increase participants' sense of safety and preparedness as they were engaging in the therapy; and second, the groups fostered a sense of connection and of belonging, which served to enrich and deepen the meaning of participants' experience, ultimately opening a dimension of self-transcendence and compassion. Other subthemes related to factors influencing the acceptability of the group approach included: 1) the importance of the therapeutic framework, 2) the complementary value of individual sessions, 3) disruptive factors related to the group and/or simultaneous setting, and 4) opportunities and challenges related to group size and how to structure interactions. CONCLUSIONS: This study enhances understanding of what promotes acceptability of the psilocybin-assisted therapy group model for the treatment of MDD in cancer patients. PLAIN LANGUAGE SUMMARY: We conducted exit interviews with participants of a phase 2 trial of psilocybin-assisted therapy (PAT) conducted in a community cancer center, to assess the acceptability of a novel psilocybin delivery model combining simultaneous individual therapy and group sessions. Our findings support the acceptability of this intervention and suggest that in addition to being feasible, it might also enhance participants' perceived safety and efficacy compared to uniquely individual or group delivery models of PAT. Our analysis highlights critical factors conditioning acceptability and suggests new ways PAT may be scaled and integrated into cancer care.", "journal": "Cancer", "publication_date": "2023-12-17", "publication_year": 2023, "doi": "10.1002/cncr.35024", "pubmed_id": "38105653", "source_url": "https://doi.org/10.1002/cncr.35024", "keywords": "Psilocybin, Medicine, Psychotherapist, Clinical psychology, Thematic analysis, Group psychotherapy, Qualitative research, Psychology, Psychiatry, Hallucinogen, Sociology, Social science, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4389895437\",\"openalex_url\":\"https://openalex.org/W4389895437\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":22,\"referenced_works\":[\"https://openalex.org/W163976722\",\"https://openalex.org/W1480983579\",\"https://openalex.org/W1513859721\",\"https://openalex.org/W1557078286\",\"https://openalex.org/W1566986267\",\"https://openalex.org/W1922474554\",\"https://openalex.org/W1965295590\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1981592659\",\"https://openalex.org/W1997084088\",\"https://openalex.org/W2025131776\",\"https://openalex.org/W2047362844\",\"https://openalex.org/W2084343441\",\"https://openalex.org/W2089047250\",\"https://openalex.org/W2115111325\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2153153465\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2168281859\",\"https://openalex.org/W2305278139\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2571392308\",\"https://openalex.org/W2582406074\",\"https://openalex.org/W2625982844\",\"https://openalex.org/W2738640210\",\"https://openalex.org/W2803238382\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2931245338\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W3001979862\",\"https://openalex.org/W3015163151\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W3166459008\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211011432\",\"https://openalex.org/W4225266953\",\"https://openalex.org/W4281784879\",\"https://openalex.org/W4285077222\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4312196530\",\"https://openalex.org/W4320491739\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W6606710515\"],\"authorships\":[{\"id\":\"https://openalex.org/A5063328366\",\"display_name\":\"Yvan Beaussant\",\"orcid\":\"https://orcid.org/0000-0003-3716-6736\"},{\"id\":\"https://openalex.org/A5017118759\",\"display_name\":\"Elise C. Tarbi\",\"orcid\":\"https://orcid.org/0000-0003-2452-6632\"},{\"id\":\"https://openalex.org/A5053570913\",\"display_name\":\"Kabir Nigam\",\"orcid\":\"https://orcid.org/0000-0002-1880-0079\"},{\"id\":\"https://openalex.org/A5076256339\",\"display_name\":\"Skye A. Miner\",\"orcid\":\"https://orcid.org/0000-0002-8848-2440\"},{\"id\":\"https://openalex.org/A5064982845\",\"display_name\":\"Zachary Sager\",\"orcid\":\"https://orcid.org/0000-0001-8209-9582\"},{\"id\":\"https://openalex.org/A5063712330\",\"display_name\":\"Justin J. Sanders\",\"orcid\":\"https://orcid.org/0000-0001-8928-4051\"},{\"id\":\"https://openalex.org/A5071091088\",\"display_name\":\"Michael Ljuslin\",\"orcid\":\"https://orcid.org/0000-0002-2386-1749\"},{\"id\":\"https://openalex.org/A5052182950\",\"display_name\":\"Benjamin Guérin\",\"orcid\":\"https://orcid.org/0000-0002-0141-7874\"},{\"id\":\"https://openalex.org/A5026954192\",\"display_name\":\"Paul Thambi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014360467\",\"display_name\":\"James A. Tulsky\",\"orcid\":\"https://orcid.org/0000-0002-7458-0453\"},{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S126033908\",\"source_display_name\":\"Cancer\",\"landing_page_url\":\"https://doi.org/10.1002/cncr.35024\",\"is_oa\":true}}", "topic_tags": "Depression,Chronic Pain,Aging,Clinical Trial,Cancer Patients,Safety,Toxicity,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4389895437" }, { "id": 1181, "title": "Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder", "normalized_title": "psilocybin assisted group therapy in patients with cancer diagnosed with a major depressive disorder", "authors": "Manish Agrawal, William A. Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli, Kimberly Roddy, Norma Stevens, Brian D. Richards, Nick Schor, Heather Honstein, Betsy Jenkins, Mark Bates, Paul Thambi", "abstract": "BACKGROUND: Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin-assisted therapy in patients with cancer and major depressive disorder. METHODS: This phase 2, open-label trial enrolled patients with curable and noncurable cancer and major depressive disorder at a single community oncology practice site. A single 25-mg dose of psilocybin was administered simultaneously to cohorts of three to four participants with individual (4.25 hours in 1:1 therapist-to-patient ratio) and group therapeutic support (3.75 hours) before, during, and after psilocybin administration. Outcomes included depression severity, anxiety, pain, demoralization, and disability. RESULTS: Thirty participants completed the study. No psilocybin-related serious adverse events occurred; treatment-related adverse events (e.g., nausea, headache) were generally mild and expected. There were no laboratory or electrocardiogram abnormalities. No suicidality was reported. Efficacy was suggested with a robust reduction in depression severity scores from baseline to posttreatment of 19.1 points (95% CI, 22.3 to -16.0; p", "journal": "Cancer", "publication_date": "2023-12-17", "publication_year": 2023, "doi": "10.1002/cncr.35010", "pubmed_id": "38105655", "source_url": "https://doi.org/10.1002/cncr.35010", "keywords": "Psilocybin, Medicine, Cancer, Major depressive disorder, Psychiatry, Internal medicine, Oncology, Hallucinogen, Cognition, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4389900078\",\"openalex_url\":\"https://openalex.org/W4389900078\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":72,\"referenced_works\":[\"https://openalex.org/W1957937187\",\"https://openalex.org/W1966158258\",\"https://openalex.org/W1990166011\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2012504366\",\"https://openalex.org/W2017346793\",\"https://openalex.org/W2023305103\",\"https://openalex.org/W2026890679\",\"https://openalex.org/W2030045599\",\"https://openalex.org/W2041265397\",\"https://openalex.org/W2077188072\",\"https://openalex.org/W2082535915\",\"https://openalex.org/W2084779737\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2115510970\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2153153465\",\"https://openalex.org/W2160070901\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2325558246\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2803692240\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2904473517\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2940589604\",\"https://openalex.org/W2969626873\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3116377810\",\"https://openalex.org/W3171418018\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4251745849\",\"https://openalex.org/W4365444032\",\"https://openalex.org/W7074234824\"],\"authorships\":[{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5039889194\",\"display_name\":\"William A. Richards\",\"orcid\":\"https://orcid.org/0000-0003-0730-9249\"},{\"id\":\"https://openalex.org/A5063328366\",\"display_name\":\"Yvan Beaussant\",\"orcid\":\"https://orcid.org/0000-0003-3716-6736\"},{\"id\":\"https://openalex.org/A5038515583\",\"display_name\":\"Sarah Shnayder\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040592691\",\"display_name\":\"Rezvan Ameli\",\"orcid\":\"https://orcid.org/0000-0001-8061-4034\"},{\"id\":\"https://openalex.org/A5093431923\",\"display_name\":\"Kimberly Roddy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108886819\",\"display_name\":\"Norma Stevens\",\"orcid\":null},{\"id\":\"https://openalex.org/A5034785335\",\"display_name\":\"Brian D. Richards\",\"orcid\":null},{\"id\":null,\"display_name\":\"Nick Schor\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092083232\",\"display_name\":\"Heather Honstein\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108886818\",\"display_name\":\"Betsy Jenkins\",\"orcid\":null},{\"id\":\"https://openalex.org/A5045651335\",\"display_name\":\"Mark Bates\",\"orcid\":\"https://orcid.org/0000-0002-5916-5403\"},{\"id\":\"https://openalex.org/A5026954192\",\"display_name\":\"Paul Thambi\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S126033908\",\"source_display_name\":\"Cancer\",\"landing_page_url\":\"https://doi.org/10.1002/cncr.35010\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Headache / Migraine,Clinical Trial,Observational Study,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4389900078" }, { "id": 3549, "title": "Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders", "normalized_title": "safety and efficacy of psilocybin for the treatment of headache disorders", "authors": "Yale University", "abstract": "The purpose of this study is to investigate the effects of an oral psilocybin pulse regimen in cluster headache. Subjects will be randomized to receive oral placebo, low dose psilocybin, or high dose psilocybin in three experimental sessions, each separated by 5 days. Subjects will maintain a headache diary prior to, during, and after the pulse regimen in order to document headache frequency and intensity before, during, and after the pulse regimen. After at least 6 months from the last experimental session, subjects may be invited for a second round, in which they will be randomized to receive either low dose or high dose psilocybin.", "journal": "ClinicalTrials.gov", "publication_date": "2023-12-14", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT02981173", "keywords": "Cluster Headache, 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT02981173\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Headache / Migraine,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1308, "title": "A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.", "normalized_title": "a systematic review of reporting practices in psychedelic clinical trials psychological support therapy and psychosocial interventions", "authors": "Brennan W, Kelman AR, Belser AB.", "abstract": "BackgroundPsychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PIs) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called \"psychological support,\" \"monitoring,\" \"psychedelic-assisted therapy,\" or \"psychedelic-assisted psychotherapy.\" A brief review of recent research, historical studies, safety considerations, and participant perspectives suggests that PI has a substantive and critical impact on treatment outcomes.MethodsThis systematic review examines the reporting practices on PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist.ResultsThirty-three published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report whether their intervention used a therapy manual, 64% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI.DiscussionThe study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.", "journal": null, "publication_date": "2023-12-12", "publication_year": 2023, "doi": "10.1089/psymed.2023.0007", "pubmed_id": "40046864", "source_url": "https://doi.org/10.1089/psymed.2023.0007", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"40046864\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1311, "title": "Drugs for depressionr.", "normalized_title": "drugs for depressionr", "authors": "", "abstract": "", "journal": "The Medical letter on drugs and therapeutics", "publication_date": "2023-12-10", "publication_year": 2023, "doi": "10.58347/tml.2023.1691a", "pubmed_id": "38133585", "source_url": "https://pubmed.ncbi.nlm.nih.gov/38133585/", "keywords": "Abilify, Aplenzin, Auvelity, Buspar, Celexa, Cymbalta, Deplin, Effexor, Emsam, Exxua, Fetzima, Forfivo, L-methylfolate, Lexapro, Marplan, Nardil, Norpramin, PamelorZurzuvae, Parnate, Paxil, Pristiq, Prozac, Remeron, SNRIs, SSRIs, Seroquel, Spravato, St. John’s wort, Symbyax, Trintellix, Viibryd, Wellbutrin, Zoloft, Zulresso, Zurzuvae, adverse effects, amitriptyline, amoxapine, antipsychotics, aripiprazole, brexanolone, bupropion, buspirone, citalopram, cognitive behavioral therapy, deep brain stimulation, depression, desipramine, desvenlafaxine, dextromethorphan, dosage, drug interactions, duloxetine, efficacy, electroconvulsive therapy, escitalopram, esketamine, fluoxetine, gepirone, imipramine, isocarboxazid, ketamine, lactation, levomilnacipran, lithium, mirtazapine, nefazodone, nortriptyline, olanzapine, paroxetine, phenelzine, pregnancy, psilocybin, quetiapine, safety, selegiline, sertraline, transcranial magnetic stimulation, tranylcypromine, trazodone, tricyclic antidepressants, triiodothyronine, venlafaxine, vilazodone, vortioxetine, zuranolone", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"38133585\"}", "topic_tags": "Depression,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1124, "title": "Psilocybin in Bipolar II Study Provides Preliminary Data on Safety", "normalized_title": "psilocybin in bipolar ii study provides preliminary data on safety", "authors": "David B. Yaden, Natalie Gukasyan, Sandeep M. Nayak", "abstract": "Our website uses cookies to enhance your experience. By continuing to use our site, or clicking \"Continue,\" you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology-Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology-Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal", "journal": "JAMA Psychiatry", "publication_date": "2023-12-05", "publication_year": 2023, "doi": "10.1001/jamapsychiatry.2023.4680", "pubmed_id": "38055240", "source_url": "http://dx.doi.org/10.1001/jamapsychiatry.2023.4680", "keywords": "Medicine, Otorhinolaryngology, Psychiatry, Family medicine, Neurology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4389397300\",\"openalex_url\":\"https://openalex.org/W4389397300\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W2113099805\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387469053\",\"https://openalex.org/W4389397550\"],\"authorships\":[{\"id\":\"https://openalex.org/A5039486115\",\"display_name\":\"David B. Yaden\",\"orcid\":\"https://orcid.org/0000-0002-9604-6227\"},{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"},{\"id\":\"https://openalex.org/A5040929530\",\"display_name\":\"Sandeep M. Nayak\",\"orcid\":\"https://orcid.org/0000-0002-6832-0639\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2495708506\",\"source_display_name\":\"JAMA Psychiatry\",\"landing_page_url\":\"http://dx.doi.org/10.1001/jamapsychiatry.2023.4680\",\"is_oa\":false}}", "topic_tags": "Cancer Patients,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4389397300" }, { "id": 1307, "title": "Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings", "normalized_title": "psilocybin for opioid use disorder in two adults stabilized on buprenorphine a technical report on study modifications and preliminary findings", "authors": "Christopher R. Nicholas, David Horton, Julia Malicki, Amelia Baltes, Paul R. Hutson, Randall Brown", "abstract": "Background: Psilocybin has demonstrated promising clinical outcomes for nicotine and alcohol use disorders, yet its potential clinical utility in the treatment of opioid use disorder (OUD) remains unreported in modern literature. This technical report presents methodological considerations and preliminary data from a safety-feasibility trial examining the interaction between psilocybin and buprenorphine in two adults diagnosed with OUD. Procedures: Two adults meeting eligibility criteria for long-term stabilization of buprenorphine/naloxone (≥6 months) enrolled and underwent two psilocybin dosing sessions in a supportive setting. Preliminary data pertaining to the safety, clinical outcomes, and subjective effects of psilocybin were collected. Main Findings: Two participants received psilocybin and completed all study visits. Feasibility considerations were identified, including limitations in provider-based recruitment strategies, participant accessibility, flexibility of the study schedule, and initial eligibility criteria. There were no serious adverse events or significant baseline changes on measures of opioid craving or withdrawal, and the subjective effects associated with psilocybin were consistent with previous studies. Principal Conclusions: Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall generalizability.clinicaltrials.gov ID: NCT05242029.", "journal": "Psychedelic Medicine", "publication_date": "2023-11-30", "publication_year": 2023, "doi": "10.1089/psymed.2023.0012", "pubmed_id": "40046866", "source_url": "https://doi.org/10.1089/psymed.2023.0012", "keywords": "Psilocybin, Buprenorphine, Opioid use disorder, Opioid, Hallucinogen, Medicine, Psychiatry, Psychology, Psychotherapist, Pharmacology, Internal medicine, Receptor, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Opioid Use Disorder Treatment", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4389304198\",\"openalex_url\":\"https://openalex.org/W4389304198\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1529179780\",\"https://openalex.org/W1965246039\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2018914766\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2029057559\",\"https://openalex.org/W2031163840\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2088785539\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2097910464\",\"https://openalex.org/W2108592835\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2116004686\",\"https://openalex.org/W2119765259\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2132974770\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2162127309\",\"https://openalex.org/W2172107654\",\"https://openalex.org/W2245231029\",\"https://openalex.org/W2332450558\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2558869493\",\"https://openalex.org/W2588071311\",\"https://openalex.org/W2594031547\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2778368513\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2808907017\",\"https://openalex.org/W2810374266\",\"https://openalex.org/W2894541203\",\"https://openalex.org/W2896128668\",\"https://openalex.org/W2902753735\",\"https://openalex.org/W2912816136\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2961061631\",\"https://openalex.org/W2974814938\",\"https://openalex.org/W2998334652\",\"https://openalex.org/W3001327571\",\"https://openalex.org/W3004690109\",\"https://openalex.org/W3014277121\",\"https://openalex.org/W3036114481\",\"https://openalex.org/W3040555638\",\"https://openalex.org/W3047090566\",\"https://openalex.org/W3088404198\",\"https://openalex.org/W3092531516\",\"https://openalex.org/W3107191109\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3135670017\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164067847\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3183684219\",\"https://openalex.org/W3185477803\",\"https://openalex.org/W3191094810\",\"https://openalex.org/W3195587140\",\"https://openalex.org/W3203599008\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4206120443\",\"https://openalex.org/W4206936697\",\"https://openalex.org/W4213457173\",\"https://openalex.org/W4214488648\",\"https://openalex.org/W4220945184\",\"https://openalex.org/W4220956513\",\"https://openalex.org/W4223525754\",\"https://openalex.org/W4236180415\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4296121375\",\"https://openalex.org/W4382776629\"],\"authorships\":[{\"id\":\"https://openalex.org/A5043044020\",\"display_name\":\"Christopher R. Nicholas\",\"orcid\":\"https://orcid.org/0000-0002-0599-4046\"},{\"id\":\"https://openalex.org/A5101447266\",\"display_name\":\"David Horton\",\"orcid\":\"https://orcid.org/0009-0001-9456-3060\"},{\"id\":\"https://openalex.org/A5040133315\",\"display_name\":\"Julia Malicki\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001460745\",\"display_name\":\"Amelia Baltes\",\"orcid\":\"https://orcid.org/0000-0002-0416-9810\"},{\"id\":\"https://openalex.org/A5088507656\",\"display_name\":\"Paul R. Hutson\",\"orcid\":\"https://orcid.org/0000-0002-6968-7096\"},{\"id\":\"https://openalex.org/A5071605998\",\"display_name\":\"Randall Brown\",\"orcid\":\"https://orcid.org/0000-0002-5445-8119\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2023.0012\",\"is_oa\":false}}", "topic_tags": "Addiction,Pharmacology,Receptor Pharmacology,Safety,Adverse Events,Toxicity,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4389304198" }, { "id": 1127, "title": "Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.", "normalized_title": "current understanding on psilocybin for major depressive disorder a review focusing on clinical trials", "authors": "Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM.", "abstract": "Previous studies suggested effectiveness of psilocybin in the field of mental health. FDA designated psilocybin as a \"breakthrough therapy\" for the treatment of treatment-resistant depression (TRD) in 2018. This paper provided a review of psilocybin's potential role in treatment of depression by focusing on published clinical trials. Studies showed that psilocybin, an agonist on 5-HT2A receptors, manifests antidepressant and anxiolytic effects by increasing glutamate transmission, reducing brain inflammation, decreasing default mode network activity. In terms of clinical trials, eleven studies (six open-label and five double blinded randomized clinical trials [DB-RCTs]) trials exploring psilocybin's impact on depression were found. Among open-label studies, a pilot study on TRD patients demonstrated significant reductions in depressive symptoms after two psilocybin sessions. Psilocybin also improved cognitive bias associated with depression. Extension studies confirmed sustained improvements and high remission rates. Among five DB-RCTs, two showed that psilocybin led to significant reductions in anxiety and depression in cancer patients, and the improvements sustained for over six months. In MDD, psilocybin showed rapid reductions in depression, with higher remission rates compared to escitalopram in a DB-RCT. Another DB-RCT showed that psilocybin induced higher decrease in depression around 6 hours after their administrations than placebo. The last DB-RCT showed that in patients with TRD, a single dose of psilocybin 25 mg, but not psilocybin 10 mg, resulted in superior antidepressant effect than psilocybin 1 mg. Overall, psilocybin showed promise in treating depression and anxiety, with notable safety profiles. Further research should explore optimal dosages and long-term effects.", "journal": null, "publication_date": "2023-11-29", "publication_year": 2023, "doi": "10.9758/cpn.23.1134", "pubmed_id": "38627070", "source_url": "https://doi.org/10.9758/cpn.23.1134", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38627070\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Receptor Pharmacology,Default Mode Network,Clinical Trial,Randomized Controlled Trial,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3629, "title": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).", "normalized_title": "a randomized double blind placebo controlled study to evaluate the safety tolerability and efficacy of psilocybin assisted psychotherapy in treating severe depression among adults with post traumatic stress disorder ptsd", "authors": "Apex Labs Ltd.", "abstract": "Post-Traumatic Stress Disorder (PTSD) is a mental disorder that may develop in people who have been exposed to a traumatic event, including actual or threatened death, serious injury, or sexual violence. Exposure to a traumatic event is defined as directly experiencing the event, learning about the event, or repeated exposure to details of the event. PTSD is often accompanied by other psychiatric and physical comorbidities, both of which are associated with elevated healthcare costs. Depression, psychosis and suicide rates are consistently reported in greater proportion of PTSD patients. Despite the overwhelming impact of PTSD and comorbid depression, there is a shortfall of effective treatments with few side effects that target the broad range of symptoms, including depression. Psilocybin has been studied for the treatment of depression, anxiety, tobacco and alcohol use disorders, obsessive-compulsive disorder, end of life depression and anxiety, demonstrating safety and efficacy for a variety of indications, with no significant adverse events occurring during the course of treatment and follow-up. Notably, in a participant group distinguished by long-standing, moderate to severe major depressive disorder, two doses of psilocybin-assisted therapy were found to be as effective in antidepressant effects as 6 weeks of daily escitalopram, a commonly used SSRI. Promising results found in these studies have led to psilocybin recently receiving breakthrough designation from the US FDA for its potential therapeutic effect in the treatment of depression. Based on previous research, psilocybin has demonstrated a favorable safety profile and has shown preliminary efficacy against depression as well as other symptoms that typically affect patients with PTSD. Unlike traditional SSRIs which are associated with treatment-resistance and addiction, psilocybin requires few doses to improve a wide-range of symptoms and has not been linked with physical dependence. Furthermore, the effect of other psychedelics can vary greatly and may potentially exacerbate existing conditions.", "journal": "ClinicalTrials.gov", "publication_date": "2023-11-28", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06141876", "keywords": "Post-traumatic Stress Disorder, Depression, APEX-002-A02, psilocybin, Placebo, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT06141876\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3781, "title": "Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach", "normalized_title": "development of a digital intervention for psychedelic preparation dipp a theory and person centred approach", "authors": "McAlpine R, Krajnović K, Khan M, Morometescu L, Simonsson O, Sacchet M, Kamboj S.", "abstract": "Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance therapeutic benefits, and maintain user safety. This paper describes the development of a self-directed, digital intervention for psychedelic preparation. Drawing on elements from the UK Medical Research Council (MRC) framework for developing complex interventions, the design was informed by a four-factor model of psychedelic preparedness, using a person-centred approach. Our mixed-methods investigation consisted of two studies. The first involved interviews with 19 participants who had previously attended a ‘high-dose’ psilocybin retreat, systematically exploring their preparation behaviours and perspectives on the proposed intervention. The second study engaged 28 attendees of an ongoing psilocybin retreat in co-design workshops, refining the intervention protocol using insights from the initial interviews. The outcome is a co-produced 21-day digital course (Digital Intervention for Psychedelic Preparation (DIPP)), that is organised into four modules: Knowledge-Expectation, Psychophysical-Readiness, Safety-Planning, and Intention-Preparation. Fundamental components of the course include daily meditation practice, supplementary exercises tied to the weekly modules, and mood tracking. DIPP provides a comprehensive and scalable solution to enhance psychedelic preparedness, aligning with the broader shift towards digital mental health interventions.", "journal": "PsyArXiv", "publication_date": "2023-11-21", "publication_year": 2023, "doi": "10.31234/osf.io/9ev27", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/9ev27", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:21", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"PPR764166\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Consciousness,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3304, "title": "Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach", "normalized_title": "development of a digital intervention for psychedelic preparation dipp a theory and person centred approach", "authors": "", "abstract": "Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance therapeutic benefits, and maintain user safety. This paper describes the development of a self-directed, digital intervention for psychedelic preparation. Drawing on elements from the UK Medical Research Council (MRC) framework for developing complex interventions, the design was informed by a four-factor model of psychedelic preparedness, using a person-centred approach. Our mixed-methods investigation consisted of two studies. The first involved interviews with 19 participants who had previously attended a ‘high-dose’ psilocybin retreat, systematically exploring their preparation behaviours and perspectives on the proposed intervention. The second study engaged 28 attendees of an ongoing psilocybin retreat in co-design workshops, refining the intervention protocol using insights from the initial interviews. The outcome is a co-produced 21-day digital course (Digital Intervention for Psychedelic Preparation (DIPP)), that is organised into four modules: Knowledge-Expectation, Psychophysical-Readiness, Safety-Planning, and Intention-Preparation. Fundamental components of the course include daily meditation practice, supplementary exercises tied to the weekly modules, and mood tracking. DIPP provides a comprehensive and scalable solution to enhance psychedelic preparedness, aligning with the broader shift towards digital mental health interventions.", "journal": "PsyArXiv", "publication_date": "2023-11-21", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/9ev27_v1", "keywords": "co-design, digital intervention, meditation, preparedness, psilocybin, psychedelic, psychedelic therapy, qualitative, Psychiatry, Life Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:50", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"9ev27_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Consciousness,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 919, "title": "Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.", "normalized_title": "efficacy and safety of four psychedelic assisted therapies for adults with symptoms of depression anxiety and posttraumatic stress disorder a systematic review and meta analysis", "authors": "Bahji A, Lunsky I, Gutierrez G, Vazquez G.", "abstract": "There has been a resurgence in psychedelic research for managing psychiatric conditions in recent years. This study aimed to present a comprehensive review of the current state of the field by applying a systematic search strategy for articles on the effectiveness and tolerability of four psychedelic-assisted therapies (psilocybin, lysergic acid diethylamide [LSD], 3,4-Methylenedioxymethamphetamine [MDMA], and ayahuasca) for adults with symptoms of depression, anxiety, and posttraumatic stress disorder (PTSD). Psychometric scores and adverse events were pooled using random-effects meta-analysis models with Hedges' g bias-corrected standardized mean differences (g) and rate ratios (RR) with 95% confidence intervals (CI). Bias evaluation followed PRISMA and Cochrane guidelines. Eighteen studies were identified, which suggested that psychedelic therapies were well tolerated and presented a large effect size for the management of depression symptoms in a transdiagnostic population with psilocybin (g = -1.92, 95% CI, -2.73 to -1.11) and MDMA (g = -0.71; 95% CI, -1.39 to -0.03). These are promising results that complement the current literature. However, evidence certainty was low to very low due to methodological limitations, small sample size, blinding, study heterogeneity, and publication bias. These results also highlight the need for more adequately powered studies exploring these novel therapies.", "journal": null, "publication_date": "2023-11-14", "publication_year": 2023, "doi": "10.1080/02791072.2023.2278586", "pubmed_id": "37968944", "source_url": "https://doi.org/10.1080/02791072.2023.2278586", "keywords": "Humans, Banisteriopsis, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Treatment Outcome, Depression, Anxiety, Stress Disorders, Post-Traumatic, Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"37968944\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Aging,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3364, "title": "Aesthetic Chills Mitigate Maladaptive Cognition In Depression", "normalized_title": "aesthetic chills mitigate maladaptive cognition in depression", "authors": "Schoeller F, Jain A, Adrien V, Maes P, Reggente N.", "abstract": "Background: Depression is a major global health challenge, affecting over 300 million people worldwide. Current pharmacological and psychotherapeutic interventions have limited efficacy, underscoring the need for novel approaches. Emerging evidence suggests that peak emotional experiences characterized by awe, transcendence, and meaning hold promise for rapidly shifting maladaptive cognitive patterns in depression. Aesthetic chills, a peak positive emotion characterized by physical sensations such as shivers and goosebumps, may influence reward-related neural pathways and hold promise for modifying core maladaptive beliefs rooted in early adverse experiences. Methods We enrolled 96 patients diagnosed with major depressive disorder. A validated database of multimedia known to elicit chills responses (ChillsDB) was used for stimulus presentation. Participants' emotional responses were assessed using the Emotional Breakthrough Inventory (EBI), while shifts in self-schema were measured via the Young Schema Questionnaire (YSQ). Results The study found that chill-inducing stimuli have the potential to positively influence the core schema of individuals with depression, impacting areas of self-related beliefs. The associated phenomenology triggered by chills appears to share similarities with the altered states of consciousness induced by psychedelic substances like psilocybin. Conclusions These preliminary results suggest that the biological processes involved in aesthetic chills could be harnessed as a non-pharmacological intervention for depression. However, further investigation is necessary to comprehensively understand the neurophysiological responses to chills and to evaluate the practicality, effectiveness, and safety of utilizing aesthetic chills as a preventive measure in mental health care.", "journal": "Research Square", "publication_date": "2023-11-13", "publication_year": 2023, "doi": "10.21203/rs.3.rs-3582420/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-3582420/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR759273\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Consciousness,Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3680, "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression", "normalized_title": "the safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment resistant depression", "authors": "COMPASS Pathways", "abstract": "The Safety and Efficacy of Psilocybin as an Adjunctive Therapy in Participants with Treatment-Resistant Depression A recent open label study of the effects of psilocybin in participants with treatment-resistant depression (TRD) showed rapid significant decrease of depressive symptoms after treatment with psilocybin coupled with psychological support. Over 40% of participants sustained response at 3 months. In this study, the aim is to explore effectiveness of 25 mg of psilocybin as an adjunctive therapy in participants with TRD.", "journal": "ClinicalTrials.gov", "publication_date": "2023-11-08", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04739865", "keywords": "Treatment Resistant Depression, Psilocybin, COMP360, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04739865\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1288, "title": "Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.", "normalized_title": "synergistic psychedelic nmdar modulator treatment for neuropsychiatric disorders", "authors": "Heresco-Levy U, Lerer B.", "abstract": "Modern research data suggest a therapeutic role for serotonergic psychedelics in depression and other neuropsychiatric disorders, although psychotomimetic effects may limit their widespread utilization. Serotonergic psychedelics enhance neuroplasticity via serotonin 2 A receptors (5HT2AR) activation and complex serotonergic-glutamatergic interactions involving the ionotropic glutamate receptors, tropomyosin receptor kinase B (TrkB) and the mammalian target of rapamycin (mTOR). N-methyl-d-aspartate receptors (NMDAR) channel antagonists, i.e. ketamine, and glycine modulatory site full and partial agonists, i.e., D-serine (DSR) and D-cycloserine (DCS), share some of these mechanisms of action and have neuroplastic and antidepressant effects. Moreover, procognitive effects have been reported for DSR and DCS and 5HT2AR-NMDAR interactions modulate neuronal excitability in prefrontal cortex and represent a target for new antipsychotics. We hypothesize that the synchronous administration of a psychedelic and a NMDAR modulator may increase the therapeutic impact of each of the treatment components and allow for dose adjustments and improved safety. We propose to initially focus research on the acute concurrent administration of psilocybin and DSR or DCS in depression.", "journal": null, "publication_date": "2023-11-08", "publication_year": 2023, "doi": "10.1038/s41380-023-02312-8", "pubmed_id": "37945694", "source_url": "https://doi.org/10.1038/s41380-023-02312-8", "keywords": "Animals, Humans, Ketamine, Cycloserine, Receptors, N-Methyl-D-Aspartate, Hallucinogens, Mental Disorders, Neuronal Plasticity, Drug Synergism", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37945694\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1321, "title": "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.", "normalized_title": "psychedelic renaissance revitalized potential therapies for psychiatric disorders", "authors": "Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST.", "abstract": "Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential interactive effects these compounds can have with psychotherapeutic approaches. We provide a cutting-edge review of active and recently completed clinical trials based on the published literature (from MEDLINE), published abstracts at citable conferences, clinical trials from the US Clinical Trials registry (clinicaltrials.gov) and media press releases.", "journal": null, "publication_date": "2023-11-01", "publication_year": 2023, "doi": "10.1016/j.drudis.2023.103818", "pubmed_id": "37925136", "source_url": "https://doi.org/10.1016/j.drudis.2023.103818", "keywords": "Humans, N,N-Dimethyltryptamine, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"37925136\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1336, "title": "Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.", "normalized_title": "beyond the 5 ht2a receptor classic and nonclassic targets in psychedelic drug action", "authors": "Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, Castrén E, McCorvy JD, Palner M, Aguilar-Valles A.", "abstract": "Serotonergic psychedelics, such as psilocybin and LSD, have garnered significant attention in recent years for their potential therapeutic effects and unique mechanisms of action. These compounds exert their primary effects through activating serotonin 5-HT2A receptors, found predominantly in cortical regions. By interacting with these receptors, serotonergic psychedelics induce alterations in perception, cognition, and emotions, leading to the characteristic psychedelic experience. One of the most crucial aspects of serotonergic psychedelics is their ability to promote neuroplasticity, the formation of new neural connections, and rewire neuronal networks. This neuroplasticity is believed to underlie their therapeutic potential for various mental health conditions, including depression, anxiety, and substance use disorders. In this mini-review, we will discuss how the 5-HT2A receptor activation is just one facet of the complex mechanisms of action of serotonergic psychedelics. They also interact with other serotonin receptor subtypes, such as 5-HT1A and 5-HT2C receptors, and with neurotrophin receptors (e.g., tropomyosin receptor kinase B). These interactions contribute to the complexity of their effects on perception, mood, and cognition. Moreover, as psychedelic research advances, there is an increasing interest in developing nonhallucinogenic derivatives of these drugs to create safer and more targeted medications for psychiatric disorders by removing the hallucinogenic properties while retaining the potential therapeutic benefits. These nonhallucinogenic derivatives would offer patients therapeutic advantages without the intense psychedelic experience, potentially reducing the risks of adverse reactions. Finally, we discuss the potential of psychedelics as substrates for post-translational modification of proteins as part of their mechanism of action.", "journal": null, "publication_date": "2023-10-31", "publication_year": 2023, "doi": "10.1523/jneurosci.1384-23.2023", "pubmed_id": "37940583", "source_url": "https://doi.org/10.1523/jneurosci.1384-23.2023", "keywords": "Humans, Serotonin, Receptor, Serotonin, 5-HT2A, Hallucinogens, Anxiety, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37940583\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Review Article,Safety,Drug Interactions", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1069, "title": "The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.", "normalized_title": "the tolerability and safety of psilocybin in psychiatric and substance dependence conditions a systematic review", "authors": "Kaminski D, Reinert JP.", "abstract": "ObjectiveThe objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions.Data sourcesA systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: \"psilocybin\" AND \"mental-disease\" OR \"substance-dependence\" AND \"disease-therapy,\" in addition to other synonymous key words.Study selection and data extractionLiterature reporting acute effects and safety data following the use of psilocybin as the pharmacologic intervention in a clinical trial in adult patients with a psychiatric or substance-dependence condition were included. Following the application of inclusion and exclusion criteria, 16 studies were ultimately included in this review.Data synthesisThe most common treatment-emergent adverse effects reported were transient nausea and headache. Transient anxiety was reported as a frequent psychiatric effect, and 3 participants received a benzodiazepine for refractory anxiety during the psilocybin session. Psilocybin demonstrated modest increases in blood pressure and heart rate, and 1 participant received an antihypertensive for sustained hypertension during the psilocybin session. No cases of psilocybin-induced psychosis or Hallucinogen Persisting Perception Disorder were reported.Relevance to patient care and clinical practiceTreatment resistance remains a concern for psychiatric patients and novel therapies are needed to help alleviate the burden of morbidity and mortality. Psilocybin demonstrates promising acute and long-term safety that may allow for its use in psychiatric or substance-dependence conditions as an alternative to standards of care or in treatment-resistant patients.ConclusionsPsilocybin has demonstrated tolerability and safety in recent literature that has investigated its therapeutic potential in a variety of psychiatric or substance-dependence conditions.", "journal": null, "publication_date": "2023-10-29", "publication_year": 2023, "doi": "10.1177/10600280231205645", "pubmed_id": "37902038", "source_url": "https://doi.org/10.1177/10600280231205645", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37902038\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3798, "title": "A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues", "normalized_title": "a protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end of life issues", "authors": "Kratina S, Lo C, Schwartz R, Strike C, Jopling S, Nayfeh A, Rush B.", "abstract": "ABSTRACTBackground: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their outcomes related to anxiety and depression, long-term effects and safety. Despite this progress, there has been a wide range of both substances and therapeutic approaches in the use of psychedelic interventions in end-of-life populations, of which there has been a paucity of research undertaken to learn from this variety. Aim: The aim of this scoping review is to comprehensively explore the literature on the range of therapeutic psychedelic interventions that have been reported in populations coping with life-threatening illness and the end-of-life. Methods: We will follow Arksey and O’Malley’s (2005) framework for scoping reviews while incorporating updated methodological guidance. The Preferred Reporting Items for Systematic Review and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guideline will be used to organize the search and identification of research focusing on psychedelic interventions, psychological suffering, and end-of-life issues. Data extracted from selected studies will cover intervention details, participant characteristics, measured outcomes, theorised mechanisms, and sociocultural contextual factors.Contribution: The insights gained from this review will be used to inform discussions about the role of psychedelic interventions in populations coping with end-of-life concerns.Ethics and Dissemination: This scoping review does not require ethics approval. Results will be disseminated through peer-reviewed publications and conferences as well as shared with stakeholders.", "journal": "PsyArXiv", "publication_date": "2023-10-26", "publication_year": 2023, "doi": "10.31234/osf.io/4gfyd", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/4gfyd", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:22", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR749041\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Mechanism of Action,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3369, "title": "A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues", "normalized_title": "a protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end of life issues", "authors": "", "abstract": "ABSTRACT Background: Psychedelic substances are increasingly recognized for their therapeutic potential to ease psychological suffering linked to end-of-life issues. However, amid renewed scientific and public interest, policy remains restrictive. Existing reviews have made progress in synthesizing the results of studies of psychedelic interventions, especially psilocybin, and particularly with regard to their outcomes related to anxiety and depression, long-term effects and safety. Despite this progress, there has been a wide range of both substances and therapeutic approaches in the use of psychedelic interventions in end-of-life populations, of which there has been a paucity of research undertaken to learn from this variety. Aim: The aim of this scoping review is to comprehensively explore the literature on the range of therapeutic psychedelic interventions that have been reported in populations coping with life-threatening illness and the end-of-life. Methods: We will follow Arksey and O’Malley’s (2005) framework for scoping reviews while incorporating updated methodological guidance. The Preferred Reporting Items for Systematic Review and Meta-Analyses extension for scoping reviews (PRISMA-ScR) guideline will be used to organize the search and identification of research focusing on psychedelic interventions, psychological suffering, and end-of-life issues. Data extracted from selected studies will cover intervention details, participant characteristics, measured outcomes, theorised mechanisms, and sociocultural contextual factors. Contribution: The insights gained from this review will be used to inform discussions about the role of psychedelic interventions in populations coping with end-of-life concerns. Ethics and Dissemination: This scoping review does not require ethics approval. Results will be disseminated through peer-reviewed publications and conferences as well as shared with stakeholders.", "journal": "PsyArXiv", "publication_date": "2023-10-26", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/4gfyd_v1", "keywords": "end of life, existential distress, life-threatening illness, psychedelic-assisted therapy, psychedelics, psychological suffering, scoping review protocol, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Therapy", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"4gfyd_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Mechanism of Action,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1323, "title": "Cardiovascular safety of psychedelic medicine: current status and future directions.", "normalized_title": "cardiovascular safety of psychedelic medicine current status and future directions", "authors": "Wsół A.", "abstract": "Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and existential distress treatment in patients facing life-threatening illness. Psychedelics are generally considered to be physiologically safe with low toxicity and low addictive potential. However, their agonism at serotonergic receptors should be considered in the context of possible serotonin-related cardiotoxicity (5-HT2A/2B and 5-HT4 receptors), influence on platelet aggregation (5-HT2A receptor), and their proarrhythmic potential. The use of psychedelics has also been associated with significant sympathomimetic effects in both experimental and clinical studies. Therefore, the present review aims to provide a critical discussion of the cardiovascular safety of psilocybin, d-lysergic acid diethylamide (LSD), N,N-dimethyltryptamine, ayahuasca, and mescaline, based on the results of experimental research and clinical trials in humans. Experimental studies provide inconsistent information on the potential cardiovascular effects and toxicity of psychedelics. Data from clinical trials point to the relative cardiovascular safety of psychedelic-assisted therapies in the population of \"healthy\" volunteers. However, there is insufficient evidence from therapies carried out with microdoses of psychedelics, and there is still a lack of data on the safety of psychedelics in the population of patients with cardiovascular disease. Therefore, the exact determination of the cardiovascular safety of psychedelic therapies (especially long-term therapies) requires further research.", "journal": null, "publication_date": "2023-10-23", "publication_year": 2023, "doi": "10.1007/s43440-023-00539-4", "pubmed_id": "37874530", "source_url": "https://doi.org/10.1007/s43440-023-00539-4", "keywords": "Humans, Mescaline, Lysergic Acid Diethylamide, Hallucinogens, Anxiety Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37874530\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Receptor Pharmacology,Microdosing,Clinical Trial,Review Article,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3094, "title": "Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms", "normalized_title": "pharmacological and behavioral effects of tryptamines present in psilocybin containing mushrooms", "authors": "Rakoczy RJ, Runge GN, Sen AK, Sandoval O, Nguyen Q, Roberts BR, Sciortino JH, Gibbons WJ, Friedberg LM, Andrew Jones J, McMurray MS.", "abstract": "ABSTRACT Demand for more efficacious antidepressants, particularly those with a rapid onset of action, has resulted in a reevaluation of psychedelic drugs for their therapeutic potential. Several tryptamines found in psilocybin-containing ‘magic’ mushrooms share chemical similarities with psilocybin, and early work suggests they may also share receptor targets. However, few studies have explored their pharmacological and behavioral effects. To accomplish this, we compared baeocystin, norbaeocystin, and aeruginascin with psilocybin to determine if they are metabolized by the same enzymes, penetrate the blood brain barrier, serve as ligands for similar centrally located receptors, and modulate behavior in rodents similarly. We first assessed the stability and optimal storage and handling conditions for each compound. In vitro enzyme kinetics assays then found that all compounds shared nearly identical rates of dephosphorylation via alkaline phosphatase and metabolism by monoamine oxidase. Further, we found that only the dephosphorylated products of baeocystin and norbaeocystin could cross a blood brain barrier mimetic to a similar degree as the dephosphorylated form of psilocybin, psilocin. Behaviorally, only psilocybin was found to induce head twitch responses in rats, a marker of 5HT2A agonism and indicator of the compound’s hallucinogenic potential. However, like psilocybin, norbaeocystin was also found to improve outcomes in the forced swim test. All compounds were found to cause minimal changes to metrics of renal and hepatic health, suggesting innocuous safety profiles. Collectively, this work suggests that other naturally-occurring tryptamines, especially norbaeocystin, may share the same therapeutic potential as psilocybin, but without causing hallucinations. HIGHLIGHTS Baeocystin, norbaeocystin, and aeruginascin may have similar therapeutic value to psilocybin, but are understudied Compound stability varied widely, with dephosphorylated forms showing lowest stability Rates of metabolism by alkaline phosphatase and monoamine oxidase were similar across compounds Blood brain barrier penetration was limited to dephosphorylated forms of psilocybin, baeocystin, and norbaeocystin Rat behavioral testing suggested norbaeocystin may have therapeutic utility similar to psilocybin, without causing hallucinations", "journal": "bioRxiv", "publication_date": "2023-10-22", "publication_year": 2023, "doi": "10.1101/2023.10.19.563138", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2023.10.19.563138", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:46", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"PPR746275\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Receptor Pharmacology,Biomarkers,Animal Study,In Vitro Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1218, "title": "Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.", "normalized_title": "psilocybin an effective treatment for major depressive disorder in adults a systematic review", "authors": "Watford T, Masood N.", "abstract": "Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive disorder have rapidly increased interest back into their potential therapeutic benefits. This systematic review provides an analysis of the studies examining the clinical use of psilocybin for major depressive disorder. In total 6 studies were selected, including 319 participants, with half being randomised controlled trials and half open label trials. In every study psychological support was included as an integral part of the treatment. It was found that every study significantly favoured the use of psilocybin in reducing depressive symptoms, with few side effects. This gives psilocybin an advantage over commonly prescribed selective serotonin reuptake inhibitors (SSRIs), which carry more risk and cause more adverse effects. This drug therefore shows promise for being used as a clinical treatment for major depressive disorder, however future research should develop a paradigm for its use, with the timing of sessions and type of psychological support specified to allow for more precise analysis of the clinical effects of the drug. Additionally, more studies into its clinical efficacy are needed for appropriate detection of any publication bias. With this, psilocybin could prove to be revolutionary in treating depression and become an alternative medication to SSRIs.", "journal": null, "publication_date": "2023-10-15", "publication_year": 2023, "doi": "10.9758/cpn.23.1120", "pubmed_id": "38247407", "source_url": "https://doi.org/10.9758/cpn.23.1120", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"38247407\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Receptor Pharmacology,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3619, "title": "Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II", "normalized_title": "safety and efficacy of psilocybin for the treatment of headache disorders sub study ii", "authors": "Yale University", "abstract": "The purpose of this study is to investigate the effects of oral psilocybin in post-traumatic headache. Subjects will be randomized to receive placebo, low dose psilocybin, or high dose psilocybin on two separate test days approximately 14 days apart. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. Blood samples will be drawn at various timepoints to measure levels of inflammatory peptides.", "journal": "ClinicalTrials.gov", "publication_date": "2023-10-11", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT03806985", "keywords": "Post-Traumatic Headache, Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin, TERMINATED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT03806985\",\"overall_status\":\"TERMINATED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Headache / Migraine,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3569, "title": "Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I", "normalized_title": "safety and efficacy of psilocybin for the treatment of headache disorders sub study i", "authors": "Yale University", "abstract": "The purpose of this study is to investigate the effects of oral psilocybin in migraine headache. Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. Subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. This preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies. The number of arms reflects the design of the enhanced blinding method. The final enrollment number reflects the number of subjects participating in study procedures.", "journal": "ClinicalTrials.gov", "publication_date": "2023-10-11", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT03341689", "keywords": "Migraine Headache, High Dose Psilocybin, Low Dose Psilocybin, Placebo, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT03341689\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Headache / Migraine,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 985, "title": "Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use", "normalized_title": "therapeutic potential of psilocybin for treating psychological distress among survivors of adverse childhood experiences evidence on acceptability and potential efficacy of psilocybin use", "authors": "Kiffer G. Card, Ashmita Grewal, Kalysha Closson, Gina Martin, Laura Baracaldo, Sandra Allison, Daniel J. Kruger, Zach Walsh", "abstract": "Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicine has highlighted the therapeutic potential of psilocybin for those who have experienced childhood adversity. However, recreational psilocybin use remains illegal and access to approved therapies is difficult. Such use provides an opportunity to explore the therapeutic potential of psilocybin for psychological distress among people with adverse childhood experiences. Therefore, we conducted an online survey to assess interest in, acceptability of, and experiences with psilocybin. We further explored whether the association between Adverse Childhood Experiences Questionnaire (ACEQ) scores and psychological distress was lower among those who had used psilocybin in the past three months. Results showed high levels of interest in and acceptability of psilocybin that did not differ across ACEQ scores. Results also showed that the effect of adverse childhood experiences on psychological distress was lower for people who had recently used psilocybin (p =.019). Taken together, these findings suggest that psilocybin therapy may be potentially acceptable and may feasibly help in supporting survivors of adverse childhood experiences with particularly strong benefits to those with more severe childhood adversity.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2023-10-09", "publication_year": 2023, "doi": "10.1080/02791072.2023.2268640", "pubmed_id": "37815125", "source_url": "https://doi.org/10.1080/02791072.2023.2268640", "keywords": "Psilocybin, Adverse effect, Distress, Hallucinogen, Psychiatry, Psychology, Clinical psychology, Adverse Childhood Experiences, Medicine, Mental health, Pharmacology, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, Psychotherapy Techniques and Applications", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4387473380\",\"openalex_url\":\"https://openalex.org/W4387473380\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":11,\"referenced_works\":[\"https://openalex.org/W1496305694\",\"https://openalex.org/W1722711020\",\"https://openalex.org/W1969298821\",\"https://openalex.org/W1970807094\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2036386130\",\"https://openalex.org/W2050039830\",\"https://openalex.org/W2055691421\",\"https://openalex.org/W2066709094\",\"https://openalex.org/W2072670605\",\"https://openalex.org/W2107101617\",\"https://openalex.org/W2116839388\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2337075201\",\"https://openalex.org/W2338770637\",\"https://openalex.org/W2344176652\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2515306146\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2577277473\",\"https://openalex.org/W2740726397\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2803489646\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2807286797\",\"https://openalex.org/W2897688263\",\"https://openalex.org/W2923285883\",\"https://openalex.org/W2945209116\",\"https://openalex.org/W2969651116\",\"https://openalex.org/W2972999459\",\"https://openalex.org/W3003519776\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3014277121\",\"https://openalex.org/W3025740195\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3129221857\",\"https://openalex.org/W3132603698\",\"https://openalex.org/W3133542189\",\"https://openalex.org/W3133597843\",\"https://openalex.org/W3135491157\",\"https://openalex.org/W3157970366\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3176922153\",\"https://openalex.org/W3178284580\",\"https://openalex.org/W3179543896\",\"https://openalex.org/W3183684219\",\"https://openalex.org/W3186772641\",\"https://openalex.org/W3201512146\",\"https://openalex.org/W3203940153\",\"https://openalex.org/W3209358220\",\"https://openalex.org/W3213562265\",\"https://openalex.org/W4205618858\",\"https://openalex.org/W4205957509\",\"https://openalex.org/W4206486089\",\"https://openalex.org/W4210325795\",\"https://openalex.org/W4210913256\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4214488648\",\"https://openalex.org/W4220656556\",\"https://openalex.org/W4220780628\",\"https://openalex.org/W4224106670\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4281899337\",\"https://openalex.org/W4283657643\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4295789857\",\"https://openalex.org/W4303415358\",\"https://openalex.org/W4303509980\",\"https://openalex.org/W4306158354\",\"https://openalex.org/W4307715481\",\"https://openalex.org/W4308072532\",\"https://openalex.org/W4308327396\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4312084004\",\"https://openalex.org/W4312093969\",\"https://openalex.org/W4317481154\",\"https://openalex.org/W4319081635\",\"https://openalex.org/W4367835241\",\"https://openalex.org/W4399523896\"],\"authorships\":[{\"id\":\"https://openalex.org/A5022830508\",\"display_name\":\"Kiffer G. Card\",\"orcid\":\"https://orcid.org/0000-0001-6545-1249\"},{\"id\":\"https://openalex.org/A5031933562\",\"display_name\":\"Ashmita Grewal\",\"orcid\":null},{\"id\":\"https://openalex.org/A5017818883\",\"display_name\":\"Kalysha Closson\",\"orcid\":\"https://orcid.org/0000-0002-2985-0610\"},{\"id\":\"https://openalex.org/A5033861613\",\"display_name\":\"Gina Martin\",\"orcid\":\"https://orcid.org/0000-0001-5295-316X\"},{\"id\":\"https://openalex.org/A5037831481\",\"display_name\":\"Laura Baracaldo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5110286108\",\"display_name\":\"Sandra Allison\",\"orcid\":null},{\"id\":\"https://openalex.org/A5012166135\",\"display_name\":\"Daniel J. Kruger\",\"orcid\":\"https://orcid.org/0000-0002-2757-7016\"},{\"id\":\"https://openalex.org/A5112603217\",\"display_name\":\"Zach Walsh\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2023.2268640\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4387473380" }, { "id": 3188, "title": "Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology", "normalized_title": "synergistic multi level understanding of psychedelics three systematic reviews and meta analyses of their pharmacology neuroimaging and phenomenology", "authors": "Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML.", "abstract": "Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disorders, including depression and addiction. Yet their modes of action are not fully understood. Here, we provide a novel, synergistic understanding of psychedelics arising from systematic reviews and meta-analyses of three hierarchical levels of analysis: 1) subjective experience (phenomenology), 2) neuroimaging and 3) molecular pharmacology. Phenomenologically, medium and high doses of LSD yield significantly higher ratings of visionary restructuralisation than psilocybin on the 5-dimensional Altered States of Consciousness Scale. Our neuroimaging results reveal that, in general, psychedelics significantly strengthen between-network functional connectivity (FC) while significantly diminishing within-network FC. Pharmacologically, LSD induces significantly more inositol phosphate formation at the 5-HT2A receptor than DMT and psilocin, yet there are no significant between-drug differences in the selectivity of psychedelics for the 5-HT2A, 5-HT2C, or D2 receptors, relative to the 5-HT1A receptor. Our meta-analyses link DMT, LSD, and psilocybin to specific neural fingerprints at each level of analysis. The results show a highly non-linear relationship between these fingerprints. Overall, our analysis highlighted the high heterogeneity and risk of bias in the literature. This suggests an urgent need for standardising experimental procedures and analysis techniques, as well as for more research on the emergence between different levels of psychedelic effects.", "journal": "bioRxiv", "publication_date": "2023-10-06", "publication_year": 2023, "doi": "10.1101/2023.10.06.561183", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2023.10.06.561183", "keywords": "", "substance_tags": "psilocybin,psilocin", "source_name": "bioRxiv", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR738055\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"bioRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Brain Imaging,Pharmacology,Receptor Pharmacology,Consciousness,Aging,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4755, "title": "Psilocybin shows promising results in subjects continuing to use an antidepressant", "normalized_title": "psilocybin shows promising results in subjects continuing to use an antidepressant", "authors": "", "abstract": "Ongoing antidepressant treatment is believed to alter the psychedelic effect of psilocybin, so most psilocybin trials have required withdrawal from antidepressants before enrollment. There has been recent evidence, however, that administration of a selective serotonin reuptake inhibitor (SSRI) does not significantly alter the acute subjective effects of psilocybin. A Phase 2 open-label trial evaluated the safety and efficacy of a single dose of psilocybin with psychological support as adjunctive treatment to an SSRI in adults with treatment-resistant depression. Outpatients who met DSM-5 criteria for major depressive disorder and had experienced inadequate response to 2 to 4 antidepressant treatments in the current episode were eligible for inclusion. Participants received a single dose of psilocybin 25 mg during a 6- to 8-hour session accompanied by a therapist who did not actively guide participants. Up to three weeks of follow-up occurred in order to monitor safety and efficacy. Among the safety outcomes were incidence of adverse events, scores on laboratory tests, and change from baseline in suicidality. The primary efficacy outcome was change from baseline to 3 weeks post-administration in total score on the Montgomery-Asberg Depression Rating Scale (MADRS). Nineteen participants completed the study. Twelve participants experienced a total of 17 treatment-emergent adverse events, none of which were considered serious. No reports of active suicidal ideation occurred. Participants showed a clinically meaningful change from baseline on the primary efficacy measure, with improvement apparent by day 2 of the study. A total of 42.1% of participants achieved response as measured by the MADRS at week 3. Improvements in anxiety and quality of life were reported. [Goodwin, G., et al. (2023). Neuropsychopharmacol. https://doi.org/10.1038/s41386-023-01648-7]", "journal": "The Brown University Psychopharmacology Update", "publication_date": "2023-10-03", "publication_year": 2023, "doi": "10.1002/pu.31089", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1002/pu.31089", "keywords": "Psilocybin, Antidepressant, Psychology, Computer science, Medicine, Psychiatry, Pharmacology, Hallucinogen, Anxiety, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:45", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4387361294\",\"openalex_url\":\"https://openalex.org/W4387361294\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S1022177896\",\"source_display_name\":\"The Brown University Psychopharmacology Update\",\"landing_page_url\":\"http://dx.doi.org/10.1002/pu.31089\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Pharmacology,Receptor Pharmacology,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4387361294" }, { "id": 1368, "title": "Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.", "normalized_title": "exploring the potential utility of psychedelic therapy for patients with amyotrophic lateral sclerosis", "authors": "Gold ND, Mallard AJ, Hermann JC, Zeifman RJ, Pagni BA, Bogenschutz MP, Ross S", "abstract": "Amyotrophic lateral sclerosis (ALS) is an aggressive, terminal neurodegenerative disease that causes death of motor neurons and has an average survival time of 3-4 years. ALS is the most common motor neuron degenerative disease and is increasing in prevalence. There is a pressing need for more effective ALS treatments as available pharmacotherapies do not reverse disease progression or provide substantial clinical benefit. Furthermore, despite psychological distress being highly prevalent in ALS patients, psychological treatments remain understudied. Psychedelics (i.e., serotonergic psychedelics and related compounds like ketamine) have seen a resurgence of research into therapeutic applications for treating a multitude of neuropsychiatric conditions, including psychiatric and existential distress in life-threatening illnesses. We conducted a narrative review to examine the potential of psychedelic assisted-psychotherapy (PAP) to alleviate psychiatric and psychospiritual distress in ALS. We also discussed the safety of using psychedelics in this population and proposed putative neurobiological mechanisms that may therapeutically intervene on ALS neuropathology. PAP has the potential to treat psychological dimensions and may also intervene on neuropathological dimensions of ALS. Robust improvements in psychiatric and psychospiritual distress from PAP in other populations provide a strong rationale for utilizing this therapy to treat ALS-related psychiatric and existential distress. Furthermore, relevant neuroprotective properties of psychedelics warrant future preclinical trials to investigate this area in ALS models. PAP has the potential to serve as an effective treatment in ALS. Given the lack of effective treatment options, researchers should rigorously explore this therapy for ALS in future trials.", "journal": "Journal of palliative medicine", "publication_date": "2023-09-30", "publication_year": 2023, "doi": "10.1089/jpm.2022.0604", "pubmed_id": "37167080", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37167080/", "keywords": "amyotrophic lateral sclerosis, ketamine, neurodegenerative, psilocybin, psychedelic-assisted psychotherapy", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37167080\"}", "topic_tags": "End-of-Life Distress,Mechanism of Action,Spirituality,Clinical Trial,Review Article,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3667, "title": "Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence", "normalized_title": "effects and therapeutic potential of psilocybin in alcohol dependence", "authors": "University of New Mexico", "abstract": "This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide preliminary outcome and safety data. Participants will receive psilocybin orally in two all-day administration sessions, conducted in a secure outpatient psychiatric setting, in a dose range that has been well-tolerated in recent studies. Psilocybin administration will occur in the context of a behavioral intervention including a total of 12 sessions over 12 weeks, incorporating Motivational Enhancement Therapy (MET (Miller, Zweben et al. 1992; Miller 1995), based on Motivational Interviewing (Miller and Rollnick 2002)) with booster sessions, as well as preparation before and debriefing after the psilocybin administration sessions. The MET will incorporate attention to spirituality as well as drinking behavior as a primary subject of change. Drinking outcomes and changes in several potential mediators of treatment effect, including motivation, self-efficacy, craving, depression, anxiety, and spiritual dimensions of the experience, will be measured during treatment and for 24 weeks after the end of treatment. The investigators hypothesize that drinking will decrease following the psilocybin sessions, and that increases in motivation, self-efficacy, and spirituality (primary contrast 12 weeks vs. baseline) will be observed among study participants.", "journal": "ClinicalTrials.gov", "publication_date": "2023-09-25", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT01534494", "keywords": "Alcohol Dependence, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT01534494\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1370, "title": "Manic episode following psilocybin use in a man with bipolar II disorder: a case report", "normalized_title": "manic episode following psilocybin use in a man with bipolar ii disorder a case report", "authors": "Haniya J. Halim, Bradley G. Burk, Rachel E. Fargason, Badari Birur", "abstract": "There has been an increase in research on the topic of psychedelic substances and their effects as treatment options in neuropsychiatric conditions. Psilocybin is a psychedelic drug that has recently garnered increased interest as an effective treatment modality for treatment-resistant depression, depression associated with terminal conditions, certain substance use disorders, and obsessive-compulsive disorder. However, sparse data exist as to the effects that psilocybin might have on patients at risk for mania, in large part secondary to the exclusion of this patient population from studies due to the concern for inducing mania or worsening illness course. We describe a case of a 21-year-old male with a recent diagnosis of bipolar II disorder who developed a manic episode following the ingestion of psilocybin in the form of hallucinogenic mushrooms. Given the incidence of depression in those with bipolar disorder, impulsivity, and a tendency to abuse substances associated with the illness, further research is needed into the risks of psilocybin and other psychedelic use in those with bipolar disorder.", "journal": "Frontiers in Psychiatry", "publication_date": "2023-09-21", "publication_year": 2023, "doi": "10.3389/fpsyt.2023.1221131", "pubmed_id": "37810598", "source_url": "https://doi.org/10.3389/fpsyt.2023.1221131", "keywords": "Psilocybin, Mania, Bipolar disorder, Psychiatry, Hallucinogen, Psychology, Depression (economics), Population, Substance abuse, Medicine, Clinical psychology, Lithium (medication), Environmental health, Macroeconomics, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386961159\",\"openalex_url\":\"https://openalex.org/W4386961159\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":13,\"referenced_works\":[\"https://openalex.org/W34641758\",\"https://openalex.org/W2016437478\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2044852143\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2152723462\",\"https://openalex.org/W2550530158\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2726744335\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W3158216155\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3201512146\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4311477082\"],\"authorships\":[{\"id\":\"https://openalex.org/A5092922800\",\"display_name\":\"Haniya J. Halim\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067523553\",\"display_name\":\"Bradley G. Burk\",\"orcid\":\"https://orcid.org/0000-0002-2681-3785\"},{\"id\":\"https://openalex.org/A5085805872\",\"display_name\":\"Rachel E. Fargason\",\"orcid\":null},{\"id\":\"https://openalex.org/A5023514274\",\"display_name\":\"Badari Birur\",\"orcid\":\"https://orcid.org/0000-0003-1258-7585\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2023.1221131\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,OCD,End-of-Life Distress,Receptor Pharmacology,Case Report,Treatment-Resistant Depression,Safety", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386961159" }, { "id": 3573, "title": "Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder", "normalized_title": "phase ii randomized double blind placebo controlled parallel group single center study of psilocybin efficacy and mechanism in alcohol use disorder", "authors": "University of Zurich", "abstract": "Effects of serotonin 2A/1A receptor stimulation by psilocybin on alcohol addicted patients: a randomized double-blind placebo-controlled study Two billion people globally consume alcohol, leading in 2016 to 2.8 million deaths (5.2% of all deaths) and 99.2 million Disability Adjusted Life Years (DALYs) lost (4.2% of all DALYs). Of all the diseases, conditions, and injuries attributable to alcohol use, alcohol use disorders (AUDs) create the largest health burden globally. However, approved pharmacological treatments for alcoholism are limited in their effectiveness. A recent proof of- concept study testing psilocybin in ten alcohol dependent patients provides encouraging efficacy results and safety data. The investigators, therefore, propose to test the efficacy of psilocybin for treating alcohol use disorder and study its underlying neurobiological mechanisms in a randomized, placebo controlled, double blind study. To evaluate effects of psilocybin on alcohol use behaviour, clinical symptoms, neurocognitive and emotional measures in patients with alcohol use disorder. The present clinical trial aims at investigation the clinical and mechanistic effects of Psilocybin in Alcohol Addicted Patients. Patients with alcohol use disorder who have undergone withdrawal treatment within the last 6 weeks will be investigated in a single-centre, double-blind, placebo-controlled, parallel-group design clinical trial contrasting the acute and persisting effects of psilocybin to those of placebo. Patients will be randomly assigned to psilocybin or placebo group with a 1:1 allocation ratio. The study comprises a total of 6 visits during 6 weeks and two follow-up online surveys (3 and 6 months after treatment). In addition, two follow-up surveys that can be completed from home will guarantee monitoring of long-lasting changes in symptomology and ensure all potential side-effects can be captured. On the treatment visit, a single dose of psilocybin (25mg) or placebo will be administered. Patients will be monitored until all effects have worn off.", "journal": "ClinicalTrials.gov", "publication_date": "2023-09-20", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04141501", "keywords": "Alcohol Use Disorder, Psilocybin, Placebo oral capsule, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04141501\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Addiction,Mechanism of Action,Receptor Pharmacology,Aging,Emotional Processing,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1373, "title": "Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder", "normalized_title": "nature themed video intervention may improve cardiovascular safety of psilocybin assisted therapy for alcohol use disorder", "authors": "Keith G. Heinzerling, Karina Sergi, Micah Linton, Rhianna Rich, Brittany Youssef, Inez Bentancourt, Jennifer E. Bramen, Prabha Siddarth, L. Schwartzberg, Daniel F. Kelly", "abstract": "Introduction: Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a connection with nature, may positively influence the psychedelic experience and therapeutic outcomes. But to date, randomized controlled trials of interventions to enhance set and setting for psychedelic-assisted therapy are lacking. Methods: This was a pilot randomized, controlled trial of Visual Healing, a nature-themed video intervention to optimize set and setting, versus Standard set and setting procedures with two open-label psilocybin 25 mg dosing sessions among 20 participants with AUD. For the first session, participants randomized to Visual Healing viewed nature-themed videos during the preparation session and the \"ascent\" and \"descent\" phases of the psilocybin dosing session while participants randomized to the Standard condition completed a meditation during the preparatory session and wore eyeshades and listened to a music playlist throughout the dosing session. For the second session 4 weeks later, participants chose either Visual Healing or Standard procedures. Primary outcomes were feasibility, safety, and tolerability of Visual Healing. Secondary and exploratory outcomes were changes in alcohol use, psychedelic effects, anxiety and stress. Results: Nineteen of 20 (95%) randomized participants (mean age 49 ± 11 years, 60% female) completed the 14-week study. During the first psilocybin session, participants viewed an average of 37.9 min of the 42-min video and there were no video-related adverse events. Peak increase in post-psilocybin blood pressure was significantly less for participants randomly assigned to Visual Healing compared to Standard procedures. Alcohol use decreased significantly in both Visual Healing and Standard groups and psychedelic effects, stress, and anxiety were similar between groups. Discussion: In this open-label pilot study, viewing Visual Healing videos during preparation and psilocybin dosing sessions was feasible, safe, and well-tolerated among participants with AUD. Preliminary findings suggest that Visual Healing has potential to reduce the cardiovascular risks of psychedelic therapy, without interfering with the psychedelic experience or alcohol-related treatment outcomes. Studies to replicate our findings as well as studies of different set and setting interventions with other psychedelic medications and indications are warranted.", "journal": "Frontiers in Psychiatry", "publication_date": "2023-09-17", "publication_year": 2023, "doi": "10.3389/fpsyt.2023.1215972", "pubmed_id": "37795513", "source_url": "https://doi.org/10.3389/fpsyt.2023.1215972", "keywords": "Psilocybin, Randomized controlled trial, Tolerability, Adverse effect, Medicine, Anxiety, Psychological intervention, Psychology, Psychiatry, Hallucinogen, Surgery, Internal medicine, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386849390\",\"openalex_url\":\"https://openalex.org/W4386849390\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":21,\"referenced_works\":[\"https://openalex.org/W621567176\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1975381773\",\"https://openalex.org/W2037317432\",\"https://openalex.org/W2065810673\",\"https://openalex.org/W2107788476\",\"https://openalex.org/W2144867145\",\"https://openalex.org/W2153454886\",\"https://openalex.org/W2170874889\",\"https://openalex.org/W2282074015\",\"https://openalex.org/W2571392308\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2790381919\",\"https://openalex.org/W2831064708\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2991597523\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3112064661\",\"https://openalex.org/W3187445852\",\"https://openalex.org/W4206344419\",\"https://openalex.org/W4214940428\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294308393\",\"https://openalex.org/W4294723946\",\"https://openalex.org/W4294767963\",\"https://openalex.org/W4298005428\",\"https://openalex.org/W4313339783\",\"https://openalex.org/W4318754695\",\"https://openalex.org/W6787656242\",\"https://openalex.org/W6844266092\"],\"authorships\":[{\"id\":\"https://openalex.org/A5068139431\",\"display_name\":\"Keith G. Heinzerling\",\"orcid\":\"https://orcid.org/0000-0001-9746-5821\"},{\"id\":\"https://openalex.org/A5059388549\",\"display_name\":\"Karina Sergi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113003665\",\"display_name\":\"Micah Linton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108864498\",\"display_name\":\"Rhianna Rich\",\"orcid\":null},{\"id\":\"https://openalex.org/A5070129323\",\"display_name\":\"Brittany Youssef\",\"orcid\":\"https://orcid.org/0000-0001-9768-5285\"},{\"id\":\"https://openalex.org/A5092899731\",\"display_name\":\"Inez Bentancourt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5017746800\",\"display_name\":\"Jennifer E. Bramen\",\"orcid\":\"https://orcid.org/0000-0001-8967-0008\"},{\"id\":\"https://openalex.org/A5024302085\",\"display_name\":\"Prabha Siddarth\",\"orcid\":\"https://orcid.org/0000-0001-8746-6353\"},{\"id\":\"https://openalex.org/A5109639421\",\"display_name\":\"L. Schwartzberg\",\"orcid\":null},{\"id\":\"https://openalex.org/A5066155034\",\"display_name\":\"Daniel F. Kelly\",\"orcid\":\"https://orcid.org/0000-0002-8358-056X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2023.1215972\",\"is_oa\":true}}", "topic_tags": "Anxiety,Addiction,Chronic Pain,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386849390" }, { "id": 3543, "title": "Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions", "normalized_title": "phase 1 open label one treatment single dose one period pharmacokinetic study of psilocin 4 mg as its mucic acid salt l 130 form in healthy subjects under fasted conditions", "authors": "Lobe Sciences Ltd.", "abstract": "Psilocin is the active metabolite of psilocybin a natural material found in several types of fungi. The bioavailability of psilocybin, the prodrug of psilocin, has been reported to be over 60%. However, pharmacokinetics and bioavailability of psilocin mucate has not been reported. This Phase I \"First in Man\" study of psilocin mucate is designed to determine its safety, pharmacokinetics, and bioavailability. The study is conducted under the supervision of physicians and psychiatrists who also will administer a mini-mental state evaluation and report observable anti-anxiolytic effect of the dosage. Safety and possible indications of efficacy will be tracked during the study period, a week following the dose administration and one month after. This study is designed to assess the bioavailability and pharmacokinetic parameters and to monitor the safety and tolerability of Psilocin 2 mg as its Mucic Acid Salt (L-130) form, a proprietary drug candidate of Lobe Sciences Ltd., in healthy subjects under fasted conditions. The study will be conducted in compliance with the protocol and applicable regulatory requirements, GCP and GLP principles and guidelines: Declaration of Helsinki as amended by the 64th WMA General Assembly, Fortaleza, Brazil, November 2013, FDA Guidelines for Bioavailability \\& Bioequivalence Studies and OECD Principles of Good Laboratory Practice will be observed. The study population will consist of 10 Healthy Subjects aged between 21 and 50 years (inclusive), body mass index 18.5 to 30.0 kg/m2 inclusive (minimum of 50 kg weight for males and 45 kg for females), nonsmokers or quit smoking 24 hours prior to dosing. The investigational test product L-130 Capsules containing 2 mg of psilocin as its Mucic Acid Salt of Lobe Sciences Ltd. consisted of single oral dose containing 2 mg of Psilocin (equivalent to 4 mg as Psilocin Mucate salt). Each dose will be administered orally, with 240 mL of water in sitting position under sodium light to healthy subjects after an overnight fast of at least 10 hours in the morning of study dosing day. The study will be conducted as an open label study. Therefore, blinding will not be done. However, the bioanalysis will be performed blinded with regard to the sequence of product administration. Each subject will have a pre-dose sample of 8 ml collected and 13 additional 8 ml samples collected over a 24 hour period. The principal and/ or clinical investigator and study staff will monitor subjects throughout the hospitalization periods. Blood pressure and heart rate will be measured before dosing and at scheduled intervals after dosing. The principal and/ or clinical Investigator will be available throughout each hospitalization period. During outpatient phases, study staff will be available during regular working hours. Subjects' safety will be observed at scheduled intervals of before dosing (-1.00) and 0.50, 0.75, 1.00, 2.00, 3.00, 5.00, 8.00, 12.00, 16.00 and 24.00 hours after drug administration. Subjects will be queried on adverse events. In addition, voluntary reporting of adverse events by subjects will be reported. Mini Mental State Examination (MMSE) score will be assessed to dosed subjects by CI/PI approximately two hours after drug administration, and the results will be tabulated in the final report. Subjects will be asked to report changes in their mood, or other observations during and following the study period. Subjects will also be followed up by phone call after one week and four weeks of dosing to assess if they are experiencing changes in feeling or having improved mood, and the outcomes of the phone calls will be tabulated in the final report. Following the collection of blood samples and appropriate processing, each sample will be analyzed with a validated analytical method to determine the pharmacokinetic profile of psilocin mucate in plasma. All clinical laboratories test results of screening lab tests will be summarized by descriptive statistics. Follow up lab tests will also be summarized by descriptive statistics. The aim of the study is to assess the bioavailability and pharmacokinetic parameters and to monitor the safety and tolerability of the formulation in healthy subjects under fasting conditions after a single oral dose of L-130 Capsules containing 2 mg of psilocin as its Mucic Acid Salt. The final report will provide safety, tolerability and pharmacokinetics of the test product. The study will also report patient reported pharmacology.", "journal": "ClinicalTrials.gov", "publication_date": "2023-09-12", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT06035900", "keywords": "Side Effect of Drug, Psilocin, Psilocin Mucate, COMPLETED", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT06035900\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Addiction,Pharmacology,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1377, "title": "Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin", "normalized_title": "predictors of pharmacy students attitudes about the therapeutic use of psilocybin", "authors": "NM Mahmudul Alam Bhuiya, Robin J. Jacobs, Karina Wang, Yiqun Sun, Brenda Nava, Luke Sampiere, Akhila Yerubandi, Joshua Caballero", "abstract": "Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on psilocybin, and little is known about their attitudes toward its use for medical purposes. Findings from recent clinical studies have attempted to establish the safety and medical efficacy of psilocybin, leading to an increased interest in therapeutic psilocybin use in the United States. This study aimed to assess if self-assessed knowledge of psilocybin, concerns about adverse effects, and opinions about legalization will make statistically significant contributions to pharmacy students' attitudes about psilocybin use in practice. Methods Pharmacy students' self-assessed knowledge, concern for potential adverse effects, and perceptions of psilocybin were investigated using a cross-sectional survey study design. Data were collected from March 13 to April 7, 2023, from a convenience sample of 161 pharmacy students enrolled in an accredited pharmacy school in the southern region of the United States using a 41-item anonymous quantitative survey developed by the researchers that contained validated scales. The survey was delivered electronically. Multiple regression modeling was conducted to determine if self-assessed knowledge, concerns for adverse effects, and opinions about legalization would predict pharmacy students' attitudes about therapy-assisted psilocybin use. This study was approved by the Institutional Review Board of the authors' university. Results The mean age of the 161 participants was 24 years (SD = 2.981; range 20-40 years). Twenty (12.4%) participants reported previous use of psilocybin for recreational purposes and two (1.2%) reported having used it therapeutically. Many (n =121; 75.2%) of the participants believed that psilocybin should be decriminalized for therapeutic use, but only 54 (33.5%) thought it should be decriminalized for recreational use. A multiple linear regression model predicting \"attitudes about psilocybin\" (dependent variable) produced significant results: (F(4, 122) = 40.575, p < 0.001), with an R2 = 0.571 (adjusted R2 = 0.557). Greater \"self-assessed knowledge about psilocybin,\" less \"concern about possible negative effects,\" greater \"belief in the decriminalization of psilocybin for recreational use,\" and greater \"belief in the decriminalization of psilocybin for therapeutic use\" (all independent variables) were associated with more positive perceptions about medical psilocybin. The percentage of variance in the scores accounted for by the model was 57%. Conclusions Pharmacy students may lack information and training regarding psilocybin and report a desire to learn more about it. Their attitudes about medical psilocybin may be driven by this desire to learn in addition to concerns about adverse effects and legalization issues. Due to the dearth of published information regarding the knowledge and acceptance of psilocybin as a viable treatment option for patients, further research in psychedelic-assisted treatments may be warranted.", "journal": "Cureus", "publication_date": "2023-09-12", "publication_year": 2023, "doi": "10.7759/cureus.45169", "pubmed_id": "37842360", "source_url": "http://dx.doi.org/10.7759/cureus.45169", "keywords": "Psilocybin, Medicine, Pharmacy, Legalization, Anxiety, Psychiatry, Family medicine, Adverse effect, Clinical psychology, Hallucinogen, Pharmacology, Psychedelics and Drug Studies, Complementary and Alternative Medicine Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386702998\",\"openalex_url\":\"https://openalex.org/W4386702998\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W2011221060\",\"https://openalex.org/W2052341973\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2093274439\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2944495881\",\"https://openalex.org/W2966840080\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3149986569\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3191608162\",\"https://openalex.org/W3193541843\",\"https://openalex.org/W4200517619\",\"https://openalex.org/W4210332402\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4224263135\",\"https://openalex.org/W4224942177\",\"https://openalex.org/W4283813871\",\"https://openalex.org/W4285047488\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4293176220\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309648711\",\"https://openalex.org/W4310940483\",\"https://openalex.org/W4364356083\",\"https://openalex.org/W4382465647\",\"https://openalex.org/W7070833347\"],\"authorships\":[{\"id\":\"https://openalex.org/A5092861250\",\"display_name\":\"NM Mahmudul Alam Bhuiya\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091609619\",\"display_name\":\"Robin J. Jacobs\",\"orcid\":\"https://orcid.org/0000-0001-8235-4096\"},{\"id\":\"https://openalex.org/A5046709170\",\"display_name\":\"Karina Wang\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101062105\",\"display_name\":\"Yiqun Sun\",\"orcid\":\"https://orcid.org/0009-0002-6860-5818\"},{\"id\":\"https://openalex.org/A5070002328\",\"display_name\":\"Brenda Nava\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005943395\",\"display_name\":\"Luke Sampiere\",\"orcid\":null},{\"id\":\"https://openalex.org/A5000054887\",\"display_name\":\"Akhila Yerubandi\",\"orcid\":\"https://orcid.org/0000-0002-5657-747X\"},{\"id\":\"https://openalex.org/A5040951969\",\"display_name\":\"Joshua Caballero\",\"orcid\":\"https://orcid.org/0000-0003-4406-2425\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2738950867\",\"source_display_name\":\"Cureus\",\"landing_page_url\":\"http://dx.doi.org/10.7759/cureus.45169\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,OCD,Pharmacology,Review Article,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386702998" }, { "id": 1364, "title": "Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.", "normalized_title": "psychedelic assisted therapy in military and veterans healthcare systems clinical legal and implementation considerations", "authors": "Wolfgang AS, Hoge CW.", "abstract": "Purpose of reviewThis review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementation considerations in Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems.Recent findings3,4-Methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted therapy have shown promising outcomes in efficacy, safety, tolerability, and durability for PTSD and depression, respectively. MDMA-assisted therapy is already approved by the Food and Drug Administration (FDA) on an Expanded Access (\"compassionate use\") basis for PTSD, with full approval projected for 2024. Psilocybin-assisted therapy is projected to be FDA-approved for depression soon thereafter. Other psychedelics are in earlier stages of development. The VA is currently conducting PAT clinical trials. Although there are clear legal pathways for the VA and DoD to conduct PAT trials, a number of implementation barriers exist, such as the very high number of clinical hours necessary to treat each patient, resource requirements to support treatment infrastructure, military-specific considerations, and the high level of evidence necessary for PAT to be recommended in clinical practice guidelines. Ongoing considerations are whether and how PAT will be made available to VA and DoD beneficiaries, feasibility and cost-effectiveness, and ethical safeguards that must be implemented to prioritize access to PAT given the likelihood of extremely limited initial availability. However, with imminent FDA approval of PATs and considerable national interest in these treatments, DoD and VA policymakers must be prepared with clearly delineated policies and plans for how these healthcare systems will approach PAT.", "journal": null, "publication_date": "2023-09-07", "publication_year": 2023, "doi": "10.1007/s11920-023-01446-4", "pubmed_id": "37682446", "source_url": "https://doi.org/10.1007/s11920-023-01446-4", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, United States Department of Veterans Affairs, Veterans, Delivery of Health Care, United States, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"37682446\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Mechanism of Action,Clinical Trial,Review Article,Veterans,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1363, "title": "The zebrafish for preclinical psilocybin research.", "normalized_title": "the zebrafish for preclinical psilocybin research", "authors": "Syed OA, Tsang B, Gerlai R.", "abstract": "In this review, we discuss the possible utility of zebrafish in research on psilocybin, a psychedelic drug whose recreational use as well as possible clinical application are gaining increasing interest. First, we review behavioral tests with zebrafish, focussing on anxiety and social behavior, which have particular relevance in the context of psilocybin research. Next, we briefly consider methods of genetic manipulations with which psilocybin's phenotypical effects and underlying mechanisms may be investigated in zebrafish. We briefly review the known mechanisms of psilocybin, and also discuss what we know about its safety and toxicity profile. Last, we discuss examples of how psilocybin may be employed for testing treatment efficacy in preclinical research for affective disorders in zebrafish. We conclude that zebrafish has a promising future in preclinical research on psychedelic drugs.", "journal": null, "publication_date": "2023-09-06", "publication_year": 2023, "doi": "10.1016/j.neubiorev.2023.105381", "pubmed_id": "37689090", "source_url": "https://doi.org/10.1016/j.neubiorev.2023.105381", "keywords": "Animals, Zebrafish, Hallucinogens, Anxiety, Anxiety Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37689090\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Mechanism of Action,Review Article,Animal Study,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1309, "title": "Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development", "normalized_title": "psilocybin assisted cognitive behavioral therapy for adults with major depressive disorder rationale and treatment development", "authors": "Marc J. Weintraub, Jessica Jeffrey, Charles S. Grob, Megan Ichinose, R. Lindsey Bergman, Ziva D. Cooper, David J. Miklowitz", "abstract": "Background: Recent studies suggest that one to two administrations of psilocybin have acute antidepressant effects for people with major depressive disorder. These data on psilocybin have generated considerable enthusiasm, but little empirical attention has been paid to the therapy that adjoins psilocybin treatment (psychedelic-assisted therapy, or PAT). Materials and Methods: In this study, we present the initial protocol and plans to empirically test the psychosocial therapy that adjoins psilocybin treatment with the goal of optimizing this therapeutic approach for adults with major depressive disorder. The psychotherapy is based on the principles of cognitive-behavioral therapy (CBT), an evidence-based treatment for major depressive disorder. Participants will be 30 adults with a history of major depressive disorder and current, active depressive symptoms. Following psychiatric and medical safety evaluations, eligible participants will be enrolled in a 12-session CBT that includes classic PAT safety elements (termed psilocybin-assisted CBT; PA-CBT). Following the third and sixth PA-CBT sessions, participants will engage in two psilocybin drug administration sessions (10 and 25 mg, respectively). Participants will provide feedback about the PA-CBT and complete measures of mood symptoms, psychosocial functioning, cognitive schemas, and affective experiences immediately following each drug administration session, at the completion of PA-CBT, and 3 months following treatment completion. Conclusions: The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.", "journal": "Psychedelic Medicine", "publication_date": "2023-09-05", "publication_year": 2023, "doi": "10.1089/psymed.2023.0018", "pubmed_id": "40046861", "source_url": "https://doi.org/10.1089/psymed.2023.0018", "keywords": "Psilocybin, Cognitive behavioral therapy, Psychotherapist, Major depressive disorder, Psychology, Cognition, Cognitive therapy, Clinical psychology, Psychiatry, Medicine, Hallucinogen, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386469528\",\"openalex_url\":\"https://openalex.org/W4386469528\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[\"https://openalex.org/W1787230849\",\"https://openalex.org/W1913659607\",\"https://openalex.org/W1990423213\",\"https://openalex.org/W2004762037\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2016125673\",\"https://openalex.org/W2017039362\",\"https://openalex.org/W2021762104\",\"https://openalex.org/W2032556867\",\"https://openalex.org/W2039763524\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2055628680\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2096987981\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2131976593\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2142420226\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163215199\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2397862430\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2522867222\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2549705997\",\"https://openalex.org/W2612845943\",\"https://openalex.org/W2613258400\",\"https://openalex.org/W2740567311\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2792161256\",\"https://openalex.org/W2883252198\",\"https://openalex.org/W2911158148\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3167074068\",\"https://openalex.org/W3176790550\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213423658\",\"https://openalex.org/W4221108429\",\"https://openalex.org/W4226207092\",\"https://openalex.org/W4240897905\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4281386961\",\"https://openalex.org/W4281397183\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294723946\",\"https://openalex.org/W4308146982\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090933971\",\"display_name\":\"Marc J. Weintraub\",\"orcid\":\"https://orcid.org/0000-0001-8724-120X\"},{\"id\":\"https://openalex.org/A5067502721\",\"display_name\":\"Jessica Jeffrey\",\"orcid\":\"https://orcid.org/0000-0003-4334-5626\"},{\"id\":\"https://openalex.org/A5108513619\",\"display_name\":\"Charles S. Grob\",\"orcid\":null},{\"id\":\"https://openalex.org/A5031377527\",\"display_name\":\"Megan Ichinose\",\"orcid\":\"https://orcid.org/0000-0003-0745-0795\"},{\"id\":\"https://openalex.org/A5108474850\",\"display_name\":\"R. Lindsey Bergman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001865213\",\"display_name\":\"Ziva D. Cooper\",\"orcid\":\"https://orcid.org/0000-0001-8001-2332\"},{\"id\":\"https://openalex.org/A5079473142\",\"display_name\":\"David J. Miklowitz\",\"orcid\":\"https://orcid.org/0000-0002-9647-6147\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2023.0018\",\"is_oa\":false}}", "topic_tags": "Depression,Chronic Pain,Mechanism of Action,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386469528" }, { "id": 1381, "title": "Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.", "normalized_title": "self administration of psilocybin for the acute treatment of migraine a case report", "authors": "David W. Lawrence", "abstract": "Background: Migraine is a common neurovascular disorder with a pathophysiology related to the serotonin (5-hydroxytryptamine; 5-HT) system. Pharmacologic modulation of 5-HT receptors has demonstrated efficacy in the acute treatment of migraines. Psilocybin, a classic psychedelic with 5-HT receptor activity, has demonstrated therapeutic potential in the management of neuropsychiatric conditions. To date, no reports have investigated the effect of psilocybin administered acutely during a migraine episode. Case presentation: mushrooms) at migraine onset is presented. Headache intensity was rated hourly using the Numerical Rating Scale (NRS) and compared to three previous migraines. Profound reductions in headache intensity and emetic episodes were reported during the migraine treated acutely with oral psilocybin administration, compared to three previous migraines. Discussion: The severe, disabling, and treatment-resistant nature of migraines warrants continued surveillance for novel pharmacologic interventions. The established congruous pathophysiology of migraine and pharmacology of psilocybin, via the 5-HT receptor system, positions psilocybin as a potential therapeutic target. Conclusion: While this report highlights the potential role of psilocybin in the acute management of migraines, it is essential to note that it should not be considered a basis for guiding clinical practice at this point. Further research is necessary to establish the safety and efficacy of psilocybin as a treatment option for migraines.", "journal": "PubMed", "publication_date": "2023-08-31", "publication_year": 2023, "doi": null, "pubmed_id": "37817818", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37817818", "keywords": "Psilocybin, Medicine, Migraine, Aura, Hallucinogen, Sumatriptan, Anesthesia, Pathophysiology, Serotonin, Psychiatry, Internal medicine, Receptor, Agonist, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4387516129\",\"openalex_url\":\"https://openalex.org/W4387516129\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W1987852744\",\"https://openalex.org/W1998573871\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2045777987\",\"https://openalex.org/W2047455969\",\"https://openalex.org/W2076321511\",\"https://openalex.org/W2142961788\",\"https://openalex.org/W2147688165\",\"https://openalex.org/W2151495151\",\"https://openalex.org/W2162104155\",\"https://openalex.org/W2166952073\",\"https://openalex.org/W2476970195\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2751240458\",\"https://openalex.org/W2800424506\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3010985439\",\"https://openalex.org/W3020424199\",\"https://openalex.org/W3081503667\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3127644232\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4205187819\",\"https://openalex.org/W4210913256\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4307167512\",\"https://openalex.org/W4319079931\"],\"authorships\":[{\"id\":\"https://openalex.org/A5080548305\",\"display_name\":\"David W. Lawrence\",\"orcid\":\"https://orcid.org/0000-0002-1386-7127\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306525036\",\"source_display_name\":\"PubMed\",\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/37817818\",\"is_oa\":false}}", "topic_tags": "Chronic Pain,Headache / Migraine,Pharmacology,Receptor Pharmacology,Case Report,Safety,Toxicity", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4387516129" }, { "id": 1380, "title": "Psychedelics for treatment resistant depression: are they game changers?", "normalized_title": "psychedelics for treatment resistant depression are they game changers", "authors": "Kalfas M, Taylor RH, Tsapekos D, Young AH.", "abstract": "IntroductionA new era of treatment for adults with treatment-resistant depression (TRD), which involves psychedelic substances, is dawning. Emerging evidence indicates that psychedelics can exert antidepressant effects through multiple neurobiological and psychological mechanisms. However, it remains to be seen if these new treatments will revolutionize the treatment of TRD.Areas coveredThe present review focuses on the efficacy of serotoninergic psychedelics psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), ayahuasca, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and mescaline (3,4,5-trimethoxyphenethylamine), as well as 3,4-methylenedioxymethamphetamine (MDMA), for TRD. A systematic search was conducted for psilocybin in TRD as emerging trials had not yet been subject to review. A narrative review summarized findings on other psychedelics.Expert opinionPsychedelic therapy has created a paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits and minimize potential risks. Psilocybin holds promise as a potential game-changer in the treatment of TRD, with initial evidence suggesting a rapid antidepressant effect sustained for some responders for at least 3 months. Nevertheless, further adequately powered, double-blind, comparator-controlled trials are required to explore and clarify the mechanisms of action and long-term effects of psychedelics in TRD. Psychedelics also hold promise for other psychiatric conditions, such as bipolar depression and post-traumatic stress disorder.", "journal": null, "publication_date": "2023-08-31", "publication_year": 2023, "doi": "10.1080/14656566.2023.2281582", "pubmed_id": "37947195", "source_url": "https://doi.org/10.1080/14656566.2023.2281582", "keywords": "Humans, N,N-Dimethyltryptamine, Mescaline, Lysergic Acid Diethylamide, Hallucinogens, Antidepressive Agents, Adult, Randomized Controlled Trials as Topic, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"37947195\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Mechanism of Action,Receptor Pharmacology,Randomized Controlled Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1378, "title": "Psilocybin for anorexia nervosa: If it helps, let’s learn how", "normalized_title": "psilocybin for anorexia nervosa if it helps let s learn how", "authors": "Evelyn Attia, Joanna Steinglass", "abstract": "", "journal": "Med", "publication_date": "2023-08-31", "publication_year": 2023, "doi": "10.1016/j.medj.2023.08.003", "pubmed_id": "37689054", "source_url": "https://doi.org/10.1016/j.medj.2023.08.003", "keywords": "Psilocybin, Anorexia nervosa, Tolerability, Peck (Imperial), Psychology, Psychiatry, Cognition, Psychotherapist, Anorexia, Hallucinogen, Medicine, Eating disorders, Adverse effect, Pharmacology, Internal medicine, Agronomy, Biology, Psychedelics and Drug Studies, Digital Mental Health Interventions, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386541001\",\"openalex_url\":\"https://openalex.org/W4386541001\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1847008447\",\"https://openalex.org/W1953843675\",\"https://openalex.org/W2134770472\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4205208574\",\"https://openalex.org/W4205900283\",\"https://openalex.org/W4280582521\",\"https://openalex.org/W4367553374\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W6639022307\"],\"authorships\":[{\"id\":\"https://openalex.org/A5041064786\",\"display_name\":\"Evelyn Attia\",\"orcid\":\"https://orcid.org/0000-0002-5602-6491\"},{\"id\":\"https://openalex.org/A5033496898\",\"display_name\":\"Joanna Steinglass\",\"orcid\":\"https://orcid.org/0000-0001-8434-8212\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210167770\",\"source_display_name\":\"Med\",\"landing_page_url\":\"https://doi.org/10.1016/j.medj.2023.08.003\",\"is_oa\":false}}", "topic_tags": "Eating Disorders,Pharmacology,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386541001" }, { "id": 1387, "title": "Psilocybin history, action and reaction: A narrative clinical review.", "normalized_title": "psilocybin history action and reaction a narrative clinical review", "authors": "Sharma P, Nguyen QA, Matthews SJ, Carpenter E, Mathews DB, Patten CA, Hammond CJ.", "abstract": "Hallucinogenic mushrooms have been used in religious and cultural ceremonies for centuries. Of late, psilocybin, the psychoactive compound in hallucinogenic mushrooms, has received increased public interest as a novel drug for treating mood and substance use disorders (SUDs). In addition, in recent years, some states in the United States have legalized psilocybin for medical and recreational use. Given this, clinicians need to understand the potential benefits and risks related to using psilocybin for therapeutic purposes so that they can accurately advise patients. This expert narrative review summarizes the scientific basis and clinical evidence on the safety and efficacy of psilocybin-assisted therapy for treating psychiatric disorders and SUDs. The results of this review are structured as a more extensive discussion about psilocybin's history, putative mechanisms of action, and recent legislative changes to its legal status. There is modest evidence of psilocybin-assisted therapy for treating depression and anxiety disorders. In addition, early data suggest that psilocybin-assisted therapy may effectively reduce harmful drinking in patients with alcohol use disorders. The evidence further suggests psilocybin, when administered under supervision (psilocybin-assisted therapy), the side effects experienced are mild and transient. The occurrence of severe adverse events following psilocybin administration is uncommon. Still, a recent clinical trial found that individuals in the psilocybin arm had increased suicidal ideations and non-suicidal self-injurious behaviors. Given this, further investigation into the safety and efficacy of psilocybin-assisted therapy is warranted to determine which patient subgroups are most likely to benefit and which are most likely to experience adverse outcomes related to its use.", "journal": null, "publication_date": "2023-08-30", "publication_year": 2023, "doi": "10.1177/02698811231190858", "pubmed_id": "37650489", "source_url": "https://doi.org/10.1177/02698811231190858", "keywords": "Humans, Alcoholism, Hallucinogens, Affect, Anxiety Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37650489\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Mechanism of Action,Clinical Trial,Review Article,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1379, "title": "Single-Dose Psilocybin Treatment for Major Depressive Disorder", "normalized_title": "single dose psilocybin treatment for major depressive disorder", "authors": "Charles L. Raison, Gerard Sanacora, Joshua Woolley, Keith G. Heinzerling, Boadie W. Dunlop, Randall Brown, Rishi Kakar, Michael Hassman, Rupal Trivedi, Reid Robison, Natalie Gukasyan, Sandeep M. Nayak, Xiaojue Hu, Kelley C. O’Donnell, Benjamin Kelmendi, Jordan Sloshower, Andrew Penn, Ellen Bradley, Daniel F. Kelly, Tanja Mletzko, Christopher R. Nicholas, Paul R. Hutson, Gary Tarpley, Malynn Utzinger, Kelsey Lenoch, Kasia Warchol, Theraysa Gapasin, Mike C. Davis, Courtney Nelson-Douthit, Steffanie H Wilson, Carrie Brown, William Linton, Matthew W. Johnson, Stephen Ross, Roland R. Griffiths", "abstract": "Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants: In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days' duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing. Interventions: Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support. Main Outcomes and Measures: The primary outcome was change in central rater-assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment. Results: A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,-12.3 [95% CI, -17.5 to -7.2]; P", "journal": "JAMA", "publication_date": "2023-08-30", "publication_year": 2023, "doi": "10.1001/jama.2023.14530", "pubmed_id": "37651119", "source_url": "https://doi.org/10.1001/jama.2023.14530", "keywords": "Medicine, Psilocybin, Major depressive disorder, Dosing, Psychiatry, Adverse effect, Bipolar disorder, Placebo, Suicidal ideation, Depression (economics), Antidepressant, Rating scale, Internal medicine, Poison control, Psychology, Hallucinogen, Anxiety, Mood, Injury prevention, Developmental psychology, Macroeconomics, Alternative medicine, Pathology, Environmental health, Economics, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386305655\",\"openalex_url\":\"https://openalex.org/W4386305655\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":488,\"referenced_works\":[\"https://openalex.org/W1993810702\",\"https://openalex.org/W2034147634\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2156458337\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2168253623\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2965468106\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3129586996\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3200483052\",\"https://openalex.org/W4205450793\",\"https://openalex.org/W4206854864\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4224223934\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4226459778\",\"https://openalex.org/W4237965053\",\"https://openalex.org/W4243089545\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4306780560\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309328263\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4361301344\",\"https://openalex.org/W6807316262\"],\"authorships\":[{\"id\":\"https://openalex.org/A5024726266\",\"display_name\":\"Charles L. Raison\",\"orcid\":\"https://orcid.org/0000-0001-6687-0066\"},{\"id\":\"https://openalex.org/A5037185919\",\"display_name\":\"Gerard Sanacora\",\"orcid\":\"https://orcid.org/0000-0003-3722-8829\"},{\"id\":\"https://openalex.org/A5101826991\",\"display_name\":\"Joshua Woolley\",\"orcid\":\"https://orcid.org/0000-0001-6753-2093\"},{\"id\":\"https://openalex.org/A5068139431\",\"display_name\":\"Keith G. Heinzerling\",\"orcid\":\"https://orcid.org/0000-0001-9746-5821\"},{\"id\":\"https://openalex.org/A5056637382\",\"display_name\":\"Boadie W. Dunlop\",\"orcid\":\"https://orcid.org/0000-0002-4653-0483\"},{\"id\":\"https://openalex.org/A5071605998\",\"display_name\":\"Randall Brown\",\"orcid\":\"https://orcid.org/0000-0002-5445-8119\"},{\"id\":\"https://openalex.org/A5082935636\",\"display_name\":\"Rishi Kakar\",\"orcid\":null},{\"id\":\"https://openalex.org/A5024428296\",\"display_name\":\"Michael Hassman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067531163\",\"display_name\":\"Rupal Trivedi\",\"orcid\":\"https://orcid.org/0000-0002-3643-4471\"},{\"id\":\"https://openalex.org/A5081129089\",\"display_name\":\"Reid Robison\",\"orcid\":\"https://orcid.org/0000-0001-6784-9568\"},{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"},{\"id\":\"https://openalex.org/A5040929530\",\"display_name\":\"Sandeep M. Nayak\",\"orcid\":\"https://orcid.org/0000-0002-6832-0639\"},{\"id\":\"https://openalex.org/A5111032624\",\"display_name\":\"Xiaojue Hu\",\"orcid\":\"https://orcid.org/0009-0005-6799-5780\"},{\"id\":\"https://openalex.org/A5042151214\",\"display_name\":\"Kelley C. O’Donnell\",\"orcid\":\"https://orcid.org/0000-0001-9983-2699\"},{\"id\":\"https://openalex.org/A5110948308\",\"display_name\":\"Benjamin Kelmendi\",\"orcid\":\"https://orcid.org/0000-0002-3141-1326\"},{\"id\":\"https://openalex.org/A5080146983\",\"display_name\":\"Jordan Sloshower\",\"orcid\":\"https://orcid.org/0000-0001-7709-5931\"},{\"id\":\"https://openalex.org/A5053850619\",\"display_name\":\"Andrew Penn\",\"orcid\":\"https://orcid.org/0000-0001-5552-7078\"},{\"id\":\"https://openalex.org/A5023606467\",\"display_name\":\"Ellen Bradley\",\"orcid\":\"https://orcid.org/0000-0001-6787-1490\"},{\"id\":\"https://openalex.org/A5066155034\",\"display_name\":\"Daniel F. Kelly\",\"orcid\":\"https://orcid.org/0000-0002-8358-056X\"},{\"id\":\"https://openalex.org/A5017664220\",\"display_name\":\"Tanja Mletzko\",\"orcid\":\"https://orcid.org/0000-0002-8900-9698\"},{\"id\":\"https://openalex.org/A5043044020\",\"display_name\":\"Christopher R. Nicholas\",\"orcid\":\"https://orcid.org/0000-0002-0599-4046\"},{\"id\":\"https://openalex.org/A5088507656\",\"display_name\":\"Paul R. Hutson\",\"orcid\":\"https://orcid.org/0000-0002-6968-7096\"},{\"id\":\"https://openalex.org/A5033314729\",\"display_name\":\"Gary Tarpley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092721397\",\"display_name\":\"Malynn Utzinger\",\"orcid\":null},{\"id\":\"https://openalex.org/A5075166971\",\"display_name\":\"Kelsey Lenoch\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092721398\",\"display_name\":\"Kasia Warchol\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092721399\",\"display_name\":\"Theraysa Gapasin\",\"orcid\":null},{\"id\":null,\"display_name\":\"Mike C. Davis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092721400\",\"display_name\":\"Courtney Nelson-Douthit\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035621912\",\"display_name\":\"Steffanie H Wilson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101610169\",\"display_name\":\"Carrie Brown\",\"orcid\":\"https://orcid.org/0000-0003-0679-6057\"},{\"id\":\"https://openalex.org/A5043376293\",\"display_name\":\"William Linton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S172573765\",\"source_display_name\":\"JAMA\",\"landing_page_url\":\"https://doi.org/10.1001/jama.2023.14530\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Clinical Trial,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386305655" }, { "id": 1315, "title": "Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers", "normalized_title": "double blind comparison of the two hallucinogens dextromethorphan and psilocybin experience dependent and enduring psychological effects in healthy volunteers", "authors": "David S. Mathai, Samantha Hilbert, Nathan D. Sepeda, Justin C. Strickland, Roland R. Griffiths, Albert Garcia-Romeu", "abstract": "Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being. Objective: The aim of this study was to further understand how the phenomenological and health-promoting effects of high-dose dextromethorphan (DXM) compared to psilocybin in the same participants when administered under experimental conditions that are typical of therapeutic psychedelic trials. Methods: Single, acute oral doses of DXM (400 mg/70 kg), psilocybin (10, 20, 30 mg/70 kg), and inactive placebo were administered under double-blind and psychologically supportive conditions to 20 healthy participants with histories of hallucinogen use. Ratings of personal meaning, spiritual significance, psychological challenge, and psychological insight attributed to acute drug experiences were assessed 7 h (at session end) and 1 week after each drug administration. Persisting psychological effects were assessed 1 week after each drug administration. Results: High-dose DXM and psilocybin produced similar increases over placebo in ratings of drug experience that was predictive of psychological benefit at 1 week, even when expectancy effects were minimized. These effects tended to favor psilocybin in a dose-dependent manner and were limited by poor physical tolerability for DXM. Conclusions: This analysis suggests the utility of exploring clinical applications of dissociatives that occur within the supportive contexts that are characteristic of psychedelic research and that prioritize the optimization of psychologically valuable drug experiences. This study was registered with ClinicalTrials.gov (NCT02033707).", "journal": "Psychedelic Medicine", "publication_date": "2023-08-29", "publication_year": 2023, "doi": "10.1089/psymed.2023.0035", "pubmed_id": "38152462", "source_url": "https://doi.org/10.1089/psymed.2023.0035", "keywords": "Psilocybin, Hallucinogen, Dextromethorphan, Psychology, Psychotherapist, Clinical psychology, Psychiatry, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386285211\",\"openalex_url\":\"https://openalex.org/W4386285211\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W1595187506\",\"https://openalex.org/W1966976587\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2024741523\",\"https://openalex.org/W2039605031\",\"https://openalex.org/W2043678991\",\"https://openalex.org/W2044783071\",\"https://openalex.org/W2053154970\",\"https://openalex.org/W2053750947\",\"https://openalex.org/W2056324512\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2160134066\",\"https://openalex.org/W2618615166\",\"https://openalex.org/W2757860301\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2790381919\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2831064708\",\"https://openalex.org/W2886435130\",\"https://openalex.org/W2895197076\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2982759837\",\"https://openalex.org/W2995178539\",\"https://openalex.org/W3016734864\",\"https://openalex.org/W3025937012\",\"https://openalex.org/W3033752070\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3112208811\",\"https://openalex.org/W3137976016\",\"https://openalex.org/W3140816870\",\"https://openalex.org/W3194499267\",\"https://openalex.org/W3198980648\",\"https://openalex.org/W3203928800\",\"https://openalex.org/W3205283070\",\"https://openalex.org/W4205576215\",\"https://openalex.org/W4226172056\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4249273517\",\"https://openalex.org/W4281297733\",\"https://openalex.org/W4281570368\",\"https://openalex.org/W4286449579\",\"https://openalex.org/W4294214983\",\"https://openalex.org/W4308067211\",\"https://openalex.org/W4310044456\",\"https://openalex.org/W4311825681\",\"https://openalex.org/W4316036302\",\"https://openalex.org/W4318912123\",\"https://openalex.org/W4377941059\"],\"authorships\":[{\"id\":\"https://openalex.org/A5020492413\",\"display_name\":\"David S. Mathai\",\"orcid\":\"https://orcid.org/0000-0001-9972-601X\"},{\"id\":\"https://openalex.org/A5111190976\",\"display_name\":\"Samantha Hilbert\",\"orcid\":null},{\"id\":\"https://openalex.org/A5061776312\",\"display_name\":\"Nathan D. Sepeda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027917357\",\"display_name\":\"Justin C. Strickland\",\"orcid\":\"https://orcid.org/0000-0003-1077-0394\"},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"},{\"id\":\"https://openalex.org/A5091708678\",\"display_name\":\"Albert Garcia-Romeu\",\"orcid\":\"https://orcid.org/0000-0003-2182-1644\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387284413\",\"source_display_name\":\"Psychedelic Medicine\",\"landing_page_url\":\"https://doi.org/10.1089/psymed.2023.0035\",\"is_oa\":false}}", "topic_tags": "Chronic Pain,Receptor Pharmacology,Consciousness,Wellbeing,Spirituality,Healthy Volunteers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386285211" }, { "id": 1405, "title": "Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests", "normalized_title": "race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests", "authors": "Grant Jones, Maha Al-Suwaidi, Franchesca Castro-Ramirez, Taylor C. McGuire, Patrick Mair, Matthew K. Nock", "abstract": "Introduction: Psilocybin use has been linked to lowered odds of crime-related outcomes across a host of observational studies. No studies have investigated how these associations may differ among those of different races and ethnicities. Methods: Using a nationally-representative sample of 734,061 adults from the National Survey on Drug Use and Health (2002-2020), we investigated whether race and ethnicity moderate the associations between lifetime psilocybin use and four measures of crime arrests (property crime, assault, serious violence, and miscellaneous crimes). Results: First, we replicated prior findings and demonstrated that psilocybin confers lowered odds of crime arrests for all four outcomes in question. Second, we demonstrated that race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests for three of our four outcomes. Third, we examined the associations between psilocybin and crime arrests across different races and ethnicities (White, Black, Indigenous, Asian, Multiracial, and Hispanic participants). Psilocybin conferred lowered odds of at least one crime arrest outcome for all racial and ethnic groups except for Black and Hispanic participants. Discussion: Future investigations should take an intersectional approach to studying the interrelationship of sociodemographic factors, psychedelic use, and crime, examine the structural factors (i.e., systemic racism) that may underlie these results, and investigate whether psychedelics can alleviate mental health disorders that contribute to cycles of recriminalization for communities of color.", "journal": "Frontiers in Psychiatry", "publication_date": "2023-08-23", "publication_year": 2023, "doi": "10.3389/fpsyt.2023.1169692", "pubmed_id": "37692301", "source_url": "https://doi.org/10.3389/fpsyt.2023.1169692", "keywords": "Psilocybin, Ethnic group, Odds, Race (biology), Mental health, Demography, Psychiatry, Suicide prevention, Psychology, Odds ratio, Poison control, Medicine, Clinical psychology, Logistic regression, Hallucinogen, Environmental health, Sociology, Pathology, Gender studies, Internal medicine, Anthropology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, HIV, Drug Use, Sexual Risk", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386165916\",\"openalex_url\":\"https://openalex.org/W4386165916\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W180410055\",\"https://openalex.org/W1581086109\",\"https://openalex.org/W1987399849\",\"https://openalex.org/W1992465642\",\"https://openalex.org/W1996143523\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2017340994\",\"https://openalex.org/W2017946173\",\"https://openalex.org/W2048718067\",\"https://openalex.org/W2065038199\",\"https://openalex.org/W2069091358\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2097420075\",\"https://openalex.org/W2109063793\",\"https://openalex.org/W2110446923\",\"https://openalex.org/W2118319420\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2129555827\",\"https://openalex.org/W2130078781\",\"https://openalex.org/W2160459066\",\"https://openalex.org/W2162297848\",\"https://openalex.org/W2163223102\",\"https://openalex.org/W2163929399\",\"https://openalex.org/W2184301893\",\"https://openalex.org/W2270553246\",\"https://openalex.org/W2306795963\",\"https://openalex.org/W2337075201\",\"https://openalex.org/W2343336459\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2560095487\",\"https://openalex.org/W2567295262\",\"https://openalex.org/W2571443797\",\"https://openalex.org/W2604748569\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2807286797\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2889351344\",\"https://openalex.org/W2894541203\",\"https://openalex.org/W2904933179\",\"https://openalex.org/W2905174224\",\"https://openalex.org/W2912806128\",\"https://openalex.org/W2914120368\",\"https://openalex.org/W2940802100\",\"https://openalex.org/W2944263526\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W2976409330\",\"https://openalex.org/W2984152228\",\"https://openalex.org/W2991818648\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3002875391\",\"https://openalex.org/W3006069447\",\"https://openalex.org/W3028908346\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112172827\",\"https://openalex.org/W3123509027\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3134607687\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3171546624\",\"https://openalex.org/W3180018060\",\"https://openalex.org/W3193146023\",\"https://openalex.org/W3193818495\",\"https://openalex.org/W4205627344\",\"https://openalex.org/W4205701940\",\"https://openalex.org/W4210325795\",\"https://openalex.org/W4213251631\",\"https://openalex.org/W4283275230\",\"https://openalex.org/W4285505414\",\"https://openalex.org/W4304118763\",\"https://openalex.org/W4307773202\",\"https://openalex.org/W6607382501\",\"https://openalex.org/W6635148198\",\"https://openalex.org/W6686480625\",\"https://openalex.org/W6762808432\",\"https://openalex.org/W6880143387\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066674976\",\"display_name\":\"Grant Jones\",\"orcid\":\"https://orcid.org/0000-0002-2426-310X\"},{\"id\":\"https://openalex.org/A5005301911\",\"display_name\":\"Maha Al-Suwaidi\",\"orcid\":\"https://orcid.org/0000-0002-2024-127X\"},{\"id\":\"https://openalex.org/A5022537224\",\"display_name\":\"Franchesca Castro-Ramirez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083274652\",\"display_name\":\"Taylor C. McGuire\",\"orcid\":\"https://orcid.org/0000-0002-2020-5746\"},{\"id\":\"https://openalex.org/A5033261896\",\"display_name\":\"Patrick Mair\",\"orcid\":\"https://orcid.org/0000-0003-0100-6511\"},{\"id\":\"https://openalex.org/A5082317510\",\"display_name\":\"Matthew K. Nock\",\"orcid\":\"https://orcid.org/0000-0001-6508-1145\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2023.1169692\",\"is_oa\":true}}", "topic_tags": "Observational Study,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386165916" }, { "id": 1042, "title": "Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.", "normalized_title": "beyond psilocybin reviewing the therapeutic potential of other serotonergic psychedelics in mental and substance use disorders", "authors": "Wong S, Yu AY, Fabiano N, Finkelstein O, Pasricha A, Jones BDM, Rosenblat JD, Blumberger DM, Mulsant BH, Husain MI.", "abstract": "There has been a resurgence of interest in the use of psychedelic therapies for several mental and substance use disorders. Psilocybin, a \"classic\" serotonergic psychedelic, has emerged as one of the primary compounds of interest in clinical research. While research on psilocybin's potential mental health benefits has grown, data on the safety and efficacy of other serotonergic psychedelics remain limited. A comprehensive scoping review on the use of mescaline, ibogaine, ayahuasca, N,N-dimethyltryptamine (DMT), and lysergic acid diethylamide (LSD) in the treatment of mental and substance disorders was conducted. Independent reviewers screened titles, abstracts, and full texts and conducted data extraction. Seventy-seven studies met the inclusion criteria. There were 43 studies of LSD, 24 studies of ayahuasca, 5 studies of DMT, 5 studies of ibogaine, and 5 studies of mescaline. Commonly reported benefits included improved mood and anxiety symptoms, improved insight, reduced substance use, improved relationships, and decreased vegetative symptoms. Commonly reported adverse effects were psychological, neurological, physical, and gastrointestinal in nature. Serious adverse events (homicide and suicide) were reported in published studies of LSD. In conclusion, there is only low-level evidence to support the safety and efficacy of non-psilocybin serotonergic psychedelics in individuals with mental and substance use disorders.", "journal": null, "publication_date": "2023-08-23", "publication_year": 2023, "doi": "10.1080/02791072.2023.2251133", "pubmed_id": "37615379", "source_url": "https://doi.org/10.1080/02791072.2023.2251133", "keywords": "Humans, Banisteriopsis, Substance-Related Disorders, N,N-Dimethyltryptamine, Mescaline, Lysergic Acid Diethylamide, Ibogaine, Serotonin Agents, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"37615379\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Addiction,Receptor Pharmacology,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1407, "title": "Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences", "normalized_title": "co use of mdma with psilocybin lsd may buffer against challenging experiences and enhance positive experiences", "authors": "Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin J. Mallard, Daniel E. Roberts, David Erritzøe, Stephen Ross, Robin Carhart-Harris", "abstract": "Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging experiences and enhances positive experiences associated with psilocybin/LSD. However, limited research has investigated the acute effects of co-use of MDMA and psilocybin/LSD. In a prospective convenience sample (N = 698) of individuals with plans to use psilocybin/LSD, we examined whether co-use of MDMA with psilocybin/LSD (n = 27) is associated with differences in challenging or positive experiences. Challenging experiences were measured using the Challenging Experiences Questionnaire and positive experiences were measured using the Mystical Experience Questionnaire and single-item measures of self-compassion, compassion, love, and gratitude. Potentially confounding variables were identified and included as covariates. Relative to psilocybin/LSD alone, co-use of psilocybin/LSD with a self-reported low (but not medium-high) dose of MDMA was associated with significantly less intense total challenging experiences, grief, and fear, as well as increased self-compassion, love and gratitude. Co-use of psilocybin/LSD and MDMA was not associated with differences in mystical-type experiences or compassion. Findings suggest co-use of MDMA with psilocybin/LSD may buffer against some aspects of challenging experiences and enhance certain positive experiences. Limitations include use of a convenience sample, small sample size, and non-experimental design. Additional studies (including controlled dose-response studies) that examine the effects and safety of co-administering MDMA with psilocybin/LSD (in healthy controls and clinical samples) are warranted and may assist the development of personalized treatments.", "journal": "Scientific Reports", "publication_date": "2023-08-21", "publication_year": 2023, "doi": "10.1038/s41598-023-40856-5", "pubmed_id": "37608057", "source_url": "https://doi.org/10.1038/s41598-023-40856-5", "keywords": "Psilocybin, MDMA, Lysergic acid diethylamide, Hallucinogen, Psychology, Grief, Clinical psychology, Gratitude, Psychiatry, Medicine, Psychotherapist, Internal medicine, Serotonin, Receptor, Psychedelics and Drug Studies, Complementary and Alternative Medicine Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386069067\",\"openalex_url\":\"https://openalex.org/W4386069067\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":30,\"referenced_works\":[\"https://openalex.org/W1525161423\",\"https://openalex.org/W1667002192\",\"https://openalex.org/W1948675593\",\"https://openalex.org/W1965713283\",\"https://openalex.org/W1994271186\",\"https://openalex.org/W2016310399\",\"https://openalex.org/W2021916581\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2093943230\",\"https://openalex.org/W2097563002\",\"https://openalex.org/W2105342126\",\"https://openalex.org/W2118539399\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2130643119\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2162090451\",\"https://openalex.org/W2163808408\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2342018515\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2603506674\",\"https://openalex.org/W2620385377\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2765997654\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2792164490\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2793566445\",\"https://openalex.org/W2797335301\",\"https://openalex.org/W2803536098\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2920559226\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2940999002\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2984882636\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W2999812626\",\"https://openalex.org/W3001327571\",\"https://openalex.org/W3015163151\",\"https://openalex.org/W3047886920\",\"https://openalex.org/W3083797211\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3096108931\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112557491\",\"https://openalex.org/W3134897339\",\"https://openalex.org/W3135650175\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W3160183306\",\"https://openalex.org/W3166553838\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3191608162\",\"https://openalex.org/W3208662682\",\"https://openalex.org/W3210733143\",\"https://openalex.org/W3211560547\",\"https://openalex.org/W3216164364\",\"https://openalex.org/W3216348943\",\"https://openalex.org/W4200517619\",\"https://openalex.org/W4205403234\",\"https://openalex.org/W4206661393\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4210376981\",\"https://openalex.org/W4220790925\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4226081049\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4291002705\",\"https://openalex.org/W4291721232\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4304118763\",\"https://openalex.org/W4307380201\",\"https://openalex.org/W4309139242\",\"https://openalex.org/W4310598708\",\"https://openalex.org/W4318754695\",\"https://openalex.org/W4365455369\",\"https://openalex.org/W4366580975\",\"https://openalex.org/W4367840575\",\"https://openalex.org/W4378903602\",\"https://openalex.org/W4387007980\"],\"authorships\":[{\"id\":\"https://openalex.org/A5000949886\",\"display_name\":\"Richard J. Zeifman\",\"orcid\":\"https://orcid.org/0000-0003-3478-4483\"},{\"id\":\"https://openalex.org/A5056016180\",\"display_name\":\"Hannes Kettner\",\"orcid\":\"https://orcid.org/0000-0001-9482-0998\"},{\"id\":\"https://openalex.org/A5066934485\",\"display_name\":\"Broc A. Pagni\",\"orcid\":\"https://orcid.org/0000-0002-9496-7604\"},{\"id\":\"https://openalex.org/A5109632366\",\"display_name\":\"Austin J. Mallard\",\"orcid\":null},{\"id\":\"https://openalex.org/A5004385044\",\"display_name\":\"Daniel E. Roberts\",\"orcid\":\"https://orcid.org/0000-0002-9375-6354\"},{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"},{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S196734849\",\"source_display_name\":\"Scientific Reports\",\"landing_page_url\":\"https://doi.org/10.1038/s41598-023-40856-5\",\"is_oa\":true}}", "topic_tags": "Receptor Pharmacology,Mystical Experience,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386069067" }, { "id": 4785, "title": "Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy", "normalized_title": "exploring the relationship between mental health drug use personality and attitudes towards psilocybin assisted therapy", "authors": "Benjamin M. Ross, James T. Neill", "abstract": "Abstract Background Psilocybin, the psychoactive compound in magic mushrooms, is increasingly discussed in terms of its psychotherapeutic potential; however, little is known about community attitudes towards psilocybin assisted therapy (PAT). Aims To address the question: What are the public's attitudes towards psilocybin and psilocybin-assisted therapy? And what factors explain these attitudes? Methods This study investigated the attitudes of 118 young adults in the Australian Capital Territory through an online survey. Results Participants who were more open to experience and who had used recreational drugs were more likely to have positive attitudes towards all aspects of PAT. Additionally, psychedelic drug use and agreeableness was positively associated with attitudes towards psilocybin safety, legality, and research; and psilocybin use was positively associated with attitudes towards psilocybin knowledge and acceptability. Conclusions This convenience sample of young adults was generally positively disposed towards PAT. People who were more open to experience and who had used recreational or psychedelic drugs had more favourable attitudes towards PAT.", "journal": "Journal of Psychedelic Studies", "publication_date": "2023-08-20", "publication_year": 2023, "doi": "10.1556/2054.2023.00264", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2023.00264", "keywords": "Psilocybin, Psychology, Lysergic acid diethylamide, Taboo, Clinical psychology, Anxiety, Psychiatry, Computer-assisted web interviewing, Hallucinogen, Medicine, Political science, Serotonin, Marketing, Internal medicine, Business, Receptor, Law, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:45", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4386021261\",\"openalex_url\":\"https://openalex.org/W4386021261\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W14392008\",\"https://openalex.org/W2042962409\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2137271651\",\"https://openalex.org/W2316003297\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2546514788\",\"https://openalex.org/W2608583841\",\"https://openalex.org/W2790381919\",\"https://openalex.org/W2790959730\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3042225060\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3109765150\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3152965122\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4200397343\",\"https://openalex.org/W4255070880\",\"https://openalex.org/W4285605468\"],\"authorships\":[{\"id\":\"https://openalex.org/A5050981201\",\"display_name\":\"Benjamin M. Ross\",\"orcid\":\"https://orcid.org/0000-0002-1713-9223\"},{\"id\":\"https://openalex.org/A5008472554\",\"display_name\":\"James T. Neill\",\"orcid\":\"https://orcid.org/0000-0003-0710-4550\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2023.00264\",\"is_oa\":true}}", "topic_tags": "Anxiety,Receptor Pharmacology,Personality Change,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4386021261" }, { "id": 1347, "title": "A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder", "normalized_title": "a proposal to study the safety and efficacy of psilocybe cubensis in preclinical and clinical studies as a therapeutic alternative for major depressive disorder", "authors": "Raúl Escamilla, María Eva González-Trujano, Jesús M. González Mariscal, J. Martı́n Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Loizaga-Velder", "abstract": "The pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico. Research on a larger scale is lacking in various populations, including the Mexican people. This proposal contemplates the experimental design of a preclinical (toxicity and pharmacological evaluation of an extract in mice) and clinical study by including the chemical analysis of a species of Psilocybe cubensis mushroom to characterize its main constituents. The clinical study will consider the safety evaluation by exploring tolerated doses of Psilocybe cubensis by measuring pharmacokinetic parameters after oral administration in healthy adults and an open trial on a sample of patients with major depressive disorder to assess the safety and efficacy of fully characterized Psilocybe cubensis in a two-single doses treatment, (with assisted psychotherapy), compared with the traditional care model at the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz in Mexico City. This report presents the design of a research project with preclinical and clinical experimental components.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2023-08-17", "publication_year": 2023, "doi": "10.1080/02791072.2023.2246459", "pubmed_id": "37594163", "source_url": "https://doi.org/10.1080/02791072.2023.2246459", "keywords": "Preclinical research, Psychiatry, Major depressive disorder, Psychology, Medicine, Pharmacology, Neuroscience, Cognition, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Alkaloids: synthesis and pharmacology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4385969211\",\"openalex_url\":\"https://openalex.org/W4385969211\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W124621362\",\"https://openalex.org/W201147263\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2016292245\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2039827824\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2073980989\",\"https://openalex.org/W2074146187\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2080507858\",\"https://openalex.org/W2087265397\",\"https://openalex.org/W2095559697\",\"https://openalex.org/W2148939709\",\"https://openalex.org/W2197078876\",\"https://openalex.org/W2306296749\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2725508837\",\"https://openalex.org/W2753941774\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2810374266\",\"https://openalex.org/W2884828036\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2973144031\",\"https://openalex.org/W2984820573\",\"https://openalex.org/W3000386776\",\"https://openalex.org/W3043077203\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3090675239\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3203310594\",\"https://openalex.org/W3215496863\",\"https://openalex.org/W3215766429\",\"https://openalex.org/W4200627112\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4210366495\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4232797145\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4302773366\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313275631\",\"https://openalex.org/W4313397998\",\"https://openalex.org/W4318393298\",\"https://openalex.org/W4322719007\",\"https://openalex.org/W4362471804\",\"https://openalex.org/W6749357005\"],\"authorships\":[{\"id\":\"https://openalex.org/A5113612103\",\"display_name\":\"Raúl Escamilla\",\"orcid\":null},{\"id\":\"https://openalex.org/A5012526517\",\"display_name\":\"María Eva González-Trujano\",\"orcid\":\"https://orcid.org/0000-0002-4399-1508\"},{\"id\":\"https://openalex.org/A5067443328\",\"display_name\":\"Jesús M. González Mariscal\",\"orcid\":\"https://orcid.org/0000-0003-1918-4076\"},{\"id\":\"https://openalex.org/A5108011741\",\"display_name\":\"J. Martı́n Torres-Valencia\",\"orcid\":\"https://orcid.org/0000-0001-6426-7562\"},{\"id\":\"https://openalex.org/A5092839041\",\"display_name\":\"Héctor Guzmán-González\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083887530\",\"display_name\":\"José Luis Vega\",\"orcid\":\"https://orcid.org/0000-0001-9333-8729\"},{\"id\":\"https://openalex.org/A5005093083\",\"display_name\":\"Anja Loizaga-Velder\",\"orcid\":\"https://orcid.org/0000-0001-9523-3023\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2023.2246459\",\"is_oa\":false}}", "topic_tags": "Depression,Pharmacology,Animal Study,Safety,Toxicity", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4385969211" }, { "id": 1388, "title": "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.", "normalized_title": "the risk of chronic psychedelic and mdma microdosing for valvular heart disease", "authors": "Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R.", "abstract": "Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT2B receptor. However, this risk has not yet been comprehensively assessed. This analysis searched for all relevant in vitro, animal, and clinical studies related to the VHD risk of lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT), and the non-psychedelic 3,4-methylenedioxymethamphetamine (MDMA). All five compounds and some metabolites could bind to the 5-HT2B receptor with potency equal to or greater than that of the 5-HT2A receptor, the primary target of psychedelics. All compounds were partial agonists at the 5-HT2B receptor with the exception of mescaline, which could not be adequately assessed due to low potency. Safety margins relative to the maximum plasma concentrations from typical microdoses were greater than known valvulopathogens, but not without potential risk. No animal or clinical studies appropriately designed to evaluate VHD risk were found for the four psychedelics. However, there is some clinical evidence that chronic ingestion of full doses of MDMA is associated with VHD. We conclude that VHD is a potential risk with chronic psychedelic microdosing, but further studies are necessary to better define this risk.", "journal": null, "publication_date": "2023-08-11", "publication_year": 2023, "doi": "10.1177/02698811231190865", "pubmed_id": "37572027", "source_url": "https://doi.org/10.1177/02698811231190865", "keywords": "Humans, Heart Valve Diseases, Serotonin, N-Methyl-3,4-methylenedioxyamphetamine, Mescaline, Lysergic Acid Diethylamide, Hallucinogens, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37572027\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Microdosing,In Vitro Study,Safety", "study_type": "In Vitro Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4788, "title": "Psilocybin's Emerging Role in Combating Depressive Disorder", "normalized_title": "psilocybin s emerging role in combating depressive disorder", "authors": "Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek", "abstract": "In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment. Depression, a widespread psychological malady affecting countless individuals across the globe, often proves stubborn against existing treatment modalities, necessitating exploration into new options. The spotlight has increasingly been cast on psilocybin, thanks to its promising therapeutic capacities for a spectrum of mental health disorders, notably including depression. This article dissects the operational mechanisms of psilocybin, referencing germane clinical trials, and weighing the prospective risks and rewards related to its usage. Pooled findings from an array of clinical studies hint at the possibility of psilocybin furnishing swift and lasting advantages for managing depression and similar disorders. Trial participants who underwent a combined regimen of psilocybin and psychotherapy recorded enduring alleviation in their anxiety and depressive symptoms. Psilocybin has been observed to trigger modifications in neural activity, predominantly in the brain's default mode network (DMN) and the prefrontal cortex (PFC). These alterations have been correlated with a decrease in self-oriented cognitive processes, an uptick in positive emotional states, and the facilitation of neuroplasticity. When compared with standard antidepressant medications, the symptomatic improvements seen with psilocybin were largely equivalent. Preclinical investigations have also underlined psilocybin's potential in augmenting neural plasticity and neurogenesis, thus hinting at its possible utility in the fields of neurosurgery and neurooncology.", "journal": "Journal of Education Health and Sport", "publication_date": "2023-08-07", "publication_year": 2023, "doi": "10.12775/jehs.2023.40.01.011", "pubmed_id": null, "source_url": "https://doi.org/10.12775/jehs.2023.40.01.011", "keywords": "Psilocybin, Psychology, Default mode network, Psychiatry, Anxiety, Neuroplasticity, Depression (economics), Antidepressant, Cognition, Clinical psychology, Neuroscience, Hallucinogen, Medicine, Psychotherapist, Economics, Macroeconomics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Mental Health Research Topics", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:45", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4385658334\",\"openalex_url\":\"https://openalex.org/W4385658334\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2052466574\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2110572089\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4311273096\",\"https://openalex.org/W4319067008\"],\"authorships\":[{\"id\":\"https://openalex.org/A5092612347\",\"display_name\":\"Anna Jaremek\",\"orcid\":\"https://orcid.org/0009-0002-7787-7938\"},{\"id\":\"https://openalex.org/A5046422345\",\"display_name\":\"Joanna Kępa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5092612348\",\"display_name\":\"Norbert Kandefer\",\"orcid\":\"https://orcid.org/0009-0007-3743-5939\"},{\"id\":\"https://openalex.org/A5020439017\",\"display_name\":\"Michał Wyszkowski\",\"orcid\":\"https://orcid.org/0009-0003-1125-4014\"},{\"id\":\"https://openalex.org/A5012213808\",\"display_name\":\"Aleksandra Grabarczyk\",\"orcid\":\"https://orcid.org/0009-0002-2232-2265\"},{\"id\":\"https://openalex.org/A5035222802\",\"display_name\":\"Anna Pawlak\",\"orcid\":\"https://orcid.org/0009-0009-8502-4987\"},{\"id\":\"https://openalex.org/A5022674489\",\"display_name\":\"Sylwia Grad\",\"orcid\":\"https://orcid.org/0009-0008-3833-5398\"},{\"id\":\"https://openalex.org/A5092612349\",\"display_name\":\"Małgorzata Gregorek\",\"orcid\":\"https://orcid.org/0009-0009-5964-6897\"},{\"id\":\"https://openalex.org/A5092612350\",\"display_name\":\"Paweł Gregorek\",\"orcid\":\"https://orcid.org/0000-0001-5678-2054\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737571363\",\"source_display_name\":\"Journal of Education Health and Sport\",\"landing_page_url\":\"https://doi.org/10.12775/jehs.2023.40.01.011\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Neurogenesis,Mechanism of Action,Default Mode Network,Aging,Emotional Processing,Clinical Trial,Review Article,Animal Study,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4385658334" }, { "id": 1349, "title": "“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy", "normalized_title": "but the reality is it s happening a qualitative study of eating disorder providers about psilocybin assisted psychotherapy", "authors": "Amanda E. Downey, Maxine Boyd, Anita V. Chaphekar, Joshua Woolley, Marissa Raymond-Flesch", "abstract": "OBJECTIVE: This study invited providers who care for patients with eating disorders to inform engagement, communication, and collaboration with psilocybin-assisted psychotherapy interventions. METHOD: Medical and mental health providers who treat patients with eating disorders were recruited via professional referral networks and participant driven sampling from across California to participate in one of five focus groups. Discussion topics included prior knowledge of psychedelic therapy, interest/concerns related to psilocybin therapy, and opportunities for collaboration. Study team members completed iterative rounds of coding with a grounded theory approach. RESULTS: A total of 32 participants reported a range of familiarity with psychedelics. Some raised concerns about the risks of administering psilocybin to malnourished patients and to those with psychological comorbidities. Despite these concerns, participants were hopeful to see psilocybin therapy as a treatment for patients with eating disorders. In anticipating challenges, providers had concerns about equity in access to care among publicly insured and non-English speaking patients. They requested opportunities for continuing education about psilocybin therapy. DISCUSSION: Our findings demonstrate provider interest in psilocybin therapy for the treatment of patients with eating disorders. As psilocybin therapy interventions are developed, providers caring for patients with eating disorders value collaboration to improve longitudinal patient outcomes. PUBLIC SIGNIFICANCE: This study invited healthcare providers of patients with eating disorders to discuss their thoughts around the use of psilocybin-assisted psychotherapy in this population. Findings will help inform emerging psilocybin therapy clinical trials with the goal of successful translation and adoption in real world clinical settings.", "journal": "International Journal of Eating Disorders", "publication_date": "2023-08-07", "publication_year": 2023, "doi": "10.1002/eat.24041", "pubmed_id": "37551650", "source_url": "https://doi.org/10.1002/eat.24041", "keywords": "Psilocybin, Psychological intervention, Eating disorders, Psychotherapist, Psychiatry, Psychology, Medicine, Hallucinogen, Clinical psychology, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4385664009\",\"openalex_url\":\"https://openalex.org/W4385664009\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W1515587369\",\"https://openalex.org/W1990140024\",\"https://openalex.org/W2014080878\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2090670445\",\"https://openalex.org/W2091142866\",\"https://openalex.org/W2107954772\",\"https://openalex.org/W2113620539\",\"https://openalex.org/W2146691185\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2789890413\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2910298407\",\"https://openalex.org/W2933488173\",\"https://openalex.org/W3027990543\",\"https://openalex.org/W3081600043\",\"https://openalex.org/W3109265558\",\"https://openalex.org/W3131603063\",\"https://openalex.org/W3184606993\",\"https://openalex.org/W3192295109\",\"https://openalex.org/W3193759217\",\"https://openalex.org/W3197311089\",\"https://openalex.org/W3204295756\",\"https://openalex.org/W4220695431\",\"https://openalex.org/W4220841869\",\"https://openalex.org/W4285605468\",\"https://openalex.org/W4288694923\",\"https://openalex.org/W4293242421\",\"https://openalex.org/W4312084004\",\"https://openalex.org/W4322719409\",\"https://openalex.org/W4385197359\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037114160\",\"display_name\":\"Amanda E. Downey\",\"orcid\":\"https://orcid.org/0000-0002-5206-7798\"},{\"id\":\"https://openalex.org/A5074475475\",\"display_name\":\"Maxine Boyd\",\"orcid\":null},{\"id\":\"https://openalex.org/A5024595487\",\"display_name\":\"Anita V. Chaphekar\",\"orcid\":\"https://orcid.org/0000-0002-8326-9077\"},{\"id\":\"https://openalex.org/A5101826991\",\"display_name\":\"Joshua Woolley\",\"orcid\":\"https://orcid.org/0000-0001-6753-2093\"},{\"id\":\"https://openalex.org/A5030878484\",\"display_name\":\"Marissa Raymond-Flesch\",\"orcid\":\"https://orcid.org/0000-0003-0037-8970\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S74080386\",\"source_display_name\":\"International Journal of Eating Disorders\",\"landing_page_url\":\"https://doi.org/10.1002/eat.24041\",\"is_oa\":true}}", "topic_tags": "Eating Disorders,Chronic Pain,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4385664009" }, { "id": 1348, "title": "Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.", "normalized_title": "psilocybin assisted therapy for depression a systematic review and dose response meta analysis of human studies", "authors": "Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M.", "abstract": "Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD42022220190) multiple electronic databases were searched from their inception until February 2023, to identify double-blind randomized placebo-controlled (RCTs) fixed-dose trials evaluating the use of psilocybin for adult patients with primary or secondary depression. A one-stage dose-response meta-analysis with restricted cubic splines was used. Cochrane risk of bias was used to assess risk of bias. Our analysis included seven studies with a total of 489 participants. Among these, four studies focused on primary depression (N = 366), including one study with patients suffering from treatment-resistant depression. The remaining three studies examined secondary depression (N = 123). The determined 95% effective doses per day (ED95) were 8.92, 24.68, and 36.08 mg/70 kg for patients with secondary depression, primary depression, and both subgroups, respectively. We observed significant dose-response associations for all curves, each plateauing at different levels, except for the bell-shaped curve observed in the case of secondary depression. Additionally, we found significant dose-response associations for various side effects, including physical discomfort, blood pressure increase, nausea/vomiting, headache/migraine, and the risk of prolonged psychosis. In conclusion, we discovered specific ED95 values for different populations, indicating higher ED95 values for treatment-resistant depression, primary depression, and secondary depression groups. Further RCTs are necessary for each population to determine the optimal dosage, allowing for maximum efficacy while minimizing side effects.", "journal": null, "publication_date": "2023-08-06", "publication_year": 2023, "doi": "10.1016/j.euroneuro.2023.07.011", "pubmed_id": "37557019", "source_url": "https://doi.org/10.1016/j.euroneuro.2023.07.011", "keywords": "Humans, Antidepressive Agents, Depression, Psychotic Disorders, Adult, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"37557019\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Headache / Migraine,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1389, "title": "The Potential of Psychedelics for the Treatment of Episodic Migraine.", "normalized_title": "the potential of psychedelics for the treatment of episodic migraine", "authors": "Schindler EAD.", "abstract": "Purpose of reviewThis review presents the existing literature of and a framework for how psychedelic drugs might be applied as therapeutic agents in episodic migraine.Recent findingsThe therapeutic effects of psychedelics in headache disorders have been reported for decades and controlled investigations are now beginning. In the first and only clinical trial of a psychedelic drug in migraine, the single administration of low-dose psilocybin reduced weekly migraine days and pain intensity for the following 2 weeks in episodic subjects. These transitional effects, along with abortive effects in two subjects and additional findings in cluster headache, offer insight into the potential medicinal use of this and other psychedelic drugs in episodic migraine. The existing evidence supports the continued investigation of psilocybin and other psychedelics as transitional treatments in episodic migraine. Acute and preventive effects also exist, but the risks may outweigh benefits with these applications. Future research of psychedelics in episodic migraine should be tailored for this condition and not modeled after protocols used in other medical or psychiatric conditions.", "journal": null, "publication_date": "2023-08-03", "publication_year": 2023, "doi": "10.1007/s11916-023-01145-y", "pubmed_id": "37540398", "source_url": "https://doi.org/10.1007/s11916-023-01145-y", "keywords": "Humans, Cluster Headache, Hallucinogens, Mental Disorders, Migraine Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"37540398\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1014, "title": "Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia", "normalized_title": "prevalence of psilocybin use in vaping and associated factors a study among amphetamine type stimulants ats use disorder in malaysia", "authors": "Ruzmayuddin Mamat, Rusdi Abd Rashid, Maw Shin Sim, Baharudin Ibrahim, Suzaily Wahab, Azmir Ahmad", "abstract": "BACKGROUND: The emergence of New Psychoactive Substances (NPS), including synthetic psilocybin, has raised concern among health experts due to the numerous health and socioeconomic consequences. The current trend is shifting to the hazardous use of synthetic psilocybin in vaping, and little is known about the prevalence of use, specifically among amphetamine-type stimulants (ATS) users. METHODS: = 355 ATS users were enrolled in this study. RESULTS: The results show a high prevalence of psilocybin vaping among ATS users (182/355, 53.1%). Most of the respondents were males (85.1%) and unmarried (69.3%), with a mean age of 29.2 (SD = 7.3). Across all respondents, five factors were associated with psilocybin vaping: tobacco smoking, aOR =5.790 (95% CI: 1.723, 8.183); cannabis uses, aOR= 9.152 (95% CI: 2.693, 10.396); and alcohol use, aOR= 3.137 (95% CI: 1.461, 5.817). Respondents of the Malay race had higher odds of being involved in psilocybin vaping compared to other races, with aOR= 1.638 (0.043, 2.459). Meanwhile, a reduction in age by 1.9 will increase the likelihood of involvement in psilocybin vaping with aOR = 1.897 (95% CI: 0.857, 1.938). CONCLUSION: Psilocybin in vaping is growing among ATS users and across all populations. Unfortunately, knowledge regarding the long-term effects on health is limited. Further studies should highlight the harmful effects of psilocybin and the potential risk of psilocybin vaping among the younger population.", "journal": "Journal of Addictive Diseases", "publication_date": "2023-08-03", "publication_year": 2023, "doi": "10.1080/10550887.2023.2240932", "pubmed_id": "37540000", "source_url": "http://dx.doi.org/10.1080/10550887.2023.2240932", "keywords": "Psilocybin, Cannabis, Medicine, Hallucinogen, Psychiatry, Amphetamine, Demography, Internal medicine, Sociology, Dopamine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Halal products and consumer behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4385564685\",\"openalex_url\":\"https://openalex.org/W4385564685\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W169103039\",\"https://openalex.org/W1782206456\",\"https://openalex.org/W1948675593\",\"https://openalex.org/W1970305111\",\"https://openalex.org/W1998603564\",\"https://openalex.org/W2002326806\",\"https://openalex.org/W2024320199\",\"https://openalex.org/W2035893127\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075547663\",\"https://openalex.org/W2084390511\",\"https://openalex.org/W2088580357\",\"https://openalex.org/W2119461820\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2413325657\",\"https://openalex.org/W2530972044\",\"https://openalex.org/W2606454891\",\"https://openalex.org/W2754202022\",\"https://openalex.org/W2771056291\",\"https://openalex.org/W2773839020\",\"https://openalex.org/W2794009758\",\"https://openalex.org/W2883273457\",\"https://openalex.org/W2937028944\",\"https://openalex.org/W2949199479\",\"https://openalex.org/W2958715698\",\"https://openalex.org/W2969628213\",\"https://openalex.org/W2990492792\",\"https://openalex.org/W2993203507\",\"https://openalex.org/W3004910645\",\"https://openalex.org/W3007125190\",\"https://openalex.org/W3007379062\",\"https://openalex.org/W3012618288\",\"https://openalex.org/W3021194803\",\"https://openalex.org/W3042112718\",\"https://openalex.org/W3092895195\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112564761\",\"https://openalex.org/W3122036581\",\"https://openalex.org/W3158405116\",\"https://openalex.org/W3209336550\",\"https://openalex.org/W4206641356\",\"https://openalex.org/W4210376981\",\"https://openalex.org/W4220656556\",\"https://openalex.org/W4220925932\",\"https://openalex.org/W4223525754\",\"https://openalex.org/W4223957063\",\"https://openalex.org/W4239113008\",\"https://openalex.org/W4281807685\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4313481725\",\"https://openalex.org/W6996063274\"],\"authorships\":[{\"id\":\"https://openalex.org/A5088486140\",\"display_name\":\"Ruzmayuddin Mamat\",\"orcid\":\"https://orcid.org/0000-0002-1502-9178\"},{\"id\":\"https://openalex.org/A5103033945\",\"display_name\":\"Rusdi Abd Rashid\",\"orcid\":\"https://orcid.org/0000-0002-1295-7382\"},{\"id\":\"https://openalex.org/A5087101827\",\"display_name\":\"Maw Shin Sim\",\"orcid\":\"https://orcid.org/0000-0002-7848-0775\"},{\"id\":\"https://openalex.org/A5078007283\",\"display_name\":\"Baharudin Ibrahim\",\"orcid\":\"https://orcid.org/0000-0001-8534-2517\"},{\"id\":\"https://openalex.org/A5063680373\",\"display_name\":\"Suzaily Wahab\",\"orcid\":\"https://orcid.org/0000-0003-3815-4489\"},{\"id\":\"https://openalex.org/A5083324635\",\"display_name\":\"Azmir Ahmad\",\"orcid\":\"https://orcid.org/0000-0002-3344-4367\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S93508928\",\"source_display_name\":\"Journal of Addictive Diseases\",\"landing_page_url\":\"http://dx.doi.org/10.1080/10550887.2023.2240932\",\"is_oa\":false}}", "topic_tags": "Addiction,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4385564685" }, { "id": 1420, "title": "Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.", "normalized_title": "psychedelic medicines for end of life care pipeline clinical trial review 2022", "authors": "Jing X, Hoeh NR, Menkes DB.", "abstract": "ObjectivesPeople with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated interest in the therapeutic use of psychedelics at end of life. Much uncertainty remains, however, mainly due to methodological difficulties that beset existing trials. We conducted a scoping review of pipeline clinical trials of psychedelic treatment for depression, anxiety, and existential distress at end of life.MethodsProposed, registered, and ongoing trials were identified from 2 electronic databases (ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform). Recent reviews and both commercial and non-profit organization websites were used to identify additional unregistered trials.ResultsIn total, 25 studies were eligible, including 13 randomized controlled trials and 12 open-label trials. Three trials made attempts beyond randomization to assess expectancy and blinding effectiveness. Investigational drugs included ketamine (n = 11), psilocybin (n = 10), 3,4-methylenedioxymethamphetamine (n = 2), and lysergic acid diethylamide (n = 2). Three trials involved microdosing, and fifteen trials incorporated psychotherapy.Significance of resultsA variety of onging or upcoming clinical trials are expected to usefully extend evidence regarding psychedelic-assisted group therapy and microdosing in the end-of-life setting. Still needed are head-to-head comparisons of different psychedelics to identify those best suited to specific indications and clinical populations. More extensive and rigorous studies are also necessary to better control expectancy, confirm therapeutic findings and establish safety data to guide the clinical application of these novel therapies.", "journal": null, "publication_date": "2023-07-31", "publication_year": 2023, "doi": "10.1017/s147895152300069x", "pubmed_id": "37334486", "source_url": "https://doi.org/10.1017/s147895152300069x", "keywords": "Humans, Death, Lysergic Acid Diethylamide, Hallucinogens, Terminal Care, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37334486\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Microdosing,Clinical Trial,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1413, "title": "Psychedelic drugs in the treatment of psychiatric disorders.", "normalized_title": "psychedelic drugs in the treatment of psychiatric disorders", "authors": "Ibrahim IB, Videbech P, Straszek SPV.", "abstract": "This review aims at RCT's of psychedelics used in the treatment of depression and PTSD. Psilocybin has shown an antidepressant effect in cancer patients that was sustained at 6- and 12-months follow-up. The effect of psilocybin was comparable to escitalopram in one study. Ketamine has shown effect for the treatment of resistant depression. Phase 2 and 3 trials have shown the effect of MDMA on PTSD. No serious adverse events were reported in controlled settings, but larger studies are needed to establish safety and long-term effects.", "journal": null, "publication_date": "2023-07-31", "publication_year": 2023, "doi": null, "pubmed_id": "37615227", "source_url": "https://europepmc.org/article/MED/37615227", "keywords": "Humans, Ketamine, Hallucinogens, Mental Disorders, Psilocybin, Escitalopram", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"37615227\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Clinical Trial,Randomized Controlled Trial,Review Article,Cancer Patients,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3519, "title": "The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study", "normalized_title": "the efficacy and tolerability of psilocybin in participants with treatment resistant depression a phase 2 randomized feasibility study", "authors": "Brain and Cognition Discovery Foundation", "abstract": "The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study. This randomized clinical trial will assess the feasibility, safety, and efficacy of single and repeat doses of psilocybin at point-of-care in persons with treatment-resistant depression as part of major depressive disorder or bipolar II disorder. The primary objective is to evaluate the feasibility of psilocybin in adults with treatment-resistant depression. The secondary objectives are to assess the efficacy and tolerability of psilocybin at point-of-care.", "journal": "ClinicalTrials.gov", "publication_date": "2023-07-26", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05029466", "keywords": "Treatment Resistant Depression, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05029466\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3279, "title": "“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance", "normalized_title": "why would you open someone s brain up lived experience insights inform a psilocybin assisted psychotherapy treatment manual for body image disturbance", "authors": "Finkelstein C, Soha O, Roy A, Phillipou A, Rossell S.", "abstract": "Abstract Background: Body Image Disturbance (BID) is the distorted experience of one’s body. BID presents a risk for the onset, maintenance and relapse of body dysmorphic disorder and eating disorders, including anorexia nervosa (AN). Current treatments tend to focus on the cognitive and behavioural aspects while overlooking the perceptual symptoms and BID frequently persists beyond physical recovery. Psilocybin-assisted psychotherapy (PAP) may bridge the gap in current BID treatments by addressing perceptual and affective symptoms. This study sought to inform the development of a PAP treatment manual for BID in AN, through a co-design process informed by individuals with lived/living experience of AN. Methods: A Lived Experience Panel (LEAP) comprising six adult women who had a lived or living experience of AN and associated BID were presented with the proposed treatment protocol, including therapeutic interventions, and invited to provide feedback. An experiential, relativist framework informed reflexive thematic analysis of the LEAP data. Results: Reflexive thematic analysis of the LEAP data identified three central themes: enduring uncertainty; managing internal experience, and ambivalence in recovery. The LEAP also proposed strategies to address the challenges they identified and enhance the treatment manual more broadly. Conclusions: The LEAP identified challenges associated with intolerance of uncertainty, harm avoidance, alexithymia, and interoceptive impairment. The LEAP provided feedback that directly informed adaptations to the PAP treatment manual, including graduated interventions, the inclusion of nominated supports, and comprehensive psychoeducation for participants and their supports. Accordingly, a PAP treatment manual to treat BID for individuals with AN has been developed through lived experience co-design.", "journal": "Research Square", "publication_date": "2023-07-26", "publication_year": 2023, "doi": "10.21203/rs.3.rs-3189970/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-3189970/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR698832\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Eating Disorders,Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3470, "title": "An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.", "normalized_title": "an open label pragmatic feasibility study on a resilience focused community of practice program with psilocybin assisted therapy pat for end of life patients", "authors": "The Roots to Thrive Society for Psychedelic Therapy", "abstract": "The purpose of the study is to understand the feasibility of a resilience focused community of practice program that includes psilocybin-assisted therapy for End-of-Life Distress. The community of practice refers to a research informed group therapy process that runs over a 10-week period of time and includes one group administered psilocybin-assisted therapy session. Target population: The treatment team will treat a total of 64 patients who have: * a terminal diagnosis (experiencing end of life distress), * AND who are eligible for the RTT + Psilocybin-assisted Therapy Treatment program through the RTT Society. Treatment will take place at the Snuneymuxw Traditional Medicines Clinic, 1984 Woobank Rd, Nanaimo, B.C.Research data will be coordinated and held through RedCap, hosted by Island Health. Data collection centres on 1) understanding the feasibility; 2) collecting safety data; 3) exploring the mental health impacts of a community of practice as the vessel for psilocybin-assisted therapy for those with end-of-life distress. There is a mixed method approach for data collection, including: * Collect attendance * Biomedical measures taken during psilocybin sessions (blood pressure, pulse, medications to manage side effects). * Quantitative Health and Wellness Questionnaires of participants before, within, immediately after, and six months after completion. * Qualitative Surveys and Exit Interviews.", "journal": "ClinicalTrials.gov", "publication_date": "2023-07-24", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05958758", "keywords": "End of Life, Psilocybin-assisted therapy within a community of practice model (group administered), UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05958758\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "End-of-Life Distress,Wellbeing,Resilience,Observational Study,Safety,Adverse Events", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1390, "title": "Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.", "normalized_title": "assessing the risk of symptom worsening in psilocybin assisted therapy for depression a systematic review and individual participant data meta analysis", "authors": "Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, Erritzoe D, Goldberg SB.", "abstract": "We conducted a meta-analysis using individual participant data from three, two-dose psilocybin trials for depression (N = 102) with the aim of assessing the risk of symptom worsening. Clinically significant symptom worsening occurred for a minority of participants in the psilocybin and escitalopram conditions (∼10%) and for a majority of participants in the waitlist condition (63.6%). Using data from the two trials with control arms, the psilocybin arm showed a lower likelihood of symptom worsening versus waitlist, and no difference in the likelihood of symptom worsening versus escitalopram. The limitation of a relatively small sample size should be addressed in future studies.", "journal": null, "publication_date": "2023-07-22", "publication_year": 2023, "doi": "10.1016/j.psychres.2023.115349", "pubmed_id": "37523886", "source_url": "https://doi.org/10.1016/j.psychres.2023.115349", "keywords": "Humans, Hallucinogens, Sample Size, Depression, Symptom Flare Up, Psilocybin, Escitalopram", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37523886\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3143, "title": "Psilocybin as an antidepressant strategy - a review of safety aspects", "normalized_title": "psilocybin as an antidepressant strategy a review of safety aspects", "authors": "Zeiss R.", "abstract": "Introduction Psilocybin is considered a classical psychedelic and is increasingly attracting scientific and media attention as an alternative approach to the treatment of various mental disorders. Apart from its efficacy, an important question is the tolerability and safety of psilocybin in general and in a controlled environment. Accurate knowledge of drug safety aspects might be essential for applicability in clinical practice and for drug adherence. Objectives This paper aims to provide an overview of drug safety aspects of psilocybin. Methods A narrative review was conducted. The literature search was conducted using the bibliographic database MEDLINE. Results The literature search of papers published in recent years showed no serious side effects under psilocybin in controlled study conditions. Common reported ADRs were headache, gastrointestinal complaints such as nausea, diarrhoea and vomiting, tachycardia and arterial hypertension. The lethal dose of psilocybin is many times higher than the therapeutic dose and overdose deaths have not been identified. An often mentioned problem is the occurrence of hallucinogenic persisting perception disorder (HPPD) which, however, did not occur in the studies examined and is most likely to be a problem in the context of recreational use. The results on the safety of psilocybin must be regarded as preliminary; in the studies conducted, risk populations were predominantly excluded, which is, however, relevant for everyday clinical practice. The risk of delusional experiences and so-called “bad trips” is also a relevant safety risk, as it can be associated with risky behaviours. However, these would also be observed more in the area of recreational use. Conclusions The use of psilocybin in rigorously controlled study designs appears to be predominantly safe and without serious side effects. At the same time, it should be noted that the results must be considered preliminary and many questions remain open. Many of the risks are more likely to occur in uncontrolled recreational use of psilocybin. At the same time, we see a certain risk in the use of a substance associated with high expectations and a certain “fame” that, without appropriate regulations, the boundaries between sensible therapeutic use and abusive use could become blurred and permeable. Disclosure of Interest None Declared", "journal": null, "publication_date": "2023-07-18", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC10405689", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PMC10405689\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Headache / Migraine,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3422, "title": "A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions", "normalized_title": "a systematic review of reporting practices in psychedelic clinical trials psychological support therapy and psychosocial interventions", "authors": "", "abstract": "Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PI) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called “psychological support,” “monitoring,” “psychedelic-assisted therapy,” or “psychedelic-assisted psychotherapy.” A brief review of recent research, historical studies, safety considerations, and participant perspectives suggest that PI has a substantive and critical impact on treatment outcomes. Methods: This systematic review examines the reporting practices of PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist. Results: 33 published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report if their intervention used a therapy manual, 67% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI. Discussion: The study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.", "journal": "PsyArXiv", "publication_date": "2023-07-17", "publication_year": 2023, "doi": "10.1089/psymed.2023.00071", "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/2ab59_v1", "keywords": "clinical trials, psychedelic-assisted therapy, psychosocial interventions, reporting practices, treatment outcomes, Psychiatry, Meta-science", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:04:24", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"2ab59_v1\",\"version\":1,\"reviews_state\":\"withdrawn\"}", "topic_tags": "Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3380, "title": "A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions", "normalized_title": "a systematic review of reporting practices in psychedelic clinical trials psychological support therapy and psychosocial interventions", "authors": "Brennan B, Kelman A, Belser AB.", "abstract": "Background: Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychosocial interventions (PI) in clinical trials of psychedelic treatment due in part to deficiencies in reporting practices found in the existing literature. These PI include non-drug support or interventions provided by psychotherapists or facilitators during all phases of treatment, sometimes called “psychological support,” “monitoring,” “psychedelic-assisted therapy,” or “psychedelic-assisted psychotherapy.” A brief review of recent research, historical studies, safety considerations, and participant perspectives suggest that PI has a substantive and critical impact on treatment outcomes. Methods: This systematic review examines the reporting practices of PI in published clinical trial results. The review employs a search of PubMed/Medline and PSYCinfo databases to identify relevant articles. It includes quantitative clinical studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) or empathogenic drugs (MDMA) since 2000. The analytic approach follows a modified version of assessment items based on CONSORT extension statement and TIDieR checklist. Results: 33 published psychedelic clinical trials met criteria. The review reveals that many published reports on psychedelic clinical trials did not report basic aspects of the intervention: 33% did not report the number of sessions, 45% did not report the duration of sessions, 42% did not report provider credentials, 52% did not report if their intervention used a therapy manual, 67% did not reference a manual that was available to readers, and 82% did not report that they assessed treatment fidelity. A comparison with non-psychedelic trials shows that psychedelic trial reports underreport on key items related to PI. Discussion: The study highlights the problems of underreporting and the importance of improving reporting practices regarding PI in psychedelic clinical trials to enhance research standardization and improve treatment outcomes. Recommendations for improving reporting practices are provided.", "journal": "PsyArXiv", "publication_date": "2023-07-17", "publication_year": 2023, "doi": "10.31234/osf.io/2ab59", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/2ab59", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR694477\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3217, "title": "Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour", "normalized_title": "administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour", "authors": "Nkadimeng SM, Hay L, Steinmann CM, Eloff JN.", "abstract": "Abstract Background Psilocybin-containing mushrooms induce antidepressant and momentary increase in blood pressure (BP) with potential risk to users with cardiovascular diseases. Irregularities in nitric oxide (NO) levels play a key role in endothelial dysfunctions leading to increases in BP. Mushrooms species show large variation in potency which may potentially induce different outcomes and mechanisms of action. Effects of the mushrooms on the endothelial nitric oxide synthase activity is not known. Aim To investigate safety and effects of administration of four psilocybin-containing mushroom species, Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis and Psilocybe cubesis leucistic A + strain, on acute haemodynamic and LV parameters in normal Wistar rat and on serotonin, NO levels and endothelial NO synthase (eNOS) activity in vivo and in vitro on H9C2 cardiomyocytes. Methods Mushrooms were extracted with hot-boiling water and administered (5 mg/kg) through a direct catheterization in anaesthetized rats. Nuzak (0.2 mg/kg) and Nω-Nitro-L-arginine methyl ester hydrochloride (LNAME) were used as positive controls and negative control group given saline. Levels of serotonin, NO and eNOS activities were measured after 1-hour treatment. Results Mushroom treatments incited non-significant increase in LV parameters peaks only after 20 minutes and not immediate like with LNAME. Mushrooms induced a significant increase in serotonin levels and a suppressing effect on the eNOS activity in vivo in rats and in vitro in cardiomyocytes. Conclusion Mushroom treatments were safe on the LV function and induced a significant serotonin level with the concentration investigated. Disturbance in eNOS pathways may be the underlying mechanism involved in the psilocybin-mushroom extracts to inducing temporary BP increase. The four mushrooms exhibited different cardiac effects indicating variations depending on mushroom species.", "journal": "Research Square", "publication_date": "2023-07-17", "publication_year": 2023, "doi": "10.21203/rs.3.rs-3088850/v1", "pubmed_id": null, "source_url": "https://doi.org/10.21203/rs.3.rs-3088850/v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR693606\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Receptor Pharmacology,Animal Study,In Vitro Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1393, "title": "Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication", "normalized_title": "psilocybin for treatment resistant depression in patients taking a concomitant ssri medication", "authors": "Guy M. Goodwin, Megan Croal, David Feifel, John R. Kelly, Lindsey Marwood, Sunil Mistry, Veronica O’Keane, Stéphanie Knatz Peck, Hollie Simmons, Claudia Sisa, S. C. Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskaia", "abstract": "Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety, tolerability, and efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective serotonin reuptake inhibitor in participants with TRD. Participants received a single 25 mg dose of psilocybin alongside psychological support and were followed-up for 3 weeks. The primary efficacy end point was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from Baseline at Week 3. Secondary end points were safety, including treatment-emergent adverse events (TEAEs), the proportion of responders and remitters at Week 3, and the change from Baseline to Week 3 in Clinical Global Impression-Severity (CGI-S) score. Nineteen participants were dosed and the mean Baseline MADRS total score was 31.7 (SD = 5.77). Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset. There were no serious TEAEs or indication of increased suicidal ideation or behavior. At Week 3, mean change from Baseline in MADRS total score was -14.9 (95% CI, -20.7 to -9.2), and -1.3 (SD = 1.29) in the CGI-S. Both response and remission were evident in 8 (42.1%) participants. Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.", "journal": "Neuropsychopharmacology", "publication_date": "2023-07-12", "publication_year": 2023, "doi": "10.1038/s41386-023-01648-7", "pubmed_id": "37443386", "source_url": "https://doi.org/10.1038/s41386-023-01648-7", "keywords": "Psilocybin, Clinical Global Impression, Tolerability, Adverse effect, Treatment-resistant depression, Psychology, Antidepressant, Major depressive episode, Serotonin reuptake inhibitor, Paroxetine, Clinical trial, Clinical endpoint, Medicine, Internal medicine, Psychiatry, Hallucinogen, Placebo, Anxiety, Cognition, Pathology, Alternative medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4384130479\",\"openalex_url\":\"https://openalex.org/W4384130479\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":165,\"referenced_works\":[\"https://openalex.org/W1742833546\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1979534890\",\"https://openalex.org/W1990166011\",\"https://openalex.org/W2002554882\",\"https://openalex.org/W2006625863\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2020187443\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2069138677\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2078389180\",\"https://openalex.org/W2083894864\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2108984307\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2148905283\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2245231029\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2913453568\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2914444775\",\"https://openalex.org/W3000661394\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3127909847\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4200117112\",\"https://openalex.org/W4200627112\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4254230094\",\"https://openalex.org/W4281784879\",\"https://openalex.org/W4291162385\",\"https://openalex.org/W4292994367\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W7074234824\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037628078\",\"display_name\":\"Guy M. Goodwin\",\"orcid\":\"https://orcid.org/0000-0002-1426-2816\"},{\"id\":\"https://openalex.org/A5072218538\",\"display_name\":\"Megan Croal\",\"orcid\":\"https://orcid.org/0000-0002-3286-1003\"},{\"id\":\"https://openalex.org/A5000063591\",\"display_name\":\"David Feifel\",\"orcid\":\"https://orcid.org/0000-0002-8185-0220\"},{\"id\":\"https://openalex.org/A5046590180\",\"display_name\":\"John R. Kelly\",\"orcid\":\"https://orcid.org/0000-0002-9545-0615\"},{\"id\":\"https://openalex.org/A5080462431\",\"display_name\":\"Lindsey Marwood\",\"orcid\":\"https://orcid.org/0000-0002-5818-2199\"},{\"id\":\"https://openalex.org/A5108850316\",\"display_name\":\"Sunil Mistry\",\"orcid\":null},{\"id\":\"https://openalex.org/A5020131072\",\"display_name\":\"Veronica O’Keane\",\"orcid\":\"https://orcid.org/0000-0002-1519-099X\"},{\"id\":\"https://openalex.org/A5011897192\",\"display_name\":\"Stéphanie Knatz Peck\",\"orcid\":\"https://orcid.org/0000-0001-9421-9158\"},{\"id\":\"https://openalex.org/A5030406378\",\"display_name\":\"Hollie Simmons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077910544\",\"display_name\":\"Claudia Sisa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5019711791\",\"display_name\":\"S. C. Stansfield\",\"orcid\":null},{\"id\":\"https://openalex.org/A5103816856\",\"display_name\":\"Joyce Tsai\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111726730\",\"display_name\":\"Sam Williams\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021278348\",\"display_name\":\"Ekaterina Malievskaia\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S175030738\",\"source_display_name\":\"Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1038/s41386-023-01648-7\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Receptor Pharmacology,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4384130479" }, { "id": 3755, "title": "Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin", "normalized_title": "psychoactive substances in psychotherapy a vision for the future a systematic review on psilocybin", "authors": "Tetem J, Fischmann T, Möller TJ.", "abstract": "This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and depressive states related to life-threatening cancer, as well as treatment-resistant depression. A rapid clinical improvement of various symptoms was observed. The greatest evidence for the use of psilocybin was found in treating tobacco addiction and anxiety and depression related to life-threatening illnesses. No serious adverse events were reported in the studies. However, current studies have limitations, such as small sample sizes, difficulties with blinding, and a treatment population considered non-representative. The results are not representative but provide indications of effective treatment and are a starting point for further studies.", "journal": "PsyArXiv", "publication_date": "2023-07-05", "publication_year": 2023, "doi": "10.31234/osf.io/ztyxh", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/ztyxh", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:19", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"PPR688396\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3161, "title": "Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin", "normalized_title": "psychoactive substances in psychotherapy a vision for the future a systematic review on psilocybin", "authors": "", "abstract": "This work is a literature review on the use of psilocybin in psychotherapeutic treatment of mental illnesses. The review answers the question of what opportunities and risks are associated with the use of the psychoactive substance psilocybin. Peer-reviewed studies between 2017 and 2022 were included. Nine studies were found regarding the following indications: tobacco addiction, anxiety and depressive states related to life-threatening cancer, as well as treatment-resistant depression. A rapid clinical improvement of various symptoms was observed. The greatest evidence for the use of psilocybin was found in treating tobacco addiction and anxiety and depression related to life-threatening illnesses. No serious adverse events were reported in the studies. However, current studies have limitations, such as small sample sizes, difficulties with blinding, and a treatment population considered non-representative. The results are not representative but provide indications of effective treatment and are a starting point for further studies.", "journal": "PsyArXiv", "publication_date": "2023-07-05", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/ztyxh_v1", "keywords": "depression, hallucinogens, mental health, Psilocybin, psychedelics, psychotherapy, review, systematic review, Psychiatry, Meta-science, Neuroscience, Computational Neuroscience, Life Sciences, Systems Neuroscience, Clinical Neuroscience", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"ztyxh_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Systematic Review,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1438, "title": "Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.", "normalized_title": "risk of bias in randomized clinical trials on psychedelic medicine a systematic review", "authors": "Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ.", "abstract": "BackgroundThe classical psychedelics, psilocybin, peyote, ayahuasca/N,N-dimethyltryptamine, and lysergic acid diethylamide are considered promising new treatments for psychiatric illnesses, such as depression, anxiety, addiction, and obsessive-compulsive disorders. However, their profound and characteristic subjective effects raise concern for distinctive biases in randomized clinical trials.MethodsWe performed a systematic literature search to identify all clinical trials on classical psychedelics with patient populations to examine descriptive data and determine the risk of bias. Two independent reviewers searched three databases (PubMed, Embase, and APA PsycNet) and extracted information on study design, study population, use of active or inactive placebo, dropouts, evaluation of blinding of intervention, and reporting of expectancy and therapeutic alliance.ResultsWe included 10 papers reporting on 10 unique trials. The trials generally included populations that were predominantly white and highly educated. The trials had small samples and considerable dropout. Blinding was either unsuccessful or not reported regardless of type of placebo. Few trials published protocols, statistical analysis plans (SAPs), and outcomes relating to psychotherapy fidelity. All trials but one were rated as high risk of bias.ConclusionSuccessful blinding of intervention is a significant challenge in this field. To better accommodate this, we suggest that future trials use a parallel-group design and utilize an active placebo on a psychedelic-naïve population. Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.", "journal": null, "publication_date": "2023-07-03", "publication_year": 2023, "doi": "10.1177/02698811231180276", "pubmed_id": "37403379", "source_url": "https://doi.org/10.1177/02698811231180276", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Anxiety Disorders, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37403379\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,OCD,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Healthcare Workers,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1439, "title": "Psilocybin's effects on cognition and creativity: A scoping review.", "normalized_title": "psilocybin s effects on cognition and creativity a scoping review", "authors": "Bonnieux JN, VanderZwaag B, Premji Z, Garcia-Romeu A, Garcia-Barrera MA.", "abstract": "BackgroundResearch on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psilocybin's effects on mental health are promising and there are ongoing efforts to investigate its clinical implementation and its effects on cognition.AimsThe purpose of this study is to report trends in publications, methods, and findings from research examining the effects of psilocybin on cognition and creativity in adults.MethodsWe conducted an Open Science Framework preregistered scoping review, guided by the JBI Manual for Evidence Synthesis, on literature pertaining to psilocybin's effects on cognition and creativity.Results/outcomesIn the 42 included studies, psilocybin was primarily administered orally (83%) in a bodyweight-adjusted manner (74%) to healthy participants (90%). Of the few studies that explicitly reported safety outcomes (26%), only one reported serious adverse reactions. During the acute phase post-intake (i.e., minutes to hours), macrodoses tended to impair cognitive performance and creativity, whereas microdoses tended toward creative enhancement. The few macrodosing studies that included post-acute measures (i.e., 1-85 days) reported primarily null but some positive effects.Conclusions/interpretationThis scoping review identified a time-based variation of psilocybin macrodosing effects on cognition and creativity, in which impairment may be observed early post-intake but withdraw over time, and some positive effects may emerge afterward. These findings are limited by methodological concerns and inadequate assessment of long-term effects. We therefore recommend that future psilocybin research be conducted according to existing guidelines and include well-validated measures of cognition and creativity at multiple timepoints.", "journal": null, "publication_date": "2023-07-02", "publication_year": 2023, "doi": "10.1177/02698811231179801", "pubmed_id": "37395359", "source_url": "https://doi.org/10.1177/02698811231179801", "keywords": "Humans, Hallucinogens, Mental Health, Cognition, Adult, Creativity, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"37395359\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Microdosing,Creativity,Review Article,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1434, "title": "Assessing potential of psilocybin for depressive disorders.", "normalized_title": "assessing potential of psilocybin for depressive disorders", "authors": "Kozak Z, Johnson MW, Aaronson ST.", "abstract": "IntroductionThere has been increasing interest in the role psilocybin may play in the treatment of depressive disorders. Several clinical trials have shown psilocybin to have efficacy in reducing symptoms of depression.AreascoveredWe discuss the current understanding of psilocybin's therapeutic mechanism of action and review existing clinical data investigating psilocybin as a novel therapeutic agent for the treatment of depression.Expert opinionThere is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.", "journal": null, "publication_date": "2023-06-30", "publication_year": 2023, "doi": "10.1080/13543784.2023.2273493", "pubmed_id": "37869790", "source_url": "https://doi.org/10.1080/13543784.2023.2273493", "keywords": "Humans, Hallucinogens, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37869790\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1427, "title": "Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial", "normalized_title": "psilocybin for treatment resistant depression without psychedelic effects study protocol for a 4 week double blind proof of concept randomised controlled trial", "authors": "Muhammad Ishrat Husain, Daniel M. Blumberger, David Castle, Nicole Ledwos, Elise Fellows, Brett D. M. Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D. Rosenblat, Benoit H. Mulsant", "abstract": "BACKGROUND: Randomised controlled trials (RCTs) of psilocybin have reported large antidepressant effects in adults with major depressive disorder and treatment-resistant depression (TRD). Given psilocybin's psychedelic effects, all published studies have included psychological support. These effects depend on serotonin 2A (5-HT2A) receptor activation, which can be blocked by 5-HT2A receptor antagonists like ketanserin or risperidone. In an animal model of depression, ketanserin followed by psilocybin had similar symptomatic effects as psilocybin alone. AIMS: To conduct a proof-of-concept RCT to (a) establish feasibility and tolerability of combining psilocybin and risperidone in adults with TRD, (b) show that this combination blocks the psychedelic effects of psilocybin and (c) provide pilot data on the antidepressant effect of this combination (compared with psilocybin alone). METHOD: In a 4-week, three-arm, 'double dummy' trial, 60 adults with TRD will be randomised to psilocybin 25 mg plus risperidone 1 mg, psilocybin 25 mg plus placebo, or placebo plus risperidone 1 mg. All participants will receive 12 h of manualised psychotherapy. Measures of feasibility will include recruitment and retention rates; tolerability and safety will be assessed by rates of drop-out attributed to adverse events and rates of serious adverse events. The 5-Dimensional Altered States of Consciousness Rating Scale will be a secondary outcome measure. RESULTS: This trial will advance the understanding of psilocybin's mechanism of antidepressant action. CONCLUSIONS: This line of research could increase acceptability and access to psilocybin as a novel treatment for TRD without the need for a psychedelic experience and continuous monitoring.", "journal": "BJPsych Open", "publication_date": "2023-06-30", "publication_year": 2023, "doi": "10.1192/bjo.2023.535", "pubmed_id": "37489299", "source_url": "https://doi.org/10.1192/bjo.2023.535", "keywords": "Psilocybin, Tolerability, Risperidone, Hallucinogen, Psychology, Adverse effect, Placebo, Antidepressant, Randomized controlled trial, Psychiatry, Pharmacology, Treatment-resistant depression, Medicine, Internal medicine, Schizophrenia (object-oriented programming), Anxiety, Pathology, Alternative medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4385230722\",\"openalex_url\":\"https://openalex.org/W4385230722\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":41,\"referenced_works\":[\"https://openalex.org/W183123008\",\"https://openalex.org/W1742833546\",\"https://openalex.org/W1991333985\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2005536744\",\"https://openalex.org/W2011148606\",\"https://openalex.org/W2020646491\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2059916690\",\"https://openalex.org/W2062339243\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2078202556\",\"https://openalex.org/W2082494913\",\"https://openalex.org/W2108696783\",\"https://openalex.org/W2109935313\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2140815719\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2165673785\",\"https://openalex.org/W2169442707\",\"https://openalex.org/W2170904543\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2481029616\",\"https://openalex.org/W2626759055\",\"https://openalex.org/W2795594181\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2808857229\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W2981767691\",\"https://openalex.org/W3034152700\",\"https://openalex.org/W3086247180\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3159976828\",\"https://openalex.org/W3161972106\",\"https://openalex.org/W3207135103\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4223456429\",\"https://openalex.org/W4236805817\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4292528167\",\"https://openalex.org/W4301392523\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4319984222\",\"https://openalex.org/W6607541484\",\"https://openalex.org/W6637656337\",\"https://openalex.org/W6782785839\",\"https://openalex.org/W6849190221\"],\"authorships\":[{\"id\":\"https://openalex.org/A5078217449\",\"display_name\":\"Muhammad Ishrat Husain\",\"orcid\":\"https://orcid.org/0000-0001-5771-5750\"},{\"id\":\"https://openalex.org/A5003880874\",\"display_name\":\"Daniel M. Blumberger\",\"orcid\":\"https://orcid.org/0000-0002-8422-5818\"},{\"id\":\"https://openalex.org/A5052884442\",\"display_name\":\"David Castle\",\"orcid\":\"https://orcid.org/0000-0002-3075-1580\"},{\"id\":\"https://openalex.org/A5051154946\",\"display_name\":\"Nicole Ledwos\",\"orcid\":\"https://orcid.org/0000-0002-8604-3313\"},{\"id\":\"https://openalex.org/A5031986806\",\"display_name\":\"Elise Fellows\",\"orcid\":\"https://orcid.org/0009-0002-3649-3882\"},{\"id\":\"https://openalex.org/A5079504997\",\"display_name\":\"Brett D. M. Jones\",\"orcid\":\"https://orcid.org/0000-0003-3248-1059\"},{\"id\":\"https://openalex.org/A5077520656\",\"display_name\":\"Abigail Ortiz\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047723483\",\"display_name\":\"Stefan Kloiber\",\"orcid\":\"https://orcid.org/0000-0002-6838-4114\"},{\"id\":\"https://openalex.org/A5100391883\",\"display_name\":\"Wei Wang\",\"orcid\":\"https://orcid.org/0000-0002-1430-1360\"},{\"id\":\"https://openalex.org/A5050740394\",\"display_name\":\"Joshua D. Rosenblat\",\"orcid\":\"https://orcid.org/0000-0002-4773-2191\"},{\"id\":\"https://openalex.org/A5019562259\",\"display_name\":\"Benoit H. Mulsant\",\"orcid\":\"https://orcid.org/0000-0002-0303-6450\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764831659\",\"source_display_name\":\"BJPsych Open\",\"landing_page_url\":\"https://doi.org/10.1192/bjo.2023.535\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Pharmacology,Receptor Pharmacology,Consciousness,Randomized Controlled Trial,Animal Study,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4385230722" }, { "id": 1394, "title": "Clinical specificity profile for novel rapid acting antidepressant drugs.", "normalized_title": "clinical specificity profile for novel rapid acting antidepressant drugs", "authors": "Scala M, Fanelli G, De Ronchi D, Serretti A, Fabbri C.", "abstract": "Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric acid, orexin, and other receptors, providing a broader range of pharmacodynamic mechanisms, that is, expected to increase the possibility of personalizing treatments on the individual clinical profile. These new drugs were developed with the aim of combining a rapid action, a tolerable profile, and higher effectiveness on specific symptoms, which were relatively poorly targeted by standard antidepressants, such as anhedonia and response to reward, suicidal ideation/behaviours, insomnia, cognitive deficits, and irritability. This review discusses the clinical specificity profile of new antidepressants, namely 4-chlorokynurenine (AV-101), dextromethorphan-bupropion, pregn-4-en-20-yn-3-one (PH-10), pimavanserin, PRAX-114, psilocybin, esmethadone (REL-1017/dextromethadone), seltorexant (JNJ-42847922/MIN-202), and zuranolone (SAGE-217). The main aim is to provide an overview of the efficacy/tolerability of these compounds in patients with mood disorders having different symptom/comorbidity patterns, to help clinicians in the optimization of the risk/benefit ratio when prescribing these drugs.", "journal": null, "publication_date": "2023-06-29", "publication_year": 2023, "doi": "10.1097/yic.0000000000000488", "pubmed_id": "37381161", "source_url": "https://doi.org/10.1097/yic.0000000000000488", "keywords": "Humans, Sleep Initiation and Maintenance Disorders, Bupropion, Antidepressive Agents, Comorbidity, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37381161\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Mechanism of Action,Receptor Pharmacology,Review Article,Healthcare Workers,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3538, "title": "Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder", "normalized_title": "investigating the therapeutic effects of psilocybin in treatment resistant post traumatic stress disorder", "authors": "Halucenex Life Sciences Inc.", "abstract": "Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD. Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline. These selective serotonin reuptake inhibitors (SSRIs) have limited efficacy. Furthermore, there is a lack of efficacious pharmacotherapy for treatment-resistant PTSD; PTSD remains a chronic and sometimes debilitating condition. New research into other treatment options for PTSD are warranted. Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Psilocybin has received breakthrough designation for treatment of depression. Research on psilocybin has shown that it facilitates fear extinction in mice and promotes neuroplasticity, increasing neurogenesis, spinogenesis and synaptogenesis. These properties may contribute to antidepressive and anxiolytic effects. Psilocybin also reduces activity in the amygdala during threat responses; decreased amygdala reactivity is correlated with positive mood. This is particularly relevant since individuals with PTSD showed increased reactivity in the amygdala, which may increase the ability to process traumatic memories. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.", "journal": "ClinicalTrials.gov", "publication_date": "2023-06-28", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05243329", "keywords": "Treatment Resistant Disorders, Post Traumatic Stress Disorder, Psilocybin, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05243329\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,PTSD,Neuroplasticity,Neurogenesis,Receptor Pharmacology,Clinical Trial,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1365, "title": "Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.", "normalized_title": "psychedelics in the treatment of eating disorders rationale and potential mechanisms", "authors": "Calder A, Mock S, Friedli N, Pasi P, Hasler G.", "abstract": "Eating disorders are serious illnesses showing high rates of mortality and comorbidity with other mental health problems. Psychedelic-assisted therapy has recently shown potential in the treatment of several common comorbidities of eating disorders, including mood disorders, post-traumatic stress disorder, and substance use disorders. The theorized therapeutic mechanisms of psychedelic-assisted therapy suggest that it could be beneficial in the treatment of eating disorders as well. In this review, we summarize preliminary data on the efficacy of psychedelic-assisted therapy in people with anorexia nervosa, bulimia nervosa, and binge eating disorder, which include studies and case reports of psychedelic-assisted therapy with ketamine, MDMA, psilocybin, and ayahuasca. We then discuss the potential therapeutic mechanisms of psychedelic-assisted therapy in these three eating disorders, including both general therapeutic mechanisms and those which are relatively specific to eating disorders. We find preliminary evidence that psychedelic-assisted therapy may be effective in the treatment of anorexia nervosa and bulimia nervosa, with very little data available on binge eating disorder. Regarding mechanisms, psychedelic-assisted therapy may be able to improve beliefs about body image, normalize reward processing, promote cognitive flexibility, and facilitate trauma processing. Just as importantly, it appears to promote general therapeutic factors relevant to both eating disorders and many of their common comorbidities. Lastly, we discuss potential safety concerns which may be associated with these treatments and present recommendations for future research.", "journal": null, "publication_date": "2023-06-20", "publication_year": 2023, "doi": "10.1016/j.euroneuro.2023.05.008", "pubmed_id": "37352816", "source_url": "https://doi.org/10.1016/j.euroneuro.2023.05.008", "keywords": "Humans, Hallucinogens, Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Feeding and Eating Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37352816\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Addiction,Eating Disorders,Mechanism of Action,Review Article,Case Report,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3190, "title": "Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 Cardiomyocytes", "normalized_title": "cardioprotective potential of the ethanol and water extracts of four psilocybin mushrooms on angiotensin ii induced hypertrophy and oxidative stress on h9c2 cardiomyocytes", "authors": "Nkadimeng SM, Steinmann CM, Eloff JN.", "abstract": "Psilocybin-containing mushrooms, commonly known as magic mushrooms have antidepressant effect, however, their safety in cardiovascular diseases such as heart failure is not fully known and needs to be investigated. Cardiac hypertrophy is an independent risk factor for heart failure morbidity and mortality. Angiotensin II (Ang-II) plays a major role in the pathogenesis of cardiac hypertrophy. We investigated the cardiovascular safety of extracts of Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis, and Psilocybe cubensis leucistic A+ strain mushrooms, well-known psilocybin-containing mushrooms in the Panaeolus and Psilocybe genus on Ang II-induced hypertrophy oxidative stress. The four mushrooms were grown, dried and extracted with 70% ethanol, cold and hot water. Extracts were tested for cytotoxicity on H9C2 cardiomyoblast cells. The cardiomyocytes were induced with (10 µM) AngII and treated with the three extracts of the four mushrooms over 48 hours. Control cells were serum starved but neither AngII induced nor treated while AngII cells were serum starved and stimulated with AngII but not treated. Losartan, an inhibitor of AngII type 1 receptor was used as positive control. Effects of the extracts on actin-filament labelling and cell surface area, mitochondrial activity, reactive oxygen species (ROS) and atrial natriuretic peptide levels were determined. Stimulation with AngII lowered cell viability, increased the cell width measurements and intracellular ROS levels significantly compared to control cells. The results indicated that the ethanol and water extracts of the four psilocybin mushrooms did not exacerbate the angiotensin II-induced hypertrophy conditions, but the extracts had cardio-protective activity against angiotensin II-induced oxidative stress. The phytochemical analysis of the extracts confirmed detections of known compounds with antioxidant and anti-inflammatory effects in the water and ethanol extracts of these four psilocybin mushrooms.", "journal": "Preprints.org", "publication_date": "2023-06-05", "publication_year": 2023, "doi": "10.20944/preprints202306.0362.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202306.0362.v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR672264\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Mitochondrial Function,Oxidative Stress,Safety,Toxicity,Inflammation", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 4808, "title": "Psilocybin therapy: A novel approach to treating depression", "normalized_title": "psilocybin therapy a novel approach to treating depression", "authors": "Tooba Noor, Areej Shakil, Aimen Waqar Khan, Syeda Mahrukh Fatima Zaidi, Hussain Sohail Rangwala, Burhanuddin Sohail Rangwala", "abstract": "The COVID-19 pandemic has resulted in a surge in depression cases, a pervasive and debilitating mental illness1. This trend is evident in the increased prescriptions for antidepressants. Depression is a chronic condition that affects a significant proportion of the global population, with ~280 million people, or about 3.8%, suffering from it. As a result, it is a significant mental health concern worldwide2. The National Institute for Health and Care Excellence in the United Kingdom recommends medication as the primary treatment for individuals with moderate to severe depression. However, it has limitations and may yield unsatisfactory outcomes. Conversely, research suggests that psychological interventions, social support, and exercise are significant factors in addressing depression3. Treatment-resistant depression (TRD), which refers to the failure to achieve remission after multiple attempts of first-line antidepressants, is a significant limitation of pharmacotherapy. The Sequenced Therapy Alternatives to Relieve Depression experiment has demonstrated the challenge of treating TRD4. Approximately 30% of individuals receiving treatment for a severe episode of depression experience TRD, which is associated with more severe illness, increased risk of recurrence, prolonged functional impairments, medical comorbidities, and higher rates of suicidal ideation and nonsuicidal deaths5. Depression is one of the primary causes of suicide, with over 700,000 reported deaths from suicide annually. Reports from clinical experience and data from placebo-controlled trials indicate that suicidal thoughts and behaviors may increase during the initial weeks of antidepressant treatment in young adults and adolescents2. Moreover, conventional antidepressants pose challenges such as a delayed onset of action that can take up to 4 weeks or more to manifest, as well as common side effects including sexual dysfunction, loss of libido, headaches, gastrointestinal problems, anxiety, and agitation. Discontinuation of these medications and high rates of relapse are also concerns6. Hence, there is a need to review current treatment approaches and incorporate novel, fast-acting therapies that result in sustained remission. Neuroimaging research has revealed that depression is characterized by abnormal brain functioning, particularly in the default mode network, which is associated with self-awareness and tends to be overactive in depression. Other higher-order brain networks, such as the executive network and salience network, have also been linked to depression. Interestingly, the serotonin 2A (5-HT2A) receptor subtype, which is the primary binding site for traditional serotonergic psychedelic drugs like psilocybin, is highly expressed in a cortical region that closely resembles a conjunction map of the default mode network, executive network, and salience network1. Psilocybin is a naturally occurring indoleamine found in mushrooms, which rapidly breaks down in living tissue to form psilocin, the hallucinogenic component that produces psychedelic effects similar to serotonin7. In 1957, Wasson first proposed that serotonergic hallucinogens could be used to treat depression, but research on their therapeutic potential was suspended due to societal and political issues. However, in recent years, with multiple successful studies and advances in neurobiology, research on the potential therapeutic benefits of psilocybin for depression has been revived8. Over the past 15 years, at least 6 clinical trials have documented significant reductions in depression symptoms with psilocybin therapy9. One of these trials was an open-label study in TRD with pretreatment and post-treatment functional magnetic resonance imaging, which showed a reduction in brain modularity linked to improvements in depressed symptomatology10. Notably, escitalopram, a common SSRI antidepressant, did not cause any changes in modularity, suggesting that this antidepressant activity may be unique to psilocybin therapy11. Psilocybin also induces an altered consciousness or hallucinogenic experience, which is thought to play a crucial role in its therapeutic effects for depression. The psychedelic experience is believed to promote introspection, emotional processing, and insights into one’s thoughts, feelings, and behaviors, leading to increased self-awareness, changes in perception, and shifts in perspective that can result in meaningful and long-lasting changes in mood and behavior12. Psilocybin therapy for depression typically involves a structured and supervised approach, with a trained therapist providing support and guidance throughout the experience. The therapy session may also include preparatory and integrative elements to optimize the therapeutic outcome. Recent clinical trials have shown promising results, with rapid reductions in depressive symptoms observed after just 1 or 2 sessions of psilocybin-assisted therapy and sustained treatment response rates that persist for several weeks or even months after treatment13. One of the unique aspects of psilocybin therapy is its potential for a rapid onset of action, with many patients reporting improvements in mood and well-being within hours or days after a single session. This is in stark contrast to traditional antidepressant medications, which typically take weeks or even months to show significant effects. The rapid and sustained antidepressant effects of psilocybin therapy may be particularly beneficial for individuals with severe depression or TRD, who may not respond adequately to conventional treatments14. Furthermore, psilocybin therapy has been reported to be well-tolerated, with a low risk of addiction and minimal withdrawal symptoms. Unlike some traditional antidepressants, which can cause side effects such as sexual dysfunction, gastrointestinal issues, and anxiety, psilocybin therapy is generally considered to be safe and well-tolerated when administered in controlled settings by trained professionals15. Despite the promising results, it is important to note that psilocybin therapy is not without risks. The psychedelic experience induced by psilocybin can be intense and overwhelming and may not be suitable for everyone. It may also cause transient psychological distress, such as anxiety, fear, or confusion during the session. Therefore, it requires careful screening, preparation, and integration to ensure safe and optimal outcomes. In addition, the long-term effects of repeated psilocybin therapy are still unknown, and further research is needed to fully understand its safety and potential risks16. In conclusion, psilocybin therapy has shown promising results as a novel and potentially effective treatment for depression, particularly for individuals with TRD or those who do not respond adequately to traditional antidepressant medications. The rapid onset of action, sustained treatment response rates, and unique psychological effects of psilocybin therapy make it a compelling option for further research and exploration in the field of mental health. However, it is important to approach psilocybin therapy with caution, ensuring proper screening, preparation, and integration, and further research is needed to fully understand its safety, optimal dosages, and long-term effects. Psilocybin therapy may represent a paradigm shift in the treatment of depression, but it should only be administered in controlled settings by trained professionals as part of an integrated treatment approach. Ethical approval Not applicable. Sources of funding None. Author contribution The conceptualization was done by TN and BSR. The literature and drafting of the manuscript were conducted by TN, AS, AWK, SMFZ and HSR. The editing and supervision were performed by BSR. All authors have read and agreed to the final version of the manuscript. Conflict of interest disclosures The authors declare that they have no financial conflict of interest with regard to the content of this report. Research registration unique identifying number (UIN) Not applicable. Guarantor All authors take responsibility for the work, access to data and decision to publish.", "journal": "International Journal of Surgery Global Health", "publication_date": "2023-06-01", "publication_year": 2023, "doi": "10.1097/gh9.0000000000000175", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1097/gh9.0000000000000175", "keywords": "Depression (economics), Psychiatry, Suicidal ideation, Medicine, Mental health, Antidepressant, Treatment-resistant depression, Medical prescription, Pharmacotherapy, Population, Psychological intervention, Suicide prevention, Poison control, Anxiety, Emergency medicine, Pharmacology, Environmental health, Economics, Macroeconomics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Treatment of Major Depression", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:46", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4379142909\",\"openalex_url\":\"https://openalex.org/W4379142909\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2104320372\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2784340661\",\"https://openalex.org/W2990102866\",\"https://openalex.org/W3036992158\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W3216164364\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4297478109\",\"https://openalex.org/W4311908682\",\"https://openalex.org/W6745059603\"],\"authorships\":[{\"id\":\"https://openalex.org/A5027735343\",\"display_name\":\"Tooba Noor\",\"orcid\":\"https://orcid.org/0000-0002-8380-3014\"},{\"id\":\"https://openalex.org/A5108922183\",\"display_name\":\"Areej Shakil\",\"orcid\":null},{\"id\":\"https://openalex.org/A5013027499\",\"display_name\":\"Aimen Waqar Khan\",\"orcid\":\"https://orcid.org/0000-0003-4401-8328\"},{\"id\":\"https://openalex.org/A5086504723\",\"display_name\":\"Syeda Mahrukh Fatima Zaidi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5080006814\",\"display_name\":\"Hussain Sohail Rangwala\",\"orcid\":\"https://orcid.org/0009-0007-2167-3481\"},{\"id\":\"https://openalex.org/A5036522565\",\"display_name\":\"Burhanuddin Sohail Rangwala\",\"orcid\":\"https://orcid.org/0009-0008-5812-9049\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210188486\",\"source_display_name\":\"International Journal of Surgery Global Health\",\"landing_page_url\":\"http://dx.doi.org/10.1097/gh9.0000000000000175\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Headache / Migraine,Brain Imaging,Pharmacology,Receptor Pharmacology,Default Mode Network,Consciousness,Aging,Wellbeing,Emotional Processing,Clinical Trial,Review Article,Adolescents,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4379142909" }, { "id": 1466, "title": "Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.", "normalized_title": "examining the rationale for studying psychedelic assisted psychotherapy for the treatment of caregiver distress", "authors": "Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD", "abstract": "More than 50 million people in the United States serve as uncompensated informal caregivers to chronically ill friends or family members. Providing care to a sick loved one can contribute to personal growth but can also cause significant strain. Caregiver distress refers to a constellation of physiological, psychological, interpersonal, and spiritual impairments that typically result when an individual's own health becomes affected while caring for another. Caregiver distress is highly prevalent, affecting an estimated 30-70% of individuals across various caregiver populations. Although evidence-based treatments for caregiver distress exist, they do not sufficiently address all its components. In recent years, clinical trials have demonstrated that psychedelic-assisted psychotherapy (PAP) may have applications for treating a range of medical and psychiatric conditions that have significant overlap in symptoms to those seen in caregiver distress. While no studies to date have examined PAP for caregiver distress, this article provides a rationale for investigating PAP as a potential novel treatment for this indication. A narrative review on the effects and clinical applications of PAP that significantly overlap with the dimensions of caregiver distress was conducted. Safety considerations, psychedelic selection, and therapeutic structure for studying PAP in the treatment of caregiver distress were also examined. Psychologically, PAP has been shown to treat anxiety, depression, and reduce suicidal ideation. Physiologically, evidence suggests that psychedelics have anti-inflammatory properties, which may aid caregivers suffering from chronic inflammation. Interpersonally, PAP has been demonstrated to enhance feelings of empathy, connectedness, and strengthen social relationships, which can often become strained while caregiving. Spiritually, PAP has been shown to ameliorate existential distress and hopelessness in cancer patients, which may similarly benefit demoralized caregivers. PAP has the potential to comprehensively treat all biopsychosocial-spiritual dimensions of caregiver distress.", "journal": "Psychedelic medicine (New Rochelle, N.Y.)", "publication_date": "2023-05-31", "publication_year": 2023, "doi": "10.1089/psymed.2022.0011", "pubmed_id": "40046728", "source_url": "https://pubmed.ncbi.nlm.nih.gov/40046728/", "keywords": "MDMA, biopsychosocial-spiritual, caregiver burden, caregiver distress, psilocybin, psychedelic-assisted psychotherapy", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"40046728\"}", "topic_tags": "Depression,Anxiety,Spirituality,Clinical Trial,Review Article,Cancer Patients,Safety,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3475, "title": "Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans", "normalized_title": "evaluation of the acceptability safety feasibility and efficacy of psilocybin assisted psychotherapy pap for the treatment of post traumatic stress disorder ptsd in military veterans", "authors": "Combat Stress", "abstract": "Post-Traumatic Stress Disorder (PTSD) is a mental health condition that occurs as a result of a traumatic experience. Symptoms include feeling anxious, flashbacks, nightmares and difficulty sleeping. Several studies indicate that psilocybin-assisted psychotherapy (PaP) may be an effective treatment for a number of mental health conditions. This has led to PaP being designated as a \"breakthrough treatment\" by the FDA in the US. Despite indications that PaP may hold benefits in treating individuals with posttraumatic stress disorder (PTSD), this remains to be investigated. As such, the present study aims to examine the acceptability, feasibility, safety, and efficacy of PaP (psilocybin administered with psychotherapy) in treating PTSD in military veterans. Recent studies have shown that Psilocybin-Assisted Psychotherapy (PaP) for individuals with treatment-resistant depression can result in outcomes that exceed routine psychotherapy. Psilocybin may have a catalytic effect on the psychotherapeutic process, enhancing introspection and interoception. PaP may similarly benefit the treatment of posttraumatic stress disorder (PTSD). Research indicates high treatment drop-out rates (approximately 30%) among PTSD patients, and moderate remission rates (approximately 44%) 40 months after completing treatment. Furthermore, some veterans with PTSD have poorer treatment responses than members of the general public. This suggests that alternative treatment approaches may be required to support veterans who do not benefit from standard evidence-based approaches. This study aims to explore the acceptability, feasibility, safety and efficacy of PaP for veterans with PTSD. A total of eight military veterans will be recruited. The study involves two non-directive preparatory sessions, two dosing sessions of psilocybin, followed by 12 sessions of Cognitive Processing Therapy. It is hypothesised that PaP will result in a significant reduction in PTSD symptoms, as indicated by PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders (DSM-5; PCL-5) scores from baseline to one-month follow-up.", "journal": "ClinicalTrials.gov", "publication_date": "2023-05-24", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05876481", "keywords": "PTSD, Psilocybin, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05876481\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,PTSD,Treatment-Resistant Depression,Veterans,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1367, "title": "Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants", "normalized_title": "comparative acute effects of mescaline lysergic acid diethylamide and psilocybin in a randomized double blind placebo controlled cross over study in healthy participants", "authors": "Laura Ley, Friederike Holze, Denis Arikci, A. Becker, Isabelle Straumann, Aaron Klaiber, Fabio Coviello, Sophie Dierbach, Jan Thomann, Urs Duthaler, Dino Luethi, Nimmy Varghese, Anne Eckert, Matthias E. Liechti", "abstract": "Mescaline, lysergic acid diethylamide (LSD), and psilocybin are classic serotonergic psychedelics. A valid, direct comparison of the effects of these substances is lacking. The main goal of the present study was to investigate potential pharmacological, physiological and phenomenological differences at psychoactive-equivalent doses of mescaline, LSD, and psilocybin. The present study used a randomized, double-blind, placebo-controlled, cross-over design to compare the acute subjective effects, autonomic effects, and pharmacokinetics of typically used, moderate to high doses of mescaline (300 and 500 mg), LSD (100 µg), and psilocybin (20 mg) in 32 healthy participants. A mescaline dose of 300 mg was used in the first 16 participants and 500 mg was used in the subsequent 16 participants. Acute subjective effects of 500 mg mescaline, LSD, and psilocybin were comparable across various psychometric scales. Autonomic effects of 500 mg mescaline, LSD, and psilocybin were moderate, with psilocybin causing a higher increase in diastolic blood pressure compared with LSD, and LSD showing a trend toward an increase in heart rate compared with psilocybin. The tolerability of mescaline, LSD, and psilocybin was comparable, with mescaline at both doses inducing slightly more subacute adverse effects (12-24 h) than LSD and psilocybin. Clear distinctions were seen in the duration of action between the three substances. Mescaline had the longest effect duration (mean: 11.1 h), followed by LSD (mean: 8.2 h), and psilocybin (mean: 4.9 h). Plasma elimination half-lives of mescaline and LSD were similar (approximately 3.5 h). The longer effect duration of mescaline compared with LSD was due to the longer time to reach maximal plasma concentrations and related peak effects. Mescaline and LSD, but not psilocybin, enhanced circulating oxytocin. None of the substances altered plasma brain-derived neurotrophic factor concentrations. In conclusion, the present study found no evidence of qualitative differences in altered states of consciousness that were induced by equally strong doses of mescaline, LSD, and psilocybin. The results indicate that any differences in the pharmacological profiles of mescaline, LSD, and psilocybin do not translate into relevant differences in the subjective experience. ClinicalTrials.gov identifier: NCT04227756.", "journal": "Neuropsychopharmacology", "publication_date": "2023-05-24", "publication_year": 2023, "doi": "10.1038/s41386-023-01607-2", "pubmed_id": "37231080", "source_url": "https://doi.org/10.1038/s41386-023-01607-2", "keywords": "Psilocybin, Mescaline, Lysergic acid diethylamide, Hallucinogen, Placebo, Pharmacology, Psychology, Serotonin, Medicine, Internal medicine, Alternative medicine, Receptor, Pathology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4378174725\",\"openalex_url\":\"https://openalex.org/W4378174725\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":126,\"referenced_works\":[\"https://openalex.org/W1965146355\",\"https://openalex.org/W1986543617\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2013576699\",\"https://openalex.org/W2017358382\",\"https://openalex.org/W2056232804\",\"https://openalex.org/W2059908347\",\"https://openalex.org/W2061607209\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2080691425\",\"https://openalex.org/W2100819236\",\"https://openalex.org/W2109884356\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2160167761\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2488739807\",\"https://openalex.org/W2528752100\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2582692487\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2805248302\",\"https://openalex.org/W2895828174\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2923436703\",\"https://openalex.org/W2983486486\",\"https://openalex.org/W3024299552\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3113337956\",\"https://openalex.org/W3124059976\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3159875688\",\"https://openalex.org/W3180562559\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W3200846882\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4289316208\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W6654893894\",\"https://openalex.org/W6677542415\",\"https://openalex.org/W6777425364\"],\"authorships\":[{\"id\":\"https://openalex.org/A5102828957\",\"display_name\":\"Laura Ley\",\"orcid\":\"https://orcid.org/0009-0003-9881-4693\"},{\"id\":\"https://openalex.org/A5028081191\",\"display_name\":\"Friederike Holze\",\"orcid\":\"https://orcid.org/0000-0003-3143-1519\"},{\"id\":\"https://openalex.org/A5092014901\",\"display_name\":\"Denis Arikci\",\"orcid\":null},{\"id\":\"https://openalex.org/A5012996786\",\"display_name\":\"A. Becker\",\"orcid\":\"https://orcid.org/0000-0001-5308-7945\"},{\"id\":\"https://openalex.org/A5069070940\",\"display_name\":\"Isabelle Straumann\",\"orcid\":\"https://orcid.org/0009-0008-2952-586X\"},{\"id\":\"https://openalex.org/A5021170956\",\"display_name\":\"Aaron Klaiber\",\"orcid\":\"https://orcid.org/0009-0004-5199-7004\"},{\"id\":\"https://openalex.org/A5092014902\",\"display_name\":\"Fabio Coviello\",\"orcid\":\"https://orcid.org/0000-0002-6007-1631\"},{\"id\":\"https://openalex.org/A5092014903\",\"display_name\":\"Sophie Dierbach\",\"orcid\":null},{\"id\":\"https://openalex.org/A5063838454\",\"display_name\":\"Jan Thomann\",\"orcid\":\"https://orcid.org/0000-0003-3820-2671\"},{\"id\":\"https://openalex.org/A5024133720\",\"display_name\":\"Urs Duthaler\",\"orcid\":\"https://orcid.org/0000-0002-7811-3932\"},{\"id\":\"https://openalex.org/A5034015135\",\"display_name\":\"Dino Luethi\",\"orcid\":\"https://orcid.org/0000-0003-0874-4875\"},{\"id\":\"https://openalex.org/A5018641310\",\"display_name\":\"Nimmy Varghese\",\"orcid\":\"https://orcid.org/0000-0001-8598-0535\"},{\"id\":\"https://openalex.org/A5052160307\",\"display_name\":\"Anne Eckert\",\"orcid\":\"https://orcid.org/0000-0002-9341-3669\"},{\"id\":\"https://openalex.org/A5071962736\",\"display_name\":\"Matthias E. Liechti\",\"orcid\":\"https://orcid.org/0000-0002-1765-9659\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S175030738\",\"source_display_name\":\"Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1038/s41386-023-01607-2\",\"is_oa\":true}}", "topic_tags": "Pharmacology,Receptor Pharmacology,Consciousness,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4378174725" }, { "id": 1481, "title": "Neurobiological Correlates of Psilocybin Response in Depression.", "normalized_title": "neurobiological correlates of psilocybin response in depression", "authors": "Qasim S, Zaheer Z, Jawad MY, Shad MU.", "abstract": "Objective: To synthesize the neurobiological basis of brain-resetting effects of psilocybin and identify neuroimaging correlates of psilocybin response in depressed patients.Data Sources: MEDLINE(R), Embase, APA PsycINFO, Cochrane, and CINAHL were systematically searched on June 3, 2022, with no date restrictions using the following string: (psilocybin) AND (psychedelics) AND (MRI) OR (fMRI)) OR (PET)) OR (SPECT)) OR (imaging)) OR (neuroimaging)).Study Selection: After duplicates were removed from 946 studies, 391 studies remained, of which 8 qualified for full-text analysis, but only 5 fulfilled the eligibility criteria of randomized, double-blind, or open-label neuroimaging study with psilocybin treatment in depressed patients.Data Extraction: The Covidence platform was used for deduplication and bias assessment. The a priori data points included concomitant psychological intervention, modality of neuroimaging technique, changes in depression scores, brain functional changes, and association between functional and psilocybin response. Assessment bias was assessed with the standard risk of bias tool for randomized controlled trials and the tool for risk of bias in nonrandomized studies of interventions.Results: Four studies were open-label, and one was a combined open-label and randomized controlled trial using functional magnetic resonance imaging. Psilocybin-assisted psychotherapy was administered in 3 studies, 1 in refractory and 2 in nonrefractory patients. The remaining 2 studies were in refractory patients. The transient increase in psilocybin-induced global connectivity in major neural tracts and specific areas of brain activation was associated with antidepressant response.Conclusions: Transient functional brain changes with psilocybin therapy resemble the \"brain reset\" phenomenon and may serve as the putative predictors of psilocybin antidepressant response.", "journal": null, "publication_date": "2023-05-22", "publication_year": 2023, "doi": "10.4088/pcc.22r03419", "pubmed_id": "37230065", "source_url": "https://doi.org/10.4088/pcc.22r03419", "keywords": "Brain, Humans, Antidepressive Agents, Depression, Psychotherapy, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37230065\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Brain Imaging,Aging,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3683, "title": "Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers", "normalized_title": "recall of experience and conscious awareness in psilocybin treatment of depression the recap study pilot phase in healthy adult volunteers", "authors": "University of Wisconsin, Madison", "abstract": "The primary objective of the RECAP Study Program is to investigate the role played by conscious experience in the antidepressant effects of the psychedelic agent psilocybin. This pilot dosing study (PILOT RECAP) is designed to determine the optimal dose of midazolam that allows a psychedelic experience to occur while inducing amnesia for the experience. This is an essential step required for subsequent evaluation of the role of memory for the psychedelic experience in the antidepressant effects of psilocybin in the full RECAP study. The PILOT RECAP Study will investigate the effect of co- administering the amnestic agent midazolam with a single 25 mg dose of psilocybin on the induction of a psychedelic experience and subsequent memory for the experience with the goal of identifying an optimal dosing regimen of midazolam that will allow a psychedelic experience to occur while also inducing amnesia for the experience. Identifying this midazolam dosing regimen will allow us in a subsequent stage of the RECAP program to test whether memory for the psychedelic experience is required/important for psilocybin to produce longer-term antidepressant effects. This is a phase 1 study in psychiatrically and medically healthy volunteers. Given this, there is no disease background for PILOT RECAP per se. However, the purpose of PILOT RECAP is to identify an optimal midazolam dosing schedule to be used in a subsequent study (RECAP) in patients with major depressive disorder (MDD). The investigational treatment for PILOT RECAP is a single 25 mg dose of psilocybin combined with repeated intravenous (IV) boluses of midazolam dosed at levels known to maintain conscious experience while inducing subsequent amnesia for the experience upon its conclusion. Because PILOT RECAP is the first study to examine this drug combination, no data are currently available on this approach. Psilocybin + midazolam will be administered within a \"Set and Setting\" (SaS) protocol that provides psychoeducation and therapeutic support prior to, during, and following psychedelic dosing, and that has been standard procedure for recent studies of psilocybin in humans. It is believed that this SaS approach enhances clinical efficacy and safety. SaS is an integral component of the PILOT RECAP intervention. The PILOT RECAP study will not enroll vulnerable populations. During this study, participants are asked to: * Refrain from use of psychotropic medications. Use of such medications prior to psilocybin/midazolam dosing will result in a participant being discontinued from the study. * Refrain from use of any illegal psychoactive substances from screening until study termination. * Refrain from using legal psychoactive substance for the following defined time periods (the exception is caffeine): * Tobacco and Nicotine: from screening until study termination * Alcohol: 72 hours prior to the Dosing Visit", "journal": "ClinicalTrials.gov", "publication_date": "2023-05-18", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04842045", "keywords": "Psychedelic Experiences, Amnesia, Psilocybin and Midazolam, Psilocybine, Psilocibin, benzodiazepine, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04842045\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Addiction,Clinical Trial,Healthy Volunteers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3634, "title": "A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin", "normalized_title": "a phase 1 study comparing the pharmacokinetics and safety of intravenous and oral psilocybin", "authors": "University of Wisconsin, Madison", "abstract": "The purpose of this research study is to compare an oral dose of psilocybin and an intravenous (IV) infusion of psilocybin to assess differences in how the drug is absorbed by the body, the psychedelic experience, and any side effects when taken by healthy adult participants. Participants can expect to be in the study for approximately 12 weeks. Psilocybin, when delivered to screened and prepared participants in a controlled environment, has shown strong evidence of positive effects in treating cancer-related psychiatric distress, depression and anxiety, treatment-resistant depression, and nicotine or alcohol addiction. Psilocybin therapy is generally safe and well-tolerated when conducted under controlled conditions. Psilocybin is very rapidly transformed to the active metabolite psilocin, which is considered the active agent from psilocybin administration. Oral and IV psilocybin are expected to have similar pharmacokinetic and psychedelic effects, as well as safety profiles, while IV psilocybin will achieve more consistent blood levels than are possible with oral psilocybin.", "journal": "ClinicalTrials.gov", "publication_date": "2023-05-14", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05467761", "keywords": "Healthy, Oral Psilocybin, IV Psilocybin, WITHDRAWN", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05467761\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,Addiction,Pharmacology,Clinical Trial,Cancer Patients,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3463, "title": "Effects of Psilocybin in Anorexia Nervosa", "normalized_title": "effects of psilocybin in anorexia nervosa", "authors": "Johns Hopkins University", "abstract": "This open-label pilot study seeks to investigate the safety and efficacy of psilocybin in persons with chronic anorexia nervosa (AN). Psilocybin has previously been demonstrated to decrease depression and anxiety and increase long-term positive behavior change in other populations. The investigators seek to determine whether similar changes can be safely produced in people with AN when psilocybin is administered in a supportive setting with close follow-up. The investigators' primary hypotheses are that psilocybin is safe to administer in people with AN, that it will reduce measures of anxiety and depression, and that it will lead to increased quality of life. The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.", "journal": "ClinicalTrials.gov", "publication_date": "2023-05-05", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04052568", "keywords": "Anorexia Nervosa, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04052568\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Anxiety,Eating Disorders,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1491, "title": "Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD", "normalized_title": "study protocol of an open label proof of concept trial examining the safety and clinical efficacy of psilocybin assisted therapy for veterans with ptsd", "authors": "Alan K. Davis, Adam W. Levin, Paul Nagib, Stacey B. Armstrong, Rafael Lancelotta", "abstract": "INTRODUCTION: Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition. Furthermore, current pharmacological and psychotherapeutic treatments for PTSD are difficult to tolerate and limited in efficacy, especially in the US Military Veteran (USMV) population. This open-label pilot study will examine the safety and efficacy of two psilocybin administration sessions (15 mg and 25 mg), combined with psychotherapy, among USMVs with severe, treatment resistant PTSD. METHODS AND ANALYSIS: We will recruit 15 USMVs with severe, treatment resistant PTSD. Participants will receive one low dose (15 mg) and one moderate/high dose (25 mg) of psilocybin in conjunction with preparatory and post-psilocybin therapy sessions. The primary safety outcome will be the type, severity and frequency of adverse events and suicidal ideation/behaviour, as measured by the Columbia Suicide Severity Rating Scale. The primary outcome measure for PTSD will be the Clinician Administered PTSD Scale-5. The primary endpoint will be 1 month following the second psilocybin administration session, and the total follow-up time will be 6 months. ETHICS AND DISSEMINATION: All participants will be required to provide written informed consent. The trial has been authorised by the Ohio State University Institutional Review Board (study number: 2022H0280). Dissemination of results will occur via a peer-reviewed publication and other relevant media. TRIAL REGISTRATION NUMBER: NCT05554094.", "journal": "BMJ Open", "publication_date": "2023-04-30", "publication_year": 2023, "doi": "10.1136/bmjopen-2022-068884", "pubmed_id": "37142308", "source_url": "https://doi.org/10.1136/bmjopen-2022-068884", "keywords": "Medicine, Psilocybin, Protocol (science), Clinical trial, Proof of concept, Psychiatry, Open label, Alternative medicine, Psychotherapist, Hallucinogen, Internal medicine, Pathology, Operating system, Psychology, Computer science, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4372336620\",\"openalex_url\":\"https://openalex.org/W4372336620\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":19,\"referenced_works\":[\"https://openalex.org/W1514491136\",\"https://openalex.org/W1970515078\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2079922358\",\"https://openalex.org/W2107489190\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2395520547\",\"https://openalex.org/W2402965079\",\"https://openalex.org/W2412976663\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2598895258\",\"https://openalex.org/W2612417324\",\"https://openalex.org/W2899448494\",\"https://openalex.org/W2985507408\",\"https://openalex.org/W3041518543\",\"https://openalex.org/W3080920519\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W4206228435\",\"https://openalex.org/W4206486089\",\"https://openalex.org/W4213429059\",\"https://openalex.org/W4225311883\",\"https://openalex.org/W4237085762\",\"https://openalex.org/W4304118763\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038141719\",\"display_name\":\"Alan K. Davis\",\"orcid\":\"https://orcid.org/0000-0003-4770-8893\"},{\"id\":\"https://openalex.org/A5048202842\",\"display_name\":\"Adam W. Levin\",\"orcid\":\"https://orcid.org/0000-0002-9167-462X\"},{\"id\":\"https://openalex.org/A5072798102\",\"display_name\":\"Paul Nagib\",\"orcid\":\"https://orcid.org/0000-0001-8538-3116\"},{\"id\":\"https://openalex.org/A5015911875\",\"display_name\":\"Stacey B. Armstrong\",\"orcid\":\"https://orcid.org/0000-0003-0869-7511\"},{\"id\":\"https://openalex.org/A5056271117\",\"display_name\":\"Rafael Lancelotta\",\"orcid\":\"https://orcid.org/0000-0002-7789-3463\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S79054089\",\"source_display_name\":\"BMJ Open\",\"landing_page_url\":\"https://doi.org/10.1136/bmjopen-2022-068884\",\"is_oa\":true}}", "topic_tags": "Anxiety,PTSD,Chronic Pain,Clinical Trial,Review Article,Veterans,Healthcare Workers,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4372336620" }, { "id": 4819, "title": "A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history", "normalized_title": "a suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history", "authors": "Eric N. Kramer, Kalyn Reddy, Bryan Shapiro", "abstract": "Several studies have been conducted and more are underway examining psilocybin-assisted therapy as a treatment for various psychiatric conditions including depressive disorders, anxiety disorders, and alcohol use disorder. However, many studies have been limited by small sample size and have not comprehensively evaluated treatment risks outside of controlled settings. To this point, we present a case of a 30 year old male with no psychiatric history who presented to the emergency department with multiple self-inflicted stab wounds to the neck in a suicide attempt in the setting of psilocybin ingestion. Despite the majority of existing evidence supporting a decreased risk of suicidality with psilocybin use, further studies are needed to determine if there is an increased risk of suicidality and other serious adverse events with psilocybin use, and whether such a potential relationship is dose-dependent and/or set and setting-dependent.", "journal": "Psychiatry Research Case Reports", "publication_date": "2023-04-25", "publication_year": 2023, "doi": "10.1016/j.psycr.2023.100118", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.psycr.2023.100118", "keywords": "Psilocybin, Psychiatry, Hallucinogen, Depression (economics), Ingestion, Anxiety, Medicine, Adverse effect, Psychology, Pharmacology, Internal medicine, Economics, Macroeconomics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:46", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4367043450\",\"openalex_url\":\"https://openalex.org/W4367043450\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W1997161439\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2757390367\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2903619067\",\"https://openalex.org/W2917218353\",\"https://openalex.org/W2991933827\",\"https://openalex.org/W3047886920\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3129584613\",\"https://openalex.org/W3135650175\",\"https://openalex.org/W3138429576\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3187215861\",\"https://openalex.org/W4206268123\",\"https://openalex.org/W4206486089\",\"https://openalex.org/W4206661393\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4284665615\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293194637\",\"https://openalex.org/W4308146982\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034914382\",\"display_name\":\"Eric N. Kramer\",\"orcid\":\"https://orcid.org/0000-0002-5740-671X\"},{\"id\":\"https://openalex.org/A5078812420\",\"display_name\":\"Kalyn Reddy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5076908901\",\"display_name\":\"Bryan Shapiro\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4220651674\",\"source_display_name\":\"Psychiatry Research Case Reports\",\"landing_page_url\":\"https://doi.org/10.1016/j.psycr.2023.100118\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Addiction,Pharmacology,Safety,Adverse Events,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4367043450" }, { "id": 1499, "title": "Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial", "normalized_title": "safety tolerability and clinical and neural effects of single dose psilocybin in obsessive compulsive disorder protocol for a randomized double blind placebo controlled non crossover trial", "authors": "Terence H. W. Ching, Rachael Grazioplene, Calvin Bohner, Stephen A. Kichuk, Giuliana DePalmer, Elizabeth J. D’Amico, Jeffrey Eilbott, Anastasia Jankovsky, Michelle Burke, Jamila Hokanson, Brad Martins, Chelsea Witherow, Prerana Patel, Lucia Amoroso, Henry Schaer, Christopher Pittenger, Benjamin Kelmendi", "abstract": "Background: Psilocybin may help treat obsessive-compulsive disorder (OCD). To date, only one open-label study of psilocybin for OCD exists, necessitating further investigation with a randomized controlled design. The neural correlates of psilocybin's effects on OCD have also not been studied. Objectives: This first-of-its-kind trial aims to evaluate the feasibility, safety, and tolerability of psilocybin in the treatment of OCD, provide preliminary evidence on the effects of psilocybin on OCD symptoms, and elucidate neural mechanisms that may mediate psilocybin's effects on OCD. Design: We use a randomized (1:1), double-blind, placebo-controlled, non-crossover design to examine the clinical and neural effects of either a single dose of oral psilocybin (0.25 mg/kg) or active placebo-control agent (250 mg of niacin) on OCD symptoms. Methods and analysis: We are enrolling 30 adult participants at a single site in Connecticut, USA who have failed at least one trial of standard care treatment (medication/psychotherapy) for OCD. All participants will also receive unstructured, non-directive psychological support during visits. Aside from safety, primary outcomes include OCD symptoms over the past 24 h, assessed by the Acute Yale-Brown Obsessive-Compulsive Scale and Visual Analog Scale ratings. These are collected by blinded, independent raters at baseline and the primary endpoint of 48 h post-dosing. Total follow-up is 12 weeks post-dosing. Resting state neuroimaging data will be collected at baseline and primary endpoint. Participants randomized to placebo will be offered the chance to return for an open-label dose of 0.25 mg/kg. Ethics statement: All participants will be required to provide written informed consent. The trial (protocol v. 5.2) was approved by the institutional review board (HIC #2000020355) and registered with ClinicalTrials.gov (NCT03356483). Discussion: This study may represent an advance in our ability to treat refractory OCD, and pave the way for future studies of neurobiological mechanisms of OCD that may respond to psilocybin.", "journal": "Frontiers in Psychiatry", "publication_date": "2023-04-24", "publication_year": 2023, "doi": "10.3389/fpsyt.2023.1178529", "pubmed_id": "37181888", "source_url": "https://doi.org/10.3389/fpsyt.2023.1178529", "keywords": "Psilocybin, Tolerability, Placebo, Randomized controlled trial, Obsessive compulsive, Crossover study, Psychiatry, Psychology, Medicine, Dosing, Clinical endpoint, Hallucinogen, Adverse effect, Pharmacology, Internal medicine, Alternative medicine, Pathology, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:36", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4366989647\",\"openalex_url\":\"https://openalex.org/W4366989647\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":27,\"referenced_works\":[\"https://openalex.org/W78677904\",\"https://openalex.org/W122113993\",\"https://openalex.org/W200847362\",\"https://openalex.org/W306343222\",\"https://openalex.org/W568533716\",\"https://openalex.org/W1269562257\",\"https://openalex.org/W1498057507\",\"https://openalex.org/W1599004146\",\"https://openalex.org/W1607171655\",\"https://openalex.org/W1742833546\",\"https://openalex.org/W1790886046\",\"https://openalex.org/W1897149844\",\"https://openalex.org/W1934577361\",\"https://openalex.org/W1965281512\",\"https://openalex.org/W1973451278\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1993810702\",\"https://openalex.org/W2000519244\",\"https://openalex.org/W2006001020\",\"https://openalex.org/W2006725552\",\"https://openalex.org/W2006748124\",\"https://openalex.org/W2011329819\",\"https://openalex.org/W2014833927\",\"https://openalex.org/W2017857669\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2031040639\",\"https://openalex.org/W2035162712\",\"https://openalex.org/W2036557604\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2051355184\",\"https://openalex.org/W2060153692\",\"https://openalex.org/W2063305190\",\"https://openalex.org/W2069973131\",\"https://openalex.org/W2079559446\",\"https://openalex.org/W2079984335\",\"https://openalex.org/W2082150145\",\"https://openalex.org/W2084244487\",\"https://openalex.org/W2084290400\",\"https://openalex.org/W2088864916\",\"https://openalex.org/W2092175415\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093106172\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2100827418\",\"https://openalex.org/W2100861230\",\"https://openalex.org/W2114570941\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2123822033\",\"https://openalex.org/W2129340715\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2139247364\",\"https://openalex.org/W2145083290\",\"https://openalex.org/W2150547685\",\"https://openalex.org/W2151487996\",\"https://openalex.org/W2159186832\",\"https://openalex.org/W2168266150\",\"https://openalex.org/W2169348857\",\"https://openalex.org/W2245231029\",\"https://openalex.org/W2401253652\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2577533646\",\"https://openalex.org/W2792256936\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2990405759\",\"https://openalex.org/W3090293687\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3129125412\",\"https://openalex.org/W3158498065\",\"https://openalex.org/W3171418018\",\"https://openalex.org/W3196904352\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4214511680\",\"https://openalex.org/W4224296821\",\"https://openalex.org/W4234021523\",\"https://openalex.org/W4252855288\",\"https://openalex.org/W4285007883\",\"https://openalex.org/W4293024119\",\"https://openalex.org/W4296782684\",\"https://openalex.org/W4303187823\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4322744805\",\"https://openalex.org/W4362635236\",\"https://openalex.org/W4399074339\",\"https://openalex.org/W6610802157\",\"https://openalex.org/W6637656337\",\"https://openalex.org/W7074234824\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038288658\",\"display_name\":\"Terence H. W. Ching\",\"orcid\":\"https://orcid.org/0000-0002-8850-2237\"},{\"id\":\"https://openalex.org/A5071673808\",\"display_name\":\"Rachael Grazioplene\",\"orcid\":\"https://orcid.org/0000-0001-8708-4531\"},{\"id\":\"https://openalex.org/A5072571463\",\"display_name\":\"Calvin Bohner\",\"orcid\":null},{\"id\":\"https://openalex.org/A5090942004\",\"display_name\":\"Stephen A. Kichuk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5028356592\",\"display_name\":\"Giuliana DePalmer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5055980478\",\"display_name\":\"Elizabeth J. D’Amico\",\"orcid\":\"https://orcid.org/0000-0002-8527-7804\"},{\"id\":\"https://openalex.org/A5112416887\",\"display_name\":\"Jeffrey Eilbott\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083774019\",\"display_name\":\"Anastasia Jankovsky\",\"orcid\":\"https://orcid.org/0000-0003-1559-0958\"},{\"id\":\"https://openalex.org/A5079717515\",\"display_name\":\"Michelle Burke\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058988830\",\"display_name\":\"Jamila Hokanson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5085578203\",\"display_name\":\"Brad Martins\",\"orcid\":null},{\"id\":\"https://openalex.org/A5083493446\",\"display_name\":\"Chelsea Witherow\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077000472\",\"display_name\":\"Prerana Patel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051611172\",\"display_name\":\"Lucia Amoroso\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065974780\",\"display_name\":\"Henry Schaer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001094886\",\"display_name\":\"Christopher Pittenger\",\"orcid\":\"https://orcid.org/0000-0003-2117-9321\"},{\"id\":\"https://openalex.org/A5110948308\",\"display_name\":\"Benjamin Kelmendi\",\"orcid\":\"https://orcid.org/0000-0002-3141-1326\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2023.1178529\",\"is_oa\":true}}", "topic_tags": "OCD,Chronic Pain,Brain Imaging,Pharmacology,Mechanism of Action,Aging,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4366989647" }, { "id": 3563, "title": "The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression", "normalized_title": "the safety and efficacy of psilocybin in participants with treatment resistant depression", "authors": "COMPASS Pathways", "abstract": "The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study", "journal": "ClinicalTrials.gov", "publication_date": "2023-04-23", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT03775200", "keywords": "Treatment Resistant Depression, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT03775200\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3176, "title": "A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy", "normalized_title": "a phase i trial to inform clinical protocols for the safe administration of psilocybin assisted psychotherapy", "authors": "Bennett JN, Blough MD, Mitchell I, Galloway L, Bains R.", "abstract": "This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effects in healthy individuals. Safety assessments (heart rate, blood pressure, temperature, and ECG data), as well as adverse event evaluations were the primary outcome measures used to assess the physiological effects of 25 mg of psilocybin extract administered to 14 healthy individuals. We hypothesized that there would be a transient, clinically insignificant rise in both blood pressure and heart rate that would not result in any long-term adverse effects. No unexpected effects were observed, blood pressure and heart rate returned to normal as drug effects waned, and all participants had normal two-month follow-ups. Mean peak systolic and diastolic blood pressures during the psilocybin session were 145.93 ( SD = 19.01) and 93.93 ( SD = 9.75), respectively. While this represents a significant increase from baseline ( p < 0.0001), a healthy cardiovascular system is capable of tolerating such levels for a longer time period than the brief duration of drug effects. Therefore, we suggest implementing focused and limited screening protocols to balance patient safety and accessibility. Secondary outcomes of this trial centered on the subjective effects of psilocybin, assessed via the QIDS-SR16 and the MEQ-30. There was a statistically significant decrease in QIDS-SR16 scores from baseline scores ( M = 3.50, SD = 2.35) to eight-week follow-up scores ( M = 1.86, SD = 0.86), p = 0.018. Mean MEQ-30 scores, assessed on day two and seven after the psilocybin session, indicate participants had full mystical experiences.", "journal": "medRxiv", "publication_date": "2023-04-18", "publication_year": 2023, "doi": "10.1101/2023.04.12.23288325", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2023.04.12.23288325", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:47", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR648094\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Mystical Experience,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1593, "title": "Psilocybin in Palliative Care: An Update.", "normalized_title": "psilocybin in palliative care an update", "authors": "Whinkin E, Opalka M, Watters C, Jaffe A, Aggarwal S.", "abstract": "Purpose of reviewThis review article summarizes clinically and socially relevant developments over the past five years in the therapeutic use of the classical tryptamine psychedelic substance psilocybin, with respect to the common challenges faced by palliative care patients and their care teams. Psilocybin is available in whole fungal and isolated forms but is not yet approved for therapeutic use in the United States. Using targeted database and gray literature searches, and author recall, key sources were identified, reviewed, and synthesized as to the safety and efficacy of psilocybin in palliative care.Recent findingsLife-threatening or life-limiting illnesses and faced by palliative care patients are comorbid with emotional and spiritual distress. Research and field reports reviewed suggest that psilocybin has significant and in some cases, sustained anxiolytic, antidepressant, anti-inflammatory and entheogenic effects with a favorable safety profile. Limitations of the research include the risk for selection bias toward healthy, white, financially privileged individuals, and in general, follow-up timelines too short to appropriately evaluate durability of outcomes in psychospiritual benefits and quality of life.SummaryWhile more research is needed for palliative care populations specifically, reasonable inferences can be made regarding the potential for benefit to palliative care patients from psilocybin's demonstrated anxiolytic, antidepressant, anti-inflammatory and entheogenic effects. However, major legal, ethical and financial barriers to access exist for the general population; obstacles which are likely worsened for geriatric and palliative care patients. Empiric treatment and large-scale controlled trials of psilocybin should be conducted to further investigate the findings of the smaller studies reviewed here across a variety of populations, for a greater understanding of therapeutic benefit and clinically relevant safety criteria, and to support thoughtful legalization and medical access.", "journal": null, "publication_date": "2023-04-13", "publication_year": 2023, "doi": "10.1007/s13670-023-00383-7", "pubmed_id": "37305379", "source_url": "https://doi.org/10.1007/s13670-023-00383-7", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"37305379\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "End-of-Life Distress,Aging,Emotional Processing,Spirituality,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1506, "title": "Use of Selective Alternative Therapies for Treatment of OCD.", "normalized_title": "use of selective alternative therapies for treatment of ocd", "authors": "Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A.", "abstract": "About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases PubMed, Science Direct, Google Scholar, Cochrane, Directory of Open Access Journals, MedRxiv and BioRxiv, were searched from inception to March 2022, using appropriate search strategies for each drug and following the Prisma guidelines 2020. Studies were selected according to the already set criteria and assessed for bias. Data were extracted, and descriptive and continuous data were analyzed and presented as frequency/percentage and mean. A total of 16 observational and interventional studies were included for data extraction. The studies focused on four drugs, Psilocybin (n=4), Cannabis (n=7), Nicotine (n=3), and Morphine (n=2), that were used to test out their effect on OCD symptoms. Overall, the majority of the studies showed promising results by documenting a reduction in Y-BOCS scores. However, few subjects, specifically those using nicotine or Cannabis, did not affect their condition or self-reported worsening symptoms. Few side effects were also noticed. This systematic review found that the drugs mostly showed a positive response. All Psilocybin and morphine users, 88.2% and 74.1% of the nicotine and Cannabis users, respectively, reported experiencing the positive effect of these drugs, indicating that these drugs have the potential to be used in the management of OCD. However, further research is required in this arena to thoroughly understand the mechanism of action by which these drugs produce their therapeutic effect. Policies to destigmatize and encourage clinical trials with these drugs are crucial for exploring the use of these drugs as a treatment option for OCD.", "journal": null, "publication_date": "2023-04-04", "publication_year": 2023, "doi": "10.2147/ndt.s403997", "pubmed_id": "37041856", "source_url": "https://doi.org/10.2147/ndt.s403997", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"37041856\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "OCD,Mechanism of Action,Clinical Trial,Systematic Review,Review Article,Observational Study,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1424, "title": "Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.", "normalized_title": "are psychedelic medicines the reset for chronic pain preliminary findings and research needs", "authors": "Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A.", "abstract": "Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks. Preliminary evidence suggests that some psychedelics may be effective for certain types of pain and/or improved quality of life with increased functionality and reduced disability and distress in people whose pain may never be completely relieved. Efficacy in these quality-of-life related outcomes would be consistent with the 'reset in thinking' about chronic pain management being increasingly called for as a more realistic goal for some people as compared to complete elimination of pain. This commentary summarizes the rationale for conducting more basic research and clinical trials to further explore the potential for psychedelics in chronic pain management. Additionally, if shown to be effective, to then determine whether the effects of psychedelics are primarily due to direct antinociceptive or anti-inflammatory mechanisms, or via increased tolerability, acceptance, and sense of spirituality, that appear to at least partially mediate the therapeutic effects of psychedelics observed in psychiatric disorders such as major depression. This commentary represents a collaboration of clinical and more basic scientists examining these issues and developing recommendations for research ranging from neuropharmacology to the biopsychosocial treatment factors that appear to be as important in pain management as in depression and other disorders in which psychedelic medicines are under development. This article is part of the Special Issue on \"National Institutes of Health Psilocybin Research Speaker Series\".", "journal": null, "publication_date": "2023-04-01", "publication_year": 2023, "doi": "10.1016/j.neuropharm.2023.109528", "pubmed_id": "37015315", "source_url": "https://doi.org/10.1016/j.neuropharm.2023.109528", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Quality of Life, United States, Chronic Pain, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37015315\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Chronic Pain,Pharmacology,Mechanism of Action,Spirituality,Clinical Trial,Safety,Adverse Events,Inflammation", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1512, "title": "Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.", "normalized_title": "prevalence and associations of challenging difficult or distressing experiences using classic psychedelics", "authors": "Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB", "abstract": "Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day as a result of such experiences. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing classic psychedelic experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.", "journal": "Journal of affective disorders", "publication_date": "2023-03-31", "publication_year": 2023, "doi": "10.1016/j.jad.2023.01.073", "pubmed_id": "36720405", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36720405/", "keywords": "Adverse, CEQ, Challenging, LSD, Psilocybin, Psychedelics, Risk", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"36720405\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1451, "title": "The need for establishing best practices and gold standards in psychedelic medicine.", "normalized_title": "the need for establishing best practices and gold standards in psychedelic medicine", "authors": "Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM.", "abstract": "Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the time for the medical community to become informed on best practices and to actively participate in developing standards of care for these new treatments. Given the emergence of numerous drug sponsors and other companies developing therapeutic modalities for combination with psychedelic medications, it is essential that the medical professional field is at the forefront of communicating unbiased information related to safety and effectiveness. Gold standards have long been a part of medicine and serve to distinguish treatments and assessments as the highest quality by which all others can be compared to. For a treatment to be established as a gold standard, several factors are considered including the quantity and quality of the supporting data, the rigor of trials, and the safety and efficacy compared to other treatments. In this article, we review the origins of psychedelic-assisted therapy (PAT), minimum requirements for safe use of psychedelics, criteria for gold standards in mental health, and the nuances regarding how to establish gold standards in psychedelic medicine and guide clinical decision making.", "journal": null, "publication_date": "2023-03-29", "publication_year": 2023, "doi": "10.1016/j.jad.2023.03.083", "pubmed_id": "37003433", "source_url": "https://doi.org/10.1016/j.jad.2023.03.083", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Mental Health, Stress Disorders, Post-Traumatic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"37003433\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1526, "title": "Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism.", "normalized_title": "psychedelic targeting of metabotropic glutamate receptor 2 and its implications for the treatment of alcoholism", "authors": "Domanegg K, Sommer WH, Meinhardt MW.", "abstract": "Alcohol abuse is a leading risk factor for the public health burden worldwide. Approved pharmacotherapies have demonstrated limited effectiveness over the last few decades in treating alcohol use disorders (AUD). New therapeutic approaches are therefore urgently needed. Historical and recent clinical trials using psychedelics in conjunction with psychotherapy demonstrated encouraging results in reducing heavy drinking in AUD patients, with psilocybin being the most promising candidate. While psychedelics are known to induce changes in gene expression and neuroplasticity, we still lack crucial information about how this specifically counteracts the alterations that occur in neuronal circuits throughout the course of addiction. This review synthesizes well-established knowledge from addiction research about pathophysiological mechanisms related to the metabotropic glutamate receptor 2 (mGlu2), with findings and theories on how mGlu2 connects to the major signaling pathways induced by psychedelics via serotonin 2A receptors (2AR). We provide literature evidence that mGlu2 and 2AR are able to regulate each other's downstream signaling pathways, either through monovalent crosstalk or through the formation of a 2AR-mGlu2 heteromer, and highlight epigenetic mechanisms by which 2ARs can modulate mGlu2 expression. Lastly, we discuss how these pathways might be targeted therapeutically to restore mGlu2 function in AUD patients, thereby reducing the propensity to relapse.", "journal": null, "publication_date": "2023-03-21", "publication_year": 2023, "doi": "10.3390/cells12060963", "pubmed_id": "36980303", "source_url": "https://doi.org/10.3390/cells12060963", "keywords": "Neurons, Humans, Alcoholism, Receptors, Metabotropic Glutamate, Hallucinogens", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36980303\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Aging,Epigenetics,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3433, "title": "Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects (\"MELO\"): A Blinded, Placebo-Controlled, Dose-Finding Study", "normalized_title": "mood and cognitive effects of low doses of psilocybin observed in healthy subjects melo a blinded placebo controlled dose finding study", "authors": "Optimi Health Corporation", "abstract": "This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects. Psilocybin is a natural psychoactive alkaloid component of more than 200 species of naturally growing mushrooms that can be found throughout the world. Psilocybin use as a ceremonious ritual has been well documented in ancient Aztec and Mesoamerican history. Psilocybin was chemically isolated and synthesized in the 1950s by American scientists, who found that mushroom varieties offered varying ranges of natural psilocybin (from 0.2-1% of dry weight). The psychological benefits of psilocybin are well-documented, as are the safety profile, low toxicity, and significant lack of abuse or overdose potential in comparison to other scheduled and non-scheduled drug, including alcohol. Many clinical studies demonstrate the benefit of psilocybin on feelings of depression, mood, and overall feelings of well-being, particularly at higher doses greater than 25mg. At these doses, hallucinations and psychedelic effects also occur. A growing body of evidence suggests that extremely low doses, or microdoses, may offer similar psychological benefits to individuals without any hallucinogenic effect that may impair daily function. The purpose of this study is to examine an optimal small/microdose of psilocybin, taken orally, that may provide such benefits. Optimi,is committed to providing MELOCIN, an oral, pharmaceutical grade, but naturally derived, mushroom powder (Psilocybe cubensis), containing a specific dose of psilocybin and a controlled range of other natural compounds and excipients within the formulation. Clinical studies will inform the desired low to very low psilocybin dosing range for specific indications which do not elicit any psychedelic effects but are correlated to specific mood and cognition-related enhancements or improvements in otherwise healthy individuals. Primary objective: To assess the safety and tolerability of varying low doses and microdoses of Optimi psilocybin-containing mushroom powder in healthy humans. Secondary objective: To assess the magnitude of effects of varying low doses and microdoses of Optimi psilocybin-containing mushroom powder on general mood, physiological responses, cognitive performance, focus, and feelings of anxiety. Methodology: Double-blind, randomized, placebo-controlled trial examining effects of six oral doses of MELOCIN, a psilocybin-containing Psilocybe cubensis mushroom powder, with 0 (placebo), 1, 2, 5, 8 and 10mg of psilocybin, administered on six separate test days in a randomized fashion. Participants will be randomized to the order that doses are administered. Study days will be scheduled 6-9 days apart to avoid any carry-over effects of a previous dose. Each study day will require ingestion of 10 capsules, which will be a combination of placebo and Psilocybe cubensis powder containing the prescribed daily dose. On the placebo study day, participants will digest 9 placebo capsules and one Chaga mushroom (non-active, non-hallucinogenic) capsule such that the mushroom after-taste commonly present with hallucinogenic magic mushrooms is mimicked and still present to preserve the blinding of the study dosing regimen. Participants will be scheduled for 7 total weekly visits (6 dosing days, 1 follow up/close out visit) at the study clinic, each estimated to be 8-9 hours in duration. At each weekly study visit, participants will be continuously monitored and asked to complete cognitive, mood, and other psychological questionnaires and provide minimal blood work at 80-105 mins, 2.5 hrs, 5 hrs, and 7.5hrs post-drug administration in order to monitor the physiological and psychological effects of the dose provided that day. At the follow-up visit, final questionnaires will be completed and qualitative feedback on the experience will be collected", "journal": "ClinicalTrials.gov", "publication_date": "2023-03-19", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05252598", "keywords": "Mood Disturbance, Mood Change, Sleep Disturbance, Drug Effect, Psychedelic Experiences, Health, Subjective, Psilocin Toxicity, Psilocybin Toxicity, Psilocybin Causing Adverse Effects in Therapeutic Use, Anxiety, Psilocybin, Melocin, Inonotus Obliquus Whole Extract, Chaga, WITHDRAWN", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT05252598\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Depression,Anxiety,Microdosing,Wellbeing,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3763, "title": "Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD", "normalized_title": "yale program for psychedelic science ypps manual for psilocybin combined with non directive support in the treatment of ocd", "authors": "Ching THW, Grazioplene R, Pittenger C, Kelmendi B.", "abstract": "The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychedelic substances on brain function, cognition, and behavior, including their therapeutic potential in treating neuropsychiatric conditions. In support of this mission, YPPS is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The current study, “Effects of repeated dosing of psilocybin on obsessive-compulsive disorder: A randomized, waitlist-controlled study” (NCT05370911), will investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology and assess psychological mechanisms that may mediate psilocybin’s therapeutic effects on OCD. The study will employ a randomized, waitlist-controlled design with blinded ratings, with participants randomized to receive either immediate treatment (two doses of oral psilocybin separated by one week) or delayed treatment (7 weeks post-randomization). An adaptive dose selection strategy will be implemented; the first dose will be fixed at 25 mg of psilocybin, and the second dose will be 25 mg or 30 mg, depending on whether or not a clinically significant response is detected after the first dose. This manual provides background and details for facilitator-related activities at various phases - pre-dosing preparation sessions, dosing sessions, and post-dosing integration sessions. The approach for psychological support by facilitators is unstructured and non-directive. In other words, facilitators do not provide any structured therapy, but rather collaborate and support participants as they prepare for psilocybin dosing sessions, ensure their psychological safety during dosing sessions, and provide them with an unstructured, non-directive context in which to process and consolidate their experiences during and after each dosing at defined time points. In doing so, while no structured therapy program is implemented, the presence and accompaniment by facilitators throughout all study sessions in the treatment phase may be experienced as supportive or even therapeutic by participants. This manual shares several features with a previous YPPS protocol-specific session monitor manual for single-dose psilocybin paired with psychological support for OCD (Ching et al., 2022), including the primary focus on a non-directive approach for preparatory, dosing, and integration sessions. Distinctive additions in this manual include a discussion of psychological processes in OCD that serve as a context for responsive facilitation of study visits, as well as updated facilitator checklists for preparatory, dosing, and integration sessions specific to the current two-dose protocol.", "journal": "PsyArXiv", "publication_date": "2023-03-16", "publication_year": 2023, "doi": "10.31234/osf.io/ba42z", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/ba42z", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:19", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR632316\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "OCD,Mechanism of Action,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3186, "title": "Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD", "normalized_title": "yale program for psychedelic science ypps manual for psilocybin combined with non directive support in the treatment of ocd", "authors": "", "abstract": "The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychedelic substances on brain function, cognition, and behavior, including their therapeutic potential in treating neuropsychiatric conditions. In support of this mission, YPPS is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The current study, “Effects of repeated dosing of psilocybin on obsessive-compulsive disorder: A randomized, waitlist-controlled study” (NCT05370911), will investigate the effects of repeated dosing of oral psilocybin on obsessive-compulsive disorder (OCD) symptomatology and assess psychological mechanisms that may mediate psilocybin’s therapeutic effects on OCD. The study will employ a randomized, waitlist-controlled design with blinded ratings, with participants randomized to receive either immediate treatment (two doses of oral psilocybin separated by one week) or delayed treatment (7 weeks post-randomization). An adaptive dose selection strategy will be implemented; the first dose will be fixed at 25 mg of psilocybin, and the second dose will be 25 mg or 30 mg, depending on whether or not a clinically significant response is detected after the first dose. This manual provides background and details for facilitator-related activities at various phases - pre-dosing preparation sessions, dosing sessions, and post-dosing integration sessions. The approach for psychological support by facilitators is unstructured and non-directive. In other words, facilitators do not provide any structured therapy, but rather collaborate and support participants as they prepare for psilocybin dosing sessions, ensure their psychological safety during dosing sessions, and provide them with an unstructured, non-directive context in which to process and consolidate their experiences during and after each dosing at defined time points. In doing so, while no structured therapy program is implemented, the presence and accompaniment by facilitators throughout all study sessions in the treatment phase may be experienced as supportive or even therapeutic by participants. This manual shares several features with a previous YPPS protocol-specific session monitor manual for single-dose psilocybin paired with psychological support for OCD (Ching et al., 2022), including the primary focus on a non-directive approach for preparatory, dosing, and integration sessions. Distinctive additions in this manual include a discussion of psychological processes in OCD that serve as a context for responsive facilitation of study visits, as well as updated facilitator checklists for preparatory, dosing, and integration sessions specific to the current two-dose protocol.", "journal": "PsyArXiv", "publication_date": "2023-03-16", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/ba42z_v1", "keywords": "manual, non-directive, obsessive-compulsive disorder, psilocybin, psychedelic, psychiatry, psychology, psychopharmacology, therapy, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Intervention Research, Obsessive-compulsive and Related Disorders, Therapy, Psychotherapy, Psychopharmacology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"ba42z_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "OCD,Pharmacology,Mechanism of Action,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3524, "title": "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder", "normalized_title": "safety and efficacy of psilocybin for body dysmorphic disorder", "authors": "New York State Psychiatric Institute", "abstract": "In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period. In this pilot study, up to 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Procedures will follow those previously established in depression studies of psilocybin. Patients will receive intensive preparation and support from two therapists, including 8-9 hours accompanying the patient on the day of medication administration in the Biological Studies Unit of New York State Psychiatric Institute. Followup visits to monitor safety and clinical outcome will be conducted at day 1, week1, and months 1,2, and 3 post-administration. Resting state function magnetic resonance imaging will be conducted prior to and one day after psilocybin administration to assess the effect of medication on brain circuits.", "journal": "ClinicalTrials.gov", "publication_date": "2023-03-12", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04656301", "keywords": "Body Dysmorphic Disorders, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04656301\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Brain Imaging,Receptor Pharmacology,Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3772, "title": "Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study", "normalized_title": "self treatment of depression and complex post traumatic stress disorder with psilocybin and lsd a retrospective case study", "authors": "Turkia M.", "abstract": "In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case concerns a young man who suffered from early-onset complex trauma due to daily abuse by his comprehensive school teacher and other pupils, resulting in severe anxiety and depression. He refused anti-depressive medication. Supportive psychotherapy failed to alleviate the situation, and interaction with psychiatric personnel subjectively experienced as rejection escalated his symptoms. At the age of 19, he resorted to unsupervised self-treatment with psilocybin. Occasional high-dose psilocybin sessions alone did not produce permanent outcomes in a constantly retraumatizing environment. After becoming unemployed at the age of 25, he dedicated himself to working with psychedelics more intensively, with gradually declining doses. The essence of his method was to relive the originally overwhelming traumatic events, maintaining a conscious focus on somatic sensations and avoiding getting overwhelmed again. In his own estimation, by the age of 30, he had resolved most of his early trauma but had been sensitized to the prevalence of trauma and its consequences (e.g. violence, racism) in the society, and his exposure to these continued to cause him suffering. Regardless, he had gained 'a foundational feeling of peace or stability that could provide safety in the middle of all this'. The information for this case study was acquired in the course of semi-structured retrospective interviews 2.5 years apart. The case illustrates that chronic treatment-resistant depression together with an unsupportive social environment may present a challenge for psychedelic therapy. As with ketamine, chronic administration may be necessary in some cases.", "journal": "PsyArXiv", "publication_date": "2023-03-09", "publication_year": 2023, "doi": "10.31234/osf.io/wupvy", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/wupvy", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:20", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR628918\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Treatment-Resistant Depression,Healthcare Workers,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3233, "title": "Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study", "normalized_title": "self treatment of depression and complex post traumatic stress disorder with psilocybin and lsd a retrospective case study", "authors": "", "abstract": "In medicine, psychedelics were initially considered as a tool for clinicians to understand psychotic states. Based on the presented case data, a reversal of that concept is proposed: psychedelics could be conceptualized as a tool for people chronically anxious and depressed since early childhood to understand ordinary states of mind (e.g. calmness, hopefulness, relaxation, and joy). The case concerns a young man who suffered from early-onset complex trauma due to daily abuse by his comprehensive school teacher and other pupils, resulting in severe anxiety and depression. He refused anti-depressive medication. Supportive psychotherapy failed to alleviate the situation, and interaction with psychiatric personnel subjectively experienced as rejection escalated his symptoms. At the age of 19, he resorted to unsupervised self-treatment with psilocybin. Occasional high-dose psilocybin sessions alone did not produce permanent outcomes in a constantly retraumatizing environment. After becoming unemployed at the age of 25, he dedicated himself to working with psychedelics more intensively, with gradually declining doses. The essence of his method was to relive the originally overwhelming traumatic events, maintaining a conscious focus on somatic sensations and avoiding getting overwhelmed again. In his own estimation, by the age of 30, he had resolved most of his early trauma but had been sensitized to the prevalence of trauma and its consequences (e.g. violence, racism) in the society, and his exposure to these continued to cause him suffering. Regardless, he had gained 'a foundational feeling of peace or stability that could provide safety in the middle of all this'. The information for this case study was acquired in the course of semi-structured retrospective interviews 2.5 years apart. The case illustrates that chronic treatment-resistant depression together with an unsupportive social environment may present a challenge for psychedelic therapy. As with ketamine, chronic administration may be necessary in some cases.", "journal": "PsyArXiv", "publication_date": "2023-03-09", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/wupvy_v1", "keywords": "Amanita muscaria, bullying, C-PTSD, dissociation, DMT, LSD, major depression, MDMA, muscimol, psilocybin, psychedelics, psychedelic therapy, treatment-resistant depression, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Dissociative Disorders, Anxiety Disorders, Depressive Disorders, Trauma and Stress", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"wupvy_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,PTSD,Treatment-Resistant Depression,Healthcare Workers,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1536, "title": "Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.", "normalized_title": "inhibition of microglial gsk3β activity is common to different kinds of antidepressants a proposal for an in vitro screen to detect novel antidepressant principles", "authors": "Kalkman HO", "abstract": "Depression is a major public health concern. Unfortunately, the present antidepressants often are insufficiently effective, whilst the discovery of more effective antidepressants has been extremely sluggish. The objective of this review was to combine the literature on depression with the pharmacology of antidepressant compounds, in order to formulate a conceivable pathophysiological process, allowing proposals how to accelerate the discovery process. Risk factors for depression initiate an infection-like inflammation in the brain that involves activation microglial Toll-like receptors and glycogen synthase kinase-3β (GSK3β). GSK3β activity alters the balance between two competing transcription factors, the pro-inflammatory/pro-oxidative transcription factor NFκB and the neuroprotective, anti-inflammatory and anti-oxidative transcription factor NRF2. The antidepressant activity of tricyclic antidepressants is assumed to involve activation of G-coupled microglial receptors, raising intracellular cAMP levels and activation of protein kinase A (PKA). PKA and similar kinases inhibit the enzyme activity of GSK3β. Experimental antidepressant principles, including cannabinoid receptor-2 activation, opioid μ receptor agonists, 5HT2 agonists, valproate, ketamine and electrical stimulation of the Vagus nerve, all activate microglial pathways that result in GSK3β-inhibition. An in vitro screen for NRF2-activation in microglial cells with TLR-activated GSK3β activity, might therefore lead to the detection of totally novel antidepressant principles with, hopefully, an improved therapeutic efficacy.", "journal": "Biomedicines", "publication_date": "2023-03-06", "publication_year": 2023, "doi": "10.3390/biomedicines11030806", "pubmed_id": "36979785", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36979785/", "keywords": "5-HT2B, GS-coupled receptor, GSK3β, NRF2, cannabinoid CBR2, depression risk factor, ketamine, microglia, psilocybin, toll-like receptor", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"36979785\"}", "topic_tags": "Depression,Addiction,Pharmacology,Mechanism of Action,Receptor Pharmacology,Review Article,In Vitro Study,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1548, "title": "Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.", "normalized_title": "research into psychedelic assisted psychotherapy for anorexia nervosa should be funded", "authors": "Otterman LS", "abstract": "Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psychological comorbidities (Blinder, Cumella, and Sanathara 2006; Casiero and Frishman 2006), including increased suicide risk (Arcelus et al. 2011; Lipson and Sonneville 2020). In addition, eating disorders are growing in prevalence (Gilmache et al. 2019) and impact women at much higher rates than men (Bearman, Martinez, and Stice 2006), especially in adolescence (Spriggs, Kettner, and Carhart-Harris 2021). Anorexia nervosa (AN) is a particularly devastating eating disorder, with one of the highest mortality rates of any psychiatric disorder (Sullivan 1995). Despite the severity of the condition, current treatments for AN are limited in their efficacy (Khalsa et al. 2017). Based on the growing body of evidence demonstrating the short-term and long-term efficacy of psychedelic-assisted psychotherapy for the treatment of other mental illnesses, I argue that research into psychedelic-assisted psychotherapy for AN should be funded.", "journal": "Journal of bioethical inquiry", "publication_date": "2023-02-28", "publication_year": 2023, "doi": "10.1007/s11673-022-10220-9", "pubmed_id": "36534233", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36534233/", "keywords": "Anorexia nervosa, Eating disorders, Health research ethics, Informed consent, LSD, Psilocybin, Psychedelic-assisted psychotherapy", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"36534233\"}", "topic_tags": "Eating Disorders,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1542, "title": "Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.", "normalized_title": "pharmacotherapies for treatment resistant depression how antipsychotics fit in the rapidly evolving therapeutic landscape", "authors": "Jha MK, Mathew SJ.", "abstract": "One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U.S. Food and Drug Administration for treatment of depression (aripiprazole, brexpiprazole, cariprazine, extended-release quetiapine, and olanzapine-fluoxetine combination). While multiple acute-phase studies have demonstrated the efficacy of these medications in improving depressive symptoms, clinically meaningful improvement (i.e., remission) remains limited, with significant concerns about side effects (including weight gain, metabolic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use. With the rapidly evolving landscape of antidepressant treatments over the past few years, which has witnessed approval of rapid-acting antidepressants (e.g., esketamine nasal spray and dextromethorphan-bupropion combination) and several more in the late-stage pipeline (e.g., zuranolone and psilocybin), it remains to be seen whether the use of atypical antipsychotics will go the way of the older and rarely prescribed antidepressants (such as tricyclics and monoamine oxidase inhibitors). Pragmatic clinical trials are needed to compare the effectiveness of atypical antipsychotics with TRD-specific pharmacotherapies and neuromodulation treatments and to identify the optimal sequencing of these varied approaches for patients with MDD. When using atypical antipsychotics, clinicians and patients are encouraged to use a shared decision-making approach by personalizing treatment selection based on anticipated side effects, tolerability, cost, and feasibility.", "journal": null, "publication_date": "2023-02-28", "publication_year": 2023, "doi": "10.1176/appi.ajp.20230025", "pubmed_id": "36855876", "source_url": "https://doi.org/10.1176/appi.ajp.20230025", "keywords": "Humans, Antipsychotic Agents, Depression, Adult, United States, Depressive Disorder, Treatment-Resistant, Drug-Related Side Effects and Adverse Reactions, Aripiprazole, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36855876\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1553, "title": "Effect of psilocybin on decision-making and motivation in the healthy rat.", "normalized_title": "effect of psilocybin on decision making and motivation in the healthy rat", "authors": "飯倉 洋治, 馬場 實, 三河 春樹, 西間 三馨, 前田 和一, 赤坂 徹, 正木 拓朗, 有田 昌彦", "abstract": "Psilocybin and its active metabolite psilocin are hallucinogenic serotonergic agonists with high affinity for several serotonin receptors. In addition to underlying the hallucinogenic effects of these compounds, serotonin receptor activation also has important effects on decision-making and goal-directed behaviors. The impact of psilocybin and psilocin on these cognitive systems, however, remains unclear. This study investigated the effects of psilocybin treatment on decision-making and motivation in healthy male and female rats. We compared probability and delay discounting performance of psilocybin treated (1 mg/kg) to vehicle rats (n = 10/sex/group), and further assessed motivation in each group using a progressive ratio task. We also confirmed drug action by assessing head twitch responses after psilocybin treatment (1 mg/kg). Results from this study demonstrated that exposure to 1 mg/kg psilocybin did not affect decision-making in the probability and delay discounting tasks and did not reduce response rates in the progressive ratio task. However, psilocybin treatment did cause the expected increase in head twitch responses in both male and female rats, demonstrating that the drug was delivered at a pharmacologically relevant dosage. Combined, these results suggest that psilocybin may not impair or improve decision-making and motivation. Considering recent interest in psilocybin as a potential fast-acting therapeutic for a variety of mental health disorders, our findings also suggest the therapeutic effects of this drug may not be mediated by changes to the brain systems underlying reward and decision-making. Finally, these results may have important implications regarding the relative safety of this compound, suggesting that widespread cognitive impairments may not be seen in subjects, even after chronic treatment.", "journal": "PubMed", "publication_date": "2023-02-24", "publication_year": 2023, "doi": "10.1016/j.bbr.2022.114262", "pubmed_id": "36529299", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36529299", "keywords": "Ketotifen, Medicine, Internal medicine, Asthma, Military Technology and Strategies, Legal and Regulatory Analysis, Linguistic, Cultural, and Literary Studies", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W36529299\",\"openalex_url\":\"https://openalex.org/W36529299\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5022257201\",\"display_name\":\"飯倉 洋治\",\"orcid\":null},{\"id\":\"https://openalex.org/A5085169588\",\"display_name\":\"馬場 實\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027984471\",\"display_name\":\"三河 春樹\",\"orcid\":null},{\"id\":\"https://openalex.org/A5057467696\",\"display_name\":\"西間 三馨\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062302446\",\"display_name\":\"前田 和一\",\"orcid\":null},{\"id\":\"https://openalex.org/A5072543795\",\"display_name\":\"赤坂 徹\",\"orcid\":null},{\"id\":\"https://openalex.org/A5018845972\",\"display_name\":\"正木 拓朗\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037970070\",\"display_name\":\"有田 昌彦\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306525036\",\"source_display_name\":\"PubMed\",\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/36529299\",\"is_oa\":false}}", "topic_tags": "Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W36529299" }, { "id": 1564, "title": "Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.", "normalized_title": "hofmann vs paracelsus do psychedelics defy the basics of toxicology a systematic review of the main ergolamines simple tryptamines and phenylethylamines", "authors": "Henríquez-Hernández LA, Rojas-Hernández J, Quintana-Hernández DJ, Borkel LF.", "abstract": "Psychedelics are experiencing a strong renaissance and will soon be incorporated into clinical practice. However, there is uncertainty about how much harm they can cause at what doses. This review aimed to collect information on the health-hazardous doses of psychedelic substances, to be aware of the risks to which patients may be subjected. We focused on ergolamines, simple tryptamines, and phenylethylamines. We reviewed articles published in major medical and scientific databases. Studies reporting toxic or lethal doses in humans and animals were included. We followed PRISMA criteria for revisions. We identified 3032 manuscripts for inclusion. Of these, 33 were ultimately useful and gave relevant information about effects associated with high psychedelics doses. Despite having different molecular structures and different mechanisms of action, psychedelics are effective at very low doses, are not addictive, and are harmful at extremely high doses. For LSD and psilocybin, no dose has been established above which the lives of users are endangered. In contrast, MDMA appears to be the most dangerous substance, although reports are biased by recreational missuses. It seems that it is not only the dose that makes the poison. In the case of psychedelics, the set and setting make the poison.", "journal": null, "publication_date": "2023-02-02", "publication_year": 2023, "doi": "10.3390/toxics11020148", "pubmed_id": "36851023", "source_url": "https://doi.org/10.3390/toxics11020148", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36851023\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Systematic Review,Review Article,Safety,Toxicity", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1514, "title": "Psychedelics: Science sabotaged by Social Media.", "normalized_title": "psychedelics science sabotaged by social media", "authors": "Sellers EM, Romach MK.", "abstract": "The substantial challenges facing high and low dose psychedelic drug development to achieve regulatory approval have been documented in the scientific literature. These limitations have not deterred drug developers and social media from repeatedly misleading patients, the public and health professionals. Developing \"micro doses\" of psychedelics overcomes many of the scientific and regulatory challenges of high dose psychedelics. If micro-dosing could be shown to be efficacious and safe for long term use, it could be administered in the typical model for treatment of mental disorders. Such a model would be more cost effective than the high dose/intense psychotherapy model currently described and could be readily available to all individuals who need another medication option. Outpatient psychotherapeutic agents have a clear route for approval and would be unlikely to be burdened by the extensive Risks Evaluation and Mitigation Strategy needed for high dose use. There may be a different therapeutic role for both high and low dose psychedelic agents. This article is part of the Special Issue on \"National Institutes of Health Psilocybin Research Speaker Series\".", "journal": null, "publication_date": "2023-01-20", "publication_year": 2023, "doi": "10.1016/j.neuropharm.2023.109426", "pubmed_id": "36693562", "source_url": "https://doi.org/10.1016/j.neuropharm.2023.109426", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Social Media, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36693562\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4856, "title": "Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder", "normalized_title": "therapeutic potential of psilocybin a promising agent in treating major depressive disorder", "authors": "Dragana Marković, Eleonora Čapelja", "abstract": "Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Beside MDD, psilocybin can alleviate symptoms of anxiety, and post-traumatic stress disorder. In the human body, psilocybin is dephosphorylated to form its active metabolite, psilocin which exhibits its effect through binding to various serotonin receptors. Is is considered relatively safe and can potentially meet the therapeutic needs without addictiveness and overdose risk. Although psilocybin has great potential in treating MDD and other psychological disorders, many studies so far lack homogeneity in their methodology, which limits conclusions. Further studies are needed in more extensive and diverse populations.", "journal": "AIDASCO Reviews", "publication_date": "2023-01-16", "publication_year": 2023, "doi": "10.59783/aire.2023.15", "pubmed_id": null, "source_url": "https://doi.org/10.59783/aire.2023.15", "keywords": "Psilocybin, Major depressive disorder, Psychiatry, Anxiety, Hallucinogen, Psychology, Depression (economics), Medicine, Cognition, Macroeconomics, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Digital Mental Health Interventions", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:46", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4406142619\",\"openalex_url\":\"https://openalex.org/W4406142619\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5077364302\",\"display_name\":\"Dragana Marković\",\"orcid\":\"https://orcid.org/0000-0003-3646-8505\"},{\"id\":\"https://openalex.org/A5031710024\",\"display_name\":\"Eleonora Čapelja\",\"orcid\":\"https://orcid.org/0000-0001-5507-7767\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4387290105\",\"source_display_name\":\"AIDASCO Reviews\",\"landing_page_url\":\"https://doi.org/10.59783/aire.2023.15\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4406142619" }, { "id": 3568, "title": "Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder", "normalized_title": "pilot trial of visual healing a nature themed virtual immersive experience to optimize set and setting in psilocybin assisted therapy for alcohol use disorder", "authors": "Keith Heinzerling", "abstract": "Twenty participants, age 18 or older, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for moderate to severe Alcohol Use Disorder will be randomized to open-label psilocybin (25 mg) therapy with the Visual Healing Set and Setting platform (N=10) versus psilocybin (25 mg) with a standard Set and Setting platform (N=10). The purpose of this study is to evaluate the feasibility, safety, and tolerability of adding Visual Healing, a nature-themed virtual immersive program, to psilocybin-assisted therapy among participants with alcohol use disorder. The objective of the study is to test a strategy for optimizing Set and Setting for psilocybin-assisted therapy of alcohol use disorder. Psilocybin shows promise in early trials for alcohol use disorder, but initial results suggest that patients with alcohol use disorder may be less likely to achieve a mystical experience with standard doses of psilocybin. Optimizing Set and Setting for the psilocybin experience may improve outcomes without requiring higher drug doses. The current study will complete a pilot randomized clinical trial to assess the feasibility, safety, and tolerability of Visual Healing Set and Setting (N=10) versus standard Set and Setting procedures (N=10) in participants with alcohol use disorder undergoing open-label psilocybin 25 mg therapy. In the Visual Healing condition, participants will view nature-themed video programs during the Prep session and during the Ascent phase of the psilocybin experience. Anecdotal reports and reviews suggest that viewing Visual Healing creates a tranquil and calming environment that fosters a stronger connection between the viewer and nature. Psilocybin increases the users feeling of connection to nature and having an intention to connect with nature during the psychedelic session is associated with better outcomes of psychedelic-assisted therapy in initial studies. Reducing pre-dosing anxiety/apprehension and enhancing connections to nature with Visual Healing may improve outcomes of psychedelic-assisted therapy without the need for higher psilocybin doses.", "journal": "ClinicalTrials.gov", "publication_date": "2023-01-16", "publication_year": 2023, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04410913", "keywords": "Alcohol Use Disorder, Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting, ACTIVE_NOT_RECRUITING", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04410913\",\"overall_status\":\"ACTIVE_NOT_RECRUITING\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Anxiety,Addiction,Mystical Experience,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1516, "title": "Are psychedelics the answer to chronic pain: A review of current literature.", "normalized_title": "are psychedelics the answer to chronic pain a review of current literature", "authors": "Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, Vissers KCP, van der Wal SEI.", "abstract": "AimsWe aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin.ContentChronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin-2A (5-HT2A) receptor, several neurophysiological responses result in the disruption of functional connections in brain regions associated with chronic pain. Healthy reconnections can be made through neuroplastic effects, resulting in sustained pain relief. However, this process is not fully understood, and evidence of efficacy is limited and of low quality. In cancer and palliative related pain, the analgesic potential of psychedelics was established decades ago, and the current literature shows promising results on efficacy and safety in patients with cancer-related psychological distress. In other areas, patients suffering from severe headache disorders like migraine and cluster headache who have self-medicated with psychedelics report both acute and prophylactic efficacy of LSD and psilocybin. Randomized control trials are now being conducted to study the effects in cluster headache Furthermore, psychedelics have a generally favorable safety profile especially when compared to other analgesics like opioids. In addition, psychedelics do not have the addictive potential of opioids.ImplicationsGiven the current epidemic use of opioids, and that patients are in desperate need of an alternative treatment, it is important that further research is conducted on the efficacy of psychedelics in chronic pain conditions.", "journal": null, "publication_date": "2023-01-10", "publication_year": 2023, "doi": "10.1111/papr.13203", "pubmed_id": "36597700", "source_url": "https://doi.org/10.1111/papr.13203", "keywords": "Humans, Neoplasms, Cluster Headache, Lysergic Acid Diethylamide, Hallucinogens, Randomized Controlled Trials as Topic, Chronic Pain, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"36597700\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,End-of-Life Distress,Chronic Pain,Headache / Migraine,Receptor Pharmacology,Randomized Controlled Trial,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4862, "title": "Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa", "normalized_title": "cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in south africa", "authors": "Sebastian William Foster", "abstract": "The principle of cognitive liberty is assessed as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. To do so, s 12 of the Constitution of the Republic of South Africa, 1996, is analysed, determining that s 12(2) is not a numerus clausa and is capable of enforcing further protections and/or entitlements, such as cognitive liberty. Further, it is suggested that the interpretation of s 12(2)(b) offers protection to both body and mind, and as such, also protecting the cognitive liberty right. Having established that the Constitution protects the right afforded by the principle cognitive liberty, it is deduced that the current criminalisation of psilocybin mushrooms - a means through which an individual may exercise their cognitive liberty rights - in terms of the Drugs and Drug Trafficking Act and Medicines and Related Substances Act, conflict with the rights established in s 12 of the Constitution. A s 36 limitation of rights analysis is presented, detailing that the criminalisation of psilocybin mushrooms is not justifiable when the nature and importance of the limited right are weighed against the importance and purpose of the criminalisation. As such, this article concludes that the current criminalising legislation is not justifiable.", "journal": "South African Journal on Human Rights", "publication_date": "2023-01-01", "publication_year": 2023, "doi": "10.1080/02587203.2023.2202875", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1080/02587203.2023.2202875", "keywords": "Constitutionality, Constitution, Psilocybin, Legislation, Law, Interpretation (philosophy), Human rights, Political science, Psychology, Psychiatry, Philosophy, Hallucinogen, Linguistics, Psychedelics and Drug Studies, Cannabis and Cannabinoid Research, HIV, Drug Use, Sexual Risk", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:46", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4376279288\",\"openalex_url\":\"https://openalex.org/W4376279288\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5076597046\",\"display_name\":\"Sebastian William Foster\",\"orcid\":\"https://orcid.org/0000-0001-5908-6177\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S115424580\",\"source_display_name\":\"South African Journal on Human Rights\",\"landing_page_url\":\"http://dx.doi.org/10.1080/02587203.2023.2202875\",\"is_oa\":true}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4376279288" }, { "id": 4887, "title": "The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study", "normalized_title": "the safety and efficacy of comp360 psilocybin therapy in treatment resistant depression results from a long term observational follow up study", "authors": "Guy M. Goodwin, Lindsey Marwood, S. Mistry, Anna Nowakowska, Zainib Shabir, H. Clifton Simmons, E.K. Teoh, Jeng-Yu Tsai, E. Malievskaia", "abstract": "", "journal": "Neuroscience Applied", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1016/j.nsa.2023.102906", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1016/j.nsa.2023.102906", "keywords": "Psilocybin, Observational study, Depression (economics), Term (time), Medicine, Psychiatry, Psychology, Hallucinogen, Psychotherapist, Internal medicine, Physics, Economics, Macroeconomics, Quantum mechanics, Psychedelics and Drug Studies, Digital Mental Health Interventions, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:47", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4390223380\",\"openalex_url\":\"https://openalex.org/W4390223380\",\"openalex_relevance_score\":8,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5037628078\",\"display_name\":\"Guy M. Goodwin\",\"orcid\":\"https://orcid.org/0000-0002-1426-2816\"},{\"id\":\"https://openalex.org/A5080462431\",\"display_name\":\"Lindsey Marwood\",\"orcid\":\"https://orcid.org/0000-0002-5818-2199\"},{\"id\":\"https://openalex.org/A5016967968\",\"display_name\":\"S. Mistry\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036831540\",\"display_name\":\"Anna Nowakowska\",\"orcid\":\"https://orcid.org/0000-0003-4016-1522\"},{\"id\":\"https://openalex.org/A5076970739\",\"display_name\":\"Zainib Shabir\",\"orcid\":\"https://orcid.org/0000-0002-1865-7241\"},{\"id\":\"https://openalex.org/A5110391116\",\"display_name\":\"H. Clifton Simmons\",\"orcid\":\"https://orcid.org/0009-0000-5738-5771\"},{\"id\":\"https://openalex.org/A5111628063\",\"display_name\":\"E.K. Teoh\",\"orcid\":null},{\"id\":\"https://openalex.org/A5008221825\",\"display_name\":\"Jeng-Yu Tsai\",\"orcid\":\"https://orcid.org/0000-0002-8657-3744\"},{\"id\":\"https://openalex.org/A5012063316\",\"display_name\":\"E. Malievskaia\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"http://dx.doi.org/10.1016/j.nsa.2023.102906\",\"is_oa\":true}}", "topic_tags": "Depression,Observational Study,Treatment-Resistant Depression,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4390223380" }, { "id": 4868, "title": "The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa", "normalized_title": "the right to privacy in the decriminalisation of psilocybin mushrooms in south africa", "authors": "Sebastian William Foster", "abstract": "This article assesses the right to privacy as a ground for challenging the constitutionality of the criminalisation of psilocybin mushrooms. In doing so, it discusses the right to privacy as found in section 14 of the Constitution of the Republic of South Africa, 1996 (Constitution). Drawing on Constitutional Court case law, the article argues that the right to privacy is a fundamental right that deserves paramount protection, even in instances where individuals engage in illicit activities within the confines of their personal realm of privacy. Accordingly, the prohibiting laws, notably the Drugs and Drug Trafficking Act 140 of 1992 and the Medicines and Related Substances Act 101 of 1965, do prima facie limit an individual's right to privacy, and therefore an analysis in terms of section 36 of the Constitution is necessary. A section-36 limitations analysis is accordingly presented, through which it is concluded that the nature and importance of the limited right outweighs the importance and purpose of the criminalisation. This paper argues that the current articles of legislation, which criminalise psilocybin mushrooms, are not justifiable, in that they unjustifiably limit the right to privacy. As such, the criminalisation of psilocybin mushrooms falls short of the standards implemented in section 36 of the Constitution and is concluded to be unconstitutional. Keywords: privacy; psilocybin mushrooms; constitutionality; limitations analysis; constitutional interpretation; drug law reform.", "journal": "Law Democracy & Development", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.17159/2077-4907/2023/ldd.v27.1", "pubmed_id": null, "source_url": "https://doi.org/10.17159/2077-4907/2023/ldd.v27.1", "keywords": "Constitutionality, Constitution, Decriminalization, Law, Right to privacy, Legislation, Political science, Privacy laws of the United States, Prima facie, Torture, Information privacy, Human rights, Sexuality, Behavior, and Technology, HIV, Drug Use, Sexual Risk, Marriage and Sexual Relationships", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:34:46", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4366774867\",\"openalex_url\":\"https://openalex.org/W4366774867\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[\"https://openalex.org/W1776069529\",\"https://openalex.org/W2030458894\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2093994427\",\"https://openalex.org/W2097578741\",\"https://openalex.org/W2462388911\",\"https://openalex.org/W2500111186\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2557428091\",\"https://openalex.org/W2804830564\",\"https://openalex.org/W2890661930\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3012354707\",\"https://openalex.org/W3159227221\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4240609879\",\"https://openalex.org/W4255225407\",\"https://openalex.org/W4298412124\",\"https://openalex.org/W4376279288\"],\"authorships\":[{\"id\":\"https://openalex.org/A5076597046\",\"display_name\":\"Sebastian William Foster\",\"orcid\":\"https://orcid.org/0000-0001-5908-6177\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764888548\",\"source_display_name\":\"Law Democracy & Development\",\"landing_page_url\":\"https://doi.org/10.17159/2077-4907/2023/ldd.v27.1\",\"is_oa\":true}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4366774867" }, { "id": 1614, "title": "Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.", "normalized_title": "linkages between psychedelics and meditation in a population based sample in the united states", "authors": "Simonsson O, Goldberg SB", "abstract": "There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative sample (n = 953) of American adults. Those who reported experience with meditation were invited to complete a follow-up survey (n = 536, 92.1% response rate) measuring meditation-related variables. Models controlled for a range of potential confounds. Exposure to meditation was associated with lifetime classic psychedelic use and ego dissolution in covariate-adjusted models. In addition, among meditators, greater ego dissolution was associated with more frequent meditation practice. Both lifetime classic psychedelic use and ego dissolution were associated with enlightenment as motivation to practice meditation as well as lower likelihood of overall perceived barriers to meditation practice. Ego dissolution was positively associated with finding meditation more effective. Neither lifetime classic psychedelic use nor ego dissolution was associated with greater likelihood of meditation-related adverse effects. Taken together, results support potential synergy between psychedelics and meditation, but randomized controlled trials are necessary to establish safety and evaluate potential causal relationships.", "journal": "Journal of psychoactive drugs", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1080/02791072.2021.2022816", "pubmed_id": "35000559", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35000559/", "keywords": "LSD, Psilocybin, Psychedelics, ego dissolution, meditation, mindfulness", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"35000559\"}", "topic_tags": "Randomized Controlled Trial,Observational Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1577, "title": "On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression", "normalized_title": "on blinding and suicide risk in a recent trial of psilocybin assisted therapy for treatment resistant depression", "authors": "Natalie Gukasyan", "abstract": "", "journal": "Med", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1016/j.medj.2022.12.003", "pubmed_id": "36640755", "source_url": "https://doi.org/10.1016/j.medj.2022.12.003", "keywords": "Psilocybin, Blinding, Depression (economics), Expectancy theory, Adverse effect, Medicine, Psychiatry, Treatment-resistant depression, Clinical trial, Hallucinogen, Major depressive disorder, Psychology, Internal medicine, Cognition, Social psychology, Economics, Macroeconomics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4315874306\",\"openalex_url\":\"https://openalex.org/W4315874306\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W2061442239\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3193440797\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4293801859\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W6846521495\"],\"authorships\":[{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210167770\",\"source_display_name\":\"Med\",\"landing_page_url\":\"https://doi.org/10.1016/j.medj.2022.12.003\",\"is_oa\":false}}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4315874306" }, { "id": 1576, "title": "Is psilocybin an effective antidepressant and what is its Mechanism of action?", "normalized_title": "is psilocybin an effective antidepressant and what is its mechanism of action", "authors": "Mann JJ.", "abstract": "Goodwin et al.1 report a single 25 mg dose of psilocybin has an antidepressant effect short-term in medication-resistant depression. Unanswered questions include drug blood level as a guide to dose, psychedelic effects relationship to antidepressant benefit, and potential suicide risk of psilocybin.", "journal": null, "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1016/j.xcrm.2022.100906", "pubmed_id": "36652915", "source_url": "https://doi.org/10.1016/j.xcrm.2022.100906", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"36652915\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1523, "title": "Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences.", "normalized_title": "magic mushroom use a qualitative interview study of post trip impacts and strategies for optimizing experiences", "authors": "Shaw L, Rea K, Lachowsky NJ, Roth EA", "abstract": "The field of psychedelic research is undergoing a revival, yet research focused on non-clinical psychedelic use remains relatively limited. The current qualitative study sheds light on how people use magic mushrooms, what they perceive the effects of such use to be, and the meanings that users attach to their magic mushroom experiences. To be eligible to participate in the study, participants were required to be young adults who had used magic mushrooms within the past three months and residents of Victoria, Canada. Semi-structured, one-on-one in-person interviews regarding magic mushroom use habits, culture, knowledge and other factors were conducted with each participant and subsequently analyzed thematically. Participants associated magic mushroom use with lasting impacts on their lives including transformation and learning experiences. Additionally, participants described strategies to optimize their magic mushroom experiences, including engaging in research regarding magic mushrooms as well as making use of peer supports. Furthermore, aspects of magic mushroom experiences conceptualized as harmful in previous studies were described by participants as associated with learning experiences and few harms. Participants' perceived positive outcomes and relatively low risk profile warrants further research to inform how magic mushroom users can maximize potential positive outcomes and also minimize harms.", "journal": "Journal of psychoactive drugs", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1080/02791072.2022.2054746", "pubmed_id": "35315749", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35315749/", "keywords": "Magic mushrooms, harm reduction, psilocybin, qualitative, recreational use, transformation", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"35315749\"}", "topic_tags": "Aging,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4220816548" }, { "id": 1509, "title": "The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.", "normalized_title": "the impact of psilocybin on patients experiencing psychiatric symptoms a systematic review of randomized clinical trials", "authors": "IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, Danovitch I.", "abstract": "ObjectiveThis systematic review aims to evaluate the impact of psilocybin on patients experiencing psychiatric symptoms, with a focus on health-related quality of life (HRQoL) and safety.Method of researchFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched the PubMed database and identified studies published from January 2011 to December 2021 pertaining to the impact of psilocybin on psychiatric symptoms. Two authors independently conducted a focused analysis and reached a final consensus on five studies meeting the specific selection criteria. Study bias was addressed using the Cochrane risk of bias tool.ResultsThe impact of psilocybin on psychiatric symptoms was examined in five randomized controlled trials (RCTs). Four studies administered 1 to 2 doses of psilocybin, with doses ranging from 14mg/70kg to 30mg/70kg, and one study administered a fixed dose of 25mg to all participants. Administration of psilocybin resulted in significant and sustained reduction in symptoms of anxiety and depression, enhanced sense of wellbeing, life satisfaction, and positive mood immediately after psilocybin administration and up to six months after conclusion of treatment. All studies included some form of psychotherapy, and none reported serious adverse effects.ConclusionRCTs show the efficacy of psilocybin in the treatment of anxiety and depression symptoms, as well as improvement in HRQoL, and no serious side effects. However, additional research is necessary to characterize predictors of treatment response, patient screening requirements, effectiveness in broader clinical populations, and guidelines for psilocybin-assisted psychotherapy.", "journal": null, "publication_date": "2022-12-31", "publication_year": 2022, "doi": null, "pubmed_id": "37387703", "source_url": "https://europepmc.org/article/MED/37387703", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"37387703\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Wellbeing,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1485, "title": "Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.", "normalized_title": "editorial appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders", "authors": "Blest-Hopley G, Amit BH, O'Neill A, Ruffell SGD", "abstract": "", "journal": "Frontiers in psychiatry", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.3389/fpsyt.2023.1191970", "pubmed_id": "37252138", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37252138/", "keywords": "cannabinoids, cannabis, hallucinogenic, psilocybin, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37252138\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1461, "title": "Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.", "normalized_title": "systematic review and rationale of using psychedelics in the treatment of cannabis use disorder", "authors": "Phan AN, Terry GE", "abstract": "Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class in other substance use disorders, and self-report surveys suggest they may result in positive outcomes for CUD. Herein, we review the existing literature pertaining to psychedelic use in persons with or at risk for CUD and consider the potential rationale underpinning psychedelics as a treatment for CUD. A systematic search was performed in several databases. Inclusion criteria were primary research reporting use of psychedelics or related substances and CUD for treatment in human subjects. Exclusion criteria were results including psychedelics or related substances without changes in cannabis use or risks associated with CUD. Three hundred and five unique results were returned. One article was identified using the non-classical psychedelic ketamine in CUD; three articles were identified as topically relevant based on their secondary data or consideration of mechanism. Additional articles were reviewed for purposes of background, review of safety considerations, and formulating rationale. Limited data and reporting are available on the use of psychedelics in persons with CUD, and more research is needed given the anticipated increase in CUD incidence and increasing interest in psychedelic use. While psychedelics, broadly, have a high therapeutic index with infrequent serious adverse effects, particular adverse effects at risk in the CUD population, such as psychosis and cardiovascular events, should be considered. Possible mechanisms by which psychedelics have therapeutic potential in CUD are explored.", "journal": "Frontiers in psychiatry", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.3389/fpsyt.2023.1144276", "pubmed_id": "37435402", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37435402/", "keywords": "MDMA, cannabis use disorder, ketamine, psilocybin, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37435402\"}", "topic_tags": "Addiction,Mechanism of Action,Systematic Review,Review Article,Observational Study,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1458, "title": "Medical student attitudes and perceptions of psychedelic-assisted therapies.", "normalized_title": "medical student attitudes and perceptions of psychedelic assisted therapies", "authors": "Li I, Fong R, Hagen M, Tabaac B", "abstract": "Although certain psychedelic agents may soon gain federal approval for use in treating specific psychiatric conditions, the utilization of such therapies in clinical practice will depend largely on the attitudes of healthcare providers. Therefore, this study assesses the current attitudes, knowledge, exposure, and acceptance of psychedelics and psychedelic-assisted therapies amongst medical students. In fall semester of 2022, surveys were emailed to 580 medical students attending medical institutions in the state of Nevada in the United States. Utilizing knowledge and attitude items from previously published studies, the survey collected demographic data and assessed student attitudes with five-point Likert-scale variables. Data was analyzed using summary statistics and Kruskal-Wallis tests for differences in mean survey scores (i.e., attitudes towards psychedelics) based on demographic factors. 132 medical students participated in the survey (22.7% response rate). Medical students demonstrated overall positive attitudes towards psychedelics, lack of knowledge regarding psychedelics, and uncertainty towards neurocognitive risks of psychedelics. Overall, 78.6% of students agreed that psychedelics have therapeutic potential, while 95.2% agreed that psychedelics deserves further research in assessing this potential. Additionally, there was no statistically significant effect of demographic variables, including age, sex, and level of training, on attitudes. Although students are overall curious and optimistic about psychedelics, they demonstrate a lack of knowledge regarding recent research efforts. As the field of psychiatry prepares to implement psychedelics and psychedelic-assisted therapies, education and awareness of such agents should be initiated early on in medical clinical training.", "journal": "Frontiers in psychiatry", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.3389/fpsyt.2023.1190507", "pubmed_id": "37441143", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37441143/", "keywords": "DMT, LSD, attitudes, medical students, opinions, perceptions, psilocybin, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37441143\"}", "topic_tags": "Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1457, "title": "Case report: Psychedelic-induced seizures captured by intracranial electrocorticography.", "normalized_title": "case report psychedelic induced seizures captured by intracranial electrocorticography", "authors": "Blond BN, Schindler EAD", "abstract": "Classic psychedelics are currently re-emerging as therapeutic agents with unique clinical benefits; however, it is also important to recognize the adverse effects of this drug class. While the risk of seizures with this drug class is known, the literature is lacking in detail. We present a case of psychedelic mushroom-induced seizures in a person with refractory right temporal lobe epilepsy implanted with a responsive neurostimulation (RNS) system. A large increase in typical seizure frequency coincided with the ingestion of a large dose of the mushrooms. This is the first reported case of electrographically confirmed seizures associated with classic psychedelic drug use. With the surge of research and movements toward the clinical application of classic psychedelic compounds, the risk for drug-induced seizures should be considered, including factors such as a history of epilepsy and drug doses and regimens.", "journal": "Frontiers in neurology", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.3389/fneur.2023.1214969", "pubmed_id": "37456653", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37456653/", "keywords": "case report, epilepsy, psilocybin, psychedelics, seizures", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37456653\"}", "topic_tags": "Case Report,Safety", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1355, "title": "Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.", "normalized_title": "editorial psychedelics as treatments for substance use disorders exploring therapeutic potential risks underlying mechanisms of action and implementation challenges", "authors": "Barnett BS, Bassir Nia A, Sackett NB, Weleff J", "abstract": "", "journal": "Frontiers in psychiatry", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.3389/fpsyt.2023.1305478", "pubmed_id": "37928914", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37928914/", "keywords": "addiction, ketamine, psilocybin, psychedelics, substance use disorder", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"37928914\"}", "topic_tags": "Addiction,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1351, "title": "\"How Do I Learn More About this?\": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.", "normalized_title": "how do i learn more about this utilization and trust of psychedelic information sources among people naturalistically using psychedelics", "authors": "Kruger DJ, Enghoff O, Herberholz M, Barron J, Boehnke KF", "abstract": "There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-seeking behavior of people using psychedelics naturalistically, given the importance of preparation and harm-reduction. We examined sources of information for people using psychedelics naturalistically, and the degree to which they are trusted in a large, anonymous, online survey ( = 1221). The most common source of participants' information on psychedelics was their own experimentation and experiences (79.52%). Most also sought information from Internet websites (61.67%), friends (61.02%), Internet discussion forums (57.08%), books (57%), and articles in peer-reviewed scientific journals (54.55%). Few sought information from their primary health care provider (4.83%). Articles published in scientific journals, psychedelic nonprofits, and researchers based in colleges or universities were the most trusted sources of psychedelic information. Government agencies and pharmaceutical companies were the least trusted. Few participants thought that the popular media accurately stated the benefits and risks of psychedelics and most thought that the popular media failed to distinguish between different types of psychedelics. Our results indicate a high level of information seeking among psychedelic users, with a diverse array of information sources typically outside of mainstream health and medical care systems.", "journal": "Journal of psychoactive drugs", "publication_date": "2022-12-31", "publication_year": 2022, "doi": "10.1080/02791072.2023.2201263", "pubmed_id": "37078418", "source_url": "https://pubmed.ncbi.nlm.nih.gov/37078418/", "keywords": "LSD, Psychedelics, information, media, psilocybin, trust", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:37", "raw_json": "{\"pubmed_id\":\"37078418\"}", "topic_tags": "Review Article,Observational Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1549, "title": "Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.", "normalized_title": "experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines", "authors": "Heal DJ, Gosden J, Smith SL, Atterwill CK.", "abstract": "Research on classical psychedelics (psilocybin, LSD and DMT) and entactogen, MDMA, has produced a renaissance in the search for more effective drugs to treat psychiatric, neurological and various peripheral disorders. Psychedelics and entactogens act though interaction with 5-HT2A and other serotonergic receptors and/or monoamine reuptake transporters. 5-HT, which serves as a neurotransmitter and hormone, is ubiquitously distributed in the brain and peripheral organs, tissues and cells where it has vasoconstrictor, pro-inflammatory and pro-nociceptive actions. Serotonergic psychedelics and entactogens have known safety and toxicity risks. For these drugs, the risks been extensively researched and empirically assessed through human experience. However, novel drug-candidates require thorough non-clinical testing not only to predict clinical efficacy, but also to address the risks they pose during clinical development and later after approval as prescription medicines. We have defined the challenges researchers will encounter when developing novel serotonergic psychedelics and entactogens. We describe screening techniques to predict clinical efficacy and address the safety/toxicity risks emerging from our knowledge of the existing drugs: 1) An early-stage, non-clinical screening cascade to pharmacologically characterise novel drug-candidates. 2) Models to detect hallucinogenic activity. 3) Models to differentiate hallucinogens from entactogens. 4) Non-clinical preclinical lead optimisation technology (PLOT) screening to select drug-candidates. 5) Modified animal models to evaluate the abuse and dependence risks of novel psychedelics in Safety Pharmacology testing. Our intention has been to design non-clinical screening strategies that will reset the balance between benefits and harms to deliver more effective and safer novel psychedelics for clinical use. This article is part of the Special Issue on 'National Institutes of Health Psilocybin Research Speaker Series'.", "journal": null, "publication_date": "2022-12-15", "publication_year": 2022, "doi": "10.1016/j.neuropharm.2022.109375", "pubmed_id": "36529260", "source_url": "https://doi.org/10.1016/j.neuropharm.2022.109375", "keywords": "Brain, Animals, Humans, Serotonin, Lysergic Acid Diethylamide, Hallucinogens, Treatment Outcome, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36529260\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Receptor Pharmacology,Animal Study,Safety,Toxicity,Drug Interactions,Inflammation", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1620, "title": "“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use", "normalized_title": "a sense of the bigger picture a qualitative analysis of follow up interviews with people with bipolar disorder who self reported psilocybin use", "authors": "Meghan DellaCrosse, Mollie Pleet, Emma Morton, Amir Ashtari, Kimberly Sakai, Josh Woolley, Erin E. Michalak", "abstract": "OBJECTIVES: People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in \"magic mushrooms,\" is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have excluded people with BD as a precaution against possible adverse effects (e.g., mania). Our study centered the experiences of adults living with BD who consumed psilocybin-containing mushrooms, and aimed to (1) understand its subjective impacts on BD symptoms, (2) deepen understanding of Phase I survey results, and (3) elucidate specific contextual factors associated with adverse reactions in naturalistic settings. METHODS: Following an international survey (Phase I), follow-up interviews were conducted with 15 respondents (Phase II) to further understand psilocybin use among adults with BD. As part of a larger mixed-methods explanatory sequential design study, reflexive thematic analysis was used to elaborate findings. RESULTS: Three major themes containing sub-themes were developed. (1) Mental Health Improvements: (1.1) decreased impact and severity of depression, (1.2) increased emotion processing, (1.3) development of new perspectives, and (1.4) greater relaxation and sleep. (2) Undesired Mental Health Impacts: (2.1) changes in sleep, (2.2) increased mania severity, (2.3) hospitalization, and (2.4) distressing sensory experiences. (3) Salient Contextual Factors for psilocybin use included: (3.1) poly-substance use and psilocybin dose, (3.2) solo versus social experiences, and (3.3) pre-psilocybin sleep deprivation. CONCLUSION: Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted.", "journal": "PLoS ONE", "publication_date": "2022-12-13", "publication_year": 2022, "doi": "10.1371/journal.pone.0279073", "pubmed_id": "36516137", "source_url": "https://doi.org/10.1371/journal.pone.0279073", "keywords": "Psilocybin, Hypomania, Mania, Bipolar disorder, Psychology, Psychiatry, Thematic analysis, Clinical psychology, Mental health, Psychosocial, Mood, Hallucinogen, Medicine, Qualitative research, Social science, Sociology, Psychedelics and Drug Studies, Bipolar Disorder and Treatment, Forensic Toxicology and Drug Analysis", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4311439362\",\"openalex_url\":\"https://openalex.org/W4311439362\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":27,\"referenced_works\":[\"https://openalex.org/W73530450\",\"https://openalex.org/W413956720\",\"https://openalex.org/W561751346\",\"https://openalex.org/W1525233425\",\"https://openalex.org/W1893938325\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1981803616\",\"https://openalex.org/W1984344128\",\"https://openalex.org/W2012360636\",\"https://openalex.org/W2014682444\",\"https://openalex.org/W2015662968\",\"https://openalex.org/W2022579575\",\"https://openalex.org/W2027476620\",\"https://openalex.org/W2033002423\",\"https://openalex.org/W2033466502\",\"https://openalex.org/W2039347664\",\"https://openalex.org/W2044115095\",\"https://openalex.org/W2059519261\",\"https://openalex.org/W2063579163\",\"https://openalex.org/W2081185462\",\"https://openalex.org/W2081397150\",\"https://openalex.org/W2086244710\",\"https://openalex.org/W2102059582\",\"https://openalex.org/W2108489849\",\"https://openalex.org/W2114807890\",\"https://openalex.org/W2116581684\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2124308499\",\"https://openalex.org/W2126093392\",\"https://openalex.org/W2133589148\",\"https://openalex.org/W2137460360\",\"https://openalex.org/W2142490107\",\"https://openalex.org/W2150291951\",\"https://openalex.org/W2152723462\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2162401463\",\"https://openalex.org/W2163145097\",\"https://openalex.org/W2166423384\",\"https://openalex.org/W2168391307\",\"https://openalex.org/W2290849147\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2410199304\",\"https://openalex.org/W2473889906\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2726744335\",\"https://openalex.org/W2742814779\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2795698014\",\"https://openalex.org/W2802164302\",\"https://openalex.org/W2802275412\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2895700889\",\"https://openalex.org/W2900619723\",\"https://openalex.org/W2901636802\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2950504429\",\"https://openalex.org/W2953946378\",\"https://openalex.org/W2960566636\",\"https://openalex.org/W2971831602\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2999443158\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3007070994\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3041342449\",\"https://openalex.org/W3048560297\",\"https://openalex.org/W3092548915\",\"https://openalex.org/W3093223973\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107150606\",\"https://openalex.org/W3120652491\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3140493070\",\"https://openalex.org/W3158216155\",\"https://openalex.org/W3166459008\",\"https://openalex.org/W3201512146\",\"https://openalex.org/W4211069648\",\"https://openalex.org/W4214570845\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4232977219\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4364348136\",\"https://openalex.org/W6767707637\"],\"authorships\":[{\"id\":\"https://openalex.org/A5063981201\",\"display_name\":\"Meghan DellaCrosse\",\"orcid\":\"https://orcid.org/0000-0001-5554-277X\"},{\"id\":\"https://openalex.org/A5038432008\",\"display_name\":\"Mollie Pleet\",\"orcid\":\"https://orcid.org/0000-0001-7786-4147\"},{\"id\":\"https://openalex.org/A5048752706\",\"display_name\":\"Emma Morton\",\"orcid\":\"https://orcid.org/0000-0001-6179-1983\"},{\"id\":\"https://openalex.org/A5006067386\",\"display_name\":\"Amir Ashtari\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088265750\",\"display_name\":\"Kimberly Sakai\",\"orcid\":null},{\"id\":\"https://openalex.org/A5052144380\",\"display_name\":\"Josh Woolley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5006308151\",\"display_name\":\"Erin E. Michalak\",\"orcid\":\"https://orcid.org/0000-0002-0812-6527\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S202381698\",\"source_display_name\":\"PLoS ONE\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pone.0279073\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Emotional Processing,Clinical Trial,Observational Study,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4311439362" }, { "id": 1597, "title": "Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption", "normalized_title": "risks and benefits of psilocybin use in people with bipolar disorder an international web based survey on experiences of magic mushroom consumption", "authors": "Emma Morton, Kimberly Sakai, Amir Ashtari, Mollie Pleet, Erin E. Michalak, Josh Woolley", "abstract": "Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder (BD). Knowledge of the risks and benefits of psilocybin in BD is limited to case studies. Aim: To support the design of clinical trials, we surveyed experiences of psilocybin use in people with BD. Methods: An international web-based survey was used to explore experiences of psilocybin use in people with a self-reported diagnosis of BD. Quantitative findings were summarised using descriptive statistics. Qualitative content analysis was used to investigate free-text responses, with a focus on positive experiences of psilocybin use. Results: A total of 541 people completed the survey (46.4% female, mean 34.1 years old). One-third (32.2%; n = 174) of respondents described new/increasing symptoms after psilocybin trips, prominently manic symptoms, difficulties sleeping and anxiety. No differences in rates of adverse events overall were observed between individuals with BD I compared to BD II. Use of emergency medical services was rare ( n = 18; 3.3%), and respondents (even those who experienced adverse effects) indicated that psilocybin use was more helpful than harmful. Quantitative findings elaborated on perceived benefits, as well as the potential for psilocybin trips to contain both positively and negatively received elements. Conclusions: The subjective benefits of psilocybin use for mental health symptoms reported by survey participants encourage further investigation of psilocybin-based treatments for BD. Clinical trials should incorporate careful monitoring of symptoms, as data suggest that BD symptoms may emerge or intensify following psilocybin use.", "journal": "Journal of Psychopharmacology", "publication_date": "2022-12-13", "publication_year": 2022, "doi": "10.1177/02698811221131997", "pubmed_id": "36515370", "source_url": "https://doi.org/10.1177/02698811221131997", "keywords": "Psilocybin, Mushroom, Mushroom poisoning, Bipolar disorder, Psychiatry, Web survey, MAGIC (telescope), Psychology, Consumption (sociology), Hallucinogen, Clinical psychology, Business, Art, Biology, Cognition, Marketing, Food science, Physics, Quantum mechanics, Aesthetics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4311477082\",\"openalex_url\":\"https://openalex.org/W4311477082\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":72,\"referenced_works\":[\"https://openalex.org/W1531015715\",\"https://openalex.org/W1936382619\",\"https://openalex.org/W1967910109\",\"https://openalex.org/W1979687576\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1982621879\",\"https://openalex.org/W1984344128\",\"https://openalex.org/W1984708171\",\"https://openalex.org/W1990140024\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2005405662\",\"https://openalex.org/W2008814488\",\"https://openalex.org/W2014682444\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2032307757\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2046060667\",\"https://openalex.org/W2048082839\",\"https://openalex.org/W2049172770\",\"https://openalex.org/W2059116130\",\"https://openalex.org/W2070200064\",\"https://openalex.org/W2070454612\",\"https://openalex.org/W2081401977\",\"https://openalex.org/W2091677454\",\"https://openalex.org/W2099945881\",\"https://openalex.org/W2110159781\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114940817\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2120917538\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2128309600\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2142225512\",\"https://openalex.org/W2150495094\",\"https://openalex.org/W2155204043\",\"https://openalex.org/W2156579583\",\"https://openalex.org/W2161282771\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2167930802\",\"https://openalex.org/W2168058604\",\"https://openalex.org/W2168391307\",\"https://openalex.org/W2186514509\",\"https://openalex.org/W2275915163\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2490303275\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2587579530\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2755651923\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2769860872\",\"https://openalex.org/W2789412903\",\"https://openalex.org/W2791560250\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2896063467\",\"https://openalex.org/W2899316941\",\"https://openalex.org/W2911902447\",\"https://openalex.org/W2936730103\",\"https://openalex.org/W2958413903\",\"https://openalex.org/W2965468106\",\"https://openalex.org/W3006460836\",\"https://openalex.org/W3033157912\",\"https://openalex.org/W3043935161\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118498264\",\"https://openalex.org/W3123670341\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3139397908\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160183306\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W3201512146\",\"https://openalex.org/W3201992062\",\"https://openalex.org/W4212903385\"],\"authorships\":[{\"id\":\"https://openalex.org/A5048752706\",\"display_name\":\"Emma Morton\",\"orcid\":\"https://orcid.org/0000-0001-6179-1983\"},{\"id\":\"https://openalex.org/A5088265750\",\"display_name\":\"Kimberly Sakai\",\"orcid\":null},{\"id\":\"https://openalex.org/A5006067386\",\"display_name\":\"Amir Ashtari\",\"orcid\":null},{\"id\":\"https://openalex.org/A5038432008\",\"display_name\":\"Mollie Pleet\",\"orcid\":\"https://orcid.org/0000-0001-7786-4147\"},{\"id\":\"https://openalex.org/A5006308151\",\"display_name\":\"Erin E. Michalak\",\"orcid\":\"https://orcid.org/0000-0002-0812-6527\"},{\"id\":\"https://openalex.org/A5052144380\",\"display_name\":\"Josh Woolley\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811221131997\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Clinical Trial,Observational Study,Safety,Adverse Events,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4311477082" }, { "id": 1517, "title": "Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.", "normalized_title": "psychedelic assisted therapy and psychedelic science a review and perspective on opportunities in neurosurgery and neuro oncology", "authors": "Kelly DF, Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ.", "abstract": "After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including depression, anxiety, addiction, post-traumatic stress disorder, anorexia, and chronic pain syndromes. The classic serotonergic psychedelics psilocybin and lysergic acid diethylamide and nonclassic psychedelics 3,4-methylenedioxymethamphetamine and ketamine are increasingly appreciated as neuroplastogens given their potential to fundamentally alter mood and behavior well beyond the time window of measurable exposure. Imaging studies with psychedelics are also helping advance our understanding of neural networks and connectomics. This resurgence in psychedelic science and psychedelic-assisted therapy has potential significance for the fields of neurosurgery and neuro-oncology and their diverse and challenging patients, many of whom continue to have mental health issues and poor quality of life despite receiving state-of-the-art care. In this study, we review recent and ongoing clinical trials, the set and setting model of psychedelic-assisted therapy, potential risks and adverse events, proposed mechanisms of action, and provide a perspective on how the safe and evidence-based use of psychedelics could potentially benefit many patients, including those with brain tumors, pain syndromes, ruminative disorders, stroke, SAH, TBI, and movement disorders. By leveraging psychedelics' neuroplastic potential to rehabilitate the mind and brain, novel treatments may be possible for many of these patient populations, in some instances working synergistically with current treatments and in some using subpsychedelic doses that do not require mind-altering effects for efficacy. This review aims to encourage broader multidisciplinary collaboration across the neurosciences to explore and help realize the transdiagnostic healing potential of psychedelics.", "journal": null, "publication_date": "2022-12-07", "publication_year": 2022, "doi": "10.1227/neu.0000000000002275", "pubmed_id": "36512813", "source_url": "https://doi.org/10.1227/neu.0000000000002275", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Neurosurgery, Quality of Life, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"36512813\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Eating Disorders,Chronic Pain,Brain Imaging,Mechanism of Action,Aging,Clinical Trial,Review Article,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1627, "title": "Psychedelic-Assisted Therapy for People with Eating Disorders.", "normalized_title": "psychedelic assisted therapy for people with eating disorders", "authors": "Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS", "abstract": "A growing body of research suggests psychedelic-assisted therapy (PAT) may be safe and effective for a variety of mental health conditions. Among these, eating disorders have been a recent target of interest. This review provides an up-to-date summary of the potential mechanisms and use of PAT in people diagnosed with eating disorders, with a focus on anorexia nervosa. Classic psychedelics may have transdiagnostic efficacy through several mechanisms relevant to eating disorder pathology. Interest in, and efforts to increase access to PAT are both high. Early clinical trials are focused on establishing the safety and utility of this treatment in eating disorders, and efficacy remains unclear. High-quality published data to support the use of PAT for people with eating disorders remains lacking. Recent studies however suggest PAT has the potential to augment the efficacy of current interventions for these difficult-to-treat conditions.", "journal": "Current psychiatry reports", "publication_date": "2022-11-30", "publication_year": 2022, "doi": "10.1007/s11920-022-01394-5", "pubmed_id": "36374357", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36374357/", "keywords": "Anorexia nervosa, Eating disorders, Hallucinogens, Psilocybin, Psychedelics, Serotonin", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"36374357\"}", "topic_tags": "Eating Disorders,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1625, "title": "Therapeutic use of psilocybin: Practical considerations for dosing and administration.", "normalized_title": "therapeutic use of psilocybin practical considerations for dosing and administration", "authors": "MacCallum CA, Lo LA, Pistawka CA, Deol JK.", "abstract": "The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals. This is particularly concerning given the medical complexity and vulnerable nature of patients for whom psilocybin-assisted psychotherapy may be considered. This article aims to provide health care professionals with an overview of practical considerations for psilocybin therapy, rooted in a patient safety focus. Within this piece we will review basic psilocybin pharmacology and pharmacokinetics, indications, practical therapeutic strategies (e.g., dosing, administration, monitoring) and safety considerations (e.g., contraindications, adverse events, and drug interactions). With this information, our goal is to increase the knowledge and comfort of health care professionals to discuss and counsel their patients on psilocybin therapy, ultimately improving patient care and safety.", "journal": null, "publication_date": "2022-11-30", "publication_year": 2022, "doi": "10.3389/fpsyt.2022.1040217", "pubmed_id": "36532184", "source_url": "https://doi.org/10.3389/fpsyt.2022.1040217", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"36532184\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Review Article,Safety,Adverse Events,Drug Interactions,Contraindications", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1635, "title": "Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.", "normalized_title": "psilocybin as a treatment for psychiatric illness a meta analysis", "authors": "Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J.", "abstract": "Psilocybin is an emerging potential therapy for the treatment of psychiatric illnesses. Microdosing has been shown to result in an overall improvement in patients with anxiety, depression, obsessive-compulsive disorder, post-traumatic stress disorder, and substance abuse. This meta-analysis explores and compiles prior research to make further inferences regarding psilocybin and its use for the treatment of psychiatric illness along with its safety and efficacy. Database searches were conducted to identify peer-reviewed randomized controlled trials and clinical trials mentioning psilocybin use and psychiatric illness. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram was created and analysis was run on the nine articles that met all established inclusion criteria. An event is defined as a participant who showed improvement, in a quantitative method, from baseline after the use of psilocybin. Another analysis was done using depression severity (Quick Inventory of Depressive Symptomatology 16-Item Self Report, QIDS-SR16) at baseline and after the use of psilocybin. Analyses of the original data and the nine articles showed a great deal of heterogeneity with an I2 value of 73.68%, suggesting that the studies in this meta-analysis cannot be considered to be studies of the same population. The Q value of 30.4 was higher than 15.507, which is the critical value for eight degrees of freedom found in a chi-square distribution. This Q value showed a high degree of variation and lacked significance. The second meta-run on QIDS-SR16 scores from three studies showed a Q value of 1.16 which was lower than 5.991, the critical value for two degrees of freedom found in a chi-square distribution. The I2 statistic for this second meta-analysis was -73% which can be equated to zero. This indicated that the data were homogeneous or that there was no observed heterogeneity. Due to low heterogeneity, the fixed-effects model was used. Based on this meta-analysis, psilocybin seems to show symptom improvement in some psychiatric illnesses. The effectiveness of psilocybin microdosing and the use of psilocybin, in general, need to be studied further to determine the efficacy and safety of potential applications in psychiatry.", "journal": null, "publication_date": "2022-11-21", "publication_year": 2022, "doi": "10.7759/cureus.31796", "pubmed_id": "36569662", "source_url": "https://doi.org/10.7759/cureus.31796", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:01", "raw_json": "{\"europe_pmc_id\":\"36569662\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,OCD,Microdosing,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1638, "title": "Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids.", "normalized_title": "extensive collection of psychotropic mushrooms with determination of their tryptamine alkaloids", "authors": "Gotvaldová K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M.", "abstract": "Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their concentration variability in wild-grown mushrooms. This article aimed to determine the PSB, psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) concentrations in a large sample set of mushrooms belonging to genera previously reported to contain psychotropic tryptamines. Ultra-high performance liquid chromatography coupled with tandem mass spectrometry was used to quantify tryptamine alkaloids in the mushroom samples. Most mushroom collections were documented by fungarium specimens and/or ITS rDNA/LSU/EF1-α sequencing. Concentrations of five tryptamine alkaloids were determined in a large sample set of 226 fruiting bodies of 82 individual collections from seven mushroom genera. For many mushroom species, concentrations of BA, NB, and AE are reported for the first time. The highest PSB/PS concentrations were found in Psilocybe species, but no tryptamines were detected in the P. fuscofulva and P. fimetaria collections. The tryptamine concentrations in mushrooms are extremely variable, representing a problem for mushroom consumers due to the apparent risk of overdose. The varied cocktail of tryptamines in wild mushrooms could influence the medicinal effect compared to therapy with chemically pure PSB, posing a serious problem for data interpretation.", "journal": "International Journal of Molecular Sciences", "publication_date": "2022-11-14", "publication_year": 2022, "doi": "10.3390/ijms232214068", "pubmed_id": "36430546", "source_url": "https://doi.org/10.3390/ijms232214068", "keywords": "Agaricales, Tryptamines, Organophosphorus Compounds, Alkaloids, Indoles, Organophosphates", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"36430546\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4309210963\",\"openalex_url\":\"https://openalex.org/W4309210963\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":49,\"referenced_works\":[\"https://openalex.org/W187808846\",\"https://openalex.org/W199370843\",\"https://openalex.org/W1257980435\",\"https://openalex.org/W1842727300\",\"https://openalex.org/W1853409021\",\"https://openalex.org/W1897916411\",\"https://openalex.org/W1903260451\",\"https://openalex.org/W1963957860\",\"https://openalex.org/W1976269574\",\"https://openalex.org/W1981584745\",\"https://openalex.org/W1985210270\",\"https://openalex.org/W1993934671\",\"https://openalex.org/W1995579500\",\"https://openalex.org/W1997859062\",\"https://openalex.org/W1998218325\",\"https://openalex.org/W2002070445\",\"https://openalex.org/W2005669807\",\"https://openalex.org/W2009390034\",\"https://openalex.org/W2012169159\",\"https://openalex.org/W2018061252\",\"https://openalex.org/W2018097408\",\"https://openalex.org/W2020266843\",\"https://openalex.org/W2027191929\",\"https://openalex.org/W2027367113\",\"https://openalex.org/W2039278365\",\"https://openalex.org/W2050577168\",\"https://openalex.org/W2054460669\",\"https://openalex.org/W2057174717\",\"https://openalex.org/W2057894705\",\"https://openalex.org/W2062765660\",\"https://openalex.org/W2065461553\",\"https://openalex.org/W2067405887\",\"https://openalex.org/W2078306949\",\"https://openalex.org/W2081244857\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2108970994\",\"https://openalex.org/W2123908079\",\"https://openalex.org/W2146719061\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2163311384\",\"https://openalex.org/W2164981793\",\"https://openalex.org/W2165984877\",\"https://openalex.org/W2269809506\",\"https://openalex.org/W2298217188\",\"https://openalex.org/W2309265562\",\"https://openalex.org/W2321137868\",\"https://openalex.org/W2367699339\",\"https://openalex.org/W2397208947\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2551258974\",\"https://openalex.org/W2616187260\",\"https://openalex.org/W2741562499\",\"https://openalex.org/W2753941774\",\"https://openalex.org/W2795698014\",\"https://openalex.org/W2809702633\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2921709639\",\"https://openalex.org/W2949965849\",\"https://openalex.org/W2953198950\",\"https://openalex.org/W2954968155\",\"https://openalex.org/W2983552824\",\"https://openalex.org/W2988070888\",\"https://openalex.org/W2992322507\",\"https://openalex.org/W3090675239\",\"https://openalex.org/W3094690508\",\"https://openalex.org/W3109915302\",\"https://openalex.org/W3128827676\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4220715824\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4252339940\",\"https://openalex.org/W4410009678\",\"https://openalex.org/W6629287382\",\"https://openalex.org/W6638808706\",\"https://openalex.org/W6681716405\",\"https://openalex.org/W6684015072\",\"https://openalex.org/W6693558971\",\"https://openalex.org/W6697428727\",\"https://openalex.org/W6752249955\"],\"authorships\":[{\"id\":\"https://openalex.org/A5063034973\",\"display_name\":\"Klára Gotvaldová\",\"orcid\":\"https://orcid.org/0000-0002-0774-4454\"},{\"id\":\"https://openalex.org/A5071778852\",\"display_name\":\"Jan Borovička\",\"orcid\":\"https://orcid.org/0000-0003-3966-558X\"},{\"id\":\"https://openalex.org/A5000277095\",\"display_name\":\"Kateřina Hájková\",\"orcid\":\"https://orcid.org/0000-0002-5828-2472\"},{\"id\":\"https://openalex.org/A5077896144\",\"display_name\":\"Petra Cihlářová\",\"orcid\":\"https://orcid.org/0000-0001-6552-0697\"},{\"id\":\"https://openalex.org/A5071015129\",\"display_name\":\"Alan Rockefeller\",\"orcid\":\"https://orcid.org/0000-0002-5746-8611\"},{\"id\":\"https://openalex.org/A5084865612\",\"display_name\":\"Martin Kuchař\",\"orcid\":\"https://orcid.org/0000-0002-7616-6352\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S10623703\",\"source_display_name\":\"International Journal of Molecular Sciences\",\"landing_page_url\":\"https://doi.org/10.3390/ijms232214068\",\"is_oa\":true}}}", "topic_tags": "Microdosing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4309210963" }, { "id": 3442, "title": "A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence", "normalized_title": "a double blind trial of psilocybin assisted treatment of alcohol dependence", "authors": "NYU Langone Health", "abstract": "Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behavior change in addictions such as alcohol dependence. The proposed investigation is a multi-site, double-blind active-controlled trial (n = 180, 90 per group) contrasting the acute and persisting effects of psilocybin to those of diphenhydramine in the context of outpatient alcoholism treatment. Two to four sites will participate in this study. Aims of the study are 1) to characterize the acute effects of PO psilocybin 25 mg/70 kg, 30 mg/70 kg, and 40 mg/70 kg in alcohol dependent patients; 2) to evaluate the effect of psilocybin treatment on drinking outcomes for 32 weeks after the first administration, relative to diphenhydramine control; 3) to test whether or not characteristics of the drug administration session experiences mediate effects of psilocybin on short-term (1 week) persisting effects and post-session drinking behavior, 4) to evaluate the explanatory value of changes in alcohol craving, self-efficacy, motivation, and other psychological domains in accounting for the observed experimental effect of psilocybin relative to diphenhydramine control, and 5) to evaluate pre-post changes in drinking in participants after they receive psilocybin in the third session. The total duration of psychosocial treatment in the double-blind period will be 12 weeks, and double-blind drug administration sessions will occur after 4 and 8 weeks. In the first psilocybin session, a dose of 25 mg/70 kg will be administered. Depending on the response in the first session, the dose for the second session may be increased to 30 mg/70 kg or 40 mg/70 kg, or held at 25mg/70kg. The dose of diphenhydramine will start at 50 mg, and may be increased to 100 mg or held at 50 mg in the second session, depending on response in the first session. Following completion of the double-blind period (34 weeks after randomization) all participants who meet interim safety criteria will be offered an additional session in which psilocybin will be administered. The drug will be administered during 8-hour sessions in an outpatient setting under close medical and psychiatric monitoring. The drug administration sessions will occur in the context of an extended version of Motivational Enhancement Therapy (Motivational Enhancement and Taking Action, META) with the addition of standardized preparation before and debriefing and follow-up after the psilocybin administration sessions. Extensive screening and baseline assessment will be completed, including thorough safety screening and assessment of participant characteristics that could potentially moderate treatment response. Within-session and short-term persisting effects will be assessed. Drinking outcomes and changes in several potential mediators of treatment effect, including motivation, self-efficacy, craving, depression, anxiety, and spiritual dimensions of the experience, will be measured until 50 weeks after the first drug administration session, for a total of 54 weeks from the initiation of treatment.", "journal": "ClinicalTrials.gov", "publication_date": "2022-11-07", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT02061293", "keywords": "Alcohol Dependence, Psilocybin, Diphenhydramine, Motivational Enhancement and Taking Action (META), COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT02061293\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1630, "title": "Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.", "normalized_title": "psilocybin for alcohol use disorder rationale and design considerations for a randomized controlled trial", "authors": "O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP.", "abstract": "Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a structured 12-week psychotherapy platform, participants (n = 96) were randomly assigned (1:1) to receive either oral psilocybin or an active placebo (oral diphenhydramine) in each of two dosing sessions (at weeks 4 and 8). Initial doses were 25 mg/70 kg psilocybin or 50 mg diphenhydramine, which could be increased in the second session depending on initial response. The psychotherapy platform combined evidence-based, manualized therapy for alcohol dependence with a supportive context for the dosing sessions. All participants were followed in the RCT through week 36. At the end of the RCT, participants who still met safety criteria were offered an open-label psilocybin session. Data collected at screening, baseline and throughout the study included: demographics, measures of alcohol use, subjective response to psilocybin and diphenhydramine, and safety measures. The primary outcome was the proportion of heavy drinking days during the 32 weeks after the first dosing session (i.e., between week 4 and week 36). Secondary outcomes included safety, additional measures of drinking (e.g., abstinence, drinking days, etc.), craving, self-efficacy, and acute effects. We will also explore moderators and mediators of the primary outcome. The primary outcomes will be published elsewhere. In this paper, we describe the protocol and rationale for our design decisions.", "journal": "Contemporary Clinical Trials", "publication_date": "2022-11-01", "publication_year": 2022, "doi": "10.1016/j.cct.2022.106976", "pubmed_id": "36332827", "source_url": "https://doi.org/10.1016/j.cct.2022.106976", "keywords": "Humans, Alcoholism, Diphenhydramine, Treatment Outcome, Alcohol Drinking, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"36332827\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4308040950\",\"openalex_url\":\"https://openalex.org/W4308040950\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":24,\"referenced_works\":[\"https://openalex.org/W62922542\",\"https://openalex.org/W157022601\",\"https://openalex.org/W162483627\",\"https://openalex.org/W207715701\",\"https://openalex.org/W1849190772\",\"https://openalex.org/W1917052505\",\"https://openalex.org/W1967146050\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1973814761\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2058760199\",\"https://openalex.org/W2067970495\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2096567449\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2243916050\",\"https://openalex.org/W2318552418\",\"https://openalex.org/W2326687065\",\"https://openalex.org/W2408251447\",\"https://openalex.org/W2537388000\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2778174446\",\"https://openalex.org/W2810374266\",\"https://openalex.org/W2953529230\",\"https://openalex.org/W2974814938\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W6606426124\",\"https://openalex.org/W6606631404\",\"https://openalex.org/W6608587748\",\"https://openalex.org/W6640214536\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042151214\",\"display_name\":\"Kelley C. O’Donnell\",\"orcid\":\"https://orcid.org/0000-0001-9983-2699\"},{\"id\":\"https://openalex.org/A5087382833\",\"display_name\":\"Sarah E. Mennenga\",\"orcid\":null},{\"id\":\"https://openalex.org/A5025551503\",\"display_name\":\"Lindsey T. Owens\",\"orcid\":\"https://orcid.org/0000-0001-7955-5209\"},{\"id\":\"https://openalex.org/A5082919402\",\"display_name\":\"Samantha K. Podrebarac\",\"orcid\":null},{\"id\":\"https://openalex.org/A5064916530\",\"display_name\":\"Tara Baron\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071920736\",\"display_name\":\"John Rotrosen\",\"orcid\":\"https://orcid.org/0000-0002-0283-5576\"},{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"},{\"id\":\"https://openalex.org/A5075574900\",\"display_name\":\"Alyssa A. Forcehimes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086692011\",\"display_name\":\"Michael P. Bogenschutz\",\"orcid\":\"https://orcid.org/0000-0003-4530-3470\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S63040059\",\"source_display_name\":\"Contemporary Clinical Trials\",\"landing_page_url\":\"https://doi.org/10.1016/j.cct.2022.106976\",\"is_oa\":false}}}", "topic_tags": "Addiction,Receptor Pharmacology,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4308040950" }, { "id": 4910, "title": "The psychedelic renaissance: can psilocybin possibly combat depression?", "normalized_title": "the psychedelic renaissance can psilocybin possibly combat depression", "authors": "Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh", "abstract": "Mental health disorders such as depression and anxiety are major contributors to the overall global health burden. COVID-19 has further aggravated mental health disorders and also increased substance abuse due to lockdowns1. The Global Burden of Disease reported that the pandemic has led to a 27.6% increase in cases of major depressive disorder (MDD) and a 25.6% increase in cases of anxiety disorders2. An estimated 137.1 (95% UI: 92.5-190.6) additional disability-adjusted life years per 100 000 population for MDD and 116.1 per 100,000 population (95% UI: 79.3-163.80) for anxiety disorders have been incurred, as well, during this period3. Nearly 10%-30% of individuals with MDD have treatment-resistant depression, which has an inadequate response to at least 2 trials of antidepressants. These patients often have adverse behavioral outcomes such as suicide and self-injurious behavior4. With the dynamic nature of SARS-COV-2 that requires measures such as social distancing measures and lockdowns to be placed unexpectedly at different times of the year, interventions that are easily obtainable and can be applied independently by individuals can be immensely useful. Psilocybin, in recent studies, has shown promising results in the remission of depression and if its effectiveness is accurately gauged, could prove to be one such option, giving patients with mental health issues the ability for self-reliant care. Psilocybin, informally known as the magic mushroom, has been employed in a variety of religious rites throughout history and is believed to possess therapeutic properties5. It is a serotonergic hallucinogen with promising benefits in the treatment of mental illness. It has been proven to decrease substance abuse such as smoking and drinking and reduce depression and anxiety in cancer patients while also improving their emotional well-being6-8. Psilocybin-assisted psychotherapy has proven to be more effective than psychotherapy and pharmacotherapy alone. Previous pharmacotherapies, such as ketamine, have demonstrated negative side effects and have low rates of depression remission9. A systematic review of 60 studies on the side effects of ketamine identified psychiatric, psychotomimetic, cardiovascular, and neurological side effects that were most frequently reported in acute dosing of ketamine10. Most commonly reported acute psychiatric side effects were reportedly anxiety, dissociation being the most psychotomimetic effect. Increased heart rate and raised blood pressure are the most frequent cardiovascular outcomes and headache and dizziness are some of the most common neurological side effects of ketamine. Kemp11 highlighted metabolic disorders such as weight gain and sedation and somnolence as one of the most common adverse effects of pharmacotherapy in treating bipolar depression. These side effects reduce adherence to treatment and reduce the clinical response of pharmacotherapies. However, psilocybin has low toxicity and addictive potential5. Although the precise mechanism of action of psilocybin is unknown, a randomized clinical trial found that it had a persistent and fast antidepressant effect when compared with escitalopram, as well as improved global brain integration12. The article by Davis et al6 entitled “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial” has piqued the interest of the entire psychiatric community. The author highlights a novel finding of significant decreases in or remission of depression in people with MDD with Psilocybin-assisted therapy. A total of 27 participants were recruited, 11 of whom underwent immediate therapy while 13 underwent delayed therapy after 8 weeks. Psilocybin was administered in 2 sessions, with the first session being a moderate dose (20 mg/70 kg) and the second session containing a high dose (30 mg/70 kg). There was a significant decrease in depression in weeks 1 and 4 of follow-up in immediate treatment compared with weeks 5 and 8 of delayed treatment that had not started the therapy. Seventeen participants showed a >50% decrease in depression in weeks 1 and 4; 14 participants in week 1 and 13 participants in week 4 showed complete remission of depression. This study highlights potential breakthrough evidence that is beginning to emerge regarding psilocybin’s use. In January 2022, Rucker et al’s phase 1 trial results delineated that Psilocybin in doses of 10 or 25 mg, respectively, had no short-term or long-term detrimental effects on participants making the case for it being a plausibly relevant and safe alternative to other psychiatric treatments13. However, for nearly 50 years, psychedelics had been prohibited for medical use owing to rigorous drug control policies and strongly held stigmatic beliefs labelling them as illicit recreational drugs only with no potential for medical benefit. Recent studies, on the other hand, have shown that psychedelics can alleviate depression and anxiety, but mental health professionals are still wary of using them for medicinal purposes14. This, in part, is because there was a lack of research regarding their efficacy, which when combined with the extreme scheduling of these drugs by law, has led to its widespread clinical use being, at best, delayed14. While most psychiatrists support its future use, many are concerned about its potential adverse effects. On the other hand, there appears to be a supportive attitude toward psychedelic use for medicinal purposes among the general populace. According to a survey, 63% of Psychedelic mushroom users reported using them for mental well-being but an alarming 19% also reported use after self-diagnosis of a mental disorder15. Nevertheless, there have been some notable shifts in perspective as legal frameworks regarding the use of psychedelics are being revised. Owing to efficacy data suggesting potential therapeutic benefits of these psychedelics, this “psychedelic renaissance” has brought about changes such as the statewide legalization of specific psychedelics, including psilocybin, in Oregon, USA16. Although Davis et al’s6 findings do pave the way for furthering the discussion, especially as there were no adverse events reported with psilocybin use, results can be overstated due to the study’s small sample size. A survey on self-reported side effects of psilocybin showed that 11% of Psilocybin consumers put themselves or another person at harm, 2.6% behaved in a physically aggressive manner and 2.7% had to seek medical help17. These negative reactions have often been seen in trials where induced stressful situations have led to patients leaving the site18. There must be additional large-scale clinical trials undertaken across a spectrum of mental diseases before they can be definitively included in medical practice and guidelines for their use can be established. In addition, psychiatric comorbidities are a pressing concern that also needs to be addressed. To make results more generalizable, the risk of using psilocybin in this group needs to be explored19. In a study evaluating the cost effectiveness of methylenedioxymethamphetamine (MDMA) associated psychotherapy in patients with posttraumatic stress disorder including 105 subjects of six double blinded phase 2 trials the MDMA saved 103.2 million dollars over a period of a 30 years and decreased 5553 quality adjusted life years compared with the standard practices20. According to a statement given by the author of this paper to multidisciplinary association for psychedelic studies MDMA has a potential to break even the cost of mental health in just over 3 years21. According to a study conducted by John Hopkins to assess the effect of psilocybin in personality changes, a single high dose of psilocybin was enough to bring about a measurable personality change such as increased openness in nearly 60% of the participants22. However researchers are still cautious of professing the cost effectiveness of psychedelic and require more data over a longer period of time to come to a conclusive finding. The usage of psychedelics to alleviate anxiety and depression appears to be more pertinent now than ever. This, however, raises concerns about self-medication with psychedelics and their excessive usage. Ensuring psychedelics are obtained only through prescription and not as over-the-counter drugs can be an effective method to curb the self-medication of psychedelics. Campaigns that sensitize individuals regarding the health repercussions of resorting to self-medication should also be held at a large scale. Provision of health insurance has also shown to reduce the incidence of self-medication23 and encourages patients to seek guidance from health care professionals. In addition satisfaction with health care service and a good doctor patient relationship are important predictors of self-medication24,25. Workshops about the use of psychedelics in medicine and their possible risks and advantages should be conducted for psychologists and psychiatrists to assist in breaking down stigma and assisting them in making educated decisions for their patients. Ethical approval None. Sources of funding None. Author contribution H.R.: conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work. U.N.: conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work. A.S.: conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work. O.A.S.: conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work. Conflict of interest disclosures The authors declare that they have no financial conflict of interest with regard to the content of this report. Research registration unique identifying number None. Guarantor Hamna Raheel, Unaiza Naeem, Asim Shaikh, and Omer Ahmed Shaikh.", "journal": "International Journal of Surgery Global Health", "publication_date": "2022-10-31", "publication_year": 2022, "doi": "10.1097/gh9.0000000000000089", "pubmed_id": null, "source_url": "http://dx.doi.org/10.1097/gh9.0000000000000089", "keywords": "Psilocybin, Psychiatry, Anxiety, Mental health, Depression (economics), Population, Major depressive disorder, Psychological intervention, Medicine, Psychology, Clinical psychology, Hallucinogen, Mood, Environmental health, Macroeconomics, Economics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Tryptophan and brain disorders", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:56", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4318965036\",\"openalex_url\":\"https://openalex.org/W4318965036\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2005405662\",\"https://openalex.org/W2016292245\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2104101984\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2741959390\",\"https://openalex.org/W2794653496\",\"https://openalex.org/W2906534435\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3087025291\",\"https://openalex.org/W3093269897\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3197311089\",\"https://openalex.org/W3203310594\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4221018864\",\"https://openalex.org/W4223461155\",\"https://openalex.org/W4225982601\",\"https://openalex.org/W6801747217\"],\"authorships\":[{\"id\":\"https://openalex.org/A5015840545\",\"display_name\":\"Hamna Raheel\",\"orcid\":\"https://orcid.org/0000-0002-8146-432X\"},{\"id\":\"https://openalex.org/A5016462981\",\"display_name\":\"Unaiza Naeem\",\"orcid\":\"https://orcid.org/0000-0002-0455-7864\"},{\"id\":\"https://openalex.org/A5101565927\",\"display_name\":\"Asim Shaikh\",\"orcid\":\"https://orcid.org/0000-0001-6984-9465\"},{\"id\":\"https://openalex.org/A5021771375\",\"display_name\":\"Omer Ahmed Shaikh\",\"orcid\":\"https://orcid.org/0000-0002-2504-390X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210188486\",\"source_display_name\":\"International Journal of Surgery Global Health\",\"landing_page_url\":\"http://dx.doi.org/10.1097/gh9.0000000000000089\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Headache / Migraine,Mechanism of Action,Wellbeing,Personality Change,Emotional Processing,Clinical Trial,Systematic Review,Review Article,Observational Study,Cancer Patients,Treatment-Resistant Depression,Safety,Adverse Events,Toxicity", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4318965036" }, { "id": 1644, "title": "[Treatment-resistant depression. From classification to new therapies.]", "normalized_title": "treatment resistant depression from classification to new therapies", "authors": "Paganin W, Signorini S, Signorini S, Leccese V, Sciarretta A.", "abstract": "AimsThis paper aims to investigate the advances in recent years in the recognition and therapy of treatment-resistant depression starting from the concepts of: depressive disorder, resistance and pseudoresistance to drug treatment in depression, and appropriate treatments of treatment-resistant depression.MethodsAn extensive research was carried out on scientific databases such as: PubMed, PsychInfo and Cochrane Library, until May 2022, using the keywords \"major depression\", \"treatment-resistant depression\", \"staging\", \"instrumental therapies for resistant depression\", \"esketamine\" and \"psilocybin\".ResultsSubjects who do not respond to antidepressants show a form of treatment resistance that requires an approach with additional pharmacological and/or instrumental therapies. Recently, esketamine and psilocybin are of particular interest among clinicians, and instrumental treatments such as: vagus nerve stimulation, deep brain stimulation, repetitive transcranial magnetic stimulation, transcranial direct current stimulation, epidural cortical stimulation, and electro convulsive therapy, are being added to them.Discussion and conclusionsTreatment-resistant depression has increasingly become a public health problem due to the significant number of relapses, hospitalizations and mortality it entails, with increased demand for the use of more drugs, therapeutic resources by health services, and loss of quality of life for patients. Treatment-resistant depression needs to be addressed through the creation of dedicated study protocols. Future research should focus on the need to establish operational, valid and appropriate criteria, both on the psychopathological, clinical governance and therapeutic levels, focusing on the latest therapies in order to provide reliable data on the benefits, risks and costs associated with their use.", "journal": "Rivista di psichiatria", "publication_date": "2022-10-31", "publication_year": 2022, "doi": "10.1708/3922.39072", "pubmed_id": "36503940", "source_url": "https://doi.org/10.1708/3922.39072", "keywords": "Humans, Ketamine, Quality of Life, Transcranial Direct Current Stimulation, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"36503940\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4311667760\",\"openalex_url\":\"https://openalex.org/W4311667760\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":5,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5084331649\",\"display_name\":\"Walter Paganin\",\"orcid\":\"https://orcid.org/0000-0001-9007-0712\"},{\"id\":\"https://openalex.org/A5043613312\",\"display_name\":\"Sabrina Signorini\",\"orcid\":\"https://orcid.org/0000-0002-3808-4372\"},{\"id\":\"https://openalex.org/A5018437057\",\"display_name\":\"Vincenzo Leccese\",\"orcid\":null},{\"id\":\"https://openalex.org/A5015630350\",\"display_name\":\"Antonio Sciarretta\",\"orcid\":\"https://orcid.org/0000-0002-4643-0706\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S28074187\",\"source_display_name\":\"Rivista di psichiatria\",\"landing_page_url\":\"https://doi.org/10.1708/3922.39072\",\"is_oa\":true}}}", "topic_tags": "Depression,Aging,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4311667760" }, { "id": 3461, "title": "The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.", "normalized_title": "the safety and efficacy of psilocybin in participants with type 2 bipolar disorder bp ii depression", "authors": "Sheppard Pratt Health System", "abstract": "The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.", "journal": "ClinicalTrials.gov", "publication_date": "2022-10-24", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04433845", "keywords": "Treatment Resistant Depression, Psilocybin, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04433845\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 3685, "title": "An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)", "normalized_title": "an exploratory open label phase 1b ascending dose study to evaluate the effects of oral 3 2 dimethylamino ethyl 1h indol 4 yl dihydrogen phosphate psilocybin bpl psilo on cognition in patients with chronic short lasting unilateral neuralgiform headache attacks sunha", "authors": "Beckley Psytech Limited", "abstract": "This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA) The study aims to: Determine the safety and tolerability of psilocybin when administered to patients with chronic SUNHA Determine the effects of psilocybin on cognition when administered to patients with chronic SUNHA Explore the change in frequency, duration, and intensity of headache attacks with escalating doses of psilocybin in patients with chronic SUNHA", "journal": "ClinicalTrials.gov", "publication_date": "2022-10-11", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04905121", "keywords": "Short Lasting Unilateral Neuralgiform Headache Attacks, Psilocybin, TERMINATED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04905121\",\"overall_status\":\"TERMINATED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Headache / Migraine,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1661, "title": "A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.", "normalized_title": "a proposed mechanism for the mdma mediated extinction of traumatic memories in ptsd patients treated with mdma assisted therapy", "authors": "Sottile RJ, Vida T.", "abstract": "Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40-70% of patients suffer from refractory disease. 3,4-Methylenedioxy-methamphetamine (MDMA), like classic psychedelics such as psilocybin, have been used to enhance the efficacy of psychotherapy almost since their discovery, but due to their perceived potential for abuse and inclusion on USFDA (United States Food and Drug Administration) schedule 1, research into the mechanism by which they produce improvements in PTSD symptomology has been limited. Nevertheless, several compelling rationales have been explored, with the pro-social effects of MDMA thought to enhance therapeutic alliance and thus facilitate therapist-assisted trauma processing. This may be insufficient to fully explain the efficacy of MDMA in the treatment of psychiatric illness. Molecular mechanisms such as the MDMA mediated increase of brain-derived neurotrophic factor (BDNF) availability in the fear memory learning pathways combined with MDMA's pro-social effects may provide a more nuanced explanation for the therapeutic actions of MDMA.", "journal": null, "publication_date": "2022-10-11", "publication_year": 2022, "doi": "10.3389/fpsyt.2022.991753", "pubmed_id": "36311515", "source_url": "https://doi.org/10.3389/fpsyt.2022.991753", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36311515\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,PTSD,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3765, "title": "Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355", "normalized_title": "yale program for psychedelic science ypps manual for psilocybin ocd session monitors for protocol hic 2000020355", "authors": "Ching THW, Kichuk S, DePalmer G, Pittenger C, Kelmendi B.", "abstract": "The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will explore the safety and efficacy of a single 0.25 mg/kg dose of psilocybin, administered in a supportive clinical environment, to eligible participants with obsessive-compulsive disorder (OCD). Monitors meet with each participant before, during, and after the dosing session. Monitors do not provide any structured therapy, but rather help participants prepare for the experience of psilocybin dosing, ensure psychological safety during dosing, and provide participants with an unstructured context in which to process their experience during and after dosing at defined timepoints. In doing so, while no structured therapy is provided, the presence and accompaniment by monitors throughout all study sessions may be experienced as supportive or even therapeutic by participants. This manual provides background and details for Monitors on the activities that are required at three points - before, during, and after the dosing session.", "journal": "PsyArXiv", "publication_date": "2022-10-04", "publication_year": 2022, "doi": "10.31234/osf.io/85s9p", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/85s9p", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:19", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR555521\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "OCD,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3204, "title": "Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355", "normalized_title": "yale program for psychedelic science ypps manual for psilocybin ocd session monitors for protocol hic 2000020355", "authors": "", "abstract": "The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, placebo-controlled study), will explore the safety and efficacy of a single 0.25 mg/kg dose of psilocybin, administered in a supportive clinical environment, to eligible participants with obsessive-compulsive disorder (OCD). Monitors meet with each participant before, during, and after the dosing session. Monitors do not provide any structured therapy, but rather help participants prepare for the experience of psilocybin dosing, ensure psychological safety during dosing, and provide participants with an unstructured context in which to process their experience during and after dosing at defined timepoints. In doing so, while no structured therapy is provided, the presence and accompaniment by monitors throughout all study sessions may be experienced as supportive or even therapeutic by participants. This manual provides background and details for Monitors on the activities that are required at three points - before, during, and after the dosing session.", "journal": "PsyArXiv", "publication_date": "2022-10-04", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/85s9p_v1", "keywords": "manual, OCD, psilocybin, psychedelic, session monitor, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Obsessive-compulsive and Related Disorders, Therapy, Psychotherapy, Psychopharmacology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"85s9p_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "OCD,Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1649, "title": "A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.", "normalized_title": "a critical appraisal of evidence on the efficacy and safety of serotonergic psychedelic drugs as emerging antidepressants mind the evidence gap", "authors": "Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI.", "abstract": "Purpose/backgroundThere has been resurgence of interest in the therapeutic use of serotonergic (\"classic\") psychedelics in major depressive disorder (MDD) and end-of-life distress. This commentary offers a critical appraisal of current evidence for antidepressant effects of classic psychedelics from contemporary clinical trials and highlights pitfalls that should be addressed before clinical translation.Methods/proceduresA narrative review was conducted to identify clinical trials of serotonergic psychedelics for the treatment of MDD and end-of-life distress. Trials published between January 1990 and May 2022 were identified on PubMed using combinations of search terms.Findings/resultsPsilocybin, lysergic acid diethylamide, and ayahuasca have clinical trials to evaluate antidepressant effects. Two studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression. Similar results were seen in lysergic acid diethylamide for end-of-life distress. Small randomized clinical trials (RCTs) of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator in MDD, with additional RCTs showing efficacy in end-of-life distress. Adverse events associated with psychedelics were reported as mild and transient. Small homogenous samples, expectancy bias, functional unblinding, and lack of consensus and standardization of psychotherapy are major limitations of all studies.Implications/conclusionsGiven the methodological limitations of published RCTs, the evidence supporting the efficacy and safety of serotonergic psychedelics for depression is currently of low level. Future research should assess the role of expectancy and psychedelic effects in moderating and mediating treatment response. Innovative trial designs are needed to overcome functional unblinding. For now, psychedelics should remain experimental interventions used within clinical trials.", "journal": null, "publication_date": "2022-10-02", "publication_year": 2022, "doi": "10.1097/jcp.0000000000001608", "pubmed_id": "36193898", "source_url": "https://doi.org/10.1097/jcp.0000000000001608", "keywords": "Humans, Banisteriopsis, Death, Lysergic Acid Diethylamide, Serotonin Agents, Hallucinogens, Antidepressive Agents, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36193898\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,End-of-Life Distress,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Review Article,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1690, "title": "Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.", "normalized_title": "towards psychedelic apprenticeship developing a gentle touch for the mediation and validation of psychedelic induced insights and revelations", "authors": "Timmermann C, Watts R, Dupuis D", "abstract": "A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced, which may persist long after psychedelic effects have subsided. We propose that processes underlying conferral of meaning and truth in psychedelic experiences may act as a double-edged sword: while these may drive important therapeutic benefits, they also raise important considerations regarding the validation and mediation of knowledge gained during these experiences. Specifically, the ability of psychedelics to induce noetic feelings of revelation may enhance the significance and attribution of reality to specific beliefs, worldviews, and apparent memories which might exacerbate the risk of iatrogenic complications that other psychotherapeutic approaches have historically faced, such as false memory syndrome. These considerations are timely, as the use of psychedelics is becoming increasingly mainstream, in an environment marked by the emergence of strong commercial interest for psychedelic therapy. We elaborate on these ethical challenges via three examples illustrating issues of validation and mediation in therapeutic, neo-shamanic and research contexts involving psychedelic use. Finally, we propose a pragmatic framework to attend to these challenges based on an ethical approach which considers the embeddedness of psychedelic experiences within larger historical and cultural contexts, their intersubjective character and the use of practices which we conceptualise here as forms of. This notion of goes beyond current approaches of and by stressing the central importance of validation practices based on by an experienced therapist or guide.", "journal": "Transcultural psychiatry", "publication_date": "2022-09-30", "publication_year": 2022, "doi": "10.1177/13634615221082796", "pubmed_id": "35313754", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35313754/", "keywords": "ayahuasca, know-how, neurophenomenology, psilocybin, psychedelic therapy, revelations", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"35313754\"}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1689, "title": "If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.", "normalized_title": "if the doors of perception were cleansed would chronic pain be relieved evaluating the benefits and risks of psychedelics", "authors": "Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC", "abstract": "Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of consciousness has been described throughout recorded history. Accounts of the subjective effects of psychedelics typically focus on spiritual and mystical-type experiences, including feelings of unity, sacredness, and transcendence. Over the past 2 decades, there has been increasing interest in psychedelics as treatments for various medical disorders, including chronic pain. Although concerns about adverse medical and psychological effects contributed to their controlled status, contemporary knowledge of psychedelics suggests that risks are relatively rare when patients are carefully screened, prepared, and supervised. Clinical trial results have provided support for the effectiveness of psychedelics in different psychiatric conditions. However, there are only a small number of generally uncontrolled studies of psychedelics in patients with chronic pain (eg, cancer pain, phantom limb pain, migraine, and cluster headache). Challenges in evaluating psychedelics as treatments for chronic pain include identifying neurobiologic and psychosocial mechanisms of action and determining which pain conditions to investigate. Truly informative proof-of-concept and confirmatory randomized clinical trials will require careful selection of control groups, efforts to minimize bias from unblinding, and attention to the roles of patient mental set and treatment setting. PERSPECTIVE: There is considerable promise for the use of psychedelic therapy for pain, but evidence-based recommendations for the design of future studies are needed to ensure that the results of this research are truly informative.", "journal": "The journal of pain", "publication_date": "2022-09-30", "publication_year": 2022, "doi": "10.1016/j.jpain.2022.05.003", "pubmed_id": "35643270", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35643270/", "keywords": "Chronic pain, LSD, clinical trials, psilocybin, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"35643270\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Mechanism of Action,Consciousness,Spirituality,Mystical Experience,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1682, "title": "Prevalence and associations of classic psychedelic-related seizures in a population-based sample.", "normalized_title": "prevalence and associations of classic psychedelic related seizures in a population based sample", "authors": "Simonsson O, Goldberg SB, Chambers R, Osika W, Long DM, Hendricks PS", "abstract": "Previous studies have reported links between classic psychedelic use and seizures, but little remains known about prevalence and potential risk factors of classic psychedelic-related seizures. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N = 2822), this study examined the prevalence and potential risk factors of classic psychedelic-related seizures, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Among those who reported lifetime classic psychedelic use, 1.5 % reported classic psychedelic-related seizures, a statistic that comports with the prevalence of epilepsy in the US population. Among those who reported seizures while using a classic psychedelic, almost half reported co-use of antidepressants, mood stabilizers, or opioid replacement therapies at the time of the seizures. Notably, classic psychedelic-related seizures were more commonly reported in certain respondents, especially those with a personal or family history of epilepsy. These results suggest that classic psychedelic use could increase the risk of seizures in certain populations, particularly those with a personal or family history of epilepsy.", "journal": "Drug and alcohol dependence", "publication_date": "2022-09-30", "publication_year": 2022, "doi": "10.1016/j.drugalcdep.2022.109586", "pubmed_id": "35981469", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35981469/", "keywords": "Adverse, LSD, Psilocybin, Psychedelics, Risk, Seizures", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"35981469\"}", "topic_tags": "Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3244, "title": "Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing", "normalized_title": "psilocybin therapy for treatment resistant depression prediction of clinical outcome by natural language processing", "authors": "Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA.", "abstract": "Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilocybin, in participants with treatment resistant depression. While promising, the treatment works for a portion of the population and early prediction of outcome is a key objective. Methods: Transcripts were made from audio recordings of the psychological support session between participant and therapist one day post COMP360 administration. A zero-shot machine learning classifier based on the BART large language model was used to compute two-dimensional sentiment (valence and arousal) for the participant and therapist from the transcript. These scores, combined with the Emotional Breakthrough Index (EBI) and treatment arm were used to predict treatment outcome as measured by MADRS scores. Code and data are available at https://github.com/compasspathways/Sentiment2DResults: Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%. Conclusions: A machine learning algorithm using NLP and EBI accurately predicts long term patient response, allowing rapid prognostication of personalized response to psilocybin treatment and insight into therapeutic model optimization. Further research is required to understand if language data from earlier stages in the therapeutic process hold similar predictive power.", "journal": "PsyArXiv", "publication_date": "2022-09-29", "publication_year": 2022, "doi": "10.31234/osf.io/kh3cx", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/kh3cx", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR553222\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Emotional Processing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 643, "title": "Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing", "normalized_title": "psilocybin therapy for treatment resistant depression prediction of clinical outcome by natural language processing", "authors": "", "abstract": "Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilocybin, in participants with treatment resistant depression. While promising, the treatment works for a portion of the population and early prediction of outcome is a key objective. Methods: Transcripts were made from audio recordings of the psychological support session between participant and therapist one day post COMP360 administration. A zero-shot machine learning classifier based on the BART large language model was used to compute two-dimensional sentiment (valence and arousal) for the participant and therapist from the transcript. These scores, combined with the Emotional Breakthrough Index (EBI) and treatment arm were used to predict treatment outcome as measured by MADRS scores. Code and data are available at https://github.com/compasspathways/Sentiment2D Results: Two multinomial logistic regression models were fit to predict responder status at week 3 and through week 12. Cross-validation of these models resulted in 85% and 88% accuracy and AUC values of 88% and 85%. Conclusions: A machine learning algorithm using NLP and EBI accurately predicts long term patient response, allowing rapid prognostication of personalized response to psilocybin treatment and insight into therapeutic model optimization. Further research is required to understand if language data from earlier stages in the therapeutic process hold similar predictive power.", "journal": "PsyArXiv", "publication_date": "2022-09-29", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/kh3cx_v1", "keywords": "Depression, Emotional Breakthrough Index, Machine Learning, Natural Language Processing, Sentiment, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Quantitative Methods, Statistical Methods", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:48:04", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"kh3cx_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Mechanism of Action,Emotional Processing,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3477, "title": "Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP001 And COMP003 Trials (P-TRD LTFU)", "normalized_title": "multicentre study to assess safety and efficacy of psilocybin in patients with treatment resistant depression following completion of comp001 and comp003 trials p trd ltfu", "authors": "COMPASS Pathways", "abstract": "The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP001). In this present study (COMP004), the aim is to follow up participants from COMP001 and COMP003 in a long-term follow up study, with both remote and digital assessments, to explore the long term efficacy and safety of the three different doses of psilocybin (1 mg, 10 mg, and 25 mg) administered to patients with TRD as a monotherapy in COMP001 and 25 mg psilocybin administered as an adjunct to an SSRI in COMP003. Patients previously treated in COMP001 will be followed for approximately 40 weeks and patients previosuly treated in COMP003 will be followed for approximately 49 weeks giving a total follow up period of 52 weeks from psilocybin dosing.", "journal": "ClinicalTrials.gov", "publication_date": "2022-09-21", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04519957", "keywords": "Treatment Resistant Depression, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04519957\",\"overall_status\":\"COMPLETED\",\"phase\":[]}", "topic_tags": "Depression,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1695, "title": "Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.", "normalized_title": "association between lifetime classic psychedelic use and sick leave in a population based sample", "authors": "Mellner C, Dahlen M, Simonsson O", "abstract": "Absenteeism from work due to illness, and related costs, has increased steadily during the past decades. In recent years, there has been a reemergence of research on the therapeutic effects of classic psychedelics showing associations with both physical and mental health. However, the association between classic psychedelics and sick leave remains unknown. The aim of this study is to investigate the association between lifetime classic psychedelic use and sick leave in the past 30 days among adults in the United States ( = 407,717), using data from the National Survey on Drug Use and Health (2005-2019), weighted to be representative of the US adult population. The primary analysis was conducted using multiple linear regression, controlling for sociodemographic characteristics, risky behavior, and use of other substances. There was a significant and negative association between lifetime classic psychedelic use and sick leave in the past 30 days (B = -0.09, < 0.01) when adjusting for all control variables. These findings suggest that classic psychedelics could potentially lead to reduced sick leave and associated costs in the general population, but more research is needed to investigate potential causal pathways of classic psychedelics on sick leave and evaluate possible mechanisms.", "journal": "International journal of environmental research and public health", "publication_date": "2022-09-08", "publication_year": 2022, "doi": "10.3390/ijerph191811353", "pubmed_id": "36141631", "source_url": "https://pubmed.ncbi.nlm.nih.gov/36141631/", "keywords": "LSD, health economics, psilocybin, psychedelics, public health, sickness absence, sickness absenteeism", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"36141631\"}", "topic_tags": "Mechanism of Action,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1606, "title": "The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.", "normalized_title": "the safety and efficacy of psychedelic assisted therapies for older adults knowns and unknowns", "authors": "Johnston CB, Mangini M, Grob C, Anderson B.", "abstract": "Psychedelics and related compounds have shown efficacy for the treatment of a variety of conditions that are prevalent among older adults, including mood disorders, the psychological distress associated with a serious medical illness, post-traumatic stress disorder (PTSD), and prolonged grief disorder. Psychedelics also have properties that could help provide therapeutic benefits for patients with dementing disorders, as well as promoting personal growth among healthy older adults. This article focuses on psilocybin, a classic psychedelic, and MDMA, a substituted amphetamine with properties similar to classic psychedelics. Both act on the 5HT2A receptor. Psychedelics can be safely administered to healthy adults in controlled conditions. However, both psilocybin and MDMA can increase blood pressure and heart rate, which could be a concern if used in older adults with cardiovascular disease. Very few older adults or patients with serious comorbidities have been included in clinical trials of psychedelics to date, raising the question of how generalizable study results are for the patients that most geropsychiatrists will be treating. Research on the neurophysiologic and mechanistic effects of psychedelics in older adults could also provide insights into the aging brain that could have clinical applications in the future. Given the potential of psychedelic compounds to benefit older adults, more research is needed to establish safety and efficacy among older adults, particularly those with multi-morbidity.", "journal": null, "publication_date": "2022-09-05", "publication_year": 2022, "doi": "10.1016/j.jagp.2022.08.007", "pubmed_id": "36184377", "source_url": "https://doi.org/10.1016/j.jagp.2022.08.007", "keywords": "Brain, Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Aged, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36184377\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Receptor Pharmacology,Aging,Clinical Trial,Older Adults,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4294723946" }, { "id": 3383, "title": "Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder", "normalized_title": "therapeutic potential of serotoninergic psychedelic substances in the treatment of obsessive compulsive disorder", "authors": "Rodrigues J, Nombora O, Ribeiro L.", "abstract": "Introduction Obsessive Compulsive Disorder (OCD) is a psychiatric disorder associated with suffering and disability. The serotoninergic system is implicated in the neurobiological processes of OCD and serotonin reuptake inhibitors (SRIs) are the first-line treatment. However, clinical improvement after starting SRIs can take long and patients may not fully recover. Meanwhile, recent data suggests that activation of 5-HT receptors may exert a therapeutic action in obsessional symptoms. Some psychedelics are strong 5-HT2 receptor agonists and there is a growing research interest as they can be a promising therapeutic approach to OCD. Objectives We aim to provide an overview on the current evidence on the therapeutic potential of serotoninergic psychoactive substances in the treatment of OCD. Methods Non-systematic review. Literature search in the PubMed database using the terms psychedelics and obsessive-compulsive disorder. Results Although research is currently limited to a few small studies, the ones conducted so far showed clinically meaningful acute reduction of OCD symptoms after treatment with serotoninergic psychoactive drugs, as well as possible longer-lasting benefits, particularly with psilocybin and lysergic acid diethylamide (LSD). Furthermore, substance-assisted psychotherapy with psychedelics has been showing promising results, being suitable for OCD treatment. It is important to add that, to date, studies have indicated relatively good tolerability to these drugs. Conclusions These promising early findings highlight the role of psychedelics in OCD treatment and the need for further research into efficacy, therapeutic mechanisms and safety, in order to determine whether these drugs may be worthy options for OCD treatment in the future. Disclosure No significant relationships.", "journal": null, "publication_date": "2022-08-31", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC9567436", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"PMC9567436\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "OCD,Mechanism of Action,Receptor Pharmacology,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3376, "title": "Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop", "normalized_title": "exploring psychedelics and entactogens as treatments for psychiatric disorders proceedings of a workshop", "authors": "National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders.", "abstract": "Psychiatric illnesses - such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) - are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients' disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts. In response to this renewed interest, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders convened a workshop on March 29-30, 2022. The workshop brought together a diverse group of stakeholders to explore the use of psychedelics and entactogens as treatments for psychiatric disorders. This Proceedings of a Workshop summarizes the presentations and discussions of the workshop.", "journal": "National Academies Press (US), Washington (DC)", "publication_date": "2022-08-31", "publication_year": 2022, "doi": null, "pubmed_id": "36049038", "source_url": "https://europepmc.org/article/MED/36049038", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36049038\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":\"National Academies Press (US), Washington (DC)\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Mechanism of Action,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1521, "title": "To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.", "normalized_title": "to treat or not to treat high potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder", "authors": "Christensen JA, Fipps DC, Bostwick JM.", "abstract": "Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis, LSD, cocaine, and nicotine use disorders who described visual distortions that resolved when he drank heavily or received benzodiazepines for withdrawal. He did not appear psychotic. Over 20 years after his last LSD use, he continued to experience illusions of halos around objects, moving walls, and figures appearing cartoonish. He understood that his perceptual disturbances were not reality based. During hospitalization for suicidal ideation, laboratory tests, head computed tomography (CT), and electroencephalogram (EEG) studies offered no explanation for his visual disturbances other than HPPD. The visual distortions remitted with scheduled clonazepam treatment, although chemical dependency treatment programs were hesitant to accept him while on a benzodiazepine. This case emphasizes the importance of diagnostic clarification when patients present with perceptual disturbances that do not fit typical psychotic presentations. Our discussion will distinguish misperceptions from hallucinations and review the pathophysiology of HPPD. Last, we will discuss management strategies for patients with co-occurring HPPD and substance use disorders. It is necessary to discern the correct cause of visual disturbances in order to provide proper treatment. The risks and benefits of long-term benzodiazepine use must be weighed when deciding whether to prescribe them for patients with comorbid HPPD and alcohol use disorder. (PsycInfo Database Record (c) 2023 APA, all rights reserved).", "journal": "Experimental and Clinical Psychopharmacology", "publication_date": "2022-08-31", "publication_year": 2022, "doi": "10.1037/pha0000597", "pubmed_id": "36048112", "source_url": "https://doi.org/10.1037/pha0000597", "keywords": "Humans, Perceptual Disorders, Alcoholism, Lysergic Acid Diethylamide, Benzodiazepines, Hallucinogens, Perception, Adult, Male", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"36048112\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4294127245\",\"openalex_url\":\"https://openalex.org/W4294127245\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5100727983\",\"display_name\":\"Julie A. Christensen\",\"orcid\":\"https://orcid.org/0000-0002-4009-0835\"},{\"id\":\"https://openalex.org/A5068524532\",\"display_name\":\"David C. Fipps\",\"orcid\":\"https://orcid.org/0000-0001-5758-704X\"},{\"id\":\"https://openalex.org/A5017175583\",\"display_name\":\"J Michael Bostwick\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S357931\",\"source_display_name\":\"Experimental and Clinical Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1037/pha0000597\",\"is_oa\":false}}}", "topic_tags": "Addiction,Brain Imaging,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4294127245" }, { "id": 1679, "title": "Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.", "normalized_title": "macrodosing to microdosing with psychedelics clinical social and cultural perspectives", "authors": "Kaypak AC, Raz A.", "abstract": "To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, and dimethyltryptamine (DMT), in typical quantities most often associated with macrodosing. More recently, however, microdosing with psychedelics has emerged as a social trend and nascent therapeutic intervention. This variation in psychedelic practice refers to repeat, intermittent ingestion of less-than-macrodose amounts that do not cause the effects associated with full-blown \"trips\". Microdosing paves the road to incorporating psychedelic drugs into a daily routine while maintaining, or even improving, cognitive and mental function. Unlike macrodosing with psychedelics, the influence of microdosing remains mostly unexplored. And yet, despite the paucity of formal studies, many informal accounts propose that microdosing plays an important role as both a therapeutic intervention (e.g., in mental disorders) and enhancement tool (e.g., recreationally-to boost creativity, improve cognition, and drive personal growth). In response to this relatively new practice, we provide an integrative synthesis of the clinical, social, and cultural dimensions of microdosing. We describe some of the overarching context that explains why this practice is increasingly in vogue, unpack potential benefits and risks, and comment on sociocultural implications. In addition, this article considers the effects that macro- and microdoses have on behavior and psychopathology in light of their dosage characteristics and contexts of use.", "journal": null, "publication_date": "2022-08-28", "publication_year": 2022, "doi": "10.1177/13634615221119386", "pubmed_id": "36031848", "source_url": "https://doi.org/10.1177/13634615221119386", "keywords": "Humans, N,N-Dimethyltryptamine, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"36031848\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Microdosing,Creativity,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1650, "title": "Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.", "normalized_title": "psychedelic drug abuse potential assessment research for new drug applications and controlled substances act scheduling", "authors": "Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ.", "abstract": "New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled globally. The implications of the CSA for research and medicines development, the path to approval of medicines, and their subsequent removal from Schedule I in the US are discussed. This entire process occurs within the framework of the CSA in the US and its counterparts internationally in accordance with international drug control treaties. Abuse potential related research in the US informs the eight factors of the CSA which provide the basis for rescheduling actions that must occur upon approval of a drug that contains a Schedule I substance. Abuse-related research also informs drug product labeling and the risk evaluation and mitigation strategies (REMS) will likely be required for approved medicines. Human abuse potential studies typically employed in CNS drug development may be problematic for substances with strong hallucinogenic effects such as psilocybin, and alternative strategies are discussed. Implications for research, medicinal development, and controlled substance scheduling are presented in the context of the US CSA and FDA requirements with implications for global regulation. We also discuss how abuse-related research can contribute to understanding mechanisms of action and therapeutic effects as well as the totality of the effects of the drugs on the brain, behavior, mood, and the constructs of spirituality and consciousness.", "journal": null, "publication_date": "2022-08-16", "publication_year": 2022, "doi": "10.1016/j.neuropharm.2022.109220", "pubmed_id": "35987353", "source_url": "https://doi.org/10.1016/j.neuropharm.2022.109220", "keywords": "Humans, Substance-Related Disorders, Lysergic Acid Diethylamide, Hallucinogens, United States, Controlled Substances, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35987353\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Consciousness,Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1608, "title": "The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.", "normalized_title": "the canadian network for mood and anxiety treatments canmat task force report serotonergic psychedelic treatments for major depressive disorder", "authors": "Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V.", "abstract": "ObjectiveSerotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder.MethodsA systematic review was conducted to identify contemporary clinical trials of serotonergic psychedelics for the treatment of major depressive disorder and cancer-related depression. Studies published between January 1990 and July 2021 were identified using combinations of search terms, inspection of bibliographies and review of other psychedelic reviews and consensus statements. The levels of evidence for efficacy were graded according to the Canadian Network for Mood and Anxiety Treatments criteria.ResultsOnly psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). Small randomized controlled trials of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator (escitalopram with supportive psychotherapy) in major depressive disorder, with additional randomized controlled trials showing efficacy specifically in cancer-related depression (Level 3 evidence). There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). Small sample sizes and functional unblinding were major limitations in all studies. Adverse events associated with psychedelics, including psychological (e.g., psychotomimetic effects) and physical (e.g., nausea, emesis and headaches) effects, were generally transient.ConclusionsThere is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder. In Canada, as of 2022, psilocybin remains an experimental option that is only available through clinical trials or the special access program. As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances.", "journal": null, "publication_date": "2022-08-16", "publication_year": 2022, "doi": "10.1177/07067437221111371", "pubmed_id": "35975555", "source_url": "https://doi.org/10.1177/07067437221111371", "keywords": "Humans, Neoplasms, Hallucinogens, Anxiety, Canada, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"35975555\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1685, "title": "Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.", "normalized_title": "inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the united states", "authors": "Levin A, Nagib PB, Deiparine S, Gao T, Mitchell J, Davis AK.", "abstract": "BackgroundEvidence points to an incongruence between international drug policy and expert opinion about safety, abuse potential, and therapeutic potential of specific drugs. However, no prior studies have directly explored psychiatrists' attitudes about the current drug schedule. Therefore, we examined whether American psychiatrists' perceptions of four psychoactive drugs differed from those indicated by their schedules.MethodsA quasi-experimental online survey of a convenience sample of psychiatrists in the United States (N=181; Mean age=48.7; Female=35%). Participants were randomized to receive 1-of-4 vignettes, each depicting a depressed patient reporting relief from symptoms after non-prescribed psychoactive drug use (i.e., psilocybin [Schedule I], methamphetamine [SchedII], ketamine [SchedIII], or alprazolam [SchedIV]). Participants responded to questions related to this clinical scenario and then rated the safety, therapeutic, and abuse potentials of these four drugs and alcohol.ResultsThere were significant differences by vignette condition in mean likelihood ratings of: warning against engaging in drug use again (p", "journal": null, "publication_date": "2022-08-10", "publication_year": 2022, "doi": "10.1016/j.drugpo.2022.103816", "pubmed_id": "35964449", "source_url": "https://doi.org/10.1016/j.drugpo.2022.103816", "keywords": "Humans, Methamphetamine, Ketamine, Alprazolam, Psychotropic Drugs, Psychiatry, Public Policy, Middle Aged, United States, Female, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"35964449\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Aging,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4290990311" }, { "id": 1700, "title": "Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.", "normalized_title": "psilocybin use patterns and perception of risk among a cohort of black individuals with opioid use disorder", "authors": "Clifton JM, Belcher AM, Greenblatt AD, Welsh CM, Cole TO, Davis AK.", "abstract": "Background and aimsThere is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst a cohort of Black individuals diagnosed with OUD.MethodsUsing a convenience sampling approach, patients were recruited from an urban methadone treatment program and paid five dollars to complete an anonymous phone-based survey.ResultsTwenty-eight patients participated (mean age 53.8; N = 28; 35.7% female). Most (N = 23; 82.1%) had \"heard of\" psilocybin mushrooms before taking the survey, but only five (N = 5; 17.8%) had ever used them. More than 80% perceived a risk or were \"unsure\" of the risk for sixteen of the seventeen items queried about psilocybin. Approximately half (N = 15; 53.6%) were willing to try therapy incorporating psilocybin and half (N = 14; 50%) said they would be more likely to try if it were FDA approved for OUD. Most (N = 18; 64.3%) preferred to stay on methadone treatment alone, 32.1% (N = 9) wanted to try treatment with both psilocybin and methadone, and only one participant opted for psilocybin treatment without methadone.ConclusionMany Black individuals with Opioid Use Disorder perceive psilocybin as dangerous and may be hesitant to try psilocybin treatment. Culturally informed treatment models, educational interventions and community outreach programs should be developed to increase racial/ethnic minority representation in psilocybin research and treatment.", "journal": "Journal of Psychedelic Studies", "publication_date": "2022-08-04", "publication_year": 2022, "doi": "10.1556/2054.2022.00214", "pubmed_id": "36686617", "source_url": "https://doi.org/10.1556/2054.2022.00214", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"36686617\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4291721232\",\"openalex_url\":\"https://openalex.org/W4291721232\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W648645029\",\"https://openalex.org/W1990140024\",\"https://openalex.org/W2021752411\",\"https://openalex.org/W2047995810\",\"https://openalex.org/W2048481507\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2088785539\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2108914738\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2153296805\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2345719282\",\"https://openalex.org/W2490107109\",\"https://openalex.org/W2578732704\",\"https://openalex.org/W2582406074\",\"https://openalex.org/W2588071311\",\"https://openalex.org/W2588924761\",\"https://openalex.org/W2614920902\",\"https://openalex.org/W2618244439\",\"https://openalex.org/W2745723818\",\"https://openalex.org/W2768925507\",\"https://openalex.org/W2802902398\",\"https://openalex.org/W2804532410\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2893642694\",\"https://openalex.org/W2909960553\",\"https://openalex.org/W2944661632\",\"https://openalex.org/W2954690399\",\"https://openalex.org/W2965468106\",\"https://openalex.org/W2967830356\",\"https://openalex.org/W2982290637\",\"https://openalex.org/W2998403265\",\"https://openalex.org/W3001327571\",\"https://openalex.org/W3112172827\",\"https://openalex.org/W3171384877\",\"https://openalex.org/W3185700361\",\"https://openalex.org/W3193146023\",\"https://openalex.org/W3197311089\",\"https://openalex.org/W3197675985\",\"https://openalex.org/W3198021583\",\"https://openalex.org/W4251765303\"],\"authorships\":[{\"id\":\"https://openalex.org/A5065747481\",\"display_name\":\"John Clifton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5003033212\",\"display_name\":\"Annabelle M. Belcher\",\"orcid\":\"https://orcid.org/0000-0003-4194-0181\"},{\"id\":\"https://openalex.org/A5070892552\",\"display_name\":\"Aaron D. Greenblatt\",\"orcid\":\"https://orcid.org/0000-0002-2558-1214\"},{\"id\":\"https://openalex.org/A5015491347\",\"display_name\":\"Christopher M. Welsh\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044804988\",\"display_name\":\"Thomas O. Cole\",\"orcid\":\"https://orcid.org/0000-0003-4238-7939\"},{\"id\":\"https://openalex.org/A5038141719\",\"display_name\":\"Alan K. Davis\",\"orcid\":\"https://orcid.org/0000-0003-4770-8893\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2022.00214\",\"is_oa\":true}}}", "topic_tags": "Addiction,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4291721232" }, { "id": 4946, "title": "Med Check: Psilocybin for OCD, Nuplazid Vote, and More", "normalized_title": "med check psilocybin for ocd nuplazid vote and more", "authors": "Terri D’Arrigo", "abstract": "Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Psilocybin for OCD, Nuplazid Vote, and MoreTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:4 Aug 2022https://doi.org/10.1176/appi.pn.2022.08.8.2AD109 Fast Tracked for Obstructive Sleep ApneaThe U.S. Food and Drug Administration (FDA) has given fast track status to AD109, an investigational oral medication for the treatment of obstructive sleep apnea, Apnimed announced in June. The FDA fast track is a process designed to facilitate the development of drugs that treat serious conditions and fill an unmet medical need and to expedite their review.AD109 contains the selective norepinephrine reuptake inhibitor atomoxetine and the selective antimuscarinic aroxybutynin. AD109 targets key neurological pathways that cause upper airway obstruction during sleep by activating the upper airway dilator muscles and maintaining an open airway during sleep.In a phase 2 trial of 32 adults with mild to moderate obstructive sleep apnea, patients who took AD109 experienced less hypoxic burden compared with patients who took placebo. Hypoxic burden is a measure of the total amount of respiratory event-related hypoxemia, or low blood oxygen during sleep. Patients who took AD109 also had fewer episodes of apnea and hypopnea per hour of sleep compared with patients who took placebo. Ceruvia to Begin Phase 2 Trial of Psilocybin for OCDThe FDA has accepted Ceruvia Lifesciences’ Investigational New Drug application for a phase 2 clinical trial to determine the efficacy and safety of SYNP-101 (synthetic psilocybin) for the treatment of obsessive-compulsive disorder (OCD), the company announced in June.In the trial, 105 patients with OCD will receive 25 mg of SYNP-101 or the active placebo niacin. The primary endpoint of the trial will be to determine the reduction in OCD symptoms for up to 12 weeks after a single dose of SYNP-101. Researchers will determine the drug’s efficacy using the Yale-Brown Obsessive Compulsive Scale. FDA Advisory Committee Votes Down Nuplazid for Alzheimer’s PsychosisIn June the FDA Psychopharmacologic Drugs Advisory Committee voted 9 to 3 that available evidence does not support Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis, Acadia Pharmaceuticals announced. The drug is currently approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.The company submitted the application in 2020 after the phase 3 HARMONY trial suggested that pimavanserin may reduce the risk of psychosis relapse in patients with common subtypes of dementia including Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease dementia, vascular dementia, and frontotemporal dementia spectrum disorders. However, the advisory committee noted that study’s conclusions about the primary endpoint-the effect of pimavanserin on time to relapse of psychosis-appeared to spring mostly from the results in patients with psychosis from Parkinson’s disease, not Alzheimer’s disease.The advisory committee also questioned the findings of a phase 2 trial of pimavanserin in patients with Alzheimer’s disease. The committee said the trial was not well controlled and that more than half of the patients in both the treatment and placebo groups deviated from the trial’s protocol.The FDA does not have to act on the advisory committee’s recommendations, although the agency will consider them in making a decision on whether to approve pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis. The target date for FDA action is August 4, 2022. AbbVie Submits Supplemental NDA for Qulipta for Migraine PreventionIn June AbbVie announced that it has submitted a supplemental New Drug Application to the FDA to expand the labeling for Qulipta (atogepant) to include prevention of chronic migraine in adults. The drug is currently approved for the preventive treatment of episodic, not chronic, migraine in adults.The submission includes data from the phase 3 PROGRESS trial in patients with chronic migraine, which found that adults with chronic migraine who took the drug experienced fewer monthly migraine days over the course of 12 weeks compared with those who took placebo.In the trial, more than 750 patients with at least a one-year history of chronic migraine were randomized to receive 60 mg of atogepant once a day, 30 mg of atogepant twice a day, or placebo for 12 weeks. All patients had at least 15 headache days with at least eight migraine days in the 28 days before randomization. The trial consisted of two analyses based on regulatory agency feedback in the United States and European Union.The U.S. analysis revealed that patients in the 60 mg and 30 mg atogepant arms experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively, compared with patients in the placebo arm, who experienced a decrease of 5.05 monthly migraine days. The European Union analysis revealed that patients in the 60 mg and 30 mg atogepant arms experienced a decrease of 6.75 and 7.33 monthly migraine days, respectively, compared with patients in the placebo arm, who experienced a decrease of 5.09 monthly migraine days. Zuranolone Promising for Postpartum DepressionZuranolone may reduce symptoms of postpartum depression, the phase 3 SKYLARK Study has found. The results of the study were announced by Sage Therapeutics and Biogen in June.In the trial, 195 women with postpartum depression were randomized to take either 50 mg of zuranolone or placebo once per night for 14 days. On Day 15, scores on the 17-item Hamilton Rating Scale for Depression dropped a mean of 15.6 points among women who took zuranolone compared with a mean decrease in score of 11.6 points among women who took placebo. Women who took zuranolone also experienced greater improvement in their depressive symptoms as measured by the Clinical Global Depression Severity Scale than those who took placebo. ■ ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2022-07-31", "publication_year": 2022, "doi": "10.1176/appi.pn.2022.08.8.2", "pubmed_id": null, "source_url": "https://doi.org/10.1176/appi.pn.2022.08.8.2", "keywords": "Medicine, Psilocybin, Placebo, Atomoxetine, Obstructive sleep apnea, Anesthesia, Apnea, Clinical trial, Internal medicine, Pharmacology, Psychiatry, Methylphenidate, Hallucinogen, Attention deficit hyperactivity disorder, Alternative medicine, Pathology, Psychedelics and Drug Studies, Digital Mental Health Interventions, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4289781881\",\"openalex_url\":\"https://openalex.org/W4289781881\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5056763663\",\"display_name\":\"Terri D’Arrigo\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"https://doi.org/10.1176/appi.pn.2022.08.8.2\",\"is_oa\":false}}", "topic_tags": "Depression,OCD,Headache / Migraine,Pharmacology,Mechanism of Action,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4289781881" }, { "id": 1729, "title": "Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.", "normalized_title": "top ten tips palliative care clinicians should know about psychedelic assisted therapy in the context of serious illness", "authors": "Rosa WE, Sager Z, Miller M, Bernstein I, Doerner Rinaldi A, Addicott K, Ljuslin M, Adrian C, Back AL, Beachy J, Bossis AP, Breitbart WS, Cosimano MP, Fischer SM, Guss J, Knighton E, Phelps J, Richards BD, Richards WA, Tulsky JA, Williams MT, Beaussant Y", "abstract": "Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within the palliative care (PC) field, one-time PAT dosing may lead to sustained reductions in anxiety, depression, and demoralization-symptoms that diminish the quality of life in both seriously ill patients and those at end of life. Despite a well-noted psychedelic renaissance in scholarship and a renewed public interest in the utilization of these medicines, serious illness-specific content to guide PAT applications in hospice and PC clinical settings has been limited. This article offers 10 evidence-informed tips for PC clinicians synthesized through consultation with interdisciplinary and international leading experts in the field with aims to: (1) familiarize PC clinicians and teams with PAT; (2) identify the unique challenges pertaining to this intervention given the current legalities and logistical barriers; (3) discuss therapeutic competencies and considerations for current and future PAT use in PC; and (4) highlight critical approaches to optimize the safety and potential benefits of PAT among patients with serious illness and their caregivers.", "journal": "Journal of palliative medicine", "publication_date": "2022-07-31", "publication_year": 2022, "doi": "10.1089/jpm.2022.0036", "pubmed_id": "35285721", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35285721/", "keywords": "LSD, MDMA, anxiety treatment, demoralization, depression, palliative care, psilocybin, psychedelic-assisted therapy, psychedelics, serious illness", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35285721\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,End-of-Life Distress,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1725, "title": "The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.", "normalized_title": "the emerging science of microdosing a systematic review of research on low dose psychedelics 1955 2021 and recommendations for the field", "authors": "Polito V, Liknaitzky P", "abstract": "The use of low doses of psychedelic substances (microdosing) is attracting increasing interest. This systematic review summarises all empirical microdosing research to date, including a set of infrequently cited studies that took place prior to prohibition. Specifically, we reviewed 44 studies published between 1955 and 2021, and summarised reported effects across six categories: mood and mental health; wellbeing and attitude; cognition and creativity; personality; changes in conscious state; and neurobiology and physiology. Studies showed a wide range in risk of bias, depending on design, age, and other study characteristics. Laboratory studies found changes in pain perception, time perception, conscious state, and neurophysiology. Self-report studies found changes in cognitive processing and mental health. We review data related to expectation and placebo effects, but argue that claims that microdosing effects are largely due to expectancy are premature and possibly wrong. In addition, we attempt to clarify definitional inconsistencies in the microdosing literature by providing suggested dose ranges across different substances. Finally, we provide specific design suggestions to facilitate more rigorous future research.", "journal": "Neuroscience and biobehavioral reviews", "publication_date": "2022-07-31", "publication_year": 2022, "doi": "10.1016/j.neubiorev.2022.104706", "pubmed_id": "35609684", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35609684/", "keywords": "Hallucinogen, LSD, Low dose, Microdosing, Psilocybin, Psychedelics, Systematic review", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35609684\"}", "topic_tags": "Chronic Pain,Consciousness,Microdosing,Wellbeing,Personality Change,Creativity,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3594, "title": "Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy", "normalized_title": "evaluation of psilocybin in anorexia nervosa safety and efficacy", "authors": "University of California, San Diego", "abstract": "The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight. Because there are no proven treatments that normalize core symptoms in adult anorexia nervosa, a disorder with high chronicity, many individuals seek out alternative approaches to care. Recent evidence has suggested that anxiety, obsessive compulsive disorder, and diminished reward or motivation play key roles in the development and maintenance of dysfunctional eating, and poor outcome. In recent years, a growing number of studies have demonstrated the safety and preliminary efficacy of psilocybin in clinical trials for a range of psychiatric illnesses including treatment resistant depression, obsessive compulsive disorder, addiction, and anxiety. Psilocybin may represent a promising new treatment for anorexia nervosa. However, no studies have tested psilocybin in this eating disorder population. Accordingly, this study aims to establish the safety, tolerability and dosing of psilocybin in adult patients with anorexia nervosa, as well as gather pilot data on possible efficacy. For this study, the investigators will recruit adults who currently have a DSM-V diagnosis of anorexia nervosa. Participants will undergo medical and psychological screening and those who are deemed eligible will partake in a maximum of 7 study visits, lasting from 4-8 weeks. On dosing day, participants will receive a single 25 mg dose of psilocybin along with psychotherapeutic support, which includes preparation and integration sessions surrounding the experience. There will be a follow-up period of one month following the psilocybin session during which a range of psychological measures (questionnaires and interviews) will be collected.", "journal": "ClinicalTrials.gov", "publication_date": "2022-07-24", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04661514", "keywords": "Anorexia Nervosa, Psilocybin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04661514\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Addiction,Eating Disorders,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1426, "title": "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.", "normalized_title": "psilocybin in neuropsychiatry a review of its pharmacology safety and efficacy", "authors": "Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M.", "abstract": "Psilocybin is a tryptamine alkaloid found in some mushrooms, especially those of the genus Psilocybe. Psilocybin has four metabolites including the pharmacologically active primary metabolite psilocin, which readily enters the systemic circulation. The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor. Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored. Psilocybin administered at doses sufficient to cause hallucinogenic experiences has been trialed for addictive disorders, anxiety and depression. This review investigates studies of psilocybin and psilocin and assesses the potential for use of psilocybin and a treatment agent in neuropsychiatry. The potential for harm is also assessed, which may limit the use of psilocybin as a pharmacotherapy. Careful evaluation of the number needed to harm vs the number needed to treat will ultimately justify the potential clinical use of psilocybin. This field needs a responsible pathway forward.", "journal": null, "publication_date": "2022-07-10", "publication_year": 2022, "doi": "10.1017/s1092852922000888", "pubmed_id": "35811423", "source_url": "https://doi.org/10.1017/s1092852922000888", "keywords": "Humans, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:00", "raw_json": "{\"europe_pmc_id\":\"35811423\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Pharmacology,Mechanism of Action,Receptor Pharmacology,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3220, "title": "Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity", "normalized_title": "psilocybin induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity", "authors": "Madsen MK, Petersen AS, Stenbæk DS, Sørensen IM, Schiønning H, Fjeld T, Nykjær CH, Ulv Larsen SM, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM.", "abstract": "Chronic cluster headache (CCH) is an excruciating disorder of unknown pathophysiology, but hypothalamic dysfunction has been implicated. CCH is difficult to treat but on a case-basis, the psychedelic compound psilocybin is said to have beneficial effects. In this first-ever clinical trial ( NCT04280055 ), we evaluate in a small open-label study of CCH patients the feasibility and prophylactic effect of three low-to-moderate doses of psilocybin as well as effects on hypothalamic functional connectivity (FC), using functional magnetic resonance imaging. The treatment was well-tolerated and without serious adverse reactions. Attack frequency was on average reduced by 30% from baseline to follow-up (P FWER =0.008). One patient experienced 21 weeks of complete remission. Changes in hypothalamic-diencephalic FC correlated negatively with relative reduction in attack frequency, implicating this neural pathway in treatment response. Further clinical studies are warranted to confirm the safety and prophylactic efficacy of psilocybin for CCH and hypothalamic involvement in treatment response.", "journal": "medRxiv", "publication_date": "2022-07-09", "publication_year": 2022, "doi": "10.1101/2022.07.10.22277414", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2022.07.10.22277414", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PPR516560\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Headache / Migraine,Brain Imaging,Mechanism of Action,Aging,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3379, "title": "Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis", "normalized_title": "pharmacotherapy for the secondary prevention of suicide leads from the social pain hypothesis", "authors": "Rajkumar RP.", "abstract": "Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment following a suicide attempt, strategies aimed at reducing further attempts in this population are a valid and feasible secondary prevention approach. An evaluation of the available evidence suggests that existing treatment approaches have limited efficacy in this setting, highlighting the need for innovative approaches to suicide prevention. Existing research on the neurobiology of social pain has highlighted the importance of this phenomenon as a risk factor for suicide, and has also yielded several attractive targets for pharmacological preventive strategies. In this paper, the available evidence related to these targets is synthesized and critically evaluated. The way in which social pain is related to the “anti-suicidal” properties of recently approved treatments, such as ketamine and psilocybin, is also examined. Such strategies may be effective for the short-term reduction of suicidal ideation and behaviour in individuals who have made a suicide attempt suicide prevention, particularly in cases where social pain is identified as a contributory factor. These pharmacological approaches may be effective regardless of the presence or absence of a specific psychiatric diagnosis.", "journal": "Preprints.org", "publication_date": "2022-07-04", "publication_year": 2022, "doi": "10.20944/preprints202207.0064.v1", "pubmed_id": null, "source_url": "https://doi.org/10.20944/preprints202207.0064.v1", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR514407\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Preprints.org\",\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1738, "title": "Psychedelics in the treatment of unipolar and bipolar depression.", "normalized_title": "psychedelics in the treatment of unipolar and bipolar depression", "authors": "Bosch OG, Halm S, Seifritz E.", "abstract": "This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory perception, as well as emotion- and self-processing are induced by stimulation of serotonin 2A receptors in cortical areas. The new paradigm of psychedelic-assisted psychotherapy suggests a therapeutic framework in which a safely conducted psychedelic experience is integrated into a continuous psychotherapeutic process. First randomized, controlled trials with psilocybin show promising efficacy, tolerability, and adherence in the treatment of unipolar depression. On the other hand, classic psychedelics seem to be associated with the induction of mania, which is an important issue to consider for the design of research and clinical protocols. So called atypical psychedelics are a heterogeneous group with overlapping subjective effects but different neurobiological mechanisms. Two examples of therapeutic value in psychiatry are 3,4-methyl​enedioxy​methamphetamine (MDMA) and ketamine. Since 2020 the ketamine enantiomer esketamine has been granted international approval for treatment-resistant unipolar depression, and also first evidence exists for the therapeutic efficacy of ketamine in bipolar depression. Whether psychedelics will fulfil current expectations and find their way into broader clinical use will depend on future rigorous clinical trials with larger sample sizes. A well-considered therapeutic and legal framework will be crucial for these substances to create new treatment settings and a potential paradigm shift.", "journal": null, "publication_date": "2022-07-04", "publication_year": 2022, "doi": "10.1186/s40345-022-00265-5", "pubmed_id": "35788817", "source_url": "https://doi.org/10.1186/s40345-022-00265-5", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35788817\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1693, "title": "Psychedelic drugs for psychiatric disorders.", "normalized_title": "psychedelic drugs for psychiatric disorders", "authors": "da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M.", "abstract": "Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and some of these compounds have been used in shamanic and spiritual ceremonies for millennia. The psychoactive effects of these drugs, particularly on human consciousness, have generated great scientific curiosity, and early research on psychedelics suggested their clinical benefits for psychiatric conditions, including alcohol use disorders and anxiety and depressive symptoms in terminal illness and life-threatening conditions. Since the 1990s, after a period of dormancy that followed the criminalization of psychedelic drugs since the Controlled Substance Act of 1970, the continued interest in their unique psychoactive effects along with the pursuit for novel and more effective treatments in psychiatry have led to a renewed interest in research on these compounds. While preliminary findings on psychedelics are encouraging, current evidence is still insufficient to support extensive use of these drugs routinely. Long-term safety and efficacy of these compounds remain unclear, and several clinical trials are underway and may add clarity to these questions. Therefore, this article intends to provide an overview of the evidence to date on psychedelic drugs - particularly psilocybin, MDMA, and LSD - for the treatment of psychiatric disorders.", "journal": null, "publication_date": "2022-07-04", "publication_year": 2022, "doi": "10.1016/j.jns.2022.120332", "pubmed_id": "35841696", "source_url": "https://doi.org/10.1016/j.jns.2022.120332", "keywords": "Humans, Alcoholism, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35841696\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Consciousness,Aging,Spirituality,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1735, "title": "A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS.", "normalized_title": "a single method for 127 recommended and additional duid drugs in blood and urine by lc ms ms", "authors": "Farley M, Tran H, Towler S, Gevorkyan J, Pearring S, Rodda LN.", "abstract": "Driving under the influence of drug (DUID) cases continue to challenge forensic toxicologists as both the volume and complexity of casework increases. Comprehensive DUID testing should also meet the drafted Academy Standards Board (ASB)/ American National Standard Institute (ANSI) standard and the National Safety Council's Alcohol, Drugs and Impairment Division (NSC-ADID) recommendations. A simple method using protein precipitation followed by filtration extraction with an 8 minute run time by liquid chromatography-tandem mass spectrometry (LC-MS-MS) was developed, and a comprehensive ASB/ANSI validation was performed. Target drugs and metabolites were quantitatively assessed in blood and qualitatively assessed in urine. Included were 127 target analytes including cannabinoids (12), amphetamines (11), cocaine and metabolites (6), benzodiazepines (36), Z-drugs (5), opioids (27), anticonvulsants (3), first-generation antihistamines (6), muscle relaxants (2), dissociatives and hallucinogens (6), barbiturates (10), and miscellaneous substances (3). Limits of detection are appropriate for DUID and other forensic casework such as drug-facilitated crime (DFC) and postmortem investigations. To demonstrate applicability, 78 proficiency test blood and urine samples and 1,645 blood and urine samples from authentic cases samples demonstrated effective detection of target analytes in forensic casework. By increasing the analytical scope of multiple drug classes via a single method, this technique detects drugs that may have previously gone undetected, such as flualprazolam, etizolam, mitragynine, gamma-hydroxybutyric acid and psilocin and improves laboratory efficiency by reducing the number of tests required. The described method is, to the authors' best knowledge, the only published single procedure to meet all drugs listed in the drafted ASB/ANSI standard and recommended Tier 1 and traditional drugs from Tier 2 for DUID screening, while also achieving many drug scope and sensitivity recommendations for DFC and postmortem testing.", "journal": null, "publication_date": "2022-06-30", "publication_year": 2022, "doi": "10.1093/jat/bkab075", "pubmed_id": "34159389", "source_url": "https://doi.org/10.1093/jat/bkab075", "keywords": "Amphetamines, Cannabinoids, Chromatography, Liquid, Substance Abuse Detection, Tandem Mass Spectrometry, Forensic Toxicology", "substance_tags": "psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"34159389\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety,Toxicity", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3177184994" }, { "id": 3653, "title": "Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults", "normalized_title": "randomized double blind placebo controlled assessing the efficacy of micro dosed psilocybin in reducing anxiety and or depression levels in adults", "authors": "Wake Network, Inc.", "abstract": "To investigate the efficacy of a 16 week treatment with PSIL428 patient reported anxiety levels in otherwise healthy individuals suffering from depression and or anxiety symptoms. Randomized, double-blind, placebo-controlled study assessing the efficacy of micro-dosed psilocybin on reducing anxiety and/or depression levels in adults Study summary: The Institute for Health Metrics and Evaluation reported that Anxiety disorders currently affect an estimated 275 million people worldwide, about one in 13 people (7.3 percent). COVID-19 has accelerated the rate of new anxiety diagnoses and exacerbated pre-existing diagnoses of anxiety in individuals worldwide. The effectiveness of full dose psilocybin for treatment of anxiety and depression has been shown in a number of clinical trials. While there is a significant evidence of clinical efficacy of full dose psilocybin, acute effects of the dose result in a significant impairment - perceptual and sensory distortions incapacitating the patient for the duration of drug activity. Recent work suggests while not producing perceptual changes, micro-dosing may indeed be associated with improved mood and enhanced well-being. The practice of micro-dosing is gaining popularity in the general population, while clinical data on its safety and efficacy is lacking. This will be a novel randomized, double-blind, placebo-controlled study aimed at establishment of safety and anxiolytic efficacy of psilocybin PSIL428 administered in a micro-dosing regimen (2-5% of a full therapeutic dose) to adults suffering from depression or anxiety. The primary outcome of this study is the change in anxiety and/or depression levels from screening to week 16. Participant anxiety levels will be monitored through Beck Anxiety inventory, depression levels - through Beck Depression Inventory forms on a bi-weekly basis across the course of the study. Study Drug PSIL428 is an experimental intervention and the active ingredient psilocybin is botanically derived. Similar interventions are currently undergoing Phase IIb/III clinical trials in international jurisdictions. It is being assessed for treatment of depressive disorders. Typically psilocybin used in full therapeutic doses associated with significant acute adverse effects. The proposed trial would utilize psilocybin in different dosing regimen - as micro-dosing - ingesting of sub-perceptual doses of the drug equal to 2-10% of the full dose. The micro-dosing practice is gaining significant popularity world-wide, however evidence-based data around it is minimal. Risks and benefits associated with the trial are not definitively established, however existing pre-clinical and clinical data around full-dose use of the drug carries a favorable risk-benefit potential. The trial will be conducted in accordance with the most recently acceptable version of the Declaration of Helsinki, Good Clinical Practice (GCP) according to International Conference on Harmonization (ICH) guidelines, and applicable Standard Operating Procedures (SOPs). The trial will be conducted under a protocol reviewed and approved by an IRB; the trial will be conducted by scientifically and medically qualified persons; the benefits of the study are in proportion to the risks; the rights and welfare of the subjects will be respected; each subject will give his or her written informed consent before any protocol-driven tests or evaluations are performed. The investigators are responsible for obtaining informed consent in adherence to GCP and according to applicable regulations prior to entering the subject into the trial. A positive change in Beck Anxiety and/or Beck Depression numeric levels between PSIL428 and placebo groups will mark our primary outcome achievement of confirming beneficial effects of micro-dose-administered psilocybin on study participants' overall anxiety and/or depression levels", "journal": "ClinicalTrials.gov", "publication_date": "2022-06-29", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04989972", "keywords": "Anxiety and Depression, PSIL428, Oyster mushroom, WITHDRAWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT04989972\",\"overall_status\":\"WITHDRAWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Wellbeing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1753, "title": "3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.", "normalized_title": "3 4 methylenedioxymethamphetamine mdma assisted therapy in hawaii a brief review", "authors": "Inouye A, Wolfgang A.", "abstract": "The Food and Drug Administration (FDA) granted breakthrough therapy status to 3,4-methyl​enedioxy​methamphetamine-assisted therapy (MDMA-AT) in 2017 due to preliminary evidence supporting its efficacy and safety in treating post-traumatic stress disorder (PTSD). A series of six phase-II clinical trials studying MDMA-AT for treatment-resistant PTSD found that 54% of MDMA-AT full-dose participants no longer met the diagnosis of PTSD after two MDMA sessions, compared to 23% in the control group. In the first phase-III clinical trial, 67% no longer met the criteria for PTSD after three sessions. The effects are durable, with 67% no longer diagnosable after one year and 74% at nearly four years. The MDMA-AT is being fast-tracked for potential FDA approval by 2023. In 2021, Hawaii's Senate Bill 738 unsuccessfully proposed that psilocybin be removed from the Schedule I controlled substances list due to its clinical efficacy for major depressive disorder. Methyl​enedioxy​methamphetamine is also a Schedule I controlled substance and has proven to be a treatment option that could potentially benefit the people of Hawaii.", "journal": null, "publication_date": "2022-06-27", "publication_year": 2022, "doi": "10.7759/cureus.26402", "pubmed_id": "35915689", "source_url": "https://doi.org/10.7759/cureus.26402", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35915689\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1703, "title": "Psychedelics as preventive treatment in headache and chronic pain disorders.", "normalized_title": "psychedelics as preventive treatment in headache and chronic pain disorders", "authors": "Schindler EAD.", "abstract": "The effects of psychedelic drugs in headache and chronic pain disorders have been reported for several decades, and now controlled studies are emerging. The existing evidence supports a lasting therapeutic benefit after limited dosing, a unique feature of the drug class that distinguishes it from conventional treatment. This commentary summarizes these reports of preventive effects of psychedelic drugs in headache and chronic pain disorders. The recently published controlled trial of psilocybin in migraine is reviewed, including its limitations. Several neurobiological targets of psychedelics that are related to headache and chronic pain are highlighted, though a clear separation of acute and lasting effects is key in uncovering the unique clinical effects of this drug class. Considerable investigation is required before the effects, safety, and mechanism of action of psychedelics in headache and chronic pain disorders can be known.", "journal": null, "publication_date": "2022-06-15", "publication_year": 2022, "doi": "10.1016/j.neuropharm.2022.109166", "pubmed_id": "35718005", "source_url": "https://doi.org/10.1016/j.neuropharm.2022.109166", "keywords": "Humans, Headache, Hallucinogens, Chronic Pain, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35718005\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4959, "title": "The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.", "normalized_title": "the safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder", "authors": "Manish Agrawal, Paul Thambi, Sarah Shnayder", "abstract": "12097 Background: More than 17 million people in the U.S. live with cancer and up to 25% of them have major depression. Depression leads to lower treatment adherence, reduced quality of life, and higher rates of mortality in cancer. Yet, interventions used to treat depression in patients with cancer have limited success. Prior trials using psilocybin to treat anxiety and depression associated with cancer suggested improvements in psychological distress. However, treatment in a homogenous psychiatric sample has yet to be investigated. Further, psilocybin has not been given in groups, and in a setting conducive to the “whole person” approach to treatment. This trial built upon previous studies and tested the safety, feasibility, and efficacy of psilocybin therapy in cancer patients diagnosed with major depressive disorder (MDD), with the novel use of group treatment in a cancer center setting. Methods: Phase II, single-center, open label trial, where 30 patients received a dose of 25 mg of psilocybin. Inclusion criteria: 1) age ≥ 18 years, 2) met criteria for MDD, 3) a Hamilton Depression Rating Scale score ≥ 18 at baseline, 4) diagnosis of a malignant neoplasm. Patients who had curative treatment for cancer as well as those with advanced metastatic disease were included. Patients were divided into cohorts and they received 1 group preparation session, simultaneous administration of psilocybin, and 2 group integration sessions. Therapeutic care was also provided before, during, and after the session using the 1:1 model of psychological support. The primary outcome measures for safety were adverse events, vital signs, ECGs, blood tests, and suicidality scores (C-SSRS). The secondary and exploratory outcome measures consisted of 15 assessments conducted at baseline and post-treatment at day 1, week 1, week 3, and week 8 to determine the efficacy of treatment. Results: A total of 30 patients were enrolled over the course of only 8 months with an attrition rate of 0%. All completed the trial with no serious adverse events. Beyond high tolerability of the treatment, we also found a clinically meaningful change in depressive symptoms. After a single administration of psilocybin therapy, the average score on the Montgomery Asberg Depression Rating Scale (MADRS) dropped by 19.1 points (95% CI, 22.3 to 16.0, p < 0.0001). A sustained response rate (a decrease of ≥ 50% in the MADRS score from baseline to week 8) was seen by 24 patients. 50% of patients showed complete remission of depression symptoms (a MADRS score < 10) one week after treatment, which was sustained for up to 8 weeks. Conclusions: This study adds to the growing body of psilocybin research with promising results showing the safety, feasibility, and efficacy of simultaneous psilocybin treatment in patients with cancer with MDD. The value of group support for patients with cancer was also explored, with implications for increased scalability of psilocybin therapy in real-world settings. Clinical trial information: NCT04593563.", "journal": "Journal of Clinical Oncology", "publication_date": "2022-05-31", "publication_year": 2022, "doi": "10.1200/jco.2022.40.16_suppl.12097", "pubmed_id": null, "source_url": "https://doi.org/10.1200/jco.2022.40.16_suppl.12097", "keywords": "Psilocybin, Medicine, Cancer, Depression (economics), Adverse effect, Major depressive disorder, Anxiety, Clinical trial, Psychiatry, Internal medicine, Hallucinogen, Cognition, Macroeconomics, Economics, Psychedelics and Drug Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4281784879\",\"openalex_url\":\"https://openalex.org/W4281784879\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5083533154\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0001-8208-0582\"},{\"id\":\"https://openalex.org/A5026954192\",\"display_name\":\"Paul Thambi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5038515583\",\"display_name\":\"Sarah Shnayder\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S15137598\",\"source_display_name\":\"Journal of Clinical Oncology\",\"landing_page_url\":\"https://doi.org/10.1200/jco.2022.40.16_suppl.12097\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Clinical Trial,Observational Study,Cancer Patients,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4281784879" }, { "id": 1776, "title": "Serotonin toxicity of serotonergic psychedelics.", "normalized_title": "serotonin toxicity of serotonergic psychedelics", "authors": "Malcolm B, Thomas K", "abstract": "In recent years, psychedelic substances with serotonergic mechanisms have accumulated substantial evidence that they may provide therapeutic benefits for people suffering with psychiatric symptoms. Psychiatric disorders targeted by these psychedelic-assisted therapies are managed with serotonergic drugs like selective serotonin reuptake inhibitors (SSRIs) as the current standard of care, so it is important to evaluate the potential risks of drug-drug interactions and serotonin toxicity (ST) between these agents. A critical evaluation of the scientific literature is necessary to delineate the risks of ST when combining psychedelics with available serotonergic pharmacotherapy options. This review article describes signs and symptoms of ST, characterizes mechanisms of ST risk, summarizes what is known about serotonergic psychedelic drug interactions, and outlines potential management strategies. True ST typically occurs with a serotonergic drug overdose or in combinations in which a drug that can increase intrasynaptic serotonin is combined with a monoamine oxidase inhibitor (MAOI). Serotonergic psychotropics that do not contain MAOIs are low risk in combination with psychedelics that also do not contain MAOIs. Signs and symptoms warranting immediate medical attention include myoclonus, extreme and fluctuating vital signs, agitation or comatose mental state, muscle rigidity, pronounced hyperthermia (fever), and/or seizure activity. Serotonin-related adverse reactions exist along a spectrum with serotonin syndrome being the most severe manifestations of ST. Due to varying serotonergic mechanisms of psychedelics and psychotropics, with varying propensities to increase intrasynaptic serotonin, some combinations may present a significant risk for serotonin toxicity (ST) while others are likely benign.", "journal": "Psychopharmacology", "publication_date": "2022-05-31", "publication_year": 2022, "doi": "10.1007/s00213-021-05876-x", "pubmed_id": "34251464", "source_url": "https://pubmed.ncbi.nlm.nih.gov/34251464/", "keywords": "Hallucinogen, MDMA, Monoamine oxidase inhibitor, Psilocybin, Psychedelic, Selective serotonin reuptake inhibitors, Serotonin syndrome, Serotonin toxicity", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"34251464\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Review Article,Safety,Toxicity,Drug Interactions", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1762, "title": "Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?", "normalized_title": "can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits", "authors": "Husain MI, Umer M, Mulsant BH", "abstract": "", "journal": "Expert opinion on drug safety", "publication_date": "2022-05-31", "publication_year": 2022, "doi": "10.1080/14740338.2022.2063274", "pubmed_id": "35387542", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35387542/", "keywords": "MDMA, Psychedelics, major depressive disorder, post-traumatic stress disorder, psilocybin, psychotherapy, substance use disorders", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35387542\"}", "topic_tags": "Depression,PTSD,Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1724, "title": "Postpartum depression: A role for psychedelics?", "normalized_title": "postpartum depression a role for psychedelics", "authors": "Jairaj C, Rucker JJ.", "abstract": "BackgroundPostpartum depression (PPD) is a major public health concern and has, at its core, a sense of maternal 'disconnection' - from the self, the infant, and the support system. While PPD bears similarities with MDD, there is increasing evidence for its distinct nature, especially with the unique aspect of the mother-infant relationship. Current treatment modalities for PPD, largely based on those used in major depressive disorder (MDD), have low remission rates with emerging evidence for treatment resistance. It is, therefore, necessary to explore alternative avenues of treatment for PPD.ObjectiveIn this narrative review, we outline the potential therapeutic rationale for serotonergic psychedelics in the treatment of PPD, and highlight safety and pragmatic considerations for the use of psychedelics in the postpartum period.MethodsWe examined the available evidence for the treatment of PPD and the evidence for psychedelics in the treatment of MDD. We explored safety considerations in the use of psychedelics in the postpartum period.ResultsThere is increasing evidence for safety, and encouraging signals for efficacy, of psilocybin in the treatment of MDD. Psilocybin has been shown to catalyse a sense of 'reconnection' in participants with MDD. This effect in PPD, by fostering a sense of 'reconnection' for the mother, may allow for improved mood and maternal sensitivity towards the infant, which can positively impact maternal role gratification and the mother-infant relationship.ConclusionPsychedelic assisted therapy in PPD may have a positive effect on the mother-infant dyad and warrants further examination.", "journal": null, "publication_date": "2022-05-29", "publication_year": 2022, "doi": "10.1177/02698811221093793", "pubmed_id": "35638179", "source_url": "https://doi.org/10.1177/02698811221093793", "keywords": "Humans, Depression, Postpartum, Hallucinogens, Mothers, Female, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35638179\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Aging,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1713, "title": "Review of potential psychedelic treatments for PTSD.", "normalized_title": "review of potential psychedelic treatments for ptsd", "authors": "Henner RL, Keshavan MS, Hill KP.", "abstract": "Post-traumatic stress disorder (PTSD) is a debilitating mental illness with limited treatment options and a high treatment dropout rate. Psychedelics, often in combination with psychotherapy, are now under investigation as a potential treatment option for a variety of psychiatric conditions including PTSD. This paper reviews the proposed mechanism of action for 3,4-Methylenedioxymethamphetamine (MDMA) and classical psychedelics such as psilocybin in treating PTSD, along with available clinical evidence, safety and side effects. MDMA-assisted psychotherapy is in FDA phase III clinical trials for PTSD and is purported to work by way of increased empathy and decreased amygdala activation during the therapeutic encounter and trauma processing. Classical psychedelics may create change by a subjective transformative experience along with an observable process of brain network alterations, though these substances have not been clinically studied in the context PTSD. In recent human-subject studies MDMA-assisted therapy resulted in significant improvement in PTSD symptoms with a good safety and side effect profile. There is not yet direct clinical evidence for classical psychedelics in treating PTSD, but the evidence supports such a trial. The studies to date have been relatively small, and participants are wellscreened for potential co-morbidities which could increase the risks of psychedelic treatment. Nonetheless, the data is promising for psychedelic-assisted treatment to become a much-needed treatment option for PTSD.", "journal": null, "publication_date": "2022-05-29", "publication_year": 2022, "doi": "10.1016/j.jns.2022.120302", "pubmed_id": "35700643", "source_url": "https://doi.org/10.1016/j.jns.2022.120302", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Combined Modality Therapy, Stress Disorders, Post-Traumatic, Psychotherapy", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35700643\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Mechanism of Action,Clinical Trial,Review Article,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 4967, "title": "Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits", "normalized_title": "psilocybin assisted therapy found to improve depression offer other benefits", "authors": "Richard Karel", "abstract": "Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsilocybin-Assisted Therapy Found to Improve Depression, Offer Other BenefitsRichard KarelRichard KarelSearch for more papers by this authorPublished Online:23 May 2022https://doi.org/10.1176/appi.pn.2022.06.6.30AbstractA small study involving 24 participants found that psilocybin therapy was safe and effective up to one year following administration. More research using larger sample sizes is needed to further clarify efficacy and safety.A study on the safety and efficacy of psilocybin-assisted therapy in a therapeutic setting in 24 participants with major depressive disorder found that the hallucinogen provided rapid and substantial antidepressant effects lasting up to one year with no serious adverse effects. The long-term efficacy and safety of such treatment, however, are not known.The study, conducted by researchers at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) in the Department of Psychiatry and Behavioral Sciences in Baltimore, was published in February in the Journal of Psychopharmacology and augments research previously published in JAMA Psychiatry.The 24 participants were randomized to either an immediate or eight-week delayed treatment protocol, involving a combination of psilocybin sessions and supportive psychotherapy. Each participant received two doses of psilocybin and were followed for up to a year.The types of features that the researchers asked about in their study on psilocybin-assisted therapy, such as personal meaning and spiritual significance, did not predict patients’ magnitude of depression, says Natalie Gukasyan, M.D.Lead author Natalie Gukasyan, M.D., an assistant professor of psychiatry and behavioral sciences at Hopkins and medical director of the CPCR, and colleagues reported “large decreases from baseline using the standardized Hamilton Depression Rating Scale (GRID-HAMD) scores at one, three, six, and 12-month follow-up.” The principal investigator was Roland Griffiths, Ph.D., director of the CPCR.At 12 months, 75% of the 24 participants achieved “treatment response”-defined as a reduction of 50% or greater in GRID-HAMD score from baseline; 58% of the participants achieved remission-defined as a GRID-HAMD score less than or equal to 7. Self-reported measures, including the Quick Inventory of Depressive Symptomatology (QIDS) and the Beck Depression Inventory II (BDI-II), were consistent with the GRID-HAMD outcomes.One intriguing finding was that “participant ratings of personal meaning, spiritual experience, and mystical experience after sessions predicted increased well-being at 12 months but did not predict improvement in depression.”The researchers employed the 30-item revised Mystical Experience Questionnaire (MEQ30) to evaluate spiritual and mystical experience. The instrument was developed from a survey of mystical-type experiences associated with the use of psilocybin. In a study explaining the MEQ30 published in 2015 in the Journal of Psychopharmacology, mystical experiences were defined as having a number of dimensions, including unity, sacredness, noetic quality (in this context, a sense of revelation hard to verbalize), ineffability, positive mood, and transcendence of time and space-with the authors emphasizing that a totality of these dimensions must occur to qualify as a complete mystical experience. The authors of that study further noted that “mystical experience is not conceptually limited to religious experience or practice....”The finding of a divergence between remission or improvement in major depression and self-reported well-being “is a somewhat counterintuitive part of our results,” Gukasyan commented. The research team was focused on determining which acute drug effects were helpful in predicting depression, she noted. Many studies of psilocybin-assisted therapy-including those whose participants had symptoms of anxiety and depression secondary to a terminal cancer diagnosis-have found that subjective ratings such as mystical experience were correlated with longer-term changes from baseline in depressive symptoms, Gukasyan said.“The important thing to understand about well-being scores is that they are not changes from baseline, but rather absolute scores taken at follow-up time points derived from a questionnaire that asks where participants continue to experience persisting changes in their well-being that they attribute to the psilocybin therapy,” Gukasyan added. “Taken together, these results suggest that the types of features we asked about-personal meaning, spiritual significance, mystical experience, and so on-did not help us predict magnitude of depression.”The finding may indicate that there are quality of life elements that are improved in people with major depression after psilocybin therapy that are not captured by depression severity scores in the GRID-HAMD and similar measures, she observed. This is an area that needs further exploration using instruments that better measure how well-being changes from baseline following psilocybin therapy, she said.Psychiatrist Charles Grob, M.D., a professor of psychiatry and biobehavioral sciences and pediatrics at the David Geffen School of Medicine at UCLA, has studied the therapeutic utility of psychedelic drugs for decades. The new Hopkins study “furthers the growing interest in the potential safety and utility of the psychedelic treatment model as an alternative-albeit novel-psycho-spiritual therapy and will likely catalyze future studies that examine even longer post-treatment time spans in order to measure the full durability of psilocybin treatment,” Grob told Psychiatric News.The divergence between self-reported findings of enhanced personal meaning and spirituality versus antidepressant measures requires further study to better understand the significance of the data, Grob said. ■ Resources“Efficacy and Safety of Psilocybin-Assisted Treatment for Major Depressive Disorder: Prospective 12-Month Follow-Up”“Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows””Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder”“Validation of the Revised Mystical Experience Questionnaire in Experimental Sessions With Psilocybin” ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2022-05-22", "publication_year": 2022, "doi": "10.1176/appi.pn.2022.06.6.30", "pubmed_id": null, "source_url": "https://doi.org/10.1176/appi.pn.2022.06.6.30", "keywords": "Psilocybin, Hallucinogen, Psychiatry, Psychology, Adverse effect, Depression (economics), Psychotherapist, Clinical psychology, Medicine, Pharmacology, Economics, Macroeconomics, Psychedelics and Drug Studies, Mental Health Research Topics, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4281400661\",\"openalex_url\":\"https://openalex.org/W4281400661\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5042986801\",\"display_name\":\"Richard Karel\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"https://doi.org/10.1176/appi.pn.2022.06.6.30\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Pharmacology,Consciousness,Wellbeing,Spirituality,Mystical Experience,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4281400661" }, { "id": 4966, "title": "An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus", "normalized_title": "an overview on the taxonomy phylogenetics and ecology of the psychedelic genera psilocybe panaeolus pluteus and gymnopilus", "authors": "Dominique Strauss, Soumya Ghosh, Zurika Murray, Marieka Gryzenhout", "abstract": "Psilocybin and psilocin, two psychoactive components found in “magic mushrooms,” have therapeutic potential in a number of mental health disorders without the addictiveness and overdose risks found in other mind-altering drugs, such as cocaine, methamphetamines and alcohol. Psychedelic mushrooms occur naturally, are wide distributed and easily accessible. The need for reviews and comprehensive field guides is urgent due to the recent surge of research into psychedelic mushrooms along with public interest. Psilocybin and psilocin are recorded in mushroom species of Psilocybe, Panaeolus, Pluteus, and Gymnopilus. This review discusses species identification, taxonomy and classification, available DNA sequence data and psychedelic species in Psilocybe, Panaeolus, Pluteus, and Gymnopilus, as well as similar looking genera that could be harmful.", "journal": "Frontiers in Forests and Global Change", "publication_date": "2022-05-22", "publication_year": 2022, "doi": "10.3389/ffgc.2022.813998", "pubmed_id": null, "source_url": "https://doi.org/10.3389/ffgc.2022.813998", "keywords": "Psilocybin, Taxonomy (biology), Biology, Zoology, Hallucinogen, Ecology, Pharmacology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Fungal Biology and Applications", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4281296724\",\"openalex_url\":\"https://openalex.org/W4281296724\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":29,\"referenced_works\":[\"https://openalex.org/W34709113\",\"https://openalex.org/W657356610\",\"https://openalex.org/W1257980435\",\"https://openalex.org/W1516728107\",\"https://openalex.org/W1842727300\",\"https://openalex.org/W1897916411\",\"https://openalex.org/W1901326980\",\"https://openalex.org/W1970868081\",\"https://openalex.org/W1973896501\",\"https://openalex.org/W1982002453\",\"https://openalex.org/W1983795907\",\"https://openalex.org/W1985210270\",\"https://openalex.org/W1987854012\",\"https://openalex.org/W1997625695\",\"https://openalex.org/W2000395425\",\"https://openalex.org/W2003763220\",\"https://openalex.org/W2007258852\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2012392031\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2020536267\",\"https://openalex.org/W2025783503\",\"https://openalex.org/W2026491585\",\"https://openalex.org/W2027740687\",\"https://openalex.org/W2028069512\",\"https://openalex.org/W2029970956\",\"https://openalex.org/W2031742889\",\"https://openalex.org/W2031831758\",\"https://openalex.org/W2035035800\",\"https://openalex.org/W2038285980\",\"https://openalex.org/W2050461051\",\"https://openalex.org/W2057894705\",\"https://openalex.org/W2062765660\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2069122038\",\"https://openalex.org/W2078802219\",\"https://openalex.org/W2079898976\",\"https://openalex.org/W2096267194\",\"https://openalex.org/W2099103834\",\"https://openalex.org/W2110375946\",\"https://openalex.org/W2123036659\",\"https://openalex.org/W2124376570\",\"https://openalex.org/W2134338523\",\"https://openalex.org/W2135562277\",\"https://openalex.org/W2143636898\",\"https://openalex.org/W2143759570\",\"https://openalex.org/W2150356107\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2269809506\",\"https://openalex.org/W2298217188\",\"https://openalex.org/W2298697723\",\"https://openalex.org/W2315096541\",\"https://openalex.org/W2325184310\",\"https://openalex.org/W2326523421\",\"https://openalex.org/W2330728699\",\"https://openalex.org/W2331205468\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2396685176\",\"https://openalex.org/W2397471800\",\"https://openalex.org/W2496404111\",\"https://openalex.org/W2528487230\",\"https://openalex.org/W2551258974\",\"https://openalex.org/W2589755038\",\"https://openalex.org/W2727728921\",\"https://openalex.org/W2730423636\",\"https://openalex.org/W2762988369\",\"https://openalex.org/W2774349944\",\"https://openalex.org/W2774534018\",\"https://openalex.org/W2797215877\",\"https://openalex.org/W2802280993\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2888856958\",\"https://openalex.org/W2901872472\",\"https://openalex.org/W2922429654\",\"https://openalex.org/W2925188901\",\"https://openalex.org/W2946047285\",\"https://openalex.org/W2955855141\",\"https://openalex.org/W2962807961\",\"https://openalex.org/W2969663209\",\"https://openalex.org/W2970371804\",\"https://openalex.org/W2972211885\",\"https://openalex.org/W2977493364\",\"https://openalex.org/W2979305454\",\"https://openalex.org/W2981489145\",\"https://openalex.org/W2988070888\",\"https://openalex.org/W2990643258\",\"https://openalex.org/W2999405129\",\"https://openalex.org/W3002980636\",\"https://openalex.org/W3003819542\",\"https://openalex.org/W3004527453\",\"https://openalex.org/W3004550124\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3008554691\",\"https://openalex.org/W3022190721\",\"https://openalex.org/W3023228010\",\"https://openalex.org/W3042296668\",\"https://openalex.org/W3092077951\",\"https://openalex.org/W3109915302\",\"https://openalex.org/W3138950369\",\"https://openalex.org/W3152690906\",\"https://openalex.org/W3153242803\",\"https://openalex.org/W3190404628\",\"https://openalex.org/W3199318186\",\"https://openalex.org/W3202284545\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4230636122\",\"https://openalex.org/W4247466629\",\"https://openalex.org/W4252245481\",\"https://openalex.org/W4253479242\",\"https://openalex.org/W4255744664\",\"https://openalex.org/W6697428727\",\"https://openalex.org/W6767109102\",\"https://openalex.org/W6801496741\",\"https://openalex.org/W6835799797\",\"https://openalex.org/W7044861287\"],\"authorships\":[{\"id\":\"https://openalex.org/A5006853101\",\"display_name\":\"Dominique Strauss\",\"orcid\":null},{\"id\":\"https://openalex.org/A5074963478\",\"display_name\":\"Soumya Ghosh\",\"orcid\":\"https://orcid.org/0000-0002-4945-3516\"},{\"id\":\"https://openalex.org/A5010272892\",\"display_name\":\"Zurika Murray\",\"orcid\":\"https://orcid.org/0000-0002-1836-3040\"},{\"id\":\"https://openalex.org/A5008558699\",\"display_name\":\"Marieka Gryzenhout\",\"orcid\":\"https://orcid.org/0000-0002-9224-4277\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210178346\",\"source_display_name\":\"Frontiers in Forests and Global Change\",\"landing_page_url\":\"https://doi.org/10.3389/ffgc.2022.813998\",\"is_oa\":true}}", "topic_tags": "Addiction,Pharmacology,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4281296724" }, { "id": 3676, "title": "Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression", "normalized_title": "psilocybin versus ketamine fast acting antidepressant strategies in treatment resistant depression", "authors": "National Institute of Mental Health, Czech Republic", "abstract": "The main goal is to compare the antidepressant effects of psilocybin and ketamine in patients with TRD versus the antidepressant inactive substance midazolam. The primary endpoint will be the antidepressant effect on the Montgomery- Asberg Depression Rating Scale (MADRS) 24 hours after treatment, the key secondary endpoints being the duration of antidepressant effect, the number of responses and remissions, and the time to standard antidepressant treatment during 3 months of observation. The exploratory part of the study aims to monitor changes in the functional brain states using simultaneous EEG / fMRI, before treatment versus 1 day and 1 week after. Based on literature data and recent data from healthy volunteers who participated in a previous study with psilocybin, the investigator will correlate antidepressant effects of drugs (using psychometric scales and reactions to emotionally salient stimuli (eye tracker)) with entropy and functional connectivity measures. Finally the investigator will explore the role of plasmatic neurobiological biomarkers in depression (BDNF, prolactin, ACTH and oxytocin). The main aim of the study is to verify the efficacy and safety of a single dose of psilocybin 20 mg in the treatment of TRD in adults in a randomized clinical trial with active comparator ketamine 200 mg (rapid onset acting antidepressant) and negative control midazolam 5 mg (drug with no antidepressant properties). Primary objective: 1) verification of the rapid antidepressant effect of psilocybin compared to ketamine using the MADRS scale at 24 hours. Secondary objectives: 1) on days 3, 7 and 14 and 3, 4, 5, 6, 8 and 12 weeks after application of the substances, evaluate / compare: a) the duration of effects of both substances using the MADRS scale b) antidepressant effects according to the subjective evaluation of patients - QIDS scale. c) response rate (50% reduction on the MADRS scale) and remission (MADRS? 10). 2) time to return of depressive symptoms defined according to the criteria for the use of antidepressants within 12 weeks 3) safety profile of study medication Exploratory objectives: 1) Evaluate the antidepressant effect depending on: a) the intensity of acute psychological effects assessed using the subjective scale of 5D-ASCs and the objective scale of BPRS, b) depending on the retrospective assessment of persistent effects using the Persisting effects scale, c) the degree of eye contact with negative and neutral emotion faces measured by eye-tracking before and after treatment (on days 1 and 7). 2) To evaluate the neurobiology of the antidepressant effect in relation to: a) plasma levels of the major metabolite of psilocin, markers of neuroplasticity, antidepressant effect and stress (BDNF, prolactin, oxytocin, ACTH) at 90 min, 3, and 6 h after administration of study medication compared to pre-administration levels, b) changes in resting-state brain activity (connectivity, entropy) measured by simultaneous EEG / fMRI functional imaging methods before and after 1 and 7 days after treatment.", "journal": "ClinicalTrials.gov", "publication_date": "2022-05-19", "publication_year": 2022, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT05383313", "keywords": "Treatment Resistant Depression, Psilocybin, Ketamine Hydrochloride, Midazolam Ph. Eur 9.0, UNKNOWN", "substance_tags": "psilocybin,psilocin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:28", "last_checked": "2026-07-01 11:22:34", "raw_json": "{\"nct_id\":\"NCT05383313\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Neuroplasticity,Brain Imaging,Biomarkers,Aging,Emotional Processing,Clinical Trial,Healthy Volunteers,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1788, "title": "Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.", "normalized_title": "safety considerations in the evolving legal landscape of psychedelic assisted psychotherapy", "authors": "Mocanu V, Mackay L, Christie D, Argento E.", "abstract": "International drug policy is rapidly evolving in tandem with promising evidence for psychedelic-assisted psychotherapy (PAP) in treating a range of mental health conditions. Canada is among the countries increasingly expanding access to psychedelic substances for therapeutic purposes. The 8-year ban on medical exemptions through the Canadian Special Access Programme was recently reversed in January 2022 and the first exemptions for legal possession and personal use of psilocybin mushrooms were granted in 2020, nearly 50 years since their criminalization. In view of the evolving evidence base and regulatory landscape for PAP illustrated by recent shifts in Canadian and international drug policy, this piece seeks to clarify the special range of factors which ought to be considered to safely expand access to psychedelics. Streamlining access to safe and evidence-based compassionate use of PAP will provide a timely treatment option to those currently in need while encouraging further research and outcome surveillance to refine best practices.", "journal": "Substance Abuse Treatment Prevention and Policy", "publication_date": "2022-05-13", "publication_year": 2022, "doi": "10.1186/s13011-022-00468-0", "pubmed_id": "35568884", "source_url": "https://doi.org/10.1186/s13011-022-00468-0", "keywords": "Humans, Hallucinogens, Mental Disorders, Psychotherapy, Canada, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"35568884\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4280525486\",\"openalex_url\":\"https://openalex.org/W4280525486\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":27,\"referenced_works\":[\"https://openalex.org/W1973613743\",\"https://openalex.org/W2092914321\",\"https://openalex.org/W2181040265\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2895740693\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3107835125\",\"https://openalex.org/W3127909847\",\"https://openalex.org/W3154528253\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3157058636\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3209277823\"],\"authorships\":[{\"id\":\"https://openalex.org/A5002298151\",\"display_name\":\"Victor Mocanu\",\"orcid\":null},{\"id\":\"https://openalex.org/A5019795838\",\"display_name\":\"Lindsay Mackay\",\"orcid\":\"https://orcid.org/0000-0002-5891-0221\"},{\"id\":\"https://openalex.org/A5018406471\",\"display_name\":\"Devon Christie\",\"orcid\":null},{\"id\":\"https://openalex.org/A5033668229\",\"display_name\":\"Elena Argento\",\"orcid\":\"https://orcid.org/0000-0003-0405-0470\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S124015537\",\"source_display_name\":\"Substance Abuse Treatment Prevention and Policy\",\"landing_page_url\":\"https://doi.org/10.1186/s13011-022-00468-0\",\"is_oa\":true}}}", "topic_tags": "Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4280525486" }, { "id": 4973, "title": "P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy", "normalized_title": "p450 pilot study evaluation of psilocybin therapy for anorexia nervosa safety acceptability and preliminary efficacy", "authors": "Stéphanie Knatz Peck, Samatha Shao, Susan Murray, Walter H. Kaye", "abstract": "", "journal": "Biological Psychiatry", "publication_date": "2022-04-27", "publication_year": 2022, "doi": "10.1016/j.biopsych.2022.02.686", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.biopsych.2022.02.686", "keywords": "Psilocybin, Anorexia nervosa, Mood, Hallucinogen, Serotonin, Psychology, Anorexia, Psychotherapist, Appetite, Medicine, Psychiatry, Receptor, Internal medicine, Eating disorders, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4293242421\",\"openalex_url\":\"https://openalex.org/W4293242421\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5011897192\",\"display_name\":\"Stéphanie Knatz Peck\",\"orcid\":\"https://orcid.org/0000-0001-9421-9158\"},{\"id\":\"https://openalex.org/A5080578011\",\"display_name\":\"Samatha Shao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007210792\",\"display_name\":\"Susan Murray\",\"orcid\":\"https://orcid.org/0000-0003-4387-7673\"},{\"id\":\"https://openalex.org/A5086371093\",\"display_name\":\"Walter H. Kaye\",\"orcid\":\"https://orcid.org/0000-0002-4478-4906\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S205482884\",\"source_display_name\":\"Biological Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/j.biopsych.2022.02.686\",\"is_oa\":false}}", "topic_tags": "Eating Disorders,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4293242421" }, { "id": 1761, "title": "Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.", "normalized_title": "safety issues of psilocybin and lsd as potential rapid acting antidepressants and potential challenges", "authors": "Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG.", "abstract": "IntroductionA limited number of preliminary open-label (n = 3) and placebo-controlled clinical trials (n = 5) have suggested psilocybin and LSD as potential rapid antidepressants. In this context, there is a growing need to verify and document their safety and tolerability as therapeutic agents, discuss the challenges associated with their administration, and develop safety protocols for their use as next-generation therapeutic agents.Areas coveredWe have analyzed all randomized, double-blind, and controlled trials that assessed the antidepressant effects of psilocybin and LSD in clinical populations to date, taking special attention to adverse events (AEs) related to their use. Prevalence, significance, and mechanisms of action related to AEs were systematically extracted, analyzed, and discussed.Expert opinionThere were no serious AEs related to psilocybin and LSD administration. Most AEs were expected, manageable, and transient. Nevertheless, safety and tolerability concerns regarding some effects, such as dissociation, paranoia, and confusion, remain. Thus, randomized controlled trials with bigger samples are warranted to confirm their therapeutic effects and further investigate their safety and tolerability.", "journal": "Expert Opinion on Drug Safety", "publication_date": "2022-04-26", "publication_year": 2022, "doi": "10.1080/14740338.2022.2066650", "pubmed_id": "35426754", "source_url": "https://doi.org/10.1080/14740338.2022.2066650", "keywords": "Humans, Lysergic Acid Diethylamide, Antidepressive Agents, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"35426754\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4223893856\",\"openalex_url\":\"https://openalex.org/W4223893856\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":24,\"referenced_works\":[\"https://openalex.org/W1996652986\",\"https://openalex.org/W2010522115\",\"https://openalex.org/W2012504366\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2025374719\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2105571318\",\"https://openalex.org/W2112884745\",\"https://openalex.org/W2120051206\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2166928505\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2730275538\",\"https://openalex.org/W2751240458\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2772887788\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2793484468\",\"https://openalex.org/W2793566445\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3031575368\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3093403723\",\"https://openalex.org/W3094915720\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W3118672806\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3133542189\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3180562559\",\"https://openalex.org/W3192307046\",\"https://openalex.org/W3193251618\",\"https://openalex.org/W4211263234\",\"https://openalex.org/W4220914774\",\"https://openalex.org/W4225258217\",\"https://openalex.org/W4231551125\",\"https://openalex.org/W4242068985\"],\"authorships\":[{\"id\":\"https://openalex.org/A5044658660\",\"display_name\":\"Giordano Novak Rossi\",\"orcid\":\"https://orcid.org/0000-0002-1952-1207\"},{\"id\":\"https://openalex.org/A5102785969\",\"display_name\":\"Jaime E. C. Hallak\",\"orcid\":\"https://orcid.org/0000-0002-8784-0189\"},{\"id\":\"https://openalex.org/A5032347558\",\"display_name\":\"José Carlos Bouso\",\"orcid\":\"https://orcid.org/0000-0003-1115-9407\"},{\"id\":\"https://openalex.org/A5058075680\",\"display_name\":\"Rafael G. dos Santos\",\"orcid\":\"https://orcid.org/0000-0003-2388-4745\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S20709540\",\"source_display_name\":\"Expert Opinion on Drug Safety\",\"landing_page_url\":\"https://doi.org/10.1080/14740338.2022.2066650\",\"is_oa\":false}}}", "topic_tags": "Depression,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4223893856" }, { "id": 1744, "title": "The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.", "normalized_title": "the effects of psilocybin in adults with major depressive disorder and the general population findings from neuroimaging studies", "authors": "Gill H, Puramat P, Patel P, Gill B, Marks CA, Rodrigues NB, Castle D, Cha DS, Mansur RB, Rosenblat JD, McIntyre RS.", "abstract": "The use of psilocybin as treatment for major depressive disorder (MDD) has been examined as a promising alternative to traditional first-line options. We reviewed existing literature to provide a synthesis of the extant neuroimaging observations with psilocybin, and to identify putative therapeutic targets for target engagement studies with psilocybin, and potentially other psychedelics. We assessed neuroimaging observations with psilocybin among participants with MDD and healthy populations. A systematic search was conducted on PubMed, Google Scholar and PsycINFO from database inception to November 17th, 2021. The study quality (i.e., risk of bias) was assessed using the revised Cochrane risk-of-bias tool for randomized trials. A total of ten studies evaluated psilocybin in healthy populations and three studies assessed psilocybin in MDD participants using neuroimaging techniques. Following psilocybin administration, a decrease in amygdala activity and a reduction in depressive symptoms was observed in two studies. Changes in functional connectivity and activation of prefrontal limbic structures, specifically the ventral medial prefrontal cortex and amygdala, was seen in healthy populations. There was high heterogeneity in methodology (e.g., dosing schedule and imaging methods) amongst included studies. Longitudinal studies are needed to further elucidate psilocybin treatment for MDD, its long-term effects and the possibility of sustained therapeutic effects.", "journal": null, "publication_date": "2022-04-25", "publication_year": 2022, "doi": "10.1016/j.psychres.2022.114577", "pubmed_id": "35580433", "source_url": "https://doi.org/10.1016/j.psychres.2022.114577", "keywords": "Amygdala, Humans, Hallucinogens, Magnetic Resonance Imaging, Adult, Neuroimaging, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35580433\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Brain Imaging,Aging,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1428, "title": "Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change?", "normalized_title": "is ptsd an evolutionary survival adaptation initiated by unrestrained cytokine signaling and maintained by epigenetic change", "authors": "Rudzki S.", "abstract": "IntroductionTreatment outcomes for PTSD with current psychological therapies are poor, with very few patients achieving sustained symptom remission. A number of authors have identified physiological and immune disturbances in Post Traumatic Stress Disorder (PTSD) patients, but there is no unifying hypothesis that explains the myriad features of the disorder.Materials and methodsThe medical literature was reviewed over a 6-year period primarily using the medical database PUBMED.ResultsThe literature contains numerous papers that have identified a range of physiological and immune dysfunction in association with PTSD. This paper proposes that unrestrained cytokine signaling induces epigenetic changes that promote an evolutionary survival adaptation, which maintains a defensive PTSD phenotype. The brain can associate immune signaling with past threat and initiate a defensive behavioral response. The sympathetic nervous system is pro-inflammatory, while the parasympathetic nervous system is anti-inflammatory. Prolonged cholinergic withdrawal will promote a chronic inflammatory state. The innate immune cytokine IL-1β has pleiotropic properties and can regulate autonomic, glucocorticoid, and glutamate receptor functions, sleep, memory, and epigenetic enzymes. Changes in epigenetic enzyme activity can potentially alter phenotype and induce an adaptation. Levels of IL-1β correlate with severity and duration of PTSD and PTSD can be prevented by bolus administration of hydrocortisone in acute sepsis, consistent with unrestrained inflammation being a risk factor for PTSD. The nervous and immune systems engage in crosstalk, governed by common receptors. The benefits of currently used psychiatric medication may arise from immune, as well as synaptic, modulation. The psychedelic drugs (3,4-Methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine) have potent immunosuppressive and anti-inflammatory effects on the adaptive immune system, which may contribute to their reported benefit in PTSD. There may be distinct PTSD phenotypes induced by innate and adaptive cytokine signaling.ConclusionIn order for an organism to survive, it must adapt to its environment. Cytokines signal danger to the brain and can induce epigenetic changes that result in a persistent defensive phenotype. PTSD may be the price individuals pay for the genomic flexibility that promotes adaptation and survival.", "journal": "Military Medicine", "publication_date": "2022-04-20", "publication_year": 2022, "doi": "10.1093/milmed/usac095", "pubmed_id": "35446412", "source_url": "https://doi.org/10.1093/milmed/usac095", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"35446412\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4224232624\",\"openalex_url\":\"https://openalex.org/W4224232624\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":7,\"referenced_works\":[\"https://openalex.org/W43991711\",\"https://openalex.org/W111804031\",\"https://openalex.org/W148918918\",\"https://openalex.org/W284014436\",\"https://openalex.org/W323985028\",\"https://openalex.org/W984827913\",\"https://openalex.org/W1482709215\",\"https://openalex.org/W1553210510\",\"https://openalex.org/W1562600728\",\"https://openalex.org/W1566766802\",\"https://openalex.org/W1577271808\",\"https://openalex.org/W1582767991\",\"https://openalex.org/W1754265819\",\"https://openalex.org/W1761323037\",\"https://openalex.org/W1769585641\",\"https://openalex.org/W1865092458\",\"https://openalex.org/W1904871314\",\"https://openalex.org/W1926095516\",\"https://openalex.org/W1964555614\",\"https://openalex.org/W1965672724\",\"https://openalex.org/W1968731032\",\"https://openalex.org/W1972708666\",\"https://openalex.org/W1979295154\",\"https://openalex.org/W1981396910\",\"https://openalex.org/W1981477005\",\"https://openalex.org/W1981964751\",\"https://openalex.org/W1982301384\",\"https://openalex.org/W1982386968\",\"https://openalex.org/W1983263255\",\"https://openalex.org/W1984443195\",\"https://openalex.org/W1985339809\",\"https://openalex.org/W1985538633\",\"https://openalex.org/W1985607497\",\"https://openalex.org/W1987071871\",\"https://openalex.org/W1988353820\",\"https://openalex.org/W1988597558\",\"https://openalex.org/W1988951832\",\"https://openalex.org/W1996642120\",\"https://openalex.org/W1997470921\",\"https://openalex.org/W2000956334\",\"https://openalex.org/W2002405829\",\"https://openalex.org/W2005650685\",\"https://openalex.org/W2009375902\",\"https://openalex.org/W2009782796\",\"https://openalex.org/W2011085122\",\"https://openalex.org/W2011766130\",\"https://openalex.org/W2012372286\",\"https://openalex.org/W2012425560\",\"https://openalex.org/W2014566626\",\"https://openalex.org/W2018222414\",\"https://openalex.org/W2018424479\",\"https://openalex.org/W2018940949\",\"https://openalex.org/W2018951395\",\"https://openalex.org/W2019438546\",\"https://openalex.org/W2022981588\",\"https://openalex.org/W2023627293\",\"https://openalex.org/W2024057471\",\"https://openalex.org/W2025784041\",\"https://openalex.org/W2027241596\",\"https://openalex.org/W2028033611\",\"https://openalex.org/W2029410796\",\"https://openalex.org/W2031379951\",\"https://openalex.org/W2033102369\",\"https://openalex.org/W2034423905\",\"https://openalex.org/W2035072797\",\"https://openalex.org/W2035552438\",\"https://openalex.org/W2037465502\",\"https://openalex.org/W2040329362\",\"https://openalex.org/W2041858687\",\"https://openalex.org/W2042468643\",\"https://openalex.org/W2043368216\",\"https://openalex.org/W2043615144\",\"https://openalex.org/W2044875682\",\"https://openalex.org/W2045076787\",\"https://openalex.org/W2046415390\",\"https://openalex.org/W2046960533\",\"https://openalex.org/W2047716652\",\"https://openalex.org/W2048380010\",\"https://openalex.org/W2051369986\",\"https://openalex.org/W2052665087\",\"https://openalex.org/W2055238656\",\"https://openalex.org/W2056578819\",\"https://openalex.org/W2061931936\",\"https://openalex.org/W2062262489\",\"https://openalex.org/W2064272303\",\"https://openalex.org/W2065514611\",\"https://openalex.org/W2067575057\",\"https://openalex.org/W2068633454\",\"https://openalex.org/W2069368135\",\"https://openalex.org/W2071256705\",\"https://openalex.org/W2074310290\",\"https://openalex.org/W2074802748\",\"https://openalex.org/W2076105394\",\"https://openalex.org/W2076246738\",\"https://openalex.org/W2076507733\",\"https://openalex.org/W2077834241\",\"https://openalex.org/W2078445602\",\"https://openalex.org/W2081694980\",\"https://openalex.org/W2086020154\",\"https://openalex.org/W2086552135\",\"https://openalex.org/W2087316628\",\"https://openalex.org/W2087987871\",\"https://openalex.org/W2089293981\",\"https://openalex.org/W2089895965\",\"https://openalex.org/W2090115746\",\"https://openalex.org/W2092447216\",\"https://openalex.org/W2092698466\",\"https://openalex.org/W2092862425\",\"https://openalex.org/W2093540755\",\"https://openalex.org/W2099803817\",\"https://openalex.org/W2100561031\",\"https://openalex.org/W2100728233\",\"https://openalex.org/W2103597752\",\"https://openalex.org/W2104012185\",\"https://openalex.org/W2104643304\",\"https://openalex.org/W2104661369\",\"https://openalex.org/W2107337543\",\"https://openalex.org/W2109356273\",\"https://openalex.org/W2110375253\",\"https://openalex.org/W2112437115\",\"https://openalex.org/W2114769428\",\"https://openalex.org/W2116745309\",\"https://openalex.org/W2118210398\",\"https://openalex.org/W2119650117\",\"https://openalex.org/W2120049814\",\"https://openalex.org/W2120474278\",\"https://openalex.org/W2121646982\",\"https://openalex.org/W2125238755\",\"https://openalex.org/W2126766019\",\"https://openalex.org/W2128838531\",\"https://openalex.org/W2129076711\",\"https://openalex.org/W2129928127\",\"https://openalex.org/W2130767132\",\"https://openalex.org/W2133151251\",\"https://openalex.org/W2135695964\",\"https://openalex.org/W2135950112\",\"https://openalex.org/W2138728119\",\"https://openalex.org/W2141900936\",\"https://openalex.org/W2142935950\",\"https://openalex.org/W2145661991\",\"https://openalex.org/W2146070554\",\"https://openalex.org/W2146562666\",\"https://openalex.org/W2146578632\",\"https://openalex.org/W2149226083\",\"https://openalex.org/W2151454086\",\"https://openalex.org/W2151504418\",\"https://openalex.org/W2152014155\",\"https://openalex.org/W2154793521\",\"https://openalex.org/W2158007484\",\"https://openalex.org/W2158199077\",\"https://openalex.org/W2158294015\",\"https://openalex.org/W2158976222\",\"https://openalex.org/W2159995838\",\"https://openalex.org/W2160517494\",\"https://openalex.org/W2165080151\",\"https://openalex.org/W2166084959\",\"https://openalex.org/W2167693963\",\"https://openalex.org/W2168675611\",\"https://openalex.org/W2169567979\",\"https://openalex.org/W2171118724\",\"https://openalex.org/W2201607793\",\"https://openalex.org/W2201725493\",\"https://openalex.org/W2286922506\",\"https://openalex.org/W2292095973\",\"https://openalex.org/W2333091651\",\"https://openalex.org/W2467438710\",\"https://openalex.org/W2507921187\",\"https://openalex.org/W2523262515\",\"https://openalex.org/W2542088537\",\"https://openalex.org/W2556294351\",\"https://openalex.org/W2568405799\",\"https://openalex.org/W2576595026\",\"https://openalex.org/W2578883169\",\"https://openalex.org/W2601570523\",\"https://openalex.org/W2744068958\",\"https://openalex.org/W2744459261\",\"https://openalex.org/W2749004660\",\"https://openalex.org/W2767077660\",\"https://openalex.org/W2790853064\",\"https://openalex.org/W2791123147\",\"https://openalex.org/W2791371888\",\"https://openalex.org/W2798109288\",\"https://openalex.org/W2800689952\",\"https://openalex.org/W2803696867\",\"https://openalex.org/W2804271072\",\"https://openalex.org/W2810984787\",\"https://openalex.org/W2887422108\",\"https://openalex.org/W2891260920\",\"https://openalex.org/W2903124759\",\"https://openalex.org/W2909211210\",\"https://openalex.org/W2909494712\",\"https://openalex.org/W2914196638\",\"https://openalex.org/W2944898513\",\"https://openalex.org/W2967130768\",\"https://openalex.org/W2992514738\",\"https://openalex.org/W2995189233\",\"https://openalex.org/W3005609732\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3015792865\",\"https://openalex.org/W3019408059\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3138719602\",\"https://openalex.org/W3188676230\",\"https://openalex.org/W4242584517\",\"https://openalex.org/W4242918118\",\"https://openalex.org/W4254547440\",\"https://openalex.org/W6601761537\",\"https://openalex.org/W6604520695\",\"https://openalex.org/W6611278999\",\"https://openalex.org/W6679586108\",\"https://openalex.org/W6683064767\",\"https://openalex.org/W6696146249\",\"https://openalex.org/W6742705334\",\"https://openalex.org/W6749114589\",\"https://openalex.org/W6845604209\"],\"authorships\":[{\"id\":\"https://openalex.org/A5081999093\",\"display_name\":\"Stephan Rudzki\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S207859457\",\"source_display_name\":\"Military Medicine\",\"landing_page_url\":\"https://doi.org/10.1093/milmed/usac095\",\"is_oa\":true}}}", "topic_tags": "PTSD,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Epigenetics,Review Article,Safety,Genomics,Inflammation,Immune Function", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4224232624" }, { "id": 4976, "title": "Combining FTIR-ATR and OPLS-DA methods for magic mushrooms discrimination", "normalized_title": "combining ftir atr and opls da methods for magic mushrooms discrimination", "authors": "Cátia Esteves, Elena M. M. de Redrojo, José Luis Manjón, Gabriel Moreno, Filipe E. Antunes, Gemma Montalvo, Fernando E. Ortega-Ojeda", "abstract": "Magic mushrooms are naturally occurring fungi that are considered hallucinogenic drugs because they contain psilocybin and psilocin. These substances are controlled in almost every country in the world, so the use, possession, cultivation, and sale of magic mushrooms are prohibited in whole or in part. Despite this, the abuse of magic mushrooms continues and can put at risk the life of the consumer and society in general if the consumer behaves in an unsafe manner. The number of mushroom species is very high, making it difficult to correctly identify them based only on physical and morphological characteristics. Therefore, there is a need to develop non-destructive mushrooms analysis methods that have less response time and higher discrimination ability. The present work used Attenuated Total Reflectance Fourier Transform Infrared (FTIR-ATR) Spectroscopy to study 64 mushroom samples from different genera including hallucinogenic, edible, and toxic species. In addition, this study used Orthogonal Partial Least Squares - Discriminant Analysis (OPLS-DA), using SIMCA chemometric software to analyse the obtained infrared (IR) spectra. The main molecular vibrations of the components of the fungus were successfully identified by IR spectroscopy. Although the specific bands corresponding to psilocybin or psilocin could not be assigned in the spectra, the regression method was able to discriminate the various species. Hallucinogenic mushrooms were well separated from other species, allowing the method to be used as an initial screening technique to determine whether or not the seized mushrooms are of forensic interest.", "journal": "Forensic Chemistry", "publication_date": "2022-04-07", "publication_year": 2022, "doi": "10.1016/j.forc.2022.100421", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.forc.2022.100421", "keywords": "Psilocybin, Mushroom, Chemistry, OPLS, Aroma, Food science, Hallucinogen, Biology, Organic chemistry, Hydrogen bond, Pharmacology, Molecule, Fungal Biology and Applications, Psychedelics and Drug Studies, Silymarin and Mushroom Poisoning", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:57", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4224903330\",\"openalex_url\":\"https://openalex.org/W4224903330\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":19,\"referenced_works\":[\"https://openalex.org/W606750168\",\"https://openalex.org/W1058094418\",\"https://openalex.org/W1138747202\",\"https://openalex.org/W1161986615\",\"https://openalex.org/W1842727300\",\"https://openalex.org/W1967849631\",\"https://openalex.org/W1984748433\",\"https://openalex.org/W2002132951\",\"https://openalex.org/W2005843750\",\"https://openalex.org/W2008261694\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2012142575\",\"https://openalex.org/W2018420238\",\"https://openalex.org/W2025650977\",\"https://openalex.org/W2027191929\",\"https://openalex.org/W2053966575\",\"https://openalex.org/W2066931811\",\"https://openalex.org/W2071759407\",\"https://openalex.org/W2080308987\",\"https://openalex.org/W2089210920\",\"https://openalex.org/W2099103834\",\"https://openalex.org/W2110879932\",\"https://openalex.org/W2122270160\",\"https://openalex.org/W2160564267\",\"https://openalex.org/W2160625945\",\"https://openalex.org/W2164981793\",\"https://openalex.org/W2310716645\",\"https://openalex.org/W2477079400\",\"https://openalex.org/W2579831332\",\"https://openalex.org/W2606454891\",\"https://openalex.org/W2782050364\",\"https://openalex.org/W2791881087\",\"https://openalex.org/W2888502690\",\"https://openalex.org/W2905495651\",\"https://openalex.org/W2922539764\",\"https://openalex.org/W2949780248\",\"https://openalex.org/W3004295865\",\"https://openalex.org/W3021906381\",\"https://openalex.org/W3043158482\",\"https://openalex.org/W3044469818\",\"https://openalex.org/W3097449446\",\"https://openalex.org/W3099286350\",\"https://openalex.org/W3127123233\",\"https://openalex.org/W6747798702\"],\"authorships\":[{\"id\":\"https://openalex.org/A5001668135\",\"display_name\":\"Cátia Esteves\",\"orcid\":\"https://orcid.org/0000-0002-4507-9328\"},{\"id\":\"https://openalex.org/A5018648206\",\"display_name\":\"Elena M. M. de Redrojo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5103486719\",\"display_name\":\"José Luis Manjón\",\"orcid\":null},{\"id\":\"https://openalex.org/A5050104617\",\"display_name\":\"Gabriel Moreno\",\"orcid\":\"https://orcid.org/0000-0002-9303-7181\"},{\"id\":null,\"display_name\":\"Filipe E. Antunes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5013901887\",\"display_name\":\"Gemma Montalvo\",\"orcid\":\"https://orcid.org/0000-0002-5640-8908\"},{\"id\":\"https://openalex.org/A5050876263\",\"display_name\":\"Fernando E. Ortega-Ojeda\",\"orcid\":\"https://orcid.org/0000-0002-2208-9830\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898252156\",\"source_display_name\":\"Forensic Chemistry\",\"landing_page_url\":\"https://doi.org/10.1016/j.forc.2022.100421\",\"is_oa\":true}}", "topic_tags": "Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4224903330" }, { "id": 1728, "title": "Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.", "normalized_title": "adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms", "authors": "Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ.", "abstract": "BackgroundPsilocybin-containing mushrooms are used for recreational, spiritual, self-development and therapeutic purposes. However, physiologically relatively nontoxic, adverse reactions are occasionally reported.AimsThis study investigated the 12-month prevalence and nature of magic mushroom-related adverse reactions resulting in emergency medical treatment seeking in a global sample of people reporting magic mushroom use.MethodsWe use data from the 2017 Global Drug Survey - a large anonymous online survey on patterns of drug use conducted between November 2016 and January 2017.ResultsOut of 9233 past year magic mushroom users, 19 (0.2%) reported having sought emergency medical treatment, with a per-event risk estimate of 0.06%. Young age was the only predictor associated with higher risk of emergency medical presentations. The most common symptoms were psychological, namely anxiety/panic and paranoia/suspiciousness. Poor 'mindset', poor 'setting' and mixing substances were most reported reasons for incidents. All but one respondent returned back to normality within 24 h.ConclusionsThe results confirm psilocybin mushrooms are a relatively safe drug, with serious incidents rare and short lasting. Providing harm-reduction information likely plays a key role in preventing adverse effects. More research is needed to examine the detailed circumstances and predictors of adverse reactions including rarer physiological reactions.", "journal": "Journal of Psychopharmacology", "publication_date": "2022-04-06", "publication_year": 2022, "doi": "10.1177/02698811221084063", "pubmed_id": "35388724", "source_url": "https://doi.org/10.1177/02698811221084063", "keywords": "Humans, Agaricales, Hallucinogens, Psilocybe, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"35388724\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4226060882\",\"openalex_url\":\"https://openalex.org/W4226060882\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":64,\"referenced_works\":[\"https://openalex.org/W70805046\",\"https://openalex.org/W1948675593\",\"https://openalex.org/W1970305111\",\"https://openalex.org/W1976604434\",\"https://openalex.org/W1985645068\",\"https://openalex.org/W1996278273\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2003771516\",\"https://openalex.org/W2011221060\",\"https://openalex.org/W2035199049\",\"https://openalex.org/W2040034137\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2057239090\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2093994427\",\"https://openalex.org/W2095349468\",\"https://openalex.org/W2099103834\",\"https://openalex.org/W2104396432\",\"https://openalex.org/W2107232050\",\"https://openalex.org/W2111452082\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119461820\",\"https://openalex.org/W2131065756\",\"https://openalex.org/W2145998697\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2163176525\",\"https://openalex.org/W2166423316\",\"https://openalex.org/W2256649040\",\"https://openalex.org/W2283526650\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2725783540\",\"https://openalex.org/W2766061290\",\"https://openalex.org/W2767725891\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2810374266\",\"https://openalex.org/W2889566085\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2994274167\",\"https://openalex.org/W3007379062\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3092151265\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3107835125\",\"https://openalex.org/W3120324921\",\"https://openalex.org/W3134897339\",\"https://openalex.org/W3139397908\",\"https://openalex.org/W3160183306\",\"https://openalex.org/W3200846882\",\"https://openalex.org/W3208662682\",\"https://openalex.org/W4200001754\",\"https://openalex.org/W4206300474\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4281793365\",\"https://openalex.org/W4301605941\"],\"authorships\":[{\"id\":\"https://openalex.org/A5022851323\",\"display_name\":\"Emma I Kopra\",\"orcid\":\"https://orcid.org/0000-0003-4447-5393\"},{\"id\":\"https://openalex.org/A5065722206\",\"display_name\":\"Jason Ferris\",\"orcid\":\"https://orcid.org/0000-0001-7474-0173\"},{\"id\":\"https://openalex.org/A5067738102\",\"display_name\":\"Adam Winstock\",\"orcid\":\"https://orcid.org/0000-0001-7854-8015\"},{\"id\":\"https://openalex.org/A5058414502\",\"display_name\":\"Allan H. Young\",\"orcid\":\"https://orcid.org/0000-0003-2291-6952\"},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811221084063\",\"is_oa\":true}}}", "topic_tags": "Anxiety,Spirituality,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4226060882" }, { "id": 1793, "title": "Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.", "normalized_title": "psilocybin therapy of psychiatric disorders is not hampered by herg potassium channel mediated cardiotoxicity", "authors": "Hackl B, Todt H, Kubista H, Kubista H, Hilber K, Koenig X.", "abstract": "Psilocybin, a hallucinogen contained in \"magic\" mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug's main metabolite, psilocin, gave rise to safety concerns. Here we show that clinical concentrations of psilocin do not cause significant human ether-a-go-go-related gene (hERG) potassium channel inhibition, a major risk factor for adverse cardiac events. We conclude that hERG channel blockage by psilocin is not liable for psilocybin- associated cardiotoxic effects.", "journal": "The International Journal of Neuropsychopharmacology", "publication_date": "2022-03-31", "publication_year": 2022, "doi": "10.1093/ijnp/pyab085", "pubmed_id": "34871422", "source_url": "https://doi.org/10.1093/ijnp/pyab085", "keywords": "Humans, Potassium Channels, Hallucinogens, Mental Disorders, Cardiotoxicity, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34871422\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4200455094\",\"openalex_url\":\"https://openalex.org/W4200455094\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":11,\"referenced_works\":[\"https://openalex.org/W1039468090\",\"https://openalex.org/W2043967076\",\"https://openalex.org/W2093986323\",\"https://openalex.org/W2113927644\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2970371804\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3113337956\",\"https://openalex.org/W3125143320\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W6627133468\",\"https://openalex.org/W6804303670\"],\"authorships\":[{\"id\":\"https://openalex.org/A5084404127\",\"display_name\":\"Benjamin Hackl\",\"orcid\":\"https://orcid.org/0009-0002-3357-9250\"},{\"id\":\"https://openalex.org/A5038127051\",\"display_name\":\"Hannes Todt\",\"orcid\":\"https://orcid.org/0000-0002-1147-4370\"},{\"id\":\"https://openalex.org/A5050882757\",\"display_name\":\"Helmut Kubista\",\"orcid\":\"https://orcid.org/0000-0002-5805-8649\"},{\"id\":\"https://openalex.org/A5085397541\",\"display_name\":\"Karlheinz Hilber\",\"orcid\":\"https://orcid.org/0000-0002-3033-0874\"},{\"id\":\"https://openalex.org/A5039231830\",\"display_name\":\"Xaver Koenig\",\"orcid\":\"https://orcid.org/0000-0002-2423-4966\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S199972112\",\"source_display_name\":\"The International Journal of Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1093/ijnp/pyab085\",\"is_oa\":true}}}", "topic_tags": "Aging,Clinical Trial,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4200455094" }, { "id": 1804, "title": "Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019.", "normalized_title": "race ethnic and sex differences in prevalence of and trends in hallucinogen consumption among lifetime users in the united states between 2015 and 2019", "authors": "Davis AK, Arterberry BJ, Xin Y, Agin-Liebes G, Schwarting C, Williams MT.", "abstract": "BackgroundThe current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the United States.MethodsData came from the 2015-2019 National Survey on Drug Use and Health and included respondent's reporting ever-using hallucinogens (n = 41,060; female = 40.4%). Descriptive and multinomial logistic regression analyses were conducted in Stata.ResultsHighest prevalence of past year hallucinogen use was among Asian females (35.06%), which was two-or-more times larger than prevalence of past year use among White males/females and Native American males. More than half of White males/females, Multiracial males, and Hispanic males reported had ever-used psilocybin or LSD, whereas less than one-quarter of Black males/females reported lifetime psilocybin use, and less than a third of Black females reported lifetime LSD use. Native American males had the lowest prevalence of lifetime MDMA use (17.62-33.30%) but had the highest lifetime prevalence of peyote use (40.37-53.24%). Pacific Islander males had the highest prevalence of lifetime mescaline use (28.27%), and lifetime DMT use was highest among Pacific Islander males/females (15.68-38.58%). Black, Asian, and Multiracial people had greater odds of past-year (ORs = 1.20-2.02; ps < 0.05) and past-month (ORs = 1.39-2.06; ps < 0.05) hallucinogen use compared to White people. Females had lower odds of past-year (OR = 0.79; ps < 0.05), past-month (OR = 0.78; ps < 0.05) hallucinogen use compared to males, except for lifetime use of MDMA (OR = 1.29; ps < 0.05).ConclusionsThese findings should inform public health initiatives regarding potential benefits and risks of hallucinogen use among racial/ethnic groups and women.", "journal": "Frontiers in Epidemiology", "publication_date": "2022-03-22", "publication_year": 2022, "doi": "10.3389/fepid.2022.876706", "pubmed_id": "38455323", "source_url": "https://doi.org/10.3389/fepid.2022.876706", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"38455323\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4220885585\",\"openalex_url\":\"https://openalex.org/W4220885585\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":20,\"referenced_works\":[\"https://openalex.org/W1595101558\",\"https://openalex.org/W1968020679\",\"https://openalex.org/W1972468585\",\"https://openalex.org/W1992465642\",\"https://openalex.org/W1994359352\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2034918627\",\"https://openalex.org/W2075042263\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2297949596\",\"https://openalex.org/W2891256775\",\"https://openalex.org/W2899027265\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W2954372647\",\"https://openalex.org/W3024299552\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3112172827\",\"https://openalex.org/W3153987748\",\"https://openalex.org/W3185700361\",\"https://openalex.org/W4211150788\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038141719\",\"display_name\":\"Alan K. Davis\",\"orcid\":\"https://orcid.org/0000-0003-4770-8893\"},{\"id\":\"https://openalex.org/A5016798906\",\"display_name\":\"Brooke J. Arterberry\",\"orcid\":\"https://orcid.org/0000-0003-3447-6085\"},{\"id\":\"https://openalex.org/A5042913979\",\"display_name\":\"Yitong Xin\",\"orcid\":\"https://orcid.org/0000-0001-5871-1137\"},{\"id\":\"https://openalex.org/A5041698353\",\"display_name\":\"Gabrielle Agin-Liebes\",\"orcid\":\"https://orcid.org/0000-0002-9754-229X\"},{\"id\":\"https://openalex.org/A5049788924\",\"display_name\":\"Corrine Schwarting\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065680812\",\"display_name\":\"Monnica T. Williams\",\"orcid\":\"https://orcid.org/0000-0003-0095-3277\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210179157\",\"source_display_name\":\"Frontiers in Epidemiology\",\"landing_page_url\":\"https://doi.org/10.3389/fepid.2022.876706\",\"is_oa\":true}}}", "topic_tags": "Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4220885585" }, { "id": 1764, "title": "Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats.", "normalized_title": "development of an e coli based norbaeocystin production platform and evaluation of behavioral effects in rats", "authors": "Adams AM, Anas NA, Sen AK, Hinegardner-Hendricks JD, O'Dell PJ, Gibbons WJ, Flower JE, McMurray MS, Jones JA.", "abstract": "Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a novel E. coli platform for the rapid and scalable production of gram-scale amounts of norbaeocystin. Through this process we compare the genetic and fermentation optimization strategies to that of a similarly constructed and previously reported psilocybin producing strain, uncovering the need for reoptimization and balancing upon even minor genetic modifications to the production host. We then perform in vivo measurements of head twitch response to both biosynthesized psilocybin and norbaeocystin using both a cell broth and water vehicle in Long-Evans rats. The data show a dose response to psilocybin while norbaeocystin does not elicit any pharmacological response, suggesting that norbaeocystin and its metabolites may not have a strong affinity for the serotonin 2A receptor. The findings presented here provide a mechanism to source norbaeocystin for future studies to evaluate its disease efficacy in animal models, both individually and in combination with psilocybin, and support the safety of cell broth as a drug delivery vehicle.", "journal": "Metabolic Engineering Communications", "publication_date": "2022-03-11", "publication_year": 2022, "doi": "10.1016/j.mec.2022.e00196", "pubmed_id": "35310468", "source_url": "https://doi.org/10.1016/j.mec.2022.e00196", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:37", "raw_json": "{\"europe_pmc_id\":\"35310468\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4220669239\",\"openalex_url\":\"https://openalex.org/W4220669239\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":21,\"referenced_works\":[\"https://openalex.org/W1897852281\",\"https://openalex.org/W1995013188\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2012142575\",\"https://openalex.org/W2025534288\",\"https://openalex.org/W2037630877\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2062765660\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2092674780\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2130996362\",\"https://openalex.org/W2132624405\",\"https://openalex.org/W2154524838\",\"https://openalex.org/W2327221240\",\"https://openalex.org/W2435600814\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2973895336\",\"https://openalex.org/W2979144408\",\"https://openalex.org/W3008629222\",\"https://openalex.org/W3013100262\",\"https://openalex.org/W3016823936\",\"https://openalex.org/W3025951714\",\"https://openalex.org/W3048387866\",\"https://openalex.org/W3092306296\",\"https://openalex.org/W3113337956\",\"https://openalex.org/W6784290885\"],\"authorships\":[{\"id\":\"https://openalex.org/A5069267630\",\"display_name\":\"Alexandra M. Adams\",\"orcid\":\"https://orcid.org/0009-0002-0518-0461\"},{\"id\":\"https://openalex.org/A5050418284\",\"display_name\":\"Nicholas A. Anas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077644431\",\"display_name\":\"Abhishek K. Sen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5035202969\",\"display_name\":\"Jordan D. Hinegardner-Hendricks\",\"orcid\":\"https://orcid.org/0000-0003-3618-5003\"},{\"id\":\"https://openalex.org/A5082807895\",\"display_name\":\"Philip J. O’Dell\",\"orcid\":\"https://orcid.org/0000-0001-8704-1806\"},{\"id\":null,\"display_name\":\"William J. Gibbons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5041542031\",\"display_name\":\"Jessica E. Flower\",\"orcid\":null},{\"id\":\"https://openalex.org/A5072282809\",\"display_name\":\"Matthew S. McMurray\",\"orcid\":\"https://orcid.org/0000-0002-1898-2933\"},{\"id\":\"https://openalex.org/A5070067902\",\"display_name\":\"J. Andrew Jones\",\"orcid\":\"https://orcid.org/0000-0002-9068-2126\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898246255\",\"source_display_name\":\"Metabolic Engineering Communications\",\"landing_page_url\":\"https://doi.org/10.1016/j.mec.2022.e00196\",\"is_oa\":true}}}", "topic_tags": "Mechanism of Action,Receptor Pharmacology,Animal Study,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4220669239" }, { "id": 1552, "title": "A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.", "normalized_title": "a systematic literature review and meta analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental behavioural or developmental disorders", "authors": "Kisely S, Connor M, Somogyi AA, Siskind D.", "abstract": "ObjectivesThere is an increasing interest in combining psilocybin or methylenedioxymethamphetamine with psychological support in treating psychiatric disorders. Although there have been several recent systematic reviews, study and participant numbers have been limited, and the field is rapidly evolving with the publication of more studies. We therefore conducted a systematic review of PubMed, MEDLINE, PsycINFO, the Cochrane Central Register of Controlled Trials, Embase, and CINAHL for randomised controlled trials of methylenedioxymethamphetamine and psilocybin with either inactive or active controls.MethodsOutcomes were psychiatric symptoms measured by standardised, validated and internationally recognised instruments at least 2 weeks following drug administration, Quality was independently assessed using the Cochrane risk of bias assessment tool and Grading of Recommendations Assessment, Development and Evaluation framework.ResultsThere were eight studies on methylenedioxymethamphetamine and six on psilocybin. Diagnoses included post-traumatic stress disorder, long-standing/treatment-resistant depression, obsessive-compulsive disorder, social anxiety in adults with autism, and anxiety or depression in life-threatening disease. The most information and strongest association was for the change in methylenedioxymethamphetamine scores compared to active controls in post-traumatic stress disorder (k = 4; standardised mean difference = -0.86; 95% confidence interval = [-1.23, -0.50]; p", "journal": null, "publication_date": "2022-03-11", "publication_year": 2022, "doi": "10.1177/00048674221083868", "pubmed_id": "35285280", "source_url": "https://doi.org/10.1177/00048674221083868", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Anxiety Disorders, Developmental Disabilities, Adult, Child, Psilocybin, Cognitive Behavioral Therapy", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35285280\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,OCD,End-of-Life Distress,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1809, "title": "Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.", "normalized_title": "mycotherapy potential of fungal bioactives for the treatment of mental health disorders and morbidities of chronic pain", "authors": "Meade E, Hehir S, Rowan N, Garvey M.", "abstract": "Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these compounds has raised awareness stimulating neuropharmacological investigations. Micro-dosing or acute dosing with psychedelics including Lysergic acid diethylamide (LSD) and psilocybin may offer patients treatment options which are unmet by current therapeutic options. Studies suggest that either dosing regimen produces a rapid and long-lasting effect on the patient post administration with a good safety profile. Psychedelics can also modulate immune systems including pro-inflammatory cytokines suggesting a potential in the treatment of auto-immune and other chronic pain conditions. This literature review aims to explore recent evidence relating to the application of fungal bioactives in treating chronic mental health and chronic pain morbidities.", "journal": null, "publication_date": "2022-03-10", "publication_year": 2022, "doi": "10.3390/jof8030290", "pubmed_id": "35330292", "source_url": "https://doi.org/10.3390/jof8030290", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35330292\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Review Article,Safety,Inflammation,Immune Function", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1813, "title": "Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.", "normalized_title": "depression and long term prescription opioid use and opioid use disorder implications for pain management in cancer", "authors": "Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF.", "abstract": "Opinion statementPreventing depression in cancer patients on long-term opioid therapy should begin with depression screening before opioid initiation and repeated screening during treatment. In weighing the high morbidity of depression and opioid use disorder in patients with chronic cancer pain against a dearth of evidence-based therapies studied in this population, patients and clinicians are left to choose among imperfect but necessary treatment options. When possible, we advise engaging psychiatric and pain/palliative specialists through collaborative care models and recommending mindfulness and psychotherapy to all patients with significant depression alongside cancer pain. Medications for depression should be reserved for moderate to severe symptoms. We recommend escitalopram/citalopram or sertraline among selective serotonin reuptake inhibitors (SSRIs), or the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine, venlafaxine, or desvenlafaxine if patients have a significant component of neuropathic pain or fibromyalgia. Tricyclic antidepressants (TCAs) (consider nortriptyline or desipramine, which have better anticholinergic profiles) should be considered for patients who do not respond to or tolerate SSRI/SNRIs. Existing evidence is inadequate to definitively recommend methylphenidate or novel agents, such as ketamine or psilocybin, as adjunctive treatments for cancer-related depression and pain. Physicians who treat patients with cancer pain should utilize universal precautions to limit the risk of non-medical opioid use (non-medical opioid use). Patients should be screened for non-medical opioid use behaviors at initial consultation and at regular intervals during treatment using a non-judgmental approach that reduces stigma. Co-management with an addiction specialist may be indicated for patients at high risk of non-medical opioid use and opioid use disorder. Buprenorphine and methadone are indicated for the treatment of opioid use disorder, and while they have not been systematically studied for treatment of opioid use disorder in patients with cancer pain, they do provide analgesia for cancer pain. While an interdisciplinary team approach to manage psychological stress may be beneficial, this may not be possible for patients treated outside of comprehensive cancer centers.", "journal": null, "publication_date": "2022-03-06", "publication_year": 2022, "doi": "10.1007/s11864-022-00954-4", "pubmed_id": "35254595", "source_url": "https://doi.org/10.1007/s11864-022-00954-4", "keywords": "Humans, Neoplasms, Pain, Opioid-Related Disorders, Analgesics, Opioid, Depression, Prescriptions, Pain Management, Serotonin and Noradrenaline Reuptake Inhibitors, Cancer Pain, Selective Serotonin Reuptake Inhibitors", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35254595\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,End-of-Life Distress,Chronic Pain,Receptor Pharmacology,Aging,Cancer Patients,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1811, "title": "Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.", "normalized_title": "methodological challenges in psychedelic drug trials efficacy and safety of psilocybin in treatment resistant major depression episode rationale and study design", "authors": "Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G.", "abstract": "Psychedelics such as psilocybin have recently gained remarkable interest in both the specialist literature and the lay press because studies suggest that these substances may have great therapeutic potential in various psychiatric disorders, including major depression. However, clinical trials with psychedelic drugs pose particular methodological challenges to researchers, some of which differ considerably from those with other psychotropic drugs. These include the problem of successful blinding, which can hardly be guaranteed in clinical trials with psychedelic substances and - directly related - the high risk of expectation bias and nocebo effects. Some of these challenges are being addressed in the given clinical trial on the efficacy and safety of psilocybin in treatment-resistant major depression. It is a phase II randomized, double-blind, active placebo-controlled parallel group trial with 144 patients. The rationale, the study design, and the core features of the study are presented here. The trial (EPIsoDE trial; EudraCT number: 2019-003984-24; NCT04670081) is funded by the German Federal Ministry of Education and Research (BMBF 01EN2006 ​A/B).", "journal": "Neuroscience Applied", "publication_date": "2022-03-06", "publication_year": 2022, "doi": "10.1016/j.nsa.2022.100104", "pubmed_id": "40656230", "source_url": "https://doi.org/10.1016/j.nsa.2022.100104", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"40656230\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4220708535\",\"openalex_url\":\"https://openalex.org/W4220708535\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":40,\"referenced_works\":[\"https://openalex.org/W1655045766\",\"https://openalex.org/W1776258049\",\"https://openalex.org/W1948877773\",\"https://openalex.org/W1970054184\",\"https://openalex.org/W1992844800\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2022191212\",\"https://openalex.org/W2043530175\",\"https://openalex.org/W2047503435\",\"https://openalex.org/W2056438596\",\"https://openalex.org/W2072833030\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2127662631\",\"https://openalex.org/W2152472333\",\"https://openalex.org/W2164182651\",\"https://openalex.org/W2164198137\",\"https://openalex.org/W2167987245\",\"https://openalex.org/W2253040643\",\"https://openalex.org/W2277633149\",\"https://openalex.org/W2330686105\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2404687886\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2779386549\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2784069100\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2791088784\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2799742551\",\"https://openalex.org/W2806188084\",\"https://openalex.org/W2895197076\",\"https://openalex.org/W2948548704\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2970458256\",\"https://openalex.org/W2974814938\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3124059976\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3162909048\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3177300439\",\"https://openalex.org/W3193440797\",\"https://openalex.org/W4288077072\",\"https://openalex.org/W6695084235\",\"https://openalex.org/W6755541052\",\"https://openalex.org/W6818643326\"],\"authorships\":[{\"id\":\"https://openalex.org/A5070309082\",\"display_name\":\"Lea J. Mertens\",\"orcid\":\"https://orcid.org/0000-0003-4415-3941\"},{\"id\":\"https://openalex.org/A5045306689\",\"display_name\":\"Michael Koslowski\",\"orcid\":\"https://orcid.org/0000-0001-8798-9875\"},{\"id\":\"https://openalex.org/A5031618523\",\"display_name\":\"Felix Betzler\",\"orcid\":\"https://orcid.org/0000-0002-1389-4870\"},{\"id\":\"https://openalex.org/A5054444045\",\"display_name\":\"Ricarda Evens\",\"orcid\":\"https://orcid.org/0000-0002-2834-2171\"},{\"id\":\"https://openalex.org/A5015683895\",\"display_name\":\"Maria Gilles\",\"orcid\":\"https://orcid.org/0000-0002-9604-4459\"},{\"id\":\"https://openalex.org/A5016321877\",\"display_name\":\"Andrea Jungaberle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001710309\",\"display_name\":\"Henrik Jungaberle\",\"orcid\":\"https://orcid.org/0000-0001-7634-4211\"},{\"id\":\"https://openalex.org/A5065637165\",\"display_name\":\"Tomislav Majić\",\"orcid\":\"https://orcid.org/0000-0003-2950-6673\"},{\"id\":\"https://openalex.org/A5066612577\",\"display_name\":\"Andreas Ströhle\",\"orcid\":\"https://orcid.org/0000-0003-0935-3702\"},{\"id\":\"https://openalex.org/A5075794355\",\"display_name\":\"Max Wolff\",\"orcid\":\"https://orcid.org/0000-0001-6896-9633\"},{\"id\":\"https://openalex.org/A5063934463\",\"display_name\":\"Stefan Wellek\",\"orcid\":\"https://orcid.org/0000-0001-8369-8122\"},{\"id\":\"https://openalex.org/A5081339058\",\"display_name\":\"Gerhard Gründer\",\"orcid\":\"https://orcid.org/0000-0001-7868-3903\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"https://doi.org/10.1016/j.nsa.2022.100104\",\"is_oa\":true}}}", "topic_tags": "Depression,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4220708535" }, { "id": 1769, "title": "The therapeutic potential of psilocybin: a systematic review.", "normalized_title": "the therapeutic potential of psilocybin a systematic review", "authors": "van Amsterdam J, van den Brink W.", "abstract": "IntroductionPsychedelic drugs were used quite extensively before their prohibition in 1968 which delayed research. However, since the 1990s, studies on the potential therapeutic benefits of psychedelics have rapidly increased.Areas coveredThis systematic review provides an overview of the clinical effects of psilocybin in the treatment of a variety of mental disorders. Only (randomized) clinical trials were selected. A total of 11 studies (15 publications) were selected, including seven randomized controlled trials (eight publications) and four single arm open-label studies (seven publications). In total, 488 patients were included in the selected studies: 333 patients treated with psilocybin and 155 patients treated with (active) placebo. In nine studies, psychotherapeutic support was provided as an integral part of the psilocybin treatment. The findings of these studies collectively show that psilocybin has a positive benefit-risk balance in the treatment of various mental disorders with an immediate and prolonged effect following 1-3 doses of psilocybin and a few (serious) adverse events.Expert opinionPsilocybin - mostly combined with psychotherapy or psychotherapeutic support - shows a promise as a treatment for various (treatment-resistant) mental disorders. Larger double-blind RCTs with objective (long-term) outcomes are needed to confirm these findings before standard clinical use of psilocybin can be considered.", "journal": null, "publication_date": "2022-03-01", "publication_year": 2022, "doi": "10.1080/14740338.2022.2047929", "pubmed_id": "35225143", "source_url": "https://doi.org/10.1080/14740338.2022.2047929", "keywords": "Humans, Hallucinogens, Double-Blind Method, Mental Disorders, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35225143\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1768, "title": "Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.", "normalized_title": "effects of the 5 ht2a receptor antagonist volinanserin on head twitch response and intracranial self stimulation depression induced by different structural classes of psychedelics in rodents", "authors": "Jaster AM, Elder H, Marsh SA, de la Fuente Revenga M, Negus SS, González-Maeso J.", "abstract": "BackgroundClinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects.ObjectivesThe present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms associated with serotonin 2A receptor (5-HT2AR) activation and behavioral disruption in two rodent models. Utilizing the selective 5-HT2AR antagonist volinanserin, we aimed to provide further pharmacological assessment of psychedelic effects in rodents.MethodsWe compared volinanserin (0.0001-0.1 mg/kg) antagonism of the phenethylamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 1.0 mg/kg) and the ergoline lysergic acid diethylamide (LSD, 0.32 mg/kg) in preclinical assays predictive of hallucinations (head-twitch response or HTR in mice) and behavioral disruption (intracranial self-stimulation or ICSS in rats). Volinanserin antagonism of the phenethylamine mescaline, the tryptamine psilocybin, and the k-opioid receptor agonist salvinorin A was also evaluated in the rat ICSS assay.ResultsVolinanserin had similar potency, effectiveness, and time-course to attenuate DOI-induced HTR in mice and ICSS depression in rats. Volinanserin completely blocked LSD-induced HTR in mice, but not LSD-induced ICSS depression in rats. Volinanserin also reversed ICSS depression by mescaline, but it was only partially effective to reduce the effects of psilocybin, and it exacerbated ICSS depression by salvinorin A.ConclusionAlthough hallucination-related HTR behavior induced by phenethylamine, ergoline, and tryptamine psychedelics appears to be 5-HT2AR-mediated, the receptor(s) responsible for behavioral disruptive effects may differ among these three structural classes.", "journal": null, "publication_date": "2022-03-01", "publication_year": 2022, "doi": "10.1007/s00213-022-06092-x", "pubmed_id": "35233648", "source_url": "https://doi.org/10.1007/s00213-022-06092-x", "keywords": "Animals, Rodentia, Mice, Rats, Tryptamines, Serotonin, Phenethylamines, Mescaline, Fluorobenzenes, Lysergic Acid Diethylamide, Piperidines, Receptor, Serotonin, 5-HT2A, Hallucinogens, Depression, Self Stimulation, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35233648\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Pharmacology,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1815, "title": "Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.", "normalized_title": "adverse effects of psychedelics from anecdotes and misinformation to systematic science", "authors": "Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ", "abstract": "Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger. This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research. Taking a high-level perspective, we address both psychological and psychiatric risks, such as abuse liability and potential for dependence, as well as medical harms, including toxicity and overdose. We explore the evidence base for these adverse effects to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny. Our review shows that medical risks are often minimal, and that many - albeit not all - of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context. This highlights the importance for clinicians and therapists to keep to the highest safety and ethical standards. It is imperative not to be overzealous and to ensure balanced media reporting to avoid future controversies, so that much needed research can continue.", "journal": "Journal of psychopharmacology (Oxford, England)", "publication_date": "2022-02-28", "publication_year": 2022, "doi": "10.1177/02698811211069100", "pubmed_id": "35107059", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35107059/", "keywords": "Psilocybin, abuse liability/dependence, ayahuasca, d-lysergic acid diethylamide, dimethyltryptamine, hallucinogen persistent perception disorder, hypertension, mescaline, toxicity", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35107059\"}", "topic_tags": "Review Article,Healthcare Workers,Safety,Toxicity,Abuse Liability", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1611, "title": "The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.", "normalized_title": "the use of psilocybin in the treatment of psychiatric disorders with attention to relative safety profile a systematic review", "authors": "Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC.", "abstract": "There has been a reemergence of research into the use of substances such as LSD, MDMA, and psilocybin for the treatment of psychiatric disorders. This increase in consideration toward the medicinal use of these compounds has been termed the \"Psychedelic Renaissance.\" This article specifically explores the background of psilocybin, a psychoactive compound that is naturally derived from certain species of fungi. Pubmed was searched by one doctoral-level researcher using specific Boolean operator terms. The results were filtered by title and abstract and 76 articles were screened and analyzed in full detail. Oral psilocybin is showing itself to be clinically efficacious by producing statistically significant reductions in depression and anxiety symptoms over time versus control in multiple clinical trials. It has also been shown to reduce cigarettes per day and drinks per day in patients with substance use disorders. Thus far, there have been no significant adverse clinical events from psilocybin and there also have been no verifiable recorded deaths reported. Larger studies need to be performed before the drug can potentially become approved for use in the general population.", "journal": null, "publication_date": "2022-02-27", "publication_year": 2022, "doi": "10.1080/02791072.2022.2044096", "pubmed_id": "35225726", "source_url": "https://doi.org/10.1080/02791072.2022.2044096", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Anxiety, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35225726\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1822, "title": "Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis.", "normalized_title": "trajectory of antidepressant effects after single or two dose administration of psilocybin a systematic review and multivariate meta analysis", "authors": "Yu CL, Liang CS, Yang FC, Tu YK, Hsu CW, Carvalho AF, Stubbs B, Thompson T, Tsai CK, Yeh TC, Yang SN, Shin JI, Chu CS, Tseng PT, Su KP.", "abstract": "We examined the cardiovascular safety, acceptability, and trajectory of the antidepressant effects of psilocybin after single- or two-dose administration. Four major electronic databases were systematically searched. Data were pooled using a multivariate random-effects meta-analysis. Primary outcomes were changes in depressive symptoms. Secondary outcomes were cardiovascular safety and acceptability. Ten studies were included. The estimated effect sizes (standardized mean difference (SMD) with 95% confidence intervals) for psilocybin were -0.75 (-1.15 to -0.35) on day 1, -1.74 (-2.15 to -1.32) at 1 week, -1.35 (-1.77 to -0.93) at 1 month, -0.91 (-1.31 to -0.51) at 3 months, and -1.12 (-1.56 to -0.68) at 6 months. Higher doses and two sessions of psilocybin treatment were significantly associated with superior antidepressant effects. The all-cause discontinuation and heart rate after psilocybin administration were comparable to placebo; meanwhile, psilocybin increased systolic and diastolic blood pressure by 19.00 mmHg and 8.66 mmHg, respectively. There were no significant differences between SMD derived from placebo-controlled trials compared to those from pre-post changes and SMD in randomized controlled trials (RCTs) compared to those in non-RCTs. The present study demonstrates that single- or two-dose psilocybin administration has rapid and sustained antidepressant effects for up to 6 months, with favorable cardiovascular safety and acceptability.", "journal": null, "publication_date": "2022-02-10", "publication_year": 2022, "doi": "10.3390/jcm11040938", "pubmed_id": "35207210", "source_url": "https://doi.org/10.3390/jcm11040938", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35207210\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1799, "title": "Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.", "normalized_title": "diversity biology and history of psilocybin containing fungi suggestions for research and technological development", "authors": "Van Court RC, Wiseman MS, Meyer KW, Ballhorn DJ, Amses KR, Slot JC, Dentinger BTM, Garibay-Orijel R, Uehling JK.", "abstract": "Therapeutic use of psilocybin has become a focus of recent international research, with preliminary data showing promise to address a range of treatment-resistant mental health conditions. However, use of psilocybin as a healing entheogen has a long history through traditional consumption of mushrooms from the genus Psilocybe. The forthcoming adoption of new psilocybin-assisted therapeutic practices necessitates identification of preferred sources of psilocybin; consequently, comprehensive understanding of psilocybin-containing fungi is fundamental to consumer safety. Here we examine psilocybin producing fungi, discuss their biology, diversity, and ethnomycological uses. We also review recent work focused on elucidation of psilocybin biosynthetic production pathways, especially those from the genus Psilocybe, and their evolutionary history. Current research on psilocybin therapies is discussed, and recommendations for necessary future mycological research are outlined.", "journal": null, "publication_date": "2022-02-10", "publication_year": 2022, "doi": "10.1016/j.funbio.2022.01.003", "pubmed_id": "35314062", "source_url": "https://doi.org/10.1016/j.funbio.2022.01.003", "keywords": "Agaricales, Biology, Psilocybe, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35314062\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1770, "title": "The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.", "normalized_title": "the therapeutic potential of psychedelic assisted therapies for symptom control in patients diagnosed with serious illness a systematic review", "authors": "Maia LO, Beaussant Y, Garcia ACM.", "abstract": "ContextPeople affected by serious illness usually experience suffering in its various dimensions, not only in the physical but also in the psychosocial and spiritual aspects. The interest in psychedelic-assisted therapies as a potential new therapeutic modality has increased since evidence suggests a significant impact of their use on the outcomes of patients with serious illness.ObjectivesTo systematically review the available evidence on the effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness.MethodsThe protocol of this systematic review has been prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. This review included randomized and non-randomized controlled trials published in peer-reviewed scientific journals. A comprehensive search for studies was carried out in the main scientific databases, including Web of Science, Scopus, Cochrane Library, PsycINFO, PubMed, CINAHL, and EMBASE. There were no limitations regarding the year or language of publication.ResultsThe sample was composed of 20 studies. The results suggest positive effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness, with considerable safety of use. Most studies have been conducted with lysergic acid diethylamide, psilocybin, and N,N-dipropyltryptamine in cancer patients. The adverse effects reported were of physical and/or psychological nature and of mild to moderate intensity, transient, and self-resolutive.ConclusionThe evaluated evidence suggests positive effects of psychedelic-assisted therapies for symptom control in patients diagnosed with serious illness, especially regarding symptoms of psychological and spiritual nature.", "journal": null, "publication_date": "2022-02-10", "publication_year": 2022, "doi": "10.1016/j.jpainsymman.2022.01.024", "pubmed_id": "35157985", "source_url": "https://doi.org/10.1016/j.jpainsymman.2022.01.024", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Anxiety, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35157985\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,Spirituality,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1825, "title": "Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.", "normalized_title": "analysis of psilocybin assisted therapy in medicine a narrative review", "authors": "Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR.", "abstract": "Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A agonists), was classified as a Schedule I substance, bringing a halt to research on its medicinal utility. The resurgence of clinical trials involving psilocybin in the 21st century has produced promising results concerning the treatment of addiction, depression, and end-of-life mood disorders. Results from these trials have shown significant reductions in depression and anxiety when compared with a placebo, and one trial found no significant difference when compared to a routinely prescribed selective serotonin reuptake inhibitor (SSRI). Studies conducted with patients with advanced-stage cancer have demonstrated that psilocybin may also be beneficial at reducing depression and anxiety associated with psychological crises due to a terminal diagnosis. Psilocybin therapy in the treatment of addiction, which is notoriously difficult to treat, has shown encouraging results. Due to its low toxicity and low risk of overuse, psilocybin has the potential to have a significant influence in the field of addiction medicine. Psilocybin addiction research has been primarily focused on nicotine and alcohol and, in a few small, open-label trials, has shown superiority over traditional therapies. Psilocybin has a relatively unique and incompletely understood mechanism of action, which allows it to be given at several isolated periods. This infrequent dosing regimen has been shown to produce durable effects with minimal toxicity. This review analyzes the potential of psilocybin in the treatment of addiction, depression, and end-of-life mood disorders. In addition, it will discuss the difficulties involved with conducting scientific research on psychedelic compounds, adverse effects, and the therapeutic measures that are necessary to accompany the safe and effective administration of these psychoactive chemicals.", "journal": null, "publication_date": "2022-02-04", "publication_year": 2022, "doi": "10.7759/cureus.21944", "pubmed_id": "35273885", "source_url": "https://doi.org/10.7759/cureus.21944", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35273885\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Mechanism of Action,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1827, "title": "Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.", "normalized_title": "efficacy and safety of psilocybin assisted treatment for major depressive disorder prospective 12 month follow up", "authors": "Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR.", "abstract": "BackgroundPreliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes.AimsThis study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin.MethodsThis randomized, waiting-list controlled study enrolled 27 patients aged 21-75 with moderate to severe unipolar depression (GRID-Hamilton Depression Rating Scale (GRID-HAMD) ⩾ 17). Participants were randomized to an immediate or delayed (8 weeks) treatment condition in which they received two doses of psilocybin with supportive psychotherapy. Twenty-four participants completed both psilocybin sessions and were followed through 12 months following their second dose.ResultsAll 24 participants attended all follow-up visits through the 12-month timepoint. Large decreases from baseline in GRID-HAMD scores were observed at 1-, 3-, 6-, and 12-month follow-up (Cohen d = 2.3, 2.0, 2.6, and 2.4, respectively). Treatment response (⩾50% reduction in GRID-HAMD score from baseline) and remission were 75% and 58%, respectively, at 12 months. There were no serious adverse events judged to be related to psilocybin in the long-term follow-up period, and no participants reported psilocybin use outside of the context of the study. Participant ratings of personal meaning, spiritual experience, and mystical experience after sessions predicted increased well-being at 12 months, but did not predict improvement in depression.ConclusionsThese findings demonstrate that the substantial antidepressant effects of psilocybin-assisted therapy may be durable at least through 12 months following acute intervention in some patients.", "journal": "Journal of Psychopharmacology", "publication_date": "2022-01-31", "publication_year": 2022, "doi": "10.1177/02698811211073759", "pubmed_id": "35166158", "source_url": "https://doi.org/10.1177/02698811211073759", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Treatment Outcome, Combined Modality Therapy, Follow-Up Studies, Prospective Studies, Psychiatric Status Rating Scales, Psychotherapy, Time Factors, Adult, Aged, Middle Aged, Female, Male, Young Adult, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"35166158\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4212903385\",\"openalex_url\":\"https://openalex.org/W4212903385\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":417,\"referenced_works\":[\"https://openalex.org/W78677904\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1987450364\",\"https://openalex.org/W2023687307\",\"https://openalex.org/W2031002884\",\"https://openalex.org/W2073441573\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2084315798\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2116416511\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2135665329\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2149402043\",\"https://openalex.org/W2149799843\",\"https://openalex.org/W2152690559\",\"https://openalex.org/W2289004134\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2418769740\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2566701931\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2891256775\",\"https://openalex.org/W2912654919\",\"https://openalex.org/W2971894339\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3005582604\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3020940623\",\"https://openalex.org/W3033752070\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3137976016\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4236038590\"],\"authorships\":[{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"},{\"id\":\"https://openalex.org/A5038141719\",\"display_name\":\"Alan K. Davis\",\"orcid\":\"https://orcid.org/0000-0003-4770-8893\"},{\"id\":\"https://openalex.org/A5005540871\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":\"https://orcid.org/0000-0001-7443-3237\"},{\"id\":\"https://openalex.org/A5025469924\",\"display_name\":\"Mary P Cosimano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5061776312\",\"display_name\":\"Nathan D. Sepeda\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811211073759\",\"is_oa\":true}}}", "topic_tags": "Depression,Wellbeing,Spirituality,Mystical Experience,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4212903385" }, { "id": 1832, "title": "Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder.", "normalized_title": "evaluating the potential use of serotonergic psychedelics in autism spectrum disorder", "authors": "Markopoulos A, Inserra A, De Gregorio D, Gobbi G.", "abstract": "Recent clinical and preclinical evidence points towards empathogenic and prosocial effects elicited by psychedelic compounds, notably the serotonin 5-HT2A agonists lysergic acid diethylamide (LSD), psilocybin, N,N-Dimethyltryptamine (DMT), and their derivatives. These findings suggest a therapeutic potential of psychedelic compounds for some of the behavioural traits associated with autism spectrum disorder (ASD), a neurodevelopmental condition characterized by atypical social behaviour. In this review, we highlight evidence suggesting that psychedelics may potentially ameliorate some of the behavioural atypicalities of ASD, including reduced social behaviour and highly co-occurring anxiety and depression. Next, we discuss dysregulated neurobiological systems in ASD and how they may underlie or potentially limit the therapeutic effects of psychedelics. These phenomena include: 1) synaptic function, 2) serotonergic signaling, 3) prefrontal cortex activity, and 4) thalamocortical signaling. Lastly, we discuss clinical studies from the 1960s and 70s that assessed the use of psychedelics in the treatment of children with ASD. We highlight the positive behavioural outcomes of these studies, including enhanced mood and social behaviour, as well as the adverse effects of these trials, including increases in aggressive behaviour and dissociative and psychotic states. Despite preliminary evidence, further studies are needed to determine whether the benefits of psychedelic treatment in ASD outweigh the risks associated with the use of these compounds in this population, and if the 5-HT2A receptor may represent a target for social-behavioural disorders.", "journal": null, "publication_date": "2022-01-26", "publication_year": 2022, "doi": "10.3389/fphar.2021.749068", "pubmed_id": "35177979", "source_url": "https://doi.org/10.3389/fphar.2021.749068", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35177979\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Review Article,Animal Study,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1773, "title": "Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.", "normalized_title": "assessing the risk benefit profile of classical psychedelics a clinical review of second wave psychedelic research", "authors": "Bender D, Hellerstein DJ.", "abstract": "RationaleA broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use.ObjectivesTo use recently published data to assess potential risks and benefits of psychedelic drugs as therapeutics, as well as to synthesize what is currently known in order to generate fruitful future research directions.MethodsA review of studies conducted since 1991 identified 14 clinical trials of classical psychedelics, including 11 of psilocybin (N = 257 participants), 1 of lysergic acid diethylamide (N = 12 participants), and 2 of ayahuasca (N = 46 participants). Other published studies (e.g., of healthy volunteers, survey studies, case reports, neuroimaging) were also considered for review.ResultsPublished studies since 1991 largely support the hypothesis that small numbers of treatments with psychedelic-assisted psychotherapy can offer significant and sustained alleviation to symptoms of multiple psychiatric conditions. No serious adverse events attributed to psychedelic therapy have been reported. Existing studies have several limitations, including small sample sizes, inherent difficulty in blinding, relatively limited follow-up, and highly screened treatment populations.ConclusionsSubstantial data have been gathered in the past 30 years suggesting that psychedelics are a potent treatment for a variety of common psychiatric conditions, though the ideal means of employing these substances to minimize adverse events and maximize therapeutic effects remains controversial. Unique factors related to study design are vital for clinical researchers in the field to address.", "journal": null, "publication_date": "2022-01-12", "publication_year": 2022, "doi": "10.1007/s00213-021-06049-6", "pubmed_id": "35022823", "source_url": "https://doi.org/10.1007/s00213-021-06049-6", "keywords": "Humans, Banisteriopsis, Lysergic Acid Diethylamide, Hallucinogens, Risk Assessment, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"35022823\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Brain Imaging,Aging,Clinical Trial,Review Article,Case Report,Observational Study,Healthy Volunteers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1849, "title": "MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.", "normalized_title": "mdma ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of us adults", "authors": "Jones GM, Nock MK.", "abstract": "BackgroundSuicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools.AimsThe aim of this study was to assess non-causal associations between MDMA/ecstasy and classic psychedelic use and psychological distress and suicide risk.MethodsIn this study, we examined the aforementioned associations among 484,732 adult participants in the National Survey on Drug Use and Health (2008-2019).ResultsLifetime MDMA/ecstasy use was associated with reduced odds of past year suicidal thinking (10% reduced odds; odds ratio (OR) = 0.90; 95% confidence interval, CI = (0.84-0.97); p", "journal": "Journal of Psychopharmacology", "publication_date": "2022-01-04", "publication_year": 2022, "doi": "10.1177/02698811211058923", "pubmed_id": "34983249", "source_url": "https://doi.org/10.1177/02698811211058923", "keywords": "Humans, Substance-Related Disorders, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Health Surveys, Stress, Psychological, Adolescent, Adult, Aged, Middle Aged, United States, Female, Male, Young Adult, Suicidal Ideation, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34983249\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4206486089\",\"openalex_url\":\"https://openalex.org/W4206486089\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":60,\"referenced_works\":[\"https://openalex.org/W1517515257\",\"https://openalex.org/W1593226667\",\"https://openalex.org/W1810864195\",\"https://openalex.org/W1973234849\",\"https://openalex.org/W1990140024\",\"https://openalex.org/W1990196711\",\"https://openalex.org/W1995183506\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W1998269363\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2024799828\",\"https://openalex.org/W2037383099\",\"https://openalex.org/W2042166241\",\"https://openalex.org/W2058609816\",\"https://openalex.org/W2060307846\",\"https://openalex.org/W2064971250\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2083524390\",\"https://openalex.org/W2087325111\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2089149909\",\"https://openalex.org/W2104320372\",\"https://openalex.org/W2109384015\",\"https://openalex.org/W2113285179\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122453635\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2124133878\",\"https://openalex.org/W2127654449\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2137981069\",\"https://openalex.org/W2138125704\",\"https://openalex.org/W2155054485\",\"https://openalex.org/W2158208927\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164487959\",\"https://openalex.org/W2165032621\",\"https://openalex.org/W2201065648\",\"https://openalex.org/W2434465376\",\"https://openalex.org/W2542493272\",\"https://openalex.org/W2550626767\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2588071311\",\"https://openalex.org/W2596575718\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2735648966\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2770648950\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2892030583\",\"https://openalex.org/W2899027265\",\"https://openalex.org/W2923355729\",\"https://openalex.org/W2943015453\",\"https://openalex.org/W2944263526\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W2981779913\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3006069447\",\"https://openalex.org/W3022868799\",\"https://openalex.org/W3027846434\",\"https://openalex.org/W3127162188\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4245112846\",\"https://openalex.org/W4247938048\",\"https://openalex.org/W4296142165\"],\"authorships\":[{\"id\":\"https://openalex.org/A5066674976\",\"display_name\":\"Grant Jones\",\"orcid\":\"https://orcid.org/0000-0002-2426-310X\"},{\"id\":\"https://openalex.org/A5082317510\",\"display_name\":\"Matthew K. Nock\",\"orcid\":\"https://orcid.org/0000-0001-6508-1145\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811211058923\",\"is_oa\":false}}}", "topic_tags": "Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4206486089" }, { "id": 1847, "title": "The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.", "normalized_title": "the effects of psilocybin on cognitive and emotional functions in healthy participants results from a phase 1 randomised placebo controlled trial involving simultaneous psilocybin administration and preparation", "authors": "Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH.", "abstract": "BackgroundPsilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive disorders. Psilocybin's effects on cognitive function have not been widely or systematically studied.AimThe aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised controlled trial of psilocybin to date. Primary and secondary endpoints assessed the short- and longer-term change in cognitive functioning, as assessed by a Cambridge Neuropsychological Test Automated Battery (CANTAB) Panel, and emotional processing scales. Safety was assessed via endpoints which included cognitive function, assessed by CANTAB global composite score, and treatment-emergent adverse event (TEAE) monitoring.MethodsIn this phase 1, randomised, double-blind, placebo-controlled study, healthy participants (n = 89; mean age 36.1 years; 41 females, 48 males) were randomised to receive a single oral dose of 10 or 25 mg psilocybin, or placebo, administered simultaneously to up to six participants, with one-to-one psychological support - each participant having an assigned, dedicated therapist available throughout the session.ResultsIn total, 511 TEAEs were reported, with a median duration of 1.0 day; 67% of all TEAEs started and resolved on the day of administration. There were no serious TEAEs, and none led to study withdrawal. There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.ConclusionsThese results indicate that 10 mg and 25 mg doses of psilocybin were generally well tolerated when given to up to six participants simultaneously and did not have any detrimental short- or long-term effects on cognitive functioning or emotional processing.Clinical trial registrationEudraCT (https://www.clinicaltrialsregister.eu/) number: 2018-000978-30.", "journal": "Journal of Psychopharmacology", "publication_date": "2022-01-03", "publication_year": 2022, "doi": "10.1177/02698811211064720", "pubmed_id": "35090363", "source_url": "https://doi.org/10.1177/02698811211064720", "keywords": "Humans, Hallucinogens, Double-Blind Method, Emotions, Cognition, Neuropsychological Tests, Dose-Response Relationship, Drug, Time Factors, Adult, Middle Aged, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"35090363\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W4205906672\",\"openalex_url\":\"https://openalex.org/W4205906672\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":101,\"referenced_works\":[\"https://openalex.org/W1269562257\",\"https://openalex.org/W1532044842\",\"https://openalex.org/W1599190429\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2000083255\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2024747286\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2056725110\",\"https://openalex.org/W2057174717\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2100958095\",\"https://openalex.org/W2108984307\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2122307809\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2134822928\",\"https://openalex.org/W2148905283\",\"https://openalex.org/W2150781787\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163072248\",\"https://openalex.org/W2169957979\",\"https://openalex.org/W2245231029\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2412432222\",\"https://openalex.org/W2461807154\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2554961705\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2567289819\",\"https://openalex.org/W2589381868\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2624901555\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2769330928\",\"https://openalex.org/W2806513910\",\"https://openalex.org/W2890724459\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2917218353\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3127006271\",\"https://openalex.org/W3127909847\",\"https://openalex.org/W3158216155\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4214728203\",\"https://openalex.org/W4230626221\",\"https://openalex.org/W4236038590\",\"https://openalex.org/W4256648276\",\"https://openalex.org/W4292994367\",\"https://openalex.org/W4294333904\",\"https://openalex.org/W4313429353\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5080462431\",\"display_name\":\"Lindsey Marwood\",\"orcid\":\"https://orcid.org/0000-0002-5818-2199\"},{\"id\":\"https://openalex.org/A5075703225\",\"display_name\":\"Riikka-Liisa Johanna Ajantaival\",\"orcid\":null},{\"id\":\"https://openalex.org/A5033191459\",\"display_name\":\"Catherine Bird\",\"orcid\":\"https://orcid.org/0000-0002-8656-6931\"},{\"id\":\"https://openalex.org/A5103127258\",\"display_name\":\"Hans Eriksson\",\"orcid\":\"https://orcid.org/0000-0002-1799-289X\"},{\"id\":\"https://openalex.org/A5055702421\",\"display_name\":\"John Harrison\",\"orcid\":\"https://orcid.org/0000-0002-0225-4923\"},{\"id\":\"https://openalex.org/A5033335673\",\"display_name\":\"Molly Lennard-Jones\",\"orcid\":null},{\"id\":\"https://openalex.org/A5108850316\",\"display_name\":\"Sunil Mistry\",\"orcid\":null},{\"id\":\"https://openalex.org/A5068780630\",\"display_name\":\"Francesco Saldarini\",\"orcid\":\"https://orcid.org/0000-0001-6798-3898\"},{\"id\":\"https://openalex.org/A5019711791\",\"display_name\":\"S. C. Stansfield\",\"orcid\":null},{\"id\":\"https://openalex.org/A5003939496\",\"display_name\":\"Sara Tai\",\"orcid\":\"https://orcid.org/0000-0002-8316-5796\"},{\"id\":\"https://openalex.org/A5111726730\",\"display_name\":\"Sam Williams\",\"orcid\":null},{\"id\":\"https://openalex.org/A5031507161\",\"display_name\":\"N. Weston\",\"orcid\":\"https://orcid.org/0000-0001-9961-7884\"},{\"id\":\"https://openalex.org/A5021278348\",\"display_name\":\"Ekaterina Malievskaia\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058414502\",\"display_name\":\"Allan H. Young\",\"orcid\":\"https://orcid.org/0000-0003-2291-6952\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811211064720\",\"is_oa\":true}}}", "topic_tags": "Depression,Receptor Pharmacology,Emotional Processing,Clinical Trial,Randomized Controlled Trial,Healthy Volunteers,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4205906672" }, { "id": 5002, "title": "The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial", "normalized_title": "the safety and efficacy of comp360 psilocybin therapy in treatment resistant depression results from a phase iib randomised controlled trial", "authors": "G.M. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, David Feifel, David J. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Antony Young, Sidney Zisook, E. Malievskaia", "abstract": "", "journal": "Neuroscience Applied", "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1016/j.nsa.2022.100511", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.nsa.2022.100511", "keywords": "Psilocybin, Depression (economics), Treatment-resistant depression, Phase (matter), Medicine, Psychotherapist, Psychology, Psychiatry, Hallucinogen, Major depressive disorder, Cognition, Chemistry, Economics, Organic chemistry, Macroeconomics, Psychedelics and Drug Studies, Digital Mental Health Interventions, Psychotherapy Techniques and Applications", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:58", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4313199626\",\"openalex_url\":\"https://openalex.org/W4313199626\",\"openalex_relevance_score\":8,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\",\"compound:comp360\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":2,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5023164918\",\"display_name\":\"G.M. Goodwin\",\"orcid\":null},{\"id\":\"https://openalex.org/A5064457148\",\"display_name\":\"Scott T. Aaronson\",\"orcid\":\"https://orcid.org/0000-0001-7616-8801\"},{\"id\":\"https://openalex.org/A5056637382\",\"display_name\":\"Boadie W. Dunlop\",\"orcid\":\"https://orcid.org/0000-0002-4653-0483\"},{\"id\":\"https://openalex.org/A5000063591\",\"display_name\":\"David Feifel\",\"orcid\":\"https://orcid.org/0000-0002-8185-0220\"},{\"id\":\"https://openalex.org/A5048687842\",\"display_name\":\"David J. Hellerstein\",\"orcid\":\"https://orcid.org/0000-0002-8031-4354\"},{\"id\":\"https://openalex.org/A5039824360\",\"display_name\":\"N. Hewitt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047032117\",\"display_name\":\"L. Marwood\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016967968\",\"display_name\":\"S. Mistry\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021140380\",\"display_name\":\"Metten Somers\",\"orcid\":\"https://orcid.org/0000-0002-9381-5596\"},{\"id\":\"https://openalex.org/A5012370983\",\"display_name\":\"S.C. Stansfield\",\"orcid\":null},{\"id\":\"https://openalex.org/A5043433258\",\"display_name\":\"J. Tsai\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042134638\",\"display_name\":\"S. Williams\",\"orcid\":null},{\"id\":\"https://openalex.org/A5087076735\",\"display_name\":\"Antony Young\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053651400\",\"display_name\":\"Sidney Zisook\",\"orcid\":\"https://orcid.org/0000-0003-3341-9185\"},{\"id\":\"https://openalex.org/A5012063316\",\"display_name\":\"E. Malievskaia\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236820\",\"source_display_name\":\"Neuroscience Applied\",\"landing_page_url\":\"https://doi.org/10.1016/j.nsa.2022.100511\",\"is_oa\":true}}", "topic_tags": "Depression,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4313199626" }, { "id": 4998, "title": "An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma", "normalized_title": "an interpretative phenomenological analysis of the use of psilocybin by veterans with symptoms of trauma", "authors": "F. N. Smith, Joanna C. Neill, Verity Wainwright", "abstract": "Veterans are at increased risk of experiencing symptoms of trauma. Although many benefit from available treatments, some find treatment inaccessible or ineffective and explore alternative substances. One such substance is psilocybin. This Interpretative Phenomenological Analysis study aimed to provide an initial insight into the experiences of veterans who have used or have considered using psilocybin and their perspectives regarding the acceptability of it as a treatment for their self-reported symptoms of trauma. Seven veterans with current or historic trauma symptoms were interviewed. All participants had either used or considered using psilocybin to alleviate their symptoms. All participants reported perceiving barriers when accessing treatment with many considering psilocybin out of desperation. All participants who had used psilocybin reported immediate and long-term improvements in their symptomatology. The study suggests that some perceive current treatments as ineffective and/or inaccessible, leading to the consideration of alternatives, such as psilocybin. The immediate and long-term symptom reductions reported suggest it may be a viable treatment option for symptoms of trauma for some. However, further research and clinical trials are required to form conclusions on the therapeutic potential of psilocybin for this group.", "journal": "Drug Science Policy and Law", "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1177/20503245221124117", "pubmed_id": null, "source_url": "https://doi.org/10.1177/20503245221124117", "keywords": "Psilocybin, Psychology, Interpretative phenomenological analysis, Psychiatry, Psychotherapist, Clinical psychology, Hallucinogen, Medicine, Qualitative research, Sociology, Social science, Psychedelics and Drug Studies, Complementary and Alternative Medicine Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:58", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4295169116\",\"openalex_url\":\"https://openalex.org/W4295169116\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W1514491136\",\"https://openalex.org/W1969426010\",\"https://openalex.org/W1979278822\",\"https://openalex.org/W1983350514\",\"https://openalex.org/W1986748622\",\"https://openalex.org/W1988648157\",\"https://openalex.org/W2007985340\",\"https://openalex.org/W2008476614\",\"https://openalex.org/W2009925557\",\"https://openalex.org/W2020127485\",\"https://openalex.org/W2023958077\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2049676413\",\"https://openalex.org/W2057344941\",\"https://openalex.org/W2072312133\",\"https://openalex.org/W2080406089\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2089149909\",\"https://openalex.org/W2097141256\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2127654449\",\"https://openalex.org/W2128960262\",\"https://openalex.org/W2131417328\",\"https://openalex.org/W2142717658\",\"https://openalex.org/W2150261153\",\"https://openalex.org/W2151025498\",\"https://openalex.org/W2152988372\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2170503011\",\"https://openalex.org/W2171540313\",\"https://openalex.org/W2177990499\",\"https://openalex.org/W2187253811\",\"https://openalex.org/W2316063445\",\"https://openalex.org/W2325558246\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2490159447\",\"https://openalex.org/W2598895258\",\"https://openalex.org/W2604674575\",\"https://openalex.org/W2613337375\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2751240458\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3002125030\",\"https://openalex.org/W3007379062\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3041518543\",\"https://openalex.org/W3087672006\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3210162930\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4212983967\",\"https://openalex.org/W4236555390\",\"https://openalex.org/W4315817451\",\"https://openalex.org/W4391468797\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034485776\",\"display_name\":\"F. N. Smith\",\"orcid\":null},{\"id\":\"https://openalex.org/A5049098570\",\"display_name\":\"Joanna C. Neill\",\"orcid\":\"https://orcid.org/0000-0002-2717-9739\"},{\"id\":\"https://openalex.org/A5087422921\",\"display_name\":\"Verity Wainwright\",\"orcid\":\"https://orcid.org/0000-0002-9876-250X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210227935\",\"source_display_name\":\"Drug Science Policy and Law\",\"landing_page_url\":\"https://doi.org/10.1177/20503245221124117\",\"is_oa\":true}}", "topic_tags": "Clinical Trial,Veterans,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4295169116" }, { "id": 1843, "title": "Psychedelics in the Treatment of Headache and Chronic Pain Disorders.", "normalized_title": "psychedelics in the treatment of headache and chronic pain disorders", "authors": "Schindler EAD.", "abstract": "The therapeutic potential of psychedelics in headache and chronic pain disorders is documented over decades of anecdotal and early investigational reports, which have paved the way for the first controlled studies of psilocybin and lysergic acid diethylamide (LSD) in these disorders. The reported lasting clinical effects after limited dosing with psychedelics present a novel means for disease management, but considerable further study will be required to address disease-specific treatments, uncover mechanism(s) of action, and verify safety. In this chapter, these topics are reviewed with particular attention to the neurobiological systems that offer potential sources of psychedelics' unique clinical effects in headache and pain.", "journal": null, "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1007/7854_2022_365", "pubmed_id": "35546382", "source_url": "https://doi.org/10.1007/7854_2022_365", "keywords": "Humans, Headache, Lysergic Acid Diethylamide, Hallucinogens, Chronic Pain, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"35546382\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Chronic Pain,Headache / Migraine,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1841, "title": "Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.", "normalized_title": "classic psychedelics in addiction treatment the case for psilocybin in tobacco smoking cessation", "authors": "Johnson MW.", "abstract": "This manuscript reviews research suggesting that classic psychedelics (5-HT2A receptor agonists) are effective in treating addictions including tobacco use disorder. I review historical research from the 1950s to 1970s suggesting that classic psychedelics are associated with addiction recovery across pharmacologically distinct drugs of addiction. I then review anthropological reports about ceremonial use of classic psychedelics and epidemiological studies that are consistent with anti-addiction efficacy. I review modern research using psilocybin in the treatment of alcohol use disorder and tobacco use disorder. Both lines of research show high success rates in preliminary studies. General anti-addiction efficacy across a variety of classes of addictive drugs is consistent with the notion that the persisting positive behavior change prompted by psychedelic therapy is due to amplification of psychotherapeutic processes. Future research should examine classic psychedelic treatment of additional substance use disorders including for opioids, cocaine, methamphetamine, and cannabis, and other disorders broadly characterized as addictions (e.g., obesity, problem gambling, hypersexual disorder). Future research should also explore addiction treatments with other classic psychedelics including LSD, mescaline, DMT, 5-MeO-DMT, and yet-to-be-discovered compounds. Experimental research is also needed to test different protocols for the delivery of classic psychedelic therapy for addictions. Given the staggering society costs of substance use disorders, including the mortality caused by tobacco smoking, it is critical that public funding be made available for scientists to follow up on promising early findings of classic psychedelics in addiction treatment. The costs and risks of not conducting such research are too great.", "journal": null, "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1007/7854_2022_327", "pubmed_id": "35704271", "source_url": "https://doi.org/10.1007/7854_2022_327", "keywords": "Humans, Substance-Related Disorders, Tobacco Use Disorder, Hallucinogens, Smoking Cessation, Psilocybin, Nicotiana", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"35704271\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Receptor Pharmacology,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1840, "title": "Psilocybin for Trauma-Related Disorders.", "normalized_title": "psilocybin for trauma related disorders", "authors": "Khan AJ, Bradley E, O'Donovan A, Woolley J.", "abstract": "Posttraumatic stress disorder (PTSD) is a debilitating, chronic disorder and efficacy rates of current PTSD treatments are underwhelming. There is a critical need for innovative approaches. We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An open-label study in traumatized AIDS survivors found that PAP reduced PTSD symptoms, attachment anxiety, and demoralization. Several PAP trials show preliminary efficacy in facilitating confronting traumatic memories, decreasing emotional avoidance, depression, anxiety, pessimism, and disconnection from others, and increasing acceptance, self-compassion, and forgiveness of abusers, all of which are relevant to PTSD recovery. There is also early evidence that other classic psychedelics may produce large reductions in PTSD symptoms in combat veterans. However, this body of literature is small, mechanisms are not yet well understood, and the risks of using psychedelic compounds for trauma-related disorders need further study. In sum, evidence supports further investigation of PAP as a radically new approach for treating PTSD.", "journal": null, "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1007/7854_2022_366", "pubmed_id": "35711024", "source_url": "https://doi.org/10.1007/7854_2022_366", "keywords": "Humans, Hallucinogens, Stress Disorders, Post-Traumatic, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"35711024\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Mechanism of Action,Emotional Processing,Veterans,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1807, "title": "Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.", "normalized_title": "effects of naturalistic psychedelic use on depression anxiety and well being associations with patterns of use reported harms and transformative mental states", "authors": "Raison CL, Jain R, Penn AD, Cole SP, Jain S", "abstract": "Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A cross-sectional, online survey was completed by 2,510 adults reporting at least one lifetime psychedelic experience. Participants retrospectively completed a battery of instruments assessing depression, anxiety, and emotional well-being prior to and following psychedelic exposure. Participants also reported preferred psychedelic agent, number of uses, and harms attributed to psychedelic use. Psychedelic use was associated with significant improvements in depressive and anxious symptoms and with increased emotional well-being. These improvements increased in magnitude with increasing psychedelic exposure, with a ceiling effect. However, improvements were noted following a single lifetime use. Strong evidence for benefit of one preferred psychedelic agent over another was not observed, but enduring increases in factors related to mystical-experience and prosocial perspective taking associated with enhanced mental health. Thirteen percent of the survey sample ( = 330) endorsed at least one harm from psychedelic use, and these participants reported less mental health benefit. Results from the current study add to a growing database indicating that psychedelic use-even outside the context of clinical trials-may provide a wide range of mental health benefits, while also posing some risk for harm in a minority of individuals.", "journal": "Frontiers in psychiatry", "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.3389/fpsyt.2022.831092", "pubmed_id": "35370864", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35370864/", "keywords": "anxiety, ayahuasca, depression, harms, patterns of use, psilocybin, psychedelics, well-being", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35370864\"}", "topic_tags": "Depression,Anxiety,Wellbeing,Emotional Processing,Mystical Experience,Clinical Trial,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1783, "title": "Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.", "normalized_title": "psychedelics and psychotherapy cognitive behavioral approaches as default", "authors": "Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW", "abstract": "The acute subjective effects of psychedelics are responsive to users' expectations and surroundings (i.e., \"set and setting\"). Accordingly, a great deal of thought has gone into designing the psychosocial context of psychedelic administration in clinical settings. But what theoretical paradigms inform these considerations about set and setting? Here, we describe several historical, sociological influences on current psychedelic administration in mainstream European and American clinical research settings, including: indigenous practices, new age spirituality from the 1960s, psychodynamic/psychoanalytic approaches, and cognitive-behavioral approaches. We consider each of these paradigms and determine that cognitive-behavioral therapies, including newer branches such as acceptance and commitment therapy (ACT), have the strongest rationale for psychedelic-assisted psychotherapy going forward. Our primary reasons for advocating for cognitive-behavioral approaches include, (1) they avoid issues of cultural insensitivity, (2) they make minimal speculative assumptions about the nature of the mind and reality, (3) they have the largest base of empirical support for their safety and effectiveness outside of psychedelic therapy. We then propose several concepts from cognitive-behavioral therapies such as CBT, DBT, and ACT that can usefully inform the preparation, session, and integration phases of psychedelic psychotherapy. Overall, while there are many sources from which psychedelic psychotherapy could draw, we argue that current gold-standard, evidence-based psychotherapeutic paradigms provide the best starting point in terms of safety and efficacy.", "journal": "Frontiers in psychology", "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.3389/fpsyg.2022.873279", "pubmed_id": "35677124", "source_url": "https://pubmed.ncbi.nlm.nih.gov/35677124/", "keywords": "LSD, acceptance and commitment therapy (ACT), cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), psilocybin, psychedelic assisted psychotherapy, psychedelic assisted therapy, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"35677124\"}", "topic_tags": "Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1708, "title": "Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.", "normalized_title": "attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the united states", "authors": "Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J", "abstract": "Psychologists are a vital component of mental health treatment and their perceptions of psychedelic-assisted therapy are critical for future implementation. This cross-sectional quasi-experimental electronic survey study explored the attitudes about psychedelics used in treatment among 366 clinical psychologists in the United States. Participants expressed cautiously favorable attitudes toward therapeutic psychedelic experiences but indicated concern about possible psychiatric and neurocognitive risks. Most participants indicated that they lack an understanding of the full range of effects of psychedelics, would need to seek out additional consultation, and endorsed positive beliefs in the potential of psychedelic treatment and the need for further research. Overall, this research identified the need to increase education and training about psychedelics for psychologists in order to help increase knowledge and reduce stigma about psychedelic therapies.", "journal": "Journal of psychoactive drugs", "publication_date": "2021-12-31", "publication_year": 2021, "doi": "10.1080/02791072.2021.1971343", "pubmed_id": "34468293", "source_url": "https://pubmed.ncbi.nlm.nih.gov/34468293/", "keywords": "Psychedelics, hallucinogens, psilocybin, psychologists, survey", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:38", "raw_json": "{\"pubmed_id\":\"34468293\"}", "topic_tags": "Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1871, "title": "Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.", "normalized_title": "palliative care provider attitudes toward existential distress and treatment with psychedelic assisted therapies", "authors": "Niles H, Fogg C, Kelmendi B, Lazenby M", "abstract": "Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Therapies (PAT) are novel treatments that have shown promise in treating existential distress, but openness to providing PAT may be limited by stigma surrounding psychedelics and the paucity of education regarding their medical use. How PAT might be integrated into existing treatments for existential distress within palliative care remains underexplored. The present study aimed to elucidate the attitudes of palliative care clinicians regarding treatments for existential distress, including PAT. We recruited palliative care physicians, advanced practice nurses, and spiritual and psychological care providers from multiple US sites using purposive and snowball sampling methods. Attitudes toward PAT were unknown prior to study involvement. Semi-structured interviews targeted at current approaches to existential distress and attitudes toward PAT were analyzed for thematic content. Nineteen respondents (seven physicians, four advanced practice nurses, four chaplains, three social workers, and one psychologist) were interviewed. Identified themes were 1) Existential distress is a common experience that is frequently insufficiently treated within the current treatment framework; 2) Palliative care providers ultimately see existential distress as a psychosocial-spiritual problem that evades medicalized approaches; 3) Palliative care providers believe PAT hold promise for treating existential distress but that a stronger evidence base is needed; 4) Because PAT do not currently fit existing models of existential distress treatment, barriers remain. PAT is seen as a potentially powerful tool to treat refractory existential distress. Larger clinical trials and educational outreach are needed to clarify treatment targets and address safety concerns. Further work to adapt PAT to palliative care settings should emphasize collaboration with spiritual care as well as mental health providers and seek to address unresolved concerns about equitable access.", "journal": "BMC palliative care", "publication_date": "2021-12-19", "publication_year": 2021, "doi": "10.1186/s12904-021-00889-x", "pubmed_id": "34930220", "source_url": "https://pubmed.ncbi.nlm.nih.gov/34930220/", "keywords": "Demoralization, Existential distress, Psilocybin, Psychedelic-assisted therapy, Spiritual distress", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"34930220\"}", "topic_tags": "End-of-Life Distress,Spirituality,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1817, "title": "Beating pain with psychedelics: Matter over mind?", "normalized_title": "beating pain with psychedelics matter over mind", "authors": "Elman I, Pustilnik A, Borsook D.", "abstract": "Basic pain research has shed light on key cellular and molecular mechanisms underlying nociceptive and phenomenological aspects of pain. Despite these advances, we still yearn for the discovery of novel therapeutic strategies to address the unmet needs of about 70 % of chronic neuropathic pain patients whose pain fails to respond to opioids as well as to other conventional analgesic agents. Importantly, a substantial body of clinical observations over the past decade cumulatively suggests that the psychedelic class of drugs may possess heuristic value for understanding and treating chronic pain conditions. The present review presents a theoretical framework for hitherto insufficiently understood neuroscience-based mechanisms of psychedelics' potential analgesic effects. To that end, searches of PubMed-indexed journals were performed using the following Medical Subject Headings' terms: pain, analgesia, inflammatory, brain connectivity, ketamine, psilocybin, functional imaging, and dendrites. Recursive sets of scientific and clinical evidence extracted from this literature review were summarized within the following key areas: (1) studies employing psychedelics for alleviation of physical and emotional pain; (2) potential neuro-restorative effects of psychedelics to remediate the impaired connectivity underlying the dissociation between pain-related conscious states/cognitions and the subcortical activity/function leading to the eventual chronicity through immediate and long-term effects on dentritic plasticity; (3) anti-neuroinflammatory and pro-immunomodulatory actions of psychedelics as the may pertain to the role of these factors in the pathogenesis of neuropathic pain; (4) safety, legal, and ethical consideration inherent in psychedelics' pharmacotherapy. In addition to direct beneficial effects in terms of reduction of pain and suffering, psychedelics' inclusion in the analgesic armamentarium will contribute to deeper and more sophisticated insights not only into pain syndromes but also into frequently comorbid psychiatric condition associated with emotional pain, e.g., depressive and anxiety disorders. Further inquiry is clearly warranted into the above areas that have potential to evolve into further elucidate the mechanisms of chronic pain and affective disorders, and lead to the development of innovative, safe, and more efficacious neurobiologically-based therapeutic approaches.", "journal": null, "publication_date": "2021-12-15", "publication_year": 2021, "doi": "10.1016/j.neubiorev.2021.12.005", "pubmed_id": "34922987", "source_url": "https://doi.org/10.1016/j.neubiorev.2021.12.005", "keywords": "Humans, Analgesics, Analgesics, Opioid, Hallucinogens, Chronic Pain, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"34922987\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Chronic Pain,Neuroplasticity,Brain Imaging,Mechanism of Action,Consciousness,Aging,Emotional Processing,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1808, "title": "Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.", "normalized_title": "psilocybin assisted psychotherapy for depression emerging research on a psychedelic compound with a rich history", "authors": "Pearson C, Siegel J, Gold JA.", "abstract": "There is a serious need for novel therapies that treat individuals with depression, including major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging body of research has demonstrated that psychedelic drugs such as psilocybin, combined with supportive psychotherapy, exert rapid and sustained antidepressant effects. The use of psychedelics is not new: they have a rich history with evidence of their use in ritual and medical settings. However, due to political, social, and cultural pressures, their use was limited until modern clinical trials began to emerge in the 2010s. This review provides a comprehensive look at the potential use of psilocybin in the treatment of depression and TRD. It includes an overview of the history, pharmacology, and proposed mechanism of psilocybin, and describes several published studies in the last decade which have provided evidence of the efficacy and safety of psilocybin-assisted psychotherapy for individuals with depression. It also includes a discussion of the limitations and barriers of current research on psychedelics. The results of these studies are contextualized within the current treatment landscape through an overview of the pathophysiology of depression and the treatments currently in use, as well as the clinical needs these novel therapies have the promise to fulfill.", "journal": null, "publication_date": "2021-12-15", "publication_year": 2021, "doi": "10.1016/j.jns.2021.120096", "pubmed_id": "34942586", "source_url": "https://doi.org/10.1016/j.jns.2021.120096", "keywords": "Humans, Hallucinogens, Depression, Psychotherapy, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"34942586\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Clinical Trial,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 5037, "title": "P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status", "normalized_title": "p 0421 efficacy and safety of psilocybin in treatment resistant major depression episode study design rationale and current status", "authors": "Lea J. Mertens, Michael Koslowski, Felix Betzler, Ricarda Evens, Maria Gilles, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Max Wolff, Andreas Ströhle, Stefan Wellek, Gerhard Gründer", "abstract": "", "journal": "European Neuropsychopharmacology", "publication_date": "2021-11-30", "publication_year": 2021, "doi": "10.1016/j.euroneuro.2021.10.394", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.euroneuro.2021.10.394", "keywords": "Psilocybin, Psychology, Consciousness, Context (archaeology), Argument (complex analysis), Psychotherapist, Mental health, Developmental psychology, Cognitive psychology, Clinical psychology, Psychiatry, Medicine, Neuroscience, Hallucinogen, Biology, Paleontology, Internal medicine, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:58", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4200326768\",\"openalex_url\":\"https://openalex.org/W4200326768\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2781316183\"],\"authorships\":[{\"id\":\"https://openalex.org/A5070309082\",\"display_name\":\"Lea J. Mertens\",\"orcid\":\"https://orcid.org/0000-0003-4415-3941\"},{\"id\":\"https://openalex.org/A5045306689\",\"display_name\":\"Michael Koslowski\",\"orcid\":\"https://orcid.org/0000-0001-8798-9875\"},{\"id\":\"https://openalex.org/A5031618523\",\"display_name\":\"Felix Betzler\",\"orcid\":\"https://orcid.org/0000-0002-1389-4870\"},{\"id\":\"https://openalex.org/A5054444045\",\"display_name\":\"Ricarda Evens\",\"orcid\":\"https://orcid.org/0000-0002-2834-2171\"},{\"id\":\"https://openalex.org/A5015683895\",\"display_name\":\"Maria Gilles\",\"orcid\":\"https://orcid.org/0000-0002-9604-4459\"},{\"id\":\"https://openalex.org/A5016321877\",\"display_name\":\"Andrea Jungaberle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5001710309\",\"display_name\":\"Henrik Jungaberle\",\"orcid\":\"https://orcid.org/0000-0001-7634-4211\"},{\"id\":\"https://openalex.org/A5065637165\",\"display_name\":\"Tomislav Majić\",\"orcid\":\"https://orcid.org/0000-0003-2950-6673\"},{\"id\":\"https://openalex.org/A5075794355\",\"display_name\":\"Max Wolff\",\"orcid\":\"https://orcid.org/0000-0001-6896-9633\"},{\"id\":\"https://openalex.org/A5066612577\",\"display_name\":\"Andreas Ströhle\",\"orcid\":\"https://orcid.org/0000-0003-0935-3702\"},{\"id\":\"https://openalex.org/A5063934463\",\"display_name\":\"Stefan Wellek\",\"orcid\":\"https://orcid.org/0000-0001-8369-8122\"},{\"id\":\"https://openalex.org/A5081339058\",\"display_name\":\"Gerhard Gründer\",\"orcid\":\"https://orcid.org/0000-0001-7868-3903\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S168041952\",\"source_display_name\":\"European Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1016/j.euroneuro.2021.10.394\",\"is_oa\":false}}", "topic_tags": "Depression,Consciousness,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4200326768" }, { "id": 5034, "title": "P.0623 The clinical relevance of the pharmacokinetics of psilocybin", "normalized_title": "p 0623 the clinical relevance of the pharmacokinetics of psilocybin", "authors": "A. Andreiev, E. Bucuci, James Chue, Charl Els, Pierre Chue", "abstract": "Nicotine dependence is a reversible risk factor of numerous oral cavity diseases. Dentist should be non-smoking and have knowledge on diagnosis and treatment of nicotine addiction.The aim of this survey is the assessment of prevalence of nicotine dependence among Polish dentists, factors associated with this addiction and knowledge on minimal anti-nicotine intervention acquired during pre- and post-graduate training.From October 2013 to March 2014 during 5 dental conferences dental practitioners (881 persons) were given anonymous proprietary questionnaires on nicotine use. 544 questionnaires were qualified for analysis, response rate 61.7%.Group of active nicotine users consisted of 72 persons (13.2% of respondents). The average duration of smoking was 20 years and number of cigarettes smoked daily was 15. Median level of nicotine dependence score 5 and predominance of scores in the range of 4-6 on Fagerström test indicate that most frequent was moderate dependence. As many as 44.4% of dentists in this group had no attempts to quit the addiction. Non-smokers prevailed among women, pedodontists and younger practitioners. Active nicotine users prevailed in dentists above 44 years of age, male, dental surgeons and maxillofacial surgeons. Up to 397 (73%) respondents declared they were never acquainted with the basis for minimal anti-nicotine intervention.The prevalence of nicotine addiction among Polish dentists is lower by 10% compared to the general population, although in relation to current foreign studies its the average level. Main factors associated with active nicotine use in this occupational group include male gender, increasing age and surgical dental specialties. It should be intended to reduce number of nicotine users among Polish dentists by 5%. For this purpose professional anti-nicotine knowledge should be disseminated more.", "journal": "European Neuropsychopharmacology", "publication_date": "2021-11-30", "publication_year": 2021, "doi": "10.1016/j.euroneuro.2021.10.588", "pubmed_id": null, "source_url": "https://doi.org/10.1016/j.euroneuro.2021.10.588", "keywords": "Nicotine, Addiction, Medicine, Nicotine dependence, Intervention (counseling), Population, Smoking cessation, Nicotine Addiction, Statistical significance, Dentistry, Psychiatry, Environmental health, Internal medicine, Pathology, Psychedelics and Drug Studies, Nicotinic Acetylcholine Receptors Study, Biochemical Analysis and Sensing Techniques", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:58", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W4200545220\",\"openalex_url\":\"https://openalex.org/W4200545220\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W2154105276\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2622982732\"],\"authorships\":[{\"id\":\"https://openalex.org/A5011301440\",\"display_name\":\"A. Andreiev\",\"orcid\":null},{\"id\":\"https://openalex.org/A5027930147\",\"display_name\":\"E. Bucuci\",\"orcid\":null},{\"id\":\"https://openalex.org/A5033757501\",\"display_name\":\"James Chue\",\"orcid\":null},{\"id\":\"https://openalex.org/A5003495786\",\"display_name\":\"Charl Els\",\"orcid\":\"https://orcid.org/0000-0002-1177-2984\"},{\"id\":\"https://openalex.org/A5061983678\",\"display_name\":\"Pierre Chue\",\"orcid\":\"https://orcid.org/0000-0002-7916-415X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S168041952\",\"source_display_name\":\"European Neuropsychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1016/j.euroneuro.2021.10.588\",\"is_oa\":true}}", "topic_tags": "Addiction,Pharmacology,Receptor Pharmacology,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W4200545220" }, { "id": 3335, "title": "Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies", "normalized_title": "bibliometric analysis of academic journal articles reporting results of psychedelic clinical studies", "authors": "Weleff J, Akiki TJ, Barnett BS.", "abstract": "ABSTRACT After a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as treatments for mental illness and addiction. The academic journals, journal articles, academic institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelic compounds have only been minimally investigated. Therefore, in we conducted a bibliometric analysis of clinical studies of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), ayahuasca, dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), ibogaine, mescaline, 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin published from 1965-2018. Our search revealed 320 articles published across 106 journals. After a nearly quarter century lull between the 1970s and 1990s, publications in this area have resurged over the last two decades and continue on an upward trajectory, with most clinical studies now focusing on LSD, MDMA, and psilocybin. A subanalysis of the ten most cited articles in psychedelic research prior to 2010 and afterwards demonstrated a shift from research on risks of psychedelics, primarily those of MDMA, to research on therapeutic applications, predominantly those of psilocybin. We also conducted network analyses of inter-country collaborations in psychedelic research, which suggested that psychedelic researchers in the United Kingdom have more diverse international collaborations.", "journal": "medRxiv", "publication_date": "2021-11-23", "publication_year": 2021, "doi": "10.1101/2021.11.22.21266718", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2021.11.22.21266718", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR423856\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1882, "title": "Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors.", "normalized_title": "psilocybin a naturally occurring indoleamine compound could be useful to prevent suicidal behaviors", "authors": "Strumila R, Nobile B, Korsakova L, Lengvenyte A, Olie E, Lopez-Castroman J, Guillaume S, Courtet P.", "abstract": "The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet; however, the current knowledge on the suicidal process and the available data on es/ketamine suggest that psylocibin could be used to modulate the thoughts and behavioral patterns in individuals who are at risk of suicidal behaviors. Here, we summarize the available evidence on the possible mechanisms underlying psilocybin positive effects on suicide risk. Major pathways related to suicidal behaviors that might be modulated by psylocibin include serotonin receptors. Specifically, psylocibin directly stimulates the serotonin 2A receptor (5HT2A), targeting the inflammatory and oxidative stress pathways and leading to a rapid increase in brain plasticity and inflammation suppression and increases in cognitive flexibility, spirituality, and empathy. We also present preliminary epidemiological data and provide a rationale for studying psilocybin in individuals with suicidal ideation or who are at risk of suicidal behaviors. This review presents a framework to understand the basis for psilocybin use in individuals who are at risk of suicidal behaviors and calls for clinical studies.", "journal": null, "publication_date": "2021-11-23", "publication_year": 2021, "doi": "10.3390/ph14121213", "pubmed_id": "34959614", "source_url": "https://doi.org/10.3390/ph14121213", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"34959614\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Oxidative Stress,Spirituality,Review Article,Safety,Inflammation", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1856, "title": "Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.", "normalized_title": "psychedelics for the treatment of depression anxiety and existential distress in patients with a terminal illness a systematic review", "authors": "Schimmers N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA.", "abstract": "BackgroundTerminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option.AimSystematically review studies on psychedelic treatment with and without psychotherapy for existential distress, depression, and anxiety in terminally ill patients.MethodsMedline, PsycINFO, and Embase were searched for original-data studies on the treatment of depression, anxiety, and existential distress with classical or a-typical psychedelics in patients with a terminal illness, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.ResultsA total of 1850 records were screened, and 33 articles were included in this review: 14 studies on classical psychedelics (DPT, LSD, and psilocybin) and 19 studies on atypical psychedelics (MDMA and ketamine). Results of early pre-post studies are promising but have serious methodological flaws. Recent (controlled) trials with LSD, psilocybin, ketamine, and MDMA are of higher methodological quality and indicate positive effects on existential and spiritual well-being, quality of life, acceptance, and reduction of anxiety and depression with few adverse and no serious adverse effects.ConclusionsBoth classical and a-typical psychedelics are promising treatment options in patients with terminal illness. To draw final conclusions on effectiveness and safety of psychedelics, we need larger high-quality studies for classical psychedelics and MDMA. Ketamine studies should pay more attention to existential dimensions of well-being and the psychotherapeutic context of the treatment.", "journal": null, "publication_date": "2021-11-22", "publication_year": 2021, "doi": "10.1007/s00213-021-06027-y", "pubmed_id": "34812901", "source_url": "https://doi.org/10.1007/s00213-021-06027-y", "keywords": "Humans, Hallucinogens, Depression, Anxiety, Quality of Life, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"34812901\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Wellbeing,Spirituality,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3459, "title": "The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder", "normalized_title": "the safety and efficacy of psilocybin in cancer patients with major depressive disorder", "authors": "Maryland Oncology Hematology, PA", "abstract": "This is a Phase II, single-center, fixed dose, open label trial to explore the safety, tolerability and efficacy of a 25mg dose of psilocybin in cancer patients with MDD. The study population will include adult men and women, 18 years of age or above, with MDD, diagnosed with a malignant neoplasm. MDD is defined as those who meet DSM5 diagnostic criteria for a single or recurrent episode of MDD without psychotic features. A diagnosis of a malignant neoplasm is defined as having a diagnostic code from C00 to C97 according to the ICD-10. Recent randomized, placebo-controlled clinical trials of psilocybin therapy for anxiety and depression associated with cancer diagnosis showed significant improvement in study endpoints reflecting psychological distress, as compared to placebo. The effects of a single psilocybin therapy session endured for up to six months with no specific follow-up care. In this study, we aim to explore the safety and efficacy of psilocybin therapy in cancer patients, diagnosed with Major Depressive Disorder (MDD).", "journal": "ClinicalTrials.gov", "publication_date": "2021-10-14", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04593563", "keywords": "Major Depressive Disorder, Psilocybin, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04593563\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Anxiety,Clinical Trial,Cancer Patients,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1899, "title": "Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis.", "normalized_title": "psilocybin for end of life anxiety symptoms a systematic review and meta analysis", "authors": "Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, Hsu CW, Li DJ, Liang CS.", "abstract": "ObjectiveTo systematically examine the effectiveness and tolerability of psilocybin for treating end-of-life anxiety symptoms.MethodsThe Medline, Embase, CENTRAL, and PsycINFO databases were searched up to November 25, 2020. We enrolled clinical trials investigating psilocybin for treating end-of-life anxiety symptoms. Meta-analysis was conducted using random-effects model.ResultsOverall, five studies were included, revealing that psilocybin was superior to the placebo in treating state anxiety at 1 day (Hedges' g, -0.70; 95% confidence interval, -1.01 to -0.39) and 2 weeks (-1.03; -1.47 to -0.60) after treatment. Psilocybin was more effective than placebo in treating trait anxiety at 1 day (-0.71; -1.15 to -0.26), 2 weeks (-1.08; -1.80 to -0.36), and 6 months (-0.84; -1.37 to -0.30) after treatment. Psilocybin was associated with transient elevation in systolic (19.00; 13.58-24.41 mm Hg) and diastolic (8.66; 5.18-12.15 mm Hg) blood pressure compared with placebo. The differences between psilocybin and placebo groups with regard to allcause discontinuation, serious adverse events, and heart rates were nonsignificant.ConclusionPsilocybin-assisted therapy could ameliorate end-of-life anxiety symptoms without serious adverse events. Because of the small sample sizes of the included studies and high heterogeneity on long-term outcomes, future randomized controlled trials with large sample sizes are needed.", "journal": null, "publication_date": "2021-10-07", "publication_year": 2021, "doi": "10.30773/pi.2021.0209", "pubmed_id": "34619818", "source_url": "https://doi.org/10.30773/pi.2021.0209", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"34619818\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Anxiety,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1862, "title": "United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.", "normalized_title": "united states national institutes of health grant funding for psychedelic assisted therapy clinical trials from 2006 2020", "authors": "Barnett BS, Parker SE, Weleff J.", "abstract": "BackgroundMedicine is currently experiencing a \"psychedelic renaissance\", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addictions. While most of this work has been privately funded, governmental biomedical research funding bodies in countries such as Australia, Canada, Israel, New Zealand, and the United Kingdom have begun supporting it. Given that the United States National Institutes of Health (NIH) is the largest public funder of biomedical research in the world, it is important to understand the degree to which the organization is supporting clinical trials of psychedelic-assisted therapies. We are unaware of existing literature quantifying direct NIH grant support for psychedelic-assisted therapy clinical trials, so we sought to answer this important question by searching all NIH grants awarded since the beginning of the psychedelic renaissance.MethodsWe queried NIH RePORTER, NIH's grant database, for grants awarded from 2006-2020 mentioning the psychedelics 3,4-Methylenedioxymethamphetamine (MDMA), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ayahuasca, dimethyltryptamine (DMT), ibogaine, lysergic acid (LSD), mescaline, peyote, and psilocybin. We manually reviewed resulting grants to determine whether they directly funded psychedelic-assisted therapy clinical trials.ResultsWe identified zero NIH grants directly funding psychedelic-assisted therapy clinical trials during the study period.ConclusionWhile governmental biomedical research funding bodies in other countries have begun funding clinical trials of psychedelic-assisted therapies during the psychedelic renaissance, NIH has yet to directly fund a single psychedelic-assisted therapy clinical trial. Concerns about risks related to psychedelics, a federal law preventing promotion of legalization of Schedule 1 drugs, and prioritization of grants for other types of studies on psychedelics may explain the dearth of NIH funding for psychedelic-assisted therapy clinical trials.", "journal": null, "publication_date": "2021-10-05", "publication_year": 2021, "doi": "10.1016/j.drugpo.2021.103473", "pubmed_id": "34624734", "source_url": "https://doi.org/10.1016/j.drugpo.2021.103473", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, National Institutes of Health (U.S.), United States, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"34624734\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3203419443" }, { "id": 1573, "title": "Novel antidepressant drugs: Beyond monoamine targets.", "normalized_title": "novel antidepressant drugs beyond monoamine targets", "authors": "Gonda X, Dome P, Neill JC, Tarazi FI.", "abstract": "Treatment of major depressive disorder (MDD) including treatment-resistant depression (TRD) remains a major unmet need. Although there are several classes of dissimilar antidepressant drugs approved for MDD, the current drugs have either limited efficacy or are associated with undesirable side effects and withdrawal symptoms. The efficacy and side effects of antidepressant drugs are mainly attributed to their actions on different monoamine neurotransmitters (serotonin, norepinephrine, and dopamine). Development of new antidepressants with novel targets beyond the monoamine pathways may fill the unmet need in treatment of MDD and TRD. The recent approval of intranasal Esketamine (glutamatergic agent) in conjunction with an oral antidepressant for the treatment of adult TRD patients was the first step toward expanding beyond the monoamine targets. Several other glutamatergic (AXS-05, REL-1017, AV-101, SLS-002, AGN24175, and PCN-101) and GABAergic (brexanolone, zuranolone, and ganaxolone) drugs are currently in different stages of clinical development for MDD, TRD and other indications. The renaissance of psychedelic drugs and the emergence of preliminary positive clinical trial results with psilocybin, Ayahuasca, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and lysergic acid diethylamide (LSD) may pave the way towards establishing this class of drugs as effective therapies for MDD, TRD and other neuropsychiatric disorders. Going beyond the monoamine targets appears to be an effective strategy to develop novel antidepressant drugs with superior efficacy, safety, and tolerability for the improved treatment of MDD and TRD.", "journal": null, "publication_date": "2021-09-29", "publication_year": 2021, "doi": "10.1017/s1092852921000791", "pubmed_id": "34588093", "source_url": "https://doi.org/10.1017/s1092852921000791", "keywords": "Humans, Norepinephrine, Serotonin, Antidepressive Agents, Adult, Depressive Disorder, Treatment-Resistant, Drug-Related Side Effects and Adverse Reactions, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"34588093\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1904, "title": "Rediscovering Psilocybin as an Antidepressive Treatment Strategy.", "normalized_title": "rediscovering psilocybin as an antidepressive treatment strategy", "authors": "Zeiss R, Gahr M, Graf H.", "abstract": "There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we provide an overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects, to provide an update on a controversial topic discussed in psychopharmacology. A database search was conducted in Medline including articles on psilocybin over the period of the last 20 years. Despite the promising progress in understanding the mechanisms of psilocybin, the exact antidepressive mechanism and the role of the psychedelic experience remain elusive. The studies included in this review found high treatment effect sizes for psilocybin as an antidepressant. However, the results must be regarded as preliminary due to several limitations. Although the current studies observed no severe adverse events, several questions regarding safety and utility remain and must be subject of future research.", "journal": null, "publication_date": "2021-09-27", "publication_year": 2021, "doi": "10.3390/ph14100985", "pubmed_id": "34681209", "source_url": "https://doi.org/10.3390/ph14100985", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"34681209\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Mechanism of Action,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1910, "title": "Treatment-Resistant Depression: Approaches to Treatment.", "normalized_title": "treatment resistant depression approaches to treatment", "authors": "Kverno KS, Mangano E.", "abstract": "Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant depression (TRD). Because the odds of remission decrease with every subsequent medication trial, it is important for clinicians to understand the characteristics and risk factors for TRD, subtypes of major depressive disorder that are more likely to be less responsive to first-line anti-depressants, and the available treatment options. In the current article, we review the approved treatments for TRD, including esketamine, and the evidence for psilocybin and pramipexole. Although limited in specificity, guidelines to help prescribers identify person-centered treatments for TRD are available. [Journal of Psychosocial Nursing and Mental Health Services, 59(9), 7-11.].", "journal": null, "publication_date": "2021-08-31", "publication_year": 2021, "doi": "10.3928/02793695-20210816-01", "pubmed_id": "34459676", "source_url": "https://doi.org/10.3928/02793695-20210816-01", "keywords": "Humans, Antidepressive Agents, Drug Therapy, Combination, Depression, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"34459676\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Review Article,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3395, "title": "Therapeutic interventions for PTSD - current evidence on the the role of psychedelics", "normalized_title": "therapeutic interventions for ptsd current evidence on the the role of psychedelics", "authors": "Figueiredo I, Viegas F, Ferreira F, Santos A, Ramos J, Miranda J.", "abstract": "Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical comorbidity are observed among patients who have undergone treatment. The psychoactive properties of psychedelics may be of particular interest within a substance-assisted psychotherapy approach, offering new treatment opportunities for this debilitating disorder. Objectives Review current evidence, therapeutic context, and possible mechanisms of action of different types of psychedelics in the treatment of PTSD. Methods Literature review using Medline database. Results 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy appears to be a potentially safe, effective, and durable treatment for individuals with treatment-refractory PTSD. Based on a small number of studies, ketamine administration appears to result in temporary symptom relief and may, in combination with psychotherapy, lead to lasting reductions in PTSD symptoms. Although these have not yet been investigated in controlled studies, it is known that psilocybin and LSD induce psychoactive effects that could as well contribute to the psychotherapeutic treatment of PTSD. Conclusions The use of psychedelic compounds within a substance-assisted psychotherapy framework offers a novel method for pharmacotherapy-psychotherapy integration, although there is still much to learn from both a clinical and neurobiological perspective. It is necessary to generate more data regarding the safety and efficacy of psychedelics, in addition to research on cost-effectiveness, its use in mental health care infrastructure and also regarding the training of specialized therapists.", "journal": null, "publication_date": "2021-08-12", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC9475922", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"PMC9475922\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Mechanism of Action,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3346, "title": "Treating addiction with psychedelics - are we waking up?", "normalized_title": "treating addiction with psychedelics are we waking up", "authors": "Miranda J, Barbosa M, Figueiredo I, Mota P, Tarelho A.", "abstract": "Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both cancer-related distress and addiction, with really promising results. Objectives We aim to provide a review about history and new insights regarding research with psychedelics specially as treatment of addictive disorders. Methods A framing analysis of articles, searched on Pubmed (articles between 2010-2020) with the key words: “ psychedelics”, “psilocybin”, “substance use disorder”, “addiction”. Results Classic psychedelics are 5HT2AR agonists such as LSD, mescaline, and psilocybin. They were shown to occasion mystical experiences, which are experiences reported throughout different cultures and religions involving a strong sense of unity. These experiences are scientifically important because they appear to cause abrupt and sustained changes in behavior and perception, that can be very useful in the substance use disorder field. From this analysis is possible to understand that the use of psychadelics in the treatment of some addictions is currently at an early stage of research. However, they show interesting results with no clinically significant adverse events when risk individuals are excluded. Conclusions In comparison to psychedelic research about cancer-related psychological distress, studies with addictions are less developed, but if they continue to suggest safety and efficacy, may be the use of psilocybin for the treatment of specific addiction can happen in a close future.", "journal": null, "publication_date": "2021-08-12", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC9480123", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PMC9480123\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Receptor Pharmacology,Mystical Experience,Review Article,Cancer Patients,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1877, "title": "Use of hallucinogens in Slovakia: Does it differ from global trends?", "normalized_title": "use of hallucinogens in slovakia does it differ from global trends", "authors": "Lukačovič M, Masaryk R.", "abstract": "BackgroundPeople have been using hallucinogens for thousands of years and interest in these substances has grown in recent years. The aim of this study was to determine the basic socio-demographic data, preferences, experiences, and attitudes associated with hallucinogen use in Slovakia.MethodsA cross-sectional research design was used whereby an online survey included participants who had had at least one experience with hallucinogens (N = 422, age M = 27.78; SD = 7.84; SE = 0.38; 35.1% females). Due to the illegal, intimate, and minority nature of the phenomena studied, data was collected using the snowball sampling method via an online social network in groups that declared a drug focus.ResultsUsers of hallucinogens were mostly employed (61,8%) and in some form of partnership (57,6%); they usually have a high school diploma (46,68%) or a university degree (45,41%). They most often use psilocybin mushrooms, while the age of initial use (M = 19,61; SD = 5,39) as well as lifetime frequency use (M = 18,26; SD = 24,21; Median = 10) are similar to global trends. Free use without rituals was preferred to ceremonial use. In general, our sample of hallucinogen users considered the integration of psychedelic experiences to be simple rather than challenging. Concurrently, they tended to see hallucinogens as useful to humans, but realised that they are not without risk and can be somewhat dangerous. Males used hallucinogens for the first time at a younger age (p", "journal": null, "publication_date": "2021-08-04", "publication_year": 2021, "doi": "10.1016/j.drugpo.2021.103385", "pubmed_id": "34364200", "source_url": "https://doi.org/10.1016/j.drugpo.2021.103385", "keywords": "Humans, Hallucinogens, Cross-Sectional Studies, Slovakia, Female, Male, Surveys and Questionnaires, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"34364200\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3193012633" }, { "id": 1911, "title": "Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.", "normalized_title": "classic psychedelic coadministration with lithium but not lamotrigine is associated with seizures an analysis of online psychedelic experience reports", "authors": "Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR.", "abstract": "IntroductionPsychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psychedelic trials. There is limited information on the use of classic psychedelics (e. g., LSD or psilocybin) in individuals using mood stabilizers to treat bipolar disorder. This is important to know, as individuals with bipolar depression may attempt to treat themselves with psychedelics while on a mood stabilizer, particularly given enthusiastic media reports of the efficacy of psilocybin for depression.MethodsThis study analyzed reports of classic psychedelics administered with mood stabilizers from 3 websites (Erowid.org, Shroomery.org, and Reddit.com).ResultsStrikingly, 47% of 62 lithium plus psychedelic reports involved seizures, and an additional 18% resulted in bad trips while none of 34 lamotrigine reports did. Further, 39% of lithium reports involved medical attention. Most of the lamotrigine reports (65%) but few (8%) of the lithium reports were judged to not affect the psychedelic experience.DiscussionAlthough further research is needed, we provisionally conclude that psychedelic use may pose a significant seizure risk for patients on lithium.", "journal": "Pharmacopsychiatry", "publication_date": "2021-08-03", "publication_year": 2021, "doi": "10.1055/a-1524-2794", "pubmed_id": "34348413", "source_url": "https://doi.org/10.1055/a-1524-2794", "keywords": "Humans, Seizures, Lithium, Hallucinogens, Psilocybin, Lamotrigine", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34348413\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3160183306\",\"openalex_url\":\"https://openalex.org/W3160183306\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":67,\"referenced_works\":[\"https://openalex.org/W88552725\",\"https://openalex.org/W1498647569\",\"https://openalex.org/W1982691685\",\"https://openalex.org/W1988862462\",\"https://openalex.org/W1991938716\",\"https://openalex.org/W2002554882\",\"https://openalex.org/W2003490971\",\"https://openalex.org/W2008038652\",\"https://openalex.org/W2037449495\",\"https://openalex.org/W2053872398\",\"https://openalex.org/W2058799830\",\"https://openalex.org/W2066154390\",\"https://openalex.org/W2074483296\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2078629064\",\"https://openalex.org/W2084459551\",\"https://openalex.org/W2085742802\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2099017168\",\"https://openalex.org/W2108722273\",\"https://openalex.org/W2111020576\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2134236426\",\"https://openalex.org/W2138401704\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2161810494\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2442863506\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2886249511\",\"https://openalex.org/W2953498115\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3105240299\",\"https://openalex.org/W4211013640\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W6603534976\"],\"authorships\":[{\"id\":\"https://openalex.org/A5040929530\",\"display_name\":\"Sandeep M. Nayak\",\"orcid\":\"https://orcid.org/0000-0002-6832-0639\"},{\"id\":\"https://openalex.org/A5048292874\",\"display_name\":\"Natalie Gukasyan\",\"orcid\":\"https://orcid.org/0000-0003-3567-1421\"},{\"id\":\"https://openalex.org/A5005540871\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":\"https://orcid.org/0000-0001-7443-3237\"},{\"id\":\"https://openalex.org/A5072823665\",\"display_name\":\"Earth Erowid\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071578213\",\"display_name\":\"Fire Erowid\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4122505\",\"source_display_name\":\"Pharmacopsychiatry\",\"landing_page_url\":\"https://doi.org/10.1055/a-1524-2794\",\"is_oa\":true}}}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3160183306" }, { "id": 2137, "title": "Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without.", "normalized_title": "migraine prevalence in visual snow with prior illicit drug use hallucinogen persisting perception disorder versus without", "authors": "van Dongen RM, Alderliefste GJ, Onderwater GLJ, Ferrari MD, Terwindt GM", "abstract": "This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS). Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25-item questionnaire. None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p", "journal": "European journal of neurology", "publication_date": "2021-07-31", "publication_year": 2021, "doi": "10.1111/ene.14914", "pubmed_id": "33979006", "source_url": "https://pubmed.ncbi.nlm.nih.gov/33979006/", "keywords": "ecstasy, hallucinogen persisting perception disorder, illicit drugs, migraine, visual snow", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"pubmed_id\":\"33979006\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3160485194\",\"openalex_url\":\"https://openalex.org/W3160485194\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":31,\"referenced_works\":[\"https://openalex.org/W1884253425\",\"https://openalex.org/W2000083255\",\"https://openalex.org/W2002178209\",\"https://openalex.org/W2004265859\",\"https://openalex.org/W2008071452\",\"https://openalex.org/W2012322843\",\"https://openalex.org/W2033849968\",\"https://openalex.org/W2036036397\",\"https://openalex.org/W2040537810\",\"https://openalex.org/W2050498247\",\"https://openalex.org/W2060895955\",\"https://openalex.org/W2123941455\",\"https://openalex.org/W2142961788\",\"https://openalex.org/W2155783963\",\"https://openalex.org/W2156895313\",\"https://openalex.org/W2204642832\",\"https://openalex.org/W2237439087\",\"https://openalex.org/W2552761136\",\"https://openalex.org/W2592608653\",\"https://openalex.org/W2790481213\",\"https://openalex.org/W2801085490\",\"https://openalex.org/W2911408453\",\"https://openalex.org/W2922093521\",\"https://openalex.org/W2949831435\",\"https://openalex.org/W2999447544\",\"https://openalex.org/W3004274906\",\"https://openalex.org/W3010805773\",\"https://openalex.org/W3013771391\",\"https://openalex.org/W3032569012\",\"https://openalex.org/W3046989084\",\"https://openalex.org/W4247665917\"],\"authorships\":[{\"id\":\"https://openalex.org/A5036086957\",\"display_name\":\"Robin M. van Dongen\",\"orcid\":\"https://orcid.org/0000-0002-7946-0485\"},{\"id\":\"https://openalex.org/A5109063674\",\"display_name\":\"Gerard J. Alderliefste\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056286322\",\"display_name\":\"Gerrit L.J. Onderwater\",\"orcid\":\"https://orcid.org/0000-0003-0958-4754\"},{\"id\":\"https://openalex.org/A5039941295\",\"display_name\":\"Michel D. Ferrari\",\"orcid\":\"https://orcid.org/0000-0001-9691-9449\"},{\"id\":\"https://openalex.org/A5054269152\",\"display_name\":\"Gisela M. Terwindt\",\"orcid\":\"https://orcid.org/0000-0003-3140-6882\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S162635963\",\"source_display_name\":\"European Journal of Neurology\",\"landing_page_url\":\"https://doi.org/10.1111/ene.14914\",\"is_oa\":true}}}", "topic_tags": "Headache / Migraine,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3160485194" }, { "id": 2139, "title": "The Potential Role of Serotonergic Hallucinogens in Depression Treatment.", "normalized_title": "the potential role of serotonergic hallucinogens in depression treatment", "authors": "Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M.", "abstract": "Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic substances for the treatment of depression. A literature search of the PubMed/MEDLINE database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, MDMA, DMT, or LSD for the treatment of depression symptoms. Some psychedelics, especially psilocybin, demonstrated an ability to reduce depressive symptoms as measured by several psychological scales, which was often sustained for months after the last psychedelic session. Moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. None of the studies reported any serious adverse events associated with psychedelic administration. The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.", "journal": null, "publication_date": "2021-07-28", "publication_year": 2021, "doi": "10.3390/life11080765", "pubmed_id": "34440508", "source_url": "https://doi.org/10.3390/life11080765", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"34440508\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3481, "title": "A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study", "normalized_title": "a randomised placebo controlled trial of psilocybin in treatment resistant depression a feasibility study", "authors": "King's College London", "abstract": "A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive disorder. The primary objective is to evaluate feasibility by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (MADRS).", "journal": "ClinicalTrials.gov", "publication_date": "2021-07-21", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT04959253", "keywords": "Treatment Resistant Depression, Psilocybin assisted therapy, Placebo assisted therapy, UNKNOWN", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT04959253\",\"overall_status\":\"UNKNOWN\",\"phase\":[\"PHASE2\"]}", "topic_tags": "Depression,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 1865, "title": "Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions.", "normalized_title": "exploring the use of psilocybin therapy for existential distress a qualitative study of palliative care provider perceptions", "authors": "Mayer CE, LeBaron VT, Acquaviva KD.", "abstract": "There is a growing body of research suggesting that palliative care patients coping with existential distress may benefit from psilocybin. However, there is a large gap regarding the perceptions of palliative care providers who may provide education, counseling services, recommendations, and/or prescriptions for psilocybin if it is decriminalized, commercialized, and/or federally rescheduled and legalized. The aim of this study was to explore the experiences and perceptions of interdisciplinary palliative care providers regarding existential distress and the use of psilocybin therapy. Five (n = 5) health care providers from a hospital-based palliative care team completed a semi-structured interview related to their experiences supporting patients with existential distress and their beliefs and attitudes related to psilocybin as a possible treatment modality. A qualitative descriptive approach was used to identify key themes which included: 1) multiple barriers to addressing existential distress at the cultural, institutional/organizational, relational, and individual levels, 2) the duality and power of presence, 3) suffering as an intrinsically subjective phenomenon, and 4) uncertainty about the risks and benefits of psilocybin. To inform an inclusive, safe, and holistic approach, more research is needed regarding the possible integration of psilocybin therapy within palliative care for the treatment of existential distress.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2021-07-15", "publication_year": 2021, "doi": "10.1080/02791072.2021.1916659", "pubmed_id": "34266372", "source_url": "https://doi.org/10.1080/02791072.2021.1916659", "keywords": "Humans, Palliative Care, Adaptation, Psychological, Existentialism, Qualitative Research, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34266372\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3178288974\",\"openalex_url\":\"https://openalex.org/W3178288974\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":17,\"referenced_works\":[\"https://openalex.org/W1597730573\",\"https://openalex.org/W1857921554\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2037317432\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119576793\",\"https://openalex.org/W2158089900\",\"https://openalex.org/W2159165123\",\"https://openalex.org/W2324833364\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2792111609\",\"https://openalex.org/W2794634193\",\"https://openalex.org/W2804532410\",\"https://openalex.org/W2809850625\",\"https://openalex.org/W2886232664\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2890770862\",\"https://openalex.org/W2894431596\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W2919995896\",\"https://openalex.org/W2938570586\",\"https://openalex.org/W2945506353\",\"https://openalex.org/W2963934185\",\"https://openalex.org/W2965468106\",\"https://openalex.org/W2973627003\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3012354707\",\"https://openalex.org/W3015163151\",\"https://openalex.org/W3036009606\",\"https://openalex.org/W3086689250\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3108632668\",\"https://openalex.org/W3112172827\",\"https://openalex.org/W3112860136\",\"https://openalex.org/W4253929641\",\"https://openalex.org/W4299699686\"],\"authorships\":[{\"id\":\"https://openalex.org/A5026930534\",\"display_name\":\"Coryn E. Mayer\",\"orcid\":\"https://orcid.org/0000-0001-5860-1528\"},{\"id\":\"https://openalex.org/A5012289666\",\"display_name\":\"Virginia LeBaron\",\"orcid\":\"https://orcid.org/0000-0002-1299-4730\"},{\"id\":\"https://openalex.org/A5037963462\",\"display_name\":\"Kimberly Acquaviva\",\"orcid\":\"https://orcid.org/0000-0003-2906-7762\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2021.1916659\",\"is_oa\":false}}}", "topic_tags": "End-of-Life Distress,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3178288974" }, { "id": 3786, "title": "Psychedelic Assisted Therapy for Major Depressive Disorder: A Review", "normalized_title": "psychedelic assisted therapy for major depressive disorder a review", "authors": "McCartney A, McGovern H, De Foe A.", "abstract": "Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this literature from a broader biopsychosocial perspective. Examining these arguably neglected social and psychological aspects of psychedelic treatment can provide a more holistic understanding of the interplay between the interconnected domains. This review of six major clinical trials applies a biopsychosocial model to evaluate the antidepressant effects of psilocybin and ketamine assisted therapy. We conclude that combination psychedelic treatment and psychotherapy facilitate more enduring and profound antidepressant effects than produced by ketamine or psilocybin alone. Emphasising the advantages of therapeutic intervention will encourage those who may attempt to self-medicate with psychedelics to instead seek a framework of psychological support, minimising associated risks of unregulated use.", "journal": "PsyArXiv", "publication_date": "2021-06-26", "publication_year": 2021, "doi": "10.31234/osf.io/9kuhs", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/9kuhs", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:22", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR363034\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3336, "title": "Psychedelic Assisted Therapy for Major Depressive Disorder: A Review", "normalized_title": "psychedelic assisted therapy for major depressive disorder a review", "authors": "", "abstract": "Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this literature from a broader biopsychosocial perspective. Examining these arguably neglected social and psychological aspects of psychedelic treatment can provide a more holistic understanding of the interplay between the interconnected domains. This review of six major clinical trials applies a biopsychosocial model to evaluate the antidepressant effects of psilocybin and ketamine assisted therapy. We conclude that combination psychedelic treatment and psychotherapy facilitate more enduring and profound antidepressant effects than produced by ketamine or psilocybin alone. Emphasising the advantages of therapeutic intervention will encourage those who may attempt to self-medicate with psychedelics to instead seek a framework of psychological support, minimising associated risks of unregulated use.", "journal": "PsyArXiv", "publication_date": "2021-06-26", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/9kuhs_v1", "keywords": "depression, ketamine, major depressive disorder, psilocybin, psychedelics, psychotherapy, Psychiatry, Social and Behavioral Sciences, Clinical Psychology, Intervention Research, Mental Disorders, Depressive Disorders, Therapy, Psychotherapy, Psychopharmacology", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"9kuhs_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Pharmacology,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 5080, "title": "Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa", "normalized_title": "psilocybin as a novel pharmacotherapy for treatment refractory anorexia nervosa", "authors": "Sarah-Catherine Rodan, Phillip Aouad, Iain S. McGregor, Sarah Maguire", "abstract": "Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity and mortality. There is an urgent need to find new interventions, especially as there are no approved pharmacological treatments for AN. Ideally, new treatments would target treatment-resistance and to decrease the chronicity associated with the disorder. Over the past two decades, emerging research into classic psychedelic substances (lysergic diethylamide acid (LSD), 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), N,N-Dimethyltryptamine (DMT) and psilocybin), indicates that marked reductions in anxiety and depression-like symptoms, and lasting improvement in mental health, can follow from one or two exposures to these psychedelic substances. Anxiety and depression are the most prevalent co-morbid psychiatric symptoms in AN. Here we suggest that classic psychedelics, particularly psilocybin, have the potential to normalise dysfunctional neurobiological systems in AN and provide a novel treatment intervention that is worthy of consideration, particularly for treatment-resistant patients.", "journal": "OBM Neurobiology", "publication_date": "2021-06-23", "publication_year": 2021, "doi": "10.21926/obm.neurobiol.2102102", "pubmed_id": null, "source_url": "https://doi.org/10.21926/obm.neurobiol.2102102", "keywords": "Psilocybin, Anorexia nervosa, Psychiatry, Anxiety, Depression (economics), Hallucinogen, Pharmacotherapy, Psychology, Treatment-resistant depression, Psychological intervention, Medicine, Eating disorders, Antidepressant, Macroeconomics, Economics, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:59", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3174884462\",\"openalex_url\":\"https://openalex.org/W3174884462\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W22529605\",\"https://openalex.org/W48152404\",\"https://openalex.org/W98713090\",\"https://openalex.org/W122113993\",\"https://openalex.org/W122691953\",\"https://openalex.org/W164629299\",\"https://openalex.org/W185824688\",\"https://openalex.org/W191267285\",\"https://openalex.org/W1037524820\",\"https://openalex.org/W1191653087\",\"https://openalex.org/W1539080424\",\"https://openalex.org/W1548863913\",\"https://openalex.org/W1783354124\",\"https://openalex.org/W1853120840\",\"https://openalex.org/W1857921554\",\"https://openalex.org/W1966542875\",\"https://openalex.org/W1968488639\",\"https://openalex.org/W1971529993\",\"https://openalex.org/W1972599083\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1973938481\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1974221081\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1986376495\",\"https://openalex.org/W1986767459\",\"https://openalex.org/W1991514583\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2001060580\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006740326\",\"https://openalex.org/W2009595390\",\"https://openalex.org/W2014622858\",\"https://openalex.org/W2015198647\",\"https://openalex.org/W2015883068\",\"https://openalex.org/W2019839644\",\"https://openalex.org/W2020775448\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2025861780\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2027535421\",\"https://openalex.org/W2030842831\",\"https://openalex.org/W2033464619\",\"https://openalex.org/W2036016939\",\"https://openalex.org/W2036076263\",\"https://openalex.org/W2036178921\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2044918967\",\"https://openalex.org/W2046435790\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2053750947\",\"https://openalex.org/W2053787369\",\"https://openalex.org/W2054806410\",\"https://openalex.org/W2065999665\",\"https://openalex.org/W2068699426\",\"https://openalex.org/W2069122038\",\"https://openalex.org/W2070290797\",\"https://openalex.org/W2070294663\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2076679144\",\"https://openalex.org/W2081886926\",\"https://openalex.org/W2086057658\",\"https://openalex.org/W2089680945\",\"https://openalex.org/W2092011726\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2093668364\",\"https://openalex.org/W2093980670\",\"https://openalex.org/W2097773758\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2100182643\",\"https://openalex.org/W2103951395\",\"https://openalex.org/W2105942623\",\"https://openalex.org/W2107028296\",\"https://openalex.org/W2107557962\",\"https://openalex.org/W2107888245\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2109814284\",\"https://openalex.org/W2113665645\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2124969939\",\"https://openalex.org/W2126175461\",\"https://openalex.org/W2128692360\",\"https://openalex.org/W2133548434\",\"https://openalex.org/W2133783100\",\"https://openalex.org/W2134770472\",\"https://openalex.org/W2137198040\",\"https://openalex.org/W2139905864\",\"https://openalex.org/W2150738348\",\"https://openalex.org/W2151168431\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2159354415\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2162636537\",\"https://openalex.org/W2168303875\",\"https://openalex.org/W2170596036\",\"https://openalex.org/W2171282210\",\"https://openalex.org/W2266543467\",\"https://openalex.org/W2276613946\",\"https://openalex.org/W2317790977\",\"https://openalex.org/W2329328307\",\"https://openalex.org/W2330988369\",\"https://openalex.org/W2340013527\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2412769982\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2537388000\",\"https://openalex.org/W2549067465\",\"https://openalex.org/W2550530158\",\"https://openalex.org/W2554715860\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2561419573\",\"https://openalex.org/W2564469912\",\"https://openalex.org/W2567295262\",\"https://openalex.org/W2580771571\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2603695154\",\"https://openalex.org/W2619816586\",\"https://openalex.org/W2624901555\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2695471189\",\"https://openalex.org/W2725596576\",\"https://openalex.org/W2746634570\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2757390367\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2763580176\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2783764167\",\"https://openalex.org/W2790698047\",\"https://openalex.org/W2790867612\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2800623007\",\"https://openalex.org/W2802902398\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2810374266\",\"https://openalex.org/W2810710828\",\"https://openalex.org/W2810742944\",\"https://openalex.org/W2831064708\",\"https://openalex.org/W2895986834\",\"https://openalex.org/W2901877120\",\"https://openalex.org/W2904557043\",\"https://openalex.org/W2910298407\",\"https://openalex.org/W2913034299\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2917218353\",\"https://openalex.org/W2919995896\",\"https://openalex.org/W2926665170\",\"https://openalex.org/W2940909888\",\"https://openalex.org/W2946770223\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2960372990\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2963936193\",\"https://openalex.org/W2981695213\",\"https://openalex.org/W2981860490\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W2990240756\",\"https://openalex.org/W2996321268\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3002940062\",\"https://openalex.org/W3005218696\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3021678070\",\"https://openalex.org/W3027990543\",\"https://openalex.org/W3037765301\",\"https://openalex.org/W3041518543\",\"https://openalex.org/W3047621140\",\"https://openalex.org/W3047886920\",\"https://openalex.org/W3080226154\",\"https://openalex.org/W3084164707\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3086773311\",\"https://openalex.org/W3092027192\",\"https://openalex.org/W3098725980\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3156649421\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4247665917\"],\"authorships\":[{\"id\":\"https://openalex.org/A5079341055\",\"display_name\":\"Sarah-Catherine Rodan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5025297705\",\"display_name\":\"Phillip Aouad\",\"orcid\":\"https://orcid.org/0000-0003-0999-7495\"},{\"id\":\"https://openalex.org/A5052009573\",\"display_name\":\"Iain S. McGregor\",\"orcid\":\"https://orcid.org/0000-0002-9307-7159\"},{\"id\":\"https://openalex.org/A5020195820\",\"display_name\":\"Sarah Maguire\",\"orcid\":\"https://orcid.org/0000-0003-0754-9189\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210221663\",\"source_display_name\":\"OBM Neurobiology\",\"landing_page_url\":\"https://doi.org/10.21926/obm.neurobiol.2102102\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Eating Disorders,Receptor Pharmacology,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3174884462" }, { "id": 3208, "title": "Psilocybin: the magic medicine for depression?", "normalized_title": "psilocybin the magic medicine for depression", "authors": "Corrigan A, Burchill E, Pelton L, Marrocu A, Mazzoleni A, Shackshaft L.", "abstract": "Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to evaluate the future feasibility and implications of psilocybin as a new antidepressant therapy. Method We reviewed and critically analysed the available literature on the efficacy and safety of psilocybin as a treatment for depression, and the potential pharmacological and psychological mechanisms of the therapeutic benefit. We discussed the relative contributions to this therapeutic effect of the pharmacological drug treatment, placebo effects, and the context and parameters of the psychotherapeutic experience. We reviewed legal, social, and economic barriers to primary research and clinical implementation. Result Psilocybin in combination with psychotherapy has been shown to be safe and effective in TRD. Its mechanism of action in TRD has not been fully elucidated, however reviewing functional neuroimaging studies demonstrated disparate short and long-term modifications of default mode network connectivity, suggested to represent a ‘reset’ mechanism of acute modular disintegration and subsequent reintegration which restores normal function, reviving emotional responsiveness. Research suggests psychedelic treatment induces lasting personality, belief and attitude changes. The psychedelic drug itself, the context of the psychotherapeutic experience, and the post-drug integration therapy all appear to have a significant role. Preparation prior to treatment, the environment, context and support during the psychedelic experience itself, and the following long-term integration and support process must be considered. Despite novel findings Psilocybin is a Schedule I drug; this imposes a persisting ethical barrier to clinical use. Prohibition of psilocybin results in high costs of drug supply, and potential for harmful drug-seeking behaviours. Therefore, complex socio-political factors currently limit wider implementation. Conclusion Psilocybin in combination with psychotherapy is safe and effective in TRD. The interacting and elusive therapeutic mechanisms have implications for clinical implementation. Preparation prior to treatment, the physical and social environment in which the psychedelic experience takes place, and long-term integration and support are considered to play a significant role. Optimisation of these parameters and cost-benefit analyses are required prior to this being feasible as a widely available therapy. Systemic legislative, political and social change will also be key to enable widespread clinical use. The promise of this therapy on a background of inadequate current antidepressant treatments indicates these must be a priority.", "journal": null, "publication_date": "2021-06-17", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://europepmc.org/article/PMC/PMC8770735", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:48", "last_checked": "2026-07-01 11:22:02", "raw_json": "{\"europe_pmc_id\":\"PMC8770735\",\"source\":\"PMC\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Brain Imaging,Mechanism of Action,Default Mode Network,Aging,Personality Change,Emotional Processing,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 5085, "title": "Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis", "normalized_title": "participant reports of mindfulness posttraumatic growth and social connectedness in psilocybin assisted group therapy an interpretive phenomenological analysis", "authors": "Gabrielle Agin-Liebes, Eve Ekman, B. Anderson, Maxx Malloy, Alexandra Haas, Josh Woolley", "abstract": "The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group therapy. This interpretive phenomenological analysis focused on an enriched study sample of gay-identified cisgender men ( n = 9) with human immunodeficiency virus diagnosed before 1996 and clinically significant trauma symptoms. Microphenomenological interviews were carried out 1 day after participants’ individual psilocybin sessions to elicit fine-grained descriptions of the psilocybin-assisted treatment. Two major thematic change processes were identified using Interpretive Phenomenological Analysis. During their psilocybin sessions, participants reported transitioning out of habitual, evaluative modes of processing and into mindful, experiential modes of processing (from “autopilot” to “meta-aware”). Freed from their emotionally avoidant tendencies, participants were able to process and release previously disowned feelings (grief, shame) and access relational and self-transcendent feelings and prosocial attitudes (joy, gratitude, love, care, compassion). The treatment also supported processes of meaning-making and the realization of posttraumatic growth (in psychological, relational, spiritual dimensions) as participants integrated past traumas into their life narratives and identities (from “trauma-dominant” to “growth-dominant”). These findings suggest that administering adjunctive group therapy with psilocybin may enhance the effectiveness of trauma processing by reinforcing social cohesion, safety, trust, and belonging. These data provide the first empirical suggestion of psilocybin’s efficacy in alleviating trauma symptoms in a group-facilitated format and provide a deeper understanding of the potential psychological change processes involved in this novel treatment approach.", "journal": "Journal of Humanistic Psychology", "publication_date": "2021-06-11", "publication_year": 2021, "doi": "10.1177/00221678211022949", "pubmed_id": null, "source_url": "https://doi.org/10.1177/00221678211022949", "keywords": "Psilocybin, Psychology, Interpretative phenomenological analysis, Mindfulness, Psychotherapist, Group cohesiveness, Gratitude, Clinical psychology, Group psychotherapy, Feeling, Qualitative research, Social psychology, Psychiatry, Hallucinogen, Sociology, Social science, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:59", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3166459008\",\"openalex_url\":\"https://openalex.org/W3166459008\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":47,\"referenced_works\":[\"https://openalex.org/W1500784617\",\"https://openalex.org/W1752708916\",\"https://openalex.org/W1885029317\",\"https://openalex.org/W1967087613\",\"https://openalex.org/W1986183554\",\"https://openalex.org/W2000389017\",\"https://openalex.org/W2005022581\",\"https://openalex.org/W2005037843\",\"https://openalex.org/W2014236079\",\"https://openalex.org/W2053154970\",\"https://openalex.org/W2055769378\",\"https://openalex.org/W2094832470\",\"https://openalex.org/W2336110886\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2610309226\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2793403693\",\"https://openalex.org/W2809905421\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2898717395\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W2910110532\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2944263526\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107630502\",\"https://openalex.org/W3112557491\",\"https://openalex.org/W3112904824\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W4300770924\"],\"authorships\":[{\"id\":\"https://openalex.org/A5041698353\",\"display_name\":\"Gabrielle Agin-Liebes\",\"orcid\":\"https://orcid.org/0000-0002-9754-229X\"},{\"id\":\"https://openalex.org/A5017016462\",\"display_name\":\"Eve Ekman\",\"orcid\":\"https://orcid.org/0000-0002-1572-5309\"},{\"id\":\"https://openalex.org/A5009662036\",\"display_name\":\"B. Anderson\",\"orcid\":\"https://orcid.org/0000-0001-5023-660X\"},{\"id\":\"https://openalex.org/A5007645183\",\"display_name\":\"Maxx Malloy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5040538470\",\"display_name\":\"Alexandra Haas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5052144380\",\"display_name\":\"Josh Woolley\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S207414187\",\"source_display_name\":\"Journal of Humanistic Psychology\",\"landing_page_url\":\"https://doi.org/10.1177/00221678211022949\",\"is_oa\":false}}", "topic_tags": "Emotional Processing,Spirituality,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3166459008" }, { "id": 1751, "title": "Psilocybin: A brief overview for psychiatric mental health nurse practitioners.", "normalized_title": "psilocybin a brief overview for psychiatric mental health nurse practitioners", "authors": "Fradkin D.", "abstract": "The use of psychedelics, such as psilocybin, has emerged in recent literature as a novel therapeutic treatment for various psychiatric disorders, including substance use, depression, and anxiety. While international and domestic trials are currently underway, there is data demonstrating both the relative safety and potential efficacy of psilocybin. Psychiatric mental health nurse practitioners are essential mental health providers that may be at the forefront of delivering these new treatment modalities. Therefore, they must be aware of the psychopharmacological and psychotherapeutic tenets of psilocybin to be prepared to treat patients.", "journal": "Perspectives In Psychiatric Care", "publication_date": "2021-06-07", "publication_year": 2021, "doi": "10.1111/ppc.12888", "pubmed_id": "34101846", "source_url": "https://doi.org/10.1111/ppc.12888", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Mental Health, Nurse Practitioners, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34101846\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3169192423\",\"openalex_url\":\"https://openalex.org/W3169192423\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1981740630\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2166423316\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2499216663\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2512668841\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2964775179\",\"https://openalex.org/W2985843276\"],\"authorships\":[{\"id\":\"https://openalex.org/A5009497260\",\"display_name\":\"Dina Fradkin\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S160642813\",\"source_display_name\":\"Perspectives In Psychiatric Care\",\"landing_page_url\":\"https://doi.org/10.1111/ppc.12888\",\"is_oa\":false}}}", "topic_tags": "Depression,Anxiety,Addiction,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3169192423" }, { "id": 1901, "title": "Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.", "normalized_title": "ethnoracial health disparities and the ethnopsychopharmacology of psychedelic assisted psychotherapies", "authors": "Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT.", "abstract": "Emerging evidence from randomized, double-blind, placebo-controlled clinical trials suggests psychedelic compounds such as 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and lysergic acid diethylamide (LSD), when administered as an adjunct to psychotherapy, that is, psychedelic-assisted psychotherapy (PAP), may be beneficial for treating substance use disorders, posttraumatic stress disorder (PTSD), depression, anxiety, and other psychiatric conditions. Previous ethnopsychopharmacological research has identified ethnoracial differences in the metabolism, safety, and efficacy of psychotropic drugs, yet no studies have directly investigated the impact of ethnoracially based differences in psychedelic drug pharmacology. Although there is an extensive global history of psychedelic use among peoples of various cultures, ethnicities, and intersectional identities, psychedelic research has been conducted almost exclusively on White populations in North America and Western Europe. The failure to include Black, Indigenous, and People of Color (BIPOC) in psychedelic research trials neglects the ethnic, racial, and cultural factors that may impact individual responses to PAP and thereby prevents generalizability of findings. This article investigates the impact of biological and social factors related to culture, ethnicity, and race on pharmacological responses to PAP, as well as clinical outcomes. The limitations of ethnopsychopharmacology are discussed, and the authors present expected cultural, clinical, and public health benefits of expanding funding for this area. This work will draw attention to the unique and individualized needs of ethnoracially diverse clients in therapeutic settings and is intended to inform future PAP trials. (PsycInfo Database Record (c) 2021 APA, all rights reserved).", "journal": "Experimental and Clinical Psychopharmacology", "publication_date": "2021-06-06", "publication_year": 2021, "doi": "10.1037/pha0000490", "pubmed_id": "34096755", "source_url": "https://doi.org/10.1037/pha0000490", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"34096755\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3171546624\",\"openalex_url\":\"https://openalex.org/W3171546624\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":53,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5003338744\",\"display_name\":\"Colleen Fogg\",\"orcid\":\"https://orcid.org/0009-0003-2084-1798\"},{\"id\":\"https://openalex.org/A5059769528\",\"display_name\":\"Timothy I. Michaels\",\"orcid\":\"https://orcid.org/0000-0002-3048-6860\"},{\"id\":\"https://openalex.org/A5050030727\",\"display_name\":\"Sara de la Salle\",\"orcid\":\"https://orcid.org/0000-0002-1698-5938\"},{\"id\":\"https://openalex.org/A5089183813\",\"display_name\":\"Zoe W. Jahn\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065680812\",\"display_name\":\"Monnica T. Williams\",\"orcid\":\"https://orcid.org/0000-0003-0095-3277\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S357931\",\"source_display_name\":\"Experimental and Clinical Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1037/pha0000490\",\"is_oa\":false}}}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Pharmacology,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3171546624" }, { "id": 5087, "title": "Psilocybin: the magic medicine for depression?", "normalized_title": "psilocybin the magic medicine for depression", "authors": "Amber Elyse Corrigan, Ella Burchill, Lucy Pelton, Alessia Marrocu, Adele Mazzoleni, Lydia Shackshaft", "abstract": "Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to evaluate the future feasibility and implications of psilocybin as a new antidepressant therapy. Method We reviewed and critically analysed the available literature on the efficacy and safety of psilocybin as a treatment for depression, and the potential pharmacological and psychological mechanisms of the therapeutic benefit. We discussed the relative contributions to this therapeutic effect of the pharmacological drug treatment, placebo effects, and the context and parameters of the psychotherapeutic experience. We reviewed legal, social, and economic barriers to primary research and clinical implementation. Result Psilocybin in combination with psychotherapy has been shown to be safe and effective in TRD. Its mechanism of action in TRD has not been fully elucidated, however reviewing functional neuroimaging studies demonstrated disparate short and long-term modifications of default mode network connectivity, suggested to represent a ‘reset’ mechanism of acute modular disintegration and subsequent reintegration which restores normal function, reviving emotional responsiveness. Research suggests psychedelic treatment induces lasting personality, belief and attitude changes. The psychedelic drug itself, the context of the psychotherapeutic experience, and the post-drug integration therapy all appear to have a significant role. Preparation prior to treatment, the environment, context and support during the psychedelic experience itself, and the following long-term integration and support process must be considered. Despite novel findings Psilocybin is a Schedule I drug; this imposes a persisting ethical barrier to clinical use. Prohibition of psilocybin results in high costs of drug supply, and potential for harmful drug-seeking behaviours. Therefore, complex socio-political factors currently limit wider implementation. Conclusion Psilocybin in combination with psychotherapy is safe and effective in TRD. The interacting and elusive therapeutic mechanisms have implications for clinical implementation. Preparation prior to treatment, the physical and social environment in which the psychedelic experience takes place, and long-term integration and support are considered to play a significant role. Optimisation of these parameters and cost-benefit analyses are required prior to this being feasible as a widely available therapy. Systemic legislative, political and social change will also be key to enable widespread clinical use. The promise of this therapy on a background of inadequate current antidepressant treatments indicates these must be a priority.", "journal": "BJPsych Open", "publication_date": "2021-05-31", "publication_year": 2021, "doi": "10.1192/bjo.2021.456", "pubmed_id": null, "source_url": "https://doi.org/10.1192/bjo.2021.456", "keywords": "Psilocybin, Psychology, Context (archaeology), Psychotherapist, Hallucinogen, Psychiatry, Clinical psychology, Medicine, Paleontology, Biology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Neurotransmitter Receptor Influence on Behavior", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:59", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3173209673\",\"openalex_url\":\"https://openalex.org/W3173209673\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5031805082\",\"display_name\":\"Amber Elyse Corrigan\",\"orcid\":\"https://orcid.org/0000-0003-0636-0114\"},{\"id\":\"https://openalex.org/A5004172567\",\"display_name\":\"Ella Burchill\",\"orcid\":\"https://orcid.org/0000-0002-1674-8844\"},{\"id\":\"https://openalex.org/A5007359388\",\"display_name\":\"Lucy Pelton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5023201944\",\"display_name\":\"Alessia Marrocu\",\"orcid\":\"https://orcid.org/0000-0001-7750-4870\"},{\"id\":\"https://openalex.org/A5015600435\",\"display_name\":\"Adele Mazzoleni\",\"orcid\":\"https://orcid.org/0000-0002-0166-105X\"},{\"id\":\"https://openalex.org/A5033009428\",\"display_name\":\"Lydia Shackshaft\",\"orcid\":\"https://orcid.org/0000-0002-9816-0488\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2764831659\",\"source_display_name\":\"BJPsych Open\",\"landing_page_url\":\"https://doi.org/10.1192/bjo.2021.456\",\"is_oa\":true}}", "topic_tags": "Depression,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Default Mode Network,Aging,Personality Change,Emotional Processing,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3173209673" }, { "id": 3385, "title": "Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders", "normalized_title": "psychedelic assisted psychotherapy for post traumatic stress disorder anxiety disorders mood disorders or substance use disorders", "authors": "Chao YS, Horton J.", "abstract": "Hallucinogens include many different drugs, which are often called “psychedelic” drugs. The US National Institute on Drug Abuse categorizes these drugs into 2 categories: classic hallucinogens and dissociative drugs. Both types of psychedelics can lead to hallucinations - sensations and images that seem real although they are imaginary. In addition, an individual using dissociative drugs can feel out of control or disconnected from their body and environment. Classic serotonergic psychedelics act primarily by a complete or partial agonist action on brain serotonin 5-hydroxytryptamine 2A receptors. Examples of classic psychedelics are LSD, mescaline, psilocybin, and ayahuasca (also identified as N,N- dimethyltryptamine [DMT]). Examples of dissociative drugs are phencyclidine, ketamine, dextromethorphan, and Salvia (Salvia divinorum). Psychedelics were tested for clinical use prior to the 1960s. However, methodological issues in clinical trials and political concerns have prevented the use of psychedelics in mainstream medicine. In 2010, it was reported that psychedelics were used by more than 30 million consumers in the US. Clinically, researchers acknowledge psychedelics as a potential effective drug for mental health conditions. Researchers and clinicians are testing the clinical effectiveness of psychedelics for mental illness treatment due to the improvement in research methods that reduce ethical and methodological concerns toward psychedelic trials. The wider application of psychedelics has also been motivated by a perceived lack of innovation in mental illness treatment. The number of new molecular entities for psychiatric conditions approved by the US FDA decreased from 13 in 1996 to 1 in 2016. One example of the psychedelics adopted for treatment is ketamine (not used in combination with psychotherapies) that has been used for the treatment of depression and post-traumatic stress disorder (PTSD), as reviewed in 2 CADTH reports. Other psychedelics, such as psilocybin and ayahuasca are increasingly being tested for their efficacy in treating mental illnesses. In addition to their use as stand-alone agents, psychedelics can be used in combination with psychotherapy (i.e., psychedelic-assisted psychotherapy). There are a wide variety of psychotherapies that may be used for the treatment of mental health conditions, including guided support that helps patients focus inward on their thoughts and better facilitate participant introspection and cognitive behavioural therapy (CBT) that combines different types of cognitive therapy and behavioural therapy. Psychedelic-assisted psychotherapy is often led by licensed professionals with training in administering psychedelics and monitoring their use. Psychedelics may work by altering a patient’s consciousness. They may also affect a patient’s subjective perspectives and approaches to processing thoughts, emotions, and behaviours, thereby providing an alternative therapeutic experience to psychotherapy alone. While psychedelic-assisted psychotherapy has been recently tried in patients with anxiety, depression, substance use disorder, and PTSD, some researchers consider the treatment response to be unsatisfactory in patients with mood disorder. This report aims to summarize the clinical effectiveness and safety of psychedelic drug-assisted psychotherapy for PTSD, anxiety disorders, mood disorders, or substance use disorders, in addition to clinical guidelines for the use of psychedelic drug-assisted psychotherapy.", "journal": "Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)", "publication_date": "2021-05-31", "publication_year": 2021, "doi": null, "pubmed_id": "36170470", "source_url": "https://europepmc.org/article/MED/36170470", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"36170470\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":\"Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,Receptor Pharmacology,Consciousness,Emotional Processing,Clinical Trial,Review Article,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1867, "title": "Psychedelics and health behaviour change.", "normalized_title": "psychedelics and health behaviour change", "authors": "Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL.", "abstract": "Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called 'lifestyle diseases'-in personal suffering, premature mortality and public health costs-is considerable. Consequently, interventions designed to promote healthy behaviours are increasingly being studied, e.g., using psychobiological models of behavioural regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive and has been shown to predict favourable changes in patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics' proposed mechanisms of action and research findings pertinent to health behaviour change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behaviour change methods (e.g., Cognitive Behaviour Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and well-being.", "journal": null, "publication_date": "2021-05-28", "publication_year": 2021, "doi": "10.1177/02698811211008554", "pubmed_id": "34053342", "source_url": "https://doi.org/10.1177/02698811211008554", "keywords": "Humans, Hallucinogens, Health Behavior, Mental Health, Mental Disorders, Psilocybin, Healthy Lifestyle", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:05", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"34053342\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Eating Disorders,Mechanism of Action,Wellbeing,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2146, "title": "The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.", "normalized_title": "the potential role of psychedelic drugs in mental health care of the future", "authors": "Gründer G, Jungaberle H.", "abstract": "Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs that trigger phenomenologically- related experiences like 3,4-methylenedioxymethamphetamine (MDMA) and ketamine, belong to the most promising treatment approaches in contemporary psychiatry. Psychedelic-assisted psychotherapy is not only a new treatment paradigm in psychopharmacology, but it also requires a redefinition of psychotherapeutic processes and the contextualization of psychopharmacological interventions within a new treatment infrastructure. Crucial for future practice and research in the field are (1) informed patient referral and co-treatment practices, (2) screening (e. g., choosing the right patients for these therapies), (3) the dosing preparation sessions, (4) the assisted dosing sessions as well as after-care procedures such as (5) psychological integration and (6) supporting the development of structured patient communities. Definition of future treatment delivery infrastructures and requirements for therapist training are further challenges for research and practice. Finally, the implementation of psychedelic-assisted psychotherapy in routine mental health care must be embedded into public communication about the potential and risks of these innovative therapeutic approaches. This paper provides a synopsis of challenges for practitioners, researchers, and regulators to be addressed in the approval processes of psychedelics.", "journal": "Pharmacopsychiatry", "publication_date": "2021-05-11", "publication_year": 2021, "doi": "10.1055/a-1486-7386", "pubmed_id": "33979868", "source_url": "https://doi.org/10.1055/a-1486-7386", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Pharmaceutical Preparations, Mental Health, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33979868\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3162909048\",\"openalex_url\":\"https://openalex.org/W3162909048\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":32,\"referenced_works\":[\"https://openalex.org/W1984534015\",\"https://openalex.org/W1994306318\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006403098\",\"https://openalex.org/W2014505180\",\"https://openalex.org/W2037402804\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2064962183\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2102963347\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2131711520\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2140787893\",\"https://openalex.org/W2149402043\",\"https://openalex.org/W2179182088\",\"https://openalex.org/W2411579829\",\"https://openalex.org/W2412591997\",\"https://openalex.org/W2413044490\",\"https://openalex.org/W2419211863\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2571392308\",\"https://openalex.org/W2579967741\",\"https://openalex.org/W2607844825\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2618615166\",\"https://openalex.org/W2716623847\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2739569800\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2790959730\",\"https://openalex.org/W2793403693\",\"https://openalex.org/W2809718318\",\"https://openalex.org/W2892664712\",\"https://openalex.org/W2895740693\",\"https://openalex.org/W2898222000\",\"https://openalex.org/W2898717395\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2944263526\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2985188679\",\"https://openalex.org/W3004910645\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3012354707\",\"https://openalex.org/W3024489493\",\"https://openalex.org/W3049149550\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3093109301\",\"https://openalex.org/W3108632668\",\"https://openalex.org/W3112173414\",\"https://openalex.org/W3112208811\",\"https://openalex.org/W3112904824\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3122801192\",\"https://openalex.org/W3124059976\",\"https://openalex.org/W4231328231\",\"https://openalex.org/W4250845827\"],\"authorships\":[{\"id\":\"https://openalex.org/A5081339058\",\"display_name\":\"Gerhard Gründer\",\"orcid\":\"https://orcid.org/0000-0001-7868-3903\"},{\"id\":\"https://openalex.org/A5001710309\",\"display_name\":\"Henrik Jungaberle\",\"orcid\":\"https://orcid.org/0000-0001-7634-4211\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4122505\",\"source_display_name\":\"Pharmacopsychiatry\",\"landing_page_url\":\"https://doi.org/10.1055/a-1486-7386\",\"is_oa\":false}}}", "topic_tags": "Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3162909048" }, { "id": 5094, "title": "Addressing the Implicit Impacts of Sexual Trauma: An Exploration of Somatic Experiencing as an Adjunct to Psilocybin-Assisted Therapy", "normalized_title": "addressing the implicit impacts of sexual trauma an exploration of somatic experiencing as an adjunct to psilocybin assisted therapy", "authors": "Despina Stratidakis", "abstract": "Sexual trauma is a life-altering violation with persistent, long term implications for survivors. Trauma can produce distinctive impacts on individuals, and therapeutic approaches that offer healing to some, may not be effective for others, particularly when the memories of trauma are implicit and are not easily treated through evidence-based therapeutic methods. The purpose of this capstone is to explore the literature on Somatic Experiencing and psilocybin-assisted therapy for treating sexual trauma, and propose a mixed method study to investigate posttraumatic growth experience in trauma surviving clients. Somatic Experiencing (SE) is a body-focused therapeutic modality that uses the mind-body connection to explore and alleviate nervous system arousal following trauma by enabling survivors to become more attuned to their physiological responses and to regulate these responses more efficiently. Psilocybin is a serotonergic psychedelic compound found in over two-hundred species of mushrooms around the world. Current research has found that psilocybin produces a rapid reduction in symptoms of psychological distress, with positive treatment outcomes such as improved relationships with loved ones, renewed optimism, understanding life meaning and purpose, and acceptance persisting for several months following a single dosing session. Combining these approaches to access and process implicit memories may enable survivors to re-establish feelings of safety and connection, to reconstruct a positive self-concept, and encourage authentic posttraumatic growth.", "journal": "National University System Repository (National University System)", "publication_date": "2021-04-30", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "http://hdl.handle.net/20.500.11803/1295", "keywords": "Adjunct, Psilocybin, Psychology, Psychotherapist, Medicine, Psychiatry, Hallucinogen, Philosophy, Linguistics, Psychedelics and Drug Studies, Psychotherapy Techniques and Applications, Sexuality, Behavior, and Technology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:51:59", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3168063229\",\"openalex_url\":\"https://openalex.org/W3168063229\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5041090642\",\"display_name\":\"Despina Stratidakis\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196956\",\"source_display_name\":\"National University System Repository (National University System)\",\"landing_page_url\":\"http://hdl.handle.net/20.500.11803/1295\",\"is_oa\":false}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3168063229" }, { "id": 2156, "title": "Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.", "normalized_title": "effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers a pilot proof of concept randomized controlled trial", "authors": "Rocha JM, Rossi GN, de Lima Osório F, Bouso JC, de Oliveira Silveira G, Yonamine M, Campos AC, Bertozi G, Cecílio Hallak JE, Dos Santos RG.", "abstract": "BackgroundThe recognition of emotions in facial expressions (REFE) is a core aspect of social cognition. Previous studies with the serotonergic hallucinogens lysergic acid diethylamide and psilocybin showed that these drugs reduced the recognition of negative (fear) faces in healthy volunteers. This trial assessed the acute and prolonged effects of a single dose of ayahuasca on the REFE.MethodsTwenty-two healthy volunteers participated in a pilot, proof-of-concept, randomized trial. Study variables included a REFE task performed before and 4 hours after drug intake, subjective effects (self-reports/observer impressions), tolerability measures (cardiovascular measures, self-reports), and brain-derived neurotrophic factor plasma levels. The REFE task was applied again 1, 7, 14, and 21 days and 3 months after drug intake. Stability of ayahuasca alkaloids during the study was also assessed (room temperature, 18 months).FindingsCompared with placebo, ayahuasca did not modify the REFE. No significant effects were observed on cardiovascular measures and brain-derived neurotrophic factor levels. Volunteers reported visual effects, tranquility/relaxation, and well-being, with few reports of transient anxiety/confusion. Ayahuasca was well tolerated, producing mainly nausea, gastrointestinal discomfort, and vomiting. A significant time-dependent deterioration of alkaloids was observed, especially for dimethyltryptamine.ConclusionsAbsence of significant effects on the REFE task could be due to lack of effects of ayahuasca (at the doses used), alkaloid degradation, learning effects, and the high educational level of the sample. Further trials with different samples are needed to better understand the effects of ayahuasca and other serotonergic hallucinogens on the REFE. Future trials should improve methods to guarantee the stability of ayahuasca alkaloids.", "journal": "Journal of Clinical Psychopharmacology", "publication_date": "2021-04-30", "publication_year": 2021, "doi": "10.1097/jcp.0000000000001396", "pubmed_id": "33843820", "source_url": "https://doi.org/10.1097/jcp.0000000000001396", "keywords": "Humans, Banisteriopsis, Hallucinogens, Plant Preparations, Pilot Projects, Double-Blind Method, Time Factors, Adult, Middle Aged, Female, Male, Young Adult, Facial Recognition, Proof of Concept Study", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33843820\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3154361912\",\"openalex_url\":\"https://openalex.org/W3154361912\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":46,\"referenced_works\":[\"https://openalex.org/W118699724\",\"https://openalex.org/W1973276415\",\"https://openalex.org/W1992914052\",\"https://openalex.org/W2015530431\",\"https://openalex.org/W2035391615\",\"https://openalex.org/W2036881116\",\"https://openalex.org/W2053750947\",\"https://openalex.org/W2060172770\",\"https://openalex.org/W2062339243\",\"https://openalex.org/W2076204392\",\"https://openalex.org/W2078638048\",\"https://openalex.org/W2092728570\",\"https://openalex.org/W2101075036\",\"https://openalex.org/W2103583518\",\"https://openalex.org/W2110475150\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2124026487\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2141538250\",\"https://openalex.org/W2161617741\",\"https://openalex.org/W2169957979\",\"https://openalex.org/W2259267629\",\"https://openalex.org/W2413573456\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2546875451\",\"https://openalex.org/W2604586582\",\"https://openalex.org/W2767171514\",\"https://openalex.org/W2781340150\",\"https://openalex.org/W2782692375\",\"https://openalex.org/W2791098778\",\"https://openalex.org/W2801092899\",\"https://openalex.org/W2801130428\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2941855003\",\"https://openalex.org/W2945335566\",\"https://openalex.org/W2948924404\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W2955047360\",\"https://openalex.org/W2983141784\",\"https://openalex.org/W2983486486\",\"https://openalex.org/W2992322507\",\"https://openalex.org/W2993940948\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3016448445\",\"https://openalex.org/W3021930083\",\"https://openalex.org/W3023636576\",\"https://openalex.org/W3082850425\",\"https://openalex.org/W6604811892\",\"https://openalex.org/W6641192170\",\"https://openalex.org/W6776045936\"],\"authorships\":[{\"id\":\"https://openalex.org/A5039823028\",\"display_name\":\"Juliana Mendes Rocha\",\"orcid\":\"https://orcid.org/0000-0003-0477-2852\"},{\"id\":\"https://openalex.org/A5044658660\",\"display_name\":\"Giordano Novak Rossi\",\"orcid\":\"https://orcid.org/0000-0002-1952-1207\"},{\"id\":\"https://openalex.org/A5026333926\",\"display_name\":\"Flávia de Lima Osório\",\"orcid\":\"https://orcid.org/0000-0003-1396-555X\"},{\"id\":\"https://openalex.org/A5032347558\",\"display_name\":\"José Carlos Bouso\",\"orcid\":\"https://orcid.org/0000-0003-1115-9407\"},{\"id\":\"https://openalex.org/A5101545087\",\"display_name\":\"Gabriela de Oliveira Silveira\",\"orcid\":\"https://orcid.org/0000-0003-2875-8764\"},{\"id\":\"https://openalex.org/A5043245878\",\"display_name\":\"Maurı́cio Yonamine\",\"orcid\":\"https://orcid.org/0000-0002-4615-1088\"},{\"id\":\"https://openalex.org/A5057308016\",\"display_name\":\"Alline C. Campos\",\"orcid\":\"https://orcid.org/0000-0003-4258-3198\"},{\"id\":\"https://openalex.org/A5072655377\",\"display_name\":\"Giuliana Bertozi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5102785969\",\"display_name\":\"Jaime E. C. Hallak\",\"orcid\":\"https://orcid.org/0000-0002-8784-0189\"},{\"id\":\"https://openalex.org/A5058075680\",\"display_name\":\"Rafael G. dos Santos\",\"orcid\":\"https://orcid.org/0000-0003-2388-4745\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S76849566\",\"source_display_name\":\"Journal of Clinical Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1097/jcp.0000000000001396\",\"is_oa\":false}}}", "topic_tags": "Anxiety,Wellbeing,Emotional Processing,Randomized Controlled Trial,Healthy Volunteers,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3154361912" }, { "id": 2164, "title": "Psilocybin: From Serendipity to Credibility?", "normalized_title": "psilocybin from serendipity to credibility", "authors": "Rucker JJ, Young AH.", "abstract": "Psilocybin has a long history of non-medical use and some seem to infer from this that it has therapeutic utility. Early phase clinical trials with psilocybin are encouraging, but suggest only that larger, multicentre trials are required. These are ongoing but will take many years to complete. Meanwhile, retreat centers offering paid experiences with psilocybin truffles have opened in some countries, often using early phase clinical trial data as a basis for bold, public facing claims. This seems unwise. Early phase trials are not designed for their results to be generalized outside the setting they were undertaken in. To do so risks being misleading. Providing what may be seen as an unregulated drug intervention as a paid service is difficult to reconcile with long-held ethical principles underpinning human research and treatment development that were laid down by the 1947 Nuremberg Code and the 1962 Kefauver Harris Amendments. By using psilocybin before it has been properly tested, retreat centers may be undermining their own credibility and the credibility of the wider field.", "journal": "Frontiers in Psychiatry", "publication_date": "2021-04-20", "publication_year": 2021, "doi": "10.3389/fpsyt.2021.659044", "pubmed_id": "33967860", "source_url": "https://doi.org/10.3389/fpsyt.2021.659044", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33967860\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3154999065\",\"openalex_url\":\"https://openalex.org/W3154999065\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":40,\"referenced_works\":[\"https://openalex.org/W1971564036\",\"https://openalex.org/W2050365988\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163445917\",\"https://openalex.org/W2314085810\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2497721881\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W3096208965\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5058414502\",\"display_name\":\"Allan H. Young\",\"orcid\":\"https://orcid.org/0000-0003-2291-6952\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2021.659044\",\"is_oa\":true}}}", "topic_tags": "Aging,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3154999065" }, { "id": 3255, "title": "Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies", "normalized_title": "evaluating the risk of psilocybin for the treatment of bipolar depression a review of the research literature and published case studies", "authors": "Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD.", "abstract": "Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However, there is little available scientific data on the risk of psilocybin use in people with bipolar disorder. Individuals with bipolar disorder have been excluded from modern clinical trials, out of understandable concerns of activating mania or worsening the illness course. As psilocybin becomes more available, people with these disorders will likely seek psilocybin treatment for depression and have likely already been doing so in unregulated settings. Our goal here is to summarize the known risks of psilocybin use (and similar substances) in bipolar disorder and to systematically evaluate examples of published case history data, in order to critically evaluate the relative risk of psilocybin as a treatment for bipolar depression. We found 17 cases suggesting that there is potential risk for activating a manic episode, thereby warranting caution. Nonetheless, the relative lack of systematic data or common case examples indicating risk appears to show that a cautious trial, using modern trial methods focusing on appropriate ‘set’ and ‘setting’, targeted at those lowest at risk for mania in the bipolar spectrum (e.g., bipolar 2 disorder), is very much needed, especially given the degree to which depression impacts this population.", "journal": "medRxiv", "publication_date": "2021-04-06", "publication_year": 2021, "doi": "10.1101/2021.04.02.21254838", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2021.04.02.21254838", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR308148\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3799, "title": "Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)", "normalized_title": "psychedelics and health behavior change journal of psychopharmacology in press", "authors": "Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris R.", "abstract": "Healthful behaviors such as maintaining a balanced diet, being physically active, and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases, and other serious conditions. The burden of the so-called “lifestyle diseases” - in personal suffering, premature mortality, and public health costs - is considerable. Consequently, interventions designed to promote healthy behaviors are increasingly being studied, e.g. using psychobiological models of behavioral regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive, and has been shown to predict favorable changes in patients with depression, anxiety, and other conditions marked by rigid behavioral patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics’ proposed mechanisms of action and research findings pertinent to health behavior change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behavior change methods (e.g., Cognitive Behavior Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure, and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and wellbeing.", "journal": "PsyArXiv", "publication_date": "2021-03-23", "publication_year": 2021, "doi": "10.31234/osf.io/8vks6", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/8vks6", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:10:23", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR321591\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Eating Disorders,Pharmacology,Mechanism of Action,Wellbeing,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 3374, "title": "Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)", "normalized_title": "psychedelics and health behavior change journal of psychopharmacology in press", "authors": "", "abstract": "Healthful behaviors such as maintaining a balanced diet, being physically active, and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases, and other serious conditions. The burden of the so-called “lifestyle diseases” - in personal suffering, premature mortality, and public health costs - is considerable. Consequently, interventions designed to promote healthy behaviors are increasingly being studied, e.g. using psychobiological models of behavioral regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive, and has been shown to predict favorable changes in patients with depression, anxiety, and other conditions marked by rigid behavioral patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics’ proposed mechanisms of action and research findings pertinent to health behavior change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behavior change methods (e.g., Cognitive Behavior Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure, and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and wellbeing.", "journal": "PsyArXiv", "publication_date": "2021-03-23", "publication_year": 2021, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/8vks6_v1", "keywords": "health behaviour change, interventions, psilocybin, psychedelics, public health, self-determination, therapy, Social and Behavioral Sciences, Health Psychology, Mental Health, Health-related Behavior", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"8vks6_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,Addiction,Eating Disorders,Pharmacology,Mechanism of Action,Wellbeing,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 1880, "title": "Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.", "normalized_title": "medicinal psychedelics for mental health and addiction advancing research of an emerging paradigm", "authors": "Perkins D, Sarris J, Rossell S, Bonomo Y, Forbes D, Davey C, Hoyer D, Loo C, Murray G, Hood S, Schubert V, Galvão-Coelho NL, O'Donnell M, Carter O, Liknaitzky P, Williams M, Siskind D, Penington D, Berk M, Castle D.", "abstract": "The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the 'Clinical Memorandum on Psychedelics' recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down-scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for access via the Special Access Scheme. We suggest that this field is worthy of rigorous research to assess potential benefits, address safety parameters and clarify therapeutic mechanisms. To this end, we outline recent research findings, provide an overview of current knowledge relating to mechanisms of action and discuss salient aspects of the psychedelic-assisted psychotherapy treatment model. The sum of this research points towards medicinal psychedelics as a potential new class of psychiatric treatments when used within a medically supervised framework with integrated psychotherapeutic support. However, before widespread translation into clinical use can occur, appropriately designed and sufficiently powered trials are required to detect both potential positive and negative outcomes. Unique safety and regulatory challenges also need to be addressed. As for any new medical therapy, psychedelic research needs to be conducted in a rigorous manner, through the dispassionate lens of scientific enquiry. Carte blanche availability to practitioners, without specific protocols and appropriate training, would be potentially harmful to individuals and detrimental to the field.", "journal": "Australian & New Zealand Journal of Psychiatry", "publication_date": "2021-03-20", "publication_year": 2021, "doi": "10.1177/0004867421998785", "pubmed_id": "33745287", "source_url": "https://doi.org/10.1177/0004867421998785", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Mental Health, Australia, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33745287\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3134642859\",\"openalex_url\":\"https://openalex.org/W3134642859\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":53,\"referenced_works\":[\"https://openalex.org/W2019379291\",\"https://openalex.org/W2416220352\",\"https://openalex.org/W2781340150\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2923355729\",\"https://openalex.org/W2942451714\",\"https://openalex.org/W2945519735\",\"https://openalex.org/W2949943874\",\"https://openalex.org/W2950747661\",\"https://openalex.org/W2953280092\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3012354707\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3027835371\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3049156731\",\"https://openalex.org/W3087672006\",\"https://openalex.org/W3120778817\"],\"authorships\":[{\"id\":\"https://openalex.org/A5049230775\",\"display_name\":\"Daniel Perkins\",\"orcid\":\"https://orcid.org/0000-0002-2055-1649\"},{\"id\":\"https://openalex.org/A5013936218\",\"display_name\":\"Jerome Sarris\",\"orcid\":\"https://orcid.org/0000-0001-9287-8854\"},{\"id\":\"https://openalex.org/A5073606057\",\"display_name\":\"Susan L. Rossell\",\"orcid\":\"https://orcid.org/0000-0002-7415-8252\"},{\"id\":\"https://openalex.org/A5063285518\",\"display_name\":\"Yvonne Bonomo\",\"orcid\":\"https://orcid.org/0000-0003-2583-0687\"},{\"id\":\"https://openalex.org/A5079370099\",\"display_name\":\"David Forbes\",\"orcid\":\"https://orcid.org/0000-0001-9145-1605\"},{\"id\":\"https://openalex.org/A5054229773\",\"display_name\":\"Christopher G. Davey\",\"orcid\":\"https://orcid.org/0000-0003-1431-3852\"},{\"id\":\"https://openalex.org/A5089197450\",\"display_name\":\"Daniël Hoyer\",\"orcid\":\"https://orcid.org/0000-0002-1405-7089\"},{\"id\":\"https://openalex.org/A5003963348\",\"display_name\":\"Colleen Loo\",\"orcid\":\"https://orcid.org/0000-0003-3267-0554\"},{\"id\":\"https://openalex.org/A5082946700\",\"display_name\":\"Greg Murray\",\"orcid\":\"https://orcid.org/0000-0001-7208-5603\"},{\"id\":\"https://openalex.org/A5046408523\",\"display_name\":\"Sean Hood\",\"orcid\":\"https://orcid.org/0000-0003-2852-7923\"},{\"id\":\"https://openalex.org/A5084579010\",\"display_name\":\"Violeta Schubert\",\"orcid\":\"https://orcid.org/0000-0001-7756-2843\"},{\"id\":\"https://openalex.org/A5041005999\",\"display_name\":\"Nicole Leite Galvão-Coelho\",\"orcid\":\"https://orcid.org/0000-0002-4887-8635\"},{\"id\":\"https://openalex.org/A5102390220\",\"display_name\":\"Meaghen O’Donnell\",\"orcid\":null},{\"id\":\"https://openalex.org/A5060157509\",\"display_name\":\"Olivia Carter\",\"orcid\":\"https://orcid.org/0000-0001-7708-6154\"},{\"id\":\"https://openalex.org/A5030212190\",\"display_name\":\"Paul Liknaitzky\",\"orcid\":\"https://orcid.org/0000-0001-5690-2263\"},{\"id\":\"https://openalex.org/A5010417984\",\"display_name\":\"M.L. Williams\",\"orcid\":\"https://orcid.org/0000-0002-9483-3008\"},{\"id\":\"https://openalex.org/A5001271340\",\"display_name\":\"Dan Siskind\",\"orcid\":\"https://orcid.org/0000-0002-2072-9216\"},{\"id\":\"https://openalex.org/A5109261264\",\"display_name\":\"David Penington\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078882374\",\"display_name\":\"Michael Berk\",\"orcid\":\"https://orcid.org/0000-0002-5554-6946\"},{\"id\":\"https://openalex.org/A5052884442\",\"display_name\":\"David Castle\",\"orcid\":\"https://orcid.org/0000-0002-3075-1580\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S179943861\",\"source_display_name\":\"Australian & New Zealand Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1177/0004867421998785\",\"is_oa\":false}}}", "topic_tags": "Addiction,Mechanism of Action,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3134642859" }, { "id": 2175, "title": "Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.", "normalized_title": "hallucinogenic psychedelic 5ht2a receptor agonists as rapid antidepressant therapeutics evidence and mechanisms of action", "authors": "Dos Santos RG, Hallak JE, Baker G, Dursun S.", "abstract": "Major depressive disorder (MDD) is among the most prevalent mental health disorders worldwide, and it is associated with a reduced quality of life and enormous costs to health care systems. Available drug treatments show low-to-moderate response in most patients, with almost a third of patients being non-responders (treatment-resistant). Furthermore, most currently available medications need several weeks to achieve therapeutic effects, and the long-term use of these drugs is often associated with significant unwanted side effects and resultant reductions in treatment compliance. Therefore, more effective, safer, and faster-acting antidepressants with enduring effects are needed. Together with ketamine, psychedelics (or classic or serotoninergic hallucinogens) such as lysergic acid diethylamide (LSD), psilocybin, and ayahuasca are among the few compounds with recent human evidence of fast-acting antidepressant effects. Several studies in the 1950s to 1970s reported antidepressive and anxiolytic effects of these drugs, which are being confirmed by modern trials (LSD, one trial; psilocybin, five trials; ayahuasca, two trials). The effects of these drugs appear to be produced primarily by their agonism at serotonin (5-hydroxytryptamine, 5-HT) receptors, especially the 5-HT2A receptor. Considering the overall burden of MDD and the necessity of new therapeutic options, the promising (but currently limited) evidence of safety and efficacy of psychedelics has encouraged the scientific community to explore more fully their beneficial effects in MDD.", "journal": "Journal of Psychopharmacology", "publication_date": "2021-03-18", "publication_year": 2021, "doi": "10.1177/0269881120986422", "pubmed_id": "33740877", "source_url": "https://doi.org/10.1177/0269881120986422", "keywords": "Humans, Ketamine, Lysergic Acid Diethylamide, Hallucinogens, Antidepressive Agents, Drug Evaluation, Preclinical, Depressive Disorder, Clinical Trials as Topic, Serotonin 5-HT2 Receptor Agonists, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33740877\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3137933781\",\"openalex_url\":\"https://openalex.org/W3137933781\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":51,\"referenced_works\":[\"https://openalex.org/W184284683\",\"https://openalex.org/W1882482010\",\"https://openalex.org/W1918269093\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1993197174\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2012834083\",\"https://openalex.org/W2021282200\",\"https://openalex.org/W2023081218\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2037606383\",\"https://openalex.org/W2050472078\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2055277208\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2093477837\",\"https://openalex.org/W2105571318\",\"https://openalex.org/W2128667819\",\"https://openalex.org/W2150663429\",\"https://openalex.org/W2157384069\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163858520\",\"https://openalex.org/W2164339448\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2546678366\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2592469547\",\"https://openalex.org/W2725596576\",\"https://openalex.org/W2749408017\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2767171514\",\"https://openalex.org/W2781340150\",\"https://openalex.org/W2801130428\",\"https://openalex.org/W2801279915\",\"https://openalex.org/W2801418002\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2810219073\",\"https://openalex.org/W2889790655\",\"https://openalex.org/W2892307734\",\"https://openalex.org/W2900791190\",\"https://openalex.org/W2919894573\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2943320709\",\"https://openalex.org/W2945318261\",\"https://openalex.org/W2948924404\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W2974916455\",\"https://openalex.org/W2983486486\",\"https://openalex.org/W2992322507\",\"https://openalex.org/W3000549374\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3014803974\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3023636576\",\"https://openalex.org/W3038388367\",\"https://openalex.org/W3082850425\",\"https://openalex.org/W3090852378\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\"],\"authorships\":[{\"id\":\"https://openalex.org/A5058075680\",\"display_name\":\"Rafael G. dos Santos\",\"orcid\":\"https://orcid.org/0000-0003-2388-4745\"},{\"id\":\"https://openalex.org/A5103536998\",\"display_name\":\"Jaime EC Hallak\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088403251\",\"display_name\":\"Glen B. Baker\",\"orcid\":\"https://orcid.org/0000-0003-1581-6486\"},{\"id\":\"https://openalex.org/A5089267199\",\"display_name\":\"Serdar Dursun\",\"orcid\":\"https://orcid.org/0000-0001-9943-851X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881120986422\",\"is_oa\":true}}}", "topic_tags": "Depression,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Animal Study,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3137933781" }, { "id": 2168, "title": "Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.", "normalized_title": "acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin assisted psychotherapy for psychiatric and existential distress in life threatening cancer", "authors": "Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE.", "abstract": "People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed a randomized controlled trial in which psilocybin-assisted psychotherapy (PAP) produced rapid and sustained improvements in depression, demoralization, and hopelessness in people with cancer. Converging epidemiologic and clinical trial findings suggests a potential antisuicidal effect of this treatment. To probe our hypothesis that PAP relieves SI through its beneficial impacts on depression and demoralization (LoM in particular), we performed secondary analyses assessing within- and between-group differences with regard to LoM and an SI composite score. Among participants with elevated SI at baseline, PAP was associated with within-group reductions in SI that were apparent as early as 8 h and persisted for 6.5 months postdosing. PAP also produced large reductions in LoM from baseline that were apparent 2 weeks after treatment and remained significant and robust at the 6.5 month and 3.2 and 4.5 year follow-ups. Exploratory analyses support our hypothesis and suggest that PAP may be an effective antisuicidal intervention following a cancer diagnosis due to its positive impact on hopelessness and demoralization and its effects on meaning-making in particular. These preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality.", "journal": "ACS Pharmacology & Translational Science", "publication_date": "2021-03-17", "publication_year": 2021, "doi": "10.1021/acsptsci.1c00020", "pubmed_id": "33860185", "source_url": "https://doi.org/10.1021/acsptsci.1c00020", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33860185\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3138429576\",\"openalex_url\":\"https://openalex.org/W3138429576\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":133,\"referenced_works\":[\"https://openalex.org/W173089895\",\"https://openalex.org/W1521287279\",\"https://openalex.org/W1545099244\",\"https://openalex.org/W1721687418\",\"https://openalex.org/W1862997372\",\"https://openalex.org/W1865092458\",\"https://openalex.org/W1964290581\",\"https://openalex.org/W1973763578\",\"https://openalex.org/W1975850253\",\"https://openalex.org/W1976396510\",\"https://openalex.org/W1990354989\",\"https://openalex.org/W1995057124\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2000806079\",\"https://openalex.org/W2001490833\",\"https://openalex.org/W2007686940\",\"https://openalex.org/W2031343230\",\"https://openalex.org/W2041805221\",\"https://openalex.org/W2043218210\",\"https://openalex.org/W2043705060\",\"https://openalex.org/W2045333532\",\"https://openalex.org/W2052159894\",\"https://openalex.org/W2061661949\",\"https://openalex.org/W2063210933\",\"https://openalex.org/W2066061643\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2071268470\",\"https://openalex.org/W2072833030\",\"https://openalex.org/W2074535951\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2079954350\",\"https://openalex.org/W2085019344\",\"https://openalex.org/W2086658449\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2094249471\",\"https://openalex.org/W2095225953\",\"https://openalex.org/W2099574711\",\"https://openalex.org/W2115111325\",\"https://openalex.org/W2118815581\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2133250764\",\"https://openalex.org/W2137699706\",\"https://openalex.org/W2140658729\",\"https://openalex.org/W2144215610\",\"https://openalex.org/W2145129925\",\"https://openalex.org/W2145839824\",\"https://openalex.org/W2154350319\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166928505\",\"https://openalex.org/W2167585823\",\"https://openalex.org/W2317070629\",\"https://openalex.org/W2474274656\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2616187260\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2757390367\",\"https://openalex.org/W2758148161\",\"https://openalex.org/W2762798648\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2787392819\",\"https://openalex.org/W2803238382\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2886232664\",\"https://openalex.org/W2886961920\",\"https://openalex.org/W2910242363\",\"https://openalex.org/W2923554041\",\"https://openalex.org/W2935505088\",\"https://openalex.org/W2959106487\",\"https://openalex.org/W2971565476\",\"https://openalex.org/W2973694044\",\"https://openalex.org/W2981779913\",\"https://openalex.org/W2996109550\",\"https://openalex.org/W3000636165\",\"https://openalex.org/W3047886920\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3095307948\",\"https://openalex.org/W3196369884\",\"https://openalex.org/W3216011893\"],\"authorships\":[{\"id\":\"https://openalex.org/A5007445878\",\"display_name\":\"Stephen Ross\",\"orcid\":\"https://orcid.org/0000-0002-7807-3037\"},{\"id\":\"https://openalex.org/A5041698353\",\"display_name\":\"Gabrielle Agin-Liebes\",\"orcid\":\"https://orcid.org/0000-0002-9754-229X\"},{\"id\":\"https://openalex.org/A5028101461\",\"display_name\":\"Sharon L. Lo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5000949886\",\"display_name\":\"Richard J. Zeifman\",\"orcid\":\"https://orcid.org/0000-0003-3478-4483\"},{\"id\":\"https://openalex.org/A5012044626\",\"display_name\":\"Leila Ghazal\",\"orcid\":null},{\"id\":\"https://openalex.org/A5052441153\",\"display_name\":\"Julia Benville\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053891811\",\"display_name\":\"Silvia Franco Corso\",\"orcid\":null},{\"id\":\"https://openalex.org/A5043329296\",\"display_name\":\"Christian Bjerre-Real\",\"orcid\":\"https://orcid.org/0000-0002-3230-9729\"},{\"id\":\"https://openalex.org/A5026405762\",\"display_name\":\"Jeffrey Guss\",\"orcid\":null},{\"id\":\"https://openalex.org/A5015516801\",\"display_name\":\"Anthony P. Bossis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5087382833\",\"display_name\":\"Sarah E. Mennenga\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210207642\",\"source_display_name\":\"ACS Pharmacology & Translational Science\",\"landing_page_url\":\"https://doi.org/10.1021/acsptsci.1c00020\",\"is_oa\":false}}}", "topic_tags": "Depression,End-of-Life Distress,Clinical Trial,Randomized Controlled Trial,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3138429576" }, { "id": 2173, "title": "On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.", "normalized_title": "on the relationship between classic psychedelics and suicidality a systematic review", "authors": "Zeifman RJ, Singhal N, Breslow L, Weissman CR.", "abstract": "Use of classic psychedelics (e.g., psilocybin, ayahuasca, and lysergic acid diethylamide) is increasing, and psychedelic therapy is receiving growing attention as a novel mental health intervention. Suicidality remains a potential safety concern associated with classic psychedelics and is, concurrently, a mental health concern that psychedelic therapy may show promise in targeting. Accordingly, further understanding of the relationship between classic psychedelics and suicidality is needed. Therefore, we conducted a systematic review of the relationship between classic psychedelics (both non-clinical psychedelic use and psychedelic therapy) and suicidality. We identified a total of 64 articles, including 41 articles on the association between non-clinical classic psychedelic use and suicidality and 23 articles on the effects of psychedelic therapy on suicidality. Findings on the association between lifetime classic psychedelic use and suicidality were mixed, with studies finding positive, negative, and no significant association. A small number of reports of suicide and decreased suicidality following non-clinical classic psychedelic use were identified. Several cases of suicide in early psychedelic therapy were identified; however, it was unclear whether this was due to psychedelic therapy itself. In recent psychedelic therapy clinical trials, we found no reports of increased suicidality and preliminary evidence for acute and sustained decreases in suicidality following treatment. We identify some remaining questions and provide suggestions for future research on the association between classic psychedelics and suicidality.", "journal": null, "publication_date": "2021-03-10", "publication_year": 2021, "doi": "10.1021/acsptsci.1c00024", "pubmed_id": "33860173", "source_url": "https://doi.org/10.1021/acsptsci.1c00024", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33860173\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3370, "title": "Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports", "normalized_title": "classic psychedelic coadministration with lithium but not lamotrigine is associated with seizures an analysis of online psychedelic experience reports", "authors": "Nayak S, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR.", "abstract": "Introduction: Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psychedelic trials. There is limited information on the use of classic psychedelics (e.g. LSD or psilocybin) in individuals using mood stabilizers to treat bipolar disorder. This is important to know as individuals with bipolar depression may attempt to treat themselves with psychedelics while on a mood stabilizer, particularly given enthusiastic media reports of the efficacy of psilocybin for depression. Methods: This study analyzed reports of classic psychedelics administered with mood stabilizers from three websites (Erowid.org, Shroomery.org, and Reddit.com). Results: Strikingly, 47% of 62 lithium plus psychedelic reports involved seizures and an additional 18% resulted in bad trips while none of 34 lamotrigine reports did. Further, 39% of lithium reports involved medical attention. Most of the lamotrigine reports (65%) but few (8%) of the lithium reports were judged to have no effect on the psychedelic experience. Discussion: Although further research is needed, we provisionally conclude that psychedelic use may pose a significant seizure risk for patients on lithium.", "journal": "PsyArXiv", "publication_date": "2021-02-23", "publication_year": 2021, "doi": "10.31234/osf.io/r726d", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/r726d", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:51", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"PPR322793\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 2198, "title": "Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.", "normalized_title": "development and evaluation of a therapist training program for psilocybin therapy for treatment resistant depression in clinical research", "authors": "Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, Reinholdt F, Richards BD, Gasser P, Malievskaia E.", "abstract": "Introduction: Psychological support throughout psilocybin therapy is mandated by regulators as an essential part of ensuring participants' physical and psychological safety. There is an increased need for specially trained therapists who can provide high-quality care to participants in clinical studies. This paper describes the development and practical implementation of a therapist training program of psychological support within a current phase IIb international, multicenter, randomized controlled study of psilocybin therapy for people experiencing treatment-resistant depression. Description of Training Program: This new and manualized approach, based on current evidence-based psychotherapeutic approaches, was developed in partnership with different mental health researchers, practitioners, and experts; and has been approved by the FDA. Training consists of four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and participation in webinars.This paper provides a brief overview of the method of support, the rationale and methodology of the training program, and describes each stage of training. The design and implementation of fidelity procedures are also outlined. Lessons Learned: As part of the phase IIb study of psilocybin therapy for treatment-resistant depression, 65 health care professionals have been fully trained as therapists and assisting therapists, across the US, Canada and Europe. Therapists provided informal feedback on the training program. Feedback indicates that the didactic and experiential interactive learning, delivered through a combination of online and in-person teaching, helped therapists build conceptual understanding and skill development in the therapeutic approach. Clinical training and engagement in participant care, under the guidance of experienced therapists, were considered the most beneficial and challenging aspects of the training. Conclusions: Clinical training for therapists is essential for ensuring consistently high-quality psilocybin therapy. Development of a rigorous, effective and scalable training methodology has been possible through a process of early, active and ongoing collaborations between mental health experts. To maximize impact and meet phase III and post-approval need, enhanced online learning and establishing pathways for clinical training are identified as critical points for quality assurance. This will require close public, academic and industry collaboration.", "journal": "Frontiers in Psychiatry", "publication_date": "2021-02-02", "publication_year": 2021, "doi": "10.3389/fpsyt.2021.586682", "pubmed_id": "33643087", "source_url": "https://doi.org/10.3389/fpsyt.2021.586682", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"europe_pmc_id\":\"33643087\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W3127909847\",\"openalex_url\":\"https://openalex.org/W3127909847\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":87,\"referenced_works\":[\"https://openalex.org/W570309327\",\"https://openalex.org/W1514273299\",\"https://openalex.org/W1565826239\",\"https://openalex.org/W1644715232\",\"https://openalex.org/W1989747464\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2018631585\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2028190754\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2053775719\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2135176444\",\"https://openalex.org/W2150839665\",\"https://openalex.org/W2152160545\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2169631639\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2895740693\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W4240789427\",\"https://openalex.org/W4321383869\"],\"authorships\":[{\"id\":\"https://openalex.org/A5003939496\",\"display_name\":\"Sara Tai\",\"orcid\":\"https://orcid.org/0000-0002-8316-5796\"},{\"id\":\"https://openalex.org/A5087298757\",\"display_name\":\"Elizabeth M. Nielson\",\"orcid\":\"https://orcid.org/0000-0003-2294-4558\"},{\"id\":\"https://openalex.org/A5033335673\",\"display_name\":\"Molly Lennard-Jones\",\"orcid\":null},{\"id\":\"https://openalex.org/A5075703225\",\"display_name\":\"Riikka-Liisa Johanna Ajantaival\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002735246\",\"display_name\":\"Rachel I. Winzer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5039889194\",\"display_name\":\"William A. Richards\",\"orcid\":\"https://orcid.org/0000-0003-0730-9249\"},{\"id\":\"https://openalex.org/A5082252502\",\"display_name\":\"Frederick Reinholdt\",\"orcid\":null},{\"id\":\"https://openalex.org/A5034785335\",\"display_name\":\"Brian D. Richards\",\"orcid\":null},{\"id\":\"https://openalex.org/A5046150668\",\"display_name\":\"Peter Gasser\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021278348\",\"display_name\":\"Ekaterina Malievskaia\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S92766711\",\"source_display_name\":\"Frontiers in Psychiatry\",\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2021.586682\",\"is_oa\":true}}}", "topic_tags": "Depression,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3127909847" }, { "id": 2180, "title": "Use and abuse of dissociative and psychedelic drugs in adolescence.", "normalized_title": "use and abuse of dissociative and psychedelic drugs in adolescence", "authors": "Bates MLS, Trujillo KA.", "abstract": "Adolescence is a period of profound developmental changes, which run the gamut from behavioral and neural to physiological and hormonal. It is also a time at which there is an increased propensity to engage in risk-taking and impulsive behaviors like drug use. This review examines the human and preclinical literature on adolescent drug use and its consequences, with a focus on dissociatives (PCP, ketamine, DXM), classic psychedelics (LSD, psilocybin), and MDMA. It is the case for all the substances reviewed here that very little is known about their effects in adolescent populations. An emerging aspect of the literature is that dissociatives and MDMA produce mixed reinforcing and aversive effects and that the balance between reinforcement and aversion may differ between adolescents and adults, with consequences for drug use and addiction. However, many studies have failed to directly compare adults and adolescents, which precludes definitive conclusions about these consequences. Other important areas that are largely unexplored are sex differences during adolescence and the long-term consequences of adolescent use of these substances. We provide suggestions for future work to address the gaps we identified in the literature. Given the widespread use of these drugs among adolescent users, and the potential for therapeutic use, this work will be crucial to understanding abuse potential and consequences of use in this developmental stage.", "journal": null, "publication_date": "2021-01-27", "publication_year": 2021, "doi": "10.1016/j.pbb.2021.173129", "pubmed_id": "33515586", "source_url": "https://doi.org/10.1016/j.pbb.2021.173129", "keywords": "Animals, Humans, Substance-Related Disorders, N-Methyl-3,4-methylenedioxyamphetamine, Ketamine, Lysergic Acid Diethylamide, Dextromethorphan, Phencyclidine, Hallucinogens, Risk-Taking, Age Factors, Adolescent, Adult, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33515586\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Review Article,Animal Study,Adolescents,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2144, "title": "Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.", "normalized_title": "psychedelic psychiatry and the consult liaison psychiatrist a primer", "authors": "Barnett BS, Greer GR.", "abstract": "BackgroundPsychedelic compounds such as lysergic acid diethylamide (LSD), psilocybin, and 3,4-Methylenedioxymethamphetamine (MDMA) share a long and complex history with psychiatry. A half century ago, psychedelics were widely employed by psychiatrists in investigational and clinical settings, with studies demonstrating promising findings for their use in the treatment of mental illness and substance use disorders. However, concerns were also raised about their abuse potential and other adverse effects. Owing to these worries and psychedelics' association with the counterculture movement, psychedelics were largely outlawed in the United States in 1970, bringing research on their therapeutic potential to a halt. However, in recent years, a resurgence of psychedelic research has revealed compelling, though early, evidence for the use of psychedelic-assisted therapy in treating alcohol use disorder, nicotine use disorder, posttraumatic stress disorder, and depression.ObjectiveHere we provide an overview of psychiatry's complicated relationship with psychedelics, while reviewing contemporary findings on psychedelic-assisted therapy, safety of psychedelic-assisted therapy, and risks of nonmedical use. We also make the case that psychiatry should consider preparing now for the possibility of Food and Drug Administration approval of psychedelic-assisted therapies in the near future. We conclude by discussing how growing societal interest in psychedelics could impact the work of consult-liaison psychiatrists, while also exploring how consult-liaison psychiatrists might contribute to future delivery of psychedelic treatments.MethodsWe reviewed literature on psychedelic-assisted therapies and adverse events resulting from nonmedical psychedelic use.ResultsWe found a small, but rapidly growing literature indicating that psychedelic-assisted therapies may have treatment potential for mental illness and addiction. Our search also revealed a variety of rare adverse events stemming from nonmedical psychedelic use.ConclusionsDespite past concerns about psychedelics, current data indicate psychedelic-assisted therapy may potentially reduce suffering owing to mental illness and addiction if administered thoughtfully and cautiously by trained professionals in medical settings.", "journal": null, "publication_date": "2021-01-20", "publication_year": 2021, "doi": "10.1016/j.jaclp.2020.12.011", "pubmed_id": "34210406", "source_url": "https://doi.org/10.1016/j.jaclp.2020.12.011", "keywords": "N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Hallucinogens, Psychiatry, United States, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"34210406\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,PTSD,Addiction,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3123670341" }, { "id": 2148, "title": "Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.", "normalized_title": "classical psychedelics as therapeutics in psychiatry current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders", "authors": "Mertens LJ, Preller KH.", "abstract": "Classical psychedelics, primarily psilocybin and lysergic acid diethylamide (LSD), have been used and extensively studied in Western medicine as part of substance-assisted psychotherapy in the 1950s and 1960s. Modern clinical research is currently gaining momentum and provides new evidence for the safety and efficacy of classical psychedelics (primarily psilocybin, but also LSD and ayahuasca) in the treatment of different psychiatric conditions, including substance use and mood disorders.In this review article, we outline common pathological mechanisms of substance use disorders (SUD) and unipolar depression. Next, the current literature on the effects of psychedelics is summarized in order to generate hypotheses regarding their potential therapeutic mechanisms of action in treating these psychiatric conditions. Finally, we review and discuss clinical trials published since 2011 investigating the effects of psychedelics in SUD and depression.While results from those modern clinical trials are promising, most of them do not meet the methodological requirements to allow firm conclusions on the clinical efficacy of psychedelics. Larger, blinded, randomized controlled trials (RCT) with clearly defined patient groups and well-defined primary endpoints are needed. Additionally, the therapeutic mechanisms of classical psychedelics are currently unknown. This review presents hypotheses derived from preclinical and human studies that need to be tested in future trials to better understand the clinical potential of psychedelic substances in modern psychiatry.", "journal": null, "publication_date": "2021-01-19", "publication_year": 2021, "doi": "10.1055/a-1341-1907", "pubmed_id": "33472250", "source_url": "https://doi.org/10.1055/a-1341-1907", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Mood Disorders, Psychiatry, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"33472250\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Mechanism of Action,Clinical Trial,Randomized Controlled Trial,Review Article,Animal Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 5143, "title": "The Effect of Psilocybin on Personality", "normalized_title": "the effect of psilocybin on personality", "authors": "Ravital LaBua", "abstract": "As classic psychedelics are increasingly legalized and reintroduced into the psychotherapeutic frame, a deeper understanding of their effect on personality and overall wellbeing - as well as their clinical contraindications and potential pitfalls - will prove essential. As a result, this study represents a preliminary investigation into the effect of psilocybin exposure on a range of personality constructs. Methods: Data was collected through a collaboration with The Psychedelic Society, an organization that legally administers psilocybin truffles in the Netherlands to self-selecting retreat attendees who have been screened for mental health disorders in accordance with Johnson et al.’s (2008) widely accepted safety guidelines. Participants completed the following measures via online questionnaire the day before psilocybin exposure, two days after psilocybin exposure, and at a one-month follow-up: Brief Symptom Inventory (BSI), Experiences in Close Relationships-Revised (ECR-R), Mentalization Scale (MentS), Inventory of Personality Organization (IPO), Pathological Narcissism Inventory (PNI), Pro-Environmental Behavior (PEB) and the Ryff Scale of Psychological Well-Being (Ryff). As rigorous double-blind clinical studies have linked psychedelic-occasioned mystical experiences to sustained improvement in personality-related domains (Maclean et al., 2011; Griffiths et al., 2006; Griffiths et al., 2008, Griffiths et al., 2011), the Mystical Experience Questionnaire (MEQ) was also administered. Lastly, participants provided self-report responses to open-ended questions regarding subjective experiences following psilocybin exposure. Results: Due to the Covid-19 pandemic, data collection was prematurely cut short, and only preliminary conclusions can be drawn. Those provisional conclusions include significantly improved overall symptomatology (BSI GSI), identity diffusion (IPO-ID) and reality testing (IPO-RT) following psilocybin exposure. Significant interactions were also identified for primitive defenses (IPO-PD) and narcissistic grandiosity (PNI-G), with the non-mystical experience group trending toward improvement, and the mystical-experience group remaining largely unchanged over time. Due to methodological constraints encountered, these findings remain preliminary. Nevertheless, the presence of multiple significant findings (however nascent) within the context of so few participants suggests the possibility of more robust findings in the context of a larger sample size.", "journal": "CUNY Academic Works (City University of New York)", "publication_date": "2020-12-31", "publication_year": 2020, "doi": null, "pubmed_id": null, "source_url": "https://academicworks.cuny.edu/gc_etds/4460", "keywords": "Psilocybin, Psychology, Personality, Hallucinogen, Social psychology, Cognitive psychology, Psychiatry, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:52:00", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3194396335\",\"openalex_url\":\"https://openalex.org/W3194396335\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W62922542\",\"https://openalex.org/W110752286\",\"https://openalex.org/W400774807\",\"https://openalex.org/W569683754\",\"https://openalex.org/W625244993\",\"https://openalex.org/W652304930\",\"https://openalex.org/W1484799892\",\"https://openalex.org/W1713632779\",\"https://openalex.org/W1966603703\",\"https://openalex.org/W1968239400\",\"https://openalex.org/W1972616052\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1978885184\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1989844817\",\"https://openalex.org/W1989868487\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2001218722\",\"https://openalex.org/W2002966074\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2019692714\",\"https://openalex.org/W2038786381\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2049518862\",\"https://openalex.org/W2060762300\",\"https://openalex.org/W2068199765\",\"https://openalex.org/W2070525857\",\"https://openalex.org/W2073166664\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2079875205\",\"https://openalex.org/W2081883085\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2089632658\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2112336497\",\"https://openalex.org/W2112884745\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2117834601\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2137780276\",\"https://openalex.org/W2139185845\",\"https://openalex.org/W2139192721\",\"https://openalex.org/W2140018908\",\"https://openalex.org/W2143350277\",\"https://openalex.org/W2150803086\",\"https://openalex.org/W2155854964\",\"https://openalex.org/W2159072822\",\"https://openalex.org/W2159879368\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2165990912\",\"https://openalex.org/W2169683554\",\"https://openalex.org/W2184086296\",\"https://openalex.org/W2184493925\",\"https://openalex.org/W2250013156\",\"https://openalex.org/W2325558246\",\"https://openalex.org/W2346262441\",\"https://openalex.org/W2412599243\",\"https://openalex.org/W2413873059\",\"https://openalex.org/W2427452470\",\"https://openalex.org/W2464426805\",\"https://openalex.org/W2522268013\",\"https://openalex.org/W2546678366\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2608583841\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2657342869\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2790959730\",\"https://openalex.org/W2906253013\",\"https://openalex.org/W3123344346\",\"https://openalex.org/W3196761093\"],\"authorships\":[{\"id\":\"https://openalex.org/A5005677099\",\"display_name\":\"Ravital LaBua\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196304\",\"source_display_name\":\"CUNY Academic Works (City University of New York)\",\"landing_page_url\":\"https://academicworks.cuny.edu/gc_etds/4460\",\"is_oa\":true}}", "topic_tags": "Wellbeing,Personality Change,Mystical Experience,Safety,Drug Interactions,Contraindications", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3194396335" }, { "id": 5141, "title": "Unmet need in depression: Psilocybin, a breakthrough treatment option", "normalized_title": "unmet need in depression psilocybin a breakthrough treatment option", "authors": "Yogesh Kumar Chahar", "abstract": "Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is experiencing an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depression is associated with greater disability than are most other chronic illnesses and is a risk factor for mortality. Additionally, depression predicts the later development of a number of medical conditions, including cardiac and cerebrovascular disease, hypertension, diabetes, obesity, metabolic syndrome, dementia, and cancer. Unfortunately, most patients with depression do not experience a complete resolution of symptoms with antidepressant treatment. Partial-but incomplete-response to antidepressants is associated with an increased risk of full symptomatic relapse (even when on therapy) and a worse long-term disease course. Combined with the high prevalence and significant disability associated with MDD, the fact that currently available treatments are not fully adequate highlights the tremendous need to identify novel treatment strategies. In this review, we have compiled the information available about the potential of psilocybin in the treatment of MDD. This is recently called as breakthrough treatment by FDA. We have presented recent clinical study data to support the notion. This will surely help all health care practitioners to consider this drug in future for the treatment of their patients suffering with MDD.", "journal": "International Journal of Advanced Research in Medicine", "publication_date": "2020-12-31", "publication_year": 2020, "doi": "10.22271/27069567.2021.v3.i1f.159", "pubmed_id": null, "source_url": "https://doi.org/10.22271/27069567.2021.v3.i1f.159", "keywords": "Depression (economics), Medicine, Major depressive disorder, Disease, Psychiatry, Dementia, Antidepressant, Intensive care medicine, Anxiety, Internal medicine, Economics, Cognition, Macroeconomics, Psychedelics and Drug Studies, Mental Health Research Topics, Digital Mental Health Interventions", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:52:00", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3164081616\",\"openalex_url\":\"https://openalex.org/W3164081616\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1965925823\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2014296006\",\"https://openalex.org/W2027225968\",\"https://openalex.org/W2051153602\",\"https://openalex.org/W2072016770\",\"https://openalex.org/W2079258526\",\"https://openalex.org/W2104320372\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2144290629\",\"https://openalex.org/W2161296293\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3080361799\",\"https://openalex.org/W3110733646\"],\"authorships\":[{\"id\":\"https://openalex.org/A5096799053\",\"display_name\":\"Yogesh Kumar Chahar\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226113\",\"source_display_name\":\"International Journal of Advanced Research in Medicine\",\"landing_page_url\":\"https://doi.org/10.22271/27069567.2021.v3.i1f.159\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3164081616" }, { "id": 2214, "title": "Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.", "normalized_title": "psychedelics in psychiatry neuroplastic immunomodulatory and neurotransmitter mechanisms", "authors": "Inserra A, De Gregorio D, Gobbi G.", "abstract": "Mounting evidence suggests safety and efficacy of psychedelic compounds as potential novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug Administration in a new class of antidepressants, and 3,4-methylenedioxymethamphetamine (MDMA) is undergoing phase III clinical trials for post-traumatic stress disorder. Psilocybin and lysergic acid diethylamide (LSD) are being investigated in several phase II and phase I clinical trials. Hence, the concept of psychedelics as therapeutics may be incorporated into modern society. Here, we discuss the main known neurobiological therapeutic mechanisms of psychedelics, which are thought to be mediated by the effects of these compounds on the serotonergic (via 5-HT2A and 5-HT1A receptors) and glutamatergic [via N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] systems. We focus on 1) neuroplasticity mediated by the modulation of mammalian target of rapamycin-, brain-derived neurotrophic factor-, and early growth response-related pathways; 2) immunomodulation via effects on the hypothalamic-pituitary-adrenal axis, nuclear factor ĸB, and cytokines such as tumor necrosis factor-α and interleukin 1, 6, and 10 production and release; and 3) modulation of serotonergic, dopaminergic, glutamatergic, GABAergic, and norepinephrinergic receptors, transporters, and turnover systems. We discuss arising concerns and ways to assess potential neurobiological changes, dependence, and immunosuppression. Although larger cohorts are required to corroborate preliminary findings, the results obtained so far are promising and represent a critical opportunity for improvement of pharmacotherapies in psychiatry, an area that has seen limited therapeutic advancement in the last 20 years. Studies are underway that are trying to decouple the psychedelic effects from the therapeutic effects of these compounds. SIGNIFICANCE STATEMENT: Psychedelic compounds are emerging as potential novel therapeutics in psychiatry. However, understanding of molecular mechanisms mediating improvement remains limited. This paper reviews the available evidence concerning the effects of psychedelic compounds on pathways that modulate neuroplasticity, immunity, and neurotransmitter systems. This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms.", "journal": null, "publication_date": "2020-12-31", "publication_year": 2020, "doi": "10.1124/pharmrev.120.000056", "pubmed_id": "33328244", "source_url": "https://doi.org/10.1124/pharmrev.120.000056", "keywords": "Pituitary-Adrenal System, Hypothalamo-Hypophyseal System, Humans, Neurotransmitter Agents, Hallucinogens, Psychiatry, Neuronal Plasticity, United States, Immunomodulation", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33328244\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "PTSD,Neuroplasticity,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Review Article,Observational Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2211, "title": "Psychedelic Medicines in Major Depression: Progress and Future Challenges.", "normalized_title": "psychedelic medicines in major depression progress and future challenges", "authors": "Bouso JC, Ona G, Dos Santos RG, Hallak JEC.", "abstract": "The volume of research on the therapeutic use of psychedelic drugs has been increasing during the last decades. Partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. The first section of this chapter will offer an introduction to psychedelic research, including a brief historical overview and discussions about appropriate terminology. In the second section, the recently published clinical trials in which psychedelic drugs were administered to patients will be analysed in detail. Then, in the third section, the main neurobiological mechanisms of these drugs will be described, noting that while some of these mechanisms could be potentially associated with their therapeutic properties, they are commonly used as adjuvants in psychotherapeutic processes. The last section suggests future challenges for this groundbreaking field of research and therapy.", "journal": null, "publication_date": "2020-12-31", "publication_year": 2020, "doi": "10.1007/978-981-33-6044-0_26", "pubmed_id": "33834416", "source_url": "https://doi.org/10.1007/978-981-33-6044-0_26", "keywords": "Humans, Hallucinogens, Depression, Psychiatry, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33834416\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Mechanism of Action,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 1889, "title": "Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.", "normalized_title": "translating psychedelic therapies from clinical trials to community clinics building bridges and addressing potential challenges ahead", "authors": "Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O'Carroll S, Puspanathan P, Ross M, Strauss N, Bennett-Levy J", "abstract": "Research exploring the potential of psychedelic-assisted therapies to treat a range of mental illnesses is flourishing, after the problematic sociopolitical history of psychedelics led to the shutdown of clinical research for almost 40 years. Encouraged by positive results, clinicians and patients are now hopeful that further interruptions to research will be avoided, so that the early promise of these therapies might be fulfilled. At this early stage of renewed interest, researchers are understandably focusing more on clinical trials to investigate safety and efficacy, than on longer-term goals such as progression to community practice. Looking to identify and avoid potential pitfalls on the path to community clinics, the authors, a group of Australian clinicians and researchers, met to discuss possible obstacles. Five broad categories of challenge were identified: 1) inherent risks; 2) poor clinical practice; 3) inadequate infrastructure; 4) problematic perceptions; and 5) divisive relationships and fractionation of the field. Our analysis led us to propose some strategies, including public sector support of research and training to establish best practice and optimize translation, and funding to address issues of equitable access to treatment. Above all, we believe that strategic planning and professional cohesion will be crucial for success. Accordingly, our key recommendation is the establishment of a multidisciplinary advisory body, broadly endorsed and representing all major stakeholders, to guide policy and implementation of psychedelic-assisted therapies in Australia. Although these challenges and strategies are framed within the Australian context, we sense that they may generalize to other parts of the world. Wherever they apply, we believe that anticipation of potential difficulties, and creative responses to address them, will be important to avoid roadblocks in the future and keep the \"psychedelic renaissance\" on track.", "journal": "Frontiers in psychiatry", "publication_date": "2020-12-31", "publication_year": 2020, "doi": "10.3389/fpsyt.2021.737738", "pubmed_id": "34803761", "source_url": "https://pubmed.ncbi.nlm.nih.gov/34803761/", "keywords": "clinical research, community clinics, depression, mental health, psilocybin, psychedelics, translation, trauma", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:48:06", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"34803761\"}", "topic_tags": "Depression,Creativity,Clinical Trial,Healthcare Workers,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2221, "title": "Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes", "normalized_title": "effects and safety of psilocybe cubensis and panaeolus cyanescens magic mushroom extracts on endothelin 1 induced hypertrophy and cell injury in cardiomyocytes", "authors": "Sanah Malomile Nkadimeng, Christiaan M.L. Steinmann, J.N. Eloff", "abstract": "Prevalence of major depression in people with chronic heart failure is higher than in normal populations. Depression in heart failure has become a major issue. Psilocybin-containing mushrooms commonly known as magic mushrooms, have been used since ancient times for their mind healing properties. Their safety in cardiovascular disease conditions is not fully known and may pose as a risk for users suffering from these illnesses. Study investigates the effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushrooms use from genus Psilocybe and Panaeolus respectively, in a pathological hypertrophy conditions in which endothelin-1 disorder is a contributor to pathogenesis. We examined the effects of the mushrooms extracts on endothelin-1-induced hypertrophy and tumor necrosis factor-α (TNF- α)-induced cell injury in H9C2 cardiomyocytes. Mushrooms were oven dried and extracted with cold and boiling-hot water. H9C2 cardiomyocytes were induced with endothelin-1 prior to treatment with extracts over 48 h. Cell injury was stimulated with TNF-α. Results proposed that the water extracts of Panaeolus cyanescens and Psilocybe cubensis did not aggravate the pathological hypertrophy induced by endothelin-1 and also protected against the TNF-α-induced injury and cell death in concentrations used. Results support medicinal safe use of mushrooms under controlled conditions and cautioned use of higher concentrations.", "journal": "Scientific Reports", "publication_date": "2020-12-17", "publication_year": 2020, "doi": "10.1038/s41598-020-79328-5", "pubmed_id": "33339902", "source_url": "https://doi.org/10.1038/s41598-020-79328-5", "keywords": "Endothelin receptor, Muscle hypertrophy, Pathological, Mushroom, Medicine, Biology, Internal medicine, Botany, Receptor, Psychedelics and Drug Studies, Fungal Biology and Applications, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3115524456\",\"openalex_url\":\"https://openalex.org/W3115524456\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":31,\"referenced_works\":[\"https://openalex.org/W365185848\",\"https://openalex.org/W1495128751\",\"https://openalex.org/W1828522958\",\"https://openalex.org/W1967128858\",\"https://openalex.org/W1997998626\",\"https://openalex.org/W2005083453\",\"https://openalex.org/W2017007318\",\"https://openalex.org/W2051880837\",\"https://openalex.org/W2054898931\",\"https://openalex.org/W2056633265\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2075888651\",\"https://openalex.org/W2083531465\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2095643252\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2136212502\",\"https://openalex.org/W2153430526\",\"https://openalex.org/W2169230321\",\"https://openalex.org/W2324476825\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2527325622\",\"https://openalex.org/W2556671514\",\"https://openalex.org/W2607257758\",\"https://openalex.org/W2610169537\",\"https://openalex.org/W2750178422\",\"https://openalex.org/W2768816200\",\"https://openalex.org/W2792314086\",\"https://openalex.org/W2894345161\",\"https://openalex.org/W3012256305\",\"https://openalex.org/W3081977832\",\"https://openalex.org/W3199318186\",\"https://openalex.org/W4231317121\"],\"authorships\":[{\"id\":\"https://openalex.org/A5007223200\",\"display_name\":\"Sanah Malomile Nkadimeng\",\"orcid\":\"https://orcid.org/0000-0001-5647-7156\"},{\"id\":\"https://openalex.org/A5113698949\",\"display_name\":\"Christiaan M.L. Steinmann\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086386072\",\"display_name\":\"J.N. Eloff\",\"orcid\":\"https://orcid.org/0000-0003-1494-9842\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S196734849\",\"source_display_name\":\"Scientific Reports\",\"landing_page_url\":\"https://doi.org/10.1038/s41598-020-79328-5\",\"is_oa\":true}}", "topic_tags": "Depression,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3115524456" }, { "id": 2170, "title": "Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience", "normalized_title": "psilocybin assisted group therapy and attachment observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience", "authors": "Christopher S. Stauffer, B. Anderson, Kile Ortigo, Joshua Woolley", "abstract": "Attachment insecurity is determined early in life, is a risk factor for psychopathology, and can be measured on two separate continuous dimensions: attachment anxiety and attachment avoidance. Therapeutic changes toward more secure attachment correlate with reduction in psychiatric symptoms. Psilocybin-assisted psychotherapy has demonstrated promise in the treatment of psychopathology, such as treatment-resistant depression and substance use disorders. We hypothesized that psilocybin-assisted psychotherapy would reduce attachment anxiety and attachment avoidance, thus increasing attachment security. We also hypothesized that baseline measures of attachment insecurity, which can reflect a diminished capacity for trust and exploration, would inform the quality of the psilocybin session. Participants were male long-term AIDS survivors with moderate-severe demoralization (n = 18). Using the Experiences in Close Relationships scale, we measured attachment insecurity at baseline as well as immediately, and 3 months, after completion of a brief group therapy course, which included a single midtreatment open-label psilocybin session conducted individually. Clinically important aspects of the psilocybin session were assessed using the revised Mystical Experience Questionnaire and the Challenging Experience Questionnaire the day following psilocybin administration. Self-reported ratings of attachment anxiety decreased significantly from baseline to 3-months post-intervention, t(16) = −2.2; p = 0.045; drm = 0.45; 95% CI0.01, 0.87. Attachment avoidance did not change significantly. Baseline attachment anxiety was strongly correlated with psilocybin-occasioned mystical-type experiences, r(15) = 0.53, p = 0.029, and baseline attachment avoidance was strongly correlated with psilocybin-related challenging experiences, r(16) = 0.62, p = 0.006. These findings have important implications for the general treatment of psychopathology as well as optimizing psilocybin-assisted psychotherapy as a broadly applicable treatment modality.", "journal": "ACS Pharmacology & Translational Science", "publication_date": "2020-12-08", "publication_year": 2020, "doi": "10.1021/acsptsci.0c00169", "pubmed_id": "33860182", "source_url": "https://doi.org/10.1021/acsptsci.0c00169", "keywords": "Psilocybin, Psychology, Anxiety, Psychopathology, Attachment theory, Clinical psychology, Hallucinogen, Psychiatry, Psychotherapist, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:38", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3112557491\",\"openalex_url\":\"https://openalex.org/W3112557491\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":65,\"referenced_works\":[\"https://openalex.org/W48793125\",\"https://openalex.org/W230843767\",\"https://openalex.org/W278113271\",\"https://openalex.org/W1480582778\",\"https://openalex.org/W1492586513\",\"https://openalex.org/W1720881856\",\"https://openalex.org/W1739148636\",\"https://openalex.org/W1831296187\",\"https://openalex.org/W1893171469\",\"https://openalex.org/W1997749778\",\"https://openalex.org/W2002249643\",\"https://openalex.org/W2003695103\",\"https://openalex.org/W2019674006\",\"https://openalex.org/W2032333542\",\"https://openalex.org/W2040047870\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2048140405\",\"https://openalex.org/W2051635542\",\"https://openalex.org/W2067614431\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2128248787\",\"https://openalex.org/W2163187022\",\"https://openalex.org/W2171544961\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2475851889\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2515306146\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2565550142\",\"https://openalex.org/W2603506674\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2756085338\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2784860341\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W2979584688\",\"https://openalex.org/W2980131837\",\"https://openalex.org/W2996321268\",\"https://openalex.org/W3001118513\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W4229920826\"],\"authorships\":[{\"id\":\"https://openalex.org/A5077197149\",\"display_name\":\"Christopher S. Stauffer\",\"orcid\":\"https://orcid.org/0000-0002-0888-095X\"},{\"id\":\"https://openalex.org/A5009662036\",\"display_name\":\"B. Anderson\",\"orcid\":\"https://orcid.org/0000-0001-5023-660X\"},{\"id\":\"https://openalex.org/A5021880959\",\"display_name\":\"Kile Ortigo\",\"orcid\":\"https://orcid.org/0000-0003-2047-8485\"},{\"id\":\"https://openalex.org/A5101826991\",\"display_name\":\"Joshua Woolley\",\"orcid\":\"https://orcid.org/0000-0001-6753-2093\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210207642\",\"source_display_name\":\"ACS Pharmacology & Translational Science\",\"landing_page_url\":\"https://doi.org/10.1021/acsptsci.0c00169\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Addiction,Mystical Experience,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3112557491" }, { "id": 3491, "title": "Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects", "normalized_title": "effects of serotonin transporter inhibition on the subjective response to psilocybin in healthy subjects", "authors": "University Hospital, Basel, Switzerland", "abstract": "Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT receptors, e.g. the 5-HT2A receptor. The aim of the study is to investigate the effects of psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects as well as effects on gene expression will be assessed. Psilocybin (the active substance in \"magic mushrooms\") is a classic serotonergic hallucinogen acting on the serotonin 5-HT2A receptor. Psilocybin is used recreationally and in psychiatric research. First studies suggest efficacy in psychiatric disorders, such as depression. SSRIs like escitalopram are currently among the first-line treatments of this disorder. Escitalopram acts as a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its positive effects on mood remains to be established. Several studies suggest a possible downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The aim of the study is to assess whether SERT inhibition reduces expression of the gene coding for the 5-HT2A receptor and the response to psilocybin. Participants will be treated with escitalopram (10 mg in the 1st and 20 mg in the 2nd week) or placebo for 14 days. Pretreatment is followed the first study day. A single dose of psilocybin (25 mg) will be administered. Primary study endpoint are the subjective effects on consciousness (measured by the 5D-ASC total score). Secondary study endpoints include additional psychological measurements, plasma concentrations of psilocybin and escitalopram, hydroxytryptamine receptor (HTR) gene expression, as well as some safety measures (autonomic effects, ECG). The washout between the first study day and the second pretreatment will be at least 2 days. In the second pretreatment period, participants will be treated with placebo or escitalopram (cross-over) for another 14 days. This is followed by the second study day and administration of psilocybin (25 mg). Based on a power analysis the sample size is 24 participants (12 female and 12 male).", "journal": "ClinicalTrials.gov", "publication_date": "2020-11-30", "publication_year": 2020, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT03912974", "keywords": "Healthy, Escitalopram, Placebo oral capsule, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT03912974\",\"overall_status\":\"COMPLETED\",\"phase\":[\"PHASE1\"]}", "topic_tags": "Depression,Neuroplasticity,Receptor Pharmacology,Consciousness,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 2226, "title": "Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.", "normalized_title": "psychedelic psychiatry preparing for novel treatments involving altered states of consciousness", "authors": "Holoyda B", "abstract": "The past decade has seen a renaissance of research interest into the psychotherapeutic potential of psychedelic compounds. In 2019, Oakland and Denver became the first two jurisdictions in the United States to decriminalize the possession of psychedelic-containing organisms. As research and public policy continue to evolve, it becomes increasingly plausible that psychedelics will become viable treatment options for psychiatric conditions. Psychiatrists should be integral to models of psychedelic prescription and patient management. The risk for adverse psychological and medical effects from psychedelic sessions necessitates psychiatric supervision. The literature on psychedelic-assisted psychotherapy may provide wisdom regarding practical aspects of managing patients' treatment sessions.", "journal": "Psychiatric services (Washington, D.C.)", "publication_date": "2020-11-30", "publication_year": 2020, "doi": "10.1176/appi.ps.202000213", "pubmed_id": "33050796", "source_url": "https://pubmed.ncbi.nlm.nih.gov/33050796/", "keywords": "LSD, psilocybin, psychedelic drugs, psychedelic psychiatry, psychedelic-assisted psychotherapy, psychedelics", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"33050796\"}", "topic_tags": "Consciousness,Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2201, "title": "Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.", "normalized_title": "therapeutic effects of classic serotonergic psychedelics a systematic review of modern era clinical studies", "authors": "Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D.", "abstract": "ObjectiveTo conduct a systematic review of modern-era (post-millennium) clinical studies assessing the therapeutic effects of serotonergic psychedelics drugs for mental health conditions. Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experiences were also reviewed and presented.MethodA systematic literature search (1 Jan 2000 to 1 May 2020) was conducted in PubMed and PsychINFO for studies of patients undergoing treatment with a serotonergic psychedelic.ResultsData from 16 papers, representing 10 independent psychedelic-assisted therapy trials (psilocybin = 7, ayahuasca = 2, LSD = 1), were extracted, presented in figures and tables, and narratively synthesized and discussed. Across these studies, a total of 188 patients suffering either cancer- or illness-related anxiety and depression disorders (C/I-RADD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD) or substance use disorder (SUD) were included. The reviewed studies established feasibility and evidence of safety, alongside promising early data of efficacy in the treatment of depression, anxiety, OCD, and tobacco and alcohol use disorders. For a majority of patients, the therapeutic effects appeared to be long-lasting (weeks-months) after only 1 to 3 treatment session(s). All studies were conducted in line with guidelines for the safe conduct of psychedelic therapy, and no severe adverse events were reported.ConclusionThe resurrection of clinical psychedelic research provides early evidence for treatment efficacy and safety for a range of psychiatric conditions, and constitutes an exciting new treatment avenue in a health area with major unmet needs.", "journal": null, "publication_date": "2020-11-30", "publication_year": 2020, "doi": "10.1111/acps.13249", "pubmed_id": "33125716", "source_url": "https://doi.org/10.1111/acps.13249", "keywords": "Humans, Alcoholism, Hallucinogens, Anxiety Disorders, Psilocybin, Major Depressive Disorder", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33125716\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,OCD,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2225, "title": "Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.", "normalized_title": "post acute psychological effects of classical serotonergic psychedelics a systematic review and meta analysis", "authors": "Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL.", "abstract": "BackgroundScientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate adverse effects and risk of bias.MethodsWe conducted a systematic review and meta-analysis of experimental studies (single-group pre-post or randomized controlled trials) that involved administration of psilocybin, ayahuasca, or LSD to clinical or non-clinical samples and assessed psychological outcomes ⩾24 h post-administration. Effects were summarized by study design, timepoint, and outcome domain.ResultsA total of 34 studies (24 unique samples, n = 549, mean longest follow-up = 55.34 weeks) were included. Classical psychedelics showed significant within-group pre-post and between-group placebo-controlled effects on a range of outcomes including targeted symptoms within psychiatric samples, negative and positive affect-related measures, social outcomes, and existential/spiritual outcomes, with large between-group effect in these domains (Hedges' gs = 0.84 to 1.08). Moderator tests suggest some effects may be larger in clinical samples. Evidence of effects on big five personality traits and mindfulness was weak. There was no evidence of post-acute adverse effects.ConclusionsHigh risk of bias in several domains, heterogeneity across studies, and indications of publication bias for some models highlight the need for careful, large-scale, placebo-controlled randomized trials.", "journal": null, "publication_date": "2020-11-03", "publication_year": 2020, "doi": "10.1017/s003329172000389x", "pubmed_id": "33143790", "source_url": "https://doi.org/10.1017/s003329172000389x", "keywords": "Humans, Banisteriopsis, Lysergic Acid Diethylamide, Hallucinogens, Mental Disorders, Randomized Controlled Trials as Topic, Evidence-Based Practice, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"33143790\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Personality Change,Spirituality,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3429, "title": "Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients", "normalized_title": "effects of psilocybin on anxiety and psychosocial distress in cancer patients", "authors": "NYU Langone Health", "abstract": "The primary objective of this double-blind, placebo-controlled pilot study is to assess the efficacy of psilocybin administration (4-phosphoryloxy-N,N-dimethyltryptamine), a serotonergic psychoactive agent, on psychosocial distress, with the specific primary outcome variable being anxiety associated with cancer. Secondary outcome measures will look at the effect of psilocybin on symptoms of pain perception, depression, existential/psychospiritual distress, attitudes towards disease progression and death, quality of life, and spiritual/mystical states of consciousness. In addition, a secondary objective of the study is to determine the feasibility of administering psilocybin to this patient population, with regards to the following issues: safety, patient recruitment, consent for treatment, and retention. The duration of the proposed investigation will be long enough to administer the drug one time to each of thirty-two patients and to conduct follow-up assessments. This study is separate but similar to a recently completed study at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, run by a psychiatrist, Dr. Charles Grob. Although the outcomes measures would be similar to those used as in the Grob study, the proposed dose of psilocybin is higher at 0.3mg/kg and the total subjects for the study would be 32 instead of 12. The study utilizes a cross-over design at 7 weeks and includes prospective follow-up of 6 months duration. This study has been approved by the Bellevue Psychiatry Research Committee, the NYU Oncology PRMC Committee, the Food and Drug Administration (FDA) through the issuance of an IND (77,138), the New York University School of Medicine Institutional Review Board (NYU IRB), the Health and Hospitals Corporation (HHC)-New York University (NYU) Clinical Translational Science Institute (CTSI), the NYU Bluestone Center for Clinical Research, and the Drug Enforcement Agency (DEA) through the issuance of a schedule I license. It is hypothesized that a one time experience with psilocybin will occasion dramatic shifts in consciousness and awareness that will lead to short-term (ie hours to days) and long-term (up to 6 months in this study, following the administration of the second dosing, either psilocybin or placebo) improvement in anxiety, depression, and pain associated with advanced cancer. The exact mechanism of action is unclear but based on studies done in the 60's using serotonergic hallucinogens in patients with advanced cancer, improvements in anxiety levels, mood and pain were reported. However, a treatment model developed by the famous British psychiatrist Humphrey Osmond, offers one possibility. In this model, serotonergic hallucinogens' therapeutic mechanism lies in their ability to allow the individual to access novel dimensions of consciousness and their efficacy or lack thereof relies on whether a transcendent and mystical state of awareness is attained. Another possible mechanism relates to what Dobkin de Rios and Grob have described as 'managed altered states of consciousness,' where the power of suggestibility, occurring in a safe setting, allows one to transcend a particular state of consciousness (i.e. anxiety and depression associated with advanced illness) as a means to facilitate emotional discharge and to manage irreconcilable conflict.", "journal": "ClinicalTrials.gov", "publication_date": "2020-10-19", "publication_year": 2020, "doi": null, "pubmed_id": null, "source_url": "https://clinicaltrials.gov/study/NCT00957359", "keywords": "Cancer, Psilocybin, 4-phosphoryloxy-N,N-dimethyltryptamine, Niacin, COMPLETED", "substance_tags": "psilocybin", "source_name": "ClinicalTrials.gov", "date_added": "2026-07-01 11:04:27", "last_checked": "2026-07-01 11:22:33", "raw_json": "{\"nct_id\":\"NCT00957359\",\"overall_status\":\"COMPLETED\",\"phase\":[\"EARLY_PHASE1\"]}", "topic_tags": "Depression,Anxiety,Chronic Pain,Mechanism of Action,Consciousness,Emotional Processing,Spirituality,Mystical Experience,Review Article,Cancer Patients,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "clinical trial", "openalex_id": null }, { "id": 2227, "title": "Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.", "normalized_title": "potential safety benefits and influence of the placebo effect in microdosing psychedelic drugs a systematic review", "authors": "Ona G, Bouso JC.", "abstract": "Microdosing psychedelic drugs-that is, taking sub-behavioral doses of lysergic acid diethylamide (LSD) or psilocybin-is a growing practice in Western societies. Taken mainly for creative or mood-enhancing purposes, thousands of users are increasingly being exposed to (micro)doses of psychedelic drugs. In this systematic review, we searched the available evidence from human studies, focusing our results in terms of three main axes: efficacy, safety, and the influence of the placebo effect in microdosing practices. While the available evidence has some strengths (e.g. large sample sizes, robust methodologies) there are also remarkable limitations (e.g. gender bias, heterogeneity of dosing schedules and drugs used). Highly contradictory results have been found, showing both the benefits and detriments of microdosing in terms of mood, creative processes, and energy, among other regards. This review provides a general overview of the methods and approaches used, which could be useful for improving future studies.", "journal": null, "publication_date": "2020-10-04", "publication_year": 2020, "doi": "10.1016/j.neubiorev.2020.09.035", "pubmed_id": "33031815", "source_url": "https://doi.org/10.1016/j.neubiorev.2020.09.035", "keywords": "Humans, Hallucinogens, Pharmaceutical Preparations, Placebo Effect, Female, Male, Sexism, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"33031815\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Microdosing,Creativity,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2237, "title": "Psilocybin-assisted group therapy: A new hope for demoralization", "normalized_title": "psilocybin assisted group therapy a new hope for demoralization", "authors": "Peter S. Hendricks", "abstract": "Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] open-label pilot study of psilocybin-assisted group therapy for demoralization among older long-term AIDS survivor (OLTAS) men is innovative and courageous. It is innovative in applying a group therapy paradigm not previously used in contemporary clinical studies of classic psychedelics. This is important because psilocybin- and other classic psychedelic-assisted treatments are typically time-intensive, involving several lengthy individual pre-drug preparatory sessions and post-drug integration sessions, raising concerns about scalability in real-world settings. The use of group therapy with classic psychedelics, though uncommon, is consistent with the anthropology of these compounds [[2]Schultes R.E. Hallucinogens of plant origin.Science. 1969; 163: 245-254Crossref PubMed Google Scholar], and may well increase the likelihood of implementing such interventions in clinical practice should they continue to prove safe and effective. Furthermore, considering the unique and ineffable nature of transcendent experiences occasioned by classic psychedelics [[3]Hendricks P.S. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy.Int Rev Psychiatry. 2018; 30: 331-342Crossref PubMed Scopus (63) Google Scholar,[4]Johnson M.W. Hendricks P.S. Barrett F.S. Griffiths R.R. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function.Pharmacol Ther. 2019; 197: 83-102Crossref PubMed Scopus (189) Google Scholar], group therapy may provide an optimal outlet for making meaning of such experiences, and critically, translating them to adaptive changes in behavior. Though comparing the effectiveness of group vs. individual therapy in this context is an objective for future research, it is nonetheless made possible by Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] trailblazing work. Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] study is courageous in its focus on OLTAS men, a marginalized population diagnosed with HIV/AIDS at a time when HIV/AIDS was considered a terminal diagnosis. OLTAS men endured unprecedented and devastating loss of loved ones, and consequently, demoralization-a sense of helplessness, hopelessness, and a loss of meaning in life-is a pervasive clinical concern. Anderson et al. [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] thus targeted a significant and difficult-to-treat problem with current demoralization-focused psychotherapies demonstrating limited effectiveness. Moreover, 50% of their sample met criteria for a comorbid mental health condition including generalized anxiety disorder, panic disorder, and borderline personality disorder. As psilocybin can produce acute anxiety/fear/panic, dysphoria, and confusion [[4]Johnson M.W. Hendricks P.S. Barrett F.S. Griffiths R.R. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function.Pharmacol Ther. 2019; 197: 83-102Crossref PubMed Scopus (189) Google Scholar], the administration of psilocybin to a group of individuals predisposed to these difficult experiences undoubtedly presented many challenges. These challenges were unquestionably amplified by the Schedule I status of psilocybin and the heightened political lens surrounding its clinical application. Still, despite these challenges, Anderson et al. [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] demonstrated the feasibility, safety, and potential efficacy of psilocybin-assisted group therapy for an underserved and vulnerable population. Of course, as with any open-label pilot study, Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] findings are not conclusive. Future randomized placebo-controlled trials with larger samples are required to more definitively inform the safety and effectiveness of psilocybin-assisted group therapy for OLTAS men. Nevertheless, Anderson et al.’s [[1]Anderson B.T. Danforth A. Daroff R. Stauffer C. Ekman E. Agin-Liebes G. et al.Psilocybin-facilitated group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study.Eclinical Med. 2020; https://doi.org/10.1016/j.eclinm.2020.100538Summary Full Text Full Text PDF Scopus (74) Google Scholar] findings open the door to future investigations testing psilocybin-assisted group therapy in other populations confronted with demoralization, including those with chronic pain, obesity, substance use disorders, and the elderly, among others [5Robinson S. Kissane D.W. Brooker J. Burney S. A review of the construct of demoralization: history, definitions, and future directions for palliative care.Am J Hosp Palliat Care. 2016; 33: 93-101Crossref PubMed Scopus (62) Google Scholar, 6Tecuta L. Tomba E. Grandi S. Fava G.A. Demoralization: a systematic review on its clinical characterization.Psychol Med. 2015; 45: 673-691Crossref PubMed Scopus (99) Google Scholar, 7Hendricks P.S. Grob C.S. Classic psychedelics and rational suicide in the elderly: exploring the potential utility of a reemerging treatment paradigm.in: McCue R. Balasubramaniam M. Rational suicide in the elderly. Springer International Publishing, Cham, Switzerland2017Crossref Google Scholar]. PSH is on the scientific advisory board of Bright Minds Biosciences Ltd. and Silo Pharma Inc. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot studyWe demonstrated the feasibility, relative safety, and potential efficacy of psilocybin-assisted group therapy for demoralization in OLTAS. Groups may be an effective and efficient means of delivering psychotherapy pre- and post-psilocybin to patients with complex medical and psychiatric needs. Full-Text PDF Open Access", "journal": "EClinicalMedicine", "publication_date": "2020-09-30", "publication_year": 2020, "doi": "10.1016/j.eclinm.2020.100557", "pubmed_id": "33073220", "source_url": "https://doi.org/10.1016/j.eclinm.2020.100557", "keywords": "Psilocybin, Hallucinogen, Psychotherapist, Medicine, Psychological intervention, Group psychotherapy, Scopus, Psychology, Psychiatry, MEDLINE, Political science, Law, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Alkaloids: synthesis and pharmacology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3089864945\",\"openalex_url\":\"https://openalex.org/W3089864945\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":5,\"referenced_works\":[\"https://openalex.org/W2016371428\",\"https://openalex.org/W2028459761\",\"https://openalex.org/W2031114136\",\"https://openalex.org/W2541133093\",\"https://openalex.org/W2541159474\",\"https://openalex.org/W2894541203\",\"https://openalex.org/W2903001666\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W6729145433\"],\"authorships\":[{\"id\":\"https://openalex.org/A5004506349\",\"display_name\":\"Peter S. Hendricks\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898347799\",\"source_display_name\":\"EClinicalMedicine\",\"landing_page_url\":\"https://doi.org/10.1016/j.eclinm.2020.100557\",\"is_oa\":true}}", "topic_tags": "Anxiety,Addiction,End-of-Life Distress,Chronic Pain,Pharmacology,Personality Change,Mystical Experience,Systematic Review,Review Article,Older Adults,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3089864945" }, { "id": 2228, "title": "The emerging role of psilocybin and MDMA in the treatment of mental illness.", "normalized_title": "the emerging role of psilocybin and mdma in the treatment of mental illness", "authors": "Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS.", "abstract": "IntroductionMental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Indeed, the economic burden of mental illness is estimated to exceed $1.8 trillion USD over the next 30 years. A significant number of individuals affected by mental illness fail to respond to first-line treatment options. Therefore, there remains an unmet need for rapidly attenuating therapeutic options for mental health disorders with minimal social and economic burden.Areas coveredThe paucity of novel treatment options warrants a renewed investigation of psychedelic-based psychotherapy. Herein, the authors will evaluate the therapeutic potential of traditional psychedelics, psilocybin, and MDMA, in the treatment of mental illness with a narrative review of available literature.Expert opinionPsychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety, tolerability, and efficacy in clinically representative populations are warranted.", "journal": null, "publication_date": "2020-09-29", "publication_year": 2020, "doi": "10.1080/14737175.2020.1826931", "pubmed_id": "32954860", "source_url": "https://doi.org/10.1080/14737175.2020.1826931", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"32954860\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Emotional Processing,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3834, "title": "Wait for the Science Before Widespread Use of Psilocybin", "normalized_title": "wait for the science before widespread use of psilocybin", "authors": "Nicole Harrington Cirino", "abstract": "Back to table of contents Previous article Next article ViewpointsFull AccessWait for the Science Before Widespread Use of PsilocybinNicole Harrington Cirino, M.D.Nicole Harrington Cirino, M.D.Published Online:28 Sep 2020https://doi.org/10.1176/appi.pn.2020.10a32AbstractThe momentum behind psilocybin as the next big \"breakthrough\" in treating psychiatric disorders is strong, but Oregon psychiatrists and APA have had to push back psilocybin enthusiasts from making unsafe and premature laws for the use of psilocybin for vulnerable psychiatric patients looking for a cure. Over 112,000 Oregon residents signed a petition and made campaign donations topping $1.2 million to put the question of whether psilocybin-which is not approved by the Food and Drug Administration (FDA)-should be legalized on the November ballot in Oregon. Measure 109, The Psilocybin Program Initiative, is the first psilocybin treatment measure being proposed in the United States. It is gaining significant support from the psilocybin community. The Oregon Psilocybin Society is leading the Yes vote on the Measure 109 campaign. The society was formed by Portland-area psychotherapists Thomas and Sheri Eckert (both master's-level psychotherapists). Missing from the planning or initiation of the initiative is any mention of or oversight by Oregon psychiatrists.The Oregon Psychiatric Physicians Association (OPPA) and APA have both voiced their opposition for this measure for three main reasons: (1) safety and efficacy have not yet been established for psilocybin, (2) using majority public vote via ballot initiative to bypass FDA approval for a new medical treatment is dangerous, and (3) if passed, the use of psilocybin will not require oversight by medical professionals, particularly psychiatrists.Measure 109 as written would allow the \"manufacture, delivery, and administration\" of the hallucinogenic drug psilocybin for the treatment of \"including but not limited to addiction, depression, anxiety disorders, and end of-life psychological distress\" by nonmedical providers.Those following the scientific data know that neither safety nor efficacy has been established according to FDA guidelines or clinical trials. The psychiatric community generally agrees with the FDA-that early limited trials have shown that this new treatment has potential. The FDA has given psilocybin \"breakthrough therapy\" status for major depressive disorder to Usona pharmaceuticals whose phase 2 trials are still under way. Phase 3 trials have yet to even start for psilocybin.Psilocybin is believed to act on serotonin receptors and induce hallucinations as its main proposed mechanism of action. Studies have not yet explored basic drug interactions with other serotonergic or dopaminergic agents, the impact on psychiatric conditions vulnerable to psychosis, dose, side-effect profile, and efficacy for the treatment of substance use disorders, anxiety disorders, and other comorbid psychiatric conditions. In essence, Measure 109 allows prescribing of a non-FDA approved Schedule 1 controlled substance by a nonmedical practitioner for an overly inclusive range of psychiatric conditions.In a letter in August to Oregon Secretary of State Bev Clarno, APA CEO and Medical Director Saul Levin, M.D., M.P.A., stated, \"Treating patients with mental health and substance use disorders is complex, due to the fact that more than half of these patients also have an underlying physical illness. Given our limited understanding of psilocybin's effects on patients and how it may interact with other medications, it is dangerous to allow practitioners-especially those with no medical training-to dispense a controlled substance.\"Psychiatrists, as physicians and experts in the treatment of psychiatric conditions, urge psilocybin nonphysician enthusiasts to slow down and wait for the science. It is dangerous to promote widespread use of psilocybin to vulnerable Oregonians with psychiatric conditions. ■The views expressed in this article do not represent the views of OHSU.The letter by Saul Levin, M.D., M.P.A., is posted here.Nicole Harrington Cirino, M.D., is president of the Oregon Psychiatric Physicians Association and an associate professor of psychiatry and obstetrics and gynecology at the Oregon Health and Science University. ISSUES NewArchived", "journal": "Psychiatric News", "publication_date": "2020-09-28", "publication_year": 2020, "doi": "10.1176/appi.pn.2020.10a32", "pubmed_id": null, "source_url": "https://doi.org/10.1176/appi.pn.2020.10a32", "keywords": "Psilocybin, Ballot, Psychiatry, Opposition (politics), Psychology, Political science, Medicine, Hallucinogen, Law, Politics, Voting, Psychedelics and Drug Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3091539953\",\"openalex_url\":\"https://openalex.org/W3091539953\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5002035022\",\"display_name\":\"Nicole Harrington Cirino\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210208841\",\"source_display_name\":\"Psychiatric News\",\"landing_page_url\":\"https://doi.org/10.1176/appi.pn.2020.10a32\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Addiction,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3091539953" }, { "id": 2238, "title": "Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study", "normalized_title": "psilocybin assisted group therapy for demoralized older long term aids survivor men an open label safety and feasibility pilot study", "authors": "B. Anderson, Alicia Danforth, Prof Robert Daroff, Christopher S. Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, James Dilley, Jennifer Mitchell, Joshua Woolley", "abstract": "BACKGROUND: Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and feasibility of psilocybin-assisted group therapy for demoralization in older long-term AIDS survivor (OLTAS) men, a population with a high degree of demoralization and traumatic loss. METHODS: Self-identified gay men OLTAS with moderate-to-severe demoralization (Demoralization Scale-II ≥8) were recruited from the community of a major US city for a single-site open-label study of psilocybin-assisted group therapy comprising 8-10 group therapy visits and one psilocybin administration visit (0·3-0·36 mg/kg po). Primary outcomes were rate and severity of adverse events, and participant recruitment and retention. The primary clinical outcome was change in mean demoralization from baseline to end-of-treatment and to 3-month follow-up assessed with a two-way repeated measures ANOVA. Trial registration: Clinicaltrials.gov (NCT02950467). FINDINGS: = 0·47, 90% CI0·21-0·60). INTERPRETATION: We demonstrated the feasibility, relative safety, and potential efficacy of psilocybin-assisted group therapy for demoralization in OLTAS. Groups may be an effective and efficient means of delivering psychotherapy pre- and post-psilocybin to patients with complex medical and psychiatric needs. FUNDING: Carey Turnbull, Heffter Research Institute, NIMH R25 MH060482, NIH UL1 TR001872, River Styx Foundation, Saisei Foundation, Sarlo Foundation, Stupski Foundation, Usona Institute, US Department of Veterans Affairs (Advanced Neurosciences Fellowship and IK2CX001495).", "journal": "EClinicalMedicine", "publication_date": "2020-09-23", "publication_year": 2020, "doi": "10.1016/j.eclinm.2020.100538", "pubmed_id": "33150319", "source_url": "https://doi.org/10.1016/j.eclinm.2020.100538", "keywords": "Psilocybin, Medicine, Adverse effect, Depression (economics), Population, Anxiety, Psychiatry, Internal medicine, Hallucinogen, Economics, Environmental health, Macroeconomics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3087859780\",\"openalex_url\":\"https://openalex.org/W3087859780\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":271,\"referenced_works\":[\"https://openalex.org/W1611751502\",\"https://openalex.org/W1969464104\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1992604744\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2010937911\",\"https://openalex.org/W2066061643\",\"https://openalex.org/W2080874345\",\"https://openalex.org/W2103115327\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2136554267\",\"https://openalex.org/W2137070227\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166928505\",\"https://openalex.org/W2336110886\",\"https://openalex.org/W2350952069\",\"https://openalex.org/W2467323865\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2582692487\",\"https://openalex.org/W2597627006\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2610614969\",\"https://openalex.org/W2612228298\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2810219060\",\"https://openalex.org/W2886232664\",\"https://openalex.org/W2906933919\",\"https://openalex.org/W2928737933\",\"https://openalex.org/W2942349161\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W2971371418\",\"https://openalex.org/W2993940948\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3001118513\",\"https://openalex.org/W3085274948\",\"https://openalex.org/W4230469801\",\"https://openalex.org/W4244471518\",\"https://openalex.org/W6680543326\",\"https://openalex.org/W6703176234\",\"https://openalex.org/W6737035451\",\"https://openalex.org/W6739822750\",\"https://openalex.org/W6767636190\",\"https://openalex.org/W6771900266\"],\"authorships\":[{\"id\":\"https://openalex.org/A5009662036\",\"display_name\":\"B. Anderson\",\"orcid\":\"https://orcid.org/0000-0001-5023-660X\"},{\"id\":\"https://openalex.org/A5051293419\",\"display_name\":\"Alicia Danforth\",\"orcid\":\"https://orcid.org/0000-0001-8726-046X\"},{\"id\":\"https://openalex.org/A5104548030\",\"display_name\":\"Prof Robert Daroff\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077197149\",\"display_name\":\"Christopher S. Stauffer\",\"orcid\":\"https://orcid.org/0000-0002-0888-095X\"},{\"id\":\"https://openalex.org/A5017016462\",\"display_name\":\"Eve Ekman\",\"orcid\":\"https://orcid.org/0000-0002-1572-5309\"},{\"id\":\"https://openalex.org/A5041698353\",\"display_name\":\"Gabrielle Agin-Liebes\",\"orcid\":\"https://orcid.org/0000-0002-9754-229X\"},{\"id\":\"https://openalex.org/A5010900227\",\"display_name\":\"Alexander Trope\",\"orcid\":\"https://orcid.org/0000-0003-1034-9110\"},{\"id\":\"https://openalex.org/A5026342430\",\"display_name\":\"Matthew Tyler Boden\",\"orcid\":\"https://orcid.org/0000-0002-7184-2518\"},{\"id\":\"https://openalex.org/A5054356516\",\"display_name\":\"James Dilley\",\"orcid\":\"https://orcid.org/0000-0002-1108-0048\"},{\"id\":\"https://openalex.org/A5078452831\",\"display_name\":\"Jennifer Mitchell\",\"orcid\":\"https://orcid.org/0000-0002-7567-8129\"},{\"id\":\"https://openalex.org/A5101826991\",\"display_name\":\"Joshua Woolley\",\"orcid\":\"https://orcid.org/0000-0001-6753-2093\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2898347799\",\"source_display_name\":\"EClinicalMedicine\",\"landing_page_url\":\"https://doi.org/10.1016/j.eclinm.2020.100538\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Chronic Pain,Veterans,Safety,Adverse Events,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3087859780" }, { "id": 2247, "title": "Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.", "normalized_title": "psilocybin as a new approach to treat depression and anxiety in the context of life threatening diseases a systematic review and meta analysis of clinical trials", "authors": "Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L.", "abstract": "Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those medical conditions. The Beck Depression Inventory (BDI) was used to measure the effects in depression and the State-Trait Anxiety Inventory (STAI) was used to measure the effects in anxiety. For BDI, 11 effect sizes were considered (92 patients) and the intervention group was significantly favored (WMD = -4.589; 95% CI = -4.207 to -0.971; p-value = 0.002). For STAI-Trait, 11 effect sizes were considered (92 patients), being the intervention group significantly favored when compared to the control group (WMD = -5.906; 95% CI = -7.852 to -3.960; p-value ˂ 0.001). For STAI-State, 9 effect sizes were considered (41 patients) and the intervention group was significantly favored (WMD = -6.032; 95% CI = -8.900 to -3.164; p-value ˂ 0.001). The obtained results are promising and emphasize the importance of psilocybin translational research in the management of symptoms of depression and anxiety, since the compound may be effective in reducing symptoms of depression and anxiety in conditions that are either resistant to conventional pharmacotherapy or for which pharmacologic treatment is not yet approved. Moreover, it may be also relevant for first-line treatment, given its safety.", "journal": null, "publication_date": "2020-09-04", "publication_year": 2020, "doi": "10.3390/biomedicines8090331", "pubmed_id": "32899469", "source_url": "https://doi.org/10.3390/biomedicines8090331", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"32899469\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Clinical Trial,Meta-Analysis,Systematic Review,Review Article,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2254, "title": "Compassionate use of psychedelics.", "normalized_title": "compassionate use of psychedelics", "authors": "Greif A, Šurkala M.", "abstract": "In the present paper, we discuss the ethics of compassionate psychedelic psychotherapy and argue that it can be morally permissible. When talking about psychedelics, we mean specifically two substances: psilocybin and MDMA. When administered under supportive conditions and in conjunction with psychotherapy, therapies assisted by these substances show promising results. However, given the publicly controversial nature of psychedelics, compassionate psychedelic psychotherapy calls for ethical justification. We thus review the safety and efficacy of psilocybin- and MDMA-assisted therapies and claim that it can be rational for some patients to try psychedelic therapy. We think it can be rational despite the uncertainty of outcomes associated with compassionate use as an unproven treatment regime, as the expected value of psychedelic psychotherapy can be assessed and can outweigh the expected value of routine care, palliative care, or no care at all. Furthermore, we respond to the objection that psychedelic psychotherapy is morally impermissible because it is epistemically harmful. We argue that given the current level of understanding of psychedelics, this objection is unsubstantiated for a number of reasons, but mainly because there is no experimental evidence to suggest that epistemic harm actually takes place.", "journal": null, "publication_date": "2020-08-31", "publication_year": 2020, "doi": "10.1007/s11019-020-09958-z", "pubmed_id": "32468195", "source_url": "https://doi.org/10.1007/s11019-020-09958-z", "keywords": "Humans, Chronic Disease, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Terminal Care, Mental Disorders, Psychotherapy, Compassionate Use Trials, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:05", "raw_json": "{\"europe_pmc_id\":\"32468195\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "End-of-Life Distress,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3846, "title": "A potential role for psilocybin in the treatment of obsessive-compulsive disorder", "normalized_title": "a potential role for psilocybin in the treatment of obsessive compulsive disorder", "authors": "Edward Jacobs", "abstract": "Abstract The recent revivification of interest in the therapeutic use of psychedelics has had a particular focus on mood disorders and addiction, although there is reason to think these drugs may be effective more widely. After outlining pertinent aspects of psilocybin and obsessive-compulsive disorder (OCD), the current review summarizes the evidence indicating that there may be a role for psilocybin in the treatment of OCD, as well as highlighting a range of potential therapeutic mechanisms that reflect the action of psilocybin on brain function. Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential.", "journal": "Journal of Psychedelic Studies", "publication_date": "2020-05-31", "publication_year": 2020, "doi": "10.1556/2054.2020.00128", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2020.00128", "keywords": "Psilocybin, Obsessive compulsive, Hallucinogen, Psychology, Mood, Psychotherapist, Addiction, Psychiatry, Medicine, Clinical psychology, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Body Image and Dysmorphia Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3048223422\",\"openalex_url\":\"https://openalex.org/W3048223422\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W62922542\",\"https://openalex.org/W122113993\",\"https://openalex.org/W200847362\",\"https://openalex.org/W592732404\",\"https://openalex.org/W1191653087\",\"https://openalex.org/W1784226620\",\"https://openalex.org/W1846321575\",\"https://openalex.org/W1964540177\",\"https://openalex.org/W1964698313\",\"https://openalex.org/W1965761294\",\"https://openalex.org/W1971459727\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1974109667\",\"https://openalex.org/W1978032191\",\"https://openalex.org/W1979963125\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1985748616\",\"https://openalex.org/W1995045083\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W1997392319\",\"https://openalex.org/W1997452831\",\"https://openalex.org/W2001090794\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2002443895\",\"https://openalex.org/W2005593798\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2012077435\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2015011531\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2029342476\",\"https://openalex.org/W2031832463\",\"https://openalex.org/W2033134445\",\"https://openalex.org/W2034593916\",\"https://openalex.org/W2036037381\",\"https://openalex.org/W2038928427\",\"https://openalex.org/W2042298460\",\"https://openalex.org/W2042307631\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2043711264\",\"https://openalex.org/W2054754029\",\"https://openalex.org/W2055110970\",\"https://openalex.org/W2058064963\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2063955964\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2071765462\",\"https://openalex.org/W2072467374\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2076256173\",\"https://openalex.org/W2078740239\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2082535915\",\"https://openalex.org/W2089130066\",\"https://openalex.org/W2092586569\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2093477837\",\"https://openalex.org/W2095643440\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2098915263\",\"https://openalex.org/W2100861230\",\"https://openalex.org/W2101309614\",\"https://openalex.org/W2101582587\",\"https://openalex.org/W2104320372\",\"https://openalex.org/W2107441654\",\"https://openalex.org/W2108292201\",\"https://openalex.org/W2111396411\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2120128279\",\"https://openalex.org/W2120918936\",\"https://openalex.org/W2129340715\",\"https://openalex.org/W2129502536\",\"https://openalex.org/W2136435696\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2140018908\",\"https://openalex.org/W2140172277\",\"https://openalex.org/W2159370497\",\"https://openalex.org/W2159990726\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166952073\",\"https://openalex.org/W2167273704\",\"https://openalex.org/W2171432760\",\"https://openalex.org/W2204342160\",\"https://openalex.org/W2319006982\",\"https://openalex.org/W2336389811\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2341558148\",\"https://openalex.org/W2345258591\",\"https://openalex.org/W2411998515\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2593476122\",\"https://openalex.org/W2596797494\",\"https://openalex.org/W2609660019\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2774876719\",\"https://openalex.org/W2780408016\",\"https://openalex.org/W2786472900\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2791704659\",\"https://openalex.org/W2792211781\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2801279915\",\"https://openalex.org/W2804362986\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2809850625\",\"https://openalex.org/W2889525702\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2895529315\",\"https://openalex.org/W2898717395\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W2999812626\",\"https://openalex.org/W3000549374\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3108285700\",\"https://openalex.org/W3142791708\",\"https://openalex.org/W3217097423\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4386315766\",\"https://openalex.org/W6649587555\",\"https://openalex.org/W6748386387\",\"https://openalex.org/W6755698176\",\"https://openalex.org/W6819150864\",\"https://openalex.org/W6821717516\"],\"authorships\":[{\"id\":\"https://openalex.org/A5014864277\",\"display_name\":\"Edward Jacobs\",\"orcid\":\"https://orcid.org/0000-0002-2622-7233\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2020.00128\",\"is_oa\":true}}", "topic_tags": "Addiction,OCD,Mechanism of Action,Receptor Pharmacology,Randomized Controlled Trial,Review Article,Animal Study,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3048223422" }, { "id": 2274, "title": "Ethics and ego dissolution: the case of psilocybin", "normalized_title": "ethics and ego dissolution the case of psilocybin", "authors": "William Smith, Dominic Sisti", "abstract": "Despite the fact that psychedelics were proscribed from medical research half a century ago, recent, early-phase trials on psychedelics have suggested that they bring novel benefits to patients in the treatment of several mental and substance use disorders. When beneficial, the psychedelic experience is characterized by features unlike those of other psychiatric and medical treatments. These include senses of losing self-importance, ineffable knowledge, feelings of unity and connection with others and encountering 'deep' reality or God. In addition to symptom relief, psychedelic experiences often lead to significant changes in a patient's personality and worldview. Focusing on the case of psilocybin, we argue that the peculiar features of psychedelics pose certain novel risks, which warrant an enhanced informed consent process-one that is more comprehensive than what may be typical for other psychiatric medications. We highlight key issues that should be focused on during the consent process and suggest discussion prompts for enhanced consent in psychedelic psychiatry. Finally, we respond to potential objections before concluding with a discussion of ethical considerations that will arise as psychedelics proceed from highly controlled research environments into mainstream clinical psychiatry.", "journal": "Journal of Medical Ethics", "publication_date": "2020-05-26", "publication_year": 2020, "doi": "10.1136/medethics-2020-106070", "pubmed_id": "32461241", "source_url": "https://doi.org/10.1136/medethics-2020-106070", "keywords": "Psilocybin, Psychology, Psychotherapist, Feeling, Mainstream, Informed consent, Psychiatry, Hallucinogen, Social psychology, Medicine, Law, Alternative medicine, Political science, Pathology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Complementary and Alternative Medicine Studies", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3029961383\",\"openalex_url\":\"https://openalex.org/W3029961383\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":142,\"referenced_works\":[\"https://openalex.org/W1495991128\",\"https://openalex.org/W1535165638\",\"https://openalex.org/W1819216112\",\"https://openalex.org/W1898248489\",\"https://openalex.org/W1972616052\",\"https://openalex.org/W1973933342\",\"https://openalex.org/W1989844817\",\"https://openalex.org/W1997096683\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2014977309\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2040939895\",\"https://openalex.org/W2047240705\",\"https://openalex.org/W2058614857\",\"https://openalex.org/W2059819102\",\"https://openalex.org/W2065217375\",\"https://openalex.org/W2071559616\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2080645517\",\"https://openalex.org/W2092831269\",\"https://openalex.org/W2107828364\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2173679640\",\"https://openalex.org/W2297074759\",\"https://openalex.org/W2336678555\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2417987369\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2568037688\",\"https://openalex.org/W2573408014\",\"https://openalex.org/W2582927459\",\"https://openalex.org/W2587622596\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2793484468\",\"https://openalex.org/W2799742551\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2892030583\",\"https://openalex.org/W2896390000\",\"https://openalex.org/W2897638859\",\"https://openalex.org/W2899027265\",\"https://openalex.org/W2945506353\",\"https://openalex.org/W2971272764\",\"https://openalex.org/W2980158818\",\"https://openalex.org/W2999261467\",\"https://openalex.org/W3080863879\",\"https://openalex.org/W4253554881\",\"https://openalex.org/W4254421317\",\"https://openalex.org/W4286446537\",\"https://openalex.org/W6638497575\",\"https://openalex.org/W6749681613\",\"https://openalex.org/W6999656228\",\"https://openalex.org/W7019640536\"],\"authorships\":[{\"id\":\"https://openalex.org/A5079442192\",\"display_name\":\"William Smith\",\"orcid\":\"https://orcid.org/0000-0001-6611-0817\"},{\"id\":\"https://openalex.org/A5069070306\",\"display_name\":\"Dominic Sisti\",\"orcid\":\"https://orcid.org/0000-0002-2282-9253\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S70185877\",\"source_display_name\":\"Journal of Medical Ethics\",\"landing_page_url\":\"https://doi.org/10.1136/medethics-2020-106070\",\"is_oa\":false}}", "topic_tags": "Addiction,Personality Change,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3029961383" }, { "id": 2283, "title": "Psilocybin Therapeutic Research: The Present and Future Paradigm", "normalized_title": "psilocybin therapeutic research the present and future paradigm", "authors": "Robert B. Kargbo", "abstract": "Psilocybin, an active component in \"magic mushroom\", may have the potential to meet the therapeutic needs for a number of indications without the addictiveness and overdose risk of other mind-altering drugs, such as cocaine, heroin, alcohol, methamphetamine, and so forth. The need for new therapies is urgent because addiction, overdose, and suicide deaths have risen throughout the United States and around the world. Anecdotal and contemporary pharmacological reports have provided some indication about the therapeutic use of psilocybin for the treatment of mental health disorders such as major depressive disorder and addiction disorders. In this Viewpoint, I summarize the current state of psilocybin therapeutic research and attempt to provide some insight into future directions on which the scientific community may wish to focus.", "journal": "ACS Medicinal Chemistry Letters", "publication_date": "2020-03-01", "publication_year": 2020, "doi": "10.1021/acsmedchemlett.0c00048", "pubmed_id": "32292538", "source_url": "https://doi.org/10.1021/acsmedchemlett.0c00048", "keywords": "Psilocybin, Computer science, Data science, Medicine, Hallucinogen, Pharmacology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Diverse academic research themes", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3009264042\",\"openalex_url\":\"https://openalex.org/W3009264042\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":48,\"referenced_works\":[\"https://openalex.org/W1973613743\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2108914738\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2887938296\",\"https://openalex.org/W2949457836\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090796568\",\"display_name\":\"Robert B. Kargbo\",\"orcid\":\"https://orcid.org/0000-0002-5539-6343\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S191852912\",\"source_display_name\":\"ACS Medicinal Chemistry Letters\",\"landing_page_url\":\"https://doi.org/10.1021/acsmedchemlett.0c00048\",\"is_oa\":false}}", "topic_tags": "Depression,Addiction,Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3009264042" }, { "id": 2295, "title": "Self-reported negative outcomes of psilocybin users: A quantitative textual analysis", "normalized_title": "self reported negative outcomes of psilocybin users a quantitative textual analysis", "authors": "Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos, Marco Aurélio Negreiros, Daniel C. Mograbi", "abstract": "Psilocybin, a substance mainly found in mushrooms of the genus psilocybe, has been historically used for ritualistic, recreational and, more recently, medicinal purposes. The scientific literature suggests low toxicity, low risk of addiction, overdose, or other causes of injury commonly caused by substances of abuse, with growing interest in the use of this substance for conditions such as treatment-resistant depression. However, the presence of negative outcomes linked to psilocybin use is not clear yet. The objective of this study is to investigate the negative effects of psilocybin consumption, according to the users' own perception through self-reports extracted from an online platform. 346 reports were analyzed with the assistance of the IRAMUTEQ textual analysis software, adopting the procedures of Descending Hierarchical Classification, Correspondence Factor Analysis and Specificities Analysis. The text segments were grouped in 4 main clusters, describing thinking distortions, emergencies, perceptual alterations and the administration of the substance. Bad trips were more frequent in female users, being associated with thinking distortions. The use of multiple doses of psilocybin in the same session or its combination with other substances was linked to the occurrence of long-term negative outcomes, while the use of mushrooms in single high doses was linked to medical emergencies. These results can be useful for a better understanding of the effects of psilocybin use, guiding harm-reduction initiatives.", "journal": "PLoS ONE", "publication_date": "2020-02-20", "publication_year": 2020, "doi": "10.1371/journal.pone.0229067", "pubmed_id": "32084160", "source_url": "https://doi.org/10.1371/journal.pone.0229067", "keywords": "Psilocybin, Hallucinogen, Psychology, Addiction, Psychiatry, Medicine, Clinical psychology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3007379062\",\"openalex_url\":\"https://openalex.org/W3007379062\",\"openalex_relevance_score\":11,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":79,\"referenced_works\":[\"https://openalex.org/W2000021284\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2024964629\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2281388340\",\"https://openalex.org/W2283526650\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2606173794\",\"https://openalex.org/W2610345163\",\"https://openalex.org/W2612228298\",\"https://openalex.org/W2616187260\",\"https://openalex.org/W2619242792\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2758523683\",\"https://openalex.org/W2791795903\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2831064708\",\"https://openalex.org/W2887140173\",\"https://openalex.org/W2891256775\",\"https://openalex.org/W2909739147\",\"https://openalex.org/W2981489145\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2991390907\",\"https://openalex.org/W3004628237\",\"https://openalex.org/W4248877989\"],\"authorships\":[{\"id\":\"https://openalex.org/A5000107619\",\"display_name\":\"Bheatrix Bienemann\",\"orcid\":\"https://orcid.org/0000-0003-4291-4612\"},{\"id\":\"https://openalex.org/A5076118196\",\"display_name\":\"Nina Stamato Ruschel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014422641\",\"display_name\":\"Maria Luiza Pesse Campos\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109585195\",\"display_name\":\"Marco Aurélio Negreiros\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037104251\",\"display_name\":\"Daniel C. Mograbi\",\"orcid\":\"https://orcid.org/0000-0002-4271-2984\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S202381698\",\"source_display_name\":\"PLoS ONE\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pone.0229067\",\"is_oa\":true}}", "topic_tags": "Depression,Addiction,Treatment-Resistant Depression,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3007379062" }, { "id": 2282, "title": "A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.", "normalized_title": "a review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses", "authors": "Chi T, Gold JA.", "abstract": "Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to highlight contemporary human studies on the use of select psychedelic drugs, such as psilocybin, LSD, MDMA and ayahuasca, in the treatment of various psychiatric illnesses, including but not limited to treatment-resistant depression, post-traumatic stress disorder, end-of-life anxiety, and substance use disorders. The safety and efficacy as reported from human and animal studies will also be discussed. Accumulated research to date has suggested the potential for psychedelics to emerge as breakthrough therapies for psychiatric conditions refractory to conventional treatments. However, given the unique history and high potential for misuse with popular distribution, special care and considerations must be undertaken to safeguard their use as viable medical treatments rather than drugs of abuse.", "journal": null, "publication_date": "2020-01-30", "publication_year": 2020, "doi": "10.1016/j.jns.2020.116715", "pubmed_id": "32044687", "source_url": "https://doi.org/10.1016/j.jns.2020.116715", "keywords": "Animals, Humans, Substance-Related Disorders, Hallucinogens, Pharmaceutical Preparations, Anxiety, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"32044687\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,End-of-Life Distress,Review Article,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2301, "title": "The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.", "normalized_title": "the experimental effects of psilocybin on symptoms of anxiety and depression a meta analysis", "authors": "Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR.", "abstract": "The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges' gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also large (gs = 0.82 to 0.83) and statistically significant. No serious adverse events were reported. Limitations include the small number of studies and risk for bias within studies. Results tentatively support future research on psilocybin for the treatment of anxiety and depression.", "journal": null, "publication_date": "2020-01-01", "publication_year": 2020, "doi": "10.1016/j.psychres.2020.112749", "pubmed_id": "31931272", "source_url": "https://doi.org/10.1016/j.psychres.2020.112749", "keywords": "Humans, Treatment Outcome, Depression, Anxiety, Female, Male, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"31931272\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Randomized Controlled Trial,Meta-Analysis,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3895, "title": "Analysis of Newspaper Coverage of Psilocybin from January 1, 1989 to December 31, 2019", "normalized_title": "analysis of newspaper coverage of psilocybin from january 1 1989 to december 31 2019", "authors": "Dax Oliver", "abstract": "Psilocybin is a chemical compound that has received a lot of attention from medical researchers in recent years. However, this research is not merely a medical issue but a social and political one as well. In the 1960s, psilocybin and other psychedelic compounds were widely ingested outside of clinical settings. This alarmed some of the American public, resulting in severe legal restrictions on psilocybin use and research. Today, many psilocybin advocates hope that it will avoid the negative public sentiment of the 1960s. To help gauge public sentiment about other psychoactive compounds, some studies have examined newspaper coverage, but there seems to be no similar published work yet on psilocybin. Building on these previous studies, I read and analyzed every article mentioning psilocybin from four regional American newspapers between January 1, 1989 and December 31, 2019. Three main issues were examined: 1) Has sentiment about psilocybin changed? 2) Has the number of articles mentioning psilocybin changed? 3) Has there been a change in the use of different terms for psilocybin? My study found that sentiment in these four newspapers fluctuated throughout the 30-year period, and a recent significant rise in positivity was only seen in one newspaper. The number of articles mentioning psilocybin significantly increased in just one newspaper. The only term for psilocybin that saw a decrease in use was “hallucinogenic mushrooms.” These results could be a warning to psilocybin advocates about the risk of negative social and political sentiment eventually growing again, though this is not conclusive. More investigation of this issue is recommended.", "journal": "CUNY Academic Works (City University of New York)", "publication_date": "2019-12-31", "publication_year": 2019, "doi": null, "pubmed_id": null, "source_url": "https://academicworks.cuny.edu/gc_etds/4074", "keywords": "Psilocybin, Newspaper, Advertising, Psychology, Business, Psychiatry, Hallucinogen, Psychedelics and Drug Studies, Sexuality, Behavior, and Technology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3121348693\",\"openalex_url\":\"https://openalex.org/W3121348693\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5077886257\",\"display_name\":\"Dax Oliver\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4377196304\",\"source_display_name\":\"CUNY Academic Works (City University of New York)\",\"landing_page_url\":\"https://academicworks.cuny.edu/gc_etds/4074\",\"is_oa\":false}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3121348693" }, { "id": 3891, "title": "The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder", "normalized_title": "the therapeutic potential of psilocybin and 3 4 methylenedioxymethamphetamine in the treatment of depression and post traumatic stress disorder", "authors": "Sofia Gyllvik", "abstract": "The psychedelic psilocybin and the entactogen 3,4-methylenedioxymethamphetamine (MDMA) are being scientifically studied again after a long hiatus, and especially for their potential in the treatment of psychiatric disorders. Their profound effect on cognitive, perceptual, and affective processes have led to several clinical studies during the last decade that have forced the reconsideration of the utility of these substances. The research includes clinical trials with psilocybin-assisted psychotherapy for depressive and anxiety symptoms, and MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorder (PTSD). The results have shown a significant reduction in depressive and anxiety symptoms in psilocybin-assisted psychotherapy, and in PTSD symptoms in MDMA-assisted psychotherapy, with acceptable adverse effects. Moreover, the reductions in symptoms have been shown to be sustained several years later. Given the results indicate short- and long-term safety and efficacy, even for treatment resistant conditions, this suggest that these substances administered with psychotherapy are promising and deserve to be taken seriously as a therapeutic tool. The present thesis provides an overview of the latest clinical studies on the treatment of depression, anxiety, and PTSD with psilocybin and MDMA, respectively, as well as reviews the history, mechanisms of action, the therapeutic process used with psilocybin and MDMA, and any adverse physiological and psychological effects of both substances.", "journal": "Diva portal (Dalarna University Library)", "publication_date": "2019-12-31", "publication_year": 2019, "doi": null, "pubmed_id": null, "source_url": "http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729", "keywords": "Psilocybin, Traumatic stress, Depression (economics), Psychology, Hallucinogen, Psychotherapist, Psychiatry, MDMA, Clinical psychology, Medicine, Economics, Macroeconomics, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Cannabis and Cannabinoid Research", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3083741926\",\"openalex_url\":\"https://openalex.org/W3083741926\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5075217865\",\"display_name\":\"Sofia Gyllvik\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400653\",\"source_display_name\":\"Diva portal (Dalarna University Library)\",\"landing_page_url\":\"http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,PTSD,Mechanism of Action,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3083741926" }, { "id": 3882, "title": "Medicinal use of psilocybin: Reducing restrictions on research and treatment.", "normalized_title": "medicinal use of psilocybin reducing restrictions on research and treatment", "authors": "James Rucker, Jessie Schnall, Daniel D’Hotman, David King, Timmy Davis, Joanna C. Neill", "abstract": "", "journal": null, "publication_date": "2019-12-31", "publication_year": 2019, "doi": null, "pubmed_id": null, "source_url": "https://www.drugsandalcohol.ie/32599/", "keywords": "Psilocybin, Risk analysis (engineering), Psychology, Medicine, Hallucinogen, Pharmacology, Psychedelics and Drug Studies, Mental Health and Psychiatry", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W3047998072\",\"openalex_url\":\"https://openalex.org/W3047998072\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":4,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5046431231\",\"display_name\":\"Jessie Schnall\",\"orcid\":null},{\"id\":\"https://openalex.org/A5081053543\",\"display_name\":\"Daniel D’Hotman\",\"orcid\":\"https://orcid.org/0000-0003-1616-6913\"},{\"id\":\"https://openalex.org/A5101987732\",\"display_name\":\"David King\",\"orcid\":\"https://orcid.org/0000-0002-8741-4761\"},{\"id\":\"https://openalex.org/A5031199581\",\"display_name\":\"Timmy Davis\",\"orcid\":null},{\"id\":\"https://openalex.org/A5049098570\",\"display_name\":\"Joanna C. Neill\",\"orcid\":\"https://orcid.org/0000-0002-2717-9739\"}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://www.drugsandalcohol.ie/32599/\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W3047998072" }, { "id": 2287, "title": "Psychedelic Microdosing: A Subreddit Analysis.", "normalized_title": "psychedelic microdosing a subreddit analysis", "authors": "Lea T, Amada N, Jungaberle H", "abstract": "Self-administration of very low doses of psychedelic drugs to improve mental health and wellbeing and enhance cognitive function, known as microdosing, has received recent media attention, but little research has been conducted. We conducted a content analysis of discussions about microdosing from the online forum Reddit. We examined motivations, dosing practices, and perceived benefits and limitations of microdosing. Motivations included self-management of mental health issues, improvement of psychosocial wellbeing, and cognitive enhancement. Self-reported benefits included cognitive and creative enhancement, reduced depression and anxiety, enhanced self-insight and mindfulness, improved mood and attitude toward life, improved habits and health behaviors, and improved social interactions and interpersonal connections. Perceived limitations included issues related to dosing, adverse physical effects, taking illegal substances, limited or no mental health or cognitive improvement, increased anxiety, unpleasant \"off\" days, only short-term benefits, and concerns about dependence and drug-related risks. Standard doses of psychedelic drugs provided in therapeutic settings have potential as novel treatments for some mental health conditions, but clinical research is needed to understand if this is also the case for microdosing. In the meantime, harm reduction resources should be developed and made available to provide the best available information on the safer use of self-administered psychedelics.", "journal": "Journal of psychoactive drugs", "publication_date": "2019-12-31", "publication_year": 2019, "doi": "10.1080/02791072.2019.1683260", "pubmed_id": "31648596", "source_url": "https://pubmed.ncbi.nlm.nih.gov/31648596/", "keywords": "LSD, Microdosing, cognitive performance, mental health, psilocybin, treatment", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:20:39", "raw_json": "{\"pubmed_id\":\"31648596\"}", "topic_tags": "Depression,Anxiety,Microdosing,Wellbeing,Creativity,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3285, "title": "Mapping Psilocybin-Assisted Therapies: A Scoping Review", "normalized_title": "mapping psilocybin assisted therapies a scoping review", "authors": "Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On.", "abstract": "We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psilocybin is a naturally-occurring tryptophan derivative found in species of mushroom with psycho-active properties. From 2022 records identified by database searching, 40 publications were included in the qualitative synthesis from which we identified 9 clinical trials with a total of 169 participants. Trials used a peak-psychedelic model of therapy, emphasizing inward journey through the use of eyeshades, set musical scores and with medium to high doses of psilocybin. No serious adverse effects were reported; mild adverse effects included transient anxiety, nausea and post-treatment headaches. Overall, the 9 trials all demonstrated safety, tolerability and preliminary efficacy in the treatments of obsessive-compulsive disorder, substance use disorder, treatment-resistant unipolar depression, anxiety or depression in patients with life-threatening cancer and demoralization among long-term AIDS survivors.The literature was found to be early and exploratory, with several limitations: only 5 were randomized controlled trials, small and homogenous patient sample size, difficulties in blinding, and the confounding influence of psychological supports provided. Further research is indicated to establish effectiveness for these and other indications, with a more diverse range of patients, and with differing program and dosing modalities.", "journal": "medRxiv", "publication_date": "2019-12-11", "publication_year": 2019, "doi": "10.1101/2019.12.04.19013896", "pubmed_id": null, "source_url": "https://doi.org/10.1101/2019.12.04.19013896", "keywords": "", "substance_tags": "psilocybin", "source_name": "medRxiv", "date_added": "2026-07-01 11:03:49", "last_checked": "2026-07-01 11:22:03", "raw_json": "{\"europe_pmc_id\":\"PPR105649\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"medRxiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,End-of-Life Distress,Headache / Migraine,Clinical Trial,Randomized Controlled Trial,Review Article,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 2224, "title": "DARK Classics in Chemical Neuroscience: NBOMes.", "normalized_title": "dark classics in chemical neuroscience nbomes", "authors": "Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL.", "abstract": "N-Benzylphenethylamines, commonly known as NBOMes, are synthetic psychedelic compounds derived from the phenethylamine class of psychedelics (2C-X compounds), which originally have been derived from the naturally occurring alkaloid mescaline. Analogously to their parent compounds and other classical psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), NBOMes are believed to exert their main pharmacological effects through activation of serotonin 2A (5-HT2A) receptors. Since their introduction as New Psychoactive Substances (NPSs) in 2010, NBOMes have been widely used for recreational purposes; this has resulted in numerous cases of acute toxicity, sometimes with lethal outcomes, leading to the classification of several NBOMes as Schedule I substances in 2013. However, in addition to their recreational use, the NBOMe class has yielded several important biochemical tools, including [11C]Cimbi-36, which is now being used in positron emission tomography (PET) studies of the 5-HT2A and 5-HT2C receptors in the mammalian brain, and 25CN-NBOH, one of the most selective 5-HT2A receptor agonists developed to date. In this Review, the history, chemistry, structure-activity relationships, ADME (absorption, distribution, metabolism, and excretion) properties, and safety profiles of NBOMes will be outlined and discussed.", "journal": null, "publication_date": "2019-11-11", "publication_year": 2019, "doi": "10.1021/acschemneuro.9b00528", "pubmed_id": "31657895", "source_url": "https://doi.org/10.1021/acschemneuro.9b00528", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"31657895\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Receptor Pharmacology,Review Article,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3920, "title": "Psilocybin for depression: Considerations for clinical trial design", "normalized_title": "psilocybin for depression considerations for clinical trial design", "authors": "Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz", "abstract": "Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question systematically. Given the subjective quality of both the psychedelic experience and depressive symptomatology, great care must be taken when designing a protocol to study the clinical efficacy of psychedelic drugs. This study will discuss many factors to consider when designing a clinical trial of psilocybin for MDD. Methods We provide a thorough review of pertinent research into antidepressant clinical trial methodology and review practical considerations that are relevant to the study of psychedelic-assisted treatment for depression. Results We discuss participant selection (including diagnostic accuracy, exclusion criteria, characteristics of the depressive episode, and the use of concurrent medications), study interventions (including dosing regimens, placebo selection, non-pharmacological components of treatment, and the importance of blinding), trial duration, outcome measures, and safety considerations. Conclusions Careful and transparent study design and data analysis will maximize the likelihood of generating meaningful, reproducible results, and identifying a treatment-specific effect. Meeting the highest standards for contemporary trial design may also broaden the acceptance of psychedelic research in the scientific community at large.", "journal": "Journal of Psychedelic Studies", "publication_date": "2019-08-31", "publication_year": 2019, "doi": "10.1556/2054.2019.026", "pubmed_id": null, "source_url": "https://doi.org/10.1556/2054.2019.026", "keywords": "Psilocybin, Blinding, Clinical trial, Major depressive disorder, Protocol (science), Psychological intervention, Depression (economics), Antidepressant, Medicine, Clinical study design, Psychology, Psychiatry, Clinical psychology, Research design, Alternative medicine, Hallucinogen, Anxiety, Cognition, Macroeconomics, Social science, Sociology, Pathology, Economics, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W2974814938\",\"openalex_url\":\"https://openalex.org/W2974814938\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":15,\"referenced_works\":[\"https://openalex.org/W1035028816\",\"https://openalex.org/W1730751745\",\"https://openalex.org/W1776258049\",\"https://openalex.org/W1908895882\",\"https://openalex.org/W1924546259\",\"https://openalex.org/W1964684482\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1978384112\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2002554882\",\"https://openalex.org/W2004762037\",\"https://openalex.org/W2017854344\",\"https://openalex.org/W2018351853\",\"https://openalex.org/W2018366064\",\"https://openalex.org/W2023081218\",\"https://openalex.org/W2023634568\",\"https://openalex.org/W2023687307\",\"https://openalex.org/W2032318019\",\"https://openalex.org/W2033784736\",\"https://openalex.org/W2034669884\",\"https://openalex.org/W2049695419\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2057880023\",\"https://openalex.org/W2063900798\",\"https://openalex.org/W2066671649\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2083644336\",\"https://openalex.org/W2083894864\",\"https://openalex.org/W2084152792\",\"https://openalex.org/W2090339413\",\"https://openalex.org/W2094608167\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2101646907\",\"https://openalex.org/W2109334244\",\"https://openalex.org/W2112249597\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2120460120\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2124295269\",\"https://openalex.org/W2128603617\",\"https://openalex.org/W2139725402\",\"https://openalex.org/W2140018908\",\"https://openalex.org/W2142133137\",\"https://openalex.org/W2146236789\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2148796661\",\"https://openalex.org/W2153403353\",\"https://openalex.org/W2159011576\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2169411569\",\"https://openalex.org/W2170904543\",\"https://openalex.org/W2171340584\",\"https://openalex.org/W2291794699\",\"https://openalex.org/W2296296811\",\"https://openalex.org/W2318643681\",\"https://openalex.org/W2319165603\",\"https://openalex.org/W2326537158\",\"https://openalex.org/W2340399189\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2410368260\",\"https://openalex.org/W2428332025\",\"https://openalex.org/W2438144546\",\"https://openalex.org/W2480021183\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2590652160\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2757390367\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2807830955\",\"https://openalex.org/W2894431596\",\"https://openalex.org/W2897080393\",\"https://openalex.org/W2942667518\",\"https://openalex.org/W2944263526\",\"https://openalex.org/W2952169207\",\"https://openalex.org/W4240995428\",\"https://openalex.org/W4245499518\",\"https://openalex.org/W6637688905\",\"https://openalex.org/W6696590373\",\"https://openalex.org/W6703672616\",\"https://openalex.org/W6717913965\"],\"authorships\":[{\"id\":\"https://openalex.org/A5042151214\",\"display_name\":\"Kelley C. O’Donnell\",\"orcid\":\"https://orcid.org/0000-0001-9983-2699\"},{\"id\":\"https://openalex.org/A5087382833\",\"display_name\":\"Sarah E. Mennenga\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086692011\",\"display_name\":\"Michael P. Bogenschutz\",\"orcid\":\"https://orcid.org/0000-0003-4530-3470\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2019.026\",\"is_oa\":true}}", "topic_tags": "Depression,Anxiety,Receptor Pharmacology,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2974814938" }, { "id": 2330, "title": "Hallucinogens and Their Therapeutic Use: A Literature Review.", "normalized_title": "hallucinogens and their therapeutic use a literature review", "authors": "Begola MJ, Schillerstrom JE.", "abstract": "The exploration of possible therapeutic benefits of hallucinogenic substances has undergone a revitalization in the past decade. This literature review investigated the published literature regarding the psychotherapeutic uses of hallucinogens in psychiatric disorders. The results showed that a variety of substances have been evaluated in the treatment of psychiatric disorders, including ayahuasca, ibogaine, ketamine, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin. The conditions treated ranged from depression to autism, with the largest volume of research dedicated to substance use disorders. The majority of studies that were reviewed demonstrated significant associations with improvement in the conditions investigated. However, it was difficult to draw definitive conclusions as most studies suffered from small sample sizes, inconsistent measures, and poor study design. To properly assess the risks and potential benefits of hallucinogens in psychiatric treatment, there is a need for well designed, standardized studies that demonstrate the impact of hallucinogenic substances on psychiatric conditions.", "journal": null, "publication_date": "2019-08-31", "publication_year": 2019, "doi": "10.1097/pra.0000000000000409", "pubmed_id": "31505518", "source_url": "https://doi.org/10.1097/pra.0000000000000409", "keywords": "Humans, Hallucinogens, Risk Assessment, Mental Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"31505518\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2320, "title": "Classical psychedelics for the treatment of depression and anxiety: A systematic review.", "normalized_title": "classical psychedelics for the treatment of depression and anxiety a systematic review", "authors": "Muttoni S, Ardissino M, John C.", "abstract": "BackgroundDepression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to traditional treatments. This review aims to determine the efficacy and tolerability of psychedelics in the management of resistant depression.MethodsClinical trials investigating psychedelics in patients with depression and/or anxiety were searched via MEDLINE, EMBASE and PsychINFO. Efficacy was assessed by measuring symptom improvement from baseline, and tolerability was evaluated by noting the incidence and type of adverse effects reported. Risk of bias was assessed.ResultsSeven studies, with 130 patients, were analysed in this review. Three were conducted in patients with depression, two in patients with anxiety and two in patients with both. In a supportive setting, ayahuasca, psilocybin, and LSD consistently produced immediate and significant anti-depressant and anxiolytic effects that were endured for several months. Psychedelics were well-tolerated. The most common adverse effects were transient anxiety, short-lived headaches, nausea and mild increases in heart rate and blood pressure.LimitationsAt present, the number of studies on this subject is very limited; and the number of participating patients within these is also limited as the treatment under investigations is a relatively novel concept.ConclusionsThough further evidence is required, psychedelics appear to be effective in significantly reducing symptoms of depression and anxiety and are well-tolerated.", "journal": null, "publication_date": "2019-07-29", "publication_year": 2019, "doi": "10.1016/j.jad.2019.07.076", "pubmed_id": "31382100", "source_url": "https://doi.org/10.1016/j.jad.2019.07.076", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Anxiety Disorders, Depressive Disorder, Adult, Female, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"31382100\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Headache / Migraine,Clinical Trial,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2331, "title": "Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.", "normalized_title": "microdosing psychedelics more questions than answers an overview and suggestions for future research", "authors": "Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D.", "abstract": "BackgroundIn the past few years, the issue of 'microdosing' psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is.AimThis critique paper is designed to address questions that need to be answered by future scientific studies and to offer guidelines for these studies.ApproachOwing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin. Psilocybin is allegedly, next to lysergic acid diethylamide (LSD), one of the two most frequently used psychedelics to microdose. Where relevant and available, data for other psychedelic drugs are also mentioned.ConclusionIt is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.", "journal": null, "publication_date": "2019-07-13", "publication_year": 2019, "doi": "10.1177/0269881119857204", "pubmed_id": "31303095", "source_url": "https://doi.org/10.1177/0269881119857204", "keywords": "Animals, Humans, Hallucinogens, Memory, Attention, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"31303095\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Pharmacology,Receptor Pharmacology,Microdosing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3926, "title": "The Potential of Psilocybin Administration in Terminal Cancer Patients", "normalized_title": "the potential of psilocybin administration in terminal cancer patients", "authors": "Richard Simoneaux", "abstract": "psilocybin; depression; terminal cancer; CME; CNE: psilocybin; depression; terminal cancer; CME; CNEPsilocybin is a naturally occurring alkaloid found in more than 200 species of mushrooms. This compound, which was first isolated by the Swiss chemist Albert Hofman in 1959, is the active constituent of psychedelic mushrooms which are thought to have been utilized by humans since prehistoric times. In vivo, psilocybin is converted by the liver to psilocin, which is in fact the active pharmacological agent. Mechanistically, psilocin is thought to function as a partial agonist to several serotonin receptors. In the 1960s, several different groups were performing research using psychedelic agents; however, these studies were drastically affected by the U.S. government's classification of both psilocybin and psilocin as Schedule I drugs in October 1970, though increasingly limited research continued at the Maryland Psychiatric Research Center until 1977. After a dormant period of 22 years, Roland Griffiths, PhD, and William Richards, PhD, successfully obtained federal and university clearances in 1999 to reinitiate human studies with psilocybin at the Johns Hopkins School of Medicine. In October 2018, the FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression. “I am hopeful that the FDA's designation of psilocybin as a breakthrough therapy for treatment-resistant depression will allow greater exploration of psychedelic therapy in other patient populations,” stated Richards, who is a psychologist in the Psychiatry Department of the Johns Hopkins University School of Medicine, Bayview Medical Center. Phase II Study in Cancer Patients Many cancer patients experience psychological stress due to their diagnosis, which can result in clinically significant depression and/or anxiety. In a phase II clinical study (NCT00465595), supported by the Heffter Research Institute and performed at Johns Hopkins, researchers evaluated psilocybin in participants who had received a potentially life-threatening cancer diagnosis who also had anxiety and depressed mood (J Psychopharm 2016;30:1181-1197). In this double-blind study, patients were randomized in a 1:1 ratio to two different psilocybin dosing regimens: high dose (22 or 30 mg/70 kg) first followed by a low dose (1 or 3 mg/70 kg) or low dose first followed by a high dose. Initially, the high dose was 30 mg/70 kg; however, this was reduced to 22 mg/70 kg after two of the first three patients receiving the high dose were discontinued by the study personnel. The low dose of psilocybin was lowered to 1 mg/70 kg from 3 mg/70 kg after dosing 12 participants at the 3 mg level. This dose was altered because data from the same dose-effect study showed significant psilocybin effects at 5 mg/70 kg, and there was concern that 3 mg/70 kg might produce psychedelic effects in some research volunteers and not serve reliably as an inactive placebo. There were two primary therapeutic outcome measures which were utilized: the widely used GRID-HAMD-17 for depression and HAM-A assessed with the SIGH-A for anxiety. These measurements were taken at baseline, 5 weeks after each session, and at 6 months. In clinician-rated measures, clinical significance was noted for those responses with a 50 percent or greater decrease in measure with respect to baseline, while symptom remission was defined as a 50 percent or greater decrease in measure relative to baseline and a score of seven or less on the GRID-HAMD or HAM-A. This study, which included 51 patients (low/high-25; high/low-26), showed that, when administered in a psychologically supportive setting by properly trained personnel, a single dose of psilocybin can produce clinically significant responses, yielding substantial and enduring decreases in both depressed mood and anxiety. In addition, many of these cancer patients also reported increases in quality of life, as well as decreases in death anxiety. Enduring effects at 6 months were noted for the patients in assessments made by the patients, clinicians, and community observers. “At 6 months, the overall rate of clinical response for clinician-rated depression was 78 percent, while the figure for clinician-rated anxiety was 83 percent,” Richards noted. Two similar studies conducted at UCLA and New York University also reported positive findings. Pharmacokinetics Study An open-label phase I dose-escalation study (NCT02163707) evaluated the safety and pharmacokinetics of psilocybin in 12 healthy adult participants in sequential doses of 0.3, 0.45, and 0.6 mg/kg (Clin Pharmacokinet 2017;56:1543-1554). In preparation for receiving psilocybin, eligible healthy adults had between 6 and 8 hours of counseling prior to receiving their dosing. Psilocybin administration was performed at monthly intervals in a controlled environment with 24-hour monitoring. In some participants, an extended elimination phase was noted; this was postulated to be due to the hydrolysis of a key psilocin metabolite. An important observation was the fact that variability in psilocin clearance was not predicted by body weight. Importantly, no serious adverse events were noted during the course of this study. Using the pharmacokinetic parameters obtained, a 25 mg oral dose of psilocybin would produce a drug exposure that approximated the 0.3 mg/kg oral dose utilized in this study. Importantly, no serious physical or psychological effects were noted during or up to 30 days after any dose, even at a dose of 0.6 mg/kg, which is roughly double that likely to be used in a clinical setting. Future Studies A randomized, double-blind phase II clinical study (NCT03866174), which is being sponsored by the Usona Institute, is planned to include 80 participants from 21 to 65 years old who meet the criteria for major depressive disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Stratification will be performed according to study site, with participants being randomized in a 1:1 ratio to a single oral dose of either 25 mg psilocybin or placebo (100 mg niacin). “The GMP quality psilocybin that will be used in this study was synthesized in a laboratory and does not come from mushrooms,” Richards noted. The primary outcome in this study is the difference in the centrally rated Montgomery-Asberg Depression Rating Scale (MADRS) total score between baseline and day 8 post-dose. This clinican-rated scale is designed to measure depression severity and to detect changes resulting from antidepressant therapy. The MADRS consists of 10 items, each being scored from 0 (if the item is not present or normal) to 6 (severe or continuous presence of the symptoms); with this scale, a higher score represents a more severe condition. Among the MADRS-derived secondary outcomes in this study were change in a centrally rated MADRS score from baseline to day 43 post-dose; sustained depressive symptom response, which is defined as a 50 percent or greater reduction from baseline in the centrally rated MADRS score at all post-dose assessments (at days 8, 15, 29, and 43 post-dose); and sustained depressive symptom remission, which is defined as a centrally rated MADRS score 10 or less at all post-dose assessments (at days 8, 15, 29, and 43 post-dose). An additional secondary outcome is the difference in the local investigator-assessed Sheehan Disability Scale (SDS) scores between baseline and day 43 post-dose. The SDS, which consists of three self-rated items, is designed to gauge the degree to which a patient's life is affected by psychiatric symptoms, including depression. The study is estimated to start in September 2019 and expected to be completed by February 2021. In another phase IIb clinical study (NCT03775200), the safety and efficacy of psilocybin is being evaluated in patients diagnosed with treatment-resistant depression. This trial, which is being conducted at treatment centers in North America and Europe, is planned to include 216 patients from 18 to 55 years of age. This study, which is quadruple-masked (patient, care provider, investigator, and outcomes assessor), includes three different treatment arms: low-dose psilocybin, medium-dose psilocybin, and high-dose psilocybin. The primary outcome measure in this trial is the MADRS, measured up to 12 weeks after dosing. Discussion When asked about his background with psilocybin therapy for cancer patients, Richards replied, “I treated my first cancer patient with psilocybin in 1967. Over the years, the responses that I have noted in cancer patients who have received psilocybin-based psychedelic therapy combined with counseling have been remarkably transformative.” Richards explained the procedure for prospective candidates receiving psychedelic therapy. “First, potential candidates for this therapy are screened to determine if this therapy would be appropriate for them. Next, the patient undergoes a total of 6-8 hours of counseling prior to being dosed with psilocybin. This counseling is extremely important, as it develops a sense of trust with the staff that will be present with the patient when they are under the influence of psilocybin, as well as prepare the participants for what they may experience during the dosing session. “It is essential that the patient establish a significant level of trust with the individuals who will be with them during the action of psilocybin, as that will put them at ease and allow them to be more open to their unfolding inner experiences; the ability to be at ease and open to the alternative states of consciousness is of paramount importance for the patient to derive the most benefit from the agent. Many [bad experiences] are often the result of the patient trying to be in control of the psychedelic experiences instead of allowing them to follow their own course.” Regarding the results he has personally observed, Richards stated, “The outcomes observed in our studies have been significantly transformative, with many patients showing positive effects many months after a single dose of psilocybin. In many instances, not only does the terminal cancer patient lose their fear of death, but they will actually take on the role of a counselor and help those grieving in their families to cope with their impending mortality. “The main thing that I would like to convey to clinicians is that the transformation that psilocybin ushers forth, which is often several months in length, is drawn from the patient's long-term memory, not the result of any lingering compound present in their system or continuing drug administration. When asked why psilocybin was still listed as a Schedule I substance, Richards replied rhetorically, “Now that is a very profound question, isn't it? The University of Wisconsin study showed that, in healthy adults, no serious psychological or physical effects were observed up to 30 days after dosing, even at supratherapeutic levels. “In terms of abuse potential, psilocybin is absolutely not habit-forming, does not result in physical dependence even with repeated use, and in my opinion has much less risk for overuse than the opioids which are routinely prescribed for pain management. That having been said, it is crucial that when someone takes psilocybin that they are in a safe environment in the company of appropriately trained professionals who can ensure their personal safety.” Summarizing, Richards stated, “Now is a very exciting time to be doing psychedelic research using psilocybin; the FDA's granting of Breakthrough Therapy designation for psilocybin for treatment-resistant depression is a noteworthy milestone which may eventually lead to the removal of its Schedule I classification. “I am hopeful that the results that have been obtained for cancer patients with psilocybin therapy and counseling may serve as a springboard to apply this treatment to others in need.” Richard Simoneaux is a contributing writer. Read This Article & Earn CME or CNE! Earn continuing education credit by completing a quiz about this article. You may read the article here or on our website, then complete the quiz, answering at least 70 percent of the questions correctly to earn credit. CONTINUING MEDICAL EDUCATION INFORMATION FOR PHYSICIANS Visit http://CME.LWW.com for more information about this educational offering and to complete the CME activity. This enduring material is available to physicians in all specialties. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity expires June 30, 2021. The cost of the exam is $10. The payment covers processing and certificate fees. PROVIDER ACCREDITATION INFORMATION FOR NURSES Lippincott Professional Development (LPD) will award 1.0 contact hour for this continuing nursing education activity. LPD is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP11749 for 1.0 contact hour. LWW is also an approved provider by the District of Columbia, Georgia, and Florida CE Broker #50-1223. Visit www.nursingcenter.com/ce for more information and to complete the CNE activity. Fee: $12.95. Deadline: June 4, 2021 For nurses who wish to take the test for CE contact hours, visit www.nursingcenter.com/ce. Learning Objectives for This Month's CME Activity: After participating in this CME/CNE activity, readers should be better able to: 1. Analyze outcomes observed in various studies that used psilocybin for patients with terminal cancer. 2.Outline the goals of future research that will treat terminal cancer patients with psilocybin. Disclosure: The author(s), faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.", "journal": "Oncology Times", "publication_date": "2019-06-27", "publication_year": 2019, "doi": "10.1097/01.cot.0000574916.46844.cf", "pubmed_id": null, "source_url": "https://doi.org/10.1097/01.cot.0000574916.46844.cf", "keywords": "Psilocybin, Hallucinogen, Depression (economics), Cancer, Medicine, Psychiatry, Pharmacology, Psychology, Internal medicine, Macroeconomics, Economics, Psychedelics and Drug Studies", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-02 20:42:13", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"openalex_id\":\"https://openalex.org/W2956046898\",\"openalex_url\":\"https://openalex.org/W2956046898\",\"openalex_relevance_score\":14,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5070426634\",\"display_name\":\"Richard Simoneaux\",\"orcid\":\"https://orcid.org/0000-0003-3505-057X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210170078\",\"source_display_name\":\"Oncology Times\",\"landing_page_url\":\"https://doi.org/10.1097/01.cot.0000574916.46844.cf\",\"is_oa\":false}}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Chronic Pain,Pharmacology,Receptor Pharmacology,Consciousness,Clinical Trial,Cancer Patients,Treatment-Resistant Depression,Healthcare Workers,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2956046898" }, { "id": 3732, "title": "Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.", "normalized_title": "microdosing psychedelics personality mental health and creativity differences in microdosers", "authors": "Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS.", "abstract": "RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing mayprovide complementary clinical benefits using lower-risk, non-hallucinogenic doses.ObjectivesThis pre-registered study aimed to investigate whether microdosing psychedelics is related to differences in personality, mental health, and creativity.MethodsIn this observational study, respondents recruited from online forums self-reported their microdosing behaviors and completed questionnaires concerning dysfunctional attitudes, wisdom, negative emotionality, open-mindedness, and mood. Respondents also performed the Unusual Uses Task to assess their creativity.ResultsCurrent and former microdosers scored lower on measures of dysfunctional attitudes (p < 0.001, r = - 0.92) and negative emotionality (p = 0.009, r = - 0.85) and higher on wisdom (p < 0.001, r = 0.88), openmindedness(p = 0.027, r = 0.67), and creativity (p < 0.001, r = 0.15) when compared to non-microdosing controls.ConclusionsThese findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.", "journal": null, "publication_date": "2019-01-01", "publication_year": 2019, "doi": "10.1007/s00213-018-5106-2", "pubmed_id": "30604183", "source_url": "https://doi.org/10.1007/s00213-018-5106-2", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Depression, Emotions, Anxiety, Personality, Mental Health, Perception, Dose-Response Relationship, Drug, Adult, Female, Male, Creativity, Surveys and Questionnaires, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 11:08:44", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"30604183\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Microdosing,Wellbeing,Personality Change,Emotional Processing,Creativity,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 3405, "title": "Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers", "normalized_title": "microdosing psychedelics personality mental health and creativity differences in microdosers", "authors": "Anderson T, Petranker R, Rosenbaum D, Weissman C, Dinh-Williams L, Hui K, Hapke E, Farb NAS.", "abstract": "Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing may provide complementary clinical benefits using lower-risk, non-hallucinogenic doses. No experimental study has evaluated psychedelic microdosing, however; this pre-registered study is the first to investigate microdosing psychedelics and mental health. Recruited from online forums, current and former microdosers scored lower on measures of dysfunctional attitudes and negative emotionality and higher on wisdom, open-mindedness, and creativity when compared to non-microdosing controls. These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.", "journal": "PsyArXiv", "publication_date": "2018-11-01", "publication_year": 2018, "doi": "10.31234/osf.io/gk4jd", "pubmed_id": null, "source_url": "https://doi.org/10.31234/osf.io/gk4jd", "keywords": "", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 11:03:52", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"PPR333294\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"PsyArXiv\",\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Microdosing,Wellbeing,Personality Change,Emotional Processing,Creativity,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 2360, "title": "Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers", "normalized_title": "microdosing psychedelics personality mental health and creativity differences in microdosers", "authors": "", "abstract": "Microdosing psychedelics - the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin - is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties, microdosing may provide complementary clinical benefits using lower-risk, non-hallucinogenic doses. No experimental study has evaluated psychedelic microdosing, however; this pre-registered study is the first to investigate microdosing psychedelics and mental health. Recruited from online forums, current and former microdosers scored lower on measures of dysfunctional attitudes and negative emotionality and higher on wisdom, open-mindedness, and creativity when compared to non-microdosing controls. These findings provide promising initial evidence that warrants controlled experimental research to directly test safety and clinical efficacy. As microdoses are easier to administer than full-doses, this new paradigm has the exciting potential to shape future psychedelic research.", "journal": "PsyArXiv", "publication_date": "2018-11-01", "publication_year": 2018, "doi": null, "pubmed_id": null, "source_url": "https://osf.io/preprints/psyarxiv/gk4jd_v1", "keywords": "microdosing, preregistered, psychedelics, Psychiatry, Life Sciences", "substance_tags": "psilocybin", "source_name": "PsyArXiv", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:30", "raw_json": "{\"osf_id\":\"gk4jd_v1\",\"version\":1,\"reviews_state\":\"accepted\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Microdosing,Wellbeing,Personality Change,Emotional Processing,Creativity,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "preprint", "openalex_id": null }, { "id": 2370, "title": "Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.", "normalized_title": "does getting high hurt characterization of cases of lsd and psilocybin containing mushroom exposures to national poison centers between 2000 and 2016", "authors": "Leonard JB, Anderson B, Klein-Schwartz W.", "abstract": "BackgroundLysergic acid diethylamide (LSD) and psilocybin are serotonergic hallucinogens that are used primarily for recreational abuse. Small studies evaluated the efficacy of LSD and psilocybin for several psychiatric conditions. There are limited safety or toxicity data for either of these substances, especially in large populations.MethodsThis was a retrospective analysis of single-substance exposures of LSD or psilocybin-containing mushrooms (PcMs) reported to United States poison centers from 1 January 2000 to 31 December 2016. The study describes the most frequent toxicities, management sites, and medical outcomes.ResultsA total of 5883 PcM and 3554 LSD exposures were included. Most patients were between 13 and 29 years of age (83.9% PcM, 88.9% LSD) and primarily male (77.9% PcM, 74.1% LSD). Most common clinical effects were hallucinations (45.8% PcM, 37.4% LSD), agitation (24.1% PcM, 42.4% LSD), and tachycardia (18.0% PcM, 38.6% LSD). Serious clinical effects were infrequent, but included hyperthermia, seizures, coma, increased serum creatinine, and cardiac arrest. Most patients were treated and released from the emergency department. More LSD patients were admitted to critical care and non-critical care units than PcM patients. Moderate effect was the most frequent outcome for both substances (61.0% PcM, 62.3% LSD).ConclusionThese data find that LSD and PcM use occurs primarily in adolescents and young adults, who experience mild to moderate adverse effects. Serious effects are infrequent but can occur. While most LSD and PcM users require only emergency department management, LSD use is more likely to require medical admission.", "journal": "Journal of Psychopharmacology", "publication_date": "2018-09-04", "publication_year": 2018, "doi": "10.1177/0269881118793086", "pubmed_id": "30182795", "source_url": "https://doi.org/10.1177/0269881118793086", "keywords": "Humans, Agaricales, Lysergic Acid Diethylamide, Hallucinogens, Retrospective Studies, Age Distribution, Adolescent, Adult, Aged, Aged, 80 and over, Middle Aged, Child, Child, Preschool, Infant, Emergency Service, Hospital, Poison Control Centers, United States, Female, Male, Young Adult, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:39", "raw_json": "{\"europe_pmc_id\":\"30182795\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2889566085\",\"openalex_url\":\"https://openalex.org/W2889566085\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":85,\"referenced_works\":[\"https://openalex.org/W1963868116\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2028825681\",\"https://openalex.org/W2031343230\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2048272107\",\"https://openalex.org/W2064283285\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2094583078\",\"https://openalex.org/W2095349468\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2109884356\",\"https://openalex.org/W2160976181\",\"https://openalex.org/W2163176525\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2557998092\",\"https://openalex.org/W2558291661\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2740495861\",\"https://openalex.org/W2757295924\",\"https://openalex.org/W2771056291\",\"https://openalex.org/W2793066401\",\"https://openalex.org/W2916306937\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4243047549\"],\"authorships\":[{\"id\":\"https://openalex.org/A5013813978\",\"display_name\":\"James B. Leonard\",\"orcid\":\"https://orcid.org/0000-0002-6444-8950\"},{\"id\":\"https://openalex.org/A5106132781\",\"display_name\":\"Bruce D. Anderson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002362757\",\"display_name\":\"Wendy Klein-Schwartz\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881118793086\",\"is_oa\":false}}}", "topic_tags": "Adolescents,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2889566085" }, { "id": 2389, "title": "Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.", "normalized_title": "efficacy tolerability and safety of serotonergic psychedelics for the management of mood anxiety and substance use disorders a systematic review of systematic reviews", "authors": "Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC.", "abstract": "IntroductionMood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic hallucinogens/psychedelics including ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) have anxiolytic, antidepressive, and antiaddictive effects. Areas Covered: A systematic review of systematic reviews assessing the efficacy, safety, and tolerability of serotonergic hallucinogens/psychedelic was performed using the PubMed data base until 11 April 2018. Systematic reviews with or without meta-analysis were analyzed, but only reviews that described at least one randomized controlled trial (RCT) were included. Expert Commentary: Psilocybin and LSD reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. Although the results are promising, several studies were open label, and only few were RCTs, and most had small sample sizes and a short duration. Single or few doses of these drugs seem to be well tolerated, but long-term studies are lacking. New RCTs with bigger samples and longer duration are needed to replicate these findings.", "journal": null, "publication_date": "2018-08-22", "publication_year": 2018, "doi": "10.1080/17512433.2018.1511424", "pubmed_id": "30102078", "source_url": "https://doi.org/10.1080/17512433.2018.1511424", "keywords": "Humans, Banisteriopsis, Substance-Related Disorders, Lysergic Acid Diethylamide, Serotonin Agents, Hallucinogens, Anxiety Disorders, Depressive Disorder, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"30102078\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Receptor Pharmacology,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2391, "title": "Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.", "normalized_title": "current perspectives on psychedelic therapy use of serotonergic hallucinogens in clinical interventions", "authors": "Garcia-Romeu A, Richards WA", "abstract": "Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20 century, considerable advances were made in developing therapeutic approaches integrating administration of low () and high () doses of serotonergic hallucinogens for treatment of a variety of conditions, often incorporating psychoanalytic concepts prevalent at that time. This work contributed seminal insights regarding how these substances may be employed with efficacy and safety in targeted therapeutic interventions, including the importance of optimizing set (frame of mind) and setting (therapeutic environment). More recently, clinical and pharmacological research has revisited the effects and therapeutic potential of psychedelics utilizing a variety of approaches. The current article provides an overview of past and present models of psychedelic therapy, and discusses important considerations for future interventions incorporating the use of psychedelics in research and clinical practice.", "journal": "International review of psychiatry (Abingdon, England)", "publication_date": "2018-07-31", "publication_year": 2018, "doi": "10.1080/09540261.2018.1486289", "pubmed_id": "30422079", "source_url": "https://pubmed.ncbi.nlm.nih.gov/30422079/", "keywords": "LSD, Psychedelic therapy, hallucinogens, psilocybin", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:20:40", "raw_json": "{\"pubmed_id\":\"30422079\"}", "topic_tags": "Spirituality,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2397, "title": "Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.", "normalized_title": "psychedelic assisted psychotherapy a paradigm shift in psychiatric research and development", "authors": "Schenberg EE.", "abstract": "Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a paradigmatic crisis. A radical innovation is psychedelic-assisted psychotherapy (PAP): professionally supervised use of ketamine, MDMA, psilocybin, LSD and ibogaine as part of elaborated psychotherapy programs. Clinical results so far have shown safety and efficacy, even for \"treatment resistant\" conditions, and thus deserve increasing attention from medical, psychological and psychiatric professionals. But more than novel treatments, the PAP model also has important consequences for the diagnostics and explanation axis of the psychiatric crisis, challenging the discrete nosological entities and advancing novel explanations for mental disorders and their treatment, in a model considerate of social and cultural factors, including adversities, trauma, and the therapeutic potential of some non-ordinary states of consciousness.", "journal": "Frontiers in Pharmacology", "publication_date": "2018-07-04", "publication_year": 2018, "doi": "10.3389/fphar.2018.00733", "pubmed_id": "30026698", "source_url": "https://doi.org/10.3389/fphar.2018.00733", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"30026698\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2831064708\",\"openalex_url\":\"https://openalex.org/W2831064708\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":241,\"referenced_works\":[\"https://openalex.org/W126579187\",\"https://openalex.org/W1144621943\",\"https://openalex.org/W1547692811\",\"https://openalex.org/W1584978701\",\"https://openalex.org/W1607733577\",\"https://openalex.org/W1792210707\",\"https://openalex.org/W1865092458\",\"https://openalex.org/W1877280491\",\"https://openalex.org/W1885564923\",\"https://openalex.org/W1939191864\",\"https://openalex.org/W1967609660\",\"https://openalex.org/W1969017941\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1974724297\",\"https://openalex.org/W1976396510\",\"https://openalex.org/W1977293782\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1984615306\",\"https://openalex.org/W1992059353\",\"https://openalex.org/W1993324335\",\"https://openalex.org/W1996143523\",\"https://openalex.org/W1997159235\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2000519244\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2001298144\",\"https://openalex.org/W2004035372\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2006931708\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2017353191\",\"https://openalex.org/W2018267671\",\"https://openalex.org/W2020659752\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2026484120\",\"https://openalex.org/W2026767598\",\"https://openalex.org/W2030744232\",\"https://openalex.org/W2033134445\",\"https://openalex.org/W2039531554\",\"https://openalex.org/W2044440339\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2055661286\",\"https://openalex.org/W2056114002\",\"https://openalex.org/W2059761623\",\"https://openalex.org/W2064971417\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2067384745\",\"https://openalex.org/W2068596607\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2072549395\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075704313\",\"https://openalex.org/W2075757880\",\"https://openalex.org/W2077534208\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2082298526\",\"https://openalex.org/W2084290400\",\"https://openalex.org/W2084385783\",\"https://openalex.org/W2084808900\",\"https://openalex.org/W2086742707\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2088813417\",\"https://openalex.org/W2089149909\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2093943230\",\"https://openalex.org/W2094570976\",\"https://openalex.org/W2094649224\",\"https://openalex.org/W2097685148\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2099158744\",\"https://openalex.org/W2100222965\",\"https://openalex.org/W2106636235\",\"https://openalex.org/W2107788476\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115164032\",\"https://openalex.org/W2117269242\",\"https://openalex.org/W2118540296\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119898869\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2123090955\",\"https://openalex.org/W2124413615\",\"https://openalex.org/W2127654449\",\"https://openalex.org/W2131536379\",\"https://openalex.org/W2132248371\",\"https://openalex.org/W2135748590\",\"https://openalex.org/W2137981069\",\"https://openalex.org/W2138172214\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2140018908\",\"https://openalex.org/W2140922502\",\"https://openalex.org/W2141217193\",\"https://openalex.org/W2145095988\",\"https://openalex.org/W2153594880\",\"https://openalex.org/W2155887402\",\"https://openalex.org/W2158775170\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2167938116\",\"https://openalex.org/W2170596036\",\"https://openalex.org/W2192023023\",\"https://openalex.org/W2197394318\",\"https://openalex.org/W2279757001\",\"https://openalex.org/W2315039785\",\"https://openalex.org/W2323128034\",\"https://openalex.org/W2325558246\",\"https://openalex.org/W2326374493\",\"https://openalex.org/W2328454126\",\"https://openalex.org/W2330686105\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2341144630\",\"https://openalex.org/W2343567633\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2409433773\",\"https://openalex.org/W2427846517\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2489085829\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2513687987\",\"https://openalex.org/W2525190545\",\"https://openalex.org/W2528752100\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2549731540\",\"https://openalex.org/W2550626767\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2559883979\",\"https://openalex.org/W2561419573\",\"https://openalex.org/W2581696375\",\"https://openalex.org/W2582550385\",\"https://openalex.org/W2583277970\",\"https://openalex.org/W2590375860\",\"https://openalex.org/W2592111319\",\"https://openalex.org/W2605399484\",\"https://openalex.org/W2605994583\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2612600212\",\"https://openalex.org/W2613258400\",\"https://openalex.org/W2618371434\",\"https://openalex.org/W2622982732\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2681791877\",\"https://openalex.org/W2735648966\",\"https://openalex.org/W2735984207\",\"https://openalex.org/W2737205065\",\"https://openalex.org/W2738683289\",\"https://openalex.org/W2740285531\",\"https://openalex.org/W2741959390\",\"https://openalex.org/W2744933359\",\"https://openalex.org/W2745716771\",\"https://openalex.org/W2751749587\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2790381919\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2792882327\",\"https://openalex.org/W2799742551\",\"https://openalex.org/W2892045952\",\"https://openalex.org/W4210676517\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W6713982387\"],\"authorships\":[{\"id\":\"https://openalex.org/A5090128248\",\"display_name\":\"Eduardo Ekman Schenberg\",\"orcid\":\"https://orcid.org/0000-0001-7111-9891\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S132108250\",\"source_display_name\":\"Frontiers in Pharmacology\",\"landing_page_url\":\"https://doi.org/10.3389/fphar.2018.00733\",\"is_oa\":true}}}", "topic_tags": "Consciousness,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2831064708" }, { "id": 2375, "title": "The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.", "normalized_title": "the abuse potential of medical psilocybin according to the 8 factors of the controlled substances act", "authors": "Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.", "abstract": "This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to guide appropriate schedule placement. Psilocybin, like other 5-HT2A agonist classic psychedelics, has limited reinforcing effects, supporting marginal, transient non-human self-administration. Nonetheless, mushrooms with variable psilocybin content are used illicitly, with a few lifetime use occasions being normative among users. Potential harms include dangerous behavior in unprepared, unsupervised users, and exacerbation of mental illness in those with or predisposed to psychotic disorders. However, scope of use and associated harms are low compared to prototypical abused drugs, and the medical model addresses these concerns with dose control, patient screening, preparation and follow-up, and session supervision in a medical facility. CONCLUSIONS: (1) psilocybin has an abuse potential appropriate for CSA scheduling if approved as medicine; (2) psilocybin can provide therapeutic benefits that may support the development of an approvable New Drug Application (NDA) but further studies are required which this review describes; (3) adverse effects of medical psilocybin are manageable when administered according to risk management approaches; and (4) although further study is required, this review suggests that placement in Schedule IV may be appropriate if a psilocybin-containing medicine is approved. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.", "journal": null, "publication_date": "2018-06-04", "publication_year": 2018, "doi": "10.1016/j.neuropharm.2018.05.012", "pubmed_id": "29753748", "source_url": "https://doi.org/10.1016/j.neuropharm.2018.05.012", "keywords": "Animals, Humans, Substance-Related Disorders, Hallucinogens, Drug and Narcotic Control, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"29753748\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Receptor Pharmacology,Review Article,Cancer Patients,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2364, "title": "Ceremonial \"plant medicine\" use and its relationship to recreational drug use: an exploratory study.", "normalized_title": "ceremonial plant medicine use and its relationship to recreational drug use an exploratory study", "authors": "Dorsen C, Palamar J, Shedlin MG.", "abstract": "BackgroundThe ceremonial use of psychoactive/hallucinogenic plant based drugs, such as ayahuasca, psilocybin and others, is a growing trend in the United States (US) and globally. To date, there has been little research documenting how many people are using psychoactive substances in this context, who the users are, what benefits/risks exist in the use of these drugs and the relationship between ceremonial drug use and recreational drug use.In this paper we describe a cohort of plant medicine facilitators in the US and explore how they differentiate plant medicine use from recreational drug use.MethodsUsing modified ethnography, individual interviews were conducted in 2016 with 15 participants who are currently facilitating plant medicine ceremonies in the US. Descriptive content analysis was performed to discover themes and to inform a larger mixed-method study.ResultsCeremonial drug use was seen by participants as a natural healing and treatment modality used in the context of community and ritual. Three main themes were identified relating to participants' differentiation between ceremonial plant medicine use and recreational drug use: 1) participants see a clear delineation between plant medicine use and recreational drug use; 2) plant medicine is seen as a potential treatment for addiction, but concerns exist regarding potential interference with recovery; and 3) plant medicine use may influence recreational use.ConclusionsMore research is needed on who is using plant medicine, motivators for use, perceived and real risks and benefits of plant medicine use and harm reduction techniques regarding safe ingestion.", "journal": "Addiction Research & Theory", "publication_date": "2018-03-29", "publication_year": 2018, "doi": "10.1080/16066359.2018.1455187", "pubmed_id": "31534445", "source_url": "https://doi.org/10.1080/16066359.2018.1455187", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"31534445\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2794634193\",\"openalex_url\":\"https://openalex.org/W2794634193\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":21,\"referenced_works\":[\"https://openalex.org/W1586595642\",\"https://openalex.org/W1597579900\",\"https://openalex.org/W1797327965\",\"https://openalex.org/W1892948428\",\"https://openalex.org/W1970305111\",\"https://openalex.org/W1981281259\",\"https://openalex.org/W1993277108\",\"https://openalex.org/W1998631480\",\"https://openalex.org/W2010516245\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2022115750\",\"https://openalex.org/W2027481157\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2045951745\",\"https://openalex.org/W2056738644\",\"https://openalex.org/W2060970768\",\"https://openalex.org/W2062495686\",\"https://openalex.org/W2064822410\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2096058212\",\"https://openalex.org/W2098185806\",\"https://openalex.org/W2112887191\",\"https://openalex.org/W2115592977\",\"https://openalex.org/W2116852450\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2126656764\",\"https://openalex.org/W2129497492\",\"https://openalex.org/W2132467809\",\"https://openalex.org/W2147495553\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2158707882\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2161617741\",\"https://openalex.org/W2334295439\",\"https://openalex.org/W2336735968\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2415329247\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2557014604\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2561135550\",\"https://openalex.org/W4206711400\",\"https://openalex.org/W4211150788\"],\"authorships\":[{\"id\":\"https://openalex.org/A5070923322\",\"display_name\":\"Caroline Dorsen\",\"orcid\":\"https://orcid.org/0000-0001-8972-9954\"},{\"id\":\"https://openalex.org/A5048935006\",\"display_name\":\"Joseph J. Palamar\",\"orcid\":\"https://orcid.org/0000-0002-8565-9415\"},{\"id\":\"https://openalex.org/A5042135243\",\"display_name\":\"Michele G. Shedlin\",\"orcid\":\"https://orcid.org/0000-0003-2112-7601\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210205888\",\"source_display_name\":\"Addiction Research & Theory\",\"landing_page_url\":\"https://doi.org/10.1080/16066359.2018.1455187\",\"is_oa\":false}}}", "topic_tags": "Addiction,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2794634193" }, { "id": 2425, "title": "The hidden therapist: evidence for a central role of music in psychedelic therapy.", "normalized_title": "the hidden therapist evidence for a central role of music in psychedelic therapy", "authors": "Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R.", "abstract": "RationaleRecent studies have supported the safety and efficacy of psychedelic therapy for mood disorders and addiction. Music is considered an important component in the treatment model, but little empirical research has been done to examine the magnitude and nature of its therapeutic role.ObjectivesThe present study assessed the influence of music on the acute experience and clinical outcomes of psychedelic therapy.MethodsSemi-structured interviews inquired about the different ways in which music influenced the experience of 19 patients undergoing psychedelic therapy with psilocybin for treatment-resistant depression. Interpretative phenomenological analysis was applied to the interview data to identify salient themes. In addition, ratings were given for each patient for the extent to which they expressed \"liking,\" \"resonance\" (the music being experienced as \"harmonious\" with the emotional state of the listener), and \"openness\" (acceptance of the music-evoked experience).ResultsAnalyses of the interviews revealed that the music had both \"welcome\" and \"unwelcome\" influences on patients' subjective experiences. Welcome influences included the evocation of personally meaningful and therapeutically useful emotion and mental imagery, a sense of guidance, openness, and the promotion of calm and a sense of safety. Conversely, unwelcome influences included the evocation of unpleasant emotion and imagery, a sense of being misguided and resistance. Correlation analyses showed that patients' experience of the music was associated with the occurrence of \"mystical experiences\" and \"insightfulness.\" Crucially, the nature of the music experience was significantly predictive of reductions in depression 1 week after psilocybin, whereas general drug intensity was not.ConclusionsThis study indicates that music plays a central therapeutic function in psychedelic therapy.", "journal": "Psychopharmacology", "publication_date": "2018-02-01", "publication_year": 2018, "doi": "10.1007/s00213-017-4820-5", "pubmed_id": "29396616", "source_url": "https://doi.org/10.1007/s00213-017-4820-5", "keywords": "Humans, Hallucinogens, Music Therapy, Emotions, Auditory Perception, Psychotherapy, Music, Adult, Female, Male, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"29396616\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2784069100\",\"openalex_url\":\"https://openalex.org/W2784069100\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":273,\"referenced_works\":[\"https://openalex.org/W254473825\",\"https://openalex.org/W1144621943\",\"https://openalex.org/W1903624862\",\"https://openalex.org/W1980423369\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2023436353\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2028880259\",\"https://openalex.org/W2033134445\",\"https://openalex.org/W2037317432\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2064094124\",\"https://openalex.org/W2067121749\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2082412835\",\"https://openalex.org/W2089149909\",\"https://openalex.org/W2101824915\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2115780895\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2127654449\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2144198023\",\"https://openalex.org/W2157023976\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2186505253\",\"https://openalex.org/W2330686105\",\"https://openalex.org/W2336389811\",\"https://openalex.org/W2337964085\",\"https://openalex.org/W2341558148\",\"https://openalex.org/W2342076491\",\"https://openalex.org/W2345322841\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2413044490\",\"https://openalex.org/W2502147470\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2560522434\",\"https://openalex.org/W2582692487\",\"https://openalex.org/W2591107398\",\"https://openalex.org/W2602946064\",\"https://openalex.org/W2608897054\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2667975260\",\"https://openalex.org/W2738683289\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2906955016\",\"https://openalex.org/W4240789427\"],\"authorships\":[{\"id\":\"https://openalex.org/A5019717586\",\"display_name\":\"Mendel Kaelen\",\"orcid\":\"https://orcid.org/0000-0002-6987-9346\"},{\"id\":\"https://openalex.org/A5061472267\",\"display_name\":\"Bruna Giribaldi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5074153650\",\"display_name\":\"Jordan Raine\",\"orcid\":\"https://orcid.org/0000-0003-0504-6019\"},{\"id\":\"https://openalex.org/A5061474054\",\"display_name\":\"Lisa Evans\",\"orcid\":\"https://orcid.org/0000-0001-6997-4143\"},{\"id\":\"https://openalex.org/A5089121796\",\"display_name\":\"Christopher Timmerman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5069950620\",\"display_name\":\"Natalie Rodriguez\",\"orcid\":\"https://orcid.org/0000-0001-6669-8737\"},{\"id\":\"https://openalex.org/A5020826324\",\"display_name\":\"Leor Roseman\",\"orcid\":\"https://orcid.org/0000-0001-9990-6029\"},{\"id\":\"https://openalex.org/A5071332026\",\"display_name\":\"Amanda Feilding\",\"orcid\":\"https://orcid.org/0000-0002-1329-1893\"},{\"id\":\"https://openalex.org/A5101507504\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-6423-9411\"},{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S80334769\",\"source_display_name\":\"Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1007/s00213-017-4820-5\",\"is_oa\":true}}}", "topic_tags": "Depression,Addiction,Emotional Processing,Mystical Experience,Treatment-Resistant Depression,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2784069100" }, { "id": 2417, "title": "Taking Psychedelics Seriously.", "normalized_title": "taking psychedelics seriously", "authors": "Byock I.", "abstract": "BackgroundPsychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. More recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored approach. A single or brief series of sessions often results in substantial and sustained improvement among people with treatment-resistant depression and anxiety, including those with serious medical conditions. Need and Clinical Considerations: Palliative care clinicians occasionally encounter patients with emotional, existential, or spiritual suffering, which persists despite optimal existing treatments. Such suffering may rob people of a sense that life is worth living. Data from Oregon show that most terminally people who obtain prescriptions to intentionally end their lives are motivated by non-physical suffering. This paper overviews the history of this class of drugs and their therapeutic potential. Clinical cautions, adverse reactions, and important steps related to safe administration of psychedelics are presented, emphasizing careful patient screening, preparation, setting and supervision.ConclusionEven with an expanding evidence base confirming safety and benefits, political, regulatory, and industry issues impose challenges to the legitimate use of psychedelics. The federal expanded access program and right-to-try laws in multiple states provide precendents for giving terminally ill patients access to medications that have not yet earned FDA approval. Given the prevalence of persistent suffering and growing acceptance of physician-hastened death as a medical response, it is time to revisit the legitimate therapeutic use of psychedelics.", "journal": null, "publication_date": "2018-01-21", "publication_year": 2018, "doi": "10.1089/jpm.2017.0684", "pubmed_id": "29356590", "source_url": "https://doi.org/10.1089/jpm.2017.0684", "keywords": "Humans, Hallucinogens, Palliative Care, Mental Disorders", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"29356590\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Emotional Processing,Spirituality,Treatment-Resistant Depression,Healthcare Workers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2441, "title": "Therapeutic Applications of Classic Hallucinogens.", "normalized_title": "therapeutic applications of classic hallucinogens", "authors": "Bogenschutz MP, Ross S.", "abstract": "This chapter reviews what is known about the therapeutic uses of the serotonergic or classic hallucinogens, i.e., psychoactive drugs such as LSD and psilocybin that exert their effects primarily through agonist activity at serotonin 2A (5HT2A) receptors. Following a review of the history of human use and scientific study of these drugs, the data from clinical research are summarized, including extensive work on the use of classic hallucinogens in the treatment of alcoholism and other addictions, studies of the use of LSD and psilocybin to relieve distress concerning death, particularly in patients with advanced or terminal cancer, and more limited data concerning the use of classic hallucinogens to treat mood and anxiety disorders. A survey of possible mechanisms of clinically relevant effects is provided. The well-established safety of classic hallucinogens is reviewed. To provide a clinical perspective, case summaries are provided of two individuals who received treatment in recent controlled trials of psilocybin: one being treated for alcoholism, the other suffering from anxiety and depression related to fear of death due to a cancer diagnosis. Although promising early phase research conducted from the 1950s through the early 1970s was discontinued before firm conclusions could be reached concerning the efficacy of any of the classic hallucinogens for any clinical condition, the research that was conducted in that era strongly suggests that classic hallucinogens have clinically relevant effects, particularly in the case of LSD treatment of alcoholism. In the past decade, clinical trials have resumed investigating the effects of classic hallucinogens in the treatment of existential distress in the face of cancer, and in the treatment of addictions including alcoholism and nicotine addiction. The studies that have been completed to date are not sufficient to establish efficacy, but the outcomes have been very encouraging, and larger trials, up to and including phase 3, are now underway or being planned. Although research has elucidated many of the acute neurobiological and psychological effects of classic hallucinogens on humans, animals, and in vitro systems, the mechanisms of clinically relevant persisting effects remain poorly understood.", "journal": null, "publication_date": "2017-12-31", "publication_year": 2017, "doi": "10.1007/7854_2016_464", "pubmed_id": "28512684", "source_url": "https://doi.org/10.1007/7854_2016_464", "keywords": "Animals, Humans, Substance-Related Disorders, Death, Lysergic Acid Diethylamide, Hallucinogens, Anxiety Disorders, Mood Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"28512684\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,End-of-Life Distress,Mechanism of Action,Receptor Pharmacology,Aging,Clinical Trial,Review Article,Observational Study,In Vitro Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2377, "title": "Psychiatry & the psychedelic drugs. Past, present & future.", "normalized_title": "psychiatry the psychedelic drugs past present future", "authors": "Rucker JJH, Iliff J, Nutt DJ.", "abstract": "The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called 'psychoneurotic' disorders sometimes benefited considerably from their tendency to 'loosen' otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events appears to be low. Since 2006, there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that provide initial evidence of safety and efficacy, however the regulatory and legal hurdles to licensing psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre and post prohibition, discusses the methodological challenges of performing good quality trials in this area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.", "journal": null, "publication_date": "2017-12-24", "publication_year": 2017, "doi": "10.1016/j.neuropharm.2017.12.040", "pubmed_id": "29284138", "source_url": "https://doi.org/10.1016/j.neuropharm.2017.12.040", "keywords": "Animals, Humans, Hallucinogens, Mental Disorders, Psychiatry, Clinical Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"29284138\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Aging,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2446, "title": "Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.", "normalized_title": "pharmacokinetics of escalating doses of oral psilocybin in healthy adults", "authors": "Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR.", "abstract": "IntroductionPsilocybin is a psychedelic tryptamine that has shown promise in recent clinical trials for the treatment of depression and substance use disorders. This open-label study of the pharmacokinetics of psilocybin was performed to describe the pharmacokinetics and safety profile of psilocybin in sequential, escalating oral doses of 0.3, 0.45, and 0.6 mg/kg in 12 healthy adults.MethodsEligible healthy adults received 6-8 h of preparatory counseling in anticipation of the first dose of psilocybin. The escalating oral psilocybin doses were administered at approximately monthly intervals in a controlled setting and subjects were monitored for 24 h. Blood and urine samples were collected over 24 h and assayed by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for psilocybin and psilocin, the active metabolite. The pharmacokinetics of psilocin were determined using both compartmental (NONMEM) and noncompartmental (WinNonlin) methods.ResultsNo psilocybin was found in plasma or urine, and renal clearance of intact psilocin accounted for less than 2% of the total clearance. The pharmacokinetics of psilocin were linear within the twofold range of doses, and the elimination half-life of psilocin was 3 h (standard deviation 1.1). An extended elimination phase in some subjects suggests hydrolysis of the psilocin glucuronide metabolite. Variation in psilocin clearance was not predicted by body weight, and no serious adverse events occurred in the subjects studied.ConclusionsThe small amount of psilocin renally excreted suggests that no dose reduction is needed for subjects with mild-moderate renal impairment. Simulation of fixed doses using the pharmacokinetic parameters suggest that an oral dose of 25 mg should approximate the drug exposure of a 0.3 mg/kg oral dose of psilocybin. Although doses of 0.6 mg/kg are in excess of likely therapeutic doses, no serious physical or psychological events occurred during or within 30 days of any dose.Clinical trials identifierNCT02163707.", "journal": "Clinical Pharmacokinetics", "publication_date": "2017-11-30", "publication_year": 2017, "doi": "10.1007/s40262-017-0540-6", "pubmed_id": "28353056", "source_url": "https://doi.org/10.1007/s40262-017-0540-6", "keywords": "Humans, Glucuronides, Hallucinogens, Chromatography, Liquid, Dose-Response Relationship, Drug, Nonlinear Dynamics, Half-Life, Adult, Middle Aged, Female, Male, Tandem Mass Spectrometry, Young Adult, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"28353056\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2600624779\",\"openalex_url\":\"https://openalex.org/W2600624779\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":188,\"referenced_works\":[\"https://openalex.org/W105671925\",\"https://openalex.org/W1510556999\",\"https://openalex.org/W1969549633\",\"https://openalex.org/W1979963125\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1989525615\",\"https://openalex.org/W1989596270\",\"https://openalex.org/W1995013188\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1999521622\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2066464642\",\"https://openalex.org/W2074371541\",\"https://openalex.org/W2083668821\",\"https://openalex.org/W2089436854\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2132624405\",\"https://openalex.org/W2148412563\",\"https://openalex.org/W2161446377\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166952073\",\"https://openalex.org/W2293035635\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2725188872\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\"],\"authorships\":[{\"id\":\"https://openalex.org/A5071605998\",\"display_name\":\"Randall Brown\",\"orcid\":\"https://orcid.org/0000-0002-5445-8119\"},{\"id\":\"https://openalex.org/A5043044020\",\"display_name\":\"Christopher R. Nicholas\",\"orcid\":\"https://orcid.org/0000-0002-0599-4046\"},{\"id\":\"https://openalex.org/A5037184848\",\"display_name\":\"Nicholas V. Cozzi\",\"orcid\":\"https://orcid.org/0000-0001-7593-6063\"},{\"id\":\"https://openalex.org/A5051969488\",\"display_name\":\"Michele Gassman\",\"orcid\":\"https://orcid.org/0000-0002-2575-2976\"},{\"id\":\"https://openalex.org/A5023584205\",\"display_name\":\"Karen M. Cooper\",\"orcid\":null},{\"id\":null,\"display_name\":\"Daniel Muller\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067372536\",\"display_name\":\"Chantelle Thomas\",\"orcid\":null},{\"id\":\"https://openalex.org/A5007698239\",\"display_name\":\"Scott Hetzel\",\"orcid\":\"https://orcid.org/0000-0002-0244-2959\"},{\"id\":\"https://openalex.org/A5017658689\",\"display_name\":\"Kelsey M. Henriquez\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056941547\",\"display_name\":\"Alexandra S. Ribaudo\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088507656\",\"display_name\":\"Paul R. Hutson\",\"orcid\":\"https://orcid.org/0000-0002-6968-7096\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S69290020\",\"source_display_name\":\"Clinical Pharmacokinetics\",\"landing_page_url\":\"https://doi.org/10.1007/s40262-017-0540-6\",\"is_oa\":false}}}", "topic_tags": "Depression,Addiction,Pharmacology,Clinical Trial,Safety,Adverse Events", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2600624779" }, { "id": 2447, "title": "The \"Endless Trip\" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.", "normalized_title": "the endless trip among the nps users psychopathology and psychopharmacology in the hallucinogen persisting perception disorder a systematic review", "authors": "Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F.", "abstract": "Hallucinogen-persisting perception disorder (HPPD) is a syndrome characterized by prolonged or reoccurring perceptual symptoms, reminiscent of acute hallucinogen effects. HPPD was associated with a broader range of LSD (lysergic acid diethylamide)-like substances, cannabis, methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, and psychostimulants. The recent emergence of novel psychoactive substances (NPS) posed a critical concern regarding the new onset of psychiatric symptoms/syndromes, including cases of HPPD. Symptomatology mainly comprises visual disorders (i.e., geometric pseudo-hallucinations, haloes, flashes of colors/lights, motion-perception deficits, afterimages, micropsia, more acute awareness of floaters, etc.), even though depressive symptoms and thought disorders may be comorbidly present. Although HPPD was first described in 1954, it was just established as a fully syndrome in 2000, with the revised fourth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). HPPD neural substrates, risk factors, and aetiopathogenesys still largely remain unknown and under investigation, and many questions about its pharmacological targets remain unanswered too. A critical mini review on psychopathological bases, etiological hypothesis, and psychopharmacological approaches toward HPPD, including the association with some novel substances, are provided here, by means of a literature search on PubMed/Medline, Google Scholar, and Scopus databases without time restrictions, by using a specific set of keywords. Pharmacological and clinical issues are considered, and practical psychopharmacological recommendations and clinical guidelines are suggested.", "journal": null, "publication_date": "2017-11-19", "publication_year": 2017, "doi": "10.3389/fpsyt.2017.00240", "pubmed_id": "29209235", "source_url": "https://doi.org/10.3389/fpsyt.2017.00240", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"29209235\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Pharmacology,Systematic Review,Review Article,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2427, "title": "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.", "normalized_title": "psilocybin with psychological support for treatment resistant depression six month follow up", "authors": "Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ.", "abstract": "RationaleRecent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy.ObjectivesHere, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression.MethodsTwenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure.ResultsTreatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p", "journal": "Psychopharmacology", "publication_date": "2017-11-07", "publication_year": 2017, "doi": "10.1007/s00213-017-4771-x", "pubmed_id": "29119217", "source_url": "https://doi.org/10.1007/s00213-017-4771-x", "keywords": "Humans, Hallucinogens, Antidepressive Agents, Treatment Outcome, Combined Modality Therapy, Follow-Up Studies, Feasibility Studies, Double-Blind Method, Time Factors, Adult, Middle Aged, Female, Male, Depressive Disorder, Treatment-Resistant, Psilocybin, Psychosocial Support Systems", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"29119217\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2767530231\",\"openalex_url\":\"https://openalex.org/W2767530231\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":976,\"referenced_works\":[\"https://openalex.org/W1144621943\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1988444307\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2005066505\",\"https://openalex.org/W2015666695\",\"https://openalex.org/W2024075080\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2100532211\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2107232050\",\"https://openalex.org/W2107743363\",\"https://openalex.org/W2111920357\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2148560706\",\"https://openalex.org/W2157384069\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2224635535\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2419844652\",\"https://openalex.org/W2502147470\",\"https://openalex.org/W2511532223\",\"https://openalex.org/W2551626080\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2586756570\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2762746674\",\"https://openalex.org/W4240789427\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073080173\",\"display_name\":\"Mark Bolstridge\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109366794\",\"display_name\":\"Camilla Day\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5110514937\",\"display_name\":\"R. Watts\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5019717586\",\"display_name\":\"Mendel Kaelen\",\"orcid\":\"https://orcid.org/0000-0002-6987-9346\"},{\"id\":\"https://openalex.org/A5061472267\",\"display_name\":\"Bruna Giribaldi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058082561\",\"display_name\":\"Michael Bloomfield\",\"orcid\":\"https://orcid.org/0000-0002-1972-4610\"},{\"id\":\"https://openalex.org/A5049702763\",\"display_name\":\"Stephen Pilling\",\"orcid\":\"https://orcid.org/0000-0002-7361-8202\"},{\"id\":\"https://openalex.org/A5065550029\",\"display_name\":\"James A. Rickard\",\"orcid\":\"https://orcid.org/0000-0003-4907-6025\"},{\"id\":\"https://openalex.org/A5083073338\",\"display_name\":\"Benjamin Forbes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071332026\",\"display_name\":\"Amanda Feilding\",\"orcid\":\"https://orcid.org/0000-0002-1329-1893\"},{\"id\":\"https://openalex.org/A5014436895\",\"display_name\":\"David Taylor\",\"orcid\":\"https://orcid.org/0000-0002-2557-1710\"},{\"id\":\"https://openalex.org/A5061200799\",\"display_name\":\"Valerie H. Curran\",\"orcid\":\"https://orcid.org/0000-0001-6041-5214\"},{\"id\":\"https://openalex.org/A5113636502\",\"display_name\":\"D.J. Nutt\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S80334769\",\"source_display_name\":\"Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1007/s00213-017-4771-x\",\"is_oa\":true}}}", "topic_tags": "Depression,Clinical Trial,Treatment-Resistant Depression,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2767530231" }, { "id": 2449, "title": "Psychedelic Drugs in Biomedicine.", "normalized_title": "psychedelic drugs in biomedicine", "authors": "Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV.", "abstract": "Psychedelic drugs, such as lysergic acid diethylamide (LSD), mescaline, and psilocybin, exert profound effects on brain and behavior. After decades of difficulties in studying these compounds, psychedelics are again being tested as potential treatments for intractable biomedical disorders. Preclinical research of psychedelics complements human neuroimaging studies and pilot clinical trials, suggesting these compounds as promising treatments for addiction, depression, anxiety, and other conditions. However, many questions regarding the mechanisms of action, safety, and efficacy of psychedelics remain. Here, we summarize recent preclinical and clinical data in this field, discuss their pharmacological mechanisms of action, and outline critical areas for future studies of psychedelic drugs, with the goal of maximizing the potential benefits of translational psychedelic biomedicine to patients.", "journal": null, "publication_date": "2017-09-21", "publication_year": 2017, "doi": "10.1016/j.tips.2017.08.003", "pubmed_id": "28947075", "source_url": "https://doi.org/10.1016/j.tips.2017.08.003", "keywords": "Brain, Animals, Humans, Hallucinogens, Psychophysiology, Mind-Body Relations, Metaphysical", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"28947075\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Brain Imaging,Mechanism of Action,Aging,Clinical Trial,Animal Study,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2424, "title": "Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.", "normalized_title": "serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life threatening disease a systematic review", "authors": "Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T.", "abstract": "Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently, after a long hiatus period of regulatory obstacles, interest in the clinical use of these substances has resumed. The current article provides a systematic review of studies investigating psychedelics in the treatment of symptoms of existential distress in life-threatening diseases across different periods of research, highlighting how underlying concepts have developed over time. A systematic search for clinical trials from 1960 to 2017 revealed 11 eligible clinical trials involving a total number of N=445 participants, of which 7 trials investigated the use of lysergic acid diethylamide (LSD) (N=323), 3 trials investigated the use of psilocybin (N=92), and one trial investigated the use of dipropyltryptamine (DPT) (N=30). The 4 more recent randomized controlled trials (RCTs) (N=104) showed a significantly higher methodological quality than studies carried out in the 1960s and 1970s. Evidence supports that patients with life threatening diseases associated with symptoms of depression and anxiety benefit from the anxiolytic and antidepressant properties of serotonergic hallucinogens. Some studies anecdotally reported improvements in patients´ quality of life and reduced fear of death. Moreover, low rates of side effects were reported in studies that adhered to safety guidelines. Further studies are needed to determine how these results can be transferred into clinical practice.", "journal": null, "publication_date": "2017-09-21", "publication_year": 2017, "doi": "10.1016/j.pnpbp.2017.09.012", "pubmed_id": "28947181", "source_url": "https://doi.org/10.1016/j.pnpbp.2017.09.012", "keywords": "Humans, Critical Illness, Serotonin Agents, Hallucinogens, Depression, Anxiety, Clinical Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"28947181\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,End-of-Life Distress,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article,Safety,Adverse Events", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2459, "title": "Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches.", "normalized_title": "psychoactive substances as a last resort a qualitative study of self treatment of migraine and cluster headaches", "authors": "Andersson M, Persson M, Kjellgren A.", "abstract": "BackgroundTreatment resistant cluster headache and migraine patients are exploring alternative treatments online. The aim of this study was to improve comprehension regarding the use of non-established or alternative pharmacological treatments used by sufferers of cluster headaches and migraines.MethodsA qualitative thematic analysis of the users' own accounts presented in online forum discussions were conducted. The forum boards https://shroomery.org/, http://bluelight.org, and https://clusterbusters.org/ met the inclusion criteria and were used for the study.ResultsThe analysis resulted in six themes: a desperate need for effective treatments; the role of the forum-finding alternative treatments and community support; alternative treatment substances; dosage and regimens; effects and treatment results; and adverse effects. The results provide an insight into why, how, and by which substances and methods sufferers seek relief from cluster headache and migraines.ConclusionsThese patients are in a desperate and vulnerable situation, and illicit psychoactive substances are often considered a last resort. There appeared to be little or no interest in psychoactive effects per se as these were rather tolerated or avoided by using sub-psychoactive doses. Primarily, psilocybin, lysergic acid diethylamide, and related psychedelic tryptamines were reportedly effective for both prophylactic and acute treatment of cluster headache and migraines. Treatment results with cannabis were more unpredictable. No severe adverse events were reported, but it was observed how desperation sometimes spurred risky behavior when obtaining and testing various treatment alternatives. The forum discourse mainly revolved around maximizing treatment results and minimizing potential harms.", "journal": "Harm Reduction Journal", "publication_date": "2017-09-04", "publication_year": 2017, "doi": "10.1186/s12954-017-0186-6", "pubmed_id": "28870224", "source_url": "https://doi.org/10.1186/s12954-017-0186-6", "keywords": "Humans, Cluster Headache, Psychotropic Drugs, Treatment Outcome, Self Care, Harm Reduction, Qualitative Research, Migraine Disorders, Illicit Drugs", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"28870224\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2751240458\",\"openalex_url\":\"https://openalex.org/W2751240458\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":93,\"referenced_works\":[\"https://openalex.org/W603684100\",\"https://openalex.org/W1572042930\",\"https://openalex.org/W1972034666\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W1993223890\",\"https://openalex.org/W1999427970\",\"https://openalex.org/W2013621465\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2039161542\",\"https://openalex.org/W2041401474\",\"https://openalex.org/W2046381760\",\"https://openalex.org/W2104063220\",\"https://openalex.org/W2106689044\",\"https://openalex.org/W2115037730\",\"https://openalex.org/W2121625436\",\"https://openalex.org/W2136536376\",\"https://openalex.org/W2140018908\",\"https://openalex.org/W2153952042\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2194069259\",\"https://openalex.org/W2306084999\",\"https://openalex.org/W2309948415\",\"https://openalex.org/W2460328649\",\"https://openalex.org/W2483415541\",\"https://openalex.org/W2755315668\"],\"authorships\":[{\"id\":\"https://openalex.org/A5101398382\",\"display_name\":\"Martin Andersson\",\"orcid\":\"https://orcid.org/0000-0001-7201-934X\"},{\"id\":\"https://openalex.org/A5001805219\",\"display_name\":\"Mari Persson\",\"orcid\":null},{\"id\":\"https://openalex.org/A5011602888\",\"display_name\":\"Anette Kjellgren\",\"orcid\":\"https://orcid.org/0000-0002-5668-0469\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S150411170\",\"source_display_name\":\"Harm Reduction Journal\",\"landing_page_url\":\"https://doi.org/10.1186/s12954-017-0186-6\",\"is_oa\":true}}}", "topic_tags": "Headache / Migraine,Safety,Adverse Events", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2751240458" }, { "id": 2418, "title": "Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.", "normalized_title": "psychedelic drugs as therapeutics no illusions about the challenges", "authors": "Sellers EM, Leiderman DB.", "abstract": "Interest in the potential therapeutic benefits of psychedelic agents has recently increased. In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.", "journal": "Clinical Pharmacology & Therapeutics", "publication_date": "2017-08-23", "publication_year": 2017, "doi": "10.1002/cpt.776", "pubmed_id": "28836272", "source_url": "https://doi.org/10.1002/cpt.776", "keywords": "Humans, Hallucinogens, Drug Approval, Mental Disorders, Patient Selection, Drug Discovery, Risk Evaluation and Mitigation", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"28836272\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2745723818\",\"openalex_url\":\"https://openalex.org/W2745723818\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":27,\"referenced_works\":[\"https://openalex.org/W2160313238\",\"https://openalex.org/W2547918114\",\"https://openalex.org/W2557428091\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2619242792\"],\"authorships\":[{\"id\":\"https://openalex.org/A5013791504\",\"display_name\":\"Edward M. Sellers\",\"orcid\":\"https://orcid.org/0000-0002-0669-2373\"},{\"id\":\"https://openalex.org/A5030244093\",\"display_name\":\"Deborah B. Leiderman\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S159852663\",\"source_display_name\":\"Clinical Pharmacology & Therapeutics\",\"landing_page_url\":\"https://doi.org/10.1002/cpt.776\",\"is_oa\":false}}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2745723818" }, { "id": 2430, "title": "The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.", "normalized_title": "the 21st century psychedelic renaissance heroic steps forward on the back of an elephant", "authors": "Sessa B.", "abstract": "Given the plethora of new studies and published papers in the scientific press and the increasingly emerging presence of articles about positive psychedelic experiences appearing in the popular media, there is little doubt that we are in the midst of a Psychedelic Renaissance. The classical psychedelic drugs LSD and psilocybin and the entactogen MDMA are showing promise as tools to assist psychotherapy for a wide range of mental disorders, with multiple pilot studies demonstrating their safety and efficacy. In this article, the author describes how MDMA in particular has inherent characteristics that make it well suited for assisting trauma-focused psychotherapy in a population of patients who have experienced child abuse. But despite these advances, there remain many obstacles ahead of the widespread mainstream acceptance of psychedelic medicines. The author argues that the Misuse of Drugs Act 1971 is one such obstacle. Other impediments include a prevailing attitude of pseudoscience and rigidity from within the non-scientific psychedelic community itself. Resolution of these conflicts must be sought if medicine and society are to see psychedelics gaining a place in mainstream culture and science.", "journal": null, "publication_date": "2017-08-22", "publication_year": 2017, "doi": "10.1007/s00213-017-4713-7", "pubmed_id": "28831571", "source_url": "https://doi.org/10.1007/s00213-017-4713-7", "keywords": "Animals, Humans, N-Methyl-3,4-methylenedioxyamphetamine, Hallucinogens, Data Collection, Emotions, Mental Disorders, Stress Disorders, Post-Traumatic, Forecasting, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"28831571\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Emotional Processing,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2454, "title": "LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark.", "normalized_title": "lsd treatment in scandinavia emphasizing indications and short term treatment outcomes of 151 patients in denmark", "authors": "Larsen JK.", "abstract": "BackgroundNew research has suggested the clinical use of lysergic acid diethylamide (LSD) and psilocybin in selected patient populations. However, concerns about the clinical use of LSD were advanced in a large Danish follow-up study that assessed 151 LSD-treated psychiatric patients approximately 25 years after their treatment in the 1960s.AimsThe purpose of the present study was to give a retrospective account of the short-term outcome of LSD treatment in these 151 Danish psychiatric patients.MethodsThe LSD case material in the Danish State Archives consists of medical case records of 151 LSD-treated patients, who complained and received economic compensation with the LSD Damages Law. The author carefully read and reviewed the LSD case material.ResultsLSD was used to treat a wide spectrum of mental disorders. Independent of diagnoses, 52 patients improved, and 48 patients worsened acutely with the LSD treatment. In a subgroup of 82 neurotic patients, the LSD dose-index (number of treatments multiplied by the maximal LSD dose) indicated the risk of acute worsening. In another subgroup of 19 patients with obsessive-compulsive neurosis, five patients later underwent psychosurgery. A small subgroup of 12 patients was treated with psilocybin. The long-term outcome was poor in most of the patients.ConclusionsDespite the significant limitations to a retrospective design, this database warrants caution in mental health patients. The use of LSD and psilocybin in mental health patients may be associated with serious short- and long-term side effects. Until further trials with rigorous designs have cleared these drugs of their potential harms, their clinical utility in these groups of patients has not been fully clarified.", "journal": "Nordic Journal of Psychiatry", "publication_date": "2017-07-04", "publication_year": 2017, "doi": "10.1080/08039488.2017.1336251", "pubmed_id": "28678583", "source_url": "https://doi.org/10.1080/08039488.2017.1336251", "keywords": "Humans, Lysergic Acid Diethylamide, Risk, Retrospective Studies, Follow-Up Studies, Mental Disorders, Adult, Denmark, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"28678583\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2727276162\",\"openalex_url\":\"https://openalex.org/W2727276162\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":15,\"referenced_works\":[\"https://openalex.org/W645199439\",\"https://openalex.org/W1861585683\",\"https://openalex.org/W1988563049\",\"https://openalex.org/W1989868487\",\"https://openalex.org/W1996512549\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2015496389\",\"https://openalex.org/W2039578242\",\"https://openalex.org/W2047240314\",\"https://openalex.org/W2075552167\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2080340712\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118403124\",\"https://openalex.org/W2140629404\",\"https://openalex.org/W2152569564\",\"https://openalex.org/W2181040265\",\"https://openalex.org/W2197468111\",\"https://openalex.org/W2211293807\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2337115112\",\"https://openalex.org/W2342018515\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2418547949\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W4249350513\"],\"authorships\":[{\"id\":\"https://openalex.org/A5074830501\",\"display_name\":\"Jens Knud Larsen\",\"orcid\":\"https://orcid.org/0000-0002-1417-7056\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S63111534\",\"source_display_name\":\"Nordic Journal of Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1080/08039488.2017.1336251\",\"is_oa\":false}}}", "topic_tags": "OCD,Review Article,Safety,Adverse Events", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2727276162" }, { "id": 2467, "title": "Potential Therapeutic Effects of Psilocybin.", "normalized_title": "potential therapeutic effects of psilocybin", "authors": "Johnson MW, Griffiths RR.", "abstract": "Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of several promising studies, validating earlier research. Here, we review therapeutic research on psilocybin, the classic psychedelic that has been the focus of most recent research. For mood and anxiety disorders, three controlled trials have suggested that psilocybin may decrease symptoms of depression and anxiety in the context of cancer-related psychiatric distress for at least 6 months following a single acute administration. A small, open-label study in patients with treatment-resistant depression showed reductions in depression and anxiety symptoms 3 months after two acute doses. For addiction, small, open-label pilot studies have shown promising success rates for both tobacco and alcohol addiction. Safety data from these various trials, which involve careful screening, preparation, monitoring, and follow-up, indicate the absence of severe drug-related adverse reactions. Modest drug-related adverse effects at the time of medication administration are readily managed. US federal funding has yet to support therapeutic psilocybin research, although such support will be important to thoroughly investigate efficacy, safety, and therapeutic mechanisms.", "journal": null, "publication_date": "2017-06-30", "publication_year": 2017, "doi": "10.1007/s13311-017-0542-y", "pubmed_id": "28585222", "source_url": "https://doi.org/10.1007/s13311-017-0542-y", "keywords": "Humans, Hallucinogens, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"28585222\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Mechanism of Action,Review Article,Cancer Patients,Treatment-Resistant Depression,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2466, "title": "[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].", "normalized_title": "psychotherapy with adjuvant use of serotonergic psychoactive substances possibilities and challenges", "authors": "Majić T, Jungaberle H, Jungaberle H, Schmidt TT, Zeuch A, Hermle L, Gallinat J.", "abstract": "Background Recently, scientific interest in the therapeutic potential of serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) within the framework of psychotherapy has resumed. The present article provides an overview on the current evidence on substance-assisted psychotherapy with these substances. Method A selective search was carried out in the PubMed and Cochrane Library including studies investigating the clinical use of serotonergic psychoactive substances since 2000. Results Studies were found investigating the following indications: alcohol (LSD and psilocybin) and tobacco addiction (psilocybin), anxiety and depression in patients suffering from life-threatening somatic illness (LSD and psilocybin), obsessive-compulsive disorder (OCD) (psilocybin), treatment-resistant major depression (psilocybin), and posttraumatic stress disorder (PTSD) (MDMA). Discussion Substance use disorders, PTSD and anxiety and depression in patients suffering from life-threatening somatic illness belong to the indications with the best evidence for substance-assisted psychotherapy with serotonergic psychoactive agents. To date, studies indicate efficacy and relatively good tolerability. Further studies are needed to determine whether these substances may represent suitable and effective treatment options for some treatment-resistant psychiatric disorders in the future.", "journal": null, "publication_date": "2017-06-30", "publication_year": 2017, "doi": "10.1055/s-0043-103085", "pubmed_id": "28768346", "source_url": "https://doi.org/10.1055/s-0043-103085", "keywords": "Humans, N-Methyl-3,4-methylenedioxyamphetamine, Lysergic Acid Diethylamide, Serotonin Agents, Hallucinogens, Treatment Outcome, Combined Modality Therapy, Mental Disorders, Psychotherapy, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"28768346\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,PTSD,Addiction,OCD,End-of-Life Distress,Receptor Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2450, "title": "Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.", "normalized_title": "psilocybin assisted therapy a review of a novel treatment for psychiatric disorders", "authors": "Thomas K, Malcolm B, Lastra D.", "abstract": "Recent research suggests that functional connectivity changes may be involved in the pathophysiology of psychiatric disorders. Hyperconnectivity in the default mode network has been associated with psychopathology, but psychedelic serotonin agonists like psilocybin may profoundly disrupt these dysfunctional neural network circuits and provide a novel treatment for psychiatric disorders. We have reviewed the current literature to investigate the efficacy and safety of psilocybin-assisted therapy for the treatment of psychiatric disorders. There were seven clinical trials that investigated psilocybin-assisted therapy as a treatment for psychiatric disorders related to anxiety, depression, and substance use. All trials demonstrated reductions in psychiatric rating scale scores or increased response and remission rates. There were large effect sizes related to improved depression and anxiety symptoms. Psilocybin may also potentially reduce alcohol or tobacco use and increase abstinence rates in addiction, but the benefits of these two trials were less clear due to open-label study designs without statistical analysis. Psilocybin-assisted therapy efficacy and safety appear promising, but more robust clinical trials will be required to support FDA approval and identify the potential role in clinical psychiatry.", "journal": null, "publication_date": "2017-05-07", "publication_year": 2017, "doi": "10.1080/02791072.2017.1320734", "pubmed_id": "28481178", "source_url": "https://doi.org/10.1080/02791072.2017.1320734", "keywords": "Brain, Animals, Humans, Hallucinogens, Treatment Outcome, Remission Induction, Mental Health, Mental Disorders, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"28481178\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Anxiety,Addiction,Receptor Pharmacology,Default Mode Network,Clinical Trial,Review Article,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2498, "title": "The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.", "normalized_title": "the challenging experience questionnaire characterization of challenging experiences with psilocybin mushrooms", "authors": "Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR.", "abstract": "Acute adverse psychological reactions to classic hallucinogens (\"bad trips\" or \"challenging experiences\"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.", "journal": "Journal of Psychopharmacology", "publication_date": "2016-11-16", "publication_year": 2016, "doi": "10.1177/0269881116678781", "pubmed_id": "27856683", "source_url": "https://doi.org/10.1177/0269881116678781", "keywords": "Humans, Agaricales, Hallucinogens, Depression, Emotions, Affect, Anxiety, Adult, Female, Male, Surveys and Questionnaires, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"27856683\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2549202270\",\"openalex_url\":\"https://openalex.org/W2549202270\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":363,\"referenced_works\":[\"https://openalex.org/W110752286\",\"https://openalex.org/W1037524820\",\"https://openalex.org/W1144621943\",\"https://openalex.org/W1665332082\",\"https://openalex.org/W1849553904\",\"https://openalex.org/W1913957972\",\"https://openalex.org/W1978885184\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1984872228\",\"https://openalex.org/W1988039343\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W1998631480\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2005532382\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2018201949\",\"https://openalex.org/W2030852069\",\"https://openalex.org/W2036881116\",\"https://openalex.org/W2041992296\",\"https://openalex.org/W2044783071\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2054754029\",\"https://openalex.org/W2054806410\",\"https://openalex.org/W2071666535\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2076192530\",\"https://openalex.org/W2077664164\",\"https://openalex.org/W2081605480\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2109884356\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2118338381\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2127603512\",\"https://openalex.org/W2128017833\",\"https://openalex.org/W2129945845\",\"https://openalex.org/W2136547541\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2163988453\",\"https://openalex.org/W2173025637\",\"https://openalex.org/W2266766602\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2337964085\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2341558148\",\"https://openalex.org/W2346262441\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2474274656\",\"https://openalex.org/W2485710272\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2582743722\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4237255258\",\"https://openalex.org/W4299927410\",\"https://openalex.org/W4388250061\"],\"authorships\":[{\"id\":\"https://openalex.org/A5005540871\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":\"https://orcid.org/0000-0001-7443-3237\"},{\"id\":\"https://openalex.org/A5021875597\",\"display_name\":\"Matthew P. Bradstreet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5084456660\",\"display_name\":\"Jeannie-Marie Leoutsakos\",\"orcid\":\"https://orcid.org/0000-0002-1010-1046\"},{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881116678781\",\"is_oa\":false}}}", "topic_tags": "Depression,Anxiety,Consciousness,Wellbeing,Emotional Processing,Spirituality,Case Report,Observational Study,Safety", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2549202270" }, { "id": 2497, "title": "Psychedelics in the treatment of unipolar mood disorders: a systematic review.", "normalized_title": "psychedelics in the treatment of unipolar mood disorders a systematic review", "authors": "Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH.", "abstract": "Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the late 1960s. They are relatively safe when used in medically controlled environments, with no reported risk of dependence. Here, we present a systematic review of published clinical treatment studies using psychedelics in patients with broadly defined UMD, and consider their place in psychiatry. Whilst all of the included studies have methodological shortcomings, of 423 individuals in 19 studies, 335 (79.2%) showed clinician-judged improvement after treatment with psychedelics. A recently completed pilot study in the UK favours the use of psilocybin with psychological support in treatment resistant depressive disorder. The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.", "journal": null, "publication_date": "2016-11-16", "publication_year": 2016, "doi": "10.1177/0269881116679368", "pubmed_id": "27856684", "source_url": "https://doi.org/10.1177/0269881116679368", "keywords": "Humans, Lysergic Acid Diethylamide, Hallucinogens, Treatment Outcome, Pilot Projects, Mood Disorders, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"27856684\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Clinical Trial,Systematic Review,Review Article,Healthcare Workers,Safety", "study_type": "Systematic Review", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2462, "title": "[New patterns of substance use and abuse among French adolescents, a knowledge synthesis].", "normalized_title": "new patterns of substance use and abuse among french adolescents a knowledge synthesis", "authors": "Jeanne G, Purper-Ouakil D, Rigole H, Franc N.", "abstract": "AimThere have been significant changes in adolescent consumption habits over the past fifteen years. New molecules have been synthesized, new devices created and a number of products have increased in popularity; and as a result clinicians sometimes lack information. We chose to focus on this population because of its vulnerability, as adolescents show low sensitivity to long-term outcomes of their actions and may be easily influenced by peers as regards experimentation of new drugs. The most consumed products by adolescents in France are tobacco, alcohol and cannabis with the physiological effects and consumption patterns of these drugs well documented. The purpose of this review is to identify and describe other products that are frequently used by adolescents to get high, to increase performance, for purposes of self-medication or because of peer pressure. We summarized the current scientific evidence regarding drug availability, physical and chemical properties, pharmacodynamics and adverse effects.MethodA literature review was conducted from 2000 to 2015 based on Pudmed, Google Scholar and governmental websites, using the following keyword alone or in combination: \"adolescent\", \"new\", \"misuse\", \"abuse\", \"toxicity\", \"pharmacology\" \"cocaine\", \"MDMA\", \"inhalant\", \"poppers\", \"magic mushroom\", \"psilocybin\", \"designer drug\", \"legal high\", \"smart drug\", \"cathinone\", \"mephedrone\", \"cannabinoid\", \"prescription drug\", \"codeine\", \"opioid\", \"methylphenidate\", \"cough syrup\", \"purple drank\".ResultsNew products, including synthetic cannabis, cathinone or purple drank seem to be the most dangerous. They are easily accessible and may lead to short-term severe or lethal complications. Other substances do not pose a major short-term health risk by themselves. However, their consumption may be an indication of other unhealthy risk behaviors, such as prescription drug use, which may be related to psychiatric comorbidity. Unfortunately, we do not have enough data to determine the long-term consequences of the use of these substances. Moreover, these products have a strong addictive potential and may be a risk factor for other addictions. For this reason, increased supervision is justified, both for surveillance and reduction of harm.ConclusionTaking care of an adolescent with substance abuse can be difficult. Updated information regarding these new substances and the particular danger they pose to adolescent health is needed. Informed clinicians can provide up to date and accurate information to the patient and family, assess potential risk factors and comorbidities, and provide appropriate support. Furthermore, because of the high prevalence of substance abuse in the adolescent population, systematic screening of adolescent consumption habit is useful to avoid or anticipate complications. Often, problematic substance consumption behaviors are signs of more complicated psychological or psychiatric issues. Substance abuse behaviors will often disappear over time but they can also become a major problem as the adolescent moves into adulthood. If problems persist, consultation with an addiction specialist may be warranted.", "journal": null, "publication_date": "2016-10-05", "publication_year": 2016, "doi": "10.1016/j.encep.2016.05.012", "pubmed_id": "27720453", "source_url": "https://doi.org/10.1016/j.encep.2016.05.012", "keywords": "Humans, Substance-Related Disorders, Designer Drugs, Prevalence, Risk Factors, Smoking, Adolescent, France, Female, Male", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"27720453\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Pharmacology,Review Article,Adolescents,Healthcare Workers,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2500, "title": "Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.", "normalized_title": "survey study of challenging experiences after ingesting psilocybin mushrooms acute and enduring positive and negative consequences", "authors": "Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR.", "abstract": "Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst \"bad trip\") after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm; factors increasing the likelihood of risk included estimated dose, duration and difficulty of the experience, and absence of physical comfort and social support. Of the respondents, 2.6% behaved in a physically aggressive or violent manner and 2.7% received medical help. Of those whose experience occurred >1 year before, 7.6% sought treatment for enduring psychological symptoms. Three cases appeared associated with onset of enduring psychotic symptoms and three cases with attempted suicide. Multiple regression analysis showed degree of difficulty was positively associated, and duration was negatively associated, with enduring increases in well-being. Difficulty of experience was positively associated with dose. Despite difficulties, 84% endorsed benefiting from the experience. The incidence of risky behavior or enduring psychological distress is extremely low when psilocybin is given in laboratory studies to screened, prepared, and supported participants.", "journal": "Journal of Psychopharmacology", "publication_date": "2016-08-29", "publication_year": 2016, "doi": "10.1177/0269881116662634", "pubmed_id": "27578767", "source_url": "https://doi.org/10.1177/0269881116662634", "keywords": "Humans, Agaricales, Hallucinogens, Emotions, Eating, Adult, Female, Male, Surveys and Questionnaires, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"27578767\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2513336695\",\"openalex_url\":\"https://openalex.org/W2513336695\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":539,\"referenced_works\":[\"https://openalex.org/W99126694\",\"https://openalex.org/W359263171\",\"https://openalex.org/W1970305111\",\"https://openalex.org/W1970807094\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1983746274\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2015086459\",\"https://openalex.org/W2025684297\",\"https://openalex.org/W2042116862\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2069122038\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2107232050\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2150903999\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166423316\",\"https://openalex.org/W2332087446\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2502147470\",\"https://openalex.org/W2769266388\",\"https://openalex.org/W4240789427\",\"https://openalex.org/W4252245481\"],\"authorships\":[{\"id\":\"https://openalex.org/A5083415921\",\"display_name\":\"Theresa M. Carbonaro\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021875597\",\"display_name\":\"Matthew P. Bradstreet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005540871\",\"display_name\":\"Frederick S. Barrett\",\"orcid\":\"https://orcid.org/0000-0001-7443-3237\"},{\"id\":\"https://openalex.org/A5110887388\",\"display_name\":\"Katherine A. MacLean\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109843219\",\"display_name\":\"Robert L. Jesse\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881116662634\",\"is_oa\":false}}}", "topic_tags": "Wellbeing,Emotional Processing,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2513336695" }, { "id": 2486, "title": "Return of the psychedelics: Psilocybin for treatment resistant depression.", "normalized_title": "return of the psychedelics psilocybin for treatment resistant depression", "authors": "Patra S.", "abstract": "Psilocybin, the clinically most researched classic psychedelic has recently been tested for its safety and efficacy in a clinical population of treatment resistant depression. The efficacy of psilocybin in clinical depression previously demonstrated in the elecrophysiologic and neuroimaging findings as also in neuropsychological assessments is further validated by the findings of this rigorously conducted randomized trial. Mechanism of action of psilocybin and efficacy in treatment resistant depression are discussed in this paper. Ethical issues of conducting clinical trials with psychedelics are also discussed with particular emphasis on their relative safety and absence of addiction potential. Implications of these issues for conduct of larger trials for establishing risk benefit ratio in treatment resistant depression are further suggested.", "journal": null, "publication_date": "2016-08-22", "publication_year": 2016, "doi": "10.1016/j.ajp.2016.08.010", "pubmed_id": "27931907", "source_url": "https://doi.org/10.1016/j.ajp.2016.08.010", "keywords": "Humans, Hallucinogens, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"27931907\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Brain Imaging,Mechanism of Action,Aging,Clinical Trial,Safety", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2478, "title": "Psilocybin for treating substance use disorders?", "normalized_title": "psilocybin for treating substance use disorders", "authors": "de Veen BT, Schellekens AF, Verheij MM, Homberg JR.", "abstract": "IntroductionEvidence based treatment for Substance use disorders (SUD) includes psychotherapy and pharmacotherapy. However, these are only partially effective. Hallucinogens, such as psilocybin, may represent potential new treatment options for SUD. This review provides a summary of (human) studies on the putative therapeutic effects of psilocybin, and discusses the receptor systems, brain regions and cognitive and emotional processes mediating psilocybin's effects. Psilocybin's chemical structure is similar to that of serotonin. Dysregulations in the serotonin system are associated with alterations in stress hormones, such as cortisol, and mood disorders. After psilocybin administration cortisol levels spike and activate the executive control network, with subsequent increased control over emotional processes, and relief of negative thinking and persistent negative emotions. Preliminary data of ongoing alcohol and smoking addiction studies in humans shows promising effects of psilocybin administration on substance use. Importantly, psilocybin has a low risk of toxicity and dependence and can be used safely under controlled clinical conditions. Areas covered: This paper is a narrative review based on the search terms: psilocybin, substance use disorder, addiction, depression, serotonin. Literature on potential efficacy and mechanisms of action of psilocybin in SUD is discussed. Expert commentary: Recent positive findings with psilocybin need confirmation in well-designed placebo controlled randomized trials employing a large sample size.", "journal": null, "publication_date": "2016-08-11", "publication_year": 2016, "doi": "10.1080/14737175.2016.1220834", "pubmed_id": "27684102", "source_url": "https://doi.org/10.1080/14737175.2016.1220834", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Depression, Emotions, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"27684102\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Depression,Addiction,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Review Article,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2511, "title": "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.", "normalized_title": "psilocybin with psychological support for treatment resistant depression an open label feasibility study", "authors": "Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ.", "abstract": "BackgroundPsilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression.MethodsIn this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797.FindingsPsilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD0·36) for the low-dose session and 0·75 (SD0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges' g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.InterpretationThis study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.FundingMedical Research Council.", "journal": "The Lancet Psychiatry", "publication_date": "2016-05-16", "publication_year": 2016, "doi": "10.1016/s2215-0366(16)30065-7", "pubmed_id": "27210031", "source_url": "https://doi.org/10.1016/s2215-0366(16)30065-7", "keywords": "Humans, Treatment Outcome, Feasibility Studies, Social Support, Adult, Middle Aged, Female, Male, Serotonin Receptor Agonists, Depressive Disorder, Treatment-Resistant, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"27210031\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2396675581\",\"openalex_url\":\"https://openalex.org/W2396675581\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1539,\"referenced_works\":[\"https://openalex.org/W183123008\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1971459727\",\"https://openalex.org/W1974109667\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2006861654\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2020472715\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2037317432\",\"https://openalex.org/W2039056175\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2055277208\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2083885069\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2137983723\",\"https://openalex.org/W2157384069\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2170915041\",\"https://openalex.org/W2266766602\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W6607541484\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073080173\",\"display_name\":\"Mark Bolstridge\",\"orcid\":null},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5109366794\",\"display_name\":\"Camilla Day\",\"orcid\":null},{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5019717586\",\"display_name\":\"Mendel Kaelen\",\"orcid\":\"https://orcid.org/0000-0002-6987-9346\"},{\"id\":\"https://openalex.org/A5058082561\",\"display_name\":\"Michael Bloomfield\",\"orcid\":\"https://orcid.org/0000-0002-1972-4610\"},{\"id\":\"https://openalex.org/A5065550029\",\"display_name\":\"James A. Rickard\",\"orcid\":\"https://orcid.org/0000-0003-4907-6025\"},{\"id\":\"https://openalex.org/A5069886359\",\"display_name\":\"Ben Forbes\",\"orcid\":\"https://orcid.org/0000-0001-8193-6107\"},{\"id\":\"https://openalex.org/A5071332026\",\"display_name\":\"Amanda Feilding\",\"orcid\":\"https://orcid.org/0000-0002-1329-1893\"},{\"id\":\"https://openalex.org/A5014436895\",\"display_name\":\"David Taylor\",\"orcid\":\"https://orcid.org/0000-0002-2557-1710\"},{\"id\":\"https://openalex.org/A5103869816\",\"display_name\":\"Steve Pilling\",\"orcid\":null},{\"id\":\"https://openalex.org/A5021720240\",\"display_name\":\"Valerie H. Curran\",\"orcid\":\"https://orcid.org/0000-0001-6041-5214\"},{\"id\":\"https://openalex.org/A5016082897\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-1286-1401\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2531556786\",\"source_display_name\":\"The Lancet Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1016/s2215-0366(16)30065-7\",\"is_oa\":true}}}", "topic_tags": "Depression,Anxiety,Addiction,OCD,End-of-Life Distress,Headache / Migraine,Receptor Pharmacology,Randomized Controlled Trial,Treatment-Resistant Depression,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2396675581" }, { "id": 2522, "title": "The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey.", "normalized_title": "the use of illicit drugs as self medication in the treatment of cluster headache results from an italian online survey", "authors": "Di Lorenzo C, Coppola G, Di Lorenzo G, Bracaglia M, Rossi P, Pierelli F.", "abstract": "BackgroundCluster headache (CH) patients often receive unsatisfactory treatment and may explore illicit substances as alternatives. We aimed to explore this use of illicit drugs for CH treatment.MethodsWe invited CH patients from an Internet-based self-help group to complete a questionnaire regarding their therapeutic use of illicit substances.ResultsOf the 54 respondents, 29 were classified as chronic and 39 were drug-resistant cases. Fifty patients had previously tried subcutaneous sumatriptan, 40 had tried O2, and 48 had tried at least one prophylactic treatment. All 54 patients specified that they were dissatisfied with conventional treatments. Thirty-four patients had used cannabinoids, 13 cocaine, 8 heroin, 18 psilocybin, 12 lysergic acid amide (LSA), and 4 lysergic acid diethylamide (LSD).DiscussionSome patients with intractable CH decided to try illicit drugs concomitantly with cessation of medical care. Most of these patients found suggestions for illicit drug use on the Internet. Many patients seemed to underestimate the judicial consequences of, and had an overestimated confidence in the safety of, such illicit treatments. Physicians are often not informed by patients of their choice to use illicit drugs. This leads to questions regarding the true nature of the physician-patient relationship among dissatisfied CH patients.", "journal": "Cephalalgia", "publication_date": "2015-04-21", "publication_year": 2015, "doi": "10.1177/0333102415583145", "pubmed_id": "25903763", "source_url": "https://doi.org/10.1177/0333102415583145", "keywords": "Humans, Cluster Headache, Self Medication, Italy, Female, Male, Social Media, Surveys and Questionnaires, Illicit Drugs", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"25903763\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W1999427970\",\"openalex_url\":\"https://openalex.org/W1999427970\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":40,\"referenced_works\":[\"https://openalex.org/W1558213836\",\"https://openalex.org/W2011745000\",\"https://openalex.org/W2049361602\",\"https://openalex.org/W2063432437\",\"https://openalex.org/W2069823906\",\"https://openalex.org/W2085174584\",\"https://openalex.org/W2109473644\",\"https://openalex.org/W2119014087\",\"https://openalex.org/W2121872045\",\"https://openalex.org/W2123828309\",\"https://openalex.org/W2127588236\",\"https://openalex.org/W2325782912\"],\"authorships\":[{\"id\":\"https://openalex.org/A5007756770\",\"display_name\":\"Cherubino Di Lorenzo\",\"orcid\":\"https://orcid.org/0000-0003-0845-5694\"},{\"id\":\"https://openalex.org/A5010978409\",\"display_name\":\"Gianluca Coppola\",\"orcid\":\"https://orcid.org/0000-0002-8510-6925\"},{\"id\":\"https://openalex.org/A5076048806\",\"display_name\":\"Giorgio Di Lorenzo\",\"orcid\":\"https://orcid.org/0000-0002-0576-4064\"},{\"id\":\"https://openalex.org/A5040916308\",\"display_name\":\"M. Bracaglia\",\"orcid\":\"https://orcid.org/0000-0003-4213-0228\"},{\"id\":\"https://openalex.org/A5022181832\",\"display_name\":\"P Rossi\",\"orcid\":\"https://orcid.org/0000-0002-6523-636X\"},{\"id\":\"https://openalex.org/A5080500923\",\"display_name\":\"Francesco Pierelli\",\"orcid\":\"https://orcid.org/0000-0003-3175-7658\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S141866484\",\"source_display_name\":\"Cephalalgia\",\"landing_page_url\":\"https://doi.org/10.1177/0333102415583145\",\"is_oa\":true}}}", "topic_tags": "Addiction,Headache / Migraine,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W1999427970" }, { "id": 2540, "title": "Legal highs: staying on top of the flood of novel psychoactive substances.", "normalized_title": "legal highs staying on top of the flood of novel psychoactive substances", "authors": "Baumeister D, Tojo LM, Tracy DK.", "abstract": "There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called 'legal highs', which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to circumvent new laws. This rapidly changing environment, 81 new substances were identified in 2013 alone, has led to confusion for clinicians, psychopharmacologists, and the public at large. Our difficulties in keeping up with the process has had a two-fold negative effect: the danger of ignoring what is confusing; and the problem that some of the newer synthesized compounds appear ever more potent. This review aims to circumscribe a quick moving and growing field, and to categorize NPS into five major groups based upon their 'parent' compounds: stimulants similar to cocaine, amphetamines and ecstasy; cannabinoids; benzodiazepine based drugs; dissociatives similar to ketamine and phencyclidine (PCP); and those modelled after classic hallucinogens such as LSD and psilocybin. Pharmacodynamic actions, subjective and physical effects, harmfulness, risk of dependency and, where appropriate, putative clinical potentials are described for each class. Clinicians might encounter NPS in various ways: anecdotal reportage; acute intoxication; as part of a substance misuse profile; and as a precipitant or perpetuating factor for longer-term physical and psychological ill health. Current data are overall limited, and much of our knowledge and treatment strategies are based upon those of the 'parent' compound. There is a critical need for more research in this field, and for professionals to make themselves more aware of this growing issue and how it might affect those we see clinically and try to help: a brave new world of so-called 'psychonauts' consuming NPS will also need informed 'psychotherapeutonauts'. The paper should serve as a primer for clinicians and interested readers, as well as provide a framework into which to place the new substances that will inevitably be synthesized in the future.", "journal": null, "publication_date": "2015-03-31", "publication_year": 2015, "doi": "10.1177/2045125314559539", "pubmed_id": "26240749", "source_url": "https://doi.org/10.1177/2045125314559539", "keywords": "", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"26240749\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Pharmacology,Review Article,Animal Study,Healthcare Workers,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2523, "title": "Classic hallucinogens in the treatment of addictions.", "normalized_title": "classic hallucinogens in the treatment of addictions", "authors": "Bogenschutz MP, Johnson MW.", "abstract": "Addictive disorders are very common and have devastating individual and social consequences. Currently available treatment is moderately effective at best. After many years of neglect, there is renewed interest in potential clinical uses for classic hallucinogens in the treatment of addictions and other behavioral health conditions. In this paper we provide a comprehensive review of both historical and recent clinical research on the use of classic hallucinogens in the treatment of addiction, selectively review other relevant research concerning hallucinogens, and suggest directions for future research. Clinical trial data are very limited except for the use of LSD in the treatment of alcoholism, where a meta-analysis of controlled trials has demonstrated a consistent and clinically significant beneficial effect of high-dose LSD. Recent pilot studies of psilocybin-assisted treatment of nicotine and alcohol dependence had strikingly positive outcomes, but controlled trials will be necessary to evaluate the efficacy of these treatments. Although plausible biological mechanisms have been proposed, currently the strongest evidence is for the role of mystical or other meaningful experiences as mediators of therapeutic effects. Classic hallucinogens have an excellent record of safety in the context of clinical research. Given our limited understanding of the clinically relevant effects of classic hallucinogens, there is a wealth of opportunities for research that could contribute important new knowledge and potentially lead to valuable new treatments for addiction.", "journal": null, "publication_date": "2015-03-13", "publication_year": 2015, "doi": "10.1016/j.pnpbp.2015.03.002", "pubmed_id": "25784600", "source_url": "https://doi.org/10.1016/j.pnpbp.2015.03.002", "keywords": "Brain, Animals, Humans, Substance-Related Disorders, Hallucinogens, Behavior, Addictive, Controlled Clinical Trials as Topic", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"25784600\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Mechanism of Action,Mystical Experience,Clinical Trial,Meta-Analysis,Review Article,Safety", "study_type": "Meta-Analysis", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2542, "title": "Psychedelics not linked to mental health problems or suicidal behavior: a population study.", "normalized_title": "psychedelics not linked to mental health problems or suicidal behavior a population study", "authors": "Johansen PØ, Krebs TS.", "abstract": "A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental health. After adjusting for sociodemographics, other drug use and childhood depression, we found no significant associations between lifetime use of psychedelics and increased likelihood of past year serious psychological distress, mental health treatment, suicidal thoughts, suicidal plans and suicide attempt, depression and anxiety. We failed to find evidence that psychedelic use is an independent risk factor for mental health problems. Psychedelics are not known to harm the brain or other body organs or to cause addiction or compulsive use; serious adverse events involving psychedelics are extremely rare. Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure.", "journal": "Journal of Psychopharmacology", "publication_date": "2015-03-04", "publication_year": 2015, "doi": "10.1177/0269881114568039", "pubmed_id": "25744618", "source_url": "https://doi.org/10.1177/0269881114568039", "keywords": "Humans, Hallucinogens, Risk Factors, Retrospective Studies, Cross-Sectional Studies, Suicide, Attempted, Mental Health, Mental Disorders, Adolescent, Adult, United States, Female, Male, Young Adult, Suicidal Ideation", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"25744618\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2097999899\",\"openalex_url\":\"https://openalex.org/W2097999899\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":299,\"referenced_works\":[\"https://openalex.org/W86493770\",\"https://openalex.org/W171888871\",\"https://openalex.org/W832142260\",\"https://openalex.org/W1494326009\",\"https://openalex.org/W1603672910\",\"https://openalex.org/W1930038940\",\"https://openalex.org/W1965993892\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1983580111\",\"https://openalex.org/W1983731006\",\"https://openalex.org/W1988574431\",\"https://openalex.org/W1996143523\",\"https://openalex.org/W1996607457\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2011221060\",\"https://openalex.org/W2013576699\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2021054271\",\"https://openalex.org/W2021752411\",\"https://openalex.org/W2031351940\",\"https://openalex.org/W2035199049\",\"https://openalex.org/W2045125835\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2055517081\",\"https://openalex.org/W2066709094\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2104320372\",\"https://openalex.org/W2108914738\",\"https://openalex.org/W2112590707\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2130373985\",\"https://openalex.org/W2137296158\",\"https://openalex.org/W2139192721\",\"https://openalex.org/W2155854964\",\"https://openalex.org/W2156895313\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2161795125\",\"https://openalex.org/W2235419790\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2335042732\",\"https://openalex.org/W2338364818\",\"https://openalex.org/W2395647020\",\"https://openalex.org/W2397494586\",\"https://openalex.org/W2409870141\",\"https://openalex.org/W2427846517\",\"https://openalex.org/W4240897905\",\"https://openalex.org/W4250575659\",\"https://openalex.org/W4256633715\"],\"authorships\":[{\"id\":\"https://openalex.org/A5078179953\",\"display_name\":\"Pål-Ørjan Johansen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5022694095\",\"display_name\":\"Teri Suzanne Krebs\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881114568039\",\"is_oa\":false}}}", "topic_tags": "Depression,Anxiety,Addiction,Adolescents,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2097999899" }, { "id": 2545, "title": "Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.", "normalized_title": "psilocybin assisted treatment for alcohol dependence a proof of concept study", "authors": "Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ.", "abstract": "UnlabelledSeveral lines of evidence suggest that classic (5HT2A agonist) hallucinogens have clinically relevant effects in alcohol and drug addiction. Although recent studies have investigated the effects of psilocybin in various populations, there have been no studies on the efficacy of psilocybin for alcohol dependence. We conducted a single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data. Ten volunteers with DSM-IV alcohol dependence received orally administered psilocybin in one or two supervised sessions in addition to Motivational Enhancement Therapy and therapy sessions devoted to preparation for and debriefing from the psilocybin sessions. Participants' responses to psilocybin were qualitatively similar to those described in other populations. Abstinence did not increase significantly in the first 4 weeks of treatment (when participants had not yet received psilocybin), but increased significantly following psilocybin administration (p < 0.05). Gains were largely maintained at follow-up to 36 weeks. The intensity of effects in the first psilocybin session (at week 4) strongly predicted change in drinking during weeks 5-8 (r = 0.76 to r = 0.89) and also predicted decreases in craving and increases in abstinence self-efficacy during week 5. There were no significant treatment-related adverse events. These preliminary findings provide a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms.Trial registrationNCT02061293.", "journal": "Journal of Psychopharmacology", "publication_date": "2015-01-12", "publication_year": 2015, "doi": "10.1177/0269881114565144", "pubmed_id": "25586396", "source_url": "https://doi.org/10.1177/0269881114565144", "keywords": "Humans, Alcoholism, Hallucinogens, Treatment Outcome, Combined Modality Therapy, Follow-Up Studies, Alcohol Drinking, Motivation, Time Factors, Adult, Middle Aged, Female, Male, Psilocybin, Cognitive Behavioral Therapy", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:40", "raw_json": "{\"europe_pmc_id\":\"25586396\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2075238613\",\"openalex_url\":\"https://openalex.org/W2075238613\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1161,\"referenced_works\":[\"https://openalex.org/W54728729\",\"https://openalex.org/W62922542\",\"https://openalex.org/W159676469\",\"https://openalex.org/W173089895\",\"https://openalex.org/W376897599\",\"https://openalex.org/W592732404\",\"https://openalex.org/W621567176\",\"https://openalex.org/W1475474724\",\"https://openalex.org/W1560741048\",\"https://openalex.org/W1896027656\",\"https://openalex.org/W1940682915\",\"https://openalex.org/W1964116811\",\"https://openalex.org/W1968488639\",\"https://openalex.org/W1973405277\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1973814761\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1975552694\",\"https://openalex.org/W1982006269\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1999159677\",\"https://openalex.org/W1999336162\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2009271136\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2012834083\",\"https://openalex.org/W2014622858\",\"https://openalex.org/W2016774883\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2031398681\",\"https://openalex.org/W2037776127\",\"https://openalex.org/W2043530175\",\"https://openalex.org/W2051861629\",\"https://openalex.org/W2052341973\",\"https://openalex.org/W2054754029\",\"https://openalex.org/W2056852922\",\"https://openalex.org/W2061900306\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2076029586\",\"https://openalex.org/W2079490870\",\"https://openalex.org/W2079836081\",\"https://openalex.org/W2080464850\",\"https://openalex.org/W2082206299\",\"https://openalex.org/W2082483310\",\"https://openalex.org/W2086552507\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2087952727\",\"https://openalex.org/W2088140721\",\"https://openalex.org/W2090179920\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2096567449\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2098258137\",\"https://openalex.org/W2102582267\",\"https://openalex.org/W2108556733\",\"https://openalex.org/W2110065044\",\"https://openalex.org/W2111139037\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2120356707\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122335802\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2123282949\",\"https://openalex.org/W2129977009\",\"https://openalex.org/W2143648030\",\"https://openalex.org/W2150894903\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2166262899\",\"https://openalex.org/W2166952073\",\"https://openalex.org/W2169216780\",\"https://openalex.org/W2170915041\",\"https://openalex.org/W2243916050\",\"https://openalex.org/W2297304494\",\"https://openalex.org/W2318552418\",\"https://openalex.org/W2319975253\",\"https://openalex.org/W2333536875\",\"https://openalex.org/W2408251447\",\"https://openalex.org/W2419156332\",\"https://openalex.org/W2474274656\",\"https://openalex.org/W2607365596\",\"https://openalex.org/W2973687702\",\"https://openalex.org/W3018382390\",\"https://openalex.org/W3196761093\",\"https://openalex.org/W3217134939\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4229920826\",\"https://openalex.org/W4232615320\",\"https://openalex.org/W4239785504\",\"https://openalex.org/W4249571112\",\"https://openalex.org/W4300870773\"],\"authorships\":[{\"id\":\"https://openalex.org/A5086692011\",\"display_name\":\"Michael P. Bogenschutz\",\"orcid\":\"https://orcid.org/0000-0003-4530-3470\"},{\"id\":\"https://openalex.org/A5075574900\",\"display_name\":\"Alyssa A. Forcehimes\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109907760\",\"display_name\":\"Jessica A. Pommy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079953298\",\"display_name\":\"Claire Wilcox\",\"orcid\":\"https://orcid.org/0000-0002-2966-7357\"},{\"id\":\"https://openalex.org/A5108481782\",\"display_name\":\"PCR Barbosa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5113712322\",\"display_name\":\"Rick J. Strassman\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881114565144\",\"is_oa\":false}}}", "topic_tags": "Addiction,Mechanism of Action,Receptor Pharmacology,Safety,Adverse Events", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2075238613" }, { "id": 2555, "title": "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.", "normalized_title": "pilot study of the 5 ht2ar agonist psilocybin in the treatment of tobacco addiction", "authors": "Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR.", "abstract": "Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically", "journal": "Journal of Psychopharmacology", "publication_date": "2014-09-10", "publication_year": 2014, "doi": "10.1177/0269881114548296", "pubmed_id": "25213996", "source_url": "https://doi.org/10.1177/0269881114548296", "keywords": "Humans, Tobacco Use Disorder, Carbon Monoxide, Cotinine, Nicotinic Agonists, Treatment Outcome, Combined Modality Therapy, Pilot Projects, Attitude, Behavior, Addictive, Smoking Cessation, Dose-Response Relationship, Drug, Middle Aged, Female, Male, Serotonin Receptor Agonists, Biomarkers, Psilocybin, Cognitive Behavioral Therapy", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"25213996\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2122459973\",\"openalex_url\":\"https://openalex.org/W2122459973\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":907,\"referenced_works\":[\"https://openalex.org/W579597471\",\"https://openalex.org/W592732404\",\"https://openalex.org/W1475474724\",\"https://openalex.org/W1492283962\",\"https://openalex.org/W1588882127\",\"https://openalex.org/W1940682915\",\"https://openalex.org/W1971596397\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1973814761\",\"https://openalex.org/W1975552694\",\"https://openalex.org/W1989421682\",\"https://openalex.org/W1991997587\",\"https://openalex.org/W1999159677\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2010214743\",\"https://openalex.org/W2013762461\",\"https://openalex.org/W2022443784\",\"https://openalex.org/W2025716661\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2039460330\",\"https://openalex.org/W2043319570\",\"https://openalex.org/W2046087798\",\"https://openalex.org/W2051572188\",\"https://openalex.org/W2051861629\",\"https://openalex.org/W2052341973\",\"https://openalex.org/W2065987376\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2070626685\",\"https://openalex.org/W2079258526\",\"https://openalex.org/W2087848624\",\"https://openalex.org/W2088785539\",\"https://openalex.org/W2091372286\",\"https://openalex.org/W2096567449\",\"https://openalex.org/W2097155663\",\"https://openalex.org/W2105805129\",\"https://openalex.org/W2107200746\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2111724200\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115129983\",\"https://openalex.org/W2118061336\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2141096096\",\"https://openalex.org/W2141348739\",\"https://openalex.org/W2145615919\",\"https://openalex.org/W2146132158\",\"https://openalex.org/W2150903999\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2164386461\",\"https://openalex.org/W2228339316\",\"https://openalex.org/W2243916050\",\"https://openalex.org/W2297304494\",\"https://openalex.org/W2318552418\",\"https://openalex.org/W2325207359\",\"https://openalex.org/W2333536875\",\"https://openalex.org/W2417827962\",\"https://openalex.org/W2513619552\",\"https://openalex.org/W2612308268\",\"https://openalex.org/W2621586846\",\"https://openalex.org/W2801279915\",\"https://openalex.org/W4236409797\",\"https://openalex.org/W4239777125\"],\"authorships\":[{\"id\":\"https://openalex.org/A5030387003\",\"display_name\":\"Matthew W. Johnson\",\"orcid\":\"https://orcid.org/0000-0001-7068-0513\"},{\"id\":\"https://openalex.org/A5091708678\",\"display_name\":\"Albert Garcia-Romeu\",\"orcid\":\"https://orcid.org/0000-0003-2182-1644\"},{\"id\":\"https://openalex.org/A5025469924\",\"display_name\":\"Mary P Cosimano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002583244\",\"display_name\":\"Roland R. Griffiths\",\"orcid\":\"https://orcid.org/0000-0001-5185-7854\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881114548296\",\"is_oa\":false}}}", "topic_tags": "Addiction,Receptor Pharmacology,Biomarkers,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2122459973" }, { "id": 2558, "title": "Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.", "normalized_title": "classical hallucinogens as antidepressants a review of pharmacodynamics and putative clinical roles", "authors": "Baumeister D, Barnes G, Giaroli G, Tracy D", "abstract": "Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on their clinic effectiveness. These drugs appear to exert their psychedelic effects through their agonist or partial agonist activity at the serotonergic 5-HT2A receptor, though they also have affinity for other metabotropic serotonin receptors. Hallucinogen binding affects a wide range of intracellular signalling pathways, the precise nature of which remains incompletely understood. They alter the serotonergic tone of brainstem raphe nuclei that project through the brain; they interact with receptors in the prefrontal cortex altering connectivity patterns and intracellular functioning; and they disrupt inhibitory control of sensory input via the thalamus to the cortex. The serotonergic system has long been implicated in anxiety and depressive disorders, and is a major target of most existing antidepressants. Classical hallucinogens alter the functioning of this system, but not in the same way current medications do: whilst there are identified receptors and neurotransmitter pathways through which hallucinogens could therein produce therapeutic effects, the neurobiology of this remains speculative at this time. There is currently an extremely limited but growing literature on hallucinogen safety and clinical application. The drugs appear well tolerated by healthy controls and clinical populations, and the rapid tolerance to repeated administration might reduce the possibility of dependency. Clinical trials reported over the past decade have generally shown positive therapeutic potential, but they are notably few in number. Legislative policy has had a freezing effect on evaluation of these compounds, a better understanding of which might improve our knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies.", "journal": "Therapeutic advances in psychopharmacology", "publication_date": "2014-07-31", "publication_year": 2014, "doi": "10.1177/2045125314527985", "pubmed_id": "25083275", "source_url": "https://pubmed.ncbi.nlm.nih.gov/25083275/", "keywords": "5-HT2A, LSD, antidepressants, anxiety, depression, hallucinogen, psilocybin", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:20:40", "raw_json": "{\"pubmed_id\":\"25083275\"}", "topic_tags": "Depression,Anxiety,Pharmacology,Mechanism of Action,Receptor Pharmacology,Consciousness,Spirituality,Clinical Trial,Review Article,Safety,Toxicity", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 5300, "title": "PSILOCYBIN RESEARCH AT JOHNS HOPKINS: A2014 REPORT", "normalized_title": "psilocybin research at johns hopkins a2014 report", "authors": "Robert L. Jesse, Roland R. Griffi", "abstract": "Historically, currently, and cross-culturally, profound mystical experiences are often reported as benefi cially life-changing, and certain plants and chemicals are reported as potent catalysts of those experiences. The research described here undertook to scientifi cally demonstrate a process using psilocybin that would occasion such events with high likelihood and reasonable safety. At least for individuals similar to those who have participated in the Hopkins psilocybin studies, we believe we can now confi rm that such a process exists and that it can yield at least some of the surmised benefi ts. This confi rmation derives from experiments in our laboratory with over 200 volunteers to date, each of whom has received at least one daylong session involving a large dose of psilocybin. Two-thirds or more of the volunteers reported one of their sessions as among the most meaningful experiences of their lives and attributed to it positive changes in their mood, behaviors, and overall well-being. Most of the volunteers were psychologically and physically healthy, hallucinogen-naive adults with some spiritual interest. Some were cancer patients seeking relief from psychological distress due to their diagnosis, and some were tobacco smokers, otherwise healthy, willing to try a cessation program including psilocybin sessions. The team’s work so far, listed in Table 3.1, comprises seven laboratory studies, completed or in progress, and two Internet-based survey studies. The laboratory work has been conducted double-blind using methods intended to maintain the blind and to minimize expectancy effects, including obscuring design elements from the volunteers and most study staff. This research has been or will be reported in detail in scientifi c journal articles. In", "journal": null, "publication_date": "2013-12-31", "publication_year": 2013, "doi": null, "pubmed_id": null, "source_url": "http://csp.org/HopkinsPsilocybin2014.pdf", "keywords": "Psilocybin, Psychology, Expectancy theory, Mood, Psychiatry, Clinical psychology, Psychotherapist, Hallucinogen, Social psychology, Psychedelics and Drug Studies, Paranormal Experiences and Beliefs, Chemical synthesis and alkaloids", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:52:04", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"openalex_id\":\"https://openalex.org/W2551216332\",\"openalex_url\":\"https://openalex.org/W2551216332\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W99126694\",\"https://openalex.org/W1550172608\",\"https://openalex.org/W1844842999\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2034911394\",\"https://openalex.org/W2044788246\",\"https://openalex.org/W2064094124\",\"https://openalex.org/W2068530650\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2096249407\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2318498932\",\"https://openalex.org/W2325207359\"],\"authorships\":[{\"id\":\"https://openalex.org/A5109843219\",\"display_name\":\"Robert L. Jesse\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051150112\",\"display_name\":\"Roland R. Griffi\",\"orcid\":null}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"http://csp.org/HopkinsPsilocybin2014.pdf\",\"is_oa\":false}}", "topic_tags": "Addiction,Wellbeing,Spirituality,Mystical Experience,Observational Study,Cancer Patients,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2551216332" }, { "id": 2577, "title": "A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.", "normalized_title": "a proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment", "authors": "Burdick BV, Adinoff B.", "abstract": "Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and non-addictiveness. However, pharmacological interventions, such as hallucinogens, should not be offered if the same effects (e.g. psychological insights/mystical experiences) and outcomes (e.g. decreased drug use) could be achieved absent pharmacological intervention. To date, there have been no clinical comparisons of drug-induced altered states with non-drug-induced states for addiction treatment. We propose and then outline a clinical trial to address this gap in knowledge. The proposed design would evaluate abstinence outcomes in a population of prescription opioid abusers after exposure to one of three conditions: a drug-induced altered state using psilocybin, a non-drug-induced altered state via hyperventilation (Holotropic Breathwork), and an active placebo with niacin. The outcomes of such a study would reveal important differences in therapeutic potential by discriminating hallucinogen-dependent effects from those psychological effects resulting from altered states.", "journal": "The American Journal of Drug and Alcohol Abuse", "publication_date": "2013-08-31", "publication_year": 2013, "doi": "10.3109/00952990.2013.811513", "pubmed_id": "23968172", "source_url": "https://doi.org/10.3109/00952990.2013.811513", "keywords": "Humans, Hyperventilation, Substance-Related Disorders, Opioid-Related Disorders, Hallucinogens, Research Design, Randomized Controlled Trials as Topic, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"23968172\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2043530175\",\"openalex_url\":\"https://openalex.org/W2043530175\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":18,\"referenced_works\":[\"https://openalex.org/W4277775\",\"https://openalex.org/W39896301\",\"https://openalex.org/W62922542\",\"https://openalex.org/W110752286\",\"https://openalex.org/W1266238005\",\"https://openalex.org/W1484799892\",\"https://openalex.org/W1495150842\",\"https://openalex.org/W1516584056\",\"https://openalex.org/W1924706543\",\"https://openalex.org/W1940682915\",\"https://openalex.org/W1961364466\",\"https://openalex.org/W1964116811\",\"https://openalex.org/W1964623504\",\"https://openalex.org/W1964661098\",\"https://openalex.org/W1973613743\",\"https://openalex.org/W1973766265\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1975606049\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1983799144\",\"https://openalex.org/W1984070202\",\"https://openalex.org/W1988074018\",\"https://openalex.org/W1988402979\",\"https://openalex.org/W1989232209\",\"https://openalex.org/W1991997587\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1998631480\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006587749\",\"https://openalex.org/W2011221060\",\"https://openalex.org/W2018267671\",\"https://openalex.org/W2025267048\",\"https://openalex.org/W2035094883\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2043678991\",\"https://openalex.org/W2044783071\",\"https://openalex.org/W2051426845\",\"https://openalex.org/W2056653066\",\"https://openalex.org/W2057521633\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2069728618\",\"https://openalex.org/W2069834899\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2076943453\",\"https://openalex.org/W2079258526\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2088785539\",\"https://openalex.org/W2089149909\",\"https://openalex.org/W2089436854\",\"https://openalex.org/W2096058212\",\"https://openalex.org/W2096571901\",\"https://openalex.org/W2098185806\",\"https://openalex.org/W2103822585\",\"https://openalex.org/W2105057498\",\"https://openalex.org/W2110003018\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2116852450\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2124791354\",\"https://openalex.org/W2127673034\",\"https://openalex.org/W2137754323\",\"https://openalex.org/W2144078056\",\"https://openalex.org/W2145026656\",\"https://openalex.org/W2145095988\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2154766235\",\"https://openalex.org/W2154896792\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2161617741\",\"https://openalex.org/W2408451005\",\"https://openalex.org/W2798667567\",\"https://openalex.org/W4252556863\",\"https://openalex.org/W4298169268\"],\"authorships\":[{\"id\":\"https://openalex.org/A5003806544\",\"display_name\":\"Brittany Vasae Burdick\",\"orcid\":null},{\"id\":\"https://openalex.org/A5060955934\",\"display_name\":\"Bryon Adinoff\",\"orcid\":\"https://orcid.org/0000-0002-7464-2642\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S162477232\",\"source_display_name\":\"The American Journal of Drug and Alcohol Abuse\",\"landing_page_url\":\"https://doi.org/10.3109/00952990.2013.811513\",\"is_oa\":false}}}", "topic_tags": "Addiction,Mystical Experience,Clinical Trial,Randomized Controlled Trial,Safety,Toxicity", "study_type": "Randomized Controlled Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2043530175" }, { "id": 2579, "title": "Psychedelics and mental health: a population study.", "normalized_title": "psychedelics and mental health a population study", "authors": "Krebs TS, Johansen PØ.", "abstract": "BackgroundThe classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline.ObjectiveTo evaluate the association between the lifetime use of psychedelics and current mental health in the adult population.MethodData drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events.Results21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems.ConclusionWe did not find use of psychedelics to be an independent risk factor for mental health problems.", "journal": "PLoS ONE", "publication_date": "2013-08-18", "publication_year": 2013, "doi": "10.1371/journal.pone.0063972", "pubmed_id": "23976938", "source_url": "https://doi.org/10.1371/journal.pone.0063972", "keywords": "Humans, Mescaline, Lysergic Acid Diethylamide, Hallucinogens, Data Collection, Odds Ratio, Risk Factors, Mental Health, Mental Disorders, Adolescent, Adult, Middle Aged, United States, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"23976938\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2014761647\",\"openalex_url\":\"https://openalex.org/W2014761647\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":337,\"referenced_works\":[\"https://openalex.org/W130785204\",\"https://openalex.org/W1173585919\",\"https://openalex.org/W1481799070\",\"https://openalex.org/W1507098867\",\"https://openalex.org/W1620211670\",\"https://openalex.org/W1644566157\",\"https://openalex.org/W1872359764\",\"https://openalex.org/W1965812297\",\"https://openalex.org/W1970742603\",\"https://openalex.org/W1980862554\",\"https://openalex.org/W1981640239\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W1983580111\",\"https://openalex.org/W1988574431\",\"https://openalex.org/W2000261029\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2011221060\",\"https://openalex.org/W2013576699\",\"https://openalex.org/W2014112381\",\"https://openalex.org/W2016744112\",\"https://openalex.org/W2021752411\",\"https://openalex.org/W2026485584\",\"https://openalex.org/W2035199049\",\"https://openalex.org/W2041968943\",\"https://openalex.org/W2054893318\",\"https://openalex.org/W2064345287\",\"https://openalex.org/W2065164655\",\"https://openalex.org/W2066709094\",\"https://openalex.org/W2083999387\",\"https://openalex.org/W2099103834\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2106413689\",\"https://openalex.org/W2108914738\",\"https://openalex.org/W2112590707\",\"https://openalex.org/W2114629758\",\"https://openalex.org/W2116942691\",\"https://openalex.org/W2117522474\",\"https://openalex.org/W2117834601\",\"https://openalex.org/W2118100568\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2130373985\",\"https://openalex.org/W2135686698\",\"https://openalex.org/W2138148662\",\"https://openalex.org/W2139192721\",\"https://openalex.org/W2150903999\",\"https://openalex.org/W2155914606\",\"https://openalex.org/W2160313238\",\"https://openalex.org/W2165935447\",\"https://openalex.org/W2409870141\",\"https://openalex.org/W2422019304\",\"https://openalex.org/W2758523683\",\"https://openalex.org/W2923749790\",\"https://openalex.org/W3092554874\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4232895479\",\"https://openalex.org/W4237682118\"],\"authorships\":[{\"id\":\"https://openalex.org/A5022694095\",\"display_name\":\"Teri Suzanne Krebs\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078179953\",\"display_name\":\"Pål-Ørjan Johansen\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S202381698\",\"source_display_name\":\"PLoS ONE\",\"landing_page_url\":\"https://doi.org/10.1371/journal.pone.0063972\",\"is_oa\":true}}}", "topic_tags": "Depression,Anxiety,PTSD,Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2014761647" }, { "id": 2060, "title": "Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities.", "normalized_title": "fungal hallucinogens psilocin ibotenic acid and muscimol analytical methods and biologic activities", "authors": "Stebelska K.", "abstract": "Psychoactive drugs of fungal origin, psilocin, ibotenic acid, and muscimol among them have been proposed for recreational use and popularized since the 1960s, XX century. Despite their well-documented neurotoxicity, they reached reputation of being safe and nonaddictive. Scientific efforts to find any medical application for these hallucinogens in psychiatry, psychotherapy, and even for religious rituals support are highly controversial. Even if they show any healing potential, their usage in psychotherapy is in some cases inadequate and may additionally harm seriously suffering patients. Hallucinogens are thought to reduce cognitive functions. However, in case of indolealkylamines, such as psilocin, some recent findings suggest their ability to improve perception and mental skills, what would motivate the consumption of \"magic mushrooms.\" The present article offers an opportunity to find out what are the main symptoms of intoxication with mushrooms containing psilocybin/psilocin, muscimol, and ibotenic acid. The progress in analytical methods for detection of them in fungal material, food, and body fluids is reviewed. Findings on the mechanisms of their biologic activity are summarized. Additionally, therapeutic potential of these fungal psychoactive compounds and health risk associated with their abuse are discussed.", "journal": null, "publication_date": "2013-07-31", "publication_year": 2013, "doi": "10.1097/ftd.0b013e31828741a5", "pubmed_id": "23851905", "source_url": "https://doi.org/10.1097/ftd.0b013e31828741a5", "keywords": "Body Fluids, Animals, Humans, Agaricales, Ibotenic Acid, Muscimol, Hallucinogens, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:52:05", "last_checked": "2026-07-01 11:22:04", "raw_json": "{\"europe_pmc_id\":\"23851905\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Mechanism of Action,Review Article,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2582, "title": "Methoxetamine (MXE)--a phenomenological study of experiences induced by a \"legal high\" from the internet.", "normalized_title": "methoxetamine mxe a phenomenological study of experiences induced by a legal high from the internet", "authors": "Kjellgren A, Jonsson K.", "abstract": "Methoxetamine (MXE), a ketamine analogue, is one of the new \"legal highs\" sold on the Internet. The aim of this qualitative study was to provide an initial understanding of what characterizes the experiences induced by MXE. Anonymously written reports (33 persons) on the effects of MXE were collected from public Internet forums and analyzed using the Empirical Phenomenological Psychological Method. The analysis generated 10 themes: (1) preparation, motivation and anticipation; (2) initial effects; (3) malfunction of cognitive processes stabilizing normal state; (4) inner personal processes and learning; (5) emotional processes; (6) altered sensory perception; (7) dissolution and transition; (8) spiritual and transcendental experiences; (9) effects and processes after the experience; (10) re-dosing and addiction. MXE induced a heavily altered state of consciousness. The effects were similar to those induced by classic hallucinogens (such as LSD, psilocybin) and the dissociative ketamine. MXE seemed to have quite a high abuse potential. Beside the positive effects described, negative effects like fear and anxiety were also reported. Acceptance was considered the best coping strategy. Dissolution of identity and body often culminated in spiritual and transcendental experiences. More research is needed on safety issues, how to minimize harm, and the motivation for using legal highs.", "journal": "Journal of Psychoactive Drugs", "publication_date": "2013-06-30", "publication_year": 2013, "doi": "10.1080/02791072.2013.803647", "pubmed_id": "24175493", "source_url": "https://doi.org/10.1080/02791072.2013.803647", "keywords": "Humans, Substance-Related Disorders, Cyclohexylamines, Cyclohexanones, Hallucinogens, Motivation, Cognition, Internet, Female, Male, Illicit Drugs", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"24175493\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2060192760\",\"openalex_url\":\"https://openalex.org/W2060192760\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":75,\"referenced_works\":[\"https://openalex.org/W62704851\",\"https://openalex.org/W581947269\",\"https://openalex.org/W939719243\",\"https://openalex.org/W1752708916\",\"https://openalex.org/W1973099427\",\"https://openalex.org/W1973527207\",\"https://openalex.org/W1976809764\",\"https://openalex.org/W1985053470\",\"https://openalex.org/W1991973363\",\"https://openalex.org/W1992051020\",\"https://openalex.org/W2000117884\",\"https://openalex.org/W2013033269\",\"https://openalex.org/W2019503836\",\"https://openalex.org/W2023081218\",\"https://openalex.org/W2023596965\",\"https://openalex.org/W2023615425\",\"https://openalex.org/W2029865781\",\"https://openalex.org/W2031683838\",\"https://openalex.org/W2040674316\",\"https://openalex.org/W2042152382\",\"https://openalex.org/W2047276596\",\"https://openalex.org/W2049105730\",\"https://openalex.org/W2053980485\",\"https://openalex.org/W2076239213\",\"https://openalex.org/W2082299145\",\"https://openalex.org/W2090636864\",\"https://openalex.org/W2091250062\",\"https://openalex.org/W2109334244\",\"https://openalex.org/W2116697656\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2121189426\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2129721670\",\"https://openalex.org/W2132467809\",\"https://openalex.org/W2133963272\",\"https://openalex.org/W2143350277\",\"https://openalex.org/W2145462275\",\"https://openalex.org/W2155241775\",\"https://openalex.org/W2158928577\",\"https://openalex.org/W2401986986\",\"https://openalex.org/W2472214535\",\"https://openalex.org/W3022607203\",\"https://openalex.org/W3214833809\",\"https://openalex.org/W4285719527\",\"https://openalex.org/W4386218079\"],\"authorships\":[{\"id\":\"https://openalex.org/A5011602888\",\"display_name\":\"Anette Kjellgren\",\"orcid\":\"https://orcid.org/0000-0002-5668-0469\"},{\"id\":\"https://openalex.org/A5017205546\",\"display_name\":\"Kristoffer Jonsson\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S149515109\",\"source_display_name\":\"Journal of Psychoactive Drugs\",\"landing_page_url\":\"https://doi.org/10.1080/02791072.2013.803647\",\"is_oa\":false}}}", "topic_tags": "Anxiety,Addiction,Consciousness,Emotional Processing,Spirituality,Safety", "study_type": "Qualitative Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2060192760" }, { "id": 2581, "title": "Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.", "normalized_title": "identification of novel psychoactive drug use in sweden based on laboratory analysis initial experiences from the strida project", "authors": "Helander A, Beck O, Hägerkvist R, Hultén P.", "abstract": "AimThe study aimed to collect information concerning the increasing use of new psychoactive substances, commonly sold through online shops as 'Internet drugs' or 'legal highs', or in terms of masked products such as 'bath salts' and 'plant food'.MethodsThe Karolinska Institutet and Karolinska University Laboratory and the Swedish Poisons Information Centre have initiated a project called 'STRIDA' aiming to monitor the occurrence and trends of new psychoactive substances in Sweden, and collect information about their clinical symptoms, toxicity and associated health risks. A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) multi-component method has been developed, currently allowing for the determination of > 80 novel psychoactive compounds or metabolites thereof. This study focused mainly on the particular drug substances identified and the population demographics of the initial STRIDA cases.ResultsIn urine and/or blood samples obtained from 103 consecutive cases of admitted or suspected recreational drug intoxications in mostly young subjects (78% were ≤ 25 years, and 81% were males) presenting at emergency departments all over the country, psychoactive substances were detected in 82%. The substances comprised synthetic cannabinoids ('Spice'; JWH analogues), substituted cathinones ('bath salts'; e.g. butylone, MDPV and methylone) and tryptamines (4-HO-MET), plant-based substances (mitragynine and psilocin), as well as conventional drugs-of-abuse. In 44% of the cases, more than one new psychoactive substance, or a mixture of new and/or conventional drugs were detected.ConclusionThe initial results of the STRIDA project have documented use of a broad variety of new psychoactive substances among mainly young people all over Sweden.", "journal": null, "publication_date": "2013-05-21", "publication_year": 2013, "doi": "10.3109/00365513.2013.793817", "pubmed_id": "23692208", "source_url": "https://doi.org/10.3109/00365513.2013.793817", "keywords": "Humans, Substance-Related Disorders, Tryptamines, Amphetamines, Methamphetamine, Secologanin Tryptamine Alkaloids, Benzodiazepines, Indoles, Psychotropic Drugs, Adolescent, Adult, Middle Aged, Sweden, Female, Male, Young Adult, Cannabinoid Receptor Agonists, Psilocybin, Illicit Drugs", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"23692208\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Receptor Pharmacology,Adolescents,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2028152704" }, { "id": 2602, "title": "Moral transhumanism: the next step.", "normalized_title": "moral transhumanism the next step", "authors": "Tennison MN.", "abstract": "Although transhumanism offers hope for the transcendence of human biological limitations, it generates many intrinsic and consequential ethical concerns. The latter include issues such as the exacerbation of social inequalities and the exponentially increasing technological capacity to cause harm. To mitigate these risks, many thinkers have initiated investigations into the possibility of moral enhancement that could limit the power disparities facilitated by biotechnological enhancement. The arguments often focus on whether moral enhancement is morally permissible, or even obligatory, and remain largely in the realm of the hypothetical. This paper proposes that psilocybin may represent a viable, practical option for moral enhancement and that its further research in the context of moral psychology could comprise the next step in the development of moral transhumanism.", "journal": "The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine", "publication_date": "2012-07-31", "publication_year": 2012, "doi": "10.1093/jmp/jhs024", "pubmed_id": "22855738", "source_url": "https://doi.org/10.1093/jmp/jhs024", "keywords": "Humans, Biomedical Enhancement, Morals, Bioethics, Philosophy, Medical", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"22855738\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2123238370\",\"openalex_url\":\"https://openalex.org/W2123238370\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":39,\"referenced_works\":[\"https://openalex.org/W50975988\",\"https://openalex.org/W147807369\",\"https://openalex.org/W1487490705\",\"https://openalex.org/W1564003910\",\"https://openalex.org/W1965467997\",\"https://openalex.org/W1967722947\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2002376579\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2026110491\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2104320558\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119134849\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122307809\",\"https://openalex.org/W2155179880\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2208649891\",\"https://openalex.org/W2900033011\",\"https://openalex.org/W3123609390\",\"https://openalex.org/W4238754099\",\"https://openalex.org/W4249693540\"],\"authorships\":[{\"id\":\"https://openalex.org/A5113995192\",\"display_name\":\"M. N. Tennison\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S166373307\",\"source_display_name\":\"The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine\",\"landing_page_url\":\"https://doi.org/10.1093/jmp/jhs024\",\"is_oa\":false}}}", "topic_tags": "Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2123238370" }, { "id": 2595, "title": "Substance use initiation: the role of simultaneous polysubstance use.", "normalized_title": "substance use initiation the role of simultaneous polysubstance use", "authors": "Olthuis JV, Darredeau C, Barrett SP.", "abstract": "Introduction and aimsSimultaneous polysubstance use (SPU) is a common phenomenon, yet little is known about its role in substance use initiation.Design and methodsIn the present study, 226 cannabis users completed structured interviews about their substance use history. For each substance ever used, participants provided details of their age of first use, their use in the preceding 30 days and whether they co-administered any other licit or illicit substances the first time they used the substance.ResultsFor most illicit substances [powder cocaine, crack, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA; ecstasy), heroin, opium, gamma-hydroxybutyric acid (GHB), ketamine, psilocybin (magic mushrooms), mescaline, phencyclidine (PCP), peyote and inhalants], results showed that a clear majority of participants (≥75%) reported SPU during their first-ever use of the substance. While SPU was less common on occasions of first use of alcohol, tobacco and cannabis, a high proportion of SPU on occasions of first use of 'harder' drugs could be accounted for by the co-use of alcohol, tobacco and/or cannabis.Discussion and conclusionsSuch findings raise the possibility that specific alcohol, tobacco and/or cannabis use episodes might directly contribute to the initiation of new substance use. Understanding the role of SPU on occasions of first use might help better identify risk factors for substance use progression and improve intervention efforts.", "journal": "Drug and Alcohol Review", "publication_date": "2012-05-20", "publication_year": 2012, "doi": "10.1111/j.1465-3362.2012.00470.x", "pubmed_id": "22612987", "source_url": "https://doi.org/10.1111/j.1465-3362.2012.00470.x", "keywords": "Humans, Substance-Related Disorders, Marijuana Abuse, Adolescent, Adult, Middle Aged, Nova Scotia, Female, Male, Young Adult, Prescription Drug Misuse, Illicit Drugs", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"22612987\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W1892791858\",\"openalex_url\":\"https://openalex.org/W1892791858\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":79,\"referenced_works\":[\"https://openalex.org/W1827704104\",\"https://openalex.org/W1964869113\",\"https://openalex.org/W1965246039\",\"https://openalex.org/W1967375686\",\"https://openalex.org/W1998584172\",\"https://openalex.org/W2001691002\",\"https://openalex.org/W2004600426\",\"https://openalex.org/W2005015693\",\"https://openalex.org/W2006057102\",\"https://openalex.org/W2009182647\",\"https://openalex.org/W2009469943\",\"https://openalex.org/W2010597114\",\"https://openalex.org/W2019588221\",\"https://openalex.org/W2021999592\",\"https://openalex.org/W2025113318\",\"https://openalex.org/W2053715270\",\"https://openalex.org/W2060940195\",\"https://openalex.org/W2063491224\",\"https://openalex.org/W2068484268\",\"https://openalex.org/W2071330075\",\"https://openalex.org/W2075508629\",\"https://openalex.org/W2090585211\",\"https://openalex.org/W2096398995\",\"https://openalex.org/W2119461820\",\"https://openalex.org/W2120516435\",\"https://openalex.org/W2129790377\",\"https://openalex.org/W2135007804\",\"https://openalex.org/W2138076342\",\"https://openalex.org/W2141994068\",\"https://openalex.org/W2167288101\",\"https://openalex.org/W2170488040\",\"https://openalex.org/W2170684975\",\"https://openalex.org/W4229930296\",\"https://openalex.org/W4236180415\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034453797\",\"display_name\":\"Janine V. Olthuis\",\"orcid\":\"https://orcid.org/0000-0003-3538-7682\"},{\"id\":\"https://openalex.org/A5035032001\",\"display_name\":\"Christine Darredeau\",\"orcid\":null},{\"id\":\"https://openalex.org/A5059241194\",\"display_name\":\"Sean P. Barrett\",\"orcid\":\"https://orcid.org/0000-0002-9495-8265\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S134936136\",\"source_display_name\":\"Drug and Alcohol Review\",\"landing_page_url\":\"https://doi.org/10.1111/j.1465-3362.2012.00470.x\",\"is_oa\":false}}}", "topic_tags": "Addiction,Adolescents,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W1892791858" }, { "id": 2622, "title": "Harm potential of magic mushroom use: a review.", "normalized_title": "harm potential of magic mushroom use a review", "authors": "van Amsterdam J, Opperhuizen A, van den Brink W", "abstract": "In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the prevalence of magic mushroom use was declining since 2000 (last year prevalence of 6.3% in 2000 to 2.9% in 2005), and further declined after possession and use became illegal in December 2008. The CAM concluded that the physical and psychological dependence potential of magic mushrooms was low, that acute toxicity was moderate, chronic toxicity low and public health and criminal aspects negligible. The combined use of mushrooms and alcohol and the quality of the setting in which magic mushrooms are used deserve, however, attention. In conclusion, the use of magic mushrooms is relatively safe as only few and relatively mild adverse effects have been reported. The low prevalent but unpredictable provocation of panic attacks and flash-backs remain, however, a point of concern.", "journal": "Regulatory toxicology and pharmacology: RTP", "publication_date": "2011-03-31", "publication_year": 2011, "doi": "10.1016/j.yrtph.2011.01.006", "pubmed_id": "21256914", "source_url": "https://pubmed.ncbi.nlm.nih.gov/21256914/", "keywords": "", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 06:54:14", "raw_json": "{\"pubmed_id\":\"21256914\"}", "topic_tags": "Review Article,Safety,Toxicity,Abuse Liability", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2626, "title": "Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.", "normalized_title": "absorption distribution metabolism and excretion pharmacogenomics of drugs of abuse", "authors": "Meyer MR, Maurer HH.", "abstract": "Pharmacologic and toxic effects of xenobiotics, such as drugs of abuse, depend on the genotype and phenotype of an individual, and conversely on the isoenzymes involved in their metabolism and transport. The current knowledge of such isoenzymes of frequently abused therapeutics such as opioids (oxycodone, hydrocodone, methadone, fentanyl, buprenorphine, tramadol, heroin, morphine and codeine), anesthetics (γ-hydroxybutyric acid, propofol, ketamine and phencyclidine) and cognitive enhancers (methylphenidate and modafinil), and some important plant-derived hallucinogens (lysergide, salvinorin A, psilocybin and psilocin), as well as of nicotine in humans are summarized in this article. The isoenzymes (e.g., cytochrome P450, glucuronyltransferases, esterases and reductases) involved in the metabolism of drugs and some pharmacokinetic data are discussed. The relevance of such data is discussed for predicting possible interactions with other xenobiotics, understanding pharmacokinetic behavior and pharmacogenomic variations, assessing toxic risks, developing suitable toxicological analysis procedures, and finally for interpretating drug testing results.", "journal": null, "publication_date": "2011-01-31", "publication_year": 2011, "doi": "10.2217/pgs.10.171", "pubmed_id": "21332315", "source_url": "https://doi.org/10.2217/pgs.10.171", "keywords": "Humans, Nicotine, Isoenzymes, Analgesics, Opioid, Hallucinogens, Nootropic Agents, Pharmacogenetics, Absorption, Tissue Distribution, Illicit Drugs", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"21332315\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Pharmacology,Safety,Drug Interactions,Genomics", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2625, "title": "Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.", "normalized_title": "maternal influenza viral infection causes schizophrenia like alterations of 5 ht₂a and mglu₂ receptors in the adult offspring", "authors": "Moreno JL, Kurita M, Holloway T, López J, Cadagan R, Martínez-Sobrido L, García-Sastre A, González-Maeso J.", "abstract": "Epidemiological studies indicate that maternal influenza viral infection increases the risk for schizophrenia in the adult offspring. The serotonin and glutamate systems are suspected in the etiology of schizophrenia, as well as in the mechanism of action of antipsychotic drugs. The effects of hallucinogens, such as psilocybin and mescaline, require the serotonin 5-HT(2A) receptor, and induce schizophrenia-like psychosis in humans. In addition, metabotropic glutamate receptor mGlu(2/3) agonists show promise as a new treatment for schizophrenia. Here, we investigated the level of expression and behavioral function of 5-HT(2A) and mGlu(2) receptors in a mouse model of maternal influenza viral infection. We show that spontaneous locomotor activity is diminished by maternal infection with the mouse-adapted influenza A/WSN/33 (H1N1) virus. The behavioral responses to hallucinogens and glutamate antipsychotics are both affected by maternal exposure to influenza virus, with increased head-twitch response to hallucinogens and diminished antipsychotic-like effect of the glutamate agonist. In frontal cortex of mice born to influenza virus-infected mothers, the 5-HT(2A) receptor is upregulated and the mGlu(2) receptor is downregulated, an alteration that may be involved in the behavioral changes observed. Additionally, we find that the cortical 5-HT(2A) receptor-dependent signaling pathways are significantly altered in the offspring of infected mothers, showing higher c-fos, egr-1, and egr-2 expression in response to the hallucinogenic drug DOI. Identifying a biochemical alteration that parallels the behavioral changes observed in a mouse model of prenatal viral infection may facilitate targeting therapies for treatment and prevention of schizophrenia.", "journal": "Journal of Neuroscience", "publication_date": "2011-01-31", "publication_year": 2011, "doi": "10.1523/jneurosci.4230-10.2011", "pubmed_id": "21289196", "source_url": "https://doi.org/10.1523/jneurosci.4230-10.2011", "keywords": "Cerebral Cortex, Frontal Lobe, Neural Pathways, Animals, Mice, Orthomyxoviridae Infections, Disease Models, Animal, Glutamic Acid, Proto-Oncogene Proteins c-fos, Receptors, Metabotropic Glutamate, Receptor, Serotonin, 5-HT2A, Antipsychotic Agents, Hallucinogens, Schizophrenia, Down-Regulation, Up-Regulation, Pregnancy, Maternal-Fetal Exchange, Female, Early Growth Response Protein 1, Early Growth Response Protein 2, Influenza A Virus, H1N1 Subtype", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"21289196\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2072898255\",\"openalex_url\":\"https://openalex.org/W2072898255\",\"openalex_relevance_score\":3,\"openalex_relevance_reasons\":[\"abstract:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":119,\"referenced_works\":[\"https://openalex.org/W1549834980\",\"https://openalex.org/W1577274024\",\"https://openalex.org/W1646300150\",\"https://openalex.org/W1951663525\",\"https://openalex.org/W1962355416\",\"https://openalex.org/W1966407955\",\"https://openalex.org/W1972018621\",\"https://openalex.org/W1975996377\",\"https://openalex.org/W1983413649\",\"https://openalex.org/W1983746474\",\"https://openalex.org/W1990535802\",\"https://openalex.org/W1990545448\",\"https://openalex.org/W1993527031\",\"https://openalex.org/W1993826962\",\"https://openalex.org/W1994600097\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1999848070\",\"https://openalex.org/W2004367185\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2009490069\",\"https://openalex.org/W2017358382\",\"https://openalex.org/W2018385636\",\"https://openalex.org/W2020301473\",\"https://openalex.org/W2021402699\",\"https://openalex.org/W2022230955\",\"https://openalex.org/W2022654189\",\"https://openalex.org/W2024942419\",\"https://openalex.org/W2025534288\",\"https://openalex.org/W2029558958\",\"https://openalex.org/W2030517797\",\"https://openalex.org/W2031607959\",\"https://openalex.org/W2034427457\",\"https://openalex.org/W2040789766\",\"https://openalex.org/W2041812587\",\"https://openalex.org/W2045837603\",\"https://openalex.org/W2048010776\",\"https://openalex.org/W2048250261\",\"https://openalex.org/W2052882602\",\"https://openalex.org/W2053544252\",\"https://openalex.org/W2055013734\",\"https://openalex.org/W2055984914\",\"https://openalex.org/W2057109524\",\"https://openalex.org/W2060018802\",\"https://openalex.org/W2061506085\",\"https://openalex.org/W2073234751\",\"https://openalex.org/W2076572271\",\"https://openalex.org/W2084257157\",\"https://openalex.org/W2086167675\",\"https://openalex.org/W2086596085\",\"https://openalex.org/W2087200563\",\"https://openalex.org/W2091447278\",\"https://openalex.org/W2092533774\",\"https://openalex.org/W2098205950\",\"https://openalex.org/W2102291283\",\"https://openalex.org/W2104148197\",\"https://openalex.org/W2105035544\",\"https://openalex.org/W2112851246\",\"https://openalex.org/W2113113845\",\"https://openalex.org/W2116386279\",\"https://openalex.org/W2117430572\",\"https://openalex.org/W2121136381\",\"https://openalex.org/W2121366540\",\"https://openalex.org/W2123403544\",\"https://openalex.org/W2125244470\",\"https://openalex.org/W2134144722\",\"https://openalex.org/W2140824803\",\"https://openalex.org/W2142525943\",\"https://openalex.org/W2143217444\",\"https://openalex.org/W2148598875\",\"https://openalex.org/W2150172575\",\"https://openalex.org/W2154965665\",\"https://openalex.org/W2155757287\",\"https://openalex.org/W2158024838\",\"https://openalex.org/W2159030941\",\"https://openalex.org/W2167272363\",\"https://openalex.org/W2169911721\",\"https://openalex.org/W2170260565\",\"https://openalex.org/W2170760271\",\"https://openalex.org/W2171104921\",\"https://openalex.org/W2254502236\",\"https://openalex.org/W2396844307\",\"https://openalex.org/W4244626365\",\"https://openalex.org/W4251040433\",\"https://openalex.org/W6640887276\"],\"authorships\":[{\"id\":\"https://openalex.org/A5065089135\",\"display_name\":\"José L. Moreno\",\"orcid\":\"https://orcid.org/0000-0003-1851-925X\"},{\"id\":\"https://openalex.org/A5070282946\",\"display_name\":\"Mitsumasa Kurita\",\"orcid\":null},{\"id\":\"https://openalex.org/A5062790531\",\"display_name\":\"Terrell Holloway\",\"orcid\":\"https://orcid.org/0000-0002-7908-8417\"},{\"id\":\"https://openalex.org/A5110351938\",\"display_name\":\"Javier López\",\"orcid\":null},{\"id\":\"https://openalex.org/A5000670715\",\"display_name\":\"Richard Cadagan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5065326739\",\"display_name\":\"Luis Martínez-Sobrido\",\"orcid\":\"https://orcid.org/0000-0001-7084-0804\"},{\"id\":\"https://openalex.org/A5004889712\",\"display_name\":\"Adolfo García-Sastre\",\"orcid\":\"https://orcid.org/0000-0002-6551-1827\"},{\"id\":\"https://openalex.org/A5047587284\",\"display_name\":\"Javier González-Maeso\",\"orcid\":\"https://orcid.org/0000-0003-3105-3204\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S5555990\",\"source_display_name\":\"Journal of Neuroscience\",\"landing_page_url\":\"https://doi.org/10.1523/jneurosci.4230-10.2011\",\"is_oa\":true}}}", "topic_tags": "Mechanism of Action,Receptor Pharmacology,Animal Study,Safety", "study_type": "Animal Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2072898255" }, { "id": 2628, "title": "Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds.", "normalized_title": "turn on tune in but don t drop out the impact of neo liberalism on magic mushroom users in ability to imagine collectivist social worlds", "authors": "Riley S, Thompson J, Griffin C.", "abstract": "BackgroundBetween 2002 and 2005 fresh or unprepared psilocin-based 'magic' mushrooms were legal to possess and traffic in the UK, and commercial sales demonstrated a significant market for this hallucinogenic drug. During and after this time there has been relatively little analysis concerning how magic mushroom users accounted for their drug use, nor on the wider political and cultural discourses that might have shaped this sense making.MethodIn this paper we present a critical analysis of contemporary discourses around magic mushroom use in the UK through a multi-level discourse analysis of focus group data from 20 magic mushroom users (13 male and 7 female, mean age 25 years), taken at a time when magic mushrooms were being legally sold in the UK.ResultsLocating participants' use of magic mushrooms within the context of a culture of intoxication, neo-liberalism and the legacy of 1960s psychedelic philosophy, we identify six interpretative repertoires in their talk, which were subsumed within two overarching discourses. The first discourse drew on neo-liberal rhetoric, constructing participants as rational risk managing subjects engaged in a form of calculated hedonism that was legitimated as an act of personal freedom and consumer choice. The second discourse, identified as 'post-psychedelic', both celebrated and problematised a collective, connected 'hippy' form of spirituality.ConclusionThe paper analyses the relationships between identity, consumption and citizenship by arguing that people's ability to imagine collectivist, spiritual or interconnected social worlds has been contained within neo-liberalism rhetoric.", "journal": null, "publication_date": "2010-10-31", "publication_year": 2010, "doi": "10.1016/j.drugpo.2010.07.001", "pubmed_id": "20810266", "source_url": "https://doi.org/10.1016/j.drugpo.2010.07.001", "keywords": "Humans, Substance-Related Disorders, Hallucinogens, Focus Groups, Spirituality, Politics, Philosophy, Adolescent, Adult, Female, Male, Psilocybe, Young Adult, United Kingdom, Psilocybin", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"20810266\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Aging,Spirituality,Adolescents,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2615, "title": "Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.", "normalized_title": "acute subacute and long term subjective effects of psilocybin in healthy humans a pooled analysis of experimental studies", "authors": "Studerus E, Kometer M, Hasler F, Vollenweider FX.", "abstract": "Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1-4 oral doses of psilocybin (45-315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.", "journal": "Journal of Psychopharmacology", "publication_date": "2010-09-19", "publication_year": 2010, "doi": "10.1177/0269881110382466", "pubmed_id": "20855349", "source_url": "https://doi.org/10.1177/0269881110382466", "keywords": "Humans, Hallucinogens, Follow-Up Studies, Double-Blind Method, Affect, Perception, Adult, Middle Aged, Female, Male, Young Adult, Surveys and Questionnaires, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"20855349\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W1981740630\",\"openalex_url\":\"https://openalex.org/W1981740630\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":529,\"referenced_works\":[\"https://openalex.org/W22529605\",\"https://openalex.org/W62922542\",\"https://openalex.org/W70805046\",\"https://openalex.org/W359263171\",\"https://openalex.org/W1513242235\",\"https://openalex.org/W1573959920\",\"https://openalex.org/W1587094587\",\"https://openalex.org/W1933205484\",\"https://openalex.org/W1965146355\",\"https://openalex.org/W1967205222\",\"https://openalex.org/W1967887881\",\"https://openalex.org/W1973927342\",\"https://openalex.org/W1980563902\",\"https://openalex.org/W1980677295\",\"https://openalex.org/W1982170313\",\"https://openalex.org/W1982233118\",\"https://openalex.org/W1986425243\",\"https://openalex.org/W1992275189\",\"https://openalex.org/W1995045083\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2000021284\",\"https://openalex.org/W2002178209\",\"https://openalex.org/W2008071452\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2013734228\",\"https://openalex.org/W2016549521\",\"https://openalex.org/W2018604380\",\"https://openalex.org/W2022544017\",\"https://openalex.org/W2024942419\",\"https://openalex.org/W2037606383\",\"https://openalex.org/W2037891934\",\"https://openalex.org/W2038593489\",\"https://openalex.org/W2040034137\",\"https://openalex.org/W2042593075\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2044704612\",\"https://openalex.org/W2047427656\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2052512884\",\"https://openalex.org/W2057174717\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2061607209\",\"https://openalex.org/W2064627176\",\"https://openalex.org/W2068199765\",\"https://openalex.org/W2069168835\",\"https://openalex.org/W2074371541\",\"https://openalex.org/W2078297889\",\"https://openalex.org/W2083152069\",\"https://openalex.org/W2089982466\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2096610047\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2102963347\",\"https://openalex.org/W2104493382\",\"https://openalex.org/W2106188235\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2114629758\",\"https://openalex.org/W2115154626\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2117834601\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2121654107\",\"https://openalex.org/W2124858522\",\"https://openalex.org/W2129576675\",\"https://openalex.org/W2144455058\",\"https://openalex.org/W2145998697\",\"https://openalex.org/W2150903999\",\"https://openalex.org/W2152569564\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2155757287\",\"https://openalex.org/W2159267296\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2245706386\",\"https://openalex.org/W2262454617\",\"https://openalex.org/W2276257934\",\"https://openalex.org/W2312475727\",\"https://openalex.org/W2398867243\",\"https://openalex.org/W2399045151\",\"https://openalex.org/W2412554478\",\"https://openalex.org/W2433136333\",\"https://openalex.org/W2486076347\",\"https://openalex.org/W2791114118\",\"https://openalex.org/W3199318186\",\"https://openalex.org/W4206439534\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4233004824\",\"https://openalex.org/W4249454396\",\"https://openalex.org/W4285719527\"],\"authorships\":[{\"id\":\"https://openalex.org/A5034712307\",\"display_name\":\"Erich Studerus\",\"orcid\":\"https://orcid.org/0000-0003-4233-0182\"},{\"id\":\"https://openalex.org/A5021802006\",\"display_name\":\"Michael Kometer\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079835073\",\"display_name\":\"Felix Hasler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086283052\",\"display_name\":\"Franz X. Vollenweider\",\"orcid\":\"https://orcid.org/0000-0001-9053-6164\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881110382466\",\"is_oa\":false}}}", "topic_tags": "Anxiety,Observational Study,Safety,Adverse Events", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W1981740630" }, { "id": 2627, "title": "Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.", "normalized_title": "pilot study of psilocybin treatment for anxiety in patients with advanced stage cancer", "authors": "Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR.", "abstract": "ContextResearchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.ObjectiveTo explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.DesignA double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.SettingA clinical research unit within a large public sector academic medical center.ParticipantsTwelve adults with advanced-stage cancer and anxiety.Main outcome measuresIn addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.ResultsSafe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.ConclusionsThis study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.Trial registrationclinicaltrials.gov Identifier: NCT00302744.", "journal": "Archives of General Psychiatry", "publication_date": "2010-09-05", "publication_year": 2010, "doi": "10.1001/archgenpsychiatry.2010.116", "pubmed_id": "20819978", "source_url": "https://doi.org/10.1001/archgenpsychiatry.2010.116", "keywords": "Humans, Neoplasms, Hallucinogens, Neoplasm Staging, Treatment Outcome, Follow-Up Studies, Pilot Projects, Double-Blind Method, Affect, Anxiety, Personality Inventory, Time Factors, Adult, Middle Aged, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"20819978\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2161555895\",\"openalex_url\":\"https://openalex.org/W2161555895\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1219,\"referenced_works\":[\"https://openalex.org/W60718584\",\"https://openalex.org/W173089895\",\"https://openalex.org/W592732404\",\"https://openalex.org/W1569173481\",\"https://openalex.org/W1582590726\",\"https://openalex.org/W1892347931\",\"https://openalex.org/W1966877000\",\"https://openalex.org/W1971680325\",\"https://openalex.org/W2020844317\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2058192111\",\"https://openalex.org/W2067495470\",\"https://openalex.org/W2086963232\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2097036111\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2115111325\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2134506226\",\"https://openalex.org/W2151985542\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2159011576\",\"https://openalex.org/W2166934228\",\"https://openalex.org/W2186557663\",\"https://openalex.org/W2278944819\",\"https://openalex.org/W2396361768\",\"https://openalex.org/W2411260068\",\"https://openalex.org/W2971371418\"],\"authorships\":[{\"id\":\"https://openalex.org/A5108513619\",\"display_name\":\"Charles S. Grob\",\"orcid\":null},{\"id\":\"https://openalex.org/A5051293419\",\"display_name\":\"Alicia Danforth\",\"orcid\":\"https://orcid.org/0000-0001-8726-046X\"},{\"id\":\"https://openalex.org/A5060572631\",\"display_name\":\"Gurpreet S Chopra\",\"orcid\":null},{\"id\":\"https://openalex.org/A5080877260\",\"display_name\":\"Marycie Hagerty\",\"orcid\":null},{\"id\":\"https://openalex.org/A5068143057\",\"display_name\":\"Charles R. McKay\",\"orcid\":null},{\"id\":\"https://openalex.org/A5036162393\",\"display_name\":\"Adam L. Halberstadt\",\"orcid\":\"https://orcid.org/0000-0001-5096-5829\"},{\"id\":\"https://openalex.org/A5060037439\",\"display_name\":\"George Greer\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S126359496\",\"source_display_name\":\"Archives of General Psychiatry\",\"landing_page_url\":\"https://doi.org/10.1001/archgenpsychiatry.2010.116\",\"is_oa\":false}}}", "topic_tags": "Depression,Anxiety,Aging,Personality Change,Safety,Adverse Events", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2161555895" }, { "id": 2616, "title": "The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.", "normalized_title": "the administration of psilocybin to healthy hallucinogen experienced volunteers in a mock functional magnetic resonance imaging environment a preliminary investigation of tolerability", "authors": "Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ.", "abstract": "This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the viability of functional magnetic resonance imaging work with psilocybin.", "journal": "Journal of Psychopharmacology", "publication_date": "2010-04-14", "publication_year": 2010, "doi": "10.1177/0269881110367445", "pubmed_id": "20395317", "source_url": "https://doi.org/10.1177/0269881110367445", "keywords": "Humans, Hallucinogens, Magnetic Resonance Imaging, Injections, Intravenous, Follow-Up Studies, Pilot Projects, Cerebrovascular Circulation, Drug Tolerance, Adult, Middle Aged, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"20395317\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2051426845\",\"openalex_url\":\"https://openalex.org/W2051426845\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":53,\"referenced_works\":[\"https://openalex.org/W60326299\",\"https://openalex.org/W592732404\",\"https://openalex.org/W1974109667\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2048509938\",\"https://openalex.org/W2057174717\",\"https://openalex.org/W2059976461\",\"https://openalex.org/W2076780080\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2102963347\",\"https://openalex.org/W2110701839\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2324093635\",\"https://openalex.org/W2801279915\",\"https://openalex.org/W2802856933\",\"https://openalex.org/W2857765758\",\"https://openalex.org/W4211150788\"],\"authorships\":[{\"id\":\"https://openalex.org/A5038609897\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101579525\",\"display_name\":\"Tom A. Williams\",\"orcid\":\"https://orcid.org/0000-0003-1072-0223\"},{\"id\":\"https://openalex.org/A5081065269\",\"display_name\":\"Ben Sessa\",\"orcid\":\"https://orcid.org/0000-0002-1212-6060\"},{\"id\":\"https://openalex.org/A5108727800\",\"display_name\":\"Robin J. Tyacke\",\"orcid\":null},{\"id\":\"https://openalex.org/A5111940587\",\"display_name\":\"Ann Rich\",\"orcid\":null},{\"id\":\"https://openalex.org/A5071332026\",\"display_name\":\"Amanda Feilding\",\"orcid\":\"https://orcid.org/0000-0002-1329-1893\"},{\"id\":\"https://openalex.org/A5016082897\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-1286-1401\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/0269881110367445\",\"is_oa\":false}}}", "topic_tags": "Brain Imaging,Aging,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2051426845" }, { "id": 5380, "title": "Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder", "normalized_title": "safety tolerability and efficacy of psilocybin in 9 patients with obsessive compulsive disorder", "authors": "J.C. Ballenger", "abstract": "", "journal": "Yearbook of Psychiatry and Applied Mental Health", "publication_date": "2007-12-31", "publication_year": 2007, "doi": "10.1016/s0084-3970(08)70820-x", "pubmed_id": null, "source_url": "https://doi.org/10.1016/s0084-3970(08)70820-x", "keywords": "Psilocybin, Tolerability, Obsessive compulsive, Psychiatry, Medicine, Psychology, Hallucinogen, Psychotherapist, Pharmacology, Adverse effect, Psychedelics and Drug Studies, Body Image and Dysmorphia Studies, Sexuality, Behavior, and Technology", "substance_tags": "psilocybin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:52:06", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"openalex_id\":\"https://openalex.org/W2323886621\",\"openalex_url\":\"https://openalex.org/W2323886621\",\"openalex_relevance_score\":6,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":5,\"referenced_works\":[\"https://openalex.org/W2043197532\"],\"authorships\":[{\"id\":\"https://openalex.org/A5108583183\",\"display_name\":\"J.C. Ballenger\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210168417\",\"source_display_name\":\"Yearbook of Psychiatry and Applied Mental Health\",\"landing_page_url\":\"https://doi.org/10.1016/s0084-3970(08)70820-x\",\"is_oa\":false}}", "topic_tags": "OCD,Pharmacology,Safety", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2323886621" }, { "id": 2675, "title": "The adverse effects of hallucinogens from intramural perspective.", "normalized_title": "the adverse effects of hallucinogens from intramural perspective", "authors": "Frecska E, Luna LE.", "abstract": "UnlabelledVery recently, after a long-lasting, worldwide moratorium on research of hallucinogenic agents, a good number of advanced countries have been revising their position, and start to approve testing the physiological and therapeutic effects of hallucinogens in human subjects. The purpose of this article is to review safety information available in the literature on hallucinogen use, and sort out those data from the reported complications of their abuse. Because of prohibitory regulations of the last 35 years, there are difficulties in achieving this kind of evaluation. Our approach has to be broad, and at times retrospective, in contrast to the well-controlled, focused, prospective design of the premarketing trials of legal drugs. The article summarizes the analyses in anticipation of supportive regulatory changes for the use of hallucinogens in well controlled studies and strictly supervised clinical trials.Keywordsadverse effects, ayahuasca, N,N-dimethyltryptamine, hallucinogenic agents, ibogaine, lysergic acid diethylamide, N-methyl-3,4-methylenedioxyamphetamine, psilocybin, therapeutic use.", "journal": "PubMed", "publication_date": "2006-11-30", "publication_year": 2006, "doi": null, "pubmed_id": "17211054", "source_url": "https://europepmc.org/article/MED/17211054", "keywords": "Humans, Poisoning, Hallucinogens, Emergency Treatment, Personality, Perception, Drug Interactions", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"17211054\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W110752286\",\"openalex_url\":\"https://openalex.org/W110752286\",\"openalex_relevance_score\":5,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":16,\"referenced_works\":[\"https://openalex.org/W107475310\",\"https://openalex.org/W126579187\",\"https://openalex.org/W203031526\",\"https://openalex.org/W266681429\",\"https://openalex.org/W428411035\",\"https://openalex.org/W1488217392\",\"https://openalex.org/W1498831570\",\"https://openalex.org/W1582590726\",\"https://openalex.org/W1787588990\",\"https://openalex.org/W1963634560\",\"https://openalex.org/W1973234849\",\"https://openalex.org/W1990198973\",\"https://openalex.org/W1993762893\",\"https://openalex.org/W1998129912\",\"https://openalex.org/W1998631480\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2024845040\",\"https://openalex.org/W2039087930\",\"https://openalex.org/W2044307156\",\"https://openalex.org/W2053052987\",\"https://openalex.org/W2053798341\",\"https://openalex.org/W2058609816\",\"https://openalex.org/W2060176686\",\"https://openalex.org/W2067384745\",\"https://openalex.org/W2079883338\",\"https://openalex.org/W2081307324\",\"https://openalex.org/W2087317982\",\"https://openalex.org/W2091746900\",\"https://openalex.org/W2095188030\",\"https://openalex.org/W2102297826\",\"https://openalex.org/W2102581653\",\"https://openalex.org/W2109334244\",\"https://openalex.org/W2114629758\",\"https://openalex.org/W2115359142\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2122935241\",\"https://openalex.org/W2123924457\",\"https://openalex.org/W2127303237\",\"https://openalex.org/W2142285082\",\"https://openalex.org/W2146561516\",\"https://openalex.org/W2150903999\",\"https://openalex.org/W2159011576\",\"https://openalex.org/W2159917347\",\"https://openalex.org/W2161617741\",\"https://openalex.org/W2166000740\",\"https://openalex.org/W2271081800\",\"https://openalex.org/W2416804157\",\"https://openalex.org/W2437748003\",\"https://openalex.org/W2798667567\",\"https://openalex.org/W3161894121\"],\"authorships\":[{\"id\":\"https://openalex.org/A5018186009\",\"display_name\":\"Ede Frecska\",\"orcid\":\"https://orcid.org/0000-0002-1931-6975\"},{\"id\":\"https://openalex.org/A5087208177\",\"display_name\":\"Luís Eduardo Luna\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306525036\",\"source_display_name\":\"PubMed\",\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/17211054\",\"is_oa\":false}}}", "topic_tags": "Personality Change,Clinical Trial,Review Article,Safety,Drug Interactions", "study_type": "Clinical Trial", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W110752286" }, { "id": 2678, "title": "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.", "normalized_title": "safety tolerability and efficacy of psilocybin in 9 patients with obsessive compulsive disorder", "authors": "Moreno FA, Wiegand CB, Taitano EK, Delgado PL.", "abstract": "BackgroundAnecdotal reports suggest that psychedelic agents may relieve symptoms of obsessive-compulsive disorder (OCD). This modified double-blind study investigated the safety, tolerability, and clinical effects of psilocybin, a potent 5-HT(1A) and 5-HT(2A/2C) agonist, in patients with OCD.MethodNine subjects with DSM-IV-defined OCD and no other current major psychiatric disorder participated in up to 4 single-dose exposures to psilocybin in doses ranging from sub-hallucinogenic to frankly hallucinogenic. Low (100 microg/kg), medium (200 microg/kg), and high (300 microg/kg) doses were assigned in that order, and a very low dose (25 microg/kg) was inserted randomly and in double-blind fashion at any time after the first dose. Testing days were separated by at least 1 week. Each session was conducted over an 8-hour period in a controlled environment in an outpatient clinic; subjects were then transferred to a psychiatric inpatient unit for overnight observation. The Yale-Brown Obsessive Compulsive Scale (YBOCS) and a visual analog scale measuring overall obsessive-compulsive symptom severity were administered at 0, 4, 8, and 24 hours post-ingestion. The Hallucinogen Rating Scale was administered at 8 hours, and vital signs were recorded at 0, 1, 4, 8, and 24 hours after ingestion. The study was conducted from November 2001 to November 2004.ResultsNine subjects were administered a total of 29 psilocybin doses. One subject experienced transient hypertension without relation to anxiety or somatic symptoms, but no other significant adverse effects were observed. Marked decreases in OCD symptoms of variable degrees were observed in all subjects during 1 or more of the testing sessions (23%-100% decrease in YBOCS score). Repeated-measures analysis of variance for all YBOCS values revealed a significant main effect of time on Wilks lambda (F = 9.86, df = 3,3; p =.046), but no significant effect of dose (F = 2.25, df = 3,3; p =.261) or interaction of time and dose (F = 0.923, df = 9,45; p =.515). Improvement generally lasted past the 24-hour timepoint.ConclusionsIn a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.", "journal": "The Journal of Clinical Psychiatry", "publication_date": "2006-10-31", "publication_year": 2006, "doi": "10.4088/jcp.v67n1110", "pubmed_id": "17196053", "source_url": "https://doi.org/10.4088/jcp.v67n1110", "keywords": "Humans, Hallucinogens, Pain Measurement, Treatment Outcome, Severity of Illness Index, Analysis of Variance, Double-Blind Method, Obsessive-Compulsive Disorder, Adult, Middle Aged, Female, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-04 07:00:41", "raw_json": "{\"europe_pmc_id\":\"17196053\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W2043197532\",\"openalex_url\":\"https://openalex.org/W2043197532\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":785,\"referenced_works\":[\"https://openalex.org/W122113993\",\"https://openalex.org/W1583327662\",\"https://openalex.org/W1756752158\",\"https://openalex.org/W1969549633\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2012834083\",\"https://openalex.org/W2024826394\",\"https://openalex.org/W2031769899\",\"https://openalex.org/W2054759608\",\"https://openalex.org/W2075352853\",\"https://openalex.org/W2079106221\",\"https://openalex.org/W2087265397\",\"https://openalex.org/W2088906118\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2115506061\",\"https://openalex.org/W2118403124\",\"https://openalex.org/W2123822033\",\"https://openalex.org/W2153960249\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2471389551\"],\"authorships\":[{\"id\":\"https://openalex.org/A5003092221\",\"display_name\":\"Francisco Moreno\",\"orcid\":\"https://orcid.org/0000-0002-9492-6108\"},{\"id\":\"https://openalex.org/A5005073454\",\"display_name\":\"Christopher B. Wiegand\",\"orcid\":null},{\"id\":\"https://openalex.org/A5072558335\",\"display_name\":\"E. Keolani Taitano\",\"orcid\":null},{\"id\":\"https://openalex.org/A5054838334\",\"display_name\":\"Pedro L. Delgado\",\"orcid\":\"https://orcid.org/0000-0002-9183-841X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S17992710\",\"source_display_name\":\"The Journal of Clinical Psychiatry\",\"landing_page_url\":\"https://doi.org/10.4088/jcp.v67n1110\",\"is_oa\":false}}}", "topic_tags": "Anxiety,OCD,Chronic Pain,Receptor Pharmacology,Safety,Drug Interactions", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2043197532" }, { "id": 2700, "title": "Hallucinogens and dissociative agents naturally growing in the United States.", "normalized_title": "hallucinogens and dissociative agents naturally growing in the united states", "authors": "Halpern JH.", "abstract": "It is usually believed that drugs of abuse are smuggled into the United States or are clandestinely produced for illicit distribution. Less well known is that many hallucinogens and dissociative agents can be obtained from plants and fungi growing wild or in gardens. Some of these botanical sources can be located throughout the United States; others have a more narrow distribution. This article reviews plants containing N,N-dimethyltryptamine, reversible type A monoamine oxidase inhibitors (MAOI), lysergic acid amide, the anticholinergic drugs atropine and scopolamine, or the diterpene salvinorin-A (Salvia divinorum). Also reviewed are mescaline-containing cacti, psilocybin/psilocin-containing mushrooms, and the Amanita muscaria and Amanita pantherina mushrooms that contain muscimol and ibotenic acid. Dangerous misidentification is most common with the mushrooms, but even a novice forager can quickly learn how to properly identify and prepare for ingestion many of these plants. Moreover, through the ever-expanding dissemination of information via the Internet, this knowledge is being obtained and acted upon by more and more individuals. This general overview includes information on the geographical range, drug content, preparation, intoxication, and the special health risks associated with some of these plants. Information is also offered on the unique issue of when bona fide religions use such plants as sacraments in the United States. In addition to the Native American Church's (NAC) longstanding right to peyote, two religions of Brazilian origin, the Santo Daime and the Uniao do Vegetal (UDV), are seeking legal protection in the United States for their use of sacramental dimethyltryptamine-containing \"ayahuasca.\"", "journal": null, "publication_date": "2004-04-30", "publication_year": 2004, "doi": "10.1016/j.pharmthera.2004.03.003", "pubmed_id": "15163594", "source_url": "https://doi.org/10.1016/j.pharmthera.2004.03.003", "keywords": "Fungi, Plants, N,N-Dimethyltryptamine, Ibotenic Acid, Muscimol, Hallucinogens, Dissociative Disorders, United States, Plant Development", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:06", "raw_json": "{\"europe_pmc_id\":\"15163594\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Review Article,Safety", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2709, "title": "[Hallucinogens, amphetamines and entactogens].", "normalized_title": "hallucinogens amphetamines and entactogens", "authors": "Vollenweider FX, Vollenweider-Scherpenhuyzen MF.", "abstract": "MDMA (\"Ecstasy\") and its analogues such as MDE and MDA are amphetamine derivatives reported to produce an altered state with emotional overtones. Since more than ten years, ecstasy is after cannabis the most frequently used recreational drug by young adults, particularly in the so-called techno-scene. However, according to a recent survey there is an increasing trend for a revival of classic amphetamine and hallucinogen abuse, possibly due to the concern about the potential neurotoxicity and somatic risks associated with ecstasy use. Of the hallucinogens consumed, psilocybin containing mushroom (\"magic mushrooms\"), but also LSD are at the forefront. The present contribution summarizes the psychological and somatic effects of hallucinogens, amphetamines, and entactogens.", "journal": null, "publication_date": "2003-05-31", "publication_year": 2003, "doi": "10.1024/0040-5930.60.6.323", "pubmed_id": "12848067", "source_url": "https://doi.org/10.1024/0040-5930.60.6.323", "keywords": "Humans, Amphetamine-Related Disorders, Amphetamines, Hallucinogens, Cross-Sectional Studies, Structure-Activity Relationship, Switzerland", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"12848067\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Emotional Processing,Observational Study,Safety,Toxicity", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2145879190" }, { "id": 5645, "title": "Electrocardiographic examination of heart function in rats exposed to hallucinogens from Psilocybe mushrooms", "normalized_title": "electrocardiographic examination of heart function in rats exposed to hallucinogens from psilocybe mushrooms", "authors": "Krzysztof Borowiak, Anna Machoy-Mokrzyńska, Leszek Domański, Sławomir Majdanik, Edward Dutkiewicz, K Safranow, Tomasz Janus, V Mikolajek", "abstract": "Introduction: It has been accepted that acute toxicity of psilocin is low and this substance does not create a serious health hazard. Few symptoms observed after intake of Psilocybe mushrooms were mostly limited to the Central Nervous System. Material and methods: In order to readdress the supposed low toxicity and relative safety of natural hallucinogens, we performed tests with 52 Wistar male rats, divided into four equal groups. The rats were injected intraperitoneally with 1 ml of solution (psilocin, phenylethylamine, ethanol, saline), three times per week during 12 weeks period. Electrocardiograms were performed after two and eight weeks of the experiment in 32 randomly selected animals from each group and repeated before the autopsy after 12 weeks in all 52 animals. The ECG was recorded under low-dose ketamine anaesthesia, exactly one hour after injection, using an AsCard B-5 apparatus (50 mm/min, 20 mm/mV). Electrodes were placed on the extremities according to Einthoven and Goldberg and in the precardiac area according to Wilson. Heart rate (beats/min) and QRS complexes were analysed. Results and conclusions: Obtained data indicate that the repeated administration of psilocin in rats produces ECG abnormalities including tachycardia, ST segment alterations, and aberrant intraventricular conduction.", "journal": "Acta Toxicologica", "publication_date": "2002-12-31", "publication_year": 2002, "doi": null, "pubmed_id": null, "source_url": "http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.agro-article-d607ea49-70b5-4739-b280-7088af5d6e30", "keywords": "Hallucinogen, Tachycardia, Saline, QRS complex, Heart rate, Medicine, Ketamine, Psilocybin, Anesthesia, Toxicity, Acute toxicity, Internal medicine, Pharmacology, Blood pressure, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Chemical synthesis and alkaloids", "substance_tags": "psilocybin,psilocin", "source_name": "OpenAlex", "date_added": "2026-07-04 06:52:11", "last_checked": "2026-07-04 06:52:11", "raw_json": "{\"openalex_id\":\"https://openalex.org/W1435711203\",\"openalex_url\":\"https://openalex.org/W1435711203\",\"openalex_relevance_score\":7,\"openalex_relevance_reasons\":[\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5045834766\",\"display_name\":\"Krzysztof Borowiak\",\"orcid\":\"https://orcid.org/0000-0002-2526-2686\"},{\"id\":\"https://openalex.org/A5032316718\",\"display_name\":\"Anna Machoy-Mokrzyńska\",\"orcid\":\"https://orcid.org/0000-0003-0419-4730\"},{\"id\":\"https://openalex.org/A5038074828\",\"display_name\":\"Leszek Domański\",\"orcid\":\"https://orcid.org/0000-0002-4712-7821\"},{\"id\":\"https://openalex.org/A5055486011\",\"display_name\":\"Sławomir Majdanik\",\"orcid\":\"https://orcid.org/0000-0003-0472-1924\"},{\"id\":\"https://openalex.org/A5073348579\",\"display_name\":\"Edward Dutkiewicz\",\"orcid\":\"https://orcid.org/0000-0002-9326-3429\"},{\"id\":\"https://openalex.org/A5075233304\",\"display_name\":\"K Safranow\",\"orcid\":null},{\"id\":\"https://openalex.org/A5028439569\",\"display_name\":\"Tomasz Janus\",\"orcid\":\"https://orcid.org/0000-0002-2363-2196\"},{\"id\":\"https://openalex.org/A5068945998\",\"display_name\":\"V Mikolajek\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4363606741\",\"source_display_name\":\"Acta Toxicologica\",\"landing_page_url\":\"http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.agro-article-d607ea49-70b5-4739-b280-7088af5d6e30\",\"is_oa\":false}}", "topic_tags": "Pharmacology,Receptor Pharmacology,Safety,Toxicity", "study_type": "Other", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W1435711203" }, { "id": 2721, "title": "Drugs of abuse monitoring in blood for control of driving under the influence of drugs.", "normalized_title": "drugs of abuse monitoring in blood for control of driving under the influence of drugs", "authors": "Moeller MR, Kraemer T.", "abstract": "Driving under the influence of drugs is an issue of growing concern in the industrialized countries as a risk and a cause for road accidents. In forensic toxicology, the increasing number of samples for determination of drugs in blood is mainly due to zero-tolerance laws in several countries and well-trained police officers who can better recognize drivers under the influence of drugs of abuse. This review describes procedures for detection of the following drugs of abuse in whole blood, plasma, and serum: amphetamine, methamphetamine, 3,4-methylenedioxy methamphetamine (MDMA), N-ethyl-3, 4-methylenedioxyamphetamine (MDEA), 3,4-methylenedioxyamphetamine (MDA), cannabinoids (delta-9-tetrahydrocannabinol [THC], 11-hydroxy-delta-9-THC, 11-nor-9-carboxy-delta-9-THC), cocaine, benzoylecgonine, ecgonine methyl ester, cocaethylene, the opiates (heroin, 6-monoacetylmorphine, morphine, or codeine), and methadone as well as gamma-hydroxybutyric acid (GHB), lysergic acid diethylamide (LSD), phencyclidine (PCP), and psilocybin/psilocin. For many of the analytes, sensitive immunologic methods for screening are available. Gas chromatography-mass spectrometry (GC-MS) is still the state-of-the-art method for confirmatory analysis or for screening and confirmation in one step. Liquid chromatography-mass spectrometry (LC-MS) procedures for such purposes are also included in this review. Basic data about the biosample assayed, internal standard, workup, GC or LC column and mobile phase, detection mode, reference data, and validation data of each procedure are summarized in two tables.", "journal": null, "publication_date": "2002-03-31", "publication_year": 2002, "doi": "10.1097/00007691-200204000-00003", "pubmed_id": "11897967", "source_url": "https://doi.org/10.1097/00007691-200204000-00003", "keywords": "Humans, Chromatography, Liquid, Substance Abuse Detection, Forensic Medicine, Accidents, Traffic, Gas Chromatography-Mass Spectrometry, Illicit Drugs", "substance_tags": "psilocybin,psilocin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"11897967\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Review Article,Safety,Toxicity", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null }, { "id": 2729, "title": "Patterns of recreational drug use at dance events in Edinburgh, Scotland.", "normalized_title": "patterns of recreational drug use at dance events in edinburgh scotland", "authors": "Riley SC, James C, Gregory D, Dingle H, Cadger M.", "abstract": "AimsTo describe the patterns of drug use at dance (rave) events in terms of prevalence, frequency, type of drugs used, patterns of use, access and risk-associated behaviours.DesignSelf-selecting participant-completed survey.SettingThree dance events in Edinburgh, Scotland, UK.ParticipantsOne hundred and twenty-two drug users (57% males, 43% females), 90% of whom were in employment or education, with an age range of 16-47, 80% between 18 and 23 years.MeasurementsParticipants who answered 'yes' to the question 'Have you used drugs for dance events in the past year' reported (i) the prevalence, types and frequency of drugs used; (ii) prevalence and contents of mixing drugs; (iii) accessing drugs; and (iv) engagement with drug-associated risk behaviours.FindingsOver 80% of the participants had used ecstasy and amphetamine, over 30% cocaine and LSD; over 10% nitrites, psilocybin and ketamine and less than 5% had used crack or tranquillizers. Participants reported regular consumption of ecstasy and amphetamine (e.g. 35% used ecstasy and 25% amphetamine on a weekly basis) often taken in combination, with the occasional use of cocaine, LSD, ketamine and psilocybin. Poly- and mixing-drug behaviours were significantly more likely than monodrug usage. Drugs were accessed through friends than from any other source. Eighty-five per cent reported mixing drugs and/or alcohol, 35% driving on drugs, 36% having a bad experience on drugs; 30% unprotected sex; and 0.9% injecting drugs. Women in the sample reported higher consumption than men.ConclusionsDance-drug use has a characteristic pattern that has implications for health promotion and criminal policy.", "journal": null, "publication_date": "2001-06-30", "publication_year": 2001, "doi": "10.1046/j.1360-0443.2001.967103513.x", "pubmed_id": "11440614", "source_url": "https://doi.org/10.1046/j.1360-0443.2001.967103513.x", "keywords": "Humans, Substance-Related Disorders, Prevalence, Risk-Taking, Sex Distribution, Dancing, Adolescent, Adult, Middle Aged, Scotland, Female, Male, Illicit Drugs", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"11440614\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2151598790" }, { "id": 2728, "title": "Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine).", "normalized_title": "characteristics of pregnant women who use ecstasy 3 4 methylenedioxymethamphetamine", "authors": "Ho E, Karimi-Tabesh L, Koren G", "abstract": "To determine the characteristics of pregnant women who use Ecstasy (3,4-methylenedioxymethamphetamine, MDMA), and to identify reproductive risk factors associated with this group of women. Prospective, observational study. Pregnant women who have contacted the Motherisk Alcohol and Substance Use Helpline at The Hospital for Sick Children, in Toronto, about exposure to drugs, chemicals, infection or radiation. All inquiries from December 1998 to October 2000 concerning pregnant women who reported use of MDMA, and control cases of women not exposed to MDMA selected within the same week of the MDMA callers. Age, maternal demographics, pregnancy characteristics, patterns of alcohol, tobacco, and illicit drug use, psychological/emotional status, sexually transmitted disease, MDMA method and pattern of use, and adverse drug reactions after ingestion of MDMA. The 132 pregnant women who used MDMA were significantly younger (mean 23.2 vs. 31.2 years, P", "journal": "Neurotoxicology and teratology", "publication_date": "2000-12-31", "publication_year": 2000, "doi": "10.1016/s0892-0362(01)00178-7", "pubmed_id": "11792525", "source_url": "https://pubmed.ncbi.nlm.nih.gov/11792525/", "keywords": "", "substance_tags": "psilocybin", "source_name": "PubMed", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 06:54:14", "raw_json": "{\"pubmed_id\":\"11792525\"}", "topic_tags": "Addiction,Emotional Processing,Observational Study,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2092775753" }, { "id": 2739, "title": "Nonmedical drug use among adolescent students: highlights from the 1999 Ontario Student Drug Use Survey.", "normalized_title": "nonmedical drug use among adolescent students highlights from the 1999 ontario student drug use survey", "authors": "Adlaf EM, Paglia A, Ivis FJ, Ialomiteanu A.", "abstract": "BackgroundDuring the 1990s, rates of nonmedical drug use among adolescents escalated. We assessed data from 5 cycles of the Ontario Student Drug Use Survey for overall trends in the proportion of students reporting illegal drug use between 1991 and 1999.MethodsThe survey is a repeated, cross-sectional, 2-stage cluster-design survey of students enrolled in grades 7, 9, 11 and 13. Outcome measures were prevalence of use of 17 drugs, including alcohol and tobacco, over the 12 months preceding the survey.ResultsThe rates of drug use increased between 1993 and 1999. The 95% confidence intervals (CIs) for the differences in proportions between 1997 and 1999 indicated significant increases in the overall use of 6 drugs: alcohol (95% CIdiff 6.1, 1.9-10.3), cannabis (95% CIdiff 46.3, 0.2-8.4), glue (95% CIdiff 2.3, 1.3-3.3), other solvents (95% CIdiff 5.0, 3.1-6.3), barbiturates (95% CIdiff 1.9, 0.4-3.4) and hallucinogens such as mescaline and psilocybin (95% CIdiff 3.5, 0.8-6.9). Fewer grade 7 students in 1999 than in earlier cohorts reported using alcohol or cigarettes by age 9.InterpretationThe public health implications of the findings are mixed. On the positive side, there is no evidence of increases in early onset of drug use. On the negative side, the overall proportion of students reporting illegal drug use has continued to rise.", "journal": null, "publication_date": "2000-05-31", "publication_year": 2000, "doi": null, "pubmed_id": "10870495", "source_url": "https://europepmc.org/article/MED/10870495", "keywords": "Humans, Substance-Related Disorders, Health Surveys, Population Surveillance, Prevalence, Cluster Analysis, Confidence Intervals, Risk Factors, Cross-Sectional Studies, Students, Adolescent, Ontario, Female, Male", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"10870495\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W1871973545" }, { "id": 2757, "title": "Recent findings from the Ontario Student Drug Use Survey.", "normalized_title": "recent findings from the ontario student drug use survey", "authors": "Adlaf EM, Ivis FJ.", "abstract": "BackgroundEvery 2 years, the Addiction Research Foundation of Ontario, a division of the Centre for Addiction and Mental Health, sponsors the Ontario Student Drug Use Survey. The results of the surveys conducted in 1995 and 1997 are presented here and compared with results from the early 1990s.MethodsQuestionnaires were completed by 3870 and 3990 Ontario public school students enrolled in grades 7, 9, 11 and 13 in 1995 and 1997 respectively. The outcome measures were prevalence of use of 20 types of drugs and other substances, including alcohol, tobacco and prescription drugs, over the previous 12 months.ResultsFor several drugs the prevalence of use in the previous 12 months had increased from 1993 to 1995, but from 1995 to 1997 there was a significant increase for only one type (hallucinogens such as mescaline and psilocybin). The inhalation of glue declined, and the use of the other 18 types of drugs remained stable.InterpretationRecent data suggest that increases in adolescent student drug use reported earlier this decade have not continued. However, the stability in rates of drug use is not a justification for complacency in this important area of public health.", "journal": null, "publication_date": "1998-08-31", "publication_year": 1998, "doi": null, "pubmed_id": "9757168", "source_url": "https://europepmc.org/article/MED/9757168", "keywords": "Humans, Substance-Related Disorders, Health Surveys, Population Surveillance, Prevalence, Risk Factors, Cross-Sectional Studies, Students, Adolescent, Ontario, Female, Male, Surveys and Questionnaires", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"9757168\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Addiction,Observational Study,Adolescents,Safety", "study_type": "Observational Study", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2098941694" }, { "id": 2760, "title": "Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction.", "normalized_title": "psilocybin mushroom psilocybe semilanceata intoxication with myocardial infarction", "authors": "Borowiak KS, Ciechanowski K, Waloszczyk P.", "abstract": "Case reportIntentional intoxication with natural hallucinogenic substances such as hallucinogenic mushrooms continues to be a major problem in the US and Europe, particularly in the harbor complex of northwest Poland (Pomerania). A case is described of Psilocybe intoxication in an 18-year-old man resulting in Wolff-Parkinson-White syndrome, arrhythmia, and myocardial infarction. The indole concentrations of hallucinogenic mushrooms may predict the risk for adverse central nervous system and cardiac toxicity.", "journal": null, "publication_date": "1997-12-31", "publication_year": 1997, "doi": "10.3109/15563659809162584", "pubmed_id": "9541042", "source_url": "https://doi.org/10.3109/15563659809162584", "keywords": "Humans, Wolff-Parkinson-White Syndrome, Myocardial Infarction, Mushroom Poisoning, Hallucinogens, Adolescent, Male, Psilocybin", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"9541042\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Randomized Controlled Trial,Case Report,Adolescents,Safety,Toxicity", "study_type": "Case Report", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": "https://openalex.org/W2139748231" }, { "id": 2778, "title": "Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically.", "normalized_title": "toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically", "authors": "Gable RS.", "abstract": "A procedure is outlined for comparing dependence potential and acute toxicity across a broad range of abused psychoactive substances. Tentative results, based on an extensive literature review of 20 substances, suggested that the margin of safety (\"therapeutic index\") varied dramatically between substances. Intravenous heroin appeared to have the greatest risk of dependence and acute lethality; oral psilocybin appeared to have the least. Hazards due to behavioral deficits, perceptual distortion, or chronic illness were not factored into the assessments.", "journal": null, "publication_date": "1992-12-31", "publication_year": 1992, "doi": "10.3109/00952999309001618", "pubmed_id": "8213692", "source_url": "https://doi.org/10.3109/00952999309001618", "keywords": "Humans, Substance-Related Disorders, Psychotropic Drugs, Risk Factors", "substance_tags": "psilocybin", "source_name": "Europe PMC", "date_added": "2026-07-01 06:54:14", "last_checked": "2026-07-01 11:22:07", "raw_json": "{\"europe_pmc_id\":\"8213692\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}", "topic_tags": "Review Article,Safety,Toxicity,Abuse Liability", "study_type": "Review Article", "hidden": 0, "false_positive": 0, "curation_notes": null, "merged_into_id": null, "curation_locked": 0, "publication_status": "published", "openalex_id": null } ] }